<SEC-DOCUMENT>0001129928-23-000008.txt : 20230303
<SEC-HEADER>0001129928-23-000008.hdr.sgml : 20230303
<ACCEPTANCE-DATETIME>20230303112301
ACCESSION NUMBER:		0001129928-23-000008
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230303
DATE AS OF CHANGE:		20230303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		23702324

	BUSINESS ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>oncyf-20221231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:63a935b1-1650-41e1-88a0-4b019d55689c,g:0488272c-958a-4da8-b3e7-8a139968e8c3,d:f2c66687cf8546c4b7655f45d9eacdf7--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:oncyf="http://www.oncolyticsbiotech.com/20221231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>oncyf-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180L2ZyYWc6NjJlMGNkNWJjYTIwNDY0ODkzYWQwMzJjMGMzMDkzMmIvdGFibGU6MzE3ODAxOWRkMWNmNDMyOGFjZGI3ZjA3Y2I2N2YxNWQvdGFibGVyYW5nZTozMTc4MDE5ZGQxY2Y0MzI4YWNkYjdmMDdjYjY3ZjE1ZF8xLTEtMS0xLTM1Mzgz_a89fd1e9-b75e-4cc4-8d29-65c71fa83a5d">0001129928</ix:nonNumeric><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180L2ZyYWc6NjJlMGNkNWJjYTIwNDY0ODkzYWQwMzJjMGMzMDkzMmIvdGFibGU6MzE3ODAxOWRkMWNmNDMyOGFjZGI3ZjA3Y2I2N2YxNWQvdGFibGVyYW5nZTozMTc4MDE5ZGQxY2Y0MzI4YWNkYjdmMDdjYjY3ZjE1ZF8yLTEtMS0xLTM1Mzgz_0391f04e-bd55-4921-927e-d021e587cd46">2022</ix:nonNumeric><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180L2ZyYWc6NjJlMGNkNWJjYTIwNDY0ODkzYWQwMzJjMGMzMDkzMmIvdGFibGU6MzE3ODAxOWRkMWNmNDMyOGFjZGI3ZjA3Y2I2N2YxNWQvdGFibGVyYW5nZTozMTc4MDE5ZGQxY2Y0MzI4YWNkYjdmMDdjYjY3ZjE1ZF8zLTEtMS0xLTM1Mzgz_a4f3af4d-704a-40a0-8b8f-39db71cf80fb">FY</ix:nonNumeric><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180L2ZyYWc6NjJlMGNkNWJjYTIwNDY0ODkzYWQwMzJjMGMzMDkzMmIvdGFibGU6MzE3ODAxOWRkMWNmNDMyOGFjZGI3ZjA3Y2I2N2YxNWQvdGFibGVyYW5nZTozMTc4MDE5ZGQxY2Y0MzI4YWNkYjdmMDdjYjY3ZjE1ZF80LTEtMS0xLTM1Mzgz_0e109876-192e-4417-a5f7-a56a86582d4d">false</ix:nonNumeric><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180L2ZyYWc6NjJlMGNkNWJjYTIwNDY0ODkzYWQwMzJjMGMzMDkzMmIvdGFibGU6MzE3ODAxOWRkMWNmNDMyOGFjZGI3ZjA3Y2I2N2YxNWQvdGFibGVyYW5nZTozMTc4MDE5ZGQxY2Y0MzI4YWNkYjdmMDdjYjY3ZjE1ZF81LTEtMS0xLTM1Mzgz_aace8447-9e47-4318-a341-e39bbfedd10b">A0</ix:nonNumeric><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180L2ZyYWc6NjJlMGNkNWJjYTIwNDY0ODkzYWQwMzJjMGMzMDkzMmIvdGFibGU6MzE3ODAxOWRkMWNmNDMyOGFjZGI3ZjA3Y2I2N2YxNWQvdGFibGVyYW5nZTozMTc4MDE5ZGQxY2Y0MzI4YWNkYjdmMDdjYjY3ZjE1ZF82LTEtMS0xLTM1Mzgz_c84b77c2-e150-440c-b786-bcecbe50cb69">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i02abfa4251e340c3988374be2db0e2d2_D20180522-20180522" decimals="INF" name="oncyf:StockholdersEquityNoteStockSplitConversionRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjMvZnJhZzpjNTQzNDZjMDRiZmE0MGVlOWRiZDA1MTBhZTU2YmQ2YS90YWJsZTpmMWY1Yzg2Y2FkODQ0MmU5ODg0MGZhODMyZTY4MjQxNi90YWJsZXJhbmdlOmYxZjVjODZjYWQ4NDQyZTk4ODQwZmE4MzJlNjgyNDE2XzEtMS0xLTEtMzUzODM_87f353ae-039e-40d7-bb46-7339632761c3">0.105263157894737</ix:nonFraction><ix:nonNumeric contextRef="if8c782e17d83404aa29f79eba0b9cef7_D20220101-20221231" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzM4Mg_95eb31db-de86-4acf-a885-2ec978a753c1">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="oncyf-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied69a4c1e8dc444497553637c429c995_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee4c1d19b10441a9fb87c20bf21e3fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib221189a8a8e442da5b933592a172090_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cadPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i34072d06dbc74709a44772e87c0d0628_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd91d05642e7401b8c8faeeb5459ba72_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b5762368dba4c919ee8061f3f934cd2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d7d4f10038048718f7928d1bab94c89_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idadaa0cf361244f49594f3ef42b55e1c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5e2093c82014efc936a23f9e66baceb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fe43ded55bb48a19706afc4c1823657_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57e65be9e20f459dbe2844e5091b0eb8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29cfb81f0a3a44299e19e6f5f7d4b3fe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic888e62d483b498baa6a74041afebae7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b5e4d511d249e2a405c432386bbc33_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6510299e4eb4121b35ad3c184f04164_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i290facf32bd147b3884843f453ff6807_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8306ac01dd1463bbd49d0c295bf272f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e1e0507b4d45e393729762660f43a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i368b44deb2be4ae8a6ca25d3395395fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i948a576781cb440eb04b08b93b5d97f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f95b5256b04475bef34fd27060d50e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e5170208d2a4bd9b4a4c6146ff70357_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c339f58b6a2498ea561adefe93e835c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3961fe68fe52450d88368027d3561fcf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a8cd87a2d5a464ba33b505012eb6589_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b43b9c4bfe449b6b1add7f653d88bf2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4041f6f067cb40d396837f84680e473b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbaf1681ace746c7a5991056ee03b717_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97c499ae0f4f4465949c6fe6c3000ab0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cdf4a3d792142928c2a62b0fe7cbb14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01f7eba52a7942aeba915d83f45b1a80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i576c2a286bbc4d11b0b6d563390fe4b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca5b15a1b7044289a0c16a41d080756_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74a140a0b6704c889a525c2e794ec55c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie50cc2fed39041bc905a4bcda62dfc62_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bdab815bf824c749bcbfc48a0d04970_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21011e791fea44a5a06778532673f5a7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ed6a69506e34074a8db38ee94834bd6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i675ad40abe414c01b53d0b9d4f0b4bac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i926bb81a27e0480ca8b1aa8523ae7dbf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77a1e98211ca443f9dfaca9d7e15ffb4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a4f596a4a24a67b57f8f348cf65e66_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee80e6ef283a466d847af7f4c18b0932_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f2d18eb4014706985a616274ce8cf0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15555db508714ca18e982d65eea9cb39_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db0e2b8debf4e1987ee224438086d51_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f01ea7a336d44d2ab368965b5d555a1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i1a49b5a6078743c4a0f6d1dc090f31ae_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc90711aec744857b2329d7bd8e24e98_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>oncyf:plan</xbrli:measure></xbrli:unit><xbrli:context id="i9166d82a922341729a9cfba07b6c19fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i8f8114e0983f40c18d9bd8848358071f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4783f947d474ec7a4043f3bd7016af3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3911bf2c955b405bac30a9b918de2d56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e33daaee7a04931a84b95d558b6feab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ef8717fa2344528d67d8af749583ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i204d523ce7ab4b52896ed6d2295ef847_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5f0b13be4b5469faca7dfca28e6f4c8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee36a908faae4b93971ba0cc2c7ca539_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia39c558d66984975b5b558b476007a29_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff1d10a78054a38a5d7f49b53d4d3b0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68bda01afab14d5cb26920e605f0ab42_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i286fea00b77e413c9c5eeffe49ab79c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe509d23f474055870d8386107bed16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2dee205e673484b94ca9942a6585f62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a0d89d731934218a9200c653646ae2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41042a36299746dfa6245b8f04eeb2fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4096288385ea4783bb39b83a9221722a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dbc93ed0aff46e895933aedb6179359_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a8e62bdf6047f6b2871d5eb585c601_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedb5bad8c9c64aeb82bab9cdcaaab035_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff71c66ed2f49d7a3a5436aa04a7517_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb257f4f952a40c895f4c48bb418df40_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79304496df494f95b80359489d58d588_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2af36eb48c0d4fe2b8f76f15361a0a7e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb1ab3d5241c42b4bc1827326301115d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a666b3f60054f4cbf818f5e3df21b12_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f67c6da798f44b594280ae812c6baaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76d7a88ee04145c194ae4be4171aa00c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73b71a1c9b2748b48f0eef3f1e218dbc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dcb43e627a74a66b65eccdde1930703_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f29e88f1e0a4dada070a283833ffdb9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic14ac3299f434c03908133a0c4a9205e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6845c74acd4eb6bdee2a26eb7d8b31_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff53065b38874233bcc1a933461017ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0daba0652a364b148a3ad3df35cb62f9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8addce8064f24c3cb69be9a37be7346b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c2b76821444aed993c937b01f9ce03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e99b1b5e9384ed6b69134ad46524aed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b3d9e57cf1f4065853436dbd64f88f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00001682505c41e0a1f6a5200e7369cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3050942226a5438fa9c685a3428ff7a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25cea6a2272341c1929aaaa1d18e0f5b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f607fc35a524cb8b063cbac9f2c139c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1784fbe9117b4ee1a7b43ddcc71a0db3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5d7a02883ec445c9158c8db51d57df8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f605b055eea4373ba168badd86607c3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee540100ac1e473dbf3745fc5ffcc5be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf594b04da5249a0841abdc72a9802ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if236c6ed5fc6436b9c2654b18b4a3ada_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id315aa54ed3e46e19f179179a56a77ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if30f9fd81d8e488390af3fade7de9e46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i513dceb1a6f14df9a09714d11d8a7b2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1feff0178e14474aaa4fc6a186497ad0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id202f8bc51ef4633b66140d696b4d861_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54cddc074de54f28b6e68ca6b670e5f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i777d047d5ec446409e8a5c8324aa324d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a8c607d0de64f79bdc2e8ce8034a59c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie70c35bbd59a4905b781c7668e5cc70f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i963844cd43c644c7932afd7741a944d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0702f9b593a943e0aa89f870ac3bbdc4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b95cc388ab54e769e83447ea9abf950_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia32318f895f946ecbe86b9b07e60fd1c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea62ebc777ac430eb1852b3dd64bf5a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i365cb71f7fa842589bd1fc05d704aec7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if692efdc55844ddd94d16e3f6ae99d73_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6541e8507efb4de5a913ca4fac61cf17_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8972058a330f4d2e80365843e754c2d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b1d0fbc8f1b4d968750fdb49b146c64_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b8eb310435f4b7089eb7c5f3035b88d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cec7f0886424478a8adab4adfe59a0b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe25ae3bb8014f7cb475d95097c9166e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b552f25ccd04fdb86d1346a3975fa1b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6493a759f124792b1e8928326aac134_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f593ff807bd4b97a79dd779ca1363b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2fe0be7fe344da59d4ec9cf38ef8816_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11172d73364741cc830ad4c4925edd65_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10f8803a04704f94b4c3b16076075a61_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6efced05728f430dbc45b4b00278027e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e9e1c91dbd64b66a3ef5f637728d726_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie67556b574354bfbbbe629f9c4f83910_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if333223790564dcb96ea8ce18000124c_I20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c01aa3f72784c8eb36e0bca515d9aff_D20181024-20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-24</xbrli:startDate><xbrli:endDate>2018-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809782423e5a496c9bb7e6d59de0f3a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i783080355c484f52b0c3ed3b1f30118c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i339d817f02da483dacfdea11d754715d_D20190816-20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-16</xbrli:startDate><xbrli:endDate>2019-08-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d502b20f5504524b12de442d39c71e8_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95f4ddbdd41f46c28a3fa7900b833ed6_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36f0549e16fb493899d3ce11e6663ed3_I20190816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8660fe469e4e3bb809b223adeb1928_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f4f12b4c9ac415291240c8cd9609fe0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i711e0a27b9344e398357548811fe1ed6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c37cce29b8346b0ba836e6e496264d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if27e5cf46efd4450807817226f0625d7_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida0bae79a8bc43eb8fd183431b5b3f2d_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23e1543579db44e78472abe042745f89_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7dd014e773644638183d9dbc0c3ba03_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63384d0a252342c890796e05d336932d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90e7609d87f34c56bb2a2970072a4155_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia82e40c581724751808cdca1dd238e9b_I20210305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i998f1448e0f242f0a37474a940e5bb85_D20210305-20210305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-05</xbrli:startDate><xbrli:endDate>2021-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98e916be7d9749dd9fdd5af0f4f92104_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i209bf45ef70c45e7b6c75d2906c6f1ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35bc0c0fb23d4de58f297cc59b64b8da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ab78014954745ca943db137b2067123_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cb45010a1f04a19bb8bb7c198eafcb7_I20220617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf3514ed6ca044d7810415c09e4274c5_D20220617-20220617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-17</xbrli:startDate><xbrli:endDate>2022-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b0440d3e41e4deaa503df6fed6a1cf7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c38fae9a1ca4c469aff3c034e794b8d_D20170601-20170601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2017-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15ebd1009ac5441788d5ea09d2d20d34_I20170601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadb9b5984e0d4be9a1b244e2d939dde2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f62a8b7a8c2458692b02a5416ac2ac4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49324b0a98f247d28e8710f0a21c58d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7cac766cbaa43fb9c4ad8b89138fec9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i451a07d69b99427c8835f34d48f9f9fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02abfa4251e340c3988374be2db0e2d2_D20180522-20180522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-22</xbrli:startDate><xbrli:endDate>2018-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d60827e07f44c119014f8e722b58bf9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aadf4823bed41b0a081530e5fc4658c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6368f5d59534a0d96175310350885fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52f9ee94ed334d309ddc1b2501e78dc1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i669145b9554d41f3b9c524309e023747_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e8be41597da42568d4f86e247044361_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie679757fac604f0cb2a738bb1dd0ac7e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd74fcb0f8c9429fadb463a6eb81e2f0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0265f11a01344f595e7fe503b2a3472_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd36a13c83d745178281e200444da7ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e89eeef735b47ceb3acd3ad40771e04_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib60b968ef3b34ea79492f56d45e6f2f1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0741691230d4e28b2d1df61be980984_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1818274641ed42299558348b53c621fd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f8f1d616d0e479fafc3b8c388acf7c8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i016d2b845c3c472d9148a20b8286ae27_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ff3b4848a624feab2a3c7841b598986_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5017488ebe3844d0ad6adf806e07f9b9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d0648f490594bd7ab0068f3dec9d739_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48e149fb587f4b6b81178a578d0bd1fa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c782e17d83404aa29f79eba0b9cef7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac8d3f09febd4cb19e47cf23fefaaf0a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="year"><xbrli:measure>oncyf:year</xbrli:measure></xbrli:unit><xbrli:context id="i771812f5ba4a4f9ba29a5246edf0bf00_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2320674fb5744c63bbf6953873d4a940_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0929be370c884a7cb1a0e5b4d741a8b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03a33fe7f4e34bb28f5d1cbf45984686_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9255ba83d384e38a8c5e9053e964622_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dec10529d90451ba902ebe59a161f0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5de5eb425bc430e9593f5e707cf066a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0daf1c1f7fbd41b2933e6fc95c01304a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia520d0c500544f84866a7d2a4c1dacd9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i103420c5cde840e79af37985d2d0bc9d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28afd4f827e34f3eae4c33b42849dabf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ab96394ca8b4ae0a266d0b54caf3191_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbbd14a8d6a34c3db1a86531714b2505_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e50e8d056f742639310ba89a351e073_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i948c9f76e8c14e789a92b32d5e0cd60d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2592d82deade43a389c57acec6861c6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa08ffbbd906412591e8727e7b92333e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie72bcfe2289d460cb870ee2ab6965abf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9934fdaa7cb54bed9e71b4949c27a412_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb1478bee3ac4873a8fa8d09e2c3af34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c467d253d145219d761e8b50d9872e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dd5a5d56ed3410cb4e81d1da02608b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b3ad9043f0443508a6e58ffe371b9e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e1578bad4a4fd8b9eeb3cc0142c022_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf87bcb9d5a348e7987675a510c51f91_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e00e20520b0484b8e24ff13c4d70e87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i192f8af4da504af0a223d7c5399c0b89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d0f7801e4734c00bb6d8dd7c4f5b818_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i085395ab16f842a1a1512a6390a303e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82ebeaf310b04401931722c6c4601410_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92fb0107f20d4b31a60191a22ac916c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d4db2a6855b40bc9001da783c6c23a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bce01bfb3c140e19bceefb885e36144_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i661bfced363d425b983b07748d5e34d9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib701cd64a09142eaa49f3229d198e9f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dc03510bb2241279358235d4f80a08e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878d9a8a28ac42caa7c1e38319e6da4c_I20220612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78092e29c72947a18acdd0770f54643c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fd69d94537a4d46b4b4f06ee6771977_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c8fd43724f84c33ae13eca3658b27f6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c04db7260c44d0a84dcee681e6b31a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4078a67cca34e859712c16c4fb4b8ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3968ebc093542fb94bd695c6069eeb0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4d7eaaabecc41fcad176194a92590f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:ConcentrationRiskType1Axis">oncyf:SupplierConcentrationRisk1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="manufacturer"><xbrli:measure>oncyf:manufacturer</xbrli:measure></xbrli:unit><xbrli:context id="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66e81fab17754d28b557975b9a91350b_D20230101-20230302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTk0_b7c1dfb1-f3f4-43b6-a176-0ae716d1cb33">20-F</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:13.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:DocumentRegistrationStatement" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6ZjEzMDBkZGE4OGZjNDA5Y2E1YTY1OTg3MzE1MjkwZGEvdGFibGVyYW5nZTpmMTMwMGRkYTg4ZmM0MDljYTVhNjU5ODczMTUyOTBkYV8wLTAtMS0xLTM1Mzgz_1aaa5e06-d196-4ce4-b8f6-db071bd31e19">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6ZjEzMDBkZGE4OGZjNDA5Y2E1YTY1OTg3MzE1MjkwZGEvdGFibGVyYW5nZTpmMTMwMGRkYTg4ZmM0MDljYTVhNjU5ODczMTUyOTBkYV8yLTAtMS0xLTM1Mzgz_0cd1b8fb-3123-4b34-8f94-59ec984a4f22">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For fiscal year ended</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6ZjEzMDBkZGE4OGZjNDA5Y2E1YTY1OTg3MzE1MjkwZGEvdGFibGVyYW5nZTpmMTMwMGRkYTg4ZmM0MDljYTVhNjU5ODczMTUyOTBkYV81LTAtMS0xLTM1MzgzL3RleHRyZWdpb246Y2NlNjlmMzE5YzBiNDk2ZDk3Y2Y5YjM3OWRmZTg2NDVfNA_4b67ebcc-09b8-493b-81bc-2cbde23b5e2d"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6ZjEzMDBkZGE4OGZjNDA5Y2E1YTY1OTg3MzE1MjkwZGEvdGFibGVyYW5nZTpmMTMwMGRkYTg4ZmM0MDljYTVhNjU5ODczMTUyOTBkYV81LTAtMS0xLTM1MzgzL3RleHRyZWdpb246Y2NlNjlmMzE5YzBiNDk2ZDk3Y2Y5YjM3OWRmZTg2NDVfNA_5ed46be8-3327-4e07-ad62-8dbccd3881b0">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6ZjEzMDBkZGE4OGZjNDA5Y2E1YTY1OTg3MzE1MjkwZGEvdGFibGVyYW5nZTpmMTMwMGRkYTg4ZmM0MDljYTVhNjU5ODczMTUyOTBkYV84LTAtMS0xLTM1Mzgz_4a5ca454-40a1-4fbf-81e2-59fd6a993cfc">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>For the transition period from ____ to ____</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:DocumentShellCompanyReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6ZjEzMDBkZGE4OGZjNDA5Y2E1YTY1OTg3MzE1MjkwZGEvdGFibGVyYW5nZTpmMTMwMGRkYTg4ZmM0MDljYTVhNjU5ODczMTUyOTBkYV8xMS0wLTEtMS0zNTM4Mw_39a62b85-10b1-4c9c-966f-6a3b89d18a36">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>Date of event requiring this shell company report:</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTg2_13f3f754-36d8-4b98-a78e-ba189af63b03">001-38512</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTk1_7ad9d4f7-02f1-4e07-933e-457f956a7361">ONCOLYTICS BIOTECH INC.</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Province of Alberta, Canada</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Jurisdiction of incorporation or organization)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTkw_abdf19a8-de63-415e-aab1-57587283e550">804, 322 11th Avenue SW</ix:nonNumeric>, <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTc5_f1553c63-6f85-49e7-a874-8076bdafb5c4">Calgary</ix:nonNumeric>, <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTkx_1520a183-6363-438f-94ca-1ecb6a0789f3">Alberta</ix:nonNumeric>, <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTcz_c27732ca-a783-4d35-a466-029dc1f5bab6">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTgy_d67545db-363a-463c-be27-99fe177932ef">T2R 0C5</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231" name="dei:ContactPersonnelName" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTc2_33196c37-8c18-4dca-829f-dbb9b548e89e">Kirk Look</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTg3_d21dca40-eb91-436c-9633-c405186c5cf5">804, 322 11th Avenue SW</ix:nonNumeric>, <ix:nonNumeric contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTgz_c8a941b6-97ee-4fd1-a89b-9ef23f1a597f">Calgary</ix:nonNumeric>, <ix:nonNumeric contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTg4_2088cef0-1a94-4456-a576-cb9c87ba9a11">Alberta</ix:nonNumeric>, <ix:nonNumeric contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTkz_06f0ad7d-15a3-47ce-8936-15e1c3a7996f">Canada</ix:nonNumeric>  <ix:nonNumeric contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTg5_2e1e1baa-c7ff-4f5b-b248-c85a6f5aeff7">T2R 0C5</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tel: (<ix:nonNumeric contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV80Nzg_47a295ae-d573-4638-847d-5d1fe5ba242c">403</ix:nonNumeric>) <ix:nonNumeric contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTg0_23671e57-848f-4c43-b5b0-3b7516df1b34">670-7377</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E-mail: <ix:nonNumeric contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231" name="dei:ContactPersonnelEmailAddress" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTg1_7d058528-8f24-43dd-833f-fa8317f93d75">info@oncolytics.ca</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.578%"><tr><td style="width:1.0%"></td><td style="width:29.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares, <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6MjE4MWE3ODExNDFkNDJmNzk0OThkZmY3NTk0YmQ1MzEvdGFibGVyYW5nZToyMTgxYTc4MTE0MWQ0MmY3OTQ5OGRmZjc1OTRiZDUzMV8xLTAtMS0xLTM1MzgzL3RleHRyZWdpb246Nzg0MGNmY2JhNjQ5NDIwMWExMjYwMGVjZmJhOWI2YzVfMTk_e067f248-3e87-4f8c-b2f7-e7bf96d092a2">no</ix:nonNumeric> par value</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6MjE4MWE3ODExNDFkNDJmNzk0OThkZmY3NTk0YmQ1MzEvdGFibGVyYW5nZToyMTgxYTc4MTE0MWQ0MmY3OTQ5OGRmZjc1OTRiZDUzMV8xLTEtMS0xLTM1Mzgz_4e7fcab2-6e9c-4fac-91f5-76dd24b49702">ONCY</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6MjE4MWE3ODExNDFkNDJmNzk0OThkZmY3NTk0YmQ1MzEvdGFibGVyYW5nZToyMTgxYTc4MTE0MWQ0MmY3OTQ5OGRmZjc1OTRiZDUzMV8xLTItMS0xLTM1MzgzL3RleHRyZWdpb246YjBhOWFkNTA2ZDFiNDdhN2IxNTMyNzI1OTFlZTQxODhfOA_6a623d14-b889-4039-99f8-7b6d8d427deb">Nasdaq</ix:nonNumeric> Stock Market LLC</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:  None</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: &#160;None</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of outstanding shares of each of the Registrant&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: <ix:nonFraction unitRef="shares" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8xMDA0_84e0793f-c1c0-4328-aa01-ca6e242709eb">61,327,914</ix:nonFraction> common shares as at December&#160;31, 2022</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTc1_6fa60c81-c219-4eeb-af8b-f0bbb74e9bfa">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this report is an annual or transition report, indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTcx_07935899-9bdf-4bdc-aecf-8f17ed93d59d">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTky_5e1bf0d9-708e-4a2f-9484-440c17e4c552">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every&#160;Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTk2_1c043148-4c7f-42ed-9544-6fad391e4e5d">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company.&#160;&#160;See definition of &#8220;large accelerated filer,&#8221;  &#8220;accelerated filer,&#8221; and &#8220;emerging growth company in Rule 12b-2 of the Exchange Act.&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6NTAzMmQzMzRhNjRlNGY4OTkxODc3YjNiMDJmYjA4Y2MvdGFibGVyYW5nZTo1MDMyZDMzNGE2NGU0Zjg5OTE4NzdiM2IwMmZiMDhjY18wLTItMS0xLTM5NDM1L3RleHRyZWdpb246MDE1ZjQ0MWM4YmU1NGNiZjkzMmQ0OWU5MzUyYmVlYmZfMjc0ODc3OTA2OTQ5Mg_dd591fbc-5b52-4033-a5fd-567cf2431a17">Non-accelerated filer</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTgx_13e2e678-3752-456b-841f-ce2fa9cebca6">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;U.S. GAAP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:DocumentAccountingStandard" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6MzI0YTc0YzUyMWZjNDM0ZWI3MTFhMjYzNDNmN2QyOTUvdGFibGVyYW5nZTozMjRhNzRjNTIxZmM0MzRlYjcxMWEyNjM0M2Y3ZDI5NV8wLTEtMS0xLTM1MzgzL3RleHRyZWdpb246OGUwMmVhNTUxYzRhNDNlMmEyN2ZhNzgxZWY1MjU3YjFfNA_9857c344-f96c-4844-b248-225ab06085fa">International Financial Reporting Standards</ix:nonNumeric> as issued&#160;&#160;by the International Accounting Standards Board</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Other&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 17 </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Item 18&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this is an annual report, indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTcy_9cefedee-04ec-4bdc-9fb5-0dda68456d5d">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 20-F</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_16">&#160;Item 1. &#160;&#160;&#160;&#160; Identity of Directors, Senior Management and Advisers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_19">&#160;Item 2.&#160; &#160;&#160;&#160; Offer Statistics and Expected Timetable</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_22">&#160;Item 3. &#160;&#160;&#160; &#160;Key Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_25">&#160;Item 4.&#160;&#160;&#160;&#160;&#160; Information on the Company</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_25">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_28">&#160;Item 4A.    Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_28">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_31">&#160;Item 5.&#160; &#160;&#160;&#160; Operating and Financial Review and Prospects</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_31">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_34">&#160;Item 6.&#160; &#160;&#160; &#160;Directors, Senior Management and Employees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_34">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_37">&#160;Item 7.&#160; &#160;&#160;&#160; Major Shareholders and Related Party Transactions</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_37">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_40">&#160;Item 8.&#160;&#160; &#160;&#160;&#160;Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_40">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_43">&#160;Item 9.&#160;&#160;&#160;&#160;&#160; The Offer and Listing</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_43">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_46">&#160;Item 10.&#160;&#160;&#160; Additional Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_46">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_49">&#160;Item 11.&#160;&#160;&#160; Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_49">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_52">&#160;Item 12.&#160;&#160;&#160; Description of Securities Other Than Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_52">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_58">&#160;Item 13.&#160;&#160;&#160; Defaults, Dividend Arrearages and Delinquencies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_58">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_61">&#160;Item 14.&#160;&#160;&#160; Material Modifications to the Rights of Security Holders and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_61">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_64">&#160;Item 15.&#160;&#160;&#160;&#160; Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_64">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_67">&#160;Item 16.     [Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_67">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_70">&#160;Item 16A. &#160;Audit Committee Financial Expert</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_70">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_73">&#160;Item 16B.&#160;&#160; Code of Ethics</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_73">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_76">&#160;Item 16C.&#160;&#160;&#160;Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_76">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_79">&#160;Item 16D.&#160; &#160;Exemptions from the Listing Standards for Audit Committees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_79">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_82">&#160;Item 16E.&#160;&#160; Purchase of Equity Securities by the Issuer and Affiliated Purchases</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_82">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_85">&#160;Item 16F.&#160;&#160; Change in Registrant's Certifying Accountants</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_85">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_88">&#160;Item 16G.&#160; Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_88">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_91">&#160;Item 16H.   Mine Safety Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_91">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_94">&#160;Item 16I.   Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_94">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_100">&#160;Item 17.&#160;&#160;&#160;&#160;&#160; Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_100">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_103">&#160;Item 18&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_103">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_106">&#160;Item 19.&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_106">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_109">&#160;Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_109">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_112">&#160;Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2c66687cf8546c4b7655f45d9eacdf7_112">F1 - F24</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this annual report on Form 20-F to the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;the Company,&#8221; and &#8220;Oncolytics&#8221; refer to Oncolytics Biotech Inc. Unless otherwise indicated, all references to "$" and "dollars" in this annual report mean Canadian dollars. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements in this annual report on Form 20-F and the documents attached as exhibits to this annual report, constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oncolytics Biotech Inc., or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified by the words &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;projects&#8221;, &#8220;potential&#8221;, &#8220;possible&#8221; and similar expressions, or that events or conditions &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could&#8221; or &#8220;should&#8221; occur.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this annual report on Form 20-F are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control. Some of the important risks and uncertainties that could affect forward-looking statements are described further under the section heading &#8220;Item 3. Key Information &#8211; D. Risk Factors&#8221; below.&#160;If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may vary materially from those expected, estimated or projected.&#160;Forward-looking statements in this document are not a prediction of future events or circumstances, and those future events or circumstances may not occur.&#160;Given these uncertainties, users of the information included herein, including investors and prospective investors are cautioned not to place undue reliance on such forward-looking statements.&#160;Investors should consult our quarterly and annual filings with the securities commissions or similar regulatory authorities in Canada and the SEC for additional information on risks and uncertainties relating to forward-looking statements.&#160;We do not assume responsibility for the accuracy and completeness of these statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are based on our beliefs, opinions and expectations at the time they are made, and we do not assume any obligation to update our forward-looking statements if those beliefs, opinions, or expectations, or other circumstances, should change, except as required by applicable law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISK FACTORS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common shares involves a high degree of risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the risks summarized below and other risks that we face, a detailed discussion of which can be found under &#8220;Item 3. Key Information &#8211; D. Risk Factors&#8221; below, together with other information in this annual report on Form 20-F and our other filings with the SEC. This summary list of risks is not exhaustive of the factors that may affect any of the Company&#8217;s forward-looking statements and our business and financial results. If any of these risks actually occur, our business, financial condition, and financial performance would likely be materially adversely affected. In such case, the trading price of our common shares would likely decline and you may lose part or all of your investment. Below is a summary of some of the principal risks we face: </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any failure or delay in clinical trials for our products, including pelareorep, may cause us to incur additional costs or delay or prevent the commercialization of our products and could severely harm our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our candidate product, pelareorep, is being and will continue to be used in combination with third-party drugs. Those currently being partnered with pelareorep are approved; however, we have limited or no control over the supply of these drugs. If our relationships with current or future collaborators or suppliers are not successful, we may be delayed in completing the development of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business, including our research and development operations, has been and may continue to be adversely affected by the COVID-19 pandemic and conflict in Ukraine;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidate may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any potential marketing approval;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmaceutical products are subject to intense regulatory approval processes;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations and products may be subject to other government manufacturing and testing regulations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have conducted, and may in the future conduct, clinical trials for pelareorep in sites outside the United States and the FDA may not accept data from trials conducted in such locations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on patents and proprietary rights to protect our technology;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations would be costly, time-consuming, distracting to management and could materially affect our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developments in patent law could have a negative impact on our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not obtain protection under the Hatch-Waxman amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intellectual property rights do not necessarily address all potential threats to our business.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products may fail or cause harm, subjecting us to product liability claims;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New products may not be accepted by the medical community or consumers;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our technologies may become obsolete;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third-party manufacturers to produce our clinical products and on other third parties to store, monitor and transport bulk drug substance, and drug product. We and our third-party partners may encounter difficulties with respect to these activities that could delay or impair our ability to initiate or complete our clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to produce and provide suitable raw materials for pelareorep production, packaging, and testing as well as clinical trial-related testing. We and our third-party partners may encounter difficulties with sourcing these materials that could delay or impair our ability to manufacture pelareorep or complete product or clinical sample testing;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to monitor, support, conduct, and oversee clinical trials of the products that we are developing and, in some cases, to maintain regulatory files for those product candidates. We may not be able to obtain regulatory approval for our products that may result from our development efforts if we are not able to maintain or secure agreements with such third parties on acceptable terms, if these third parties do not perform their services as required, or if these third parties fail to timely transfer any regulatory information held by them to us;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our license, development, supply, and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees, independent contractors, principal investigators, contract research organizations, consultants, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations could be adversely affected by events outside of our control, such as natural disasters, wars, or health epidemics;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The cost of director and officer liability insurance may increase substantially and may affect our ability to retain quality directors and officers;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on our key employees and collaborators;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is likely a "passive foreign investment company" which may have adverse U.S. federal income tax consequences for U.S. shareholders;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a non-accelerated filer, we are not required to comply with auditor attestation requirements of the Sarbanes-Oxley Act;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential dilution of present and prospective shareholdings; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations may be adversely affected by disruptions to our information technology ("IT") systems, including disruptions from cybersecurity breaches of our IT infrastructure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_16"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_19"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_22"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. KEY INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">[RESERVED] </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Capitalization and Indebtedness</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Reasons for the Offer and Use of Proceeds</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Risk Factors</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in our common shares ("Common Shares") involves a high degree of risk. You should carefully consider, among other matters, the following risk factors in addition to the other information in this annual report on Form 20-F when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the material risks described below or in subsequent reports we file with the SEC actually occur, they may materially harm our business, financial condition, operating results, or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results, or cash flow.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, pelareorep, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals and early-stage human clinical trials, whether pelareorep will prove to be safe and effective in humans. Pelareorep will require additional research and development, including extensive additional clinical testing, before we will be able to obtain the approvals of the relevant regulatory authorities in applicable countries to market pelareorep commercially. There can be no assurance that the research and development programs we conduct will result in pelareorep or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve profitable operations we, alone or with others, must successfully develop, introduce and market our products. To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy. Unsatisfactory results obtained from a particular study relating to a program may cause us to abandon our commitment to that program or the product being tested. No assurances can be provided that any current or future animal or human test, if undertaken, will yield favorable results. If we are unable to establish that pelareorep is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are inherent risks in pharmaceutical research and development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk. The marketability of any product we develop will be affected by numerous factors beyond our control, including but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preliminary results as seen in animal and/or limited human testing may not be substantiated in larger, controlled clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing costs or other production factors may make manufacturing of products ineffective, impractical, and non-competitive;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proprietary rights of third parties or competing products or technologies may preclude commercialization;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requisite regulatory approvals for the commercial distribution of products may not be obtained; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors may become apparent during the course of research, up-scaling, or manufacturing which may result in the discontinuation of research and other critical projects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products under development have never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable. Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges or others that may arise in the course of development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any failure or delay in clinical trials for our products, including pelareorep, may cause us to incur additional costs or delay or prevent the commercialization of our products and could severely harm our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must conduct extensive clinical trials to demonstrate the safety and efficacy of our products in humans. Clinical testing, in particular, is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to the outcome.&#160;A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process, which could delay or prevent us from receiving marketing approval or commercializing our product candidates, including the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may produce negative or inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials, or we may abandon projects that we expect to be promising;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of subjects required for our clinical trials may be larger than we anticipate, enrollment in our clinical trials may be slower than we anticipate, or participants may drop out of our clinical trials at a higher rate than we anticipate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We might have to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulators or institutional review boards may require that we hold, suspend, or terminate clinical research for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulators may refuse to accept or consider data from clinical trials for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to governmental or regulatory delays and changes in regulatory requirements, policy, and guidelines, including guidelines specifically addressing requirements for the development of treatments for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We might have difficulty adding new clinical trial sites on a timely basis, or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The cost of our clinical trials may be greater than we anticipate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The supply, storage, distribution, or quality of our products or other materials necessary to conduct our clinical trials may be insufficient or inadequate</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject enrollment, which is a significant factor in the timing of clinical trials, is affected by a variety of factors, including the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The size and nature of the subject population;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The proximity of subjects to clinical sites;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The eligibility criteria for the trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The design of the clinical trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competing clinical trials; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinicians&#8217; and subjects&#8217; perceptions as to the potential advantages of the medication being studied in relation to other available therapies, including any new medications that may be approved for the indications we are investigating.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we plan to rely on clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Any delays, concerns over the quality of the clinical data, or unanticipated problems during clinical testing, such as enrollment in our clinical trials being slower than we anticipate or participants dropping out of our clinical trials at a higher rate than we anticipate, could increase our costs, slow down our product development and approval process, and jeopardize our ability to commence product sales and generate revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the federal Right to Try Act, among other things, provides a federal framework for patients to access certain investigational new drug products that have completed a Phase 1 clinical trial. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. While there is no obligation to make product candidates available to eligible patients as a result of the Right to Try Act, new and emerging legislation regarding expanded access to unapproved drugs could negatively impact enrollment in our clinical trials and our business in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our candidate product, pelareorep, is being and will continue to be used in combination with third-party drugs. Those currently being partnered with pelareorep are approved; however, we have limited or no control over the supply of these drugs. If our relationships with current or future collaborators or suppliers are not successful, we may be delayed in completing the development of our product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In several of our current and planned studies, pelareorep is being or will be administered in combination with immune checkpoint inhibitors ("ICIs"), a class of drugs intended to stop tumor cells from interfering with the ability of the patient&#8217;s immune system to attack their tumor. We have entered into agreements with Pfizer and Roche to supply their ICIs, avelumab and atezolizumab, respectively, for use in our ongoing Oncolytics-sponsored studies. Specifically, avelumab is being used in our ongoing Phase 2 study in breast cancer (BRACELET study), and atezolizumab was used in our window-of-opportunity study in breast cancer (AWARE study) and is being used in our ongoing Phase 1/2 study in gastrointestinal cancer (GOBLET study). In addition, other ICIs that are being used or have been used in combination with pelareorep in investigator-sponsored studies include retifanlimab (Incyte) in a Phase 2 study in breast cancer (IRENE study) and nivolumab (BMS) in a Phase 1 study in myeloma. Additionally, we may enter into future agreements for the supply of ICIs for use in connection with the development of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop pelareorep for use in combination with ICIs depends on our ability to access ICIs for use in our clinical trials on commercially reasonable terms. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs on commercially reasonable terms or at all. Any failure to maintain or enter into new successful commercial relationships or the expense of purchasing checkpoint blockade therapies in the market may delay our development timelines, increase our costs, and jeopardize our ability to develop pelareorep as a commercially viable therapy. If any of these occur, our business, financial condition, results of operations, stock price, and prospects may be materially harmed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any current or any future collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing appropriate ICIs. Additionally, should the supply of products from any current or future collaborator or supplier be interrupted, delayed, or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source a supply of an alternative appropriate ICI or are unable to do so on commercially reasonable terms, our business, financial condition, results of operations, stock price, and prospects may be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the development of pelareorep for use in combination with ICIs may present challenges that are not faced for single agent product candidates. Developments related to the other product may impact our clinical trials as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the other product's safety or efficacy profile, changes to the availability of the approved product, and changes to the standard of care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our business, financial condition, results of operations, and prospects may be materially adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, we make estimates regarding the incidence and prevalence of target patient populations for particular diseases based on various third-party sources and internally generated analysis and use such estimates in making decisions regarding our product development strategy, including determining indications on which to focus in preclinical or clinical trials.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity will depend on, among other things, the acceptance of such data by the medical community and patient access, product pricing and reimbursement, any limitations on populations and indications in approved product labeling, as well as the approval of new or competing medicines. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which could materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, including our research and development operations, has been and may continue to be adversely affected by a variety of external factors outside our control, including the COVID-19 pandemic and conflict in Ukraine.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, a variety of external factors, including the ongoing coronavirus infectious disease 2019 (COVID-19) pandemic and the global political conflict in Ukraine, have touched elements of our business operations. COVID-19, including its variants, has created challenges affecting our clinical trial activities, including delayed patient enrollment related to our BRACELET-1 study and contributed to the disruption of our manufacturing supply chain, while the conflict in Ukraine has increased market volatility and uncertainty. Some challenges included, among other things, patients choosing to delay treatments, clinical sites suspending study activity temporarily, vendor and collaborator staff shortages, and raw material and components delays. While these challenges have largely impacted the timing of certain activities, we believe the impact on our overall business to date has not been significant. As well, we believe our financial condition, liquidity, and longer-term strategic development remain on track. However, these events have caused and may continue to cause significant fluctuations in stock markets, global economic activity, including inflation and rising interest rates, and healthcare systems. The scale and duration of these developments remain uncertain and could affect our ability to finance and execute our operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these external factors worsens or continues for a prolonged period of time, particularly in regions where we or our collaborators and suppliers do business, we could experience disruptions that could significantly impact our current and planned clinical trials, preclinical research, and other business activities, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption to and delays in preclinical research or product manufacturing or testing activities due to an extended closure or reduced capacity of lab facilities; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays or difficulties in enrolling patients in our ongoing and planned clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients discontinuing their treatment or follow-up visits; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions in supply, logistics, or other activities related to the procurement of materials, which could have a negative impact on our ability to conduct preclinical research, product manufacturing or testing, and initiate or complete our clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving approvals from regulatory authorities to initiate our planned clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted and incur unexpected costs, or require us to discontinue clinical trials altogether; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with regulators (including the FDA), ethics committees, and other important agencies and contractors due to limitations in employee resources or furlough of government or contractor personnel; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to the global financial markets and increased market volatility may continue to negatively affect our ability to secure and drastically increase the costs of products and supplies, and reduce our ability to access capital, which could in the future negatively affect our liquidity and the value of common shares. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events might prolong and/or cause significant disruptions to our business and materially impact our results of operations, including our ongoing and planned clinical studies and manufacturing activities, will depend on future developments. These future developments are highly uncertain, cannot be predicted, and could negatively impact our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidate may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any potential marketing approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, pelareorep is generally well-tolerated and has a manageable side effect profile for most patients. However, there can be no assurance that additional undesirable side effects or serious adverse events will not be caused by or associated with pelareorep as it continues through its clinical development, including when co-administered with approved products. As with many pharmaceutical and biological products, treatment with our product candidate may produce undesirable side effects or adverse reactions or events, including potential adverse side effects related to cytokine release, and may exacerbate known adverse events associated with co-administered approved products. If our product candidates or similar products or product candidate under development by third parties demonstrate unacceptable adverse events, or unacceptably exacerbate adverse events associated with co-administered approved products, we may be required to halt or delay further clinical development of our product candidate. The FDA, the EMA, or other foreign regulatory authorities could order us to cease further development of or deny approval of our product candidate for any or all targeted indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately or timely recognized or managed by the treating medical staff, particularly outside of the institutions that collaborate with us, as toxicities resulting from our novel technologies may not be normally encountered in the general patient population and by medical personnel. We expect to have to train medical personnel using our product candidate to understand its side effect profiles, both for our planned clinical trials and upon any commercialization. Inadequate training in recognizing or managing the potential side effects of our product candidate could result in adverse effects to patients, including death.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if our product candidate receives marketing approval, and we or others later identify undesirable side effects caused or exacerbated by such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our product, a number of potentially significant negative consequences could result, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a risk evaluation and mitigation strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputations may suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. Furthermore, any of these occurrences may harm our business, financial condition, and prospects significantly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and therapeutic platforms that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and therapeutic platforms for specific indications may not yield any commercially viable products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition Risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no operating revenues and a history of losses. We have no products approved for commercial sale, and we may never achieve or sustain profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit. As of December&#160;31, 2022, we had an accumulated deficit of $418.3 million and we incurred net losses of $24.8 million, $26.3 million, and $22.5 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. We anticipate that we will continue to incur significant losses during 2023 and in the foreseeable future. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. We do not expect to reach profitability at least until after the successful and profitable commercialization of one or more of our products. Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash, cash equivalents, and marketable securities of $32.1 million. We anticipate that we will need additional financing in the future to fund research and development and to meet our ongoing capital requirements.&#160;The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our preclinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting, and enforcing our patent claims, and costs associated with obtaining regulatory approvals.&#160;In order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics, from time to time, along with all other pharmaceutical research and development entities, may have restricted access to capital, bank debt, and equity, and, from time to time, may face increased borrowing costs. Although our business and asset base have not changed, the lending capacity of all financial institutions fluctuates causing a corresponding change in risk premiums. As future operations will be financed out of funds generated from financing activities, our ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the pharmaceutical industry and our securities in particular.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should we elect to satisfy our cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that our efforts to raise such funding will be successful, or achieved on terms favorable to us or our existing shareholders.&#160;If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production, and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product. There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur some of our expenses in foreign currencies and therefore, we are exposed to foreign currency exchange rate fluctuations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur some of our research and development and general and administrative expenses in foreign currencies, primarily the U.S. dollar.&#160;We are therefore exposed to foreign currency rate fluctuations.&#160;Also, as we expand to other foreign jurisdictions, there may be an increase in our foreign exchange exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party credit risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of our business, we have entered into contractual arrangements with third parties which subject us to the risk that such parties may default on their obligations. Oncolytics may be exposed to third-party credit risk through our contractual arrangements with our current contract manufacturer, the institutions which operate our clinical trials, or our contract research organizations and other parties.&#160;In the event such entities fail to meet their contractual obligations to Oncolytics, such failures could have a material adverse effect on Oncolytics and our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain third-party reimbursement for the cost of our product. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Uncertainty exists regarding the reimbursement status of newly-approved pharmaceutical products and reimbursement may not be available for pelareorep.&#160;&#160;Any reimbursements granted may not be maintained or limits on reimbursements available from third-party payors may reduce the demand for, or negatively affect the price of, these products. If pelareorep does not qualify for reimbursement, if reimbursement levels diminish, or if reimbursement is denied, our sales and profitability would be adversely affected.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical products are subject to intense regulatory approval processes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory process for pharmaceuticals, which includes preclinical studies and multiple phases of clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed. Failure to comply with applicable regulatory requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution. Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products. In addition, a marketed drug and its manufacturer are subject to continual review. Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Food and Drug Administration (&#8220;FDA&#8221;) and similar regulatory authorities in other countries may deny approval of a new drug application if required regulatory criteria are not satisfied, or may require additional testing. Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA and similar regulatory authorities in other countries may require further testing and surveillance programs to monitor the pharmaceutical product that has been commercialized. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions, and criminal prosecutions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in our customers&#8217; drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and possibly other regulatory authorities in other jurisdictions.&#160;Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly, and time consuming. We cannot predict how long the necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to the approval of the facility to manufacture a specific drug, our manufacturing facilities may never become approved of, or there can be considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical regulatory regime in Europe and other countries is generally similar to that of the United States. We could face similar risks in these other jurisdictions as the risks described above.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations and products may be subject to other government manufacturing and testing regulations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing. Approval to market products may be for limited applications or may not be received at all.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we anticipate manufacturing will have to comply with the FDA&#8217;s current Good Manufacturing Practices (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cGMP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines. Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend time, money, and effort in production, and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the cGMP requirements, the facilities may become subject to possible FDA or other regulatory action and manufacturing at the facility could consequently be suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions: (i) restrict the release of the product; (ii) suspend manufacturing of the specific lot of the product; (iii) order a recall of the lot of the product; or (iv) order a seizure of the lot of the product.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to regulation by governments in many jurisdictions.&#160;If we do not comply with healthcare, drug, manufacturing, and environmental regulations, among others, in such jurisdiction, our existing and future operations may be curtailed, and we could be subject to liability.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal, and foreign law, including, but not limited to, requirements regarding occupational health, safety, laboratory practices, healthcare fraud and abuse, environmental protection, and hazardous substance control, and may be subject to other present and future local, provincial, state, federal, and foreign regulations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have conducted, and may in the future conduct, clinical trials for pelareorep in sites outside the United States and the FDA may not accept data from trials conducted in such locations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted, and may in the future choose to conduct, clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deem clinically meaningful. Generally, the patient population for any clinical trials conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside the United States. If the FDA does not accept the data from any clinical trials we may conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt our development of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on patents and proprietary rights to protect our technology.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing the rights of third parties. We have received Granted Patents in countries throughout the world, including the United States, Canada, Europe, and Japan.&#160;We file our Applications for Patent in the United States and under the PCT, allowing us to subsequently file in other jurisdictions.&#160;Our success will depend, in part, on our ability to obtain, enforce and maintain patent protection for our technology in Canada, the United States and other countries. We cannot be assured that patents will issue from any pending applications or that claims now or in the future, if any, allowed under issued patents will be sufficiently broad to protect our technology. In addition, no assurance can be given that any patents issued to, or licensed by us, will not be challenged, invalidated, infringed, or circumvented, or that the rights granted thereunder will provide continuing competitive advantages to us.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. In addition, it is not known whether any of our current research endeavors will result in the issuance of patents in Canada, the United States, or elsewhere, or if any patents already issued will provide significant proprietary protection or will be circumvented or invalidated. Since patent applications in the United States and Canada may be maintained in secrecy until at least 18 months after filing of the original priority application, and since publication of discoveries in the scientific or patent literature tends to lag behind actual discoveries by several months, we cannot be certain that we or any licensor were the first to create inventions claimed by pending patent applications or that we or the licensor were the first to file patent applications for such inventions. Loss of patent protection could lead to generic competition for these products, and others in the future, which would materially and adversely affect our financial prospects for these products.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, since patent applications filed before November 29, 2000 in the United States may be maintained in secrecy until the patents issue or foreign counterparts, if any, publish, we cannot be certain that we or any licensor were the first creator of inventions covered by pending patent applications or that we or such licensor were the first to file patent applications for such inventions. There is no assurance that our patents, if issued, would be held valid or enforceable by a court or that a competitor&#8217;s technology or product would be found to infringe such patents.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we may not be able to obtain and enforce effective patents to protect our proprietary rights from use by competitors.&#160;If other such parties obtain patents for certain information relied on by us in conducting our business, then we may be required to stop using, or pay to use, certain intellectual property, and as such, our competitive position and profitability could suffer as a result.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations would be costly, time-consuming, distracting to management, and could materially affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be claimed to infringe patents and other intellectual property rights of third parties under which we do not hold sufficient licenses or other rights. Additionally, third parties may be successful in obtaining patent protection for technologies that cover development activities in which we are already engaged. Third parties may own or control these patents and intellectual property rights in the United States and abroad. These third parties may have substantially greater financial resources than us and could bring claims against us that could cause us to incur substantial expenses to defend against these claims and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement or other similar suit were brought against us, we could be forced to stop or delay development, manufacturing, or sales of the product or product candidate that is the subject of the suit. Intellectual property litigation in the biopharmaceutical industry is common, and we expect this trend to continue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of patent infringement or other similar claims, or to avoid potential claims, we may choose or be required to seek a license from the third party and be required to pay license fees or royalties, or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, if at all, or if an injunction is granted against us, which could harm our business significantly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">know-how, the value of our technology and products could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patented technology, we rely upon unpatented proprietary technology, processes, and know-how. However, these types of trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants, and third parties, as well as confidentiality policies and audits, although these may not be successful in protecting our trade secrets and confidential information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known, including through a potential cybersecurity breach, or may be independently developed by competitors. If we are unable to protect the confidentiality of our proprietary information and know-how, competitors may be able to use this information to develop products that compete with our products, which could adversely impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to research and develop and to manufacture pelareorep, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, consulting agreements or other similar agreements with our advisors, employees, third-party contractors, and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increase the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. Moreover, enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. These lawsuits also may impact our ability to pursue agreements with third parties in the future.</span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Developments in patent law could have a negative impact on our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, authorities in the United States, the European Union, and other government authorities may change the standards of patentability, and any such changes could have a negative impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in the United States, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a "first-to-invent" system to a "first-to-file" system, changes to the way issued patents are challenged, and changes to the way patent applications are disputed during the examination process. As a result of these changes, patent law in the United States may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. The USPTO has developed new and untested regulations and procedures to govern the full implementation of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions became effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them. Also, case law may have a substantial impact on the way patents are prosecuted, examined and litigated. This also affects the scope of protection that is available in a specific jurisdiction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments of patent law in other jurisdictions may impact our business. For example, it is currently not clear what impact the planned introduction of the Unified Patent Court in the European Union will have. Patents that are valid and enforceable under the current system may be considered invalid and/or unenforceable under the new system. Also, patents may be invalidated not just in one single jurisdiction, but across multiple countries of the European Union in one single trial. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration, and conditions of FDA marketing approval of pelareorep, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for pelareorep will be shortened. If this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our business. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make compounds or formulations that are similar to pelareorep but that are not covered by the claims of any patents, should they issue, that we own or control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending patent applications will not lead to issued patents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we own or control may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Business Risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The biotechnology industry is extremely competitive and if our competitors develop and market products that are more effective, safer, or less expensive than our products, our business could be adversely impacted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technological competition in the pharmaceutical industry is intense and we expect competition to increase. Other companies are conducting research on therapeutics involving innate and adaptive immune responses as well as other novel treatments or therapeutics for the treatment of cancer which may compete with our product. Many of these competitors are more established, benefit from greater name recognition, and have substantially greater financial, manufacturing, technical, marketing, drug development, and human resources than us. In addition, many of these competitors have significantly greater experience in undertaking research, preclinical studies, and human clinical trials of new pharmaceutical products, obtaining regulatory approvals, manufacturing, and marketing such products. In addition, there are several other companies and products with which we may compete from time to time, and which may have significantly better and larger resources than we do. Accordingly, our competitors may succeed in manufacturing and/or commercializing products more rapidly or effectively, which could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive, or not economical.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will face increased competition in the future as new products enter the market and advanced technologies become available. There can be no assurance that existing products or new products developed by our competitors will not be more effective, or be more effectively manufactured, marketed, and sold, than any that may be developed or sold by us. Competitive products may render our products obsolete and uncompetitive prior to recovering research, development, or commercialization expenses incurred with respect to any such products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may fail or cause harm, subjecting us to product liability claims.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use of our product during current clinical trials may entail risk of product liability. We maintain clinical trial liability insurance; however, it is possible this coverage may not provide full protection against all risks.&#160;Given the scope and complexity of the clinical development process, the uncertainty of product liability litigation, and the shrinking capacity of insurance underwriters, it is not possible at this time to assess the adequacy of current clinical trial coverage, nor the ability to secure continuing coverage at the same level and at reasonable cost in the foreseeable future.&#160;While we carry, and intend to continue carrying amounts believed to be appropriate under the circumstances, it is not possible at this time to determine the adequacy of such coverage.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the sale and commercial use of our product entails risk of product liability. We currently do not carry any product liability insurance for this purpose. There can be no assurance that we will be able to obtain appropriate levels of product liability insurance prior to any sale of our pharmaceutical products. An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us. The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition, and future prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future legal proceedings and the impact of any finding of liability or damages could adversely impact the company and its financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be named as a defendant in various legal actions or other proceedings, including class action lawsuits. Certain of these actions include, and future actual or threatened legal actions may include, claims for substantial and indeterminate amounts of damages, or may result in other results adverse to us. Management does not currently know of any pending, material legal proceedings against the Company, but such legal action could be brought in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of possible future legal proceedings cannot be predicted with certainty. Accordingly, we cannot determine whether our insurance coverage would be sufficient to cover the costs or potential losses, if any. Regardless of merit, litigation may be both time-consuming and disruptive to our operations and cause significant expense and diversion of management attention. If we do not prevail in future legal proceedings, we may be faced with significant monetary damages or injunctive relief against us that may adversely affect our business, financial condition, and results of operations, possibly materially.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New products may not be accepted by the medical community or consumers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary activity to date has been research and development and we have no experience in marketing or commercializing products. We will likely partner with or rely on third parties to market our products, assuming that they receive regulatory approvals. If we partner with or rely on third parties to market our products, the commercial success of such product will be subject to a number of risks that may be outside of our control, including:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition in relation to alternative treatments, including efficacy advantages and cost advantages;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived ease of use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage or reimbursement by third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties regarding marketing and distribution support; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution or use restrictions imposed by regulatory authorities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there can be no assurance that physicians, patients, or the medical community will accept our product, even if it proves to be safe and effective and is approved for marketing by the FDA, Health Canada, and other regulatory authorities. A failure to successfully market our product would have a material adverse effect on our revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, pelareorep may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our technologies may become obsolete.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards, and frequent introduction of new products. The introduction of new products embodying new technologies, including new manufacturing processes, and the emergence of new industry standards may render our products obsolete, less competitive, or less marketable. The process of developing our products is extremely complex and requires significant continuing development </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efforts, and third-party commitments. Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using our new technologies or exploiting our niche markets effectively, or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of pelareorep manufacturing or formulation may result in additional costs or delay. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As pelareorep is developed through preclinical to late-stage clinical trials toward approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives or be acceptable to the FDA or similar regulatory authorities in other countries. Any of these changes could cause pelareorep to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay the completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability, or our strategic partners&#8217; ability, to commence product sales and generate revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party manufacturers to produce our clinical products and on other third parties to test, package, store, monitor, and transport bulk drug substance and drug product. We and our third-party partners may encounter difficulties with respect to these activities that could delay or impair our ability to initiate or complete our clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own or operate any manufacturing facilities. We rely on a contract manufacturer to source suitable raw materials and produce sufficient quantities of pelareorep for preclinical testing and clinical trials, in compliance with applicable regulatory and quality standards. If we are unable to arrange for such third-party manufacturing sources or materials are not available in a timely manner, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of pelareorep or we may be delayed in doing so. The manufacture of biopharmaceutical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. The process of manufacturing pelareorep is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the third-party manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any failure by our third-party manufacturers to comply with applicable regulatory and quality standards or any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have relied upon a contract manufacturer to manufacture small quantities of pelareorep. The manufacturer may encounter difficulties in scaling up production, including production yields, quality control, and quality assurance. Only a limited number of manufacturers can supply therapeutic viruses and failure by the manufacturer to deliver the required quantities of pelareorep on a timely basis at a commercially reasonable price may have a material adverse effect on us. We have completed a program for the development of a commercial process for manufacturing pelareorep and have filed a number of patent applications related to the process. There can be no assurance that we will successfully obtain sufficient patent protection related to our manufacturing process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to third-party manufacturers, we rely on other third parties to test, package, store, monitor, and transport bulk drug substance and drug product. If we are unable to arrange for such third-party sources, or fail to do so on commercially reasonable terms, we may not be able to successfully supply sufficient product candidate or we may be delayed in doing so. Such failure or substantial delay could materially harm our business.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to produce and provide suitable raw materials for pelareorep production, packaging, and testing as well as clinical trial-related testing. We and our third-party partners may encounter difficulties with sourcing these materials that could delay or impair our ability to manufacture pelareorep or complete product or clinical sample testing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on contract manufacture and testing facilities to source required materials for production and evaluation of pelareorep, as well as testing of clinical trial-related samples. As a result, we have less control over the supply timing and cost of these materials than if we sourced these materials directly. In addition, these are often specialized materials and third-party suppliers may also encounter challenges in producing, testing, or distributing materials that can impact delivery quantities and timeframes. If we are unable to arrange for sufficient supply or materials are not available in a timely manner, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of pelareorep or we may be delayed in doing so. If we are unable to arrange for appropriate testing materials or they are not available in a timely manner, we may be unable to execute some clinical trial testing or we may be delayed in doing so.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to monitor, support, conduct, and oversee clinical trials of the products that we are developing and, in some cases, to maintain regulatory files for those product candidates. We may not be able to obtain regulatory approval for our products that may result from our development efforts if we are not able to maintain or secure agreements with such third parties on acceptable terms, if these third parties do not perform their services as required, or if these third parties fail to timely transfer any regulatory information held by them to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on entities outside of our control, which may include clinical and research consultants, academic institutions, and contract research organizations ("CROs"), to perform, monitor, support, conduct, and oversee preclinical studies and clinical trials of pelareorep. As a result, we have less control over the timing and cost of these studies and the ability to recruit trial subjects than if we conducted these trials with our own personnel.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain or enter into agreements with these third parties on acceptable terms, or if any such engagement is terminated prematurely, we may be unable to enroll patients on a timely basis or otherwise conduct our trials in the manner we anticipate. In addition, there is no guarantee that these third parties will devote adequate time and resources to our studies or perform as required by our contract or in accordance with regulatory requirements, including maintenance of clinical trial information regarding our products. If these third parties fail to meet expected deadlines, fail to transfer to us any regulatory information in a timely manner, fail to adhere to protocols, or fail to act in accordance with regulatory requirements or our agreements with them, or if they otherwise perform in a substandard manner or in a way that compromises the quality or accuracy of their activities or the data they obtain, then clinical trials of our product candidates may be extended or delayed with additional costs incurred, or our data may be rejected by the FDA, EMA or other regulatory agencies. Ultimately, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our CROs fail to comply with applicable regulatory regulations, the clinical data generated in our clinical trials may be deemed unreliable, and our submission of marketing applications may be delayed, or we may be required to perform additional clinical trials before approving our marketing applications. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and increase our costs. Moreover, our business may be implicated if any of our CROs violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our clinical trial sites terminate for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. Further, if our relationship with any of our CROs is terminated, we may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our license, development, supply, and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2017, we announced that we had entered into a license, development, supply, and distribution agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan (the &#8220;Territories&#8221;). Pursuant to the Licensing Agreement, along with payments to be received by us upon meeting certain requirements and milestones, we are also eligible to receive royalty payments in excess of 10% associated with the commercialization of pelareorep for all indications, subject to regulatory approval. Under the terms of the Licensing Agreement, Adlai will be responsible for all clinical, regulatory, and commercialization activities respecting pelareorep in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Territories and therefore the Company will be dependent upon Adlai in successfully undertaking those actions in a timely and economic manner and in compliance with all applicable legal and regulatory requirements within the Territories. If Adlai is unable to fulfill its obligations under the terms of the Licensing Agreement and in compliance with all applicable legal and regulatory requirements, including clinical, regulatory and commercialization of pelareorep, our prospective revenue from royalty payments related to the commercialization of pelareorep in the Territories may be materially diminished, delayed or never realized, which could negatively affect our operating results and financial condition.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting business with Adlai within the Territories, and specifically China, subjects us to certain economic, political, currency, and legal risks, and uncertainties regarding, among other things, the development and commercialization of pelareorep and the release and receipt of payments under the terms of the Licensing Agreement, including the payment of royalties upon commercialization of pelareorep. These risks include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different standards of care in various countries that could complicate the evaluation of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different U.S. and foreign drug import and export rules;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in certain countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, and regulatory requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the FCPA, and other anti-corruption and anti-bribery laws;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. and foreign taxes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reliance on CROs, clinical trial sites, principal investigators, and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability resulting from development work conducted by foreign distributors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The governments of the Territories, and specifically the Chinese government, exercise significant control over all aspects of their respective economies.&#160;Accordingly, any adverse change in the economy, the legal system, or governmental, economic or other policies could have a material adverse effect on the business prospects of the Licensing Agreement with Adlai, including our ability to receive money out of China under the terms of the Licensing Agreement. Any disruption in relations, inability to work efficiently, or disadvantageous treatment of Adlai by the governments of the Territories or other authorities could have a material adverse effect on our business prospects under the Licensing Agreement. Additionally, the regulatory environment in the Territories is evolving, and officials in the governments in the Territories exercise broad discretion in deciding how to interpret and apply regulations. There can be no assurance that Adlai will be successful in the development and commercialization of pelareorep in the Territories.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative developments in the field of immuno-oncology could damage public perception of pelareorep and negatively affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of pelareorep depends in part on public acceptance of the use of cancer immunotherapies including ICIs. Adverse events in clinical trials of pelareorep or in clinical trials of similar products and the resulting publicity, as well as any other negative developments in the field of immuno-oncology that may occur in the future including in connection with competitor therapies, could result in decreased acceptance of and demand for pelareorep. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to pelareorep or to competitors&#8217; products, pelareorep may not be accepted by the general public or the medical community, and potential clinical trial participants may be discouraged from enrolling in our trials. As a result, we may not be able to continue or may be delayed in conducting our development programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep is an oncolytic virus and, as such, adverse developments related to vaccines for viral diseases or in clinical trials of other virus-based oncolytic immunotherapy products may result in a disproportionately negative effect on the perception of pelareorep compared to other products in the field of immuno-oncology that are not based on viruses. Future negative developments in the field of immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements, and potential regulatory delays in the testing or approval of pelareorep. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for pelareorep.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, contract research organizations, consultants, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (1) FDA regulations, including those laws that require the reporting of true, complete, and accurate information to the FDA, (2) manufacturing standards, (3) federal and state healthcare fraud and abuse laws and regulations, or (4) laws that require the reporting of true and accurate financial information and data. Specifically, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and if we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from collaborators, prospective licensees, and other third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. We may also be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patents or other intellectual property. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our drug candidates. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management and employees.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations could be adversely affected by events outside of our control, such as natural disasters, wars&#160;or health epidemics.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19, geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods, and fires. An outbreak of infectious disease, a pandemic or a similar public health threat, such as the COVID-19 pandemic, or a fear of any of the foregoing, could adversely impact us by causing operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how we may be affected if such an epidemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results, and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The cost of director and officer liability insurance may increase substantially and may affect our ability to retain quality directors and officers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry liability insurance on behalf of our directors and officers. Given a number of large director and officer liability insurance claims in the U.S. equity markets, director and officer liability insurance has become increasingly more expensive with increased restrictions. Consequently, there is no assurance that we will continue to be offered this insurance or be able to obtain adequate coverage. The inability to acquire the appropriate insurance coverage may limit our ability to attract and maintain directors and officers as required to conduct our business.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our key employees and collaborators.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop the product will depend, to a great extent, on our ability to attract and retain highly qualified scientific personnel and to develop and maintain relationships with leading research institutions. Intense competition for attracting key skill-sets may limit our ability to retain and motivate key personnel on acceptable terms. We are highly dependent on the principal members of our management staff as well as our advisors and collaborators, the loss of whose services might impede the achievement of development objectives. The persons working with us are affected by a number of influences outside of our control. In the U.S., the SEC recently proposed mandatory clawback rules which would require listed companies to adopt a clawback policy providing for recovery of incentive-based compensation awarded to executive officers if we are required to prepare an accounting restatement resulting from material noncompliance with financial reporting requirements. There is the potential that new compensation rules will make it more difficult for us to attract and retain executive officers. The loss of key employees and/or key collaborators may affect the speed and success of product development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Barbados law differs from the laws in effect in Canada and the United States and may afford less protection to holders of our securities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our assets and intellectual property are held by our wholly-owned subsidiary, Oncolytics Biotech (Barbados) Inc., which is organized under the laws of Barbados. It may not be possible to enforce court judgments obtained in Canada or the United States against Oncolytics Biotech (Barbados) Inc. in Barbados based on the civil liabilities provisions of applicable securities laws. In addition, there is some doubt as to whether the courts of Barbados would recognize or enforce judgments of courts in Canada or the United States obtained against us or our directors or officers based on the civil liabilities provisions of Canadian and United States securities laws or hear actions against us or those persons based on such laws.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to complex laws and regulations that address privacy and data security. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. In the U.S., numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. For example, the State of California enacted the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;), which came into effect on January 1, 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Similar laws have been proposed in Virginia, Colorado, Connecticut and Utah and at the federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the course of our business, we may obtain health information from third party that is subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;). Although we are not directly subject to HIPAA (other than potentially with respect to providing certain employee benefits) we could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA/HITECH.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be negatively impacted by existing and proposed laws and regulations, as well as government policies and practices related to cybersecurity, data privacy, data localization, and data protection outside of the U.S., such as the General Data Protection Regulation (&#8220;GDPR&#8221;), which took effect in the EU in May 2018. The GDPR extends the geographical scope of EU data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles, and creates new obligations for companies and new rights for individuals. The GDPR may increase our responsibility and potential liability in relation to personal data that we process, expose us to substantial potential fines, and increase our compliance costs.&#160;The GDPR could also cause our development costs to increase in connection with clinical trials we are currently conducting and may conduct in the future in the EU for our products and product candidates. Further, recent legal developments in Europe have created complexity and uncertainty regarding transfers of personal data from the EU to the United States. As well, from January 1, 2021, the GDPR and the United Kingdom (&#8220;UK&#8221;) GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The relationship between the United Kingdom and the EU in relation to certain aspects of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with data protection laws and regulations both within and outside of the U.S. could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company may fail to achieve and maintain adequate internal control over financial reporting pursuant to the requirements of the Sarbanes-Oxley Act and equivalent Canadian legislation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documented and tested during its most recent fiscal year its internal control procedures in order to satisfy the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;) and equivalent Canadian legislation. SOX requires an annual assessment by management of the effectiveness of the Company&#8217;s internal control over financial reporting and an attestation report by the Company&#8217;s independent auditors addressing this assessment, if applicable. The Company may fail to achieve and maintain the adequacy of its internal control over financial reporting as such standards are modified, supplemented, or amended from time to time, and the Company may not be able to ensure that it can conclude, on an ongoing basis, that it has effective internal control over financial reporting in accordance with Section&#160;404 of SOX. The Company&#8217;s failure to satisfy the requirements of Section&#160;404 of SOX on an ongoing, timely basis could result in the loss of investor confidence in the reliability of its financial statements, which in turn could harm the Company&#8217;s business and negatively impact the trading price of the common shares or the market value of its other securities. In addition, any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company&#8217;s operating results or cause it to fail to meet its reporting obligations. Future acquisitions of companies, if any, may provide the Company with challenges in implementing the required processes, procedures, and controls in its acquired operations. No evaluation can provide complete assurance that the Company&#8217;s internal control over financial reporting will detect or uncover all failures of persons within the Company to disclose material information otherwise required to be reported. The effectiveness of the Company&#8217;s processes, procedures, and controls could also be limited by simple errors or faulty judgments. In addition, if the Company expands, the challenges involved in implementing appropriate internal control over financial reporting will increase and will require that the Company continue to improve its internal control over financial reporting.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because the Company is a Canadian Company and some of its directors and officers are residents outside the United States, it may be difficult for investors in the United States to enforce civil liabilities against the Company based solely upon the federal securities laws of the United States.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a Canadian company, with its principal place of business in Canada. Some of the Company&#8217;s directors and officers, including the Company's Chief Executive Officer and Chief Financial Officer, are residents outside the United States and a significant portion of the Company&#8217;s assets are located outside the United States. Consequently, it may be difficult for U.S. investors to effect service of process within the United States upon the Company or these directors or officers who are not residents of the United States, or to realize in the United States upon judgments of courts of the United States predicated upon civil liabilities under the U.S. Securities Act of 1933, as amended. Investors should not assume that Canadian courts (1)&#160;would enforce judgments of U.S. courts obtained in actions against the Company or such directors or officers predicated upon the civil liability provisions of the U.S. federal securities laws or the securities or &#8220;blue sky&#8221; laws of any state within the United States or (2)&#160;would enforce, in original actions, liabilities against the Company or such directors or officers predicated upon the U.S. federal securities laws or any such state securities or &#8220;blue sky&#8221; laws. In addition, the protections afforded by Canadian securities laws may not be available to investors in the United States.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a foreign private issuer, our shareholders may have less complete and timely data.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a &#8220;foreign private issuer&#8221; as defined in Rule&#160;3b-4 under the United States Securities Exchange Act of 1934, as amended (the &#8220;U.S. Exchange Act&#8221;). Equity securities of the Company are accordingly exempt from Sections&#160;14(a), 14(b), 14(c), 14(f), and 16 of the U.S. Exchange Act pursuant to Rule&#160;3a12-3 of the U.S. Exchange Act. Therefore, the Company is not required to file a Schedule&#160;14A proxy statement in relation to its annual meeting of shareholders. The submission of proxy and annual meeting of&#160;shareholder information on Form 6-K may result in shareholders having less complete and timely information in connection with shareholder actions. The exemption from Section&#160;16 rules regarding reports of beneficial ownership and purchases and sales of common shares by insiders and restrictions on insider trading in our securities may result in shareholders having less data and there being fewer restrictions on insiders&#8217; activities in our securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we were to lose our foreign private issuer status under U.S. federal securities law, we would likely incur additional expenses associated with compliance with the U.S. securities law applicable to U.S. domestic issuers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, as discussed above under the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As a foreign private issuer, our shareholders may have less complete and timely data,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; we are exempt from certain provisions of the U.S. federal securities law. The determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50% of our common shares are directly or indirectly held by residents of the United States and we fail to meet additional requirements necessary to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors, and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance requirements under the Nasdaq listing rules. As a U.S. listed public company that is not a foreign private issuer, we will incur significant additional legal, accounting, and other expenses that we will not incur as a foreign private issuer, and accounting, reporting, and other expenses in order to maintain a listing on a U.S. securities exchange. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors and more expensive to procure director and officer liability insurance. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a non-accelerated filer, we are not required to comply with the auditor attestation requirements of the Sarbanes-Oxley Act.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a non-accelerated filer under the Exchange Act and we are not required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002. Therefore, our internal controls over financial reporting will not receive the level of review provided by the process relating to the auditor attestation included in annual reports of issuers that are subject to the auditor attestation requirements. In addition, we cannot predict if investors will find our common shares less attractive because we are not required to comply with the auditor attestation requirements. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and trading price for our common shares may be negatively affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company is likely a "passive foreign investment company" which may have adverse U.S. federal income tax consequences for U.S. shareholders.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. holders of Common Shares should be aware that the Company believes it was classified as a passive foreign investment company (&#8220;PFIC&#8221;) during the tax year ended December&#160;31, 2022, and based on current business plans and financial expectations, the Company expects that it will be a PFIC for the current tax year and may be a PFIC in future taxable years.&#160;If the Company is a PFIC for any year during a U.S. holder&#8217;s holding period of the Common Shares, then such U.S. shareholder generally will be required to treat any gain realized upon a disposition of Common Shares, or any &#8220;excess distribution&#8221; received on its Common Shares, as ordinary income, and to pay an interest charge on a portion of such gain or distribution, unless the shareholder makes a timely and effective qualified electing fund election (&#8220;QEF Election&#8221;) or a mark-to-market election with respect to the Common Shares.&#160;A U.S. holder who makes a QEF Election generally must report on a current basis its share of the Company's net capital gain and ordinary earnings for any year in which the Company is a PFIC, whether or not the Company distributes any amounts to its shareholders.&#160;However, U.S. holders should be aware that there can be no assurance that the Company will satisfy the record keeping requirements that apply to a qualified electing fund, or that the Company will supply U.S. holders with information that such U.S. holders require to report under the QEF Election rules, in the event that the Company is a PFIC and a U.S. holder wishes to make a QEF Election. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thus, U.S. holders may not be able to make a QEF Election with respect to their Common Shares. A U.S. holder who makes the mark-to-market election generally must include as ordinary income each year the excess of the fair market value of the Common Shares over the taxpayer&#8217;s adjusted tax basis therein.&#160;This paragraph is qualified in its entirety by the discussion below under the heading &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Material United States Federal Income Tax Considerations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;&#160;Each U.S. holder should consult its own tax advisors regarding the PFIC rules and the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our Common Shares </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Volatility of market price of the Common Shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of the Common Shares may be volatile. The volatility may affect the ability of holders of Common Shares to sell the Common Shares at an advantageous price. Market price fluctuations in the Common Shares may be due to the Company&#8217;s operating results failing to meet the expectations of securities analysts or investors in any quarter, downward </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revision in securities analysts&#8217; estimates, governmental regulatory action, adverse change in general market conditions or economic trends, acquisitions, dispositions or other material public announcements by the Company or its competitors, along with a variety of additional factors, including, without limitation, those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in this annual report on Form 20-F. In addition, the market price for securities in the stock markets, including the NASDAQ and the TSX, recently experienced significant price and trading fluctuations. These fluctuations have resulted in volatility in the market prices of securities that often has been unrelated or disproportionate to changes in operating performance. These broad market fluctuations may adversely affect the market price of the Common Shares</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential dilution of present and prospective shareholdings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to finance future operations and development efforts, the Company may raise funds through the issue of common shares or the issue of securities convertible into common shares. The Company cannot predict the size of future issues of common shares or the issue of securities convertible into common shares or the effect, if any, that future issues and sales of the Company&#8217;s common shares will have on the market price of its common shares. Any transaction involving the issue of previously authorized but unissued shares, or securities convertible into shares, would result in dilution, possibly substantial, to present and prospective holders of shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company does not intend to pay cash dividends in the foreseeable future.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not declared or paid any dividends since its incorporation. The Company intends to retain earnings, if any, to finance the growth and development of its business and does not intend to pay cash dividends on the Common Shares in the foreseeable future. Any return on an investment in the common shares will come from the appreciation, if any, in the value of the Common Shares. The payment of future cash dividends, if any, will be reviewed periodically by the board of directors and will depend upon, among other things, conditions then existing including earnings, financial condition, and capital requirements, restrictions in financing agreements, business opportunities and conditions, and other factors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in law could adversely affect our business and corporate structure.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurances that changes will not occur in corporate, tax, property, and other laws in Canada and/or Barbados (or the interpretation thereof by regulatory or tax authorities) which may materially and adversely affect our businesses and corporate structure.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may be adversely affected by disruptions to our information technology ("IT") systems, including disruptions from cybersecurity breaches of our IT infrastructure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology networks and systems, including those of third-party service providers, to process, transmit and store electronic information. In particular, we depend on our information technology infrastructure for a variety of functions, including financial reporting, data management, and email communications. Any of these systems may be susceptible to outages due to fire, floods, power loss, telecommunications failures, terrorist attacks, sabotage, and similar events. Global cybersecurity threats and incidents can range from uncoordinated individual attempts to gain unauthorized access to our information technology systems to sophisticated and targeted measures known as advanced persistent threats. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our systems or in non-encrypted portable media or storage devices. We could also experience a business interruption, information theft of confidential information, or reputational damage from industrial espionage attacks, malware or other cyber-attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. Despite the implementation of network security measures and disaster recovery plans, our systems and those of third parties on which we rely may also be vulnerable to computer viruses, break-ins, and similar disruptions. If we or our vendors are unable (or are perceived as unable) to prevent such outages and breaches, our operations may be disrupted, and our business reputation could be adversely affected. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that risks and exposures related to cybersecurity attacks will remain high for the foreseeable future due to the rapidly evolving nature and sophistication of these threats. In addition, as a result of the COVID-19 pandemic, we may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to meet regulatory or ethical expectations on environmental impact, including climate change. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Environmental issues will become more material in the marketplace as the wider healthcare system embraces net -zero climate targets. The environmental targets and performance of our business will come under increased scrutiny by investors, governments, and non-governmental organizations. Environmental considerations are starting to become embedded in the public procurement of goods and services, including medicinal products and devices. Specific intermediates used to manufacture medicines, or those used as excipients or propellants, are coming under increased regulation and some may be subject to time-limited exemptions or potential phase-out. The physical impacts of climate change could impact the resilience of our business operations and supply chain.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_25"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;INFORMATION ON THE COMPANY</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">History and Development of the Company</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was formed under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Corporations Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Alberta) on April 2, 1998 as 779738 Alberta Ltd.&#160;&#160;On April 8, 1998, we changed our name to Oncolytics Biotech Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal place of business is located at 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5, telephone (403) 670-7377. Our agent for service in the U.S. is Registered Agent Solutions, Inc., 838 Walker Road Suite 21-2 Delaware 19904.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of the important events in our development including licensing transactions, our principal capital expenditures and divestitures and a description of acquisitions of material assets can be found in our MD&amp;A and in the notes to our financial statements included elsewhere in this annual report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains a Website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC at www.sec.gov. The filings are also contained on the Company&#8217;s website at www.oncolyticsbiotech.com. Information on the Company's website is not incorporated by reference herein. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Business Overview </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep is a proprietary isolate of a naturally occurring, non-pathogenic double-stranded RNA (dsRNA) virus commonly found in environmental waters, known as reovirus. Pelareorep has demonstrated the ability to create a more permissive tumor microenvironment (TME) and conditions the tumor for multiple treatment combinations, including chemotherapies, checkpoint inhibitors and other immuno-oncology drugs, like CAR T therapies, bispecific antibodies, and CDK4/6 and PARP inhibitors. Pelareorep creates a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and promotes the overexpression of PD-1/PD-L1. By priming the immune system with pelareorep, we believe we can increase the proportion of patients who respond to immunotherapies and other cancer treatments, especially in cancers where immunotherapies have failed or provided limited benefit. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through the issuance of additional capital via public offerings, equity distribution arrangements, and through the exercise of warrants and stock options. There can be no assurance that we will be able to raise additional funds through the sale of our common shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Strategy</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is to develop and seek regulatory approval to market pelareorep in an effective and timely manner, and access additional technologies at a time and in a manner that we believe is best for our development.&#160;We intend to achieve our business strategy by focusing on these key areas:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continue to assess the safety and efficacy of pelareorep in human subjects through our clinical development program;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintain existing and establish new collaborations with experts to assist us with scientific and clinical developments of this new potential pharmaceutical product;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implement strategic alliances with select biopharmaceutical companies and laboratories, at a time and in a manner whereby such alliances may complement and expand our own research and development efforts. Such alliances may also result in an eventual expansion to include providing additive sales and marketing capabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use our broadening patent base and collaborator network as a mechanism to meet our strategic objectives; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop relationships with companies that could be instrumental in assisting us to access other innovative therapeutics.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our clinical development program advances, we anticipate pelareorep's ability to enhance innate and adaptive immune responses within the TME will play an increasingly important role. This greatly increases opportunities for expansion of our clinical program along with business development and partnering opportunities to address a broad range of cancers in combination with a variety of other therapies. We believe this approach has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) and advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) to phase 3 licensure-enabling studies. In addition, we are exploring opportunities for registrational programs in gastrointestinal cancers through our GOBLET platform study.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is based on attaining a number of commercial objectives, which, in turn, are supported by a number of product development goals.&#160;In the context of this annual report, statements of our "belief" are based primarily upon our results derived to date from our research and development program with animals, early-stage human trials, and our most recent data from our mid-stage clinical trials, upon which we believe that we have a reasonable scientific basis to expect the particular results to occur.&#160;It is not possible to predict, based upon studies in animals, or early- to -mid-stage human trials, whether a new therapeutic will ultimately prove to be safe and effective in humans.&#160;There are no assurances that the particular result expected by us will occur.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing a strategy of establishing relationships with larger companies as strategic partners.&#160;It is anticipated that future clinical development into large international or pivotal trials would generally occur in conjunction with a strategic partner or partners, who would contribute expertise and financial assistance.&#160;In exchange for certain product rights and commitments to market our products, the strategic partners would be expected to share in proceeds from the sale of our product or products.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Scientific Background &amp; Summary of Research and Development Highlights </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep&#8217;s anti-tumor activity is based on three complementary modes of action (Figure 1): </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selective viral replication in permissive cancer cells which leads to tumor cell lysis.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A specific adaptive immune response targeted to tumor- and viral-associated antigens displayed by antigen-presenting cells (APCs), infected tumor cells and/or dendritic cells to T cells.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical and translational research to date indicates the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep has anticancer effects in a variety of animal models demonstrating that it can reduce tumor burden and prolong survival in these models. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The anticancer effects in animal models can be enhanced when pelareorep is given in combination with chemotherapy, immunotherapy, radiotherapy, and other targeted cancer therapies, highlighting the ability of pelareorep to enhance the anticancer effects of a broad range of cancer therapeutics.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">A toxic dose of pelareorep has not been reached/established in animal models and doses as high as 9.0 x 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TCID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">have been well-tolerated in humans;  treatment with pelareorep causes manageable side-effects.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical data to date indicate the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">More than 1,500 patients have received at least one dose of study treatment in clinical studies with pelareorep. Of these, more than 1,100 patients received pelareorep, over 600 patients patients in Oncolytics-sponsored trials, and over 500 in investigator-sponsored trials received pelareorep by intravenous (IV) administration.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep has been administered as single or multiple doses (intratumoral or intravenous), either as a monotherapy or in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors), and/or radiotherapy.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep is generally well-tolerated and has a manageable side effect profile. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When combined with chemotherapy or immunotherapy, pelareorep does not appear to enhance either the frequency or severity of the adverse effects of these agents.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Efficacy results from clinical studies show that treatment with pelareorep can improve the outcome of cancer patients with a variety of different tumors: </span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a randomized Phase 2 study with 74 metastatic breast cancer (mBC) patients, known as IND.213, treatment with pelareorep plus paclitaxel versus paclitaxel alone demonstrated a statistically significant improvement in median overall survival: 17.4 months versus 10.4 months, respectively (HR = 0.65; 80% CI 0.46&#8211;0.91; p=0.1). In a post hoc subgroup analysis of patients with hormone receptor-positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) diseases, the median OS benefit from the addition of pelareorep to paclitaxel was even greater compared to paclitaxel alone: 21.0 months versus 10.8 months, respectively (HR = 0.60; p=0.1).</span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the AWARE-1 window-of-opportunity study, most HR+/HER2- early breast cancer patients treated with pelareorep showed an increase in CeLTIL score, a measure of tumor cellularity and tumor infiltrating lymphocytes (TILs) that is associated with a better prognosis in breast cancer.  Importantly, addition of the immune checkpoint inhibitor atezolizumab to pelareorep increased both the magnitude of the increase in CeLTIL score and the proportion of patients with a positive CelTIL score thereby achieving the study&#8217;s primary endpoint. Biomarker data from AWARE-1 further demonstrated that pelareorep treatment reversed immunosuppressive tumor microenvironments, generated and expanded T cell clones, upregulated PD-L1 expression, and promoted CD8+ T cell tumor infiltration into tumors. Many of these effects were even more prominent when pelareorep was combined with atezolizumab demonstrating synergy between the two agents.</span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the GOBLET platform study interim results, the objective response rate (ORR) and clinical benefit rate (CBR) were 69% and 85%, respectively, in the first-line advanced/metastatic pancreatic ductual adenocarcinoma (PDAC) cohort. The observed ORR of 69% is substantially higher than the average ORR of ~25% reported in historical control trials of gemcitabine and nab-paclitaxel in pancreatic cancer. Additional data also included:</span></div><div style="margin-top:3pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">One of thirteen evaluable patients achieved a confirmed complete response</span></div><div style="margin-top:3pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Eight of thirteen evaluable patients achieved a partial response (PR)</span></div><div style="margin-top:3pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Two of thirteen evaluable patients achieved stable disease (SD)</span></div><div style="margin-top:3pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The cohort exceeded the protocol-specified success criterion for Stage 1 of &#8805; 3/12 objective responses</span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a single-arm study with gemcitabine plus pelareorep, in first-line patients with metastatic pancreatic ductal adenocarcinoma, known as REO 017, the median OS was 10.2 months with 1-year and 2-year survival rates of 45% and 24%, respectively. These results were encouraging when compared to 20&#8211;22% and 2&#8211;5% benchmark 1-year and 2-year survivals, respectively for metastatic PDAC patients treated with gemcitabine alone from two different phase 3 studies.  </span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a two-arm Phase 2 study (NCI 8601), patients with metastatic PDAC were randomized to receive either carboplatin, paclitaxel and pelareorep (test arm) or carboplatin and paclitaxel alone (control arm). The median OS was similar for both arms, but the probability of survival at Year 2 was 20% in the test arm vs. 9% in the control arm. Evaluation of patient samples collected during this clinical trial identified the immunomodulatory CEA cell adhesion molecule 6 (CEACAM6) as a potential predictive biomarker for response to pelareorep therapy. Specifically, low levels of CEACAM6 mRNA expression were associated with prolonged progression-free survival in pelareorep-treated patients (10.3 months in CEACAM6 low versus 5.7 months in CEACAM6 high patients, p=0.05); importantly, this effect was not seen in the control arm.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Mechanism of Action</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 1. Proposed mechanism of action for pelareorep</span></div><div style="text-align:justify"><img src="oncyf-20221231_g1.jpg" alt="oncyf-20221231_g1.jpg" style="height:341px;margin-bottom:5pt;vertical-align:text-bottom;width:424px"/></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Direct cell lysis - Reovirus Replication in Permissive Cancer Cells</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selective viral replication and lysis in cancer cells and not normal cells is mediated by the host cellular protein dsRNA-activated protein kinase (PKR). PKR is activated in non-cancer cells infected with reovirus,  which in turn inhibits viral gene translation. However, in permissive cancer cells, PKR activation is inhibited, allowing viral gene translation and eventual cell lysis. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It was originally established that selective lysis of tumor cells was mediated by the activated rat sarcoma virus oncogene (RAS)-pathway, since active RAS inhibits PKR activation. However, more recent investigations have revealed that reovirus replication is not restricted to cells with an active RAS pathway; rather oncogenic mutations and amplifications in upstream and downstream mediators of the RAS-pathway also allow viral replication and oncolysis. Moreover, active RAS is known to stimulate over 18 downstream effector proteins, many of which have been shown to facilitate viral replication. Cells bearing dysfunctional or deleted tumor suppressor genes and/or undergoing chemo- or radiation-induced cell stress also show increased sensitivity to reovirus replication and lysis.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Induction of Innate Immunity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical and clinical studies provide compelling evidence that pelareorep functions as a systemically-delivered immunogenic agent that acts locally at the site of the tumor. Indeed, preclinical studies demonstrated that cancer cells infected with pelareorep can produce an innate immune response triggering the release of inflammatory cytokines. This inflammatory environment promotes a chemotactic response in NK cells, dendritic cells, and cytotoxic T-cells, altering the tumor microenvironment to support bystander immune-mediated cancer cell death. Intriguingly, preclinical studies have also demonstrated that the beneficial immunogenic functions of pelareorep can occur independently of viral replication. Pelareorep performs this immunogenic function, in part, by activating dendritic cells, key regulators of both adaptive and innate immunity. Dendritic cells activated by reovirus, in turn, stimulate the innate antitumor activity of NK cells and aid in the priming of specific antitumor cytotoxic lymphocyte, demonstrating that dendritic cell recognition of reovirus may trigger a beneficial innate immune response.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial with pelareorep (REO 013) provided an opportunity to study human NK cell activation in a controlled manner. Ten colorectal cancer patients with liver metastases received between one and five doses of pelareorep prior to surgical resection of their tumor. NK cell activation peaked 24-48 hours post-infection, coincident with a peak in pro-inflammatory cytokines. NK cells within a population of reovirus-treated blood mononuclear cells were stimulated to kill tumor targets, but not normal hepatocytes. Moreover, peripheral blood mononuclear cells were able to hand-off virus to tumors for direct oncolytic killing. Similarly, NK cells within a liver mononuclear cell population became selectively cytotoxic toward tumor </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cells when activated by reovirus. These results showed that reovirus modulates human NK cell activity in vivo and suggest that this may contribute to the therapeutic effect of pelareorep.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Induction of Adaptive Immunity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adaptive anti-tumor immunity eliminates existing cancer cells and performs constant surveillance, preventing relapse, and increasing overall survival. An adaptive immune response requires two signals: a signal from an APC, as well as a co-stimulation signal in the form of cytokines. In the absence of either signal, the adaptive immune response fails. Therapy with pelareorep has the potential to activate both signals. Following administration, pelareorep enhances the expression of &#8216;foreign&#8217; antigens/markers on tumor cells. Oncolysis of tumor cells exposes tumor-associated antigens (TAAs) and viral-associated antigens (VAAs) for processing and presentation by APCs, such as dendritic cells. Through this process, pelareorep facilitates the display of novel &#8216;foreign&#8217; antigens on the surface of infected tumor cells and APCs. Simultaneously, pelareorep induces an inflammatory response including the expression of co-stimulatory molecules and inflammatory cytokines. Together, these pelareorep-mediated immunological events initiate adaptive anti-tumor immunity.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By promoting the expression of novel antigens and the release of inflammatory cytokines, pelareorep, promotes an inflamed tumor phenotype. An inflamed tumor phenotype is characterized by NK and T-cell infiltration, increased expression of chemokines/cytokines, and increased expression of checkpoint ligands such as PD-L1. This phenotype correlates with an increase in overall survival and has a positive prognostic value for early-stage cancers. In patients with metastatic cancer, an inflamed tumor phenotype is associated with better clinical outcomes when treated with immunotherapies, including immune checkpoint inhibitors, cancer vaccines, and adaptive T-cell therapies. By promoting an inflamed tumor phenotype, pelareorep primes an anti-cancer immune response (Figure 2).  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 2. Pelareorep primes an anti-cancer immune response</span></div><div style="margin-bottom:8pt"><img src="oncyf-20221231_g2.jpg" alt="oncyf-20221231_g2.jpg" style="height:345px;margin-bottom:5pt;vertical-align:text-bottom;width:513px"/></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Breast Cancer Program</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2022, the results of our AWARE-1 window-of-opportunity study were presented at multiple conferences. This study examined the use of pelareorep with or without the checkpoint inhibitor atezolizumab (Tecentriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in patients with breast cancer. The results of this study showed that pelareorep primed the tumor microenvironment for checkpoint blockade therapy including increasing both PD-L1 expression in the tumor and T cell trafficking into the tumor. The potentially beneficial effects of pelareorep therapy, also including the creation and expansion of T cell clones, were enhanced further by combining pelareorep with atezolizumab. Notably, patients treated with pelareorep and atezolizumab reached the primary endpoint of the study with 60% of the patients showing an increase of more than 30% in the CelTIL score, a measure that correlates with efficacy in breast cancer patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we presented clinical biomarker analyses from AWARE-1's first two cohorts at the European Society for Medical Oncology Breast Cancer Meeting (ESMOBC), the Society for Immunotherapy of Cancer Annual Meeting (SITC), and the San Antonio Breast Cancer Symposium (SABCS). The data demonstrated pelareorep's immunotherapeutic effects, synergy with checkpoint inhibition, and potential to improve the outlook for patients with HR+/HER2- breast cancer. Patients in AWARE-1's first two cohorts were treated with pelareorep and the aromatase inhibitor letrozole without (cohort 1), or with (cohort 2), the PD-L1 checkpoint inhibitor atezolizumab approximately 21 days prior to the surgical resection of their tumors. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key data and conclusions presented at ESMOBC included:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gene expression analyses showed 100% of evaluable patients had a Risk of Recurrence Score (ROR-S) classified as "low" at surgery vs. 55% with a "low" ROR-S at baseline</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pooled analysis of tumors from cohorts 1 and 2 shows a statistically significant 4-fold post-treatment increase in the average expression of caspase 3, which is a marker of apoptotic cell death</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pooled analysis across cohorts 1 and 2 shows statistically significant increases in markers of T cell activation and no significant changes in markers of T cell exhaustion from baseline to surgery</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Treatment with pelareorep with (cohort 2) or without (cohort1) atezolizumab led to the conversion of tumors from the more aggressive luminal B to the luminal A subtype, which is associated with improved clinical outcomes</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">100% of evaluable cohort 2 tumors were luminal A at surgery (21 days post-treatment) vs. 70% at baseline (pre-treatment)</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">70% of evaluable cohort 1 patients had luminal A tumors at surgery vs. 40% at baseline</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented at SITC demonstrated that flow cytometry analyses of blood samples from these patients showed a statistically significant increase in anti-cancer natural killer (NK) cells on day 21 post-treatment in cohort 2 compared to cohort 1. In addition, cohort 2 patients showed higher levels of HLA-DR expression (a marker of T cell activation) in anti-cancer CD8+ T cells, and better maintained low levels of T cell exhaustion markers on day 21 compared to cohort 1 patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented at SABCS demonstrated that based on the gene expression profiling data, it was shown that pelareorep primes the tumor for further checkpoint blockade therapy by activating the interferon-gamma pathway. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, enrollment into our BRACELET-1 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">east c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r with the Oncolytic Reovirus Pe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">areor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">p in Combina</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ion with anti-PD-L1 and Paclitaxel) study concluded. We continued re-treating patients still on-study, monitored those patients who came off treatment due to progression, and assisted with follow-up activities. These activities included analyzing data on the study's primary endpoint of week 16 overall response rate and secondary endpoints of progression-free survival (PFS) and overall survival. BRACELET-1 is a randomized study of HR+/HER2-metastatic breast cancer patients and is evaluating tumor and immune responses following treatment with either paclitaxel  (standard of care therapy), paclitaxel + pelareorep or paclitaxel + pelareorep + the checkpoint inhibitor avelumab (Bavencio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The results of the BRACELET-1 study may provide important confirmatory data in the same patient population as our IND.213 study, for which we presented a statistically significant near doubling of overall survival with pelareorep treatment in HR+/HER2- mBC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, our partner, Adlai Nortye Biopharma Co., Ltd. ("Adlai"), announced interim results at the 2022 SABCS. Fifteen patients were treated in the bridging clinical trial, with fourteen having had at least one post-baseline tumor assessment (i.e., evaluable for efficacy). All patients enrolled into the trial were previously treated with at least one endocrine therapy and no more than one line of chemotherapy for recurrent/metastatic disease. The data and conclusions are summarized as follows:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disease control, partial response (PR), or stable disease (SD), was achieved in thirteen of fourteen evaluable patients (93%), with twelve (86%) showing tumor shrinkage from baseline</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Seven of fourteen evaluable patients achieved a PR (50%). Three of these patients achieved a confirmed PR (20%), while two patients are awaiting potential confirmatory scans</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">One patient achieving a PR at week 8 has maintained the PR through week 48 and remains on study</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evolving median PFS for trial participants as of the data cut-off date was 9.1 months (95% confidence interval: 3.8 - NA)</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The studied combination has been well tolerated, with no dose-limiting toxicities or serious adverse events (SAEs) reported to date </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adlai&#8217;s bridging clinical trial is evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. Data from the bridging trial are expected to accelerate Adlai's development of pelareorep in China by allowing future regulatory submissions to include data from Oncolytics' North American metastatic breast cancer trials, IND.213 and BRACELET-1.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Gastrointestinal Cancer Program</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our breast cancer program, we continued to explore pelareorep in gastrointestinal cancers. Notably, in 2021 enrollment began into the platform study known as GOBLET (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">astrointestinal tum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rs exploring the treatment com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inations with the oncolytic reovirus pe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orep and an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i-PD-L1). GOBLET is examining combination therapy with pelareorep and atezolizumab (Tecentriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in four gastrointestinal indications: (1) Patients with first-line locally advanced/metastatic unresectable pancreatic ductal adenocarcinoma (PDAC); (2) Patients with first-line metastatic colorectal cancer (mCRC), limited to microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors; (3) Patients with third-line mCRC independent of microsatellite instability (MSI)/dMMR status; and (4) Patients with second-line or later locally advanced/metastatic unresectable squamous cell carcinoma of the anal canal (SCCA). This study is currently enrolling patients, and the 3-patient safety run-ins for Cohort 1 and Cohort 3 were completed in the first and second quarter of 2022 (Cohorts 2 and 4 do not require safety run-ins). Therefore, all of the trial's four cohorts were cleared for full enrollment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, GOBLET&#8217;s pancreatic cancer cohort met the efficacy expansion criteria for Stage 1 of the trial and interim clinical results were presented at SITC. Per the study's Simon two-stage design, any cohort meeting a pre-specified efficacy threshold in Stage 1 (defined as achieving a minimum number of objective radiologic responses by week 16) may be expanded to enroll additional patients in an optional Stage 2 study expansion. The initial results from the safety run-in of this cohort met the primary endpoint as all patients achieved a partial response (n = 3).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional interim data presented at the SITC meeting included:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORR and CBR in GOBLET's PDAC cohort (n=13) were 69% and 85%, respectively; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">One of thirteen evaluable patients achieved a confirmed complete response;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Eight of thirteen evaluable patients achieved a PR;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Two of thirteen evaluable patients achieved SD;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The observed ORR of 69% is substantially higher than the average ORR of ~25% reported in historical control trials of gemcitabine and nab-paclitaxel in pancreatic cancer;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The PDAC cohort exceeded the protocol-specified success criterion for Stage 1 of &#8805; 3/12 objective responses;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The studied treatment combination has been well tolerated, with no safety concerns identified to date; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On the strength of the data, Oncolytics and its stakeholders determined that the Stage 2 expansion will not be necessary.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, we received the U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of advanced/metastatic PDAC using pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel. Fast Track designation is designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill an unmet medical need. A clinical program that receives Fast Track designation may benefit from more frequent meetings and communications with the FDA to discuss development plans and ensure the collection of appropriate data needed to support approval.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patents and Trade Secrets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our patent portfolio to protect the development of pelareorep. Currently, we have 243 issued patents including 24 issued in the U.S. and 11 in Canada. We also have 17 patents pending in the U.S., Canada, and other jurisdictions. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have established a robust and defensive intellectual property position that includes claims covering:</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compositions of matter comprising reovirus;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmaceutical use of reoviruses to treat neoplasia and cellular proliferative diseases;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Combination therapy with radiation, chemotherapy, and/or immunosuppressants; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Methods for manufacturing reovirus.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently aware of competing intellectual property relating to our pelareorep project. While we believe that we have the necessary freedom to operate in these areas, there can be no assurance that others will not challenge our position in the future. Litigation to defend our position could be costly and time-consuming and we cannot be certain we will be successful.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on unpatented trade secrets and improvements, unpatented know-how, and continuing technological innovation to develop and maintain our competitive position. No assurance can be given that others will not independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our rights to our unpatented trade secrets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We require our employees and consultants to execute confidentiality agreements upon the commencement of employment and consulting relationships with us. These agreements provide that all confidential information developed by or made known to an individual during the course of their employment or consulting relationship generally must be kept confidential. In the case of employees, the agreements provide that all inventions conceived by the individual, while employed by us, relating to our business are our exclusive property. While we have implemented reasonable business processes and agreements with which to protect confidential information, these actions may not provide meaningful protection for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of new pharmaceuticals is strongly influenced by a country's regulatory environment.&#160;The primary regulatory body in the United States is the FDA and in Europe is the European Medicines Agency (the &#8220;EMA&#8221;). The drug approval process in Canada is regulated by Health Canada.&#160;Similar processes are conducted in specific countries by equivalent regulatory bodies.&#160;Regulations in each jurisdiction require the licensing of manufacturing facilities and mandate strict research and product testing standards.&#160;Companies must establish the safety and efficacy of their products, comply with cGMP and potentially submit marketing materials before being allowed to market pharmaceutical products.&#160;While we plan to pursue or support the pursuit of the approval of our product, success in acquiring regulatory approval for any product is not assured.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market our pharmaceutical product in Canada, the United States, Europe, and other jurisdictions, we must successfully meet the requirements of those jurisdictions. The requirements of the appropriate regulatory authority will generally include the following stages as part of the regulatory process:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Pre-Pharmacological Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Pre-Pharmacological studies involve extensive testing on laboratory animals to determine if a potential therapeutic product has utility in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease model and has any adverse toxicology in a disease model.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Investigational New Drug Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - An Investigational New Drug (IND) Submission, or the equivalent, must be submitted to the appropriate regulatory authority prior to conducting Pharmacological Studies.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Pharmacological Studies&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or Phase 1 Clinical Trials)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Pharmacological studies are designed to assess the potential harmful or other side effects that an individual receiving the therapeutic compound may experience.&#160;These studies, usually short in duration, are often conducted with healthy volunteers or actual patients and use up to the maximum expected therapeutic dose.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Therapeutic Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(or Phase 2 and 3 Clinical Trials) - Therapeutic studies are designed primarily to determine the appropriate manner for administering a drug to produce a preventive action or a significant beneficial effect against a disease.&#160;&#160;These studies are conducted using actual patients with the condition that the therapeutic is designed to remedy. Prior to initiating these studies, the organization sponsoring the program is required to satisfy a number of requirements via the submission of documentation to support the approval for a clinical trial.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">New Drug Submission </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- After all three phases of a clinical trial have been completed, the results are submitted with the original IND Submission to the appropriate regulatory authority for marketing approval.&#160;&#160;Once marketing approval is granted, the product is approved for commercial sales.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Manufacturing and Controls</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Concurrent with pharmacological and therapeutic studies, the manufacturing process is developed, and applicable controls implemented. This information is submitted to the appropriate regulatory authority with more defined requirements for process and product control by later stage studies and prior to New Drug Submission. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Marketing Approvals</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the preclinical and clinical testing, together with manufacturing and controls information, are submitted to regulatory agencies in order to obtain approval to commence commercial sales. In responding to such an application, regulatory agencies may grant marketing approval, request additional information or further research, or deny the application if they determine that the application does not satisfy their regulatory approval criteria. Approval for a pharmaceutical or biologic product may not be granted on a timely basis, if at all. If granted, the approval may not cover all the clinical indications for which approval is sought, or may contain significant limitations in the form of warnings, precautions, or contraindications with respect to conditions of use.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The satisfaction of pre-market approval requirements for new drugs and biologics typically takes several years, with the actual time required varying substantially based upon the type, complexity, and novelty of the product or targeted disease. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government regulation may delay or prevent marketing of potential products for a considerable period of time and impose costly procedures upon our activities. Success in early-stage clinical trials or with prior versions of products does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Post-Marketing Regulations</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once approved, regulatory agencies may withdraw the product approval if compliance with pre- and/or post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, they may require post-marketing studies, referred to as Phase 4 studies, to monitor the effect of an approved product, and may limit further marketing of the product based on the results of these post-market studies. The FDA and other foreign regulatory agencies have broad post-market regulatory and enforcement powers, including the ability to levy fines and penalties, suspend or delay issuance of approvals, seize or recall products, or withdraw approvals.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Manufacturing Regulations</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by identifying an alternative toll manufacturer, establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our toll manufacturers are subject to periodic inspection by the FDA, the United States Drug Enforcement Administration, or DEA, and other domestic and foreign authorities where applicable, and must comply with cGMP regulations. Manufacturers of biologics also must comply with general biological product standards. Failure to comply with the statutory and regulatory requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product, or mandatory or voluntary recall of a product.&#160;Adverse experiences with the product must be reported to the FDA and foreign agencies and could result in the imposition of market restrictions through labeling changes or in product removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Advertising and Promotion Regulations</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to both pre- and post-market product advertising and promotion, the FDA and similar foreign agencies impose a number of complex regulations on entities that advertise and promote pharmaceuticals and biologics, which include, among other things, standards and regulations relating to direct-to-consumer advertising, on vs. off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the internet. These agencies have very broad enforcement authority and failure to abide by these regulations can result in penalties including the issuance of a warning letter directing the entity to correct deviations from requisite standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA or relevant foreign agencies. Foreign, state and federal civil and criminal investigations, fines, and prosecutions are also possible if advertising and promotion regulations are breached.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Government Regulations</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the government has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals, any one or more of which could have a material adverse effect upon us.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market and Competition </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to estimates for 2023 from the American Cancer Society, more than 1.9 million Americans are expected to be diagnosed with cancer in the year, and approximately 609,820 Americans are expected to die of cancer.&#160;Cancer is the second most common cause of death in the U.S., exceeded only by heart disease.&#160;In the United States, the relative lifetime risk of a male or female developing cancer is 1 in 2 and 1 in 3, respectively (Source: American Cancer Society's Cancer Facts &amp; Figures 2023). It was projected that there will be 195,738 patients with HR+/HER2- mBc in 2021. (Source: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">https://seer.cancer.gov/statfacts/html/breast-subtypes.html (accessed Feb 9, 2023)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of this disease state are also significant.&#160;In the United States, the American Cancer Society reported in its Cancer Facts &amp; Figures 2023 that The National Cancer Institute estimated that the 2020 cancer-related medical costs were $208.9 billion.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry emphasizes the importance of proprietary rights and is typically defined by fast-paced advancements in technologies with intense competition. We do business in an extremely competitive oncology market and face significant competition from many sources, including pharmaceutical, biopharmaceutical, and biotechnology companies as well as universities and private and public research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, and drug development resources than we do. Large biopharmaceutical companies in particular have extensive experience in clinical development and in obtaining regulatory approvals for drugs and biologicals. These companies also have significantly greater research capabilities than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly those with collaborative arrangements with large and established companies or universities and research institutions. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors fall primarily into the following groups of treatment: </span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">traditional cancer therapies, including chemotherapy, surgery, radiation therapy, and targeted therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approved immunotherapy antibodies and immunotherapy antibodies in clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other approved oncolytic virus-based immunotherapies and those in clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cancer vaccines including personalized vaccines and those targeting tumor neo-antigens; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cell-based therapies, such as CAR-T, T cell receptor-based, and NK cell therapies. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business opportunity will be limited, or possibility eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, or are less expensive alone or in combination with other therapies than pelareorep especially if these get to market sooner than our product. Our competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep, if and when sold, will compete with a number of drugs that are currently marketed or in development that also target cancer but utilize different mechanisms of action. To compete effectively with these agents, pelareorep will need to show improved clinical efficacy and/or safety compared to competing products. We believe that pelareorep, if and when ultimately marketed, will likely be used in combination with other existing cancer treatments like checkpoint blockade therapies, surgery, chemotherapy, radiation therapy and other biological therapies. Consequently, we believe pelareorep, if and when marketed, would largely complement rather than compete directly with these existing treatment options. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do, however, expect to face direct and increasing competition from a number of companies that are also seeking to develop cancer therapies based on oncolytic viruses and other ways to prime the immune system. We believe that our ability to successfully compete will depend, among other things, on our ability to:</span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively advance the development of pelareorep;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">design, enroll patients in and successfully complete appropriate clinical trials in an efficient manner;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gain regulatory approval for pelareorep;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish collaborations and partnerships for the development of pelareorep;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize successfully, including demonstrating the safety and efficacy of pelareorep over currently approved therapies to physicians, insurers, and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">secure sufficient coverage from insurers and other payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">secure, maintain, and protect intellectual property rights based on our innovations; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture and sell commercial quantities of pelareorep to the market.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Marketing Strategy</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets for the cancer product being developed by us may be large and could require substantial sales and marketing capability.&#160;Before or upon successful completion of the development of a cancer product, we intend to enter into one or more strategic partnerships or other collaborative arrangements with a pharmaceutical company or other company with marketing and distribution expertise to address this need.&#160;If necessary, we will establish arrangements with various partners for different geographical areas or specific applications at various times in the development process.&#160;Our management and consultants have relevant experience with the partnering process.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations have not been materially impacted by seasonality.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raw Materials</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that sources of raw material pertinent for manufacturing our pelareorep product are generally available. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Social Responsibility and ESG </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a rapidly growing, clinical-stage biotech company, we are not yet in a position to implement a broad-based ESG policy and program. However, our corporate goals are inspired by our potential to impact the care of patients with cancer, especially those with late-stage breast cancer and are informed by our corporate values of acting with integrity, collaboration, innovation, and embracing diversity. In 2022, our corporate goals focused on certain clinical, manufacturing, and business operations and support our desire to obtain an approval for an innovative cancer treatment that extends patient lives. Each year we work hard to achieve our goals and objectives while maintaining a respectful, collaborative, and caring work environment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not formally report on our ESG policies and compliance, we publicly disclose elements of our ESG activities. Our governance policies like our board mandates, code of ethics and conduct, and our public filings are all on our website at https://ir.oncolyticsbiotech.com/corporate-governance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Organizational Structure</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;31, 2022, we had one material wholly-owned operating subsidiary; Oncolytics Biotech (Barbados) Inc. (&#8220;OBB&#8221;), a Barbados company.&#160;In addition, Oncolytics Biotech (U.S.) Inc., a Delaware corporation, is a material wholly-owned subsidiary of OBB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.&#160;&#160;&#160;&#160;&#160;&#160;Property, Plant and Equipment</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease our head office in Calgary, Alberta, Canada as well as our office spaces in San Diego, California, U.S. and Barbados. We do not own or lease any other office space, manufacturing facilities or equipment and do not have any current plans to construct or acquire any facilities.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4A.&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_31"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management Discussion and Analysis (&#8220;MD&amp;A&#8221;) contains forward-looking statements, including our belief as to the potential of pelareorep, a therapeutic reovirus, as a cancer therapeutic and our expectations as to the success of our research and development and manufacturing programs in 2023 and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.&#160;See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the forward-looking statements made within our MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our development program, our ability to receive regulatory approval to commence enrollment in our clinical trial program, the final results of our co-therapy clinical trials, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.&#160;Investors are cautioned against placing undue reliance on forward-looking statements.&#160;We do not undertake to update these forward-looking statements except as required by applicable law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Operating Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see our 2022 Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see our 2022 Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Research and Development, Patents and Licenses, etc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see the disclosure in "Item 4.&#160;&#160;Information on the Company B. Business Overview" and our 2022 Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference. for information on the Company&#8217;s research and development policies.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Trend Information</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important to note that historical patterns of expenditures cannot be taken as an indication of future expenditures. Our current and future expenditures are subject to numerous uncertainties, including the duration, timing, and costs of R&amp;D activities ongoing during each period and the availability of funding from investors and prospective partners. As a result, the amount and timing of expenditures and, therefore, liquidity and capital resources may vary substantially from period to period. See our 2022 MD&amp;A in Exhibit 15.1 for our comparative discussion on our expenditures between 2020 - 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as disclosed elsewhere in our annual report, we know of no trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our liquidity or capital resources or that would cause reported financial information not necessarily to be indicative of future operating results or financial conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Critical Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_34"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Directors and Senior Management</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the names and places of residence of all our directors and senior management as at December&#160;31, 2022, as well as the positions and offices held by such persons and their principal occupations.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah M. Brown, MBA, ICD.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Brown currently leads Canadian Strategic Partnerships at Eversana, a leading provider of global commercial services to the life sciences industry. She held progressively senior roles at EMD Serono from 2000 to 2014, including Executive Vice President of Neuroimmunology for the company's U.S. operations, and President and Managing Director of the company's Canadian operations. In 2012, Ms. Brown was Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its Board of Directors from 2007 to 2014. She also currently sits on the Boards of the HBSPCA and Sernova Corp. Ms. Brown holds an MBA from Western University&#8217;s School of Business, an Hons B.Sc. from the University of Guelph, and has completed the Institute of Corporate Directors Designation (ICD.D).</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Coffey, PhD, MBA<br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A co-founder of the Company, Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey took over as Chief Executive Officer in late 2016, prior to which he was Chief Operating Officer since December 2008. Since co-founding Oncolytics he has also held the positions of Chief Scientific Officer from December 2004 to December 2008, Vice-President of Product Development from July 1999 to December 2004, and Chief Financial Officer from September 1999 to May 2000.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2011</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro<br/>California, USA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. de Guttadauro began his career at TAP Pharmaceuticals, supporting the launch of blockbuster drugs, Lupron</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and Prevacid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. He held a variety of marketing positions at Amgen, contributing to the success of Enbrel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Aranesp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, and Epogen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;before joining MedImmune to lead marketing efforts for the FluMist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;inhaled influenza vaccine. Following a two-year assignment overseeing the commercial development of Zevalin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the first radioimmunotherapy product approved for use in the United States, Mr. de Guttadauro took on the role of Senior Director of Strategy at Biogen Idec. He then served as Vice President of Corporate Development at Vical, supporting the execution of distribution agreements for Allovectin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Prior to joining Oncolytics, Mr. de Guttadauro was a Principal at 1798 Consultants Inc., a healthcare consulting firm providing commercialization, market access, and compliance strategic advice to leading and emerging biopharmaceutical companies. Mr. de Guttadauro has a Bachelor of Science degree in engineering from the United States Military Academy at West Point.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman, P.Eng., PMP, MBT <br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Product Development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A Professional Engineer focused on biotechnology, Ms. Hagerman joined Oncolytics in 2010. Prior to being appointed as Vice President of Product Development, Ms. Hagerman was the Director, Manufacturing and Engineering from 2013-2017 and Project Manager from 2010-2013. Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas C. Heineman, MD, PhD<br/>California, USA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to joining Oncolytics, Dr. Heineman most recently served as Senior Vice President and Head of Clinical Development at Denovo Biopharma. Prior to his time at Denovo, Dr. Heineman served as Vice President and Head of Clinical Development at Genocea Biosciences and Halozyme Therapeutics, where he was also the Head of Translational Medicine, and oversaw clinical trials in indications such as breast and pancreatic cancer. Dr. Heineman&#8217;s experience further extends to big pharma and academia where he previously held roles as Senior Director, Global Clinical Research and Development at GlaxoSmithKline and Associate Professor at the Saint Louis University School of Medicine. Dr. Heineman has co-authored over 60 peer-reviewed publications and is board certified in Internal Medicine and Infectious Diseases. He completed his fellowship in Infectious Diseases at the National Institutes of Health and his internship and residency at the University of Maryland. Dr. Heineman earned his MD at the University of Chicago, where he also received a PhD in molecular genetics.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham, MBA, FCPA, FCMA, ICD.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Holtham held a number of financial positions over a 19-year career with the Canadian subsidiary of Nabisco Inc., rising to become Senior Vice President and Chief Financial Officer. In 2002, she joined Toronto, Ontario-based Hospital for Sick Children as Vice President, Finance and Chief Financial Officer, a position she held for eight years. Through her career she has participated in myriad initiatives ranging from traditional finance functions and operations oversight to intellectual property portfolio management and mergers and acquisitions. In more recent years she has held numerous governance roles on various Boards in both the publicly traded and not-for-profit sectors and held short term contract positions. Ms. Holtham is an FCPA, FCMA, holds an MBA from the University of Toronto - Rotman School of Management and has completed the Institute of Corporate Directors Designation (ICD.D).</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 18, 2014</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk J. Look, CA, MSJ<br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Look joined Oncolytics as the Company's Controller in April 2003, and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager of Audit and Assurance Services with Ernst &amp; Young LLP in Canada. From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst &amp; Young LLP in Chile.  Mr. Look is a Chartered Accountant, and holds a Master of Science in Jurisprudence (MSJ) from the Seton Hall University School of Law and a Bachelor of Commerce from the University of Calgary.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James T. Parsons, MAcc, CPA, CA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Parsons served as the Chief Financial Officer (CFO) of Trillium Therapeutics Inc. (TSX: TRIL) (NASDAQ: TRIL) from August 2011 through its acquisition by Pfizer in November 2021 for an aggregate purchase price of approximately U.S.$2.2 billion. Prior to his time at Trillium, Mr. Parsons served as Vice President, Finance, at DiaMedica Therapeutics Inc, CFO of ProMIS Neurosciences (formerly Amorfix Life Sciences Ltd.), and CFO and Vice President, Finance and Administration, at Aptose Biosciences Inc. (formerly Lorus Therapeutics). Mr. Parsons has been a Director and the Chair of the Audit Committees of Sernova Corp. (TSX: SVA) and DiaMedica Therapeutics Inc. (NASDAQ: DMAC) since 2012 and 2015, respectively.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 16, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano, MBA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">                                                            Pennsylvania, USA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Pisano has served as a Director/Chairman of several publicly traded companies in the US and Canada and has more than 30 years of experience as a pharmaceutical industry executive. He served as the president and CEO of VaxInnate, a privately held biotech company from January 2012 to November 2016. Mr. Pisano is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He joined Sanofi Pasteur in 1997, assuming increasing levels of responsibility. He was promoted to President and CEO in 2007, the position he successfully held until his retirement in 2011. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor's degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2013</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Rigby, MBA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Louisiana, USA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Rigby is currently the Group Chief Executive Officer (CEO) of Revolo Biotherapeutics, where he leads a team focused on the development of therapies for autoimmune and allergic diseases. Previously, he was the CEO of SteadyMed Ltd., which he led through a NASDAQ listing and sale to United Therapeutics Corporation. Prior to his time at SteadyMed, Mr. Rigby co-founded Zogenix, Inc., a CNS-focused specialty pharmaceutical company that was acquired by UCB earlier this year in a transaction valued at up to approximately U.S. $1.9 billion. Before co-founding Zogenix, Mr. Rigby held roles of increasing responsibility in commercial and business development functions at large pharmaceutical companies such as Merck, Bristol Myers Squibb, and Profile Therapeutics (now Phillips Medical). In addition to his Oncolytics appointment, Mr. Rigby is also a member of the Revolo Biotherapeutics and ImmunoMolecular Therapeutics Boards of Directors and the Chairman of BioPlus Acquisition Corp., a Nasdaq-listed biotech acquisition company. He holds a B.S. with Honors in Biological Sciences from Sheffield University, UK, and an M.B.A. from Portsmouth University, UK.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger, MD, PhD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey, USA and Munich, Germany</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Seizinger has been board member/chairman in multiple public and private biotech companies in the US and Europe. From 1998 to 2009, he served as President and Chief Executive Officer of GPC Biotech. He also served as Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances at Bristol-Myers Squibb. Prior to his appointments in the biotechnology and pharmaceuticals sectors, Dr. Seizinger held professorships and senior staff appointments at Harvard Medical School, Princeton University, and Massachusetts General Hospital. He also currently sits on multiple biotech boards, including four additional public boards: Aptose Biosciences, Aprea Therapeutics, Nykode Therapeutics, and BioInvent.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 8, 2015</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Audit Committee.&#160;Ms. Holtham is Chair of this Committee.</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Compensation Committee.&#160;Ms. Brown is Chair of this Committee. </span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Governance Committee.&#160;Mr. Pisano is Chair of this Committee. </span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Science &amp; Development Committee. Dr. Seizinger is Chair of this Committee.</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Mr. Pisano, as Chair of the Board, serves as an ex-officio member of the Compensation, Audit, and Science &amp; Development Committees.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at February&#160;27, 2023, the directors and senior management as a group beneficially owned, directly or indirectly, 847,866 of our common shares, representing 1.35% of the issued and outstanding common shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our directors are associated with other companies, which may give rise to conflicts of interest.&#160;In accordance with the Alberta Business Corporations Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABCA), directors who have a material interest in any person who is a party to a material contract or a proposed material contract with us are required, subject to certain exceptions, to disclose that interest and abstain from voting on any resolution to approve that contract.&#160;In addition, the directors are required to act honestly and in good faith with a view to the best interests of Oncolytics Biotech Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers are related by blood, marriage, or adoption to any other director or officer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not aware of any arrangement or understanding with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a director or senior management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt"> Compensation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board of Directors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning the total compensation paid in 2022 to each director.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fees Earned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">based awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">based awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-equity incentive plan compensation<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension value<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All other compensation<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Brown</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,036</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,848</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,884</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,036</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,848</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,884</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard Kruimer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,246</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,246</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James T. Parsons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,375</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,272</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,647</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,896</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,560</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,456</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Rigby</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,752</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,483</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,235</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,264</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,848</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,112</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Directors are paid fees in U.S. Dollars.&#160;These amounts are presented in Canadian dollars and have been converted at a U.S./CDN exchange rate of $1.3544.</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">The value of share-based and option based awards are based on the grant date assumptions as disclosed in note 10 "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2022 audited consolidated financial statements.  </span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Mr. Kruimer ceased to be a director effective June 16, 2022.</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Mr. Parsons was appointed as a director on June 16, 2022.</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Mr. Rigby was appointed as a director on August 30, 2022. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each director who is not a salaried employee of the Company receives a base retainer of US$40,000. In addition to the base retainer, directors are eligible to receive the following additional fees depending on committee involvement:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional Retainers (USD):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$40,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Committee chair</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Governance &amp; Compensation Committee chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Science &amp; Development Committee chair</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-chair member of the Audit Committee</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-chair member of the Governance, Compensation, or Science &amp; Development  Committee</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,000</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the combined retainer, the Corporation will grant 30,000 options annually for directors other than the Chair. The Chair will receive 37,500 options annually. All such options vest in their entirety one year following the grant date. New Directors will be entitled to receive an initial grant of 45,000 options, which vest immediately. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also reimburse the directors for any reasonable expenses incurred by them while acting in their directors' capacity.&#160;During the year ended December 31, 2022, total compensation of $658,464 was paid to the independent directors which consisted of fee payments of $474,605 and option based awards of $183,859. </span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Management </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning the total compensation paid to our senior management in 2022.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salary<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-<br/>based awards<br/>($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option-<br/>based </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">awards </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bonus<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-equity incentive<br/>plan compensation<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension value<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All other compensation<br/>  ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>compensation <br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Matthew C. Coffey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">654,404</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,616</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,842</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,198</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,185,060</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kirk J. Look<br/>Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">486,593</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,293</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,905</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,354</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850,145</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">599,999</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,293</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,679</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">981,971</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President, Oncolytics Biotech (U.S.) Inc.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454,829</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,293</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,231</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,679</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744,032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390,774</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,293</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,932</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,449</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691,448</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The value of share- and option-based awards are based on the grant date assumptions as disclosed in note 10 "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2022 audited consolidated financial statements.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The dollar amounts set forth under this column are related to contributions to the senior management's respective retirement savings plan and amounts provided for health care benefits by the Company. </span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">None of the compensation paid to Dr. Coffey related to his role as a director of the Company.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">U.S. Employees are paid salaries, bonuses, and other compensation in U.S. Dollars.&#160;These amounts are presented in Canadian dollars and have been converted at a U.S./CDN exchange rate of $1.3544.  </span></div><div style="padding-left:4.5pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment agreements with each member of the Company's senior management (each an "Employment Agreement"). For 2022, the Chief Executive Officer of the Corporation is eligible for a cash bonus of up to 50% of his base salary, the Chief Financial Officer and Chief Medical Officer are eligible for a cash bonus of up to 40% of their respective base salary, and the President, Oncolytics Biotech (U.S.) Inc. and Vice President, Product Development are eligible for a cash bonus of up to 35% of their respective base salary. In addition, when available, the officers are eligible for a combination of Option and Share Award grants. The amount of each grant is determined and approved by the Board with the actual bonus provided and the number of Options and Share Awards granted based upon the overall performance of the Corporation as assessed by the Compensation Committee and approved by the Board. The overall performance of the Corporation is determined by the annual goals and objectives approved by the Board and includes specific objectives with respect to the clinical, manufacturing, and intellectual property plans in combination with financial goals. Previous grants are taken into account when considering new grants of Options and Share Awards. As well, the Employment Agreements provide that each member of the Company's senior management is subject to certain confidentiality and non-competition restrictions during and following the course of their respective employment with the Company. Each Employment Agreement shall continue until terminated by either party in accordance with the notice provisions thereof.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not provide pension plan benefits to its senior management and employees. The Company does not currently have a stock appreciation rights plan.&#160;</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following base salaries for 2023 were approved by the Board of Directors:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Salary<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew C. Coffey<br/>President and Chief Executive Officer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk J. Look<br/>Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Oncolytics Biotech (U.S.) Inc.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">U.S. Employees are paid in U.S. Dollars and salaries above for those U.S. employees are presented in U.S. dollars. All other employees are paid in Canadian Dollars and salaries above for those Canadian employees are presented in Canadian dollars. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Termination of Employment or Change of Control </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects amounts payable to each member of the Company's senior management based on their respective Employment Agreements assuming that their employment was terminated on December 31, 2022 without cause or due to a change of control of the Company.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Termination without Cause Severance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change of Control Severance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Matthew C. Coffey<br/>President and Chief Executive Officer</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk J. Look<br/>Chief Financial Officer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Oncolytics Biotech (U.S.) Inc.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As at December 31, 2022, all options granted to senior management had fully vested except for the options granted on August 1, 2020 (expiring August 1, 2025), March 8, 2021 (expiring March 8, 2026), December 10, 2021 (expiring December 10, 2025), and December 9, 2022 (expiring December 9, 2026). As a result, all members of senior management shall be entitled to exercise all or any part of their vested Options, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such member is terminated unless otherwise approved by the Board of Directors.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">On a change of control of the Company, senior management shall be entitled to exercise all or a part of their Options, whether vested or not, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such member is terminated.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">U.S. Employees are paid in U.S. Dollars and are presented in U.S. dollars.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Board Practices</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors are elected by the shareholders at each Annual General Meeting (or Annual Special Meeting) and typically hold office until the next meeting, at which time they may be re-elected or replaced.&#160;Casual vacancies on the board are filled by the remaining directors and the persons filling those vacancies hold office until the next Annual General Meeting (or Annual Special Meeting), at which time they may be re-elected or replaced.&#160;The officers are appointed by the Board of Directors and hold office indefinitely at the pleasure of the Board of Directors.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Corporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Corporation Since</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Expiration of Current Term of Office</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Coffey, PhD, MBA<br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2011</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2023 Annual General Meeting of the Shareholders</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Brown, MBA, ICD.D<br/>Ontario, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2023 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham, MBA, FCPA, FCMA, ICD.D<br/>Ontario, Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 18, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2023 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James T. Parsons, MAcc, CPA, CA<br/>Ontario, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 16, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2023 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano, MBA<br/>Pennsylvania, USA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair and Director</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2013</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2023 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Rigby, MBA<br/>Louisiana, USA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2023 Annual General Meeting of the Shareholders</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger, MD, PhD<br/>New Jersey, USA and Munich Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 8, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of 2023 Annual General Meeting of the Shareholders</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors&#8217; Contracts</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a director&#8217;s consent from each of the independent directors upon their acceptance of their director&#8217;s position.&#160;We also enter into an Indemnity Agreement and Directors Confidentiality and Intellectual Property Assignment Agreement with each director.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any contracts with any of its directors which provide for benefits upon the termination of employment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation has formed a compensation committee (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in accordance with Rule 5605(d)(1) of the Nasdaq Capital Market which consists of four outside, independent directors, Dr. Seizinger, Ms. Holtham, Ms. Brown, and Mr. Pisano, the Chair of the Board, each of whom is independent in accordance with Rule 5605(a)(2) and Rule 5605(d)(2)(A) of the Nasdaq Capital Market. Ms. Brown is the Chair of the Compensation Committee. No member of the Compensation Committee has been an employee or officer of the Company or any of its affiliates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objectives of the Corporation&#8217;s compensation arrangements are: (i)&#160;to attract and retain key personnel; (ii)&#160;to encourage commitment to the Corporation and its goals; (iii)&#160;to align executive interests with those of its shareholders; and (iv)&#160;to reward executives for performance in relation to overall corporate progress goals.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key elements of the compensation program are the base salary, health benefits, and payments allocated to employees to be directed by them to their personal retirement accounts. Bonuses and the granting of Options (as defined herein) and Share Awards (as defined herein) are also part of the Corporation&#8217;s compensation program and are based on corporate performance. Part of corporate performance includes goals and objectives that are determined based on the strategic planning and budgeting process, which is conducted at least annually. The elements of the compensation plan are intended to reward performance, and the various elements are intended to provide a blend of short-term and long-term incentives to align the interests of management and the shareholders.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arriving at its recommendations for compensation, the Compensation Committee considers the long-term interests of the Corporation as well as its current stage of development and the economic environment within which it operates. The market for biotechnology companies in the development phase is challenging. Based on these factors, the Compensation Committee recognized the need to strike a balance between compensation to retain employees and resources expended to maintain operations. In the past, the Compensation Committee has engaged specialist consultants to assist in benchmarking its </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation practices and provide recommendations to the committee with respect to compensation for directors and senior management. The Compensation Committee had retained Radford, an Aon Hewitt Corporation, as a specialist consultant to assist with the benchmarking of officer and director compensation for 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a review of the risks in the Corporation&#8217;s compensation policies and practices, the Compensation Committee found no risks that are reasonably likely to have a material adverse effect on the Corporation. The Compensation Committee&#8217;s role of approving the compensation policies and practices includes considering whether the compensation policies and practices could encourage senior management of the Company to take inappropriate or excessive risks.</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Corporation&#8217;s corporate trading policy, insiders (including senior management and directors) are not permitted to hedge their position in Common Shares, Options, Share Awards, deferred share units, performance share units, debentures or other debt instruments by use of any financial instrument, which would include but is not limited to options, puts, calls, warrants or short sells, designed to benefit the holder from a change in the market value of the Common Shares of the Corporation.</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee's written mandate is located on the Company&#8217;s website at https://ir.oncolyticsbiotech.com/corporate-governance. </span></div><div style="text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation has formed an Audit Committee in accordance with Section 3(a)(58)(A) of the United States Securities Exchange Act of 1934, as amended ("Exchange Act"), consisting of four independent directors pursuant to the Rule 5605(a)(2) and Rule 5605(c)(2) of the Nasdaq Capital Market and Rule 10A-3 of the Exchange Act: Ms. Brown, Ms. Holtham, Mr. Parsons, and Mr. Pisano, none of whom are nor have been employees or officers of the Company or any of its affiliates.&#160;&#160;Ms. Holtham is presently the Chair of the Audit Committee.&#160;Each Audit Committee member is financially literate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee reviews and approves the scope of the annual audits of our financial statements, reviews our internal control over financial reporting, reviews and approves services performed by the independent auditors, reviews the findings and recommendations of the independent auditors, and periodically reviews major accounting policies.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee's written mandate is located on the Company&#8217;s website at https://ir.oncolyticsbiotech.com/corporate-governance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.78pt">Employees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the number of our employees at the end of each of the last three fiscal years by activity and geographic location.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By Function:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By Geographic Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States of America</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Share Ownership</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the share ownership and options held of our directors and officers as of February&#160;27, 2023. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common shares<br/>(#)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of&#160;&#160;<br/>ownership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option exercise<br/>price<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option expiration date</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Officers</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew C. Coffey</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/16/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/19/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk J. Look</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/16/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/19/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas Heineman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/1/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew de Guttadauro</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/3/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/14/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.84</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/28/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common shares<br/>(#)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of&#160;&#160;<br/>ownership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option exercise<br/>price<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option expiration date</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.73</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/14/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507,683&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Brown</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/7/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/18/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James T. Parsons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/9/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Rigby</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/30/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/8/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL:</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847,866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,034,942&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Less than 1% ownership</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Based on 62,826,958 common shares issued and outstanding on February&#160;27, 2023. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Options granted to acquire common shares. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Ownership percentage assumes aggregate beneficial ownership of common shares, common shares acquirable upon exercise of options and fully diluted shares outstanding of 68,854,178.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Mr. Parsons was appointed as a director on June 16, 2022.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Mr. Rigby was appointed as a director on August 30, 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two share-based compensation plans: the Stock Option Plan and the Share Award Plan.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Corporation&#8217;s Amended and Restated Stock Option Plan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) dated effective as of May 4, 2017.  </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation, with the approval of its Shareholders, has established the Stock Option Plan. The number of Common Shares reserved for issuance under the Stock Option Plan and all other security based compensation arrangements of the Corporation (including the Share Award Plan) in aggregate shall not exceed 10% of the total number of issued and outstanding Common Shares from time to time. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Stock Option Plan, the Board of Directors or the Compensation Committee may from time to time designate directors, officers, employees of, or consultants to, the Corporation or any subsidiary of the Corporation (such persons being &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eligible Persons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to whom Options may be granted and the number of Options to be granted to each. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options may be exercised at a price (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) which shall be fixed by the Board at the time the Option is granted. No Option can be granted with an Exercise Price at a discount to the market, which shall be the closing price of the Common Shares on the stock exchange upon which the Common Shares are listed on the first day preceding the date of grant on which at least one board lot of Common Shares traded on such exchange.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any Option shall be exercised or shall expire or terminate for any reason without having been exercised in full, any Common Shares to which such Option relates shall be available for the purposes of the granting of Options under the Stock Option Plan.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Shares that may be acquired under an Option granted to a participant under the Stock Option Plan shall be determined by the Board as at the time the Option is granted, provided that the aggregate number of Shares reserved for issuance to any one participant under the Stock Option Plan or any other security based compensation arrangement of the Corporation, shall not exceed five percent (5%) of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without obtaining the approval of Shareholders in accordance with the rules of the TSX or the requirements of any other stock exchange on which the Common Shares are then listed, no Options shall be granted pursuant to the Stock Option Plan, if such grant together with grants pursuant to all other share compensation arrangements of the Corporation, could result, at any time, in:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a number of Common Shares issuable pursuant to Options granted to insiders exceeding ten percent (10%) of the number of outstanding Common Shares at any time;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the issuance within a one year period to insiders, of a number of Common Shares exceeding ten percent (10%) of the number of outstanding Common Shares; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the issuance to any one insider and such insider&#8217;s associates, within a one year period, of a number of Common Shares exceeding five percent (5%) of the number of outstanding Common Shares.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of Option grants to each non-employee director shall not exceed $150,000 annually for any individual non-employee director (other than initial Option grants to new directors).</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expiration of options is to be no greater than ten years from the date of grant and typically either vest immediately or as to one-third on each of the first, second and third anniversary following the date of grant, as determined by the Board at the time the Option is granted. Options are not transferable or assignable except to the person or persons to whom the participant&#8217;s rights pass by the participant&#8217;s will or applicable law following the death or permanent disability of a participant.  The Stock Option Plan provides that if the expiration date of an Option occurs during a &#8220;blackout period&#8221; or within five (5) business days after a blackout period, such expiration date shall be deemed to be extended to the date which is the tenth (10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) business day after the last day of the applicable blackout period.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any written agreement between the Corporation and a participant providing otherwise, if any participant shall cease to be an Eligible Person for any reason other than the termination for cause or the death or permanent disability of the participant, such participant&#8217;s Option will terminate immediately as to the then unvested portion thereof and at 5:00 p.m. (Calgary time) on the earlier of the date of the expiration of the applicable option period and the ninetieth (90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) day after the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date such participant ceases to be an Eligible Person as to the then vested portion of the Option. If a participant ceases to be an Eligible Person as a result of the termination of such participant for cause, effective as of the date notice is given to the participant of such termination, all outstanding Options shall be terminated and all rights to receive Common Shares thereunder shall be forfeited by such participant, and the participant shall not be entitled to receive any Common Shares or other compensation in lieu thereof.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any written agreement between the Corporation and a participant providing otherwise, if in the event of the death or permanent disability of a participant, any Option previously granted to such participant shall be exercisable until the end of the applicable option period or until the expiration of 12 months after the date of death or permanent disability of such participant, whichever is earlier, and then only: (i) by the person or persons to whom the participant&#8217;s rights under the Option shall pass by the participant&#8217;s will or applicable law; (ii) to the extent that he or she was entitled to exercise the Option as at the date of the participant&#8217;s death or permanent disability.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Board may, at its sole discretion, extend the period during which any Options may be exercised, in the case of Options held by non-employee directors, by not more than one year, and in the case of Options held by other persons, by not more than three years, but in no case longer than the normal expiry of the Options.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a change of control of the Corporation (as such term is defined in the Stock Option Plan), all Options which have not otherwise vested in accordance with their terms shall immediately vest and be exercisable, notwithstanding the other terms of the Options or the Stock Option Plan for a period of time ending on the earlier of the expiry time of the Option and the ninetieth (90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) day following the change of control.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any required approval of the TSX and any other stock exchange on which the Common Shares are then listed, the Stock Option Plan and any Options granted thereunder may be amended, modified or terminated by the Board without approval of any participant or Shareholder (provided that no such amendment may be made that will materially prejudice the rights of any participant under any Option previously granted to the participant without consent by such participant). Such changes may include, without limitation: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;amending, modifying or terminating the Stock Option Plan with respect to all Common Shares in respect of Options which have not yet been granted thereunder; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;making any amendment of a &#8220;housekeeping nature&#8221;; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;changing the provisions relating to the manner of exercise of Options; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;accelerating vesting or extending the expiration date of any Option (provided that such Option is not held by an insider), provided that the period during which an Option is exercisable does not exceed 10 years from the date the Option is granted;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;adding a cashless exercise feature, payable in cash or securities, whether or not providing for a full deduction of the number of underlying Common Shares from the Stock Option Plan reserve; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;making any addition to, deletion from or alteration of the provisions of the Stock Option Plan or any Option that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other exchange on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of the Stock Option Plan.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Shareholder approval is required for any change to the Stock Option Plan or Options granted under it which:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;increases the number of Common Shares reserved for issuance under the Stock Option Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;extends eligibility to participate in the Stock Option Plan to persons other than Eligible Persons;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;permits Options to be transferred, other than for normal estate settlement purposes or to an RRSP or similar plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;permits awards other than Options to be made under the Stock Option Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;extends the term of an Option beyond the maximum expiry date set out in the Stock Option Plan (except where an expiry date would have fallen within a blackout period;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;reduces the exercise price of an Option, except for the purpose of maintaining Option value in connection with a conversion, change, reclassification, redivision, redesignation, subdivision or consolidation of shares or a reorganization, amalgamation, consolidation, merger, takeover bid or similar transaction involving the Corporation (for this purpose, cancellation or termination of an Option prior to its expiry date for the purpose of reissuing Options to the same Option-holder with a lower exercise price will be considered an amendment to reduce the exercise price of an Option);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;changes the insider participation limitation at any time under the Stock Option Plan; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;amends the amending provision of the Stock Option Plan. </span></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Award Plan</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Corporation&#8217;s Amended and Restated Incentive Share Award Plan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Award Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) dated effective as of May 4, 2017.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation, with the approval of its Shareholders, has established the Share Award Plan. Under the Share Award Plan, the Board may, at such times and in such amounts as the Board may deem advisable in its sole and absolute discretion, issue Performance Share Awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PSAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to eligible employees, including officers, and Restricted Share Awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, together with PSAs, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to Eligible Persons. The number of Common Shares reserved for issuance under the Share Award Plan and all other security based compensation arrangements of the Corporation (including the Stock Option Plan) in aggregate shall not exceed 10% of the total number of issued and outstanding Common Shares from time to time.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to earlier vesting in accordance with the terms of the Share Award Plan and unless otherwise determined by the Board, Share Awards granted under the Share Award Plan vest on the third anniversary date of the date of grant. Upon vesting, each RSA is deemed to be redeemed for no further consideration for one&#160;Common Share (subject to adjustment for dividend equivalents) and each PSA is deemed to be redeemed for no further consideration for one&#160;Common Share (subject to adjustment for dividend equivalents) multiplied by the percentage (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vesting Percentage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of outstanding PSAs that will vest based upon the relative achievement of any performance-related measures or criteria as determined by the Board in its sole discretion, which may include the Corporation&#8217;s performance compared to identified operational or financial targets and the Corporation&#8217;s shareholder return.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate number of Common Shares issuable at any time to insiders, under all security based compensation arrangements of the Corporation shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted basis). The aggregate number of Common Shares issued pursuant to all security based compensation arrangements of the Corporation, within a one year period, shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted basis). The Share Award Plan further provides that the aggregate number of Common Shares reserved for issuance to any one participant under all security based compensation arrangements of the Corporation, shall not exceed 5% of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum number of Common Shares that may be reserved for issuance to non-employee directors pursuant to RSAs under the Share Award Plan is 1% of the Common Shares outstanding at the time of the grant (on a non-diluted basis), less the aggregate number of Common Shares reserved for issuance to such non-employee director under any other security based compensation arrangement, and the total annual grant of RSAs to any one non-employee director cannot exceed a grant value of $150,000 (less the amount awarded to such non-employee director).</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Award Plan provides that if the issue date of any Share Award occurs during a blackout period, then the issue date for such Share Award shall not occur until the date which is the tenth (10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) business day after the last day of the such blackout period.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise determined by the Board in its sole discretion, upon a Change of Control (as such term is defined in the Share Award Plan), all unvested Share Awards shall become automatically vested (in the case of PSAs, with a deemed Vesting Percentage of 100). Common Shares issuable in respect of Share Awards shall be, and shall be deemed to be, issued to participants effective immediately prior to the completion of the transaction which would result in the Change of Control unless issued prior thereto in accordance with the Share Award Plan.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise determined by the Board or unless otherwise expressly set forth in a Share Award agreement pertaining to a particular Share Award or any written employment or other agreement governing a participant&#8217;s role as an Eligible Person if a participant ceases to be an Eligible Person as a result of the termination of such participant for cause or if a participant voluntarily ceases to be an Eligible Person for any reason other than as a result of the death, permanent disability or retirement of the participant, all outstanding Share Awards Agreements under which Share Awards have been granted to such participant shall be terminated. Upon the death, permanent disability or retirement of a participant (other than the early retirement of an eligible employees), all outstanding Share Awards shall immediately vest. If a participant ceases to be an Eligible Person other than in the circumstances provided above, all Share Awards awarded to such participant under any outstanding Share Awards shall fully vest effective as of the date of cessation of employment (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cessation Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), unless otherwise determined by the Board, and the participant shall be entitled to receive the number of Common Shares equal to the number of Share Awards granted multiplied by a fraction (A) the numerator of which is the number of days from the date of grant thereof to the Cessation Date; and (B) the denominator of which is the total number of days during which such Share Award were scheduled to vest upon grant. In such circumstances, the Vesting Percentage in respect of PSAs shall be determined as of the Cessation Date.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Award Plan and any Share Awards granted thereunder may be amended, modified or terminated by the Board without approval of Shareholders, subject to any required approval of the TSX. Such changes may include, without limitation: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;amending, modifying or terminating the Share Award Plan with respect to all Common Shares in respect of Share Awards which have not yet been granted thereunder; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;making any amendment of a &#8220;housekeeping nature&#8221;; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;making any addition to, deletion from or alteration of the provisions of this Plan or any Share Award that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other stock exchange on which the Common Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Share Award Plan or a Share Award may not be amended without shareholder approval to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;increase the number of Common Shares issuable pursuant to outstanding Share Awards at any time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;change the insider participation limit under the Share Award Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;expand the categories of individuals who are &#8220;eligible employees&#8221; who are eligible to participate in the Share Award Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;extend the term of any Share Award beyond the term of such awards provided for under the terms and conditions of the Share Award Plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;permit the transfer or assignment of Share Awards, except to permit a transfer to a family member, an entity controlled by the holder of the Share Awards or a family member, a charity or for estate planning or estate settlement purposes; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;change the amendment provisions of the Share Award Plan.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, no amendment to the Share Award Plan or any Share Awards granted pursuant thereto may be made without the consent of an Share Award Plan participant if it adversely alters or impairs the rights of such participant in respect of any Share Award previously granted to such participant under the Share Award Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_37"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Major Shareholders</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the knowledge of our directors and senior officers, as at March&#160;3, 2023, we are not aware of any shareholder who beneficially owns, directly or indirectly, or exercises control or direction over, our common shares carrying more than 5% of the voting rights.   </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Held in the United States</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates, as of February&#160;24, 2023, the total number of common shares issued and outstanding, the approximate total number of holders of record of common shares, the number of holders of record of common shares with U.S.&#160;addresses, the portion of the outstanding common shares held by U.S.&#160;holders of record, and the percentage of common shares held by U.S.&#160;holders of record. This table does not indicate beneficial ownership of common&#160;shares.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total number of holders of record</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total number of common shares issued and outstanding</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of U.S.&#160;holders of record</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of common shares held by U.S.&#160;holders of record</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of common shares held by U.S.&#160;holders of record&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,826,958</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,495,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change of Control</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;3, 2023, there were no arrangements known to the Company which may, at a subsequent date, result in a change of control of the Company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Control by Others</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the best of the Company&#8217;s knowledge, the Company is not directly or indirectly owned or controlled by another corporation(s), any foreign government, or any other natural or legal person, severally or jointly.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Related Party Transactions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment contracts with each of our senior management members (see Item 6).&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of the fiscal year ended December 31, 2022 up to March&#160;3, 2023, we did not enter into any other related party transactions and we do not have any loans outstanding with any officer, director or major shareholder.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Interests of Experts and Counsel</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_40"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Consolidated Statements and Other Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements filed as part of this annual report are filed under Item 18.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The directors and the management of the Company do not know of any material, active or pending, legal and bankruptcy proceedings against them; nor is the Company involved as a plaintiff in any material proceeding or pending litigation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The directors and the management of the Company know of no active or pending proceedings against anyone that might materially adversely affect an interest of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not paid any dividends on its common shares.&#160;The Company may pay dividends on its common shares in the future if it generates profits.&#160;Any decision to pay dividends on common shares in the future will be made by the board of directors on the basis of the earnings, financial requirements and other conditions existing at such time.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Significant Changes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No significant changes have occurred since the date of our annual financial statements included in this annual report on Form 20-F.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_43"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. THE OFFER AND LISTING</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable except for Item 9.A.4 and Item 9.C.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Shares, no par value, are traded/quoted on the Nasdaq and the TSX under the symbols &#8220;ONCY" and &#8220;ONC&#8221;, respectively.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160; ADDITIONAL INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Share Capital</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Memorandum and Articles of Association</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Articles of Continuance</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are governed by our amended articles of incorporation (the "Articles") under the Business Corporations Act of Alberta (the &#8220;Act&#8221;) and by our by-laws (the&#160;"By-laws"). Our Alberta corporate access number is 207797382. Our Articles provide that there are no restrictions on the business we may carry on or on the powers we may exercise. Companies incorporated under the Act are not required to include specific objects or purposes in their articles or by-laws.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subject to certain exceptions, including in respect of voting on any resolution to approve a contract that relates primarily to the director's remuneration, directors may not vote on resolutions to approve a material contract or material transaction if the director is a party to such contract or transaction. The directors are entitled to remuneration as shall from time to time be determined by the Board of Directors with no requirement for a quorum of independent directors. The directors have the ability under the Act to exercise our borrowing power, without authorization of the shareholders. The Act permits shareholders to restrict this authority through a company's articles or by-laws (or through a unanimous shareholder agreement), but no such restrictions are in place for us. Our Articles and By-laws do not require directors to hold shares for qualification. Neither the Articles or the By-laws contain an age limit requirement for the retirement of directors. The Corporation actively encourages independent board member renewal through its formal term limit policy, adopted on June 30, 2015, whereby the independent director term limit is set at 12 years. Under the policy, the Board of Directors maintains the discretion to extend a directors&#8217; term, if under the circumstances, it is in the best interest of the Corporation and its shareholders. This in practice ensures that new independent directors are appointed regularly, without losing the experience base of long serving directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights, Preferences, and Dividends Attaching to Shares</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common shares have the right to receive dividends if and when declared. Each holder of common shares, as of the record date prior to a meeting, is entitled to attend and to cast one vote for each common share held as of such record date at such annual and/or special meeting, including with respect to the election or re-election of directors. Subject to the provisions of our By-laws, all directors may, if still qualified to serve as directors, stand for re-election. The numbers of our Board of Directors are not replaced at staggered intervals but are elected annually.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a distribution of assets on a winding-up, dissolution, or other return of capital (subject to certain exceptions) the holders of common shares shall have a right to receive their </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pro&#160;rata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of such distribution. There are no sinking fund or redemption provisions in respect of the common shares. Our shareholders have no liability to further capital calls as all shares issued and outstanding are fully paid and non-assessable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other classes of shares are currently permitted to be issued.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Action Necessary to Change the Rights of Shareholders</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights attaching to the different classes of shares may be varied by special resolution passed at a meeting of that class's shareholders.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual and Special Meetings of Shareholders</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Act and our By-laws, we are required to mail a Notice of Meeting and Management Information Circular to registered shareholders not less than 21&#160;days and not more than 50 days prior to the date of the meeting. Such materials must be filed concurrently with the applicable securities regulatory authorities in Canada and the U.S..&#160;Subject to certain provisions of the By-laws, a quorum of two or more shareholders in person or represented by proxy holding or representing by proxy not less than five (5%) percent of the total number of issued and outstanding shares enjoying voting rights at such meeting is required to properly constitute a meeting of shareholders.&#160;Shareholders and their duly appointed proxies and corporate representatives are entitled to be admitted to our annual and/or special meetings.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations on the Rights to Own Shares</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Articles do not contain any limitations on the rights to own shares. Except as described below, there are currently no limitations imposed by Canadian federal or provincial laws on the rights of non-resident or foreign owners of Canadian securities to hold or vote the securities held. There are also no such limitations imposed by the Articles and By-laws with respect to our common&#160;shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Share Ownership</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under applicable securities regulation in Canada, a person or company who beneficially owns, directly or indirectly, voting securities of an issuer or who exercises control or direction over voting securities of an issuer or a combination of both, carrying more than 10% of the voting rights attached to all the issuer's outstanding voting securities is an insider and must, within 10&#160;days of becoming an insider, file&#160;a report in the required form effective the date on which the person became an insider. The report must disclose any direct or indirect beneficial ownership of, or control or direction over, securities of the reporting issuer. Additionally, securities regulation in Canada provides for the filing of a report by an insider of a reporting issuer whose holdings change, which report must be filed within 5&#160;days from the day on which the change takes place.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules in the U.S. governing the ownership threshold above which shareholder ownership must be disclosed are more stringent than those discussed above. Section 13 of the Exchange Act imposes reporting requirements on persons who acquire beneficial ownership (as such term is defined in Rule 13d-3 under the Exchange Act) of more than 5% of a class of an equity security registered under Section 12 of the Exchange Act.&#160;In general, such persons must file, within 10&#160;days after such acquisition, a report of beneficial ownership with the SEC containing the information prescribed by the regulations under Section&#160;13 of the Exchange Act. This information is also required to be sent to the issuer of the securities and to each exchange where the securities are&#160;traded.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Provisions of Articles and By-laws</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no provisions in the Articles or By-laws:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delaying or prohibiting a change in control of our company that operate only with respect to a merger, acquisition or corporate restructuring;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discriminating against any existing or prospective holder of shares as a result of such shareholder owning a substantial number of&#160;shares;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring disclosure of share ownership; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governing changes in capital, where such provisions are more stringent than those required by&#160;law.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Material Contracts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have employment contracts with each of our officers as summarized in Item 6B. Other than these employment contracts, we have not entered into any other contract other than in the ordinary course of business over the last two years.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Exchange Controls </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada presently has no system of exchange controls. There are no Canadian restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no laws in Canada or exchange restrictions affecting the remittance of dividends, profits, interest, royalties, and other payments to non-resident holders of our securities, except as discussed below in Section E, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restrictions on Share Ownership by Non-Canadians</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no limitations under the laws of Canada or in our organizing documents on the right of foreigners to hold or vote securities of our company, except that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Canada Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may require review and approval by the Minister of Industry (Canada) of certain acquisitions of &#8220;control&#8221; of our company by a &#8220;non-Canadian&#8221;. The threshold for acquisitions of control is generally defined as being one-third or more of the voting shares of the company. &#8220;Non-Canadian&#8221; generally means an individual who is not a Canadian citizen, or a corporation, partnership, trust, or joint venture that is ultimately controlled by non-Canadians.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Taxation  </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL CANADIAN FEDERAL INCOME TAX CONSIDERATIONS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is, as of the date of this annual report, a summary of the principal Canadian federal income tax considerations under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Canada) and the regulations thereunder  (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) generally applicable to an investor who acquires as beneficial owner Common Shares and who, for the purposes of the Tax Act and the Regulations and at all relevant times deals at arm&#8217;s length with the Corporation and the Agent, is not affiliated with the Corporation or the Agent, is not exempt from tax under Part I of the Tax Act, and who acquires and holds the Common Shares, as capital property (a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Generally, the Common Shares will be considered to be capital property to a Holder provided that the Holder does not hold the Common Shares in the course of carrying on a business as part of an adventure or concern in the nature of trade.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is generally applicable to a Holder who, at all relevant times, for purposes of the Tax Act: (i) is not, and is not deemed to be, resident in Canada for the purposes of the Tax Act or any applicable income tax treaty or convention; and (ii) does not and will not use or hold, and is not and will not be deemed to hold, the Common Shares in connection with carrying on a business in Canada (a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special rules, which are not discussed in this summary, may apply to certain holders that are insurers carrying on an insurance business in Canada and elsewhere or an &#8220;authorized foreign bank&#8221; (as defined in the Tax Act). Such Holders should consult their own tax advisors with respect to an investment in Common Shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is based upon the current provisions of the Tax Act in force as of the date of this annual report and counsel&#8217;s understanding of the current administrative policies and assessing practices of the Canada Revenue Agency (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) published in writing by the CRA prior to the date of this annual report. This summary takes into account all specific proposals to amend the Tax Act publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date of this annual report (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Proposals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and assumes that the Tax Proposals will be enacted in the form proposed, although no assurance can be given that the Tax Proposals will be enacted in their current form or at all. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the Tax Proposals, this summary does not otherwise take into account or anticipate any changes in law, whether by legislative, governmental, administrative, or judicial decision or action, nor does it take into account or consider any provincial, territorial or foreign income tax considerations (other than those described below under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which considerations may differ significantly from the Canadian federal income tax considerations discussed in this summary. This summary also does not take into account any change in the administrative policies or assessing practices of the CRA. No assurances can be given that the subsequent changes in law or administrative policy will not affect or modify the contents of this summary. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">This summary is of a general nature only, is not exhaustive of all possible Canadian federal income tax considerations and is not intended to be, nor should it be construed to be, legal or tax advice to any particular Holder. Holders should consult their own tax advisors with respect to the tax consequences to them in their particular circumstances, including the application and effect of the income and other tax laws of any country, province, state or local tax authority.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currency</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the Tax Act, all amounts relating to the acquisition, holding, or disposition of the Common Shares (including dividends, adjusted cost base and proceeds of disposition) must, to the extent such amounts are not in Canadian dollars, be converted into Canadian dollars based on an exchange rate determined in accordance with the Tax Act.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid or credited or deemed to be paid or credited on the Common Shares to a Non-Resident Holder by the Corporation are subject to Canadian withholding tax at the rate of 25% on the gross amount of the dividend, unless such rate is reduced by the terms of an applicable tax treaty. For example, under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada-United States Tax Convention (1980)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the rate of withholding tax on dividends paid or credited to a Non-Resident Holder who is a beneficial owner of dividends and who is a resident of the United States for purposes of the Treaty and who is fully entitled to the benefits of the Treaty is generally limited to 15% of the gross amount of the dividend (or 5% in the case of a Non-Resident Holder that is a company that beneficially owns at least 10% of the Common Shares). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holders are urged to consult their own tax advisors to determine their entitlement to relief under an applicable income tax treaty.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dispositions of Common Shares</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a disposition (or a deemed disposition) of a Common Share (other than to the Corporation unless purchased by the Corporation in the open market in the manner in which shares are normally purchased by any member of the public in the open market), a Non-Resident Holder generally will realize a capital gain (or a capital loss) equal to the amount by which the proceeds of disposition of such Common Shares, net of any reasonable costs of disposition, are greater (or are less) than the adjusted cost base of such Common Share to the Non-Resident Holder.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Non-Resident Holder generally will not be subject to tax under the Tax Act in respect of a capital gain realized on the disposition or deemed disposition of a Common Share and a capital loss arising on such a disposition or deemed disposition will not be recognized under the Tax Act unless the Common Share constitutes &#8220;taxable Canadian property&#8221; and is not &#8220;treaty-protected property&#8221; (each as defined under the Tax Act) of the Non-Resident Holder at the time of disposition or deemed disposition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provided the Common Shares are listed on a &#8220;designated stock exchange&#8221;, as defined in the Tax Act (which currently includes the NASDAQ and TSX), at the time of disposition, the Common Shares generally will not constitute taxable Canadian property of a Non-Resident Holder at that time, unless at any time during the 60 month period immediately preceding the disposition the following two conditions are met concurrently: (i) one or any combination of (a) the Non-Resident Holder, (b) persons with whom the Non-Resident Holder did not deal at arm&#8217;s length, and (c) partnerships in which the Non-Resident Holder or a person with whom the Non-Resident Holder did not deal at arm&#8217;s length held a membership interest directly or indirectly through one or more partnerships, owned 25% or more of the issued shares of any class or series of shares of the Corporation; and (ii) more than 50% of the fair market value of such shares was derived directly or indirectly from one or any combination of (a) real or immovable property situated in Canada, (b) &#8220;Canadian resource properties&#8221; (as defined in the Tax Act), (c) &#8220;timber resource properties&#8221; (as defined in the Tax Act) or (d) an option in respect of, an interest in, or for civil law a right in any of the foregoing property, whether or not such property exists. Notwithstanding the foregoing, a Common Share may otherwise be deemed to be taxable Canadian property to a Non-Resident Holder for purposes of the Tax Act in certain circumstances.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holders whose Common Shares may be taxable Canadian property should consult their own tax advisors.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a general summary of certain material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition, ownership and disposition of Common Shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and disposition of Common Shares. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, without limitation, specific tax consequences to a U.S. Holder under an applicable income tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder. This summary does not address the U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of Common Shares. In addition, except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. Each prospective U.S. Holder should consult its own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the &#8220;IRS&#8221;) has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.  This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the conclusions described in this summary.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Scope of this Summary</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Authorities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is based on the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury Regulations (whether final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the &#8220;Canada-U.S. Tax Convention&#8221;), and U.S. court decisions that are applicable, and, in each case, as in effect and available, as of the date of this document. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied retroactively. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation that, if enacted, could be applied on a retroactive or prospective basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Holders</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this summary, the term &#8220;U.S. Holder&#8221; means a beneficial owner of Common Shares that is for U.S. federal income tax purposes:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an individual who is a citizen or resident of the United States;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof, or the District of Columbia;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a trust that (1) is subject to the primary supervision of a court within the U.S. and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders that: (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method; (d) have a &#8220;functional currency&#8221; other than the U.S. dollar; (e) own Common Shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other integrated transaction; (f) acquire Common Shares in connection with the exercise of employee stock options or otherwise as compensation for services; (g) hold Common Shares other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); (h) are partnerships or other flow-through entities (and partners or other owners thereof); (i) are S corporations (and shareholders thereof); (i) are subject to special tax accounting rules </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with respect to Common Shares; or (j) own, have owned or will own (directly, indirectly, or by attribution) 10% or more of the total combined voting power or value of the outstanding shares of the Corporation; (k) are subject to taxing jurisdictions other than, or in addition to, the United States or otherwise hold Common Shares in connection with a trade or business, permanent establishment, or fixed base outside the United States; (l) are U.S. expatriates or former long-term residents of the United States subject to Section 877 or 877A of the Code; or (m) are subject to the alternative minimum tax. U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders described immediately above, should consult their own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership, and disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity or arrangement that is classified as a partnership (or other &#8220;pass-through&#8221; entity) for U.S. federal income tax purposes holds Common Shares, the U.S. federal income tax consequences to such entity or arrangement and the partners (or other owners or participants) of such entity or arrangement generally will depend on the activities of the entity or arrangement and the status of such partners (or owners or participants). This summary does not address the tax consequences to any such partner (or owner or participants). Partners (or other owners or participants) of entities or arrangements that are classified as partnerships or as &#8220;pass-through&#8221; entities for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership, and disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Passive Foreign Investment Company Rules</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PFIC Status of the Corporation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Corporation were to constitute a &#8220;passive foreign investment company&#8221; under the meaning of Section 1297 of the Code (a &#8220;PFIC&#8221;, as defined below) for any year during a U.S. Holder&#8217;s holding period, then certain potentially adverse rules would affect the U.S. federal income tax consequences to a U.S. Holder as a result of the acquisition, ownership and disposition of Common Shares. The Corporation believes that it was classified as a PFIC during the tax year ended <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180Ni9mcmFnOjdlMTJlYzU5NzFmYzQwY2Q4YTQ4MTZiMzk1ZmJjY2ZiL3RleHRyZWdpb246N2UxMmVjNTk3MWZjNDBjZDhhNDgxNmIzOTVmYmNjZmJfMTA5OTUxMTY4MjA1NQ_4b67ebcc-09b8-493b-81bc-2cbde23b5e2d"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180Ni9mcmFnOjdlMTJlYzU5NzFmYzQwY2Q4YTQ4MTZiMzk1ZmJjY2ZiL3RleHRyZWdpb246N2UxMmVjNTk3MWZjNDBjZDhhNDgxNmIzOTVmYmNjZmJfMTA5OTUxMTY4MjA1NQ_5ed46be8-3327-4e07-ad62-8dbccd3881b0">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric>, and based on current business plans and financial expectations, the Corporation expects that it will be a PFIC for the current tax year and may be a PFIC in future tax years. No opinion of legal counsel or ruling from the IRS concerning the status of the Corporation as a PFIC has been obtained or is currently planned to be requested. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any determination made by the Corporation (or any subsidiary of the Corporation) concerning its PFIC status. Each U.S. Holder should consult its own tax advisors regarding the PFIC status of the Corporation and each subsidiary of the Corporation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In any year in which the Corporation is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621 annually.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation generally will be a PFIC if, for a tax year, (a) 75% or more of the gross income of the Corporation is passive income (the &#8220;PFIC income test&#8221;) or (b) 50% or more of the value of the Corporation&#8217;s assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the &#8220;PFIC asset test&#8221;). &#8220;Gross income&#8221; generally includes all sales revenues less the cost of goods sold, plus income from investments and from incidental or outside operations or sources, and &#8220;passive income&#8221; generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the PFIC income test and PFIC asset test described above, if the Corporation owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Corporation will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes of the PFIC income test and PFIC asset test described above, and assuming certain other requirements are met, &#8220;passive income&#8221; does not include certain interest, dividends, rents, or royalties that are received or accrued by the Corporation from certain &#8220;related persons&#8221; (as defined in Section 954(d)(3) of the Code) also organized in Canada, to the extent such items are properly allocable to the income of such related person that is not passive income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain attribution rules, if the Corporation is a PFIC, U.S. Holders will generally be deemed to own their proportionate share of the Corporation&#8217;s direct or indirect equity interest in any company that is also a PFIC (a &#8216;&#8216;Subsidiary PFIC&#8217;&#8217;), and will generally be subject to U.S. federal income tax on their proportionate share of (a) any &#8220;excess distributions,&#8221; as described below, on the stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the stock of a Subsidiary PFIC by the Corporation or another Subsidiary PFIC, both as if such U.S. Holders directly held the shares of such Subsidiary PFIC. In addition, U.S. Holders may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary PFIC on the sale or disposition of Common Shares. Accordingly, U.S. Holders should be aware that they could be subject to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of Common Shares are made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Default PFIC Rules Under Section 1291 of the Code</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Corporation is a PFIC for any tax year during which a U.S. Holder owns Common Shares, the U.S. federal income tax consequences to such U.S. Holder of the acquisition, ownership, and disposition of Common Shares will depend on whether and when such U.S. Holder makes an election to treat the Corporation and each Subsidiary PFIC, if any, as a &#8220;qualified electing fund&#8221; or &#8220;QEF&#8221; under Section 1295 of the Code (a &#8220;QEF Election&#8221;) or makes a mark-to-market election under Section 1296 of the Code (a &#8220;Mark-to-Market Election&#8221;). A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election will be referred to in this summary as a &#8220;Non-Electing U.S. Holder.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code (described below) with respect to (a) any gain recognized on the sale or other taxable disposition of Common Shares and (b) any &#8220;excess distribution&#8221; received on the Common Shares. A distribution generally will be an &#8220;excess distribution&#8221; to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder&#8217;s holding period for the Common Shares, if shorter).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of Common Shares (including an indirect disposition of the stock of any Subsidiary PFIC), and any &#8220;excess distribution&#8221; received on Common Shares or with respect to the stock of a Subsidiary PFIC, must be ratably allocated to each day in a Non-Electing U.S. Holder&#8217;s holding period for the respective Common Shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferred rates). The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as &#8220;personal interest,&#8221; which is not deductible.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Corporation is a PFIC for any tax year during which a Non-Electing U.S. Holder holds Common Shares, the Corporation will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether the Corporation ceases to be a PFIC in one or more subsequent tax years. A Non-Electing U.S. Holder may terminate this deemed PFIC status by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above), but not loss, as if such Common Shares were sold on the last day of the last tax year for which the Corporation was a PFIC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">QEF Election</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a timely and effective QEF Election for the first tax year in which the holding period of its Common Shares begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its Common Shares. A U.S. Holder that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Holder&#8217;s pro rata share of (a) the net capital gain of the Corporation, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the ordinary earnings of the Corporation, which will be taxed as ordinary income to such U.S. Holder. Generally, &#8220;net capital gain&#8221; is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and &#8220;ordinary earnings&#8221; are the excess of (a) &#8220;earnings and profits&#8221; over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Corporation is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Corporation. However, for any tax year in which the Corporation is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as &#8220;personal interest,&#8221; which is not deductible.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a timely and effective QEF Election with respect to the Corporation generally (a) may receive a tax-free distribution from the Corporation to the extent that such distribution represents &#8220;earnings and profits&#8221; of the Corporation that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF Election will be treated as &#8220;timely&#8221; if such QEF Election is made for the first year in the U.S. Holder&#8217;s holding period for the Common Shares in which the Corporation was a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year. If a U.S. Holder does not make a timely and effective QEF Election for the first year in the U.S. Holder&#8217;s holding period for the Common Shares, the U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Holder meets certain requirements and makes a &#8220;purging&#8221; election to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above) as if such Common Shares were sold for their fair market value on the day the QEF Election is effective. If a U.S. Holder makes a QEF Election but does not make a &#8220;purging&#8221; election to recognize gain as discussed in the preceding sentence, then such U.S. Holder shall be subject to the QEF Election rules and shall continue to be subject to tax under the rules of Section 1291 discussed above with respect to its Common Shares. If a U.S. Holder owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the Subsidiary PFIC for the QEF rules to apply to both PFICs. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A QEF Election will apply to the tax year for which such QEF Election is timely made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Corporation ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Corporation is not a PFIC. Accordingly, if the Corporation becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which the Corporation qualifies as a PFIC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation: (a) will make available to U.S. Holders, upon their written request, information as to its status as a PFIC and the PFIC status of any subsidiary in which the Corporation owns more than 50% of such subsidiary&#8217;s total aggregate voting power and (b) for each year in which the Corporation is a PFIC, provide to a U.S. Holder, upon written request, such information and documentation that a U.S. Holder making a QEF Election with respect to the Corporation and such more than 50% owned subsidiary which constitutes a PFIC is reasonably required to obtain for U.S. federal income tax purposes. The Corporation may elect to provide such information on its website. With respect to any Subsidiary PFIC in which the Corporation owns 50% or less of the aggregate voting power, upon the written request of a U.S. Holder acquiring Common Shares, the Corporation will request that such Subsidiary PFIC provide such U.S. Holder with the information that such U.S. Holder requires to report under the QEF rules; provided, however, the Corporation can provide no assurances that such Subsidiary PFIC will provide such information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed United States federal income tax return. However, if the Corporation does not provide the required information with regard to the Corporation or any of its Subsidiary PFICs, U.S. Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Mark-to-Market Election</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder may make a Mark-to-Market Election only if the Common Shares are marketable stock. The Common Shares generally will be &#8220;marketable stock&#8221; if the Common Shares are regularly traded on (a) a national securities exchange that is registered with the Securities and Exchange Commission, (b) the national market system established pursuant to section 11A of the U.S. Exchange Act, or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and surveillance requirements, and meets other requirements, and the laws of the country in which such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange effectively promote active trading of listed stocks. If such stock is traded on such a qualified exchange or other market, such stock generally will be &#8220;regularly traded&#8221; for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Provided that the Common Shares are &#8220;regularly traded&#8221; as described in the preceding sentence, the Common Shares are expected to be marketable stock. However, each U.S. Holder should consult its own tax advisor in this matter. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a Mark-to-Market Election with respect to its Common Shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such Common Shares. However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder&#8217;s holding period for the Common Shares for which the Corporation is a PFIC and such U.S. Holder has not made a timely QEF Election, the rules of Section 1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Corporation is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the Common Shares, as of the close of such tax year over (b) such U.S. Holder&#8217;s adjusted tax basis in such Common Shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Holder&#8217;s adjusted tax basis in the Common Shares, over (b) the fair market value of such Common Shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of Common Shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years). Losses that exceed this limitation are subject to the rules generally applicable to losses provided in the Code and Treasury Regulations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder makes a Mark-to-Market Election by attaching a completed IRS Form 8621 to a timely filed United States federal income tax return. A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the Common Shares cease to be &#8220;marketable stock&#8221; or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a Mark-to-Market Election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the Common Shares, no such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning, because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective to avoid the application of the default rules of Section 1291 of the Code described above with respect to deemed dispositions of Subsidiary PFIC stock or excess distributions from a Subsidiary PFIC to its shareholder.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other PFIC Rules</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize gain (but not loss) upon certain transfers of Common Shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations). However, the specific U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which Common Shares are transferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain additional adverse rules may apply with respect to a U.S. Holder if the Corporation is a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For example, under Section 1298(b)(6) of the Code, a U.S. Holder that uses Common Shares as security for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a U.S. Holder who acquires Common Shares from a decedent will not receive a &#8220;step up&#8221; in tax basis of such Common Shares to fair market value unless such decedent had a timely and effective QEF Election in place.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such special rules, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should consult with its own tax advisors regarding the availability of the foreign tax credit with respect to distributions by a PFIC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PFIC rules are complex, and each U.S. Holder should consult its own tax advisors regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Rules Applicable to the Ownership and Disposition of Common Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion describes the general rules applicable to the ownership and disposition of the Common Shares but is subject in its entirety to the special rules described above under the heading &#8220;Passive Foreign Investment Company Rules.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Distributions on Common Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that receives a distribution, including a constructive distribution, with respect to a Common Share will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the current and accumulated &#8220;earnings and profits&#8221; of the Corporation, as computed for U.S. federal income tax purposes. A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates if the Corporation is a PFIC for the tax year of such distribution or the preceding tax year. To the extent that a distribution exceeds the current and accumulated &#8220;earnings and profits&#8221; of the Corporation, such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder&#8217;s tax basis in the Common Shares and thereafter as gain from the sale or exchange of such Common Shares. (See &#8220;Sale or Other Taxable Disposition of Common Shares&#8221; below). However, the Corporation may not maintain the calculations of its earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder may have to assume that any distribution by the Corporation with respect to the Common Shares will constitute ordinary dividend income. Dividends received on Common Shares by corporate U.S. Holders generally will not be eligible for the &#8220;dividends received deduction.&#8221; Subject to applicable limitations and provided the Corporation is eligible for the benefits of the Canada-U.S. Tax Convention or the Common Shares are readily tradable on a United States securities market, dividends paid by the Corporation to non-corporate U.S. Holders, including individuals, generally will be eligible for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including that the Corporation not be classified as a PFIC in the tax year of distribution or in the preceding tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisors regarding the application of such rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sale or Other Taxable Disposition of Common Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the sale or other taxable disposition of Common Shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the U.S. dollar value of cash received plus the fair market value of any property received and such U.S. Holder&#8217;s tax basis in such Common Shares sold or otherwise disposed of. A U.S. Holder&#8217;s tax basis in Common Shares generally will be such holder&#8217;s U.S. dollar cost for such Common Shares. Gain or loss recognized on such sale or other disposition generally will be long-term capital gain or loss if, at the time of the sale or other disposition, the Common Shares have been held for more than one year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferential tax rates currently apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation. Deductions for capital losses are subject to significant limitations under the Code.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Considerations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Receipt of Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of any distribution paid to a U.S. Holder in foreign currency, or on the sale, exchange or other taxable disposition of Common Shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time). A U.S. Holder will have a basis in the foreign currency equal to its U.S. dollar value on the date of receipt. Any U.S. Holder who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method of tax accounting. Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Tax Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid on the Common Shares will be treated as foreign-source income, and generally will be treated as &#8220;passive category income&#8221; or &#8220;general category income&#8221; for U.S. foreign tax credit purposes. The Code applies various complex limitations on the amount of foreign taxes that may be claimed as a credit by U.S. taxpayers. In addition, Treasury Regulations that apply to taxes paid or accrued in taxable years beginning on or after December 28, 2021 (the &#8220;Foreign Tax Credit Regulations&#8221;) impose additional requirements for Canadian withholding taxes to be eligible for a foreign tax credit, and there can be no assurance that those requirements will be satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the PFIC rules and the Foreign Tax Credit Regulations, each as discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the Common Shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax. Generally, a credit will reduce a U.S. Holder&#8217;s U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder&#8217;s income that is subject to U.S. federal income tax. This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder during a year. The foreign tax credit rules are complex and involve the application of rules that depend on a U.S. Holder&#8217;s particular circumstances. Accordingly, each U.S. Holder should consult its own U.S. tax advisors regarding the foreign tax credit rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Backup Withholding and Information Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. federal income tax law, certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Holders that hold certain specified foreign financial assets in excess of certain thresholds. The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity. U.S. Holders may be subject to these reporting requirements unless their Common </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares are held in an account at certain financial institutions. Penalties for failure to file certain of these information returns are substantial. U.S. Holders should consult with their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made within the U.S., or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of, Common Shares will generally be subject to information reporting and backup withholding tax if a U.S. Holder (a) fails to furnish such U.S. Holder&#8217;s correct U.S. taxpayer identification number (generally on Form W-9), (b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding tax. However, certain exempt persons generally are excluded from these information reporting and backup withholding rules. Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Holder&#8217;s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS in a timely manner. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder. A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement. Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF COMMON SHARES. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO THEM IN THEIR OWN PARTICULAR CIRCUMSTANCES.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Dividends and Paying Agents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Not Applicable.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Statements by Experts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Documents on Display</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the informational requirements of the Exchange Act and file reports and other information with the SEC. The SEC maintains a Website that contains reports, proxy and information statements, and other information regarding registrants that file electronically with the SEC at www.sec.gov. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to file reports and other information with the securities commissions in Canada. You are invited to read and copy any reports, statements, or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval ("SEDAR") (www.sedar.com), the Canadian equivalent of the SEC's electronic document gathering and retrieval system.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We "incorporate by reference" information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this Form&#160;20-F and&#160;more recent information automatically updates and supersedes more dated information contained or incorporated by reference in this Form&#160;20-F.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will provide without charge to each person, including any beneficial owner, to whom a copy of this annual report has been delivered, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this annual report (not&#160;including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">address: Oncolytics Biotech Inc., 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5, Attention:&#160;Kirk Look.&#160;&#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.61pt">Subsidiary Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_49"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Please see Item 4 &#8211; &#8220;Information on the Company&#8221; and Note 16 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our audited consolidated financial statements beginning on page F-1 of this annual report on Form 20-F.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any long-term debt, nor do we currently utilize interest rate swap contracts to hedge against interest rate&#160;risk.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use financial instruments for trading purposes and are not parties to any leverage derivatives.&#160;We do not currently engage in hedging transactions. </span></div><div><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160; DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_55"></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_58"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160; &#160;DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_61"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160; MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A. - D. Material Modification to the Rights of Security Holders</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E. Use of Proceeds</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_64"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the conclusion of our Chief Executive Officer and Chief Financial Officer that our Company's disclosure controls and procedures (as defined in Exchange Act rules 13a-15(e) and 15d-15(e)), based on their evaluation of these controls and procedures as of the end of the period covered by this annual report, are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements for external purposes in accordance with International Reporting Standards as issued by the International Accounting Standards Board ("IFRS"), and includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2022. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, 2013 Framework, (COSO) in Internal Control-Integrated Framework.&#160;Based on this assessment, management believes that, as of December 31, 2022, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Attestation Report of the Registered Public Accounting Firms</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Securities and Exchange Commission&#8217;s rules regarding non-accelerated filers, this annual report does not</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include an attestation report of the Company's independent registered public accounting firm regarding the Company's internal</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">control over financial reporting.</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Controls over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal controls over financial reporting that occurred during the period that is covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.&#160;</span></div><div><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16 .&#160; [RESERVED]</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_70"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16A.&#160; AUDIT COMMITTEE FINANCIAL EXPERT</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has determined that each of the Audit Committee members, Angela Holtham, Wayne Pisano, Deborah Brown, and James T. Parsons is an audit committee financial expert and each is independent pursuant to the Rule 5605(d)(2) of the Nasdaq Capital Market and Rule 10A-3 of the Exchange Act. For a description of the education and experience of each member of the Audit Committee, see Item 6A. Directors, Senior Management and Employees."</span></div><div><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_73"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16B.&#160; CODE OF ETHICS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has adopted a Code of Ethics for the Company that includes our Chief Executive Officer, Chief Financial Officer and Accounting Officer that applies to our Chief Executive Officer, Chief Financial Officer, and Controller.&#160;A copy of this Code of Ethics may be found on the Company&#8217;s website at www.oncolyticsbiotech.com.&#160;&#160;Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5, Attention:&#160;&#160;Kirk Look &#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no amendments to our Code of Ethics during the fiscal year ended December 31, 2022. We did not grant any waivers to the provisions of our Code of Ethics during the fiscal year ended December 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16C.&#160; PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Fees and Services</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the financial years ended December 31, 2022 and 2021, Ernst &amp; Young LLP (PCAOB ID: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN183Ni9mcmFnOmVkYjVkNmQ2NTUzOTRkMjU5ZjkxMDIzMGYwODNhMTlkL3RleHRyZWdpb246ZWRiNWQ2ZDY1NTM5NGQyNTlmOTEwMjMwZjA4M2ExOWRfMTA5OTUxMTYyOTcyMg_cfb304af-8150-4e14-8a58-71788f76ebbb">1263</ix:nonNumeric>) received the following fees:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit-related fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Audit fees were for professional services rendered for the audit of our annual financial statements and services provided in connection with statutory and regulatory filings or engagements, including review of interim financial statements, accounting consultations, assistance with prospectus filings, and matters relating to the provision of a consent letter for various filings.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Audit-related fees were for assurance and related services reasonably related to the performance of the audit or review of the annual statements and are not reported under the heading Audit Fees above.&#160;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Tax fees were for tax return preparations, scientific research and development return, and other tax consultation fees.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Other fees are for products and services other than those described under the headings Audit Fees, Audit-Related Fees and Tax Fees above.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee pre-approves all audit services to be provided to us by our independent auditors. The Audit Committee&#8217;s policy regarding the pre-approval of non-audit services to be provided to us by our independent auditors is that all such services shall be pre-approved by the Audit Committee or by the Chair of the Audit Committee, who must report all such pre-approvals to the Audit Committee at their next meeting following the granting thereof. Non-audit services that are prohibited to be provided to us by our independent auditors may not be pre-approved. In addition, prior to the granting of any pre-approval, the Audit Committee or the Chair, as the case may be, must be satisfied that the performance of the services in question will not compromise the independence of the independent auditors.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_79"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_82"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16E. PURCHASE OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_85"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16F.&#160; CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_88"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16G. CORPORATE GOVERNANCE</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NASDAQ CORPORATE GOVERNANCE</span></div><div style="margin-top:3.4pt;padding-left:4.5pt;padding-right:333pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common shares are quoted for trading on the Nasdaq Capital Market. Section 5615(a)(3) of the Nasdaq Marketplace Rules permits the Nasdaq to grant exemptions to a foreign private issuer for the provisions of the Rule 5600 series, Rule 5250 (d), and Rules 5210(c) and 5255 related to qualitative listing requirements. We are organized under the laws of the Province of Alberta and our common shares are listed for trading on The Toronto Stock Exchange. We comply with the laws of the Province of Alberta and rules and regulations of The Toronto Stock Exchange, including rules related to corporate governance practices. A description of the significant ways in which our governance practices differ from those followed by domestic companies pursuant to the Nasdaq Marketplace Rules is as follows:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Shareholder Meeting Quorum Requirement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">: The Nasdaq minimum quorum requirement for a shareholder meeting under Section 5620(c) of the Nasdaq Marketplace Rules is one-third of the outstanding shares of common stock. In addition, a company listed on Nasdaq is required to state our quorum requirement in our bylaws. Our quorum </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">requirement is set forth in our corporate bylaws. A quorum for our shareholder meeting is two persons present and being, or representing by proxy, members holding not less than 5% of the issued shares entitled to be voted at such meeting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The foregoing is consistent with the laws, customs and practices in Canada and the rules of The Toronto Stock Exchange.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Board Diversity Matrix (as of February&#160;24, 2023)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country of Principal Executive Offices:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Private Issuer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosure Prohibited Under Home Country Law</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Number of Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Female</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Male</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Binary</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Did Not Disclose Gender</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I: Gender Identity</span></td><td colspan="12" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II: Demographic Background</span></td><td colspan="12" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underrepresented Individual in Home Country Jurisdiction</span></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LGBTQ+</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Did Not Disclose Demographic Background</span></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_91"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16H.&#160; MINE SAFETY DISCLOSURE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_94"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16I.&#160; DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_97"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 17. FINANCIAL STATEMENTS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 18.  &#8211; &#8220;Financial Statements&#8221;.</span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_103"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 18 FINANCIAL STATEMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements appear on pages F-1 through F-24.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 19. EXHIBITS.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this annual report:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NUMBER</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">DESCRIPTION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Constating Documents</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992822000017/articles.htm">Articles of Incorporation</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992822000017/ex12onc-2017byxlaws1636459.htm">By-laws</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Securities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex21exdescriptionofsecurit.htm">Description of Securities Registered Under Section 12 of the Exchange Act</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Material Contracts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex41august2013hagerman.htm">Employment Agreement, dated August 1, 2013 between Oncolytics Biotech Inc. and its Director, Manufacturing and Engineering, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex42hagermandec2015.htm">Amending Agreement, dated December 1, 2015 between Oncolytics Biotech Inc. and its Director, Manufacturing and Engineering, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/ex443deguttadauro.htm">Employment Agreement, dated June 29, 2017 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)#</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/ex444regionallicensingagre.htm">License, development, supply and distribution agreement with Adlai Nortye Biopharma Co., Ltd dated November 14, 2017 </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex47hagermanamendment2019.htm">Amending Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex48kirklook2019.htm">Executive Employment Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex49coffey2019.htm">Executive Employment Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex412employmentagreementth.htm">Employment Agreement, dated August 3, 2020 between Oncolytics Biotech (U.S.) Inc. and its Global Head of Clinical Development and Operations, Thomas C. Heineman </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex413mattcoffeyamendment-e.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex414kirklookamendment-emp.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex415allisonhagermanamendm.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex416andrewdeguttadauroame.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex417thomasheinemanamendme.htm">Amending Agreement, dated January 1, 2021 between Oncolytics Biotech (U.S.) Inc. and its Global Head of Clinical Development and Operations, Thomas C. Heineman </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992822000017/ex418mattcoffeyamendment3-.htm">Amending Agreement, dated January 1, 2022 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992822000017/ex419kirklookamendment3-em.htm">Amending Agreement, dated January 1, 2022 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992822000017/ex420allisonhagermanamendm.htm">Amending Agreement, dated January 1, 2022 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992822000017/ex421andrewdeguttadauroame.htm">Amending Agreement, dated January 1, 2022 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992822000017/ex422thomasheinemanamendme.htm">Amending Agreement, dated January 1, 2022 between Oncolytics Biotech (U.S.) Inc. and its Chief Medical Officer, Thomas C. Heineman </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex419mattcoffeyamendment4-.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex420kirklookamendment4-em.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex421allisonhagermanamendm.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex422andrewdeguttadauroame.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech (U.S.) Inc. and its President, Andrew de Guttadauro</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex423thomasheinemanamendme.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech (U.S.) Inc. and its Chief Medical Officer, Thomas C. Heineman </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiaries</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex80subsidiaries2022.htm">List of subsidiaries</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certifications</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex121ceocertification2022.htm">Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex122cfocertification2022.htm">Certificate of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex131ceocertification2022.htm">Certificate of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex132cfocertification2022.htm">Certificate of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Exhibits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex151-2022mda.htm">The Registrant's Management's Discussion and Analysis for the Year Ended December 31, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex152ey2022consent.htm">Consent of Ernst &amp; Young LLP</a></span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Schema.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Calculation Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Definition Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Label Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Presentation Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover page interactive data file (formatted as Inline XBRL and included in Exhibit 101)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">* - Denotes management contract or agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"># - Certain portions of this exhibit have been redacted pursuant to a confidential treatment request filed with the SEC on March 19, 2018</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Previously filed with the SEC on Form 20-F dated March 19, 2018, and incorporated by reference.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Previously filed with the SEC on Form 20-F dated March 6, 2020, and incorporated by reference.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Previously filed with the SEC on Form 20-F dated March 5, 2021, and incorporated by reference.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Previously filed with the SEC on Form 20-F dated March 3, 2022, and incorporated by reference. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March&#160;3, 2023 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENT OF MANAGEMENT&#8217;S RESPONSIBILITY</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for the preparation and presentation of the consolidated financial statements, Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;), and all other information in the annual report.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the accompanying consolidated financial statements have been properly prepared within reasonable limits of materiality and in accordance with the appropriately selected International Financial Reporting Standards as issued by the International Accounting Standards Board consistently applied and summarized in the consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include estimates that are necessary when transactions affecting the current accounting period cannot be finalized with certainty until after the balance sheet date.&#160;Based on careful judgments by management, such estimates have been properly reflected in the accompanying consolidated financial statements.&#160;The financial information presented elsewhere in the annual report has been reviewed to ensure consistency with that in the consolidated financial statements. The MD&amp;A also includes information regarding the impact of current transactions and events, sources of liquidity and capital resources, and risks and uncertainty.&#160;Actual results in the future may differ materially from our present assessment of this information because future events and circumstances may not occur as expected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Systems of internal controls, including organizational and procedural controls and internal controls over financial reporting, assessed as reasonable and appropriate in the circumstances, are designed and maintained by management to provide reasonable assurance that assets are safeguarded from loss or unauthorized use and to produce reliable records for preparation of financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMTUvZnJhZzpjZWMzYzA0MjE3MDQ0M2I4OTZjOTg4NDExMjI4ZmRkZS90ZXh0cmVnaW9uOmNlYzNjMDQyMTcwNDQzYjg5NmM5ODg0MTEyMjhmZGRlXzQ2MDE_2b016e78-338c-42ac-ab79-c6b169a1e20d">Ernst &amp; Young LLP</ix:nonNumeric>, an independent firm of Chartered Professional Accountants, has been engaged, as approved by a vote of the shareholders' at the Company's most recent Annual General Meeting, to audit and provide their independent audit opinion on the Company's consolidated financial statements as at and for the year ended December&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young has full and free access to our Board of Directors and its Committees to discuss audit, financial reporting, and related matters.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is responsible for ensuring that management fulfills its responsibilities for financial reporting and internal control.&#160;The Board exercises this responsibility through the Audit Committee of the Board, which is comprised entirely of independent directors.&#160;This Committee meets with management and the external auditors to satisfy itself that management&#8217;s responsibilities are properly discharged and to review the consolidated financial statements and MD&amp;A before they are presented to the Board of Directors for approval. The consolidated financial statements have been approved by the Board on the recommendation of the Audit Committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Oncolytics Biotech Inc. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated statements of financial position of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements of loss and comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with International Financial Reporting Standards (IFRSs) as issued by the International Accounting Standards Board.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/Ernst &amp; Young LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chartered Professional Accountants </span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.877%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="5" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 1999.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMTgvZnJhZzoyNzNjMTUyYjhjZjU0Y2M5YmQ2YzBhNzkwNWI0ZjMxYi90YWJsZTpkMDJjMzllY2Q5M2M0ZGRiODdjYzI0N2EzODMyODBjMS90YWJsZXJhbmdlOmQwMmMzOWVjZDkzYzRkZGI4N2NjMjQ3YTM4MzI4MGMxXzMtMC0xLTEtMzUzODM_72faa160-3800-4e8d-b006-d4e8bcb09fa1">Calgary, Canada</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2, 2023</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:67.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzMtMS0xLTEtMzUzODM_24885483-90b2-4164-a37c-c467ee314055">11,666</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzMtMy0xLTEtMzUzODM_9f5e037e-442e-46be-ba7f-4872942e9a4d">41,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:CurrentFinancialAssetsAvailableforsale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzQtMS0xLTEtMzc0MDc_c04797eb-05d0-4732-b160-aba2a2dee5fa">20,472</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:CurrentFinancialAssetsAvailableforsale" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzQtMy0xLTEtMzczOTk_5642a183-27ef-4421-8aa4-728e3e6237d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables (note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:OtherCurrentReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzQtMS0xLTEtMzUzODM_5c4cca4a-e409-4cc7-b7c7-663f905e7dc3">521</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:OtherCurrentReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzQtMy0xLTEtMzUzODM_43a78718-b117-46ff-9669-b23df6c9735d">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses (note 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:CurrentPrepayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzUtMS0xLTEtMzUzODM_1aa3447a-4283-433c-8d75-5cae83b03c74">3,025</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:CurrentPrepayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzUtMy0xLTEtMzUzODM_acfb028b-2f83-40a5-8c78-b6b0bb824ef5">2,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzYtMS0xLTEtMzUzODM_6521a759-c9f4-4b54-b2a1-c721f3ea2373">35,684</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzYtMy0xLTEtMzUzODM_9ae517a6-adee-4018-9ecb-2c8fb9821180">44,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment (note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzctMS0xLTEtMzUzODM_92c16ea8-01bc-463f-9439-00b34ec650c8">356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzctMy0xLTEtMzUzODM_aa4e1ff2-55b1-4b75-bbf0-195683c87cd1">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets (note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzgtMS0xLTEtMzUzODM_03adbcaf-5666-422b-bafc-2c7e17b5dc93">296</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzgtMy0xLTEtMzUzODM_76f6b90a-b491-4c7e-ac2e-d63d4dc06dcb">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses (note 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:NoncurrentPrepayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzEwLTEtMS0xLTQ2MDEz_f63100f1-c93a-481e-8a9a-b634841f5469">998</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:NoncurrentPrepayments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzEwLTMtMS0xLTQ2MDIy_5cf5ed06-2ea8-4b2a-af97-8ceb2a714ca4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzktMS0xLTEtMzUzODM_23688763-26d9-4a15-96fa-ca1e7bda49ba">37,334</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzktMy0xLTEtMzUzODM_af2a7ecb-c40b-4f18-9a6e-f14ad91f5755">45,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities And Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities (note 7)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzEyLTEtMS0xLTM1Mzgz_9eff9e6a-b91f-4bd9-a4ff-03a91743e111">3,650</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzEyLTMtMS0xLTM1Mzgz_49ee55c9-3f5e-4bf8-84bd-9d1b869e3797">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities (note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzEzLTEtMS0xLTM1Mzgz_9e343fac-7d8e-48b4-a2e8-d520b94f71a3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzEzLTMtMS0xLTM1Mzgz_6b629c9d-3427-40cd-918b-abf2452dbbc3">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE0LTEtMS0xLTM1Mzgz_ee1dbf8c-65f4-4356-8790-bfadf1c66ae2">216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE0LTMtMS0xLTM1Mzgz_7e70d0a4-213c-4686-8115-5a8b0c8e6996">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative (notes 9(b), 16)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE1LTEtMS0xLTM1Mzgz_fddbbb79-40cb-4506-ba5c-a3e3c6e49b01">79</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE1LTMtMS0xLTM1Mzgz_e564b154-ab98-4fcb-89de-347cb6d4ad4e">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE2LTEtMS0xLTM1Mzgz_5eaa39ce-117a-4ef0-824d-40837ea2ef6b">3,945</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE2LTMtMS0xLTM1Mzgz_3a483890-201a-4ff3-82bd-b2a64dc858e0">2,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability (note 12)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE3LTEtMS0xLTM1Mzgz_910c6111-5bba-4031-b487-97fc0ebafa25">6,730</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE3LTMtMS0xLTM1Mzgz_5be23796-4751-49ff-9c59-3a7f642885f1">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE4LTEtMS0xLTM1Mzgz_1f4efc1c-4ed3-43f4-b931-0770dd942351">157</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE4LTMtMS0xLTM1Mzgz_da4719c2-48d1-4f73-b57a-e653db1e0ee3">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE5LTEtMS0xLTM1Mzgz_9f588a0e-8c56-4688-9371-111e4a0eb38b">10,832</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE5LTMtMS0xLTM1Mzgz_8d5e8490-1e11-4612-b1d5-74ee4deee880">9,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (notes 13)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" xsi:nil="true" name="oncyf:CommitmentsAndContingencies1" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIwLTEtMS0xLTM1Mzgz_af243222-6d95-496a-bc8b-f908a29ad344"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" xsi:nil="true" name="oncyf:CommitmentsAndContingencies1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIwLTMtMS0xLTM1Mzgz_a60da0b6-4d69-4124-a81d-57d75eb2d683"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital (note 9)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Authorized: unlimited</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Issued: December 31, 2022 &#8211; <ix:nonFraction unitRef="shares" contextRef="ied69a4c1e8dc444497553637c429c995_I20221231" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIyLTAtMS0xLTM1MzgzL3RleHRyZWdpb246MWM3MWMzOGM4YmZiNGVjMzg5YjE0NDE5OTMzY2Y2N2ZfMTA5OTUxMTYyNzkxMA_c7640ad5-435c-494d-8c5b-129845408eb6">61,327,914</ix:nonFraction></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;December 31, 2021 &#8211; <ix:nonFraction unitRef="shares" contextRef="ieee4c1d19b10441a9fb87c20bf21e3fa_I20211231" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIyLTAtMS0xLTM1MzgzL3RleHRyZWdpb246MWM3MWMzOGM4YmZiNGVjMzg5YjE0NDE5OTMzY2Y2N2ZfMTA5OTUxMTYyNzkyMw_7dcc1e13-351c-438a-bd4c-eb1b5316673e">55,043,789</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIyLTEtMS0xLTM1Mzgz_830880b7-21af-4567-a0eb-49a7421b7ddc">404,040</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIyLTMtMS0xLTM1Mzgz_7a054ba7-eb8f-4535-9263-f1a2bd0abf91">391,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="oncyf:WarrantsandRightsOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIzLTEtMS0xLTM1Mzgz_bce8a5fc-5c08-48ee-bf8d-f0b275378390">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="oncyf:WarrantsandRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIzLTMtMS0xLTM1Mzgz_b52dede6-6af3-4c5a-b442-158709e5eb90">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributed surplus (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:AdditionalPaidinCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI0LTEtMS0xLTM1Mzgz_7baa9be0-bb71-41b5-9a07-567acac1c947">40,051</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:AdditionalPaidinCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI0LTMtMS0xLTM1Mzgz_7a233600-fb03-4f8f-ba9a-944b994ce3f8">34,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI1LTEtMS0xLTM1Mzgz_e99d32db-4c7f-4f93-880b-53435def52d1">662</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI1LTMtMS0xLTM1Mzgz_993e3576-c403-4eee-a90f-1f73f7fdf336">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI2LTEtMS0xLTM1Mzgz_1fc38420-d3ff-4663-850e-0f69a45bb844">418,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI2LTMtMS0xLTM1Mzgz_d69a3896-3e0b-4ba7-a3af-659372e700aa">393,416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI3LTEtMS0xLTM1Mzgz_1c8eafd2-989f-44e7-8700-9b18308c20a9">26,502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI3LTMtMS0xLTM1Mzgz_16d029e1-c716-4612-9c87-8481899eb49f">36,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders' equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI4LTEtMS0xLTM1Mzgz_a6f1071f-9037-453f-aa4e-341216f40dea">37,334</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI4LTMtMS0xLTM1Mzgz_0589c07b-a92b-4471-9a70-bd883ae20890">45,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">          See accompanying notes</span></div><div style="padding-left:22.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:5pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"></td><td style="width:46.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;On behalf of the Board:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Angela Holtham</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Wayne Pisano</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Director&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Director&#160;&#160;&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development (note 19)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzItMS0xLTEtMzUzODM_adc16455-d36d-458f-93bd-6537389276cd">15,432</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzItMy0xLTEtMzUzODM_8fbec08f-f42c-4ea3-b090-113116dd6b15">12,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzItNS0xLTEtMzUzODM_48a98b30-cd3e-489b-b790-056b3000f82a">12,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;General and administrative (note 19)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzMtMS0xLTEtMzUzODM_bd94e035-1e09-4a13-8050-fe920494abec">11,492</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzMtMy0xLTEtMzUzODM_3f85011b-4017-48ba-9924-d552ca2b8f77">13,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzMtNS0xLTEtMzUzODM_da2db7c7-4135-4b7b-94cf-4b463e60242b">12,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before the following</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzQtMS0xLTEtMzUzODM_46db4bac-4fb5-45de-a9b2-9ab3fe9440e0">26,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzQtMy0xLTEtMzUzODM_a5d5a010-62dc-4992-aa5b-e1affb4d7465">26,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzQtNS0xLTEtMzUzODM_af47bd97-6009-4ca6-8c2e-f8622c2fb0fb">25,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Change in fair value of warrant derivative (notes 9(b), 16)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzUtMS0xLTEtMzUzODM_b2fb888f-755c-40b9-9bc2-ec86c067dc93">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzUtMy0xLTEtMzUzODM_1ab593af-eece-41f4-a41c-953e9466a56c">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzUtNS0xLTEtMzUzODM_126f8f4d-8ea0-4e5b-ba99-dffbe404625f">3,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign exchange gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzYtMS0xLTEtMzUzODM_658233ac-0291-40bd-8351-44b439d323f3">1,665</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzYtMy0xLTEtMzUzODM_30681a4b-6949-46e5-bea8-0cd1609182e6">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzYtNS0xLTEtMzUzODM_46d9ba3c-e640-4279-8a28-f086515788eb">659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzctMS0xLTEtMzUzODM_6a06203d-2839-45bd-a8e3-049bdf3e30bc">528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzctMy0xLTEtMzUzODM_553f3020-4c6c-4988-a9e7-ae9e12a3fec2">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzctNS0xLTEtMzUzODM_6e0cc011-c134-4965-b7ac-8dd73b38c78a">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzgtMS0xLTEtMzUzODM_d3fe07c8-758a-42d0-baeb-a5febff9491b">24,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzgtMy0xLTEtMzUzODM_7b0c6a71-0ca6-4cab-93e9-844d68a0e4b4">26,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzgtNS0xLTEtMzUzODM_98110736-ed67-4df7-b624-303ce032bea6">22,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense (note 14)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzktMS0xLTEtMzUzODM_26d39ef3-01ea-4ab9-84da-b57cfaa9fbcc">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzktMy0xLTEtMzUzODM_40859681-09f9-4f80-9c78-156ef981801a">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzktNS0xLTEtMzUzODM_4137b0c3-b4a6-47df-aed0-e23b3d0423e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEwLTEtMS0xLTM1Mzgz_1fc14330-df34-4d11-bb33-c02ed54779cb">24,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEwLTMtMS0xLTM1Mzgz_8cec9357-c29f-4097-a48f-357dcbd55ddd">26,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEwLTUtMS0xLTM1Mzgz_2e044fc2-857e-46d4-82fd-8599a468e8e9">22,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss) items that may be reclassified to net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEyLTEtMS0xLTM1Mzgz_1043b641-2656-4ecc-93ee-9f2b69066d33">274</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEyLTMtMS0xLTM1Mzgz_fde1b278-a744-467c-a4ed-2f79a3d7408f">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEyLTUtMS0xLTM1Mzgz_12f25d4d-3e4c-4f42-b87b-f2401a3e6179">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEzLTEtMS0xLTM1Mzgz_5291b83a-695b-4f96-bd91-e25d14679ce0">24,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEzLTMtMS0xLTM1Mzgz_926b2d8d-fbae-41e1-8358-7b9ba243a588">26,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEzLTUtMS0xLTM1Mzgz_fb8e4a73-8790-4d7e-966a-7af2258c2465">22,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per common share (note 11)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE1LTEtMS0xLTM1Mzgz_35fa8cbb-85b7-437f-9a77-1b5fbea47724"><ix:nonFraction unitRef="cadPerShare" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE1LTEtMS0xLTM1Mzgz_d12df9c3-7b42-4da5-b382-df49eec0058a">0.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE1LTMtMS0xLTM1Mzgz_7f25ba13-4693-4cd5-8025-4be66095fe14"><ix:nonFraction unitRef="cadPerShare" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE1LTMtMS0xLTM1Mzgz_eab74f69-785c-4288-b4b8-7e83a48c040a">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE1LTUtMS0xLTM1Mzgz_1499e731-493b-4979-92cd-8f6ccd4ef476"><ix:nonFraction unitRef="cadPerShare" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE1LTUtMS0xLTM1Mzgz_c28840be-6f90-49a8-8792-ac17f79fda82">0.56</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted) (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE2LTEtMS0xLTM1Mzgz_7c2a5fec-8b12-4cb7-93bc-eb9d39c8cfc6"><ix:nonFraction unitRef="shares" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE2LTEtMS0xLTM1Mzgz_aa847d69-2a67-4fe1-ba4c-0da07f68006a">58,029,745</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE2LTMtMS0xLTM1Mzgz_50d877c4-f94f-4413-aea7-048943c0ce53"><ix:nonFraction unitRef="shares" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE2LTMtMS0xLTM1Mzgz_62892829-bde9-4d3e-bdcb-222261987844">53,513,225</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE2LTUtMS0xLTM1Mzgz_608ec0f0-a6d4-49be-837e-e4517c46b4e3"><ix:nonFraction unitRef="shares" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE2LTUtMS0xLTM1Mzgz_e5fd7995-c12c-4604-9fa5-7fd48ebc3a7d">40,338,789</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.350%"><tr><td style="width:1.0%"></td><td style="width:35.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contributed Surplus</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i34072d06dbc74709a44772e87c0d0628_I20191231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEtMS0xLTEtMzUzODM_83dbb6f7-00d5-4f9d-90e1-bd5e71fb1653">311,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifd91d05642e7401b8c8faeeb5459ba72_I20191231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEtMy0xLTEtMzUzODM_6f798099-2489-420a-985c-9330b12a22bc">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b5762368dba4c919ee8061f3f934cd2_I20191231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEtNS0xLTEtMzUzODM_040c90c1-407e-4588-81a0-6eaf28b3f655">29,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9d7d4f10038048718f7928d1bab94c89_I20191231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEtNy0xLTEtMzUzODM_3815b28b-12c8-4d9d-84e9-2bd079d564ee">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="idadaa0cf361244f49594f3ef42b55e1c_I20191231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEtOS0xLTEtMzUzODM_7ede28ac-697b-4ab8-a13b-8c91de34836f">344,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie5e2093c82014efc936a23f9e66baceb_I20191231" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEtMTEtMS0xLTM1Mzgz_6cf194b0-a793-4723-a46b-51f9986eedf6">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i3fe43ded55bb48a19706afc4c1823657_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzItNy0xLTEtMzUzODM_70859dbb-a6da-45d3-b679-59d56a629e1c">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i57e65be9e20f459dbe2844e5091b0eb8_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzItOS0xLTEtMzUzODM_ebb37e59-9f0d-4b93-8d1c-3f46294df259">22,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzItMTEtMS0xLTM1Mzgz_622965ae-f942-4a68-b634-97b3e3671fa5">22,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i29cfb81f0a3a44299e19e6f5f7d4b3fe_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzMtMS0xLTEtMzUzODM_392d8c2b-bd0f-4b6d-ab2a-80c4a0ca0bd1">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ic888e62d483b498baa6a74041afebae7_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzMtNS0xLTEtMzUzODM_0721db19-9797-457c-a328-1e83ea9942e2">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzMtMTEtMS0xLTM1Mzgz_cfbf5ae1-fe0e-4d27-b5b9-0f004cdfe22d">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i29cfb81f0a3a44299e19e6f5f7d4b3fe_D20200101-20201231" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzUtMS0xLTEtMzUzODM_d0367f14-d810-4d85-88c8-674c69049600">732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ic888e62d483b498baa6a74041afebae7_D20200101-20201231" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzUtNS0xLTEtMzUzODM_627f7f47-e10b-4db2-9a5e-d1d4e2c3c855">732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzUtMTEtMS0xLTM1Mzgz_e9844b9e-62c0-4650-b9e8-45a37e304d2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i11b5e4d511d249e2a405c432386bbc33_D20200101-20201231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzYtMS0xLTEtMzUzODM_d625096f-f583-4c7d-989c-1855a85a05ed">40,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie6510299e4eb4121b35ad3c184f04164_D20200101-20201231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzYtMTEtMS0xLTM1Mzgz_9f9deb94-7ae7-43a1-a76f-b27083b3a90f">40,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i29cfb81f0a3a44299e19e6f5f7d4b3fe_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzctMS0xLTEtMzUzODM_c4f2c850-f615-4808-ac7b-c9533ba7dd6e">6,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzctMTEtMS0xLTM1Mzgz_bb4ad3ab-65a5-49d0-9358-7f9bdd101db0">6,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic888e62d483b498baa6a74041afebae7_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzgtNS0xLTEtMzUzODM_b14e76bf-77d1-4ee6-9c22-ea676afd05a3">2,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzgtMTEtMS0xLTM1Mzgz_84f64af9-cb21-44f1-8d70-db7f9091ca05">2,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i29cfb81f0a3a44299e19e6f5f7d4b3fe_D20200101-20201231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzktMS0xLTEtMzUzODM_38796f0f-57a5-4626-bf08-5e0e86e0fb57">1,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzktMTEtMS0xLTM1Mzgz_87dbdd5d-510c-48dc-b4f8-71d438d763b0">1,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i290facf32bd147b3884843f453ff6807_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEwLTEtMS0xLTM1Mzgz_3687b16a-356f-4c1a-9174-835d5f5b3bdb">356,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia8306ac01dd1463bbd49d0c295bf272f_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEwLTMtMS0xLTM1Mzgz_9f541448-e635-496e-be28-5f1e5636c6e7">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i22e1e0507b4d45e393729762660f43a4_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEwLTUtMS0xLTM1Mzgz_6b4f97d1-00c1-499d-82e2-70470b780725">31,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i368b44deb2be4ae8a6ca25d3395395fd_I20201231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEwLTctMS0xLTM1Mzgz_e82ce132-f408-4fc0-a0c0-2c995b59eb28">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i948a576781cb440eb04b08b93b5d97f4_I20201231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEwLTktMS0xLTM1Mzgz_85616805-46ee-4ccb-9d74-245a9691f155">367,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEwLTExLTEtMS0zNTM4Mw_3ac85dcb-d320-4c7f-a518-c1651b08409b">24,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i55f95b5256b04475bef34fd27060d50e_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzExLTctMS0xLTM1Mzgz_991e2918-f72b-484b-90dc-c48f4e7e50b7">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i3e5170208d2a4bd9b4a4c6146ff70357_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzExLTktMS0xLTM1Mzgz_f51dc2e7-eb60-40bb-8b61-c289b9da0f35">26,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzExLTExLTEtMS0zNTM4Mw_6c211d6a-b853-4a7c-92e9-5184a9b69b02">26,316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1c339f58b6a2498ea561adefe93e835c_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEyLTEtMS0xLTM1Mzgz_fc0d61a6-5c19-44b5-9e7f-4a3329a98c35">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i3961fe68fe52450d88368027d3561fcf_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEyLTUtMS0xLTM1Mzgz_d0d4a202-dd46-4f29-8698-b2f9ea265f2a">143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEyLTExLTEtMS0zNTM4Mw_3600a658-0142-4469-a2df-877baf7839f2">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1c339f58b6a2498ea561adefe93e835c_D20210101-20211231" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEzLTEtMS0xLTM1Mzgz_365cda18-6d88-44d6-aeed-08992e1ab50f">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i3961fe68fe52450d88368027d3561fcf_D20210101-20211231" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEzLTUtMS0xLTM1Mzgz_a68b3c1d-b47b-4b9b-bb29-9bab401ba565">544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEzLTExLTEtMS0zNTM4Mw_3be0bde4-ae87-4267-ac98-75020c90bd2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7a8cd87a2d5a464ba33b505012eb6589_D20210101-20211231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE0LTEtMS0xLTM1Mzgz_92ef31f7-3955-439d-aaca-6bc9b2fd4174">34,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b43b9c4bfe449b6b1add7f653d88bf2_D20210101-20211231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE0LTExLTEtMS0zNTM4Mw_c29f4686-37c9-429d-baf8-a3cfbcad0cbb">34,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1c339f58b6a2498ea561adefe93e835c_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE1LTEtMS0xLTM1Mzgz_c6998d52-6694-48ce-a80c-89238a75affc">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE1LTExLTEtMS0zNTM4Mw_85824ab1-5260-4746-a070-a19bde163b20">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i3961fe68fe52450d88368027d3561fcf_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE2LTUtMS0xLTM1Mzgz_71d541da-e775-4c56-b3be-5b9e9c694133">3,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE2LTExLTEtMS0zNTM4Mw_0ce2a1cb-71f3-40f9-afe5-5715c18426f9">3,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i1c339f58b6a2498ea561adefe93e835c_D20210101-20211231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE3LTEtMS0xLTM1Mzgz_d1eeaf5c-f959-43f8-83d4-7150c7f0da67">1,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE3LTExLTEtMS0zNTM4Mw_adc1aaaf-d6f2-4973-a466-9d58bd5bd6a9">1,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4041f6f067cb40d396837f84680e473b_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE4LTEtMS0xLTM1Mzgz_613b1a36-ee16-4d90-b498-71b327c237c4">391,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifbaf1681ace746c7a5991056ee03b717_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE4LTMtMS0xLTM1Mzgz_94b00978-2ac2-4fa5-bf3b-3e40106bc08a">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i97c499ae0f4f4465949c6fe6c3000ab0_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE4LTUtMS0xLTM1Mzgz_8d5aad5c-2e4b-459b-9b78-e3b6344aab51">34,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5cdf4a3d792142928c2a62b0fe7cbb14_I20211231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE4LTctMS0xLTM1Mzgz_d17b490b-a027-4c02-911b-8297b60a3790">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i01f7eba52a7942aeba915d83f45b1a80_I20211231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE4LTktMS0xLTM1Mzgz_4aa0cf3f-f0ab-4bda-82d1-9fbefe357343">393,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE4LTExLTEtMS0zNTM4Mw_21c3f69a-5e29-423e-9b64-8a2ebb039288">36,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i576c2a286bbc4d11b0b6d563390fe4b3_D20220101-20221231" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE5LTctMS0xLTM1Mzgz_c803e678-f44c-4e8a-9ec7-125ea360b40e">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i1ca5b15a1b7044289a0c16a41d080756_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE5LTktMS0xLTM1Mzgz_50ba96c2-9978-4573-ac4b-d4e58ef60a1d">24,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE5LTExLTEtMS0zNTM4Mw_aa461135-c6ca-41f1-a89c-b762d97f621f">24,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i74a140a0b6704c889a525c2e794ec55c_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIwLTEtMS0xLTM1Mzgz_a78b2654-263c-49b0-9cb6-2e550be65904">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie50cc2fed39041bc905a4bcda62dfc62_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIwLTUtMS0xLTM1Mzgz_c8f776e2-68fc-4c69-9554-2c7df4c23459">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIwLTExLTEtMS0zNTM4Mw_844b58c4-3219-4945-877f-f8f2e3411180">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i74a140a0b6704c889a525c2e794ec55c_D20220101-20221231" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIxLTEtMS0xLTM1Mzgz_60de8914-25c1-4cbb-bf22-9a0bac25afe1">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie50cc2fed39041bc905a4bcda62dfc62_D20220101-20221231" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIxLTUtMS0xLTM1Mzgz_4b71f5f8-2668-4be6-8250-aed136b5369d">98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIxLTExLTEtMS0zNTM4Mw_53d3e74b-2b4a-4cbe-8d35-a5763728e1bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of equity warrant agreement (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i5bdab815bf824c749bcbfc48a0d04970_D20220101-20221231" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIxLTMtMS0xLTQ0MDEx_f8feec20-fda0-4b1c-8d22-52d8e357ba77">3,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie50cc2fed39041bc905a4bcda62dfc62_D20220101-20221231" decimals="-3" name="oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIxLTUtMS0xLTQ0MDE5_7e2c71eb-02b3-4cd8-9840-4d533301ad77">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIxLTExLTEtMS00NDA0Mw_3b3a61bd-9250-432b-9deb-b4e7bf3f87e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i21011e791fea44a5a06778532673f5a7_D20220101-20221231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIyLTEtMS0xLTM1Mzgz_c6c4e3df-0d2d-4981-b21a-24603727fb46">13,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8ed6a69506e34074a8db38ee94834bd6_D20220101-20221231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIyLTExLTEtMS0zNTM4Mw_faf0dd7d-b395-4fc7-b4cf-dc4adbb95373">13,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie50cc2fed39041bc905a4bcda62dfc62_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI0LTUtMS0xLTM1Mzgz_e06a7260-fe07-4445-8852-d1852f52da28">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI0LTExLTEtMS0zNTM4Mw_a1b805da-f25f-492b-bbc3-2c9cca4d9ba4">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i74a140a0b6704c889a525c2e794ec55c_D20220101-20221231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI1LTEtMS0xLTM1Mzgz_14e2674f-f36b-4125-b2ab-1e77e95e95fa">764</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI1LTExLTEtMS0zNTM4Mw_e3b9addf-8d56-4105-b0d3-8a41d92e617a">764</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i675ad40abe414c01b53d0b9d4f0b4bac_I20221231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI2LTEtMS0xLTM1Mzgz_2878762d-6347-48e3-90a7-ffa4547cb2bb">404,040</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i926bb81a27e0480ca8b1aa8523ae7dbf_I20221231" decimals="-3" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI2LTMtMS0xLTM1Mzgz_15d3613b-48b9-4dea-bd1d-9bc989974960">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i77a1e98211ca443f9dfaca9d7e15ffb4_I20221231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI2LTUtMS0xLTM1Mzgz_44263089-c3e8-4c7f-b8eb-36dbec6deaf1">40,051</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i92a4f596a4a24a67b57f8f348cf65e66_I20221231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI2LTctMS0xLTM1Mzgz_cbd96f54-522f-421b-80e5-040918d04596">662</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="iee80e6ef283a466d847af7f4c18b0932_I20221231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI2LTktMS0xLTM1Mzgz_39e9a010-a88d-435c-9569-fa073baa4350">418,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI2LTExLTEtMS0zNTM4Mw_1e13610f-206a-41ec-9e55-6b45bf53e0dc">26,502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss for the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzItMS0xLTEtMzUzODM_31058465-6f1f-4405-9859-9e4699cb99ae">24,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzItMy0xLTEtMzUzODM_87c5465e-f65d-40a5-8947-6b09d0a256f7">26,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzItNS0xLTEtMzUzODM_590eec4f-5554-4dc7-bc93-c58acc7e3769">22,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment (notes 6, 19)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzMtMS0xLTEtMzUzODM_55a3231b-c0fc-4aee-95da-ff2831049fee">93</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzMtMy0xLTEtMzUzODM_93d49763-a9ad-4605-8a8f-207e8946b7d2">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzMtNS0xLTEtMzUzODM_01f9745e-7bc8-4bf6-a59e-42c3c39d9efb">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets (notes 8, 19)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="oncyf:AdjustmentsForDepreciationRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzQtMS0xLTEtMzUzODM_62dd1ae7-02a3-45a4-8b2d-13ea87ae7014">299</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="oncyf:AdjustmentsForDepreciationRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzQtMy0xLTEtMzUzODM_f3dbdf69-0b9a-4496-8d0d-f6237922bf44">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="oncyf:AdjustmentsForDepreciationRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzQtNS0xLTEtMzUzODM_874c3301-0659-42ad-bc34-b2997bc6327d">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (notes 10, 19, 20)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzUtMS0xLTEtMzUzODM_3206c960-c230-4198-84ab-65fdb8550c37">2,378</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzUtMy0xLTEtMzUzODM_28cf69ff-d7a5-4377-86c6-88cfd1da195d">3,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzUtNS0xLTEtMzUzODM_136a9029-546a-4b7d-9088-a7cd1e55eeac">2,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:InterestRevenueExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzYtMS0xLTEtMzUzODM_0f0bf05d-646e-4b82-87cb-8eb756382a08">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:InterestRevenueExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzYtMy0xLTEtMzUzODM_b2d802a0-9df8-4a5c-9ffd-f3c74970c1c6">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:InterestRevenueExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzYtNS0xLTEtMzUzODM_23b7cee2-5e70-4a90-89ef-6d87d0877fef">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzctMS0xLTEtMzUzODM_49f82822-f879-4578-a427-2adb1820ea3b">1,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzctMy0xLTEtMzUzODM_bfd6c951-3e4a-4c7b-b43f-2ced0668be95">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzctNS0xLTEtMzUzODM_de7c2f2d-0165-440f-9333-077872fa6a64">645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative (note 16)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzgtMS0xLTEtMzUzODM_42254430-5643-4304-9e79-6002932ad311">20</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzgtMy0xLTEtMzUzODM_331aa4fb-769f-45ad-9dca-cb10e0cfd208">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzgtNS0xLTEtMzUzODM_9e07496e-4018-4f41-a3ec-d9a08b25ca2b">3,492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in non-cash working capital (note 17)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzktMS0xLTEtMzUzODM_f7f2ee95-f207-4926-a98e-c7001a63ff8e">391</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzktMy0xLTEtMzUzODM_18be0f30-bb7a-4b2b-b921-b242a8043634">908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzktNS0xLTEtMzUzODM_4c00b6d6-7cb5-41da-8ebf-776e20af5693">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEwLTEtMS0xLTM1Mzgz_aac9cb2f-b9f1-44ff-a131-615c1e7ba6b6">23,355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEwLTMtMS0xLTM1Mzgz_bf292f22-697d-4a4d-a848-a86ba421b48f">22,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEwLTUtMS0xLTM1Mzgz_209e56ce-d949-4675-8efd-783ccf4f8fb0">22,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEyLTEtMS0xLTQ0MDU1_36f4c626-54e0-4d2d-b0a7-412e282b9f81">20,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEyLTMtMS0xLTQ0MDYz_1e44bc8b-9b38-410f-b367-b30c25776342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEyLTUtMS0xLTQ0MDcx_8aa188e3-478b-4b85-943d-41eb597b151a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment (note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEyLTEtMS0xLTM1Mzgz_303c618e-7213-4381-9b90-aa093e268197">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEyLTMtMS0xLTM1Mzgz_234bc89f-ccfe-41d6-abb4-b0bfe7b145f4">286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEyLTUtMS0xLTM1Mzgz_773c8b88-eb0e-4e7d-9ef8-a4476eceda2c">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEzLTEtMS0xLTM1Mzgz_698b1235-6fe0-4a7e-87a3-81b5bcd242be">20,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEzLTMtMS0xLTM1Mzgz_b5e78f8d-88a7-453e-80ae-422bb46a04a1">286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEzLTUtMS0xLTM1Mzgz_f91f46a4-b3f7-496d-b682-ba88509059d0">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE1LTEtMS0xLTM1Mzgz_8d9ddc50-4982-41ed-84ba-421fc442a952">12</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE1LTMtMS0xLTM1Mzgz_ff6e88cf-99a8-4359-bf41-d167579b28a8">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE1LTUtMS0xLTM1Mzgz_e0b8d5b8-db75-43e1-b9a2-4e341d30464a">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic8f2d18eb4014706985a616274ce8cf0_D20220101-20221231" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE2LTEtMS0xLTM1Mzgz_0f882653-b346-4d66-b4ad-c19368a927db">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i15555db508714ca18e982d65eea9cb39_D20210101-20211231" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE2LTMtMS0xLTM1Mzgz_975afb9b-92a6-4b19-8ef2-6982306192e4">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5db0e2b8debf4e1987ee224438086d51_D20200101-20201231" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE2LTUtMS0xLTM1Mzgz_1e33574f-541c-4331-98d2-43472f21210a">1,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from "At the Market" equity distribution agreement (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8ed6a69506e34074a8db38ee94834bd6_D20220101-20221231" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE4LTEtMS0xLTM1Mzgz_36ee32ce-ed47-4aa2-aedb-d2c2775ac4a5">12,574</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i5b43b9c4bfe449b6b1add7f653d88bf2_D20210101-20211231" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE4LTMtMS0xLTM1Mzgz_eb32bc47-9b38-46fa-84a1-c7006d8deeef">32,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie6510299e4eb4121b35ad3c184f04164_D20200101-20201231" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE4LTUtMS0xLTM1Mzgz_79332a0f-ee51-432a-8b82-29cecbc537e5">38,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities (note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIwLTEtMS0xLTM1Mzgz_90998dc7-47b5-4995-9b7c-410af9a99dce">381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIwLTMtMS0xLTM1Mzgz_b701c200-db3a-493d-b7d6-ae4a14020418">366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIwLTUtMS0xLTM1Mzgz_c1f37c9f-c6b9-44d4-b418-db09f1ec1bbb">461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIxLTEtMS0xLTM1Mzgz_bfe52465-39e4-446d-a6ed-4ce74e215dc7">12,205</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIxLTMtMS0xLTM1Mzgz_5c405128-285a-404b-a049-9b7742548cd0">33,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIxLTUtMS0xLTM1Mzgz_b280cc5c-44d5-4c43-948b-bbf35bea2690">39,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIyLTEtMS0xLTM1Mzgz_e345d845-250a-40b1-8a4d-827cf4e62827">31,553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIyLTMtMS0xLTM1Mzgz_e79e05f2-500e-46a5-ac07-264bdb89abbe">10,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIyLTUtMS0xLTM1Mzgz_d8aab862-d729-437b-ab00-83ac9dc37608">17,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIzLTEtMS0xLTM1Mzgz_a9ffeb01-a7c8-434b-ac7c-a1d2149c3f51">41,262</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIzLTMtMS0xLTM1Mzgz_1fd72f49-4fab-41e6-9516-ca79ee672c6d">31,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie5e2093c82014efc936a23f9e66baceb_I20191231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIzLTUtMS0xLTM1Mzgz_1f217491-0495-4d29-b58d-e1e2b3e93ce6">14,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzI0LTEtMS0xLTM1Mzgz_da2c177c-70a4-4173-a48b-a273c5f94e60">1,957</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzI0LTMtMS0xLTM1Mzgz_f4bb3bd5-c819-45b9-9dab-0dee97158a11">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzI0LTUtMS0xLTM1Mzgz_de8571a8-3e4c-4603-8e31-a32315df57eb">604</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzI1LTEtMS0xLTM1Mzgz_00e92efd-83aa-4b21-a29d-3dc289c5709b">11,666</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzI1LTMtMS0xLTM1Mzgz_e727cfa1-2599-4e87-a4ed-7652dcdc1be1">41,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzI1LTUtMS0xLTM1Mzgz_d0efcc28-ad08-499b-b045-e532a27722dd">31,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_133"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 1: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzYvZnJhZzozMTAyZTAzNTk4YzU0ZjE4OTYwMTI3ZGYwNGQ5NzlmNC90ZXh0cmVnaW9uOjMxMDJlMDM1OThjNTRmMTg5NjAxMjdkZjA0ZDk3OWY0XzE0NjM_92d54099-ef82-4788-9bb8-3b498b185612" continuedAt="i5cfe9ce4b48646239151678cf455cb31" escape="true">Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="i5cfe9ce4b48646239151678cf455cb31"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998, under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue S.W., Calgary, Alberta, Canada.   </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, we are exploring opportunities for registrational programs in gastrointestinal cancers through our GOBLET platform study.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue our research and development efforts. As at December&#160;31, 2022, we had an accumulated deficit of $<ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzYvZnJhZzozMTAyZTAzNTk4YzU0ZjE4OTYwMTI3ZGYwNGQ5NzlmNC90ZXh0cmVnaW9uOjMxMDJlMDM1OThjNTRmMTg5NjAxMjdkZjA0ZDk3OWY0XzEwOTk1MTE2MzIzOTQ_1fc38420-d3ff-4663-850e-0f69a45bb844">418,251</ix:nonFraction>. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through the issuance of additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. There can be no assurance that we will be able to raise additional funds through the sale of our common shares. Failure to raise additional capital would have a material adverse impact on our business, results of operations, and financial condition. As at December&#160;31, 2022, we had cash and cash equivalents and marketable securities of $<ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="oncyf:CashAndCashEquivalentsAndCurrentInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzYvZnJhZzozMTAyZTAzNTk4YzU0ZjE4OTYwMTI3ZGYwNGQ5NzlmNC90ZXh0cmVnaW9uOjMxMDJlMDM1OThjNTRmMTg5NjAxMjdkZjA0ZDk3OWY0XzEwOTk1MTE2MzI2NDM_0a2f219d-c90f-46a3-9b3e-4d721e178d39">32,138</ix:nonFraction>. We believe we have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 2: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzkvZnJhZzpmM2JmZDU3MzJiZDI0YjhmODM4Y2I0NWI2MTNmZTk3NC90ZXh0cmVnaW9uOmYzYmZkNTczMmJkMjRiOGY4MzhjYjQ1YjYxM2ZlOTc0XzEyMjk_931989b6-8bec-4a04-a75e-b47139cd2e5a" continuedAt="i2cecec3e0ad9466da0fd75c70cc43cff" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i2cecec3e0ad9466da0fd75c70cc43cff" continuedAt="i182cc72395a94f6d91a61df1f0d1bb81"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statement of compliance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements for the year ended December&#160;31, 2022, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;2, 2023. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries, Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc., and are presented in Canadian dollars, our functional currency. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and have the ability to affect those returns through our power to govern. The accounting policies of our subsidiaries are consistent with our accounting policies and all intercompany transactions, balances, income, and expenses are eliminated on consolidation. </span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i182cc72395a94f6d91a61df1f0d1bb81">Our accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.</ix:continuation>  </span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_142"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 3: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODQw_1244a4b9-3111-45a8-899b-fbb02fa8c361" continuedAt="i9a05e83ba0594b1ea5cc9c666379c6c8" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i9a05e83ba0594b1ea5cc9c666379c6c8" continuedAt="icf5d84fe1581497281e5ec591785fe8c"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.</span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzU0OTc1NTg1MjMxNQ_5a6e170b-48cf-46a4-8031-9b87ba2c9702" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents and marketable securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include interest-bearing deposits with our bank totaling $<ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE2NDkyNjc0ODAxMDk_579d0c67-1123-4428-806a-18f09489f10f">9,501</ix:nonFraction> as at December&#160;31, 2022 (December&#160;31, 2021 - $<ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE2NDkyNjc0ODAxMzc_e238d4c1-0d3f-4032-9dd5-eb6cc574b044">39,902</ix:nonFraction>). Marketable securities include foreign currency term deposits with a maturity of greater than 90 days and less than one year.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred income taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODE4_4272b77f-37ef-45a5-838b-95adba679806" escape="true">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.</ix:nonNumeric>  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial instruments </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification and measurement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial assets</span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODA2_1d9b272c-ef10-47fb-8583-d63ba5c60310" continuedAt="i7e041c52d6f645e89dd9c9027dcb6c1c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). </span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7e041c52d6f645e89dd9c9027dcb6c1c">Our financial assets include cash and cash equivalents, marketable securities, and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODQ3_fdeef2e3-0f6f-4418-9c8c-1684759eb450" escape="true">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of the warrant derivative is at FVPL.</ix:nonNumeric>  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODEy_5f2f8dd9-9fab-41a9-9f25-cc7861bd902e" escape="true">Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derecognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODEz_18f548f2-d6cb-4b26-8f5d-3730e40f5107" continuedAt="i2947095e85134f1684c39c5c02175cba" escape="true">A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="icf5d84fe1581497281e5ec591785fe8c" continuedAt="i026ffdcea2a34ab19e8981dacafd8a09"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2947095e85134f1684c39c5c02175cba">A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODQy_03419fae-4a2e-43de-83f9-85d15824c93b" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency translation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODI4_42f7a0af-f71c-4132-94f8-2265d1d5e92f" continuedAt="id8529b334b4c4f2086bfadc18c73b9ac" escape="true">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id8529b334b4c4f2086bfadc18c73b9ac">Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.</ix:continuation>  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzU0OTc1NTg1MjMxNw_3bba5c03-d12e-4c65-ac78-05276f47de4e" continuedAt="i3355b83aee21480aa6142cad5ceefab0" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i026ffdcea2a34ab19e8981dacafd8a09" continuedAt="i8607252513f94e79aae9d884ceff0e81"><ix:continuation id="i3355b83aee21480aa6142cad5ceefab0" continuedAt="i4e1a102ba0d64f17ac8204d1d9577474"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4e1a102ba0d64f17ac8204d1d9577474">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per common share</span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODI5_fc37763c-f960-469e-9862-0be908de5866" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is determined using the weighted average number of common shares outstanding during the year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants if dilutive. The number of additional common shares is calculated by assuming that any outstanding "in the money" options, restricted share units, performance share units, and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment </span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODM4_3178e8f5-40f3-44bd-9fa5-19b8601b5586" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODM5_c5653fe9-c1fb-42f1-a066-d5e7ac08e31b" continuedAt="i6c4fb1a258344a9a8a02100c9976e015" escape="true">Depreciation is recorded using the declining balance method at the following annual rates:</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><ix:continuation id="i6c4fb1a258344a9a8a02100c9976e015" continuedAt="i07969c0c2d274149b071ba39fa0825f2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f01ea7a336d44d2ab368965b5d555a1_D20220101-20221231" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90YWJsZToyMjVjNGFjMzhjNWM0Nzc2YTY0NTVkYWEwMzNmMjY3OS90YWJsZXJhbmdlOjIyNWM0YWMzOGM1YzQ3NzZhNjQ1NWRhYTAzM2YyNjc5XzAtMS0xLTEtMzUzODM_f0c75a85-f5f7-4cb4-bace-d6e85e4ae563">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a49b5a6078743c4a0f6d1dc090f31ae_D20220101-20221231" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90YWJsZToyMjVjNGFjMzhjNWM0Nzc2YTY0NTVkYWEwMzNmMjY3OS90YWJsZXJhbmdlOjIyNWM0YWMzOGM1YzQ3NzZhNjQ1NWRhYTAzM2YyNjc5XzEtMS0xLTEtMzUzODM_04e9fd9b-756d-4508-8880-d6b222e326f3">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc90711aec744857b2329d7bd8e24e98_D20220101-20221231" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90YWJsZToyMjVjNGFjMzhjNWM0Nzc2YTY0NTVkYWEwMzNmMjY3OS90YWJsZXJhbmdlOjIyNWM0YWMzOGM1YzQ3NzZhNjQ1NWRhYTAzM2YyNjc5XzItMS0xLTEtMzUzODM_abf102c4-7c36-4ffc-ba85-a7b68fa4f884">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></ix:continuation></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODE1_236a3c46-d4d0-47d3-9b9c-622962b4a0b4" escape="true">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed.</ix:nonNumeric> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition</span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODA4_c09a586c-316d-40eb-a06d-e85f2228fcba" continuedAt="i28a46c952e9b4a76b1dad7487ff30c44" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i8607252513f94e79aae9d884ceff0e81" continuedAt="i90579610349f4a148f1843dbd46b6d9f"><ix:continuation id="i28a46c952e9b4a76b1dad7487ff30c44"><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based compensation </span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODUw_7e37da91-301a-4041-8216-5ea1696bd6ff" continuedAt="ifeca6148e6fa450e806a8e093d8fd2cd" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="plan" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="INF" name="oncyf:NumberOfStockOptionPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE0Njkz_561f61c4-5095-4afc-aea3-f30fe1568806">one</ix:nonFraction> stock option plan (the "Option Plan") available to officers, directors, employees, and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE1MjA0_fe088af5-7509-42d7-abed-90819f05c995">ten years</ix:nonNumeric> from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value-based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive share award plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incentive share award plan (the "Share Plan") is available to directors, officers, and employees. Under our Share Plan, performance and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are awarded to certain officers and employees and non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifeca6148e6fa450e806a8e093d8fd2cd">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSUs/RSUs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change.</ix:continuation> </span></div></ix:continuation><div style="margin-bottom:10pt;margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i90579610349f4a148f1843dbd46b6d9f" continuedAt="i9fa392c6366f419999107c5bcc72c343"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODI3_8f422752-971e-4fce-87f4-adc02d750ab3" continuedAt="i183a8a290f6048cda8504bd487ab13ce" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduced a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies, and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9fa392c6366f419999107c5bcc72c343"><ix:continuation id="i183a8a290f6048cda8504bd487ab13ce">In May 2021, the IASB issued amendments to IAS 12, which narrowed the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 4:  <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDUvZnJhZzowMjA5MTAwZTJiMDU0OTQwOGRjN2MwYzNmZDA2N2YyOC90ZXh0cmVnaW9uOjAyMDkxMDBlMmIwNTQ5NDA4ZGM3YzBjM2ZkMDY3ZjI4Xzc3NDE_59778405-5a53-45ec-ba1f-ecd63ca6e9ad" continuedAt="i493d8dadd11e4316aa76debab69b05fd" escape="true">Significant Judgments, Estimates, and Assumptions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i493d8dadd11e4316aa76debab69b05fd" continuedAt="ie4cacacbb5714af7b6b0d802f8ad3d1b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which external factors outside of our control, including those related to the coronavirus infectious disease 2019 ("COVID-19") pandemic and the global political conflict in Ukraine, may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain. We considered the potential impact of these events, including global supply chain disruptions, inflation, and rising interest rates, when making certain estimates and judgments relating to the preparation of these audited consolidated financial statements. While there was no material impact to our consolidated financial statements as of and for the year ended December&#160;31, 2022, our future assessment of the magnitude and duration of COVID-19 and conflict in Ukraine, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Judgments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make judgments, estimates, and assumptions that affect the reported amount of revenue, expenses, assets, liabilities, and the disclosure of contingent liabilities at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and assumptions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates, and such differences could be material. Significant estimates made by management affecting our consolidated financial statements include:</span></div></ix:continuation><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ie4cacacbb5714af7b6b0d802f8ad3d1b"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement which provides, among other payments, upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress toward completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses represent significant components of our research and development expenses, and we outsource a significant portion of these activities to third-party contract research/manufacturing organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as achieving certain milestones. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that the contract research/manufacturing organizations have performed. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based compensation </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value for stock options granted requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options granted are disclosed in Note 10. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, share price volatility, and dividend yield, and making assumptions about them. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry-forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgment is required to determine the amount of deferred tax assets that can be recognized based on the likely timing and the level of future taxable profits together with future tax planning strategies.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. There are also no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_1917"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 5: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfOtherLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF81NDk3NTU4MTU3NzY_08d8a78a-cd7f-4f6e-b9d0-d6df31e5f06e" continuedAt="ib18138afb17447daa4e2284f36be5724" escape="true"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfOtherAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF81NDk3NTU4MTU3NzY_e318e447-e4e9-49d8-8666-142586b0de78" continuedAt="i1e1e1f4e80ee45d0852db8967c605a2b" escape="true">Other Assets and Liabilities </ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><ix:continuation id="ib18138afb17447daa4e2284f36be5724" continuedAt="i144eac8ed628427c9f32c51d520a7cc3"><ix:continuation id="i1e1e1f4e80ee45d0852db8967c605a2b" continuedAt="i3925c997738c48a7912a353c86d42c43"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1. This phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2022, we recorded US$<ix:nonFraction unitRef="usd" contextRef="i9166d82a922341729a9cfba07b6c19fc_I20221231" decimals="-3" name="ifrs-full:OtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4MTU5_292e4eef-8211-4a2e-b97a-60fbf9da1e91">360</ix:nonFraction> ($<ix:nonFraction unitRef="cad" contextRef="i9166d82a922341729a9cfba07b6c19fc_I20221231" decimals="-3" name="ifrs-full:OtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4MTY0_6cdfbbaf-8099-43a4-80c4-74f535a0d0c3">488</ix:nonFraction>) (December&#160;31, 2021 - US$<ix:nonFraction unitRef="usd" contextRef="i8f8114e0983f40c18d9bd8848358071f_I20211231" decimals="-3" name="ifrs-full:OtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4MTc2_a4704a7e-7567-4973-b587-439bb98bcc2a">617</ix:nonFraction> ($<ix:nonFraction unitRef="cad" contextRef="i8f8114e0983f40c18d9bd8848358071f_I20211231" decimals="-3" name="ifrs-full:OtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4MTgx_b9ceba8f-ca98-49cb-8361-1107ea4338a3">782</ix:nonFraction>)) in other receivables related to unbilled BRACELET-1 cost from Pfizer and <ix:nonFraction unitRef="cad" contextRef="i9166d82a922341729a9cfba07b6c19fc_I20221231" decimals="INF" name="ifrs-full:OtherCurrentLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4Mjk2_492f512f-9da4-440c-81b8-b043f25da7e3">nil</ix:nonFraction> (December&#160;31, 2021 - US$<ix:nonFraction unitRef="usd" contextRef="i8f8114e0983f40c18d9bd8848358071f_I20211231" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4MzA3_1e224f8e-6be4-4e0d-b1af-b472a6963141">278</ix:nonFraction> ($<ix:nonFraction unitRef="cad" contextRef="i8f8114e0983f40c18d9bd8848358071f_I20211231" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4MzEy_3151b0c6-3a67-427c-8390-28a600a61103">352</ix:nonFraction>)) in other liabilities representing unused payments received from Pfizer.</span></ix:continuation></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><ix:continuation id="i144eac8ed628427c9f32c51d520a7cc3"><ix:continuation id="i3925c997738c48a7912a353c86d42c43"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">In 2022, we paid deposits to our manufacturer related to the production of pelareorep required for our clinical trial program. We classify the related prepaid expenses as current or non-current based on the timing of when we expect to receive services. As at December&#160;31, 2022, we recorded $<ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4NzE1_84438060-973e-444e-b8e3-9065837fa032">1,327</ix:nonFraction> in current prepaid expenses and $<ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:NoncurrentPrepayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4NzUx_bf3f28ee-f11e-4b30-b3bb-9b2d4785e435">998</ix:nonFraction> in non-current prepaid expenses.</span></ix:continuation></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 6: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90ZXh0cmVnaW9uOmEzODVkYmIwMGI0NjRmZjBiNDk2OWJmZDRiZDIzNTE3XzM5_f66d3351-879b-44cf-b643-b3012dfb4de3" continuedAt="ie52a98b3463345f4acfe23eb03731b84" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i07969c0c2d274149b071ba39fa0825f2"><ix:continuation id="ie52a98b3463345f4acfe23eb03731b84"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4783f947d474ec7a4043f3bd7016af3_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzItMS0xLTEtMzUzODM_a039cb85-8709-4c29-a53f-ad3599d2087f">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i3911bf2c955b405bac30a9b918de2d56_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzItMy0xLTEtMzUzODM_902f9dc2-7c49-4ab0-ac96-7156387a27a4">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6e33daaee7a04931a84b95d558b6feab_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzItNS0xLTEtMzUzODM_f46c35ab-0852-47db-9470-455fa8df919e">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i81ef8717fa2344528d67d8af749583ee_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzItNy0xLTEtMzUzODM_669afd6c-1c74-41e1-ad32-36052891151b">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i204d523ce7ab4b52896ed6d2295ef847_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzItOS0xLTEtMzUzODM_7fe3091b-3d5b-4126-b8b7-2253e488806c">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie5f0b13be4b5469faca7dfca28e6f4c8_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzMtMS0xLTEtMzUzODM_c3d0ba32-a56a-410a-9fc4-cdea27743be7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iee36a908faae4b93971ba0cc2c7ca539_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzMtMy0xLTEtMzUzODM_2fd2123a-c189-42ba-8899-1fdfd5e5ef42">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia39c558d66984975b5b558b476007a29_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzMtNS0xLTEtMzUzODM_3a1fb845-2396-4b45-a962-b8a25366a8a9">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8ff1d10a78054a38a5d7f49b53d4d3b0_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzMtNy0xLTEtMzUzODM_e7561551-40f6-4ff9-918d-6c119dd7522b">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i68bda01afab14d5cb26920e605f0ab42_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzMtOS0xLTEtMzUzODM_5ba9b9bc-24b3-4e9b-98df-8f9e602ae3fc">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie5f0b13be4b5469faca7dfca28e6f4c8_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzQtMS0xLTEtMzUzODM_7b97503d-3c34-41f7-9488-82aa05566a3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iee36a908faae4b93971ba0cc2c7ca539_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzQtMy0xLTEtMzUzODM_c26e0aec-16d5-4cae-b94b-634685f6616b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ia39c558d66984975b5b558b476007a29_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzQtNS0xLTEtMzUzODM_75ced53b-4fdf-447e-951f-100586faeac0">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8ff1d10a78054a38a5d7f49b53d4d3b0_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzQtNy0xLTEtMzUzODM_ab65be88-ceb9-4a77-8f50-2ecf93d23cef">374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i68bda01afab14d5cb26920e605f0ab42_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzQtOS0xLTEtMzUzODM_c3884802-52e4-4106-8a1d-45279b7e4af7">651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i286fea00b77e413c9c5eeffe49ab79c1_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzUtMS0xLTEtMzUzODM_5e666289-2d16-4fea-a03c-eeea40d2cefb">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iefe509d23f474055870d8386107bed16_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzUtMy0xLTEtMzUzODM_5450a442-b2af-468f-8a8e-4204f13e8c38">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia2dee205e673484b94ca9942a6585f62_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzUtNS0xLTEtMzUzODM_08c66b4b-b24a-46cd-bf4b-98ad1f209c9e">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6a0d89d731934218a9200c653646ae2d_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzUtNy0xLTEtMzUzODM_aeb22eef-b01a-4e65-9330-5cd2447cce9a">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i41042a36299746dfa6245b8f04eeb2fa_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzUtOS0xLTEtMzUzODM_17d56b75-9a65-4b02-acf9-c2164450141d">913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4096288385ea4783bb39b83a9221722a_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzYtMS0xLTEtMzUzODM_a4e9eb1a-ec82-41a4-8db9-74fdd3c50beb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2dbc93ed0aff46e895933aedb6179359_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzYtMy0xLTEtMzUzODM_c83531da-4647-442e-80b4-3596fdbc7768">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i22a8e62bdf6047f6b2871d5eb585c601_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzYtNS0xLTEtMzUzODM_7bbcb187-73d7-49c7-aea1-b3b3d68bb6ed">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iedb5bad8c9c64aeb82bab9cdcaaab035_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzYtNy0xLTEtMzUzODM_004d720d-6aba-4da0-8cf2-2bab6d3ab7b0">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icff71c66ed2f49d7a3a5436aa04a7517_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzYtOS0xLTEtMzUzODM_dcf02bc2-c122-47d3-8b60-4f55be452427">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icb257f4f952a40c895f4c48bb418df40_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzgtMS0xLTEtMzUzODM_af6633b3-c383-43d1-ae51-73859f2283aa">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i79304496df494f95b80359489d58d588_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzgtMy0xLTEtMzUzODM_394602a8-1cde-45f7-bb60-d21a78a0e9b3">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2af36eb48c0d4fe2b8f76f15361a0a7e_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzgtNS0xLTEtMzUzODM_eca9cdd2-ad27-42fd-a9af-510b49878d3e">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icb1ab3d5241c42b4bc1827326301115d_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzgtNy0xLTEtMzUzODM_f85379aa-084d-4619-8be5-719e4ea2858b">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8a666b3f60054f4cbf818f5e3df21b12_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzgtOS0xLTEtMzUzODM_e10ed8cf-18fe-45b0-bd00-6920f65c3296">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1f67c6da798f44b594280ae812c6baaf_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzExLTEtMS0xLTM1Mzgz_23dd7765-85d9-417f-b367-d7b2e25bcad0">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i76d7a88ee04145c194ae4be4171aa00c_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzExLTMtMS0xLTM1Mzgz_7c5b5de2-98bc-4cab-b3e6-2464afe146ef">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i73b71a1c9b2748b48f0eef3f1e218dbc_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzExLTUtMS0xLTM1Mzgz_c4789f93-30bd-4265-8e17-0f285c307c22">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0dcb43e627a74a66b65eccdde1930703_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzExLTctMS0xLTM1Mzgz_fb1ddf5b-ce8d-4019-8c80-7004573dcad8">482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9f29e88f1e0a4dada070a283833ffdb9_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzExLTktMS0xLTM1Mzgz_3f6db12a-e42c-401c-89cd-61a41680b0d6">1,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic14ac3299f434c03908133a0c4a9205e_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEyLTEtMS0xLTM1Mzgz_3f5ae8db-5fa5-4c8c-84a9-2996b732ab9a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0c6845c74acd4eb6bdee2a26eb7d8b31_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEyLTMtMS0xLTM1Mzgz_823e33bf-ebbb-4e50-94c1-64105144b6ee">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iff53065b38874233bcc1a933461017ac_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEyLTUtMS0xLTM1Mzgz_06cda8c0-e2f7-4eb3-86ee-2eab5bd22673">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0daba0652a364b148a3ad3df35cb62f9_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEyLTctMS0xLTM1Mzgz_b661bab6-2e75-4a1c-be42-cba8501d5340">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8addce8064f24c3cb69be9a37be7346b_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEyLTktMS0xLTM1Mzgz_f748c1e2-9dfd-4bcb-be1a-794e0447161a">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic14ac3299f434c03908133a0c4a9205e_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEzLTEtMS0xLTM1Mzgz_48c2910f-f8d9-45ae-b914-9ff90f57ce90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0c6845c74acd4eb6bdee2a26eb7d8b31_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEzLTMtMS0xLTM1Mzgz_8e0fab97-294d-41bc-a0da-c4274cf4889f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="iff53065b38874233bcc1a933461017ac_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEzLTUtMS0xLTM1Mzgz_ba526a89-88c4-4760-ba20-d9cdc7412c83">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i0daba0652a364b148a3ad3df35cb62f9_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEzLTctMS0xLTM1Mzgz_29b9347e-e045-4740-9381-20aff6a9d6c0">374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i8addce8064f24c3cb69be9a37be7346b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEzLTktMS0xLTM1Mzgz_c45b3092-b02e-4fce-8f7f-a47b3c449f9a">651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic3c2b76821444aed993c937b01f9ce03_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE0LTEtMS0xLTM1Mzgz_2691ff6e-a842-4e3b-b04b-4e93c5551860">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i2e99b1b5e9384ed6b69134ad46524aed_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE0LTMtMS0xLTM1Mzgz_7f0106f0-9c88-4849-9e89-4d04d4b75034">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0b3d9e57cf1f4065853436dbd64f88f9_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE0LTUtMS0xLTM1Mzgz_915f224c-2ebc-4db7-a503-da36de3794eb">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i00001682505c41e0a1f6a5200e7369cc_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE0LTctMS0xLTM1Mzgz_5ffae66f-83e4-4b38-8955-7dd9db7f8adb">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i3050942226a5438fa9c685a3428ff7a1_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE0LTktMS0xLTM1Mzgz_e48cbe3f-59f6-48c8-ad47-7a9d9be310bb">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i25cea6a2272341c1929aaaa1d18e0f5b_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE1LTEtMS0xLTM1Mzgz_83ffcd68-fd27-4b1a-a92b-37fc5d1bd19c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0f607fc35a524cb8b063cbac9f2c139c_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE1LTMtMS0xLTM1Mzgz_6c30531b-180d-4853-8c0c-2b41504b1093">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1784fbe9117b4ee1a7b43ddcc71a0db3_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE1LTUtMS0xLTM1Mzgz_e964a25d-63ee-4899-875c-bb9666b5d9ea">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie5d7a02883ec445c9158c8db51d57df8_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE1LTctMS0xLTM1Mzgz_416d2905-69a0-4fb1-9572-f962002bb22d">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i4f605b055eea4373ba168badd86607c3_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE1LTktMS0xLTM1Mzgz_5782b229-eb2e-4a53-876f-3e0ac19af879">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iee540100ac1e473dbf3745fc5ffcc5be_I20221231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE3LTEtMS0xLTM1Mzgz_910be633-62d6-4b4b-9c69-fb6eaffa31ff">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaf594b04da5249a0841abdc72a9802ec_I20221231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE3LTMtMS0xLTM1Mzgz_94d27e6c-5cd9-4cec-8831-ecf8c1ec752d">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if236c6ed5fc6436b9c2654b18b4a3ada_I20221231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE3LTUtMS0xLTM1Mzgz_18b9366b-cbe9-485a-9b29-e4110776258c">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id315aa54ed3e46e19f179179a56a77ee_I20221231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE3LTctMS0xLTM1Mzgz_a0a563da-39c8-4c4a-9511-7848b256dc2d">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if30f9fd81d8e488390af3fade7de9e46_I20221231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE3LTktMS0xLTM1Mzgz_a3aca7be-cadc-415a-aefd-541b086fd85a">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i513dceb1a6f14df9a09714d11d8a7b2d_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIwLTEtMS0xLTM1Mzgz_7f18d94c-3c7c-4da7-a6af-6ae1e5ced3f8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1feff0178e14474aaa4fc6a186497ad0_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIwLTMtMS0xLTM1Mzgz_9c3f60f7-2253-4e1e-9cac-696c06437870">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id202f8bc51ef4633b66140d696b4d861_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIwLTUtMS0xLTM1Mzgz_9b59b4fa-e16e-4cb5-929c-0bb3437065a3">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i54cddc074de54f28b6e68ca6b670e5f7_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIwLTctMS0xLTM1Mzgz_6070f269-945c-483b-9f68-82f68531823e">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIwLTktMS0xLTM1Mzgz_2775bfd3-5a03-4c91-a0e9-4d79abf4a38d">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i777d047d5ec446409e8a5c8324aa324d_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIxLTEtMS0xLTM1Mzgz_7ef910a3-0c4a-4f52-8c1f-b16ae5afdc03">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0a8c607d0de64f79bdc2e8ce8034a59c_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIxLTMtMS0xLTM1Mzgz_7f34cad2-23c3-4a7f-a3cd-52201688addf">108</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie70c35bbd59a4905b781c7668e5cc70f_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIxLTUtMS0xLTM1Mzgz_c344e870-bf8e-4c60-875b-7b5fc6f941d5">156</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i963844cd43c644c7932afd7741a944d5_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIxLTctMS0xLTM1Mzgz_4ad5bdac-a3a7-49c9-8c63-74d94a7eadd5">83</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIxLTktMS0xLTM1Mzgz_1ea8dcca-9672-4c54-b3a5-16cc48311633">356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_1099511629597"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 7: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGV4dHJlZ2lvbjoxZDhlNGE0MDE4MTQ0YjM5OGM3YTM4OTExMTYxZWIxM181NDk3NTU4MTU5OTQ_589990a5-1845-4f0a-8bca-e0103c748e08" continuedAt="i47024837317b4ad390c3645c811c93d8" escape="true">Accounts payable and accrued liabilities</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i47024837317b4ad390c3645c811c93d8"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGV4dHJlZ2lvbjoxZDhlNGE0MDE4MTQ0YjM5OGM3YTM4OTExMTYxZWIxM181NDk3NTU4MTU5OTU_acc084c3-5ac2-4201-87c6-20e796f8fe46" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGFibGU6ODJhMDI1YjJiNTQwNDQxMjk1M2YzM2ZhOTRhNGI1ZGQvdGFibGVyYW5nZTo4MmEwMjViMmI1NDA0NDEyOTUzZjMzZmE5NGE0YjVkZF8xLTEtMS0xLTQ0NjY5_8292ee41-5b4a-4e8f-8bb9-122c006e9300">2,252</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGFibGU6ODJhMDI1YjJiNTQwNDQxMjk1M2YzM2ZhOTRhNGI1ZGQvdGFibGVyYW5nZTo4MmEwMjViMmI1NDA0NDEyOTUzZjMzZmE5NGE0YjVkZF8xLTMtMS0xLTQ0NjY5_fcfc4486-dca8-493b-8bcc-078ad4275492">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:AccrualsClassifiedAsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGFibGU6ODJhMDI1YjJiNTQwNDQxMjk1M2YzM2ZhOTRhNGI1ZGQvdGFibGVyYW5nZTo4MmEwMjViMmI1NDA0NDEyOTUzZjMzZmE5NGE0YjVkZF8yLTEtMS0xLTQ0NjY5_89697c82-ca8e-4f50-bb89-8f940155b9f8">1,398</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:AccrualsClassifiedAsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGFibGU6ODJhMDI1YjJiNTQwNDQxMjk1M2YzM2ZhOTRhNGI1ZGQvdGFibGVyYW5nZTo4MmEwMjViMmI1NDA0NDEyOTUzZjMzZmE5NGE0YjVkZF8yLTMtMS0xLTQ0NjY5_d4c9ccb0-9e3b-45cb-a422-abd261975a27">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGFibGU6ODJhMDI1YjJiNTQwNDQxMjk1M2YzM2ZhOTRhNGI1ZGQvdGFibGVyYW5nZTo4MmEwMjViMmI1NDA0NDEyOTUzZjMzZmE5NGE0YjVkZF82LTEtMS0xLTQ0NjY5_6d8aefb1-37b1-483e-8323-10c46f88f31c">3,650</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGFibGU6ODJhMDI1YjJiNTQwNDQxMjk1M2YzM2ZhOTRhNGI1ZGQvdGFibGVyYW5nZTo4MmEwMjViMmI1NDA0NDEyOTUzZjMzZmE5NGE0YjVkZF82LTMtMS0xLTQ0NjY5_aee920f2-38ac-4d36-a058-46276907b3e8">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_154"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 8: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfLeasesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzEwMjA_15aacf43-66de-4dd5-94f9-11abeb38bc8e" continuedAt="ie2ecef496aeb4dbfa36f4009a44e371c" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie2ecef496aeb4dbfa36f4009a44e371c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with lease terms generally between <ix:nonNumeric contextRef="i0702f9b593a943e0aa89f870ac3bbdc4_D20220101-20221231" name="oncyf:OperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzEwNg_bfd19354-b968-410c-8bf4-acf5539394a3">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i0b95cc388ab54e769e83447ea9abf950_D20220101-20221231" name="oncyf:OperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzExMg_e2eb5a18-c00c-4fb0-81dd-3977b1a0abaf">6</ix:nonNumeric> years. We currently do not have leases with residual value guarantees or leases not yet commenced to which we are committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was <ix:nonFraction unitRef="number" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="2" name="ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzEwOTk1MTE2MjkyNDE_1f6d9b4d-7178-4fe9-b08d-2bf3d3831dfd">15</ix:nonFraction>%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recorded an addition for a new office space lease for our Canadian head office and a lease modification related to the office lease extension for one of our subsidiaries. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzEwMTc_06d9ac29-6062-4929-8b63-f5300374d858" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzEtMS0xLTEtMzUzODM_8666f3d6-d0c1-4d69-a5ea-768fe788903e">584</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzEtMy0xLTEtMzUzODM_b9987946-9b00-4e2d-83dc-dd77a6c0b621">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzItMS0xLTEtMzUzODM_16728520-8e54-41fe-aab0-f5bd324b4635">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzItMy0xLTEtMzUzODM_ac9a49c1-2bdc-41a5-8938-a7a476931c71">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease modification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="oncyf:LeaseModificationRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzMtMS0xLTEtMzUzODM_864d2da2-8221-4a1e-a973-bb1ef8cbfad0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="oncyf:LeaseModificationRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzMtMy0xLTEtMzUzODM_251b2eee-be7b-4ec1-b194-fc7b2c506150">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzQtMS0xLTEtMzUzODM_c1269302-0e5e-4514-9c56-2876414c098e">299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzQtMy0xLTEtMzUzODM_6cf6329e-1b9d-4223-89e5-a2d447baaa4e">322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="oncyf:ForeignExchangeImpactRightofUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzUtMS0xLTEtMzUzODM_3a233808-b5e5-47b8-9c0f-4925c6cac112">11</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="oncyf:ForeignExchangeImpactRightofUseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzUtMy0xLTEtMzUzODM_e8c48ca9-82bc-47a7-8415-000c23827d9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzYtMS0xLTEtMzUzODM_60412f4c-23fb-4143-bd6f-3cd656d551f7">296</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzYtMy0xLTEtMzUzODM_8ca06ffe-f9c2-46ff-a9de-32f65d25df10">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzEwMTg_3bf2ec7a-c50d-4e54-a2b3-7f39c9cf1e9e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease liabilities activity for the years ended December&#160;31:    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzEtMS0xLTEtMzUzODM_b6c6e0bd-ed85-41e9-ada6-c981b3df61ce">655</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzEtMy0xLTEtMzUzODM_abf638ad-9d1e-465f-8e09-9aaaf461d368">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzItMS0xLTEtMzUzODM_72442b9c-3916-40db-9eb4-810f33c88f5c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzItMy0xLTEtMzUzODM_b384126e-33b0-4acf-bdb5-7de2796a8e59">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease modification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="oncyf:EffectOfLeaseModificationOnLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzMtMS0xLTEtMzUzODM_dddf44c5-819f-44ca-b780-fe213777767d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="oncyf:EffectOfLeaseModificationOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzMtMy0xLTEtMzUzODM_77506c62-61c2-4593-9257-1cc84e5aa378">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzQtMS0xLTEtMzUzODM_8ea1d9a1-6003-46e7-9f19-c7d6eade2f21">381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzQtMy0xLTEtMzUzODM_b74db20a-9758-43cc-a6cc-fe4c3dcc63ba">366</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzUtMS0xLTEtMzUzODM_23071cb6-bbff-458d-91a6-15da71f50f9f">80</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzUtMy0xLTEtMzUzODM_ba72cbee-821c-4b81-b548-bd372b464607">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="oncyf:GainsLossesFromForeignExchangeImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzYtMS0xLTEtMzUzODM_11215f40-3d6b-4841-9f8a-fbdb76cf83fb">19</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="oncyf:GainsLossesFromForeignExchangeImpact" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzYtMy0xLTEtMzUzODM_e60b3fe4-3823-4c6e-bb9b-c6e0e2ac1b57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzctMS0xLTEtMzUzODM_4aff6427-13ab-4f41-ad7b-fcb673002366">373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzctMy0xLTEtMzUzODM_3b1335be-fa6f-443e-8681-e43045d822eb">655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzEwMjI_f05d1afe-c63b-4d5e-a3b1-1e3eeb272de6" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at December&#160;31, 2022 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:81.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ia32318f895f946ecbe86b9b07e60fd1c_I20221231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTo2ZDUzZDg5OThmZjU0YjliYThlOWQzNjNjOGE2YTMxNC90YWJsZXJhbmdlOjZkNTNkODk5OGZmNTRiOWJhOGU5ZDM2M2M4YTZhMzE0XzEtMS0xLTEtMzUzODM_b4ab8461-0787-405b-9916-fef547e3836f">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iea62ebc777ac430eb1852b3dd64bf5a0_I20221231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTo2ZDUzZDg5OThmZjU0YjliYThlOWQzNjNjOGE2YTMxNC90YWJsZXJhbmdlOjZkNTNkODk5OGZmNTRiOWJhOGU5ZDM2M2M4YTZhMzE0XzItMS0xLTEtMzUzODM_7d073e1d-707b-41ef-bb27-4eae43b5734b">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i365cb71f7fa842589bd1fc05d704aec7_I20221231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTo2ZDUzZDg5OThmZjU0YjliYThlOWQzNjNjOGE2YTMxNC90YWJsZXJhbmdlOjZkNTNkODk5OGZmNTRiOWJhOGU5ZDM2M2M4YTZhMzE0XzMtMS0xLTEtMzUzODM_b026283d-dfa9-4f94-9e8f-4d254d31786d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTo2ZDUzZDg5OThmZjU0YjliYThlOWQzNjNjOGE2YTMxNC90YWJsZXJhbmdlOjZkNTNkODk5OGZmNTRiOWJhOGU5ZDM2M2M4YTZhMzE0XzQtMS0xLTEtMzUzODM_19b416c4-5493-4b43-9baa-c198bc79519e">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_160"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 9: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM5MjM_ca9250dd-c3fc-442b-a6dc-79af8d30d58c" continuedAt="i439306ad81df4ed58d18738e3a01bf12" escape="true">Share Capital</ix:nonNumeric></span></div><ix:continuation id="i439306ad81df4ed58d18738e3a01bf12" continuedAt="ic8d0485a04184751a4405008a86bb9d9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM5MjU_6684721f-bb37-4ab6-bfba-54c928896ca1" continuedAt="i0b652eb781924fc19524ed1a1f5ad5ef" escape="true"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if692efdc55844ddd94d16e3f6ae99d73_I20191231" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzItMS0xLTEtMzUzODM_09a78326-48d8-4b29-9c21-a292d63fa49b">32,198,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if692efdc55844ddd94d16e3f6ae99d73_I20191231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzItMy0xLTEtMzUzODM_4e0c9d9c-ab2f-4b92-aa1f-91baf75010f7">311,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6541e8507efb4de5a913ca4fac61cf17_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzMtMS0xLTEtMzUzODM_8011d346-4d34-4e90-8d67-1cb1802e91b1">133,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6541e8507efb4de5a913ca4fac61cf17_D20200101-20201231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzMtMy0xLTEtMzUzODM_2c1b4b40-a218-4562-b44e-384abb8e5019">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8972058a330f4d2e80365843e754c2d1_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzQtMS0xLTEtMzUzODM_76164e53-3a15-4b5c-89ca-306de7595b96">234,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8972058a330f4d2e80365843e754c2d1_D20200101-20201231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzQtMy0xLTEtMzUzODM_f71b1f91-de70-4baf-9ea3-d515763db73c">732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b1d0fbc8f1b4d968750fdb49b146c64_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzUtMS0xLTEtMzUzODM_28f7e432-686b-4d35-9d58-516de0fc334b">12,182,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6b1d0fbc8f1b4d968750fdb49b146c64_D20200101-20201231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzUtMy0xLTEtMzUzODM_32ac45c4-3b77-4423-927e-a4a0fd2380f7">40,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b8eb310435f4b7089eb7c5f3035b88d_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzctMS0xLTEtMzUzODM_8f9e3041-85a5-41ca-a082-37e5d15b85d7">1,418,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6b8eb310435f4b7089eb7c5f3035b88d_D20200101-20201231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzctMy0xLTEtMzUzODM_455b3db5-7c02-4b6c-b94b-ac4b1bc87b8a">6,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i6cec7f0886424478a8adab4adfe59a0b_D20200101-20201231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzgtMy0xLTEtMzUzODM_15c7ebd4-75c5-4d58-85bc-77586077956d">1,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe25ae3bb8014f7cb475d95097c9166e_I20201231" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzktMS0xLTEtMzUzODM_06908972-c0c2-4ecd-8920-86d697eb0809">46,166,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibe25ae3bb8014f7cb475d95097c9166e_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzktMy0xLTEtMzUzODM_b7ff970c-f305-4dc9-a99b-5f0208cf807c">356,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b552f25ccd04fdb86d1346a3975fa1b_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzEwLTEtMS0xLTM1Mzgz_d32f1f84-0ae4-466b-b552-d114204a2dc5">123,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i8b552f25ccd04fdb86d1346a3975fa1b_D20210101-20211231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzEwLTMtMS0xLTM1Mzgz_8d751118-6e2c-4d25-80ea-aa18c8dddce2">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6493a759f124792b1e8928326aac134_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzExLTEtMS0xLTM1Mzgz_067d6cd5-fd67-4ce6-85f7-b4e1c2655781">150,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic6493a759f124792b1e8928326aac134_D20210101-20211231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzExLTMtMS0xLTM1Mzgz_f4991dbd-117e-4bc8-9c67-a0ef4ec80ddc">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f593ff807bd4b97a79dd779ca1363b4_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzEyLTEtMS0xLTM1Mzgz_b002db3b-3660-4d79-b7f6-a7ee63cb1844">8,401,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i7f593ff807bd4b97a79dd779ca1363b4_D20210101-20211231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzEyLTMtMS0xLTM1Mzgz_e4e071ea-2f7d-423c-9004-3acf6340322e">34,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2fe0be7fe344da59d4ec9cf38ef8816_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzEzLTEtMS0xLTM1Mzgz_5674b61d-5b7d-449f-844a-5bde8f7cca76">201,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic2fe0be7fe344da59d4ec9cf38ef8816_D20210101-20211231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzEzLTMtMS0xLTM1Mzgz_92558305-a175-44e6-83bd-d50cd72cc4d2">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="i11172d73364741cc830ad4c4925edd65_D20210101-20211231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE0LTMtMS0xLTM1Mzgz_ec92d503-1338-4af8-a7a1-a35bf0efefaf">1,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieee4c1d19b10441a9fb87c20bf21e3fa_I20211231" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE1LTEtMS0xLTM1Mzgz_7dcc1e13-351c-438a-bd4c-eb1b5316673e">55,043,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ieee4c1d19b10441a9fb87c20bf21e3fa_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE1LTMtMS0xLTM1Mzgz_e7aeac44-e294-4130-a183-56f7eed771e4">391,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10f8803a04704f94b4c3b16076075a61_D20220101-20221231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE2LTEtMS0xLTM1Mzgz_0cfb61b9-cfb7-4c8a-b9c8-1020190969dd">8,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i10f8803a04704f94b4c3b16076075a61_D20220101-20221231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE2LTMtMS0xLTM1Mzgz_d242abf3-6710-4f8b-91a7-3952a57ccf4b">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6efced05728f430dbc45b4b00278027e_D20220101-20221231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE3LTEtMS0xLTM1Mzgz_06a6ff74-b59d-4b04-a783-ede0b3da6191">40,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6efced05728f430dbc45b4b00278027e_D20220101-20221231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE3LTMtMS0xLTM1Mzgz_33901540-2d8d-4939-bb96-6054934b6073">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)(e)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e9e1c91dbd64b66a3ef5f637728d726_D20220101-20221231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE4LTEtMS0xLTM1Mzgz_e264fa33-917a-4171-96d4-b05056b04882">6,235,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0e9e1c91dbd64b66a3ef5f637728d726_D20220101-20221231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE4LTMtMS0xLTM1Mzgz_9c6c639c-d8c0-4dea-bc3a-57b6af20f964">13,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie67556b574354bfbbbe629f9c4f83910_D20220101-20221231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzIwLTMtMS0xLTM1Mzgz_674be6ae-0db1-45b0-8712-6b22e8cd1782">764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied69a4c1e8dc444497553637c429c995_I20221231" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzIxLTEtMS0xLTM1Mzgz_c7640ad5-435c-494d-8c5b-129845408eb6">61,327,914</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ied69a4c1e8dc444497553637c429c995_I20221231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzIxLTMtMS0xLTM1Mzgz_c7075f23-371f-48f7-8c3b-c47544666e23">404,040</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$<ix:nonFraction unitRef="usd" contextRef="if333223790564dcb96ea8ce18000124c_I20181024" decimals="INF" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzg3NQ_52b04d8a-3cbd-43c0-bbc2-f374d4505102">30,000</ix:nonFraction> over a <ix:nonNumeric contextRef="i9c01aa3f72784c8eb36e0bca515d9aff_D20181024-20181024" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM5Mjk_0c5b20ee-f235-4c06-87e9-ec0057ef5a61">19-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement expired on June 4, 2020. In 2020, we sold <ix:nonFraction unitRef="shares" contextRef="i809782423e5a496c9bb7e6d59de0f3a5_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwODg_a36333b0-12c0-4131-a2e6-e9c62665b9b4">6,741,518</ix:nonFraction> common shares for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i809782423e5a496c9bb7e6d59de0f3a5_D20200101-20201231" decimals="-3" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzExMzg_55a93b9a-dbb5-4961-9e56-f6d997af2baa">17,538</ix:nonFraction> at an average price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i783080355c484f52b0c3ed3b1f30118c_I20201231" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzExNzQ_f0312a12-a6cb-4453-a8fe-8e95964b289f">2.42</ix:nonFraction>. We received, net of commissions of US$<ix:nonFraction unitRef="usd" contextRef="i809782423e5a496c9bb7e6d59de0f3a5_D20200101-20201231" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEyMjM_36b30698-4731-435d-9f6f-1ea9047b3903">526</ix:nonFraction>, proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i809782423e5a496c9bb7e6d59de0f3a5_D20200101-20201231" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEyNDk_19f7802a-6d26-411d-84ca-0ebf7bda25fd">17,012</ix:nonFraction>. In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="i809782423e5a496c9bb7e6d59de0f3a5_D20200101-20201231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEzMzA_d9c79b5a-2d02-412e-940c-e86f288b6222">857</ix:nonFraction>. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On August 16, 2019, pursuant to an underwritten public offering, <ix:nonFraction unitRef="shares" contextRef="i339d817f02da483dacfdea11d754715d_D20190816-20190816" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE0MDI_3391e198-acf8-4391-9666-6429d09f389c">4,619,773</ix:nonFraction> units were sold at a purchase price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i0d502b20f5504524b12de442d39c71e8_I20190816" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE0NDQ_8d9b49d0-10e1-4e3a-a594-33d813d577b6">0.81</ix:nonFraction> per unit for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i339d817f02da483dacfdea11d754715d_D20190816-20190816" decimals="-3" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE0Nzg_2b6dc86f-b39c-4faf-b0f3-9e4cb58ed5ce">3,742</ix:nonFraction>. Each unit included <ix:nonFraction unitRef="shares" contextRef="i95f4ddbdd41f46c28a3fa7900b833ed6_I20190816" decimals="INF" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE1MDE_e6e6df0a-b2b2-461d-ace8-1b6b442d4f12">one</ix:nonFraction> common share with a fair value of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i95f4ddbdd41f46c28a3fa7900b833ed6_I20190816" decimals="2" name="oncyf:SharesIssuedFairValueOfCommonShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE1Mzg_b4a8f6ab-a455-477e-9a3b-f1ecbd648992">0.54</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i36f0549e16fb493899d3ce11e6663ed3_I20190816" decimals="INF" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE1NDU_be456a62-9a6f-4cff-99cc-c9883c1c04e6">one</ix:nonFraction> common share purchase warrant with a fair value of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i36f0549e16fb493899d3ce11e6663ed3_I20190816" decimals="2" name="oncyf:SharesIssuedFairValueOfCommonShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE1OTk_98fab594-875b-4360-bb67-d19efc6cda1e">0.27</ix:nonFraction>. These warrants were classified as a financial liability (see Note 16). Each common share purchase warrant entitled the holder to purchase <ix:nonFraction unitRef="shares" contextRef="i0d502b20f5504524b12de442d39c71e8_I20190816" decimals="INF" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE3NDA_dd6507fb-fa9e-47ed-a46b-cb21f111bb1e">one</ix:nonFraction> common share at an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i36f0549e16fb493899d3ce11e6663ed3_I20190816" decimals="2" name="oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE3ODA_c4d1b9a6-2f51-4446-b5e2-ea890bdd885a">0.90</ix:nonFraction> until August 16, 2024. In 2022, <ix:nonFraction unitRef="shares" contextRef="ibb8660fe469e4e3bb809b223adeb1928_D20220101-20221231" decimals="INF" name="oncyf:ClassofWarrantorRightNumberofWarrantsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzYzNjE_6eff737b-1907-45ba-aa67-834a3f42530d">no</ix:nonFraction> warrants were exercised. In 2021, <ix:nonFraction unitRef="shares" contextRef="i6f4f12b4c9ac415291240c8cd9609fe0_D20210101-20211231" decimals="INF" name="oncyf:ClassofWarrantorRightNumberofWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE2NDkyNjc0NTA1ODI_bcd0efbe-fe3f-4b27-9c3f-ee1fcc30ee26">201,722</ix:nonFraction> (2020 - <ix:nonFraction unitRef="shares" contextRef="i711e0a27b9344e398357548811fe1ed6_D20200101-20201231" decimals="INF" name="oncyf:ClassofWarrantorRightNumberofWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE2NDkyNjc0NTA1OTM_af0512d3-ca36-4bb0-958d-fb2a03f54989">1,418,369</ix:nonFraction>) warrants with a fair value of $<ix:nonFraction unitRef="cad" contextRef="i6f4f12b4c9ac415291240c8cd9609fe0_D20210101-20211231" decimals="-3" name="oncyf:ClassofWarrantorRightWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzIwMjk_99d0b608-7087-4dd2-9e1b-028b0c5d922b">456</ix:nonFraction> (2020 - $<ix:nonFraction unitRef="cad" contextRef="i711e0a27b9344e398357548811fe1ed6_D20200101-20201231" decimals="-3" name="oncyf:ClassofWarrantorRightWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzIwMzg_27d8d09f-27f1-421a-bf25-041269d4ad8d">4,636</ix:nonFraction>) were exercised for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="oncyf:ProceedsfromWarrantExercises1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzIwODQ_48a2b865-c8fb-4bf5-9043-4b7c12f141fd">182</ix:nonFraction> (2020 - US$<ix:nonFraction unitRef="usd" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="oncyf:ProceedsfromWarrantExercises1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzIwOTM_8d37c23f-b147-4ce5-8e96-c13a9c770c8a">1,277</ix:nonFraction>). As at December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i9c37cce29b8346b0ba836e6e496264d0_I20221231" decimals="INF" name="oncyf:ClassOfWarrantOrRightOutstanding1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzY0NjY_be4b9d0d-7821-4a53-9bd4-9fc40115b3ed">64,035</ix:nonFraction> warrants outstanding (December&#160;31, 2021 - <ix:nonFraction unitRef="shares" contextRef="i9c37cce29b8346b0ba836e6e496264d0_I20221231" decimals="INF" name="oncyf:ClassOfWarrantOrRightOutstanding1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzY1MDA_be4b9d0d-7821-4a53-9bd4-9fc40115b3ed">64,035</ix:nonFraction>). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up US$<ix:nonFraction unitRef="usd" contextRef="if27e5cf46efd4450807817226f0625d7_I20200615" decimals="INF" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzIzODA_155a9add-9eb1-4a4b-8d94-1c2898126adc">40,000</ix:nonFraction> over a <ix:nonNumeric contextRef="ida0bae79a8bc43eb8fd183431b5b3f2d_D20200615-20200615" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM5MzA_5cdfda69-4438-46cd-903b-e1c0db95a277">25-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on March 4, 2021. In 2021, we sold <ix:nonFraction unitRef="shares" contextRef="i23e1543579db44e78472abe042745f89_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzI1MDQ_7d9621af-bfa5-4894-9850-494e80a6794a">5,685,097</ix:nonFraction> (2020 - <ix:nonFraction unitRef="shares" contextRef="id7dd014e773644638183d9dbc0c3ba03_D20200101-20201231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzM4NDE_03530b9a-d87d-4c47-8b26-9ba915f99aee">5,441,014</ix:nonFraction>) common shares for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i23e1543579db44e78472abe042745f89_D20210101-20211231" decimals="-3" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzI1NTM_6cd7bb5a-7bae-4888-a164-d723cc0fd639">18,503</ix:nonFraction> (2020 - US$<ix:nonFraction unitRef="usd" contextRef="id7dd014e773644638183d9dbc0c3ba03_D20200101-20201231" decimals="-3" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzM5NTg_4f2dce15-a25e-425b-9ced-734deab594e3">12,629</ix:nonFraction>) at an average price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i63384d0a252342c890796e05d336932d_I20211231" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzM5ODI_08b15831-759e-4921-9596-9aea8e86232a">3.25</ix:nonFraction> (2020 - US$<ix:nonFraction unitRef="usdPerShare" contextRef="i90e7609d87f34c56bb2a2970072a4155_I20201231" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzI1ODk_0d6b9981-6c09-4754-9634-250817be6438">2.11</ix:nonFraction>). We received, net of commissions of US$<ix:nonFraction unitRef="usd" contextRef="i23e1543579db44e78472abe042745f89_D20210101-20211231" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzM5OTM_7c298a88-b66f-4256-87de-6d15251655eb">555</ix:nonFraction> (2020 - US$<ix:nonFraction unitRef="usd" contextRef="id7dd014e773644638183d9dbc0c3ba03_D20200101-20201231" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzI2Mzg_68ebd544-5eb9-4f13-aa9a-b4520204914d">379</ix:nonFraction>), proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i23e1543579db44e78472abe042745f89_D20210101-20211231" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQwMDU_f5430843-e40e-47a3-ad90-7844ba16ab0f">17,948</ix:nonFraction> (2020 - US$<ix:nonFraction unitRef="usd" contextRef="id7dd014e773644638183d9dbc0c3ba03_D20200101-20201231" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzI2NjQ_5d75bfbe-7eee-4e10-bb7b-36f65fef7650">12,250</ix:nonFraction>). In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="i23e1543579db44e78472abe042745f89_D20210101-20211231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzI3NDU_3aa3abdd-d293-4648-8ea1-a6bea4d59ef4">707</ix:nonFraction> (2020 - $<ix:nonFraction unitRef="cad" contextRef="id7dd014e773644638183d9dbc0c3ba03_D20200101-20201231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxMTU_9cb5caca-35c8-4987-bd3e-48f349fa739c">885</ix:nonFraction>).</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$<ix:nonFraction unitRef="usd" contextRef="ia82e40c581724751808cdca1dd238e9b_I20210305" decimals="INF" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMwNDg_519482ec-2578-4f57-a994-198151e18324">80,000</ix:nonFraction> over a <ix:nonNumeric contextRef="i998f1448e0f242f0a37474a940e5bb85_D20210305-20210305" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM5Mjc_a9fcb434-8263-4ee8-a518-f242c84d403c" continuedAt="i6fb81aae1ae94f408d4718b464e1abce">16-</ix:nonNumeric></span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ic8d0485a04184751a4405008a86bb9d9"><ix:continuation id="i0b652eb781924fc19524ed1a1f5ad5ef"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6fb81aae1ae94f408d4718b464e1abce">month</ix:continuation> period through the facilities of the Nasdaq Capital Market in the United States. In 2022, we sold <ix:nonFraction unitRef="shares" contextRef="i98e916be7d9749dd9fdd5af0f4f92104_D20220101-20221231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxMjQ_00f66ef1-4c06-4050-81bd-abf4e6b6ea2a">2,719,770</ix:nonFraction> (2021 - <ix:nonFraction unitRef="shares" contextRef="i209bf45ef70c45e7b6c75d2906c6f1ad_D20210101-20211231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMxNjM_b6089d1a-2842-4282-9520-4fe6e27b90ee">2,715,932</ix:nonFraction>) common shares for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i98e916be7d9749dd9fdd5af0f4f92104_D20220101-20221231" decimals="-3" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxNDM_d23ee2a2-2177-4146-bf5c-8c64f2418290">4,560</ix:nonFraction> (2021 - US$<ix:nonFraction unitRef="usd" contextRef="i209bf45ef70c45e7b6c75d2906c6f1ad_D20210101-20211231" decimals="-3" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMyMDI_80aecb0a-7792-415d-9b15-941fbbf79acb">8,655</ix:nonFraction>) at an average price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i35bc0c0fb23d4de58f297cc59b64b8da_I20221231" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxNTc_c9a6c91c-9648-4a2f-b42b-9505423b089d">1.68</ix:nonFraction> (2021 - US$<ix:nonFraction unitRef="usdPerShare" contextRef="i5ab78014954745ca943db137b2067123_I20211231" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMyMjg_119058b1-12ef-47eb-b493-e982817f4659">3.19</ix:nonFraction>). We received, net of commissions of US$<ix:nonFraction unitRef="usd" contextRef="i98e916be7d9749dd9fdd5af0f4f92104_D20220101-20221231" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxNjk_8a3c3538-7a34-4898-9812-50dd64f8fef6">137</ix:nonFraction> (2021 - US$<ix:nonFraction unitRef="usd" contextRef="i209bf45ef70c45e7b6c75d2906c6f1ad_D20210101-20211231" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMyNjc_2ebac8d3-9fb7-49e4-8f15-b6761739ccbe">260</ix:nonFraction>), proceeds of US$<ix:nonFraction unitRef="usd" contextRef="i98e916be7d9749dd9fdd5af0f4f92104_D20220101-20221231" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxNzQ_949af166-f2b9-42f8-9f0b-8b7f159b844c">4,423</ix:nonFraction> (2021 - US$<ix:nonFraction unitRef="usd" contextRef="i209bf45ef70c45e7b6c75d2906c6f1ad_D20210101-20211231" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMyODM_c1de8248-5490-4876-87e2-a86df7682cb4">8,395</ix:nonFraction>). In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="i98e916be7d9749dd9fdd5af0f4f92104_D20220101-20221231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxOTY_c1e4cfcb-12ec-4d41-b5bc-882ad271f37a">209</ix:nonFraction> (2021 - $<ix:nonFraction unitRef="cad" contextRef="i209bf45ef70c45e7b6c75d2906c6f1ad_D20210101-20211231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMzNTQ_6ecaa692-95e8-4f21-88e9-f64824879ce9">549</ix:nonFraction>). This sales agreement was terminated on June 16, 2022.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$<ix:nonFraction unitRef="usd" contextRef="i6cb45010a1f04a19bb8bb7c198eafcb7_I20220617" decimals="INF" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ1MjY_be02c942-e1de-4242-ba91-b58c1f3510b6">65,000</ix:nonFraction> over a <ix:nonNumeric contextRef="ibf3514ed6ca044d7810415c09e4274c5_D20220617-20220617" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzU0OTc1NTgyMTEzMA_b9cd41d9-0a7a-48cf-abde-388c69b33a80">25-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. In 2022, we sold <ix:nonFraction unitRef="shares" contextRef="ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ1NjI_12b54cff-47cc-4f9a-901d-37693e3a4203">3,515,462</ix:nonFraction> common shares for gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231" decimals="-3" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ2MjY_3592095b-02b9-469a-ae8e-91833bf8a623">5,632</ix:nonFraction> at an average price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i7b0440d3e41e4deaa503df6fed6a1cf7_I20221231" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ2NTQ_2de9d73c-597f-4c0a-a202-a16ffa3cf1e7">1.60</ix:nonFraction>. We received, net of commissions of US$<ix:nonFraction unitRef="usd" contextRef="ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ2OTc_3baad7f0-0f41-4fe7-bda1-2d67aead4e18">169</ix:nonFraction>, proceeds of US$<ix:nonFraction unitRef="usd" contextRef="ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ3MTU_744c6d00-f3df-4289-8b12-8f394a1b1996">5,463</ix:nonFraction>. In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ3OTA_4a3b0709-5b41-47dc-abfa-02cd7a518446">555</ix:nonFraction>.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrants</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2017, pursuant to an underwritten public offering, <ix:nonFraction unitRef="shares" contextRef="i8c38fae9a1ca4c469aff3c034e794b8d_D20170601-20170601" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM0Mzk_c27f7fce-b171-4b35-a6c5-9b67f8565761">16,445,000</ix:nonFraction> units were sold for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="i8c38fae9a1ca4c469aff3c034e794b8d_D20170601-20170601" decimals="-3" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM0ODA_9c0c64bb-cd42-4be2-8f5d-864253a8484b">11,512</ix:nonFraction>. Each unit included <ix:nonFraction unitRef="shares" contextRef="i15ebd1009ac5441788d5ea09d2d20d34_I20170601" decimals="0" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM1MDM_d6752cbf-af25-481b-94a0-c7ff9f521b6b">one</ix:nonFraction> common share and <ix:nonFraction unitRef="shares" contextRef="i15ebd1009ac5441788d5ea09d2d20d34_I20170601" decimals="0" name="oncyf:CommonSharePurchaseWarrantPerUnit" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM1MjM_c2a5788d-d497-41b8-ba09-eef61ea6d9ad">one</ix:nonFraction> common share purchase warrant. Following the 2018 share consolidation, <ix:nonFraction unitRef="shares" contextRef="i15ebd1009ac5441788d5ea09d2d20d34_I20170601" decimals="1" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM1OTc_cf4b42f7-312e-40a4-b7cb-820f416073c0">9.5</ix:nonFraction> common share purchase warrants entitled the holder to purchase <ix:nonFraction unitRef="shares" contextRef="i15ebd1009ac5441788d5ea09d2d20d34_I20170601" decimals="0" name="oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM2NjM_c8fb9612-caa8-421e-9d64-dc73417b4cba">one</ix:nonFraction> common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $<ix:nonFraction unitRef="cadPerShare" contextRef="i15ebd1009ac5441788d5ea09d2d20d34_I20170601" decimals="3" name="oncyf:SharesIssuedWarrantPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM3Njc_e9416b98-ece4-4457-878f-f0cf445087fa">9.025</ix:nonFraction>. These warrants were classified as equity. These warrants expired on June 1, 2022, and were transferred to contributed surplus on the consolidated statement of financial position upon expiry. There was no cash flow impact as a result of the warrant expiry. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM5MzY_895cf3bf-cbbe-474c-8087-5b6673d0192e" continuedAt="id27244ce52534e689079ac5bebb6bad4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadb9b5984e0d4be9a1b244e2d939dde2_I20191231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzEtMS0xLTEtNDExOTk_4404899a-9ec7-467d-801d-c60499c6eff8">16,445,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie5e2093c82014efc936a23f9e66baceb_I20191231" decimals="-3" name="oncyf:WarrantsAndRightsOutstanding1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzEtMy0xLTEtNDEyMDk_df35f0e7-6f3d-40a8-a967-f100cee346b0">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f62a8b7a8c2458692b02a5416ac2ac4_I20201231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzEtMS0xLTEtMzUzODM_4ce1eab2-45ae-417f-ac80-221c7ccf8c16">16,443,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="-3" name="oncyf:WarrantsAndRightsOutstanding1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzEtMy0xLTEtMzUzODM_41c58865-f34e-47cf-874a-159bb2da1749">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49324b0a98f247d28e8710f0a21c58d2_I20211231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzItMS0xLTEtMzUzODM_1f5a4962-d6a7-455d-90bb-7eed35512f1e">16,443,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="oncyf:WarrantsAndRightsOutstanding1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzItMy0xLTEtMzUzODM_1a143a95-1af5-4109-abed-8875f87b53ed">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic7cac766cbaa43fb9c4ad8b89138fec9_D20220101-20221231" decimals="INF" name="oncyf:NumberOfSharesExpired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzMtMS0xLTEtMzcxNzI_b24892b0-58cb-4951-ad47-58afae05c46a">16,443,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="oncyf:WarrantsAndRightsExpired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzMtMy0xLTEtMzcxODA_dcc5d613-d6f5-47a5-8ccd-0111e09ebbf2">3,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i451a07d69b99427c8835f34d48f9f9fa_I20221231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzMtMS0xLTEtMzUzODM_89806d01-df94-46be-ae57-bde3ea0125e5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="oncyf:WarrantsAndRightsOutstanding1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzMtMy0xLTEtMzUzODM_37b79888-ddff-4d8e-ab63-5a4705c5454e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_166"></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 10: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMzc_00c0693e-a71f-4ad4-8eff-9278a789b1a4" continuedAt="i4fd5775177494a1498eec6a3c0aa49b8" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i4fd5775177494a1498eec6a3c0aa49b8" continuedAt="ibe9c069cf94a4040ad754354907a7176"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan </span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMzg_f2a5552d-14f8-4875-84e8-08d284ebb1e1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted stock options to acquire common stock through our stock option plan. Our stock option activity for the years ended December&#160;31 was as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzItMS0xLTEtMzUzODM_315d2d2b-b525-4de3-b1ba-ded6d53ac69d">5,334,420</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzItMi0xLTEtMzUzODM_70d2db3c-9d3a-4385-bf48-ffacc9b1ff44">3.53</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzItNC0xLTEtMzUzODM_7ac725d5-d022-4a30-970b-2e9f523d0962">3,764,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzItNS0xLTEtMzUzODM_eff78988-627c-4ad2-aa58-de4ebc8236b8">4.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5e2093c82014efc936a23f9e66baceb_I20191231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzItNy0xLTEtMzUzODM_08cd9e6d-bb65-4240-955e-4ec2d0d3648c">2,246,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ie5e2093c82014efc936a23f9e66baceb_I20191231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzItOC0xLTEtMzUzODM_dc9a22b1-ce8a-4930-9ebe-1b3251b563a5">5.31</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzMtMS0xLTEtMzUzODM_c94a07ac-47a5-4783-a931-6303deec3f8d">1,005,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzMtMi0xLTEtMzUzODM_90639db4-d453-4547-ade2-fa3b6a15a2e2">2.04</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzMtNC0xLTEtMzUzODM_0afe0f0e-fbdc-42c2-be68-b45f90afe82e">1,832,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzMtNS0xLTEtMzUzODM_9a6b1432-db2e-4b87-9a49-c30c66a600cf">2.99</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzMtNy0xLTEtMzUzODM_8ac60755-1ff2-4bdd-aa3d-e27b3083e3e5">1,817,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzMtOC0xLTEtMzUzODM_9066c33a-355d-4d82-953b-016a87910b44">3.19</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzQtMS0xLTEtMzUzODM_285e346e-a4e9-438e-a6af-97b21120ef11">62,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzQtMi0xLTEtMzUzODM_85dbae98-e3a7-4709-a354-386989e11405">3.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzQtNC0xLTEtMzUzODM_1ddbeb71-4284-4d96-b74d-ce3dbbc0a749">110,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzQtNS0xLTEtMzUzODM_f3c4db5d-387a-4109-b19f-5a21807ff3d3">6.21</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzQtNy0xLTEtMzUzODM_f4bdbe78-4c74-42fe-b51d-007a6e8832e3">141,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzQtOC0xLTEtMzUzODM_3609b04a-e1f2-4146-99e2-8ac9f478859a">3.84</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzUtMS0xLTEtMzUzODM_333518c8-0799-4dfb-80dc-416c0a3b5950">304,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzUtMi0xLTEtMzUzODM_877a4f76-2238-402c-9853-08099b924364">10.80</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzUtNC0xLTEtMzUzODM_3817cb2a-1e1e-486b-932d-00f0ead3e2e5">28,364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzUtNS0xLTEtMzUzODM_570f79a6-50bb-414f-8c47-73b312a78d39">37.63</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzUtNy0xLTEtMzUzODM_ea0bf491-5d93-4b2c-8557-189ae56753e3">25,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzUtOC0xLTEtMzUzODM_0edb2057-8f15-45c9-9a48-7bf91a60bfba">62.49</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzYtMS0xLTEtMzUzODM_c3f30ebf-a0fb-48e8-a426-572029448105">8,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzYtMi0xLTEtMzUzODM_588ba3d5-ad72-40fe-883a-2775f6a7f0bc">1.45</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzYtNC0xLTEtMzUzODM_e8471f0c-ecb6-4739-9f66-845616c87a37">123,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzYtNS0xLTEtMzUzODM_77e2ab83-aa6e-4c11-a8ab-322720c83b00">1.94</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzYtNy0xLTEtMzUzODM_3e609f3e-3fcd-4ad3-a292-9b88cfe81814">133,454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzYtOC0xLTEtMzUzODM_ad4b0764-c57d-4a05-adfc-6da9a8a46e4a">1.81</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzctMS0xLTEtMzUzODM_c111ffc9-6469-4e25-99db-1eff42d53a8d">5,963,185</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzctMi0xLTEtMzUzODM_73f0e3fa-5856-4071-870e-9556fe76ea0c">2.91</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzctNC0xLTEtMzUzODM_e9320b8d-c942-4756-b187-9a5382fa6627">5,334,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzctNS0xLTEtMzUzODM_da101e60-a57f-46bd-9d7f-bac0cc53ce98">3.53</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzctNy0xLTEtMzUzODM_2aadf2c9-9dca-4304-bc88-38745d4eb72a">3,764,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzctOC0xLTEtMzUzODM_cd5a6d20-4138-4947-865e-f35cbc647695">4.08</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzgtMS0xLTEtMzUzODM_1db31b13-448c-410d-89d2-3bded39f0d5b">4,420,482</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzgtMi0xLTEtMzUzODM_b160bbf9-e0b8-42d2-bdd9-83fd6c1b1d4c">3.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzgtNC0xLTEtMzUzODM_ae96e4ee-9573-48fa-bb10-c39ef5a67c28">3,165,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzgtNS0xLTEtMzUzODM_aeb69241-7111-42ab-b537-7de0d214046c">3.82</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzgtNy0xLTEtMzUzODM_a08af516-1d7c-41d3-87bf-e6d03909bb6d">2,164,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzgtOC0xLTEtMzUzODM_8e5ec239-7dec-4976-a037-702bf0fbb93f">4.84</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ibe9c069cf94a4040ad754354907a7176" continuedAt="i5457f44ecabc4ed3a0bb61bc9e7685e8"><ix:continuation id="id27244ce52534e689079ac5bebb6bad4"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMTc_8d3e58dd-5b9e-4b72-a280-c05ab9f0c695" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="i5d60827e07f44c119014f8e722b58bf9_I20221231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjozMGIzNmU2ZmVkOGM0OTJhYTgxN2Y3NzlhNDRmMzAyNV80_35313e50-3213-4d09-8e14-be3b9d36bd0b">0.54</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="i9aadf4823bed41b0a081530e5fc4658c_I20221231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjozMGIzNmU2ZmVkOGM0OTJhYTgxN2Y3NzlhNDRmMzAyNV85_4e7ac235-92b8-48ef-9588-b1094e74374d">1.89</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6368f5d59534a0d96175310350885fc_I20221231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtMi0xLTEtMzUzODM_0ca6bd58-93ad-44e9-82fa-67a0c0b2f0f5">1,002,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52f9ee94ed334d309ddc1b2501e78dc1_D20220101-20221231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtNC0xLTEtMzUzODM_17e5a84a-e6df-4f7b-8e08-5fc976dd90f1">1.76</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ic6368f5d59534a0d96175310350885fc_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtNi0xLTEtMzUzODM_b8d9e3d4-b67b-403a-ae77-8f48b1bfd395">1.39</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6368f5d59534a0d96175310350885fc_I20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtOC0xLTEtMzUzODM_62759f93-bf07-4238-8313-733f7c24efe7">799,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ic6368f5d59534a0d96175310350885fc_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtMTAtMS0xLTM1Mzgz_5233bd4b-3149-4072-aea3-e2e60315026c">1.40</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="i669145b9554d41f3b9c524309e023747_I20221231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjpiM2QxODI4YjFjY2E0YTYyYTAwODQ5ZTU3N2U3OTg1ZV80_7e8a2f5d-e1ff-424e-bdd3-4ceaed9d70a4">1.90</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="i9e8be41597da42568d4f86e247044361_I20221231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjpiM2QxODI4YjFjY2E0YTYyYTAwODQ5ZTU3N2U3OTg1ZV85_e34b430e-dddc-4993-a6b0-127260545c5a">3.05</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie679757fac604f0cb2a738bb1dd0ac7e_I20221231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItMi0xLTEtMzUzODM_e9ab9a06-d474-4daa-a11a-bcad5c631ad6">1,724,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifd74fcb0f8c9429fadb463a6eb81e2f0_D20220101-20221231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItNC0xLTEtMzUzODM_8d81d02c-391c-416b-a27d-186e138daaee">3.31</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ie679757fac604f0cb2a738bb1dd0ac7e_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItNi0xLTEtMzUzODM_5a9aca0d-8809-4bff-a962-39764c7b9b32">2.34</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie679757fac604f0cb2a738bb1dd0ac7e_I20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItOC0xLTEtMzUzODM_8936d444-a3f4-4b71-9362-53a31e39290c">1,001,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="ie679757fac604f0cb2a738bb1dd0ac7e_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItMTAtMS0xLTM1Mzgz_58ed95c5-70f8-4cf5-8031-de998ae861fd">2.37</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="if0265f11a01344f595e7fe503b2a3472_I20221231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjozMWYzZWIwNDY1M2M0ZjJlYWJjNjA2Y2Y1YWY0MWQzOF80_27199d5f-07ba-4500-a393-2a6c259de60c">3.06</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="idd36a13c83d745178281e200444da7ee_I20221231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjozMWYzZWIwNDY1M2M0ZjJlYWJjNjA2Y2Y1YWY0MWQzOF85_726cd574-e1f1-40f0-8070-b2e2b5131dc2">3.29</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e89eeef735b47ceb3acd3ad40771e04_I20221231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtMi0xLTEtMzUzODM_74906f0a-ece9-4a39-9e73-3792cbb91f53">1,532,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib60b968ef3b34ea79492f56d45e6f2f1_D20220101-20221231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtNC0xLTEtMzUzODM_368e133f-7662-43e0-9e1d-37023ae56ff5">1.95</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i3e89eeef735b47ceb3acd3ad40771e04_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtNi0xLTEtMzUzODM_f9508348-04f8-40e0-95d0-59a8c6fa4c34">3.17</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e89eeef735b47ceb3acd3ad40771e04_I20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtOC0xLTEtMzUzODM_de68095b-1726-41fa-a141-42b9b310b664">1,532,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i3e89eeef735b47ceb3acd3ad40771e04_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtMTAtMS0xLTM1Mzgz_e6b479c1-44f0-465a-b615-dca8471ce018">3.17</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="id0741691230d4e28b2d1df61be980984_I20221231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjpiMDM4YWExNjA0MmY0OTcwYWI3MGE1YzY4Y2Q1YWM4Ml80_576fadea-1ae1-4ae0-a297-fb5c6d85274c">3.30</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="i1818274641ed42299558348b53c621fd_I20221231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjpiMDM4YWExNjA0MmY0OTcwYWI3MGE1YzY4Y2Q1YWM4Ml85_49a6ed47-5039-42c0-b63b-51cfd63c6d0e">3.75</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f8f1d616d0e479fafc3b8c388acf7c8_I20221231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtMi0xLTEtMzUzODM_69592c84-7293-4f02-a23b-9d06d6202c72">1,393,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i016d2b845c3c472d9148a20b8286ae27_D20220101-20221231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtNC0xLTEtMzUzODM_e6c9ddbb-a138-4988-8a19-66d6bc92d1c8">2.87</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i8f8f1d616d0e479fafc3b8c388acf7c8_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtNi0xLTEtMzUzODM_5754d3d8-01de-4982-8d35-32b6f782ad6b">3.42</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f8f1d616d0e479fafc3b8c388acf7c8_I20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtOC0xLTEtMzUzODM_0afd9ae0-6749-40b6-bd84-24e65463fb17">775,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i8f8f1d616d0e479fafc3b8c388acf7c8_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtMTAtMS0xLTM1Mzgz_77b855bf-c7eb-4658-89be-8fbde142bba6">3.43</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="i6ff3b4848a624feab2a3c7841b598986_I20221231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjo4ZWY5NDhiNDdkYjM0ZDU4YjA1NWRhYTU1ODNhOGZiZV80_1e2b4ce3-421c-455e-9212-4f9d2812ca44">3.76</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="i5017488ebe3844d0ad6adf806e07f9b9_I20221231" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjo4ZWY5NDhiNDdkYjM0ZDU4YjA1NWRhYTU1ODNhOGZiZV85_d229d30f-7d79-4e3a-8a3e-72030cae5e02">27.46</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d0648f490594bd7ab0068f3dec9d739_I20221231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtMi0xLTEtMzUzODM_1887d196-8bdc-4657-897d-669a6574a3f1">310,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48e149fb587f4b6b81178a578d0bd1fa_D20220101-20221231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtNC0xLTEtMzUzODM_87b58632-f217-48e6-8da3-e7a8f4141039">2.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i0d0648f490594bd7ab0068f3dec9d739_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtNi0xLTEtMzUzODM_468fc655-60fb-4f4b-ba97-d449aad2f50f">7.39</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d0648f490594bd7ab0068f3dec9d739_I20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtOC0xLTEtMzUzODM_a9a5c5e0-5912-46cc-a074-de1e13ae8514">310,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i0d0648f490594bd7ab0068f3dec9d739_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtMTAtMS0xLTM1Mzgz_23005542-1bae-4955-abbf-0a2a573e1684">7.39</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzYtMi0xLTEtMzUzODM_9a8a3595-9989-40a6-8094-02bd88cb580c">5,963,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzYtNC0xLTEtMzUzODM_03b11e84-c96a-4494-9664-eb178630e6fb">2.54</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzYtNi0xLTEtMzUzODM_ccc3a79b-f2d7-46cf-ac39-8a01266c0ae4">2.91</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzYtOC0xLTEtMzUzODM_b19edfa2-7eab-4ca3-95c2-c0d6fa929efd">4,420,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzYtMTAtMS0xLTM1Mzgz_ffa18d99-3be0-4016-b026-0651750bb696">3.01</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants vest either immediately or annually over periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzM4Mg_95eb31db-de86-4acf-a885-2ec978a753c1">one</span> to <ix:nonNumeric contextRef="iac8d3f09febd4cb19e47cf23fefaaf0a_D20220101-20221231" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzM4OA_018919db-8220-419c-9452-e1c192c6fb66">three years</ix:nonNumeric>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMzM_eb5072a4-26e2-4a47-9db9-f8651fcc2d21" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzEtMS0xLTEtMzUzODM_9757b9cc-a287-418a-b953-8cd93e7871c5">3.35</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzEtMy0xLTEtMzUzODM_143e9fc3-949f-4c6b-96b3-e5d010c222d4">0.66</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzEtNS0xLTEtMzUzODM_183fbb83-3802-45e7-8e52-5f96044d172a">0.34</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="year" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzItMS0xLTEtMzUzODM_b0a92d3c-02c5-4501-87b9-2ff6a146a573">3.0</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzItMy0xLTEtMzUzODM_80fbb3fb-9180-4e18-8cd1-6c1ccf35c07c">3.0</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzItNS0xLTEtMzUzODM_3979b5ad-4f26-4e63-b9c5-8fabe92c6470">3.0</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzMtMS0xLTEtMzUzODM_9403e806-77a0-4714-983a-e872625ab135">96.02</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzMtMy0xLTEtMzUzODM_954ced68-e2fb-4dc4-a788-461bcc82d1dc">110.45</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzMtNS0xLTEtMzUzODM_b62dd4b9-ffeb-4cb3-9ce6-9325fcb42175">110.82</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="INF" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzQtMS0xLTEtMzUzODM_ea1b6a80-de2a-4415-b8bf-e7019653b31a">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="INF" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzQtMy0xLTEtMzUzODM_09301c9a-dfdd-494f-9455-5bf706cbe13f">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="INF" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzQtNS0xLTEtMzUzODM_8c5f2ec9-66fc-4ac0-8769-1e36381f865a">Nil</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzUtMS0xLTEtMzUzODM_ace4c685-2b64-4bf4-9556-b1e355428ea9">1.24</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzUtMy0xLTEtMzUzODM_a2577c6c-cdee-42d9-86c4-5411e801f221">1.99</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzUtNS0xLTEtMzUzODM_b356b7fa-a0d2-4305-a6ca-8ffa5a67342c">2.12</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Incentive Share Award Plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Units</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted RSUs to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date, or when the director ceases to be a member of the board. We have also granted RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a <ix:nonNumeric contextRef="i771812f5ba4a4f9ba29a5246edf0bf00_D20220101-20221231" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMjM_0fa62ac7-91f4-4d0c-bbb7-ac85966b81c9">three-year</ix:nonNumeric> period. </span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMzQ_66933618-a8ec-47a9-bbe1-845a93267189" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RSU activity for the years ended December&#160;31 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2320674fb5744c63bbf6953873d4a940_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzEtMS0xLTEtMzUzODM_d7afefcf-adf7-4e0c-b144-9ff031d28ba4">40,560</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0929be370c884a7cb1a0e5b4d741a8b2_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzEtMy0xLTEtMzUzODM_81748905-0245-4990-8c41-b0e1d5bdbfc3">134,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03a33fe7f4e34bb28f5d1cbf45984686_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzEtNS0xLTEtMzUzODM_b88871d1-0f4e-4c6b-a089-44ed8574665b">209,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i771812f5ba4a4f9ba29a5246edf0bf00_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzItMS0xLTEtMzUzODM_348704d4-18ac-4654-a79b-2cca2a268d3b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9255ba83d384e38a8c5e9053e964622_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzItMy0xLTEtMzUzODM_d7601cf4-df27-4c74-a66e-48386c1e0f9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2dec10529d90451ba902ebe59a161f0a_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzItNS0xLTEtMzUzODM_260509cf-42b5-420b-9b49-a53bc661de57">154,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i771812f5ba4a4f9ba29a5246edf0bf00_D20220101-20221231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzMtMS0xLTEtMzUzODM_67ef235b-9056-4058-a584-967fe4998fd0">40,560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie9255ba83d384e38a8c5e9053e964622_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzMtMy0xLTEtMzUzODM_d668d04f-b52a-4d48-b5a9-79ece9890113">94,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2dec10529d90451ba902ebe59a161f0a_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzMtNS0xLTEtMzUzODM_1df72c1f-8bac-441a-9ba5-72a0d5dc6143">229,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5de5eb425bc430e9593f5e707cf066a_I20221231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzQtMS0xLTEtMzUzODM_2c87cd0a-3f15-4011-8b2f-f79bed16861a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2320674fb5744c63bbf6953873d4a940_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzQtMy0xLTEtMzUzODM_8175e4e5-3041-4480-b5bb-d41a49733547">40,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0929be370c884a7cb1a0e5b4d741a8b2_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzQtNS0xLTEtMzUzODM_b4717941-37f2-4105-84d0-48090464f5f5">134,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (1) The weighted average fair value of the RSUs granted was <ix:nonFraction unitRef="cad" contextRef="if5de5eb425bc430e9593f5e707cf066a_I20221231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzE1Nzc_91a38a87-925c-492e-91ac-e388d532779c">nil</ix:nonFraction> in 2022 (2021 - <ix:nonFraction unitRef="cad" contextRef="i2320674fb5744c63bbf6953873d4a940_I20211231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzE1OTE_68875ccc-a791-4e38-890c-4d8bf41b9201">nil</ix:nonFraction>; 2020 - $<ix:nonFraction unitRef="cad" contextRef="i0929be370c884a7cb1a0e5b4d741a8b2_I20201231" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzE2MDE_9bf41e55-27c2-4935-92bd-3599eaae3624">2.41</ix:nonFraction>).</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5457f44ecabc4ed3a0bb61bc9e7685e8">We have reserved <ix:nonFraction unitRef="shares" contextRef="i0daf1c1f7fbd41b2933e6fc95c01304a_I20221231" decimals="INF" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzE5MTM_30096b6c-5bab-45fc-81ef-82e89712745d">6,132,791</ix:nonFraction> common shares for issuance relating to our outstanding equity compensation plans. Our share-based compensation expense for the year ended December&#160;31, 2022, was $<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIwODU_14a7cf8c-bcf2-4338-8d55-3c30e8cf928a">2,378</ix:nonFraction> (2021 - $<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIwOTQ_c3dc72bf-5f2e-45d8-b3f6-bcb0530be893">3,826</ix:nonFraction>; 2020 - $<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMDM_db721b1e-7a57-4e2e-8fc3-f2f0c1b52edf">2,559</ix:nonFraction>).</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_169"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 11: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzQxMQ_4b2bf72e-265a-4acc-b94d-e76233d690e6" continuedAt="id7cab407cba54f23852b686f290e57a3" escape="true">Loss Per Common Share</ix:nonNumeric></span></div><ix:continuation id="id7cab407cba54f23852b686f290e57a3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding for the year ended December&#160;31, 2022, of <ix:nonFraction unitRef="shares" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzE4OA_7c2a5fec-8b12-4cb7-93bc-eb9d39c8cfc6"><ix:nonFraction unitRef="shares" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzE4OA_aa847d69-2a67-4fe1-ba4c-0da07f68006a">58,029,745</ix:nonFraction></ix:nonFraction> (2021 - <ix:nonFraction unitRef="shares" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzE5Nw_50d877c4-f94f-4413-aea7-048943c0ce53"><ix:nonFraction unitRef="shares" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzE5Nw_62892829-bde9-4d3e-bdcb-222261987844">53,513,225</ix:nonFraction></ix:nonFraction>; 2020 - <ix:nonFraction unitRef="shares" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzIwNg_608ec0f0-a6d4-49be-837e-e4517c46b4e3"><ix:nonFraction unitRef="shares" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzIwNg_e5fd7995-c12c-4604-9fa5-7fd48ebc3a7d">40,338,789</ix:nonFraction></ix:nonFraction>). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_172"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 12: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90ZXh0cmVnaW9uOjA1NmFhNzIyM2U4ZjQ0NzZhOTAyZjFmYzk0N2JjODAzXzY2OQ_502e06c6-fa9f-4e4f-9be7-d476f6f3cd64" continuedAt="i7ab9cb2e72ac400ab8832de0ef697996" escape="true">Contract Liability</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i7ab9cb2e72ac400ab8832de0ef697996"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regional licensing agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract liability</span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90ZXh0cmVnaW9uOjA1NmFhNzIyM2U4ZjQ0NzZhOTAyZjFmYzk0N2JjODAzXzY2OA_9ce014fb-acaf-4fa7-b487-7bef13785222" escape="true"><div style="text-align:justify"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:ContractLiabilityRecognitionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90ZXh0cmVnaW9uOjA1NmFhNzIyM2U4ZjQ0NzZhOTAyZjFmYzk0N2JjODAzXzY0Ng_ede879f6-e388-4ac8-bc5f-601c49ebc646">five years</ix:nonNumeric>, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90YWJsZTowOGRkOTdjMjU3ZTM0MmU2YTI4MDAzZTkyNDQwOGFhZi90YWJsZXJhbmdlOjA4ZGQ5N2MyNTdlMzQyZTZhMjgwMDNlOTI0NDA4YWFmXzEtMS0xLTEtMzUzODM_cfc29551-9102-45af-8948-fe03b4b6b52d">6,730</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90YWJsZTowOGRkOTdjMjU3ZTM0MmU2YTI4MDAzZTkyNDQwOGFhZi90YWJsZXJhbmdlOjA4ZGQ5N2MyNTdlMzQyZTZhMjgwMDNlOTI0NDA4YWFmXzEtMy0xLTEtMzUzODM_dcae6ed9-7409-4eaa-a827-f8dee162b2d3">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90YWJsZTowOGRkOTdjMjU3ZTM0MmU2YTI4MDAzZTkyNDQwOGFhZi90YWJsZXJhbmdlOjA4ZGQ5N2MyNTdlMzQyZTZhMjgwMDNlOTI0NDA4YWFmXzMtMS0xLTEtMzUzODM_5ee995b1-f697-40f4-ac9a-213e2c6f65c5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90YWJsZTowOGRkOTdjMjU3ZTM0MmU2YTI4MDAzZTkyNDQwOGFhZi90YWJsZXJhbmdlOjA4ZGQ5N2MyNTdlMzQyZTZhMjgwMDNlOTI0NDA4YWFmXzMtMy0xLTEtMzUzODM_e9686eba-2c3c-41ee-876b-2c8783b55614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90YWJsZTowOGRkOTdjMjU3ZTM0MmU2YTI4MDAzZTkyNDQwOGFhZi90YWJsZXJhbmdlOjA4ZGQ5N2MyNTdlMzQyZTZhMjgwMDNlOTI0NDA4YWFmXzQtMS0xLTEtMzUzODM_7437afa8-32d7-4523-94e0-232a64eb763f">6,730</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90YWJsZTowOGRkOTdjMjU3ZTM0MmU2YTI4MDAzZTkyNDQwOGFhZi90YWJsZXJhbmdlOjA4ZGQ5N2MyNTdlMzQyZTZhMjgwMDNlOTI0NDA4YWFmXzQtMy0xLTEtMzUzODM_e581bd29-596d-4b8c-a48d-e37b35ab3913">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 13: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzUvZnJhZzozNjJiZmUxNjhlZDA0MjYxOTAxYTVhYjUwNzE1ZDNhYy90ZXh0cmVnaW9uOjM2MmJmZTE2OGVkMDQyNjE5MDFhNWFiNTA3MTVkM2FjXzExNzk_c8a61482-8ee7-43c7-b7c0-32ec2b90eb30" continuedAt="i0465192b0d3842f4b664d376049f99f3" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i0465192b0d3842f4b664d376049f99f3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments totaling approximately $<ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="oncyf:PurchaseObligation1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzUvZnJhZzozNjJiZmUxNjhlZDA0MjYxOTAxYTVhYjUwNzE1ZDNhYy90ZXh0cmVnaW9uOjM2MmJmZTE2OGVkMDQyNjE5MDFhNWFiNTA3MTVkM2FjXzY2_80e67f4c-f189-4606-becd-e5a3ec19cefe">16,775</ix:nonFraction> for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:PurchaseObligationCommitmentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzUvZnJhZzozNjJiZmUxNjhlZDA0MjYxOTAxYTVhYjUwNzE1ZDNhYy90ZXh0cmVnaW9uOjM2MmJmZTE2OGVkMDQyNjE5MDFhNWFiNTA3MTVkM2FjXzIwNw_560863af-3b6a-400e-822f-b72d68d1cbb6">three years</ix:nonNumeric>. We are able to cancel most of these agreements with notice.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification of Officers and Directors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges, and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_181"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 14: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzE2MzU_5a18df19-2e80-40c4-b352-5079aaf19bc7" continuedAt="i3088c60085b445df9cb43e8003410ee5" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i3088c60085b445df9cb43e8003410ee5" continuedAt="ib33e866056154fef879aa83dd72d83ca"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzE2Mjc_3fa70936-8e38-4e26-b2f4-4a3f9b5f1a24" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEtMS0xLTEtMzUzODM_c22a7823-94b1-4ce6-8e21-5e6d9458924f">24,751</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEtMy0xLTEtMzUzODM_83ddc947-c9a2-4187-833e-2ea2cea1df7b">26,255</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEtNS0xLTEtMzUzODM_09a73375-e524-4298-aca2-8d0cf65a1c3e">22,505</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzItMS0xLTEtMzUzODM_2b3bf521-14b1-476f-aeed-53edd202b762">23.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzItMy0xLTEtMzUzODM_41ee8d40-96fe-4999-bebc-15c00d10d691">23.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzItNS0xLTEtMzUzODM_e1a2cfcc-94bc-43e2-85b1-7278c8b2c4e0">24.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzMtMS0xLTEtMzUzODM_f2c05afc-548a-4230-ad62-ab61d6eddf7b">5,693</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzMtMy0xLTEtMzUzODM_1c20b0b4-79e3-481a-807f-c9f1fafffa49">6,039</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzMtNS0xLTEtMzUzODM_07a9f71c-0b4b-4493-b591-32fb361a124d">5,401</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference in tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzQtMS0xLTEtMzUzODM_300936ee-d396-464e-980f-6fc94dabcd6a">3,552</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzQtMy0xLTEtMzUzODM_d13fdb49-873c-4214-ad73-5a2873160c07">2,716</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzQtNS0xLTEtMzUzODM_591a96b2-87c0-4856-b61a-f9d6c56a8cae">3,334</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="oncyf:TaxEffectOfStockBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzUtMS0xLTEtMzUzODM_752bdf72-849e-4fe3-9f30-fe713c244955">547</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="oncyf:TaxEffectOfStockBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzUtMy0xLTEtMzUzODM_2e900fd3-c3e5-4871-a057-7d16b989f142">880</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="oncyf:TaxEffectOfStockBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzUtNS0xLTEtMzUzODM_18e4ce54-4b60-4e07-805d-6d9033d33ab2">614</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of tax pools</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="oncyf:TaxEffectOfTaxPools" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzgtMS0xLTEtMzUzODM_598aeb45-b241-4bf8-9312-88c423f2955d">338</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="oncyf:TaxEffectOfTaxPools" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzgtMy0xLTEtMzUzODM_11958a72-9a28-4847-b13d-ce613c485af7">552</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="oncyf:TaxEffectOfTaxPools" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzgtNS0xLTEtMzUzODM_4d944ca7-0e29-43b8-8b7b-a659f976c578">21</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzktMS0xLTEtMzUzODM_90b05941-8724-4a34-a024-7202302244ee">368</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzktMy0xLTEtMzUzODM_a4835a93-37e5-4dfe-9154-e6ccf5eee6ab">45</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzktNS0xLTEtMzUzODM_63e05ed7-37e6-4295-bd2d-3618a0a4db8f">108</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="oncyf:TaxEffectOfExpirationOfTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEwLTEtMS0xLTM1Mzgz_8a688a8f-1a96-47e1-ab85-34c2ddb41f13">1,614</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="oncyf:TaxEffectOfExpirationOfTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEwLTMtMS0xLTM1Mzgz_5d78c594-fab3-485c-a786-bb36e74ec49d">1,661</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="oncyf:TaxEffectOfExpirationOfTaxBenefits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEwLTUtMS0xLTM1Mzgz_311f4f7a-5bfe-4531-be91-924251393303">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEwLTEtMS0xLTQ2NTE2_8da565f9-a243-4c78-ae71-ffdb98e9b2f5">5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEwLTMtMS0xLTQ2NTE2_86d63b3f-a589-49df-aa6e-605f81ee4f74">4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEwLTUtMS0xLTQ2NTE2_de2d727c-258e-4e40-aef4-01365c4c6040">838</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to offset deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzExLTEtMS0xLTM1Mzgz_2a36de01-dc85-4881-8425-56a7ecdbb5a3">765</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzExLTMtMS0xLTM1Mzgz_152d0d3c-14fb-4de1-9036-21f93c14a010">1,342</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzExLTUtMS0xLTM1Mzgz_05990097-750f-4f8c-ae6f-077e3a914798">2,162</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEyLTEtMS0xLTM1Mzgz_180a1674-0aa7-48f4-924a-9bb46a9d3eac">84</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEyLTMtMS0xLTM1Mzgz_e6cd0291-ac04-4935-abae-63b0b6e59416">49</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEyLTUtMS0xLTM1Mzgz_7684a0be-a512-4edb-bf6c-6ed3084b7c1f">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A<ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzE2MzY_526c6418-de6e-4b57-9018-5e7a95d68e64" continuedAt="i97fbb71569d24c6dac4185c09dff630b" escape="true">t December&#160;31, 2022, we have non-capital losses of $<ix:nonFraction unitRef="cad" contextRef="ia520d0c500544f84866a7d2a4c1dacd9_I20221231" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2Mjk2NzQ_24b4a3e4-3bf7-4ad3-8f2a-65bab0ae75b6">98,475</ix:nonFraction> and $<ix:nonFraction unitRef="cad" contextRef="i103420c5cde840e79af37985d2d0bc9d_I20221231" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2Mjk2ODI_3678fb69-179e-48aa-bfc6-eed9e3755869">145,405</ix:nonFraction> in Canada and Barbados, respectively (December&#160;31, 2021 - $<ix:nonFraction unitRef="cad" contextRef="i28afd4f827e34f3eae4c33b42849dabf_I20211231" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2Mjk3NjE_4f3d9da2-8229-4e07-ad4d-97471540a97f">89,537</ix:nonFraction> and $<ix:nonFraction unitRef="cad" contextRef="i4ab96394ca8b4ae0a266d0b54caf3191_I20211231" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2Mjk3Njk_fe30e426-4cfa-4a82-8826-a1066e2bfc6a">162,986</ix:nonFraction>, respectively). These losses are expected to expire between 2023 and 2042, if not utilized. At December&#160;31, 2022, we have Canadian investment tax credits of $<ix:nonFraction unitRef="cad" contextRef="ibbbd14a8d6a34c3db1a86531714b2505_I20221231" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2Mjk5NDU_d51b274a-8a51-42b6-b61b-fa4660b38b5d">4,368</ix:nonFraction> (December&#160;31, 2021 - $<ix:nonFraction unitRef="cad" contextRef="i9e50e8d056f742639310ba89a351e073_I20211231" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2Mjk5NTY_affb94a7-b335-4c38-8602-06d05dfdf6a4">4,834</ix:nonFraction>) that are expected to expire between 2023 and 2040, if not utilized. As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of $<ix:nonFraction unitRef="cad" contextRef="i948c9f76e8c14e789a92b32d5e0cd60d_I20221231" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2MzA5NDQ_1fd932ee-d608-48f6-9efc-915351c74103">27,663</ix:nonFraction> (December&#160;31, 2021 - $<ix:nonFraction unitRef="cad" contextRef="i2592d82deade43a389c57acec6861c6b_I20211231" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2MzA5Mzg_99397de0-eef6-4a0a-8c2f-d08e49ccd0ac">27,663</ix:nonFraction>).&#160;We also have unclaimed U.S. credits for increasing research activities available to reduce future years' taxable income of $<ix:nonFraction unitRef="cad" contextRef="iaa08ffbbd906412591e8727e7b92333e_I20221231" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2MzA5ODU_5b6a1d3c-33e0-48a7-8b24-81c02c358243">1,285</ix:nonFraction> (December&#160;31, 2021 - $<ix:nonFraction unitRef="cad" contextRef="ie72bcfe2289d460cb870ee2ab6965abf_I20211231" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2MzA3ODI_dd8412fb-ddf0-4150-8a06-d58a977f1211">1,343</ix:nonFraction>) expiring between 2031 and 2041. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. </ix:nonNumeric></span></div><ix:continuation id="i97fbb71569d24c6dac4185c09dff630b"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital losses carried forward</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9934fdaa7cb54bed9e71b4949c27a412_I20221231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzEtMS0xLTEtMzUzODM_9a2c0306-f1f9-4e41-ac81-b82c984849d1">26,726</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifb1478bee3ac4873a8fa8d09e2c3af34_I20211231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzEtMy0xLTEtMzUzODM_4a9fc99e-28fe-4906-be3f-90f16264c618">25,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i66c467d253d145219d761e8b50d9872e_I20201231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzEtNS0xLTEtMzUzODM_b6b18a9a-6cfa-4ad2-9e64-3a0d1ab4661c">21,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1dd5a5d56ed3410cb4e81d1da02608b8_I20221231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzItMS0xLTEtMzUzODM_2d06600b-dec8-4b9b-87f5-0abad118f490">7,648</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0b3ad9043f0443508a6e58ffe371b9e3_I20211231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzItMy0xLTEtMzUzODM_60f8f550-468d-466f-931f-50b3d9bb9bab">7,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i97e1578bad4a4fd8b9eeb3cc0142c022_I20201231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzItNS0xLTEtMzUzODM_00c4f411-a339-4661-b578-621669732a5c">6,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ibf87bcb9d5a348e7987675a510c51f91_I20221231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzMtMS0xLTEtMzUzODM_fd256cac-f9de-4ac8-80a5-20350d7038ce">3,363</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6e00e20520b0484b8e24ff13c4d70e87_I20211231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzMtMy0xLTEtMzUzODM_a071fbb7-125f-4fca-b7ea-f45ff5d17aec">3,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i192f8af4da504af0a223d7c5399c0b89_I20201231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzMtNS0xLTEtMzUzODM_11db9901-e92e-4b3f-b6c5-e01128c7639a">4,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9d0f7801e4734c00bb6d8dd7c4f5b818_I20221231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzQtMS0xLTEtMzUzODM_9d055a87-d79e-4147-a008-601ebc5a4da9">366</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i085395ab16f842a1a1512a6390a303e9_I20211231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzQtMy0xLTEtMzUzODM_28b31cd2-9240-445f-8503-a75a7437d355">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i82ebeaf310b04401931722c6c4601410_I20201231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzQtNS0xLTEtMzUzODM_cb4547f0-6823-4746-a93d-c287ffb0968e">1,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i92fb0107f20d4b31a60191a22ac916c4_I20221231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzUtMS0xLTEtMzUzODM_9774bbe8-716d-4e31-bedf-c75ca5a3f150">518</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i9d4db2a6855b40bc9001da783c6c23a2_I20211231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzUtMy0xLTEtMzUzODM_defe0420-2546-4a25-b362-aba10073da10">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i1bce01bfb3c140e19bceefb885e36144_I20201231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzUtNS0xLTEtMzUzODM_b24cf817-3b59-4428-bae8-395800a74b78">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i661bfced363d425b983b07748d5e34d9_I20221231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzYtMS0xLTEtMzUzODM_39a20e94-6918-4404-8ea9-61dd1beab5d1">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib701cd64a09142eaa49f3229d198e9f1_I20211231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzYtMy0xLTEtMzUzODM_baa26899-e8af-4536-9c6d-070026d61c70">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i6dc03510bb2241279358235d4f80a08e_I20201231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzYtNS0xLTEtMzUzODM_78534b8f-b8f7-46a6-adff-c13875bc9e6d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzctMS0xLTEtMzUzODM_eab9c9e2-63d6-44cb-bf36-5ce9e0073e64">38,627</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzctMy0xLTEtMzUzODM_40fb0044-a9be-4734-b5c5-f7e5ff5eebc2">37,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzctNS0xLTEtMzUzODM_7c5a9db3-3f33-4431-9d83-c17bc9638b6c">34,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib33e866056154fef879aa83dd72d83ca">The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any material income tax examinations currently in progress by any taxing jurisdiction.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 15: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90ZXh0cmVnaW9uOjhhYjRiNmY3N2E1YzQ1NjNhYTc0MTIxNmFmYmE1YzBmXzM2MTI_1edc376e-2096-495f-835b-8f16c3df38a7" continuedAt="i83a30b725e4f4e5ea28e8d85642e96ca" escape="true">Capital Disclosures</ix:nonNumeric></span></div><ix:continuation id="i83a30b725e4f4e5ea28e8d85642e96ca" continuedAt="i319c1f9cda1843b090ec1f3e6d7b175c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;We include shareholders' equity, cash and cash equivalents, and marketable securities in the definition of capital.  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i319c1f9cda1843b090ec1f3e6d7b175c"><div style="margin-top:5pt"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:DisclosureOfCapitalComponentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90ZXh0cmVnaW9uOjhhYjRiNmY3N2E1YzQ1NjNhYTc0MTIxNmFmYmE1YzBmXzM2MTE_9fc5c0b0-2ced-44b1-9ae6-ebe8b2e7f8ae" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90YWJsZTpkY2E3YmU4NmI3NWU0ODQ0YTIxODZiNDhkM2QxZDczNC90YWJsZXJhbmdlOmRjYTdiZTg2Yjc1ZTQ4NDRhMjE4NmI0OGQzZDFkNzM0XzEtMS0xLTEtMzUzODM_24885483-90b2-4164-a37c-c467ee314055">11,666</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90YWJsZTpkY2E3YmU4NmI3NWU0ODQ0YTIxODZiNDhkM2QxZDczNC90YWJsZXJhbmdlOmRjYTdiZTg2Yjc1ZTQ4NDRhMjE4NmI0OGQzZDFkNzM0XzEtMy0xLTEtMzUzODM_9f5e037e-442e-46be-ba7f-4872942e9a4d">41,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:CurrentFinancialAssetsAvailableforsale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90YWJsZTpkY2E3YmU4NmI3NWU0ODQ0YTIxODZiNDhkM2QxZDczNC90YWJsZXJhbmdlOmRjYTdiZTg2Yjc1ZTQ4NDRhMjE4NmI0OGQzZDFkNzM0XzItMS0xLTEtMzc0MTU_c04797eb-05d0-4732-b160-aba2a2dee5fa">20,472</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:CurrentFinancialAssetsAvailableforsale" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90YWJsZTpkY2E3YmU4NmI3NWU0ODQ0YTIxODZiNDhkM2QxZDczNC90YWJsZXJhbmdlOmRjYTdiZTg2Yjc1ZTQ4NDRhMjE4NmI0OGQzZDFkNzM0XzItMy0xLTEtMzc0MTk_5642a183-27ef-4421-8aa4-728e3e6237d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90YWJsZTpkY2E3YmU4NmI3NWU0ODQ0YTIxODZiNDhkM2QxZDczNC90YWJsZXJhbmdlOmRjYTdiZTg2Yjc1ZTQ4NDRhMjE4NmI0OGQzZDFkNzM0XzItMS0xLTEtMzUzODM_1c8eafd2-989f-44e7-8700-9b18308c20a9">26,502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90YWJsZTpkY2E3YmU4NmI3NWU0ODQ0YTIxODZiNDhkM2QxZDczNC90YWJsZXJhbmdlOmRjYTdiZTg2Yjc1ZTQ4NDRhMjE4NmI0OGQzZDFkNzM0XzItMy0xLTEtMzUzODM_16d029e1-c716-4612-9c87-8481899eb49f">36,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 12, 2022, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $<ix:nonFraction unitRef="cad" contextRef="i878d9a8a28ac42caa7c1e38319e6da4c_I20220612" decimals="INF" name="oncyf:EquityAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90ZXh0cmVnaW9uOjhhYjRiNmY3N2E1YzQ1NjNhYTc0MTIxNmFmYmE1YzBmXzE5MzU_a1355ee8-8e93-4cda-9103-7806f3c40230">150,000</ix:nonFraction> of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 16, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreements (see Note 9). We use these equity arrangements to assist us in achieving our capital objective. These arrangements provide us with the opportunity to raise capital and better manage our cash resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 16: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzM1NDA_5026a7a4-311b-4142-876b-3cfef4bbc24c" continuedAt="ic506d9fac77b488dba3348e8deb69d28" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="ic506d9fac77b488dba3348e8deb69d28" continuedAt="i7e89fe32c79a41bf9082732f566321cc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents, marketable securities,&#160;other receivables, accounts payable and accrued liabilities, and warrant derivative.&#160;As at December&#160;31, 2022, the carrying amount of our cash and cash equivalents, marketable securities,&#160;other receivables, and accounts payable and accrued liabilities approximated their fair value due to their short-term maturity. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative, initially measured at fair value, with subsequent changes in fair value at each reporting period end recognized through profit and loss. Our warrants with an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="i36f0549e16fb493899d3ce11e6663ed3_I20190816" decimals="2" name="oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzEwOTk1MTE2MzM2NTk_61375e40-749c-4f0c-be62-6b2f5de12afd">0.90</ix:nonFraction> (see Note 9(b)) meet this requirement, and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i7e89fe32c79a41bf9082732f566321cc" continuedAt="i0ec6ce2fa18142cf8ab7197befed5203"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December&#160;31, 2022, the fair value of our warrant derivative was $<ix:nonFraction unitRef="cad" contextRef="i78092e29c72947a18acdd0770f54643c_I20221231" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzYwNA_8a42b91c-6675-4afd-822b-53515f1078bf">79</ix:nonFraction> (December&#160;31, 2021 - $<ix:nonFraction unitRef="cad" contextRef="i7fd69d94537a4d46b4b4f06ee6771977_I20211231" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzYxMw_fbdbeb39-b6b9-48f3-a079-407e9ab23a94">56</ix:nonFraction>). We use the Black-Scholes valuation model to estimate fair value.   </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents, marketable securities, and other receivable from Pfizer in connection with the BRACELET-1 study (see Note 5) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents, marketable securities, and other receivable from Pfizer. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also mitigate our exposure to credit risk by restricting our portfolio to investment-grade securities with short-term maturities and monitoring counterparties' credit risk and credit standing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest savings accounts that have variable interest rates. Our marketable securities have fixed interest rates.&#160;We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market interest rates do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and the Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $<ix:nonFraction unitRef="cad" contextRef="i9c8fd43724f84c33ae13eca3658b27f6_D20220101-20221231" decimals="2" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzI3NDU_634dbc6c-f343-4e48-9ca2-368406a89fd4">0.01</ix:nonFraction> increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2022 by approximately $<ix:nonFraction unitRef="cad" contextRef="i9c8fd43724f84c33ae13eca3658b27f6_D20220101-20221231" decimals="-3" sign="-" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzI4ODg_eedd2d4e-1386-4cb5-9a93-527070ed6436">170</ix:nonFraction>. The impact of a $<ix:nonFraction unitRef="cad" contextRef="i8c04db7260c44d0a84dcee681e6b31a3_D20220101-20221231" decimals="2" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzEwOTk1MTE2MzI0NjQ_94b974fe-5458-4900-a035-4e6c66691c49">0.01</ix:nonFraction> increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in 2022 by approximately $<ix:nonFraction unitRef="cad" contextRef="i8c04db7260c44d0a84dcee681e6b31a3_D20220101-20221231" decimals="-3" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzEwOTk1MTE2MzIzMDI_deaff2f9-e2ef-404b-b335-de94cd134f5a">22</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies through the purchase of foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable and accrued liabilities.</span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzM1Mzg_d94a72f8-37a8-4cf8-9a94-fed93a86e6af" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies at December&#160;31, 2022, are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4078a67cca34e859712c16c4fb4b8ef_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzEtMS0xLTEtMzUzODM_7bd8cb02-2eac-4393-8bb2-3f849ced1dbb">6,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3968ebc093542fb94bd695c6069eeb0_I20221231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzEtMy0xLTEtNDQyODk_f97ae185-a8d7-47af-b856-850d4cc2e186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="id4078a67cca34e859712c16c4fb4b8ef_I20221231" decimals="-3" name="ifrs-full:FinancialAssetsAvailableforsale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzItMS0xLTEtNDQyNjc_5cd89210-0040-4649-99fc-5891101f7689">15,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="if3968ebc093542fb94bd695c6069eeb0_I20221231" decimals="-3" name="ifrs-full:FinancialAssetsAvailableforsale" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzItMy0xLTEtNDQyODk_4a6b574c-cf9b-40f8-bdd2-6d1a3620ab79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4078a67cca34e859712c16c4fb4b8ef_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzMtMS0xLTEtMzUzODM_b534b818-aac2-4e0e-88f9-d0c3e1b660b5">1,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3968ebc093542fb94bd695c6069eeb0_I20221231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzQtMy0xLTEtNDQyNzU_d7a74626-1d9e-4286-8697-fba271781975">1,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4078a67cca34e859712c16c4fb4b8ef_I20221231" decimals="-3" name="oncyf:BalanceHeldInForeignCurrencyNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzQtMS0xLTEtMzUzODM_8954bf41-1856-499d-9cdd-75d0a2dc236b">20,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3968ebc093542fb94bd695c6069eeb0_I20221231" decimals="-3" sign="-" name="oncyf:BalanceHeldInForeignCurrencyNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzUtMy0xLTEtNDQzNDM_7049e8c7-e37d-434c-83ee-24ff0dbe0d06">1,035</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i0ec6ce2fa18142cf8ab7197befed5203"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 15. Accounts payable and accrued liabilities are all due within the current operating period.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_190"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 17: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfCashFlowStatementExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90ZXh0cmVnaW9uOjMzMjA4YWRiYmM0NzQzN2NhMDJlMzUzZGJmYjg1ZGIwXzEyNQ_e280f70b-c199-4bad-8156-76aaaaf3ed4c" continuedAt="i606aee8bdd4142e7948ce5036bebb3b1" escape="true">Additional Cash Flow Disclosures</ix:nonNumeric></span></div><ix:continuation id="i606aee8bdd4142e7948ce5036bebb3b1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:CashFlowOperatingCapital1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90ZXh0cmVnaW9uOjMzMjA4YWRiYmM0NzQzN2NhMDJlMzUzZGJmYjg1ZGIwXzEyNg_495cc6e8-e779-4d7e-bb9b-3f9bb6334aec" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzItMS0xLTEtMzUzODM_6ce66037-ace9-4f44-992c-26f457306bba">345</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzItMy0xLTEtMzUzODM_7b6eb412-fc5b-47a4-89f8-f51063259101">776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzItNS0xLTEtMzUzODM_714a9922-eaa1-4264-b45a-9f4849e6459f">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzMtMS0xLTEtMzUzODM_b047ee59-afc7-4620-a2e8-ca9a00c9ce2c">1,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzMtMy0xLTEtMzUzODM_81597387-fdbb-4edd-9ba2-71e760c96f3e">349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzMtNS0xLTEtMzUzODM_871b2e91-15a7-43c9-b725-faf0677d27ab">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzQtMS0xLTEtMzUzODM_1db09ab2-a5da-404a-8d6e-595ea4bf3ed5">1,662</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzQtMy0xLTEtMzUzODM_bbe337b3-0082-4434-8f9d-d2c08a57932c">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzQtNS0xLTEtMzUzODM_2a275a61-e20a-4974-a5e4-29b7bd95ab44">1,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzUtMS0xLTEtMzUzODM_1b56ebd3-3822-4a22-ac16-9ebead01faae">352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzUtMy0xLTEtMzUzODM_ad99e36f-974d-474d-8e11-ac8cabf4066f">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzUtNS0xLTEtMzUzODM_fb0964df-bfc9-4d2f-a4fc-615d938165fb">723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzYtMS0xLTEtMzUzODM_d263dc05-c274-4bc0-a8c6-d4aae6e8ed06">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzYtMy0xLTEtMzUzODM_cb6aeb40-ed9a-405a-831a-c014d20001aa">194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzYtNS0xLTEtMzUzODM_9098f892-5879-4c0e-87d4-eac5d7059379">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzctMS0xLTEtMzUzODM_545e0401-e17b-417d-bfa3-a2d419c05609">391</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzctMy0xLTEtMzUzODM_5c60a739-a442-4730-8526-a714e1ce5b9e">908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzctNS0xLTEtMzUzODM_4e30d3c0-9e5e-46f5-a315-78585a074230">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90ZXh0cmVnaW9uOjMzMjA4YWRiYmM0NzQzN2NhMDJlMzUzZGJmYjg1ZGIwXzEyMg_2239b96d-e3b6-4684-b960-6bf976c584b9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="oncyf:ProceedsfromInterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTpmNDhkYTMyODM3ODM0NjAwYTFhNzI3MTlmNDBkNmNkYS90YWJsZXJhbmdlOmY0OGRhMzI4Mzc4MzQ2MDBhMWE3MjcxOWY0MGQ2Y2RhXzEtMS0xLTEtMzUzODM_4fee8e8f-3df1-4fcd-8f83-223b594b7336">452</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="oncyf:ProceedsfromInterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTpmNDhkYTMyODM3ODM0NjAwYTFhNzI3MTlmNDBkNmNkYS90YWJsZXJhbmdlOmY0OGRhMzI4Mzc4MzQ2MDBhMWE3MjcxOWY0MGQ2Y2RhXzEtMy0xLTEtMzUzODM_83c72ba2-ac08-4f23-8334-f4db3f868cc3">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="oncyf:ProceedsfromInterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTpmNDhkYTMyODM3ODM0NjAwYTFhNzI3MTlmNDBkNmNkYS90YWJsZXJhbmdlOmY0OGRhMzI4Mzc4MzQ2MDBhMWE3MjcxOWY0MGQ2Y2RhXzEtNS0xLTEtMzUzODM_21b7cf92-da98-439a-a8c5-645f403f81f0">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefund" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTpmNDhkYTMyODM3ODM0NjAwYTFhNzI3MTlmNDBkNmNkYS90YWJsZXJhbmdlOmY0OGRhMzI4Mzc4MzQ2MDBhMWE3MjcxOWY0MGQ2Y2RhXzItMS0xLTEtMzUzODM_a255c668-5a3d-4e50-854a-b441107cf6dd">46</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefund" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTpmNDhkYTMyODM3ODM0NjAwYTFhNzI3MTlmNDBkNmNkYS90YWJsZXJhbmdlOmY0OGRhMzI4Mzc4MzQ2MDBhMWE3MjcxOWY0MGQ2Y2RhXzItMy0xLTEtMzUzODM_e88ca83d-471e-4503-8c7a-9410302530cc">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefund" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTpmNDhkYTMyODM3ODM0NjAwYTFhNzI3MTlmNDBkNmNkYS90YWJsZXJhbmdlOmY0OGRhMzI4Mzc4MzQ2MDBhMWE3MjcxOWY0MGQ2Y2RhXzItNS0xLTEtMzUzODM_a5dab940-bc26-4bd2-95f3-d41d848016f8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_196"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 18: <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:DisclosureOfEconomicDependenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTYvZnJhZzo3ZjU1M2Y0OTliMzA0OWFlYjQ0MDQ5OTFlMzM3OTJkZi90ZXh0cmVnaW9uOjdmNTUzZjQ5OWIzMDQ5YWViNDQwNDk5MWUzMzc5MmRmXzc5Ng_2dc51586-90d2-49df-898a-14b822216a71" continuedAt="ia887a3fa9da04f539255c87ebe6bd31c" escape="true">Economic Dependence</ix:nonNumeric></span></div><ix:continuation id="ia887a3fa9da04f539255c87ebe6bd31c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use <ix:nonFraction unitRef="manufacturer" contextRef="ic4d7eaaabecc41fcad176194a92590f5_D20220101-20221231" decimals="INF" name="oncyf:ConcentrationRiskNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTYvZnJhZzo3ZjU1M2Y0OTliMzA0OWFlYjQ0MDQ5OTFlMzM3OTJkZi90ZXh0cmVnaW9uOjdmNTUzZjQ5OWIzMDQ5YWViNDQwNDk5MWUzMzc5MmRmXzExMA_cfbfc848-b33a-4bea-b369-a7f11a4fc53a">one</ix:nonFraction> toll manufacturer in the U.S. to produce the clinical-grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical-grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by identifying an alternative toll manufacturer, establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_199"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 19:  <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzQ0NA_645fbf9e-3112-46e9-be8f-2751ed2737e2" continuedAt="ifce46a8ff05849c5bf220d2fb48dea9c" escape="true">Components of Expenses</ix:nonNumeric></span></div><ix:continuation id="ifce46a8ff05849c5bf220d2fb48dea9c" continuedAt="i68ec8e10d5ba4e7d8877b154874ed8bf"><div style="margin-top:5pt"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="oncyf:OtherExpensesAndAdjustmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzQ0OA_c0c31ec0-6f07-4a8a-8ee8-44bca876a24c" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231" decimals="-3" name="oncyf:ClinicalTrailExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzEtMS0xLTEtMzUzODM_aa9c93eb-f6f5-4d0d-a367-0357bce5917d">4,970</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231" decimals="-3" name="oncyf:ClinicalTrailExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzEtMy0xLTEtMzUzODM_af1680e0-ffde-41e6-a6a2-c48d80bd4b82">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231" decimals="-3" name="oncyf:ClinicalTrailExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzEtNS0xLTEtMzUzODM_ae4cea9a-21b3-4977-803a-ed19a6a7ee38">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing &amp; related process development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231" decimals="-3" name="oncyf:ManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzItMS0xLTEtMzUzODM_956797c8-2386-49ff-b0b1-a28e3e63f236">2,148</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231" decimals="-3" name="oncyf:ManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzItMy0xLTEtMzUzODM_c65ac3b3-846c-4bd2-b7c9-3a5458fe210e">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231" decimals="-3" name="oncyf:ManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzItNS0xLTEtMzUzODM_287bdcf8-90e7-48b5-a14d-480517a89b73">3,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231" decimals="-3" name="oncyf:IntellectualPropertyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzMtMS0xLTEtMzUzODM_cd9982c7-5528-4646-81c3-45be1f8d71b7">544</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231" decimals="-3" name="oncyf:IntellectualPropertyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzMtMy0xLTEtMzUzODM_29c43de1-8bb6-4e61-8027-b3c96439f662">618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231" decimals="-3" name="oncyf:IntellectualPropertyExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzMtNS0xLTEtMzUzODM_a866f30c-53ff-4b16-aebf-faef087f24ce">907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231" decimals="-3" name="oncyf:TranslationalScienceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzQtMS0xLTEtMzk3MDY_51343bde-e16a-4e8e-bc5f-88471df48376">264</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231" decimals="-3" name="oncyf:TranslationalScienceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzQtMy0xLTEtMzk3MDY_c69275a1-50d3-424b-86a3-ccca64009fbc">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231" decimals="-3" name="oncyf:TranslationalScienceExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzQtNS0xLTEtMzk3MDY_66baa284-b3c5-403d-9e31-3970fbf14741">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzUtMS0xLTEtMzk3MDY_7f1087d2-fb0e-48b5-b14a-bcb781a15def">6,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzUtMy0xLTEtMzk3MDY_3ffd3004-e813-425e-a8e2-fce415592712">4,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzUtNS0xLTEtMzk3MDY_c100b4e2-9e81-4b33-8788-293474376c30">4,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzYtMS0xLTEtMzk3MDY_e03c1d9d-757c-4b6a-a1e6-2dcb879c76df">1,371</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzYtMy0xLTEtMzk3MDY_b98be474-61c3-4820-8782-dbc93dc87240">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzYtNS0xLTEtMzk3MDY_0735dfc6-01ac-4e63-8c4c-06eed2080a9c">1,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzctMS0xLTEtMzk3MDY_69f10c65-4857-46be-9d7a-45914d9d005d">112</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzctMy0xLTEtMzk3MDY_8e6a576b-74f0-4c74-96b5-74a50ba273dd">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzctNS0xLTEtMzk3MDY_8f1db406-9ee8-472e-bb95-e1f39df2fbb1">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzgtMS0xLTEtMzk3MTE_ab4a0006-195a-4bc2-8dfb-41cbebcc84d5">15,432</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzgtMy0xLTEtMzk3MTE_db8cf775-0bee-46c4-a572-c8a7244b857a">12,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzgtNS0xLTEtMzk3MTE_143dcb23-e283-4948-99e0-2744bf5a8a7c">12,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231" decimals="-3" name="oncyf:PublicCompanyExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzEyLTEtMS0xLTM5NzMz_94477279-9d87-4d91-9463-c8aca4303df0">6,790</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231" decimals="-3" name="oncyf:PublicCompanyExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzEyLTMtMS0xLTM5NzMz_97151d19-d551-4247-8d1e-a75ee8dbf9dd">8,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231" decimals="-3" name="oncyf:PublicCompanyExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzEyLTUtMS0xLTM5NzMz_e25f941a-bb6f-4829-8474-5c74b087e574">7,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231" decimals="-3" name="oncyf:OfficeExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzQtMS0xLTEtMzUzODM_0d0ece23-0bff-4501-9700-7dc4f32f170d">3,303</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231" decimals="-3" name="oncyf:OfficeExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzQtMy0xLTEtMzUzODM_0dad6110-f557-4e51-a79e-2f9946df3165">2,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231" decimals="-3" name="oncyf:OfficeExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzQtNS0xLTEtMzUzODM_2560aef9-95bc-4f6e-a9c6-3cd3c745ca33">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzUtMS0xLTEtMzUzODM_9542cabb-0feb-490f-92f0-53ae14e93171">1,007</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzUtMy0xLTEtMzUzODM_311b7af5-bab7-4c86-a328-10d6b57d1169">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzUtNS0xLTEtMzUzODM_cafcc352-42c5-4074-8324-d2e2c48cff18">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzYtMS0xLTEtMzUzODM_53e08834-aa57-4963-bf39-104668db8dd4">93</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzYtMy0xLTEtMzUzODM_09788c68-353d-4ee0-b71e-3c70cd2d21f5">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzYtNS0xLTEtMzUzODM_a8fe0d5d-9211-427a-894b-d80d6151b08b">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzctMS0xLTEtMzUzODM_d64270f1-d46e-431c-8fdc-4907d7362c8a">299</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzctMy0xLTEtMzUzODM_eea7b43b-9016-4f68-befd-cee998d2a856">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzctNS0xLTEtMzUzODM_d30bab00-91ee-47c5-b88b-83bb60e8a306">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzgtMS0xLTEtMzUzODM_a5c13b2b-c657-4df3-aaa8-226dcbed6bf7">11,492</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzgtMy0xLTEtMzUzODM_5c6e0b22-8f6f-4d46-ac7d-137429d99b57">13,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzgtNS0xLTEtMzUzODM_13df979b-d049-4690-90b5-2bb0fd077d03">12,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, our research and development personnel-related expenses included employee compensation and benefits of $<ix:nonFraction unitRef="cad" contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzEwOTk1MTE2Mjg4OTU_404b0131-446b-4e53-8944-4d4ac6e5b163">5,983</ix:nonFraction> (2021 - $<ix:nonFraction unitRef="cad" contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzEwOTk1MTE2Mjg5MjQ_af7889db-43af-4d31-b0b0-be8abad011b1">4,645</ix:nonFraction>; 2020 - $<ix:nonFraction unitRef="cad" contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzEwOTk1MTE2Mjg5MzY_aca3cb22-73ac-47a6-8a91-69cd582f7fa4">3,775</ix:nonFraction>).</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i68ec8e10d5ba4e7d8877b154874ed8bf">In 2022, our general and administrative office expenses included employee compensation and benefits of $<ix:nonFraction unitRef="cad" contextRef="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzEwOTk1MTE2Mjg5MDA_14b5b0b3-aef1-49ac-bf50-940ff2d0a9b4">2,870</ix:nonFraction> (2021 - $<ix:nonFraction unitRef="cad" contextRef="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzEwOTk1MTE2Mjg5NTA_b6a4768c-0935-4544-9a25-62750cf08ea0">2,542</ix:nonFraction>; 2020 - $<ix:nonFraction unitRef="cad" contextRef="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzEwOTk1MTE2Mjg5NjE_e476e9ca-fa0c-4c3c-8774-3b6d5ea628c7">2,635</ix:nonFraction>).</ix:continuation> </span></div><div style="text-align:center"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_202"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 20:  <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90ZXh0cmVnaW9uOmNhYmRjNmE3MTBlMzQ1ODliM2ZiNTdlY2M0YzE0M2FiXzM4MA_f063d5bf-336b-4d55-bbe1-a64d6ab192c0" continuedAt="i8cc745371d784be087225e562c9a7da0" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i8cc745371d784be087225e562c9a7da0"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation of Key Management Personnel</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel consists of the Board of Directors, the President and Chief Executive Officer, and the executives who report directly to the President and Chief Executive Officer.   </span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90ZXh0cmVnaW9uOmNhYmRjNmE3MTBlMzQ1ODliM2ZiNTdlY2M0YzE0M2FiXzM4MQ_dede2c7e-5680-430e-8144-e2563c710e16" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzEtMS0xLTEtMzUzODM_654dfe71-18df-450f-9d98-1e5e6eceb47c">4,308</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzEtMy0xLTEtMzUzODM_39e44e0c-5b03-480e-b710-670da40981c2">3,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzEtNS0xLTEtMzUzODM_b2eccc70-e416-491f-94b5-88d5eea9f703">3,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzItMS0xLTEtMzUzODM_cde8762f-a0c4-4f8a-bdfb-de4ac87398ad">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzItMy0xLTEtMzUzODM_0ddd62d8-0732-4870-8f60-4f47ebf146cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzItNS0xLTEtMzUzODM_c4f43749-7670-4a50-8e75-0de92dee2c83">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzMtMS0xLTEtMzUzODM_1426309c-0e5e-4717-9255-8b7480824315">1,615</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzMtMy0xLTEtMzUzODM_e4080561-b55c-400e-aa27-59da2c0bee68">2,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzMtNS0xLTEtMzUzODM_d011b5a3-5a93-479c-ae49-1b1539966957">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzQtMS0xLTEtMzUzODM_d23d7884-caec-42ca-932e-ab2c66026744">5,923</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzQtMy0xLTEtMzUzODM_1e50328f-dd80-42d3-9b1d-18541d108556">6,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzQtNS0xLTEtMzUzODM_1027b0d6-d15e-48cb-8a90-f7a1e583cd38">5,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="if2c66687cf8546c4b7655f45d9eacdf7_205"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 21:  <ix:nonNumeric contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDUvZnJhZzozMWVjZGY5OWY2NTI0NWI3OWZiZjgxMTA0ODAzZTE0YS90ZXh0cmVnaW9uOjMxZWNkZjk5ZjY1MjQ1Yjc5ZmJmODExMDQ4MDNlMTRhXzU4Nw_1e58c703-629a-4da1-b899-9cfd9e895f68" continuedAt="if07459506cdc4bfbba8b83aff6681970" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if07459506cdc4bfbba8b83aff6681970">Between January 1, 2023 and March 2, 2023, we issued <ix:nonFraction unitRef="shares" contextRef="i66e81fab17754d28b557975b9a91350b_D20230101-20230302" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDUvZnJhZzozMWVjZGY5OWY2NTI0NWI3OWZiZjgxMTA0ODAzZTE0YS90ZXh0cmVnaW9uOjMxZWNkZjk5ZjY1MjQ1Yjc5ZmJmODExMDQ4MDNlMTRhXzE2NDkyNjc0NDMzNjU_1eebbe03-a632-499f-a4af-3084cafe7d02">1,499,044</ix:nonFraction> shares for gross proceeds of US$<ix:nonFraction unitRef="cad" contextRef="i66e81fab17754d28b557975b9a91350b_D20230101-20230302" decimals="-3" name="oncyf:GrossProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDUvZnJhZzozMWVjZGY5OWY2NTI0NWI3OWZiZjgxMTA0ODAzZTE0YS90ZXh0cmVnaW9uOjMxZWNkZjk5ZjY1MjQ1Yjc5ZmJmODExMDQ4MDNlMTRhXzE2NDkyNjc0NDMzNzg_195e534f-e238-46bd-8ea6-ffaf49de5198">2,570</ix:nonFraction> through our June 2022 ATM equity distribution agreement.</ix:continuation>  </span></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ex21exdescriptionofsecurit.htm
<DESCRIPTION>EX-2.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib1b6cd920926485faf35ae8d4bce194c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">EXHIBIT 2.1</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">DESCRIPTION OF RIGHTS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Our authorized capital consists of an unlimited number of Common Shares. The following is a summary of the provisions attached to our Common Shares&#58;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">The holders of our Common Shares are entitled to one vote per share at meetings of shareholders, to receive such dividends as declared by the Board and to receive our remaining property and assets upon dissolution or wind up. Our Common Shares are not subject to any future call or assessment and there are no pre-emptive, conversion or redemption rights attached to such shares. As at March&#160;2, 2023, we have 62,826,958 Common Shares issued and outstanding. After giving effect to the exercise or distribution of all outstanding options to acquire Common Shares, all outstanding share awards granted under the Corporation&#8217;s Incentive Share Award Plan and Common Share purchase warrants, we would have 68,854,178 Common Shares issued and outstanding. As at March&#160;2, 2023, we have 64,035 Common Share purchase warrants issued in 2019 (the &#8220;2019 Warrants&#8221;) outstanding. Each 2019 Warrant entitles the holder to purchase one Common Share until August 16, 2024, at an exercise price of US$0.90. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:137%">The Corporation has neither declared nor paid dividends on the Common Shares and has no present intention of paying dividends on the Common Shares for the foreseeable future.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.19
<SEQUENCE>3
<FILENAME>ex419mattcoffeyamendment4-.htm
<DESCRIPTION>EX-4.19
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i200a88f894e74f1f8e9bb740390277ac_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 4.19</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDING AGREEMENT # 4</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AMENDING AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of January, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#34;Oncolytics&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Matt Coffey</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;Employee&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2019, amended by Amending Agreement # 1, Amending Agreement # 2 and Amending Agreement # 3 (together the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Amendment to the Employment Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Commencing January 1, 2023, Oncolytics shall pay to the Employee a salary of SIX HUNDRED EIGHTY-SEVEN THOUSAND ONE HUNDRED AND TWENTY-FOUR ($687,124.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of TWENTY-EIGHT THOUSAND SIX HUNDRED AND THIRTY DOLLARS AND SEVENTEEN CENTS ($28,630.17) on the 15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and last day of each month.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 4.19</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Confirmation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ONCOLYTICS BIOTECH INC.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Wayne Pisano</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Wayne Pisano</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chair, Board of Directors</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Deborah Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deborah Brown</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chair, Compensation Committee</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Director</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Matt Coffey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MATT COFFEY</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.20
<SEQUENCE>4
<FILENAME>ex420kirklookamendment4-em.htm
<DESCRIPTION>EX-4.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i52d1cc8fbfb64463a653dd58d8a69155_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 4.20</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDING AGREEMENT # 4</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AMENDING AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of January, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#34;Oncolytics&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Kirk Look</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;Employee&#8221;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2019 amended by Amending Agreement # 1, Amending Agreement # 2, and by Amending Agreement # 3 (together the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND WHEREAS Oncolytics and the Employee wish to amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Amendment to the Employment Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">Commencing January 1, 2023, Oncolytics shall pay to the Employee a salary of FIVE HUNDRED TEN THOUSAND NINE HUNDRED AND TWENTY-THREE ($510,923.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of TWENTY-ONE THOUSAND TWO HUNDRED EIGHTY-EIGHT DOLLARS and FORTY-SIX CENTS ($21,288.46) on the 15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and last day of each month.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 4.20</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Confirmation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ONCOLYTICS BIOTECH INC.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Wayne Pisano</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Wayne Pisano</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chair, Board of Directors</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Deborah Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deborah Brown</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chair, Compensation Committee</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Director</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Kirk Look</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">__________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">KIRK LOOK</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.21
<SEQUENCE>5
<FILENAME>ex421allisonhagermanamendm.htm
<DESCRIPTION>EX-4.21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i541e9206aa86440ab7609e719b7a801c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 4.21</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDING AGREEMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AMENDING AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of January, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#34;Oncolytics&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Allison Hagerman,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#34;Employee&#34;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS Oncolytics and the Employee entered into a Letter of Employment dated August 3, 2010&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND WHEREAS Oncolytics and the Employee entered into an Employment Agreement dated August 1, 2013, which has been amended by amending agreements including that dated January 1, 2022 (collectively the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND WHEREAS Oncolytics and the Employee wish to further amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Amendments to the Employment Agreement</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Employment Agreement Section 3 &#8211; Remuneration is amended by replacing subsection (1) with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Commencing January 1, 2023, Oncolytics shall pay to the Employee a salary of FOUR HUNDRED TEN THOUSAND THREE HUNDRED AND THIRTEEN ($410,313.00) CANADIAN DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of SEVENTEEN THOUSAND NINETY-SIX DOLLARS and THIRTY-EIGHT CENTS ($17,096.38) on the 15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and last day of each month.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The Employment Agreement Section 9 &#8211; Term and Termination is amended by replacing subsections (4) and (5) with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:70.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.67pt">Subject to Section 9(5), if this Agreement is terminated by Oncolytics at any time other than pursuant to Section 9(3), or if this Agreement is terminated by the Employee for Good Reason, the Employee shall be entitled to severance payment equal to 12 months salary.  Such severance compensation shall be paid </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 4.21</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:70.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to the Employee so as to maximize any reduction in income tax payable thereon as permitted by the Income Tax Act (Canada).  The severance payment as provided pursuant to this Section 9(4) shall include an amount equal to the value of all benefits to which the Employee would otherwise have been entitled during the notice period.</font></div><div style="margin-bottom:12pt;padding-left:70.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.67pt">Notwithstanding Section 9(4), if there is a change of control of Oncolytics, as defined herein, and if this Agreement is terminated by Oncolytics at any time within one (1) year following the change of control other than pursuant to Section 9(3), the Employee shall be entitled to severance payment equal to 12 months salary.  Such severance compensation shall be paid to the Employee so as to maximize any reduction in income tax payable thereon as permitted by the Income Tax Act (Canada).  For the purposes of this Section 9(5), &#8220;change of control&#8221; means any amalgamation, merger or other corporate reorganization which results in any change in the present effective voting control of Oncolytics, or will result in a change of the person or persons who own or control sufficient voting shares in Oncolytics to elect a majority of the directors of Oncolytics, or will result in a person acquiring sufficient voting shares in Oncolytics to elect a majority of the directors of Oncolytics.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Confirmation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Miscellaneous</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 4.21</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written. </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ONCOLYTICS BIOTECH INC.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Wayne Pisano</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Wayne Pisano</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chair, Board of Directors</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Deborah Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deborah Brown</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chair, Compensation Committee</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Director</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;Allison Hagerman</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ALLISON HAGERMAN</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.22
<SEQUENCE>6
<FILENAME>ex422andrewdeguttadauroame.htm
<DESCRIPTION>EX-4.22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1d78108b011242f79dbcaa4b814f5f90_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 4.22</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMENDING AGREEMENT #6</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AMENDING AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">day of January, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ONCOYLYTICS BIOTECH (U.S.), INC.,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#34;OBUS&#34;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ANDREW DE GUTTADAURO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#34;Employee&#34;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement dated effective June 29, 2017, as amended by Amending Agreement #1, Amending Agreement #2, Amending Agreement #3, Amending Agreement #4 and Amending Agreement #5 (collectively the &#8220;Employment Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AND WHEREAS OBUS and the Employee wish to further amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Interpretation</font></div><div style="padding-left:54pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Amendment to the Employment Agreement</font></div><div style="padding-left:54pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Employment Agreement Section 3 &#8211; Remuneration is amended as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;Commencing January 1, 2023, OBUS shall pay to the Employee a salary of THREE HUNDRED FIFTY-TWO THOUSAND SIX HUNDRED AND SEVEN ($352,607.00) UNITED STATES DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of FOURTEEN THOUSAND SIX HUNDRED NINETY-ONE UNITED STATES DOLLARS and NINETY-SIX CENTS ($14,691.96) on the 15th and last day of each month.</font></div><div><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Confirmation</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The parties confirm that the increase in Base Salary is a result of an assessment of increases in cost-of-living indices and salary benchmarking.</font></div><div style="padding-right:72pt;text-align:justify"><font><br></font></div><div style="padding-right:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="padding-right:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 4.22</font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:54pt;padding-right:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:29.89pt">Miscellaneous</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">This Agreement shall be governed by and construed in accordance with the laws of California.  </font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.57pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="padding-right:72pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ONCOLYTICS BIOTECH (U.S.), INC.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;Gilles Gosselin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gilles Gosselin</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Director</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;Matthew Coffey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Matthew Coffey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Director</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;Andrew de Guttadauro</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANDREW DE GUTTADAURO</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="padding-right:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.23
<SEQUENCE>7
<FILENAME>ex423thomasheinemanamendme.htm
<DESCRIPTION>EX-4.23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i39476534abd24f2fbb53d031853d607e_1"></div><div style="min-height:65.52pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT4.23</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">AMENDING AGREEMENT # 3</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">THIS AMENDING AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%"> made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.82pt;font-weight:400;line-height:100%;position:relative;top:-3.67pt;vertical-align:baseline">st </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">day of January, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">ONCOYLYTICS BIOTECH (U.S.), INC.,</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(&#34;OBUS&#34;)</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">THOMAS C. HEINEMAN, M.D., Ph.D.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(the &#34;Employee&#34;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement dated effective August 3, 2020, as amended by Amending Agreement #1 and Amending Agreement # 2 (collectively the &#8220;Employment Agreement&#8221;)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">AND WHEREAS OBUS and the Employee wish to amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:30.17pt">Interpretation</font></div><div style="padding-left:54pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:30.17pt">Amendments to the Employment Agreement</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">The Employment Agreement Section 3.1 &#8211; Base Salary is amended as follows&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Commencing January 1, 2023, OBUS shall pay to the Employee a Base Salary at an annual rate of FOUR HUNDRED AND SIXTY-FIVE THOUSAND ONE HUNDRED AND FIFTY ($465,150.00) UNITED STATES DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of NINETEEN THOUSAND AND THREE HUNDRED AND EIGHTY-ONE UNITED STATES DOLLARS and TWENTY-FIVE CENTS ($19,381.25) on the 15th and last day of each month.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">The Employment Agreement Section 5.2 &#8211; Without Cause is amended as follows&#58;</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Employer may terminate Employee&#8217;s employment under this Agreement without Cause and without advance notice&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">, that Employer will continue to pay, as severance pay, Employee&#8217;s Base Salary at the rate in effect on the termination date through the date that is 12 months from the termination date&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">, that Employer will be entitled to offset any severance pay otherwise payable to Employee by the amount of any compensation or consulting fees being paid to Employee by another party while severance pay would otherwise be payable.  Employee shall only be entitled to such severance pay if Employee signs (and then Employee does not rescind, as may be permitted by law) a general release of claims in favor of Employer in a form acceptable to Employer, provided, however, that such release of claims shall only require Employee to release Employer from claims relating directly to Employee&#8217;s employment and the termination thereof, and shall not require Employee to release claims relating to vested employee benefits or relating to other matters, including, but not limited to, claims relating to his status as a shareholder of the Company.  Such payments will be at usual and customary pay intervals of Employer and will be subject to all appropriate </font></div><div style="height:65.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:65.52pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT4.23</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">deductions and withholdings.  Upon termination, Employee will have no rights to any unvested benefits or any other compensation or payments except as stated in this paragraph.</font></div><div style="padding-left:35.45pt"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:30.17pt">Confirmation</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="padding-right:0.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The parties confirm that the increase in Base Salary is a result of an assessment of increases in cost-of-living indices and salary benchmarking.</font></div><div style="padding-right:0.2pt;text-align:justify"><font><br></font></div><div style="padding-right:0.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="padding-right:0.2pt"><font><br></font></div><div style="padding-left:54pt;padding-right:0.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:30.17pt">Miscellaneous</font></div><div style="padding-left:54pt;padding-right:0.2pt"><font><br></font></div><div style="padding-left:54pt;padding-right:0.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">This Amending Agreement shall be effective from and after January 1, 2023.</font></div><div style="padding-left:54pt;padding-right:0.2pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:0.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">This Agreement shall be governed by and construed in accordance with the laws of California.  </font></div><div style="padding-left:54pt;padding-right:0.2pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:0.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.77pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="padding-right:0.2pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:0.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="padding-left:54pt;padding-right:0.2pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written. </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.400%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">ONCOLYTICS BIOTECH (U.S.), INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;Gilles Gosselin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Gilles Gosselin</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Director</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;Matthew Coffey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Matthew Coffey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Director</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#47;s&#47;Thomas C. Heineman</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">____________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">THOMAS C. HEINEMAN, M.D., Ph.D.</font></div><div style="height:65.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.0
<SEQUENCE>8
<FILENAME>ex80subsidiaries2022.htm
<DESCRIPTION>EX-8.0
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i73530cdf69ce425da9811a7afb47bf01_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 8.0</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.222%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncolytics Biotech (Barbados) Inc.</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbados</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncolytics Biotech (US) Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>9
<FILENAME>ex121ceocertification2022.htm
<DESCRIPTION>EX-12.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i95c5cf7eac6f4df8ba5f46408e5c6c27_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 12.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Matthew Coffey, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5. &#160;&#160;&#160;&#160;The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;Matthew Coffey</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA<br>Chief Executive Officer<br>Principal Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>10
<FILENAME>ex122cfocertification2022.htm
<DESCRIPTION>EX-12.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8870de4d6d194537a637e874096703c3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 12.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Kirk Look, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5. &#160;&#160;&#160;&#160;The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div><div style="margin-bottom:2pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:5.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;Kirk Look</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA<br>Chief Financial Officer<br>Principal Accounting and Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>11
<FILENAME>ex131ceocertification2022.htm
<DESCRIPTION>EX-13.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i63fa1c1a78a94f94961900f443b7278c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 13.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">18 U.S.C. &#167;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Matthew Coffey, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;s&#47;Matthew Coffey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Dr. Matthew Coffey, PhD, MBA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Principal Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">March&#160;3, 2023 </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>12
<FILENAME>ex132cfocertification2022.htm
<DESCRIPTION>EX-13.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icc3f0315b95d4e2a87300eec6bb2a497_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 13.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">18 U.S.C. &#167;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Kirk Look, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;s&#47;Kirk Look</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">__________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Kirk Look, CA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Principal Accounting and Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">March&#160;3, 2023 </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>13
<FILENAME>ex151-2022mda.htm
<DESCRIPTION>EX-15.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><img alt="oncolyticslogotaglineblueaa.jpg" src="oncolyticslogotaglineblueaa.jpg" style="height:298px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION &#38; ANALYSIS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">2022 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;2, 2023 </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BASIS OF PRESENTATION </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management's Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&#38;A&#8221;) should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2022, which have been prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;) as issued by the International Accounting Standards Board (&#34;IASB&#34;). Our IFRS accounting policies are set in note 3 of our audited consolidated financial statements for the year ended December&#160;31, 2022. This MD&#38;A, along with our consolidated financial statements for the year ended December&#160;31, 2022, were authorized for issue in accordance with a resolution of the Board of Directors (the &#34;Board&#34;) on March&#160;2, 2023. Unless otherwise indicated, all references to &#34;$&#34; and &#34;dollars&#34; in this discussion and analysis mean thousands of Canadian dollars.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this MD&#38;A to &#34;the Company&#34;, &#34;Oncolytics&#34;, &#34;we&#34;, &#34;us&#34;, or &#34;our&#34; and similar expressions refer to Oncolytics Biotech Inc. and the subsidiaries through which it conducts its business, unless otherwise indicated.  </font></div><div style="text-align:justify"><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_7"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains forward-looking statements, within the meaning of Section 21E of the United States </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as &#34;forward-looking statements&#34;). Forward-looking statements, including&#58; our belief as to the potential and mode of action of pelareorep, an intravenously delivered immunotherapeutic agent, as a cancer therapeutic&#59; our expectation that we will incur substantial losses and will not generate significant revenues until and unless pelareorep becomes commercially viable&#59; our business strategy, goals, focus and objectives for the development of pelareorep, including our immediate primary focus on advancing our program in hormone receptor-positive &#47; human epidermal growth factor 2-negative metastatic breast cancer to a phase 3 licensure-enabling study&#59; our exploration of opportunities for registrational programs in gastrointestinal cancers through our GOBLET platform study&#59; the impact of the COVID-19 pandemic and the global political conflict in Ukraine on our research and development activities, business operations and financial condition, our plans to monitor and mitigate any such impact&#59; our expectations regarding the delivery of additional clinical data, the timing thereof and the anticipated benefits and value to us of such additional clinical data&#59; our current clinical development approach&#59; our plan to actively manage the development of our clinical trial program, our preclinical and collaborative programs, our manufacturing process and pelareorep supply&#59; our plans respecting regulatory approval for pelareorep&#59; our expectations as to the purpose, design, outcomes and benefits of our current or pending clinical trials involving pelareorep&#59; our expectations regarding enrollment under our clinical trials&#59; our anticipated milestones and catalysts&#59; our planned 2023 development program for pelareorep and primary 2023 clinical objectives&#59; our 2023 manufacturing program&#59; our anticipated 2023 cash requirements to fund our operations&#59; our anticipated 2023 expenses relating to clinical trials, manufacturing and related process development, intellectual property, translational science, personnel-related and other and operating expenses&#59; our plans respecting the maintenance of adequate cash reserves to support our planned activities&#59; our anticipated cash usage in 2023&#59; our plans for funding our capital expenditure requirements&#59; our approach to credit rate, interest rate, foreign exchange and liquidity risk mitigation&#59; the effectiveness of our internal control systems&#59; and other statements that are not historical facts or which are related to anticipated developments in our business and technologies. In any forward-looking statement in which we express an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation, or belief will be achieved. Forward-looking statements involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements. We may be impacted by business interruptions resulting from COVID-19 coronavirus and the global political conflict in Ukraine, including manufacturing supply chain, clinical trial and project development delays and disruptions, labor shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may be affected if the COVID-19 pandemic and the global political conflict in Ukraine persist for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results, and financial condition.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development, and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process, and general changes to the economic environment.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the forward-looking statements made within this MD&#38;A, we have made numerous assumptions regarding, among other things&#58; our ability to recruit and retain talented employees, our continued ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates, and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and&#47;or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake any obligation to update these forward-looking statements except as required by applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_10"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company Overview</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep is a proprietary isolate of a naturally occurring, non-pathogenic double-stranded RNA (dsRNA) virus commonly found in environmental waters, known as reovirus. Pelareorep has demonstrated the ability to create a more permissive tumor microenvironment (TME) and conditions the tumor for multiple treatment combinations, including chemotherapies, checkpoint inhibitors and other immuno-oncology drugs, like CAR T therapies, bispecific antibodies, and CDK4&#47;6 and PARP inhibitors. Pelareorep creates a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and promotes the overexpression of PD-1&#47;PD-L1. By priming the immune system with pelareorep, we believe we can increase the proportion of patients who respond to immunotherapies and other cancer treatments, especially in cancers where immunotherapies have failed or provided limited benefit.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our clinical development program advances, we anticipate pelareorep's ability to enhance innate and adaptive immune responses within the TME will play an increasingly important role. This greatly increases opportunities for expansion of our clinical program along with business development and partnering opportunities to address a broad range of cancers in combination with a variety of other therapies. We believe this approach has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary focus is to advance our programs in hormone receptor-positive &#47; human epidermal growth factor 2-negative (HR+&#47;HER2-) metastatic breast cancer (mBC) and advanced&#47;metastatic pancreatic ductal adenocarcinoma (PDAC) to phase 3 licensure-enabling studies. In addition, we are exploring opportunities for registrational programs in gastrointestinal cancers through our GOBLET platform study.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. As at December&#160;31, 2022, we had cash, cash equivalents, and marketable securities of $32,138. We believe we have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2022 Developments</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Trial Program</font></div><div style="margin-top:10pt;text-align:justify"><img alt="oncolyticspipeline3.jpg" src="oncolyticspipeline3.jpg" style="height:367px;margin-bottom:5pt;vertical-align:text-bottom;width:690px"></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Breast cancer program</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-development Agreement with Pfizer Inc. and Merck KGaA, Darmstadt, Germany&#58; BRACELET-1 study</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab (Bavencio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a human anti-PD-L1 antibody, for the treatment of HR+&#47;HER2- mBC. This phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. The study, known as BRACELET-1, is a randomised open-label study that enrolled 48 patients into three cohorts&#58; paclitaxel alone, paclitaxel in combination with pelareorep, and paclitaxel in combination with both pelareorep and avelumab. PrECOG LLC, a leading cancer research network, is managing the BRACELET-1 study.   </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study is examining the expression of immune-related biomarkers to identify changes in the T cell population between pretreatment and on-therapy biopsies and seeks to confirm our previously identified biomarker. It is designed to assess efficacy in terms of overall response rate at week 16 per RECIST 1.1. The safety of the combination is also being evaluated.&#160;The results of this study may provide an opportunity to add an arm to our proposed registration study that includes a checkpoint inhibitor in addition to the chemotherapy-pelareorep combination. Furthermore, the results of the BRACELET-1 study may provide important confirmatory data in the same patient population as our IND.213 study, for which we presented a statistically significant near doubling of overall survival with pelareorep treatment in HR+&#47;HER2- mBC. These endpoints, including the biomarker data, are expected to further de-risk our contemplated registration study, permitting for a smaller study with a higher likelihood of clinical success.   </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we concluded patient enrollment, continued re-treating patients still on-study, monitored those patients who came off treatment due to progression, and assisted with follow-up activities. These activities included analyzing data on the study's primary endpoint of week 16 overall response rate and secondary endpoints of progression-free survival (PFS) and overall survival. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with SOLTI&#58; AWARE-1 study</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received approval for our AWARE-1 study from the Spanish Agency for Medicine and Health Products. This clinical collaboration with SOLTI, an academic research group dedicated to breast cancer research, was a window of opportunity study in the neoadjuvant setting for breast cancer using pelareorep in combination with F. Hoffmann-La Roche (Roche)'s anti-PD-L1 checkpoint inhibitor, atezolizumab (Tecentriq&#174;). We completed enrollment in 2022. Throughout 2020, 2021, and 2022, we published various clinical data which demonstrated most HR+&#47;HER2- early breast cancer patients treated </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with pelareorep showed an increase in CeLTIL score, a prognostic metric associated with improved overall and progression-free survival that is calculated based upon measures of (1) tumor cellularity (a measure of the proportion of cancerous vs. non-cancerous cells in a tumor tissue sample) and (2) the number of infiltrating lymphocytes in a tumor tissue sample. Importantly, the addition of atezolizumab to pelareorep increased both the magnitude of the increase in CeLTIL score and the proportion of patients with a positive CelTIL score, thereby achieving the study&#8217;s primary endpoint. It was noted that patients treated with pelareorep and atezolizumab reached the primary endpoint of the study with 60% of the patients showing an increase of more than 30% in the CelTIL score. Biomarker data from AWARE-1 further demonstrated that pelareorep treatment reversed immunosuppressive tumor microenvironments, generated and expanded T cell clones, upregulated PD-L1 expression, and promoted CD8+ T cell tumor infiltration into tumors. Many of these effects were even more prominent when pelareorep was combined with atezolizumab demonstrating synergy between the two agents.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we presented clinical biomarker analyses from AWARE-1's first two cohorts at the European Society for Medical Oncology Breast Cancer Meeting (ESMOBC), the Society for Immunotherapy of Cancer Annual Meeting 37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Meeting (SITC), and the San Antonio Breast Cancer Symposium (SABCS). The data demonstrated pelareorep's immunotherapeutic effects, synergy with checkpoint inhibition, and potential to improve the outlook for patients with HR+&#47;HER2- breast cancer. Patients in AWARE-1's first two cohorts were treated with pelareorep and the aromatase inhibitor letrozole without (cohort 1), or with (cohort 2), the PD-L1 checkpoint inhibitor atezolizumab approximately 21 days prior to the surgical resection of their tumors. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key data and conclusions presented at ESMOBC included&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gene expression analyses showed 100% of evaluable patients had a Risk of Recurrence Score (ROR-S) classified as &#34;low&#34; at surgery vs. 55% with a &#34;low&#34; ROR-S at baseline</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pooled analysis of tumors from cohorts 1 and 2 shows a statistically significant 4-fold post-treatment increase in the average expression of caspase 3, which is a marker of apoptotic cell death</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pooled analysis across cohorts 1 and 2 shows statistically significant increases in markers of T cell activation and no significant changes in markers of T cell exhaustion from baseline to surgery</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Treatment with pelareorep with (cohort 2) or without (cohort1) atezolizumab led to the conversion of tumors from the more aggressive luminal B to the luminal A subtype, which is associated with improved clinical outcomes</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">100% of evaluable cohort 2 tumors were luminal A at surgery (21 days post-treatment) vs. 70% at baseline (pre-treatment)</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">70% of evaluable cohort 1 patients had luminal A tumors at surgery vs. 40% at baseline</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented at SITC demonstrated that flow cytometry analyses of blood samples from these patients showed a statistically significant increase in anti-cancer natural killer (NK) cells on day 21 post-treatment in cohort 2 compared to cohort 1. In addition, cohort 2 patients showed higher levels of HLA-DR expression (a marker of T cell activation) in anti-cancer CD8+ T cells, and better maintained low levels of T cell exhaustion markers on day 21 compared to cohort 1 patients.   </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented at SABCS demonstrated that based on the gene expression profiling data, it was shown that pelareorep primes the tumor for further checkpoint blockade therapy by activating the interferon-gamma pathway.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreement with Adlai Nortye Biopharma Co., Ltd&#58; bridging clinical trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our regional licensing agreement (the &#34;Licensing Agreement&#34;) with our partner, Adlai Nortye Biopharma Co., Ltd. (&#34;Adlai&#34;), Adlai will have exclusive development and commercialization rights to pelareorep in certain Asian regions and we are entitled to certain milestone payments. The bridging clinical trial is evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced&#47;metastatic HR+&#47;HER2- breast cancer. Data from the bridging trial are expected to accelerate Adlai's development of pelareorep in China by allowing future regulatory submissions to include data from Oncolytics' North American metastatic breast cancer trials, IND.213 and BRACELET-1.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, Adlai advanced the bridging clinical trial to the third and final dose-escalation cohort. The trial's first two cohorts completed their dose escalation evaluation periods and indicated pelareorep in combination with paclitaxel was well-tolerated,  with no new safety signals observed to date. The dosing regimens for the second and third cohorts are equivalent to those administered in the IND.213 study and the BRACELET-1 study, respectively. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adlai further announced interim results at the 2022 SABCS meeting. Fifteen patients were treated in the trial, with fourteen having had at least one post-baseline tumor assessment (i.e., evaluable for efficacy). All patients enrolled into the trial were previously treated with at least one endocrine therapy and no more than one line of chemotherapy for recurrent&#47;metastatic disease. The data and conclusions are summarized as follows&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disease control, partial response (PR), or stable disease (SD), was achieved in thirteen of fourteen evaluable patients (93%), with twelve (86%) showing tumor shrinkage from baseline</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Seven of fourteen evaluable patients achieved a PR (50%). Three of these patients achieved a confirmed PR (20%), while two patients are awaiting potential confirmatory scans</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">One patient achieving a PR at week 8 has maintained the PR through week 48 and remains on study</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evolving median PFS for trial participants as of the data cut-off date was 9.1 months (95% confidence interval&#58; 3.8 - NA)</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The studied combination has been well tolerated, with no dose-limiting toxicities or serious adverse events (SAEs) reported to date</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gastrointestinal cancer program  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Roche and AIO-Studien-gGmbH&#58; GOBLET platform study</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our GOBLET platform study is a collaboration with Roche and AIO-Studien-gGmbH, a leading academic cooperative medical oncology group based in Germany. The study is investigating the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq&#174;), in patients with first-line advanced&#47;metastatic pancreatic, first- and third-line metastatic colorectal, and advanced anal cancers. Approximately 55 patients are planned for enrollment across these four separate cohorts and the study is being conducted at 14 centers in Germany. The study's co-primary endpoints are safety and objective response rate (ORR) at week 16. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential blood-based biomarkers (T cell clonality and CEACAM6). We received clearance from the Paul Ehrlich Institute (PEI&#59; Germany's medical regulatory body) for full enrollment of the first-line metastatic pancreatic cancer and third-line metastatic colorectal cancer cohorts in the first and second quarters of 2022, respectively. As the trial's anal cancer and first-line metastatic colorectal cancer cohorts do not include safety run-ins, all of the trial&#8217;s four cohorts were cleared for full enrollment.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, GOBLET&#8217;s pancreatic cancer cohort met the efficacy expansion criteria for Stage 1 of the trial and interim clinical results were presented at SITC. Per the study's Simon two-stage design, any cohort meeting a pre-specified efficacy threshold in Stage 1 (defined as achieving a minimum number of objective radiologic responses by week 16) may be expanded to enroll additional patients in an optional Stage 2 study expansion. The initial results from the safety run-in of this cohort met the primary endpoint as all patients achieved a partial response (n &#61; 3).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional interim data presented at the SITC meeting included&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORR and clinical benefit rate (CBR) in GOBLET's PDAC cohort (n&#61;13) were 69% and 85%, respectively&#59; </font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">One of thirteen evaluable patients achieved a confirmed complete response&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Eight of thirteen evaluable patients achieved a PR&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Two of thirteen evaluable patients achieved SD&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The observed ORR of 69% is substantially higher than the average ORR of &#126;25% reported in historical control trials of gemcitabine and nab-paclitaxel in pancreatic cancer&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">GOBLET's PDAC cohort exceeded the protocol-specified success criterion for Stage 1 of &#8805; 3&#47;12 objective responses&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The studied treatment combination has been well tolerated, with no safety concerns identified to date&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On the strength of the data, Oncolytics and its stakeholders determined that the Stage 2 expansion will not be necessary.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, we received the U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of advanced&#47;metastatic PDAC using pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel. Fast Track designation is designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill an unmet medical need. A clinical program that receives Fast Track designation may benefit from more frequent meetings and communications with the FDA to discuss development plans and ensure the collection of appropriate data needed to support approval. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAR T preclinical activities</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we published preclinical data demonstrating the synergistic anti-cancer activity of pelareorep combined with CAR T cell therapy in solid tumors in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Science Translational Medicine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in collaboration with researchers at several institutions, including the Mayo Clinic and Duke University. The paper, entitled &#34;Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice,&#34; evaluated the persistence and efficacy of pelareorep-loaded CAR T cells (&#34;CAR&#47;Pela therapy&#34;) in multiple murine solid tumor models. The effects of combining CAR&#47;Pela therapy with a subsequent intravenous dose of pelareorep (&#34;pelareorep boost&#34;) were also investigated. Key data and conclusions from the paper included&#58;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The persistence and anti-cancer activity of CAR T cells improved drastically when loaded with pelareorep. Compared to either treatment alone, treatment with CAR&#47;Pela therapy led to statistically significant survival benefits in murine skin and brain cancer models.</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CAR&#47;Pela therapy followed by a pelareorep boost led to enhanced efficacy in murine skin and brain cancer models and tumor cures in &#62;80% of treated mice in each model.</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loading CAR T cells with pelareorep led to improved cancer cell targeting and prevented antigen escape</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by generating CAR T cells with dual specificity that target their designed antigen and the native T cell receptor antigen. These results indicate that CAR&#47;Pela therapy may provide longer-lasting therapeutic benefits compared to treatment with CAR T cells alone.</font></div><div style="text-align:justify"><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_16"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing and Process Development </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2022, we continued distribution and storage activities, sourcing materials required for our planned product fills, and completed a product fill along with the applicable release testing. While we currently have sufficient drug product supply to support our clinical development program, we continued our activities to maintain our production capabilities. Ongoing bulk manufacturing and expanded filling capabilities are both part of the planned process validation. Continued process validation is required to ensure that the resulting product meets the required specifications and quality standards and will form part of our submission to regulators, including the FDA, for product approval. </font></div><div style="text-align:justify"><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_19"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of 2022, we had been issued 243 patents, including 24 US and 11 Canadian patents, as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus and formulations that we use in our clinical trial program. These patent rights extend to at least the end of 2031.</font></div><div style="text-align:justify"><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_25"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financing Activity</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. &#34;at-the-market&#34; (ATM) equity distribution agreement</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we sold 6,235,232 common shares for gross proceeds of US$10,192 at an average price of US$1.63. We received proceeds of US$9,886 after commissions of US$306. In total, we incurred share issue costs (including commissions) of $764.</font></div><div style="text-align:justify"><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_31"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Resources </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ended 2022 with cash, cash equivalents, and marketable securities of $32,138 (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Business Conditions</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, a variety of external factors, including the ongoing coronavirus infectious disease 2019 (COVID-19) pandemic and the global political conflict in Ukraine, have touched elements of our business operations. COVID-19, including its variants, has created challenges affecting our clinical trial activities, including delayed patient enrollment related to our BRACELET-1 study and contributed to the disruption of our manufacturing supply chain, while the conflict in Ukraine has increased market volatility and uncertainty. Some challenges included, among other things, patients choosing to delay treatments, clinical sites suspending study activity temporarily, vendor and collaborator staff shortages, and raw material and components delays. While these challenges have largely impacted the timing of certain activities, we believe the impact on our overall business to date has not been significant. We also believe our financial condition, liquidity, and longer-term strategic development remain on track. However, these events have caused and may continue to cause significant fluctuations in stock markets, global economic activity, including inflation and rising interest rates, and healthcare systems. The scale and duration of these developments remain uncertain and could affect our ability to finance and execute our operations.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events might prolong and&#47;or cause significant disruptions to our business and materially impact our results of operations, including our ongoing and planned clinical studies and manufacturing activities, will depend on future developments. These future developments are highly uncertain, cannot be predicted, and could negatively impact our business.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor these events and their impact on our industry and business. We are collaborating with our investigators, partners, and vendors to minimize its effect and ensure the safety of patients and employees, minimize the effect of supply chain challenges, and maintain the advancement of our clinical programs. We expect these measures will allow us to respond to future challenges that may arise adequately. Moving forward, we plan to remain in contact with relevant stakeholders and keep the market apprised of any new information that may materially impact clinical timelines.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_34"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subsequent Events</font></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between January 1, 2023 and March 2, 2023, we issued 1,499,044 shares for gross proceeds of US$2,570 through our June 2022 ATM equity distribution agreement.  </font></div><div><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_37"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Expected Pelareorep Development For 2023</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary 2023 clinical objectives will focus on delivering interim data from our BRACELET-1 and GOBLET clinical studies and assessing our clinical data to help form the nature of our registration strategy, our path to approval, and other possible clinical development opportunities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2023 manufacturing program will focus on progressing a process development program implementing single-use equipment for our drug substance production process and executing a manufacturing production run. We also expect to fill product and perform the associated analytical testing, as well as labeling, packaging, and distribution of pelareorep to our various clinical sites for ongoing and upcoming activities. Additionally, we will advance other product and analytical development activities towards registration readiness. Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.  </font></div><div style="text-align:justify"><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_49"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Selected Annual Information</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts below are presented in thousands of Canadian dollars, except for share amounts.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(24,835)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,304)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,505)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.43)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.56)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,334</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,880&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,346&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared per share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes&#58;</font></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)  Included in consolidated net loss and loss per common share for 2022,  2021, and 2020 are non-cash changes in fair value of warrant derivative (loss) gain of $(20), $17, and $3,492, respectively. </font></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)  Included in consolidated net loss and loss per common share for 2022, 2021, and 2020 are share-based compensation expenses of $2,378, $3,826, and $2,559, respectively.</font></div></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)  Included in consolidated net loss and loss per common share for 2022, 2021, and 2020 are foreign exchange gain (loss) of $1,665,  $(136), and $(659), respectively.</font></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)   We issued 6,284,125 common shares for net cash proceeds of $12.6 million in 2022 (2021 - 8,876,809 common shares for net cash proceeds of $33.4 million&#59; 2020 - 13,968,527 common shares for net cash proceeds of $40.2 million).  </font></div></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)  We have not declared or paid any dividends since incorporation.</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_798"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Components of Results of Operations</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#34;R&#38;D&#34;)</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses consist primarily of costs incurred to conduct research and development on pelareorep. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses include expenses related to the preparation and development of our breast and gastrointestinal cancer programs and immunotherapy combinations in other selected cancers. Clinical trial expenses include regulatory and consulting activities, contract research organization expenses, data management expenses, and other costs associated with our clinical trial program.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing &#38; related process development (&#8220;M&#38;P&#8221;) expenses include product manufacturing and process development activities. Product manufacturing expenses include third-party direct manufacturing costs, quality control testing, filling, labeling, packaging, and storage costs. Process development expenses include costs associated with studies examining components of our manufacturing and analytical processes and costs associated with planned process validation and related conformity testing.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property expenses include legal and filing fees associated with our patent portfolio.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translational science expenses are intended to expand our intellectual property related to pelareorep and identify potential licensing opportunities arising from our technology base.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related, share-based compensation, and other expenses are employee-related expenses. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (&#34;G&#38;A&#34;)</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses consist primarily of public company-related expenses, office expenses, share-based compensation expense, and depreciation. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public company-related expenses include investor relations, business development, and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent, and other fees relating to our U.S. and Canadian stock listings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Office expenses include compensation costs (excluding share-based compensation expense), rent related to short-term leases, and other office-related costs. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued warrants in connection with our August 2019 underwritten public offering. Warrants issued with an exercise price denominated in a foreign currency are reported as a liability until they are exercised or expire. These warrants are adjusted to fair value at each exercise date and at each reporting period and any change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_52"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts below are presented in thousands of Canadian dollars, except for share amounts.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the year ended December&#160;31, 2022, was $24,835 compared to $26,304 and $22,505 for the years ended December&#160;31, 2021, and December&#160;31, 2020, respectively. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#34;R&#38;D&#34;)</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses increased by $2,512 for the year ended December&#160;31, 2022, compared to 2021, and decreased by $25 for the year ended December&#160;31, 2021, compared to 2020. The following table summarizes our R&#38;D expenses for the years ended December&#160;31, 2022, 2021, and 2020&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:0 10pt 0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 to 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 to 2021</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,970</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M&#38;P expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,148</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,384&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">544</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(289)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,754&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,135&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,371</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(716)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,432</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,945&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our R&#38;D expenses for the year ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased clinical trial expenses as a result of an increase in our clinical study costs due to higher GOBLET set-up, patient enrollment, and sample analysis costs and increased clinical and safety data management consulting costs, partly offset by lower AWARE-1 patient activities as study closure began in 2022&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased personnel-related expenses due to higher salaries and annual incentive awards, the strengthening of the U.S. dollar, and additional headcount to support our R&#38;D program&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased M&#38;P expenses associated with higher production process and analytical activities as we focus on ensuring our active drug substance and finished drug product meet the regulatory specifications and standards. The increase was partly offset by lower routine testing activities. </font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above increases were partly offset by the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased share-based compensation expense as a result of a lower number of options granted in 2022 and the impact of the vesting of options granted in prior periods&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased translational science expenses as our bispecific antibodies and CAR T studies ongoing throughout 2021 were largely completed by the end of the first quarter of 2022.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our R&#38;D expenses for the year ended December&#160;31, 2021 was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased M&#38;P expenses as a result of the completion of a production run, two product fills, and the associated release testing activities in 2020&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased intellectual property expenses as a result of the lapsing of non-core patents in certain jurisdictions and foreign exchange fluctuations.</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above decreases were partly offset by the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased share-based compensation expense due to the impact of the vesting of options granted in prior periods&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased personnel-related expenses caused by a change in salary level and an increase in headcount as we expanded our U.S. office, partly offset by lower recruitment-related costs&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased translational science expenses as a result of the bispecific antibodies and CAR T studies initiated in 2021.</font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (&#34;G&#38;A&#34;)</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses decreased by $1,823 for the year ended December&#160;31, 2022, compared to 2021, and increased by $801 for the year ended December&#160;31, 2021, compared to 2020. The following table summarizes our G&#38;A expenses for the years ended December&#160;31, 2022, 2021, and 2020&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 to 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 to 2021</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,790</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,161&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,432&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,371)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,303</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,963&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,120&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,007</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(732)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">299</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,492</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,315&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,514&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,823)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our G&#38;A expenses for the year ended December&#160;31, 2022 was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased public company-related expenses as a result of lower investor relations activities, partly offset by increased travel expenses with the easing of COVID-19-related restrictions and higher board of directors advisory costs&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased share-based compensation expense caused by a lower number of options granted in 2022 and the impact of the vesting of options and share awards granted in prior periods.</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increased office expenses partly offset the above decreases as a result of higher salaries and annual incentive awards, and additional headcount to support our administrative activities. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our G&#38;A expenses for the year ended December&#160;31, 2021 was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased public company-related expenses due to an increase in directors and officers insurance premiums and investor relations activities, partly offset by lower business development consulting activities&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased share-based compensation expense on account of the impact of the vesting of options granted in prior periods, partly offset by a lower number of vesting share awards granted to independent board members due to a change in compensation arrangement.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, we recognized a loss of $20 on the change in fair value of our warrant derivative compared to gains of $17 and $3,492 for the years ended December&#160;31, 2021, and December&#160;31, 2020, respectively. The change in fair value in 2021 and 2020 was based on several factors, including changes in the market price of our shares and the revaluation of warrants exercised. The number of outstanding warrants was 64,035, 64,035, and 265,757 as at December&#160;31, 2022, December&#160;31, 2021, and December&#160;31, 2020, respectively.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, our foreign exchange gain was $1,665 compared to losses of $136 and $659 for the years ended December 31, 2021, and December&#160;31, 2020, respectively. The foreign exchange gain&#47;loss incurred in all three years was primarily due to unrealized translation gain&#47;loss on U.S. dollar-denominated cash balances as a result of the fluctuation of the U.S. dollar versus the Canadian dollar throughout the respective periods. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_55"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Summary of Quarterly Results</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historical patterns of expenditures cannot be taken as an indication of future expenditures. Our current and future expenditures are subject to numerous uncertainties, including the duration, timing, and costs of R&#38;D activities ongoing during each period and the availability of funding from investors and prospective partners. As a result, the amount and timing of expenditures and, therefore, liquidity and capital resources may vary substantially from period to period.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sept.</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sept.</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,554)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,407)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,095)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,779)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,751)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,872)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,246)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,435)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per common share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,334</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,959&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,239&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,446&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,880&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,593&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,309&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,180&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,138&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,689&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,483&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,262&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,087&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,799&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss earnings per common share are share-based compensation expenses of $749, $500, $490, $639, $1,129, $1,007, $1,032, and $658, respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share are foreign exchange (loss) gain of $(274), $1,526, $888, $(474), $(326), $1,212, $(631), and $(391), respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share were annual short-term incentive awards. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We issued 6,284,125 common shares for net cash proceeds of $12.6 million in 2022 (2021 - 8,876,809 common shares for net cash proceeds of $33.4 million).  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We have not declared or paid any dividends since incorporation.</font></div><div style="padding-left:36pt"><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_58"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fourth Quarter</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statement of loss for the three months ended December&#160;31, 2022, and 2021 was as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,841</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,679&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,667</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before the following</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,508)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,455)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(29)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign exchange loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(274)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">314</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,497)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,709)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(57)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,554)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,751)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Other comprehensive loss - translation adjustment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(61)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net comprehensive loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,615)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,770)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per common share</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59,512,765</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,025,655&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_61"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fourth Quarter Review of Operations</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the three months ended December&#160;31, 2022, was $8,554 compared to $7,751 for the three months ended December&#160;31, 2021. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#34;R&#38;D&#34;)</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses increased by $1,162 from $3,679 for the three months ended December&#160;31, 2021, to $4,841 for the three months ended December&#160;31, 2022. The following table summarizes our R&#38;D expenses for the three months ended December&#160;31, 2022, and 2021&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,295</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M&#38;P expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">477</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,431</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,848&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">460</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,841</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,679&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our R&#38;D expenses for the three months ended December&#160;31, 2022 was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased clinical trial expenses as a result of higher GOBLET patient costs and safety data management consulting costs&#59; </font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased personnel-related expenses attributable to higher salaries and annual incentive awards, the strengthening of the U.S. dollar, and additional headcount to support our R&#38;D program&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased M&#38;P expenses associated with higher production process and analytical activities as we focus on ensuring our active drug substance and finished drug product meet the regulatory specifications and standards plus higher distribution costs related to GOBLET. </font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above increases were partly offset by the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased translational sciences expenses as our bispecific antibodies and CAR T studies ongoing in the fourth quarter of 2021 were largely completed by the end of the first quarter of 2022&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased share-based compensation expense as a result of the impact of the vesting of options granted in prior periods.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (&#34;G&#38;A&#34;)</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses decreased by $109 from $3,776 for the three months ended December&#160;31, 2021, to $3,667 for the three months ended December&#160;31, 2022. The following table summarizes our G&#38;A expenses for the three months ended December&#160;31, 2022, and 2021&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,003</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,095&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,276</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,667</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our G&#38;A expenses for the three months ended December&#160;31, 2022 was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased share-based compensation expense attributable to the impact of the vesting of options granted in prior periods&#59; </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Partly offset by increased office expenses as a result of higher salaries and annual incentive awards, and additional headcount to support our administrative activities.</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_64"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_73"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical-stage biopharmaceutical company, we have not been profitable since our inception. We expect to continue to incur substantial losses as we continue our research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through the issuance of additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. In 2022, we were able to raise funds through our U.S. ATM equity distribution agreement.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no assurances that we will be able to raise additional funds through the sale of our common shares. Consequently, we will continue to evaluate all types of financing arrangements. On June 16, 2022, we renewed our short form base shelf prospectus (the &#34;Base Shelf&#34;) that qualifies for distribution of up to $150.0&#160;million of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be affected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 16, 2024. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreements (see Note 9 of our audited consolidated financial statements). We use these equity arrangements to assist us in achieving our capital objective. These arrangements provide us with the opportunity to raise capital and better manage our cash resources. Our current ATM equity distribution agreement provides us with access to, subject to terms and conditions, US$65.0 million, of which we have raised gross proceeds of approximately US$5.6 million at December&#160;31, 2022. We expect to continue to access our equity arrangement to help support our operations.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2022, and 2021, we had cash and cash equivalents, marketable securities, and working capital ratios as follows&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,666</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,262&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,472</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital ratio</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.69&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define working capital ratio as current assets divided by current liabilities, as presented on our audited consolidated statement of financial position. The change in our cash and cash equivalents between December&#160;31, 2021, and December&#160;31, 2022, reflects the cash used in our operating activities of $23.4 million, cash used in our investing activities of $20.4 million, and cash provided by our financing activities of $12.2 million for the year ended December&#160;31, 2022. We have no debt other than accounts payable and accrued liabilities and lease liabilities. We have commitments and contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated&#58;</font></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 to 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 to 2021</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23,355)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,433)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,068)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(922)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20,403)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,117)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,205</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,015&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,773&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,810)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,758)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,957</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(604)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in cash and cash equivalents</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(29,596)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,042&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,072&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,638)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,030)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash used in operating activities</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change between 2022 and 2021 was primarily related to higher net operating activities and non-cash working capital changes. The change between 2021 and 2020 reflected lower net operating activities and non-cash working capital changes. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2022, consisted of a net loss of $24,835 less non-cash adjustments of $1,089 and non-cash working capital changes of $391. Non-cash items primarily included share-based compensation expense and unrealized foreign exchange gain. Non-cash working capital changes were mainly due to additions to accounts payable and accrued liabilities and prepaid expenses and deposits.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2021, included a net loss of $26,304 less non-cash adjustments of $4,779 offset by non-cash working capital changes of $908. Non-cash items mainly consisted of share-based compensation expense and unrealized foreign exchange loss. An increase in other receivables primarily caused the non-cash working capital changes.   </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2020, comprised a net loss of $22,505 less non-cash adjustments of $227 and non-working capital changes of $210. Non-cash items primarily included share-based compensation expense, change in fair value of warrant derivative, and unrealized foreign exchange loss. Non-cash working capital changes were mainly attributable to a decrease in other receivables, accounts payable and accrued liabilities, and other liabilities. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash used in investing activities </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change between 2022 and 2021 was principally related to acquiring marketable securities. The change between 2021 and 2020 directly related to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leasehold improvements and furnishing of our Calgary headquarters in 2021.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash provided by financing activities</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes were mainly due to our U.S. ATM activities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December&#160;31, 2022, we sold 6,235,232 common shares for gross proceeds of US$10,192 at an average price of US$1.63. During the year ended December&#160;31, 2021, we sold 8,401,029 common shares for gross proceeds of US$27,158 at an average price of US$3.23. During the year ended December&#160;31, 2020, we sold 12,182,532 common shares for gross proceeds of US$30,167 at an average price of US$2.48, and 1,418,369 warrants in connection with our August 2019 underwritten public offering were exercised for gross proceeds of US$1,277.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to maintain adequate cash reserves to support our planned activities, including our clinical trial program, product manufacturing, administrative costs, and intellectual property protection. To do so, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to manage our research and development plan to ensure optimal use of our existing resources as we expect to fund our expenditure requirements and commitments with existing working capital. Additional activities continue to be subject to adequate resources, and we believe we will have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months. Factors that will affect our anticipated cash usage for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&#38;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2022.</font></div><div style="text-align:justify"><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_76"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant contractual obligations as at December&#160;31, 2022&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 1 year</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2 -3 years</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4 - 5 years</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">More than <br>5 years</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,650&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,650&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,097&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,901&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are committed to payments totaling approximately $16,775 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next three years. We are able to cancel most of these agreements with notice. The ultimate amount and timing of these payments are subject to changes in our research and development plan.  </font></div><div><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_79"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2022, we had not entered into any off-balance sheet arrangements.</font></div><div><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_82"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transactions with Related Parties</font></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021, and 2020, we did not enter into any related party transactions other than compensation paid to key management personnel. Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel consists of the Board of Directors, the President and Chief Executive Officer, and the executives who report directly to the President and Chief Executive Officer.  </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,308</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,615</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,923</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,768&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_43"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Estimates</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our audited consolidated financial statements, we use IFRS as issued by the IASB. IFRS requires us to make certain estimates, judgements, and assumptions that we believe are reasonable based upon the information available in applying our accounting policies. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the audited consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods presented. Actual results could differ from those estimates, and such differences could be material. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judgment, estimates and assumptions made by management that are significant to the financial statements are described below and in Note 4 of our audited consolidated financial statements for the year ended December&#160;31, 2022.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement with Adlai, which provides, among other payments, upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress toward completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses represent significant components of our research and development expenses, and we outsource a significant portion of these activities to third-party contract research&#47;manufacturing organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as achieving certain milestones. As part of preparing our audited consolidated financial statements, we estimate the expense to recognize based on services that the contract research&#47;manufacturing organizations have performed. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.    </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based compensation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value for stock options granted requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. We have chosen to use the Black-Scholes valuation model (&#34;Black-Scholes&#34; or the &#34;Model&#34;) to calculate the fair value of our stock options. Black-Scholes is widely used and accepted by other publicly traded companies. Therefore, we have concluded that Black-Scholes is the appropriate option pricing model to use for our stock options at this time. This estimate also requires determining the most appropriate inputs to the model, including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options granted issued are disclosed in Note 10 of our audited consolidated financial statements. Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we have recorded non-cash share-based compensation expense for the years ended December&#160;31, 2022, 2021, and 2020, of $2,378, $3,826, and $2,559, respectively. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. We have chosen to use Black-Scholes to calculate the fair value of our warrant derivative. This estimate also requires determining the most appropriate inputs to the model including, the expected life, share price volatility, and dividend yield, and making assumptions about them, as discussed in Note 16 of our audited consolidated financial statements. Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we have recorded a non-cash change in fair value of warrant derivative for the years ended December&#160;31, 2022, 2021, and 2020, of $(20), $17, and $3,492, respectively. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry-forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgment is required to determine the amount of deferred tax assets that can be recognized based on the likely timing and the level of future taxable profits together with future tax planning strategies.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. There are also no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_40"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accounting Policies </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note 3 of our audited consolidated financial statements for the year ended December&#160;31, 2022. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduced a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</font><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the IASB issued amendments to IAS 12, which narrowed the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.</font></div><div style="text-align:justify"><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_85"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Instruments and Other Instruments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents, marketable securities,&#160;other receivables, accounts payable and accrued liabilities, and warrant derivative.&#160;As at December&#160;31, 2022, the carrying amount of our cash and cash equivalents, marketable securities,&#160;other receivables, and accounts payable and accrued liabilities approximated their fair value due to their short-term maturity.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative, initially measured at fair value, with subsequent changes in fair value at each reporting period end recognized through profit and loss. Our warrants with an exercise price of US$0.90 (see Note 9(b) of our audited consolidated financial statements) meet this requirement, and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December 31, 2022, the fair value of our warrant derivative was $79 (December&#160;31, 2021 - $56). We use the Black-Scholes valuation model to estimate fair value. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents, marketable securities, and other receivable from Pfizer in connection with the BRACELET-1 study (see Note 5 of our audited consolidated financial statements) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents, marketable securities, and other receivable from Pfizer. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also mitigate our exposure to credit risk by restricting our portfolio to investment-grade securities with short-term maturities and monitoring counterparties' credit risk and credit standing. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest savings accounts that have variable interest rates. Our marketable securities have fixed interest rates.&#160;We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market interest rates do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and the Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2022 by approximately $170. The impact of a $0.01 increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in 2022 by approximately $22.&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies through the purchase of foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable and accrued liabilities.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies at December&#160;31, 2022, are as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,115&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,093)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,657&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in the notes to our audited financial statements.  Accounts payable and accrued liabilities are all due within the current operating period.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_88"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other MD&#38;A Requirements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 62,826,958 common shares outstanding at March&#160;2, 2023. If all of our options (5,963,185) and common share purchase warrants with a US$0.90 exercise price (64,035) were exercised or were to vest, we would have 68,854,178 common shares outstanding.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2022 annual report on Form 20-F is available on SEDAR at www.sedar.com and EDGAR at www.sec.gov.</font></div><div style="text-align:justify"><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_91"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief executive and financial officers reviewed and evaluated our disclosure controls and procedures. Based on that evaluation, they have concluded that our disclosure controls and procedures are effective in providing timely material information relating to the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting and has designed such internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with International Financial Reporting Standards.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls and procedures over financial reporting will prevent all errors and all fraud. A control system can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that the controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the design and operation of our internal control over financial reporting as of December&#160;31, 2022, and has concluded that such internal control over financial reporting is effective as of December&#160;31, 2022. There are no material weaknesses that have been identified by management in this regard. This assessment was based on criteria for effective internal control over financial reporting described in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Controls over Financial Reporting</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the year ended December&#160;31, 2022, that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><font><br></font></div><div id="id4ee0c9b5ac3472a9e57c3f4ef01919a_94"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks and Uncertainties</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative. It is not possible to predict, based on studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval. If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful. There can be no assurance that we will generate adequate funds to continue development, or will ever achieve significant revenues or profitable operations. Many factors (e.g., competition, patent protection, appropriate regulatory approvals) can influence the revenue and product profitability potential. In developing a pharmaceutical product, we rely on our employees, contractors, consultants and collaborators, and other third-party relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that this reliance and these relationships will continue as required. In addition to developmental and operational considerations, market prices for securities of biotechnology </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies generally are volatile, and may or may not move in a manner consistent with the progress we have made or are making.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in our common shares involves a high degree of risk. An investor should carefully consider, among other matters, the risk factors in addition to the other information in our annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the &#34;SEC&#34;), as well as our other public filings with the Canadian securities regulatory authorities and the SEC, when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the described material risks in our annual report or in subsequent reports we file with the regulatory authorities actually occur, they may materially harm our business, financial condition, operating results or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results, or cash flow. For information on risks and uncertainties, please refer to the &#34;Risk Factors&#34; section of our most recent annual report on Form 20-F and our other public filings available on www.sedar.com and www.sec.gov&#47;edgar.shtml. </font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>14
<FILENAME>ex152ey2022consent.htm
<DESCRIPTION>EX-15.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icd905caa474c489f93702c5bade5a68f_1"></div><div style="min-height:42.7pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 15.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Form S-8 nos. 333-171625 and 333-205708</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Form F-10 no. 333-265510</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) of our report dated March 2, 2023, with respect to the consolidated statements of financial position as at December 31, 2022 and December 31, 2021 and the consolidated statements of loss and comprehensive loss, changes in equity and cash flows for each of the years in the three-year period ended December 31, 2022 included in this Annual Report on Form 20-F.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.295%"><tr><td style="width:1.0%"></td><td style="width:57.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calgary, Alberta</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#47;s&#47;Ernst &#38; Young LLP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chartered Professional Accountants</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:324pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>oncyf-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:63a935b1-1650-41e1-88a0-4b019d55689c,g:0488272c-958a-4da8-b3e7-8a139968e8c3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:oncyf="http://www.oncolyticsbiotech.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.oncolyticsbiotech.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.oncolyticsbiotech.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.oncolyticsbiotech.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION">
        <link:definition>0000003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperations" roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperations">
        <link:definition>0000008 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.oncolyticsbiotech.com/role/BasisofPresentation">
        <link:definition>0000009 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantJudgmentsEstimatesandAssumptions" roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions">
        <link:definition>0000011 - Disclosure - Significant Judgments, Estimates and Assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsandLiabilities" roleURI="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities">
        <link:definition>0000012 - Disclosure - Other Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipment">
        <link:definition>0000013 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilities" roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities">
        <link:definition>0000014 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.oncolyticsbiotech.com/role/Leases">
        <link:definition>0000015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapital" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital">
        <link:definition>0000016 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensation">
        <link:definition>0000017 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare">
        <link:definition>0000018 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiability" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiability">
        <link:definition>0000019 - Disclosure - Contract Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies">
        <link:definition>0000020 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes">
        <link:definition>0000021 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures">
        <link:definition>0000022 - Disclosure - Capital Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments">
        <link:definition>0000023 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures">
        <link:definition>0000024 - Disclosure - Additional Cash Flow Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndemnificationofOfficersandDirectors" roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors">
        <link:definition>0000025 - Disclosure - Indemnification of Officers and Directors</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependence" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence">
        <link:definition>0000026 - Disclosure - Economic Dependence</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComponentsofExpenses" roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpenses">
        <link:definition>0000027 - Disclosure - Components of Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions">
        <link:definition>0000028 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents">
        <link:definition>0000029 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000030 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000031 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables">
        <link:definition>0000032 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables">
        <link:definition>0000033 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables">
        <link:definition>0000034 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables">
        <link:definition>0000035 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables">
        <link:definition>0000036 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityTables" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityTables">
        <link:definition>0000037 - Disclosure - Contract Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables">
        <link:definition>0000038 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables">
        <link:definition>0000039 - Disclosure - Capital Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables">
        <link:definition>0000040 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables">
        <link:definition>0000041 - Disclosure - Additional Cash Flow Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComponentsofExpensesTables" roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables">
        <link:definition>0000042 - Disclosure - Components of Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables">
        <link:definition>0000043 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperationsDetails" roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails">
        <link:definition>0000044 - Disclosure - Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000045 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails">
        <link:definition>0000046 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsandLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails">
        <link:definition>0000047 - Disclosure - Other Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails">
        <link:definition>0000048 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>0000049 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails">
        <link:definition>0000050 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRightofuseAssetsandLeaseLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails">
        <link:definition>0000051 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTotalUndiscountedLeaseLiabilityDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails">
        <link:definition>0000052 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleofShareCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails">
        <link:definition>0000053 - Disclosure - Share Capital - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleofShareCapitalFootnotesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails">
        <link:definition>0000054 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalEquityWarrantsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails">
        <link:definition>0000055 - Disclosure - Share Capital - Equity Warrants Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalSummaryofOutstandingWarrantsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails">
        <link:definition>0000056 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails">
        <link:definition>0000057 - Disclosure - Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails">
        <link:definition>0000058 - Disclosure - Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>0000059 - Disclosure - Share-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails">
        <link:definition>0000060 - Disclosure - Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails">
        <link:definition>0000061 - Disclosure - Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareDetails" roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails">
        <link:definition>0000062 - Disclosure - Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails">
        <link:definition>0000063 - Disclosure - Contract Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails">
        <link:definition>0000064 - Disclosure - Contract Liability - Schedule of Contract Revenues and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000065 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails">
        <link:definition>0000066 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000067 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails">
        <link:definition>0000068 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails">
        <link:definition>0000069 - Disclosure - Capital Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>0000070 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails">
        <link:definition>0000071 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails">
        <link:definition>0000072 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails">
        <link:definition>0000073 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependenceDetails" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails">
        <link:definition>0000074 - Disclosure - Economic Dependence (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComponentsofExpensesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails">
        <link:definition>0000075 - Disclosure - Components of Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails">
        <link:definition>0000076 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails">
        <link:definition>0000077 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="oncyf_MedicalEquipmentMember" abstract="true" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_ManufacturingExpense" abstract="false" name="ManufacturingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TaxEffectOfExpirationOfTaxBenefits" abstract="false" name="TaxEffectOfExpirationOfTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" abstract="false" name="IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" abstract="false" name="ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_GrossProceedsFromIssueOfOrdinaryShares" abstract="false" name="GrossProceedsFromIssueOfOrdinaryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_WarrantsMember" abstract="true" name="WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_SharesPublicOfferingEquityWarrantsMember" abstract="true" name="SharesPublicOfferingEquityWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_WarrantsandRightsOutstanding" abstract="false" name="WarrantsandRightsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" abstract="true" name="A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_ShareCapitalNumberSharesAbstract" abstract="true" name="ShareCapitalNumberSharesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ForeignExchangeImpactRightofUseAssets" abstract="false" name="ForeignExchangeImpactRightofUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ConcentrationRisk1Table" abstract="true" name="ConcentrationRisk1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" abstract="false" name="ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_WeightedAverageExercisePriceOutstandingAbstract" abstract="true" name="WeightedAverageExercisePriceOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_UnusedNetOperatingLossCarryForwardsMember" abstract="true" name="UnusedNetOperatingLossCarryForwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsLineItems" abstract="true" name="OtherExpensesAndAdjustmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_BalanceHeldInForeignCurrencyNet" abstract="false" name="BalanceHeldInForeignCurrencyNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ProceedsfromWarrantExercises1" abstract="false" name="ProceedsfromWarrantExercises1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TaxEffectOfTaxPools" abstract="false" name="TaxEffectOfTaxPools" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_UnusedCapitalLossCarryForwardNetMember" abstract="true" name="UnusedCapitalLossCarryForwardNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_ClinicalTrailExpense" abstract="false" name="ClinicalTrailExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureOfCapitalComponentsTableTextBlock" abstract="false" name="DisclosureOfCapitalComponentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_EquityAuthorized" abstract="false" name="EquityAuthorized" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ResearchAndDevelopmentExpenseMember" abstract="true" name="ResearchAndDevelopmentExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" abstract="true" name="DisclosureOfShareBasedPaymentArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_LeaseModificationRightOfUseAssets" abstract="false" name="LeaseModificationRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_Statement1LineItems" abstract="true" name="Statement1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_AdjustmentsForDepreciationRightOfUseAssets" abstract="false" name="AdjustmentsForDepreciationRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" abstract="true" name="A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_OfficeExpenses" abstract="false" name="OfficeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" abstract="true" name="PropertyPlantEquipmentRelatedTemporaryDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_TaxEffectOfStockBasedCompensation" abstract="false" name="TaxEffectOfStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" abstract="true" name="SignificantJudgmentsEstimatesAndAssumptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_PurchaseObligationCommitmentTerm" abstract="false" name="PurchaseObligationCommitmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_PublicCompanyExpense" abstract="false" name="PublicCompanyExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_Statement1Table" abstract="true" name="Statement1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_CashFlowOperatingCapital1TableTextBlock" abstract="false" name="CashFlowOperatingCapital1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1Axis" abstract="true" name="ConcentrationRiskType1Axis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1Domain" abstract="true" name="ConcentrationRiskType1Domain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_Currency1Table" abstract="true" name="Currency1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1LineItems" abstract="true" name="ConcentrationRiskType1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_GeneralAndAdministrativeExpenseAbstract" abstract="true" name="GeneralAndAdministrativeExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_IncomeStatementLocation1Domain" abstract="true" name="IncomeStatementLocation1Domain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsTableTextBlock" abstract="false" name="OtherExpensesAndAdjustmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="oncyf_StockholdersEquityNoteStockSplitConversionRatio" abstract="false" name="StockholdersEquityNoteStockSplitConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ConcentrationRiskNumber" abstract="false" name="ConcentrationRiskNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_GainsLossesFromForeignExchangeImpact" abstract="false" name="GainsLossesFromForeignExchangeImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_CommonSharesPerUnit" abstract="false" name="CommonSharesPerUnit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_CashAndCashEquivalentsAndCurrentInvestments" abstract="false" name="CashAndCashEquivalentsAndCurrentInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" abstract="false" name="ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="oncyf_SharesIssuedPricePerShare1" abstract="false" name="SharesIssuedPricePerShare1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="oncyf_NumberOfSharesExpired" abstract="false" name="NumberOfSharesExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_DisclosureOfEconomicDependenceTextBlock" abstract="false" name="DisclosureOfEconomicDependenceTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" abstract="false" name="IncreaseDecreaseThroughExpirationOfWarrantEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_Currency1LineItems" abstract="true" name="Currency1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_NumberOfStockOptionPlans" abstract="false" name="NumberOfStockOptionPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_SharePurchaseAgreementTerm" abstract="false" name="SharePurchaseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_DisclosureofeventsafterreportingperiodAbstract" abstract="true" name="DisclosureofeventsafterreportingperiodAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureofsharebasedpaymentarrangementAbstract" abstract="true" name="DisclosureofsharebasedpaymentarrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" abstract="false" name="MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_OfficeEquipmentAndFurnitureMember" abstract="true" name="OfficeEquipmentAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_PurchaseObligation1" abstract="false" name="PurchaseObligation1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" abstract="true" name="CorporateInformationAndStatementOfIFRSComplianceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_CommitmentsAndContingencies1" abstract="false" name="CommitmentsAndContingencies1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_CommonSharePurchaseWarrantPerUnit" abstract="false" name="CommonSharePurchaseWarrantPerUnit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_TranslationalScienceExpense" abstract="false" name="TranslationalScienceExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SharesUnderStockOptionPlanMember" abstract="true" name="SharesUnderStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_WarrantsAndRightsExpired" abstract="false" name="WarrantsAndRightsExpired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_RightOfUseAssetsAbstract" abstract="true" name="RightOfUseAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" abstract="false" name="ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="oncyf_GeneralAndAdministrativeExpenseMember" abstract="true" name="GeneralAndAdministrativeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_RestrictedShareUnitsMember" abstract="true" name="RestrictedShareUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" abstract="true" name="DisclosureofrevenuefromcontractswithcustomersAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" abstract="true" name="WarrantDerivativeAndSharesUnderWarrantAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" abstract="false" name="PropertyPlantandEquipmentAnnualDepreciationRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="oncyf_IntellectualPropertyExpense" abstract="false" name="IntellectualPropertyExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SharePurchaseAgreementAmount" abstract="false" name="SharePurchaseAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsTable" abstract="true" name="OtherExpensesAndAdjustmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" abstract="true" name="DisclosureOfNotesAndOtherExplanatoryInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_AdditionalCashFlowDisclosuresAbstract" abstract="true" name="AdditionalCashFlowDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureofrelatedpartyAbstract" abstract="true" name="DisclosureofrelatedpartyAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightNumberofWarrantsExercised" abstract="false" name="ClassofWarrantorRightNumberofWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_StockOptionsOutstandingAbstract" abstract="true" name="StockOptionsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ContingenciesAbstract" abstract="true" name="ContingenciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SharesUnderIncentiveAwardPlanMember" abstract="true" name="SharesUnderIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" abstract="true" name="A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_IncomeStatementLocation1Axis" abstract="true" name="IncomeStatementLocation1Axis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SupplierConcentrationRisk1Member" abstract="true" name="SupplierConcentrationRisk1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" abstract="true" name="DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ShareIssueRelatedCostCommissions" abstract="false" name="ShareIssueRelatedCostCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ContractLiabilityRecognitionPeriod" abstract="false" name="ContractLiabilityRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_SharesPublicOfferingWarrantDerivativesMember" abstract="true" name="SharesPublicOfferingWarrantDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_ProceedsfromInterestReceived" abstract="false" name="ProceedsfromInterestReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" abstract="false" name="IncreaseDecreaseThroughIncentiveShareAwardsEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SharesIssuedFairValueOfCommonShare" abstract="false" name="SharesIssuedFairValueOfCommonShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="oncyf_InvestmentTaxCreditsMember" abstract="true" name="InvestmentTaxCreditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" abstract="false" name="ClassofWarrantorRightExercisePriceofWarrantsorRights2" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="oncyf_IssueOfEquityShares" abstract="false" name="IssueOfEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" abstract="false" name="DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" abstract="false" name="DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="oncyf_WarrantsAndRightsOutstanding1" abstract="false" name="WarrantsAndRightsOutstanding1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SharesUnderAtthemarketAgreementMember" abstract="true" name="SharesUnderAtthemarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_ShareIssueCostsMember" abstract="true" name="ShareIssueCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_OperatingLeaseRemainingLeaseTerm" abstract="false" name="OperatingLeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ResearchAndDevelopmentExpenseAbstract" abstract="true" name="ResearchAndDevelopmentExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ShareCapitalAmountAbstract" abstract="true" name="ShareCapitalAmountAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_EffectOfLeaseModificationOnLeaseLiabilities" abstract="false" name="EffectOfLeaseModificationOnLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" abstract="false" name="ScheduleOfForeignCurrencyHeldTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightWarrantsExercised" abstract="false" name="ClassofWarrantorRightWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" abstract="true" name="SharesUnderAtthemarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_SaleOfStockDomain" abstract="true" name="SaleOfStockDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_ClassOfWarrantOrRightOutstanding1" abstract="false" name="ClassOfWarrantOrRightOutstanding1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SharesIssuedWarrantPricePerShare" abstract="false" name="SharesIssuedWarrantPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="oncyf_DisclosureOfEconomicDependenceAbstract" abstract="true" name="DisclosureOfEconomicDependenceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" abstract="false" name="TaxEffectOfChangeinFairValueOfWarrantDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureofincometaxAbstract" abstract="true" name="DisclosureofincometaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" abstract="false" name="DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="oncyf_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SaleOfStockAxis" abstract="true" name="SaleOfStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" abstract="true" name="UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>oncyf-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:63a935b1-1650-41e1-88a0-4b019d55689c,g:0488272c-958a-4da8-b3e7-8a139968e8c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_ae0dda83-4710-438a-91f1-c3dfdfcc42cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_8910ede7-19ea-45d7-bccd-b2b0e6cc7202" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_ae0dda83-4710-438a-91f1-c3dfdfcc42cb" xlink:to="loc_ifrs-full_IssuedCapital_8910ede7-19ea-45d7-bccd-b2b0e6cc7202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsandRightsOutstanding_b12064fb-dcb6-4cbb-9f49-3a817a3d7fa6" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsandRightsOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_ae0dda83-4710-438a-91f1-c3dfdfcc42cb" xlink:to="loc_oncyf_WarrantsandRightsOutstanding_b12064fb-dcb6-4cbb-9f49-3a817a3d7fa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_e5ed0651-ba6d-4620-9843-e42fa6235855" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_ae0dda83-4710-438a-91f1-c3dfdfcc42cb" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_e5ed0651-ba6d-4620-9843-e42fa6235855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_cc950185-8316-4b6c-8e54-8b73a8d7d079" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_ae0dda83-4710-438a-91f1-c3dfdfcc42cb" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_cc950185-8316-4b6c-8e54-8b73a8d7d079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_27d5ab60-833f-4f85-ac16-541006677884" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_ae0dda83-4710-438a-91f1-c3dfdfcc42cb" xlink:to="loc_ifrs-full_RetainedEarnings_27d5ab60-833f-4f85-ac16-541006677884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_b41d51a1-d567-4e53-9c9b-b5fe96376f2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_57270716-7b06-427b-b401-c953651a6ae5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_b41d51a1-d567-4e53-9c9b-b5fe96376f2d" xlink:to="loc_ifrs-full_CurrentLiabilities_57270716-7b06-427b-b401-c953651a6ae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_36892fc8-c42a-495c-b199-7696e3732525" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_b41d51a1-d567-4e53-9c9b-b5fe96376f2d" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_36892fc8-c42a-495c-b199-7696e3732525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_8551b81e-11d4-42e5-afe0-2d1193d94f28" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_b41d51a1-d567-4e53-9c9b-b5fe96376f2d" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_8551b81e-11d4-42e5-afe0-2d1193d94f28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_0c96abb4-abdb-4bca-b2c1-9cc683b7ec3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_2443f308-68a7-49e1-bbce-0773ede239a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_0c96abb4-abdb-4bca-b2c1-9cc683b7ec3b" xlink:to="loc_ifrs-full_CashAndCashEquivalents_2443f308-68a7-49e1-bbce-0773ede239a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAvailableforsale_3527a383-45bd-4d6d-ac99-ff28ce436555" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssetsAvailableforsale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_0c96abb4-abdb-4bca-b2c1-9cc683b7ec3b" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAvailableforsale_3527a383-45bd-4d6d-ac99-ff28ce436555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_a2fbc429-abee-4df9-8988-22343c95de74" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_0c96abb4-abdb-4bca-b2c1-9cc683b7ec3b" xlink:to="loc_ifrs-full_OtherCurrentReceivables_a2fbc429-abee-4df9-8988-22343c95de74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepayments_1a9ebba9-10c8-4513-a389-a1354e89f2d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_0c96abb4-abdb-4bca-b2c1-9cc683b7ec3b" xlink:to="loc_ifrs-full_CurrentPrepayments_1a9ebba9-10c8-4513-a389-a1354e89f2d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_b790b2ae-21bc-48ce-a906-3678746e48f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_1d1a0984-dbb1-4c65-868b-41bbb1fd132e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_b790b2ae-21bc-48ce-a906-3678746e48f1" xlink:to="loc_ifrs-full_Liabilities_1d1a0984-dbb1-4c65-868b-41bbb1fd132e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1_5073710a-619b-4f01-a59e-ff2a64b6ebbf" xlink:href="oncyf-20221231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_b790b2ae-21bc-48ce-a906-3678746e48f1" xlink:to="loc_oncyf_CommitmentsAndContingencies1_5073710a-619b-4f01-a59e-ff2a64b6ebbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_99237957-a6d8-45ea-a3cd-2e99f9d5c0f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_b790b2ae-21bc-48ce-a906-3678746e48f1" xlink:to="loc_ifrs-full_Equity_99237957-a6d8-45ea-a3cd-2e99f9d5c0f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_74c6cc3b-b77b-43ec-981d-7511dc59c443" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_f787e0dc-682b-43c3-81ea-605c231204a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_74c6cc3b-b77b-43ec-981d-7511dc59c443" xlink:to="loc_ifrs-full_CurrentAssets_f787e0dc-682b-43c3-81ea-605c231204a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_027ac151-3b67-46a7-b25d-9285739a504e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_74c6cc3b-b77b-43ec-981d-7511dc59c443" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_027ac151-3b67-46a7-b25d-9285739a504e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_acbb57a2-9163-4a7b-8194-e2dc104c8e13" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_74c6cc3b-b77b-43ec-981d-7511dc59c443" xlink:to="loc_ifrs-full_RightofuseAssets_acbb57a2-9163-4a7b-8194-e2dc104c8e13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPrepayments_d23b906b-ac90-4ac0-9a13-34cc89c6bbee" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_74c6cc3b-b77b-43ec-981d-7511dc59c443" xlink:to="loc_ifrs-full_NoncurrentPrepayments_d23b906b-ac90-4ac0-9a13-34cc89c6bbee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_70f24acd-60aa-4c0c-838f-a3de6daa6d07" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_a29fa13a-fca8-4014-863d-6ffca760b0a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_70f24acd-60aa-4c0c-838f-a3de6daa6d07" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_a29fa13a-fca8-4014-863d-6ffca760b0a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_130eb4cd-7825-411e-9c72-b0d8c4d87c79" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_70f24acd-60aa-4c0c-838f-a3de6daa6d07" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_130eb4cd-7825-411e-9c72-b0d8c4d87c79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_09e7cefd-c1fa-49fd-acaa-9bd588f45a90" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_70f24acd-60aa-4c0c-838f-a3de6daa6d07" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_09e7cefd-c1fa-49fd-acaa-9bd588f45a90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_8121cdd3-b0b8-4d40-87a1-14cdddc4d0a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_70f24acd-60aa-4c0c-838f-a3de6daa6d07" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_8121cdd3-b0b8-4d40-87a1-14cdddc4d0a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_1ff616d1-3903-4cb1-9cdd-43ad5817c613" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_41a3029a-b252-4b15-a3f1-22b45c327fb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_1ff616d1-3903-4cb1-9cdd-43ad5817c613" xlink:to="loc_ifrs-full_ProfitLoss_41a3029a-b252-4b15-a3f1-22b45c327fb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ec24b693-6bc6-4763-b18a-d78dcd2de224" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_1ff616d1-3903-4cb1-9cdd-43ad5817c613" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ec24b693-6bc6-4763-b18a-d78dcd2de224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_d2113091-ef57-48b2-bf2f-7ab56243b98a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_543c6823-76eb-42d7-8781-9f8b4f68d38d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_d2113091-ef57-48b2-bf2f-7ab56243b98a" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_543c6823-76eb-42d7-8781-9f8b4f68d38d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_3451d6ff-cfee-4232-a843-1623f28e3fc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_d2113091-ef57-48b2-bf2f-7ab56243b98a" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_3451d6ff-cfee-4232-a843-1623f28e3fc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_51ff53da-386f-4dbc-a442-e20217ed4dd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_20e97236-39b4-492c-81a0-2c7172ff09ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_51ff53da-386f-4dbc-a442-e20217ed4dd4" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_20e97236-39b4-492c-81a0-2c7172ff09ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_0fd74761-db93-479e-84c3-82afaf85fb70" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_51ff53da-386f-4dbc-a442-e20217ed4dd4" xlink:to="loc_ifrs-full_OperatingExpense_0fd74761-db93-479e-84c3-82afaf85fb70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_f448336f-ae39-4cf1-8694-3ff835bada89" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_89be48db-edac-40b6-8a97-b99cc176a3e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_f448336f-ae39-4cf1-8694-3ff835bada89" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_89be48db-edac-40b6-8a97-b99cc176a3e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_2ae984a3-d4ec-4092-8351-b61f9b45c46f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_f448336f-ae39-4cf1-8694-3ff835bada89" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_2ae984a3-d4ec-4092-8351-b61f9b45c46f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_1197f9a8-b19f-4c23-bcd5-7fd7fc74d954" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_f448336f-ae39-4cf1-8694-3ff835bada89" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_1197f9a8-b19f-4c23-bcd5-7fd7fc74d954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_6a806f25-412f-4eda-8437-81fbeb0cb4b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_f448336f-ae39-4cf1-8694-3ff835bada89" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_6a806f25-412f-4eda-8437-81fbeb0cb4b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_26b593af-961a-4751-8cb2-a25ebf478c69" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_36ef156e-d039-42d0-912e-5abb0b3268e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_26b593af-961a-4751-8cb2-a25ebf478c69" xlink:to="loc_ifrs-full_ProfitLoss_36ef156e-d039-42d0-912e-5abb0b3268e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_98eef2a0-90af-4148-8f07-abdcfd7cd1e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_26b593af-961a-4751-8cb2-a25ebf478c69" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_98eef2a0-90af-4148-8f07-abdcfd7cd1e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_3b7a0eaf-cd7b-4af9-b75d-4efa94e357d9" xlink:href="oncyf-20221231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_26b593af-961a-4751-8cb2-a25ebf478c69" xlink:to="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_3b7a0eaf-cd7b-4af9-b75d-4efa94e357d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_9afe4b02-2ea4-434d-829e-6e2177331cc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_26b593af-961a-4751-8cb2-a25ebf478c69" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_9afe4b02-2ea4-434d-829e-6e2177331cc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_da90b305-4194-404a-8afa-3b05aae5bc3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_26b593af-961a-4751-8cb2-a25ebf478c69" xlink:to="loc_ifrs-full_InterestRevenueExpense_da90b305-4194-404a-8afa-3b05aae5bc3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_c10764f2-c9ff-411c-9105-745418c2af1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_26b593af-961a-4751-8cb2-a25ebf478c69" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_c10764f2-c9ff-411c-9105-745418c2af1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_f8fc6dc1-d5c7-451b-ad5e-4ae06f4a0c43" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_26b593af-961a-4751-8cb2-a25ebf478c69" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_f8fc6dc1-d5c7-451b-ad5e-4ae06f4a0c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_bacaff5b-6405-44b3-ae12-ea9a5a7049e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_26b593af-961a-4751-8cb2-a25ebf478c69" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_bacaff5b-6405-44b3-ae12-ea9a5a7049e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_99416173-8a52-4949-be02-135ab5666dcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_afd835f7-e286-42d2-a20f-53c355e12c56" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_99416173-8a52-4949-be02-135ab5666dcc" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_afd835f7-e286-42d2-a20f-53c355e12c56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_0d8845a4-3343-42ba-b6e7-75b265e8a40b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_99416173-8a52-4949-be02-135ab5666dcc" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_0d8845a4-3343-42ba-b6e7-75b265e8a40b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_f78e97d4-3134-41ed-868b-6a72e3bc8a22" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_35dcdd94-3098-4d3c-b4dd-8ca33ec51db0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_f78e97d4-3134-41ed-868b-6a72e3bc8a22" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_35dcdd94-3098-4d3c-b4dd-8ca33ec51db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_bcf66b6e-48c7-4a72-a475-3df3cdaa5db0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_f78e97d4-3134-41ed-868b-6a72e3bc8a22" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_bcf66b6e-48c7-4a72-a475-3df3cdaa5db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_32d837ce-660b-4def-8017-350349ee8f88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_f78e97d4-3134-41ed-868b-6a72e3bc8a22" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_32d837ce-660b-4def-8017-350349ee8f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_43a77ccc-e25b-45f0-8edf-9d545e3d6662" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_e46e3b5a-829a-43f9-93f3-a75680e3e850" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_43a77ccc-e25b-45f0-8edf-9d545e3d6662" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_e46e3b5a-829a-43f9-93f3-a75680e3e850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_195fad55-b3ae-4dfc-b716-7ace800e71b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_43a77ccc-e25b-45f0-8edf-9d545e3d6662" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_195fad55-b3ae-4dfc-b716-7ace800e71b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_bdbef811-b97b-4905-bd5c-5001e0973e86" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_43a77ccc-e25b-45f0-8edf-9d545e3d6662" xlink:to="loc_ifrs-full_CashOutflowForLeases_bdbef811-b97b-4905-bd5c-5001e0973e86" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_37655313-475c-415c-97f6-8e2df610ce9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_e6872aff-fe0c-460d-ab15-90593bc51059" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_37655313-475c-415c-97f6-8e2df610ce9a" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_e6872aff-fe0c-460d-ab15-90593bc51059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_741af619-a489-4bef-ae3b-43e1c8dca6b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_37655313-475c-415c-97f6-8e2df610ce9a" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_741af619-a489-4bef-ae3b-43e1c8dca6b8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_b7d981e1-c053-4aae-bdf3-a36bd32000c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_f0dc22cd-8e8f-4545-8b04-eed8bac462f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b7d981e1-c053-4aae-bdf3-a36bd32000c8" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_f0dc22cd-8e8f-4545-8b04-eed8bac462f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_7362f004-96b3-4dbf-8cfe-d9eab2dd61a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b7d981e1-c053-4aae-bdf3-a36bd32000c8" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_7362f004-96b3-4dbf-8cfe-d9eab2dd61a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_1f325516-27e8-4cf3-ba5b-9d13e50af1b9" xlink:href="oncyf-20221231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b7d981e1-c053-4aae-bdf3-a36bd32000c8" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_1f325516-27e8-4cf3-ba5b-9d13e50af1b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools_232a38b3-1748-4552-84fb-fc0ee6458af7" xlink:href="oncyf-20221231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b7d981e1-c053-4aae-bdf3-a36bd32000c8" xlink:to="loc_oncyf_TaxEffectOfTaxPools_232a38b3-1748-4552-84fb-fc0ee6458af7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_9fc792e9-686e-4d91-b7b9-0e8eb769a0ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b7d981e1-c053-4aae-bdf3-a36bd32000c8" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_9fc792e9-686e-4d91-b7b9-0e8eb769a0ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_56e1deb4-3b76-40a6-a385-e84f41050c88" xlink:href="oncyf-20221231.xsd#oncyf_TaxEffectOfExpirationOfTaxBenefits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b7d981e1-c053-4aae-bdf3-a36bd32000c8" xlink:to="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_56e1deb4-3b76-40a6-a385-e84f41050c88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_e7893b88-d7b3-4f7e-9f3b-2e0121a949db" xlink:href="oncyf-20221231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b7d981e1-c053-4aae-bdf3-a36bd32000c8" xlink:to="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_e7893b88-d7b3-4f7e-9f3b-2e0121a949db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_51ab0f85-18d3-47ed-b39f-865d92dccfef" xlink:href="oncyf-20221231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_b7d981e1-c053-4aae-bdf3-a36bd32000c8" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_51ab0f85-18d3-47ed-b39f-865d92dccfef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_bb72292e-7299-4c29-a488-86e15f2f1e46" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_3ff498a4-1bd7-4c41-b5ad-6796cec998e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_bb72292e-7299-4c29-a488-86e15f2f1e46" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_3ff498a4-1bd7-4c41-b5ad-6796cec998e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_c4d4d976-e5d4-4b39-81b3-3112965b4708" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_bb72292e-7299-4c29-a488-86e15f2f1e46" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_c4d4d976-e5d4-4b39-81b3-3112965b4708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_a844ede8-0424-42ba-803d-3572c5da266c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_bb72292e-7299-4c29-a488-86e15f2f1e46" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_a844ede8-0424-42ba-803d-3572c5da266c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_d4d0a1d7-75fd-4193-9fb2-763d8dff3bc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_bb72292e-7299-4c29-a488-86e15f2f1e46" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_d4d0a1d7-75fd-4193-9fb2-763d8dff3bc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_f683d0e1-7fca-482f-bef6-7f322d1369ff" xlink:href="oncyf-20221231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_bb72292e-7299-4c29-a488-86e15f2f1e46" xlink:to="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_f683d0e1-7fca-482f-bef6-7f322d1369ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_890cc271-8c80-4ae8-9857-b5835a5af6d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_536b3198-7331-4a87-b71f-0993ffea26f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_890cc271-8c80-4ae8-9857-b5835a5af6d5" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_536b3198-7331-4a87-b71f-0993ffea26f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_6885a438-8e72-494f-8408-3ab21c8f6775" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_890cc271-8c80-4ae8-9857-b5835a5af6d5" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_6885a438-8e72-494f-8408-3ab21c8f6775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_a22b28bf-fa1b-4a27-abe1-52d03f6f1d96" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_890cc271-8c80-4ae8-9857-b5835a5af6d5" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_a22b28bf-fa1b-4a27-abe1-52d03f6f1d96" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>oncyf-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:63a935b1-1650-41e1-88a0-4b019d55689c,g:0488272c-958a-4da8-b3e7-8a139968e8c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="simple" xlink:href="oncyf-20221231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="extended" id="ib3c020fc13b146c588770a28c78d746c_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2ab59305-68dd-43cc-adf8-5f63f00b07a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentType_2ab59305-68dd-43cc-adf8-5f63f00b07a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_14999a28-b035-4ef8-908a-95e98c9e19cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentRegistrationStatement_14999a28-b035-4ef8-908a-95e98c9e19cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_9ced5cc9-dcfb-4d3a-898e-819d5b713647" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentAnnualReport_9ced5cc9-dcfb-4d3a-898e-819d5b713647" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d98dfb90-ed56-4ef0-9e3e-64335967cecc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentPeriodEndDate_d98dfb90-ed56-4ef0-9e3e-64335967cecc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8aca0603-43c3-49f1-8e36-ed325de50987" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_CurrentFiscalYearEndDate_8aca0603-43c3-49f1-8e36-ed325de50987" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_170e42ac-255b-4135-b820-f4792e6d4ef5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentTransitionReport_170e42ac-255b-4135-b820-f4792e6d4ef5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_e1608f78-f5a2-4dc0-b087-2789168a6650" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentShellCompanyReport_e1608f78-f5a2-4dc0-b087-2789168a6650" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6b4270e8-1073-465a-8445-3c932a22fe67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityFileNumber_6b4270e8-1073-465a-8445-3c932a22fe67" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_073653ad-6bf3-4577-a2fd-595bbf731b0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityRegistrantName_073653ad-6bf3-4577-a2fd-595bbf731b0a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c175f6ea-ffc6-4636-aa52-2aa4d75521ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c175f6ea-ffc6-4636-aa52-2aa4d75521ae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1c75a068-d252-4f83-b67b-3bb39ffad6e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityAddressAddressLine1_1c75a068-d252-4f83-b67b-3bb39ffad6e8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2ca6fa57-12f5-41e2-8b72-7b5c9957c029" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityAddressCityOrTown_2ca6fa57-12f5-41e2-8b72-7b5c9957c029" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5f13a920-897c-48ff-b29a-ef1f75f56c61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityAddressStateOrProvince_5f13a920-897c-48ff-b29a-ef1f75f56c61" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_9e6b2a89-f7b5-411c-8901-b19edddfd62f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityAddressCountry_9e6b2a89-f7b5-411c-8901-b19edddfd62f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8bec47a9-0340-4fa2-bb5a-f962d4b65ff0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityAddressPostalZipCode_8bec47a9-0340-4fa2-bb5a-f962d4b65ff0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_2d4980fe-5170-4902-a0fc-ef7cc9c6a93a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_ContactPersonnelName_2d4980fe-5170-4902-a0fc-ef7cc9c6a93a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_697b9919-aa2e-4492-9c9c-6caa485ef2e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_CityAreaCode_697b9919-aa2e-4492-9c9c-6caa485ef2e3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_52922b70-b738-44f3-887e-c7292df9e645" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_LocalPhoneNumber_52922b70-b738-44f3-887e-c7292df9e645" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress_b5d8c08a-af97-40cd-b6b5-642da7fc7e74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_ContactPersonnelEmailAddress_b5d8c08a-af97-40cd-b6b5-642da7fc7e74" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c6dd71e8-83d2-4803-9375-74aed3073231" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_Security12bTitle_c6dd71e8-83d2-4803-9375-74aed3073231" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d5017ca0-81f8-4508-b934-315d896571da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_TradingSymbol_d5017ca0-81f8-4508-b934-315d896571da" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_06e3d239-44bf-4b06-bfb8-e01c90efe1cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_SecurityExchangeName_06e3d239-44bf-4b06-bfb8-e01c90efe1cd" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d243a5bd-5768-442f-bf72-ff59bd096bff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d243a5bd-5768-442f-bf72-ff59bd096bff" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9ae064ef-4fc4-453f-a977-eb2d8a3c74d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9ae064ef-4fc4-453f-a977-eb2d8a3c74d6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_9188bca7-0318-4c08-a4e5-170dc35d5b19" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityVoluntaryFilers_9188bca7-0318-4c08-a4e5-170dc35d5b19" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6ea9d224-f4fe-40b3-a429-9323f608bdea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityCurrentReportingStatus_6ea9d224-f4fe-40b3-a429-9323f608bdea" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4271da10-5082-4a19-9436-f1c8574c09f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityInteractiveDataCurrent_4271da10-5082-4a19-9436-f1c8574c09f1" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e3638092-dc49-4b65-a27e-b74c44cef3e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityFilerCategory_e3638092-dc49-4b65-a27e-b74c44cef3e1" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9dbc65d6-d5c1-4661-8ebb-2218a8a36a2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityEmergingGrowthCompany_9dbc65d6-d5c1-4661-8ebb-2218a8a36a2b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_d3bd9bce-4fdf-4072-9cbb-3669e2142b2c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_IcfrAuditorAttestationFlag_d3bd9bce-4fdf-4072-9cbb-3669e2142b2c" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_60233f11-645a-42c7-98b5-f08d6ab969b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentAccountingStandard_60233f11-645a-42c7-98b5-f08d6ab969b0" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1c3529d2-5f9d-4173-a12e-33ca95ab1831" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityShellCompany_1c3529d2-5f9d-4173-a12e-33ca95ab1831" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ca88c503-8373-4f5a-b25a-783126a89c81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityCentralIndexKey_ca88c503-8373-4f5a-b25a-783126a89c81" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0fecea22-85aa-4d19-a1e6-5c1abd76ca51" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentFiscalYearFocus_0fecea22-85aa-4d19-a1e6-5c1abd76ca51" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b33814db-a5ff-4234-b24e-4fd4c937e4a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b33814db-a5ff-4234-b24e-4fd4c937e4a7" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3c22d76f-d5f1-46d7-9252-c9394d2996fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_AmendmentFlag_3c22d76f-d5f1-46d7-9252-c9394d2996fe" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_66d40515-536d-4a21-adc6-488198181a52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityPublicFloat_66d40515-536d-4a21-adc6-488198181a52" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_f44ae470-c02a-4235-abe3-527f283bb3a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentInformationTable_f44ae470-c02a-4235-abe3-527f283bb3a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_983646b5-fe90-4799-975d-f960d45b623b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_f44ae470-c02a-4235-abe3-527f283bb3a6" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_983646b5-fe90-4799-975d-f960d45b623b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_983646b5-fe90-4799-975d-f960d45b623b_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_983646b5-fe90-4799-975d-f960d45b623b" xlink:to="loc_dei_AddressTypeDomain_983646b5-fe90-4799-975d-f960d45b623b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_31f16624-623c-4ab2-b0cd-cca504963c4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_983646b5-fe90-4799-975d-f960d45b623b" xlink:to="loc_dei_AddressTypeDomain_31f16624-623c-4ab2-b0cd-cca504963c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_0fd5a68a-e3ce-40ed-8a3f-94dab2758c61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_31f16624-623c-4ab2-b0cd-cca504963c4b" xlink:to="loc_dei_BusinessContactMember_0fd5a68a-e3ce-40ed-8a3f-94dab2758c61" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended" id="i812d1cf05eda49a98afa8c469f3d3418_CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_3e76ebf7-05ac-4391-ac8d-56fc0133125d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_Equity_3e76ebf7-05ac-4391-ac8d-56fc0133125d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_c807b641-30c1-4e0a-a529-8a614c3e7d35" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_ComprehensiveIncome_c807b641-30c1-4e0a-a529-8a614c3e7d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_e0a775d3-ba22-4776-ab84-40f4a5213638" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_e0a775d3-ba22-4776-ab84-40f4a5213638" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_5c361ec8-b162-46f0-ae74-4c72359f1992" xlink:href="oncyf-20221231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_5c361ec8-b162-46f0-ae74-4c72359f1992" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_b86f4ffb-ad9c-41a3-aa30-87fa0d9387b3" xlink:href="oncyf-20221231.xsd#oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_b86f4ffb-ad9c-41a3-aa30-87fa0d9387b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_a6d6ea87-3043-4009-be1b-a0d1ce5f3335" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_IssueOfEquity_a6d6ea87-3043-4009-be1b-a0d1ce5f3335" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_6799635e-165d-4022-b3ee-08ae4ca61fc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_6799635e-165d-4022-b3ee-08ae4ca61fc1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_06522490-4fc0-4955-b72c-34ae40a8e1c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_06522490-4fc0-4955-b72c-34ae40a8e1c3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_1feeb2b9-91b5-4f4e-9d20-bf38e614974b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_1feeb2b9-91b5-4f4e-9d20-bf38e614974b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_ded9a66d-53a9-470c-b322-3ba28df6cecb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_377d410d-63ee-4b13-8f4d-63739acd75af" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_377d410d-63ee-4b13-8f4d-63739acd75af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_239c8528-d122-4e8f-ac85-7e790c6fba9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_377d410d-63ee-4b13-8f4d-63739acd75af" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_239c8528-d122-4e8f-ac85-7e790c6fba9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_239c8528-d122-4e8f-ac85-7e790c6fba9f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_239c8528-d122-4e8f-ac85-7e790c6fba9f" xlink:to="loc_ifrs-full_EquityMember_239c8528-d122-4e8f-ac85-7e790c6fba9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_239c8528-d122-4e8f-ac85-7e790c6fba9f" xlink:to="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_f84f411f-739f-4350-989e-31a23b8d6044" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:to="loc_ifrs-full_IssuedCapitalMember_f84f411f-739f-4350-989e-31a23b8d6044" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_b32c4d5a-aadf-4439-96a9-7d69c9694ee0" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:to="loc_oncyf_WarrantsMember_b32c4d5a-aadf-4439-96a9-7d69c9694ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_b9b1d52a-d90d-4593-bad3-f5464b040b8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:to="loc_ifrs-full_SharePremiumMember_b9b1d52a-d90d-4593-bad3-f5464b040b8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_21460ec9-a96d-4cd8-90ba-26820c88258c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_21460ec9-a96d-4cd8-90ba-26820c88258c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_875964cc-6b41-4854-9137-3c22096fd22e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:to="loc_ifrs-full_RetainedEarningsMember_875964cc-6b41-4854-9137-3c22096fd22e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_4915bcb4-0bae-4e93-9575-d43b90dc525a" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_377d410d-63ee-4b13-8f4d-63739acd75af" xlink:to="loc_oncyf_SaleOfStockAxis_4915bcb4-0bae-4e93-9575-d43b90dc525a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_4915bcb4-0bae-4e93-9575-d43b90dc525a_default" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_4915bcb4-0bae-4e93-9575-d43b90dc525a" xlink:to="loc_oncyf_SaleOfStockDomain_4915bcb4-0bae-4e93-9575-d43b90dc525a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_c51f8433-ccff-469f-a9d0-89f173f89dd9" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_4915bcb4-0bae-4e93-9575-d43b90dc525a" xlink:to="loc_oncyf_SaleOfStockDomain_c51f8433-ccff-469f-a9d0-89f173f89dd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_220798e3-96c8-4fd2-86b9-72b6cddab8ab" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_c51f8433-ccff-469f-a9d0-89f173f89dd9" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_220798e3-96c8-4fd2-86b9-72b6cddab8ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="ibad8037d2a4b44778c8ecd4e3a420f51_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:href="oncyf-20221231.xsd#oncyf_Statement1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_29149144-9b4a-49b2-a9a7-77c3a10c9ad4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_ProfitLoss_29149144-9b4a-49b2-a9a7-77c3a10c9ad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_aaa34943-59dd-4cdf-90dd-9e78c7416d0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_aaa34943-59dd-4cdf-90dd-9e78c7416d0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_e750e7b1-f3af-4312-ab0c-90619df7f01c" xlink:href="oncyf-20221231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_e750e7b1-f3af-4312-ab0c-90619df7f01c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_ca5cfcbc-ff61-4583-9701-ad4d17003ce1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_ca5cfcbc-ff61-4583-9701-ad4d17003ce1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_fa61d9ea-0b9a-4cd9-a84a-e0c2ea918ace" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_InterestRevenueExpense_fa61d9ea-0b9a-4cd9-a84a-e0c2ea918ace" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_68427d57-569c-45d3-a919-5d999632802d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_68427d57-569c-45d3-a919-5d999632802d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_d00cd239-cdf3-4363-aeaf-27027bc75672" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_d00cd239-cdf3-4363-aeaf-27027bc75672" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_83b3624b-a8d9-4c7e-8278-7b2e516f83cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_83b3624b-a8d9-4c7e-8278-7b2e516f83cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_8736868e-cc2b-48d1-a112-9562c27b28a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_8736868e-cc2b-48d1-a112-9562c27b28a8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_a67901b0-1d50-44bd-94ca-b2a41821a39d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_a67901b0-1d50-44bd-94ca-b2a41821a39d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_91bf568a-a3c2-4f8d-8d25-9c463f90d001" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_a67901b0-1d50-44bd-94ca-b2a41821a39d" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_91bf568a-a3c2-4f8d-8d25-9c463f90d001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_add8cb23-06b9-433c-8884-f59b6bf4d688" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_a67901b0-1d50-44bd-94ca-b2a41821a39d" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_add8cb23-06b9-433c-8884-f59b6bf4d688" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7738fd44-223c-43fc-9aa0-3ce06478429b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_a67901b0-1d50-44bd-94ca-b2a41821a39d" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7738fd44-223c-43fc-9aa0-3ce06478429b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b49d250c-65ce-495b-908d-e94c7ed93dea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b49d250c-65ce-495b-908d-e94c7ed93dea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_2689de68-66a7-4085-90f9-846f737b2266" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b49d250c-65ce-495b-908d-e94c7ed93dea" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_2689de68-66a7-4085-90f9-846f737b2266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1efe7495-23b0-4cc0-a15a-2f623b116ca2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b49d250c-65ce-495b-908d-e94c7ed93dea" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_1efe7495-23b0-4cc0-a15a-2f623b116ca2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_fc4e3011-de3c-40c9-a67a-11865878824e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b49d250c-65ce-495b-908d-e94c7ed93dea" xlink:to="loc_ifrs-full_CashOutflowForLeases_fc4e3011-de3c-40c9-a67a-11865878824e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_7d325172-61a0-419f-8206-a3da754bcb28" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b49d250c-65ce-495b-908d-e94c7ed93dea" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_7d325172-61a0-419f-8206-a3da754bcb28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_c4b6dcbf-8484-4d55-9732-eff2e5ad8b02" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_c4b6dcbf-8484-4d55-9732-eff2e5ad8b02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_965f2000-f154-4879-ab3e-a5f2197a8b35" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_CashAndCashEquivalents_965f2000-f154-4879-ab3e-a5f2197a8b35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_cc3b0ccf-f99b-4a6a-8881-08b25c08db93" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_cc3b0ccf-f99b-4a6a-8881-08b25c08db93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_4d3b23db-2f06-403f-95c6-9cbff9a0be86" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table_b7567ea8-25e4-4010-a51a-0267a11a83b4" xlink:href="oncyf-20221231.xsd#oncyf_Statement1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_oncyf_Statement1Table_b7567ea8-25e4-4010-a51a-0267a11a83b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_84b8d29d-5800-4d3e-8746-ab66980ce1db" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Statement1Table_b7567ea8-25e4-4010-a51a-0267a11a83b4" xlink:to="loc_oncyf_SaleOfStockAxis_84b8d29d-5800-4d3e-8746-ab66980ce1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_84b8d29d-5800-4d3e-8746-ab66980ce1db_default" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_84b8d29d-5800-4d3e-8746-ab66980ce1db" xlink:to="loc_oncyf_SaleOfStockDomain_84b8d29d-5800-4d3e-8746-ab66980ce1db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_32d64b49-abe3-4e4a-a2b2-822d4d6e5c9c" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_84b8d29d-5800-4d3e-8746-ab66980ce1db" xlink:to="loc_oncyf_SaleOfStockDomain_32d64b49-abe3-4e4a-a2b2-822d4d6e5c9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_0f93f981-1812-4419-bb9d-1fbb1779d9b7" xlink:href="oncyf-20221231.xsd#oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_32d64b49-abe3-4e4a-a2b2-822d4d6e5c9c" xlink:to="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_0f93f981-1812-4419-bb9d-1fbb1779d9b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_640d7b24-3e27-4ac5-bf58-733c9b70b2ed" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_32d64b49-abe3-4e4a-a2b2-822d4d6e5c9c" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_640d7b24-3e27-4ac5-bf58-733c9b70b2ed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="extended" id="if1f338a4d15749409b4b99781c08c7de_SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b6dfe65a-d8c1-4f3f-8bfb-cfa4a80daab9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_7c5eb7d0-b4fd-4e5a-9c45-ef2960b46152" xlink:href="oncyf-20221231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b6dfe65a-d8c1-4f3f-8bfb-cfa4a80daab9" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_7c5eb7d0-b4fd-4e5a-9c45-ef2960b46152" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69d5c0ef-c3d2-4724-986f-848ab20a8328" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b6dfe65a-d8c1-4f3f-8bfb-cfa4a80daab9" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69d5c0ef-c3d2-4724-986f-848ab20a8328" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ed6566ff-77a7-4e55-90c3-4f2259c91099" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69d5c0ef-c3d2-4724-986f-848ab20a8328" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ed6566ff-77a7-4e55-90c3-4f2259c91099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_ed6566ff-77a7-4e55-90c3-4f2259c91099_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ed6566ff-77a7-4e55-90c3-4f2259c91099" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_ed6566ff-77a7-4e55-90c3-4f2259c91099_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_99feb80d-32f6-493a-a74c-80fb5969c88e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ed6566ff-77a7-4e55-90c3-4f2259c91099" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_99feb80d-32f6-493a-a74c-80fb5969c88e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_c6bb702b-f9b0-40c1-b74b-18d91df13d85" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_99feb80d-32f6-493a-a74c-80fb5969c88e" xlink:to="loc_ifrs-full_OfficeEquipmentMember_c6bb702b-f9b0-40c1-b74b-18d91df13d85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_f2b52223-a0c7-48c7-b9dc-6706b3e62027" xlink:href="oncyf-20221231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_99feb80d-32f6-493a-a74c-80fb5969c88e" xlink:to="loc_oncyf_MedicalEquipmentMember_f2b52223-a0c7-48c7-b9dc-6706b3e62027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_4c82c548-3ecb-42b0-8c06-6363abe2e34f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_99feb80d-32f6-493a-a74c-80fb5969c88e" xlink:to="loc_ifrs-full_ComputerEquipmentMember_4c82c548-3ecb-42b0-8c06-6363abe2e34f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#OtherAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails" xlink:type="extended" id="i6b2f13955b124d2cb2730180329c5b44_OtherAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_1a411410-8120-4834-a29a-eeaf4186f3da" xlink:href="oncyf-20221231.xsd#oncyf_Currency1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_3964171e-d2fc-49c0-aacd-236bc66e62d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_1a411410-8120-4834-a29a-eeaf4186f3da" xlink:to="loc_ifrs-full_OtherReceivables_3964171e-d2fc-49c0-aacd-236bc66e62d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_aa9ad035-8e25-4fac-8768-b290946eee5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_1a411410-8120-4834-a29a-eeaf4186f3da" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_aa9ad035-8e25-4fac-8768-b290946eee5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_4f751cf7-c154-415f-bc55-e5d37a0ea27c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_1a411410-8120-4834-a29a-eeaf4186f3da" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_4f751cf7-c154-415f-bc55-e5d37a0ea27c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPrepayments_ef5cb532-384c-4aec-958b-e00bc630218b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_1a411410-8120-4834-a29a-eeaf4186f3da" xlink:to="loc_ifrs-full_NoncurrentPrepayments_ef5cb532-384c-4aec-958b-e00bc630218b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_1aaf37a2-c2c3-4832-bc33-1a64ed462e96" xlink:href="oncyf-20221231.xsd#oncyf_Currency1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Currency1LineItems_1a411410-8120-4834-a29a-eeaf4186f3da" xlink:to="loc_oncyf_Currency1Table_1aaf37a2-c2c3-4832-bc33-1a64ed462e96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_4f07fa00-d549-4548-ae40-e1646340bfc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Currency1Table_1aaf37a2-c2c3-4832-bc33-1a64ed462e96" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_4f07fa00-d549-4548-ae40-e1646340bfc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_4f07fa00-d549-4548-ae40-e1646340bfc5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_4f07fa00-d549-4548-ae40-e1646340bfc5" xlink:to="loc_ifrs-full_OtherProvisionsMember_4f07fa00-d549-4548-ae40-e1646340bfc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_b51d5c7b-1a0e-462d-9efb-87f110f331e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_4f07fa00-d549-4548-ae40-e1646340bfc5" xlink:to="loc_ifrs-full_OtherProvisionsMember_b51d5c7b-1a0e-462d-9efb-87f110f331e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CollaborationAgreementMember_96bc9724-8a04-4122-a410-b1373e83a8fd" xlink:href="oncyf-20221231.xsd#oncyf_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_b51d5c7b-1a0e-462d-9efb-87f110f331e8" xlink:to="loc_oncyf_CollaborationAgreementMember_96bc9724-8a04-4122-a410-b1373e83a8fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="i0b2a6944667f4a0ab75e9c7b76ea8c48_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9febe0cd-de73-49ac-8164-e5685e45b011" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9febe0cd-de73-49ac-8164-e5685e45b011" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_a10f6f54-fd85-4e6c-bb05-b597240b9a88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_a10f6f54-fd85-4e6c-bb05-b597240b9a88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_d58e5f06-2801-488d-939b-d0ac92f452d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_d58e5f06-2801-488d-939b-d0ac92f452d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_c57082ff-cceb-401e-8e0e-b0b30d64caab" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_c57082ff-cceb-401e-8e0e-b0b30d64caab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_c2d68ffa-7983-4281-83b7-c06a223dc611" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_c2d68ffa-7983-4281-83b7-c06a223dc611" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_dd7cc258-fea2-4eb2-8437-c0a673af57f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_41bd974c-3a6f-4594-bd21-7656a44ec1fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9febe0cd-de73-49ac-8164-e5685e45b011" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_41bd974c-3a6f-4594-bd21-7656a44ec1fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eb9e9caa-89c0-4507-86dd-4b71c2c7a392" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_41bd974c-3a6f-4594-bd21-7656a44ec1fc" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eb9e9caa-89c0-4507-86dd-4b71c2c7a392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_eb9e9caa-89c0-4507-86dd-4b71c2c7a392_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eb9e9caa-89c0-4507-86dd-4b71c2c7a392" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_eb9e9caa-89c0-4507-86dd-4b71c2c7a392_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_ea9cc01f-159f-486e-b792-96a4956234ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eb9e9caa-89c0-4507-86dd-4b71c2c7a392" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_ea9cc01f-159f-486e-b792-96a4956234ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_4b321f66-3602-407a-a9e7-5a0bd792b4e0" xlink:href="oncyf-20221231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_ea9cc01f-159f-486e-b792-96a4956234ef" xlink:to="loc_oncyf_MedicalEquipmentMember_4b321f66-3602-407a-a9e7-5a0bd792b4e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_61e55cd0-0f0b-40c2-8538-1e7274018b40" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_ea9cc01f-159f-486e-b792-96a4956234ef" xlink:to="loc_ifrs-full_ComputerEquipmentMember_61e55cd0-0f0b-40c2-8538-1e7274018b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeEquipmentAndFurnitureMember_a36b6287-0a86-4bcb-96f6-3c285879bd45" xlink:href="oncyf-20221231.xsd#oncyf_OfficeEquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_ea9cc01f-159f-486e-b792-96a4956234ef" xlink:to="loc_oncyf_OfficeEquipmentAndFurnitureMember_a36b6287-0a86-4bcb-96f6-3c285879bd45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_867fd38c-0591-4d25-8573-4ac66f977789" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_ea9cc01f-159f-486e-b792-96a4956234ef" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_867fd38c-0591-4d25-8573-4ac66f977789" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_db361485-54b9-4dd1-95b5-0de55a65ab90" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_41bd974c-3a6f-4594-bd21-7656a44ec1fc" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_db361485-54b9-4dd1-95b5-0de55a65ab90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_db361485-54b9-4dd1-95b5-0de55a65ab90_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_db361485-54b9-4dd1-95b5-0de55a65ab90" xlink:to="loc_ifrs-full_CarryingAmountMember_db361485-54b9-4dd1-95b5-0de55a65ab90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_01253023-624d-40af-bc30-7d6c2daf6226" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_db361485-54b9-4dd1-95b5-0de55a65ab90" xlink:to="loc_ifrs-full_CarryingAmountMember_01253023-624d-40af-bc30-7d6c2daf6226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_161a2b24-44ae-441d-b9bd-31eff51e3913" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_01253023-624d-40af-bc30-7d6c2daf6226" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_161a2b24-44ae-441d-b9bd-31eff51e3913" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_6edda9b6-5237-4d5b-897e-22331f59643d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_01253023-624d-40af-bc30-7d6c2daf6226" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_6edda9b6-5237-4d5b-897e-22331f59643d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended" id="idd60ad1cd17a4337b336e406ae6e8029_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_06f6ccb5-6e22-4d77-b214-a2edb37af15a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm_bd5a2e2a-dc11-43b4-af75-642e1e52ced9" xlink:href="oncyf-20221231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_06f6ccb5-6e22-4d77-b214-a2edb37af15a" xlink:to="loc_oncyf_OperatingLeaseRemainingLeaseTerm_bd5a2e2a-dc11-43b4-af75-642e1e52ced9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_36b40830-ee71-4781-a6f8-f312919ad842" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_06f6ccb5-6e22-4d77-b214-a2edb37af15a" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_36b40830-ee71-4781-a6f8-f312919ad842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d17a916-2b92-493a-ad91-aeed1b191ffa" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_06f6ccb5-6e22-4d77-b214-a2edb37af15a" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d17a916-2b92-493a-ad91-aeed1b191ffa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8ad7c4c0-cdf2-4967-839e-d76bf62dc112" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d17a916-2b92-493a-ad91-aeed1b191ffa" xlink:to="loc_srt_RangeAxis_8ad7c4c0-cdf2-4967-839e-d76bf62dc112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ad7c4c0-cdf2-4967-839e-d76bf62dc112_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8ad7c4c0-cdf2-4967-839e-d76bf62dc112" xlink:to="loc_srt_RangeMember_8ad7c4c0-cdf2-4967-839e-d76bf62dc112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f742ccb-521f-40e1-b486-df5ec49659e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8ad7c4c0-cdf2-4967-839e-d76bf62dc112" xlink:to="loc_srt_RangeMember_7f742ccb-521f-40e1-b486-df5ec49659e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b1beb32c-a988-4457-9a00-d50815b875f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7f742ccb-521f-40e1-b486-df5ec49659e6" xlink:to="loc_srt_MinimumMember_b1beb32c-a988-4457-9a00-d50815b875f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a9f0561d-e592-43a5-961c-c84456515655" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7f742ccb-521f-40e1-b486-df5ec49659e6" xlink:to="loc_srt_MaximumMember_a9f0561d-e592-43a5-961c-c84456515655" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended" id="i0b005cf52a4c4de19e5812f940b0fa0d_LeasesTotalUndiscountedLeaseLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_037a083c-9938-4a7e-a515-d48fc219f8ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_00bfcc39-3d96-48f7-a9ad-ef3220334bdb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_037a083c-9938-4a7e-a515-d48fc219f8ce" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_00bfcc39-3d96-48f7-a9ad-ef3220334bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_40c37db2-190b-4f90-a924-6aad418eb1db" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_037a083c-9938-4a7e-a515-d48fc219f8ce" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_40c37db2-190b-4f90-a924-6aad418eb1db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_a73be13b-0717-4f93-9226-87241b318f2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_40c37db2-190b-4f90-a924-6aad418eb1db" xlink:to="loc_ifrs-full_MaturityAxis_a73be13b-0717-4f93-9226-87241b318f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_a73be13b-0717-4f93-9226-87241b318f2e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_a73be13b-0717-4f93-9226-87241b318f2e" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_a73be13b-0717-4f93-9226-87241b318f2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_66432636-85a2-41bb-8d6c-0944c2aaf2c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_a73be13b-0717-4f93-9226-87241b318f2e" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_66432636-85a2-41bb-8d6c-0944c2aaf2c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_74c45163-fdd9-4817-8270-468d385d78a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_66432636-85a2-41bb-8d6c-0944c2aaf2c6" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_74c45163-fdd9-4817-8270-468d385d78a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_347e87f7-bd0e-408d-8ec8-d868d80d17f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_66432636-85a2-41bb-8d6c-0944c2aaf2c6" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_347e87f7-bd0e-408d-8ec8-d868d80d17f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_40369ea9-bfae-4065-87f5-ac87d7f4b0d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_66432636-85a2-41bb-8d6c-0944c2aaf2c6" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_40369ea9-bfae-4065-87f5-ac87d7f4b0d8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareCapitalScheduleofShareCapitalDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="extended" id="i11ea9601283c4c329ce5e723c569268c_ShareCapitalScheduleofShareCapitalDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1679ad8c-4184-4dcc-a2f1-cac6619ae9b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalNumberSharesAbstract_d436920d-2c5a-47eb-9dfa-2c4a33c9d907" xlink:href="oncyf-20221231.xsd#oncyf_ShareCapitalNumberSharesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1679ad8c-4184-4dcc-a2f1-cac6619ae9b1" xlink:to="loc_oncyf_ShareCapitalNumberSharesAbstract_d436920d-2c5a-47eb-9dfa-2c4a33c9d907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_4f8b2f1a-2c9b-48ac-8d91-7b78168b9797" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_d436920d-2c5a-47eb-9dfa-2c4a33c9d907" xlink:to="loc_ifrs-full_NumberOfSharesIssued_4f8b2f1a-2c9b-48ac-8d91-7b78168b9797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_fb6862ea-eee9-42ef-8d69-01e66e0b8e56" xlink:href="oncyf-20221231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_d436920d-2c5a-47eb-9dfa-2c4a33c9d907" xlink:to="loc_oncyf_IssueOfEquityShares_fb6862ea-eee9-42ef-8d69-01e66e0b8e56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_f4895457-7846-4aa9-89d8-89e342582809" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalAmountAbstract_4790f534-fffc-4d62-85e1-cdc115c2141f" xlink:href="oncyf-20221231.xsd#oncyf_ShareCapitalAmountAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1679ad8c-4184-4dcc-a2f1-cac6619ae9b1" xlink:to="loc_oncyf_ShareCapitalAmountAbstract_4790f534-fffc-4d62-85e1-cdc115c2141f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_ab9eb5ab-fdd3-4d2b-bf94-04d7cdc1208f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_4790f534-fffc-4d62-85e1-cdc115c2141f" xlink:to="loc_ifrs-full_Equity_ab9eb5ab-fdd3-4d2b-bf94-04d7cdc1208f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_af229bb1-51f6-4006-965d-a5e4a3e5ec67" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_4790f534-fffc-4d62-85e1-cdc115c2141f" xlink:to="loc_ifrs-full_IssueOfEquity_af229bb1-51f6-4006-965d-a5e4a3e5ec67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_3ebddc09-add0-470d-8149-2f43e8d59418" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_4790f534-fffc-4d62-85e1-cdc115c2141f" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_3ebddc09-add0-470d-8149-2f43e8d59418" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5fead105-b563-47e8-ac9e-be2c8bbc6dc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1af78e31-6aa4-4bff-b3fb-86d445963aa0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1679ad8c-4184-4dcc-a2f1-cac6619ae9b1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1af78e31-6aa4-4bff-b3fb-86d445963aa0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_e49bf961-cf9f-4e48-9245-287e756bbda4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1af78e31-6aa4-4bff-b3fb-86d445963aa0" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_e49bf961-cf9f-4e48-9245-287e756bbda4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_e49bf961-cf9f-4e48-9245-287e756bbda4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e49bf961-cf9f-4e48-9245-287e756bbda4" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_e49bf961-cf9f-4e48-9245-287e756bbda4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_2dfff518-ece7-4a86-bb1e-9d9b449c4695" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e49bf961-cf9f-4e48-9245-287e756bbda4" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_2dfff518-ece7-4a86-bb1e-9d9b449c4695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_64f440bc-89e0-4cfe-ad6c-2730200a8167" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_2dfff518-ece7-4a86-bb1e-9d9b449c4695" xlink:to="loc_ifrs-full_IssuedCapitalMember_64f440bc-89e0-4cfe-ad6c-2730200a8167" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_cc83086d-9241-4c31-b165-27c13dc5b785" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1af78e31-6aa4-4bff-b3fb-86d445963aa0" xlink:to="loc_oncyf_SaleOfStockAxis_cc83086d-9241-4c31-b165-27c13dc5b785" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_cc83086d-9241-4c31-b165-27c13dc5b785_default" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_cc83086d-9241-4c31-b165-27c13dc5b785" xlink:to="loc_oncyf_SaleOfStockDomain_cc83086d-9241-4c31-b165-27c13dc5b785_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_7a3d6a1d-0c41-43a7-8f70-33212bf95d89" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_cc83086d-9241-4c31-b165-27c13dc5b785" xlink:to="loc_oncyf_SaleOfStockDomain_7a3d6a1d-0c41-43a7-8f70-33212bf95d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_2c255332-a095-418f-a45e-8169e65039d0" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_7a3d6a1d-0c41-43a7-8f70-33212bf95d89" xlink:to="loc_oncyf_SharesUnderStockOptionPlanMember_2c255332-a095-418f-a45e-8169e65039d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_c089fa6f-6345-4f1f-820d-e74e6c640d6a" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_7a3d6a1d-0c41-43a7-8f70-33212bf95d89" xlink:to="loc_oncyf_SharesUnderIncentiveAwardPlanMember_c089fa6f-6345-4f1f-820d-e74e6c640d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_763cf8dc-c033-4191-aa5c-134f733340e1" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_7a3d6a1d-0c41-43a7-8f70-33212bf95d89" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_763cf8dc-c033-4191-aa5c-134f733340e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_7b898b92-6a67-4c3b-85fa-3702dd1d6573" xlink:href="oncyf-20221231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_7a3d6a1d-0c41-43a7-8f70-33212bf95d89" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_7b898b92-6a67-4c3b-85fa-3702dd1d6573" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareCapitalScheduleofShareCapitalFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="extended" id="i8b3066a151ba489b835a1f9164d96ac1_ShareCapitalScheduleofShareCapitalFootnotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_abc5a18c-1b97-4228-b0a1-47fae7ed147a" xlink:href="oncyf-20221231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_abc5a18c-1b97-4228-b0a1-47fae7ed147a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_4c12930c-5ab6-427b-b672-c729186977c4" xlink:href="oncyf-20221231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_4c12930c-5ab6-427b-b672-c729186977c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_3e6f9cc7-3a4f-4a2a-b4a6-ac3b5532d02d" xlink:href="oncyf-20221231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_IssueOfEquityShares_3e6f9cc7-3a4f-4a2a-b4a6-ac3b5532d02d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_4ed3fedb-6905-4771-aa32-0d4a8618620d" xlink:href="oncyf-20221231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_4ed3fedb-6905-4771-aa32-0d4a8618620d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_6a27ce4d-a8ae-462f-96cc-25ca7b55e336" xlink:href="oncyf-20221231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_6a27ce4d-a8ae-462f-96cc-25ca7b55e336" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_d0e4f6eb-4467-47d5-886d-0958e89cde40" xlink:href="oncyf-20221231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_d0e4f6eb-4467-47d5-886d-0958e89cde40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_8b08efcd-1f38-42d4-94c0-c7059cda3f3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_8b08efcd-1f38-42d4-94c0-c7059cda3f3d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_07388143-fbcd-4f2f-8b2a-d7498e1988c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_07388143-fbcd-4f2f-8b2a-d7498e1988c2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_39c49edd-bd97-4b55-8954-d12e5e2e12a0" xlink:href="oncyf-20221231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_CommonSharesPerUnit_39c49edd-bd97-4b55-8954-d12e5e2e12a0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedFairValueOfCommonShare_457f61c3-8118-44b9-99b5-9fb72fb0d659" xlink:href="oncyf-20221231.xsd#oncyf_SharesIssuedFairValueOfCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_SharesIssuedFairValueOfCommonShare_457f61c3-8118-44b9-99b5-9fb72fb0d659" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_58470cc9-4147-4517-aaf7-e403c7586493" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_58470cc9-4147-4517-aaf7-e403c7586493" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_f822342e-aa47-4047-8232-447014667655" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_f822342e-aa47-4047-8232-447014667655" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_2762413e-cac4-4fd9-93aa-c6b3e5ca3815" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_2762413e-cac4-4fd9-93aa-c6b3e5ca3815" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_c987bf5c-6ea9-47a1-893e-d19ffd9242c8" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_c987bf5c-6ea9-47a1-893e-d19ffd9242c8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_118de2a6-f725-4ade-b498-2b4915dc30ac" xlink:href="oncyf-20221231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_118de2a6-f725-4ade-b498-2b4915dc30ac" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_14798667-2d6e-4d43-9979-e4460f3c55f4" xlink:href="oncyf-20221231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ClassOfWarrantOrRightOutstanding1_14798667-2d6e-4d43-9979-e4460f3c55f4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_dbf16feb-a72e-4f39-87be-9b78eb01d4b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_dbf16feb-a72e-4f39-87be-9b78eb01d4b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_fe927c39-15c1-4e97-b770-8b153204f4a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_dbf16feb-a72e-4f39-87be-9b78eb01d4b9" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_fe927c39-15c1-4e97-b770-8b153204f4a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_fe927c39-15c1-4e97-b770-8b153204f4a5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_fe927c39-15c1-4e97-b770-8b153204f4a5" xlink:to="loc_ifrs-full_LiabilitiesMember_fe927c39-15c1-4e97-b770-8b153204f4a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_dfde3734-b410-45f7-9251-2aba83b822d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_fe927c39-15c1-4e97-b770-8b153204f4a5" xlink:to="loc_ifrs-full_LiabilitiesMember_dfde3734-b410-45f7-9251-2aba83b822d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_c52f95df-f702-44c8-b47d-121e704377fa" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_dfde3734-b410-45f7-9251-2aba83b822d6" xlink:to="loc_oncyf_WarrantsMember_c52f95df-f702-44c8-b47d-121e704377fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_703ba524-71d5-4bd5-b064-1f30f4449063" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_dbf16feb-a72e-4f39-87be-9b78eb01d4b9" xlink:to="loc_oncyf_SaleOfStockAxis_703ba524-71d5-4bd5-b064-1f30f4449063" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_703ba524-71d5-4bd5-b064-1f30f4449063_default" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_703ba524-71d5-4bd5-b064-1f30f4449063" xlink:to="loc_oncyf_SaleOfStockDomain_703ba524-71d5-4bd5-b064-1f30f4449063_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_703ba524-71d5-4bd5-b064-1f30f4449063" xlink:to="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_47427ff6-64ec-4299-a0e0-b08b338c51d3" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_47427ff6-64ec-4299-a0e0-b08b338c51d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_60c37acb-f1a2-47c0-a229-fa817e72d1d8" xlink:href="oncyf-20221231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_60c37acb-f1a2-47c0-a229-fa817e72d1d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_594d3501-ce8a-4c8d-81a1-769c96dc593e" xlink:href="oncyf-20221231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:to="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_594d3501-ce8a-4c8d-81a1-769c96dc593e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_47f9e083-a54b-4949-89c4-06598119a9cd" xlink:href="oncyf-20221231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:to="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_47f9e083-a54b-4949-89c4-06598119a9cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_ee5c77e7-0b43-42c1-bd94-eb88539ae75b" xlink:href="oncyf-20221231.xsd#oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:to="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_ee5c77e7-0b43-42c1-bd94-eb88539ae75b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_64665a2c-cdac-4d53-a042-2a5862787af0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_dbf16feb-a72e-4f39-87be-9b78eb01d4b9" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_64665a2c-cdac-4d53-a042-2a5862787af0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_64665a2c-cdac-4d53-a042-2a5862787af0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_64665a2c-cdac-4d53-a042-2a5862787af0" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_64665a2c-cdac-4d53-a042-2a5862787af0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_235788d8-5ccb-40b8-a789-d95b2b250597" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_64665a2c-cdac-4d53-a042-2a5862787af0" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_235788d8-5ccb-40b8-a789-d95b2b250597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_a4d98cfa-c760-4e28-b2b5-f8068d3a3a5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_235788d8-5ccb-40b8-a789-d95b2b250597" xlink:to="loc_ifrs-full_IssuedCapitalMember_a4d98cfa-c760-4e28-b2b5-f8068d3a3a5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_caea1ced-9e52-46ef-aff3-9135fcbd60c7" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_235788d8-5ccb-40b8-a789-d95b2b250597" xlink:to="loc_oncyf_WarrantsMember_caea1ced-9e52-46ef-aff3-9135fcbd60c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareCapitalEquityWarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="extended" id="i0e82975f43244626b7e549eb7a8317d3_ShareCapitalEquityWarrantsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_b4f52036-e8bd-4059-b17d-42cc4936de4e" xlink:href="oncyf-20221231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_IssueOfEquityShares_b4f52036-e8bd-4059-b17d-42cc4936de4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_a6f29ffd-47d0-4583-8621-0478f1302c34" xlink:href="oncyf-20221231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_a6f29ffd-47d0-4583-8621-0478f1302c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_ca1690c7-67b1-4c59-b916-d27107efea61" xlink:href="oncyf-20221231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_CommonSharesPerUnit_ca1690c7-67b1-4c59-b916-d27107efea61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit_9a651b2c-a516-448f-b8c6-483527f0ac4d" xlink:href="oncyf-20221231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_CommonSharePurchaseWarrantPerUnit_9a651b2c-a516-448f-b8c6-483527f0ac4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_2909c647-a6ce-4517-8717-41d6895c3641" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_2909c647-a6ce-4517-8717-41d6895c3641" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_1616742f-efae-48de-ab44-17567a3c68f5" xlink:href="oncyf-20221231.xsd#oncyf_StockholdersEquityNoteStockSplitConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_1616742f-efae-48de-ab44-17567a3c68f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_5ac94d9b-0e3c-4277-af88-9ebc984c7303" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_5ac94d9b-0e3c-4277-af88-9ebc984c7303" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare_74f7fac7-852a-41d9-b38d-9359833e47c1" xlink:href="oncyf-20221231.xsd#oncyf_SharesIssuedWarrantPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_SharesIssuedWarrantPricePerShare_74f7fac7-852a-41d9-b38d-9359833e47c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e962bf1e-8b58-4a2b-86cb-1b41c4618f81" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e962bf1e-8b58-4a2b-86cb-1b41c4618f81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_21c141ef-022f-44c7-a505-fa91ba86c5b8" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e962bf1e-8b58-4a2b-86cb-1b41c4618f81" xlink:to="loc_oncyf_SaleOfStockAxis_21c141ef-022f-44c7-a505-fa91ba86c5b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_21c141ef-022f-44c7-a505-fa91ba86c5b8_default" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_21c141ef-022f-44c7-a505-fa91ba86c5b8" xlink:to="loc_oncyf_SaleOfStockDomain_21c141ef-022f-44c7-a505-fa91ba86c5b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_25f785b3-5081-4d71-8325-aea6f941e618" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_21c141ef-022f-44c7-a505-fa91ba86c5b8" xlink:to="loc_oncyf_SaleOfStockDomain_25f785b3-5081-4d71-8325-aea6f941e618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_5f38bb67-228b-45c4-9854-8a026e5924e0" xlink:href="oncyf-20221231.xsd#oncyf_SharesPublicOfferingEquityWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_25f785b3-5081-4d71-8325-aea6f941e618" xlink:to="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_5f38bb67-228b-45c4-9854-8a026e5924e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareCapitalSummaryofOutstandingWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="extended" id="i1def26d23c5947d28b44a1410dc16481_ShareCapitalSummaryofOutstandingWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_024b27c7-b903-45f4-88c8-afecb38baa68" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_024b27c7-b903-45f4-88c8-afecb38baa68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfSharesExpired_4e3fe762-0813-4d1e-a47f-3e6b85c6c033" xlink:href="oncyf-20221231.xsd#oncyf_NumberOfSharesExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:to="loc_oncyf_NumberOfSharesExpired_4e3fe762-0813-4d1e-a47f-3e6b85c6c033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_8b6edaee-6550-4ec1-ac27-d040f3fa333c" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_8b6edaee-6550-4ec1-ac27-d040f3fa333c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsExpired_844ebf5b-1f7f-4da0-b332-cb55b8151cd1" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsAndRightsExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:to="loc_oncyf_WarrantsAndRightsExpired_844ebf5b-1f7f-4da0-b332-cb55b8151cd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_2d677ed2-291b-4c35-9957-c38469a12773" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_2d677ed2-291b-4c35-9957-c38469a12773" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_a7d061ee-8a3a-46bf-a930-cf3ef2a3715e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_a7d061ee-8a3a-46bf-a930-cf3ef2a3715e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_66c95e2f-18e7-4759-885c-6ff7fefe0612" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_a7d061ee-8a3a-46bf-a930-cf3ef2a3715e" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_66c95e2f-18e7-4759-885c-6ff7fefe0612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_66c95e2f-18e7-4759-885c-6ff7fefe0612_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_66c95e2f-18e7-4759-885c-6ff7fefe0612" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_66c95e2f-18e7-4759-885c-6ff7fefe0612_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_4dce9c76-5338-4a63-87cb-045f05ce6a31" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_66c95e2f-18e7-4759-885c-6ff7fefe0612" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_4dce9c76-5338-4a63-87cb-045f05ce6a31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_4baa9946-2e0c-4a40-be9d-23706cd13b23" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_4dce9c76-5338-4a63-87cb-045f05ce6a31" xlink:to="loc_oncyf_WarrantsMember_4baa9946-2e0c-4a40-be9d-23706cd13b23" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="extended" id="i41629752a448466695bc7afff4bf73bf_ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_ecc7f745-74d6-463a-b35a-b52f3aa720c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_ecc7f745-74d6-463a-b35a-b52f3aa720c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_d8b7e962-2ca1-4740-bb97-e079d690b498" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_d8b7e962-2ca1-4740-bb97-e079d690b498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dbed1d66-cd3d-4528-900d-aeef13b2f1e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dbed1d66-cd3d-4528-900d-aeef13b2f1e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_03ad76dd-4fa0-47dc-b134-e1289a612171" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_03ad76dd-4fa0-47dc-b134-e1289a612171" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_94712600-ff65-4a72-a052-987b19106d2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_94712600-ff65-4a72-a052-987b19106d2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_0a707835-9504-44c3-8682-f13f4de27626" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_0a707835-9504-44c3-8682-f13f4de27626" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9df1bf31-8c63-49d6-afe2-ad601dd3f0b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9df1bf31-8c63-49d6-afe2-ad601dd3f0b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_42ff73dc-4243-49e9-9357-d1ab3c8afee9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9df1bf31-8c63-49d6-afe2-ad601dd3f0b3" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_42ff73dc-4243-49e9-9357-d1ab3c8afee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_42ff73dc-4243-49e9-9357-d1ab3c8afee9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_42ff73dc-4243-49e9-9357-d1ab3c8afee9" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_42ff73dc-4243-49e9-9357-d1ab3c8afee9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_42ff73dc-4243-49e9-9357-d1ab3c8afee9" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_6d8decc1-0b90-4821-9be7-47b751b70ea1" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_6d8decc1-0b90-4821-9be7-47b751b70ea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_eba45827-909d-477b-a1fb-1dc1765bb8a9" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_eba45827-909d-477b-a1fb-1dc1765bb8a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_716730bc-099b-4ef7-8614-d40d0e7a48d5" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_716730bc-099b-4ef7-8614-d40d0e7a48d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_61dd43f0-bdda-4985-af0f-83f9ed608f93" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_61dd43f0-bdda-4985-af0f-83f9ed608f93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_11c94248-d469-4b91-a33c-008190a6028e" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_11c94248-d469-4b91-a33c-008190a6028e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_963c7d5f-7e55-4372-bdcf-c9f519eb2f03" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9df1bf31-8c63-49d6-afe2-ad601dd3f0b3" xlink:to="loc_ifrs-full_RangeAxis_963c7d5f-7e55-4372-bdcf-c9f519eb2f03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_963c7d5f-7e55-4372-bdcf-c9f519eb2f03_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_963c7d5f-7e55-4372-bdcf-c9f519eb2f03" xlink:to="loc_ifrs-full_RangesMember_963c7d5f-7e55-4372-bdcf-c9f519eb2f03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_ac01572c-39be-460e-8ffb-c0703efc41a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_963c7d5f-7e55-4372-bdcf-c9f519eb2f03" xlink:to="loc_ifrs-full_RangesMember_ac01572c-39be-460e-8ffb-c0703efc41a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_86bae842-bcc3-42fd-9b20-03d289f4dfdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_ac01572c-39be-460e-8ffb-c0703efc41a8" xlink:to="loc_ifrs-full_BottomOfRangeMember_86bae842-bcc3-42fd-9b20-03d289f4dfdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_5c82875c-35eb-40a6-8093-a80b09f876fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_ac01572c-39be-460e-8ffb-c0703efc41a8" xlink:to="loc_ifrs-full_TopOfRangeMember_5c82875c-35eb-40a6-8093-a80b09f876fe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="i18e491c4492048d7b5ecfda7d435ea77_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_d6d62fc1-ef38-4fc2-ba4f-019b8bd7411b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_fdeffcc8-46a5-4c6a-acf6-a01f84185da7" xlink:href="oncyf-20221231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_d6d62fc1-ef38-4fc2-ba4f-019b8bd7411b" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_fdeffcc8-46a5-4c6a-acf6-a01f84185da7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_797190a3-bdda-430f-924d-17c839f54bff" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_d6d62fc1-ef38-4fc2-ba4f-019b8bd7411b" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_797190a3-bdda-430f-924d-17c839f54bff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_db2cab7f-6606-4816-a622-80d6d6bae566" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_d6d62fc1-ef38-4fc2-ba4f-019b8bd7411b" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_db2cab7f-6606-4816-a622-80d6d6bae566" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c806a4aa-0ca1-4db9-b649-5db3fd91f032" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_d6d62fc1-ef38-4fc2-ba4f-019b8bd7411b" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c806a4aa-0ca1-4db9-b649-5db3fd91f032" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_804145bb-d3b3-4c99-8e7f-8ce8c6e457ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c806a4aa-0ca1-4db9-b649-5db3fd91f032" xlink:to="loc_ifrs-full_RangeAxis_804145bb-d3b3-4c99-8e7f-8ce8c6e457ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_804145bb-d3b3-4c99-8e7f-8ce8c6e457ab_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_804145bb-d3b3-4c99-8e7f-8ce8c6e457ab" xlink:to="loc_ifrs-full_RangesMember_804145bb-d3b3-4c99-8e7f-8ce8c6e457ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_8956ea42-0fce-4600-a3f0-cb3d6b08279e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_804145bb-d3b3-4c99-8e7f-8ce8c6e457ab" xlink:to="loc_ifrs-full_RangesMember_8956ea42-0fce-4600-a3f0-cb3d6b08279e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_b4df5288-5f87-4934-a6b4-bc38cf9d2d72" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_8956ea42-0fce-4600-a3f0-cb3d6b08279e" xlink:to="loc_ifrs-full_BottomOfRangeMember_b4df5288-5f87-4934-a6b4-bc38cf9d2d72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_32b1822d-2477-4af1-8dfe-8b8881763c12" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_8956ea42-0fce-4600-a3f0-cb3d6b08279e" xlink:to="loc_ifrs-full_TopOfRangeMember_32b1822d-2477-4af1-8dfe-8b8881763c12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5bcccaa3-20fd-48e0-a972-446feb86143c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c806a4aa-0ca1-4db9-b649-5db3fd91f032" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5bcccaa3-20fd-48e0-a972-446feb86143c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_5bcccaa3-20fd-48e0-a972-446feb86143c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5bcccaa3-20fd-48e0-a972-446feb86143c" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_5bcccaa3-20fd-48e0-a972-446feb86143c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_485bfce9-e482-42f5-93b3-c230a2645998" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5bcccaa3-20fd-48e0-a972-446feb86143c" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_485bfce9-e482-42f5-93b3-c230a2645998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember_99b9f847-ce5f-4cdf-9934-48b114e503af" xlink:href="oncyf-20221231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_485bfce9-e482-42f5-93b3-c230a2645998" xlink:to="loc_oncyf_RestrictedShareUnitsMember_99b9f847-ce5f-4cdf-9934-48b114e503af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_4b31fd0f-819a-43ad-af10-5268666279bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_485bfce9-e482-42f5-93b3-c230a2645998" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_4b31fd0f-819a-43ad-af10-5268666279bf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="extended" id="iebe58c1745cb48d39f3abf1d790bf5af_ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_30fde05c-078c-469e-9319-ccb2064b5c11" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_30fde05c-078c-469e-9319-ccb2064b5c11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_7f6b2a02-9f77-44b0-ad9e-4f69471d15b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_7f6b2a02-9f77-44b0-ad9e-4f69471d15b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_c2e16f38-3e19-43d4-86f6-28c4c66ef53a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_c2e16f38-3e19-43d4-86f6-28c4c66ef53a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_66796cde-c1b6-4a83-a181-d439dd72337d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_f5c68302-1400-46e9-a074-1cf715251f63" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_f5c68302-1400-46e9-a074-1cf715251f63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5ac90d1b-35d5-4082-9e84-da136f12e90a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5ac90d1b-35d5-4082-9e84-da136f12e90a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b43e0fbd-336e-452a-be4b-4ef0ba5d4e98" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5ac90d1b-35d5-4082-9e84-da136f12e90a" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b43e0fbd-336e-452a-be4b-4ef0ba5d4e98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_b43e0fbd-336e-452a-be4b-4ef0ba5d4e98_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b43e0fbd-336e-452a-be4b-4ef0ba5d4e98" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_b43e0fbd-336e-452a-be4b-4ef0ba5d4e98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_b4a56552-c035-4a81-9424-f636df15884e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b43e0fbd-336e-452a-be4b-4ef0ba5d4e98" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_b4a56552-c035-4a81-9424-f636df15884e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember_a6671679-2589-4936-ada9-7bb964e91b2d" xlink:href="oncyf-20221231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_b4a56552-c035-4a81-9424-f636df15884e" xlink:to="loc_oncyf_RestrictedShareUnitsMember_a6671679-2589-4936-ada9-7bb964e91b2d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i4754a3acc97042fa8a9c215535964dcf_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_3191d0e8-5864-41fa-897c-b65ffeaa3c1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_70ec24a8-fd31-42d0-9628-de5db86ff1fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_3191d0e8-5864-41fa-897c-b65ffeaa3c1f" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_70ec24a8-fd31-42d0-9628-de5db86ff1fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_bd57c7fe-dae5-4aff-adbf-77ef53eb62fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_3191d0e8-5864-41fa-897c-b65ffeaa3c1f" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_bd57c7fe-dae5-4aff-adbf-77ef53eb62fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e237dd6d-19ac-4bc2-a1d9-f3e117640897" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_3191d0e8-5864-41fa-897c-b65ffeaa3c1f" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e237dd6d-19ac-4bc2-a1d9-f3e117640897" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_56243936-b63e-4aa9-9f77-73221d128f95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e237dd6d-19ac-4bc2-a1d9-f3e117640897" xlink:to="loc_srt_StatementGeographicalAxis_56243936-b63e-4aa9-9f77-73221d128f95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_56243936-b63e-4aa9-9f77-73221d128f95_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_56243936-b63e-4aa9-9f77-73221d128f95" xlink:to="loc_srt_SegmentGeographicalDomain_56243936-b63e-4aa9-9f77-73221d128f95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ba60762b-050a-4ebe-af96-ce497569d0c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_56243936-b63e-4aa9-9f77-73221d128f95" xlink:to="loc_srt_SegmentGeographicalDomain_ba60762b-050a-4ebe-af96-ce497569d0c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_1d777637-2fc4-4827-8577-356648d9b66e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ba60762b-050a-4ebe-af96-ce497569d0c2" xlink:to="loc_country_CA_1d777637-2fc4-4827-8577-356648d9b66e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BB_7422724a-10f7-45bc-9a59-88eaf6993cd6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ba60762b-050a-4ebe-af96-ce497569d0c2" xlink:to="loc_country_BB_7422724a-10f7-45bc-9a59-88eaf6993cd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f8e9a7ae-54b7-4c31-998b-1ad7ff3d24bf" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ba60762b-050a-4ebe-af96-ce497569d0c2" xlink:to="loc_country_US_f8e9a7ae-54b7-4c31-998b-1ad7ff3d24bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0f1d1f77-8312-4b38-b365-646ac7287399" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e237dd6d-19ac-4bc2-a1d9-f3e117640897" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0f1d1f77-8312-4b38-b365-646ac7287399" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_0f1d1f77-8312-4b38-b365-646ac7287399_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0f1d1f77-8312-4b38-b365-646ac7287399" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_0f1d1f77-8312-4b38-b365-646ac7287399_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_724aa575-8cb3-436f-a9fd-00c62c2bca2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0f1d1f77-8312-4b38-b365-646ac7287399" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_724aa575-8cb3-436f-a9fd-00c62c2bca2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_0ca4df1a-5ac5-4b54-ba74-65c611365057" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_724aa575-8cb3-436f-a9fd-00c62c2bca2d" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_0ca4df1a-5ac5-4b54-ba74-65c611365057" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_00dc2ec2-7193-4080-9f99-ae55cbaeb0ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_724aa575-8cb3-436f-a9fd-00c62c2bca2d" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_00dc2ec2-7193-4080-9f99-ae55cbaeb0ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_68982a41-d7a3-4804-840e-eb08f94cefc2" xlink:href="oncyf-20221231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_724aa575-8cb3-436f-a9fd-00c62c2bca2d" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_68982a41-d7a3-4804-840e-eb08f94cefc2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended" id="i20b023dc1b6c4223a106044df60d991c_IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c4a020ec-89c1-49f9-9216-6d0afd4bd673" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_1a318b28-6014-4028-91a7-d84f14c69944" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c4a020ec-89c1-49f9-9216-6d0afd4bd673" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_1a318b28-6014-4028-91a7-d84f14c69944" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eff5ecb8-d1d2-41a9-bc51-101c7b4b80f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c4a020ec-89c1-49f9-9216-6d0afd4bd673" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eff5ecb8-d1d2-41a9-bc51-101c7b4b80f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_efc600f2-0889-4283-a0f9-cdc64a4150a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eff5ecb8-d1d2-41a9-bc51-101c7b4b80f2" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_efc600f2-0889-4283-a0f9-cdc64a4150a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_efc600f2-0889-4283-a0f9-cdc64a4150a7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_efc600f2-0889-4283-a0f9-cdc64a4150a7" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_efc600f2-0889-4283-a0f9-cdc64a4150a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_efc600f2-0889-4283-a0f9-cdc64a4150a7" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_4b053aeb-17e3-4c45-9732-5fc51318e411" xlink:href="oncyf-20221231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_4b053aeb-17e3-4c45-9732-5fc51318e411" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_cc6be7ec-b0b0-40a6-9ca3-216a5d8936ed" xlink:href="oncyf-20221231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_cc6be7ec-b0b0-40a6-9ca3-216a5d8936ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_b08384a7-f87e-4c41-8e45-a1bca2f1845f" xlink:href="oncyf-20221231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_b08384a7-f87e-4c41-8e45-a1bca2f1845f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_21f0c9e1-c8b7-46ee-a7a9-6a39e6bde72e" xlink:href="oncyf-20221231.xsd#oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:to="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_21f0c9e1-c8b7-46ee-a7a9-6a39e6bde72e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember_3f9b9287-3db6-44ee-9dbc-2e194cf95eca" xlink:href="oncyf-20221231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:to="loc_oncyf_ShareIssueCostsMember_3f9b9287-3db6-44ee-9dbc-2e194cf95eca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_7a40c24d-c488-4b37-a547-c9201cdfd57b" xlink:href="oncyf-20221231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_7a40c24d-c488-4b37-a547-c9201cdfd57b" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i21660dd7b7244d98a0a93fea5b193043_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_dad902a6-4ead-4298-a5f8-d35cc48475b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_221e07ff-d260-4ae8-aaff-4b493f2d5a2d" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_dad902a6-4ead-4298-a5f8-d35cc48475b1" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_221e07ff-d260-4ae8-aaff-4b493f2d5a2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_e26f4e62-8e21-4a94-a619-f74dce3a0788" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_dad902a6-4ead-4298-a5f8-d35cc48475b1" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_e26f4e62-8e21-4a94-a619-f74dce3a0788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_e6633809-4010-44f5-bd3f-818f6d0e3902" xlink:href="oncyf-20221231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_dad902a6-4ead-4298-a5f8-d35cc48475b1" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_e6633809-4010-44f5-bd3f-818f6d0e3902" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_e1b6f019-2259-4218-9fec-10c068085eb5" xlink:href="oncyf-20221231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_dad902a6-4ead-4298-a5f8-d35cc48475b1" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_e1b6f019-2259-4218-9fec-10c068085eb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_dad902a6-4ead-4298-a5f8-d35cc48475b1" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c3aa41c6-b212-4b32-896d-7ff3e1091087" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c3aa41c6-b212-4b32-896d-7ff3e1091087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_c3aa41c6-b212-4b32-896d-7ff3e1091087_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c3aa41c6-b212-4b32-896d-7ff3e1091087" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_c3aa41c6-b212-4b32-896d-7ff3e1091087_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9abc5be9-2354-4bdd-bb32-5e2157c3990e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c3aa41c6-b212-4b32-896d-7ff3e1091087" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9abc5be9-2354-4bdd-bb32-5e2157c3990e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_12a12684-85c6-4ec1-b9ea-b3f2c54822a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9abc5be9-2354-4bdd-bb32-5e2157c3990e" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_12a12684-85c6-4ec1-b9ea-b3f2c54822a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2441e717-999f-447e-8dcf-edb76d0cc1df" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2441e717-999f-447e-8dcf-edb76d0cc1df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_2441e717-999f-447e-8dcf-edb76d0cc1df_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2441e717-999f-447e-8dcf-edb76d0cc1df" xlink:to="loc_ifrs-full_TypesOfRisksMember_2441e717-999f-447e-8dcf-edb76d0cc1df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_60b0838a-96f3-4afd-a4d0-5ecfb0c1e15a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2441e717-999f-447e-8dcf-edb76d0cc1df" xlink:to="loc_ifrs-full_TypesOfRisksMember_60b0838a-96f3-4afd-a4d0-5ecfb0c1e15a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_4c7b4d4f-ebc5-417d-a64b-340334ae65e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_60b0838a-96f3-4afd-a4d0-5ecfb0c1e15a" xlink:to="loc_ifrs-full_CurrencyRiskMember_4c7b4d4f-ebc5-417d-a64b-340334ae65e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_a44bd3f9-48de-4be0-976a-8c67ff552014" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:to="loc_srt_CurrencyAxis_a44bd3f9-48de-4be0-976a-8c67ff552014" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_a44bd3f9-48de-4be0-976a-8c67ff552014_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_a44bd3f9-48de-4be0-976a-8c67ff552014" xlink:to="loc_currency_AllCurrenciesDomain_a44bd3f9-48de-4be0-976a-8c67ff552014_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_41cc7e14-4293-40a6-904f-3e2731fd079b" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_a44bd3f9-48de-4be0-976a-8c67ff552014" xlink:to="loc_currency_AllCurrenciesDomain_41cc7e14-4293-40a6-904f-3e2731fd079b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_407e3108-f379-4ad8-a80c-8d88e073cb3d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_41cc7e14-4293-40a6-904f-3e2731fd079b" xlink:to="loc_currency_USD_407e3108-f379-4ad8-a80c-8d88e073cb3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_87698739-a347-4047-ad06-f4fc004e5507" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_41cc7e14-4293-40a6-904f-3e2731fd079b" xlink:to="loc_currency_EUR_87698739-a347-4047-ad06-f4fc004e5507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_76349e35-6bd5-4dfc-ba72-969ad333db95" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:to="loc_oncyf_SaleOfStockAxis_76349e35-6bd5-4dfc-ba72-969ad333db95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_76349e35-6bd5-4dfc-ba72-969ad333db95_default" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_76349e35-6bd5-4dfc-ba72-969ad333db95" xlink:to="loc_oncyf_SaleOfStockDomain_76349e35-6bd5-4dfc-ba72-969ad333db95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_d0855494-bcde-4496-9b0f-5c4cd23926d6" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_76349e35-6bd5-4dfc-ba72-969ad333db95" xlink:to="loc_oncyf_SaleOfStockDomain_d0855494-bcde-4496-9b0f-5c4cd23926d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_995c4c29-73df-41e0-bfda-94c4c2126411" xlink:href="oncyf-20221231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_d0855494-bcde-4496-9b0f-5c4cd23926d6" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_995c4c29-73df-41e0-bfda-94c4c2126411" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_3444fbdd-8c83-4a87-b6af-01bbf85fca12" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_3444fbdd-8c83-4a87-b6af-01bbf85fca12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_3444fbdd-8c83-4a87-b6af-01bbf85fca12_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_3444fbdd-8c83-4a87-b6af-01bbf85fca12" xlink:to="loc_ifrs-full_LiabilitiesMember_3444fbdd-8c83-4a87-b6af-01bbf85fca12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_95fa7940-bc62-4c9e-a5a3-777a99eff867" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_3444fbdd-8c83-4a87-b6af-01bbf85fca12" xlink:to="loc_ifrs-full_LiabilitiesMember_95fa7940-bc62-4c9e-a5a3-777a99eff867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_949ad059-de73-4f17-b38f-2050e3528755" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_95fa7940-bc62-4c9e-a5a3-777a99eff867" xlink:to="loc_oncyf_WarrantsMember_949ad059-de73-4f17-b38f-2050e3528755" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="extended" id="iacd4e55b237b4c08ba14b9d1c4f5d7a8_FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_07f352dc-a842-47dd-aa45-dcf4fcf0c8f7" xlink:href="oncyf-20221231.xsd#oncyf_Currency1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_83a59b89-fddd-48b1-9062-3cee562c84bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_07f352dc-a842-47dd-aa45-dcf4fcf0c8f7" xlink:to="loc_ifrs-full_CashAndCashEquivalents_83a59b89-fddd-48b1-9062-3cee562c84bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAvailableforsale_c4f08b7d-95e8-432d-95aa-7c6d0453b58d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAvailableforsale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_07f352dc-a842-47dd-aa45-dcf4fcf0c8f7" xlink:to="loc_ifrs-full_FinancialAssetsAvailableforsale_c4f08b7d-95e8-432d-95aa-7c6d0453b58d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_1654decd-40e8-44e9-acad-11937e8923f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_07f352dc-a842-47dd-aa45-dcf4fcf0c8f7" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_1654decd-40e8-44e9-acad-11937e8923f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_26946b59-e3e1-4272-bb38-a00beaa29ddd" xlink:href="oncyf-20221231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_07f352dc-a842-47dd-aa45-dcf4fcf0c8f7" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_26946b59-e3e1-4272-bb38-a00beaa29ddd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_2dccf764-486d-4826-97f2-7e66f197324b" xlink:href="oncyf-20221231.xsd#oncyf_Currency1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Currency1LineItems_07f352dc-a842-47dd-aa45-dcf4fcf0c8f7" xlink:to="loc_oncyf_Currency1Table_2dccf764-486d-4826-97f2-7e66f197324b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_a0368f91-7e31-44e1-80a9-313363f8facd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Currency1Table_2dccf764-486d-4826-97f2-7e66f197324b" xlink:to="loc_srt_CurrencyAxis_a0368f91-7e31-44e1-80a9-313363f8facd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_a0368f91-7e31-44e1-80a9-313363f8facd_default" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_a0368f91-7e31-44e1-80a9-313363f8facd" xlink:to="loc_currency_AllCurrenciesDomain_a0368f91-7e31-44e1-80a9-313363f8facd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_725ce18d-609b-437e-85e4-282747164e1b" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_a0368f91-7e31-44e1-80a9-313363f8facd" xlink:to="loc_currency_AllCurrenciesDomain_725ce18d-609b-437e-85e4-282747164e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_bd92e5c7-fc25-40a0-bad8-a18d2668a8aa" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_725ce18d-609b-437e-85e4-282747164e1b" xlink:to="loc_currency_USD_bd92e5c7-fc25-40a0-bad8-a18d2668a8aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_89133528-63c3-4b6e-a09a-3d53a502ec0e" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_725ce18d-609b-437e-85e4-282747164e1b" xlink:to="loc_currency_EUR_89133528-63c3-4b6e-a09a-3d53a502ec0e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#EconomicDependenceDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended" id="i8b14c4c8e4e74b98a7d00f19efde3bfc_EconomicDependenceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_99607810-ca05-4e69-a86e-f94603073956" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber_a9e96681-0274-41bf-aa96-3881e147225c" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_99607810-ca05-4e69-a86e-f94603073956" xlink:to="loc_oncyf_ConcentrationRiskNumber_a9e96681-0274-41bf-aa96-3881e147225c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table_2599eeda-de2c-4f3f-9200-dd759c5d5a3f" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_99607810-ca05-4e69-a86e-f94603073956" xlink:to="loc_oncyf_ConcentrationRisk1Table_2599eeda-de2c-4f3f-9200-dd759c5d5a3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_951d55ad-b108-408a-926b-9b595126d312" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_ConcentrationRisk1Table_2599eeda-de2c-4f3f-9200-dd759c5d5a3f" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_951d55ad-b108-408a-926b-9b595126d312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_951d55ad-b108-408a-926b-9b595126d312_default" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_951d55ad-b108-408a-926b-9b595126d312" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_951d55ad-b108-408a-926b-9b595126d312_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_eff5c2fc-7848-4f39-bebb-12f7263b8e5d" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_951d55ad-b108-408a-926b-9b595126d312" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_eff5c2fc-7848-4f39-bebb-12f7263b8e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_8595fe59-36db-4c87-ba85-81503c3a5bfd" xlink:href="oncyf-20221231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_eff5c2fc-7848-4f39-bebb-12f7263b8e5d" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_8595fe59-36db-4c87-ba85-81503c3a5bfd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ComponentsofExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails" xlink:type="extended" id="i42cf588f284945d5834b6787c6cb0052_ComponentsofExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_55325471-a36e-46b7-b927-8333441c529c" xlink:href="oncyf-20221231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:href="oncyf-20221231.xsd#oncyf_ResearchAndDevelopmentExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_55325471-a36e-46b7-b927-8333441c529c" xlink:to="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrailExpense_9e63db83-9e38-4a99-a4a7-606c9b940b0c" xlink:href="oncyf-20221231.xsd#oncyf_ClinicalTrailExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_oncyf_ClinicalTrailExpense_9e63db83-9e38-4a99-a4a7-606c9b940b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ManufacturingExpense_7820dd9b-4758-411e-aed6-1ed77a9a6ea4" xlink:href="oncyf-20221231.xsd#oncyf_ManufacturingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_oncyf_ManufacturingExpense_7820dd9b-4758-411e-aed6-1ed77a9a6ea4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IntellectualPropertyExpense_5af5bdd6-b781-4428-b5a4-55733b7d1340" xlink:href="oncyf-20221231.xsd#oncyf_IntellectualPropertyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_oncyf_IntellectualPropertyExpense_5af5bdd6-b781-4428-b5a4-55733b7d1340" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TranslationalScienceExpense_97eee56d-9646-4221-82d2-865aa26ec6cc" xlink:href="oncyf-20221231.xsd#oncyf_TranslationalScienceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_oncyf_TranslationalScienceExpense_97eee56d-9646-4221-82d2-865aa26ec6cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense_f7ac6fcf-e01f-4b70-bde7-8c4563974a94" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_ifrs-full_OtherEmployeeExpense_f7ac6fcf-e01f-4b70-bde7-8c4563974a94" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_86c14305-30c2-479d-8b56-9279cb24a07c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_86c14305-30c2-479d-8b56-9279cb24a07c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_55ce90e4-03eb-4497-9539-cdd5d6eb1cf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_55ce90e4-03eb-4497-9539-cdd5d6eb1cf1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_cc922912-f832-4da6-85d3-96406f371d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_cc922912-f832-4da6-85d3-96406f371d52" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:href="oncyf-20221231.xsd#oncyf_GeneralAndAdministrativeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_55325471-a36e-46b7-b927-8333441c529c" xlink:to="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PublicCompanyExpense_9431e904-15f4-4cb7-8859-9655ca73e121" xlink:href="oncyf-20221231.xsd#oncyf_PublicCompanyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:to="loc_oncyf_PublicCompanyExpense_9431e904-15f4-4cb7-8859-9655ca73e121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeExpenses_80c4c93d-4ef4-4828-936e-f2fd52905911" xlink:href="oncyf-20221231.xsd#oncyf_OfficeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:to="loc_oncyf_OfficeExpenses_80c4c93d-4ef4-4828-936e-f2fd52905911" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_cc0dd047-c738-4dc7-8bb9-ceec9164995a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:to="loc_ifrs-full_AmortisationExpense_cc0dd047-c738-4dc7-8bb9-ceec9164995a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_7a56e628-ec03-42de-8284-f892899e6356" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_7a56e628-ec03-42de-8284-f892899e6356" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_f9e34078-f968-4f99-a9e6-55fa74474597" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_f9e34078-f968-4f99-a9e6-55fa74474597" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_ba567067-caf4-4e07-851a-2bc56e42a867" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_55325471-a36e-46b7-b927-8333441c529c" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_ba567067-caf4-4e07-851a-2bc56e42a867" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_6fd8b88c-4a6a-489d-90e4-724a54401b1d" xlink:href="oncyf-20221231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_55325471-a36e-46b7-b927-8333441c529c" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_6fd8b88c-4a6a-489d-90e4-724a54401b1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_c7df7e78-45c0-4cfb-952a-44899aa72ad2" xlink:href="oncyf-20221231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_6fd8b88c-4a6a-489d-90e4-724a54401b1d" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_c7df7e78-45c0-4cfb-952a-44899aa72ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_c7df7e78-45c0-4cfb-952a-44899aa72ad2_default" xlink:href="oncyf-20221231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_c7df7e78-45c0-4cfb-952a-44899aa72ad2" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_c7df7e78-45c0-4cfb-952a-44899aa72ad2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_b6998ef6-5eb5-461a-b39f-db01ec5008de" xlink:href="oncyf-20221231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_c7df7e78-45c0-4cfb-952a-44899aa72ad2" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_b6998ef6-5eb5-461a-b39f-db01ec5008de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpenseMember_d57af6d0-9f0d-4a44-bc5b-af4b0d2de041" xlink:href="oncyf-20221231.xsd#oncyf_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_b6998ef6-5eb5-461a-b39f-db01ec5008de" xlink:to="loc_oncyf_ResearchAndDevelopmentExpenseMember_d57af6d0-9f0d-4a44-bc5b-af4b0d2de041" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpenseMember_21d34fe5-67dc-4b2d-a677-3226f3f6c5b1" xlink:href="oncyf-20221231.xsd#oncyf_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_b6998ef6-5eb5-461a-b39f-db01ec5008de" xlink:to="loc_oncyf_GeneralAndAdministrativeExpenseMember_21d34fe5-67dc-4b2d-a677-3226f3f6c5b1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="extended" id="i7926958974a848da830a87f18fc53791_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_8307bbe2-4f00-4ac8-a250-090ad2488db4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_bdc6bd2b-0222-433b-b0ad-beba95506912" xlink:href="oncyf-20221231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_8307bbe2-4f00-4ac8-a250-090ad2488db4" xlink:to="loc_oncyf_IssueOfEquityShares_bdc6bd2b-0222-433b-b0ad-beba95506912" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_988897f2-01f9-412d-bbf4-802610061d97" xlink:href="oncyf-20221231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_8307bbe2-4f00-4ac8-a250-090ad2488db4" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_988897f2-01f9-412d-bbf4-802610061d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_7ebfac7b-2f54-44c3-89c2-77eb7cf54187" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_8307bbe2-4f00-4ac8-a250-090ad2488db4" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_7ebfac7b-2f54-44c3-89c2-77eb7cf54187" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a2e2918e-8b25-43e5-882f-174089b9c29d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_7ebfac7b-2f54-44c3-89c2-77eb7cf54187" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a2e2918e-8b25-43e5-882f-174089b9c29d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_a2e2918e-8b25-43e5-882f-174089b9c29d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a2e2918e-8b25-43e5-882f-174089b9c29d" xlink:to="loc_ifrs-full_NonadjustingEventsMember_a2e2918e-8b25-43e5-882f-174089b9c29d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_9252bf9b-70a3-4b18-ae65-066aa6d123cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a2e2918e-8b25-43e5-882f-174089b9c29d" xlink:to="loc_ifrs-full_NonadjustingEventsMember_9252bf9b-70a3-4b18-ae65-066aa6d123cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_8d5348c4-c564-43e3-9840-8435e7404bf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_9252bf9b-70a3-4b18-ae65-066aa6d123cd" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_8d5348c4-c564-43e3-9840-8435e7404bf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_24abcf8d-5f0b-4510-8ccc-41d4d50fb8c1" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_7ebfac7b-2f54-44c3-89c2-77eb7cf54187" xlink:to="loc_oncyf_SaleOfStockAxis_24abcf8d-5f0b-4510-8ccc-41d4d50fb8c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_24abcf8d-5f0b-4510-8ccc-41d4d50fb8c1_default" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_24abcf8d-5f0b-4510-8ccc-41d4d50fb8c1" xlink:to="loc_oncyf_SaleOfStockDomain_24abcf8d-5f0b-4510-8ccc-41d4d50fb8c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_1677f002-4bfb-452b-bc02-1777e1040d39" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_24abcf8d-5f0b-4510-8ccc-41d4d50fb8c1" xlink:to="loc_oncyf_SaleOfStockDomain_1677f002-4bfb-452b-bc02-1777e1040d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_666381e4-9b59-49a4-a7d2-93f9bc9d56f5" xlink:href="oncyf-20221231.xsd#oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_1677f002-4bfb-452b-bc02-1777e1040d39" xlink:to="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_666381e4-9b59-49a4-a7d2-93f9bc9d56f5" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>oncyf-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:63a935b1-1650-41e1-88a0-4b019d55689c,g:0488272c-958a-4da8-b3e7-8a139968e8c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_abbe7544-92f6-4c87-b18c-5a6bfc27eb28_terseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of increase in value of currency, amount</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Amount</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:href="oncyf-20221231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_91cc15b0-7936-4b73-9c0a-678cf77d1162_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issue of ordinary shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b286e189-71f9-4c77-b016-b0eddbd07b4e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_fa0c211c-a0d6-4c80-8721-c75db4c1eecd_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable federal investment tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsMember" xlink:to="lab_ifrs-full_UnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_c89defe2-e078-4451-a3a0-5e271edfa439_terseLabel_en-US" xlink:label="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivative and Shares Under Warrant Agreement</link:label>
    <link:label id="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_label_en-US" xlink:label="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivative And Shares Under Warrant Agreement [Member]</link:label>
    <link:label id="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_documentation_en-US" xlink:label="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivative And Shares Under Warrant Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:href="oncyf-20221231.xsd#oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:to="lab_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_9f9a7d45-8fd7-4faf-9b4e-cb2dbec6feaf_terseLabel_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum option expiration term</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_label_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_documentation_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:href="oncyf-20221231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:to="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_72d0b02c-dac2-4d82-bcf8-38342276b54d_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued pursuant to incentive share award plan (note 10)</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Incentive Share Awards, Equity</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Incentive Share Awards, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:href="oncyf-20221231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:to="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e5455f86-7b47-4c82-84c2-b88adbcb1798_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_1087c778-6d01-47ec-9b5e-20c734587460_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_label_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Outstanding1</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsOutstanding1_documentation_en-US" xlink:label="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Outstanding1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsAndRightsOutstanding1" xlink:to="lab_oncyf_WarrantsAndRightsOutstanding1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_8863495b-f623-4414-a182-3145dc93379d_terseLabel_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_label_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_09abc2b8-58d1-45ba-ba18-ecb41c508ff6_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_a16d4a24-4144-4ade-b786-8c2ce9deffaa_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derecognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for derecognition of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_f00977fe-d4cf-4795-b846-b4492815dcfb_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for impairment of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_b230b9c3-b0fd-4379-81d3-41f3f24883fd_terseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development (note 19)</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_0df485d1-825e-491b-9828-cb7b3f3c03b5_verboseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_a5d6a12d-ab35-41fc-880f-cb204d31de53_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (cad and usd per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_label_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1" xlink:href="oncyf-20221231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedPricePerShare1" xlink:to="lab_oncyf_SharesIssuedPricePerShare1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_aab83e71-3e44-47d4-ab7e-7c1db39dd312_terseLabel_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment tax credits</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_label_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_documentation_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember" xlink:href="oncyf-20221231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_InvestmentTaxCreditsMember" xlink:to="lab_oncyf_InvestmentTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_c2335743-2a17-4926-ab23-65776f2a85b9_terseLabel_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, outstanding</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_label_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding1</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightOutstanding1_documentation_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Outstanding1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:href="oncyf-20221231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:to="lab_oncyf_ClassOfWarrantOrRightOutstanding1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarnings_b114a54d-a17e-47b2-9d4f-8fd2b2927030_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_e0003f76-f77d-428d-9ee5-af687ccff768_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_f9a90ec8-f38b-472c-bc68-736a4065f9dd_terseLabel_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_label_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b2247fa9-2330-42c1-b0a2-ff1640292844_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_df2c3acf-a39e-4725-9e3e-4e524ca83a27_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareCapitalAmountAbstract_75b9ece7-7f3c-4d1c-92d6-db1215d00a2d_terseLabel_en-US" xlink:label="lab_oncyf_ShareCapitalAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_oncyf_ShareCapitalAmountAbstract_label_en-US" xlink:label="lab_oncyf_ShareCapitalAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Amount [Abstract]</link:label>
    <link:label id="lab_oncyf_ShareCapitalAmountAbstract_documentation_en-US" xlink:label="lab_oncyf_ShareCapitalAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalAmountAbstract" xlink:href="oncyf-20221231.xsd#oncyf_ShareCapitalAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareCapitalAmountAbstract" xlink:to="lab_oncyf_ShareCapitalAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_04ec2ebd-e758-4b1b-80e4-a6010432ddcd_negatedLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_f5ef1cef-3b7a-4973-a726-3b28c65eaedc_verboseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation - right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_93578477-2ea0-42d1-8b4d-8193ebf6cc25_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_fcc09798-280f-4c49-81e5-0e714ed91b4c_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_2123af28-fc4f-45bf-ae9c-431375bc8fc8_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (cad per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_label_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Warrant Price Per Share</link:label>
    <link:label id="lab_oncyf_SharesIssuedWarrantPricePerShare_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedWarrantPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Warrant Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare" xlink:href="oncyf-20221231.xsd#oncyf_SharesIssuedWarrantPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedWarrantPricePerShare" xlink:to="lab_oncyf_SharesIssuedWarrantPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_f46018ec-d388-4e9e-8529-093e994963b2_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment (note 6)</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_4b652d67-81db-4988-ac98-6bd07ec4c5e4_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, beginning balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_069b92ba-1a67-48df-b96a-577bf0517e40_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, ending balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_31641d93-ebf2-4c96-8967-acfd978a6469_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options outstanding and exercisable by range of exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_d882a2f1-27f1-4c9c-8fe9-e37bb7067463_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax effects for reconciliation between accounting profit and tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_2562e00d-e3a8-41de-b931-cadcafcf4bd0_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_046bd53a-accc-4f9f-9577-9e20b6e1caf7_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_a337f0ea-166b-46aa-b532-2e466e0030b5_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Exercisable (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_391d4ee3-607a-43a6-bb59-539de201d387_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_e7d77d4d-f5e7-44f3-a020-48a20cc28b49_terseLabel_en-US" xlink:label="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 United States ATM</link:label>
    <link:label id="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Shares Under At-the-market Agreement, United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:href="oncyf-20221231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_705fe3e1-1d5f-431e-a585-0b56f0a5d74f_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from share issuance</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_606fca9d-717b-4ac6-b9bb-bccd6de45dea_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants (note 9)</link:label>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_label_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:label id="lab_oncyf_WarrantsandRightsOutstanding_documentation_en-US" xlink:label="lab_oncyf_WarrantsandRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsandRightsOutstanding" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsandRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsandRightsOutstanding" xlink:to="lab_oncyf_WarrantsandRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_ca8c6168-8ce0-4407-a112-fdb0aa2c547a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_006cfc94-0ebb-4843-b56a-e8eb43671033_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant derivative</link:label>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_label_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Change in Fair Value Of Warrant Derivative</link:label>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Change in Fair Value Of Warrant Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:href="oncyf-20221231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:to="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_d053dba9-f61a-4c61-9da4-19c1cad369af_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_253d0202-5e3d-42ca-b889-0210066e2e11_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_892748f6-2bd0-484e-b76b-aa41bcff8f12_terseLabel_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_label_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_documentation_en-US" xlink:label="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="oncyf-20221231.xsd#oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="lab_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_c1f96673-0274-43b2-bb72-0b66578ad896_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OfficeExpenses_62b95932-aaac-4c1f-90dd-b9e103d4af19_terseLabel_en-US" xlink:label="lab_oncyf_OfficeExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office expenses</link:label>
    <link:label id="lab_oncyf_OfficeExpenses_label_en-US" xlink:label="lab_oncyf_OfficeExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Expenses</link:label>
    <link:label id="lab_oncyf_OfficeExpenses_documentation_en-US" xlink:label="lab_oncyf_OfficeExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeExpenses" xlink:href="oncyf-20221231.xsd#oncyf_OfficeExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OfficeExpenses" xlink:to="lab_oncyf_OfficeExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_aebdad2d-9dd5-48ad-8488-2933a2a46589_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, termination benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_7f60deac-1f29-4eb8-912b-50260d42a701_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables (note 5)</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_e7f78b01-d2a9-4d12-8d93-151a8638f1e1_terseLabel_en-US" xlink:label="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 United States ATM</link:label>
    <link:label id="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Shares Under At-the-market Agreement, United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:href="oncyf-20221231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_5b91d0a7-9e78-49a4-bb3f-bcdfaaecfcf1_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_f3f4cb0c-5228-4301-9448-9ad2b9b0957e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_69d96c70-4348-45c2-b2ef-09a2c80dc03a_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:to="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1bec3737-36c1-4dc2-b100-4075cd9acf7d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_439c85e4-37e2-408f-b56f-8160eb5c1b63_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_884d2969-8060-4924-80d2-f336f0a79a1e_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States ATM</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_7e4a5227-7b6b-4890-9f46-b1cb290fbb32_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash impact of foreign exchange</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:href="oncyf-20221231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:to="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_899b02fb-0189-469a-9fd6-5a8956dee7ab_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of depreciation rates</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_a2c373ae-2bce-4486-a01f-4f67af88f8c3_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_2d8c59b8-a126-4526-8aec-b4e39a5b7aa6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets and Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_1ac4d6a8-c15d-4153-bdca-ff75f32b0bac_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementMember" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SaleOfStockAxis_c27cdaf5-8608-403e-95a9-f3093c522569_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_label_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockAxis" xlink:to="lab_oncyf_SaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_242cc469-f0ba-4fbd-b52f-7e6bb474d379_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_38875f73-eb8b-4fc2-a13c-8cd513f8a896_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingExpense_592ec939-0271-409a-b4bf-9522cfac52d7_terseLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative (note 19)</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_label_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="lab_ifrs-full_OperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_5f444b21-7837-4555-977c-83d2f8946e97_terseLabel_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares reserved for issuance (shares)</link:label>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_label_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory_dbd91212-3a52-4bcf-87da-25581f0bd088_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets and Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Currency1Table_b064fcaa-148f-447b-b288-8654c36d630f_terseLabel_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_label_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_documentation_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table" xlink:href="oncyf-20221231.xsd#oncyf_Currency1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1Table" xlink:to="lab_oncyf_Currency1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_919e9ba3-18c3-4c59-a7c8-a24d6999c045_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of options (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_fa69710d-7b10-4dfd-abf4-56d1b509b0e4_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c65e79dc-4943-4e4c-a780-07f2b1523327_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_88d5ce93-f270-48e1-9e01-aac18b3dd518_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AdditionalCashFlowDisclosuresAbstract_label_en-US" xlink:label="lab_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Disclosures [Abstract]</link:label>
    <link:label id="lab_oncyf_AdditionalCashFlowDisclosuresAbstract_documentation_en-US" xlink:label="lab_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:href="oncyf-20221231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:to="lab_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_be820133-faa9-4a91-b807-95a869d5f27a_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_9fe60d85-feb6-4182-b858-58d8d1ac8424_terseLabel_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-capital losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_label_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_documentation_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:href="oncyf-20221231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:to="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_d069e2e3-6ff0-40ac-bc92-d2e894c45594_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_51c1e034-dfbc-426b-b42b-b92dc843094d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_afea1dd1-e8bf-404c-b942-8af8eb6feaf6_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_61e56a14-ee5f-44d7-8089-866dcd727a42_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in other operating payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_99d00484-4d25-4203-8956-9ae53b43f8fa_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_4b9f9488-2c18-4937-a6bb-9254a8f4012d_verboseLabel_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease liability</link:label>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLeaseLiabilities" xlink:to="lab_ifrs-full_GrossLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_7de73791-00fc-4217-8e80-a146a1547e6c_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from warrant exercises</link:label>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_label_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises1</link:label>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1" xlink:href="oncyf-20221231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromWarrantExercises1" xlink:to="lab_oncyf_ProceedsfromWarrantExercises1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_77925c37-d1bd-4148-99d8-3b4cf130eed0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_5470d066-e127-4a5d-ba1d-1062a7d807b2_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Canadian corporate tax rate</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_StockOptionsOutstandingAbstract_6f370cf6-75a1-4b06-8f08-1432b2701bd4_terseLabel_en-US" xlink:label="lab_oncyf_StockOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_oncyf_StockOptionsOutstandingAbstract_label_en-US" xlink:label="lab_oncyf_StockOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Outstanding [Abstract]</link:label>
    <link:label id="lab_oncyf_StockOptionsOutstandingAbstract_documentation_en-US" xlink:label="lab_oncyf_StockOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockOptionsOutstandingAbstract" xlink:href="oncyf-20221231.xsd#oncyf_StockOptionsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract" xlink:to="lab_oncyf_StockOptionsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_8047fc5f-dd58-4acf-a6aa-51dccfde3451_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_008768bb-10db-4972-bf1f-50f388565860_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax credits for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_c0b0f7ce-e3c3-43b9-9ed2-1743a9efc8cf_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_e0143dcc-3b39-4f7f-8c88-18424a65e940_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_335775d0-c940-4972-8797-739f003c4745_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8a91fa4d-1dea-479d-84cc-53ef0c23b467_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_RightOfUseAssetsAbstract_d65ddfd5-239b-40d3-bdbe-6c9d66c1d43e_terseLabel_en-US" xlink:label="lab_oncyf_RightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets [Abstract]</link:label>
    <link:label id="lab_oncyf_RightOfUseAssetsAbstract_label_en-US" xlink:label="lab_oncyf_RightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets [Abstract]</link:label>
    <link:label id="lab_oncyf_RightOfUseAssetsAbstract_documentation_en-US" xlink:label="lab_oncyf_RightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RightOfUseAssetsAbstract" xlink:href="oncyf-20221231.xsd#oncyf_RightOfUseAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RightOfUseAssetsAbstract" xlink:to="lab_oncyf_RightOfUseAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_058edb5d-2895-4c7b-9ab2-2c9e16bc7ba9_terseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember" xlink:to="lab_ifrs-full_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_17ef0809-1aba-4448-8a3b-54d4be6fd01d_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:to="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_a3eef2b4-debc-4081-bf37-bb13d0c1c610_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous other operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_94212033-e918-434c-bada-0eab248ea678_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8a9e832b-9963-4725-a621-46d94178c5b1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c804a5aa-38d7-432a-8241-085f63244f86_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_e8e3a08a-51aa-4369-a941-740d8b07897d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Judgments, Estimates and Assumptions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_b481328c-ff11-40ce-a70d-be1ccc3a2a73_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_2587bb08-fb77-4d3c-ab93-e46b5967b8f6_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:to="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_04c34dde-15ec-4582-b9cf-c1adabc027b9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_3658e83b-b77e-45c1-8802-e60978595f89_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other cash flow disclosures</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:href="oncyf-20221231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:to="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments_b5960066-e4de-4dd3-8b40-3cf393aceca4_terseLabel_en-US" xlink:label="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and current investments</link:label>
    <link:label id="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments_label_en-US" xlink:label="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Current Investments</link:label>
    <link:label id="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments_documentation_en-US" xlink:label="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Current Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashAndCashEquivalentsAndCurrentInvestments" xlink:href="oncyf-20221231.xsd#oncyf_CashAndCashEquivalentsAndCurrentInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashAndCashEquivalentsAndCurrentInvestments" xlink:to="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_111612fd-a39a-43ca-890e-f0ed56ee7c2e_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_3ea0a3de-c9b7-4884-917f-58f2e145b329_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable into common shares (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_LeaseModificationRightOfUseAssets_b7206d1f-4275-44a7-a72f-c5c0fee6b921_terseLabel_en-US" xlink:label="lab_oncyf_LeaseModificationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease modification</link:label>
    <link:label id="lab_oncyf_LeaseModificationRightOfUseAssets_label_en-US" xlink:label="lab_oncyf_LeaseModificationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Modification, Right-Of-Use Assets</link:label>
    <link:label id="lab_oncyf_LeaseModificationRightOfUseAssets_documentation_en-US" xlink:label="lab_oncyf_LeaseModificationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Modification, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_LeaseModificationRightOfUseAssets" xlink:href="oncyf-20221231.xsd#oncyf_LeaseModificationRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_LeaseModificationRightOfUseAssets" xlink:to="lab_oncyf_LeaseModificationRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CollaborationAgreementMember_426d1606-4159-4572-94e5-ad1cf28902ef_terseLabel_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRACELET-1 collaboration agreement</link:label>
    <link:label id="lab_oncyf_CollaborationAgreementMember_label_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_oncyf_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CollaborationAgreementMember" xlink:href="oncyf-20221231.xsd#oncyf_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CollaborationAgreementMember" xlink:to="lab_oncyf_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_be007112-7b15-4db6-82fc-a52ef3e5e56d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_bd6c5398-5924-4fa9-8326-73af76e81cd8_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SaleOfStockDomain_b25bb6ba-d7e7-45ba-bb5b-cb6728cdb682_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_label_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Sale Of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockDomain" xlink:to="lab_oncyf_SaleOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_1bfe7a64-9bb7-4a18-951c-ad4cf312b941_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_d26d9808-aea6-414e-a602-3c932c4669fd_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherEmployeeExpense_c619a51a-1785-4387-acec-daf931fdcb6a_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personnel-related expenses</link:label>
    <link:label id="lab_ifrs-full_OtherEmployeeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other employee expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherEmployeeExpense" xlink:to="lab_ifrs-full_OtherEmployeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_1babf59e-2455-4976-9a7c-a60e92c59ae5_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$3.02 - $3.90</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeThreeMember" xlink:to="lab_oncyf_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_85f158ee-7966-49df-af95-de0c1bbe699a_verboseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_fa8ac833-595b-48e0-a330-93a4f6e875b3_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:href="oncyf-20221231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_81787dc6-0792-4d1c-bdb5-505207957964_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities (note 8)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_13b468a5-6c4d-49f5-aaa5-bd67b0afe2ed_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IntellectualPropertyExpense_3669152b-c0e3-424f-b8ce-44c1cfa56318_terseLabel_en-US" xlink:label="lab_oncyf_IntellectualPropertyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property expenses</link:label>
    <link:label id="lab_oncyf_IntellectualPropertyExpense_label_en-US" xlink:label="lab_oncyf_IntellectualPropertyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Expense</link:label>
    <link:label id="lab_oncyf_IntellectualPropertyExpense_documentation_en-US" xlink:label="lab_oncyf_IntellectualPropertyExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IntellectualPropertyExpense" xlink:href="oncyf-20221231.xsd#oncyf_IntellectualPropertyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IntellectualPropertyExpense" xlink:to="lab_oncyf_IntellectualPropertyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_91cdb5ea-f029-4dae-9591-fa40ff7d7d57_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term employee compensation and benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsMember_ed1dbea4-0d7e-4be6-8ec7-632d53398fe1_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_oncyf_WarrantsMember_e172ea19-caa3-4bde-b43e-d084777d8678_verboseLabel_en-US" xlink:label="lab_oncyf_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_oncyf_WarrantsMember_label_en-US" xlink:label="lab_oncyf_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Member]</link:label>
    <link:label id="lab_oncyf_WarrantsMember_documentation_en-US" xlink:label="lab_oncyf_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsMember" xlink:to="lab_oncyf_WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1412aa21-eee4-477c-80f6-83952be681ba_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f1a6900b-04bf-4c7b-a403-ade89ad61b82_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_6aa81838-ee5e-487a-af81-044672b1d697_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_e17436ff-4a6d-492c-9aa8-dc2eaf46d174_terseLabel_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:href="oncyf-20221231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_0473585d-7190-4cef-b70f-1773815cbc20_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain" xlink:href="oncyf-20221231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Domain" xlink:to="lab_oncyf_IncomeStatementLocation1Domain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_6862773a-6c1c-4f14-bf58-1236b365604a_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseholdImprovementsMember" xlink:to="lab_ifrs-full_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_de783eb7-a0ac-4b4f-baae-9a8f7fb66a23_terseLabel_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net capital losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_label_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_documentation_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:href="oncyf-20221231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:to="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_441ae173-d0af-44ab-9aa6-41486fa5cb19_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustment</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IssueOfEquityShares_12cbb77a-d344-4b2a-b8ca-598ca98ac6a1_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_label_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares" xlink:href="oncyf-20221231.xsd#oncyf_IssueOfEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquityShares" xlink:to="lab_oncyf_IssueOfEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_59202961-39b0-477e-a18c-4f92a1721a61_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9bb11086-0140-4ec8-879f-52e825be1a47_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_321acf7b-000c-423c-afa8-1d41d27fc700_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Domain" xlink:to="lab_oncyf_ConcentrationRiskType1Domain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_d48ba1a1-3806-453d-a2ff-ac2d6799ff35_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_590ad9f6-41be-4b36-ab6c-5af1d5a8eaf6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_78554bfb-5bc6-4b23-a174-fef747d72638_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_5b9a00e3-efc9-497a-8ab3-072f13f687bc_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of tax pools</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_label_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools" xlink:href="oncyf-20221231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfTaxPools" xlink:to="lab_oncyf_TaxEffectOfTaxPools" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_736cffa7-9dfd-4eec-8e4f-80ea11058e85_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of lease liabilities (note 8)</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_dc815b42-80cd-446f-8131-ffeb46cfc140_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_276d5466-8f32-4268-bca5-698e240b54a1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_4eb5dfad-99d6-46a5-83c5-184b2666a546_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_8e7e0653-dfd8-4381-a329-b975cfd027a1_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference in tax rates</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_d452abec-34ea-4ed1-8514-8b07b9a8607a_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration, number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskNumber" xlink:to="lab_oncyf_ConcentrationRiskNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_379347b8-c702-46ae-85d8-217b5933b782_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_6d846132-10bf-4be0-83f4-5d1bb8451b7d_terseLabel_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common share purchase warrant per unit (shares)</link:label>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_label_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Share Purchase Warrant Per Unit</link:label>
    <link:label id="lab_oncyf_CommonSharePurchaseWarrantPerUnit_documentation_en-US" xlink:label="lab_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Share Purchase Warrant Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:href="oncyf-20221231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:to="lab_oncyf_CommonSharePurchaseWarrantPerUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_fbf868ce-4f87-49b9-ab66-4820f0e15714_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease liability</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_1e4c92ae-fcfa-465a-a551-f2630ef3c539_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:to="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_e877fa95-a12a-4e16-bc20-639b18758276_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_0b2cd1f5-7705-4420-b38d-30dfa6903926_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities (note 8)</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_94c7c831-dc8f-4fbd-8176-942d097ff0e0_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification of Officers and Directors</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:to="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_be124bc0-6c57-487d-a47b-2b4586355bc7_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-capital losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember" xlink:to="lab_ifrs-full_UnusedTaxLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_06084b19-ba22-48e9-bb72-e8ca151a799c_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_7419c406-db97-42cb-ae3b-dac741391256_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_0102f6f0-6f88-45ce-939d-2e79ffd7c6cf_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, end of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_bb50156f-0216-44d7-b79f-542ecc6550c5_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_2ef15602-27f9-4b85-ba25-0cb03e623c1b_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_421a4301-dcf8-422b-a9e6-17eedd6a78fa_terseLabel_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue related cost, commissions</link:label>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_label_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Related Cost, Commissions</link:label>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_documentation_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Related Cost, Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions" xlink:href="oncyf-20221231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareIssueRelatedCostCommissions" xlink:to="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_cd0b460d-c79f-4b08-9488-7c080ee4435e_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:href="oncyf-20221231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:to="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_6bd7f796-9c69-4bfd-9e05-9868a94e11ed_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_de263ded-101a-4471-b669-963c7c0f7bff_verboseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember" xlink:to="lab_ifrs-full_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_fb33898c-3e46-4988-86c3-0a1a7ec5c2e5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of number of other equity instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_9eee6cc3-a17d-4813-84c4-e4cfca0c5bd9_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) items that may be reclassified to net loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_ccf30bc3-e6cb-49eb-bfb8-f2f86aac96bf_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$0.54 - $1.79</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeOneMember" xlink:to="lab_oncyf_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_32dcd877-f588-4a43-b615-58b509b5f140_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other operating expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentPrepayments_e260fd7b-9a0e-4831-b67c-2a4c58851c82_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses (note 5)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentPrepayments_872d4aaf-c288-49cb-9e9a-22723334b5c9_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_NoncurrentPrepayments_label_en-US" xlink:label="lab_ifrs-full_NoncurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current prepayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentPrepayments" xlink:to="lab_ifrs-full_NoncurrentPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_16f54925-2b89-45e5-8807-88c687abee19_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReceivables_443a5857-6626-41ee-89c4-27b969805701_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReceivables" xlink:to="lab_ifrs-full_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BB_80070e51-529d-4438-91b9-f2206a8ba208_terseLabel_en-US" xlink:label="lab_country_BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARBADOS</link:label>
    <link:label id="lab_country_BB_label_en-US" xlink:label="lab_country_BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARBADOS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BB" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BB" xlink:to="lab_country_BB" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9971f968-665c-4f1d-9b18-bfa335d9f110_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_a43ad51e-debd-417b-98fc-7ac9d650c743_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_2b726ef3-ee49-4fe0-a2b1-31732ee6c4c2_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$7.42 - $52.63</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFiveMember" xlink:to="lab_oncyf_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_1c92f002-2991-409e-8858-85371036c9f0_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_37f74ecf-7f57-4013-aee6-c31a1fa6762a_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected share price volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_219cc354-4a20-4529-b87f-4c40bb49d02a_terseLabel_en-US" xlink:label="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and marketable securities</link:label>
    <link:label id="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_label_en-US" xlink:label="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents And Marketable Securities [Policy Text Block]</link:label>
    <link:label id="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_documentation_en-US" xlink:label="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents And Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:href="oncyf-20221231.xsd#oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:to="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_a51225e9-87c7-4e0b-b4ad-3f32b144d6fe_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_78ff0f06-e524-4d17-98c7-29f53d83a9f3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_9bb4523d-c270-474a-80a4-b3b7c84c83d7_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_01125432-55d0-4ee8-a8cc-274bd53a54bd_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_afabf587-3238-42a7-96ac-2c2bde9a077f_terseLabel_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_4999c2e7-6399-4736-81d3-42c862925ca2_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options (note 10)</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f0232ef2-5d9d-4488-bd5d-a3215a2c50fc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_39fcaefc-b6d2-41e3-ad54-98bf3b797f77_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend as percentage, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7e119f1b-2747-44fd-963f-a8240adc511b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_26985ddb-c3bf-49e8-9c3a-6c3ffe9db550_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of related party transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_a4be83c8-3cdd-4f19-8c89-67d7f54e79d9_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation - property and equipment (notes 6, 19)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_943bd78a-6645-47ac-8fa4-8b5fdbc3b063_terseLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefits expense</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_fa4a136f-73e3-41a5-a7a5-a6b823fbb0f5_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_label_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_documentation_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfStockOptionPlans" xlink:href="oncyf-20221231.xsd#oncyf_NumberOfStockOptionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfStockOptionPlans" xlink:to="lab_oncyf_NumberOfStockOptionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_be90b88d-e1e9-4f05-bd87-234726246093_terseLabel_en-US" xlink:label="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounts payables and accrued liabilities</link:label>
    <link:label id="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Disclosure Of Trade And Other Payables Explanatory [Table Text Block]</link:label>
    <link:label id="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Disclosure Of Trade And Other Payables Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:href="oncyf-20221231.xsd#oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:to="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_ae2424f9-6c2f-4799-9811-7cbf241fbf0f_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_60e4cc34-ab3d-4222-95da-df74a10fd604_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital issued (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_48d919ce-a44a-4a66-9599-24bf2188df08_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital issued, beginning (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_8c410f28-380b-4404-8e47-cbdc092d7dde_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital issued ending (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_5b6605be-c5dc-4053-8372-8151165b6433_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_BusinessContactMember_14de4332-e0e9-479f-b10c-dbb1e296dbfa_terseLabel_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Contact</link:label>
    <link:label id="lab_dei_BusinessContactMember_label_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Contact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_4cbb2f08-5916-453e-b2ae-5c348e283e9f_terseLabel_en-US" xlink:label="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 United States ATM</link:label>
    <link:label id="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Shares Under At-the-market Agreement, United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:href="oncyf-20221231.xsd#oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_14abf64f-f99f-40cc-b016-997b9b454dd4_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ee16755b-0560-49e1-a75e-db837d0d44fd_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_84d4581c-2831-4581-ab73-ca1fae9c67a5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_51af0182-eae8-4488-9422-ce679389c8c7_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_label_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, Equipment Related Temporary Differences [Member]</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:href="oncyf-20221231.xsd#oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:to="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_9e6f0de2-1348-44cc-a05e-d1c127b62df5_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1.80 - $3.01</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeTwoMember" xlink:to="lab_oncyf_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_489947d8-c185-439f-9046-f4a28914d77c_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated tax recovery</link:label>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income) at applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_fda822b5-b21b-4de1-8d6c-d1385d7d28ec_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationExpense_851fe5d4-6449-46d5-824b-a302460ff8e4_terseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation - property and equipment</link:label>
    <link:label id="lab_ifrs-full_AmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense" xlink:to="lab_ifrs-full_AmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_faddb596-f47f-4ed4-a8a8-46999aa5e51d_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:to="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_cae988c5-4740-4234-8bd4-24b94fd507e7_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:to="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_54b791b4-0931-4c3e-ab9c-6c62497bac49_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_1a2c0e4f-68e7-424f-8427-371fcce6af7d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_a47931f5-61d2-4488-b2cc-9f6bad594c51_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of cash flow statement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_7b9e1a30-b854-49f8-b211-d29896985b21_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_label_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRisk1Table" xlink:to="lab_oncyf_ConcentrationRisk1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_06a4dbc2-e2b9-4a84-8262-61486219585d_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiry of equity warrant agreement (note 9)</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Expiration Of Warrant, Equity</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Expiration Of Warrant, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:href="oncyf-20221231.xsd#oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:to="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_419391f8-1a3c-46b6-ac9d-80b641e42920_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_eb66950a-adc0-4d4f-af86-3d6340199999_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_07a1206d-1790-4e24-a30b-a32ddee27678_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_36ab5521-7674-4946-9379-b995e90a2dd8_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_72b2d98b-fa03-42a3-87e2-f4c481dc2c54_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepayments_5777a810-fa47-48dd-8851-3e527ab0b837_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses (note 5)</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepayments_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current prepayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepayments" xlink:to="lab_ifrs-full_CurrentPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_7e52f0ae-5e4c-4424-acd9-510521e173d3_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued pursuant to warrant derivative exercised (note 9)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_5220c35a-c1b8-4eea-ad5f-d18c88f506a1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_e8631618-04f7-41b1-9a4e-472d97ec55c8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccrualsClassifiedAsCurrent_d01d6dd7-181d-4c3b-a8de-06dfb677176c_terseLabel_en-US" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_AccrualsClassifiedAsCurrent_label_en-US" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals classified as current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="lab_ifrs-full_AccrualsClassifiedAsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_df10a057-6fca-4802-bea9-3e898472b803_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfEquity_06e1d272-3079-4058-b897-09eb83f2ccf8_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued pursuant to "At the Market" Agreement (note 9)</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_a2fdb77d-4efe-409a-8b3c-c7343076e300_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued shares</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_a7188cfa-dd65-4dab-a6f5-d1f8bcf82458_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses and adjustments</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:href="oncyf-20221231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_e20cf0cb-75ed-4a2d-b2f9-8240246f2f17_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets_76f87907-6a86-437d-be78-b7398552260c_terseLabel_en-US" xlink:label="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation - right-of-use assets (notes 8, 19)</link:label>
    <link:label id="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets_label_en-US" xlink:label="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Depreciation, Right-of Use Assets</link:label>
    <link:label id="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets_documentation_en-US" xlink:label="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Depreciation, Right-of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:href="oncyf-20221231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:to="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_48651715-0f04-4d23-b609-3cfaf9fd4dee_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_35aa845d-d974-4f2b-a90a-5685e0f66aba_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_cf9a78b0-6af3-4fe6-9481-e9e803faf3a1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_cebed5c4-9d90-46cf-b4d6-80ac9cef0a9d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_8da6a287-fdfe-4371-9b09-1951dec60135_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_ba081118-144c-416b-922c-b0bbb0379b48_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, beginning balance</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_c404b61e-66be-4cb9-8a83-78ab98377a30_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, ending balance</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_dbfb0a2b-9bfa-4999-9f64-9c15174a15c4_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_d869e6e8-f9c8-4ada-8eef-c47831520775_terseLabel_en-US" xlink:label="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_label_en-US" xlink:label="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label id="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio_documentation_en-US" xlink:label="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:href="oncyf-20221231.xsd#oncyf_StockholdersEquityNoteStockSplitConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:to="lab_oncyf_StockholdersEquityNoteStockSplitConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_287e8094-2ad0-40c5-b68b-253a0b985d22_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesMember_583beba7-b00c-4c7d-9713-a9f9d02e8e9f_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges</link:label>
    <link:label id="lab_ifrs-full_RangesMember_label_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_2a531b39-69f4-4ffb-a00a-f7cbeeaf2454_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_Equity_2b9629a7-8a6c-46fb-a076-d241b43e5edc_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity balance at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Equity_b0fbaf52-8411-44a8-a0ea-549f33ead9fb_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity balance at end of period</link:label>
    <link:label id="lab_ifrs-full_Equity_3b560122-1daf-4697-9610-97de728842b4_terseLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_b2181946-68bd-4eb5-9bfe-f6163280ce1e_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_f1f6fca0-da42-4f9a-ba52-2d6e2e6b983c_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClinicalTrailExpense_5f930f5d-fa8e-45cc-8f4d-01a11aa3f76e_terseLabel_en-US" xlink:label="lab_oncyf_ClinicalTrailExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial expenses</link:label>
    <link:label id="lab_oncyf_ClinicalTrailExpense_label_en-US" xlink:label="lab_oncyf_ClinicalTrailExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trail Expense</link:label>
    <link:label id="lab_oncyf_ClinicalTrailExpense_documentation_en-US" xlink:label="lab_oncyf_ClinicalTrailExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trail Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrailExpense" xlink:href="oncyf-20221231.xsd#oncyf_ClinicalTrailExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClinicalTrailExpense" xlink:to="lab_oncyf_ClinicalTrailExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_235c8266-a331-49b4-907b-8b61ec8773f5_terseLabel_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_label_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Impact, Right-of-Use Assets</link:label>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_documentation_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Impact, Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:href="oncyf-20221231.xsd#oncyf_ForeignExchangeImpactRightofUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:to="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesIssuedFairValueOfCommonShare_cde34409-9cb9-4f8d-8014-23cf5fe364fc_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedFairValueOfCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, fair value of common share (usd per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedFairValueOfCommonShare_label_en-US" xlink:label="lab_oncyf_SharesIssuedFairValueOfCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Fair Value Of Common Share</link:label>
    <link:label id="lab_oncyf_SharesIssuedFairValueOfCommonShare_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedFairValueOfCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Fair Value Of Common Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedFairValueOfCommonShare" xlink:href="oncyf-20221231.xsd#oncyf_SharesIssuedFairValueOfCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedFairValueOfCommonShare" xlink:to="lab_oncyf_SharesIssuedFairValueOfCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_a4f8eeba-1302-4e46-ba02-7283a3edaa07_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_28871645-c3e2-4d0c-a45c-88137e85ac41_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued pursuant to stock option plan (note 10)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_c15b9fe0-7e14-47f5-b6c5-3ca65b223d8b_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_4cda6781-981f-441f-aba8-ad53c925e3d4_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRevenueExpense_39dbf9d9-72b4-49c4-91a2-324b5cc8aa75_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestRevenueExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income) expense, net</link:label>
    <link:label id="lab_ifrs-full_InterestRevenueExpense_label_en-US" xlink:label="lab_ifrs-full_InterestRevenueExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRevenueExpense" xlink:to="lab_ifrs-full_InterestRevenueExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Statement1LineItems_62c2412c-c368-4f75-b418-7a8419d62c2b_terseLabel_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_label_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_documentation_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Statement1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems" xlink:href="oncyf-20221231.xsd#oncyf_Statement1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1LineItems" xlink:to="lab_oncyf_Statement1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_fb386c3f-0644-429d-abe7-e9c863d39eb1_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_5898ccd4-444f-4a1b-b504-eab7d2ab2a2b_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_625849c8-2a86-48b3-a3c0-0b3cfdf8cc29_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_629d7baf-5106-4fe9-8761-127540f80ac7_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9c34578d-d28a-4194-8786-60626d4e2355_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OfficeEquipmentAndFurnitureMember_fd6759bd-17f0-4863-b1d6-3212ee84824e_terseLabel_en-US" xlink:label="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment and Furniture</link:label>
    <link:label id="lab_oncyf_OfficeEquipmentAndFurnitureMember_label_en-US" xlink:label="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment and furniture [Member]</link:label>
    <link:label id="lab_oncyf_OfficeEquipmentAndFurnitureMember_documentation_en-US" xlink:label="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeEquipmentAndFurnitureMember" xlink:href="oncyf-20221231.xsd#oncyf_OfficeEquipmentAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OfficeEquipmentAndFurnitureMember" xlink:to="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_9d6cb453-f171-4264-81b4-627ae480868c_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_fd19c6e6-9092-451d-9d1e-4856cce14c09_verboseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of capital components</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:to="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_2ae2c382-b626-4d85-a884-d8d7e2b4df8d_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:href="oncyf-20221231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:to="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_ee69c55d-d5f3-43c2-b634-e40de8e4e0a4_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Concentration Risk Type1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems" xlink:to="lab_oncyf_ConcentrationRiskType1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_d83b97e7-47b0-4c85-ad54-1949f09c5f2e_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_78d5a10b-0f42-476b-90d1-a746bba90237_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and other comprehensive income (loss)</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_0c111e71-b4e8-41fe-8b1d-89e040581958_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:to="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContingenciesAbstract_6ac35a3c-7f2f-44e6-808c-b01d3f5d8467_terseLabel_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:label id="lab_oncyf_ContingenciesAbstract_label_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:label id="lab_oncyf_ContingenciesAbstract_documentation_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract" xlink:href="oncyf-20221231.xsd#oncyf_ContingenciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingenciesAbstract" xlink:to="lab_oncyf_ContingenciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_1d4d5f00-090a-488b-b68b-e6d0b413917b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue costs (note 9)</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_e92da9df-1d1e-493a-b0dc-48aebbc13d93_negatedLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_0051e06f-f7b3-430a-bca1-0ef7d0f1b146_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue related cost</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_label_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue related cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost" xlink:to="lab_ifrs-full_ShareIssueRelatedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_16e35839-458e-4b50-9aac-a2761f0b3a89_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_ffd88836-0355-4aac-a412-df30fb4b95c7_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_f4bc9c74-752d-4713-8a61-6157ad3cc093_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_b07c8971-5853-4504-95a1-48d4efc54b1e_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm" xlink:href="oncyf-20221231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementTerm" xlink:to="lab_oncyf_SharePurchaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9f9d695e-b296-4cfe-ac39-c46b39392558_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions, net of foreign exchange impact</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_737e758b-ea7e-4114-aeec-8ac3437df2e8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_c71202a0-4faf-443c-91e1-fcb544a93dc3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_5e3b4322-bc09-4045-80c6-7721f843fc69_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in other operating receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_a8b7604e-1fd6-4d6a-aa6c-d74c9ec83315_terseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed scientific research and experimental development expenditures</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_e23be321-a385-42cc-8c13-45d76a3bac2a_verboseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific research and experimental development</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_label_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_documentation_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:href="oncyf-20221231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:to="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_EquityAuthorized_4e358b8e-ac9b-461e-a744-7525b83a4506_terseLabel_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Shelf securities authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_label_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_documentation_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EquityAuthorized" xlink:href="oncyf-20221231.xsd#oncyf_EquityAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_EquityAuthorized" xlink:to="lab_oncyf_EquityAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_330f5482-89b0-4b35-bf4a-c9ac8c69e07c_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual depreciation rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_label_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:href="oncyf-20221231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:to="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_6ce4af50-46c7-43d8-bab7-78bc1924bbb4_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_f6badd15-2786-4b49-b123-80310bf12665_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_74f781d8-9567-4ec3-9531-3a5b4bdbab1c_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_833b3c85-9716-4521-b2ce-22832df10042_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_083883b6-3906-4c08-9bad-637302273114_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_93f60cdc-9499-4202-b239-c386473dc692_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_dad808f7-5851-43a9-973b-ca1a89a48464_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccountingProfit_830a960e-3169-4c1f-8d59-2ea806e3c464_terseLabel_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_AccountingProfit_label_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccountingProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit" xlink:to="lab_ifrs-full_AccountingProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_680adfd6-0d51-42d5-871e-550985e343e7_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Axis" xlink:to="lab_oncyf_ConcentrationRiskType1Axis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_1420c3e1-f3e3-4068-9336-1d0a951e05e2_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares (basic) (shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_2e1fb4f7-88a4-4cb6-b679-f15f373861ed_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding (shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_6bbdeb8a-ef83-45fc-93e9-2bfc1c864690_terseLabel_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted share units</link:label>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_label_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units [Member]</link:label>
    <link:label id="lab_oncyf_RestrictedShareUnitsMember_documentation_en-US" xlink:label="lab_oncyf_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember" xlink:href="oncyf-20221231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RestrictedShareUnitsMember" xlink:to="lab_oncyf_RestrictedShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_9a658744-bdb2-48c5-a614-7c0264e3eea8_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights2</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:to="lab_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_62aa10a3-a064-412e-ad1c-01f6c5672b93_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5b128b9a-8307-4874-bb73-864b47334c5e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_c8ff3616-7db8-41ab-8898-d88b2139ba5a_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesMember_a733a9b2-47a6-4678-989b-c59caee585d3_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesMember" xlink:to="lab_ifrs-full_LiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities_da4fe56a-e41f-4826-9e90-3f2c1a71b186_terseLabel_en-US" xlink:label="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease modification</link:label>
    <link:label id="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities_label_en-US" xlink:label="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Lease Modification on Lease Liabilities</link:label>
    <link:label id="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities_documentation_en-US" xlink:label="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Lease Modification on Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EffectOfLeaseModificationOnLeaseLiabilities" xlink:href="oncyf-20221231.xsd#oncyf_EffectOfLeaseModificationOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_EffectOfLeaseModificationOnLeaseLiabilities" xlink:to="lab_oncyf_EffectOfLeaseModificationOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_0830be63-7a9e-4cfe-8ff7-22926b5aa214_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_13b59828-17d5-4b4f-a26d-97653845e075_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_f9a62dd1-905e-42b0-a6c2-79c5a48bce2a_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_19adc8aa-fe54-4c63-9b32-513468808b30_verboseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_c923b8de-33c9-48d5-b9ce-480a0cfee139_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per common share (cad per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_bf0c01dc-08e1-4284-83a3-420e5a105504_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share transactions</link:label>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_label_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major ordinary share transactions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_fd004b37-a382-4a9d-ad71-eb487e433ba0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_885d947c-13af-4bca-ac87-e221fa078b7e_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Currency1LineItems_a3169e60-4acb-4196-b876-fac08ea62e99_terseLabel_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_label_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_documentation_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Currency1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems" xlink:href="oncyf-20221231.xsd#oncyf_Currency1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1LineItems" xlink:to="lab_oncyf_Currency1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PublicCompanyExpense_5f3d65f6-e253-42a8-8a93-16bdd78c4658_terseLabel_en-US" xlink:label="lab_oncyf_PublicCompanyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public company-related expenses</link:label>
    <link:label id="lab_oncyf_PublicCompanyExpense_label_en-US" xlink:label="lab_oncyf_PublicCompanyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Company Expense</link:label>
    <link:label id="lab_oncyf_PublicCompanyExpense_documentation_en-US" xlink:label="lab_oncyf_PublicCompanyExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Company Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PublicCompanyExpense" xlink:href="oncyf-20221231.xsd#oncyf_PublicCompanyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PublicCompanyExpense" xlink:to="lab_oncyf_PublicCompanyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_bbedabcb-7d63-4408-ae2b-76be57cfc2c7_terseLabel_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from common shares</link:label>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds From Issue Of Ordinary Shares</link:label>
    <link:label id="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares_documentation_en-US" xlink:label="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds From Issue Of Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:href="oncyf-20221231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:to="lab_oncyf_GrossProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_ea91e68b-652e-43e6-834e-f64c68f1a602_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign exchange on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_195377cf-4dd9-4170-887f-1e43153ffc6b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_7cf1b949-d9aa-48e3-a33a-fd0f5237362a_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributed surplus (note 10)</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapital" xlink:to="lab_ifrs-full_AdditionalPaidinCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GainsLossesFromForeignExchangeImpact_0137b25f-3b15-44f3-8bcf-68b564a1af77_terseLabel_en-US" xlink:label="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_oncyf_GainsLossesFromForeignExchangeImpact_label_en-US" xlink:label="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) From Foreign Exchange Impact</link:label>
    <link:label id="lab_oncyf_GainsLossesFromForeignExchangeImpact_documentation_en-US" xlink:label="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) From Foreign Exchange Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact" xlink:href="oncyf-20221231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GainsLossesFromForeignExchangeImpact" xlink:to="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_54475386-f14c-4881-bc25-f1176dc7ab81_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_9cb78c43-34f2-4eb4-ba59-a03985e5b66d_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_a8bce03e-ebc6-4748-88ed-4677d490f994_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_label_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses by nature [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract" xlink:to="lab_ifrs-full_ExpenseByNatureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_b8dcedbf-018c-448b-a8d0-6d3763bd7d63_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before the following</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_872a6ff8-2f91-4141-aa42-0ce10d126136_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareCapitalNumberSharesAbstract_52b6d78f-7f03-4f82-8c0f-b45be6f45dbb_terseLabel_en-US" xlink:label="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number</link:label>
    <link:label id="lab_oncyf_ShareCapitalNumberSharesAbstract_label_en-US" xlink:label="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Number, Shares [Abstract]</link:label>
    <link:label id="lab_oncyf_ShareCapitalNumberSharesAbstract_documentation_en-US" xlink:label="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Number, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalNumberSharesAbstract" xlink:href="oncyf-20221231.xsd#oncyf_ShareCapitalNumberSharesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract" xlink:to="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_9081b1d5-e36c-45e5-b11d-9cf17f4475c4_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_46d4183b-8bca-4f01-bead-91e07b1e2e4e_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommonSharesPerUnit_0c09afb8-ee07-4aa2-b926-1cb10f98f532_terseLabel_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares per unit (shares)</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_label_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_documentation_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit" xlink:href="oncyf-20221231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommonSharesPerUnit" xlink:to="lab_oncyf_CommonSharesPerUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_2270da47-3d69-4afd-b4cf-5030071a61fe_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in non-cash working capital (note 17)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_17c7c12f-3f87-45f9-96b3-dcbec99d99af_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-cash working capital related to operating activities</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsAndRightsExpired_fff9b2de-b9ca-492e-877c-7f2a9eae77ba_negatedTerseLabel_en-US" xlink:label="lab_oncyf_WarrantsAndRightsExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsExpired_label_en-US" xlink:label="lab_oncyf_WarrantsAndRightsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Expired</link:label>
    <link:label id="lab_oncyf_WarrantsAndRightsExpired_documentation_en-US" xlink:label="lab_oncyf_WarrantsAndRightsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsExpired" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsAndRightsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsAndRightsExpired" xlink:to="lab_oncyf_WarrantsAndRightsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_02aefd15-6250-46c5-8550-e6384a8cf0cf_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_bff5420c-3d5b-4910-84d5-980a6a289e40_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense (notes 10, 19, 20)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_f5234fbd-bb8c-4c34-a133-505c271d3121_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_05dc2988-abe8-4189-8066-25a445cd6970_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant derivative (notes 9(b), 16)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_98db7312-eaf9-44b5-82f4-c07833ba9c99_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant derivative (note 16)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_87cf1007-3a05-4783-93a4-ccfcaac84a99_terseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease through performance obligation being satisfied, contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:to="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_a9c08a40-8058-4254-99b3-a8683c1c0230_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_7f575fa8-74c6-4583-b7e4-f76b7f10f107_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_eaa4e70d-e766-4cbd-8e29-9f7d2a617ec6_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_8cbeed9d-1ff2-4244-ae58-b1564275ab2e_negatedTerseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in net loss due to change in currency value</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:href="oncyf-20221231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_e70f2ad4-38fa-4ac4-bd8f-51e9665f6f08_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares issuable per warrant (shares)</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:to="lab_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityMember_8295992d-4279-402e-bf7a-0b0a1f64c35b_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_EquityMember_label_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_MedicalEquipmentMember_54a0aa55-509e-48d5-8689-82359f1bb868_terseLabel_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical equipment</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_4c9a62b7-1e6d-4253-9572-3642308c8a6e_verboseLabel_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Equipment</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_label_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_documentation_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember" xlink:href="oncyf-20221231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MedicalEquipmentMember" xlink:to="lab_oncyf_MedicalEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_4a3c8f62-5d69-4c34-8727-0cb6e01d39a1_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurement</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_12760440-b993-4c78-8004-68a5f8a8a5e9_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of marketable securities</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of financial instruments, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_14571a4a-b228-4bbe-8781-13ab77c9d5b7_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable" xlink:href="oncyf-20221231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentInvestments_7e0ec2e6-2407-4939-a4df-71e36ffca06a_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_ifrs-full_CurrentInvestments_label_en-US" xlink:label="lab_ifrs-full_CurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentInvestments" xlink:to="lab_ifrs-full_CurrentInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_91fbe55c-af1d-4f54-9ccf-ae306e8428b9_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_d595ffcb-3bf8-44a8-88b1-ae5caebc8104_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_1cc76985-d2a4-4d07-908f-b0e3e23e146e_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Outstanding (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_c9854a34-a6e1-485e-9d90-28d6a8fc548f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of trade and other payables [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_16c0ea56-8ebf-4e6c-95a1-4353ff024bc7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_d73d1fad-b0d4-4b26-b559-df071eff56d0_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More than five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_9abe2aff-2616-4715-a123-6a28212548a8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Statement1Table_5ff9ff33-9415-4366-b555-890200212828_terseLabel_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_label_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_documentation_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table" xlink:href="oncyf-20221231.xsd#oncyf_Statement1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1Table" xlink:to="lab_oncyf_Statement1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_a8bccd6b-26be-4c9f-863c-839b5e44ddea_terseLabel_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected recognition period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_label_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_documentation_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod" xlink:href="oncyf-20221231.xsd#oncyf_ContractLiabilityRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContractLiabilityRecognitionPeriod" xlink:to="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_89c7535e-b52c-4e19-84ba-b059d48ae8a5_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of share-based payments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_01742652-d131-4781-968d-11df40ec9e87_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract" xlink:to="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_4112ef11-a067-4263-ad3c-77faa16a84b5_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpenseMember_a51568e6-ab5b-48db-907e-4c32bb4edd55_terseLabel_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense [Member]</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpenseMember_documentation_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpenseMember" xlink:href="oncyf-20221231.xsd#oncyf_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseMember" xlink:to="lab_oncyf_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_07691f58-10cb-4af0-9478-c74e96782b04_terseLabel_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All levels of fair value hierarchy</link:label>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_95743476-729d-496d-95a3-55fbf747f771_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_78769069-3868-47f9-acd9-525294fe7fca_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_70ce31c1-b000-43b1-8803-1d68a89d6340_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and deposits</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_b6a251e2-704b-420d-8e83-bc9bcbf4e5d2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_fbc283f2-aecd-416f-ad72-c4851276246d_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities (note 5)</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_3c28c563-1e5d-4a23-9af2-2466b1a6e41b_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_534b7e35-3fc8-4296-88de-d54768e94503_verboseLabel_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period, if not immediately vested</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_documentation_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:href="oncyf-20221231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_07f7af82-4ec5-4024-8337-95c804b636b7_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (years)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_6107311a-a7e2-4140-9a0b-994520e6a6d1_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_65eb1770-b72b-4c64-b411-a2bba60d1d47_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_2fafa275-2b75-4ff8-8784-e918257bc324_terseLabel_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_label_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_documentation_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:href="oncyf-20221231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:to="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits_69fd3363-61ca-445c-9a23-19cede9e5523_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiry of tax benefits</link:label>
    <link:label id="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits_label_en-US" xlink:label="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Expiration Of Tax Benefits</link:label>
    <link:label id="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Expiration Of Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:href="oncyf-20221231.xsd#oncyf_TaxEffectOfExpirationOfTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:to="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_56c185cf-0100-4e84-8a8b-6e44923cdd94_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_8ce3d8e3-64a4-4836-8014-e9fa11b53c85_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_13b8a307-3798-41a0-a5ef-cb9db697f3ec_terseLabel_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_98e41262-0760-4efa-9a44-bf89da8412f7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_a0c203aa-e63f-4e0e-be8f-e85ba809af86_terseLabel_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:href="oncyf-20221231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:to="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_d39baad4-bf12-4c82-838e-bbb6aa3d5bbc_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount" xlink:href="oncyf-20221231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementAmount" xlink:to="lab_oncyf_SharePurchaseAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentFinancialAssetsAvailableforsale_e6e3b0e9-608a-4b97-a327-a0eec45c2a82_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_ifrs-full_CurrentFinancialAssetsAvailableforsale_label_en-US" xlink:label="lab_ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current financial assets available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssetsAvailableforsale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:to="lab_ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_9ced9e7f-adc6-4c7d-84b7-687f1e5b64fe_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_852c15ce-53d3-4146-85b2-575ece1fa675_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense (note 10)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_b141a004-1281-464a-b087-48ffd983527c_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8eef235e-33a9-4919-abc2-07acb0545b23_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_0f3792b9-3056-4223-aaa7-4d97440a55f0_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for deferred income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_841d4a26-2b4c-4f4a-a289-ab2961b090d2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_eccfb813-2fb9-4c17-ba1f-ecc405c48978_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributed Surplus</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAvailableforsale_84ae821b-d369-4333-8514-1856fe454659_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAvailableforsale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAvailableforsale_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAvailableforsale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAvailableforsale" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAvailableforsale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAvailableforsale" xlink:to="lab_ifrs-full_FinancialAssetsAvailableforsale" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_85606ad9-1c11-4e86-9d9c-cfbff07f2992_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards and Interpretations Issued but Not Yet Effective</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AuditorInformationAbstract_label_en-US" xlink:label="lab_oncyf_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_oncyf_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_oncyf_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AuditorInformationAbstract" xlink:href="oncyf-20221231.xsd#oncyf_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AuditorInformationAbstract" xlink:to="lab_oncyf_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_81e0355c-cbf7-43c4-a04e-e8f8d23189ae_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_832e6217-14d1-4422-8abc-194d46e59e06_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_0f0d316a-ea56-4f9d-8286-5750f286760d_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_aeba039c-da4f-410e-8ac0-ae85d8780137_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_46e82cc0-a3b0-4766-a9d2-35d12d225be2_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant derivative (notes 9(b), 16)</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_2ab0b034-2b6d-49cb-977e-06e79741571b_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant derivative</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_f9ab1526-ee6a-4a52-9ddf-2df34c3a0052_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_5c25c15d-faaa-44da-9884-a56e9bfb0966_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PurchaseObligation1_27ec6dac-c4bb-44a7-a208-b52d613d9073_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment for payment</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_label_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1" xlink:href="oncyf-20221231.xsd#oncyf_PurchaseObligation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligation1" xlink:to="lab_oncyf_PurchaseObligation1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_0f218f39-34f3-49a6-a093-c3353582252b_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_774f3b20-6926-4d39-a1f8-a4906b0e2ddc_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:to="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpenseAbstract_7620d442-9730-45a1-8af0-757a3e326b9f_terseLabel_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpenseAbstract_label_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense [Abstract]</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpenseAbstract_documentation_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpenseAbstract" xlink:href="oncyf-20221231.xsd#oncyf_ResearchAndDevelopmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract" xlink:to="lab_oncyf_ResearchAndDevelopmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_093582af-770c-4c49-92bb-6629d8145210_negatedTerseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_label_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation" xlink:href="oncyf-20221231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfStockBasedCompensation" xlink:to="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_4c271136-87ef-4067-920b-1359a1bd6362_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_1990f36c-eb32-437b-95d2-32bb6437c00a_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_569fdabb-b532-4888-963c-8ff630982f83_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_0c869e2b-e9a0-4156-900a-b41b6a22a8d1_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_3db42abb-5308-4b43-9d00-a4032ca5ef7f_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_086a976f-7184-4b9d-8f4d-a04be4d88e87_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_74c69194-6a00-46c0-aa70-032b804f3faa_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital (note 9) &#160;&#160;Authorized: unlimited &#160;&#160;Issued: December 31, 2022 &#8211; 61,327,914 December 31, 2021 &#8211; 55,043,789</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_3790cdab-e74b-433d-8311-e5a0902ca683_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (notes 13)</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_label_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_documentation_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1" xlink:href="oncyf-20221231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsAndContingencies1" xlink:to="lab_oncyf_CommitmentsAndContingencies1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_2b1d2aaf-2d93-4dfa-b4f7-536ee96653fe_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability (note 12)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_e608ceea-2392-438c-9c60-dabba675ae82_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Economic Dependence</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_eeb5cebb-493b-49b8-a6fb-dc0e674d0176_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_c4a5b47a-2efd-4d95-aa15-216e48f27eb4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_b3400cc1-2cfa-42e7-b737-c1e70511b538_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_fe0d2dbb-bb4f-4fab-b97c-17769cbd7079_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$3.91 - $7.41</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFourMember" xlink:to="lab_oncyf_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_f1ed579b-2803-45c3-9415-dbbfa49aad50_terseLabel_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toll manufacturer</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_label_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_documentation_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member" xlink:href="oncyf-20221231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SupplierConcentrationRisk1Member" xlink:to="lab_oncyf_SupplierConcentrationRisk1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_be254765-6b8c-4392-b9b8-23ed4cfc2592_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_35372205-63c5-4701-aaa9-9a2fbc29b333_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_85d391b9-71c8-4469-acd6-8cc89c29fade_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelName_e8e3b8ea-e82b-48f8-b509-5a016d99d5dc_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:label id="lab_dei_ContactPersonnelName_label_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_74043cc4-7377-425d-9777-65d907e391a1_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment (note 6)</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_e9d5aae1-3eee-4fd1-bb95-ba394ba827c1_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities And Shareholders&#8217; Equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_d31f8aba-dd8e-458b-bcd4-53470e33b5e4_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_f39af9d8-1f47-40c9-891e-4b37b4fb2d97_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofincometaxAbstract" xlink:to="lab_oncyf_DisclosureofincometaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_81e01f49-3119-4a7b-9a11-5df9284c5ea5_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities (note 7)</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_b50109ca-2f2a-4796-a034-18ebcef7c712_totalLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_bf7d1834-5fc2-4861-a91b-1e00f6add251_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_f6b1076f-eaf2-4c92-aaa5-425b5f730c0e_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_1680c71e-9bab-41e9-b24a-fec318dc6582_terseLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_00a3aa2a-738a-4367-92cd-2d3a36fcfd89_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure weighted average assumptions and fair value of options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_35a839ca-ccd8-4391-9885-a86035c96e56_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment term</link:label>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_label_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Commitment Term</link:label>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Commitment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentTerm" xlink:href="oncyf-20221231.xsd#oncyf_PurchaseObligationCommitmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligationCommitmentTerm" xlink:to="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_602c0495-e298-4357-943c-e27880f06d89_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive award plan</link:label>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_label_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Incentive Award Plan [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:to="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_ff44ba87-8a10-4fd5-a213-d176f1c3cb3a_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability balances</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Explanation of significant changes in contract assets and contract liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_9242ceca-29c4-4be5-8ef2-12243ad45974_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_45f98eff-8675-4755-8009-7e3d88172146_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions</link:label>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisionsMember" xlink:to="lab_ifrs-full_OtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_649b7bff-12a0-40fa-b3ec-18f48e58091c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_12bb396d-6949-4a32-a17e-45c6412f4d70_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpenseMember_c005f5cb-fd99-434a-8528-07337fa3e7c4_terseLabel_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General And Administrative Expense [Member]</link:label>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpenseMember_documentation_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpenseMember" xlink:href="oncyf-20221231.xsd#oncyf_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseMember" xlink:to="lab_oncyf_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfSharesExpired_f2d759bc-81d0-4cdb-aaa6-e84386880a48_negatedTerseLabel_en-US" xlink:label="lab_oncyf_NumberOfSharesExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (shares)</link:label>
    <link:label id="lab_oncyf_NumberOfSharesExpired_label_en-US" xlink:label="lab_oncyf_NumberOfSharesExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Expired</link:label>
    <link:label id="lab_oncyf_NumberOfSharesExpired_documentation_en-US" xlink:label="lab_oncyf_NumberOfSharesExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfSharesExpired" xlink:href="oncyf-20221231.xsd#oncyf_NumberOfSharesExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfSharesExpired" xlink:to="lab_oncyf_NumberOfSharesExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_b2db20c0-d67d-43e5-a073-29778aaeda78_terseLabel_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in non-cash working capital</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_label_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:href="oncyf-20221231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:to="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_0ebc557e-da2f-4e4d-ae39-aa73a495cc69_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liability</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_c01a713e-a378-4ec9-be46-081b30ef797c_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. dollars</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_22e134ca-6d38-42ba-80d3-6fccf740751e_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_92652be6-65f3-48ea-a1ce-af71cf03d2cc_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss for the year</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_8e62639f-d756-44f5-9ffe-f9698bf09f0a_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash interest received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_label_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromInterestReceived" xlink:href="oncyf-20221231.xsd#oncyf_ProceedsfromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromInterestReceived" xlink:to="lab_oncyf_ProceedsfromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_54553426-9e74-4cdf-9cb0-b2579c3ba1cc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelEmailAddress_87d21f10-71c7-498d-9719-fdd8ad888def_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelEmailAddress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Email Address</link:label>
    <link:label id="lab_dei_ContactPersonnelEmailAddress_label_en-US" xlink:label="lab_dei_ContactPersonnelEmailAddress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Email Address</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress" xlink:to="lab_dei_ContactPersonnelEmailAddress" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract_adab6106-5da8-477a-b7dd-4f85cf39dc37_terseLabel_en-US" xlink:label="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price $</link:label>
    <link:label id="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract_label_en-US" xlink:label="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Outstanding [Abstract]</link:label>
    <link:label id="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract_documentation_en-US" xlink:label="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:href="oncyf-20221231.xsd#oncyf_WeightedAverageExercisePriceOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:to="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_bc65c79c-e43d-4edd-a74a-2adf5c7cea69_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One to five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractLiabilities_b7f8835f-83f8-46d4-b2ce-01ec31715f41_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_723c9bee-02c2-42fa-8f12-724b68c65211_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities" xlink:to="lab_ifrs-full_ContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_5ab65003-bba2-4a3f-81a5-59c966642c61_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per common share (cad per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashEquivalents_74b08135-eb0f-45a6-b08d-c33a25ce721a_terseLabel_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashEquivalents" xlink:to="lab_ifrs-full_CashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_de88f0df-1b0d-45ef-9def-0feea4c8d973_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesPublicOfferingEquityWarrantsMember_d453f031-f49a-4ad0-bc39-9ecb3dd39669_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Equity Warrants</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingEquityWarrantsMember_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Equity Warrants [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingEquityWarrantsMember_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Equity Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:href="oncyf-20221231.xsd#oncyf_SharesPublicOfferingEquityWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:to="lab_oncyf_SharesPublicOfferingEquityWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_24808744-6ff8-4e17-a7a8-83ff2c3b0465_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_135b5050-362b-431d-8cc9-6b2421558c30_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TranslationalScienceExpense_6b27c424-6866-442c-a6d0-f1e1e6c29184_terseLabel_en-US" xlink:label="lab_oncyf_TranslationalScienceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translational science expenses</link:label>
    <link:label id="lab_oncyf_TranslationalScienceExpense_label_en-US" xlink:label="lab_oncyf_TranslationalScienceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translational Science Expense</link:label>
    <link:label id="lab_oncyf_TranslationalScienceExpense_documentation_en-US" xlink:label="lab_oncyf_TranslationalScienceExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translational Science Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TranslationalScienceExpense" xlink:href="oncyf-20221231.xsd#oncyf_TranslationalScienceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TranslationalScienceExpense" xlink:to="lab_oncyf_TranslationalScienceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_33b5c6fd-b6ff-4d4f-bfce-039bb4f18c8a_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation of key management personnel</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_3007ea0d-fc46-4d28-a0c8-86d517867f96_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (note 14)</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_67c323c4-9165-47ac-9404-acc0194a6dfd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_13e4527c-3771-466f-b486-e6427f939cb9_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_60a91d7b-0f94-4993-9787-49f22995d7fe_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign exchange (gain) loss</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3b34aeaf-3c8a-4b28-a1ab-202f85f55d82_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_87c8e658-1053-4291-8893-497655bc1b4c_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of outstanding warrants</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_947f923b-a89c-45e5-aa49-f6f012eff5c5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_af5d6a48-80ae-4309-a34f-45ccf61f2046_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_fcd19244-64f6-476d-a291-ec78dad9c2dd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_76f93e6c-8684-4682-9a9c-05fd1e8bd167_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_14b261bd-7eaa-4045-aada-157e951787ff_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_8e7b2049-1a0d-4b0a-b527-3669c04d031c_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets (note 8)</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_57d1641a-e1d8-44ff-ab7d-0fb02d5abf21_periodStartLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, beginning balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_b64dfc6a-1724-4126-a2ad-f48e417a57f7_periodEndLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, ending balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_e8c7760e-bd74-4835-9729-3c696920e6a2_terseLabel_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_label_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_documentation_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet" xlink:href="oncyf-20221231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_BalanceHeldInForeignCurrencyNet" xlink:to="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_6ac32766-8c26-49f8-8baa-6083a119d359_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d721eb4c-aa0c-454a-95b9-b8359bfaac03_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_12499c91-e8ae-416e-9b2f-c675bc65ec0e_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average rate</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:to="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_d043f2ec-e127-4024-97e3-bff0e33044a9_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares (diluted) (shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_0ef870b8-bbea-4686-8464-9db972c33ed7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_b686e1f8-213d-4034-a680-2354a2fbbd93_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_a290b2fc-831a-4f56-9c5a-82c74ced4146_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ManufacturingExpense_b5029a73-c97a-43ac-86ed-b41c3a6e6086_terseLabel_en-US" xlink:label="lab_oncyf_ManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing &amp; related process development expenses</link:label>
    <link:label id="lab_oncyf_ManufacturingExpense_label_en-US" xlink:label="lab_oncyf_ManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Expense</link:label>
    <link:label id="lab_oncyf_ManufacturingExpense_documentation_en-US" xlink:label="lab_oncyf_ManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ManufacturingExpense" xlink:href="oncyf-20221231.xsd#oncyf_ManufacturingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ManufacturingExpense" xlink:to="lab_oncyf_ManufacturingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_f44f70f9-47df-4462-9523-4626b210a524_verboseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Derivatives</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_72571d7b-2d75-4a8f-a99a-cf12800feb22_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Warrant Derivative Agreement</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Warrant Derivatives [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Public Offering, Warrant Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:href="oncyf-20221231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:to="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_b4c7ae76-10f6-42ab-a17b-417ef0899a60_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_bb0cdd23-4785-4b58-842a-4dcd9c3c7941_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_bf0f06ac-94cd-4964-9892-425d42196680_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:to="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareIssueCostsMember_4f4213d2-9e19-4b43-8e3d-7ce087e0c477_terseLabel_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_label_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_documentation_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember" xlink:href="oncyf-20221231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareIssueCostsMember" xlink:to="lab_oncyf_ShareIssueCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_30411654-4c60-47ed-80fd-8223548fe5bc_terseLabel_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized deferred tax asset</link:label>
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_label_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductible temporary differences for which no deferred tax asset is recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_28b6dabc-c72f-484f-aceb-af764e9ffd94_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_2737578f-0e04-4f9e-960a-6171a399b17b_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpenseAbstract_d0bc841f-fc42-4568-b669-9b8e89b13b98_terseLabel_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General And Administrative Expense [Abstract]</link:label>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpenseAbstract_documentation_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpenseAbstract" xlink:href="oncyf-20221231.xsd#oncyf_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_oncyf_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_3655e3c2-0cfd-47f1-8f35-18071fd0e367_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis" xlink:href="oncyf-20221231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Axis" xlink:to="lab_oncyf_IncomeStatementLocation1Axis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_1592b563-8ae3-4674-83d8-ccfc7b900c12_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash taxes paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid (refund)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefund" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_fa59db84-53aa-4b9d-b461-851b4394e942_negatedTerseLabel_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision to offset deferred tax asset</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_label_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_documentation_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:href="oncyf-20221231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:to="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_1bbe45c4-1c8e-4d3a-bc80-e7945528c582_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option plan</link:label>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_label_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Stock Option Plan [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Under Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderStockOptionPlanMember" xlink:to="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_35d0dc83-2da9-447e-bdd3-9bc70f554daf_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock options and weighted average exercise prices of share options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_f5d68e54-2a4e-46a4-aab4-ada418058f5f_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>oncyf-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:63a935b1-1650-41e1-88a0-4b019d55689c,g:0488272c-958a-4da8-b3e7-8a139968e8c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="simple" xlink:href="oncyf-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f4e2dd11-f8e9-411a-89fc-a29073f7be11" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_f44ae470-c02a-4235-abe3-527f283bb3a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f4e2dd11-f8e9-411a-89fc-a29073f7be11" xlink:to="loc_dei_DocumentInformationTable_f44ae470-c02a-4235-abe3-527f283bb3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_983646b5-fe90-4799-975d-f960d45b623b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_f44ae470-c02a-4235-abe3-527f283bb3a6" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_983646b5-fe90-4799-975d-f960d45b623b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_31f16624-623c-4ab2-b0cd-cca504963c4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_983646b5-fe90-4799-975d-f960d45b623b" xlink:to="loc_dei_AddressTypeDomain_31f16624-623c-4ab2-b0cd-cca504963c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_0fd5a68a-e3ce-40ed-8a3f-94dab2758c61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_31f16624-623c-4ab2-b0cd-cca504963c4b" xlink:to="loc_dei_BusinessContactMember_0fd5a68a-e3ce-40ed-8a3f-94dab2758c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_f44ae470-c02a-4235-abe3-527f283bb3a6" xlink:to="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2ab59305-68dd-43cc-adf8-5f63f00b07a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentType_2ab59305-68dd-43cc-adf8-5f63f00b07a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_14999a28-b035-4ef8-908a-95e98c9e19cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentRegistrationStatement_14999a28-b035-4ef8-908a-95e98c9e19cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_9ced5cc9-dcfb-4d3a-898e-819d5b713647" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentAnnualReport_9ced5cc9-dcfb-4d3a-898e-819d5b713647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d98dfb90-ed56-4ef0-9e3e-64335967cecc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentPeriodEndDate_d98dfb90-ed56-4ef0-9e3e-64335967cecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8aca0603-43c3-49f1-8e36-ed325de50987" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_CurrentFiscalYearEndDate_8aca0603-43c3-49f1-8e36-ed325de50987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_170e42ac-255b-4135-b820-f4792e6d4ef5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentTransitionReport_170e42ac-255b-4135-b820-f4792e6d4ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_e1608f78-f5a2-4dc0-b087-2789168a6650" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentShellCompanyReport_e1608f78-f5a2-4dc0-b087-2789168a6650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6b4270e8-1073-465a-8445-3c932a22fe67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityFileNumber_6b4270e8-1073-465a-8445-3c932a22fe67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_073653ad-6bf3-4577-a2fd-595bbf731b0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityRegistrantName_073653ad-6bf3-4577-a2fd-595bbf731b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c175f6ea-ffc6-4636-aa52-2aa4d75521ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c175f6ea-ffc6-4636-aa52-2aa4d75521ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1c75a068-d252-4f83-b67b-3bb39ffad6e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityAddressAddressLine1_1c75a068-d252-4f83-b67b-3bb39ffad6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2ca6fa57-12f5-41e2-8b72-7b5c9957c029" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityAddressCityOrTown_2ca6fa57-12f5-41e2-8b72-7b5c9957c029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5f13a920-897c-48ff-b29a-ef1f75f56c61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityAddressStateOrProvince_5f13a920-897c-48ff-b29a-ef1f75f56c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_9e6b2a89-f7b5-411c-8901-b19edddfd62f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityAddressCountry_9e6b2a89-f7b5-411c-8901-b19edddfd62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8bec47a9-0340-4fa2-bb5a-f962d4b65ff0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityAddressPostalZipCode_8bec47a9-0340-4fa2-bb5a-f962d4b65ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_2d4980fe-5170-4902-a0fc-ef7cc9c6a93a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_ContactPersonnelName_2d4980fe-5170-4902-a0fc-ef7cc9c6a93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_697b9919-aa2e-4492-9c9c-6caa485ef2e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_CityAreaCode_697b9919-aa2e-4492-9c9c-6caa485ef2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_52922b70-b738-44f3-887e-c7292df9e645" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_LocalPhoneNumber_52922b70-b738-44f3-887e-c7292df9e645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress_b5d8c08a-af97-40cd-b6b5-642da7fc7e74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_ContactPersonnelEmailAddress_b5d8c08a-af97-40cd-b6b5-642da7fc7e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c6dd71e8-83d2-4803-9375-74aed3073231" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_Security12bTitle_c6dd71e8-83d2-4803-9375-74aed3073231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d5017ca0-81f8-4508-b934-315d896571da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_TradingSymbol_d5017ca0-81f8-4508-b934-315d896571da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_06e3d239-44bf-4b06-bfb8-e01c90efe1cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_SecurityExchangeName_06e3d239-44bf-4b06-bfb8-e01c90efe1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d243a5bd-5768-442f-bf72-ff59bd096bff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d243a5bd-5768-442f-bf72-ff59bd096bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9ae064ef-4fc4-453f-a977-eb2d8a3c74d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9ae064ef-4fc4-453f-a977-eb2d8a3c74d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_9188bca7-0318-4c08-a4e5-170dc35d5b19" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityVoluntaryFilers_9188bca7-0318-4c08-a4e5-170dc35d5b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6ea9d224-f4fe-40b3-a429-9323f608bdea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityCurrentReportingStatus_6ea9d224-f4fe-40b3-a429-9323f608bdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4271da10-5082-4a19-9436-f1c8574c09f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityInteractiveDataCurrent_4271da10-5082-4a19-9436-f1c8574c09f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e3638092-dc49-4b65-a27e-b74c44cef3e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityFilerCategory_e3638092-dc49-4b65-a27e-b74c44cef3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9dbc65d6-d5c1-4661-8ebb-2218a8a36a2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityEmergingGrowthCompany_9dbc65d6-d5c1-4661-8ebb-2218a8a36a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_d3bd9bce-4fdf-4072-9cbb-3669e2142b2c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_IcfrAuditorAttestationFlag_d3bd9bce-4fdf-4072-9cbb-3669e2142b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_60233f11-645a-42c7-98b5-f08d6ab969b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentAccountingStandard_60233f11-645a-42c7-98b5-f08d6ab969b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1c3529d2-5f9d-4173-a12e-33ca95ab1831" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityShellCompany_1c3529d2-5f9d-4173-a12e-33ca95ab1831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ca88c503-8373-4f5a-b25a-783126a89c81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityCentralIndexKey_ca88c503-8373-4f5a-b25a-783126a89c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0fecea22-85aa-4d19-a1e6-5c1abd76ca51" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentFiscalYearFocus_0fecea22-85aa-4d19-a1e6-5c1abd76ca51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b33814db-a5ff-4234-b24e-4fd4c937e4a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b33814db-a5ff-4234-b24e-4fd4c937e4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3c22d76f-d5f1-46d7-9252-c9394d2996fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_AmendmentFlag_3c22d76f-d5f1-46d7-9252-c9394d2996fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_66d40515-536d-4a21-adc6-488198181a52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ee608d79-7104-417b-9f27-9907e9a0e398" xlink:to="loc_dei_EntityPublicFloat_66d40515-536d-4a21-adc6-488198181a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AuditInformation" xlink:type="simple" xlink:href="oncyf-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AuditorInformationAbstract_8f17d4fd-098f-460a-b5fd-059c5f14f55b" xlink:href="oncyf-20221231.xsd#oncyf_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_368fd3af-0e93-471e-b484-f29e535ec0e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AuditorInformationAbstract_8f17d4fd-098f-460a-b5fd-059c5f14f55b" xlink:to="loc_dei_AuditorFirmId_368fd3af-0e93-471e-b484-f29e535ec0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_70eafca0-403e-4548-a7e8-773707993041" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AuditorInformationAbstract_8f17d4fd-098f-460a-b5fd-059c5f14f55b" xlink:to="loc_dei_AuditorName_70eafca0-403e-4548-a7e8-773707993041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_80650579-28a8-45f2-8f84-412664622de9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AuditorInformationAbstract_8f17d4fd-098f-460a-b5fd-059c5f14f55b" xlink:to="loc_dei_AuditorLocation_80650579-28a8-45f2-8f84-412664622de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_81c3a97b-df5d-4a9d-a62f-a256d766d84e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_2aff70ef-7d47-4d0a-97d9-5e1bf4af36f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_81c3a97b-df5d-4a9d-a62f-a256d766d84e" xlink:to="loc_ifrs-full_AssetsAbstract_2aff70ef-7d47-4d0a-97d9-5e1bf4af36f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_f5d3d83f-3f16-4ee7-bcef-525ae70e5c42" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_2aff70ef-7d47-4d0a-97d9-5e1bf4af36f7" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_f5d3d83f-3f16-4ee7-bcef-525ae70e5c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_173fcc07-ef4a-4048-8183-ad3180ad7477" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_f5d3d83f-3f16-4ee7-bcef-525ae70e5c42" xlink:to="loc_ifrs-full_CashAndCashEquivalents_173fcc07-ef4a-4048-8183-ad3180ad7477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAvailableforsale_5fd1dd30-2970-4e31-8470-b7b41ad51a5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssetsAvailableforsale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_f5d3d83f-3f16-4ee7-bcef-525ae70e5c42" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAvailableforsale_5fd1dd30-2970-4e31-8470-b7b41ad51a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_27401837-d6be-4c9b-8ee3-af633be9ac43" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_f5d3d83f-3f16-4ee7-bcef-525ae70e5c42" xlink:to="loc_ifrs-full_OtherCurrentReceivables_27401837-d6be-4c9b-8ee3-af633be9ac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepayments_378ef902-78ee-4116-b233-50c221ba74a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_f5d3d83f-3f16-4ee7-bcef-525ae70e5c42" xlink:to="loc_ifrs-full_CurrentPrepayments_378ef902-78ee-4116-b233-50c221ba74a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_6782e89a-2524-48f3-a8cc-2902e7a8cc22" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_f5d3d83f-3f16-4ee7-bcef-525ae70e5c42" xlink:to="loc_ifrs-full_CurrentAssets_6782e89a-2524-48f3-a8cc-2902e7a8cc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_7eb03726-59f6-4a1b-9e8d-ce852ceb1a76" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_2aff70ef-7d47-4d0a-97d9-5e1bf4af36f7" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_7eb03726-59f6-4a1b-9e8d-ce852ceb1a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_8fdc82ea-b162-4608-835b-5577ab922131" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_2aff70ef-7d47-4d0a-97d9-5e1bf4af36f7" xlink:to="loc_ifrs-full_RightofuseAssets_8fdc82ea-b162-4608-835b-5577ab922131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPrepayments_576ef750-11fa-4956-b160-793d3f74597e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_2aff70ef-7d47-4d0a-97d9-5e1bf4af36f7" xlink:to="loc_ifrs-full_NoncurrentPrepayments_576ef750-11fa-4956-b160-793d3f74597e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_59c88e53-d9a3-4208-bef7-c76048946538" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_2aff70ef-7d47-4d0a-97d9-5e1bf4af36f7" xlink:to="loc_ifrs-full_Assets_59c88e53-d9a3-4208-bef7-c76048946538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_f55325bb-b517-479b-a26c-e89f41207c27" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_81c3a97b-df5d-4a9d-a62f-a256d766d84e" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_f55325bb-b517-479b-a26c-e89f41207c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_ddb5905a-b7ef-4585-a3b3-b1d745229f5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_f55325bb-b517-479b-a26c-e89f41207c27" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_ddb5905a-b7ef-4585-a3b3-b1d745229f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_d24e79c4-9ed3-4051-bb70-a94c85c1e2ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_ddb5905a-b7ef-4585-a3b3-b1d745229f5e" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_d24e79c4-9ed3-4051-bb70-a94c85c1e2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_fcf6db7b-5fa8-48fd-ab11-a870f65f1fed" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_ddb5905a-b7ef-4585-a3b3-b1d745229f5e" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_fcf6db7b-5fa8-48fd-ab11-a870f65f1fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_664aaee7-ff8e-4553-9a2c-3b8514948533" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_ddb5905a-b7ef-4585-a3b3-b1d745229f5e" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_664aaee7-ff8e-4553-9a2c-3b8514948533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_ea45c968-af92-47f6-b841-457f7adf46ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_ddb5905a-b7ef-4585-a3b3-b1d745229f5e" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_ea45c968-af92-47f6-b841-457f7adf46ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_2aa777fe-1586-47e1-b92e-ef56fbf3371e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_ddb5905a-b7ef-4585-a3b3-b1d745229f5e" xlink:to="loc_ifrs-full_CurrentLiabilities_2aa777fe-1586-47e1-b92e-ef56fbf3371e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_1fe00b6f-ebc5-4f2e-a656-cd0677ab2270" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_f55325bb-b517-479b-a26c-e89f41207c27" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_1fe00b6f-ebc5-4f2e-a656-cd0677ab2270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_6f6c6535-773c-4608-b198-e3d7b9c0eada" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_f55325bb-b517-479b-a26c-e89f41207c27" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_6f6c6535-773c-4608-b198-e3d7b9c0eada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_84b45a65-b489-41de-8bea-5c3d9b31d2ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_f55325bb-b517-479b-a26c-e89f41207c27" xlink:to="loc_ifrs-full_Liabilities_84b45a65-b489-41de-8bea-5c3d9b31d2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1_a0703afd-905a-4ed3-8fc7-ad6ee1da1e8e" xlink:href="oncyf-20221231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_f55325bb-b517-479b-a26c-e89f41207c27" xlink:to="loc_oncyf_CommitmentsAndContingencies1_a0703afd-905a-4ed3-8fc7-ad6ee1da1e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_6b8eab57-a90c-4cf3-aecd-10c9400fc5a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_f55325bb-b517-479b-a26c-e89f41207c27" xlink:to="loc_ifrs-full_EquityAbstract_6b8eab57-a90c-4cf3-aecd-10c9400fc5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_6dbeb466-d8a8-4c41-9d4c-7ce047dda7d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_6b8eab57-a90c-4cf3-aecd-10c9400fc5a0" xlink:to="loc_ifrs-full_IssuedCapital_6dbeb466-d8a8-4c41-9d4c-7ce047dda7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsandRightsOutstanding_df7e91db-9609-4c3a-8006-915f2961651f" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsandRightsOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_6b8eab57-a90c-4cf3-aecd-10c9400fc5a0" xlink:to="loc_oncyf_WarrantsandRightsOutstanding_df7e91db-9609-4c3a-8006-915f2961651f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_fe5c213c-08fa-47d8-bb67-ffb812ed74cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_6b8eab57-a90c-4cf3-aecd-10c9400fc5a0" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_fe5c213c-08fa-47d8-bb67-ffb812ed74cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_6f2ff50d-d94b-42cc-9470-697ce224db94" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_6b8eab57-a90c-4cf3-aecd-10c9400fc5a0" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_6f2ff50d-d94b-42cc-9470-697ce224db94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_a9bf470b-e33f-4eb6-ab76-d48c1c8a6df8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_6b8eab57-a90c-4cf3-aecd-10c9400fc5a0" xlink:to="loc_ifrs-full_RetainedEarnings_a9bf470b-e33f-4eb6-ab76-d48c1c8a6df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_ec0bd484-1f77-4641-ab18-70e915913462" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_6b8eab57-a90c-4cf3-aecd-10c9400fc5a0" xlink:to="loc_ifrs-full_Equity_ec0bd484-1f77-4641-ab18-70e915913462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_7c099fda-7be0-40bd-889c-41f81cd16fe0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_f55325bb-b517-479b-a26c-e89f41207c27" xlink:to="loc_ifrs-full_EquityAndLiabilities_7c099fda-7be0-40bd-889c-41f81cd16fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_c4a98be1-cda3-4f3c-82d3-9e7836c9db3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_a9dcbb00-8458-4d88-84fd-937571f9e607" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_c4a98be1-cda3-4f3c-82d3-9e7836c9db3d" xlink:to="loc_ifrs-full_EquityAbstract_a9dcbb00-8458-4d88-84fd-937571f9e607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_17373f1a-9c9a-4861-846a-80eaa929ec0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_a9dcbb00-8458-4d88-84fd-937571f9e607" xlink:to="loc_ifrs-full_NumberOfSharesIssued_17373f1a-9c9a-4861-846a-80eaa929ec0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_6fe4f064-c8d2-4716-83d5-f7989e9ca5a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_ExpenseByNatureAbstract_6fe4f064-c8d2-4716-83d5-f7989e9ca5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_8b529d8e-2fd2-4c9b-8283-2593a7e7732a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_6fe4f064-c8d2-4716-83d5-f7989e9ca5a7" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_8b529d8e-2fd2-4c9b-8283-2593a7e7732a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_bee1d523-c3bf-4b6c-b34b-2369dfe58a21" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_6fe4f064-c8d2-4716-83d5-f7989e9ca5a7" xlink:to="loc_ifrs-full_OperatingExpense_bee1d523-c3bf-4b6c-b34b-2369dfe58a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_86fd8d8f-660f-41e2-b650-f7bade31f23d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_86fd8d8f-660f-41e2-b650-f7bade31f23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_5694e203-16df-4a46-98fc-852e82a7626d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_5694e203-16df-4a46-98fc-852e82a7626d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_e21bc8b8-59b5-46db-9443-75e174c48def" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_e21bc8b8-59b5-46db-9443-75e174c48def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_d5fdde3e-0592-4b3c-9bc1-09aea9e5993a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_d5fdde3e-0592-4b3c-9bc1-09aea9e5993a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_25ab6acd-b0ce-423b-bb03-530a57154ca9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_25ab6acd-b0ce-423b-bb03-530a57154ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_23a14d3d-1e5b-41d3-acfa-7f934213b3fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_23a14d3d-1e5b-41d3-acfa-7f934213b3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_99601747-1424-480d-bc2f-167c48390744" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_ProfitLoss_99601747-1424-480d-bc2f-167c48390744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_17786846-93d2-4a36-ac03-9b4d41bfcee7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_17786846-93d2-4a36-ac03-9b4d41bfcee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_6d7bd847-4b67-4262-896e-86b8c06b1661" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_17786846-93d2-4a36-ac03-9b4d41bfcee7" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_6d7bd847-4b67-4262-896e-86b8c06b1661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_eabe3ec4-140a-4174-b843-1c5271f5190c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_ComprehensiveIncome_eabe3ec4-140a-4174-b843-1c5271f5190c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_70a7b9ba-9f2e-4db4-b736-f5cfc192f0db" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_70a7b9ba-9f2e-4db4-b736-f5cfc192f0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_1ca996cb-5cd0-4668-860d-9d0b69e2a226" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_1ca996cb-5cd0-4668-860d-9d0b69e2a226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_7bc476e5-89f5-4ef3-a837-3d41f38ab26d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_WeightedAverageShares_7bc476e5-89f5-4ef3-a837-3d41f38ab26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_6907b4b9-ace4-46a9-ba07-8833babc1c8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_8c8b2b93-3c21-464f-813a-2e0361363d86" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_6907b4b9-ace4-46a9-ba07-8833babc1c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_d8c4b143-9bbe-4329-b9f9-f44732a20023" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_377d410d-63ee-4b13-8f4d-63739acd75af" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_d8c4b143-9bbe-4329-b9f9-f44732a20023" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_377d410d-63ee-4b13-8f4d-63739acd75af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_239c8528-d122-4e8f-ac85-7e790c6fba9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_377d410d-63ee-4b13-8f4d-63739acd75af" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_239c8528-d122-4e8f-ac85-7e790c6fba9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_239c8528-d122-4e8f-ac85-7e790c6fba9f" xlink:to="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_f84f411f-739f-4350-989e-31a23b8d6044" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:to="loc_ifrs-full_IssuedCapitalMember_f84f411f-739f-4350-989e-31a23b8d6044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_b32c4d5a-aadf-4439-96a9-7d69c9694ee0" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:to="loc_oncyf_WarrantsMember_b32c4d5a-aadf-4439-96a9-7d69c9694ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_b9b1d52a-d90d-4593-bad3-f5464b040b8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:to="loc_ifrs-full_SharePremiumMember_b9b1d52a-d90d-4593-bad3-f5464b040b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_21460ec9-a96d-4cd8-90ba-26820c88258c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_21460ec9-a96d-4cd8-90ba-26820c88258c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_875964cc-6b41-4854-9137-3c22096fd22e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a4cfe98b-f0c9-4dcd-bb76-49b0b27f7abf" xlink:to="loc_ifrs-full_RetainedEarningsMember_875964cc-6b41-4854-9137-3c22096fd22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_4915bcb4-0bae-4e93-9575-d43b90dc525a" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_377d410d-63ee-4b13-8f4d-63739acd75af" xlink:to="loc_oncyf_SaleOfStockAxis_4915bcb4-0bae-4e93-9575-d43b90dc525a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_c51f8433-ccff-469f-a9d0-89f173f89dd9" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_4915bcb4-0bae-4e93-9575-d43b90dc525a" xlink:to="loc_oncyf_SaleOfStockDomain_c51f8433-ccff-469f-a9d0-89f173f89dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_220798e3-96c8-4fd2-86b9-72b6cddab8ab" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_c51f8433-ccff-469f-a9d0-89f173f89dd9" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_220798e3-96c8-4fd2-86b9-72b6cddab8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_377d410d-63ee-4b13-8f4d-63739acd75af" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_3e76ebf7-05ac-4391-ac8d-56fc0133125d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_Equity_3e76ebf7-05ac-4391-ac8d-56fc0133125d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_c807b641-30c1-4e0a-a529-8a614c3e7d35" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_ComprehensiveIncome_c807b641-30c1-4e0a-a529-8a614c3e7d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_e0a775d3-ba22-4776-ab84-40f4a5213638" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_e0a775d3-ba22-4776-ab84-40f4a5213638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_5c361ec8-b162-46f0-ae74-4c72359f1992" xlink:href="oncyf-20221231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_5c361ec8-b162-46f0-ae74-4c72359f1992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_b86f4ffb-ad9c-41a3-aa30-87fa0d9387b3" xlink:href="oncyf-20221231.xsd#oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_b86f4ffb-ad9c-41a3-aa30-87fa0d9387b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_a6d6ea87-3043-4009-be1b-a0d1ce5f3335" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_IssueOfEquity_a6d6ea87-3043-4009-be1b-a0d1ce5f3335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_6799635e-165d-4022-b3ee-08ae4ca61fc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_6799635e-165d-4022-b3ee-08ae4ca61fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_06522490-4fc0-4955-b72c-34ae40a8e1c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_06522490-4fc0-4955-b72c-34ae40a8e1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_1feeb2b9-91b5-4f4e-9d20-bf38e614974b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_1feeb2b9-91b5-4f4e-9d20-bf38e614974b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_ded9a66d-53a9-470c-b322-3ba28df6cecb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_465f8a2a-1ce9-4be5-82a9-d207397d0488" xlink:to="loc_ifrs-full_Equity_ded9a66d-53a9-470c-b322-3ba28df6cecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_7985b382-e9e2-451a-b2cb-4d8c613519a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table_b7567ea8-25e4-4010-a51a-0267a11a83b4" xlink:href="oncyf-20221231.xsd#oncyf_Statement1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7985b382-e9e2-451a-b2cb-4d8c613519a6" xlink:to="loc_oncyf_Statement1Table_b7567ea8-25e4-4010-a51a-0267a11a83b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_84b8d29d-5800-4d3e-8746-ab66980ce1db" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_b7567ea8-25e4-4010-a51a-0267a11a83b4" xlink:to="loc_oncyf_SaleOfStockAxis_84b8d29d-5800-4d3e-8746-ab66980ce1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_32d64b49-abe3-4e4a-a2b2-822d4d6e5c9c" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_84b8d29d-5800-4d3e-8746-ab66980ce1db" xlink:to="loc_oncyf_SaleOfStockDomain_32d64b49-abe3-4e4a-a2b2-822d4d6e5c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_0f93f981-1812-4419-bb9d-1fbb1779d9b7" xlink:href="oncyf-20221231.xsd#oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_32d64b49-abe3-4e4a-a2b2-822d4d6e5c9c" xlink:to="loc_oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember_0f93f981-1812-4419-bb9d-1fbb1779d9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_640d7b24-3e27-4ac5-bf58-733c9b70b2ed" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_32d64b49-abe3-4e4a-a2b2-822d4d6e5c9c" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_640d7b24-3e27-4ac5-bf58-733c9b70b2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:href="oncyf-20221231.xsd#oncyf_Statement1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_b7567ea8-25e4-4010-a51a-0267a11a83b4" xlink:to="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_29149144-9b4a-49b2-a9a7-77c3a10c9ad4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_ProfitLoss_29149144-9b4a-49b2-a9a7-77c3a10c9ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_aaa34943-59dd-4cdf-90dd-9e78c7416d0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_aaa34943-59dd-4cdf-90dd-9e78c7416d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_e750e7b1-f3af-4312-ab0c-90619df7f01c" xlink:href="oncyf-20221231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_e750e7b1-f3af-4312-ab0c-90619df7f01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_ca5cfcbc-ff61-4583-9701-ad4d17003ce1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_ca5cfcbc-ff61-4583-9701-ad4d17003ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_fa61d9ea-0b9a-4cd9-a84a-e0c2ea918ace" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_InterestRevenueExpense_fa61d9ea-0b9a-4cd9-a84a-e0c2ea918ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_68427d57-569c-45d3-a919-5d999632802d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_68427d57-569c-45d3-a919-5d999632802d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_d00cd239-cdf3-4363-aeaf-27027bc75672" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_d00cd239-cdf3-4363-aeaf-27027bc75672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_83b3624b-a8d9-4c7e-8278-7b2e516f83cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_83b3624b-a8d9-4c7e-8278-7b2e516f83cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_8736868e-cc2b-48d1-a112-9562c27b28a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_e6846678-e5d4-40d8-9099-136560aaa03c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_8736868e-cc2b-48d1-a112-9562c27b28a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_a67901b0-1d50-44bd-94ca-b2a41821a39d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_a67901b0-1d50-44bd-94ca-b2a41821a39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_91bf568a-a3c2-4f8d-8d25-9c463f90d001" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_a67901b0-1d50-44bd-94ca-b2a41821a39d" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_91bf568a-a3c2-4f8d-8d25-9c463f90d001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_add8cb23-06b9-433c-8884-f59b6bf4d688" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_a67901b0-1d50-44bd-94ca-b2a41821a39d" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_add8cb23-06b9-433c-8884-f59b6bf4d688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7738fd44-223c-43fc-9aa0-3ce06478429b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_a67901b0-1d50-44bd-94ca-b2a41821a39d" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_7738fd44-223c-43fc-9aa0-3ce06478429b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b49d250c-65ce-495b-908d-e94c7ed93dea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b49d250c-65ce-495b-908d-e94c7ed93dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_2689de68-66a7-4085-90f9-846f737b2266" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b49d250c-65ce-495b-908d-e94c7ed93dea" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_2689de68-66a7-4085-90f9-846f737b2266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1efe7495-23b0-4cc0-a15a-2f623b116ca2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b49d250c-65ce-495b-908d-e94c7ed93dea" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_1efe7495-23b0-4cc0-a15a-2f623b116ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_fc4e3011-de3c-40c9-a67a-11865878824e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b49d250c-65ce-495b-908d-e94c7ed93dea" xlink:to="loc_ifrs-full_CashOutflowForLeases_fc4e3011-de3c-40c9-a67a-11865878824e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_7d325172-61a0-419f-8206-a3da754bcb28" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b49d250c-65ce-495b-908d-e94c7ed93dea" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_7d325172-61a0-419f-8206-a3da754bcb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_c4b6dcbf-8484-4d55-9732-eff2e5ad8b02" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_c4b6dcbf-8484-4d55-9732-eff2e5ad8b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_965f2000-f154-4879-ab3e-a5f2197a8b35" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_CashAndCashEquivalents_965f2000-f154-4879-ab3e-a5f2197a8b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_cc3b0ccf-f99b-4a6a-8881-08b25c08db93" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_cc3b0ccf-f99b-4a6a-8881-08b25c08db93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_4d3b23db-2f06-403f-95c6-9cbff9a0be86" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_7c51120a-3b33-43da-8d15-7d60c4a2df8a" xlink:to="loc_ifrs-full_CashAndCashEquivalents_4d3b23db-2f06-403f-95c6-9cbff9a0be86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperations" xlink:type="simple" xlink:href="oncyf-20221231.xsd#NatureofOperations"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/NatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_363f0ca2-1747-4dc2-933f-75c81bd330ec" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_c94ffb9d-a5cb-4a91-bc31-85515f73f008" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_363f0ca2-1747-4dc2-933f-75c81bd330ec" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_c94ffb9d-a5cb-4a91-bc31-85515f73f008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisofPresentation" xlink:type="simple" xlink:href="oncyf-20221231.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_4fa7b36c-4389-4d74-b9b9-2210c592925d" xlink:href="oncyf-20221231.xsd#oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_8d0293e0-a9e2-4ae3-8f57-fd247806ada0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract_4fa7b36c-4389-4d74-b9b9-2210c592925d" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_8d0293e0-a9e2-4ae3-8f57-fd247806ada0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="oncyf-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c3d3e75-e095-4a0b-8663-7fbdc833f877" xlink:href="oncyf-20221231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_c2f7ce53-b343-4e95-a658-861389e763f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c3d3e75-e095-4a0b-8663-7fbdc833f877" xlink:to="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_c2f7ce53-b343-4e95-a658-861389e763f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="simple" xlink:href="oncyf-20221231.xsd#SignificantJudgmentsEstimatesandAssumptions"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_4d58ef94-67d3-42b0-ae1a-d67c5577a090" xlink:href="oncyf-20221231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_1d9f9f46-d853-4ecc-904e-90dd7e5a2636" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_4d58ef94-67d3-42b0-ae1a-d67c5577a090" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_1d9f9f46-d853-4ecc-904e-90dd7e5a2636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities" xlink:type="simple" xlink:href="oncyf-20221231.xsd#OtherAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_cf182efb-36fc-4eed-8f42-b0b97f29480a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory_257aa2d3-7b8a-4584-bd78-7ec6cb9a580e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_cf182efb-36fc-4eed-8f42-b0b97f29480a" xlink:to="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory_257aa2d3-7b8a-4584-bd78-7ec6cb9a580e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_00e63cb4-850a-4992-b59b-8b95bdafe009" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_cf182efb-36fc-4eed-8f42-b0b97f29480a" xlink:to="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_00e63cb4-850a-4992-b59b-8b95bdafe009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="oncyf-20221231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_b518cf8d-d9dd-4103-b52a-a5b88fe4c275" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_96bcb929-6fa9-4659-b607-10dd8c9dec5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_b518cf8d-d9dd-4103-b52a-a5b88fe4c275" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_96bcb929-6fa9-4659-b607-10dd8c9dec5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="oncyf-20221231.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_2fcba2fb-f452-4f9f-b53a-b09b72457b12" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_8886cb91-8782-498d-b6a9-462a3205ca81" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_2fcba2fb-f452-4f9f-b53a-b09b72457b12" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_8886cb91-8782-498d-b6a9-462a3205ca81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="simple" xlink:href="oncyf-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_b3310424-23bf-437a-82ca-7b313e1feb01" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_34c06768-851b-4243-b86c-7659d8d20e30" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_b3310424-23bf-437a-82ca-7b313e1feb01" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_34c06768-851b-4243-b86c-7659d8d20e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareCapital"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ca0fd700-a36c-426e-8b05-8f602e4a6029" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_4f3adbf4-fb3f-4c78-b668-84e77ae5ca6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ca0fd700-a36c-426e-8b05-8f602e4a6029" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_4f3adbf4-fb3f-4c78-b668-84e77ae5ca6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_0ffe655b-2ded-45cb-94d9-c72126488faa" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_09737e02-8e69-43d0-9b9f-a0fcef2d9de5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_0ffe655b-2ded-45cb-94d9-c72126488faa" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_09737e02-8e69-43d0-9b9f-a0fcef2d9de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="oncyf-20221231.xsd#LossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_c1fb3c09-5465-4fae-9e0d-d349eefc945d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_a1add9bf-6015-4cd7-adf3-41c128c987fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_c1fb3c09-5465-4fae-9e0d-d349eefc945d" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_a1add9bf-6015-4cd7-adf3-41c128c987fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiability" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ContractLiability"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_3f1b0371-1b54-4e13-bdc6-8076acc167d3" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_bac5d977-a24a-46c9-a4f2-12e8b2c39941" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_3f1b0371-1b54-4e13-bdc6-8076acc167d3" xlink:to="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_bac5d977-a24a-46c9-a4f2-12e8b2c39941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract_8bad4f91-a94e-4ec6-965b-edc3e0db0f68" xlink:href="oncyf-20221231.xsd#oncyf_ContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_62b24dd3-306a-460e-a538-40aaca2117e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_8bad4f91-a94e-4ec6-965b-edc3e0db0f68" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_62b24dd3-306a-460e-a538-40aaca2117e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="oncyf-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_25b6cece-f07a-4f74-b2cd-11a171508db3" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_0cfea8c1-446e-4abf-99fc-d2e06d1fc589" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_25b6cece-f07a-4f74-b2cd-11a171508db3" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_0cfea8c1-446e-4abf-99fc-d2e06d1fc589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CapitalDisclosures"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_eb286aa5-374e-49c0-86b6-5d018de493da" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_9a57268f-2af0-4add-9e8d-d6d2e9bbaab8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_eb286aa5-374e-49c0-86b6-5d018de493da" xlink:to="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_9a57268f-2af0-4add-9e8d-d6d2e9bbaab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="simple" xlink:href="oncyf-20221231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_43cdcd49-a8d0-460e-aaba-c054f824364a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_9b27a0ab-5ed6-46f5-af2c-c1cd6d30fee5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_43cdcd49-a8d0-460e-aaba-c054f824364a" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_9b27a0ab-5ed6-46f5-af2c-c1cd6d30fee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="simple" xlink:href="oncyf-20221231.xsd#AdditionalCashFlowDisclosures"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_d16eac46-478b-42ac-8416-c68407fff2a4" xlink:href="oncyf-20221231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_715a1d63-3cac-42b5-9d27-4d63498978c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_d16eac46-478b-42ac-8416-c68407fff2a4" xlink:to="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_715a1d63-3cac-42b5-9d27-4d63498978c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors" xlink:type="simple" xlink:href="oncyf-20221231.xsd#IndemnificationofOfficersandDirectors"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_af8b848b-d66d-4f1e-ac7b-6f60fbeb6990" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_ad100c81-4576-412b-bfd8-996e3d2205a3" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_af8b848b-d66d-4f1e-ac7b-6f60fbeb6990" xlink:to="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_ad100c81-4576-412b-bfd8-996e3d2205a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="simple" xlink:href="oncyf-20221231.xsd#EconomicDependence"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_8858f552-3797-4787-81f4-51e13c769c60" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_25fd766f-6bd2-4c06-a77f-e5ceb42f44af" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_8858f552-3797-4787-81f4-51e13c769c60" xlink:to="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_25fd766f-6bd2-4c06-a77f-e5ceb42f44af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpenses" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ComponentsofExpenses"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ComponentsofExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_a5d63560-9c7e-4ac1-bbdf-e586e16e3613" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_85137020-6ee6-4cd2-bf09-5d8cfb0d093f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_a5d63560-9c7e-4ac1-bbdf-e586e16e3613" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_85137020-6ee6-4cd2-bf09-5d8cfb0d093f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="oncyf-20221231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_a173d6c7-b057-430b-9af7-9e33f1e6c012" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_4b7701dc-461b-4168-9a71-357709074771" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_a173d6c7-b057-430b-9af7-9e33f1e6c012" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_4b7701dc-461b-4168-9a71-357709074771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="simple" xlink:href="oncyf-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_8de41046-2880-4680-a72f-bbdfd877aeb8" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_4003b02b-6c4e-4260-bba4-88b711ba6dc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_8de41046-2880-4680-a72f-bbdfd877aeb8" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_4003b02b-6c4e-4260-bba4-88b711ba6dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="oncyf-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:href="oncyf-20221231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_7b502c7b-d632-4f44-b790-4afb8acfb59b" xlink:href="oncyf-20221231.xsd#oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_7b502c7b-d632-4f44-b790-4afb8acfb59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_f7188f2d-49ac-469f-b36b-e17d0deee0b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_f7188f2d-49ac-469f-b36b-e17d0deee0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_6d403ae3-7339-49c2-9667-88d37e30bf8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_6d403ae3-7339-49c2-9667-88d37e30bf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_4eedd0a5-e17a-4c67-a60a-f44e2f240685" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_4eedd0a5-e17a-4c67-a60a-f44e2f240685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_e056e041-07b7-481a-8cac-84fc05b4f6cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_e056e041-07b7-481a-8cac-84fc05b4f6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_eb206d93-44ec-4b7a-86d2-55a443c7abea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_eb206d93-44ec-4b7a-86d2-55a443c7abea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_9cf4d2fa-776e-42dd-accf-dfca952f36fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_9cf4d2fa-776e-42dd-accf-dfca952f36fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_6a6ced54-a665-4721-aa08-6afd80400062" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_6a6ced54-a665-4721-aa08-6afd80400062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_218950bf-67c8-4df0-8a30-012b050bcd1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_218950bf-67c8-4df0-8a30-012b050bcd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_479ed219-9c4e-4981-b8c0-b42df33919be" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_479ed219-9c4e-4981-b8c0-b42df33919be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_2365542c-4eb8-4ef0-804f-6c054452cb7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_2365542c-4eb8-4ef0-804f-6c054452cb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_2d7abcae-a19b-4d63-a2c7-a9fb660770ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_2d7abcae-a19b-4d63-a2c7-a9fb660770ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_1dbea054-1999-4cc9-ad3a-560976405c68" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_1dbea054-1999-4cc9-ad3a-560976405c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_dad2222a-7a17-47de-8313-7bae5013676f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_dad2222a-7a17-47de-8313-7bae5013676f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_12b36639-707a-40f7-933e-06e899469fdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dccd170f-7c48-45ed-8f00-851af7a10914" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_12b36639-707a-40f7-933e-06e899469fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_6ffb91ea-49e8-4ac3-84ee-566653d3ea6e" xlink:href="oncyf-20221231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_932215f4-c2d5-448a-a9e4-8d282cf4c632" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_6ffb91ea-49e8-4ac3-84ee-566653d3ea6e" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_932215f4-c2d5-448a-a9e4-8d282cf4c632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_2fb05096-58e6-49a1-b3ea-43e0f4faee28" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_d46655c8-1ff5-4f0b-ae3f-9a72b58dd518" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_2fb05096-58e6-49a1-b3ea-43e0f4faee28" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_d46655c8-1ff5-4f0b-ae3f-9a72b58dd518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_69f76a8b-6a90-4ec1-838f-0c36f527b423" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_9110dbd2-2e08-4e49-905f-a27e0e40ef73" xlink:href="oncyf-20221231.xsd#oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_69f76a8b-6a90-4ec1-838f-0c36f527b423" xlink:to="loc_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_9110dbd2-2e08-4e49-905f-a27e0e40ef73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_1657f232-667a-43f8-a490-30b7579e5d92" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_ab81af6c-1706-4bd0-a1f2-0d0f2660153c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_1657f232-667a-43f8-a490-30b7579e5d92" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_ab81af6c-1706-4bd0-a1f2-0d0f2660153c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_11728818-b348-4937-9162-b9344e8130bb" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_1657f232-667a-43f8-a490-30b7579e5d92" xlink:to="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_11728818-b348-4937-9162-b9344e8130bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_540d2cdc-f54e-4315-a58a-184d8a294a1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_1657f232-667a-43f8-a490-30b7579e5d92" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_540d2cdc-f54e-4315-a58a-184d8a294a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareCapitalTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_7c4f94c5-3a78-4d8b-a2ae-9bb7262a671e" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_6b0cb6ce-26b0-4ce7-8dcc-57d1febee401" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_7c4f94c5-3a78-4d8b-a2ae-9bb7262a671e" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_6b0cb6ce-26b0-4ce7-8dcc-57d1febee401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_b51896af-b20f-4184-a7d9-3bf54065ace7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_7c4f94c5-3a78-4d8b-a2ae-9bb7262a671e" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_b51896af-b20f-4184-a7d9-3bf54065ace7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_6b9d3c46-bcf2-4964-b523-e2eac42dda8c" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_061b6f3d-4d75-40f2-ba8a-9ed5ee324379" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_6b9d3c46-bcf2-4964-b523-e2eac42dda8c" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_061b6f3d-4d75-40f2-ba8a-9ed5ee324379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_55b1e7e3-a9f2-45ad-b6b6-ef602231a978" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_6b9d3c46-bcf2-4964-b523-e2eac42dda8c" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_55b1e7e3-a9f2-45ad-b6b6-ef602231a978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_872ac850-4cff-4823-aa19-404c9998e9a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_6b9d3c46-bcf2-4964-b523-e2eac42dda8c" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_872ac850-4cff-4823-aa19-404c9998e9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_2baf28fa-3dbc-4db0-a358-a9454fee7155" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_6b9d3c46-bcf2-4964-b523-e2eac42dda8c" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_2baf28fa-3dbc-4db0-a358-a9454fee7155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_188672be-1be5-439e-beba-3a0a3412ff6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_6b9d3c46-bcf2-4964-b523-e2eac42dda8c" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_188672be-1be5-439e-beba-3a0a3412ff6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ContractLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_00bed75e-50d3-41d2-819a-1740c0cc357f" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_6bfa2dc9-0860-473a-8c1d-f1f169a576af" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_00bed75e-50d3-41d2-819a-1740c0cc357f" xlink:to="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_6bfa2dc9-0860-473a-8c1d-f1f169a576af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_b877382c-6f9e-4a44-8991-286ca6474128" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_f4567573-6ab3-4ac9-a08e-6f854de9fd7d" xlink:href="oncyf-20221231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_b877382c-6f9e-4a44-8991-286ca6474128" xlink:to="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_f4567573-6ab3-4ac9-a08e-6f854de9fd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_30b5703e-563c-4f5c-90f6-6f514f7990c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_b877382c-6f9e-4a44-8991-286ca6474128" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_30b5703e-563c-4f5c-90f6-6f514f7990c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CapitalDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_2af369bf-c8fc-4eb3-8358-c01ca86af32c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2d5aec26-1b49-4fd3-bd88-4b3af2ce6ba0" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_2af369bf-c8fc-4eb3-8358-c01ca86af32c" xlink:to="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_2d5aec26-1b49-4fd3-bd88-4b3af2ce6ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_d91aaaf3-e13c-4594-b51f-94970a03067a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_c1888a37-228a-4596-b344-087c847c09e5" xlink:href="oncyf-20221231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_d91aaaf3-e13c-4594-b51f-94970a03067a" xlink:to="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_c1888a37-228a-4596-b344-087c847c09e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#AdditionalCashFlowDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_ee3bd396-00ee-452f-b3f2-c5b494b4f999" xlink:href="oncyf-20221231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_f683582d-e1e3-4698-8464-a8456a029f7a" xlink:href="oncyf-20221231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_ee3bd396-00ee-452f-b3f2-c5b494b4f999" xlink:to="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_f683582d-e1e3-4698-8464-a8456a029f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_4420bf13-f3c6-40af-9338-629c03a2fba1" xlink:href="oncyf-20221231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_ee3bd396-00ee-452f-b3f2-c5b494b4f999" xlink:to="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_4420bf13-f3c6-40af-9338-629c03a2fba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ComponentsofExpensesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_a21f7416-e6f9-4ba4-b01a-c5ad045aab72" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_010e803a-40f6-4b98-bea7-c028b5b4b14a" xlink:href="oncyf-20221231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_a21f7416-e6f9-4ba4-b01a-c5ad045aab72" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_010e803a-40f6-4b98-bea7-c028b5b4b14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="oncyf-20221231.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_60639dba-6c46-42e4-8d2c-9fcf3270642c" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_f1561b55-021f-4275-8d80-da6be75f6110" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_60639dba-6c46-42e4-8d2c-9fcf3270642c" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_f1561b55-021f-4275-8d80-da6be75f6110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#NatureofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_cdb364b1-5f57-4b68-aa6c-28cdb8e6785e" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_3bc05a8a-df6e-4274-bc15-6efb5fddaaba" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_cdb364b1-5f57-4b68-aa6c-28cdb8e6785e" xlink:to="loc_ifrs-full_RetainedEarnings_3bc05a8a-df6e-4274-bc15-6efb5fddaaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashAndCashEquivalentsAndCurrentInvestments_c2997d96-c098-4593-b23d-d8a26ed6731c" xlink:href="oncyf-20221231.xsd#oncyf_CashAndCashEquivalentsAndCurrentInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_cdb364b1-5f57-4b68-aa6c-28cdb8e6785e" xlink:to="loc_oncyf_CashAndCashEquivalentsAndCurrentInvestments_c2997d96-c098-4593-b23d-d8a26ed6731c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_57826b98-afb8-4fb8-ac73-0a96ae5b15b2" xlink:href="oncyf-20221231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_bd7f9366-4aeb-4e37-af5d-fa61fc98a986" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_57826b98-afb8-4fb8-ac73-0a96ae5b15b2" xlink:to="loc_ifrs-full_CashEquivalents_bd7f9366-4aeb-4e37-af5d-fa61fc98a986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfStockOptionPlans_44e83666-1dca-417f-a15b-3ea5b785967d" xlink:href="oncyf-20221231.xsd#oncyf_NumberOfStockOptionPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_57826b98-afb8-4fb8-ac73-0a96ae5b15b2" xlink:to="loc_oncyf_NumberOfStockOptionPlans_44e83666-1dca-417f-a15b-3ea5b785967d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_4a4afc48-38d7-4923-89f9-e5f08dd523f8" xlink:href="oncyf-20221231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_57826b98-afb8-4fb8-ac73-0a96ae5b15b2" xlink:to="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_4a4afc48-38d7-4923-89f9-e5f08dd523f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_78913da2-cc87-43cc-9117-90d9ff54cac8" xlink:href="oncyf-20221231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69d5c0ef-c3d2-4724-986f-848ab20a8328" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_78913da2-cc87-43cc-9117-90d9ff54cac8" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69d5c0ef-c3d2-4724-986f-848ab20a8328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ed6566ff-77a7-4e55-90c3-4f2259c91099" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69d5c0ef-c3d2-4724-986f-848ab20a8328" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ed6566ff-77a7-4e55-90c3-4f2259c91099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_99feb80d-32f6-493a-a74c-80fb5969c88e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ed6566ff-77a7-4e55-90c3-4f2259c91099" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_99feb80d-32f6-493a-a74c-80fb5969c88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_c6bb702b-f9b0-40c1-b74b-18d91df13d85" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_99feb80d-32f6-493a-a74c-80fb5969c88e" xlink:to="loc_ifrs-full_OfficeEquipmentMember_c6bb702b-f9b0-40c1-b74b-18d91df13d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_f2b52223-a0c7-48c7-b9dc-6706b3e62027" xlink:href="oncyf-20221231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_99feb80d-32f6-493a-a74c-80fb5969c88e" xlink:to="loc_oncyf_MedicalEquipmentMember_f2b52223-a0c7-48c7-b9dc-6706b3e62027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_4c82c548-3ecb-42b0-8c06-6363abe2e34f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_99feb80d-32f6-493a-a74c-80fb5969c88e" xlink:to="loc_ifrs-full_ComputerEquipmentMember_4c82c548-3ecb-42b0-8c06-6363abe2e34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b6dfe65a-d8c1-4f3f-8bfb-cfa4a80daab9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69d5c0ef-c3d2-4724-986f-848ab20a8328" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b6dfe65a-d8c1-4f3f-8bfb-cfa4a80daab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_7c5eb7d0-b4fd-4e5a-9c45-ef2960b46152" xlink:href="oncyf-20221231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b6dfe65a-d8c1-4f3f-8bfb-cfa4a80daab9" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_7c5eb7d0-b4fd-4e5a-9c45-ef2960b46152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#OtherAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_1e27d069-3a43-4f7c-8669-a5393fccd3de" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_1aaf37a2-c2c3-4832-bc33-1a64ed462e96" xlink:href="oncyf-20221231.xsd#oncyf_Currency1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_1e27d069-3a43-4f7c-8669-a5393fccd3de" xlink:to="loc_oncyf_Currency1Table_1aaf37a2-c2c3-4832-bc33-1a64ed462e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_4f07fa00-d549-4548-ae40-e1646340bfc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_1aaf37a2-c2c3-4832-bc33-1a64ed462e96" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_4f07fa00-d549-4548-ae40-e1646340bfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_b51d5c7b-1a0e-462d-9efb-87f110f331e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_4f07fa00-d549-4548-ae40-e1646340bfc5" xlink:to="loc_ifrs-full_OtherProvisionsMember_b51d5c7b-1a0e-462d-9efb-87f110f331e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CollaborationAgreementMember_96bc9724-8a04-4122-a410-b1373e83a8fd" xlink:href="oncyf-20221231.xsd#oncyf_CollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_b51d5c7b-1a0e-462d-9efb-87f110f331e8" xlink:to="loc_oncyf_CollaborationAgreementMember_96bc9724-8a04-4122-a410-b1373e83a8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_1a411410-8120-4834-a29a-eeaf4186f3da" xlink:href="oncyf-20221231.xsd#oncyf_Currency1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_1aaf37a2-c2c3-4832-bc33-1a64ed462e96" xlink:to="loc_oncyf_Currency1LineItems_1a411410-8120-4834-a29a-eeaf4186f3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_3964171e-d2fc-49c0-aacd-236bc66e62d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_1a411410-8120-4834-a29a-eeaf4186f3da" xlink:to="loc_ifrs-full_OtherReceivables_3964171e-d2fc-49c0-aacd-236bc66e62d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_aa9ad035-8e25-4fac-8768-b290946eee5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_1a411410-8120-4834-a29a-eeaf4186f3da" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_aa9ad035-8e25-4fac-8768-b290946eee5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_4f751cf7-c154-415f-bc55-e5d37a0ea27c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_1a411410-8120-4834-a29a-eeaf4186f3da" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_4f751cf7-c154-415f-bc55-e5d37a0ea27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPrepayments_ef5cb532-384c-4aec-958b-e00bc630218b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_1a411410-8120-4834-a29a-eeaf4186f3da" xlink:to="loc_ifrs-full_NoncurrentPrepayments_ef5cb532-384c-4aec-958b-e00bc630218b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_3bd03343-8897-48cd-864c-549e2f60d514" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_41bd974c-3a6f-4594-bd21-7656a44ec1fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_3bd03343-8897-48cd-864c-549e2f60d514" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_41bd974c-3a6f-4594-bd21-7656a44ec1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eb9e9caa-89c0-4507-86dd-4b71c2c7a392" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_41bd974c-3a6f-4594-bd21-7656a44ec1fc" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eb9e9caa-89c0-4507-86dd-4b71c2c7a392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_ea9cc01f-159f-486e-b792-96a4956234ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_eb9e9caa-89c0-4507-86dd-4b71c2c7a392" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_ea9cc01f-159f-486e-b792-96a4956234ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_4b321f66-3602-407a-a9e7-5a0bd792b4e0" xlink:href="oncyf-20221231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_ea9cc01f-159f-486e-b792-96a4956234ef" xlink:to="loc_oncyf_MedicalEquipmentMember_4b321f66-3602-407a-a9e7-5a0bd792b4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_61e55cd0-0f0b-40c2-8538-1e7274018b40" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_ea9cc01f-159f-486e-b792-96a4956234ef" xlink:to="loc_ifrs-full_ComputerEquipmentMember_61e55cd0-0f0b-40c2-8538-1e7274018b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeEquipmentAndFurnitureMember_a36b6287-0a86-4bcb-96f6-3c285879bd45" xlink:href="oncyf-20221231.xsd#oncyf_OfficeEquipmentAndFurnitureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_ea9cc01f-159f-486e-b792-96a4956234ef" xlink:to="loc_oncyf_OfficeEquipmentAndFurnitureMember_a36b6287-0a86-4bcb-96f6-3c285879bd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_867fd38c-0591-4d25-8573-4ac66f977789" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_ea9cc01f-159f-486e-b792-96a4956234ef" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_867fd38c-0591-4d25-8573-4ac66f977789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_db361485-54b9-4dd1-95b5-0de55a65ab90" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_41bd974c-3a6f-4594-bd21-7656a44ec1fc" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_db361485-54b9-4dd1-95b5-0de55a65ab90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_01253023-624d-40af-bc30-7d6c2daf6226" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_db361485-54b9-4dd1-95b5-0de55a65ab90" xlink:to="loc_ifrs-full_CarryingAmountMember_01253023-624d-40af-bc30-7d6c2daf6226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_161a2b24-44ae-441d-b9bd-31eff51e3913" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_01253023-624d-40af-bc30-7d6c2daf6226" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_161a2b24-44ae-441d-b9bd-31eff51e3913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_6edda9b6-5237-4d5b-897e-22331f59643d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_01253023-624d-40af-bc30-7d6c2daf6226" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_6edda9b6-5237-4d5b-897e-22331f59643d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9febe0cd-de73-49ac-8164-e5685e45b011" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_41bd974c-3a6f-4594-bd21-7656a44ec1fc" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9febe0cd-de73-49ac-8164-e5685e45b011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_9febe0cd-de73-49ac-8164-e5685e45b011" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_a10f6f54-fd85-4e6c-bb05-b597240b9a88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_a10f6f54-fd85-4e6c-bb05-b597240b9a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_d58e5f06-2801-488d-939b-d0ac92f452d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_d58e5f06-2801-488d-939b-d0ac92f452d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_c57082ff-cceb-401e-8e0e-b0b30d64caab" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_c57082ff-cceb-401e-8e0e-b0b30d64caab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_c2d68ffa-7983-4281-83b7-c06a223dc611" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_c2d68ffa-7983-4281-83b7-c06a223dc611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_dd7cc258-fea2-4eb2-8437-c0a673af57f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_ae59ef8f-eb06-4272-a635-d0304d87939d" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_dd7cc258-fea2-4eb2-8437-c0a673af57f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d47988ac-081d-42e5-b604-cb5faf13111e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_17d3b0d1-6d1b-4d50-8a6d-af313f1d9b86" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d47988ac-081d-42e5-b604-cb5faf13111e" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_17d3b0d1-6d1b-4d50-8a6d-af313f1d9b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_3231ca0e-fc98-4721-b45d-84c938719562" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d47988ac-081d-42e5-b604-cb5faf13111e" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_3231ca0e-fc98-4721-b45d-84c938719562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_f6443fac-f4d3-404f-8809-546ed49b599f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_d47988ac-081d-42e5-b604-cb5faf13111e" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_f6443fac-f4d3-404f-8809-546ed49b599f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_7c5f8765-4727-4124-a8d0-2ac5f9b2fc9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d17a916-2b92-493a-ad91-aeed1b191ffa" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_7c5f8765-4727-4124-a8d0-2ac5f9b2fc9d" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d17a916-2b92-493a-ad91-aeed1b191ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8ad7c4c0-cdf2-4967-839e-d76bf62dc112" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d17a916-2b92-493a-ad91-aeed1b191ffa" xlink:to="loc_srt_RangeAxis_8ad7c4c0-cdf2-4967-839e-d76bf62dc112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f742ccb-521f-40e1-b486-df5ec49659e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8ad7c4c0-cdf2-4967-839e-d76bf62dc112" xlink:to="loc_srt_RangeMember_7f742ccb-521f-40e1-b486-df5ec49659e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b1beb32c-a988-4457-9a00-d50815b875f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7f742ccb-521f-40e1-b486-df5ec49659e6" xlink:to="loc_srt_MinimumMember_b1beb32c-a988-4457-9a00-d50815b875f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a9f0561d-e592-43a5-961c-c84456515655" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7f742ccb-521f-40e1-b486-df5ec49659e6" xlink:to="loc_srt_MaximumMember_a9f0561d-e592-43a5-961c-c84456515655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_06f6ccb5-6e22-4d77-b214-a2edb37af15a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_7d17a916-2b92-493a-ad91-aeed1b191ffa" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_06f6ccb5-6e22-4d77-b214-a2edb37af15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm_bd5a2e2a-dc11-43b4-af75-642e1e52ced9" xlink:href="oncyf-20221231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_06f6ccb5-6e22-4d77-b214-a2edb37af15a" xlink:to="loc_oncyf_OperatingLeaseRemainingLeaseTerm_bd5a2e2a-dc11-43b4-af75-642e1e52ced9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_36b40830-ee71-4781-a6f8-f312919ad842" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_06f6ccb5-6e22-4d77-b214-a2edb37af15a" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_36b40830-ee71-4781-a6f8-f312919ad842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#LeasesRightofuseAssetsandLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_8a25176f-82ee-4d3a-980e-d3aa5d58bc52" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RightOfUseAssetsAbstract_259f0f6a-d164-44f4-b409-62e77d0a1ed2" xlink:href="oncyf-20221231.xsd#oncyf_RightOfUseAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_8a25176f-82ee-4d3a-980e-d3aa5d58bc52" xlink:to="loc_oncyf_RightOfUseAssetsAbstract_259f0f6a-d164-44f4-b409-62e77d0a1ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_d5830a74-9683-4fc7-9be4-7a920cfe94ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_259f0f6a-d164-44f4-b409-62e77d0a1ed2" xlink:to="loc_ifrs-full_RightofuseAssets_d5830a74-9683-4fc7-9be4-7a920cfe94ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_5f3958e3-4f62-4e28-9462-808c9d8dc44d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_259f0f6a-d164-44f4-b409-62e77d0a1ed2" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_5f3958e3-4f62-4e28-9462-808c9d8dc44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_LeaseModificationRightOfUseAssets_96710568-bdaf-492e-9b64-52803f511a54" xlink:href="oncyf-20221231.xsd#oncyf_LeaseModificationRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_259f0f6a-d164-44f4-b409-62e77d0a1ed2" xlink:to="loc_oncyf_LeaseModificationRightOfUseAssets_96710568-bdaf-492e-9b64-52803f511a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_57dd8ad9-33d1-4024-b87b-cf258f51071f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_259f0f6a-d164-44f4-b409-62e77d0a1ed2" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_57dd8ad9-33d1-4024-b87b-cf258f51071f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ForeignExchangeImpactRightofUseAssets_13d7f7e7-c2e3-434d-98c8-027d85ec2d05" xlink:href="oncyf-20221231.xsd#oncyf_ForeignExchangeImpactRightofUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_259f0f6a-d164-44f4-b409-62e77d0a1ed2" xlink:to="loc_oncyf_ForeignExchangeImpactRightofUseAssets_13d7f7e7-c2e3-434d-98c8-027d85ec2d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_c76cc151-54a9-4c1c-bd64-1de0c2b9bc27" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_259f0f6a-d164-44f4-b409-62e77d0a1ed2" xlink:to="loc_ifrs-full_RightofuseAssets_c76cc151-54a9-4c1c-bd64-1de0c2b9bc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_477e5939-521f-491d-9a41-fb6e02330c63" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_8a25176f-82ee-4d3a-980e-d3aa5d58bc52" xlink:to="loc_ifrs-full_LeaseLiabilitiesAbstract_477e5939-521f-491d-9a41-fb6e02330c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_37f317ca-8596-42bd-b1b3-6c254aa30b60" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_477e5939-521f-491d-9a41-fb6e02330c63" xlink:to="loc_ifrs-full_LeaseLiabilities_37f317ca-8596-42bd-b1b3-6c254aa30b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_9977d9a4-a730-4415-85d4-5032d8447796" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_477e5939-521f-491d-9a41-fb6e02330c63" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_9977d9a4-a730-4415-85d4-5032d8447796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EffectOfLeaseModificationOnLeaseLiabilities_12e65080-07d6-43a2-8a2a-8968b2ce8eec" xlink:href="oncyf-20221231.xsd#oncyf_EffectOfLeaseModificationOnLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_477e5939-521f-491d-9a41-fb6e02330c63" xlink:to="loc_oncyf_EffectOfLeaseModificationOnLeaseLiabilities_12e65080-07d6-43a2-8a2a-8968b2ce8eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_0fc85f4c-e3a0-4586-b349-15eadf969c95" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_477e5939-521f-491d-9a41-fb6e02330c63" xlink:to="loc_ifrs-full_CashOutflowForLeases_0fc85f4c-e3a0-4586-b349-15eadf969c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_44072602-f99b-43a7-99e8-6172afd6f681" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_477e5939-521f-491d-9a41-fb6e02330c63" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_44072602-f99b-43a7-99e8-6172afd6f681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact_d1c67d12-b555-44e1-b42b-37936d425400" xlink:href="oncyf-20221231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_477e5939-521f-491d-9a41-fb6e02330c63" xlink:to="loc_oncyf_GainsLossesFromForeignExchangeImpact_d1c67d12-b555-44e1-b42b-37936d425400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_2ee7a73c-850c-4b8c-9b09-d05b3af75316" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_477e5939-521f-491d-9a41-fb6e02330c63" xlink:to="loc_ifrs-full_LeaseLiabilities_2ee7a73c-850c-4b8c-9b09-d05b3af75316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d1173e5c-5f54-4325-ae43-b1c69a329d0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_40c37db2-190b-4f90-a924-6aad418eb1db" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_d1173e5c-5f54-4325-ae43-b1c69a329d0c" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_40c37db2-190b-4f90-a924-6aad418eb1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_a73be13b-0717-4f93-9226-87241b318f2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_40c37db2-190b-4f90-a924-6aad418eb1db" xlink:to="loc_ifrs-full_MaturityAxis_a73be13b-0717-4f93-9226-87241b318f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_66432636-85a2-41bb-8d6c-0944c2aaf2c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_a73be13b-0717-4f93-9226-87241b318f2e" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_66432636-85a2-41bb-8d6c-0944c2aaf2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_74c45163-fdd9-4817-8270-468d385d78a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_66432636-85a2-41bb-8d6c-0944c2aaf2c6" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_74c45163-fdd9-4817-8270-468d385d78a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_347e87f7-bd0e-408d-8ec8-d868d80d17f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_66432636-85a2-41bb-8d6c-0944c2aaf2c6" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_347e87f7-bd0e-408d-8ec8-d868d80d17f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_40369ea9-bfae-4065-87f5-ac87d7f4b0d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_66432636-85a2-41bb-8d6c-0944c2aaf2c6" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_40369ea9-bfae-4065-87f5-ac87d7f4b0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_037a083c-9938-4a7e-a515-d48fc219f8ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_40c37db2-190b-4f90-a924-6aad418eb1db" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_037a083c-9938-4a7e-a515-d48fc219f8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_00bfcc39-3d96-48f7-a9ad-ef3220334bdb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_037a083c-9938-4a7e-a515-d48fc219f8ce" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_00bfcc39-3d96-48f7-a9ad-ef3220334bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareCapitalScheduleofShareCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_6c18d4a6-46e9-4f30-8b27-87eb823b1e7f" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1af78e31-6aa4-4bff-b3fb-86d445963aa0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_6c18d4a6-46e9-4f30-8b27-87eb823b1e7f" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1af78e31-6aa4-4bff-b3fb-86d445963aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_e49bf961-cf9f-4e48-9245-287e756bbda4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1af78e31-6aa4-4bff-b3fb-86d445963aa0" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_e49bf961-cf9f-4e48-9245-287e756bbda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_2dfff518-ece7-4a86-bb1e-9d9b449c4695" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e49bf961-cf9f-4e48-9245-287e756bbda4" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_2dfff518-ece7-4a86-bb1e-9d9b449c4695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_64f440bc-89e0-4cfe-ad6c-2730200a8167" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_2dfff518-ece7-4a86-bb1e-9d9b449c4695" xlink:to="loc_ifrs-full_IssuedCapitalMember_64f440bc-89e0-4cfe-ad6c-2730200a8167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_cc83086d-9241-4c31-b165-27c13dc5b785" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1af78e31-6aa4-4bff-b3fb-86d445963aa0" xlink:to="loc_oncyf_SaleOfStockAxis_cc83086d-9241-4c31-b165-27c13dc5b785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_7a3d6a1d-0c41-43a7-8f70-33212bf95d89" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_cc83086d-9241-4c31-b165-27c13dc5b785" xlink:to="loc_oncyf_SaleOfStockDomain_7a3d6a1d-0c41-43a7-8f70-33212bf95d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_2c255332-a095-418f-a45e-8169e65039d0" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_7a3d6a1d-0c41-43a7-8f70-33212bf95d89" xlink:to="loc_oncyf_SharesUnderStockOptionPlanMember_2c255332-a095-418f-a45e-8169e65039d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_c089fa6f-6345-4f1f-820d-e74e6c640d6a" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_7a3d6a1d-0c41-43a7-8f70-33212bf95d89" xlink:to="loc_oncyf_SharesUnderIncentiveAwardPlanMember_c089fa6f-6345-4f1f-820d-e74e6c640d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_763cf8dc-c033-4191-aa5c-134f733340e1" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_7a3d6a1d-0c41-43a7-8f70-33212bf95d89" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_763cf8dc-c033-4191-aa5c-134f733340e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_7b898b92-6a67-4c3b-85fa-3702dd1d6573" xlink:href="oncyf-20221231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_7a3d6a1d-0c41-43a7-8f70-33212bf95d89" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_7b898b92-6a67-4c3b-85fa-3702dd1d6573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1679ad8c-4184-4dcc-a2f1-cac6619ae9b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1af78e31-6aa4-4bff-b3fb-86d445963aa0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1679ad8c-4184-4dcc-a2f1-cac6619ae9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalNumberSharesAbstract_d436920d-2c5a-47eb-9dfa-2c4a33c9d907" xlink:href="oncyf-20221231.xsd#oncyf_ShareCapitalNumberSharesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1679ad8c-4184-4dcc-a2f1-cac6619ae9b1" xlink:to="loc_oncyf_ShareCapitalNumberSharesAbstract_d436920d-2c5a-47eb-9dfa-2c4a33c9d907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_4f8b2f1a-2c9b-48ac-8d91-7b78168b9797" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_d436920d-2c5a-47eb-9dfa-2c4a33c9d907" xlink:to="loc_ifrs-full_NumberOfSharesIssued_4f8b2f1a-2c9b-48ac-8d91-7b78168b9797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_fb6862ea-eee9-42ef-8d69-01e66e0b8e56" xlink:href="oncyf-20221231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_d436920d-2c5a-47eb-9dfa-2c4a33c9d907" xlink:to="loc_oncyf_IssueOfEquityShares_fb6862ea-eee9-42ef-8d69-01e66e0b8e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_f4895457-7846-4aa9-89d8-89e342582809" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_d436920d-2c5a-47eb-9dfa-2c4a33c9d907" xlink:to="loc_ifrs-full_NumberOfSharesIssued_f4895457-7846-4aa9-89d8-89e342582809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalAmountAbstract_4790f534-fffc-4d62-85e1-cdc115c2141f" xlink:href="oncyf-20221231.xsd#oncyf_ShareCapitalAmountAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1679ad8c-4184-4dcc-a2f1-cac6619ae9b1" xlink:to="loc_oncyf_ShareCapitalAmountAbstract_4790f534-fffc-4d62-85e1-cdc115c2141f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_ab9eb5ab-fdd3-4d2b-bf94-04d7cdc1208f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_4790f534-fffc-4d62-85e1-cdc115c2141f" xlink:to="loc_ifrs-full_Equity_ab9eb5ab-fdd3-4d2b-bf94-04d7cdc1208f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_af229bb1-51f6-4006-965d-a5e4a3e5ec67" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_4790f534-fffc-4d62-85e1-cdc115c2141f" xlink:to="loc_ifrs-full_IssueOfEquity_af229bb1-51f6-4006-965d-a5e4a3e5ec67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_3ebddc09-add0-470d-8149-2f43e8d59418" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_4790f534-fffc-4d62-85e1-cdc115c2141f" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_3ebddc09-add0-470d-8149-2f43e8d59418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5fead105-b563-47e8-ac9e-be2c8bbc6dc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_4790f534-fffc-4d62-85e1-cdc115c2141f" xlink:to="loc_ifrs-full_Equity_5fead105-b563-47e8-ac9e-be2c8bbc6dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareCapitalScheduleofShareCapitalFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_f8452547-5910-43cd-b717-c978b10ed1ae" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_dbf16feb-a72e-4f39-87be-9b78eb01d4b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_f8452547-5910-43cd-b717-c978b10ed1ae" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_dbf16feb-a72e-4f39-87be-9b78eb01d4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_fe927c39-15c1-4e97-b770-8b153204f4a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_dbf16feb-a72e-4f39-87be-9b78eb01d4b9" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_fe927c39-15c1-4e97-b770-8b153204f4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_dfde3734-b410-45f7-9251-2aba83b822d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_fe927c39-15c1-4e97-b770-8b153204f4a5" xlink:to="loc_ifrs-full_LiabilitiesMember_dfde3734-b410-45f7-9251-2aba83b822d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_c52f95df-f702-44c8-b47d-121e704377fa" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_dfde3734-b410-45f7-9251-2aba83b822d6" xlink:to="loc_oncyf_WarrantsMember_c52f95df-f702-44c8-b47d-121e704377fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_703ba524-71d5-4bd5-b064-1f30f4449063" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_dbf16feb-a72e-4f39-87be-9b78eb01d4b9" xlink:to="loc_oncyf_SaleOfStockAxis_703ba524-71d5-4bd5-b064-1f30f4449063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_703ba524-71d5-4bd5-b064-1f30f4449063" xlink:to="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_47427ff6-64ec-4299-a0e0-b08b338c51d3" xlink:href="oncyf-20221231.xsd#oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember_47427ff6-64ec-4299-a0e0-b08b338c51d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_60c37acb-f1a2-47c0-a229-fa817e72d1d8" xlink:href="oncyf-20221231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_60c37acb-f1a2-47c0-a229-fa817e72d1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_594d3501-ce8a-4c8d-81a1-769c96dc593e" xlink:href="oncyf-20221231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:to="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_594d3501-ce8a-4c8d-81a1-769c96dc593e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_47f9e083-a54b-4949-89c4-06598119a9cd" xlink:href="oncyf-20221231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:to="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_47f9e083-a54b-4949-89c4-06598119a9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_ee5c77e7-0b43-42c1-bd94-eb88539ae75b" xlink:href="oncyf-20221231.xsd#oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_84e2ecde-8033-4dfa-b75d-88c63203cbaf" xlink:to="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_ee5c77e7-0b43-42c1-bd94-eb88539ae75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_64665a2c-cdac-4d53-a042-2a5862787af0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_dbf16feb-a72e-4f39-87be-9b78eb01d4b9" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_64665a2c-cdac-4d53-a042-2a5862787af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_235788d8-5ccb-40b8-a789-d95b2b250597" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_64665a2c-cdac-4d53-a042-2a5862787af0" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_235788d8-5ccb-40b8-a789-d95b2b250597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_a4d98cfa-c760-4e28-b2b5-f8068d3a3a5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_235788d8-5ccb-40b8-a789-d95b2b250597" xlink:to="loc_ifrs-full_IssuedCapitalMember_a4d98cfa-c760-4e28-b2b5-f8068d3a3a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_caea1ced-9e52-46ef-aff3-9135fcbd60c7" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_235788d8-5ccb-40b8-a789-d95b2b250597" xlink:to="loc_oncyf_WarrantsMember_caea1ced-9e52-46ef-aff3-9135fcbd60c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_dbf16feb-a72e-4f39-87be-9b78eb01d4b9" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_abc5a18c-1b97-4228-b0a1-47fae7ed147a" xlink:href="oncyf-20221231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_abc5a18c-1b97-4228-b0a1-47fae7ed147a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_4c12930c-5ab6-427b-b672-c729186977c4" xlink:href="oncyf-20221231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_4c12930c-5ab6-427b-b672-c729186977c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_3e6f9cc7-3a4f-4a2a-b4a6-ac3b5532d02d" xlink:href="oncyf-20221231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_IssueOfEquityShares_3e6f9cc7-3a4f-4a2a-b4a6-ac3b5532d02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_4ed3fedb-6905-4771-aa32-0d4a8618620d" xlink:href="oncyf-20221231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_4ed3fedb-6905-4771-aa32-0d4a8618620d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_6a27ce4d-a8ae-462f-96cc-25ca7b55e336" xlink:href="oncyf-20221231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_6a27ce4d-a8ae-462f-96cc-25ca7b55e336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_d0e4f6eb-4467-47d5-886d-0958e89cde40" xlink:href="oncyf-20221231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_d0e4f6eb-4467-47d5-886d-0958e89cde40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_8b08efcd-1f38-42d4-94c0-c7059cda3f3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_8b08efcd-1f38-42d4-94c0-c7059cda3f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_07388143-fbcd-4f2f-8b2a-d7498e1988c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_07388143-fbcd-4f2f-8b2a-d7498e1988c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_39c49edd-bd97-4b55-8954-d12e5e2e12a0" xlink:href="oncyf-20221231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_CommonSharesPerUnit_39c49edd-bd97-4b55-8954-d12e5e2e12a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedFairValueOfCommonShare_457f61c3-8118-44b9-99b5-9fb72fb0d659" xlink:href="oncyf-20221231.xsd#oncyf_SharesIssuedFairValueOfCommonShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_SharesIssuedFairValueOfCommonShare_457f61c3-8118-44b9-99b5-9fb72fb0d659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_58470cc9-4147-4517-aaf7-e403c7586493" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_58470cc9-4147-4517-aaf7-e403c7586493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_f822342e-aa47-4047-8232-447014667655" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_f822342e-aa47-4047-8232-447014667655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_2762413e-cac4-4fd9-93aa-c6b3e5ca3815" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofWarrantsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofWarrantsExercised_2762413e-cac4-4fd9-93aa-c6b3e5ca3815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_c987bf5c-6ea9-47a1-893e-d19ffd9242c8" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_c987bf5c-6ea9-47a1-893e-d19ffd9242c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_118de2a6-f725-4ade-b498-2b4915dc30ac" xlink:href="oncyf-20221231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_118de2a6-f725-4ade-b498-2b4915dc30ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightOutstanding1_14798667-2d6e-4d43-9979-e4460f3c55f4" xlink:href="oncyf-20221231.xsd#oncyf_ClassOfWarrantOrRightOutstanding1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6f2906d8-ceeb-44ab-9adb-9782c54b347a" xlink:to="loc_oncyf_ClassOfWarrantOrRightOutstanding1_14798667-2d6e-4d43-9979-e4460f3c55f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareCapitalEquityWarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e962bf1e-8b58-4a2b-86cb-1b41c4618f81" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_21c141ef-022f-44c7-a505-fa91ba86c5b8" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e962bf1e-8b58-4a2b-86cb-1b41c4618f81" xlink:to="loc_oncyf_SaleOfStockAxis_21c141ef-022f-44c7-a505-fa91ba86c5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_25f785b3-5081-4d71-8325-aea6f941e618" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_21c141ef-022f-44c7-a505-fa91ba86c5b8" xlink:to="loc_oncyf_SaleOfStockDomain_25f785b3-5081-4d71-8325-aea6f941e618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_5f38bb67-228b-45c4-9854-8a026e5924e0" xlink:href="oncyf-20221231.xsd#oncyf_SharesPublicOfferingEquityWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_25f785b3-5081-4d71-8325-aea6f941e618" xlink:to="loc_oncyf_SharesPublicOfferingEquityWarrantsMember_5f38bb67-228b-45c4-9854-8a026e5924e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e962bf1e-8b58-4a2b-86cb-1b41c4618f81" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_b4f52036-e8bd-4059-b17d-42cc4936de4e" xlink:href="oncyf-20221231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_IssueOfEquityShares_b4f52036-e8bd-4059-b17d-42cc4936de4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_a6f29ffd-47d0-4583-8621-0478f1302c34" xlink:href="oncyf-20221231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_a6f29ffd-47d0-4583-8621-0478f1302c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_ca1690c7-67b1-4c59-b916-d27107efea61" xlink:href="oncyf-20221231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_CommonSharesPerUnit_ca1690c7-67b1-4c59-b916-d27107efea61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharePurchaseWarrantPerUnit_9a651b2c-a516-448f-b8c6-483527f0ac4d" xlink:href="oncyf-20221231.xsd#oncyf_CommonSharePurchaseWarrantPerUnit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_CommonSharePurchaseWarrantPerUnit_9a651b2c-a516-448f-b8c6-483527f0ac4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_2909c647-a6ce-4517-8717-41d6895c3641" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_2909c647-a6ce-4517-8717-41d6895c3641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_1616742f-efae-48de-ab44-17567a3c68f5" xlink:href="oncyf-20221231.xsd#oncyf_StockholdersEquityNoteStockSplitConversionRatio"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_StockholdersEquityNoteStockSplitConversionRatio_1616742f-efae-48de-ab44-17567a3c68f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_5ac94d9b-0e3c-4277-af88-9ebc984c7303" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1_5ac94d9b-0e3c-4277-af88-9ebc984c7303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedWarrantPricePerShare_74f7fac7-852a-41d9-b38d-9359833e47c1" xlink:href="oncyf-20221231.xsd#oncyf_SharesIssuedWarrantPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_b99cd885-2e64-4677-b858-c5f2f3d318ad" xlink:to="loc_oncyf_SharesIssuedWarrantPricePerShare_74f7fac7-852a-41d9-b38d-9359833e47c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareCapitalSummaryofOutstandingWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_e2abf70f-84b3-4c2f-bc4f-25b67d78bdbe" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_a7d061ee-8a3a-46bf-a930-cf3ef2a3715e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_e2abf70f-84b3-4c2f-bc4f-25b67d78bdbe" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_a7d061ee-8a3a-46bf-a930-cf3ef2a3715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_66c95e2f-18e7-4759-885c-6ff7fefe0612" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_a7d061ee-8a3a-46bf-a930-cf3ef2a3715e" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_66c95e2f-18e7-4759-885c-6ff7fefe0612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_4dce9c76-5338-4a63-87cb-045f05ce6a31" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_66c95e2f-18e7-4759-885c-6ff7fefe0612" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_4dce9c76-5338-4a63-87cb-045f05ce6a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_4baa9946-2e0c-4a40-be9d-23706cd13b23" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_4dce9c76-5338-4a63-87cb-045f05ce6a31" xlink:to="loc_oncyf_WarrantsMember_4baa9946-2e0c-4a40-be9d-23706cd13b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_a7d061ee-8a3a-46bf-a930-cf3ef2a3715e" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_024b27c7-b903-45f4-88c8-afecb38baa68" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_024b27c7-b903-45f4-88c8-afecb38baa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfSharesExpired_4e3fe762-0813-4d1e-a47f-3e6b85c6c033" xlink:href="oncyf-20221231.xsd#oncyf_NumberOfSharesExpired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:to="loc_oncyf_NumberOfSharesExpired_4e3fe762-0813-4d1e-a47f-3e6b85c6c033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsOutstanding1_8b6edaee-6550-4ec1-ac27-d040f3fa333c" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsAndRightsOutstanding1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:to="loc_oncyf_WarrantsAndRightsOutstanding1_8b6edaee-6550-4ec1-ac27-d040f3fa333c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsAndRightsExpired_844ebf5b-1f7f-4da0-b332-cb55b8151cd1" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsAndRightsExpired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:to="loc_oncyf_WarrantsAndRightsExpired_844ebf5b-1f7f-4da0-b332-cb55b8151cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_2d677ed2-291b-4c35-9957-c38469a12773" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_df1bc77c-edd7-4be3-a91f-ad591cc442d5" xlink:to="loc_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1_2d677ed2-291b-4c35-9957-c38469a12773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_29ae64f3-86f7-433d-b71f-b7781a78c285" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockOptionsOutstandingAbstract_221d4788-44c9-44cd-bffb-e0f1bd8f17b9" xlink:href="oncyf-20221231.xsd#oncyf_StockOptionsOutstandingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_29ae64f3-86f7-433d-b71f-b7781a78c285" xlink:to="loc_oncyf_StockOptionsOutstandingAbstract_221d4788-44c9-44cd-bffb-e0f1bd8f17b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_3a49d979-b14b-48a7-b18b-3a1358ac5e95" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_221d4788-44c9-44cd-bffb-e0f1bd8f17b9" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_3a49d979-b14b-48a7-b18b-3a1358ac5e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_bcbd939a-7733-4a3d-9b3c-27572b2bab45" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_221d4788-44c9-44cd-bffb-e0f1bd8f17b9" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_bcbd939a-7733-4a3d-9b3c-27572b2bab45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_afecab2c-e46d-452c-aba8-42c5453b2e76" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_221d4788-44c9-44cd-bffb-e0f1bd8f17b9" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_afecab2c-e46d-452c-aba8-42c5453b2e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_b4ae3a2f-4633-48a6-bb76-5f5ff3173bff" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_221d4788-44c9-44cd-bffb-e0f1bd8f17b9" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_b4ae3a2f-4633-48a6-bb76-5f5ff3173bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_da323522-81b6-44ec-aa18-fa22dfd719f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_221d4788-44c9-44cd-bffb-e0f1bd8f17b9" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_da323522-81b6-44ec-aa18-fa22dfd719f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_05e41d4e-fd36-4b12-950a-32e100db1c3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_221d4788-44c9-44cd-bffb-e0f1bd8f17b9" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_05e41d4e-fd36-4b12-950a-32e100db1c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_04e9c1e3-e679-40ba-858d-b2ae353f63fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_29ae64f3-86f7-433d-b71f-b7781a78c285" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_04e9c1e3-e679-40ba-858d-b2ae353f63fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_a019ae84-6799-45e6-a29e-2ddb25fd20da" xlink:href="oncyf-20221231.xsd#oncyf_WeightedAverageExercisePriceOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_29ae64f3-86f7-433d-b71f-b7781a78c285" xlink:to="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_a019ae84-6799-45e6-a29e-2ddb25fd20da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_4a3bfe4a-78cc-4354-b551-a89a600cf480" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_a019ae84-6799-45e6-a29e-2ddb25fd20da" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_4a3bfe4a-78cc-4354-b551-a89a600cf480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_b82f890c-f67c-4dac-9b45-3c1901176726" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_a019ae84-6799-45e6-a29e-2ddb25fd20da" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_b82f890c-f67c-4dac-9b45-3c1901176726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_4287cf3e-2395-445e-bbcb-758f3577303e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_a019ae84-6799-45e6-a29e-2ddb25fd20da" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_4287cf3e-2395-445e-bbcb-758f3577303e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_60f11755-9d2e-433c-9b2c-6b3e15e47a2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_a019ae84-6799-45e6-a29e-2ddb25fd20da" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_60f11755-9d2e-433c-9b2c-6b3e15e47a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_58267414-3596-4533-aca2-e7d314f42e24" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_a019ae84-6799-45e6-a29e-2ddb25fd20da" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_58267414-3596-4533-aca2-e7d314f42e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2d604c1b-9fb3-403e-a30a-878452bad231" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_a019ae84-6799-45e6-a29e-2ddb25fd20da" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2d604c1b-9fb3-403e-a30a-878452bad231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_8ca1475f-08a0-4e79-a9d8-a52fe7269d1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_29ae64f3-86f7-433d-b71f-b7781a78c285" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_8ca1475f-08a0-4e79-a9d8-a52fe7269d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_bc058c01-6df2-4e40-9003-4de760118b5e" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9df1bf31-8c63-49d6-afe2-ad601dd3f0b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_bc058c01-6df2-4e40-9003-4de760118b5e" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9df1bf31-8c63-49d6-afe2-ad601dd3f0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_42ff73dc-4243-49e9-9357-d1ab3c8afee9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9df1bf31-8c63-49d6-afe2-ad601dd3f0b3" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_42ff73dc-4243-49e9-9357-d1ab3c8afee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_42ff73dc-4243-49e9-9357-d1ab3c8afee9" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_6d8decc1-0b90-4821-9be7-47b751b70ea1" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_6d8decc1-0b90-4821-9be7-47b751b70ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_eba45827-909d-477b-a1fb-1dc1765bb8a9" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_eba45827-909d-477b-a1fb-1dc1765bb8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_716730bc-099b-4ef7-8614-d40d0e7a48d5" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_716730bc-099b-4ef7-8614-d40d0e7a48d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_61dd43f0-bdda-4985-af0f-83f9ed608f93" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_61dd43f0-bdda-4985-af0f-83f9ed608f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_11c94248-d469-4b91-a33c-008190a6028e" xlink:href="oncyf-20221231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0cb76ac4-6ac7-4119-be2b-2c5f5caf6b7d" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_11c94248-d469-4b91-a33c-008190a6028e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_963c7d5f-7e55-4372-bdcf-c9f519eb2f03" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9df1bf31-8c63-49d6-afe2-ad601dd3f0b3" xlink:to="loc_ifrs-full_RangeAxis_963c7d5f-7e55-4372-bdcf-c9f519eb2f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_ac01572c-39be-460e-8ffb-c0703efc41a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_963c7d5f-7e55-4372-bdcf-c9f519eb2f03" xlink:to="loc_ifrs-full_RangesMember_ac01572c-39be-460e-8ffb-c0703efc41a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_86bae842-bcc3-42fd-9b20-03d289f4dfdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_ac01572c-39be-460e-8ffb-c0703efc41a8" xlink:to="loc_ifrs-full_BottomOfRangeMember_86bae842-bcc3-42fd-9b20-03d289f4dfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_5c82875c-35eb-40a6-8093-a80b09f876fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_ac01572c-39be-460e-8ffb-c0703efc41a8" xlink:to="loc_ifrs-full_TopOfRangeMember_5c82875c-35eb-40a6-8093-a80b09f876fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9df1bf31-8c63-49d6-afe2-ad601dd3f0b3" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_ecc7f745-74d6-463a-b35a-b52f3aa720c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_ecc7f745-74d6-463a-b35a-b52f3aa720c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_d8b7e962-2ca1-4740-bb97-e079d690b498" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_d8b7e962-2ca1-4740-bb97-e079d690b498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dbed1d66-cd3d-4528-900d-aeef13b2f1e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dbed1d66-cd3d-4528-900d-aeef13b2f1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_03ad76dd-4fa0-47dc-b134-e1289a612171" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_03ad76dd-4fa0-47dc-b134-e1289a612171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_94712600-ff65-4a72-a052-987b19106d2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_94712600-ff65-4a72-a052-987b19106d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_0a707835-9504-44c3-8682-f13f4de27626" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_1d4f466d-2073-49e2-9de6-83e73e31ef03" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_0a707835-9504-44c3-8682-f13f4de27626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_05a42785-bf98-47d2-a265-d4dc42679f1a" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c806a4aa-0ca1-4db9-b649-5db3fd91f032" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_05a42785-bf98-47d2-a265-d4dc42679f1a" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c806a4aa-0ca1-4db9-b649-5db3fd91f032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_804145bb-d3b3-4c99-8e7f-8ce8c6e457ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c806a4aa-0ca1-4db9-b649-5db3fd91f032" xlink:to="loc_ifrs-full_RangeAxis_804145bb-d3b3-4c99-8e7f-8ce8c6e457ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_8956ea42-0fce-4600-a3f0-cb3d6b08279e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_804145bb-d3b3-4c99-8e7f-8ce8c6e457ab" xlink:to="loc_ifrs-full_RangesMember_8956ea42-0fce-4600-a3f0-cb3d6b08279e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_b4df5288-5f87-4934-a6b4-bc38cf9d2d72" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_8956ea42-0fce-4600-a3f0-cb3d6b08279e" xlink:to="loc_ifrs-full_BottomOfRangeMember_b4df5288-5f87-4934-a6b4-bc38cf9d2d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_32b1822d-2477-4af1-8dfe-8b8881763c12" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_8956ea42-0fce-4600-a3f0-cb3d6b08279e" xlink:to="loc_ifrs-full_TopOfRangeMember_32b1822d-2477-4af1-8dfe-8b8881763c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5bcccaa3-20fd-48e0-a972-446feb86143c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c806a4aa-0ca1-4db9-b649-5db3fd91f032" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5bcccaa3-20fd-48e0-a972-446feb86143c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_485bfce9-e482-42f5-93b3-c230a2645998" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_5bcccaa3-20fd-48e0-a972-446feb86143c" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_485bfce9-e482-42f5-93b3-c230a2645998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember_99b9f847-ce5f-4cdf-9934-48b114e503af" xlink:href="oncyf-20221231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_485bfce9-e482-42f5-93b3-c230a2645998" xlink:to="loc_oncyf_RestrictedShareUnitsMember_99b9f847-ce5f-4cdf-9934-48b114e503af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_4b31fd0f-819a-43ad-af10-5268666279bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_485bfce9-e482-42f5-93b3-c230a2645998" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_4b31fd0f-819a-43ad-af10-5268666279bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_d6d62fc1-ef38-4fc2-ba4f-019b8bd7411b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c806a4aa-0ca1-4db9-b649-5db3fd91f032" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_d6d62fc1-ef38-4fc2-ba4f-019b8bd7411b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_fdeffcc8-46a5-4c6a-acf6-a01f84185da7" xlink:href="oncyf-20221231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_d6d62fc1-ef38-4fc2-ba4f-019b8bd7411b" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_fdeffcc8-46a5-4c6a-acf6-a01f84185da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_797190a3-bdda-430f-924d-17c839f54bff" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_d6d62fc1-ef38-4fc2-ba4f-019b8bd7411b" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_797190a3-bdda-430f-924d-17c839f54bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_db2cab7f-6606-4816-a622-80d6d6bae566" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_d6d62fc1-ef38-4fc2-ba4f-019b8bd7411b" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_db2cab7f-6606-4816-a622-80d6d6bae566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_a09869d6-c46e-46bc-b69f-9921ad845ff5" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_646cefb9-f2f5-4d43-ba7e-332a3841aef3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_a09869d6-c46e-46bc-b69f-9921ad845ff5" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_646cefb9-f2f5-4d43-ba7e-332a3841aef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_d6e94ba5-5681-4d60-ac16-29fcf8c56401" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_a09869d6-c46e-46bc-b69f-9921ad845ff5" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_d6e94ba5-5681-4d60-ac16-29fcf8c56401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_db295738-5733-49f7-a025-6812109d749d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_a09869d6-c46e-46bc-b69f-9921ad845ff5" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_db295738-5733-49f7-a025-6812109d749d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_4a3fb83b-5b5e-4983-938b-372c800c20dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_a09869d6-c46e-46bc-b69f-9921ad845ff5" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_4a3fb83b-5b5e-4983-938b-372c800c20dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_fc0669ca-f490-4c00-8929-720f3b80cb63" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_a09869d6-c46e-46bc-b69f-9921ad845ff5" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_fc0669ca-f490-4c00-8929-720f3b80cb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_412d8d98-a872-4d01-931c-72a79d27dc50" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5ac90d1b-35d5-4082-9e84-da136f12e90a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_412d8d98-a872-4d01-931c-72a79d27dc50" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5ac90d1b-35d5-4082-9e84-da136f12e90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b43e0fbd-336e-452a-be4b-4ef0ba5d4e98" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5ac90d1b-35d5-4082-9e84-da136f12e90a" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b43e0fbd-336e-452a-be4b-4ef0ba5d4e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_b4a56552-c035-4a81-9424-f636df15884e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b43e0fbd-336e-452a-be4b-4ef0ba5d4e98" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_b4a56552-c035-4a81-9424-f636df15884e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestrictedShareUnitsMember_a6671679-2589-4936-ada9-7bb964e91b2d" xlink:href="oncyf-20221231.xsd#oncyf_RestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_b4a56552-c035-4a81-9424-f636df15884e" xlink:to="loc_oncyf_RestrictedShareUnitsMember_a6671679-2589-4936-ada9-7bb964e91b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_5ac90d1b-35d5-4082-9e84-da136f12e90a" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_30fde05c-078c-469e-9319-ccb2064b5c11" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_30fde05c-078c-469e-9319-ccb2064b5c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_7f6b2a02-9f77-44b0-ad9e-4f69471d15b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_7f6b2a02-9f77-44b0-ad9e-4f69471d15b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_c2e16f38-3e19-43d4-86f6-28c4c66ef53a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_c2e16f38-3e19-43d4-86f6-28c4c66ef53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_66796cde-c1b6-4a83-a181-d439dd72337d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_66796cde-c1b6-4a83-a181-d439dd72337d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_f5c68302-1400-46e9-a074-1cf715251f63" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e5908f95-852d-4b69-aeec-f61f06e6ad1c" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_f5c68302-1400-46e9-a074-1cf715251f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#LossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_2d467428-c3c6-4ca8-b0f6-f3e78b0abf81" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_4d2cdc12-8733-4590-a34d-9cca644ae0a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_2d467428-c3c6-4ca8-b0f6-f3e78b0abf81" xlink:to="loc_ifrs-full_WeightedAverageShares_4d2cdc12-8733-4590-a34d-9cca644ae0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ContractLiabilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_6e02adf3-5f40-4e15-bb58-9ccb4b431cdd" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod_3e3b7d13-6f9a-4d3d-b9f9-85452a1f89d5" xlink:href="oncyf-20221231.xsd#oncyf_ContractLiabilityRecognitionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_6e02adf3-5f40-4e15-bb58-9ccb4b431cdd" xlink:to="loc_oncyf_ContractLiabilityRecognitionPeriod_3e3b7d13-6f9a-4d3d-b9f9-85452a1f89d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_65cea262-8db4-49e9-83a1-a3f7a8b78ce9" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_79fd91b2-1bb1-4ec7-a0e7-590c438664d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_65cea262-8db4-49e9-83a1-a3f7a8b78ce9" xlink:to="loc_ifrs-full_ContractLiabilities_79fd91b2-1bb1-4ec7-a0e7-590c438664d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_0c54aa93-6ce1-4853-8939-6d55ffee3ddb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_65cea262-8db4-49e9-83a1-a3f7a8b78ce9" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_0c54aa93-6ce1-4853-8939-6d55ffee3ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_c7a1c8ec-5708-4284-98e6-81ec34dbab9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_65cea262-8db4-49e9-83a1-a3f7a8b78ce9" xlink:to="loc_ifrs-full_ContractLiabilities_c7a1c8ec-5708-4284-98e6-81ec34dbab9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract_9b545191-4089-4b72-af03-3ac52935a435" xlink:href="oncyf-20221231.xsd#oncyf_ContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1_5a18f770-f168-40df-ad16-88c9d67497a3" xlink:href="oncyf-20221231.xsd#oncyf_PurchaseObligation1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_9b545191-4089-4b72-af03-3ac52935a435" xlink:to="loc_oncyf_PurchaseObligation1_5a18f770-f168-40df-ad16-88c9d67497a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentTerm_b8d0fc20-276a-4502-8763-779a96f25ac7" xlink:href="oncyf-20221231.xsd#oncyf_PurchaseObligationCommitmentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_9b545191-4089-4b72-af03-3ac52935a435" xlink:to="loc_oncyf_PurchaseObligationCommitmentTerm_b8d0fc20-276a-4502-8763-779a96f25ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_600d02ac-42c3-411f-b543-4f0d25061c73" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit_8975f576-c3cb-42e5-8017-cc2247d6208e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccountingProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_600d02ac-42c3-411f-b543-4f0d25061c73" xlink:to="loc_ifrs-full_AccountingProfit_8975f576-c3cb-42e5-8017-cc2247d6208e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_056c3f9c-1371-44d1-afb4-4c6d91f96224" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_600d02ac-42c3-411f-b543-4f0d25061c73" xlink:to="loc_ifrs-full_ApplicableTaxRate_056c3f9c-1371-44d1-afb4-4c6d91f96224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_2cfdd1ab-a444-43c0-9c43-0ac7676373db" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_600d02ac-42c3-411f-b543-4f0d25061c73" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_2cfdd1ab-a444-43c0-9c43-0ac7676373db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_75caf435-bb96-4dbc-b847-9850848adc1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_600d02ac-42c3-411f-b543-4f0d25061c73" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_75caf435-bb96-4dbc-b847-9850848adc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_815a3125-f955-44c2-a44d-60ea1fdcf7b1" xlink:href="oncyf-20221231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_600d02ac-42c3-411f-b543-4f0d25061c73" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_815a3125-f955-44c2-a44d-60ea1fdcf7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools_0077801d-c990-4ab1-805e-60e9d5d66422" xlink:href="oncyf-20221231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_600d02ac-42c3-411f-b543-4f0d25061c73" xlink:to="loc_oncyf_TaxEffectOfTaxPools_0077801d-c990-4ab1-805e-60e9d5d66422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_54c0c46b-f7e4-4f19-a162-3de44571c489" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_600d02ac-42c3-411f-b543-4f0d25061c73" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_54c0c46b-f7e4-4f19-a162-3de44571c489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_d04edb5f-021d-495a-82bf-3af41aeeaffd" xlink:href="oncyf-20221231.xsd#oncyf_TaxEffectOfExpirationOfTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_600d02ac-42c3-411f-b543-4f0d25061c73" xlink:to="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_d04edb5f-021d-495a-82bf-3af41aeeaffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_38f2fa06-0dd5-4988-b797-f62cbad2de23" xlink:href="oncyf-20221231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_600d02ac-42c3-411f-b543-4f0d25061c73" xlink:to="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_38f2fa06-0dd5-4988-b797-f62cbad2de23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_a7a22807-e75e-41a1-8802-3d66a6c6ebac" xlink:href="oncyf-20221231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_600d02ac-42c3-411f-b543-4f0d25061c73" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_a7a22807-e75e-41a1-8802-3d66a6c6ebac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_397e7864-6d3c-4621-8d70-c630d872e280" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_600d02ac-42c3-411f-b543-4f0d25061c73" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_397e7864-6d3c-4621-8d70-c630d872e280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e237dd6d-19ac-4bc2-a1d9-f3e117640897" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_56243936-b63e-4aa9-9f77-73221d128f95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e237dd6d-19ac-4bc2-a1d9-f3e117640897" xlink:to="loc_srt_StatementGeographicalAxis_56243936-b63e-4aa9-9f77-73221d128f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ba60762b-050a-4ebe-af96-ce497569d0c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_56243936-b63e-4aa9-9f77-73221d128f95" xlink:to="loc_srt_SegmentGeographicalDomain_ba60762b-050a-4ebe-af96-ce497569d0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_1d777637-2fc4-4827-8577-356648d9b66e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ba60762b-050a-4ebe-af96-ce497569d0c2" xlink:to="loc_country_CA_1d777637-2fc4-4827-8577-356648d9b66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BB_7422724a-10f7-45bc-9a59-88eaf6993cd6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BB"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ba60762b-050a-4ebe-af96-ce497569d0c2" xlink:to="loc_country_BB_7422724a-10f7-45bc-9a59-88eaf6993cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f8e9a7ae-54b7-4c31-998b-1ad7ff3d24bf" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ba60762b-050a-4ebe-af96-ce497569d0c2" xlink:to="loc_country_US_f8e9a7ae-54b7-4c31-998b-1ad7ff3d24bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0f1d1f77-8312-4b38-b365-646ac7287399" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e237dd6d-19ac-4bc2-a1d9-f3e117640897" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0f1d1f77-8312-4b38-b365-646ac7287399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_724aa575-8cb3-436f-a9fd-00c62c2bca2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_0f1d1f77-8312-4b38-b365-646ac7287399" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_724aa575-8cb3-436f-a9fd-00c62c2bca2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_0ca4df1a-5ac5-4b54-ba74-65c611365057" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_724aa575-8cb3-436f-a9fd-00c62c2bca2d" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_0ca4df1a-5ac5-4b54-ba74-65c611365057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_00dc2ec2-7193-4080-9f99-ae55cbaeb0ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_724aa575-8cb3-436f-a9fd-00c62c2bca2d" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_00dc2ec2-7193-4080-9f99-ae55cbaeb0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_68982a41-d7a3-4804-840e-eb08f94cefc2" xlink:href="oncyf-20221231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_724aa575-8cb3-436f-a9fd-00c62c2bca2d" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_68982a41-d7a3-4804-840e-eb08f94cefc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_3191d0e8-5864-41fa-897c-b65ffeaa3c1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_e237dd6d-19ac-4bc2-a1d9-f3e117640897" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_3191d0e8-5864-41fa-897c-b65ffeaa3c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_70ec24a8-fd31-42d0-9628-de5db86ff1fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_3191d0e8-5864-41fa-897c-b65ffeaa3c1f" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_70ec24a8-fd31-42d0-9628-de5db86ff1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_bd57c7fe-dae5-4aff-adbf-77ef53eb62fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_3191d0e8-5864-41fa-897c-b65ffeaa3c1f" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_bd57c7fe-dae5-4aff-adbf-77ef53eb62fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_8ce1792b-9351-49fc-b8cb-e5949f8eca5e" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eff5ecb8-d1d2-41a9-bc51-101c7b4b80f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_8ce1792b-9351-49fc-b8cb-e5949f8eca5e" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eff5ecb8-d1d2-41a9-bc51-101c7b4b80f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_efc600f2-0889-4283-a0f9-cdc64a4150a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eff5ecb8-d1d2-41a9-bc51-101c7b4b80f2" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_efc600f2-0889-4283-a0f9-cdc64a4150a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_efc600f2-0889-4283-a0f9-cdc64a4150a7" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_4b053aeb-17e3-4c45-9732-5fc51318e411" xlink:href="oncyf-20221231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_4b053aeb-17e3-4c45-9732-5fc51318e411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_cc6be7ec-b0b0-40a6-9ca3-216a5d8936ed" xlink:href="oncyf-20221231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_cc6be7ec-b0b0-40a6-9ca3-216a5d8936ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_b08384a7-f87e-4c41-8e45-a1bca2f1845f" xlink:href="oncyf-20221231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_b08384a7-f87e-4c41-8e45-a1bca2f1845f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_21f0c9e1-c8b7-46ee-a7a9-6a39e6bde72e" xlink:href="oncyf-20221231.xsd#oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:to="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_21f0c9e1-c8b7-46ee-a7a9-6a39e6bde72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember_3f9b9287-3db6-44ee-9dbc-2e194cf95eca" xlink:href="oncyf-20221231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:to="loc_oncyf_ShareIssueCostsMember_3f9b9287-3db6-44ee-9dbc-2e194cf95eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_7a40c24d-c488-4b37-a547-c9201cdfd57b" xlink:href="oncyf-20221231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_211b0a3c-5d00-4eb9-8cd5-d3cc936b6a05" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_7a40c24d-c488-4b37-a547-c9201cdfd57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c4a020ec-89c1-49f9-9216-6d0afd4bd673" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eff5ecb8-d1d2-41a9-bc51-101c7b4b80f2" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c4a020ec-89c1-49f9-9216-6d0afd4bd673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_1a318b28-6014-4028-91a7-d84f14c69944" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c4a020ec-89c1-49f9-9216-6d0afd4bd673" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_1a318b28-6014-4028-91a7-d84f14c69944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#CapitalDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_d99a30e4-ff60-4d88-a47f-797a96c0eb5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_fa15f3ea-f14e-4f9f-9a8e-04d94a72d9ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_d99a30e4-ff60-4d88-a47f-797a96c0eb5b" xlink:to="loc_ifrs-full_CashAndCashEquivalents_fa15f3ea-f14e-4f9f-9a8e-04d94a72d9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentInvestments_6d75336b-d07d-4850-8517-b5ab4190a8d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_d99a30e4-ff60-4d88-a47f-797a96c0eb5b" xlink:to="loc_ifrs-full_CurrentInvestments_6d75336b-d07d-4850-8517-b5ab4190a8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_55314c0c-0330-4f2a-9720-283755eea040" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_d99a30e4-ff60-4d88-a47f-797a96c0eb5b" xlink:to="loc_ifrs-full_Equity_55314c0c-0330-4f2a-9720-283755eea040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EquityAuthorized_3d3edb96-3e00-4dd7-8077-c6e57813f34c" xlink:href="oncyf-20221231.xsd#oncyf_EquityAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_d99a30e4-ff60-4d88-a47f-797a96c0eb5b" xlink:to="loc_oncyf_EquityAuthorized_3d3edb96-3e00-4dd7-8077-c6e57813f34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_a9550362-4ccf-4658-ab6e-9706dfb656d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_a9550362-4ccf-4658-ab6e-9706dfb656d0" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c3aa41c6-b212-4b32-896d-7ff3e1091087" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c3aa41c6-b212-4b32-896d-7ff3e1091087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9abc5be9-2354-4bdd-bb32-5e2157c3990e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c3aa41c6-b212-4b32-896d-7ff3e1091087" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9abc5be9-2354-4bdd-bb32-5e2157c3990e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_12a12684-85c6-4ec1-b9ea-b3f2c54822a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9abc5be9-2354-4bdd-bb32-5e2157c3990e" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_12a12684-85c6-4ec1-b9ea-b3f2c54822a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_2441e717-999f-447e-8dcf-edb76d0cc1df" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:to="loc_ifrs-full_TypesOfRisksAxis_2441e717-999f-447e-8dcf-edb76d0cc1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_60b0838a-96f3-4afd-a4d0-5ecfb0c1e15a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_2441e717-999f-447e-8dcf-edb76d0cc1df" xlink:to="loc_ifrs-full_TypesOfRisksMember_60b0838a-96f3-4afd-a4d0-5ecfb0c1e15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_4c7b4d4f-ebc5-417d-a64b-340334ae65e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_60b0838a-96f3-4afd-a4d0-5ecfb0c1e15a" xlink:to="loc_ifrs-full_CurrencyRiskMember_4c7b4d4f-ebc5-417d-a64b-340334ae65e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_a44bd3f9-48de-4be0-976a-8c67ff552014" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:to="loc_srt_CurrencyAxis_a44bd3f9-48de-4be0-976a-8c67ff552014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_41cc7e14-4293-40a6-904f-3e2731fd079b" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_a44bd3f9-48de-4be0-976a-8c67ff552014" xlink:to="loc_currency_AllCurrenciesDomain_41cc7e14-4293-40a6-904f-3e2731fd079b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_407e3108-f379-4ad8-a80c-8d88e073cb3d" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_41cc7e14-4293-40a6-904f-3e2731fd079b" xlink:to="loc_currency_USD_407e3108-f379-4ad8-a80c-8d88e073cb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_87698739-a347-4047-ad06-f4fc004e5507" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_41cc7e14-4293-40a6-904f-3e2731fd079b" xlink:to="loc_currency_EUR_87698739-a347-4047-ad06-f4fc004e5507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_76349e35-6bd5-4dfc-ba72-969ad333db95" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:to="loc_oncyf_SaleOfStockAxis_76349e35-6bd5-4dfc-ba72-969ad333db95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_d0855494-bcde-4496-9b0f-5c4cd23926d6" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_76349e35-6bd5-4dfc-ba72-969ad333db95" xlink:to="loc_oncyf_SaleOfStockDomain_d0855494-bcde-4496-9b0f-5c4cd23926d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_995c4c29-73df-41e0-bfda-94c4c2126411" xlink:href="oncyf-20221231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_d0855494-bcde-4496-9b0f-5c4cd23926d6" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_995c4c29-73df-41e0-bfda-94c4c2126411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_3444fbdd-8c83-4a87-b6af-01bbf85fca12" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_3444fbdd-8c83-4a87-b6af-01bbf85fca12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_95fa7940-bc62-4c9e-a5a3-777a99eff867" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_3444fbdd-8c83-4a87-b6af-01bbf85fca12" xlink:to="loc_ifrs-full_LiabilitiesMember_95fa7940-bc62-4c9e-a5a3-777a99eff867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsMember_949ad059-de73-4f17-b38f-2050e3528755" xlink:href="oncyf-20221231.xsd#oncyf_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_95fa7940-bc62-4c9e-a5a3-777a99eff867" xlink:to="loc_oncyf_WarrantsMember_949ad059-de73-4f17-b38f-2050e3528755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_dad902a6-4ead-4298-a5f8-d35cc48475b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c8a8a92d-69a7-42a2-8048-085cff2f91ba" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_dad902a6-4ead-4298-a5f8-d35cc48475b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_221e07ff-d260-4ae8-aaff-4b493f2d5a2d" xlink:href="oncyf-20221231.xsd#oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_dad902a6-4ead-4298-a5f8-d35cc48475b1" xlink:to="loc_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2_221e07ff-d260-4ae8-aaff-4b493f2d5a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_e26f4e62-8e21-4a94-a619-f74dce3a0788" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_dad902a6-4ead-4298-a5f8-d35cc48475b1" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_e26f4e62-8e21-4a94-a619-f74dce3a0788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_e6633809-4010-44f5-bd3f-818f6d0e3902" xlink:href="oncyf-20221231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_dad902a6-4ead-4298-a5f8-d35cc48475b1" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_e6633809-4010-44f5-bd3f-818f6d0e3902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_e1b6f019-2259-4218-9fec-10c068085eb5" xlink:href="oncyf-20221231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_dad902a6-4ead-4298-a5f8-d35cc48475b1" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_e1b6f019-2259-4218-9fec-10c068085eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_f898d16e-aa8f-4f0b-b487-cebf36d6ae49" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_2dccf764-486d-4826-97f2-7e66f197324b" xlink:href="oncyf-20221231.xsd#oncyf_Currency1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_f898d16e-aa8f-4f0b-b487-cebf36d6ae49" xlink:to="loc_oncyf_Currency1Table_2dccf764-486d-4826-97f2-7e66f197324b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_a0368f91-7e31-44e1-80a9-313363f8facd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_2dccf764-486d-4826-97f2-7e66f197324b" xlink:to="loc_srt_CurrencyAxis_a0368f91-7e31-44e1-80a9-313363f8facd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_725ce18d-609b-437e-85e4-282747164e1b" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_a0368f91-7e31-44e1-80a9-313363f8facd" xlink:to="loc_currency_AllCurrenciesDomain_725ce18d-609b-437e-85e4-282747164e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_bd92e5c7-fc25-40a0-bad8-a18d2668a8aa" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_725ce18d-609b-437e-85e4-282747164e1b" xlink:to="loc_currency_USD_bd92e5c7-fc25-40a0-bad8-a18d2668a8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_89133528-63c3-4b6e-a09a-3d53a502ec0e" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_725ce18d-609b-437e-85e4-282747164e1b" xlink:to="loc_currency_EUR_89133528-63c3-4b6e-a09a-3d53a502ec0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_07f352dc-a842-47dd-aa45-dcf4fcf0c8f7" xlink:href="oncyf-20221231.xsd#oncyf_Currency1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_2dccf764-486d-4826-97f2-7e66f197324b" xlink:to="loc_oncyf_Currency1LineItems_07f352dc-a842-47dd-aa45-dcf4fcf0c8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_83a59b89-fddd-48b1-9062-3cee562c84bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_07f352dc-a842-47dd-aa45-dcf4fcf0c8f7" xlink:to="loc_ifrs-full_CashAndCashEquivalents_83a59b89-fddd-48b1-9062-3cee562c84bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAvailableforsale_c4f08b7d-95e8-432d-95aa-7c6d0453b58d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAvailableforsale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_07f352dc-a842-47dd-aa45-dcf4fcf0c8f7" xlink:to="loc_ifrs-full_FinancialAssetsAvailableforsale_c4f08b7d-95e8-432d-95aa-7c6d0453b58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_1654decd-40e8-44e9-acad-11937e8923f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_07f352dc-a842-47dd-aa45-dcf4fcf0c8f7" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_1654decd-40e8-44e9-acad-11937e8923f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_26946b59-e3e1-4272-bb38-a00beaa29ddd" xlink:href="oncyf-20221231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_07f352dc-a842-47dd-aa45-dcf4fcf0c8f7" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_26946b59-e3e1-4272-bb38-a00beaa29ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_d6161804-6989-4edc-ba12-83f5ad94e923" xlink:href="oncyf-20221231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_5e439e27-0901-4b71-bdb7-343674364cc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_d6161804-6989-4edc-ba12-83f5ad94e923" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_5e439e27-0901-4b71-bdb7-343674364cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_ace3e7ca-3de8-4351-8535-0ca7e8e41886" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_d6161804-6989-4edc-ba12-83f5ad94e923" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_ace3e7ca-3de8-4351-8535-0ca7e8e41886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_1d823b65-7854-4d80-ba79-3c77e71bd866" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_d6161804-6989-4edc-ba12-83f5ad94e923" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_1d823b65-7854-4d80-ba79-3c77e71bd866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_2d3ce568-6037-4ac7-8dea-cb6cb8762d0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_d6161804-6989-4edc-ba12-83f5ad94e923" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_2d3ce568-6037-4ac7-8dea-cb6cb8762d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_04b08da3-1443-46bd-a9b3-d3fa8d633528" xlink:href="oncyf-20221231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_d6161804-6989-4edc-ba12-83f5ad94e923" xlink:to="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_04b08da3-1443-46bd-a9b3-d3fa8d633528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_98b86682-56c1-416a-9b80-2ac8fd5afdcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_d6161804-6989-4edc-ba12-83f5ad94e923" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_98b86682-56c1-416a-9b80-2ac8fd5afdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_7e2d76c7-03ca-4137-b7ea-b56361fb16df" xlink:href="oncyf-20221231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromInterestReceived_da1521a8-1a1f-47af-868a-1a3826ac4f04" xlink:href="oncyf-20221231.xsd#oncyf_ProceedsfromInterestReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_7e2d76c7-03ca-4137-b7ea-b56361fb16df" xlink:to="loc_oncyf_ProceedsfromInterestReceived_da1521a8-1a1f-47af-868a-1a3826ac4f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund_27f7cfbf-16d1-461c-b3d9-46d9b50c6edf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_7e2d76c7-03ca-4137-b7ea-b56361fb16df" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefund_27f7cfbf-16d1-461c-b3d9-46d9b50c6edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#EconomicDependenceDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_cc3c6290-3b08-47af-9448-02959e702abd" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table_2599eeda-de2c-4f3f-9200-dd759c5d5a3f" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_cc3c6290-3b08-47af-9448-02959e702abd" xlink:to="loc_oncyf_ConcentrationRisk1Table_2599eeda-de2c-4f3f-9200-dd759c5d5a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_951d55ad-b108-408a-926b-9b595126d312" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_2599eeda-de2c-4f3f-9200-dd759c5d5a3f" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_951d55ad-b108-408a-926b-9b595126d312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_eff5c2fc-7848-4f39-bebb-12f7263b8e5d" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_951d55ad-b108-408a-926b-9b595126d312" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_eff5c2fc-7848-4f39-bebb-12f7263b8e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_8595fe59-36db-4c87-ba85-81503c3a5bfd" xlink:href="oncyf-20221231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_eff5c2fc-7848-4f39-bebb-12f7263b8e5d" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_8595fe59-36db-4c87-ba85-81503c3a5bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_99607810-ca05-4e69-a86e-f94603073956" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_2599eeda-de2c-4f3f-9200-dd759c5d5a3f" xlink:to="loc_oncyf_ConcentrationRiskType1LineItems_99607810-ca05-4e69-a86e-f94603073956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber_a9e96681-0274-41bf-aa96-3881e147225c" xlink:href="oncyf-20221231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_99607810-ca05-4e69-a86e-f94603073956" xlink:to="loc_oncyf_ConcentrationRiskNumber_a9e96681-0274-41bf-aa96-3881e147225c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#ComponentsofExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e188247b-8226-4fe2-a2e8-e33338bf6605" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_6fd8b88c-4a6a-489d-90e4-724a54401b1d" xlink:href="oncyf-20221231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e188247b-8226-4fe2-a2e8-e33338bf6605" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_6fd8b88c-4a6a-489d-90e4-724a54401b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_c7df7e78-45c0-4cfb-952a-44899aa72ad2" xlink:href="oncyf-20221231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_6fd8b88c-4a6a-489d-90e4-724a54401b1d" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_c7df7e78-45c0-4cfb-952a-44899aa72ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_b6998ef6-5eb5-461a-b39f-db01ec5008de" xlink:href="oncyf-20221231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_c7df7e78-45c0-4cfb-952a-44899aa72ad2" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_b6998ef6-5eb5-461a-b39f-db01ec5008de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpenseMember_d57af6d0-9f0d-4a44-bc5b-af4b0d2de041" xlink:href="oncyf-20221231.xsd#oncyf_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_b6998ef6-5eb5-461a-b39f-db01ec5008de" xlink:to="loc_oncyf_ResearchAndDevelopmentExpenseMember_d57af6d0-9f0d-4a44-bc5b-af4b0d2de041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpenseMember_21d34fe5-67dc-4b2d-a677-3226f3f6c5b1" xlink:href="oncyf-20221231.xsd#oncyf_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_b6998ef6-5eb5-461a-b39f-db01ec5008de" xlink:to="loc_oncyf_GeneralAndAdministrativeExpenseMember_21d34fe5-67dc-4b2d-a677-3226f3f6c5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_55325471-a36e-46b7-b927-8333441c529c" xlink:href="oncyf-20221231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_6fd8b88c-4a6a-489d-90e4-724a54401b1d" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_55325471-a36e-46b7-b927-8333441c529c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:href="oncyf-20221231.xsd#oncyf_ResearchAndDevelopmentExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_55325471-a36e-46b7-b927-8333441c529c" xlink:to="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrailExpense_9e63db83-9e38-4a99-a4a7-606c9b940b0c" xlink:href="oncyf-20221231.xsd#oncyf_ClinicalTrailExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_oncyf_ClinicalTrailExpense_9e63db83-9e38-4a99-a4a7-606c9b940b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ManufacturingExpense_7820dd9b-4758-411e-aed6-1ed77a9a6ea4" xlink:href="oncyf-20221231.xsd#oncyf_ManufacturingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_oncyf_ManufacturingExpense_7820dd9b-4758-411e-aed6-1ed77a9a6ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IntellectualPropertyExpense_5af5bdd6-b781-4428-b5a4-55733b7d1340" xlink:href="oncyf-20221231.xsd#oncyf_IntellectualPropertyExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_oncyf_IntellectualPropertyExpense_5af5bdd6-b781-4428-b5a4-55733b7d1340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TranslationalScienceExpense_97eee56d-9646-4221-82d2-865aa26ec6cc" xlink:href="oncyf-20221231.xsd#oncyf_TranslationalScienceExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_oncyf_TranslationalScienceExpense_97eee56d-9646-4221-82d2-865aa26ec6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense_f7ac6fcf-e01f-4b70-bde7-8c4563974a94" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_ifrs-full_OtherEmployeeExpense_f7ac6fcf-e01f-4b70-bde7-8c4563974a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_86c14305-30c2-479d-8b56-9279cb24a07c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_86c14305-30c2-479d-8b56-9279cb24a07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_55ce90e4-03eb-4497-9539-cdd5d6eb1cf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_55ce90e4-03eb-4497-9539-cdd5d6eb1cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_cc922912-f832-4da6-85d3-96406f371d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_91b31a7a-eec0-4749-b710-2ddc326ec2d9" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_cc922912-f832-4da6-85d3-96406f371d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:href="oncyf-20221231.xsd#oncyf_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_55325471-a36e-46b7-b927-8333441c529c" xlink:to="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PublicCompanyExpense_9431e904-15f4-4cb7-8859-9655ca73e121" xlink:href="oncyf-20221231.xsd#oncyf_PublicCompanyExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:to="loc_oncyf_PublicCompanyExpense_9431e904-15f4-4cb7-8859-9655ca73e121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeExpenses_80c4c93d-4ef4-4828-936e-f2fd52905911" xlink:href="oncyf-20221231.xsd#oncyf_OfficeExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:to="loc_oncyf_OfficeExpenses_80c4c93d-4ef4-4828-936e-f2fd52905911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_cc0dd047-c738-4dc7-8bb9-ceec9164995a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:to="loc_ifrs-full_AmortisationExpense_cc0dd047-c738-4dc7-8bb9-ceec9164995a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_7a56e628-ec03-42de-8284-f892899e6356" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_7a56e628-ec03-42de-8284-f892899e6356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_f9e34078-f968-4f99-a9e6-55fa74474597" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_ba2f09fc-bfed-4d20-a644-426e48fc178d" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_f9e34078-f968-4f99-a9e6-55fa74474597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_ba567067-caf4-4e07-851a-2bc56e42a867" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_55325471-a36e-46b7-b927-8333441c529c" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_ba567067-caf4-4e07-851a-2bc56e42a867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_3cd14c22-18f8-40ff-8a9d-f69cb6a59899" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_bab486b3-2e78-4049-9e55-91c0a4b887ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_3cd14c22-18f8-40ff-8a9d-f69cb6a59899" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_bab486b3-2e78-4049-9e55-91c0a4b887ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_df922b28-1d74-450d-b132-7343bf9d151c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_3cd14c22-18f8-40ff-8a9d-f69cb6a59899" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_df922b28-1d74-450d-b132-7343bf9d151c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_9b206a7d-3484-4cfe-9787-7ff6e9a7a24b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_3cd14c22-18f8-40ff-8a9d-f69cb6a59899" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_9b206a7d-3484-4cfe-9787-7ff6e9a7a24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_b85328fd-6939-4cd2-8277-b711505fbdd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_3cd14c22-18f8-40ff-8a9d-f69cb6a59899" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_b85328fd-6939-4cd2-8277-b711505fbdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="oncyf-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_18bf7ff5-47b3-494c-a621-a17efedeb5f1" xlink:href="oncyf-20221231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_7ebfac7b-2f54-44c3-89c2-77eb7cf54187" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_18bf7ff5-47b3-494c-a621-a17efedeb5f1" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_7ebfac7b-2f54-44c3-89c2-77eb7cf54187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a2e2918e-8b25-43e5-882f-174089b9c29d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_7ebfac7b-2f54-44c3-89c2-77eb7cf54187" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a2e2918e-8b25-43e5-882f-174089b9c29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_9252bf9b-70a3-4b18-ae65-066aa6d123cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_a2e2918e-8b25-43e5-882f-174089b9c29d" xlink:to="loc_ifrs-full_NonadjustingEventsMember_9252bf9b-70a3-4b18-ae65-066aa6d123cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_8d5348c4-c564-43e3-9840-8435e7404bf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_9252bf9b-70a3-4b18-ae65-066aa6d123cd" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_8d5348c4-c564-43e3-9840-8435e7404bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_24abcf8d-5f0b-4510-8ccc-41d4d50fb8c1" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_7ebfac7b-2f54-44c3-89c2-77eb7cf54187" xlink:to="loc_oncyf_SaleOfStockAxis_24abcf8d-5f0b-4510-8ccc-41d4d50fb8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_1677f002-4bfb-452b-bc02-1777e1040d39" xlink:href="oncyf-20221231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_24abcf8d-5f0b-4510-8ccc-41d4d50fb8c1" xlink:to="loc_oncyf_SaleOfStockDomain_1677f002-4bfb-452b-bc02-1777e1040d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_666381e4-9b59-49a4-a7d2-93f9bc9d56f5" xlink:href="oncyf-20221231.xsd#oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_1677f002-4bfb-452b-bc02-1777e1040d39" xlink:to="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_666381e4-9b59-49a4-a7d2-93f9bc9d56f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_8307bbe2-4f00-4ac8-a250-090ad2488db4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_7ebfac7b-2f54-44c3-89c2-77eb7cf54187" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_8307bbe2-4f00-4ac8-a250-090ad2488db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_bdc6bd2b-0222-433b-b0ad-beba95506912" xlink:href="oncyf-20221231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_8307bbe2-4f00-4ac8-a250-090ad2488db4" xlink:to="loc_oncyf_IssueOfEquityShares_bdc6bd2b-0222-433b-b0ad-beba95506912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_988897f2-01f9-412d-bbf4-802610061d97" xlink:href="oncyf-20221231.xsd#oncyf_GrossProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_8307bbe2-4f00-4ac8-a250-090ad2488db4" xlink:to="loc_oncyf_GrossProceedsFromIssueOfOrdinaryShares_988897f2-01f9-412d-bbf4-802610061d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>oncolyticslogotaglineblueaa.jpg
<TEXT>
begin 644 oncolyticslogotaglineblueaa.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
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M9(2CU'7BI/_:  P# 0 "$0,1 #\ W^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                       "&H!$
M$JN0EVP"H"GTGF*:J 7!*KD*( *NV@VT*.HU0 J;9#:4I[:$-M +%7:4;2E+
M;\RD-I>SX 9M^+HJ[2D"GM+V? -I>SX +?BZ*@)-5[$([_,!;\71,"7?YB&_
MS 6_%T3D=5*6TO8-I>SX +?BZ*VTHVE*.TO9\!';[4 M^+HJ[2D=M2CMH-M
M+?BZ+C;&VA1VD&H,%='H3:EN "X!;DZ/\P!5!3Z3S$R/0 F!#4B
M
M
M
M
M
M
M
M
M
M
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MXR*A%'*4MI4XH11X%BNCR9'(40#!< H:J3(\ J@E1R*3
M
M
M
M
M
M
M
M
M
M
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M@JC4IZ*GG(H_M L5D>5$<A0U !< I(]2='H 3
M
M
M
M
M
M
M
M
M
M
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M)HOF([T\Z ^D8JW J(I51Y;H]"<'R+C4%!%)VO[0"H""*1
M
M
M
M
M
M
M
M
M
M
M   &I35_8 3JNA2<[4EU(*N@!$E5VA)M*-W7O!FW7\Z(ZJO +HGG4D5RJ2Z@
MP3:DBNT)=5Z]R=A!7(G#V@$V_KW)W[_,2ZIV>THJ\IJ[4 JND]?Q$BO]135V
MA263U %95[2GTGF*+I/64ED\X!<.D[H4^D+97]A363S@%RKBDLI;*_L*?2[^
M_P 0!<])KUDJR>DMG2)Q*2R^< NEE)'2*6BR*2=)Y_B +Q9//N]92Z3SEJZ3
MUE)9>Z %\LNO42]+Z2PZ9>^A(LWH +[I/.0=(8]9>Z$.E](!?=)Z1MF.67OJ
M2]+Z #)++WU(=*G=3'=+Z""R^?V &0Z=.P=-WWF-Z;ON'3=]P!DNF[[R/3(8
MSIN^X=-WW &4Z5.ZCI4[J8SI?/\  3=+Z #)[8Z3TF,Z7T$4E]'M ,HDGG)U
MD\^ABTF[\29)0#*I+N[Z$4D0Q:2^@J=-WW &365/03-?V+[=?F,8DI4;( 9/
MI.^[YR9)3'])Y_B)DD4 R22%3:\YC>E[[BHD@!D&RE5':]:F,20J)+Y_F ,F
MCR=LGZC'I)YRHD@!D>D\Q.UW86"/TZRHCP"^1ZDZ2>KT%HDGG0J(Y "\1R+Q
MWDWH7U+W[]I:(I.C^T ND=U+N)]2W:Y/3\Q/Z%]7ZP"NBHO'VD=Z>="DB^HB
MB]@,W_%BJC]2<I:HO'B-I?2@/I*ULK%9':%5':ENCM28'R+@%)'E1% (@
M
M
M
M
M
M
M
M
M
M
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M"HCNW>#-RMJ"DB=B^HF1W;N L5T?VE0MR9KM 8*P)4=J3
M
M
M
M
M
M
M
M
M
M                                             IN?U $SG:>DI*I
M@JZ $2FKM=R#37CU$JJG4#EDN_LX$>'G)5<2JY$)->M?8##9-M;]$)51$\ZD
MBN]2%!SM08*KI>_44574E5="@YX!55_847/*3G:E%S^P JN>45D*+I"B]_6
M5E>A1>\H+)QWE)7^H JND_44ED+=\GZRW=* 7;Y._46[YBV=(6ZR>L NG2E%
M9>Z%NY_:472H 72R%%7^LMG3%LZ8 OEE0D68QZRE-TO=0"^6;OQ*3I2Q67TE
M)9/. 7RR]T*2R%BLJ=OPE/IN^\ O^E)%D,>Z=.WV$G3^E0"_64=+WWF.61W9
M\1)TBKUIZC*0,CTOI)>E[ZF/V^U?B)=M.U?@%N_T.WIX R"R+V?"0Z7S?"GT
MF.Z1.M=299/9ZS%_Q8?C-V7IX%^LOH(=/YN_M,;MH3=*G8'ES]&8L9#I_-W]
MI'IC']*WL[^PE5Z!-/A?SJWSCT>DR72^CX/I(](O9\)C.E[ZJ1Z1.TRU8&3Z
M3OP)^F])BTD3M^!"*/UZ_B7XC'X_#,I&527SDW2^@Q72+V^TF1ZKOW+Y]P_'
M68,JDG="=)?.8I)53J4BD_G ,NDI5;*8=L_H[^@JME](!F&R]T*J3&&23S^T
MK-E ,PDV[NI424P[9>_ K)+W4 RR2%7I/08=LR%RR;O^@ R;9>ZE9LIBTE0K
M,D ,JV4KME[H8E)"JV3U@&8;)ZRLDOJ,0V4N&S &5:_VE='F)1_G*Z2)Z #*
M-D*S9#&,?W[2NV0 R2/*R2&.:XJM=V &012HC^TLFO*[7:@%ZBHOTH3*NA9H
M[0KM?^H N$=V$^NO$H<>!,CNKK *J:IZ"HBE%%)_.G !LJ%1KNTHHY%)@"X!
M1:XK(H
M
M
M
M
M
M
M
M
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MBZ%+AZ"=% :\Y<([4B4$70JM=J#!,
M
M
M
M
M
M
M
M
M
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M$UZW5TE1M*_5&^ZO,D01$ZD3NNOQD0#TSR0 !Z?2/,O1\P  ]'H08
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MJM<BDQ23?O3BA.UVH,M?[%9KRH6Y4:_J!Q*@
M
M
M
M
M
M
M
M
M
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M[S;\[\Q#>E-.8S&U.DQ6(K5IO-=)*Z7<E:*[-V*RXL=_1NTW=F[< #T;GDV
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MW4 5
M
M
M
M
M
M
M
M
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M7:[4 N44J<?26R=O=2HUVH!7:[J4G*6NOI[29KNI0+%=KNTJ%N5&OZ@"H
M
M
M
M
M
M
M
M
M
M                        2N71"*KH454 @JDKG:$570I^=?4G &4/.O'J
M0D<[K"KVE)5]@,,CKUKPZOTE-[_T(0<[0H:@!5[2@Y^X.=["V<X BYY;/?\
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MT7=Y_F*B* 5FN)REQ37K0G:[4&;<RNUQ.6Z*5FNU!@F
M
M
M
M
M
M
M
M
M
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M% :\Y<(NI$HM70K P
M
M
M
M
M
M
M
M
M                                 "#ET )7.ZBD%4D<[V@RB"NZD(.7
MJ'#TJ4G.T 8<OPE-5ZO:15=/2O$H.=V P2N74HO=U$7KU%H]WL (/>6SWD7O
M+1[P!(XM'N#W>PLY9 "$C^_F+&20C)(6CWZ;P"+GZ<2QED$LOG,=)( 322%H
MY_:0<\L9)=>'ZP":23L[^@LW/[^?]/8FJ^;>FL'2:\-.SKX_#NTU5>OL136[
MYV;GLZ/+U;GEOE/54]SQVC):.^XHB5E1:\'.DC1'4]%JV2&Z8A1KUT1BOH[4
M[?5+-5-2C/7T)H3$8^O&AAZ;DWG*2\6G&]M^;>2BO2WDDSQ-/ZPX;1N'E7Q-
M112RA'C.I/E3IQ6;E+MR6=VD?6'.>\[OA;(FBDP]9$I,3YG5D".I+$R9LE#8
M(YFNZ*Z8GDA<KX(TT1U+:XG,K:_5'N6"CVZA-$_._//%N9&)+AB[&U[J[_?[
MD_6>LJG:,AB:J=#1T%,Q4IJ"@IV-;'3T=+%'#%&W1-J1TDLGYQ>+S67*LJ[C
M<:JIK[A7U,M;75U;/)55E;63N>^>JJZF972U%1,^1[I)9'*YRN=JNRNAC2S>
MJNJ&'T92\%1J5VDJU>WA3_1@GXL4^JU^94?6_7?$Z8J^'O4\-!MTL)!^!!\.
MDF\MZ;6;;YO*P !MQI3_  EP       ^E$]:HNGQ:>M""N1$55T1$3555=-$
M3BOH1./8F\]<^0-S.69F=KZ.]54;L#8 E5DLF*+S2R+5W2F5Z:LPU:%6.2XR
M2LU5M;5R4EJB8K9NGK-8Z:;H:2TIA\)2E6Q%6-*$><GQ?*,8^--OJBKKJL>E
MHK0^)QU54,+1G6J-KP8Q=E&^<I3\6"77)V\YY6X4PG=;]<J.S6.UW&]7BXS-
M@M]IM-#57&Y5LSUT9%2T-)%+4S/=OT:R-=-%VM-EVFS3R'O!U;G=&TM_SSN$
M]DHG)%,S UAK(UO$K7:N6&]WR!\U-;T<FRV2&U=/4HNW%%70O5)6;%O(XY .
M6F1UI908(L;&7.6%L=SQ1<4CJ\1W9RZ.D6JN"L3H8'R)MMHJ-M/1Q^2V.%K6
M1M9]LL9IIHG#5$TW(FNG#33]6[AN(*UGVHUJV_1P$>@INZZ>3M4JVY1?"FNK
MB^MK@6*U3V.X>ANU=)..(JKPEAHJ]&DWG>:R=67)MV@O<OB?D.2N0F#LNK'3
M8<P/ANUX8LU*S9CHK93]$LBJNKYJJI<YU775,KM7S55;-/53RJZ:>:29[Y'?
MKZ-[$^C]'JTUWJJ*N]*K6%PD>[4B>K6G4DYSE*<I<92;;???CYR9Z-"%.$84
MX1A"*W8QC%12CU)+)+L*#8RLD?:5V1^8N&0>;O\ $?/+DDNX^O9R^;N+=C.Q
M"NV%>*ZEXV+S%9L?F]@!:LB*Z1^;VETR'O\ I*[(?, 6:1>DKMB4O6P^;YRN
MV+NH!8MB[H54B\WM+Y(T["=(_, 6;82JD7H+ML?K)TA\P!:(Q"9&>8O4B4G2
M+S* 621D=@OT@\WSDZ1>GV &.Z/SD_1^92_Z+T]_41Z/S* 8[HO23=%YC)]$
MG="7H>^\ QRQ>;XB7HO29/HO03=%Z/8 8OHO,O?T$G1F46+S?&2]%YE ,:L9
M+T?H,IT7I)%@\WP: &,Z/S$JL0R*Q>8E6)>H QBQ>@D=#WXF26'S=_@)%B]0
M!BEB\R%)T/F]IEEC]936/S &&=$45B\WL,TZ(H.B\P!AUC4HNC0S#X2V=#Y@
M##NA[]I;K'VF;6/OU%NZ+M0 PSH^PHOC,L^'OW0MWL7L[_$ 8M6=OM3O\>J>
M8_E\6X/M5]M]5:;Y;*"\VJNBD@K;;=*2"NH:N&5BLDBJ*6ICEAECD8YS'M>U
M45KE3=JJ+_:+&4',]1F$G%IIM-.Z<6TT^M6L<9Q36ZTI1X;K2:=^M<#6#Y;?
M@Z^&KRRJON2=>F%;J]TM1)@Z\5-358:JU=M/?%:;@]9KA95Z1R)'2S.KZ")C
MG-ACI(8X8V:H.=^0N,LMK_4X8QUARZ8:O=,NOBMRIW1QUD"ZHRMM=8W:I+K0
M2*CFLK;?-44W2,DA=(V:*6-G4S='ZO1N^+CZS\,S_P"3=@G-&PSX:QWARWXA
MM4J/Z)E7%_?5#*]NRE5;:V/9JK?5,W/9/2R1N1[6J[:1$0E'5K:9BL+N4L8I
MXF@LG-2BZL%UIOQK+BGYFF1#K9LDP6+4JV!E#!XCW"B^AJ2ZG%>)O/G&UGG:
M2R.7']"+Y]^_AQTTXNT1O5JJ[@;"_+[Y@K&> O',2Y4RU..\(,Z6HFL3FM_9
M?8H47;<C86(V#$-$Q%39J*3HKE&UC4J*.H<BU<FO;/"^)\D4L;XI89'PS12M
M='+#-$]8Y89(WM:]DD4C'LD8]&O8]JL<Q%;JL\:)TYA<;257#UHS5KM)^'']
M&<'X2?<K=3L5PTYJ_B]'5G0Q=)TIWM%M-TY_I0J+P6NQNZX-(I  ]5/N\W#Y
M3Q@ #(   ,I8[W6VRMI+E;:RIM]PH*B*KH:ZCFDIZNCJH'H^&HIJB)S)89HW
M)JR1CT5-Z;T547<8YJ;GS*;%KK=EWG3<*6W8H<D=%8L<3]!1V[$LRN;#34E^
MT1M/;K[,BMA;6(V*@N<J[2^+54BL=IIDLC$<U6N1'-=]DU4U1=VFBHNY=VOM
M\R&O:P:LX;25%TJT5&5K4ZRBG.F^5NM/G%Y/OL;1JQK9B]%5U6H2;C==)1DW
MN5%U6Y/DI>U7'*Z?6=CD1=%XHNFBHJ</4O#SZ:::+KHK=;N-_L[/-YE-+GFF
MN>\JL'K:,M,XJ^IN&%'/@M^'L;U,CJFNPRLLC8J6BQ%)*_I:RP-VD:EUVIZJ
MUL2)U2V6A;-4T>Y9:KM3UE-!5T<\-52U,4=13U-/(V:">"9J/BF@FC5S)(Y&
M*CF/:NRYJZ[2*K4?6'6'5O$Z-K=%6AO0;?158WZ.<;\6_:R7.);C5?6S":4H
M*K0G::LJM"7Y6E-J[RX2AU2637 _J&/U+N-YA8Y/9UH7T<FOS&O77+N-H,S'
M)W^8R#)-3 QO+Z*3S@&:C>7T<AAV/U+IC_;\8!FV.]A=1O[^@Q$<I>L> 95C
MRZ8Y#%1O+QCP#),=UEPBF/8XNF+\/= "^:[V*3M73=ZT+5KM"NCMVG4 7+7$
M=="DU>KK0JHNNY?4#*?H*I.UW446KU$X#5BX!(QVI.#
M
M
M
M
M
M
M
M
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MFE!SD_,F8LR@2Y8PP/)6XSRWB<^IE1(>DQ-A6E<[>R[PP)I=;?3JYJ>[5)'
MZ.!46X4,2Q2U,U@M4MH]#&[M#%)8?$^*I7?1U9=E\HR?N>%^#M8K-KKLKQ&
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M9%+=%U)VJ 5@
M
M
M
M
M
M
M
M
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MW %9NY="H4DW[NOJ)VNU!GM*[%)R@BZ%9%!@B
M
M
M
M
M
M
M
M
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M6KV>;U&<?%UH63X@#"/B3J+&1O:9Q\99R1:]0!A7L+9[._?>99T:IWX%H^,
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MTLT4N&._2 7"*5.&_M*#=V[V%5%Z@$5B=CNHHM7J)P&7 )6KJA,
M
M
M
M
M
M
M
M
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M9?A?ZD-$[2&J)Y^_H)T:A,#-UU7^0I:^;X"._L0J "ZZOE*>B]B#1>Q/@*@
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MT(U*34J4XJ4))W3B^:*D8O#5*-6=*K%PJ4Y.$X25I1E')J2^;K68 !]CK@
M']+@[&-UP]=[9?[)73VR]6>NIKE:[C32.CJ*.NI9&RT\\;V^4BM>U-I/L7L5
MS'HK'.1>AOS6G.)VO/\ P&RMJ%AH<=8<Z&W8RLS5:W2H5G][7RW,1=9+3=HV
M](Q=&NHZUM502-V8(9ZGG1GT]R/>5GBG)7'=HQWA63;J*)Z076TR2/918ALL
MSV>/V>M1J.V4J(V[5+4I'(ZBK&0521RMCDIYM+UTU4AI+#6BDL32O*A/FV_&
MA)Y>#+CGDI9Y9F^Z@ZYST1BO";>$K6CB*>;2:RC5BL\X<TLW&Z=[1MU F/\
M;U&1ADU/G[D\9^X;S.P=8L<82K$K+)?J1M33;6RE333-\BKMU;&U7+%<*"='
MTU7#KJR5FJ)LN:J_ND3NOON*L5Z,J<Y0FG&492C*+R:E%V::>:S+C8>O"K3A
M5IR4H3C&49+-.,E=-/FFN#,W$XR$4AA(WZH7T4A\CZF=8[<BEY&\Q$3^'?U%
M\QWL ,Q&\OHWF'B=O+Z-WP &6C?J7;'&,C=V%ZQW6 9)CBNU=Y8,7J+MJ@%Z
MG#T%1%+9B]G$K\%UZE *RKNU3B5$4I,7>3-W+H#EQ\R*S5WE8MRLUVH.),
M
M
M
M
M
M
M
M
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MS#R]FKPOB)Q?Y*BWE!_I5,T^:CWHQ"K\&G'T(GMT1$U[$X(0 + _)W%9>_,
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M1T O^+(EV4(DZ,]1,C$!@I$^PI5 !31A'80G !+L)V#83L)@ 2["=@V$["8
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M*7+'?  7#7:E7BGG0H*O65F*#*94:NI4:NA23<NG:3@P7 )6KN)@
M
M
M
M
M
M
M
M
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MW[# (LC_ %E]''W[!%&7S&:( 1C9YB[C9^D@QA?1Q $8HR]9'YA&SS%VQOM
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M7109Y>C[2LQ2L6Y7:NX&"(
M
M
M
M
M
M
M
M
M               )'J4B+EU)'+N )47557L*:KQ7UDZKHFGM*3EX(#,GF2+P
M]);/7>5Y'%L#!1>I9/7<5WKU%H]P!;R.+.1VI6D<64C@"VFD,?(I7E>63W %
MM,_<8V5Y<ROXF.D4 H2N,;(N_?N[]]Q<3.5==-Q8O<J[N_T:=NJ:>A=%1?G;
MAP['UF?/9<SY8Y9?*DL^3>76),?WEK)FVBC<ELM[W[#KO>JE5@M5KB75'(E7
M6JQDTC-70P-FD;Y;$.9]F3F1>\8X@O6*\2UKKC?\0W&INMVK7IL]-5U3]IZ1
MLU7HJ>!NS3TD#5V:>EAA@9Y,:(>Y//\ _+@7,#,B/+6PUG282RY<Z*X+"_ZQ
M=L:SL<VX5#M$V9(+%2R,L](J[7]]NNLS5?$^E>G@#W[]]_'KT+,[-]6E@L)T
M]5>SXI*=VLXTLW"+]]X_[!4K:KK8\=CO4U)KU-@[P23\?$+*<_U/R?[?%  $
MCWZ^)%8  'X] ,G9+)67.MH[;;:6>NN-QJJ>AH*&E8LM565M7,RGI:6GB;Y4
MDU1/+'%&Q.+GIP3>8SO\.G5YS:?\'NYOE:^IESVQ=;M*.AEFMV7-+5QI_?52
MQBPW;%;(W:_WO3.DDM5IET:^6J;<ZB-%A93RU'AZPZ<I:/PE3$U'>T6J<;J\
MYOQ4O/FWR2;-AU7U>JZ4QM+"4LM]WG.U^C@LY3\RR2YMI.RN>VO-7<@&BR&R
MZI;?5LAGQOB-E-=L:7&-&.V*^2)'16.FE1J*Z@LC)%I6O1=FIJTJ:E-&2M1/
M3UC?82L:7<;?@*D:0TA5Q5:I7K2<JE23DV^2Y)=2BLDNHNOHO1U'!X>EAJ$5
M&E2BHPZWUN77)O-OFW<J,9[2^BCX%*)FOP&18PZ1Z!.QGL,A%&4HHS)1, *D
M;="ZC:2L9J7T<??OU $\;/T%ZR/V$C&%\QF@!%C"Z8P@QA=,9[ "+6>PN6L]
M@:SV%9$U #6]A7:W]9%K=WF*FFOH[ "")U)PZU*B)U($3J0G3S<092((FGIZ
MD)MG7C["9&^TF!EV\_6"9&ZD485$30'$@C="8
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M$JHI48I19UH3HH,%P B@
M
M
M
M
M
M
M
M
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MT((W0G1-09;ZN! JM;H3(FA$'$
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M#%+MJ[@"]3>GH*B*4(W%5J[] "NJ[T7M*A23@OM)V+N!FV5RNQ2<H-7>5P8
M
M
M
M
M
M
M
M
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M^9.'6H!%%1?5U%5K=?02HA/YD]8,I#CN0J(F@1-"9$ ;_'6$34K(F@1-"(,
M
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MT4NV;TT *S2=NY="BU=4*SEX*#**A71=2AJ5&+U P5
M
M
M
M
M
M
M
M
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MQO)=,;["_B9P+>)O?SF3A8@!<1M+V)G?SE&-/T&0B8 5HVE]&THQL[]I?QM
M*C&?H+MC/TDC$ZRZC8 5&)UE=J:DK4WZ<"Z:W=Z.H ::>GXBHU-$")UE5$TW
M_  .&[K)VIH2L3K*B RWR";]Q71-"#6Z$P,
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MHW%TQ=X!=)N70JIU^TH:\%[-Q78N\ J,7<5&KO*2;E5"<&6N'<7 ((NJ$08
M
M
M
M
M
M
M
M
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M$: %Q&W]!D8VEM&W]!?QH 5XFE\UO44(4W:EZQ "K&WX"[:FGK*;&^PN6)J
M3QL[^8K:;].I"")HGIW%1J:( 3-0GTU] TZNOK)T30&5^/E(E1C>LE:F\K P
M
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MB>8:-=WH,E"[=H5V+1&8B4R<;OI0PL;OA,I"[AWX@&6B7YC(QNU0P\;C)1.
M,HQ>_M+^->'G,9"[M+]B[@"_C7XR[12Q8I>,7< 7K=Z*A4:O MXW%9O6@!5<
MO7U[_@*Q1ZE\Q5:NX&?]/M*S%W$Y28N\J@P
M
M
M
M
M
M
M
M
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M$T?AJ/!JFI3Y7G+PIO\ :;*/:Y:6]6Z3Q>(O>,JLH0[*='V*"7ZL4^]OAP
M-@-9   /V/D[Y*W',?'F$,!VIKW5F+,0VZRI(U$<E)1U,[%NER>W<YT%JMC*
MRXSHGE]#12+%J](]>H3@_"E!8K5;;):H&TMLL]OH[7;J9FFD-'04[*2F9NW.
M<VGB:CW_ &3WZO?Y;C3;\&[Y.;;WF!BO,FLAVJ7!=JCLMJ>K46/W:Q"U75$J
M:M56S4UJIY6,=&Y-&U4S951LR--TAC>HKMM7TPZN,IX56Z/#4VIVYUJGA?\
M;#<3[;WX%HMBVA%0P-3&27AXR=H/JH4KJ+[I3WVGP:W2XB;P]I>1-U4H1IW\
MQD(&? I%!,Q=QM,E"TM(FF2B: 7D:;B^8W@6T;?@,A"T NHF[B]C9])1C3X"
M_C3X@"LQI>1H4&(7L;4]@!4:FXNHV_2I28F\N--$](!.F]=?456]I(B=1/IU
M=@,I$S6]?P$X*C$ZP)/,G1-"( ,
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M)%+K7=Z "X9Q(L7J*;5X%37?Z087WE5%WE<MRNBZ@R1
M
M
M
M
M
M
M
M
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M1-2LA(Q.LJ P
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M  $47JZS%_QWF+_C\=Q, #)D $BN7L,-@G!+KV_J)C*8
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MKH 1!(JJGSD6KJ84D"8 &0 "&H%R(((I$        $NJZ[N!AL$P(:]A$R
M  "!$           $ "(                  !*J^P F!+KN)D,7  !D
M        E<J]0N"8$NUWWDPN    "57>TCK^@Q<$0 9
M                 !+M(-3%_,$R8$NTA%%,@B"55[]_H)=OCU>I?H[[MQCS
M"Y4!+M=]4^D;7?=])DQ=$P*>VOF^'KX=7H3T^8F:NH,DP)5=H05W9\0!."3:
MW?H(HNH!,"":]9$                             E7J&O?NOT@$P)&JN
MOFZB;4Q<(B"15Z^/?OU!'=_4G?=N,W!."7:[ZI](VN_Z@8NB8$B.[[^^J#5>
MZ*8O^+,S<G!(CEZR"/X_ 9N"H"1'$=KUBX)@
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MT@RE<G:G63D$X%5@,-DZ$0
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M5->W?UG):JXT?%(U>#F.;V<6JG'J.HQR0\V?V=96Y?8O67II;_A&Q5U7*O\
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MZ(TA4I3G3J0H2E"=.3A.+33O&2S75D:PG[=ORK_PVXD_HC!W^[1+^W;<J_\
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M'A:]:G*E6JN,TJ-.+LJ<Y9-)-9Q1OP_#P]>[C["J2IW]JDQ *998  R
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MO>/9)Y$:[3M8\7HS!T:^$G&%2>(5.3E",UNNG)VM*ZXQZC98^JQLN/P28_\
MZ3PS^>CZK&RX_!)C_P#I/#/YZ:.@)@]:[0_YFI^_J?>0;Z[FF_S]+_IZ7\)O
M%_58V7'X),P/Z3PS^>CZK$RW_!'C]./_ +4PRO4NY?[]W)U:[^KCJ:.@#V7Z
M(2RH5+\,ZU3[^ ]=W3=K=/2S_P"!3X?LG5XYOOEL6GE!9:6[,NRV.Z8>H+E<
M[U;8[9>)J.>NBDLMQGMLTCY*"26F5DTD#I(D:]7(Q41^CM43[8/!/P:[[U3#
M'OKQ]^55Q/>PKSI_"4\/C<30I)JG2K3A!-W:C%V6;S9:+5S'5,3@,)B*K3J5
MJ$*DVDHK>DKNR62  /(/:                        *4G4OG_ $_,:ZO*
M\\(>P]DMF'B++C%N4&.ENMAJ&]%74MSPYXA>;94M26VWBW.GJX974== J*J2
M1MDIJAM122MZ6G>IL6K])KB^$2\W,[-++EN9N%;>M1CO+6FGJJFFI8GRU.(<
M&JJRW:WLBC1SIZZTJGNO;6MC?+,V&MH6H]]5#T>QZIT\%4QM.CCX;U&L]Q24
MY4]RI+*$I.+7@N5HRZKWY&J:YUM(4L#4KZ-DE7H+I)0E3C4Z2G'.HHJ7ME'P
MEUM;N5SYW7PL;+C\$F/_ .D\,_GI#ZK&RX_!)C_^D\,_GIHYL>CD1R>4B\%3
M>B]?'KW*B]NBIJ1)Y6R_0_.C4SS7L]3/MXE;O7<TWQ]44LU=+U/2Z[-6MDTC
M>+^JQLN/P28__I/#/YZ/JL;+C\$F/_Z3PS^>FCH#/K7:'_,U/W]3[QZ[FF_S
M]+_IZ7\)O%_58V7'X),?_P!)X9_/3VVYN;G&\'<I/!M;BS"M)7V>IM%VFLU]
MPW=WTK[K:*E&)444LSJ226GFH[G1/95455 ]T:JE13/5*JDJH8>5\>K',[\X
M#-R?<WK=>+A5OAP+BE*?#V.X%5%@CMTDZK0WUS%:[27#]5(M2LD>S*E#-7L5
M9&2K')X>L6R[!K"598&G4CB8+?@G4E-34<Y0M)Y-QONOW5ES-AU7VMXYXVC#
M2%2G/"U'T<VJ4(.&]E&=XI91E9R_1N^1T\^OV%4LZ&M@J8(:FGECGIZB*.>"
M:%[9(IH9F(^*6*1BJR2.1CFO8]JJUS51S55%+PK]:V7"W(LTG?/C=+N[   9
M                !!0")1G?HW771-^J[MR(G'?N3U_H)G;D[/;Z>KXNL\!_
M" N<5_N-96I@_#EPZ#,/,R&MM=K\7<BU-DPW"V.&_P"('[+T6F>K*EELM+Y$
MTJ*ZIFEA9/';JU(O0T3HVIC,12PU)7G5FHKL7&4GEE&,<V^I,\K36EZ6 PM;
M%5G:%&#D^U\(Q5^+E)I)?8?@6='A1.56%<78DPQ;L!8RQ51X>O-;9H\1VRNL
M-/;+Q);I74M566YE55MJ'T#JN.=E)4O:C:RG9%61(D4\:)^9_58V7'5E)C_^
MD\,_GIHZ(F[BJ]>JZJJJO%55=ZJJ[U5?*5555X@L53V7:)4(J=.I*2NI2Z:H
ME)QM=V3LK]2*N5=K^F93FX5*,(WO&/04VXJ5VHW:N[*V;\YO%_58V7'X),?_
M -)X9_/1]5C9<?@DQ_\ TGAG\]-'0'/UKM#_ )FI^_J?>?/UW--_GZ7_ $]+
M^$WB_JL;+C\$>/U_^JF&4_\ LTSN%?"F\$WVZ6VR6?);,BYW>\W"CM5JMU)<
M<,255=<;A41TE%20,6N:CI:BHECC;JJ-;M;3U:QKG)HKZ\?I5/B5./#CU^HV
M\/!G.;G9=:RIY0N*K>KZ.U5%;9<MHJF/R*BY1))27[$].U[-E\5$LE18K?.B
MN1M:V\-VE?!JGA:R:F:$T=@ZN)G1J72W*477J>'5DO!BL^O-]44W9VL]BU6U
M\T_I/'4<)3KTEO-SJS6'I^QT8VWYO+CFHQ7NI17.YNFV6HGFI*::JI_$ZJ6"
M&2II%E94>*SOC:Z:FZ>)$CGZ"171=-&B,EV>D8B-<ADR1G#U^?Y]Y.5_+,I6
M27$  &0   ?)W+8Y55NR2RQQ1F?=[3<+Y;\+0VZ:HM5KDI8:ZK2XW>WV>-M/
M+6214S%CEN+)G](]/K<;T:JO5$7ZQ/';G]OO2LW/Y)A;\N,,GHZ'PT:V+PU&
M?B5:]*E*SL]VI4C&6?%9/D>3I[%SH8+%UZ=E.C0JU875UO4X.2NGD\US/,-?
M"Q<M^/\ <CQ_K_.F&?ST?58V7'X),?\ ])X9_/31T!8SUK]#O^IJ_OZGWE65
MM<TW^?HK-\,/27V&\7]5C9<?@DQ__2>&?ST?58V7'X),?_TGAG\]-'0#UKM#
M_F:G[^I]X]=S3?Y^E_T]+^$WB_JL;+C\$F/_ .D\,_GH^JQLN/P28_\ Z3PS
M^>FCH!ZUVA_S-3]_4^\>NYIO\_2_Z>E_";Q?U6-EQ^"3'_\ 2>&?ST?58V7'
MX),?_P!)X9_/31T ]:[0_P"9J?OZGWCUW--_GZ7_ $]+^$WB_JL;+C\$F/\
M^D\,_GH^JQLN/P28_P#Z3PS^>FCH!ZUVA_S-3]_4^\>NYIO\_2_Z>E_";Q?U
M6-EQ^"3'_P#2>&?ST?58V7'X),?_ -)X9_/31T ]:[0_YFI^_J?>/7<TW^?I
M?]/2_A-XOZK&RX_!)C_^D\,_GH^JQLN/P28__I/#/YZ:.@'K7:'_ #-3]_4^
M\>NYIO\ /TO^GI?PF\7]5C9<?@DQ_P#TGAG\]'U6-EQ^"3'_ /2>&?STT= /
M6NT/^9J?OZGWCUW--_GZ7_3TOX3>+^JQLN/P28__ *3PS^>CZK&RX_!)C_\
MI/#/YZ:.@'K7:'_,U/W]3[QZ[FF_S]+_ *>E_";Q?U6-EQ^"3'_])X9_/1]5
MC9<?@DQ__2>&?STT= /6NT/^9J?OZGWCUW--_GZ7_3TOX3>+^JQLN/P28_\
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M._$Q\2?$92%O#OP +^-"^B3>6K$X>8OXD^D OHT^$OF-UTT]9;1MWIYC(1H
M7$:%[&G M&)N+YB %=J;RX37VE&-/H+GKT[ "HU."%3BOH)&]O83,3K!E,J%
M9J;BFWB5@8
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M/B^YOM/[2$474I,<BKU\._L[>!50A-/EZ?N+ )D0 9,@
M    &J?X6%]RS*K\9-3^2=[-%\WH/"PON695?C)J?R3O9HOEF]EWDFG\+6^F
MRI.V#RU5^ P_T&  2*1:#9J\%B^[GC'\6]7\O6@UE39J\%B^[GC'\6]7\O6@
MU+7OR1CO@E].!NNSGRWH[X:7U50WY$[^U28E3O[5)BI:^_YRZ8 !D
M            E5VA,2N (ZH05R%)7:>GON3OZ#X6Y=?.)Y9\GS#K;WCN\,9<
M*UD_['\+4#HY\18BGIVMZ1MNM^TCVTL#Y(FUESJ>BH*%)8O&)T?+!%+]\)A:
MM>I&C1A*K5D[1A"+<I/J[,LV^2XV5SJXW&TL-2G6KU(4J--7E4F[02[^>>22
MS;R69]L7W$%#:Z.JN%RK*:@H**"2IK*VLGCIJ2EIXF[4DU143.9%#&QJ:N>]
MS6HG%35LYP?PF#"6$9J["N2%L@QW?H$DIZG&EQ<Z#!EMG^N,5MK@CV:[$U7
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M*#\9?\2VZGPWF1KKEM)PFC-ZA3W<3C+/V&,TH0R_K9K*+7%T_&:ZD;%_+_\
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M!TM#V&?1UXI;^'J-*:X7<>52-VEO0O;@[/(_? 2)P[Z_#\_L)S5S<0
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M"V&R?6OU=@_4E:7\YP:4&F_"G0RC2GQN]VVY)VY1OQ/VG4B2H3$;(E@
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MZ_?)^_>'@?WH8;^1:(A/;)XFC_?8KYJ!8#83XVD^["_XQ^P  @LL0
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MM-^[KX\/5\7J*Q%-^/83.F  9,@
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M#A^BT3A%;QX3J/M<ZLFGYU<IEM*QO3:9QDKW49TZ2[%3I137FD_3<  W$T0
M  ]6>9-RU_9+RD\ ;3.EAP[[LXIGC73166RV3TT+G:HNZ*LN%-,W31=N-N_3
M5%Z&S&\$[^GU_&:6O@TV DK,S<>XCD8BML>#J>B@D5-Z3W>YL25C55/X4%)M
M*FN_9WIHFJ;IC$T733315\W#T[_:B+ZMZUJVK8S?TGT?YC#PCW.I>7RW7H+8
M;&\&J>B%4:_+XBI/O46J:OV+=;7?<O843B7T*::%BS@9.%"-&2PB^B3Z3*0_
M06$3?H,I$G#V@%Y'UF1A:6$:?&9.) "]B3K[[B]C+2)-WQE_&G  NV)P\Q>,
MX%JQ.LO "O'U=^LK,[21C=WHX%5J: %3J])41-"14X(5 9ZB=B=95)&<"<&
M
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M!KOO5,,>^O'OY57$]["G^M?E+'?&:OTF7CU,\E:/^*TOH@ &OFS
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MYVE\$\3A<1AU)1=:C4I;S5TNDA*-VN=KWM=''FU0:H=6M.;%Y-G_ $>\D/\
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MA_8JO[RG]P]8RO\ V^E^YE_&<I3:3M0(O?CU[^"*NY/-Z51-YU;$YL7DV?\
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M?\.I'>7:X>.EV-$:Z2T)B\')QQ6'J8=_\:$XQ?O:ENCEW)F. !WUZ>Z_VGF
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MTTO8J/ZL7O37NVT[V1#9)@#022P
M      4WE0IR=0!3**<%]157@I13AZ_I!R7!^8IOX%*7K*SNKTE&5>(.):/7
M<6<G7Z"\?P+.3K]'S %E(NXL).KOU%]+W^ L).(!83+O,:]3(3+Q,<]=X!83
M+Q,7*IDIE,7*OQ@&-G4L7KO37U^;OZ4]*<4O)OT=_@+-_P!DGI^?CNT^!4]*
M<3*XH-G/"Y[S&#KQRF,PT<Y7>XWN'84UVO);16>EG:SRG.U1$K-4T5$;JJ:*
MJN4\GSZ]YP'%?NWGEFW<-4=MX_Q'1ZZHO_%5=):=-4:U-WB.RNC4T5-ERN<B
MN7Y"+E:!P_18'"4_<8>BO.Z:D\N\HCK%7Z7'XVI[K%5W?NJ2BOD7R  'JGB@
MBG9V_%U_!PW+O($4^CXTZNO3[+33JUW*B*F&^/=?Y&OMOYA]ME\J?SJWG-PS
MP8S![8\&YJXA5OEUN++'8XY-$71MILKKC/&W<BIM.O=.^3:<]';$>RC=^NT-
M%]'Q<4]/GWZGA/X.U@_W-Y.<%?LZ+B7'N,+VKM_USQ9ULPQM>5V+ASH_)5S?
M(WNZ3I$3W:C0J7KQ7Z32V-=[[M9T_P!TE3^>)=;9[ANBT-H^+5MZ@JG"WY5N
MHODD7L?!._49&)-QCX^*&3C7@:H;D9"%._H,I%P]ACH3)Q)N +V)/B,E%P]A
M81_09*- "^C0OF<4+.+YR^C0 N8^!>MXEK%U%VSB 7/\'OVE5"BB[D])6:F\
M G3[(J$C.LJ-XH#+XLK(1 !@
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M  -?-F                           !*Y-RZ:=_9\9,04-@\(.?GYN?\
MNV95SXCP]0NJ<P\N:>OO5B93QH^KO=G9&L][PW&C6]+45%5! E5:8&O3;N5/
M# B.=4'.+AE:]C'M5'->U'-<U45'([>BHJ<45%UU3<NNO'4[)ZMW::)V>;37
M?JG7JB\/B.=GX05S=ZY/YH-QQAZAZ' 69]777"G2GCTI;+BYKO&KW9W(U5;
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M/\7B#Y'J#I?)P0KEM;\HTOBL/K*I:;8IY,K_ !RI]"F1 !%A,0
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M5^/BQ648*_*$;)=?>2_H'0U+1^$HX2DK1HP2;]U-YSF^-W.6;SR[BH #S3V
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M35"LA(C?-U$Z$2+S][_'^Y-=_F5^_L["( ,F0
M                4Y.HJ%.3J *3EW*4M=WK*C^!37@GK!GEZ/M*3N*%"1>/
MI+A>*>LMG\ 8+=_ LGKQ+U_ L9.OOU@%G(GQ_06$J[U+V1>'I^=2PE7CZ #'
M3=_:8Z3K,C-W]IC9%X@%A-\1BI>'M,G*IBIEW=^T Q\O%/3J8RH?LM>[ALM<
MY%XZ;+55%]2IKVIU;S)2)Q]?Q'\EBRZI0VRYURL61**WUU6L:.Z-9$I:6696
M(]4<C%>D>SMJUVSKM;*Z:+]*4;RBNN27I:1\ZSM"3ZHR?R,Y8N;=_P#=;%N+
M+MM;?NMBK$ETVO+7;]T+U75FTBOT>NO3;2K(G2:NW[]H_/BTM[WNIX'2.625
M\4;Y)'*KGR2.:BO<]7+JKW.57.5=?*<J[2ZEV77H)1A"*X))+NBFE\A0+$3<
MJE1OBYRD^V4I-_:P #ZGP!'OQT\R>G1=%TZ]-^[4@0<[915[$UW\-W;YO0+7
M3_&6=_DN935\^'VJS1T3>9?PTEJY,N5-.C=GQFSW*[Z(C4U6^8@NUX<[1JJF
MKW5RO557:<YSG/1KE5J>I4?SGQ9S==@6UY#Y/6YS7,=1Y<83@>U[6L?MMM%,
MKEE:WR4E<JJZ33755VE55<I]J1IP*9Z<K=)C<54]WB*T_P!J<I+YR]^K]#HL
M!@Z?N,-0CZ*<47S$W^HR42</:8^/C[$]OZC)0]_:>6>P9&$RS.KU&-BW[C),
MZO4 7T2?'\1DHTX=_.8^$R,?5Z "_C3X"]9P+1G7ZD]I>1IP\X!>QI\1<,*$
M?67+ "LG%._G*[>OT%%$W^@K)P7OQ )V<"JSB4V<"JP&7Q95  ,
M
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M3;S;;>;=RV5"A3I0C3I0C"G!*,(12C&,5DDDK))  ' ^H
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MI3$1]DJK=PB:\2B_&JQ[:CRB^4(]4B"*NXJ$$0B0XE;TW)V0 !D
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M\X_DT_ZRJGXTGQIJW@Y2:WK;LC45J+W[^O\ 054(;),0PO23TE;(  R9
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M4*5MMW;=VVVV^-V[E^8P44HI622274EDD  #D
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MX)W[0"=G K1]92;P0JQ]8#94
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M?T3HRE@\-1PU".[2HP4(\+NW&4NN4I7E)OC)M@ '2/1
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M&-.$:<(J,(14(05DHQBK122X)))+L0 !P/J
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M^HIU^^3]^\/ _O0PW\BT1">V3Q-'^^Q7S4"P&PGQM)]V%_QC]@ !!98@
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M)/<
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M-Z_2I57[%._:4F\5*J_8IW[0"HG!"K'UE)."%6/K *@
M
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M]18'8AH6[Q6D)K-6H4F[9-VE4MS\7<2[')9IA$T7ON*@!!J5BPX !D
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MMMN]R\E&E&G"-."480BHQBE9*,59))<DLDN  !P/H
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M\&N^]4PQ[Z\>_E5<3WL*?ZU^4L=\9J_29>/4SR5H_P"*TOH@ &OFS
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M\U14U$TBMCB@@BC?)+*]S6,8QSG*B(IR\N=>Y?-;RA,V[SBB&:H;@ZS/FL.
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MNHJ,>1<K9[JI'16 A"27JFONU<3+FI6\&E?JI)[MN#EO2MFR8 &GF^
M                            U:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^
M,-OR#<C:M1O*^"^%_N3-+VB>1=(? KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P
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MZCT30;5JF+OBJE^-JBBJ<?U::CE[J[RX$Z*1 -))&
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MM545-%1="LU=33S>T[DP !D
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M67,?S@%RG%?45-=W?SE).*E5."^H J-7<A6CZRBS@5F*#+*@ !@
M
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M^Y9E5^,FI_).]FB^;T'A87W+,JOQDU/Y)WLT7RS>R[R33^%K?394G;!Y:J_
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MZ[OQ?22;B^+]HHV[+$0 :6;^
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MG$-?D,.DGU3K3W?3N4WZ>&=SZ= !7LLZ
M  "16[^_'O\ $3DCDZ^S] _'R"YS=O"&\BF8+Y3.):ZFIE@H<<6JSXMA=L(R
M.6LFI_<RZ.A:GDHQE3;VK)L(U'S22R*BRNE4\.S<.\+)RS8RNR7QG$Q5=4P8
MOPM6/5&HUB4S[1>+8U%TU5TGC%W<NKM$;%Y">4]33Q+9:B8WI]$X.;=W&FZ3
M?;2G.G\T44LVB8!8?3..@DE&5558K+A6A"KR[9M>8  VXTH&SUX*YFPMLSIQ
MU@Y[T;!BW+[W58CN$E?A&]T3(8F?_=746);C-N31T5*[:76.-%UA3U\YAC'+
M[%RL<II$?L076HQ18*M-K1)8[MA"^Q4L:^2__P!J1VZ9$16[3HMCR45SFZSK
MEA>FT7CJ=N&'J5$LO&I7K+Y:?^QM6HN,Z#2^CZE[+U73I^:M:A+Y*ATU  5%
M+O             @O5WZE(D%ZN_4H!#J]7S'+DYYG[Z?._WX1_(%E.HWU>KY
MCER<\S]]/G?[\(_D"RDL;'_Z=B/BO^) AC;=Y-PWQN/U50\S  6(*O  !\%W
M_<8?+\<F=&3P:[[U3#'OKQ[^55Q/>P\$_!KOO5,,>^O'OY57$]["G^M?E+'?
M&:OTF7CU,\E:/^*TOH@ &OFS                                  ET
M\_P$P )%3S]1JX>$C<V\F-\(P9W83MW28MP)0^*XLAI(VK/?<%,E=*E5*U-'
MS5>%IIIZN&1C7SOM=174[VRM@I/%MI%>!C[A;H*J">EJ8(JFFJ8I*>HIYV,E
MAG@G8L<T,T<B.9)%(QSF21O16/:YS7(J*J'J:$TO4P&*HXFEXU.6:OX\'E.#
M[)1R['X7%'B:Q:$I:1P=;"5EX-6/@RYPJ+.%1=L'GVJ\>#:.. G!%[414Z]V
MB=_A35%10>K//"<WE-R><V*^T6V&=<!8G6HO^!JN35[:>WRS;59AZ255\J>P
M5$GBL+Y56>:VK1U$SIZA9Y5\IN_?S:\.U-%ZRW^CM(4L50IXBC)2IU8J46N5
M^,6N4HOP9+DTRD6E-&5L'B*N&KQW:M&3A-<FU[:+YQDO"B^IH  [IYX[]^OV
M;S<V\&2YQ!CZ:MY/6*+A]?I4K[[EL^I>OUVB5TE;?\-TRO54VZ65\UZH:-FC
M_%Y;ET<:QTDG1Z9)_>Y5YFWK!6);!B_#E;);[]AF[T%[M%7$]T;HJZ@G;-$C
MW-^RIY]E:>LA5%954DLU-*BQ2O:NOZT:"AI'!U,/.RE9RHR]Q66<'W2?@RYN
M,G;.S-EU2UBJ:*QU'%1;E"^Y6CRG1E;?CWI+>B^4HKE=/L'HY=.'H[]_@/GK
ME5\I'#N467V*LQL5U*4UEPM;)*Z5J;YZZK<YE-:[51L56I+77>Y3TEMHHU<U
MLE551->^-B/D;_!<A+E>V3/+*[#&8UD6.+W7I5BN]M8[:=9[_1Z07>U2HKG.
M:ZEJVOZ';<JR4SX)D5[)&O=I[^$E\XHW'&,X,DL+UJ38;P!7.J,734TJOAN>
M-F,?%[E[3=(Y6X8CDE@JF*V1&7:6H@<L<U#-&E:=7=5ZV,TBL'.,H*G-^J;Y
M.G"E*TUWR?@Q[6N1:_6K6^C@=&/'4Y1FZU->I$L^EG4BW3=G[6*]DGU13ZC7
MPY2W*%Q#FMCO$V8.*9WS7G$URFKIHUE=+%04VZ*@M5*JHU&T=LHXX:2G8QL<
M>S&KTC:KU1/PP MA1HPIPC3@E&G"*C&,?%22LHKL5K+L*85Z\JLYU)R<YSE*
M4IR\:4I.\F^'%L  ^Q\@GJ]&_7J[$7COTW;U14-P[P9OFXW35%7RA<86[ZS$
ME19<LJ6KB:J22KK%>\7-C57*U&(CK/99'M:JHMTJVM<Q;=.FN9S>G(FO6?\
MFGA_+VUNFI+?4RMN&*KS$Q'>X>%Z.6);K6LVVK$ZMEB<E':X9%5LU?4P[;?%
MHJAS.I[EQEW9L)V"SX8P]0PVRQV&W4EJM5# FD5+144+(((VJOE/=L,19)'J
MLDLBODD<Y[W.6(]J.M'04?4%*2Z7$1O6:;O3HJUH]2=65[_H)]:9-6R#5'U3
M7_E&O'V'"S]@3652NT[RSXJC'ARWVE[1I_VB,T[[N&GM\Y.A$%>RSP
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M5E]\-15*G3IQ5HTX1A%=D(J*^1  'S/N
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MHU'WQBU;G<DO1&U30^*<8NO+"S=ENXI*$;]E5.5+LSDG?E;,VA]2&UOX>L_
M\C.4_E]F;;DNF <8X?Q91;#9)'6:XT]544S7*K4\;HT<E92*KD5J)500[2M<
MB<#]Y:NO7KJF[=NX<4WKN7J\W6:/4I3@]V<7&2XJ2<6N]/-><D*C7A4CO4YQ
MG%\)1:DFNQK)KM*B*1((FA$X'V
M              !3DZBH4Y.H HNX%+J*RE+J]8,\O1]I37BGK+9_ N'<4])1
MDZ^_6#!:OX%D_K]9>OX%G)U]^H L9$X>LQ\W%>_:7\K=?A^8L9>(!C)N_M,=
M+UF2F,?(G'SH 8V7K]7S&*E3YS*S&+E3YP#%2IO3SZ_"8NL9M1RMTUUC>FGI
M:OZ]VJ]B*NXRTO5Z2R<W5R)VJB>G5=-$]/5IOUX;]#E!V:?4T_E.,UX+[G\Q
MR>;_ &%;5<+A:G(B+:[A76U6M5SFIXA52T:HUSFHYR(L&B*_9<J:+L_9:8D^
MA^5YAQUHS9S1MJMV&TN8>,TA9H_5M/-B.Y3TJ.5_E.5*:2'REW*NTK=474^>
M"Z^%GOTJ<_=0A++AX<(S*!XZCT=>K#G"I4IY\? G*.=^>6?;D  ?<ZH'?OU^
MC37?HBZ)JJ"*=O9\'5KZD77S\%W*H_W]%W\_XX&4[?-Z6CH]<TIB'W3Y-V3D
M^NJ4V"K;:MR-31;,LMJ<GDJJ:HM&J<=I41%>C7J]C?1N/YSQ?Y@K%*7'DRX/
MIM5=)8[YC6S3*KMI=4Q1<;O U4V&;"QT5WI(D;Y7D1L>BM1Z1M]GV<"G6LM'
MH](8V'N<562OU*I*WR%Y]5*_2Z,P%3+P\)0;MPOT<;_*9&-=%]1DXEX>@Q<7
M$R,2\/2>(; 9>%>'J^<R4?5WZS%0_J[^LRD:\/2 9&'YS)1]1BXN/L,E%U &
M2C7CH7C.!8QKP])>Q]8!D(^LN(^LM(UX%TSB 7"<?5\Q7;U^@MT3AWZRY9Q
M)F<"LSB4&=95:N] 9?%E<  P
M                                                   4W]127@5'
M\2D]=P.4>)3ZO647<4*[NHH]?H0&'Q*$CMQ;/4N'\"V?U P6;UXEA,7CU^$L
MY-_?S@%C)\QC9N_M,C(OP&-E7B 63^)BYU^ R,O7ZC&2K\_P &,E^8QLR\/3
M^A/B,E*O'T&,E3X-?I +&5=ZG\WB2LCI[?7SRO;%%!15DTDKW(UD<<5/(]\C
MW*BHUC&HKG*J:(U%5=Q_1R+Q/EWEI8T_8YD_FM?T=L/LN6^.+G&NNR[IJ/#5
MSG@:Q=IOUR29D<<34<USI7,:UR.5%3LX*EOUJ45[:K3BN^<U$ZV-K='0K3?"
M%*I)]T8N7V?<<Q&KN[[A-/<)=4EN$\]?(CM-KI*R5U2]';"-8JM=*J*K6M9J
MODHGE-;;E.&/88UF[R6M;NW:*U$3ANW;MVY.O1$X)4+K1C9)=67HR*!3E>4G
MUMOTY_:  9.()7+HFO4F]=Z)N3?JNNG#34F+:L<J0RJB:JD4BHB;U54:NB(B
M<55=R)UKHB(J[A:^769CQ.E_S9MC=;N3UDK2/1S9&Y:81FE:[9U9-5V>EJYH
M_)545&33O:BZ\$1.H^[H^._L73YC\3Y/&%_<3 6";.B(B6S"N'Z'1%:Y$\6M
M5)%IJQK6KHC4UV6M3_JH?MT:;_84LTG5W\17J>[K57Z9N7GXE^-%4>BPN'I_
MFZ%*'[$%'[#(P]_892'J,;#\QDH.HZ1WS)1I\9D8>/?SEA'U=^LR$/?V &0C
MZC(,;\'_ (>_K+"+J,A'Q7S:@%ZS@7T?'U%BS@7S% +F/K+E.*>@MH^LNNOU
M %5G6:P7A3_W&,#^_P#A]ON/7&SXWK]!K">%0?<8P/\ C A^1[@;9J/Y5P/Q
MB'VFG;0O(FDOB\C0X !;-<$4H  ,@VBO!5?NP9B>\"E^6HS?%Z_9\YH=>"J_
M=@S$]X%+\M1F^+U^SYRKVTWRO6^#I?01;G9%Y%H?#8CZ;(D-"(- )/!;RL8J
M.:K6N:YJM<U416JU=RHJ*FBM5%5%1=RHJ]I<%/9W+\&O48[ONN8:OE^/1S-!
MWG[>9\?E?=*W./+>UHW+B^U[Y\4V6ABTCP3>[A4*[QNFI8V(VFPM<ZF9611P
MZ4]EK)&4;8X*&:F2/65.Q/C/!UJQ!:+E8KY04MULUXH:FW72VUT+)Z2MH:N)
MT%335$4B*U\4T3W,>U4Z]45%1%.;7SR'-75_)PQI'5V1E77Y68LJ9G82NT[E
MF?:*W26IFPC<ZA=7.K**G8^:VU4ZK+=;9$LCG/JJ&O<MA=G&NOJF,<!BI?SB
M*W<-5;SK02SA-M^/"*\%\9)=:SK%M2U ]22GI+!P_F\FY8FDEX-"3=E.*2OT
M4Y/PE[278U;QL []_.G!4XHNY02Y?GP^;\/B0K;EY_QV=78"#DU3LX+JB[*H
MJ+M(Y%U145KO*145'(N]OE:$0++--73XKA?K3[UD+OEE;AV=5NXWT.8/YX5N
M9EMILFLR+BC<P[#;VIAB]ULFS^S>QT34C=32RO\ LL3VF'HUJ8G*DMVH4=<8
M&NDI;@D6SXSU]6NOH^CLW>O4XZV#\7W7#]UMU]L=PJ[3>;1607"V7.@F=!64
M-;3/22"HIY6[VOC>B+HNK'MU9(U\;G,=TB^9JYU2W\HK Z45]DHZ#-/"M-#!
MBVU0:0P72)J]#3XIM$#WOD;07/1KJRFVI%M=Q?-1])+!XM435WVB:D^I9/'8
M6/\ -ZCO6@E^1J/VZ7*G/GRA.ZX-6L[LMU_]5P6C\7/^<TU;#U)/\O37M9-\
M:M.UDN,X6>;4F>T0(:D2)[DU@     &J?X6%]RS*K\9-3^2=[-%\WH/"PON6
M95?C)J?R3O9HOEF]EWDFG\+6^FRI.V#RU5^ P_T&  2*1:#9J\%B^[GC'\6]
M7\O6@UE39J\%B^[GC'\6]7\O6@U+7OR1CO@E].!NNSGRWH[X:7U50WY$[^U2
M8E3O[5)BI:^_YRZ8 !D            %K65$<,4DLKVQQ1,?+)(]4:R..-JN
M>][G*C6M:U%<YSE1$:BKJ<;IUXFN+GW&HU\8N#WU]1J][UZ>L<M3-J^15D?]
M<E=Y4JK*[[*3RU<J]A+-.ZLH<,8BK96N='1V*[U4C6?9.93VZIF>UJ\$<YK%
M1%7K5#CNVENE+3(O%*>%%ZMZ1M0G'8U#RA+XM\G3?>5ZVZSST9'MQ//K]3WR
MX/@LWPY<67X )N17M<$"*+IWU^#K]";^P@._?<IR1DZ2/@[^%4MG)4P',C=G
MW7K\5755V7-VE?B&OH=K5SG([]P(B.;LM7339U1RK[?(AY,<QE;DIN2?DS&U
MRN1]ANM4Y5T14=68HOM6]B:?P8WSN8W_ *K4/6@IMK#/>Q^-;XO%XCY*LT7J
MU7IJ&C<!%</4>&?IHP8 !XY[P
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MSLDB[FAM%4<#AJ.%H1M3HP48O*\G;PIRLEG)W;=EFRH #I'J
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MI71T%SQ=%_LS3_NG1^9P[]_,3$D?#OV)\Y.4_+Q@
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MC4IRC.$U>,HR4HR76G%M/S,F!#:0(NI\S[D0
M                 "1Y.2/X %(I(NY2J4T;Q3T Y)9/S%%R\/249.LK/X%)
MZ\?1\P.)9OX%G)U]^HO7<"SD3X@"PD12RE3AWZB_?P+&3Z/B ,;-])C7\3)R
MIW])C9$^@ QLR=_68N7YS+S)O,3-W]@!B9T^ LY4TW]FOQ:Z>M-W9VHJ;C(3
MIQ[\2Q?O5-$5=53<FNOP)\P".;YSN>$4LO*0S8IF,2.&HQ##<J=J)IK%<+50
M3O?HC6HFW4K4*FSJG'>JGG&>X_A"N"UMG*(JZ]L:LAO^$<.5[%T?I)-3QU%#
M4R(Y^YVLD"-5&KHQ6JBHURN1?#@N%JQB.ET=@I^ZP]*_?&.Y_=91G6[#=%I3
M'PM;=Q-5V[)RWT_/O)@ 'O&N@@OKZ^'H7O\ ,O B._?TIN,_CYG]AE?-FN^Z
M^RYNG^#.XO6IRDQ[8GOVG6?,F:X1MW?6Z:^88L+(V-1%5R,\9LU9(FJ?9R2+
MM+KLLV16=G?OP-0'P8W':Q7W-C#"R-1M7:L.7]D;G(BODH*NMMRO:U7(CE;'
M7+MJC5V6*CG.8B:KM^L7?U^OC\._V[RJ.T.AT>E\9E92E"IW])"+;\\KERMF
M.)570F!L[N$9TGV.%222\T;<,DB_C7@O?>9.-?C,4QV[V? 9*)33#?3*Q.,I
M%P]AB(OH,K%U &2C4R,:[C%1+P,I%\R &2C[>S]9>L7>8Z->'JU+]G4 7T:\
M"\8N\LF%X@!=IP]"E5O%"BU=RE1J\% *J+O4J%->*+VE0&65T4B2M7<3 P
M
M                       ""J 454I/ZBH2+Q0'*/$E>N\H=:^@JN7>4>KT
M@XE"3B6DB\?07+EWEI([B 6DG463UT]I>/+!_;J 64B\3&RK\9?2*8^5?B +
M*1>)BYE^(R,KC%RKQ]@!CY>LQLCM_P !?RK\.IC'KQ +21?A4\N^>7QBEEY,
M^:\R/5DEQLE!8HD17-61+[?;5;*F/5J+HCJ"IJW*U^C9&-=&NYV_U"?U&O\
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ML?L,JKH-(0Y]-1DEV.$U?_M+\ $,$\@
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MVC454\[3$]S"8J;Y8:N_-&G*_GR9ZFA*6_C<)#W6)PR7>ZU-(ZK " I@7T
M          !!>KOU*1(+U=^I0"'5ZOF.7)SS/WT^=_OPC^0+*=1OJ]7S'+DY
MYG[Z?._WX1_(%E)8V/\ ].Q'Q7_$@0QMN\FX;XW'ZJH>9@ +$%7@  ^"[_N,
M/E^.3.C)X-=]ZIACWUX]_*JXGO8>"?@UWWJF&/?7CW\JKB>]A3_6ORECOC-7
MZ3+QZF>2M'_%:7T0 #7S9@
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MM%^J,7&.Y?C2H+.-N:=7*4OT=Q=8;P)@"+R80
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M$K_M$W\5)_44Z_?)^_>'@?WH8;^1:(A/;)XFC_?8KYJ!8#83XVD^["_XQ^P
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M--W?3LW>;L)R1B]G:OZOU>CJ)RGI>4
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MJL(SA)<U+DUQ33NFGFGD^HF !USN
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M"HBE)%XH3L7<#/V?>7#%)RBSB5@8
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M0<\/)9-Q<)-Q3_4E#+_<B #1B1
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MV)Z05/2&(P[?](H7@NN5'P[_ +$Y&PZ "O):
M       $C^_Q?.3DJ]_48;RS!I4^%D9F)+?,FL&,?IXC;<6XHJ8T<NCEN=3:
M;1;WN9]BBPI;+DD3M[M)Y4W-XZ@Y[3>$ YZ-QMRF\90T\R34.#:2TX/IMA[9
M(4FH:5*NXNB>Q53]V5TD<S=?(FBD9N5KCQ9+:ZCX%X?16#A)6DZ7227#.K*5
M59<K*:_T*4:_Z06)TQCZD7>"K*E!WOE1IPI>B\&UW@ &V&G ]E>8 P&^_<K'
M+%W1I)3V"+%V(ZSCY$5%A"]4=)(GDKHK;Q<K9JJZ-TU:B[:M/&HVF_!4,I?'
M\ULR<;21KL8:P-1X>IY'M=LK48KO4%;/T2_8=+!3X78UZ_;&15J-;I'4.1VK
MZZ8I4=%8Z3=O8)4U[ZL^C5N[?3[C;M1,%T^F-'4^JO"JU^C1DZS]*IM&]J "
MHY=H            $%ZN_4I$@O5WZE (=7J^8Y<G/,_?3YW^_"/Y LIU&^KU
M?,<N3GF?OI\[_?A'\@64EC8__3L1\5_Q($,;;O)N&^-Q^JJ'F8 "Q!5X  /@
MN_[C#Y?CDSHR>#7?>J88]]>/?RJN)[V'@GX-=]ZIACWUX]_*JXGO84_UK\I8
M[XS5^DR\>IGDK1_Q6E]$  U\V8
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MJ(9<E30F*LW;S>;?'O+BI)*R5DLDEDDN278N0  ,@
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M4N-.<X2[XMK["_&!Q*K4:56.<:E.G43ZU.*E]I.""$3X':
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M]15*Z*4"JQ0<2<
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MM)/M3R9>>A6C4A"I"2E"I%3A*+NI1DKQ:?4UFNPF !P/J
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M][#P3\&N^]4PQ[Z\>_E5<3WL*?ZU^4L=\9J_29>/4SR5H_XK2^B  :^;,
M                                       04_@\T/WM8BX_\17?T?\
M%]0?WI_"YH?O9Q%_,5W^3Z@^V'_*4_?P^DCK8Q>Q5?@Y_19QV+1^Y*7^3P?V
M33(F/LW[DI?Y-#_9-,@76I>+%=27T44$K>//WTOG8 !]#YEI7K]8G_B9/ZCC
MKY<G1O\ YOL"+_\ @;A?Y#H4.0;7_:)OXJ3^HIU]N3G]SW GO-PO\B4)"FV1
M7IX%?IUOHP)\V%KV72/P>'^E4?V'[&U-._?L)B1.*^CZ"<@E?/F6,  ,@
M                                    &K5X5A]Q[+S\8;?D&Y&TJ:M7
MA6'W'LO/QAM^0;D;5J-Y7P7PO]R9I>T3R+I#X%?60-$5?H^(@17Z/B(%M5P1
M2I??\X !DR>R/,#_ 'U.7/\ %X@^1Z@Z7R<$.:#S _WU.7/\7B#Y'J#I?)P0
MKEM;\HTOBL/K*I:;8IY+K_'*GT($0 183$
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MP<G0DGQW$DZ4NNVYX-^N$N1<@ CXE
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M@)VKHI11=%])5!E_<7 )6KN)@8
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MPR:W9UE*O-9IJ563:7["@^K/@4VVFZ46*TQBG%[T*#CAH-<&J44I/]XZB\R
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MR'XN_P Y>QI\):QIUE[&G  NXT^ N&%%A=1)\(!5TWHG9O*["DG%?456[D4
MF8G7VFL%X5']QG _XP(OD>O-GYO!#6!\*C^XS@?\8$7R/7FUZD>5<#\8I_::
M=M#\BZ2^+5#0W !;7J[E\R*4]7XYL  &#:*\%5^[!F)[P*7Y:C-\7K]GSFAU
MX*K]V#,3W@4ORU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB #0"3P
M     04B0=P,,'YWFGEA8,9X>N^%<46NEO-@OU%-;;I;:R-LE/54D[5:YCFK
M]B]NY\4K%;+%*ULD3FR-:Y.9[SK?-F7[DVX]EMVE5<LO\03U55@;$<K%<LM(
MSZX^Q7:9K&Q-OMJ8Y(I516)<J5C;E!%&CIZ>GZ@:IJN_X%X'S!RPN27A'.O
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M-2U[\D8[X)?3@;KLY\MZ.^&E]54-^1._M4F)4[^U28J6OO\ G+I@ &0
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M*-G\G%,N_H#35'2&%I8JB_!J1SC?.$UE*$NIQE=?Z  'EGL@
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M.[(-;EB,/_)M>2Z?#QOA[V\/#>Y3YRI/)KW#C;Q6>A()$>G=%3X.HG(F)K
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MOZWT8$^["ORND?>8?Z50_8D^R7OV$Y(GV2]^PG((7!%BP #(
M                           !JU>%8?<>R\_&&WY!N1M*FK5X5A]Q[+S\
M8;?D&Y&U:C>5\%\+_<F:7M$\BZ0^!7UD#1%7Z/B($5^CXB!;5<$4J7W_ #@
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MSC*+X-/_ %L3  'T
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MCBY5>"@%9$U0G:NXIM7>3)N4 K-712L6Y68NX F
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M:'7@JOW8,Q/>!2_+49OB]?L^<J]M-\KUO@Z7T$6YV1>1:'PV(^FR( - )/
M       !!4(@ AHA!40F L#S,YT+FV\+\I' 3\/W+HK;BNR^,7#!&*&LUJ+-
M=98D9)3U&QH^JLMT:R*GNU _:8]J4]9$C*VCHYHN9;G+E!B'+_%=_P $XMMT
M]HQ)AFXS6R[4$R>5%/&B.BGA?LHVHHJVF?%76^KC1T%725%/40O='(QR]@/1
M.!X/<]QS2]-G]A-V*L(TM+3YM82H7+9I7;,#<5VB![ZB?"MPJ4;NF>V2HEL-
M1-M0TURE\7F?3TE;4U,,F[/M=7@JBPF)F_4M67@2?]14;XN_]7)OV1*UGX2]
MM>(=IFH"Q].6-PL4L93C[)%+/$4XQ\56_K8I+<R\)+=RRMSD@96^6.MME;5V
MRYTE107&W54]%<*&KB?#54=;2R.BJ*6HAD1'Q30RL='(QR(K7)IPT,462332
M:S4DFFG>]UQ5LL^*L56E%IVDK23::X-6=K-/--6LT\TP._S@&?\ ;_0Q_OYS
M--Q'<$MKK.E;4I:7W".[/MO3/\2==(J62BCN"T^O1^-LHYI:9)M-OH7K&JJW
M1$PH!B,4KV25\W96NWU]9RE-NUVW965W>R7!+L74  9.(-FKP6+[N>,?Q;U?
MR]:#65-FKP6+[N>,?Q;U?R]:#4M>_)&.^"7TX&Z[.?+>COAI?55#?D3O[5)B
M5._M4F*EK[_G+I@ &0            "&A$ 'S'RQ>319LXLM<8Y;7QRPTF*;
M-4T$-:QC7S6NY(WIK5=J=K_)?-;;C%35C8E\B=(74\NU%+(U>4AF[E1?,"8I
MQ#@O$U(ZBQ!A>[5EFNU-I(C&U5%(K%FA61K'R4E7$Z&MHY7,:DU%/3S-:B3:
M)V"%U[.^XT[?":N;MFJJ>@Y0>$Z!)'6^&&R9DTM-']=6WHYK+)BK88W5S*"5
MSK7>9/*>VFJ+?5JQ*:CK:B.4ME^LGJ;$RP=625'%>(VTE&LO%6?!5$MR_NE'
MK9#>U[55XK"QQU&%ZV$6[-16<J$G>4LLWT;=[>Y<S3$ !8XJV  !9/)_CO/U
M7)#.O$F7.+;#CC"%P?:\28:KX[C;*QJ*]B2,18Y::IB1\?C-'74[Y:.NI7/1
MM11SRPKLJYDC>FYS9G.-87Y1V7]+B:U.AMV);<D-%C/"O3MDJK#=^C17.B1V
MS+46>OT=46JO6-K9H=8)=BKIZF)G+./J7D=\L7&V1F.*#'>!:YM/<*5$IKA;
MJGI'6R_VE[VR5-HN\#')TM-,K4?%+&Y*BCJ&QU4,C7J^)VC:[ZG0TI0WH6AB
MJ*O2J<IKCT,^>[)YJ7M'GP;O(6H&O-31&(<:F]/!U6E6IJ[<7P5:'+>BLFO;
MK)YQC;K4IZ28\Y.;FYR[ '*-PLEWPS5-MV([=#"W%6#:Z5B7BPUCVHCGM;N]
MT+1-)M>(W6G189FZ1S)!5-EIXO1E')VH5AQF#JX>I*C6A*G4@[3A)6:?VI\4
MUDUFLBW6 Q]'$TH5J%2-2E-7A*+337V-<&GFGDR8$-4"*=8[A$
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M[5[N$O;0EU.+NL^J_!E'M.Z&JX#%UL)634Z4GG9VG!YQJ1ZXR6=UDG=<4T
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M^'TO05G&&+A%=/0OG=9.=.]MZFWFFK[M]V6?']F!#:3M0B:@;R
M         052"JFG4 2N7<N_V=]V[NIXD<\[SK]!R>,'OLN':JCJ\U\54,J8
M9M\B,JFV*BE<^EDQ7=:3;36GIGME;::>I1D-QN-.]BI44U+5PG]?SK'.ZX/Y
M-]@=0P=!B7,R[T[VX>PE#4,THFOC?L7[$KT=TE#9X'[/1QL:ZNN<ZLIJ2)D"
M55;1\XW.S.C$N8N++[CC&%RDN^)<1UJUUTKY6HSI'I&R&""&)JJR"DHJ6*&C
MHJ9GD4]+!#"U7(S=*&H6HD\;*.*Q<7#"1=X1?C8B2ZNJDGXTO;<%S9#VTC:+
M# PE@L'.,L9-;M2:LXX:+XWM>]5KQ8^U7A2SLG^?WB\UERK*JY7&KJ:^XW"J
MJ*ZOKZR9]35UM;53/FJ:NIJ)-9)ZB>9\DLLSU57O>YVN\QH!8^,4DDENI)+=
MY*V2MV6*M2DY-R?MFWF[N3OG)MYYL  R<0?>?-H\C*NSYSCPI@*&.1+*ZI;>
M\85K--FWX3M,L4]T>YSFN:DU>Y8+11-5J])67"':1(63/;\&HBKHB(YRJJ(U
MK6JYSG*NC6M:U%<YSET1J-3:5RHC=7*B+T=^8;YNJ3)#*F&^XEMZ4F8N8L5)
M>L0QRQM2JLMI1CY+!AR945RMGHJ:H=57*%%1M/<JRII4:JTRRRZ7KSK(M'8*
M<HOV>LI4Z$<K[TE9S[%36=^#EN1]L[;YL\U6EI/2$(N/\VH.-7$R?#<3RH=K
MK<E[E2ER1[?X>L5';*&BMU!3QTE#04L%%1TT3=F*GI:6)L$$$:=3(HF,8U-^
MY-ZJNJF81J=A!I,53[7FWQ?7W_*7+C%)))625EV+J^1   R            "
M"]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/WT^=_OPC^
M0+*2QL?_ *=B/BO^) AC;=Y-PWQN/U50\S  6(*O  !\%W_<8?+\<F=&3P:[
M[U3#'OKQ[^55Q/>P\$_!KOO5,,>^O'OY57$]["G^M?E+'?&:OTF7CU,\E:/^
M*TOH@ &OFS                                           _A<T/WL
MXB_F*[_)]0?W1_"YH?O9Q%_,5W^3Z@^V'_*4_?Q^DCKXO\E5^#G]%G'9LW[D
MI?Y-#_9-,@8^S?N2E_DT/]DTR!=:EXJ[E\R*!U?'E[Z7SL  ^A\RTK_M$W\5
M)_44Z^W)S^Y[@3WFX7^1*$Y!-?\ :)OXJ3^HIU]N3G]SW GO-PO\B4)"NV/\
MG@??UOHP)]V%?E=(^\P_TJA^Q)]DO?L)R1/LE[]A.00N"+%@ &0
M                              #5J\*P^X]EY^,-OR#<C:5-6KPK#[CV
M7GXPV_(-R-JU&\KX+X7^Y,TO:)Y%TA\"OK(&B*OT?$0(K]'Q$"VJX(I4OO\
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MJ.8]CE:Y%1454T,BBD$O)M/EQOR+&QDFDUFFKIKJ9$$-I"(,@
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M]' M]KK]6A61= +E5JZH3HNA1X+KU+W^ J@S+B7 *;'=14!@
M
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M]V#,3W@4ORU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB #0"3P
M        2=O$G(+J88L:G/A ',[-Q=27#//+"V._99;*-TV/,.4$"O3$ULHX
MU=^R"WTL$:R+B"WTZ*EP8Q')=J"**16Q5=&Z2JT=6JBHBIP5$5/7^C1?0J'9
M*6+YNI//\RK\R&B5S_?,^K@&X7'._+2UHF![M6.J,<6"WP(D>$;M6R^7?:6G
MB32+#URJ7JE8V%B06FND1RLBHZC6*;]FVNUMS1V+GEXN&JR>>?\ 4S?7^;?7
MX*Y%>]JFS_*II/!0_2Q=&$?"2X=-22YO^M5K)>$N9JU@BJ;]./?L714W;]^B
M^9"!.7^V?'SKCY[%?$OMMGD[9Y/GEP  !A,   &S5X+%]W/&/XMZOY>M!K*F
MS5X+%]W/&/XMZOY>M!J6O?DC'?!+Z<#==G/EO1WPTOJJAOR)W]JDQ*G?VJ3%
M2U]_SETP #(               ('\IC7!ELQ#:;E8[U107&T7>BJK=<J"I;M
MP5=%61.@J()4U:NQ)$]S55JHYJJCV.:YJ*?U:IZB"H9C)IIIV:S3ZO\ 8XS@
MI)QDKQ:LT^#3.75SKG-UW;DZ9G5^'VQ5%1@>^R5%UP#>I=7I4V=ST=)9ZR94
M:Q+O8'R-HJK1$6KIDI;DU52JEC@\QNSSG5SY?O(<PMG_ )<7? 6)6MIII6.K
M,-WZ.!DU;AG$$,;O<^[4C7.9TD<;UZ*NH^DCCKZ%\])(]NVV2/F&\J#DPXQR
M=QM>, 8ZMWB%]M$FTKX>DDH;I0RJYM)>+342QPOJ[=<&QJ^GF='&]$;T,\<-
M3%/#'9S4#7".D*'0UI16,HQ2G=YUJ:7Y6'+EX=N$L[)2*C;2-2):,Q+K48RE
M@L1)NGNK*A4?]7.W#C[&WQAX*SB?/P'?=WWZIHNO#14T502%?Y<T1EV@=_T>
ML RA:^1^K9)YY8NRWQ+;\88&O]?AK$EL<Y:2YVZ1&OZ-^B34E5!*DE-6T-2C
M4;44-5#+2SM^VPN5K53>KYLGPAC V9U/;<)YMU%JR_S!>L-''<99DHL&XFJ7
M[$4<E!6U<FEDKZR5=4M5QJ'1],_HJ.NJ=J-IS_B#D145JHCFJBHK7)JUR+N5
M')UHJ;E3L-6UDU1PFDX)58[M6*?1UH652-^3=O"A?/<=UU;KS-OU6UUQNB:C
M=">_1DTZE"=W3G;FE=;L[>W5G;)W1V24D335531>"]O9HO7JO?>A61?7^DYG
MG(&Y[W.;(F.ELD=>W'6!J5(8HL)8HJJA_N=2QJ].AL-[:V:OM3&,D1&4TC:Z
MWQ-CA;#21QQ.BDW$.1ES^&0>;K*.WU=ZERYQ94K#"[#>-W4U#'/52.2/8L]_
MAFDLUUB?+KT".GHKDZ%$EJK71:JQM?=/[/\ 'X%N:I/$4E_6T+SM'DYT_'B^
MMV<5[HLOJSM+T;I%0BZGJ7$2RZ'$-1WGPM2GXD\^"OO6M>*>2]M06%%<H*F&
M.HIIHJB"9C9(9X9&2PRQO3:;)'+&KV/8Y-[7,<Y%14T52\1^O5Z32GEV?/Z"
M04T\UFNOEYGP?F)P052&OF[_   R3  Q< #4AJ+H$02JX.=IW_0+@F&I3V_;
MW[\#\5SJY1^ \N;;+>,=8ML&%K=%&LJSWJY4U"KVHNGUF&5Z33N5R*QK88WJ
MY^C$U<J(?2E3E4:C",IR>24$Y-M]25VV?*M6A3BY5)QA%*[E.2C%+KN[*Q^V
M.7J/R'.O//!^76'ZS%..<1VG"V'Z%$\8N=XK(Z2#;5=(X(4<O2U55,ODP4E-
M'-4S.W0Q/<J(:P/+6\*+PO;&UMCR.PS5XGN*;4+,9XI@EM6'8WZJU9K79E<V
M]756;W,DN,=FI5<C'1LKX'JJ:CO*?Y7.8N<M_3$F9&*+AB2X0I*RWP3OZ&U6
M:"5R.DI[+:H=FBML<FQ&D[X(_&*M(H/')ZA8(E9).KNR_&XIQJ8JV$H-I^$K
MUI+KC"_@]KG9KJ9$^L^UW X13I8.^,Q"5DXY4(2ZY5/;6Y*%TWEO+BNCES?O
M.PY;<HR\8WLN"V7.BJ\'STTD,-[CBHZN^V.I58FW^@HFO=-%1,K$=230U&S5
MTKWTSJJ.)M92K)ZFMX)Z.HY,_(7Y6]XR-S3PKF59DEE]Q*IU/>;="]&I>,-W
M!&P7NTO:JM9)T]*B5%+'(]K8[E24-0BLDA;-'U4\I\U+)C;#5AQ=ANMBN-AQ
M':Z.[VJMA>Q\<]'70,GB=JQ7-1[4?L2M1SMB1KV+O:IT-?=4EHRO3E2WGAJT
M4H2D]YQJ1LIQ;R\;*:R7%I7W7;U-G&NTM+X><:^['%T9>'""W8RIRNX3BKOA
MG3EG>\4VO"3?Z,"!$T*Y)(              !\V\K?DO87SER_Q)EUBZG=+:
M<0T$M.VJA1J5UHN+$62V7RV2/:]L=RM%:V&NI5D9)3ROB6GJX:BCFJ*>;EN\
ML+DGXJR3S!OV7F+H%9<+1/MT=>R-[*2]V>=SUMUZH5<KU\6KH6[;F*]ZTU0V
M>F>]SH'.7K8N3@>07._<UU9^4?@9K:)*6VYD85AJZG!5^>UL?2+*C):G#MSF
M:FTZT71\,6CG[?N?6MCK8$:O3I+(6H&M_P#)U=T:TGZDQ#2EF_8JGM:B[';=
MJ)+Q<U=Q2<7[2M1UI3#^J*"2QV'A+<:M[-2XRHRNU=KQJ;Y2\%V4FSF7@_L,
MP<O[UA.^WC#&)+956:_V"X5%JO%JK(UBJ:&NI7JR6&1KM$<U=&R03-UAJ89(
M9Z>22":*5W\>6<ISC)*46G&2O&2?@M-75GPS7#KY%2ITY1;C).,XY2BU:2:R
M>3SR?'++F  <C@#T!Y 7.49E<G7$*W7!E>RLL5=40OQ'@RZ.D?8;_"Q6->Y6
ML7I+9=60HYE)>*-.GB=T:5<%?21K1R>?P.MC,'2Q%*=&M3A5IS5I0G&Z:[.I
MKBFK-<LSM8+'5L-5A6P]2=*K!WC4A)Q<?1Q3X.+3B^#5CJ4<W]SI.5?*'M+)
M<*79ENQ53TR3WG MWGAI\16U&JC99X:;;1+I;62.:WW5MZ3TR;<3*ET$DL3%
M](MK=W3AN7JU^94WG'6PCBZZX?NMOOMBN5=9KU:JEE7;+M;*J:BN%!4QZHR>
MEJZ=S)HGZ*YKME^R]CY(Y&NCD>Q=IOD'>$[8EPW%08>STL55C&UQ)'3?LVPW
M'1PXH@9HR-L]VLDTE%;;PUB_7:N>AJ;?6I'TLD%%<)DAI'P+K/LKK47*KH]J
MO2X]#)^S07&T6[*I%<%PGRL^)8S5+;%0K*%#2:]3U79*O!>P2>2O/BZ3;S?&
M':N"WDF_03'ROR9N6ME;G!;&77+G&MEQ+"K&NFI*:I2&ZT2N8V18KA9ZML%S
MH9V-<WI(:FEB?&KD1[6ZH?4G2)WX^I--Y$U>A.E)TZD)4YQ=G&:<9)]34K/N
MZ^1->&Q-.M!5*4X5(25U.G)2BUV.+:*@)=K=J-KOW0^9]R8$$4AM>CV_H%P3
M @B^CVD-I._Z@"8$-259$3]'Z=#%P3D%<G?OWZBD^9K4U541$15<JKHUJ(FJ
MJY5W(B=:KN1-5ZCR$Y<'/=9%Y)1U-#5WY<:8OB16Q80P9+2W.NCE1&JSW6N"
MS,M5DI_+1SWUE2M4^)LCJ2AK9(G1'=P&CJ^*J*EAZ-2K.7",(MY=;?!)<V[)
M<V>?I+2N&PE*5;$UJ=&G'C*<DO,EQDWR44V^"39Z\33L8USWN1C&-5[WO78:
MUJ(JN<YSM&M:B)JY5TTXKHAJ[\Z9X1%AS ;+A@G(ZIMN+L:_WQ1UN,&I%<<)
MX8E1'12+1.8]U/B*\4TFZ.)BR6FGFC5U:^J8U:.77,YP;GMLWL^XZZPR5+,#
M8 J]N*3!V':J9?=*E55TAQ%>',IZN[M>W1M31LCH[;/HYDE')&J-3QR1$3<B
M(GFT31$W:(B:;M$1$33<B<-":=5-EB@X5])-2DLXX:+3@NKII)VGVPCX/6Y)
MV(!URVORJ*>'T4G3B_!EC)IJHUSZ&#7@W]U-7MP47F?V&/LP+[BJ\W'$>)KO
M<+]?KO4R5=SNUUJ9*NNK:B5RN?)--*JN7>ODL;LQ1)I'#''$B,3^0 )HIPC%
M*,(*$8K=48Y127#=2X$$5*LIR<IR;E)WDV]Z4Y<Y3E+-W[VP #F< 13XM_LW
M^KT]7'=H0/3OFM.;0Q-RD,>TUIITFM>!;)4TU7CG%'1/5E);D<DON-:W*B,F
MQ!=XVK3TK'+T5NADDNE0DS:>*BK.EI#'TL-1J5ZTU3I4H[TI/+->U7.\O%26
M=VLCO:-T=6Q=:GAZ$)3JU9J$4LT^M]5HKPFV[**=ST?\'CYKQ^9F+69Q8TMK
MUP'@BX1+AFFK(%\7Q7B^C?M=/$V1.CJK5AJ5D4M1-L212WGH:*)R2V^N2+?O
M:FFJ+V>SL/X#*;*RP8(PY9L)87MM/:+!8+?3VRUVZE:C8::EIF(R-O\ A/D=
MHKY97ZOED>Y[W.<YRGZ)IO\ ,5.UJUBJ:4Q<J\DX4X^#0I7NH4UDD_TGQD^;
M[BYVIVJU/1.#AAXN,JLFJF(JI6Z2I;.WZ,?%BK\,^;(M4B :Z;8
M      ""]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/WT
M^=_OPC^0+*2QL?\ Z=B/BO\ B0(8VW>3<-\;C]54/,P %B"KP  ?#N:^5HP^
MOJX^A_C(Z,G@UWWJF&/?7CW\JKB>]AX)>#7K_P"BIACWUX^_*JXGO9M(4_UK
M\I8[XS5^DR\>IGDK1_Q6E]$B"&T@VD-?-F(@AM(-I "((;2#:0 B"&T@VD (
M@AM(-I "((;2#:0 B"&T@VD (@AM(05WK%P3 EVMY,
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M"%<MK?E&E\5A]95+3;%/)=?XY4^A B "+"8@
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MZZN#NFDU8F'5O3M/2."HXNG9=)%;\4[]'55ND@^=T_2FFFT3  \@]T
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M\9I?#MQ;I89O$U';+P%[&G[ZHX6YV3MP9L1MZNO=W\WL*I+IP7S$Q5<N(E8
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M@!7!!%(@
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MRZFN*+B-N]/09*)-VA:1LU7X/5V>PR,:=9!Q80O(6]_092)-Q8Q-[^@R<:<
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M5M"JM2>!(G122V<U.UWH:3@J<FJ6+BO"HWRG[J=%OBN?1\8*_%+>*D:\;/\
M$:)J2J0C*M@Y/V.LEG36=J=9+*,EE[(_!J96\*Z/CL#3OW54^%?2#>_]O1\I
M'@   [_']*[_ +).I4(.:BHJ*B*B\==^OF=KKM)O7<[7BI$#\9.WX?6_D,9]
MG;=7OV6X>?,^QN3MSA&=N4[V+E]F7BBP4S71N6UNJHKQ8Y$CUV626*^P7.TN
M;LJYFTVC;(QCW]%)&Y4>GNYD'X5+F7:FT]+F-@##&+8F*UDMVPY4U.&;FZ)J
M(G2.MU0ZZ6^IJI5T5[H)[93(Y?)@C;Y)JN@U_2>JVC\7^7PE&4GQJ1CT=1_K
MPM)V[9-=AL^B=<=)8*RP^,K1@N%.<ND@NQ0FI12[HI]IT$<J/">^3[>F1MQ'
M08UP;4/<UJMK+,V[TL:+]DY]7::B?1&KNT; ]=W!--#[UP7SU?)9ONQXMG7@
MZA5Z(JMQ#45N&.C56.>K9),14EK@;LHU6J_I5CVMEK7*KV([E\CX-."IN5/0
MJ</4:9BMDFCIN].KB:2]S&<))=V]!RMWMOM-[P>VG2=-)5:6%K?I2A.,N_P9
MJ-^Z-NPZSF%^7OD9?-CW&SGRHNVVKT9[F9BX/KMM8M.E1OBUXEVEBU3I$356
M:IM:'Z9;.4/@*N29U#CC!]8V!J.G=2XFLM0D+5X.F6&M>D353545^RBZ;E.0
MD^%CM[F-<OG:B\.'%"@ZWTZZ:P0KIPUB8NGM:>4]CE+ECJENIT(OY>D5_0CV
MH;=*WMM'4^]8B7FRZ+[?0=="OY7>5%)"ZHJ\S\O*:FC:CGSU&-<-0PL1=$:K
MI9;FUC45531RN1%541%WGX=B?G4N33:$D6LSYRF5\+G,EI[?CS#=WJV/8J(]
MCJ*TW"MK$>U=RLZ#:3BJ:(NG*C;1PIO2*-%[48U/7N3CY^)<HFG!$3T(B'.E
ML<PZ?AXVM)=4*4(/TN4_F.%;;IB&O P%&+ZY5IS5^Y0IO_N.DUF-X0GR5[ U
MRP8^K,2R-U18L-X:OU8JNU<FRR:MHK?32:[.J/CG?&J.14>N_3S8SE\*XP?2
M1RQX!RPO]]G35(JK$ESH['0/5?L$<RC9=*YKD^R5CH$5R*B,55VE;I&=]V[X
M?B[.H?1IZNSOZ#VL'LIT73LY^J*W6JE5*+\U.--_+W6->Q^V/2]5-4WA\.N7
M1T=Z2\]6I47R=]SW3Y0_A%/*7QPDU+9\06?+>UR+(Q:?!=II_=-\,B*B1SXA
MOGNM6LE9KY%59662;7393:35?%_'^8^(L5W"2[8IOUYQ)=)7.<^XWZYUEVK7
M.>J*YWC-?-/*BN5$5=ER(J^L_C._?Z ;OH_0F$PBMA\/2I=L81C+]NSFWWLC
M[26GL;C'?%8JM6Y[LYRE!=JA=07F2'J[^CAN^+=PT0 'IV[_ #N[7<>3G_LK
M#S]GJ^+U\-^]4X;C<:\&,YP9L/NCR>\3W%.C66MQ%ENZJE:U(TE5:G$.&:7:
MT396IZ>_T5-]M=+/>GPH^%NQ3:<I_:Y;9CWO!^(;)BS#5?-:\0X;NE'>;-<(
M7:24M?0RMFA<J<)(9-E8:JG?K%54LDU+,U\,KV+X&LV@X:1P53#22WY*]*;]
MI56<'?ESB^N+:YFQZI:?J:+QU+%P<G&+W*T%PG1G93BU?-Y)PZI)/E8[#2$3
MXVY!?+ LV>F5^%\Q;-T<#KO1)'>K6R1)76:_TND%VM;W;2NV:>K21:=STVY:
M5T$KME7JT^R2HN(P\Z,YTJD=V=.4H3C[F479KS-%W<)BJ=>E3K4I*=.I",X2
M7.,E=/T  'Q.P            2/[^8I*W7OZ/AW;E]FXKJU!H8MY^?=W!^CJ
M?-?A'@3ST/,W6S/VSS8TP9#2VS-RQ6]644SE2"BQA;Z9'21V*\/3R8ZIBND2
MT7-S5=2RR+3SJ^BFD:SGGXWP/>L,WBXX?Q':KA8K]:*J6BNMGNM+)17"WU4.
MRCX*FFF1LC')JCV/1%CFB?'-$]\,D<C^Q%HB;OU\>_I/%7G7N9MPARC;;[N6
MV2EPGFE;*58;5BI*57TMX@B3:CLN*((%CDK*+^!17!O25UI<]\E.D].LM'/*
MVHNT)X+=P>,DY863]CF_"E0[.MT[YV6<>,4U=$-;1-FJQV]C,!",<9&[J4[J
M$<0K-[R]JJO+DI\&T\SFO _<.43R;\;948JN&#,?V&JP_?[>]VU!.FW2UM.C
MW,CN%JK6)XO<;;4(B/@JZ=SFJB[,G1RH^)GX>6'P]:-6$9TY*<)14HRBTTT^
M#35TT^M-HK#7H3I3E3J0E"I"6[.$DXRB^&:=FO.  <[GR []_1Q3SIOW;@#-
MO]T[/TF&O]FK^?L?:?T6$\7W:P7""[V&ZW&R76F5KJ>Y6BNJ;;7PJUR.;T=9
M1R0U#4:YK7:=)IJUNNNA[=<F+PBCE'9?MIJ*^WFV9H62!6,2DQG2,CO;8(VK
M]9I\56IE)<)9'N\I]7?8,0U'\%KV)L(WPC'?Y_CW^D\O2.A<)BX[N)P]*LN3
MG",IKNJ-;Z_5::Y,]C1>GL9@I;V%Q-6B^+4)RC"7OH)[LO.K/FC>SR.\*@RK
MND<46/L$8LPC5:-Z:>U)38DMVVO%8EC?0U_1,_A224C=$WHU5U1/4G+?GM>2
MSB9D7BV<N$[1+*QKG0XJGJ<)] Y4UZ.>JQ#3V^@1S>"NCK)(]==EZH<P/]??
MX_3O(JNO'OZ.ST(:)C=D^C:CO2GB*'.T)J<?14C)V_6X(D?1^V?2E)*-6&'Q
M"5LYTY0GVYTYQC_V=N9URL%<K+*[$D;9L.YDX OT+F[39;-C##MSC5J(Q5<C
MZ&Y3M5J))&Y51=-'LW^4W7]L2_T7_+*3_M,/7_[_ &:?&<;^2BA?]G#$_P#R
MHV.[>U%[5+7W$HO^1TO_ &>+_P !X538W#VN/DO?8=-^E5HKY#8J6W6=O#T=
M%OKAB'%>ATG\YV/+EC2ST<?35=UMM+"CFM66IKZ2"-'.71K>DEF8S:<NYJ:Z
MKU(I\R8^YP3(G"RJF(LYLK+-+Y6S3U^/<+05DJQZ;;8*)US\;G>W7RHX(9)$
MW>3V<F!EGI&[VTM,U>U((D7VHPO8XF,^P:UG5Y+4;\2)WU[3-+8W3NM_'S:_
M1P\8OTRJSMZ#A6VZ5+>QZ.@GUSQ$I)>:-*-_VN!THLU_"$.2UAEDJ4^/I\5U
M$:JWQ;"=BNUR1S]G5J1UM12T-NF8[<G24]7,Q-=ZZHJ)Y%\H'PK:)(YJ;*[*
M^26;21D=VQM<VPP,<GVJ>.T6?I)ZIFGV=/-<*%Z?_34T--4&QX#9;HNBTZD:
MN):SM5GNPR_1IJ%_UFT[6M8U726U_2]=.-*5#"IW5Z-)N>?Z56<[9<-U1Z[\
M+>D/*?YW+E"YN^-4V*\QKI262J<[_P E\*,BPOA^.)ZHOBZQ6ML=SN<#535B
MWRZ7>5NJHD^SY*>;R<55.+G*YRKO5SEU57.UUVG*JJJJN]RJNNNX WW!8"AA
MH='0HTZ4/<PA&*\^[%;S[7F1SC])8C%3W\17JU9<I3G*3[;;SENKCDLAW[_.
MJ[UXKJH .V=(  PV  G=?T'KES8'-!8]Y2%SAN#%FPIEI1UCHKUC:II5E6J\
M6>K:NV87I95CCN=SVVNI)*I9%MUKFZ62J\9J*1]LJ>CI/25#"49UL15C2IQ]
ML\^[=7MI/E#B^H]+1>B<1C:T,/AZ4JM6>2@N76Y/@HJ_A-Y),_%>;BYN?&?*
M/QNS#>'HIK?AVV+#4XQQ?-3/?;</6Z1^C(6O79BJKW<$:]EJM;9.FFZ.>L>U
M*&CJI8^E=R3>2=@G);!-JP%@.UMMMGMC'/GF>[IKE=[E/Y==>;Q6.3I:VY5T
MJ+)+([2&*-(J.BAIJ"GI:6'(<F3DP8*R@PE;,$8"LT%FL5M;KL,^N5==4N8Q
MDUQNE6YJS5]QJ5:U9ZJ=VVY-EK=F...-/HC93L*R:Y:YUM)U=V*Z+"P=Z=&_
MC2X=+5MQG)<%FH<N=[9ZB:A4=$T5*>[5QE2*56K;*$>*HT_T(OC+)SYY62@U
MJ)V]GS_.3D$0B:0B0P #(               !!>KOU*1(+U=^I0"'5ZOF.7)
MSS/WT^=_OPC^0+*=1OJ]7S'+DYYG[Z?._P!^$?R!926-C_\ 3L1\5_Q($,;;
MO)N&^-Q^JJ'F8 "Q!5X$4]"[]R:=O'3SKLH[1$3J]2P!BU_2OD:'^OI:MZ#=
M%YD;G9\A,H.3_8L$9@8V]P\2T6(,6UU3;TLE^K^CIKI?JRNHI?&;?;:FE<DU
M-,R1$9,KF:[+T:Y%0];OJ@/DH?A,7_-?%?\ L4YIGK7VJ/6OM4CC2.S# XFO
M5Q$ZV)C.M4E4DH.GNIR=[*\&[><E;1FUW2.%P]'#0HX64*%.-.,IQJ.345:[
MM42OW)'2S^J!.2A^$Q?\U\5_[%(?5 ?)/_"8O^:^*]__ -93FF^M?:H]:^U3
MI>M%H_\ /XKTTOX#O>O;I/\ ,8/]BK_FG2R^J ^2?^$Q?\U\5[O_ *RCZH#Y
M)_X3%_S7Q7_L4YIOK7VJ/6OM4>M%H_\ /XKTTOX!Z]ND_P Q@_V*O^:=++ZH
M#Y)_X3%_S7Q7_L7U? /J@/DG_A,7_-?%?^Q3FF^M?:H]:^U1ZT6C_P _BO32
M_@'KVZ3_ #&#_8J_YITLOJ@/DG_A,7_-?%?^Q2/U0)R4/PF+_FOBO_8IS3/6
MOM4>M?:H]:+1_P"?Q7II?P#U[=)_F,'^Q5_S3I9_5 G)0_"8O^:^*_\ 8H^J
M ^2A^$Q?\U\5_P"Q3FF>M?:H]:^U1ZT6C_S^*]-+^ >O;I/\Q@_V*O\ FG2R
M^J ^2?\ A,7_ #7Q7O\ _K*/J@/DG_A,7_-?%>[_ .LIS3?6OM4>M?:H]:+1
M_P"?Q7II?P#U[=)_F,'^Q5_S3I9?5 ?)/_"8O^:^*_\ 8H^J ^2?^$Q?\U\5
M_P"Q?4<TWUK[5'K7VJ/6BT?^?Q7II?P#U[=)_F,'^Q5_S3I9?5 ?)/\ PF+_
M )KXK_V*07P@3DH)_P#1-77L_8QBOA_0QS3O6OM4>WVJ'LBT=^?Q3X>VI+O_
M *M_8/7LTG_9\'^Q5X\OZWO.OODEG3AS,3"UCQIA&N6Z8<Q%11W"TUZTU12+
M4TDBN:R;Q>LB@J8D<K%T26)JZ(BZ:*BGZR>7G,M;^2WDLO7^PRA_KS)\1ZAD
M Z2PT:.(KT8W<:5:I33?%J$W%7M;JZBRNBL5*OAL/6DDI5:-.I)1X;TXJ3MY
MV  =([X               /X7-#][.(OYBN_R?4']T?PN:'[V<1?S%=_D^H/
MMA_RE/W\?I(Z^+_)5?@Y_19QV;-^Y*7^30_V33(&/LW[DI?Y-#_9-,@76I>*
MNY?,B@=7QY>^E\[  /H?,M*_[1-_%2?U%.OMR<_N>X$]YN%_D2A.037_ &B;
M^*D_J*=?;DY_<]P)[S<+_(E"0KMC_)X'W];Z,"?=A7Y72/O,/]*H?L2?9+W[
M"<D3[)>_83D$+@BQ8 !D
MU:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^,-OR#<C:M1O*^"^%_N3-+VB>1=(?
M KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P #)D]D>8'^^IRY_B\0?(]0=+Y."'-
M!Y@?[ZG+G^+Q!\CU!TODX(5RVM^4:7Q6'UE4M-L4\EU_CE3Z$"( (L)B
M                       !^>9N_O4Q/[W[S\G5)^AGYYF[^]3$_O?O/R=4
MGTH^/'WT?G1\<1^3G[R7T6<?>H^V2_QLO]HXI%6H^V2_QLO]HXI%V:?BH_/^
M?C2]\P #F<2TK_M$W\5)_44Z_?)^_>'@?WH8;^1:(Y E?]HF_BI/ZBG7[Y/W
M[P\#^]##?R+1$)[9/$T?[[%?-0+ ;"?&TGW87_&/V  $%EB
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MJ&,>ZKW:IXB*2@^SI%:#[=SJ-[8%!J]JK^DJM77>5O[&OQYLD6JO]W-<.\F
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M#LWU2_DK!>RJV+Q.[5K\]S+P*2?5!-WMEO-D0 :,2(
M                           47IO*;N!7?P*0"915=40I.XHI61.*%-R
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M47V$Z+IZ.H'*W^Q68N\K%N3-=H#B5@
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M?R]:#4M>_)&.^"7TX&Z[.?+>COAI?55#?D3O[5)B5._M4F*EK[_G+I@ &0
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MV$":1T9B,)4=+$T:E"I')QJ1S[U;*2[8MJW,F [[]WP*#N'0
M     'XR  (/<C4555$1$55<JIHB)O55771-.WJ,-K@G?KR>7??GW,S9^Y:\
MZ:?=8B%73?Y]$XKO541$W;U555$1$WJJHB;U0]+>1+S2^=>>\M+4X6PQ-:,+
M3[$BXUQ/'46K#SJ9ZM5)[<^2)U7>VJQ5=&ZTP3T\FPYOC+9&JB;GG-[<P)E+
MDNM%B#$J?W3L?PJDR7N^T4,5AM$^BM1F',-JZIAI]AJHUU?=*FZ7&27I98)J
M"FG;0PZ7K#KY@-'QE%U%7KK)8>EG)2Y;\K.--)\;O?ZHF]ZL[.M(Z3<91INA
MAV\\36\%)<'T<,I596>5EN=<T['P-X,KR;L]<%1XJON)[5+AW*3%]N@J[7:;
M^LU+>Z_$U++31TN(+/9E8CZ"UU-J=54=PJZ]M))<UIK5)1TTL%/XPNW 46MW
MIKQ_7YN&_AU=7FK%:].Z9EC\55Q4Z4*4JC7@4U:-HI)9^V=DDY<6UR+8:MZ"
MAHW!T<)3J5*L::?AU7>3<G>5O<QWKN,<]V]KNP !Y![@              !2
MXZ\>/L[_  !6[N'LU^(J@,'Q?RT^0;EOGYA=V&LP;%'6+!M36:^TNS3XAP]6
M.31:FT71&NFA1^YM51R=)0UK&HRJIY=B-T>@ASD7,J9IY U=9=Z>BJ\<9:H]
M7TN,K/2++/;(U5=FFQ5:X5DJ;5/&U$9[IQ,EL]2B,7QNEJ)&T4?2_+2NI(JB
M*2">*.>":-\4T,T;98I8I&JR2*2-Z*R2-[55KV.:YKFJJ.313;M6==,7HR5H
M-U<.WX6'FWNJ_%TW[1\W9-/G%NS-%UMU P6EH[TUT.)2M'$TXK?:7"-19=)%
M<KYKE)(XW+51=--%1>&SHJ+NU\G3=IIO31$\G?IQ(G0%YP/P</+;,N2LQ+EA
M5Q97XPF=)45%!3TK:G!%[ED\N3QJTQ=%462LEET=[HVF1:?5TKZJSULCVR0Z
M:?+ YN_-[(RMF@S"PC74%K;.V&EQ30L=<<*URR.1L/0WFG:L%-+,]>CBI+@E
M'5O>CFQPO1$<MA= :ZX#2$8JG55.NUX5"J]R=^:C?*:YIP;R\91>167674'2
M.BY-UJ?2T+^#B:*<Z5N6];PJ<NM3LO<RES^)@/9U]>[=QW\ ;;R[?1\CS7GX
M\LC2_N_'X^<                   $NTGDIQ5SFL:WK>][D:QC4357/>Y4:
MQK45SE5$:U55$#M_KP2\_P"$<HQ;X*_8GG]OW]A'4RUBL5==*VFMMKHJVY7*
MNE93T5NMM--6U]9/(Y&LAI*2F;)/43/<J(QD;'+M*B[M-3VUY#7,"YW9OK17
M:^T2Y8X/J%CE=>,4T<R7RKI7;+NDM>&'.@K7/DC5>C=<GVR)%:BN5S'-VMU3
MD'\T_E!R?:.-<(V1USQ.^-&5^-\1+#<,2UKU8C)$AF;#%36FD>B+LT%HIZ.E
M:CG*]DLLDTLD?:Q[1L%@5*%*2Q.(5TJ=)WA%_IS2W5;FHN4ES2XDD:K;+](:
M0<:E6+PF&=GTE56G)=5.G???OFHQZFV:Y_-@^#<W"Y/MV-N4/3NMUN^MUE#E
ME35&S<:I-(Y8/V75M+)I0P/U7IK#1RK5(W9BKJFGD6:DAW.L&8.M.'[5;[)8
MK90V:SVJDAH;;:K920T-OH**GC2*"DI*2G9'#!!#&UK(XXV,:UJ(B(A_0HS3
M]"?!Z$^+SE9J[BONGM9<5I*KTF(G>*ON4HW5*G[V/NG[:3NWS99G5O5/!:+I
M='A:5I.W25YVE6JOCX4[7W5[6*M&/)7S)--/@[\"H >$;*
M       ""]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/W
MT^=_OPC^0+*2QL?_ *=B/BO^) AC;=Y-PWQN/U50\S  6(*O
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M"0KMC_)X'W];Z,"?=A7Y72/O,/\ 2J'[$GV2]^PG)$^R7OV$Y!"X(L6  9
M                                      -6KPK#[CV7GXPV_(-R-I4U
M:O"L/N/9>?C#;\@W(VK4;RO@OA?[DS2]HGD72'P*^L@:(J_1\1 BOT?$0+:K
M@BE2^_YP #)D]D>8'^^IRY_B\0?(]0=+Y."'-!Y@?[ZG+G^+Q!\CU!TODX(5
MRVM^4:7Q6'UE4M-L4\EU_CE3Z$"( (L)B
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MLM3]&:B]9."NLG>3EDKW=EDLW?)<K<$N2+2PCNI1NWNI)-N[LDEF^;=KM\V
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MLZ>'OV/*=5<IK*.:C?BX-1=.SOW[->S30J-UZR8$7DP
M                               $%*!<%%Z;P"DNY=21W$J.3<2<4U[-
MP,E#M3V%L]"Z=NT4I2)Q]H,%D]"S>GP&0=P+-Z=8!CY$+"1/,91[>KV%A+O]
M0!BIF=_B,>]#,2-^@QTK._?M ,3,TQ<K3-R-,9,WOZ ##3LU34QKVZF;D;Q,
M9*WJ%_O]!E?A&NQX0YR/UQGEK;\R;32=+?\ +:65:]T4>U/4X/NDD;;E')LK
MM/9:ZQE+=(=4DZ"-:]D36K63.-(!.'?ONW:Z:IOW*IU?L4X:H;S;KA:+I2QU
MEMNE%56^OI)->CJ:*MA?3U4#]-Z-EA>YNJ>4U?*8K7;SF4<M;DNW')K,[%67
MU>LLL-HKGS6.OE:UKKKAJM<Z:Q7%48UD?2RT:-@K$B:D3*^FJXXDZ-C7.L!L
MIT\JM&>!G+PZ3Z2BGQ=-OPXWY[LL^M*74LJT;9]6^BKT])4X^!771UVLDJL5
M[&VN3E!-763W.N1\L  F @T   =_H]:+O3L5$7J-JSP<KEL)3U-ZR.Q#6KT-
M4LV)< OG>Y6QU"(KL1X=AUU1C)U6.^6^/5K5G6\,U5\]-&FJF?W&6>9-ZP=B
M&RXJPY5NH;[8+C37.UU2;2HRJII$>UDL;7,6:GF36&I@VF]-3OEBU1'*IX6L
M>A(:0P=7#2\::O3D_:U4[P?I\%_HMFQZIZ?GHS'4,5&[C"6[5A?QJ4E::[TO
M"77)*YU6&OX+Z/BW^=.S?OZ^&A=QN/E#D9\J*SYQY;X8S!LZ-A;>J*-MTMR3
M)-)9K[3(D-XM$TB-C1SJ&M;(R*161K/2NIZKHF=/L)]3QKVE0\3AIT:DZ51.
M,Z<G"<6K;LHMQ<>U75T^:LR[^%Q5.O2IUJ34J=6$9PFGE*,DI1?9D^'+GF9:
M%YDHW&$8[KZS(Q2:[CX'V,W"XR,;S!1/,E"_> 9B-Y?QN,.Q_L+Z)P!F(W_,
M7K'?H,3&\O&/ ,JQW674;S&L=\!=,?[ #(-=H7+7:II\/86#7=17:[0 O$["
MHCNI>!;IO^8J(O;Q 3*Z+HNA.447J7@3HNFY?4#D\^'G*K7:%8MR=KM <2J!
MJ
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M)63]XENI<%=OF4KUZUE>E,?5KQ;Z&F^CH)\%265[<+U))RD^-E%/@  ;4::
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M3CNSLI)Q23X.2^4G3470%71FCX82O*$ZD*E6=Z>]NVG-N/C)/)9$P -9-Q
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MDB"1Z:+KP^C3OZ5)]GAYB8&JV-R(:;@B$09
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MFVW6?,S ]S8FUT<=707JW3.T:]6[2HRJA9M.2-BKMJC5<KOL6GSW>_!D>4G
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MS!:.AT>$H0I)^-*UZD[>[J.\I>=V)=-Y%$(@\BQ[@ !D
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M$VNGG0')YY\.PK-=H544H:A%!Q+@$J.)@
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M"(                               (;*#0B  2JU%)@ 05"(
M                           (:$0 0V4&RA$ $-!HA$ $$1.'4-"( (:$
M-E.SOP]7I)@8L"&R@V4(@R"&R@T(@ AHA$
M         $$30B ""H1  (:(-"( (:!$(@ AH@1J=U]1$&+ @J$%:BDP,@AH
MA$  AH@1J$0                                  0T"(1
M                        !#0B                             ""(
M1                                              !!4"(1
M!#0B $@                                   $@     +
M                        $--^I$  @J:D08L"&R@V4[._'XR(,@EV$&PG
M'3>3 "Y#0:$08LNH$NPG8-E"8&1<ALIV)["&PA,#%@01"(!D$$30B
M                   "&A$ $- J:\2( (:#93L(@ AH$:B=^PB "&A#93AH
MFG9Z>/MZ^TF L"&B!$(@PU?B@0V4(@&0
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M7]I11VG$G 2+C4%!%*K7:@P3
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MIGQ%)B=97TW(G: 3M[>TJ\$])*B=1.G'T RB9J:(5&)O)2JQ-P,$X
M
M
M
M
M
M
M
M
M                                              !1>F\K$KDW %!4
MU*?4J=A5*:IHOF7B B@Y"1R)IKZBX<FA;KV>P M53J+9[2]>G64'\ #'2)]!
M92MT]!DGH6CVZZH 8M[?A+"1AEGMX^TL9&Z@&'D;]!8RM,M*TLWL ,'(PL)6
MF:F88V1N@!A'MZCXFY?O(YM&>66=[P+<NCIZZ79N>&;J^-KY++B6ABF]S:Z)
M55B]$]LT]%7QMDCZ>WU=3"KD1Z.;]RRQ]982M\WF]1V<'BZE"K"M2DX5*<HR
MBUR<7>_G7@]S.KC<'3Q%&I0K04J=6$J<X-74XR5O"X<+Y6X<5F<I+,/ -WPI
M?KQAB_T<EOO=@N-5:KI1R(NU!64<KXY417-8Y\;D:DL$BL:V:)\<B*B2;OX]
M3<!\(.YNQ;M1.SVPA;M;G:J6"ES$IJ2/1]?9J6-D%#B>1C43I:FS0)'07&HT
M65;0VE5[UBM;=C3]+;:LZ>IZ1PM.O%K?MNUH+^KJ)+>B\WWQZXM,I1K;JY5T
M5C:N&G=TK[V'F^$J3;W6G97:2W9Y*TD^5FP -A-8  "8)7-145%35%145.W:
M147=Y]571.M3=?YBSG,UQ_8H\I<<5Z/QOAFE_P#)JYU,JK)BC#--$QK8)W/3
M:FO5DV5BJ%3:?66]U-4-CZ>"J?/I1']1@G&]YPS=[;B##MSJ[+?+-607"U76
MAD2.JH:RG=M0S1*YKXY$1=ILE/-')35,3Y*>IBE@FEC?K>M.KE+2>&E1FDJJ
M\*C4YPJ+->:7"2\_%(VS4[6JKHG%PKP;E3=H5J;>52F^*ZMZ*\*+=K--+QF=
M6=KO@7S:Z=6J;]-W'>I=QR'F/S9/.'63/_!$=Q1U-0XUL,=-2XSL$/UOQ:KD
M:K8KI01/<KW6>ZJQTM&]JRMAD;+0R2^,0N1WI<QW7Z?C5/@T]?'=KHE3\?@*
MN%K5*->#ISA)[R=^>>\N;B[^#E=]5[ES]':1HXNA3Q&'FJE*I%2A*/5PL^J2
M:::Y-&79)O,@R3L,)&_V=]Q=Q2:=9TSNF<BDX&2CD,$Q_!2]CD ,XQ_L+R.0
MQ$<I>,?[ #,QO\Y>1R&%CD+UC_8 9=LA<M>8ILA=,D ,FU_L+EK_ &&,8[K+
MEK_8 9!KNPK,>6#'_J*[7=@!>M7K^#Z"9'(I:I(5D5%X^T N-KM(Z=:%#73T
M=2H5$7L!E,K([U$Q1UUX^TFWIYT R[BLCE0J(Y"W1Y,#EN%P"@BDR/!P*H((
MY"(                          (*Y$ (C4IJ_L)%4 J*_L)%=J2DBO )R
M17H0WKZ"&NG#B#.7G([^O<A+M:</:052GKKPX=H#9,KB55[=WFZR35$\ZE)T
MGZP8)W.]2=A05Q!7=I1?( 3N?V%LYY*LA;N?[ "+G^PM7R$7/+1[_: 'O+1[
M] ^30L99._?K $DGG[_26;W>P.?["TDD (22F/ED[]^LC)(6$CP ]Y83/U]!
M&237K+-[UX>T IR.+5SNOO\ I]'7VH1>_P!G?OP7T*?+_*YY5V%<F<$77'&+
M:I(Z6A;XO;K>Q46NOMXFCD6AL]OB1562IJGL<Y[TTBIJ6*>KF<R&"5[>QAL/
M4K3A2I1<ISFHP45>4IOQ5;FN?I/AB<53H4YUZLU3ITH.52;:2C!9R;;LK<N/
M&RYH^-N=HYQ>DR'P))%:9*>IS%Q3#/082H)'->EN14Z*JQ+70HNV^FM:.5U)
M"Y&LK;DM-32.2G;42)SZ[[>ZVYUM9<KE55%?<+C4S5M?6U4CI:FLJZF1TT]3
M42.\ITDTCG2.UW-5RM;N1#]LY4/*5Q1FYC>^8\Q=6/J+G>*ART]*CW^(V6U1
MJYMNL=J@=HRFH+=3.2-$C:CZNH?4W"M?/<:VLGE^?RU.INJT-&89)VEB*J4J
M]2R>\VOR:;]I%MM))7DV^JU.-?M<)Z7Q;E&\,-1O##4D[)*^=:2_.363XVC9
M==P -N1HS  ,F %\R*J]2(FJJJ[D1J:HJKKINZTW(JN5$(FP1S#O-V-S(Q@W
M-+%=!TV"L"W*%]GIZJ-WBV(,8TCHZJE:K51&U-#AU_07"JB17L?7.HX9T=$V
M2"7R]-Z5IX'#5:]6UH1RB\MZ;SA!=LFLNQ-NQ[6KVA:VD,71PM#QZDK.5KJ$
M%X]1_HQBV^UY+B>_',M\WVF2V77NQ?J5K,P,>0T=SQ!TD:)46>VL8Z6TX;:O
ME.9XHR=U7<MG9Z6X3N:Y'L@@2'V=8WX25C57CKNZE7SZKNUT3?OW=9?0LU5/
M;[2H>E=)U,9B*N(JMN=26\[\EP4;<MU)1LLK)%VM"Z)HX'"T<+0BE2HQW%EF
MVLY2EURE*3DWV]A6A9N0OXVE.-OF,A$P\\]0K1-,@QI28S3YB\C8 5XF&18W
MJ]I0B:7T3>L KL;P[]]Q>,3X"BQO67;$X( 5F(736]2%-B? 7+$ *K$^ JM[
M279ZN^A51.H F;N15]1.U/A)535=$X(5 9N10KE-B=94!@
M
M
M
M
M
M
M
M
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MJ"EMJ2ZJ 5R&J%  %57D-LID%5 ";:4@2*_L&_T Y;K)]217DN[MU\PV^Q-
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MY8WV%)B%QYD]8!%O:56KHBD&IU$Z[UTZD!E*Y,U"=$(%1C>L&"H
M
M
M
M
M
M
M
M
M                                                   47(5B5R:@
M%!4U0IIO30JDCDZP<HJY1<FI35-=_7UE=W:4G;EU[>(.):.0MWM+U[?T%NJ
M&.>TM'H9.1A9R- ,6].)8R,,N]A9/;H 8:1I:/9KN,M+&6#V>T P\L9CY&_I
M,Y)&8Z6/O\P!A9H^PQ\C>M-4T^/L[^U%WF;>PQ\L867-K*SMU7O?M8M?+C=W
ML^%^&74>&'/0\V=%G/A%^+L*TC4S+P?0SRV^.)(XY,46>/:GJ<.S/=LL=61K
MM5-DFE5.CJD?2OD;3U<VNA3-%)&^2*6.2&:&22*:&9CXIH)HGK'+!+%(C9(I
M87L6.2)Z(^-[7,>B.:J)UF9&:<./SJBIU[M%54157<B*J^<U'.?@YK.2*:MS
MQR\MC702*Z;,:PT,*I)$_1NSC"@IHFZ.C54=%B&"-J/8]8KHQKHFUKDF;9MK
MFJ3AH_%2M3E?U-5D_$;SZ#/A%VWD[Y/+F03M8U%==3TGA(+I(I/%4H1SE%*S
MKI+.4H+*2XN-GQ1JB@(NJ(J:*BIJFG#1=Z*GI14W\%X@GM_[/KZ[KDUV<BMO
MR/J?S]W5SS  , #T\._M]&GH5 !^/]A^/].[[<SU)YL#G,+_ ,G[%&S4NJ[O
MEY?9&QXGP[MN<M,]SFL;B*QQO<C8;M2Z(D\#']'<J5\M/(B5'BE13] #*?-C
M#V-\.VG%F%;I37G#]\I6UEMN-(]'Q31JKF/8N_6.HIYF24U732(V>FJ8I()F
M,D8Y$Y6R=_A^9=-."[M471#U0YL'G/,0<G[$7BM2VKO67%[K(GXEP[$]'3TD
MC]F.6_6)CG] RZ00M1)J1[XHKI%!%3RR02MAG;&&OFHBQT98K"Q2Q27APX+$
M)<+\E47M9<'SS)@V;[1Y:/G'!XV4I8-OV.I)[WJ:^32Y]"^,X<4\UEPZ(;7E
MRQ_ZS\KRHS9P[C?#]KQ3A2ZTMZL%YIF5=ON%(_:CFB>B+LN:NDD$\2JK*BFG
M;'/3RHL4L3'HY$_2VO\ 85RJTI0E*,TXN+<6I*SWEQC;)W7H9:6G4C.,9PDI
M1DE*+BTTXOQ7=9>$LU\IEHI5+YK^PPK)."=]2Z9)W[]9\SF9R.3SE_'*8)DA
M>1R]_H ,ZV3L+EC_ -1AHY._?K+UC^H R[)"\8_SF%8_]9<LET ,TU_G+ADA
MB8Y=>)<M> 95KRNV3U?$8MK_ %H7#7^P R39.Z%9KO88UK^PK-?Z@#((XJH_
MM+!']I61X!?MD_41U3SHOF+-'(3HY0"Z1?/\9/M>DM4>54?Z% *Z.["9'J6V
M[]7Z29/-[% +G:1>*$-$ZE*.TJ<4&V@%ROLKV_"$U*2/3M)D?YP"IM+V$-OS
M$-M1MJ#E==7RD4?YB.VA)M^9!M>9/8!==7RD^VA#;)=KS)[!M>9/8!==7RDW
M2>8CM+V$NWZ!MJ!==7RDV\ALKV_"2*Y>TE5_G!B_XR^XJ*G:I!%3L^$I[:$-
MI>I +_BR*VVI(KBGQZT0E70&"IM)Z2#M?0A)M:=A2=)ZP"MJB>=21TG="BKE
M)%5 "JK^PI*[M*;G]A1<\ K.?V%%SRB]_P"HHN?Z@"LYY;N?^HIN>4'2( 5'
MR?J+9\A3?(6SI>_6 5'O+1\A3?(6KI% )Y'_ *"V<_M)'R:%E)* 59)>_P!!
M8OEU*4DG?M+5\@!,]_:8^2022:ZZ>WJ]9:2/[J 'N]I:O>'/,/=[O2T--45M
M;4PTE%1PR5-75U,K(:>FIH6+)-//*]6MCAB8U722.5&,:BJY43>946\HIMO@
MDKOT<^NQAR2S;LEQ>2MYWD372Z4U'35%965$%)1TD$U55U=3*R"FI:6G8LM1
M4U,\KFQ04\$372S2R.:R.-KGO5&HJFCSSPW.ZSYMU<^767E7/2Y:6^I<ESND
M+I8*C'5=$JM1ST\AS,,4BLVJ.E5K5N<SUJZK;@;21LN>> YWZHS7JJ[+C+>L
MJ*7+2CGZ"[7:-705..JJF?J[91%;+#AF&9JK2P2(DET6-E95,CA='2IK_;M-
M$7=YNM//\:]J\=2P&H&H*PZAC<9&];)T:,E^23S4ZBX=)U1MX'%^%E&M&TK:
M3ZI=3 :/G_-XO=KUXNSKM<84[?U-\G*_AM67@)N0 $O)$(7_ !W@ &3   !!
M5\^G?XNTVX^8.YL9*:&ASWQW;T2JJ&.DRWM%7&BNIZ*1%8N,)XGMUCFK6*^*
MQM^SCI%?7HK/&8=?-_F9^; J<YL418TQ=0OCRNPQ5(^9LS4;^R^^0.8^"QTS
M/*Z2TTV^:^5:Z1O1(;=!TKZFI=2[Z-%1QP1100QLA@ACCBBAC:UD44<;&QLC
MCC:B,8QC&M8UK41J-:B::[UAC:7KFH)Z/PTKS:MB*D6K03XTD_=/V_-1\'BV
ME/&RC41U)1TGBX6IJ5\+3E'\I**SJM/VL7^3R:DUO+))NYC9IO7OU_3\VG!+
MZ&->/L]!(QFJZ=7?]1D(V_I(&+(?C[O03QM^ R$3"E$PR,48!5C9H7C&^TD8
MW]!?1Q]^T J0L+^-I38WJZD+V- ">)FF\NV)UDC6^PNV-_0 5&,_27+4)&MT
M+AC?A )T3V(5&IVD$XZ=2%9J:J 1X)Z2=J:(2\5\R%0')NQ%$U*Z$C$ZR<'$
M
M
M
M
M
M
M
M
M
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M:>PCJWL+1%([2@%WJG4NGJ(;7G^#]!;;2DVWY@"Y_P#>3X"&_M0M^D\PZ3S
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MI,U.L&5UDR)H3M3524K-3<#!,          0U (@               AJ1
M               !#4 B   "&I$7                      !#4B  -0
M!J  "&H!$                :@ #4
M                                               #4  $-2(  &H
M!#4B              !J     "&H!$             :@     AJ 1
M                               &H  U               (:@$00U(@
M              AJ 1    &H                    (:@$00U0B  "&H!$
M$-2(
M
M
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MX^U]_P",[<D51UWVB8G2TG3@Y4,'%^!1CDZG+?KN]I99QAXL6^;28 !O9'0
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M.NX CL]7M*B)U$&IH5.&[K4&5;F1TUW=2%0@U-"9$U ;^0F8G652")HA$&
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M+&$E9O)9R=^LE+9=KICM*U<9#%RIR5"%&4.CI*GG4<U)/-MVW4?48 (L)C
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M)::**-8-1<?H^]2=-5:"O[-1O**7Z<7:</UENWX29,VK.T;1VD[0A4="N_\
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MV(HTI[M%1ENSJ1B[.^63.FFUJ>TJDBKN]&A%O KNOQ\I: F !D
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MK#4+]%2FHPWI.3LX1EQ?'-LL=J9I:KCM&83%UW%U:T)2GNQW8W52<5:/+)(
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M
M
M
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M:SY#Q7O\/]?3-54 %I2GY2G^UR?Y#_ZJG6RY$/W',K?>#A3Y$HSDFS_:Y/\
M(?\ U5.MER(?N.96^\'"GR)1D.;9?R& ^$K?0ID\["OR^DO>4/IU3ZC ! 18
M\         $%7@1*<B]^_9Q]6]4,/\?C\=HN4U7ANZ^M=WM^+OIXO<ZQSRF"
M^3I;WV.WI2XJS3N%(V>U83CJ-*>U4\RN9#=\35$*/?043MF5U'2MTK;BL3T@
M:R%KYVX'GG>=OMO)VPQ%8,.)2W;-;%='4)8;=(]74N'+>K70OQ1>FL15Z*&5
M>CM%M562W6M8N]E!2UU1%SG<:XVO.)+O<L08AN=;>KY>:R6X76[7*HDJJZOK
M)W(]\]1-(JN<J;+&0QII%301Q4U.R.GBCC;*>H>H,L:UB\7O1PJ=Z=+.+Q%G
M9YI75-6:<DTY/*-EF0[M&VD+1[E@L&XSQF[[)5R:P^\KK*[O4::<4TU%.[S5
MC]AY3G*OS SCQ/4XNS%Q)6XANT[GI31S/=%:[/2N>][+=8K4UWBMJH(.D<V.
M&G8DDFU)-5RU-5--42?._P"CUZ(B>;L]&_AU@%B</0IT8QA2A&G""M&$(J,8
MKJBEDDO]2K^(Q%2M.52M4G4G-[TISDYRE)\7)R=V !V>G3OUIYM$7:71-W$^
MMCX]OX?< ?U6"<"WW$U8ZW8:L=YQ'<6HU74&'[57WJL:UZJC7.I+93UD[479
M5&*K-'[M-%VD3[MPAS1?*9OL;)K=DOC/H7['UVMI[?;$:DBJC'.CN5PHYVHF
MR[;3H7.:B>4C55J.Z6)TEAJ/Y;$4*794JTX/T.2^_L._A=%8JO\ D,-7K+KI
M4IU/HQ9YT ]/KUS+O*EH6+))DQB>=B1K(YU)56*H6-&HFJ.C9=ND>[5=S8V*
MJHFJ)OT3XLS:Y->8F TDDQK@3%^%8(WHQU9?,/W2@MNVJM1&LNDU*RVRJJNT
MTCJW*CM&[UW+\L-IG"5LJ6)H5'PM"K!N_59,^F*T+C*"O6PN(IK].A47GNXV
MMVW/Q0$&N14U145.U%U3XD(GI?A<,_QVV/+;MQOZ&_FN#)6>\5ENJZ:OMU75
MVZX44T=115]OJ9Z*NHZB-VU'/25=+)#44T\;M%9-#)',B_PW:-TQH.+2=TU=
M-6<7PSZU;/YCG";34HNUN$X\;KJ>5K=?+D;H/-%>$..N51:LM>4#<H(JN5L-
MOL&9]1T=-3UDZ*R&EH<9*C8H(*NHU2-F(8VQTLTZ,]U&P23/K';@E/4,F8V2
M-S9(Y&M?%(QS7L>QR(YCV/8JM<Q[516N:JM<W147LXW6RBZHJ(K5W*B\%;IH
MJ+N=JFSKNTWIJBJB*IMV\PEST4]KJ[/D5FS=GS6RLE@MN7F+;E4;3K?5RN2.
MEPG>:N9RN?25;W,BL-?._6GG7W-F<L<E$I!VOFSR,8SQN A91\*OAX*RZW4I
M)<++.5-96ON^Y+![.=ILI2A@=)5+[UHT,5.7!OP52K-YO>>4)N[3LI<5)[L2
M?.1**+P\^_U*3(OG])"/FY?A=Y8)?[]A4 !DR    "1573=H :J'A8?W+,J?
MQEU'Y(7\T83?[\)?Y/\ CC,++?+6WX&PI?,65UNS GKZZDL5#)6STE$N%[U2
MI53,9HK(5J9X84<NNLDC6IVIIQ?M:?*#_ SF%_0%06.V9Z1H4]%0C4K4H2Z:
ML]V52$79R364FG\A57:QHW$5=,5)4\/6J1Z&BMZ%.<HW46GG%-<NL^(0?;W[
M6GR@_P #.87] 5 _:T^4'^!G,+^@)R0/Y8PO]HH?OJ?\1&G\BXS^R8C]S4_A
M/B$'V]^UI\H/\#.87] 5 _:T^4'^!G,+^@*@?RQA/[30_?4OXA_(N,_LF)_<
M5/X3XA!]5YB<AG.3"-FKL1XHRQQG8+#;&PON-WNEGFIJ"B9454%%"^HG<J-C
M22JJ:>!BKKK+-&FY%54^55[]^KL5-5T7=J=O#XJE5CO4JD*D;V;ISC-)V3LW
M%M)V:R.GB,+5HRW*M*I2EN[R52$H-Q;:NE))\4R  ^#SKP0^Y\/QYLE]H!^^
M9.\E?,K,*FK:W N!L2XLH[;4,HZ^HL=NDK8Z6JDB;.R"=S-$CE6%[)-C>NRY
MJZZ'[%^UI\H/\#.87] 5!T*FE,-"3C*O1C)<8RJ0C)/J:DTUEGW'?I:*Q4XJ
M4,-7G%^+*-*<HR2RNG%--7/B$'V]^UI\H/\  SF%_0$X_:T^4'^!G,+^@*@X
M?RQA?[10_?4_XCZ?R+C/[)B/W-3^$^(0?;W[6GR@_P #.87] 3D?VM+E!_@9
MS"_H"H'\L87^T4/WU+^(?R+C/[)B?W%3^$]D?!8/NW8V_%U-\N6TWWF_1\2&
ME5X-]R1\S\ 9OXNNF-\ XIPK;JK <U%35M[MDM%33U7NQ;Y?%XY7^2LO1L>_
M8X[+'*B:(INJM7S:%;MI=>G4TM5G3G"I#HJ"4H2C*+:I)-)Q;3:?'J+6;)\/
M4I:&HPJPG3FJM>\*D7"272RLW&235UFLN!, #0B20     #^7QM_Q-=_YKK_
M /59CCC6?]R4O\G@_LFG8YQM_P 37?\ FNO_ -5F..-9_P!R4O\ )X/[)I.6
MQKAI'OPGS8DKSMW_ /IG?B?\$R( )N^Q7]!7T _2\I\FL68[NJV+!F';MBB]
M-HY[BMLLU(^LK$H:62"*HJEA8J*D$,E33QOD7<UT[$T550^D_P!K3Y0?X&<P
MOZ!G.IB,?0I2W:E:E"5D]V52$79WL[.2?)G<P^CL16COTJ%:I"[6]"E.4;KB
MKJ+5SXA!]O?M:?*#_ SF%_0$X_:T^4'^!G,+^@*@^'\L87^T4/WU/^(^_P#(
MN,_LF(_<U/X3XA!]O?M:?*#_  ,YA?T!4$?VM/E!_@9S"_H"H'\L87^T4/WU
M/^(?R+C/[)B/W-3^$^( ?;W[6GR@_P #.87] 5 _:T^4'^!G,+^@*@?RQA?[
M10_?4_XA_(N,_LF(_<U/X3XA/7?F&_OLLH_Y7B?\B\0GS-^UI\H/\#.87] 3
MGJ)S+W(:SDPCRF<L,0XHRQQE8+%;JK$3J^[72SS4U#2-GPG?:6%T\[EV8TEJ
M9X8&:IY4DK&\%4\;6+2N%E@,;%8BBV\+722JTVV^CE9)*3;;>2[3WM5M$8N.
MDL!*6%Q"C'&8=MNE-))58MMMQ222SS9T*NI?5\2$Z?3\931=4[?@^#OIH5$*
MDIY_C\<RZ]R( ,@      $'$BKW^,_BLRLQK+A&P7?$^([C36BPV*WU-SNMQ
MJY$C@HZ*DC=+-*]R[U79399&U'22R.;%&UTCVM7*BY-1BFY2:48KBVW9)+G=
MY'"I4C"+E)J,8IRDWPBEFV^62S/YS._/'"F7&&+KC+&U\H,/8<LM.M17W.X3
M-AB9JY&0T\*+]<JJVKF<RGHJ*G;)55E3)'3T\4DKVM70 YU+GV,;YX55PPG@
M6>XX)RJ:Y8%I()5I<0XOB:O[IO\ 5P/Z2CMLKO+@L-)*C.C1K[G/4RN2FI/G
M/G8^=3Q'RD\7?6O&[1EKA^ME=@[#$C]E\KVMDIVXEO4;-&27JMIY)>AB7;2T
M4=1)0P2/?)533^2W L1J/L\IX6$,5C8QJXIVE"C**<*'8T\G465Y--1?"[5R
MKVT#:95QE2>$P,Y4L'%N,ZL)6J8F]UE)9PI/.T5G-*\FDTB"-1-S41$3<B-1
M&HB=B-:B-TW;D5%V45=G95=4B 2OW9]2Y_+;AUWSY)$-M\W9=BX+JZWGSX]X
M )7O1J*KE1J(FJN<Y$1$W:JJJBIHFY%UXJJ)JU5VD=^77=K+Y;&4GPL_O[4G
M9LF!^M9;9!8\QDQLN$<$8PQ1 ]6HVJL&&;S=Z1-I=E.DK*&DEHXD5V[;DJ&L
M3MW:K]=6+FCN4U<FM?19*8VD:YG2(L]/;:+5FNSO;77*E<U5=HFRJ(]&^5L'
M0Q&E,-2OTF(HT[<=^K3C;]J2/1P^A\75_)X:O._#<I5)7[K19YU@]"<1<TYR
ME;2U[J_)7'$38]E7K!1T5>J(]$5JHVWU]4K]=';:,558O%4UT3X]S$R<QA@_
M3]EV$<4X51SD8U^),/7>Q1R/<NRQL4MSI*:*17N161K$^5)'*FPCE5&+G#Z3
MP]6W1UZ-2_#<JPE?NW9,XXC1.*I?E<-7IVX[]*<;<L[Q7/(_. $<B[VJBHO9
MPWHBIIO775JH[77?KN1$T!W;JU[_ &7[NOYCS^QY?9WVO8'N[X//R3+]F)GS
M0XFHJVZVG#F6<$-]Q%<[56U=M?55%:L\%EPW)5T,U/)+'>*BFJZFJI%D?3S6
M^V5:5#%9(V.;PNMUMJ*RIIJ*C@DJJRMJ:>CHZ6%JOEJ:JJF9!34T+$17/EGG
MD9#&U-ZR.:G6=0[FG.0G2<G_ ">L>$Y(XG8HNNF(<;5S&LZ2JQ%<88>FIUD3
M57P6FGC@M5&FTYK8J7::KG2.>[0-H^L"P. E27Y?%[U&FKIK<LNEDUG>T96C
M^DU;@R2]ENK4L?I&G7DFJ&":KSE9K>FFU2@I9<9)N5L]V+7//TPC;HJKW]GG
M75>Z%8D:J$Y5R'#[>;[7VLM[^+=7.WW  ',    E7J[]:$Q*O5WZT -5OPL#
M[DF5OXT7?D;B8T53>J\+ ^Y)E;^-%WY&XF-%4L[LM\CT?A:_TRH^V#RW5^ P
M_P! $4Z^_6A BG7WZT)#(O7%=YTB?!ROO1\N_P">,Q_^\G%A[C'ASX.5]Z/E
MW_/&8_\ WDXL/<8IUK+Y1QWQO$?6S+SZI>3,!\5H_00 !XAL(      /)GGR
M/O5\W?>]%\I4)ZS'DSSY'WJ^;OO>B^4J$]?0'].P?QFA]9$\367R?C?BU;ZN
M1S%0 7*?%E$5P0-U_P $P_>OG7[Y<(_(]T-* W7_  3#]Z^=?OEPC\CW0CW:
M?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP                           0
M7Z/C(D%^CXP#RKY[3[UG.3WK2?ZU2G,%7BIT^N>T^]9SD]ZTG^M4IS!5XJ6'
MV0?T'$_&?\.)6+;AY0PGQ7_%F0 !+2^_YB%'P_:^B;N/@FG[S<YO?7ACY#JS
M;?-2#P33]YN<WOKPQ\AU9MOE3-?/*^-^$A]53+G;-/(>C_@I?6U  #43>@
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M;$? 5?JY')QI_M<?^0W^JA6*-/\ :X_\AO\ 50K%TEP104&XCX);^[<\OXG
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MYYO/F\_LX=R+I15E;JY=0 !R,@
M
M
M                                        %%R:$I75"BJ: %'@NB\"
M#DT*JIJ2=6B^H H*FG5N4I.9^A2X5.HIKV+PZ@"S5.HMWL+Y[?:4'-ZE ,<]
MGP%J]NXR;V%J]B@&*>SJ+5[#*OCU+1[/T &'D863FZ&;D9W\Q8R1]_I!E&)?
M'N+"6(S#V:%M)&F@,&">PLY(47CU>U#-21%D^, PCH].Q?G3NA_'XVP1:,1V
MFX6&_P!LH+S9+M2RT-RM5SIHJR@KJ2H:K)J>IIIF/BDC<U555<U%8NDD;V2-
M:]OZ!)'KU?2GH+!\6GH.4)N+4HNTDTTUEFLT\K.Z?.YQG",DXR2E&2M*,LTT
M\FK/*S7%&B[SJ7,I7K*R2MQUEC1UV(<N'.DGN5JC62MO>"FNUDZ21NLE7=,/
MMTV&UK$GK+<Q4]T]8?[\CU_6JBHBHNJ*FNJ;T5/,=9:HIF2->Q[6OCD8YCV/
M1KF.8Y-E['M5-'L>U51S7[2+HB;*M<K35FYTGF'H+P^[9B9(4D=)=I.EKKWE
MW'T4-NN<J-5]16845RQLM]PJ--N6TR2)054ZN?2^*S33]-.FI6TA3Z/":0E:
M7"GB7XLK9)579;KY.?#KMF5WU_V4[CGC=&0>ZO"J86/&%\VZ"OG#BW3LW=^#
ME9&H$"^NEJJJ"JJJ&NIJBAK:.>6EK**L@EIJNDJH'K'/3U5/.UDT$\+T<V2&
M5C9(W(J/:BECW[^K?ZR:4[I-6DGFG%WR?!OL?)JZ?(@.4&N*LTVFN::ZURMS
M7%,  R<0   %WIHN]."HO8 &NQ=O;]QE?(^*?!]7:K=CS?&ZR/5WD&\[YFED
MB^ELZ5DN,L",D:C\)7ZMGE6VP.<O2_L:N4[I9K,FBND9;V[=J=4*^1:.GDFE
MJG[E'(NYS?*C/*F9'A6^);\2QQ)+7X,OJ)08@I?)17OI8GHE/>:1JJU/'K7+
M4PM5494I2SJD#N;T7]JNM70U5/6T-54T-;22-FI:VBGEI:NFF:ODR4U53NCG
MIY4ZI(7QO;O1K_*<BZ'K)L^P6D+S2]3XAW?34UX[_P")%64N^.Z^WD2/JIM.
MQ^C%&C.7JG"\Z59WE'MIU&FX^]:E'EEQ.K^U_J*S7_K-'_D5>$&9AX)6AL>:
M5)_=#PNQ6Q.O,:LI<;6R#145[:A[F6Z_Q1JB*E+<8Z2L1JN5MW>D;*9^V+R6
M.7!EEG)0>.8!Q3176ICB;+6V.9ZT=_MR*FKO'+14]'6(QBIY=1&R6F:BL7I&
M]*UJ0-K!J;CM'2;JTG.CRKT_"I^>WA1\Z7VECM6M>M':3BNAK='6MGAZW@5O
MU8\)K]*+:^0^P^D[>_J*[7]GZ#%-=ZE_6GLU1?85D?VFJV_'^O W-JW5GPS7
M RK9NW<7#9OUF';-IUE5'IVZ&#!FV2%9)?289CU[2X;, 9ALNA79,89LOG]A
M6;)ZP#+MF[\"NDQA4E*K9>_  S"2%5)//[3#I-W_ %%1LW?] !E^D]!%)#&)
M,56S=^(!D4D\Y-TOH,=TOG^ CTW?> 9)LO?@3=*O=3'))W0FZ3T@%_TJ]U'3
M:?K+'I/.OPCI//\ & 7W3:_K'2KW4L>D\_QCI//\8!?=*O=2'2>8QZR#I4 +
MWIN^\E67NA9=+Z"59N_ZP"\Z12&V6/3Z$BS=]X!?K)YRBLA9+-WX%)9@"_68
MHK/Y_C+!TW?]!368 O73=_T%%TJ]19NE[\2BZ5.WOZP"\?(472>HLW3ENYZ]
M_P! !>.F\Q;NF\_PEHLB>GOU%-TH!<*_NI;ND]105_847/\ 6O'TIVIVIKN3
M3=KNX[C*79?NM\SM\@NN;2\ZOZ.HK+(I163UGX/G_P IK F5UG=?<>XGM>&Z
M#1WBZ5U0U*RO>W72*VV]BK67"7:V6;--#(Q'JULCF;2*:KW+6\(NQ%=G5=AR
M3M#,-VKRH5QM?H4JL05D:H[5]GL[O[RL['(K'1U=>M=7.:Y&I16R:-)I-DT%
MJGC=(/V"DU3X2K3\&G'SNV]+]&-W?TFJ:Q:YZ/T9'^<UO9+7C0IVE6EGE:"=
MXI^ZENQ2YFR[RL>71EEDK:O=/'^)::W3RM<MML-(UUQQ'>9&HGUNVV:DVZM[
M$5S$GK:EM/;:-'L?65<#7L<[3XY>G/H9C9II78>P0^MRXP1/MPR,MU:YF*KU
M3*BM='<KU1NC=;Z:9%5M1;[6^))HEZ&JJIX'S0/\7<:8WO.)+G57K$%UN-[N
M]:Y7U=SNE7-75L^]51KYYWN=L-57+&QJ,CC15V(V(NA_+$ZZL[-\'@=RI6?J
MK$1M)2J9PB^N--KEPO+/FDGF5UUKVJX_2"G2H?S3"RRW:;M5E'W-2I&UK\7&
M#_6:NF3K[5555>M55=5557>JN7>JKO5=Z[Q^A/8FB>Q$1$\P!(NZK6SMU7R]
M"1%CZ[1OUVSOUW?/M8 !D     @YR-17.79:B*JN5=E$33_"7<WJ;M+N1%5%
MXA-9\<EQMDGU-]76QV<._FNSK(GJ'S;_ #6V-.4!>65+8JG#V7=OF1M\QC/"
MC6SN:YJNM.'8IMGW4NCTUZ66%LM%;(M9:Z1LKZ6FJ?M_FO\ F-KQF0EMQUFQ
M#<,.8#D='5V[#>CZ#$&+(&JR2)]3M-2HLMBJDW22;++I60.=XFZD:Z.I3=/P
M3@BTX=M5!8[#;J.T6>V4T5)06V@@CIJ.CIXD1K(H88F,:U&MW:Z*KW:OD>YV
MBD2ZZ;18893PN"DIXFSC.M'.%%VSW)9QG/NO&/.[R)JU#V65,6X8O2,)4L-=
M2IT)95:ZXK?5]ZG3:Z_"DN&ZLS\OY-W)IP;E1A6@P=@>S4]HL]$CGOZ-NW67
M&LE<KJBY7:N<WI[A<*AZ^543R2(D21TU-T5)#%!'^_M9V)YD[]FY/8G83,9K
MPW%_'%HGQ^<K]7KSJ3E4G)SG)N4IS\*3D^+<GG=]I9C#X>%*$84XQA""W80@
ME&$4E9)0225EU<>))%%IUZ]J_,7C&DS&?H+V.,^1]B6*(R$<9&.(N6,]@ :P
MNXX^ CC[_.7\;- !&PO8V$K&>TO&1@$S&_H+EC2#&?H+EC "+&%RB:$&IH5V
M- (L;[2LG9[2"=G65$30 BB=1.J]2>T<.'$G:FB Y6_V(HFA.U-2"(5FIH@.
M)$               U>_"I/N,8'_ !@0_(]<;0AJ]^%2?<8P/^,"'Y'KC:=2
M?*V ^,0^TTW:%Y%TC\6G]AH9@ MOU=R^9%*GR_'-@Z?/,B+_ .BIDOY\,U2?
M_7^\',&.GQS(?WJ62WO:JOEZ\$1;8/Z'ANKU5P[>AJ?<B:]AO]/QGQ1?74CU
M4U\_Q?2.^FXJ KW8LX0(*U"8"P/Q3//D\8'S,L=3AG'V%K+BNQU;522BO-##
M5-BDV%1E31S.:E1;ZZ#:VJ6OH9J>MII/KE-/%(U')SUN>AYI:HY..)+=?,,N
MKKGE;BVHJ(+16U2]-4X;O4375#L-72I3[:E12I+56:M>W:K(*6N@ETGHDDFZ
M2AY><\IDO28YY-F:ELJ8$FGM^'9L16MZMVG4]UP_(VYT4[-&N<BL= J/V-E7
MQ*]CE1KE1=UU)UFKX#&4(J;>'J5(TZM)MN&[.2CO1C>RE&]\N*5GD:!K_JCA
M](8&O/HHK%4:<ZE&K&*4]Z$7+<DU9RC*UK-Y/-)LY>0)6.U1%[41?;O)BU:^
M?\/Y;HINW^.O\*P-_+P6[-2HN^06(L,U,KY$P7F+>:2W1JYRMI[3?K=:L0-C
MC14T8C[Y6W^=S&*J*^=SU:BR+M:!INZ^";1.3!&<DFR[87&&&VH_1=E7,L50
MKV([@KFMD8KD1=6H]BJB(Y-8\VHTHRT14;XPK49Q]\Y*G?\ 8G)6).V0U91T
MW1BF[5*.(C+J<%3E/=:ZXSIP=_-S9MM(1((1*QEN0        "5W5Z4-%OPK
MS[J65'O"O'Y1&]([J]*&BWX5Y]U+*CWA7C\HC>]FWEC#>]K_ %%0C?:SY#Q7
MO\/]?3-54 %I2GY2G^UR?Y#_ .JIULN1#]QS*WW@X4^1*,Y)L_VN3_(?_54Z
MV7(A^XYE;[P<*?(E&0YME_(8#X2M]"F3SL*_+Z2]Y0^G5/J, $!%CP
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M4)=GSK[1L^=?:3 6[?F^X$NSYU]I#9\Z^W]!.!;M^;[@2[/G7V_H)53Y^)4
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M?OEPC\CW0CW:?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP
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MYB=)XE8?#1O:W25'XE&+\:4W]%*[D^'-KR=YO;F0\X,^DI;ZZC_8'E],J/\
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M5J;]2JXJ,I12M3A:[M&"X9YMN7,E3C\/K12< U8W,
M
M
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MJ<7G"2>3BT5;TQH;%8"LZ&*HRHU%=V?BRC?*4)\))]:_T40 >B>8[<@  8
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MVJKY>O!S!SI\<R']ZEDM[VJKY>O!$6V#^AX7XS_A5":]AO\ 3\;\47UU(]6
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M^VG^2*OPM#Z9).R3RWAO@:_T)&WB "L!;\
M $%^CXR)!?H^, \J^>T^]9SD]ZTG^M4IS!5XJ=/KGM/O6<Y/>M)_K5*<P5>*
MEA]D']!Q/QG_  XE8MN'E#"?%?\ %F0 !+2^_P"8A1\/VOHF[CX)I^\W.;WU
MX8^0ZLVWS4@\$T_>;G-[Z\,?(=6;;Y4S7SROC?A(?54RYVS3R'H_X*7UM0
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M15;$2MX6]*\H0[%3C+=MU[SYDFG G -.2-^
M
M
M
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M.U4Z*K](Z.E8UF(XH6(J*^VPLKY&L1S;=*][T;/VK&TK"XS<I8FV%Q#LK/\
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MW_6[\F;<;8IJ=>"=_<[S;]_UN_)FW&V*5.U[\K8WX2/U<"Y^S7R)@/@Y_6S
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M:-;2VCZ<E=/$TW;D]SP\^SP?/P-_EJ=_0I,2\-WI)BH1=\  R
M           2KU=^M"8E7J[]: &JWX6!]R3*W\:+OR-Q,:*IO5>%@?<DRM_&
MB[\C<3&BJ6=V6^1Z/PM?Z94?;!Y;J_ 8?Z (HO?OQ]9 $AD7GJCR7>>8SWR=
MP3:\OL"WJQ46&;-/=:BAIJW#U-7U+);S=:V]5RR54DS'R(^OKZE\:*U.CC<V
M--4;JOT#]4:\J7_&7"_^:5'^<GA:#P:VJ^CJDY3G@L/*<Y.4I.G%N4F[MM\V
MWFWUFQT-;]*4H1IT\=B80A%1A&-1I1BE9)+J2/=+ZHUY4O\ C+A?_-*C_.1]
M4:\J7_&7"_\ FE1_G!X6@^?_ (1T9_8<-^ZB?7_QKI;_ -PQ7[V1[I?5&O*E
M_P 9<+_YI4?YP/JC7E2_XRX7_P TJ/\ .#PM _\ ".C/[#AOW41_XUTM_P"X
M8K][(]TOJC7E2_XRX7_S2H_S@?5&O*E_QEPO_FE1_G!X6@?^$=&?V'#?NHC_
M ,:Z6_\ <,5^]D>Z7U1KRI?\9<+_ .:5'^<'XSRA.>YY0.:&#[W@3%]]L%5A
MW$-,VDND%)ANFHJB6!LL<R-BJ63N?$NW&SRD:NY%30\DP<Z6JVCH2C.&"P\9
MPDI1DJ<4XRB[II]:9\ZNN&E*D)4YX_$RA-.,HNHVI1:LT^QIV'?V)HGQ  ]\
MUL&Z_P""8?O7SK]\N$?D>Z&E ;K_ ()A^]?.OWRX1^1[H1]M/\D5?A:'TR2=
MDGEO#? U_H2-O$ %8"WX                           (+]'QD2"_1\8!
MY5\]I]ZSG)[UI/\ 6J4Y@J\5.GUSVGWK.<GO6D_UJE.8*O%2P^R#^@XGXS_A
MQ*Q;</*&$^*_XLR  ):7W_,0H^'[7T3=Q\$T_>;G-[Z\,?(=6;;YJ0>":?O-
MSF]]>&/D.K-M\J9KYY7QOPD/JJ9<[9IY#T?\%+ZVH  :B;T         >(OA
M%GWH>9O\Y9;?]Z6"SFU+U=^M3I*^$6?>AYF_SEEM_P!Z6"SFU+U=^M2Q6R+R
M?7^-R^JI%6MM?E.C\5A].9  $KOBR'#H->#!Z?\ R<*O<GW0\3Z;DX]';N_H
MW'\OS[/,Y-S:M59FKEK:X4S0LM'TMYM-,U(5QW9Z&'9Z)B,8J38GH:>-K;8^
M96.KZ>-MLDF1S*1$_J?!@/O<:O\ &%B?^SMQL8O3=NW;^Q.M-/U>?3J*L::T
MQ7P.G,7B*$MV<,3.ZN]V<<KPFEQC+@_2K.Q<+0.@Z&D=7<%AL1'>A/"0L_;0
MG9J-2#?"4;MI^9W3:.-U54TD$LL$T4D,T$LD$T,T;HIX9H7K'-#/$_22*:*1
MKHY8I&,?&]JM<U%12@;I7/\ /,RON:73/?*:T.?<X8I*W,?"=MIW/DN<,36*
M_%MFI(DT\>I8&2/O]%$S6MIV-N$#$JXJE*K2T:Y%1'-5%:J:M5.M/:N_V>=$
M75$L/JWK%0TEAHUZ+S5E5A[:E4YP?7^C+VRSXW16+6G5G$:*Q4\/6C=-N5*K
M[6K3]K."Y<;2CQBU;ANMQ/IOD@\K/%^26/[/F'@JJ2GNULVZ>LHY7R-H+Y9J
ME8_'['=6,5>FH:Q(HI$VVR+2UM/25\+4J:6)R?,@/9Q-"-:G.E4BIPJ1<)0:
MNI*637HN>#AL5.C4A6IRE"I3DIPG%V<91:::?)WMW^+P9U>^0;RYL&\H# %N
MQUA"H5BN5*._V*I?%[K8:OL4;75EHN<$3Y&L<W:2:CJ6O=!<**6"LIGNBE:I
M]I(IRJN;MYPC&')TQY28LPY)+766L?#28OPL^5K*+$EG2366-O2?6Z:ZTJ.=
M/::].C?%,U8IU?1RSM7IM<FCE(X2S:P99<>8)ND5UL-[IDEA>U=*BCJF:,K+
M;7PJNW2W*WU"/IJVFD1'1S1NTVF*U[JNZ[:GST96<J:<\'5;Z&?.'72J-<)+
MVO6NU,MYJ!KS3TMAU"JU#&T8I5J:R51++IJ:OG'W?N)9<&C]\3K/CGG#/N&9
ML^\'$OR;.?8S5/CGG#/N&9L^\'$OR;.:IHU_SC#_  U+Z<3=])O^;8CX"K]7
M(Y.-/]KC_P AO]5"L4:?[7'_ )#?ZJ%8NDN"*"@W$?!+?W;GE_$X"_KXH-.X
MW$?!+?W;GE_$X"_KXH-&VD>2,3WTOK(D@[+O+>#_ .;]5,W.TXIWZD*A33BG
M?J0J%6%]_P Y<<  R""E.25&HY7;FM17*O8B)JN[CP3J0J*O#TF)OC]FDJG)
MQ;33K[(G*FJ<.KV:A<5VM+Y3A4E:+?4F_0F<F?ENX[EQ/G+FM?II.E?<,PL7
M;$FNJR4M'>JJ@HG+JJZ)XE24^B:\':<$1$^7C/XKN,E9=KM5S:=-576Y5,NR
MFC>EJ*Z>:393J;MO793J30P!=?!TU"C1@EE"G!)<E:"7S%!<?5<Z]:;O>56H
M\^-I3E+GGQ=\P?O_ "4,LW8SS0R[PFC4=^R+&N&;4YCD16OCJ;O2-E8Y%ZGQ
M(YBZ]3UZ]R_@!Z6\S=;HJKE29(Q3(JL;C-M2B)QZ6CM-SK(%_P ELT#%=YCK
MZ7K.GA,547&&'K27?&G)KY3LZ$PZJXW"4I>+4Q-"#[5*K!->=9'44M]%%3P0
MTT#$C@IX8X((V[FQQ1,2.-C?^JUC6M3S)VE\A!J=TX=9,4P;=W<OG%)))9))
M+T*P  ,@
M
M
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M5'35E9+)5UDSDW(Z6IG5\\BHFY%?(_<FNC2D >NDEDE9=AX<IR><G=L  R8
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M!PI\B49#FV7\A@/A*WT*9/.PK\OI+WE#Z=4^HP 0$6/      !!2)!>'=?@
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ML;\)'ZN!<_9KY$P'P<_K9@ &HF]               '\OC;_ (FN_P#-=?\
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M47>+G=6DD^:+!;-M!XG1VC5AL7!0K=/5G92C);LMW=SBVN7R$P -*-^
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M>'J-)<7N+?LN_=-GU+Q2HZ6T?4?!8FG']N\/[QT\T0B2M7OZU)BH*+P@ &0
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M&Z_X)A^]?.OWRX1^1[H1[M/\D5?A:'TR2MDGEO#? U_H2-O$ %8"WX
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M14U3RHY&KN54[%,X4O::;3XIM6ZK9%]8M-)KFD[]C28  .0
M
M
M
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M3G!KS22?GX+F1 !V%^.5^ZYU5^,U?OM>]@
M              !8=O+K  ,V?5_MUWX?+<Q=<;JW6LU\@ 54[=.U5X(FFJN7
M>FY$U5=-^[<BJJ(O[UDGR6LR,R:IE'@+ ^(\4S/T^N6R@=XA&U7*U'U%VJEI
MK521(Y-ATM7601-=HBOU4^-:M"G%SJ3A""XRG*,8KO;:2.QAL+4K24*5.=6<
MN$*<7*3[DD[^8_!2#G(FFJHFJHU-=VKE5&HUNNFJJJHUO:]4;N54UV:^3'X-
MCC.[>+U^:^++?A2D=H^7#^&EBO=Z1NRB]%579Z-L]+*CO(FCHV71NCM8JQ-$
MUV+.2]S7F2.4:T]5A; ]KJ;] U-G%.(88[_B-KU31\E)7W".5MKVVKL.6TPT
M.VQW0R+*U%UC[3&TW1V&3C1G+%SS\&A+V)-==1Y\;7W5;J9)>@=D6E<7:=>,
M,#3;7A5TW6MSM2BUYE)IWXHTN.2GS-^>6:RTU738<7!V'JA&/_9#C)M1:H%@
MD1%2>EM:PNNU:BHY%A1M+''+JUZ/6%=I=FKDA\P!E%E_XM=,:/J,T,2Q[,BR
MWJF;088I)D1-/<_#D$]1TB1N1%;-=KA<IMIJ21^+(Y84]XFLT\R(B(FG4B;D
M1%3>FG5HNY-R;MQ4:WOWX=I$>G-HND,9O0A-X:B^-.B[.2_2J>.^U)J+ZN9-
MNKVRW1F!W9RI^JJR=^DKK>C>W&-)>!%]3:E)>Z,5:K+2T--#14-+3T5'31I%
M3TM)!%34L$+6[+8H:>!D<43&Z)HV-K4W(FB(91(^W?ZOC+A(E7JT+F.+0T.4
MW)W;;;XWS^5YLD>,4DDDHI*R2R7H62\R+5L6OF^$O(X43J*[8^ZE=L1Q.12:
MSU%PV+7J+F.(N60@%O'$7C(N^A6:PKMC *3&?K+EL959&7;(P"BR/S%TV/OH
M56L]A<,C[]H!(R,N&1D[&%RC.T D8S])<L83,87#6;@"1C/UZ%=$T(M;U(5F
MLW@$&,]I61-/.OQ$4W+HGK4G1 ""-]941O6H1O6I,B:^@&;97()O]"%4$S6Z
M@-D$34K-30(FA$&                         :O?A4GW&,#_C A^1ZXVA
M#5[\*D^XQ@?\8$/R/7&TZD^5L!\8A]IINT+R+I'XM/[#0S !;?J[E\R*5/E^
M.;!T^.9#^]2R6][55\O7@Y@YT^.9#^]2R6][55\O7@B+;!_0\+\9_P *H37L
M-_I^-^*+ZZD>K  *^%G    ?FV:^4V'<<8>NN%<56BBOE@O5-)2W&VU\+9H)
MXI$T141V^.:-R))!/'LRP2M;+$]CVM5/TDI+UH9C.46I0;4DTTT[--9W3Y-<
M;G"I2C.+C.*E&2<91DKIIY--<TT[-<SE6\YCR(:SD^YO8CR_?--66-',O6#K
MG.B=-785N<DS[:RJ<W1CKC;'1SVFXR,9$RHJ:%U='#3P5D,+?@8V\/"P\-4C
M+_D]=VM:VNDM>)[=(K4:UTE(VJMU0Q7Z.VWHR5-(MMJMC:YS6JU7*TU#RW>J
M.E9XS1V%KU6W4<'&<LO"E"<H.2MDMZUVO=-E)==]$4\#I3%X>DK4XS4J:]S&
MI",U%W]S?=78D#Z4Y'/*+JLI,T\!YCTSWM9A3$ENN%RCC5^M587RI2XAH]&;
M2JM59)J^*-5CE2.=8)NBE6)K%^:RE4-UCD1>"L5/@5-WGT4][$X>%6E.E-*2
MJ0E3E%\'&::?X[#7,+BIT:E.K"3C*E.-2+7%2A*,HV]#N=E""9DC&21N:^.1
MK7QO:J.:]CD16N:Y-4<US516JBZ*BHJ%4^9>1?B9UXR@RKNDDJSRU^76"ZF>
M54>BOJ),.6YU2Y4D3I%59^DWNUVM-=IVJ*OTT4IK0W)SC[F4H^AM?87[H5-^
M$)Y>%",LN'A)/+LS  /F?4      E=U>E#1;\*\^ZEE1[PKQ^41O2.ZO2AHM
M^%>?=2RH]X5X_*(WO9MY8PWO:_U%0C?:SY#Q7O\ #_7TS55 !:4I^4I_M<G^
M0_\ JJ=;+D0_<<RM]X.%/D2C.2;/]KD_R'_U5.MER(?N.96^\'"GR)1D.;9?
MR& ^$K?0ID\["OR^DO>4/IU3ZC ! 18\         UA?"E,A),09,83QY20]
M)49=XQ9'72::K%A_&$"6FM5J(BN5WN[2X8<[^"R".=[M$:BIH4]^KCUZ:*O#
M@OGU3AHJ]<7E:Y T&:66N-<OK@UBP8JP]<K2Q[]&I!5ST[_$JA'[+G1K3UB0
MS)(QNW'LJZ-4?HIR8,:X-N6'+S=\/7B"2EN]ANEPLMUI96.CDIKC:ZN6AK(7
ML>B*Q8ZB"5NQHBMTT5&[D2PVR/2G2X.KA6[RP]3>BLKJG5O++NJ=)?JWD5?V
MU:'Z+'4L8E:.)I[LGUU:5HV?_*W+<?%? _F0 2TU^/G^3F0NODS_ -/E-KCP
M7#E?P8?QCC#)NZ5+8J/&K(\5X;2231B8CM%)'17:FC1SFLZ:YV6*BE5$1TKT
ML\+8V[+97)O*M?KU=^_;\YQZ,M<R+Y@[$-CQ9AJOEM6(,.7.DO%GN$*NVJ:N
MH96S1*YC5;TM/+LK#64VYE92RU%-.CXIY6NZDG-T<N_#7*#RUM.-[)+!3W5D
M<5OQ=8&2[=1AW$<,+%K:&6-VDOBDJN\:M=2]J-K+?+!*U=OI$97K:GJW*CB%
MCZ<6Z->T:K6:C6BDE?J4XI=EXM\RS>QW6J-;#/1M6:5;#[TZ"?&=&4G*276Z
M<Y/)9[K7)'WL"5JKUDQ$B9-H        N""FNIX25ROX<!Y(_L!HJAJ8BS5J
MEM#(6O;TT.&[;)!67^N='JDB1.UHK8V5J[IZ^)KD='TB'O9F=F?8\&X?O.*<
M37*EL^'[!;ZJYW:YULC(J>CHZ2-9999'N5$^Q398S[)[U8QB*YS47EU<Y=RX
M[GR@LVK[CRI6I@L<;66/!MJG>Y&VG"]ODE=1,Z%=$CJKC/-4W6XNV=M:NL?"
M]4BIH8H9!V<ZNRQN.A6E%NAA6JLY6\&52.=.G?@WO)2E'J5GDR,-J6M,<#H^
M>'IR7JK&)T8136]&D\JL^M+<;BI>Z>6:R^!$[]GJ^#K !9_\=V7 J*O3:^8-
MGGP6K(N2\YPXOQ[-$]:/!F$76JFD5FL2W/$]7!JC9--&U%-0VR9VFNO05RJN
MJJFFL*KD3CNZ]==-V_?JN[CIKV)JIT:_!VN2M+EUR>+/?;E2+27[,ZLEQM5M
M>U63,LM0GBN%6/1=Z]/8H8+JQ'(U[$NG0O1KHU1(^VEZ5]3:+JP3M/$-48\F
MU+PYVY[J@FG[Y+F27LHT.\5IBE-Q;IX2,L5)YVWX^QTT^5]Z2DD^.Z^H]YD
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M23K02IXB'MHUH*TG;CNS:WHOFGV%8$J.)C5S<        0U (@E1Q,
M    "5>KOUH3$J]7?K0 U6_"P/N296_C1=^1N)C15-ZKPL#[DF5OXT7?D;B8
MT52SNRWR/1^%K_3*C[8/+=7X##_0!%.OOUH0(IU]^M"0R+UQ7>=(GP<K[T?+
MO^>,Q_\ O)Q8>XQX<^#E?>CY=_SQF/\ ]Y.+#W&*=:R^4<=\;Q'ULR\^J7DS
M ?%:/T$  >(;"      #R9Y\C[U?-WWO1?*5">LQY,\^1]ZOF[[WHOE*A/7T
M!_3L'\9H?61/$UE\GXWXM6^KD<Q4 %RGQ91%<$#=?\$P_>OG7[Y<(_(]T-*
MW7_!,/WKYU^^7"/R/="/=I_DBK\+0^F25LD\MX;X&O\ 0D;>( *P%OP
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MF[M2@E>7NU+L/Z($B.4G-%)&       !  B"5%\Q,@
M
M
M
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MR:=CG&W_ !-=_P":Z_\ U68XXUG_ ')2_P G@_LFDY;&N&D>_"?-B2O.W?\
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M$=JJZZ:(F_4;KZGZ']PZ2/NH^E&0!1:N_=W^,JIYSBG_ *=QR3[NVV=GU$0
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MR<6'N,>'/@Y7WH^7?\\9C_\ >3BP]QBG6LOE''?&\1];,O/JEY,P'Q6C]!
M'B&P@      \F>?(^]7S=][T7RE0GK,>3//D?>KYN^]Z+Y2H3U] ?T[!_&:'
MUD3Q-9?)^-^+5OJY',5 !<I\6417! W7_!,/WKYU^^7"/R/=#2@-U_P3#]Z^
M=?OEPC\CW0CW:?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP
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M!?U\4&B[2/)&)[Z7UD20=EWEO!_\WZJ9N=IQ3OU(5"FG%._4A4*L+[_G+C@
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M$G&<)*SC)9--$NX/%TZ].%:E)3IU(J<)Q=U)/A;\73R:31, #XG9
M
M
M
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M[@@ :G9Q[>I"9&^TBB:$^B=OJ (:$WHX=9%$U]'85 9_'XR)6MT)B*(54;H
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MT;Y5*BS3J+C&+\3B_"MNS(S<-%T[]^!.A$AU>GO)U_#((1 ,@
M    \@>?M^])SB_F[#/Y<88.9<O%3IH\_;]Z3G%_-V&?RXPP<RY>*EB-D'D_
M$?')?4T"KVW#RGA?B,/_ )&((  E=\OQR9"[^[YS>+\$[^YWFW[_ *W?DS;C
M;%-3KP3O[G>;?O\ K=^3-N-L4J=KWY6QOPD?JX%S]FOD3 ?!S^MF  :B;T
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M+>_SX_.0/4M+\W#]B/W#U;6_/5?WL_XC]&_NQXQ_QPQ9_G+>_P ^']V/&/\
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M2@-U_P $P_>OG7[Y<(_(]T(]VG^2*OPM#Z9)6R3RWAO@:_T)&WB "L!;\
M                        $%^CXR)!?H^, \J^>T^]9SD]ZTG^M4IS!5XJ
M=/KGM/O6<Y/>M)_K5*<P5>*EA]D']!Q/QG_#B5BVX>4,)\5_Q9D  2TOO^8A
M1\/VOHF[CX)I^\W.;WUX8^0ZLVWS4@\$T_>;G-[Z\,?(=6;;Y4S7SROC?A(?
M54RYVS3R'H_X*7UM0  U$WH         \1?"+/O0\S?YRRV_[TL%G-J7J[]:
MG25\(L^]#S-_G++;_O2P6<VI>KOUJ6*V1>3Z_P ;E]52*M;:_*='XK#Z<R
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MGQLLRT.Q+%59Z/Q%.;;ITL0NBO[53IJ4HK]:[:7-LF !%),X
M
M
M
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MXN5]U2G%Q3=L\F^1R#".[NGZ3I<LY@KDK]66<*?_ %8O"?\ V:I/^T$\E?\
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M>?.3;RO8LMJMJY1T5@Z>$I/>M>=2H^-2I*V]-]5\E&/",4DB( /#-C
M
M
M
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M2= G:9/HR78[[_H ,=T/?>.A[[S)=&.B3N@!C>A[[QT/?>9+HD[H.C[ #&]
MG:3=%WT+_8[[_H(I& 6/1+W0BD/?@7R1DW1^90"Q2'O^HF2)"^Z+S?"12+S
M%DD9/T?F+U(NZ(3I%Y@"R2/U$_1=]"];%YOG*J0^;X@"P;%YB=(B_2)"HV).
MI "Q;#VE5L)=I%YBJV/]0!:I%H56Q^;UERD:%5L0!:HPK)%H7+8RJUG8@!:I
M'YO@^<JI&7",[2HC>Q "@C.K3VE5(^Z%=K.TK-9Z@"W1JE5L>G:5T:B$Z-4
MIHPJ:$[6?J*VSIQW %%L?ZBMLHG'=YB9J=F[SDR-]8!+HJ\-R=A.UNA-LJ3)
MYMZ@RD$;V[B.O8GK&SKQ*@&7G)$83@J-9V@-DK6ZE5$T(@&
M                                         "&A$  AH1
M
M                (:$0
M                                  0T(@    AH1
M
M
M                 (:$0
M
M
M
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M
M
M
M
M
M
M
M
M
M
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MJ(3
M
M
M
M
M
M
M
M
M
M                                    @J$0 4U9V$NRI6 !;D%34N%0
MIJP H[!#14\Z=^_65- #-REN] 5O9P*FGF)58@!35"FK$]!<:*0VNI4 4;E%
M&KV^TEW]B*5M$_7^@(WL4!JQ0T3T$%:G:GK*^RO82JGF!@H+%YB7H_25]CTA
M$7M]H!;]&2JQ2[W]:(O?SD%5$ZOB +/1>P@J>8NET\Y#< 6NB=A!6H7>SZ._
MJ'1^@ L]A!L(7O1>COZB'1^9/@ +/80;"%YT?F^(;'F +/80;"%WL>8CT?F^
M( L]A!L(7G1^9"/1>@ LT8A'1.PN^C]!#91.P MD3S$=E>PN-$[>_P !'=YP
M"WV%)TC*V[L4GU7L +;H_23)%YBOHOH]!#8[5 *>SIV(3:-)T;YB?3S?  4]
M/,A'1>W3T%78[=Q+HG: 4]CSZDZ)V$Z.1."$V]?,#-OQ<D1JD=W?]1-L=I,B
M(!D2;UX)IY]Q'8[5)P!?L((FA$F1BE1&Z P4D34F1G:50 01$0B
M
M
M
M
M
M
M
M
M
M
M                                      "56HI, "FK.PDV5["N "W(
M:%PK44E5B %#93L&SZ4*NPI!6J#-RBNO4-I>SX"H +]GSE+5.Q0B)YRJ05$
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MC.TCLH#!21J]A,C.TJ@ E1J(3
M
M
M
M
M
M
M
M
M
M
M                                 $-!HG81 !3Z/SCHRH "BK%(:+V*
M5P 4-%[!H5P 6X*RM0AL( 4@5=A!L( 4B&B=A6V$&P@!1T3L(E780;" %(%7
M80;" %(%780BC4 *)'1>PK@ H:+V*1V%*P *6P1Z/SE0 $J-0CHG81
M
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M.CL?5='"8N%>JH.;A&-2+4$TG+PJ<4[-I//*Z/N9%(D$(GA(V8  R
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M.K!/H5&$J<7&,\E-WG>\4XY/,]GT74F)6IYNLF-9CP^<VX  R
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MM'XO'>H,+5=>HH3G*<%>DE#=36^_&=Y>UNNT][D!+KV$QK!N(
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MGN6HK?IT\FVYU/%Y-6BY._&QM\*OGX?$3E!K>&O??H5D\YJR_'G-R_U(@ R
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M6I&K1DVHSBFDW%V=KI/)IIY<28 '3.^
M
M
M
M
M
M
M
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MY4C)FVN7_DRG?^V4[6ZNCKV((V+6_E:LU_8*J:XYJI0OZ38$ !6\M4
M "&\ B""*1       !KH>%!(B\FNBU373,W":IZ?<_$7L[-?CX+L7FNEX4!]
M[71_C-PG\GXA-BU12>E-'W5UZKH9=?LD35]=G_Y1I+XEB.'P<CGN]^_I75?7
MVZZ[\W@M'W"\4_C N'^H4!H,&_/X+/\ <+Q3^,"X?ZA0$Z[5%;1+7+U31\WC
ME==CC7\M*RM_-<1QS;_)YW-F5O'V?$I4*;>/L^)2H5G7/\<D6Q7!  &3(
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M=9;S9?IOU9HF@I.]3"_S>I?C:FET<NW>A97[.?$J)P0B$!I!(B  !D
M @NHW@$3YKY97W(\SO>#BWBFO_L*NZCZ40^;.63]R/,[W@XM^0JX[6!_+T?A
M:?TT=+27]'K_  -7A[R1R.:-$Z&)$X)''IV(B,:B(B:*N[?_  M-Z^2BFR/X
M+.G_ *2V(U__ $(XP^''65WT&MS2?:HOXMG]5#9%\%H^^6Q'^)'&'Y=96EI]
M>$OY(QMLET$<N2\4ISL]\M:/XWZ9MW=V\JAT#^OO_A%0I]??_"*A4XNF
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M."$;[3?+&(^#H?5(EC9+Y#PWPF(^NF1 !H))0
M
M
M
M
M
M
M
M          -7OPJ3[C&!_P 8$/R/7&T(:O?A4GW&,#_C A^1ZXVG4GRM@/C$
M/M--VA>1=(_%I_8:&9T0O!F?O8:7W^8R_MZ(YWIT0O!F?O8:7W^8R_MZ(F?:
MUY+I?&Z/U-8@;8MY8G\1K_78<V#4X(1()P0B5O+5@%)5]/#JZC3RYZ?GBL\<
MD\\ZS N KO8:3#T.%,-79D%QP_'<:A*NYMK_ !IWC+ZB)58Y::/8C5%5FKMZ
MZMV?9T#H*OI&OZGH.FJFY*?LDMV-HVNKV:;SR7,\'6+6&AHS#^JL0JCI[\8>
MQQWI)S4FFTVK++-O)<>1N) YQL?A'G*E<YC?V082\I[6K_Y(P)N<Y$X^.KIO
M7354TU5.!ME<OOGF,$<GW"&&_==DF+,RL38?M]SMF#[4^.%6-J*&*66\X@JU
M5T5ELWC+^B@8C9[G<)55ELH)Z>FN%90^UI34/2&%J4*4H0JU,1O]'&C)S:Z/
M=WG+P4HQ2DFVW9+-Y'@:)VD:,Q='$5U.=*EA=SI9UHQBKU-[<4;2DY2ENNT8
MIN^1[3*O?O\ JT)4<OG]AS*>4_SY'*/S-JZQ?V>7# UEG>_Q>PX!FEP^E+"N
MJ1M??*5S<032M8NPZ9ESIF/55D\71R-1/..X9_X_K)GU%7CW'%742KM2U%5B
M_$=142N_PI9IKD^5[N.][U7CO-KPFQ[%SBG6Q5"E.R>Y&]2U^N2E%7ZTK]YI
MV,VWX*,FJ&$KUH)V4Y2A1WEUJ,E)I=]GV'7S:J_H[Z^;L^8G.3YE1SBV?>")
MX:C#6<.8=&E.K5BHZW$]QOMI8C$1J-]Q\0U%TM:,5B(QS6T3$5B)LNU8Q4V+
M>0?X4!<J>KI+#R@+/#46N5[(?V>86H965=N;HUOC%\PY"LSJVE9HKZBHLVU7
M(JN?%:YT5D9YNEMEFD,-!SHRIXM)-N%.\:N7'=IROO)991;D^29Z>A-L6C,3
M-4Z\:F#<FHJ=7=E1N^4JL,H/WR2ZVC=6!_+8-QG:L0VFWWRQW&BN]FNM+#76
MRZ6ZIBJZ&OHZAB205--4PN=%+#*Q4<U['*F]4UW']-M<",W=.S333::>337%
M-/GES)9A-22<6FFKIK--=::R:)P"#N!BYR(@\]^=-Y0>)LJ\A\?X]PA44M-B
M+#]NI:BVS5M*VMIF2RW&DIWK+3.<ULJ+%*]J(KFZ*J*BZHAI)KX1_P J7@F(
M<)>G]B-.J(O_ &W?U:ZZ+KQ1#;]7]2\7I*E.MAW14(5'3EOS:E=14KV47EFE
MWFD:RZ_8+15:%#$QK.=2"J1Z."DK.3CQWEPLWW'1T!JU\R)SNV/,U(\Z+QG?
MB;#5%AO+NQ8/N\5TCMT-BI+=%=*G%3+I/6S]/-TR.CM5$VGB1-O;:]D;'R3-
M0^!.7MX3CBJ]5E?8,A;<W#5ACDEIF8VQ!10U.(;FUCW1K6VFS3NEHK/33*C9
M:);HRJKW0Z.K*"CGD6DA^U/4'2,\74P<:<'.CN=+5W_8(=)!3C>HTKO=:=HI
MOLYGQK;2-&4\%2QLZDU"OTG0T=R^(J='-PENTDWDI+QFU&V=S>+VO9Z%^/OP
MW\4(-5=R;_/JFGLW>CCIYCDJ9E<MW.;&-1)58GS8S%N[Y7](L,V,+W3V]DBJ
MU56GM%#74EJI-58QRI24,+%5C%TU1-/XK#W*6S+M$Z55HS(S"M52FG]\6S'&
M*+?/HFJM3IJ6[0OTU5=RNTT<[<J*J+MZV.5[9XVDI6X=%4W>[>WEZ=VUC1I;
M<\-O98&JXWX]/23]&[Q[+W3RY'7D12)S7N3#S_O*.RYJ:=MRQ4F8UDB5K9;/
MC:)M75.@;Q;!B"FC@O$<ZKI]=K);DNG5H]53=-YM[G:<MN4C;)8K')-A[&]M
MIUGO>!;M- ZYTT+',C=<;541*D5ZL[GR1HE93MCFIWR,AN%+1S*UKM.U@U$Q
MVCHNI4BJU!.SKT7OQC?ATD<I0ZKM6ZFS>M6-HNCM*35&G.5#$/A0KI1E+X.2
M;A/N4MZV>[8]5 0;P[_I^,B::;X "1W4 3@_*<X\[,)Y?V*LQ-C3$-JPQ8+>
MQ'U5TO%9%1TK-7(QL;5D<CI97O<UD4$*23RR.8R.-[G(BZM_*Y\*;PU;9JJU
M9+8.J\3R1JZ)N+,6]-9;-*NBIT]ML;?^&JJ'>CHY;E[D/5S%8ZA5CDE3V]#Z
MNXS'NV%H3J).SJ>+3C[ZI*T5W7;[#7=.:UX#1ROB\1"G)^+2SE6DNN-.*<FN
MVRCRO=HVYB1'+UIW^#Z=-%.8]G9SY?*?QO)/T^9E=ABBFU1;=@NBH\/01M5V
MB;%=%'4WMCFM78UBN::JJ.<UGV1\"XDY4&9]YDZ:\9F9C7>5';22W3'6*K@]
M%5$;JCJN[3.8NRC6;ME$8C6-1&HB$A8;8]BY*]7%4*;MPBI5%Z;P5^ZZ[R,L
M9MQP,)-4L)B*D5[>4H4K_J^&UY_0==IRZ]2^Q29%W;SD,6+E)9D6J9*FUYC9
M@VNI39TJ;;C;$]!.BL<CF:34EUBEU:]$<W155KDU313T<Y.?/L\I7+R>GUQ[
M4XVM,.PU]HQU%'?$EC33;1MXV8L0-FD:U&]+45]8K=5>D.VJJ_&+V08R$&Z6
M(HU9+A&2E3;[$VYJ_4G8S@=M^"J22K82O1C?.:E"I999N-H.WRY<&=,Q%(GB
M#S8G/?9>\H62/"]? N!LRXZ=9787KZEDU!?61,:ZHJ,*W5-AE?T7EOFM<[(;
MM3L8^9D%511/K%]NTZN_P$8Z1T;7PE65'$4Y4JD7G%]7)IK*2?6FU?+BB7-%
M:7P^-HQKX6K&K2EPE'BGU2B\XOG9I96? G ,-B&J?!0UD\:[,D-)4RQKIJB/
MCA>]JJG6B.:BJB[E3=Z.DE?(]&4DDV^",R:M?A5_W(<O?Q@+\B5QX(VSPD7E
M324T$CL081VI(8I':80@1-I[&N73:K$735=WFZU/DSEE<ZIG%GU8K9AW,:YV
M2MM=GN?NO1,MEDCM<S:U:>2E1TDS:B;I(^ADD1(_(U>J*BJNXFG5O9OI#"8[
M#8FI+#NG1JJ<E"KO2<;-72W;<>5[D"ZV[4M&XS1V-PE*.)Z6K2=*.]2M%2;7
M%[WBY>-:QYR'1,\&C^]<M7OVQM\J1G.S7OWW_.>HG),YXC/#)/!\&!< W:P4
M>'J>X7&YQPW'#\=QJ4J[I,V>K<M2^HC5T:R-^M,5/(:KD57*J:2)K[J]7TG@
MH4,,X*<:T*EZLNCBXQA4BTI6:3O-<;9)D7;.=9,/HG'U,1BM]PEAJE+V)*<E
M*<Z4EE>-TE!IVYV.H8#G%KX1]RI?\8,)?YHT_P">GVKS<W/I<H7,C/++3 V*
M;UAN?#V)<1QVZ[0T>&8:.IDI5I:F96PU3:J187;<+$VD8J[*JB;]Z0OBMF&D
M:-*I6E/#.%&G.I/=JMM1A%R=EN9NRRL[=I/6"VNZ+KUJ5&$<3OUJD*=.]));
MTY1@MY[[W5>2O<WGP2,7<A.1R2D 4M>^O#V'Y?G/G7A3+W#MPQ9C2_6_#F'K
M5$LM;<[E+T4$:(BN;'&UJ/FJ*B395(:6FBFJ9W)L0Q/?Y*\H0<FHQ3E*345&
M*;;;RLDLV^P^=6K&$92G)0C%.4I2:BE%<VVTDNUL_5215[Z=_-OW[]=QI-<M
M+PH^^UU376?(O"\-IMC7RT\&,<94Z5%SK6L<YBUENP[3U"T]#3U#$Z6B6XU,
M]:C%BEJJ&FG62@9K[9K<Y;R@L:U#Y\19R9A3;:NUI;3B6NPS;E:Y?)8ZVX8F
MM-!*QJ(B,Z>G>[=JKE>YSEDG1FRS2%>*G6=/")YJ-5MU//"/B]TFFN:1%&E]
ML6C,/-TZ$:F,DG9NE:%/MW9S7A+AG&+B^3=CJV[7F7V?HZNKX2*:]_I]'F]9
MR X<\\<QO;)'CC&D<C'(]KX\5X@9(QZ<'-<VXHYKD7@Y%U1>"GUYDKSL?*/P
M%-%)8\W\9U=/&]'K;L576?&%#(Q-E.@='B);G44\"[*;+*.IH]$W->Q%=KZU
M;8[B5%NGC*,Y<HRA."?ZUY67;NGCX?;CA7)*K@L1"-\Y*I3E;N34-Y]B=SJA
M@U(^0-X3K9+_ %M!AK/:RTV$JNJ?%3P8ZL22RX:Z=Z(C77^VRR2UME@E?JU*
M^EDN%% KF^.>*T[9:MFV%8KW1W.CIKA;JNGKJ"M@CJ:.LHYXZBEJ::9NW#/3
MU$3GQS12,5',?&YS7-5%:JIHJQMIK0&+T?45/%4G3O=QE=2A-+G"2NI?.NHE
M706LN"TE3=3"5E4W;;\&G&I3;Y3A))KL?BM\&9H$K28\<]X&NEX4!][71_C,
MPG\GXB-BTUTO"@/O:Z/\9F$_D_$1L>J'E71_QNA]9$U?7;R1I+XEB/JY'/<-
M^?P6?[A>*?Q@7#_4* T&#?G\%G^X7BG\8%P_U"@)TVJ^2G\8H_WRNFQORTOB
MN(^>F;,K>/L^)2H4V\?9\2D%3]&\K.G^/,6R7+N_"*H-)'G2>=]Y4.1>>&,<
MOZ*^X;3#\+Z*]X2FJL*T\TU3AB]4_C%"Z2=:J+QB6BJX[A9ZF=(V))5VR=6M
M1NCE^+,NO"3^432XAL=3B:[X8K<-PW:WR7^DI<+105,]E;51>ZC*::.J>Z.H
M\3Z9:=4:JK*C&]>I(6%V:Z0KT*>(I2PTZ=2$9P2JO>:E#?22W/&LK-7REX/$
MC3&;5M&8?$3PU:.)IU*=5TI7I+=3C/<<FU.Z@GGO-6<?"61T008#"V(Z.\6V
M@NUOG94T%THZ6X451&YKXYJ6L@CJ*>5CV*YCFR12,<US7*U475%74SY'[33:
M:LUDUU-$E1DFDTTTU=-<&GP8 )7*8.1,"DJKN[^SCO3JW*:C7/=<]EF5E%FW
M1Y<Y3W"R4D5CPU1UV+*FY6J*[22WV]3RU-+;XMNJB2G9;K/#0U$BZHZ:6[2,
M<UJTS%?[.@=!5](UUA\.H[^Y*;<W:,8QXMM)\[+AQ9X6L6L6&T9AWB<2Y='O
MQII02E*4I<$DVN2;;ZLS;J!SB7>$?\J1$72_X4<O\%K<'P.>]5X-1/'=5<O4
MW375=G34WS^1=78\K,K,#5^9U52U>.[G8*2ZXE?14C*"DIZZZ(M>EO@IHGRL
M1EK@J(;=TNTCJE:9:IZ,?*Z-OHZQ:H8K1D*<\3*E[*VH1IS<I/=2;=MU9*Z7
M>>1JQKS@]+3JPPL*WL,%*<JD%&"WK[L;J3SDDVNQ'U."DS7K]7GW%4U4W0
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MLJ&AITAMU^RSLL52Z-$=!)BG#K&4>)W-F:QC)99JJLIZMRM1=(:BGU75=_\
M-<QCR6O[J7*.P3'50=-8\"SMS O6VQ5A=)ARHAJ+%2O79=&JSX@=;IUBE3HZ
MFCHJN+1-51=K[PDSDM.QYR?Y,64-.DEZRJO4.*XWHUO2R8=JH'6K$]+TB_:X
M8Z:>CO<NB.622PP0HGEZI(.L&M/J;3.C\)O6@XS59)Y*6)M"AO+]'=4NZ9&>
MKFISQ.@=*8W=<JD73>'?-QPMYXA1]^I.+XYP]'/BPGBFNL=VM-\M<SZ>Z6.Z
M6Z\VRHC79?!<;5605]%.QR;VOAJ:>*1CFJBM5NO4=:_DJYZT.9V7."L?V]S'
M4V*\.VR\*V-%1D514TL:U<#6JKG-2"KZ:)&O7;:C/*T7<<C)?IW+U=6GP=>_
M?O-Z;P6GE4^[^7.,<IJ^9RW#+Z[P7RRH]Z?7L,XM?5R200M<]99%M-]H:_QE
M4:V"GI[O:88UU5[6^;M9T3TV"I8J*\+#32D_^'6:@W^K4W/-)OD>ML9TRZ..
MJ8.;M'&0O!<E5H1<[=7A0WTNV,5Q9M4@@G B5W+1     E50"8'\MC/&EIP[
M:JZ]WVY45HM%LIY*NX7*X5$=+1T=-$W:DFGJ)7-9&QJ=;G;U5&IJY41=/KEX
M^% R1UEPP]D#8H:BE@?+3?W0<4TSU@K7,5K756'L/-DCF=2*FVE-57EU/-.]
M6O6V0QHQU1[F@]7,9I&;AA:+FH^/4?@TH=\WE?\ 15Y/DC7=8=:L#HNFIXNM
M&%_$IQ\*K-_H4UF^]VBN;-RMZKNTU]7?OPXJ2)QW:^S3O]&J]ARE<W><LY0.
M.JB2?$N<./Y6R:M=0VG$5;AJU;*KJD;K7AJ2U4$S6:)L+403R(G&357*[YVH
M<_,>TLS*BEQYC>FJ(UVHYZ?%^(H)XG;*MU9+%<VR,=LJY-6.1=E5;KIJA(]'
M8[B'&\\91C*V:C3J32\]X_,B+*VW/"J5H8&M*-\FZM.,G^K9V?6KY/F=?E#Y
MLY9/W),SO>%BWY"KCG(\G;GI>4GEO4P/H<S+WBBVQ.:Z6S8[J),74U2U%T5J
MW"ZOEOT*HW:1GB]U;"Q%1TD3W-C1-E_)7G_, 9VY:8\P3C&B3+[,:NP#BF"@
MIJBI;-A?$]8MBK46FL5TD<V2FN$CD58K1=&1S3MT2WU5<])HX?#QVSG2&"J4
MJEH8BDJM.\Z+;E%;ZNYTWX226;:WDEFVL[;!H_:CHW'T:]%N>&KNA5W:=9+=
MF]R64*J\!OJ3W6WDD\KZ)-)]JB_BV?U4-D7P6C[Y;$?XD<8?EUE::W5(FD42
M=D;/ZJ&R-X+/]\MB/\2.,/RZRM)KUX\D8WMH)^AQ1 .S[RW@.RLUW^#-_:=
M[K[_ .$5"GU]_P#"*A4TNF 0=P4_+LW,Z,)X!L57B7&F(K1ABQ4+=JINEYKH
M*&E8O!&-?.YO33/7<R&)'RR.71C'*<H0<I1C%.4I.T8K.3?))+-ON.%2K&$7
M*;48Q5Y2DTHQ2XMMY)'ZD#4>Y7?A36%[7/6VG);!]9BF2%SH(\78KZ6RV.9V
MG[IMEF:JWNJI]^U')=665[GL<CJ-8%9,_7\SLY\OE/XWEFZ?,NNPS12JO_!V
M"J*BP_ Q-5V5;7,BGO37,:J(NS=(HWN57*CW;.S(&BMF>D\2E*<88:#2?L\F
MIV^#BG*_9+=[;$9:8VMZ)PKE&G.IBYQ;3Z"/L=U?^MGNP:NK7C=<U=9G3@5R
MZZ)W[^KM&J[N/?U'(GQ+RH\T+U)TMYS,S&NTFTKT?=<=XJN#VN5$35KJN[SJ
MWR4:Q%1478:UNY$1$LK#RDLR+5/XU:LQLP;75::)4VS&^*+?4Z:HNB5%)=H)
M=-41?LT35$7J138_6<KVOZMI+OI2LNO^LOQ[/,:N]NN'WK?R?6MV5H-VZ[*%
MK^>QUZ0<S+D[<^SRELO:JG<['U5C>U1*WI+-CF*.]-FCW;;6W=60WR.1[-T<
MTMQJ4C<FUT#M7:[B/-@<]W@#E$2?L8K:1^!\R8(>F_8U754=30WZ&.-'5%;A
MBY(D2U;8=[JBV5<5/<:9CFR1MK:=LE2S4M/[/\?H^+JRC'$4$KNK0>^HKKG&
MRE%=;S2ZS==6MIFC=)2C2C*>&KR=E1Q"W7)]4)J\9/C99-\D>W@***OP[M_'
M]"<"JW@:.2&1 ,9=9GQTM1(Q='QP32-<J:HCF1N>U53K1%1-4UT7@.Q?+DO2
M8;LF^K,R8.<M<?".>5''45$;,083V(JB>)FN$J95V8IG,;KI6[UV43RD715/
MN[FMN?,SVS*S^RZP-C_$.%DP9?9,8/Q"Z&P4]J?'26/+S%^)*>;W16L<VD9#
M<;-133RN:YJT[)8W[+7J]LAXO9GI&C1J5Y/#RC2ISK24*CE)TX1WFXK<S?9>
M]R,<%M9T77KTL/%5XU*M14H[\(QBIMM9O?=HJV<N"-WLD<J]2=^_F-1CG"/"
M;K98ZVOPKD':Z/$M33=)33Y@WQDBX=\9:YS'KAZUQOCJ;S3Q.:B-N57)1T=2
MJN=1PU-*D5;-J^YR\YER@<?54M3B3-['KXY5>BV^S8@KL,6A(G*KDB]RL.36
MFCGCC1=ABU<-3-LHFW+(_:>[Z:%V8X_%0Z2JX86FTFE54I56GPM1CX2_6<7V
M'PT]M>T9@Y]'2W\9)/=E*BXJBFN*Z:7@R:_0WEVG5F1>Q%[--._T$Z:]^_T'
M(+MV?^/Z.5M11X]QS23QZK'44F,,1TT\>J;UCF@N+96+PWL5%W<>L]!.3SSV
MG*5RZJJ9]-F5=\66V#5)+-CN1,54]2UR(B[=SKWK?FRHU%2)WNQT;'NVY&2:
M(B>MBMC^*BFZ.+HU9K^KDI4V^R[<\^JYXF#VXX.4E&M@\13C?\I"5.JK=>ZM
MUNW.UW8Z>8-?KFSN?VR_SPJZ'!N+J9F7N9%4U64=#4U'38:Q-*UNTK,/W:16
MOAK]E'/2SW-D%3*QJNH9Z[9F;![_ +5T1.U>.O%._K3L54(STGHK$8.JZ.)I
M2I5%[62XKKB^$D^N+?5QR)=T1IK"XZBJ^%JQJTWE>/&+YQG%VE"2YJ276LLR
ML"BO7KJ'<%T[-./Q'G?C[CU'U<^157J[]2DOZ?ZR&L3S^W.>YMY 8GRUMF6U
MRLU#1XFL.)*Z[,NEFCNKY*FVW"TT](Z!\D\*P,2*LG21NCD>Y6*BILJKO 3Z
MH^Y4NJ?^4&$=/>C3]NG_ "Y%^9.LWO1&SO'XW#4\72=!4JF];>G)2M&<J;;2
M@^<7S(YT[M.T;H_$U<'75?IJ=D]RFG"\H1FEO.2Y27G/+#EC_=CS?_&OF5^6
MU\/ICF>?OH,D_?BGR-=CX#QSC*NQ'?+YB.Z/9)=,17F[8@N<D4:0Q27*]W"H
MNE?)'"BN;#&^JJI71Q-<YL;%1J.70_K,C<Y[_EUB_#^.<+S4]-B'#%?[I6F>
MKIDK*:.JZ":F5TU*JM2>-8:B1NPLC?*<CDT5"Q^*P<Y8&IAU9U)X65!6=UO2
MH]&I7LO!OGPO8JQA](TXZ1I8N5U3CC57?!O=5;I+9-J]LN-CK]@YQ?U1_P J
M7_&#"7^:-/\ GI'ZH_Y4O^,&$?\ -&G_ #T@/UIM*=>&_>R_RRR7KT:'ZL5^
MZ7\9T<P>4',O<J_&6=.1%EQ[CRJHJS$5=B#%5OJ)K?0MMU*M-:;U4T5&UE*R
M25K7-@C8DCD>[;?M.UTT0]7D4CO'82>'KUL//=<Z-2=*;B[QWH2<79V3:;3M
MEP)/T=CH8FA1Q%--0KTX58;RL]V<5)76=G9D0#2OYW+GJ<^LH,_\;9?8)O&'
MJ7#=CI\+R4$%?AZ"OJHW73#%INE6DE4^JC=(CJNLF<Q',:K6.1C=4:AZ.@-7
MZ^DJTJ&'<%.-.53PVTK*4(Y6C+.\UYCR=9M9\-HJA#$8I5.CE55*].*DU)PG
M--IM96@^!NGZ(1.;W=O"1N5/%2U,S,081VXJ>:1BKA"!4VF1N<W5$KF[M437
M>AT;K94/EIX)'KY3X8GNZDVGQM<JHF[=JO4NB</1VM8]4\5HKHEB73?3;SAT
M<M_Q-VZ:LFO&B=35C7/":657U*JJZ'=WNEBH>/>UG=]3R,L"CJJ[CX&YS?'N
M9&$\DL<XNRGK*.FQEA.@AQ'315]N;<Z>NM-JJ8I\0T?BBZ/EJ76-*^HM[(5;
M)+<*>E@UV)GH>#A*#K5:=*+495)Q@I3>[!.;25Y<E=I._#B;)C<4J%&K6<9S
MC2A*I)4X[TG&";>ZN;LGDLV??X.<3]4@\J141R8APCIIKNPC3*B]>Y4K4^/0
M]^>86YWS'.>N*,<X#S1KK34X@M]FH\486EMEL;:DJ;52UC+5B&GEC;+*U\M%
M4UUDJ(EVD?(RMJ=&)'2J]=TTOL[TA@L/4Q-7H94Z23GT<W*5FTKI;BNE>[?)
M9FA:%VH:,Q^)I86CTZJUFU#I*:A%R2<K-N>3:B[99O)9FSZ"33S^?CQ(LX&A
MWSMS^PD:_P"/,3 $FUQ,@G!XE\^7SB.(.3[EA:*_!53008WQ3B2EM=G?<*1M
M?3T]NH6.KKW5.I'2Q)([H(X*.)55&M=5OEVMJ)K7:H'U1]RI/\8,):>]&G^'
M^_47V&ZZ!U#QVD:"Q%#H8TY3<(]+-Q<G'BXI0E>-\K]:?4:%K%M&T?HS$O"X
MCII55"-27104U%2X)O>5G;.W4T^9T<P>+W,@<I7-_.#*NNS$S7N%MJEO%_JJ
M3"D-MM#+0QMGM;&TM35SL:^59WU=Q2HZ*5).BZ&!FRQKE>KO:!J[C5](X&6&
MKU</-QE.C-TYN#WH[T<I).RO9W3RXIFW:+TA#%X>CB:<9QIUX*I!5([L]V6<
M6XW=KJSM?@R(*6NGPA7]TZ^KT>O<GG0Z7<=\JD%/(7G&^>7RLY.S$M5RDJL7
M8]J8DEH\$X?DA6JIH7M<L==B&XS?WG8J%SFHQC)/&+I5*[;HK7401U513:>W
M*9\(7Y1V/JFHCL>(:3+:R3=(R.W81I('W!*>1%:K)[[=(*JNZ1&Z/2>@903Q
MN149(U=43=- Z@Z0TA%5*=/HJ+X5JMXQ?O$DY2[U'=_2-!UCVDZ,T;)TYU76
MKQXT*%ISB^J4K[D7V.6];/=L=(%5W]??U$NJKNT^ Y%F*>53FG?9NGO>9V8U
MXF5RO1]SQSBBN5JJB-^MI4761L2(U$:C8D8UK$1C41J(A'"7*KS2P_.E58LS
M\Q;-.CFO5]MQSBFBZ16*CD;.VGN:1SQKL)MQ5#)(9&:,?&XW)[&ZZ2OC*=VL
MO8*EK]2>]?\ [317MTPZDE_)]>W'\M2O;M6[;Y3KK(1.<IR7?"*>4/@*H@AQ
M-=Z',VQM>Q)J/%%-!37=(&HC.CI+Y:J:FF1R,U?TE?25TCI%:LLSDU0W)^;N
MYV?*WE&V]8\-5D]BQE1TZ2WG E]?#'>J/8:U)JNW2Q.6EOMH217)%<*%>D:Q
M&^Z%%;IU=3-TG6#4?'Z.BZE6FJE!6O6I7E&-^&_&RE"_6U:^5\T;]JWM#T=I
M.2I4IRI5WPHUDHRE[R2;C/N3N^K)V]1 2M7<3&GF]   %->KT+\1S.^?N^^H
MS*]-B^1Z4Z8B]7H7XCF=\_=]]1F5Z;%\CTI*6R+RE/XK/Z=(A_;5Y+I?&X?5
M53TG\%"^Z9FO[R[!\LUQO0FB]X*%]TS-?WEV#Y9KC>A/,VF^6,1[RA]3 ]?9
M-Y#PWOZ_UL@:;?A:GVK(C^/S"_U?"9N2&FWX6I]JR(_C\PO]7PF=79WY8PG_
M #_J*A]]J?D/&=^'_P#D4C343]?H/TO)C-^^9?8NPUCK#,[:>_X2O5!?;5(_
M;Z&2HH)VS+2U36.:^6AKX6RT-?"CF=/1U$\6TNUHGT1S<V5EIQQGCEI@V^T[
M*JSXGQ"EFN,#TVFNIZR@K8]K1%1=J.3HY6*U45KF(Y%:Y$5/PG/_ "5N^7&-
M\58#OL;H[KA.]U]EJMK369*29S::K;LJK-BLI%@JV*Q59LSILN<GE+9VIB:5
M2M5P<DI3="-7<E:TZ52<Z4EW7C:7+=DBI5/"5J=&GCH-QC'%.E&I&Z=.K3A3
MJQSZVI;T+>VBSK'Y YV6?,;!6%L=8?DZ2S8KLE#>Z%7*CGQQUL#97TLJIHWI
MZ.7I:6=$33IH9$1=$37]'Q%B"CM5OKKI<:F&CM]NHZJOKJRH>R*FI**CA?45
M53/*]6LC@@AC?++(]4:QC'.5R-34U-/!<.6DVZX?Q3D9>*I5N.&>EQCA%DCM
M5J<.5]5#37VCB7>Y76:]55'4*QSD3Q:]0,A8K*6=6_8/A(?+,;E[DH_ -MJE
MBQ%FR^HL"MBDV9H<*0-CDQ-.[22-Z4];#+#99=&R,DCN,D$D>Q*JMJWBM5:L
M=+?R;%/PJR4)6O[!+PU4[=VEG+M3+?837.C/0G\JR:6[0;G&Z_I$?8W37;*K
M9+*]FLC2:Y?G*TK<[\V\99CU+I$HKQ<G4^'::5'L=187MVU2V*F6*362&5]$
MQM950O5W15E751L=L1M1/CHRU@P_77:OH+3:Z26NN=SK*6VVVAAT6:LKZZ:.
MEHZ6+543;GGEBB:KE1J;2*Y4:BJGVGSC?)H@R=S1J,MHECDJ,,80R^BN]3$C
MT96XAN.#;/=L1US4D\ML=5>ZZNDIXG*JP4JP0:Z1M1+0X>5'#/#X*-HM4WT<
M%;*E1Z.&\^S>FDNMMO/,J'BU7Q*Q./GO24JJ52I*^=6MTD]U=O@R;7))+A8]
MO/!0_NK9I_B^MOY1P&]4G!#15\%#^ZMFG^+ZV_E' ;U2<$*W;3?+&(^#H?5(
MM7LE\AX;X3$?73(@ T$DH
M
M
M
M
M
M
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MJJ="'9(Z=>Y/1V$/8W:MCJ]&K0G0PNY5ISINT:EXJ<7%N-ZC5TG=732?(G#
M;&]'X:O1Q$,3B]ZC5A5BM^FHR<)QFE*U--IN*3SX97YD6KN0F((1(O)>/SO-
M3-"Q8*PW?,6XFN-/:</X=MM7=[M<*E^S%345#$Z:9^G&21R-Z.&"-'2U$SXX
M(8Y)9&,=S-.=)YSC%7*0QM/7U,]9;, 6:HEBP9A+I5;2TE,U71^[5RB;LMJ;
M]<H]9*B>7;=10O914BQQQJLFP-X4ARU):*@POD19ZE6.O44.,<:-AE<W6V4M
M6^+#MKJ6M1$DAK+E2U5P=$Y[F+[EPNDBUZ%YI<HNF_AIJO'M1-=Z\-R:*O\
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MU#9L*XJ2*-'>(X?Q-&ET>Y'2*K88+O1VNDD1K4:J:5T;G*[HVQ.5%5_B5CS
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MB #022@
M
M
M
M
M
M
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M &BDC@
M
M
M
M
M
M
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M,86IH/3DMRZ6&Q,*]*%K;U"<G-1NN3IWA+-VNUF=D!R_-Z34K\*AY5WN7A+
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MU$1$1$1$1$3@B(FY$3J1.!. +$-!H1 !!41>*!$(@
M
M
M
M
M
M
M
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M6.U0F-7-S!KI>% ?>UT?XS,)_)^(C8M-=+PH#[VNC_&9A/Y/Q$;'JAY5T?\
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ME:Z3M>QNLIQ)BE&NO!=?TIJB_"5343>$P  9
M
M
M
M
M
M
M
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MJ8:IJTD]=07.EC>LD#$<Z6BF385R(U':.3PN^I7N3SK^^[.3S?\ E)@Y?_X
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M+@3#J-LJ6CZT,9BZW2XBF[TJ=)RC2@[6WIR=I5&N"64.;3Y0CX)W^GA[.PG
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MSY+)<BR%"C&G"%."M&$5"*NW:,59*[S>2Y@ 'S/J
M
M
M
M
M
M
M
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M1T[]T(@IZEDB[Q)KYE[^A""MWK]!4!RL"GO[./Q$S4)@82M_NW\YBP !DR
M 0(*3  IJWNI'3A[-Q. P4U[=^[J)F<"8  I-3J*H!AHIJW<15.Z(A.##5S)
M*U-/C)@#(2!!5(@ $JH3 Q;F"DJ*A43@1!DPE^.0  ,@   E=PW;B8 %-.W?
M\_ FZ^!,##0*:-[[R;90F L/QED0T(@"P  ,@
M
M
M
M
M
M
M
M
M
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M2'ZL;+S$NZ$T7'!83#X6%K4*4(-KVTU'PY?K2;?G)@ = ]4
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M@
M
M
M
M
M
M
M
M
M
M                                     @J#93L(@   6
M                                                        (:$0
M 0T0:$0+
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
D                                             __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>oncolyticspipeline3.jpg
<TEXT>
begin 644 oncolyticspipeline3.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_X3'F17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(S.C S.C R(#$V.C,P.C4S   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P,   DI(  @    ,P,   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,SHP,SHP,B Q-CHR.#HS,@ R,#(S.C S.C R(#$V.C(X.C,R      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  (#D         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ B $  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M+&,61Y8KO'\/3;SGH*;'JWAJ8@0VMA*Q&0L=L&)&2. !SR#^1HY&'.B2TO\
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MUT8>2C>[./$Q<K61!'X(NOLRB;P_JXF!);84P>G&2?KV[U!_PA6H<#_A'M3
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M73-1UBYDB%WI\42LQ#M'*K!0!G/WL\\# SU[8Y-"FH=S;KQ2;QAKZS.JZBP
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MJ/D>/?$]G^(AF\0XYGU7_ON2CSO$/_/?5?\ OY)1:CY#OB>S#SO$/_/?5?\
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M;XGNP_M;7,<ZEJ'_ '^>C^UM<_Z"6H?]_G_QI>RH^0>WQ/=A_:VN?]!+4?\
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M_P"M1SA[,/(D_P!G\_\ ZU MY/\ 9_/_ .M1S#]F'D2?[/Y__6H\B3_9_/\
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M]OSIWVK5/(@(TY?-91YJM*H"'^+G)[]/UQ0 "YU=H;=OL$4<CAA,GFAO+/\
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M 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M0_\ A7S/10!],?\ #<6M_P#0M6/_ ($/_A1_PW%K?_0M6/\ X$/_ (5\ST4
M?3'_  W%K?\ T+5C_P"!#_X4?\-Q:W_T+5C_ .!#_P"%?,]% 'TQ_P -Q:W_
M -"U8_\ @0_^%'_#<6M_]"U8_P#@0_\ A7S/10!],?\ #<6M_P#0M6/_ ($/
M_A1_PW%K?_0M6/\ X$/_ (5\ST4 ?3'_  W%K?\ T+5C_P"!#_X4?\-Q:W_T
M+5C_ .!#_P"%?,]% 'TQ_P -Q:W_ -"U8_\ @0_^%'_#<6M_]"U8_P#@0_\
MA7S/10!],?\ #<6M_P#0M6/_ ($/_A1_PW%K?_0M6/\ X$/_ (5\ST4 ?3'_
M  W%K?\ T+5C_P"!#_X4?\-Q:W_T+5C_ .!#_P"%?,]% 'TQ_P -Q:W_ -"U
M8_\ @0_^%'_#<6M_]"U8_P#@0_\ A7S/10!],?\ #<6M_P#0M6/_ ($/_A1_
MPW%K?_0M6/\ X$/_ (5\ST4 ?3'_  W%K?\ T+5C_P"!#_X4?\-Q:W_T+5C_
M .!#_P"%?,]% 'TQ_P -Q:W_ -"U8_\ @0_^%'_#<6M_]"U8_P#@0_\ A7S/
M10!],?\ #<6M_P#0M6/_ ($/_A1_PW%K?_0M6/\ X$/_ (5\ST4 ?3'_  W%
MK?\ T+5C_P"!#_X4?\-Q:W_T+5C_ .!#_P"%?,]% 'TQ_P -Q:W_ -"U8_\
M@0_^%'_#<6M_]"U8_P#@0_\ A7S/10!],?\ #<6M_P#0M6/_ ($/_A1_PW%K
M?_0M6/\ X$/_ (5\ST4 ?3'_  W%K?\ T+5C_P"!#_X4?\-Q:W_T+5C_ .!#
M_P"%?,]% 'TQ_P -Q:W_ -"U8_\ @0_^%'_#<6M_]"U8_P#@0_\ A7S/10!]
M,?\ #<6M_P#0M6/_ ($/_A1_PW%K?_0M6/\ X$/_ (5\ST4 ?3'_  W%K?\
MT+5C_P"!#_X4?\-Q:W_T+5C_ .!#_P"%?,]% 'TQ_P -Q:W_ -"U8_\ @0_^
M%'_#<6M_]"U8_P#@0_\ A7S/10!],?\ #<6M_P#0M6/_ ($/_A1_PW%K?_0M
M6/\ X$/_ (5\ST4 ?3'_  W%K?\ T+5C_P"!#_X4?\-Q:W_T+5C_ .!#_P"%
M?,]% 'TQ_P -Q:W_ -"U8_\ @0_^%'_#<6M_]"U8_P#@0_\ A7S/10!],?\
M#<6M_P#0M6/_ ($/_A1_PW%K?_0M6/\ X$/_ (5\ST4 ?3'_  W%K?\ T+5C
M_P"!#_X4?\-Q:W_T+5C_ .!#_P"%?,]% 'TQ_P -Q:W_ -"U8_\ @0_^%'_#
M<6M_]"U8_P#@0_\ A7S/10!],?\ #<6M_P#0M6/_ ($/_A1_PW%K?_0M6/\
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M0_\ A7S/10!],?\ #<6M_P#0M6/_ ($/_A1_PW%K?_0M6/\ X$/_ (5\ST4
M?3'_  W%K?\ T+5C_P"!#_X4?\-Q:W_T+5C_ .!#_P"%?,]% 'TQ_P -Q:W_
M -"U8_\ @0_^%'_#<6M_]"U8_P#@0_\ A7S/10!],?\ #<6M_P#0M6/_ ($/
M_A1_PW%K?_0M6/\ X$/_ (5\ST4 ?3'_  W%K?\ T+5C_P"!#_X4?\-Q:W_T
M+5C_ .!#_P"%?,]% 'TQ_P -Q:W_ -"U8_\ @0_^%'_#<6M_]"U8_P#@0_\
MA7S/10!],?\ #<6M_P#0M6/_ ($/_A1_PW%K?_0M6/\ X$/_ (5\ST4 ?3'_
M  W%K?\ T+5C_P"!#_X4?\-Q:W_T+5C_ .!#_P"%?,]% 'TQ_P -Q:W_ -"U
M8_\ @0_^%'_#<6M_]"U8_P#@0_\ A7S/10!],?\ #<6M_P#0M6/_ ($/_A1_
MPW%K?_0M6/\ X$/_ (5\ST4 ?3'_  W%K?\ T+5C_P"!#_X4?\-Q:W_T+5C_
M .!#_P"%?,]% 'TQ_P -Q:W_ -"U8_\ @0_^%'_#<6M_]"U8_P#@0_\ A7S/
M10!],?\ #<6M_P#0M6/_ ($/_A1_PW%K?_0M6/\ X$/_ (5\ST4 ?3'_  W%
MK?\ T+5C_P"!#_X4?\-Q:W_T+5C_ .!#_P"%?,]% 'TQ_P -Q:W_ -"U8_\
M@0_^%'_#<6M_]"U8_P#@0_\ A7S/10!],?\ #<6M_P#0M6/_ ($/_A1_PW%K
M?_0M6/\ X$/_ (5\ST4 ?3'_  W%K?\ T+5C_P"!#_X4?\-Q:W_T+5C_ .!#
M_P"%?,]% 'TQ_P -Q:W_ -"U8_\ @0_^%'_#<6M_]"U8_P#@0_\ A7S/10!]
M,?\ #<6M_P#0M6/_ ($/_A1_PW%K?_0M6/\ X$/_ (5\ST4 ?3'_  W%K?\
MT+5C_P"!#_X4?\-Q:W_T+5C_ .!#_P"%?,]% 'TQ_P -Q:W_ -"U8_\ @0_^
M%'_#<6M_]"U8_P#@0_\ A7S/10!],?\ #<6M_P#0M6/_ ($/_A1_PW%K?_0M
M6/\ X$/_ (5\ST4 ?3'_  W%K?\ T+5C_P"!#_X4?\-Q:W_T+5C_ .!#_P"%
M?,]% 'TQ_P -Q:W_ -"U8_\ @0_^%'_#<6M_]"U8_P#@0_\ A7S/10!],?\
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M8_X;BUO_ *%JQ_\  A_\*/\ AN+6_P#H6K'_ ,"'_P *^9Z* /IC_AN+6_\
MH6K'_P "'_PH_P"&XM;_ .A:L?\ P(?_  KYGHH ^F/^&XM;_P"A:L?_  (?
M_"C_ (;BUO\ Z%JQ_P# A_\ "OF>B@#Z8_X;BUO_ *%JQ_\  A_\*/\ AN+6
M_P#H6K'_ ,"'_P *^9Z* /IC_AN+6_\ H6K'_P "'_PH_P"&XM;_ .A:L?\
MP(?_  KYGHH ^F/^&XM;_P"A:L?_  (?_"C_ (;BUO\ Z%JQ_P# A_\ "OF>
MB@#Z8_X;BUO_ *%JQ_\  A_\*/\ AN+6_P#H6K'_ ,"'_P *^9Z* /IC_AN+
M6_\ H6K'_P "'_PH_P"&XM;_ .A:L?\ P(?_  KYGHH ^F/^&XM;_P"A:L?_
M  (?_"C_ (;BUO\ Z%JQ_P# A_\ "OF>B@#Z8_X;BUO_ *%JQ_\  A_\*/\
MAN+6_P#H6K'_ ,"'_P *^9Z* /IC_AN+6_\ H6K'_P "'_PH_P"&XM;_ .A:
ML?\ P(?_  KYGHH ^F/^&XM;_P"A:L?_  (?_"C_ (;BUO\ Z%JQ_P# A_\
M"OF>B@#Z8_X;BUO_ *%JQ_\  A_\*/\ AN+6_P#H6K'_ ,"'_P *^9Z* /IC
M_AN+6_\ H6K'_P "'_PH_P"&XM;_ .A:L?\ P(?_  KYGHH ^F/^&XM;_P"A
M:L?_  (?_"C_ (;BUO\ Z%JQ_P# A_\ "OF>B@#Z8_X;BUO_ *%JQ_\  A_\
M*/\ AN+6_P#H6K'_ ,"'_P *^9Z* /IC_AN+6_\ H6K'_P "'_PH_P"&XM;_
M .A:L?\ P(?_  KYGHH ^F/^&XM;_P"A:L?_  (?_"C_ (;BUO\ Z%JQ_P#
MA_\ "OF>B@#Z8_X;BUO_ *%JQ_\  A_\*/\ AN+6_P#H6K'_ ,"'_P *^9Z*
M /IC_AN+6_\ H6K'_P "'_PH_P"&XM;_ .A:L?\ P(?_  KYGHH ^F/^&XM;
M_P"A:L?_  (?_"C_ (;BUO\ Z%JQ_P# A_\ "OF>B@#Z8_X;BUO_ *%JQ_\
M A_\*/\ AN+6_P#H6K'_ ,"'_P *^9Z* /IC_AN+6_\ H6K'_P "'_PH_P"&
MXM;_ .A:L?\ P(?_  KYGHH ^F/^&XM;_P"A:L?_  (?_"C_ (;BUO\ Z%JQ
M_P# A_\ "OF>B@#[J^(G[06H>"?AGX1\40:5;W,^N1QO);O*P6/=$'X(Y/)Q
M7EO_  W%K?\ T+5C_P"!#_X5%\>O^3=_A7_U[P?^DPKYLH ^F/\ AN+6_P#H
M6K'_ ,"'_P */^&XM;_Z%JQ_\"'_ ,*^9Z* /IC_ (;BUO\ Z%JQ_P# A_\
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M(?\ PKYGHH ^F/\ AN+6_P#H6K'_ ,"'_P */^&XM;_Z%JQ_\"'_ ,*^9Z*
M/IC_ (;BUO\ Z%JQ_P# A_\ "C_AN+6_^A:L?_ A_P#"OF>B@#Z8_P"&XM;_
M .A:L?\ P(?_  H_X;BUO_H6K'_P(?\ PKYGHH ^F/\ AN+6_P#H6K'_ ,"'
M_P */^&XM;_Z%JQ_\"'_ ,*^9Z* /IC_ (;BUO\ Z%JQ_P# A_\ "C_AN+6_
M^A:L?_ A_P#"OF>B@#Z8_P"&XM;_ .A:L?\ P(?_  H_X;BUO_H6K'_P(?\
MPKYGHH ^F/\ AN+6_P#H6K'_ ,"'_P */^&XM;_Z%JQ_\"'_ ,*^9Z* /IC_
M (;BUO\ Z%JQ_P# A_\ "C_AN+6_^A:L?_ A_P#"OF>B@#Z8_P"&XM;_ .A:
ML?\ P(?_  H_X;BUO_H6K'_P(?\ PKYGHH ^F/\ AN+6_P#H6K'_ ,"'_P *
M/^&XM;_Z%JQ_\"'_ ,*^9Z* /IC_ (;BUO\ Z%JQ_P# A_\ "C_AN+6_^A:L
M?_ A_P#"OF>B@#Z8_P"&XM;_ .A:L?\ P(?_  H_X;BUO_H6K'_P(?\ PKYG
MHH ^F/\ AN+6_P#H6K'_ ,"'_P */^&XM;_Z%JQ_\"'_ ,*^9Z* /IC_ (;B
MUO\ Z%JQ_P# A_\ "C_AN+6_^A:L?_ A_P#"OF>B@#Z8_P"&XM;_ .A:L?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7TGX+_P"3,_%__7\?_1EO7S97TGX+
M_P"3,_%__7\?_1EO0!\V4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'N/['?_)8/^X?/_-*\P^(W_)0O%'_84NO_
M $<U>G_L=_\ )8/^X?/_ #2O,/B-_P E"\4?]A2Z_P#1S4 <[1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'TG\>O\ DW?X5_\
M7O!_Z3"OFROI/X]?\F[_  K_ .O>#_TF%?-E !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?27[
M:W_(>\)_]>$G_H0KYMKZ2_;6_P"0]X3_ .O"3_T(5\VT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"B;BOFR@#ZK_;R_P"0MX4_[??_ $**OE2OJO\ ;R_Y"WA3_M]_]"BKY4H
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M#-?0OA'_ ()S^(M3TV.?Q!XJL]#NG ;[-:VAO-F1T9MZ#<.AQD>A-<M^S_\
M'KP?X=^-'BSQUXW6\74-4DD:QFA@\]+42.Q?=SN!"[$&T'C<.*]&_:$_;J*"
MPL?A7JB,)(S+=ZK-9'?&V<+$B3)C. 225(Y&.])-Q@N;5O?R&U>;2T2_$I:Q
M_P $V]2M[&1]*\=VM[=@?)#>::UNC'T+K)(1_P!\FOE7XA?#O7_A?XFN-!\1
MV#6&H0@,!D,DB'[KHPX93@\CT(.""*^\_P!C'XZ>._BVNM6_BV(WUK:HDEKK
M"V0@5VW$/&Q0!">A  !&#G-</_P4CT:$6O@C5 BBXWW5LS8Y9<1LH^@.[_OJ
ME-N#3>P4_P!Y=+=?IJ>&?![]DOQ=\;?"C^(-#U+1+2R6Y>U,>H3S))N4*2<)
M$PQ\P[UI>'OV*?'VO?$#5O#6^PAMM)>-+S6@\AM SHLFR/*!I'"N., #N1D$
M_4/_  3Z_P"2&7'_ &&+C_T".J/[8/[36L_!FZT_PYX56W@UN^@-W<7TT0D,
M$98JNQ2-I8E6Y8$ +TYR-9M0E:VY%.]2+?\ 6AYYJG_!-O4(=-EDT[QY;W=^
M%S'!<Z8T$;-Z&02N0/?::\,\,_LM_$'Q-\1-0\'1Z0+*_P!/(-Y=W3%;6!#R
MCF0 [@W\(4$GGC@X^ROV+_CYX@^,^A:_9^*)DO-4TF6)EO8X5B,T<N_ 94 7
M*E#R ."/3)Z/]JGXZ3_ ?P1!>:3;6\^O:K/Y%K]H7*1A5R\C $%L#  SU8=A
M@Q/]V[R_JY<?WBY5O_D>%-_P38NQ9%U\?PF[VY$+:21'N]-_G9Q[[?PKY?\
MBM\)/$/P;\3OHGB*V1)RGF0W$#%X;B/IO1B!D9XP0".XK[(_8U_:8\7?%;Q9
MJWAKQ;=1ZI(EJU];7BV\<+IM=%:,B-0I'S@@XSP>3D8L?\%%]%MKCX9^'-4:
M-?MEMJOD))CG9)$Y9<^F8T/X5,[PL^C'3]YN/5?IJ?GY1115DA1110 4444
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M#J@<%0H.5Y4DXSD"NY_9(_:TU/XL:Q+X3\6K;MK:PF>SO[>,1BY"CYT=!P'
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M@Y?!X))5>HSD$53US_@FWJEOI\DFD>.;6_OE&4@O-.:VC8^A=9)"/^^:[/\
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M'/05B_!/]FWQ-\>K75I_#]]I-HFFO&DPU*:5"Q<,1MV1OG[IZXKZ,_X*3?\
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M8VT8BA^VF=4 P!YJ+*<>V7-2^:-3D?G^!46I0YE_5SR^BBBK)"BBB@ HHHH
M**** "BBB@ HHHH ^D_CU_R;O\*_^O>#_P!)A7S97TG\>O\ DW?X5_\ 7O!_
MZ3"OFR@ HHHH **** "BBB@ HHHH ^LO^"<__)4O$7_8(/\ Z.CKW/\ ;N\5
M:WX/^$^EWFA:QJ&BWCZO'$UQIUT]O(4,4I*ED()&0#CV%>%_\$Y_^2I>(O\
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M>Q-<[^UY\4K'XJ_&*[N])F6YTG38$TZVN$.5F",S.X]B[L >X />OT/^ /\
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MH/H&,ZY_(5R/Q#_X)^^+_"NF37_A[5[7Q4L*%WM5A-M<MC^XA9E8XR<;@>.
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M"YCM[Z>W9NP,D:L/_11K"M:T;=U?[S6@WS-RVL[?<=9_P3Y_Y(9<?]A>X_\
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M;?XQ_P"N=O\ ^E,5> _\$VYXEO/'D1_U[)9,/]T&8']2*]]_;&_Y-O\ &/\
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M7F*QE00!P,@@LPX(S7DO[#/QAL_AW\1+S0M6G6VTOQ L<27$C82*X0GR]Q/
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MC7_)1/"__8,?_P!&-7LO_!/K_DAEQ_V%[C_T".HP_P##E_74=?XX?UT/G?\
MX*!?\EZB_P"P/;_^ARU]3?L-_P#)NFA?]=[K_P!'O7RS_P % O\ DO47_8'M
M_P#T.6OJ;]AO_DW30O\ KO=?^CWJ:/POY_F55^)?+\CXZ_;<D9OVC_$@9B0L
M5H%!/0?9XS@?B3^=>A?\$Y?^2@>*?^P:G_HQ:\[_ &W/^3D/$W_7.T_])HZ]
M$_X)R_\ )0/%/_8-3_T8M:8?;[QXSI_V[^AZ'_P4?_Y$3PE_V$I/_11KF?\
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MY_Y(9<?]A>X_] CKYV_X*!?\EZB_[ ]O_P"ARU]$_P#!/G_DAEQ_V%[C_P!
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M133/H_XR_LD^!_BCI5U)9Z5;>'_$)5FAU+3XA$&DZ_O47"N">I(W>A%?,G[
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M3OCA_P D9\<?]@2\_P#1+U57^!]_Z%4OXR^7YGX_T445"V$]PHHHIB"BBB@
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MI*QF[QC>.IZ5^TM^R#X3\0>$-6\0>%-+AT#Q!86[W(@L%$=O=*BY9#$/E5L
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M))Y/>O+J*%[JL@>NK/3?"/[2/Q!\&>,-1\26&NL][J4WVB_@FB4VUTYQDM$
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M&V-5'\1YQGFN9HH?O.[!>[HCT_X1?M'^-_@HLD&@:A'-IDK;WTR_C,MN6_O
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M &M/BMX7T2PTC2_%7V73;&!+>W@&FVC;(U "C+1$G@=22:\AHJKNUA>9[?\
M\-J?&;_H<O\ REV7_P 9H_X;4^,W_0Y?^4NR_P#C->(44@.S^)7QB\7_ !>N
M+&?Q;J_]K2V*NENWV:&'8&(+#]VBYSM'7/2N,HHI62V ****8!1110 4444
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M_P!"BKY4KZK_ &\O^0MX4_[??_0HJ^5* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ3\%_P#)F?B__K^/_HRWKYLK
MZ3\%_P#)F?B__K^/_HRWH ^;**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#W']CO_DL'_</G_FE>8?$;_DH7BC_L
M*77_ *.:O3_V._\ DL'_ '#Y_P":5YA\1O\ DH7BC_L*77_HYJ .=HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z3^/7_)N_PK
M_P"O>#_TF%?-E?2?QZ_Y-W^%?_7O!_Z3"OFR@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /I+]
MM;_D/>$_^O"3_P!"%?-M?27[:W_(>\)_]>$G_H0KYMH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^D_V;?^
M2+_%C_KQD_\ 2:6OFROI/]FW_DB_Q8_Z\9/_ $FEH ^;**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O:_P!D'_DLEO\ ]>4_\A7BE>U_L@_\
MEDM_^O*?^0H \Z^*7_)3?%W_ &&+S_T<]<S73?%+_DIOB[_L,7G_ *.>N9H
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M_P")H_X5_8?\][G_ +Z7_P")H _'S_A'=6_Z!=Y_X#O_ (4?\([JW_0+O/\
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M_P"%?V'_ #WN?^^E_P#B: /Q\_X1W5O^@7>?^ [_ .%'_".ZM_T"[S_P'?\
MPK]@_P#A7]A_SWN?^^E_^)H_X5_8?\][G_OI?_B: /Q\_P"$=U;_ *!=Y_X#
MO_A1_P ([JW_ $"[S_P'?_"OV#_X5_8?\][G_OI?_B:/^%?V'_/>Y_[Z7_XF
M@#\?/^$=U;_H%WG_ (#O_A1_PCNK?] N\_\  =_\*_8/_A7]A_SWN?\ OI?_
M (FC_A7]A_SWN?\ OI?_ (F@#\?/^$=U;_H%WG_@._\ A1_PCNK?] N\_P#
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M^%'_  CNK?\ 0+O/_ =_\*_8/_A7]A_SWN?^^E_^)H_X5_8?\][G_OI?_B:
M/Q\_X1W5O^@7>?\ @._^%'_".ZM_T"[S_P !W_PK]@_^%?V'_/>Y_P"^E_\
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M;_H%WG_@._\ A1_PCNK?] N\_P# =_\ "OV#_P"%?V'_ #WN?^^E_P#B:/\
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MW_0+O/\ P'?_  H_X1W5O^@7>?\ @._^%?L'_P *_L/^>]S_ -]+_P#$T?\
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MX1W5O^@7>?\ @._^%?L'_P *_L/^>]S_ -]+_P#$T?\ "O[#_GO<_P#?2_\
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M_P *_L/^>]S_ -]+_P#$T ?CY_PCNK?] N\_\!W_ ,*/^$=U;_H%WG_@._\
MA7[!_P#"O[#_ )[W/_?2_P#Q-'_"O[#_ )[W/_?2_P#Q- 'X^?\ ".ZM_P!
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M>Y_[Z7_XFC_A7]A_SWN?^^E_^)H _'S_ (1W5O\ H%WG_@._^%'_  CNK?\
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M_A7]A_SWN?\ OI?_ (FC_A7]A_SWN?\ OI?_ (F@#\?/^$=U;_H%WG_@._\
MA1_PCNK?] N\_P# =_\ "OV#_P"%?V'_ #WN?^^E_P#B:/\ A7]A_P ][G_O
MI?\ XF@#\?/^$=U;_H%WG_@._P#A1_PCNK?] N\_\!W_ ,*_8/\ X5_8?\][
MG_OI?_B:/^%?V'_/>Y_[Z7_XF@#\?/\ A'=6_P"@7>?^ [_X4?\ ".ZM_P!
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M (#O_A1_PCNK?] N\_\  =_\*_8/_A7]A_SWN?\ OI?_ (FC_A7]A_SWN?\
MOI?_ (F@#\?/^$=U;_H%WG_@._\ A1_PCNK?] N\_P# =_\ "OV#_P"%?V'_
M #WN?^^E_P#B:/\ A7]A_P ][G_OI?\ XF@#\?/^$=U;_H%WG_@._P#A1_PC
MNK?] N\_\!W_ ,*_8/\ X5_8?\][G_OI?_B:/^%?V'_/>Y_[Z7_XF@#\?/\
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M_ =_\*_8/_A7]A_SWN?^^E_^)H_X5_8?\][G_OI?_B: /Q\_X1W5O^@7>?\
M@._^%'_".ZM_T"[S_P !W_PK]@_^%?V'_/>Y_P"^E_\ B:/^%?V'_/>Y_P"^
ME_\ B: /Q\_X1W5O^@7>?^ [_P"%'_".ZM_T"[S_ ,!W_P *_8/_ (5_8?\
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MC_A'=6_Z!=Y_X#O_ (5^P?\ PK^P_P">]S_WTO\ \31_PK^P_P">]S_WTO\
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M[S_P'?\ PH_X1W5O^@7>?^ [_P"%?L'_ ,*_L/\ GO<_]]+_ /$T?\*_L/\
MGO<_]]+_ /$T ?CY_P ([JW_ $"[S_P'?_"C_A'=6_Z!=Y_X#O\ X5^P?_"O
M[#_GO<_]]+_\31_PK^P_Y[W/_?2__$T ?CY_PCNK?] N\_\  =_\*/\ A'=6
M_P"@7>?^ [_X5^P?_"O[#_GO<_\ ?2__ !-'_"O[#_GO<_\ ?2__ !- 'X^?
M\([JW_0+O/\ P'?_  H_X1W5O^@7>?\ @._^%?L'_P *_L/^>]S_ -]+_P#$
MT?\ "O[#_GO<_P#?2_\ Q- 'X^?\([JW_0+O/_ =_P#"C_A'=6_Z!=Y_X#O_
M (5^P?\ PK^P_P">]S_WTO\ \31_PK^P_P">]S_WTO\ \30!^/G_  CNK?\
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M_P ][G_OI?\ XF@#\?/^$=U;_H%WG_@._P#A1_PCNK?] N\_\!W_ ,*_8/\
MX5_8?\][G_OI?_B:/^%?V'_/>Y_[Z7_XF@#\?/\ A'=6_P"@7>?^ [_X4?\
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MX#O_ (4?\([JW_0+O/\ P'?_  K]@_\ A7]A_P ][G_OI?\ XFC_ (5_8?\
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M[W/_ 'TO_P 30!^/G_".ZM_T"[S_ ,!W_P */^$=U;_H%WG_ (#O_A7[!_\
M"O[#_GO<_P#?2_\ Q-'_  K^P_Y[W/\ WTO_ ,30!^/G_".ZM_T"[S_P'?\
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M_GO<_P#?2_\ Q- 'X^?\([JW_0+O/_ =_P#"C_A'=6_Z!=Y_X#O_ (5^P?\
MPK^P_P">]S_WTO\ \31_PK^P_P">]S_WTO\ \30!^/G_  CNK?\ 0+O/_ =_
M\*/^$=U;_H%WG_@._P#A7[!_\*_L/^>]S_WTO_Q-'_"O[#_GO<_]]+_\30!^
M/G_".ZM_T"[S_P !W_PH_P"$=U;_ *!=Y_X#O_A7[!_\*_L/^>]S_P!]+_\
M$T?\*_L/^>]S_P!]+_\ $T ?CY_PCNK?] N\_P# =_\ "C_A'=6_Z!=Y_P"
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MG_".ZM_T"[S_ ,!W_P */^$=U;_H%WG_ (#O_A7[!_\ "O[#_GO<_P#?2_\
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MX^?\([JW_0+O/_ =_P#"C_A'=6_Z!=Y_X#O_ (5^P?\ PK^P_P">]S_WTO\
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M_P */^$=U;_H%WG_ (#O_A7[!_\ "O[#_GO<_P#?2_\ Q-'_  K^P_Y[W/\
MWTO_ ,30!^/G_".ZM_T"[S_P'?\ PH_X1W5O^@7>?^ [_P"%?L'_ ,*_L/\
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MNC:M=LK+ Q!!F?!!Q7-?\([JW_0+O/\ P'?_  K]@_\ A7]A_P ][G_OI?\
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M_P")H_X5_8?\][G_ +Z7_P")H _'S_A'=6_Z!=Y_X#O_ (4?\([JW_0+O/\
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M_P"%?V'_ #WN?^^E_P#B: /Q\_X1W5O^@7>?^ [_ .%'_".ZM_T"[S_P'?\
MPK]@_P#A7]A_SWN?^^E_^)H_X5_8?\][G_OI?_B: /Q\_P"$=U;_ *!=Y_X#
MO_A1_P ([JW_ $"[S_P'?_"OV#_X5_8?\][G_OI?_B:/^%?V'_/>Y_[Z7_XF
M@#\?/^$=U;_H%WG_ (#O_A1_PCNK?] N\_\  =_\*_8/_A7]A_SWN?\ OI?_
M (FC_A7]A_SWN?\ OI?_ (F@#\?/^$=U;_H%WG_@._\ A1_PCNK?] N\_P#
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M^%'_  CNK?\ 0+O/_ =_\*_8/_A7]A_SWN?^^E_^)H_X5_8?\][G_OI?_B:
M/Q\_X1W5O^@7>?\ @._^%'_".ZM_T"[S_P !W_PK]@_^%?V'_/>Y_P"^E_\
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M;_H%WG_@._\ A1_PCNK?] N\_P# =_\ "OV#_P"%?V'_ #WN?^^E_P#B:/\
MA7]A_P ][G_OI?\ XF@#X'_9?TN]L_A_\4$GM)X7DL5"+)$RECY5QTR.>HKY
MT_X1W5O^@7>?^ [_ .%?L'_PK^P_Y[W/_?2__$T?\*_L/^>]S_WTO_Q- '3T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >>3?$;4_[2U"
MVM=%CN8[6Y>#S/M 3.TD="*3_A8FN?\ 0N)_X%K_ (5D:;_R&?$/_82F_P#0
MC6G0!)_PL37/^A<3_P "U_PH_P"%B:Y_T+B?^!:_X5'10!)_PL37/^A<3_P+
M7_"C_A8FN?\ 0N)_X%K_ (5'10!)_P +$US_ *%Q/_ M?\*/^%B:Y_T+B?\
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M_P +$US_ *%Q/_ M?\*/^%B:Y_T+B?\ @6O^%1T4 2?\+$US_H7$_P# M?\
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M^A<3_P "U_PH_P"%B:Y_T+B?^!:_X5'10!)_PL37/^A<3_P+7_"C_A8FN?\
M0N)_X%K_ (5'10!)_P +$US_ *%Q/_ M?\*/^%B:Y_T+B?\ @6O^%1T4 2?\
M+$US_H7$_P# M?\ "C_A8FN?]"XG_@6O^%1T4 2?\+$US_H7$_\  M?\*/\
MA8FN?]"XG_@6O^%1T4 2?\+$US_H7$_\"U_PH_X6)KG_ $+B?^!:_P"%1T4
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M10!)_P +$US_ *%Q/_ M?\*/^%B:Y_T+B?\ @6O^%1T4 2?\+$US_H7$_P#
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M1T4 2?\ "Q-<_P"A<3_P+7_"C_A8FN?]"XG_ (%K_A4=% $G_"Q-<_Z%Q/\
MP+7_  H_X6)KG_0N)_X%K_A4=% $G_"Q-<_Z%Q/_  +7_"C_ (6)KG_0N)_X
M%K_A4=% $G_"Q-<_Z%Q/_ M?\*/^%B:Y_P!"XG_@6O\ A4=% $G_  L37/\
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M_"C_ (6)KG_0N)_X%K_A4=% $G_"Q-<_Z%Q/_ M?\*/^%B:Y_P!"XG_@6O\
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M%1T4 2?\+$US_H7$_P# M?\ "C_A8FN?]"XG_@6O^%1T4 2?\+$US_H7$_\
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M?]"XG_@6O^%1T4 2?\+$US_H7$_\"U_PH_X6)KG_ $+B?^!:_P"%1T4 2?\
M"Q-<_P"A<3_P+7_"C_A8FN?]"XG_ (%K_A4=% $G_"Q-<_Z%Q/\ P+7_  H_
MX6)KG_0N)_X%K_A4=% $G_"Q-<_Z%Q/_  +7_"C_ (6)KG_0N)_X%K_A4=%
M$G_"Q-<_Z%Q/_ M?\*/^%B:Y_P!"XG_@6O\ A4=% $G_  L37/\ H7$_\"U_
MPH_X6)KG_0N)_P"!:_X5'10!)_PL37/^A<3_ ,"U_P */^%B:Y_T+B?^!:_X
M5'10!)_PL37/^A<3_P "U_PH_P"%B:Y_T+B?^!:_X5'10!)_PL37/^A<3_P+
M7_"C_A8FN?\ 0N)_X%K_ (5'10!)_P +$US_ *%Q/_ M?\*/^%B:Y_T+B?\
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M_P +$US_ *%Q/_ M?\*/^%B:Y_T+B?\ @6O^%1T4 2?\+$US_H7$_P# M?\
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M^A<3_P "U_PH_P"%B:Y_T+B?^!:_X5'10!)_PL37/^A<3_P+7_"C_A8FN?\
M0N)_X%K_ (5'10!)_P +$US_ *%Q/_ M?\*/^%B:Y_T+B?\ @6O^%1T4 2?\
M+$US_H7$_P# M?\ "C_A8FN?]"XG_@6O^%1T4 2?\+$US_H7$_\  M?\*/\
MA8FN?]"XG_@6O^%1T4 2?\+$US_H7$_\"U_PH_X6)KG_ $+B?^!:_P"%1T4
M2?\ "Q-<_P"A<3_P+7_"C_A8FN?]"XG_ (%K_A4=% &9IO\ R&?$/_82F_\
M0C6G69IO_(9\0_\ 82F_]"-:= !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!F:;_ ,AGQ#_V$IO_ $(UIUF:;_R&?$/_ &$IO_0C6G0
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MQ6(QE.JXT8)QTU^6I]E_\-Q?!/\ Z'7_ ,I5]_\ &:/^&XO@G_T.O_E*OO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@-CU4D5XA^U[^V+X9D\#ZEX,\$:G'K>I:I&;:[U"S8FWMX#]\*_1V8?+\N0
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MF ^X3_=<?*?J#VK\CKJWN=-NKBSN$DMYXG,4T+@JRLIP58>H(_2OW.KX:_;
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &9
MIO\ R&?$/_82F_\ 0C6G69IO_(9\0_\ 82F_]"-:= !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/^?V'_OJC_A(M,_Y_8?^^J -&BL[_A(M,_Y_8?\ OJC_ (2+3/\ G]A_[ZH
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M?^^J -&BL[_A(M,_Y_8?^^J/^$BTS_G]A_[ZH T:*SO^$BTS_G]A_P"^J/\
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M #^P_P#?5 &C16=_PD6F?\_L/_?5'_"1:9_S^P_]]4 :-%9W_"1:9_S^P_\
M?5'_  D6F?\ /[#_ -]4 :-%9W_"1:9_S^P_]]4?\)%IG_/[#_WU0!HT5G?\
M)%IG_/[#_P!]4?\ "1:9_P _L/\ WU0!HT5G?\)%IG_/[#_WU1_PD6F?\_L/
M_?5 &C16=_PD6F?\_L/_ 'U1_P )%IG_ #^P_P#?5 &C16=_PD6F?\_L/_?5
M'_"1:9_S^P_]]4 :-%9W_"1:9_S^P_\ ?5'_  D6F?\ /[#_ -]4 :-%9W_"
M1:9_S^P_]]4?\)%IG_/[#_WU0!HT5G?\)%IG_/[#_P!]4?\ "1:9_P _L/\
MWU0!HT5G?\)%IG_/[#_WU1_PD6F?\_L/_?5 &C16=_PD6F?\_L/_ 'U1_P )
M%IG_ #^P_P#?5 &C16=_PD6F?\_L/_?5'_"1:9_S^P_]]4 :-%9W_"1:9_S^
MP_\ ?5'_  D6F?\ /[#_ -]4 :-%9W_"1:9_S^P_]]4?\)%IG_/[#_WU0!HT
M5G?\)%IG_/[#_P!]4?\ "1:9_P _L/\ WU0!HT5G?\)%IG_/[#_WU1_PD6F?
M\_L/_?5 &C16=_PD6F?\_L/_ 'U1_P )%IG_ #^P_P#?5 &C16=_PD6F?\_L
M/_?5'_"1:9_S^P_]]4 :-%9W_"1:9_S^P_\ ?5'_  D6F?\ /[#_ -]4 :-%
M9W_"1:9_S^P_]]4?\)%IG_/[#_WU0!HT5G?\)%IG_/[#_P!]4?\ "1:9_P _
ML/\ WU0!HT5G?\)%IG_/[#_WU1_PD6F?\_L/_?5 &C16=_PD6F?\_L/_ 'U1
M_P )%IG_ #^P_P#?5 &C16=_PD6F?\_L/_?5'_"1:9_S^P_]]4 :-%9W_"1:
M9_S^P_\ ?5'_  D6F?\ /[#_ -]4 :-%9W_"1:9_S^P_]]4?\)%IG_/[#_WU
M0!HT5G?\)%IG_/[#_P!]4?\ "1:9_P _L/\ WU0!HT5G?\)%IG_/[#_WU1_P
MD6F?\_L/_?5 &C16=_PD6F?\_L/_ 'U1_P )%IG_ #^P_P#?5 &C16=_PD6F
M?\_L/_?5'_"1:9_S^P_]]4 :-%9K>)-,49-[%^!S2_\ "1:9_P _L/\ WU0!
MHT5G?\)%IG_/[#_WU1_PD6F?\_L/_?5 &C16=_PD6F?\_L/_ 'U1_P )%IG_
M #^P_P#?5 &C16=_PD6F?\_L/_?5'_"1:9_S^P_]]4 :-%9W_"1:9_S^P_\
M?5'_  D6F?\ /[#_ -]4 :-%9W_"1:9_S^P_]]4?\)%IG_/[#_WU0!HT5G?\
M)%IG_/[#_P!]4?\ "1:9_P _L/\ WU0!HT5G?\)%IG_/[#_WU1_PD6F?\_L/
M_?5 &C16=_PD6F?\_L/_ 'U1_P )%IG_ #^P_P#?5 &C16=_PD6F?\_L/_?5
M'_"1:9_S^P_]]4 :-%9W_"1:9_S^P_\ ?5'_  D6F?\ /[#_ -]4 :-%9W_"
M1:9_S^P_]]4?\)%IG_/[#_WU0!HT5G?\)%IG_/[#_P!]4?\ "1:9_P _L/\
MWU0!HT5G?\)%IG_/[#_WU1_PD6F?\_L/_?5 &C16=_PD6F?\_L/_ 'U1_P )
M%IG_ #^P_P#?5 &C16=_PD6F?\_L/_?5'_"1:9_S^P_]]4 :-%9W_"1:9_S^
MP_\ ?5'_  D6F?\ /[#_ -]4 :-%9W_"1:9_S^P_]]4?\)%IG_/[#_WU0!HT
M5G?\)%IG_/[#_P!]4?\ "1:9_P _L/\ WU0!HT5G?\)%IG_/[#_WU1_PD6F?
M\_L/_?5 &C16=_PD6F?\_L/_ 'U1_P )%IG_ #^P_P#?5 &C16=_PD6F?\_L
M/_?5'_"1:9_S^P_]]4 :-%9W_"1:9_S^P_\ ?5'_  D6F?\ /[#_ -]4 :-%
M9W_"1:9_S^P_]]4?\)%IG_/[#_WU0!HT5G?\)%IG_/[#_P!]4?\ "1:9_P _
ML/\ WU0!HT5G?\)%IG_/[#_WU1_PD6F?\_L/_?5 &C16=_PD6F?\_L/_ 'U1
M_P )%IG_ #^P_P#?5 &C16=_PD6F?\_L/_?5'_"1:9_S^P_]]4 :-%9W_"1:
M9_S^P_\ ?5'_  D6F?\ /[#_ -]4 :-%9W_"1:9_S^P_]]4?\)%IG_/[#_WU
M0!HT5G?\)%IG_/[#_P!]4?\ "1:9_P _L/\ WU0!HT5G?\)%IG_/[#_WU1_P
MD6F?\_L/_?5 &C16=_PD6F?\_L/_ 'U1_P )%IG_ #^P_P#?5 &C16=_PD6F
M?\_L/_?5'_"1:9_S^P_]]4 :-%9O_"2:9DC[;%Q[TO\ PD6F?\_L/_?5 &C1
M6=_PD6F?\_L/_?5'_"1:9_S^P_\ ?5 &C16=_P )%IG_ #^P_P#?5'_"1:9_
MS^P_]]4 :-%9W_"1:9_S^P_]]4?\)%IG_/[#_P!]4 :-%9W_  D6F?\ /[#_
M -]4?\)%IG_/[#_WU0!HT5G?\)%IG_/[#_WU1_PD6F?\_L/_ 'U0!HT5G?\
M"1:9_P _L/\ WU1_PD6F?\_L/_?5 &C16=_PD6F?\_L/_?5'_"1:9_S^P_\
M?5 &C16=_P )%IG_ #^P_P#?5'_"1:9_S^P_]]4 :-%9W_"1:9_S^P_]]4?\
M)%IG_/[#_P!]4 :-%9W_  D6F?\ /[#_ -]4?\)%IG_/[#_WU0!HT5G?\)%I
MG_/[#_WU1_PD6F?\_L/_ 'U0!HT5G?\ "1:9_P _L/\ WU1_PD6F?\_L/_?5
M &C16=_PD6F?\_L/_?5'_"1:9_S^P_\ ?5 &C16=_P )%IG_ #^P_P#?5'_"
M1:9_S^P_]]4 :-%9W_"1:9_S^P_]]4?\)%IG_/[#_P!]4 :-%9W_  D6F?\
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M(M,_Y_8?^^J -&BL[_A(M,_Y_8?^^J/^$BTS_G]A_P"^J -&BL[_ (2+3/\
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MS_G]A_[ZH_X2+3/^?V'_ +ZH T:*SO\ A(M,_P"?V'_OJC_A(M,_Y_8?^^J
M-&BL[_A(M,_Y_8?^^J/^$BTS_G]A_P"^J -&BL[_ (2+3/\ G]A_[ZH_X2+3
M/^?V'_OJ@#1HK._X2+3/^?V'_OJC_A(M,_Y_8?\ OJ@#1HK._P"$BTS_ )_8
M?^^J/^$BTS_G]A_[ZH T:*SO^$BTS_G]A_[ZH_X2+3/^?V'_ +ZH T:*SO\
MA(M,_P"?V'_OJC_A(M,_Y_8?^^J -&BL[_A(M,_Y_8?^^J/^$BTS_G]A_P"^
MJ -&BL[_ (2+3/\ G]A_[ZH_X2+3/^?V'_OJ@#1HK._X2+3/^?V'_OJC_A(M
M,_Y_8?\ OJ@#1HK._P"$BTS_ )_8?^^J/^$BTS_G]A_[ZH T:*SO^$BTS_G]
MA_[ZH_X2+3/^?V'_ +ZH T:*SO\ A(M,_P"?V'_OJC_A(M,_Y_8?^^J -&BL
M[_A(M,_Y_8?^^J/^$BTS_G]A_P"^J -&BL[_ (2+3/\ G]A_[ZH_X2+3/^?V
M'_OJ@#1HK._X2+3/^?V'_OJC_A(M,_Y_8?\ OJ@#1HK._P"$BTS_ )_8?^^J
M/^$BTS_G]A_[ZH T:*SO^$BTS_G]A_[ZH_X2+3/^?V'_ +ZH T:*SO\ A(M,
M_P"?V'_OJC_A(M,_Y_8?^^J -&BL[_A(M,_Y_8?^^J/^$BTS_G]A_P"^J -&
MBL[_ (2+3/\ G]A_[ZH_X2+3/^?V'_OJ@#1HK._X2+3/^?V'_OJC_A(M,_Y_
M8?\ OJ@#1HK._P"$BTS_ )_8?^^J1O$FF*,F]B_ YH TJ*SO^$BTS_G]A_[Z
MH_X2+3/^?V'_ +ZH T:*SO\ A(M,_P"?V'_OJC_A(M,_Y_8?^^J -&BL[_A(
MM,_Y_8?^^J/^$BTS_G]A_P"^J -&BL[_ (2+3/\ G]A_[ZH_X2+3/^?V'_OJ
M@#1HK._X2+3/^?V'_OJC_A(M,_Y_8?\ OJ@#1HK._P"$BTS_ )_8?^^J/^$B
MTS_G]A_[ZH T:*SO^$BTS_G]A_[ZH_X2+3/^?V'_ +ZH T:*SO\ A(M,_P"?
MV'_OJC_A(M,_Y_8?^^J -&BL[_A(M,_Y_8?^^J/^$BTS_G]A_P"^J -&BL[_
M (2+3/\ G]A_[ZH_X2+3/^?V'_OJ@#1HK._X2+3/^?V'_OJC_A(M,_Y_8?\
MOJ@#1HK._P"$BTS_ )_8?^^J/^$BTS_G]A_[ZH T:*SO^$BTS_G]A_[ZH_X2
M+3/^?V'_ +ZH T:*SO\ A(M,_P"?V'_OJC_A(M,_Y_8?^^J -&BL[_A(M,_Y
M_8?^^J/^$BTS_G]A_P"^J -&BL[_ (2+3/\ G]A_[ZH_X2+3/^?V'_OJ@#1H
MK._X2+3/^?V'_OJC_A(M,_Y_8?\ OJ@#1HK._P"$BTS_ )_8?^^J/^$BTS_G
M]A_[ZH T:*SO^$BTS_G]A_[ZH_X2+3/^?V'_ +ZH T:*SO\ A(M,_P"?V'_O
MJC_A(M,_Y_8?^^J -&BL[_A(M,_Y_8?^^J/^$BTS_G]A_P"^J -&BL[_ (2+
M3/\ G]A_[ZH_X2+3/^?V'_OJ@#1HK._X2+3/^?V'_OJC_A(M,_Y_8?\ OJ@#
M1HK._P"$BTS_ )_8?^^J/^$BTS_G]A_[ZH T:*SO^$BTS_G]A_[ZH_X2+3/^
M?V'_ +ZH T:*SO\ A(M,_P"?V'_OJC_A(M,_Y_8?^^J -&BL[_A(M,_Y_8?^
M^J/^$BTS_G]A_P"^J -&BL[_ (2+3/\ G]A_[ZH_X2+3/^?V'_OJ@#1HK._X
M2+3/^?V'_OJC_A(M,_Y_8?\ OJ@#1HK._P"$BTS_ )_8?^^J/^$BTS_G]A_[
MZH T:*SO^$BTS_G]A_[ZH_X2+3/^?V'_ +ZH T:*SO\ A(M,_P"?V'_OJC_A
M(M,_Y_8?^^J -&BL[_A(M,_Y_8?^^J/^$BTS_G]A_P"^J -&BDT5H_$$LD=A
M+'.T8W/AN@-;'_"+WWI'_P!]4 4_!>D6&HZAXF>[LK>Z==4F ::)7(&>G(KJ
MO^$7T;_H$V/_ (#)_A6!\/O^/[Q1_P!A6;^==E0!F?\ "+Z-_P! FQ_\!D_P
MH_X1?1O^@38_^ R?X5IT4 9G_"+Z-_T";'_P&3_"C_A%]&_Z!-C_ . R?X5I
MT4 9G_"+Z-_T";'_ ,!D_P */^$7T;_H$V/_ (#)_A6G10!F?\(OHW_0)L?_
M  &3_"C_ (1?1O\ H$V/_@,G^%:=% &9_P (OHW_ $";'_P&3_"C_A%]&_Z!
M-C_X#)_A6G10!F?\(OHW_0)L?_ 9/\*/^$7T;_H$V/\ X#)_A6G10!F?\(OH
MW_0)L?\ P&3_  H_X1?1O^@38_\ @,G^%:=% &9_PB^C?] FQ_\  9/\*/\
MA%]&_P"@38_^ R?X5IT4 9G_  B^C?\ 0)L?_ 9/\*/^$7T;_H$V/_@,G^%:
M=% &9_PB^C?] FQ_\!D_PH_X1?1O^@38_P#@,G^%:=% &9_PB^C?] FQ_P#
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M/\*/^$7T;_H$V/\ X#)_A6G10!F?\(OHW_0)L?\ P&3_  H_X1?1O^@38_\
M@,G^%:=% &9_PB^C?] FQ_\  9/\*/\ A%]&_P"@38_^ R?X5IT4 9G_  B^
MC?\ 0)L?_ 9/\*/^$7T;_H$V/_@,G^%:=% &9_PB^C?] FQ_\!D_PH_X1?1O
M^@38_P#@,G^%:=% &9_PB^C?] FQ_P# 9/\ "C_A%]&_Z!-C_P" R?X5IT4
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M (#)_A1_PB^C?] FQ_\  9/\*TZ* ,S_ (1?1O\ H$V/_@,G^%'_  B^C?\
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M#)_A1_PB^C?] FQ_\!D_PK3HH S/^$7T;_H$V/\ X#)_A1_PB^C?] FQ_P#
M9/\ "M.B@#,_X1?1O^@38_\ @,G^%'_"+Z-_T";'_P !D_PK3HH S/\ A%]&
M_P"@38_^ R?X4?\ "+Z-_P! FQ_\!D_PK3HH S/^$7T;_H$V/_@,G^%'_"+Z
M-_T";'_P&3_"M.B@#,_X1?1O^@38_P#@,G^%'_"+Z-_T";'_ ,!D_P *TZ*
M,S_A%]&_Z!-C_P" R?X4?\(OHW_0)L?_  &3_"M.B@#,_P"$7T;_ *!-C_X#
M)_A1_P (OHW_ $";'_P&3_"M.B@#,_X1?1O^@38_^ R?X4?\(OHW_0)L?_ 9
M/\*TZ* ,S_A%]&_Z!-C_ . R?X4?\(OHW_0)L?\ P&3_  K3HH S/^$7T;_H
M$V/_ (#)_A1_PB^C?] FQ_\  9/\*TZ* ,S_ (1?1O\ H$V/_@,G^%'_  B^
MC?\ 0)L?_ 9/\*TZ* ,S_A%]&_Z!-C_X#)_A1_PB^C?] FQ_\!D_PK3HH X3
MXE:%IMGX-OYK?3K6"93'B2*!589D4<$"NCM_#.CM;Q$Z38DE1_R[)Z?2LKXJ
M?\B+J/UB_P#1BUT]M_QZP_[@_E0!2_X1?1O^@38_^ R?X4?\(OHW_0)L?_ 9
M/\*TZ* ,S_A%]&_Z!-C_ . R?X4?\(OHW_0)L?\ P&3_  K3HH S/^$7T;_H
M$V/_ (#)_A1_PB^C?] FQ_\  9/\*TZ* ,S_ (1?1O\ H$V/_@,G^%'_  B^
MC?\ 0)L?_ 9/\*TZ* ,S_A%]&_Z!-C_X#)_A1_PB^C?] FQ_\!D_PK3HH S/
M^$7T;_H$V/\ X#)_A1_PB^C?] FQ_P# 9/\ "M.B@#,_X1?1O^@38_\ @,G^
M%'_"+Z-_T";'_P !D_PK3HH S/\ A%]&_P"@38_^ R?X4?\ "+Z-_P! FQ_\
M!D_PK3HH S/^$7T;_H$V/_@,G^%'_"+Z-_T";'_P&3_"M.B@#,_X1?1O^@38
M_P#@,G^%'_"+Z-_T";'_ ,!D_P *TZ* ,S_A%]&_Z!-C_P" R?X4?\(OHW_0
M)L?_  &3_"M.B@#,_P"$7T;_ *!-C_X#)_A1_P (OHW_ $";'_P&3_"M.B@#
M,_X1?1O^@38_^ R?X4?\(OHW_0)L?_ 9/\*TZ* ,S_A%]&_Z!-C_ . R?X4?
M\(OHW_0)L?\ P&3_  K3HH S/^$7T;_H$V/_ (#)_A1_PB^C?] FQ_\  9/\
M*TZ* ,S_ (1?1O\ H$V/_@,G^%'_  B^C?\ 0)L?_ 9/\*TZ* ,S_A%]&_Z!
M-C_X#)_A1_PB^C?] FQ_\!D_PK3HH S/^$7T;_H$V/\ X#)_A1_PB^C?] FQ
M_P# 9/\ "M.B@#,_X1?1O^@38_\ @,G^%'_"+Z-_T";'_P !D_PK3HH S/\
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MH S/^$7T;_H$V/\ X#)_A1_PB^C?] FQ_P# 9/\ "M.B@#,_X1?1O^@38_\
M@,G^%'_"+Z-_T";'_P !D_PK3HH S/\ A%]&_P"@38_^ R?X4?\ "+Z-_P!
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MIG_0.M/^_"_X4?V#IG_0.M/^_"_X5?HH H?V#IG_ $#K3_OPO^%']@Z9_P!
MZT_[\+_A5^B@"A_8.F?] ZT_[\+_ (4?V#IG_0.M/^_"_P"%7Z* *']@Z9_T
M#K3_ +\+_A1_8.F?] ZT_P"_"_X5?HH H?V#IG_0.M/^_"_X4?V#IG_0.M/^
M_"_X5?HH H?V#IG_ $#K3_OPO^%']@Z9_P! ZT_[\+_A5^B@"A_8.F?] ZT_
M[\+_ (4?V#IG_0.M/^_"_P"%7Z* *']@Z9_T#K3_ +\+_A1_8.F?] ZT_P"_
M"_X5?HH H?V#IG_0.M/^_"_X4?V#IG_0.M/^_"_X5?HH H?V#IG_ $#K3_OP
MO^%']@Z9_P! ZT_[\+_A5^B@"A_8.F?] ZT_[\+_ (4?V#IG_0.M/^_"_P"%
M7Z* *']@Z9_T#K3_ +\+_A1_8.F?] ZT_P"_"_X5?HH H?V#IG_0.M/^_"_X
M4?V#IG_0.M/^_"_X5?HH H?V#IG_ $#K3_OPO^%']@Z9_P! ZT_[\+_A5^B@
M"A_8.F?] ZT_[\+_ (4?V#IG_0.M/^_"_P"%7Z* *']@Z9_T#K3_ +\+_A1_
M8.F?] ZT_P"_"_X5?HH H?V#IG_0.M/^_"_X4?V#IG_0.M/^_"_X5?HH H?V
M#IG_ $#K3_OPO^%']@Z9_P! ZT_[\+_A5^B@"A_8.F?] ZT_[\+_ (4?V#IG
M_0.M/^_"_P"%7Z* *']@Z9_T#K3_ +\+_A1_8.F?] ZT_P"_"_X5?HH H?V#
MIG_0.M/^_"_X4?V#IG_0.M/^_"_X5?HH H?V#IG_ $#K3_OPO^%']@Z9_P!
MZT_[\+_A5^B@"A_8.F?] ZT_[\+_ (4?V#IG_0.M/^_"_P"%7Z* *']@Z9_T
M#K3_ +\+_A7/>(]*LH=<T!([.W1))G#JL2@,,#@\<UV%<SXG_P"1@\.?]=W_
M )"C4#7_ +!TS_H'6G_?A?\ "C^P=,_Z!UI_WX7_  J_10!0_L'3/^@=:?\
M?A?\*/[!TS_H'6G_ 'X7_"K]% %#^P=,_P"@=:?]^%_PH_L'3/\ H'6G_?A?
M\*OT4 4/[!TS_H'6G_?A?\*/[!TS_H'6G_?A?\*OT4 4/[!TS_H'6G_?A?\
M"C^P=,_Z!UI_WX7_  J_10!0_L'3/^@=:?\ ?A?\*/[!TS_H'6G_ 'X7_"K]
M% %#^P=,_P"@=:?]^%_PH_L'3/\ H'6G_?A?\*OT4 4/[!TS_H'6G_?A?\*/
M[!TS_H'6G_?A?\*OT4 4/[!TS_H'6G_?A?\ "C^P=,_Z!UI_WX7_  J_10!0
M_L'3/^@=:?\ ?A?\*/[!TS_H'6G_ 'X7_"K]% %#^P=,_P"@=:?]^%_PH_L'
M3/\ H'6G_?A?\*OT4 4/[!TS_H'6G_?A?\*/[!TS_H'6G_?A?\*OT4 4/[!T
MS_H'6G_?A?\ "C^P=,_Z!UI_WX7_  J_10!0_L'3/^@=:?\ ?A?\*/[!TS_H
M'6G_ 'X7_"K]% %#^P=,_P"@=:?]^%_PH_L'3/\ H'6G_?A?\*OT4 4/[!TS
M_H'6G_?A?\*/[!TS_H'6G_?A?\*OT4 4/[!TS_H'6G_?A?\ "C^P=,_Z!UI_
MWX7_  J_10!0_L'3/^@=:?\ ?A?\*/[!TS_H'6G_ 'X7_"K]% %#^P=,_P"@
M=:?]^%_PH_L'3/\ H'6G_?A?\*OT4 4/[!TS_H'6G_?A?\*/[!TS_H'6G_?A
M?\*OT4 4/[!TS_H'6G_?A?\ "C^P=,_Z!UI_WX7_  J_10!0_L'3/^@=:?\
M?A?\*/[!TS_H'6G_ 'X7_"K]% %#^P=,_P"@=:?]^%_PH_L'3/\ H'6G_?A?
M\*OT4 4/[!TS_H'6G_?A?\*/[!TS_H'6G_?A?\*OT4 4/[!TS_H'6G_?A?\
M"C^P=,_Z!UI_WX7_  J_10!0_L'3/^@=:?\ ?A?\*/[!TS_H'6G_ 'X7_"K]
M% %#^P=,_P"@=:?]^%_PH_L'3/\ H'6G_?A?\*OT4 4/[!TS_H'6G_?A?\*/
M[!TS_H'6G_?A?\*OT4 4/[!TS_H'6G_?A?\ "C^P=,_Z!UI_WX7_  J_10!0
M_L'3/^@=:?\ ?A?\*/[!TS_H'6G_ 'X7_"K]% %#^P=,_P"@=:?]^%_PH_L'
M3/\ H'6G_?A?\*OT4 4/[!TS_H'6G_?A?\*P_&VDV-MX7O9(;*WBD4)ATB4$
M?.O<"NKKG_'O_(J7_P!$_P#0UI,"Y:Z'IK6L).GVI)12285]/I4O]@Z9_P!
MZT_[\+_A5FS_ ./6#_<7^534P*']@Z9_T#K3_OPO^%']@Z9_T#K3_OPO^%7Z
M* *']@Z9_P! ZT_[\+_A1_8.F?\ 0.M/^_"_X5?HH H?V#IG_0.M/^_"_P"%
M']@Z9_T#K3_OPO\ A5^B@"A_8.F?] ZT_P"_"_X4?V#IG_0.M/\ OPO^%7Z*
M *']@Z9_T#K3_OPO^%']@Z9_T#K3_OPO^%7Z* *']@Z9_P! ZT_[\+_A1_8.
MF?\ 0.M/^_"_X5?HH H?V#IG_0.M/^_"_P"%']@Z9_T#K3_OPO\ A5^B@"A_
M8.F?] ZT_P"_"_X4?V#IG_0.M/\ OPO^%7Z* *']@Z9_T#K3_OPO^%']@Z9_
MT#K3_OPO^%7Z* *']@Z9_P! ZT_[\+_A1_8.F?\ 0.M/^_"_X5?HH H?V#IG
M_0.M/^_"_P"%']@Z9_T#K3_OPO\ A5^B@"A_8.F?] ZT_P"_"_X4?V#IG_0.
MM/\ OPO^%7Z* *']@Z9_T#K3_OPO^%']@Z9_T#K3_OPO^%7Z* *']@Z9_P!
MZT_[\+_A1_8.F?\ 0.M/^_"_X5?HH H?V#IG_0.M/^_"_P"%']@Z9_T#K3_O
MPO\ A5^B@"A_8.F?] ZT_P"_"_X4?V#IG_0.M/\ OPO^%7Z* *']@Z9_T#K3
M_OPO^%']@Z9_T#K3_OPO^%7Z* *']@Z9_P! ZT_[\+_A1_8.F?\ 0.M/^_"_
MX5?HH H?V#IG_0.M/^_"_P"%']@Z9_T#K3_OPO\ A5^B@"A_8.F?] ZT_P"_
M"_X4?V#IG_0.M/\ OPO^%7Z* *']@Z9_T#K3_OPO^%']@Z9_T#K3_OPO^%7Z
M* *']@Z9_P! ZT_[\+_A1_8.F?\ 0.M/^_"_X5?HH H?V#IG_0.M/^_"_P"%
M']@Z9_T#K3_OPO\ A5^B@"A_8.F?] ZT_P"_"_X4?V#IG_0.M/\ OPO^%7Z*
M *']@Z9_T#K3_OPO^%']@Z9_T#K3_OPO^%7Z* *']@Z9_P! ZT_[\+_A1_8.
MF?\ 0.M/^_"_X5?HH H?V#IG_0.M/^_"_P"%']@Z9_T#K3_OPO\ A5^B@"A_
M8.F?] ZT_P"_"_X4?V#IG_0.M/\ OPO^%7Z* *']@Z9_T#K3_OPO^%']@Z9_
MT#K3_OPO^%7Z* *']@Z9_P! ZT_[\+_A1_8.F?\ 0.M/^_"_X5?HH H?V#IG
M_0.M/^_"_P"%']@Z9_T#K3_OPO\ A5^B@"A_8.F?] ZT_P"_"_X4?V#IG_0.
MM/\ OPO^%7Z* ,.ZE_L'6]%CT^.&S2\N1#.(HE&]>.#Q7HE><>(/^1@\,?\
M7\/Z5Z/6;W*1QOP^_P"/[Q1_V%9OYUV5<;\/O^/[Q1_V%9OYUV5(84444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<;J7_
M "5#2/\ KRD_FU=E7&ZE_P E0TC_ *\I/YM0!V5%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R7Q4_Y$74?K%_Z,
M6NGMO^/6'_<'\JYCXJ?\B+J/UB_]&+73VW_'K#_N#^5 $U%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ><Z;_R.WBK_ *Z0?^@M
M6]6#IO\ R.WBK_KI!_Z"U;U:+8EA1113$%%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KG_'O_(J7_T3_P!#6N@KG_'O_(J7_P!$_P#0UH>P&U9_\>L'^XO\JFJ&
MS_X]8/\ <7^534 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!@>(/\ D8/#'_7\/Z5Z/7G'B#_D8/#'_7\/Z5Z/6;W*1QOP^_X_O%'_
M &%9OYUV5<;\/O\ C^\4?]A6;^==E2&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7&ZE_R5#2/^O*3^;5V5<;J7_)4-
M(_Z\I/YM0!V5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!R7Q4_Y$74?K%_Z,6NGMO\ CUA_W!_*N8^*G_(BZC]8
MO_1BUT]M_P >L/\ N#^5 $U%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ><Z;_R.WBK_KI!_P"@M6]6#IO_ ".WBK_KI!_Z"U;U
M:+8EA1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% ',^!/^/35/^PA+_):Z:N9\"?\>FJ?]A"7^2UT
MU" **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *YGQ/_P C!X<_Z[O_ "%=-7,^)_\ D8/#G_7=_P"0H Z:BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_ ![_ ,BI?_1/_0UK
MH*Y_Q[_R*E_]$_\ 0UH>P&U9_P#'K!_N+_*IJAL_^/6#_<7^534 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ><Z;_ ,CMXJ_ZZ0?^@M6]6#IO_([>*O\
MKI!_Z"U;U:+8EA1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% ',^!/^/35/\ L(2_R6NFKF? G_'I
MJG_80E_DM=-0@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N9\3_\C!X<_P"N[_R%=-7,^)_^1@\.?]=W_D*
M.FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y_Q[_P BI?\
MT3_T-:Z"N?\ 'O\ R*E_]$_]#6A[ ;5G_P >L'^XO\JFJ&S_ ./6#_<7^534
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZV5?FPKK0ZQO^!\I_L6_!"S^.WQNLM*U:(SZ#IT#ZCJ$.2OG1H558B1T#.Z
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M^/35/^PA+_):Z:OSST/_ (*=?V+#=)_PK;SO/N'GS_;NW;NQQ_Q['TZUI?\
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M (>I?]4P_P#+@_\ N6C_ (>I?]4P_P#+@_\ N6C^SL3_ "?B@_M3"_S?@_\
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M (>I?]4P_P#+@_\ N6C_ (>I?]4P_P#+@_\ N6C^SL3_ "?B@_M3"_S?@_\
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M'I/_ %3+_P K_P#]S4_[.Q/\GXH?]IX3^;\&?>=%?!W_  ](_P"J9?\ E?\
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M,_\ ,-_\C_\ V-'LY=A^TCW.XHKB/^%E?]0[_P C_P#V-.'Q(S_S#O\ R/\
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M_P#]:CE8<R-FBLC^W_\ IA_X_P#_ %J4:]G_ )8?^/\ _P!:CE8<R-:BLO\
MMK=_RQ_\>_\ K4HUG/\ RQ_\>_\ K4<K#F1IT5F_VQ_TR_\ 'O\ ZU+_ &O_
M -,O_'O_ *U'*Q\R-&BL_P#M;_IE_P"/?_6I?[4_Z9_^/?\ UJ5F%T7Z*H_V
ME_TS_P#'O_K4O]H?],__ ![_ .M2LPNB[15/^T/^F?ZTOV[_ &/UHLPNBW15
M7[9_L?K2_:_]C]:+!=%FBJ_VK_9_6E%UG^']:+#N3T5#]H_V/UH%QG^']:+
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MX)[_ /)I_@W_ 'KW_P!+9Z^CZY\<_P#:ZC7=_F;8!?[+!>1^,_\ P[_^/?\
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M_P!LCX9:38O<6^K7&K2*0!;6=G()&]QY@1?_ !ZN7;]OCP-VT3Q!_P!^(/\
MX]7PAQ1Q7I1X4P$5JY/Y_P"2/&J<=9I)^ZHKT7^;/N__ (;X\#'_ )@OB'_P
M'@_^/5T7A[]L_P"&NM6CRW=_>Z)(K;1#?6C%S[CRMXQ]37YW'!Z"DHEPI@)*
MR<E\_P#-"AQUFL)7EROR:_X*/U&\._'_ .'OB:W:6Q\5:>%5MA%U)]G;/LL@
M4G\!7>6]Y!<QAXIDE0@$,C @@]#Q7X_J^WH2*Z#P_P#$3Q)X7:5M*UF\LC*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMHW? &XK&H!. !D^E=!UHH-)MR=V"BHJR%HHHH&%%%% !1110 4444 %%%%
M!1110 5QNI?\E0TC_KRD_FU=E7&ZE_R5#2/^O*3^;4 =E1110 4444 %%%%
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MX7T^\>N17Y^>-/ _B'X?ZP^F^(]+N=+OASLN%X<?WE;HP]P2*^M?B)_R;O\
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M?IE^U%XEU+PG\%->U31[V73[^'RA'<0-M=<R*#@]N*_/@?M(?$T9/_";:O\
M7SS7T5=?$>^^)'[#NJW.J2F?4-/ECT^6=CEI=DD95C[[6 )[D9KY#\'^'9?%
MWBG2=$AE$4FH74=L)&&0N]@N?PSFM\CP-&CAZL<3!-PDTVTGLD<W$>8U\1B:
M,\+.45.*:2;6K;[':P_M+?%"UD#IXUU0MVW2!Q^1!!KVGX2_MZ:]I=[!9>.8
M(]6T]B%;4+6,1SQ_[1485Q] #]:]ZL_V*?A=;^'(]-FT>:XN=F&U%KJ19V;'
M+<':/IMQ7#>$?V M"T'QL-1U369-9T.%_,ATZ2':SG.0LK X*CO@#/M7%6S+
M),53G&=*UMM$F_1K]3TZ&4\0X.K"5.KS7WU;2]4_T/J+0]<L_$>C66J:=.MS
M8WD2SP3+G#HPR#S[5\"_M-?'3Q[X1^.WB/3='\4W]A86;0B&VA<"-,PHQ^7&
M#R2>?6OT&M[>.U@2&&-8XHU"JB#  '0 =A7Y>_M? G]HCQ</]N#_ -$1UY'#
M-&E7QDU.*:L]]>J/<XNK5J& IRA)QE=7:;70^YOV6_BMJ'Q>^%<&JZNJ_P!I
MVUQ)9S2Q@*LQ4*0^!T)##..X-=[\0/B!HWPT\,W6NZ[=K:V5N/J[MV11W8^E
M?,O[(/Q T7X9_LXZQKNNW(MK2'5IN.KR-Y46$4=V/I7S!\=/CMK7QN\3M>WK
M-:Z3;DK8Z:K92)?4^KGN?P'%73R1XW,*D8KEIQD_^&7]:&-3B)8#*Z,I/FK2
MBK+]7_6IUOQ+_;*\?^--<GETC5)O#>D*Q%O9V1"OM[%WQDM]#CVK[(_9,\7>
M)O''P>L=4\42-<7C3RI#<R+M>>%2 K-ZG.X9[@"ODG]EW]EVZ^*U_#X@UZ&2
MU\)P/D*<JUZP/W%_V?5OP'/3]%--T^VTFQ@LK*".VM;=!''#$H544#   Z"M
M.(*N!HTXX/"P7-%ZM+;RONWW(X8H9C7J2Q^+F^62T3;U\[=%V+M%%%?#GZ0%
M%%% !1110!R7Q4_Y$74?K%_Z,6NGMO\ CUA_W!_*N8^*G_(BZC]8O_1BUT]M
M_P >L/\ N#^5 $U%%% !1110 4444 %%%% !1110 4444 )W-?E_^V7_ ,G)
M^,/^W/\ ](X*_4#N:_+_ /;+_P"3D_&'_;G_ .D<%?5\-?[Z_P#"_P T>5F7
M\)>OZ,]=_8I\5?\ "#_"/XH>(/)^U'3$2[\G.-^R*1MN??%?2/PA_:(\(_&*
MT4:7>"UU0#,FF73!9E]Q_>'N*^4/V9O^3;/C=_UX-_Z3RU\NV-_<Z7>175G<
M2VMS$VZ.:%RCH?4$<@UZ]7*Z>8XC$-NTDU9_]NKH<<,5+#TZ?5-?J?KYXZ^'
MOA[XCZ+)I?B#38=0M7! \Q?GC)'WD;JI]Q6')\$O#<^@>&=%N(9+O3] C\JV
MBF?(<8 &_P#O?=%> _L>_M+>)_B%XB7P?XD\O4?+M'FAU(_+-\F/E?'#<'KP
M?7-?7LCB.-B>PS7R&*HXC U/83EMJK/37J>A*&&QU%^U@I1>Z:[.^OSU(+.S
MM]+M4AMX8[>",85(U"@#V KSW7OCMX>TGQ18>'[*3^U-1NKA;=Q;L-D.3C+-
MZCT%?.OQ@^/_ (C\4:G?Z3:2_P!DZ7#*T1CMV/F2 '&7?K^ P.>]<-\+/^2B
M>'O47T/_ *&*Z*6 ?(ZE5_(_'<R\0(_6X8#*H:<RBY-=+V=E^K-G]H9MWQA\
M1G_II'_Z)2O9OV,_^0-XB_Z^(_\ T$UXQ^T)_P E@\0_[\7_ *)2O9_V,_\
MD#>(O^OB/_T$UU8C_<UZ+]#Y3AS_ )+2?^*I^I1_X*!?\D?TO_L+Q_\ HJ6O
M+/V%OB3X7\!V/BI/$6N6>D-<20&(74@3> &SC\Q7J?\ P4#_ .2/Z7_V%X__
M $5+7R'\&_V>_$GQPAU.30+C3X%T]D67[9(R9W9QC"GT->QE].C6RB4*\N6-
M]_FC]_Q$IPQ:<%=V/M7XZ?M&?#F7X6^(+.UU[3]<N[RV:WBL;>3S&=FX!([
M=<^U?+G[$/AN_P!:^.NGZC;1,;/3(9I[F7'RJ&C9%'U+,/UIGC+]B?XB>#_#
MM[K$ITS48;-#++#8SN\NP=6"E!G Y/->B?L(_&*VTW6'\ W6G6UO)?[Y[:^@
MCVRR2*I8I*?XAM!VGMC'>K]G1PN6U5@I>TOOKMI_D+FG4Q$/;+E['VSK6J0Z
M'I%[J%PZQP6L+S.S'  4$]:_+GP7X>N_VB/CG/;W,TN[5IKFZDFZF-0CLOX
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M3AAZ$'D&OS0_9GUIO#/QZ\*3DD+]L-NZ@]0ZLF/S(/X5^I6JMC3;HGIY+_\
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MW9QD9QUKT!?^"&N?^:U_^6I_]VTH^]'FZ7?X%S2C+EOK9/[S]4Z/YU^4M_\
M\$2M;T:SDO/#GQFAEUB(;K=9]!>S0N.F94N9&3GN%/TK'_9!_:D^+?[-O[3<
M7P+^,FKWNL:;>7J:8K:I=-=R6-Q(!]GD@G8EF@DS&-I. '! 4A@;@E*7*GK^
M9$KQ3ET1^N=+2#H*1FVY)J6[##WHXYKR?X+?M2?#+]H:\UFU^'_B;_A(+G1O
M+-\GV"ZMO)WE@G,T2!LE&^[GI]*]8JK"V;743N*/6EK\X-&_XR,_X*U7]\,3
MZ'\,-+,"-G<AG12F/9A/<R'_ +8U*]Z:CZOY('[L'/L?H]G%*.M?D'^W@,_\
M%0OA@?\ IOH'_I8:_7M>5'TII7IJIW;7W#?NSY?)/[QWL*;N R:%_I7Y ^/_
M /E,]8G_ *C5C_Z;HJF+YJD8=PEI3E/LC]?BW&3TI:X#X_'_ (L7\0?^Q>O_
M /TG>OQ)_8G_ &$I/VR++Q9<1^-4\)?V#);(5;2S>>?YHD.?]='MQY?OG/:B
M-Y2E%+9)_>-VC%2;W/WWI*_*3_AQK=?]%FA_\)D__)='_#C6Z_Z+-#_X3)_^
M2ZH1^K'O2YZ8Z5R'PE\"M\+_ (6>$O!YO1J+>'](M=+-X(O*$_DQ+'OV9.W.
MW.,G&>IK\39OV>?^&HO^"A'Q*\!'Q!_PC1O/$6M3_P!H_8OM>SRI97QY?F1Y
MSC&=W'O2=W4]G'71N_H"_A\\M-OQ/WCZT=*_*S_AQGC_ )K9_P"6I_\ =M87
MC+_@D/\ $WX1Z-/XA^%WQ6?6/$%FAF6SM[:71KF7:,[894GD!<XX#%1_M"AM
M)78TKNQ^MU'X5^=__!+O]M+Q3\8+G6/A?\0[R74_$ND6OVO3]4NP?M-Q"CA)
M8IS_ !2(60AC\Q!;=DKD_1O[;O[3J?LK? ^]\3VT$-]XAO)ET_1[6X)\M[EP
M6WN!R41%9B,C. N1NS14_=I-ZWV\Q4[SDXVU6Y]"?SH)!K\D?A!^PO\ %G]N
M/PO:?$GXR?%75K+2]7)N=-TUHS<2/"<XD6(NL5LAP"JHIR.<#(SF_&3]FGXU
M?\$W;&T^(7PR^)5_KW@FUNT6_P!/F1XHH=[;5%Q:[VCEC8D)Y@VL"PP%X:F_
M==JFG]=07O?!J?L .E+7E'[,?QVT_P#:0^#'A[QY80?8GU"-H[NRW;OLUQ&Q
M26//<;AD'NI4UZOZTY)Q=F3&2EJ+1112*"BBB@ HHI* %HHI#T- "4=*_#G]
MIKX0GX^?\%/O$_@%=5_L1M;U&WA_M!K?SQ#MTZ)\^7N7=]S'WAUKVS_AQO=-
M_P UFA_\)D__ "74P?-!3[A*RDXWU1^K1-%?B]\7/V5?C]_P3OT6/Q_X(^)<
MVI>%[.XC%W_9K2P+$SG:IN+-RT4D9)5<Y;!8<#@U^FO[(7[1$'[3OP.T3QIY
M$=CJ3%[/4[2)LI#=QD!PN>=K JZ@\@. >16B2DG*+O;?R)DW%JZW/;**\D_:
M7_:*\-_LP_"V_P#&7B,M.(V$%CIT;!9;VY8$I$A/3H26Q\JJ3SC!_-WP=9_M
M6_\ !2.\N]=3Q6_P[^&AF:&-;>>6TM'7.&CBCB_>797'+2-MSN 9?NC.+<FU
M'IN6TDDY.U]C]?*6ORIN/^"+'B708)-4\-_&Q?\ A(HP9(#)HLMF#)U&9TN7
M=>?X@A/M65\$_P!LSXQ?L:_&Z'X3_M"W=SK7AR1U1=6OY3<3VL;L1'=Q7)^:
M>W)SN#Y90#C:4*&XI2:C?4EW2<NB/UL4T5#!.EQ"DL3*\<BAE93D,",@@^E3
M TABT444 %%%% !1110 4444 %<;J7_)4-(_Z\I/YM795QNI?\E0TC_KRD_F
MU '94444 %%%% !1110 4C':I-+3)O\ 5/\ [IIB;LKGYH_M0>-Y?&WQBUQM
MSBVT^8V,$;L" (CM8KCLS!F_X%7DC?+DU(\CS2-)(Q=V.69CDDGO79_!?PJ_
MC3XJ>&=)7 62]260M'O4(GSMN'H0N.>.:_H"G&& P:7V81_)'\FU95,RS!O[
M527YL_17X(^$U\$_"OP[I>^.1X[5)))(H]@=F&XL1Z\]?:O#/&'[9'@_3/%E
M]'_PAC:E=V,QA2^D\M7+(<9!*DC!]Z^@_B9X@C\&_#C7]4VR;+.QD95M\!ON
MD#;TQ@X_*ORHFFDGEEED9GDD8LS,<DDG.2:_.LAR^GFE2MB,2F]>[6KU>Q^O
M<49M5R2CA\)A&D[=4GHK);GTOJG[>'BVZT^2&QT33=/N6QMF&^3;_P !)P:\
M2\5^-/%/Q=\36QU>^EU6_N)1;VL!.$1G8 (B]!DD?I7)5ZQ^RWX-_P"$R^-6
MA120>?::>S:A.N_;M6,?(WOB0Q\5]O+!8+*J,Z]*FDXIN_7;NS\TCF&8YWB*
M6%KU7)2:5NF_9'Z%^$]%L_ ?@73]/3_1[/3;-5S(V=BJN22?;FOS \?:]-XV
M\?ZUJBK&\NH7TC(L(^5MSX7&?7BOT8_:(\6_\(9\'_$=^DT,5PULUO )AD.[
M_*% SR>37P)\ /!9\>?%OP]I;1+/;+.+FX5GVCRH_F//KTXKY+AO]U2Q&/J?
MUU9]]QA>M7PF5T?N]=%^I^B7PJ\.Q^ _A=H6F/$UH+.Q1YHY6W&-RN^0$^S%
MJ_-[XL^(I?'/Q0\0:DK+=M=7K1P?9T/[Q0=J!1U)( ^M?HS\;?%Z^!OA;K^J
M>;'')';-''Y@+*7;Y0,#ZU\N?L3_  CC\1:U<>/-3^>/39VBLX1M*O.5.]V!
MZ;0PQ[D'/RURY+B(X.EB,RJZO9>;>OYG=Q'A)8ZMA,GH.R6K\DM+_=<[S]F?
M]F"#P/;0^+?&,"'6POFV]G+C98KC.YNV_'X+^M<=^T1^UTVK+J'A;P8=EHV8
M)]74\R#HRQ>@/3=WKZ*^.G@KQ/\ $+P9)H'AW4+33$NCMN[BX9PWE_W5V@]>
M^3TKYA/[!/BN/G_A(=)'_ 9/\*67XG!XNL\9F=3WOLQULA9K@\?@,,LNR:BU
M"WO2TNWZG:_L)_#^WM?#^J^+9DCEN[F3[' W4QHH!?Z9)7\J[W]H+X4VWQ:U
MC1['5O&%MH>BV*O,]D&03R2L,*_S'  &1TZ$US?[%?B:SL?#^O\ @N>6-=4T
MC49LC?S,N=A95/. 4_45G_M3?LS^(OB9XLM/$?AIH;N9X%M9[29Q%L"Y*N&/
M!SG!'TK"K)O.)RK5/9]I-7TMIOIL=6'@H\/4X4*/M=N:*=FW?6]M7K^!+X9\
M<?!O]FG0;^+1M2&N:YO,,[1?O+B61>-I; 54R.W'UKQGX?ZYJ_[2'[26C:CK
M4/FP6[_:#;V[;5MH(B60 ]2 [+GU+&NG^'O['%QH[RZU\2+RSTO1;)6>2UCF
M!+X'!9QP%]AR:Z3]AWP3;0Z]XS\0Q>3>VD,PTZPOXRPW $O)A3@@%3">1V^M
M>M.I@\-1Q&(I5'4J6MS/N]+)[:;Z=#P:=/'XW$X3"8BFJ5+F;4%IHM;M;Z^9
M] ?'3QX/AO\ "_6M9CECBO$A\JU\P]9G^5<>XR3^%?EY-<27%Q)/(Q:61R[-
MW+$YS7VM^WIXN^Q^%=#\/130E[VX,\T+*2^Q!\K ]AN-?$JJ78*HR3P *]+A
M;"JE@W6DM9O\%_3/(XXQLJV81P\7I!?B_P"D=I87WBSXO:YHWA^YU6\U:3>L
M%NEU*SK'D]?_ *YYK]+/AQX-@^'_ ('TC08,%;. (S+G#.>7;D]V+'\:\1_9
M._9]'@/38?%>M(?[=OH<P6[#'V:)AGG_ &B,9].E?2M?)<0YC3Q-18;#_P .
M';JS[SA')ZN#HO&XN_M)I;[I=!U+117R!^B!1110 4444 %%%% 'D_[5'_)O
M_C/_ *]!_P"AK7Y9Z9I\VK:C:V-NNZXN95AC7U9B /U-?JC^TY9S7WP%\9Q6
M\332_82^U1DX5@S'\ "?PK\R/AU_R/\ X;]?[2M__1BU^G<+3Y<%5:Z-_DC\
M;XRAS9C03V:2_$^TM._X)[^%SX;BAO=>U/\ MHQ@R74!3R0^.0(RN2H/^UD^
MU?+/QL_9_P#$7P1U98]23[;I,S$6VI0*?+?_ &3_ '6QV/X9K]6DSM'TK&\5
M>$=)\;Z'=Z-K5E'J&GW*[7BE7\B#V([$<BOG<%Q%B\/6YJ\N:+W7^7^1]3F'
M"F"Q.'Y<-'DFMGW]3\=8+J>T;=#-)&WJC$&G7%]=77_'Q<S2_P#71RW\Z]X^
M//[(_B/X7ZE/?:':W&N^&Y&+1S0H7FMQ_=D4#M_>'!]JY#X5_LZ^,_BIK4=M
M:Z7/IVGJP%QJ5[$T<4:]^OWC[#]*_2X9A@ZE'ZSSKE[_ -=?(_(ZF68^G7^J
M.#YNW?S]#E_AS\-M>^*7B6'1M M&N;I^9)#Q'"G=W;L!7V7X=_X)Z^&H=%VZ
MWKVHW>JLG,EF4BA1O0*RDL/J1GVKWKX1_!WP_P#!OPW'I6B0;I&PUS?2 >;<
M/_>8^GHHX%=X/O<FOSG,N(\17J<N%?)!?>S]7RCA/#8>ES8V*G-_<O)?YGY$
M?%_X;W/PF^(&J>&KBX^U"U<&*X QYD; ,K8['!Y'J#7TE^S/X2G\<?LM_$?0
M[5=]W=2OY"?WI%C5T7\64#\:\Y_;BMIK?X]ZB\D;(DUK \;$<,NS&1^(/Y5[
M_P#\$]N?AMK_ /V$O_::U]-F6*G/**>(;][W7\]&?'Y5@X1SRKA$K1]]?*S1
M\+>'=<NO"?B;3M6MP4O--NH[A%;(^9&# '\17VY\8?A;I_[6_@_1_&_@:^MQ
MK4$(AFM)Y-NX=?+<_P +J2<9X(/TKC_VLOV4+^#6+WQGX.L6O+&Z8S7^FVZY
MDBD/+2(HZJ>I Y!SVZ?+GAOQGXA\"7SS:'JU]HMUG:_V:9HR<=F //XUU>[F
MT*>,P=3EJ1[Z[[IHX[3R.I5P&/IN5*?;3;9IGJ3?L9?%9<_\2",_]O<7_P 5
M7:_!O]COX@:7\2?#^IZW91:5IFGWD5Y+-]H1F/EL&"J%)))(Q^->2_\ #2?Q
M-Z#QKJW_ '^->C? 3]JCQW;_ !,T+3M;URXUK2M1NX[.6&\PY7S&"AE;&002
M#Z'GBC%K-_J\[N&SV3O\KZ#P4LC>)IZ5%JMVK;]>ISO[9@_XR&\2#_8M_P#T
M1'7K7[/]YJFG_L=^/KG1IKBWU.&YGDAFM6*RIA(B2I'(P :\C_;-;=^T+XD/
MJ+?_ -$1U]9?L.^%KO1?@>LM_ T:ZG>2W44<@^]$55 <>AVG\,5YN85HTLHP
M\FKVY-.]E<]3*Z$J^>XJ,':_.K]KZ7/D6U_:]^*]GI+6"^*7==NT32V\3S ?
M[Y7.?<\UYWH7A_Q#\3/$WV73[6ZUK6+R4R.Z@R.S$Y+NW;D\DFOL?]H[]BN'
M6?M?B3P! MK?',EQHZ_+',>[1?W6_P!GH>V._P >>&_%'B3X4>+%OM.N+C1=
M9LG*.C@JPY^9'4]0>X(KV<OQ&%Q5&53 1C&H]U:VOG;H>#FF%QN$Q$:692E*
MFGH[MZ=;7ZGWG;_L\77A/]E'6O!B,MUKEQ;R7T_EC*FX&U]B^N @4>I&>]?G
MOH>K7/AG7K'4[;Y+JQN$GCS_ 'D8,,_B*_1/]GG]K72OC!-;:#JMJVF>*&1F
MV(I:WN-HR60]5..=I_ FO$?VL/V5=0T?6K[QCX1L6N](NF,]Y80)E[:0\LRJ
M.J$\\=#GMBO!RG&3PN(JX/,/=<W=7V;>C^_H?2YU@:>,PE''96^94U9I;I+5
M?-=3Z_\ A+\4M)^+7@ZSUS295;>H6XM]WSP2X^9&'UZ'N.:=\5OB=I7PB\&W
M?B+5_,>&$A(X(L;YI&^ZBY_GV -?E9X-^('B/X;ZH;_P]JMUI-U]U_);Y7'H
MRGAA[$&M#X@_&#QA\5&M_P#A)M;FU)(,F*$JL<8)ZD(@ S[XS63X5?UE24_W
M5_G;M_P39<:VPG(Z;]K:U^E^_?Y'VCX"_;GL/'GC+2/#T'A2ZMY-1N5MUF:Y
M5MN3UQM[5\O?M??\G$>+O]^#_P!$1UZM^PY\#=0OO$R>/-6M'MM,LT8:?YJX
M-Q(PQO4?W5!//<GV->5?M??\G%>+S_TT@_\ 1$==^7T<'A\UG2PBLE'76^MT
M>9FE?'8K)8U\:[N4U;2VEOU/*9=:OIM)@TQ[N5M/@E::.UW?(KL &;'J0H&?
M:JL,BI-&[IYBJP)0G&1Z5[E\#_V2_$WQBTE]6>XCT'16X@N;J-F:X/<HHQE1
M_>SCTS5_XA_L0^/_  7&]SID<'B6S49+6)(E ]XVY/X9KZ%YG@(57AW42E^O
MKM<^8649E.BL2J4G'H]]/3>Q]I?!/XS>"OB)X7T^W\/7MM9SP0I$VD.1'+ 0
M -H3N/<9%>I@>G-?C)<6^H^&]2,<\5SIM] V2KJT<B']"#7Z6?LA_$35?B1\
M';2[UF9KK4+*XDLGN7.6F"!2K,>YPP!/?&:_.LZR6."C]9HSO%O9[J_GU/U;
MA[B&683^IUX<LTMUL[>70]RHHHKX\^^"BBB@ HHHH Y+XJ?\B+J/UB_]&+73
MVW_'K#_N#^5<Q\5/^1%U'ZQ?^C%KI[;_ (]8?]P?RH FHHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M21>U/7M3%[4]>U)@.I?2DI?2CH4AU.IM.I#'TX=J;3AVH =_C3O2F_XT[TJ
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M-?X<_LT?L_ZKXY\-^(/%&H:I:W5K MOJMQ;/ 5DE"$D) C9 /'-?8W_!*O\
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M-%_X*7?#O4-0NH;&QM9-"GN+JYD$<4,:W99G=F("J "23P *_2]?VL/@@/\
MFL?@#_PJ+'_X[7Y??\%)O"=KX]_X*%>#_#5_)-!8ZS!H^G3RV[ 2)'+<-&Q4
MD$!@&.,@C/8U](_\.5/@T<?\5?XZ_P# NR_^1:JG?V$;[7D:5+>T\[+\CZQ_
MX:P^"./^2Q^ /_"HL?\ X[7Y?ZMXIT7QK_P6 TG6/#VKV&O:/<ZS9^1J&EW2
M7%O+ML(U;;(A*MA@0<'J"*^C_P#ARI\&O^AO\=?^!=E_\BU\C^!O@UH_[/\
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MRF^ G_!3KXNZ]\/[GPS#8S_%;XS:QJQAT>V.FQ06]G:")"9)%MTC#_/OZD8
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M,M(ETO6?$%S?V$I!>"3&UB#D4SPK\8O&7@?2AINA:[<:=8[R_D18"[CC)^O
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M\N1OJRX)KO?TH[5-.K4HOFIR<7Y.Q=6C2Q"Y:L5)>:N>.?\ #(/PF_Z%./\
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MC[PZUC6BY0:1K3DHSC)[)GRQ_P $:S_QBOJO_8S77_HBWK[Q%>"?L;_LN_\
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MF_8O*_=JFS;YLF[[N<Y'7I2I^[*=^J27WFE1WIP2Z-OY6$_X*)?\F9?$X?\
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MU;T(G>24+:)W/AK_ (*[?LTZC\2/A[I'Q+\.V;W6J^%%DCU&&%"TDEBY#;P
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MIO[;\16=LN!Y7V*-Y<G/.=VW'ZUZIX4_8M\#Z$\,M^;G5Y5BV2+*P6-V/\0
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M2<?<&%)PJGH/2N:E;EO*UOQ-I7O[NY)>?VOX U"WUJ^O+35(M2NHK?4C%8K
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M_A"]#_MG^S)+C[7_ *7!!Y?F+!L_UKKG/EOTSC'/45\P_P##"/QR_P"A(_\
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M^UJW\J_'_,7]CT?YG^'^1^6'_#&?QB_Z$_\ \J=G_P#'J3_AC7XP_P#0G_\
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MM:OV0?V/0_F?]?(_+_\ X9#^+?\ T*?_ )4;3_X[1_PR'\6_^A3_ /*C:?\
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M+]A%/6S':G_:M;L@_L>CW9^6_P#PQQ\7_P#H4/\ RI6?_P >I?\ AC?XP?\
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M/:GB'VXH_M6MV0?V/0_F?X'Y4?\ #$_QH_Z$S_RJ67_QZC_AB;XT_P#0F?\
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M*/[5K=E^(_['H?S/^OD?D_\ \,._&S_H2O\ RJV/_P >IW_##_QL_P"A*_\
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MN**/:,/9HXI?#NH?\^__ (^O^-.7P_J'_/O_ ./K_C79T4N=C]FCC_[!O_\
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MBBB@# \0?\C!X8_Z_A_2O1Z\X\0?\C!X8_Z_A_2O1ZS>Y2.-^'W_ !_>*/\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /.-/\ ^1U\5?\
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MI/[-]JW/LHH^RBG<+&'_ &;[4?V;[5N_9Q1Y ICL87]F^U+_ &:/2MSR!1Y
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M\>_\BI?_ $3_ -#6N@KG_'O_ "*E_P#1/_0UH>P&U9_\>L'^XO\ *IJAL_\
MCU@_W%_E4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 8'B#_D8/#'_7\/Z5Z/7G'B#_D8/#'_ %_#^E>CUF]RD<;\/O\ C^\4?]A6
M;^==E7&_#[_C^\4?]A6;^==E2&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7&ZE_P E0TC_ *\I/YM795QNI?\ )4-(
M_P"O*3^;4 =E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 <E\5/^1%U'ZQ?^C%KI[;_CUA_W!_*N8^*G_(BZC]8O
M_1BUT]M_QZP_[@_E0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"/RZ/+J2B@"/RZ/+J2B@#EO L?\ HFJ?]A"7^2UTOEUSO@3_ (]-4_["$O\
M):Z:A 1^71Y=244 1^71Y=244 1^71Y=244 1^71Y=244 1[#1L-244 1[#1
ML-244 1[#1L-244 1^71Y=244 1^71Y=244 1^71Y=244 1^71Y=244 1^71
MY=244 1^71Y=244 1^71Y=244 1^71Y=244 1^71Y=244 1^71Y=244 1^71
MY=244 1^71Y=244 1^71Y=244 1^71Y=244 1^71Y=244 1^71Y=244 1^71
MY=244 1^77->)X_^)_X<_P"N[_R%=37,^)_^1@\.?]=W_D* .B\NCRZDHH C
M\NCRZDHH C\OVH\OVJ2B@"/R_:E\NGT4 1^71Y?M4E% $?E^U+Y=/HH 9Y='
MET^B@!GET>73Z* &>71Y=/HH ;L%&P4ZB@!NVC;3J* $VBC:*6B@!-HHVBEH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y_P >_P#(J7_T3_T-:Z"N
M?\>_\BI?_1/_ $-:'L!M6?\ QZP?[B_RJ:H;/_CU@_W%_E4U !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 8'B#_D8/#'_7\/Z5Z/7G
M'B#_ )&#PQ_U_#^E>CUF]RD<;\/O^/[Q1_V%9OYUV5>8>'=2UNRU;Q&NEZ.F
MHQMJ<Q>1KA8]K;CQ@GTK>_X2#QA_T*T7_@='_C2&=C17'?\ "0>,/^A6B_\
M Z/_ !H_X2#QA_T*T7_@='_C0!V-%<=_PD'C#_H5HO\ P.C_ ,:/^$@\8?\
M0K1?^!T?^- '8T5QW_"0>,/^A6B_\#H_\:/^$@\8?]"M%_X'1_XT =C17'?\
M)!XP_P"A6B_\#H_\:/\ A(/&'_0K1?\ @='_ (T =C17'?\ "0>,/^A6B_\
M Z/_ !H_X2#QA_T*T7_@='_C0!V-%<=_PD'C#_H5HO\ P.C_ ,:/^$@\8?\
M0K1?^!T?^- '8T5QW_"0>,/^A6B_\#H_\:/^$@\8?]"M%_X'1_XT =C17'?\
M)!XP_P"A6B_\#H_\:/\ A(/&'_0K1?\ @='_ (T =C17'?\ "0>,/^A6B_\
M Z/_ !H_X2#QA_T*T7_@='_C0!V-%<=_PD'C#_H5HO\ P.C_ ,:/^$@\8?\
M0K1?^!T?^- '8T5QW_"0>,/^A6B_\#H_\:/^$@\8?]"M%_X'1_XT =C17'?\
M)!XP_P"A6B_\#H_\:/\ A(/&'_0K1?\ @='_ (T =C17'?\ "0>,/^A6B_\
M Z/_ !H_X2#QA_T*T7_@='_C0!V-%<=_PD'C#_H5HO\ P.C_ ,:/^$@\8?\
M0K1?^!T?^- '8T5QW_"0>,/^A6B_\#H_\:/^$@\8?]"M%_X'1_XT =C17'?\
M)!XP_P"A6B_\#H_\:/\ A(/&'_0K1?\ @='_ (T =C17'?\ "0>,/^A6B_\
M Z/_ !H_X2#QA_T*T7_@='_C0!V-%<=_PD'C#_H5HO\ P.C_ ,:/^$@\8?\
M0K1?^!T?^- '8T5QW_"0>,/^A6B_\#H_\:/^$@\8?]"M%_X'1_XT =C17'?\
M)!XP_P"A6B_\#H_\:/\ A(/&'_0K1?\ @='_ (T =C17'?\ "0>,/^A6B_\
M Z/_ !H_X2#QA_T*T7_@='_C0!V-%<=_PD'C#_H5HO\ P.C_ ,:/^$@\8?\
M0K1?^!T?^- '8T5QW_"0>,/^A6B_\#H_\:/^$@\8?]"M%_X'1_XT =C17'?\
M)!XP_P"A6B_\#H_\:/\ A(/&'_0K1?\ @='_ (T =C17'?\ "0>,/^A6B_\
M Z/_ !H_X2#QA_T*T7_@='_C0!V-%<=_PD'C#_H5HO\ P.C_ ,:/^$@\8?\
M0K1?^!T?^- '8T5QW_"0>,/^A6B_\#H_\:/^$@\8?]"M%_X'1_XT =C17'?\
M)!XP_P"A6B_\#H_\:/\ A(/&'_0K1?\ @='_ (T =C17'?\ "0>,/^A6B_\
M Z/_ !H_X2#QA_T*T7_@='_C0!V-%<=_PD'C#_H5HO\ P.C_ ,:/^$@\8?\
M0K1?^!T?^- '8T5QW_"0>,/^A6B_\#H_\:/^$@\8?]"M%_X'1_XT =C17'?\
M)!XP_P"A6B_\#H_\:/\ A(/&'_0K1?\ @='_ (T =C17'?\ "0>,/^A6B_\
M Z/_ !H_X2#QA_T*T7_@='_C0!V-%<=_PD'C#_H5HO\ P.C_ ,:/^$@\8?\
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M#IJ*YG^V?$G_ $ (_P#P+3_&C^V?$G_0 C_\"T_QH Z:BN9_MGQ)_P! "/\
M\"T_QH_MGQ)_T (__ M/\: .FHKF?[9\2?\ 0 C_ / M/\:/[9\2?] "/_P+
M3_&@#IJ*YG^V?$G_ $ (_P#P+3_&C^V?$G_0 C_\"T_QH Z:BN9_MGQ)_P!
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M!'_X%I_C0!TU%<S_ &SXD_Z $?\ X%I_C1_;/B3_ * $?_@6G^- '345S/\
M;/B3_H 1_P#@6G^-']L^)/\ H 1_^!:?XT =-17,_P!L^)/^@!'_ .!:?XT?
MVSXD_P"@!'_X%I_C0!TU%<S_ &SXD_Z $?\ X%I_C1_;/B3_ * $?_@6G^-
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M-17,_P!L^)/^@!'_ .!:?XT?VSXD_P"@!'_X%I_C0!TU%<S_ &SXD_Z $?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7&ZE_R5#2/^O*3^;5V5<;J7_)4-(_
MZ\I/YM0!V5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!R7Q4_P"1%U'ZQ?\ HQ:Z>V_X]8?]P?RKF/BI_P B+J/U
MB_\ 1BUT]M_QZP_[@_E0!-1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'G&G_\ ([>*?^ND'_H)K<K#T_\ Y';Q3_UT@_\ 036Y
M6BV,WN%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <UX%_X\]3_["$O\EKI:YKP+_P >>I_]A"7^
M2UTM"!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5QNI?\E0TC_KRD_FU=E7&ZE_R5#2/^O*3^;4 =E1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <E\5
M/^1%U'ZQ?^C%KI[;_CUA_P!P?RKF/BI_R(NH_6+_ -&+73VW_'K#_N#^5 $U
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ><:?_
M ,CMXI_ZZ0?^@FMRL/3_ /D=O%/_ %T@_P#036Y6BV,WN%%%%,04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <UX%_P"//4_^PA+_ "6NEKFO O\ QYZG_P!A"7^2UTM"!A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-
M^)O^0]X=_P"N[_R%=)7-^)O^0]X=_P"N[_R% (Z2BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ K \>?\ (IW_ -$_]#6M^L#QY_R*=_\ 1/\
MT-:;V!;FS9_\>D'^XO\ *IJAL_\ CT@_W%_E4U( HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** ,'7O\ D8/#/_7\O]*])KS;7O\ D8/#
M/_7\O]*])K-[EQV.-^'W_']XH_["LW\Z[*N-^'W_ !_>*/\ L*S?SKLJ1044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5QNI?\E0TC_KRD_FU=E7&ZE_R5#2/^O*3^;4 =E1110 4444 %%%% !1110
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M_KI!_P"@FMRM%L9O<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH YKP+_P >>I_]A"7^2UTM<UX%
M_P"//4_^PA+_ "6NEH0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *YOQ-_R'O#O_ %W?^0KI*YOQ-_R'O#O_
M %W?^0H!'24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8'CS
M_D4[_P"B?^AK6_6!X\_Y%._^B?\ H:TWL"W-FS_X](/]Q?Y5-4-G_P >D'^X
MO\JFI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@Z]
M_P C!X9_Z_E_I7I->;:]_P C!X9_Z_E_I7I-9O<N.QQOP^_X_O%'_85F_G79
M5QOP^_X_O%'_ &%9OYUV5(H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M::?8P/<W-Q)]V.-%+,QQZ &O"K7]OCX#W=U#;P^.U\V5UC7?I-\BY)P,L8
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MYI_P3\^..J?&3X-RVVOW+7NM^'[@6$MU*Q:2XB*AHG<GJV-RD]]F3R37RO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'G&G_\CMXI_P"ND'_H)K<KE+[Q!I?A7Q!XPU36M2L](TR"2W\V
M]OYT@ACW#:NYV( RQ &3R2!67_PT!\+O^BD^$?\ P>VO_P <K>$)25TKF$ZD
M8NTG8[^BN _X:!^%W_12?"/_ (/;7_XY1_PT#\+O^BD^$?\ P>VO_P <J_95
M/Y7]Q'MJ?\R^\[^BN _X:!^%W_12?"/_ (/;7_XY1_PT#\+O^BD^$?\ P>VO
M_P <H]E4_E?W![:G_,OO._HK@/\ AH'X7?\ 12?"/_@]M?\ XY1_PT#\+O\
MHI/A'_P>VO\ \<H]E4_E?W![:G_,OO._HK@/^&@?A=_T4GPC_P"#VU_^.4?\
M- _"[_HI/A'_ ,'MK_\ '*/95/Y7]P>VI_S+[SOZ*X#_ (:!^%W_ $4GPC_X
M/;7_ ..4?\- _"[_ **3X1_\'MK_ /'*/95/Y7]P>VI_S+[SOZ*X#_AH'X7?
M]%)\(_\ @]M?_CE'_#0/PN_Z*3X1_P#![:__ !RCV53^5_<'MJ?\R^\[^BN
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M?\- _"[_ **3X1_\'MK_ /'*/95/Y7]P>VI_S+[SOZ*X#_AH'X7?]%)\(_\
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M^$?_  >VO_QRE[*I_*_N#VM/^9?>=_17 ?\ #0/PN_Z*3X1_\'MK_P#'*/\
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M_P <H]E4_E?W![:G_,OO._HK@/\ AH'X7?\ 12?"/_@]M?\ XY1_PT#\+O\
MHI/A'_P>VO\ \<H]E4_E?W![:G_,OO._HK@/^&@?A=_T4GPC_P"#VU_^.4?\
M- _"[_HI/A'_ ,'MK_\ '*/95/Y7]P>VI_S+[SOZ*X#_ (:!^%W_ $4GPC_X
M/;7_ ..4?\- _"[_ **3X1_\'MK_ /'*/95/Y7]P>VI_S+[SOZ*X#_AH'X7?
M]%)\(_\ @]M?_CE'_#0/PN_Z*3X1_P#![:__ !RCV53^5_<'MJ?\R^\[^BN
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M?\- _"[_ **3X1_\'MK_ /'*/95/Y7]P>VI_S+[SOZ*X#_AH'X7?]%)\(_\
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M !_>*/\ L*S?SKLJ104444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\%]/;+<^=G"MGM]*\$;_ (*'6:LO_$FC"GON:OF</E.,QD/:TH73ZGU>)SC
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M_P!!6]_\"'_QK*7M4BTK+L+F?<U%\2:M_P!!2]_\"'_QI_\ PD6K?]!2\_\
M A_\:RUJ2ILNQ7,^YI+XBU;_ *"=Y_X$/_C3AXBU7'_(3O/_  (?_&LQ:>M*
MR*YF:B^(-4_Z"5Y_W_?_ !J1/$&J<_\ $RN_^_[?XUF+4D?>BR'=FG_;VI\?
M\3&[_P"_[?XTY=>U/_H(W?\ W_;_ !K.]*<M39!=FBNNZE_T$+K_ +_-_C3A
MKFI9_P"0A=?]_F_QJ@M*O6CE15V:2:WJ/_/_ '7_ '^;_&I%UK4/^?\ N?\
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M_P#CA>O@7Q)_P3Y^-NC^+-2CT'PFU_IEM>2"PU!-5LHS+$KGRY,-,K*2,'D
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M>-?AWI<=[KUQBVU73Q/%;^< /DG#2,J[@!M89R1M/8UAEN,^KSY*C]V7X/\
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MXMWA*N,$D) ASCIS7TATHSFL)8NO*+BYNS.F."P\6I*"NM0KX'_X*Q_\BO\
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M>O:D62+69XJ_Y%^Z_P" _P#H0K36LSQ5_P B_=?\!_\ 0A4L:W-.V_X]XO\
M<'\JE'>HK;_CWB_W!_*I1WJA#J>O6F4]>M06*M/6F+3UH <M._AIJT[^&@!R
M]*=_%35Z4[^*DQH<M.IJTZD5U'4444"'KVI],7M3Z %_AI:3^&EH <M+2+2U
M #Z5:2E6@L6E6DI5H =2^E)2^E "CO2T@[TM "_Q4M)_%2T +_"*=3?X13J
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M3K:Z.JHHFA20Y#<9 ->SF4, J&'6+DXV6EO1'AY9/,/K.)^IP4KO6_JSY_\
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M([&U.EW""20\;BR$#]#7WYX@_:H^&7A>W>:^\30(J@'"(SDYZ  "OS%_9O\
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MHH **** "BBB@ HHHH ^//VWO^2$_&#_ *Z:5_Z605^4]?JQ^V]_R0GXP?\
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M!/A]H-A'K<UOYEM:R*?LUC;AB/-=00SN[!L9/)#,Q/1OD_P5_P %(_C!X?\
M$"7FN:A8^*-+9QYNG7-E#;X3/(CDA165L< MN'J#7C4\3BL2G.A%*/2^[/:J
M8;"X9J&(DW/K:UD?,.JZ3?:#J5QI^I65QIU_;N8YK6ZB:*6)AU5E8 @^Q%=)
M\+_A+XK^,WB&70_!VD_VQJL=NUT]N+B&'$2LJEMTKJO5UXSGFOT>_:?^&7A3
M]K3]G.'XI>%[91XAL].;4+2Z5 )I8H\F:TFQ]XKAP!V=>#ACGYP_X)>_\G$Z
MC_V+]Q_Z.@K6GC7.C4E:TXIW7FOT,ZN!4*U-*5X3M9^6GXGA>G_LV_$O5OB%
MJ7@BQ\)7=YXETPJM[:V[QR1VVY0R^9,&,2@@\$OSTZUT_B/]B/XW^%-*EU&^
M\ 7KVT8RXL+FWO) /7RX9'<_@*^UOVS/VL(_V<-0E\+> =/LX?&6L_\ $QU+
M4I(0X@W#8CD'AY2$&-V0JJO!! 'S_P#!#_@I!\0-!\86</Q!OX?$WANZE6.Y
ME:TB@GM%)P9(S$BA@,Y*L#D# (KGHXC&8BFJE.*MYWU[V_0WK8;!X:HZ=2;?
MI;1=+GQRRM&Q5@593@J1@@UZ5\*_V;_B+\:M+O=0\&>'O[9L[&40W$GVVV@V
M.5W 8ED4GCT!KZV_X*6_ 32K73],^*WA^WC@DNYUM-76W4!)RZEHK@X_B."I
M/?<GH<]?_P $IE$GPS\;J1D-JT8/_?E:T>/<L)*O!>]'2SZ.Z,E@5#&1P\G>
M,M;KJK7/AKX:?LV_$OXP6\]QX2\)7FJVD+F-[IGCMX-P."JRRLJ,1W )([U<
M^(W[*_Q7^$^DMJGB?P5?6.FH,R7EN\5W%$/61H7<(/=L5].?M.?MT:O\//$T
M_P ._@^MGX;T?PZ_V&;4(K2.1FEC.UXXD<,BHI!4DJ2Q!(('7HOV-OV[/$7Q
M!\:6O@'XD/:ZF^JAH['5U@2%S+@GR9D0!&# $ @ YP#NW9$_6,9.G[>,5R[V
M=[M%RP^#A4]A.3YMKJUD^W<_.JKFDZ/?^(-2M].TNQN-2U"X;9#:VD32RR-Z
M*B@DGV KZ-_;X^ 6G_!'XNQ7.@VPL_#?B*%KVUM8QA+>56 FB0=E!*L!V#X'
M KZX_9M^&_A3]D']G&;XG>)K42:_=:<M_>W&P&=$DVF&SBS]W)9 >>6/)P!C
M>6/@L.JZ6KT2\SGCE\WB7AV]M6_+N?%.F_L)?'75;&&[A\ W"Q2*'5;C4+2"
M0 ^J23*P/L0#7F_Q(^#?C?X0WR6OC#PSJ&A/(=L<MQ%F&4XR0DJY1R/]ECBO
M=?&?_!23XQ:_XA>\T;4+'PQIBN?+TVVLH;@%,Y DDE1F9L<$KM![ 5]9_LS_
M +1FA_MI>"=>\"_$'0[%M:CM]]U:1J?(O+<D 31 DM&Z,5S@Y!*LI&<+C+$8
MRE#VM2*<5NEND;QP^"K3]C3DU)[-VLV?E(.3@5ZUXT_91^*_P_L])N=;\'W$
M*:M=)8V*6MU;W<MQ,R,ZHL<,CMDJC'ICBLOX_P#PEG^"/Q@U_P 'RR//;V4X
M:TN)!S+;N \3'MG:0#CC(-?KQ\=/B=8?!?X*W?CBYL(M1NM(MHS80R=[B7$2
M<]0/GY(YV[JO%8YTZ=*I25U-_P"5D+#9?[2=2G6=G#[O4_++6?V(_C?H.CRZ
MG=^ +QK2--["UNK:XEQ_URCD9S]-M?>__!/CX)^-/@KX'\46/C/1?[&NK[48
MY[>/[5!/OC$04G,3L!R.AP:^)M4_X*!?&37-+\0Z=?ZU8S6.L6\EKY2Z?'&;
M-'!!,+H%8$ D N7_ #YK[8_X)[?&KQG\:/ OBB^\9ZTVM7-CJ$<%O(UO##LC
M,0)7$:*#SW/-<N.>+>&E[11MI>U^Z_7<Z<$L&L3#V3?-KO:VQ\(?M$_LR_$K
MX<:IXD\8^(O#7]G>&[K5YO)O?M]M+N\V5VC^1)&<9'JO'?%<WIO[+OQ.UCX9
MR_$&S\,^=X0CM);YM2^W6JXABW>8WEF42<;&XVY.. :Z+]HC]I;XD_$75?$G
M@_Q%XE;4?#EKJ\WE61L[>,+Y4KK'\Z1AC@>IY[U]N_#/_E&;J//_ #*NK?SN
M*N->MA\%"H[;I+?9K\]#-T*&)QLJ<;VLV]MT_P C\K*] ^$_P%\=_'*34H_!
M&A?VV^G>6;H?;(+?RP^[9_K9$SG8W3/2O/Z_0'_@DW_R$OB3_P!<M/\ YW->
MKB*CHX>56.Z7ZH\O"T8UJ\:<MFSX2\4>&=2\%^(M3T'6;;['JVFW#VMU;^8K
M^7*A*LNY25."#R"17=>/_P!FKXC_  O\)Z?XE\2^'#IVBW\T<%K=+>VTQDDD
M0N@V1R,PRJD\CM2?M/?\G%?$C_L/WO\ Z.:OUF\;>)O#'P]^ ^D^-?%%@FH6
MWAFRM]1M(6 +?:O*$46S/ <F3:#VW9[5Y];'3HTJ4TK\V_W=#T:6!A4Q-6C=
MVC>Q^7OAW]B+XW^*-+AU"Q\ 7B6\HW(M]=6UG)CWCFD1Q^(K@/B1\'?&OPAU
M%++QCX;OM!ED)$4EQ'F&7 !/ERJ2CXR,[6..]?0&N?\ !3'XNZAXB^W:>NBZ
M5IJ2$II:V7FHR9X621CO)QU*E,^@Z5]GZ#XBTO\ ;:_9+O[C5=-AM+R\M9X9
M(5!=;6^B!VR1D\XSM8#KAMI)YSG4Q>*P\?:UHKD?;=%4L)A,1+V-.3Y^[V9^
M3G@/3=?UCQGHMCX5>X3Q)<7<<>G-:W MY1.6 0K(678<X^;(QZUZ%^T)X&^,
MO@N;05^+MQK%Q)<K,=,_M?6EU$@*4\W85FDV<F//3/'7%9W[,.?^&A_AUCK_
M &[:_P#HP5]9?\%9&_XF7PQ/?RM1S_WU;5UU:W+B:-.VDKW[KT.*A14J%:;;
MO&WHSUO_ ()X_!'QI\&?#/BR+QEHG]C2:E<6\UHOVJ"?S%57!.8G;'WAUQUK
MXH_:/_9?^)G@OQ-XN\9ZWX;6P\,WFN3M#?MJ-JP837#&(E5E+*#N'4#'?%?:
MW_!._P"-GC/XR^%_%DWC'6VUB33KBWAM6-M##Y:LKDC]VBYZ#KGI7Q'^TI^T
MQ\2?'/B+QCX)USQ*U_X8M];N(XK V=N@589W$8WK&'. !U;GOFO,A]8_M"6U
M]+[VMIMYV/2E]6_LV&]KNVU[Z[^1R_Q)_99^*/PB\+KXB\5^%FTW13*D'VM+
MZUN%#N"5R(I6(!QU(QT&>17E%?K!\);N+]K?]ANYT*[=;K6H].?29'D;)6\M
MP&MY&/7)Q"Y_WC7Y1W%O):W$D$T;131L4>-A@JP.""/7->IA<1.I4G2JVYHO
MIU7<\[%8:%.E3K4K\LEK?H^QV_PI^!OCCXWWVH6G@G0FUJ>QC66Y N88%C5B
M0N6E=1DD'@'/!]*Y[QIX-U?X?>*-1\.Z];+9:QI\GDW5ND\<PC? .W?&S*2,
M\X)P>.HK](_V)M'L_P!GO]DKQ#\2=8A$=QJ$<VK,&X9X(E*6\?\ P)MQ'_74
M5^:.OZY>>)M=U'6-0E\^_P!0N9+JXE/\<CL68_B2:=+$2JXFI3C\,;>M_P#@
M:BJ8>-/"PJR?O2>G:W_!*%*JM(RJJEF8X"@9)/I25]G_ /!,7X9Z-XO^)WB#
MQ'JD,=U<^';>$V4,H!"2RLX\T#U41D#T+YZ@5UUJGL:<JCV1QT:;K5(TUNW8
M\?\ #/[%'QN\7:7%J&G_  _ODMI#\OV^XM[.3'KY<\B-C\.:Y[XD?LS?%#X1
MV/V[Q7X,U#3=/ R]['LN;>/D ;Y86=4R2 -Q&:^E_P!J7]NCXN>#_B_XA\+^
M'Y8?!VGZ1=M;PAK"*:>Y08Q*YF5QA_O+M X8=>M>B_LD_MXI\1QJWACXP:CH
M5B8[4RPZQ?-%:07B9"O%*K$(7.[("@ @-QQD^.L3BY4_;J,7'>VM['M2PN#C
M5>'E*2DM+Z6N?GIX$\":Y\3/%5CX:\-V/]I:U?%EMK7SHXMY5&=OFD95'RJ3
MR1TK]9O#OPD\5V7[#-Q\/Y=)\OQ=)X?NK(:;]HA/[YS(53S _E\[ASNQSUK\
MW?B5X@L_@O\ M(:UK/PGU^U^PV-X\^DZA8B.XBB26/YD4,K*P7S'3D'@5^D'
MA_XL^*K[]ABY\?S:LTGBU/#]U?+J7D1 ^<ADVOY879QM'&W''2LLSG4J8>$T
MK1;3UWOK^!>6TZ5+%3IR;<DGJK6MI?YGY<?%;X%>-_@A?:=9>-=$_L:YU"-I
M;:/[7!/YBJ0"<Q.P')'7%:WQ._9C^)GP;\.P:YXQ\,G1]*GG6UCN/MUK/ND9
M68+MBE9APK')&.*ROBA\</&_QNU/3+OQIKC:W<6"F*V=K:&'RU9@6&(D4'D#
MKFOT/_X*??\ )NOA_P#[#UO_ .D\]=E2O7P\:*G:\FT[7M;2UO/74YZ.%H8A
MU7!OEBKJ^][=?FC\LZ]5\&_LN?$_X@> W\9Z!X8^W^&E2:4WWV^UCPL1(D.Q
MY0_&T_P\XXS7E5?JK^QW_P F%W8/_/GJY_\ 'YJUQ^)GA:+J06OF<V7X:.*K
MJG-M+R/RJKT#X9? #XA_&,2OX/\ "M[K%O&2KW:A8;<,,97SI"J;N1\N[//2
MM#]FGX0GXX_&;P]X4D++83RF>^DCZI;QC?)@]BP&T'L6%??O[7'[5$/[*.EZ
M'\/_ (=Z3I]MK#68D4/%FWTZVR53;&,!G8JQY.!MR0=U3B<5.E*-*FKSE_5V
M5A<)&LIU*DK0CN_/LCX/\??LD_%WX8:&^L^(O!%[:Z9&"TMU:S0W:0J!DLYA
M=]B_[38'O7WE^TQ_RCGM,_\ 0(T7_P!&VU?//P9_X*3>/M'\3V]O\1)[?Q3X
M;NI1'=2BSB@N+9#P63RE56 SDJRDG& 17UC^WE'8P_L;^(X],2&/35&G"U2W
M4",1_:H=@4#@+C&,=J\O&3Q'/2C7BOB336V^QZ>$IX9QJU*$GI%II[^I^;OP
MW_97^*'Q;\+_ /"1>$?#"ZSI'F/&;A-2M(V#I]Y2CRJX/3J.001UKRF2-HW9
M'4HZG!5A@@^AK[L_X):?%;^R_%?B3P!=S8@U.(:G9*Q&/.C 651[LA4_2(UX
M/^VU\+_^%6?M%>)K.&'R=.U20:O98Z>7,2S >@$@D7'HHKU5B)QQ;H36C5T_
MZ^9Y?U:$L)[>#U3M)?D>,:#H5_XHUS3]'TRV:\U+4+B.UMK=" 9)78*JY) &
M21R3BNW^+'[//C_X'V^G2^-M"315U%G6U'V^VG:0H 6^6*1B -R\D <BO:_^
M";OPM_X3GX[-X@N8=^G^&+8W63T^T292$?EYC?5!63_P4*^*O_"Q_P!H34-.
MMIO,TOPS$-*A"ME3*#NG;Z[SL/\ US%.IB)_6HT(+HV_)=/Z\Q4\/!X6=>I?
M1I+S9\R4445Z)YP4444 %%%% !1110 4444 .6O9_@OKS7FFW.ERMEK4AXLG
MG8Q.1^!_]"KQA:ZSX9R7B>--/%F,EF(E!Z>7CYL_AT]\5C6CS19M2ERS1]#Q
M]ZK7G_'U9?[Y_D*LQ]ZK7G_'U9?[Y_D*\L]>)J+VJ6/O42]JEC[TF-#ZF6H:
MF6I--25.E2KVJ).E2KVI= )EJ6/O42U+'WJ2R6I$^]4=2)]ZI8$RU(O:HUJ1
M>U!9*M2KVJ):E7M4 2KVJ1:C7M4BT%$B]JE3K42]JE3K2970E6I*C6I*D$/6
MI8^]1+4L?>I-"5>U2+4:]JD6@"5/NU(O:HT^[4B]J3*)DIU-2G5($BT]:8M/
M6@I$B]J>O6F+VIZ]:3&2+4R]JA6IE[5(T2+3UIBT]:-2B1>U2+4:]JD6I >M
M25&M24%"K3UIBT]:@"5:DC[U&M21]Z"R3^&G+3?X:<M2P)%I5ZTBTJ]:0$L=
M2+4<=2+062+VI],7M3Z3 *>M,IZTBB1:>O2F+3UZ4 *M/6F+3UI,!_I3EIOI
M3EI= )%IZ]J8M/7M2+)%K,\5?\B_=?\  ?\ T(5IK69XI_Y%^Z_X#_Z$*EC6
MYIVW_'O%_N#^52CO45K_ ,>T7^Z/Y5*.]4(=3UZU&O2I%ZU!8JT]:8M/6@!R
MT[^&FK3OX: '+TIW\5-7I3OXJ3&ARTZFK3J174=1110(>O:GTQ>U/H 7^&EI
M/X:6@!RTM(M+4 /I5I*5:"Q:5:2E6@!U+Z4E+Z4 *.]+2#O2T +_ !4M)_%2
MT +_  BG4W^$4Z@ I?X124O\- #J***@!>PI?XA2=A2_Q"@ ;I1Z4-TH]*"P
MIW\--IW\- !_%0.]'\5 [T$ M+2+2T%A1110 O\ %1V-'\5'8T !^Z*2E/W1
M24 %%%% !1110 4444 %%%% !1110 4444 %%%% &#KW_(P>&?\ K^7^E>DU
MYMKW_(P>&?\ K^7^E>DUF]RX['&_#[_C^\4?]A6;^==E7&_#[_C^\4?]A6;^
M==E2*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M2EH **** "BBB@ HHHH **** "BBDH 6BDI: "BBB@ HHHH **** "BBB@ H
MHHH **** "N-U+_DJ&D?]>4G\VKLJXW4O^2H:1_UY2?S:@#LJ*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $Q5>]LH-0M9;:XA6:"5
M=KQN,JP]"*L44T[.Z$TGHS\^/VFO@-?_  @\5)XQ\*-+#8M*)2T9(\M\YVX'
M\-?1_P"R[^T!;_%SPNEK?2K'KMFH2>-C@N?4>M>Q>)/#=AXJTBXTW48%GMIU
M*LK#/48S7YW_ !8^'?B#]EWXD0:[X>FDCT^20O R]-N>5-?<X:M3SS#+"5W:
MK'X9=_)GYYBJ-3A_%O&4%>C+XH]O-'Z2<<4OK7F'P)^-&G_&+PC!?P,L=\B[
M9[?=D@CC/XFO3J^+K4:F'J.E45FC[S#UZ>)I1K4G>+V/D7_@H/(%\)Z2"0,[
M^OU%9/\ P3P8'2]4PP)VGH?]H5],_%#X1Z%\6-/BM-;MEG2+.S=VS5;X5?!7
MP_\ ".WFBT2W6%91AL#WKZ6.:4/[(>"L^>_RW/EI957><+'77);Y[6/*OV]X
M$;X+O,2 RW48!/UK@/\ @GIK,5UI_B+2R074+Q]<U]4?$OX:Z1\4_#;:+K,0
MFLV<2;3ZCI6!\*?@'X:^$-W=W&AVXA>YP'P/2IHYC0CE4L'._.W==BJV5UY9
MO'&QMR)6?<^ ?CQX1U'X._&[^T3:;88[@7L3A?W;$MG&:]P\3?MW:3J7PU-E
M9Q2+K\T/E2?+A!D8.#7U5\0_A5X;^)VGBUUW3X[M1]QF'*FO(+?]AOP%%=B5
M[=9(LY\LKQ].M>I'-LOQ=*E]>@^>';J>//)<QP=:I]0FN2IWZ'SA^Q3\.]0\
M5?$X>(I+4_8;*3SC)(IVMDGH>]>Q_M[_  ZU#7O#-IK5A$]RL#J)(XP254#K
MBOI[P;X)T?P'H\6EZ+9QV5G&.$C%:FH:?;ZG9S6EU$LUO,I1T8<,#U%>97SR
M4\QCC(1TCHEY'K8?A]4\ME@YR]Z6K?F?GU^S-^UII_PM\/SZ)XA666!>;?8,
ME,#I[5Y3\3O%5[^T9\7#<V%J2]\RPQ1QJ2% X!-?;?B;]B?P)K]])<VULNG^
M8VXK&N1_.NT^&G[-_@WX870O--TV)KX8Q.PY'O7N?VSEE"<\70@_:R7R/ 61
M9I7A3P=>:]E%_,XSXC>%_P#A"?V95TIR?,AM%$FX]&V<BO#O^"=LBMK6M@,"
M=XZ'VK[=\8>$;'QMH4^E:C&)+:889:X[X4_ 'PS\(I[F;1+987G.6(%>%1S2
ME' UJ$[\TW?R/HJV4U7CZ->%N2"L>2_\% I!'\-])R0,W3=3_LBN)_X)W,&M
M=74$-EV!'X"OJGXG?"W1?BMI,6G:W )X(7+J/0D8K.^%7P.\._"&.9=$MUA\
MTDM@>M.GF5"&4RP;OSM_+<BIE5:6<+&Z<B2]=CX5_; \!7_@?XO3ZZMIMT^\
MF$L+JORC&.M>K-^W9HTWPN>P,$D.O_9OLZ&-?D!"X!S7UEX\^'>A?$?1WT[6
M[&.\@8<;QRM>()^PKX&_M SE 8#TAV\?SKT:.:X#%8>G3Q\7S4]K=3S*^3YC
MA,34J9?)<M3>_0^;_P!D?PIK7Q%^,3:[<27'V-=TDLQSM+=<9K])0-J@5S?@
M;X>Z%\.M(73]"L8[*#JVP?>/J:Z0\9)KY[-LP68U^>$;12LD?2Y/ELLMP_).
M7-)N[8R:9+>-I)'5$499F. !ZU\%_M9_M 7OCSQ%_P (3X6FD:S23RIY+<G,
MCYZ CJ*[+]K[]I6;32_@SPO<?Z9,-MS/$<_*>"M6/V0_V;8M/LXO&'B2W\Z]
MF_>6\<HSP1]ZO<RW"TLLH?VCC%K]F/=]SY_,\95S6O\ V9@GI]J79=CL_P!E
M3]GBT^&N@1:QJ5NK:W=#<0XSY/IM/K7T8M, "X X]J<.W-?*XS%5<96E6JN[
M9]A@L'2P-"-"DK)?CYCJ***XSO"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#DOBI_P B+J/UB_\ 1BUT]M_QZP_[@_E7,?%3_D1=
M1^L7_HQ:Z>V_X]8?]P?RH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%G$J?\"0LOXU]\_\%-/ -KXR^%GA3XDZ2!<KI\JP37$?(>TN &C<GT#A0/\
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M2K24JT .I?2DI?2@!1WI:0=Z6@!?XJ6D_BI: %_A%.IO\(IU !2_PTE+_#0
MZBBBH 7^&E_B%)_#2_Q"@ ;I1Z4-TH]*"PI?X:2B@!W\5 [T?Q4#O00"TM(M
M+06%%%% "_Q4=C1_%1V-  ?NBDI3]T4E !1110 4444 %%%% !1110 4444
M%%%% !1110!@Z]_R,'AG_K^7^E>DUYMKW_(P>&?^OY?Z5Z36;W+CL<;\/O\
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M9?\ P6Z_Y$WX6?\ 7[?_ /H$-:5_W<DEUM^)%!>T;3\_P.Y_X?4_!$=?"WQ
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M!=M_P3__ ."@7@S4OA[<3:;X9UH6]S+I8E9U2UFG,-S:G))9/DWKNS@[<9*
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MT*,DDY:-]!MJ[BM;=3D?@I_P48^!OQRU6VTC2_$TF@:]=,$@TOQ%!]DDE8D
M*LF6B9B2 %#ECV%?3E?GG^W)_P $T? OB/X=:WXQ^%WAZ'PMXNTJ%[QM,TM2
MEIJ,2#+QK#]V.0*"5,8 )X(.05[O_@EY\:O'GQ-^"LNC>/=*UH76A&./3=>U
M*SEC34K-P=@$SC$KQE2I())4H3DY)<;33MNM_P#@$RO"SW3/M6BBBD4%%%%
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M2@YR?P->KV/FBRMQ<8\_RU\S'][ S^M("S1110 4444 %%%% !1110 4444
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MZ/J4?GVI8]6 R&0GOL9<]\UY#16:P])4_9<ON]BY8BK*HJO-[RZ]3ZO\4?\
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M (([C_XBC_5^7_/Z'_@0?ZS4_P#GQ/[C]$MP]11N'J*_.W_A;'[1G_0I:_\
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MJL]6_P!!:6BBOGCZ<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOZ"K'A3X8P>'=6.JWNI7NMZ@H(ADOI-_V8'[PCXX![T 5_&WC"?1_LWAOPQ
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M\1:[:W9F^S6T<\=S(D3$-+(A^4GCFGH!W=%%%( HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /CS]M[_ )(3\8/^NFE?^ED%?E/7[:^*_ >A_$RX
M\;>&O$EC_:6BWTEK]HM?.DBW[")%^9&5AAD4\$=/2O.S^PG\#O\ H2/_ "K7
MW_Q^OH,OQU/"TG":=[WT/G,PR^KBJRG!JUK:GY'45^MQ_85^!W/_ !1'_E6O
MO_C]-/["WP/_ .A(_P#*M??_ !^O3_M6CV9Y7]CXC^9?C_D?DG17ZTM^PO\
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M6CV?X!_9-?NOQ/S2HK]+/^&-_A1_T*?_ )4;O_X[1_PQO\*/^A3_ /*C=_\
MQVC^U:/9_@']DU^Z_$_-.BOTL_X8W^%'_0I_^5*[_P#CM)_PQO\ "G_H5/\
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M#^R:_=?B?FU17Z3?\,;_  K_ .A5/_@QN_\ X[1_PQO\+/\ H53_ .#&[_\
MCM']JT>S_ /[)K]U^)^;-%?I/_PQQ\*_^A5_\J-W_P#':/\ ACCX5_\ 0JG_
M ,&-W_\ ':/[5H]G^ ?V37[K\3\V**_2?_AC?X5_]"M_Y4;O_P".TO\ PQO\
M*O\ H5O_ "HW?_QVC^U:/9_@']DU^Z_$_->BOTH_X8W^%7_0K?\ E1N__CM'
M_#&_PK_Z%7_RHW?_ ,=H_M6CV?X!_9-?NOQ/S7HK]*?^&-_A3_T*O_E1N_\
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M/9_@']DU^Z_$_-&BOTO_ .&,_A1_T*?_ )4KO_X[2_\ #&?PG_Z%3_RI7?\
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MI/\ SZ?^1'_QI?\ A$]*_P"?7_R(_P#C1[1#]FSS]:>O2N]_X172_P#GU_\
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MH] ,40]UR?5I+Y+4):QBNSN4/B)SX#\1_P#8.N/_ $4U?E__ ,$/^=>^+?\
MUPTS_P!"N:_5JYMHKRWE@GB6:&52CQR*&5E(P00>H([5R_@?X1^!_AC+>/X.
M\%^'_";W@47+:'I4%D9]N=H<Q(N[&YL9Z9/K13]R<I=TD*?O04?.YUY%>2_M
M:?\ )KWQ8_[%;4O_ $FDKUJJ&L:18^(M+N],U2RM]1TV\B:"YL[N)989XV&&
M1T8$,I!(((P0:BI'F@X]S2G+DFI=G<_.S_@B6<_"KXB?]AB#_P!$UE_\%NN/
M!WPM_P"OV_\ _0(:_0_P/\,_"'PSM;FU\'^%=$\*VUTXEGAT33H;-)7 P&98
ME4,0.,FF>./A;X-^)D5I%XP\):%XLBM&9[>/7--AO5A9@ Q02JVTD 9QUP*N
MM^\::Z6_ FB_9-OO?\3\]_A-_P %>OA+\/\ X6>$/#5]X7\:7%[I&CVEA/+;
MVMH8VDBA1&*DW(.TE3C(!QVKK?\ A]9\&_\ H4/'7_@)9?\ R57UA_PR?\$!
M_P T<^'_ /X2]C_\:H_X9/\ @A_T1OP!_P"$O8__ !JJE+FDVR(Q4$HK9'SI
M\,_^"M7PJ^*?Q"\.>#],\+^,+74=<OH=/MIKRVM%B221PJERMP2%!/. 3[5V
M7_!47_DR?Q\?]NP_]+H*]CT?]FGX1>'=4L]3TGX5^"M+U.SE6>WO;/P[9PS0
M2*<JZ.L896!Y!!R*['Q5X1T3QQH=QHWB/1M/U_1[@KYVGZI:QW-O+M8,NZ-P
M5.& (R." :SJ14HI+<TIMPJ<SV/D7_@D:/\ C#S3#_U%K[_T97VIW-8/A'P1
MX>^'^BKI'A?0=,\-Z2KM(MCI%G':0!F.681QJ%R>YQS6\*UE+F=S&$>56\V_
MO9^97_!7#]D]]5TF#XV^%K5AJ>F+'!X@CMU^:2 $"*ZX_BC.%8_W2IX"&O?O
M^"<W[62_M*_!F.SUJ[63QUX;5+/55<C?=1XQ%=8[[P"&_P!M6Z BOJK4]+M-
M;TZZT_4+6&^L+J)H+BUN8UDBFC8$,CJP(92"00>"#7)>"_@C\.OAQJ,FI>$_
M 7ACPOJ$D1ADN]%T:VLY7C)!*%XT4E20#C..!44[PC*'1[>3-*GOM2ZK\C\4
M/VQ/VG]/_:/_ &HMWBR\U0?"GP]?M96UEHJH\[6R/B6:-7=4\R8K]YC\JE>#
MMP?L3P%_P5J_9[^&/A+3O#7A?X>^,=&T/3HA#;6=M9605!U)/^E99B<DL<DD
MDDDFOM!OV4_@G(2S?![P"S-R6;PQ8DGW_P!51_PR?\$/^B.?#_\ \)>Q_P#C
M5$&XP5/^F5.TI<WW'RUH_P#P66^$.M:K8Z?!X2\;)-=3I"C26MF%#,P4$XN>
MF37WT.M>5P_LK_!>UFCF@^$/@.":-@Z21^&K)65@<@@B+@@]Z]3]35:67<SU
MN^P^BBBD4-:OSQ_X+6<?L^>"_P#L9T_]);BOT-S7->-OAQX3^)=C;V'B[POH
MWBJQMY?.BM=:T^&\B23!7>JRJP#8)&1S@FHE&Z+C+E=_4_-W]G?_ (*Q?"SX
M1? _P1X,U;PSXPNM2T/2X+&XFLK:U:%W1<$H6N%)'U /M79ZY_P6O^%]OI<[
MZ-X%\77VHA?W5O??9;:%FQP&D660J/<(:^P?^&3_ ((?]$;^'_\ X2]C_P#&
MJLZ7^S+\']%O([O3OA1X'L+N,Y2>U\.6<;J?4,L8(K23YVV^IG%**21^6?[/
M/PY^(O\ P4&_:VM?C'XNT:32O!&GWD-V]QL9;7R[=@8+&W9O]:=RC>PX&7)V
MEE!_8V^LX-2LY[2ZB6>VGC:*6.095U88*D=P02*ECA2"-4C1411A548  Z "
MI*4N5P4$M$"OS.3>I^.GQ4^!OQ<_X)K_ !MU#XE_"NSEUOX<W1?S5\E[B"&U
M9MQMKU5^9%0@;9LCH/F!)4^Y^%?^"UOPTNM%CD\2^!/%>FZN1B2WTK[->0 ^
MTDDL+8^J<>]?HNPSU%>>Z]^SK\*?%6H27^M?#'P=K%](<O=:AH%I/*Q]2SQD
MFDKI<KU2*E:3YK6?7S/RW_:"_;J^)/[=CM\*/@SX'U2QT;4&"WOEMYM[>0Y&
M!,R_N[:#)^?+$' RX&5/W[^PY^R;:_LF_"-='GEAOO%6J2+>ZU?0@[&FVX6&
M,D9,<8R 3U)9L#=@>[^&O".A>"]-33?#^BZ?H6GIRMKIEK';Q#Z(@ _2MBKB
MU%-1Z[^9$DY-7V70=1114E!1110 4444 %%%% !1110 4444 %<;J7_)4-(_
MZ\I/YM795QNI?\E0TC_KRD_FU '94444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 )1M'H/RI:*!#=J_W1^5&U?[
MH_*G44!9#=J_W1^5&U?[H_*G44!9#=J_W1^5&U?[H_*G44!9#=J_W1^5&U?[
MH_*G44!9#=J_W1^5&U?[H_*G44!9#=J_W1^5&U?[H_*G44!9";1Z#\J-H'0"
MEHH"R"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <E\5/^1%U'ZQ?^C%KI[;_CUA_P!P?RKF/BI_R(NH
M_6+_ -&+73VW_'K#_N#^5 $U%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@Z]_R,'AG_K^7^E>D
MUYMKW_(P>&?^OY?Z5Z36;W+CL<;\/O\ C^\4?]A6;^==E7&_#[_C^\4?]A6;
M^==E2*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N-U+_DJ&D?]>4G\VKLJXW4O^2H:1_UY2?S:@#LJ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#DOBI_R
M(NH_6+_T8M=/;?\ 'K#_ +@_E7,?%3_D1=1^L7_HQ:Z>V_X]8?\ <'\J )J*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \WL?\
MD=O%/_72#_T!JVJQM/\ ^1V\4_\ 72#_ -!-;E:+8S>XRBGT4Q#**?10 RDV
MU)10!%M-&VI:* (MOM1M]JEHH BV^U&WVJ6B@"'91LJ:B@"'RZ/+]JFHH AV
M>U)Y=3T4 0>7[?I1Y9_R*GHH @V"CRZGHH @\OVHVGTJ>B@"#:?2CR_:IZ*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#!U[_D8/#/_7\O]*])KS;7O^1@\,_]
M?R_TKTFLWN7'8XWX??\ ']XH_P"PK-_.NRKC?A]_Q_>*/^PK-_.NRI%!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QN
MI?\ )4-(_P"O*3^;5V5<;J7_ "5#2/\ KRD_FU '94444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ')?%3_D1=1^L7
M_HQ:Z>V_X]8?]P?RKF/BI_R(NH_6+_T8M=/;?\>L/^X/Y4 34444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YQI__([>*?\ KI!_
MZ":W*P]/_P"1V\4_]=(/_036Y6BV,WN%%%%,04444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <UX%_X\]3_
M .PA+_):Z6N:\"_\>>I_]A"7^2UTM"!A1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-^)O^0]X=_Z[O\ R%=)
M7-^)O^0]X=_Z[O\ R% (Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K \>?\BG?_1/_ $-:WZP/'G_(IW_T3_T-:;V!;FS9_P#'I!_N+_*I
MJAL_^/2#_<7^534@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH P=>_Y&#PS_P!?R_TKTFO-M>_Y&#PS_P!?R_TKTFLWN7'8XWX??\?W
MBC_L*S?SKLJXV7X;6[WMY<Q:MJEJUU,T[I;SA%W,<GC%+_PK=/\ H8-;_P#
MO_ZU(H[&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG
M_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\
MA6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6
MH [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:
MW_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?
M]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&
MBN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%
M_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K
M?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._
MX5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#U
MJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7
M_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG
M_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\
MA6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6
MH [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:
MW_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?
M]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&
MBN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%
M_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K
M?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._
MX5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#U
MJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7
M_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG
M_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\
MA6Z?]#!K?_@7_P#6H [&BN._X5NG_0P:W_X%_P#UJ/\ A6Z?]#!K?_@7_P#6
MH [&N-U+_DJ&D?\ 7E)_-J7_ (5NG_0P:W_X%_\ UJA;X6VS7"3MK6L&=1M6
M0W W >@.WI0!V]%<=_PK=/\ H8-;_P# O_ZU'_"MT_Z&#6__  +_ /K4 =C1
M7'?\*W3_ *&#6_\ P+_^M1_PK=/^A@UO_P "_P#ZU '8T5QW_"MT_P"A@UO_
M ,"__K4?\*W3_H8-;_\  O\ ^M0!V-%<=_PK=/\ H8-;_P# O_ZU'_"MT_Z&
M#6__  +_ /K4 =C17'?\*W3_ *&#6_\ P+_^M1_PK=/^A@UO_P "_P#ZU '8
MT5QW_"MT_P"A@UO_ ,"__K4?\*W3_H8-;_\  O\ ^M0!V-%<=_PK=/\ H8-;
M_P# O_ZU'_"MT_Z&#6__  +_ /K4 =C17'?\*W3_ *&#6_\ P+_^M1_PK=/^
MA@UO_P "_P#ZU '8T5QW_"MT_P"A@UO_ ,"__K4?\*W3_H8-;_\  O\ ^M0!
MV-%<=_PK=/\ H8-;_P# O_ZU'_"MT_Z&#6__  +_ /K4 =C17'?\*W3_ *&#
M6_\ P+_^M1_PK=/^A@UO_P "_P#ZU '8T5QW_"MT_P"A@UO_ ,"__K4?\*W3
M_H8-;_\  O\ ^M0!V-%<=_PK=/\ H8-;_P# O_ZU'_"MT_Z&#6__  +_ /K4
M =C17'?\*W3_ *&#6_\ P+_^M1_PK=/^A@UO_P "_P#ZU '8T5QW_"MT_P"A
M@UO_ ,"__K4?\*W3_H8-;_\  O\ ^M0!V-%<=_PK=/\ H8-;_P# O_ZU'_"M
MT_Z&#6__  +_ /K4 =C17'?\*W3_ *&#6_\ P+_^M1_PK=/^A@UO_P "_P#Z
MU '8T5QW_"MT_P"A@UO_ ,"__K4?\*W3_H8-;_\  O\ ^M0!V-%<=_PK=/\
MH8-;_P# O_ZU'_"MT_Z&#6__  +_ /K4 =C17'?\*W3_ *&#6_\ P+_^M1_P
MK=/^A@UO_P "_P#ZU '8T5QW_"MT_P"A@UO_ ,"__K4?\*W3_H8-;_\  O\
M^M0!V-%<=_PK=/\ H8-;_P# O_ZU'_"MT_Z&#6__  +_ /K4 =C17'?\*W3_
M *&#6_\ P+_^M1_PK=/^A@UO_P "_P#ZU '8T5QW_"MT_P"A@UO_ ,"__K4?
M\*W3_H8-;_\  O\ ^M0!V-%<=_PK=/\ H8-;_P# O_ZU'_"MT_Z&#6__  +_
M /K4 =C17'?\*W3_ *&#6_\ P+_^M1_PK=/^A@UO_P "_P#ZU '8T5QW_"MT
M_P"A@UO_ ,"__K4?\*W3_H8-;_\  O\ ^M0!V-%<=_PK=/\ H8-;_P# O_ZU
M'_"MT_Z&#6__  +_ /K4 =C17'?\*W3_ *&#6_\ P+_^M1_PK=/^A@UO_P "
M_P#ZU '8T5QW_"MT_P"A@UO_ ,"__K4?\*W3_H8-;_\  O\ ^M0!V-%<=_PK
M=/\ H8-;_P# O_ZU'_"MT_Z&#6__  +_ /K4 =C17'?\*W3_ *&#6_\ P+_^
MM1_PK=/^A@UO_P "_P#ZU '8T5QW_"MT_P"A@UO_ ,"__K4?\*W3_H8-;_\
M O\ ^M0!V-%<=_PK=/\ H8-;_P# O_ZU'_"MT_Z&#6__  +_ /K4 =C17'?\
M*W3_ *&#6_\ P+_^M1_PK=/^A@UO_P "_P#ZU $GQ4_Y$74?K%_Z,6NGMO\
MCUA_W!_*N.N/A?;WD+13ZWK$T3=4DN RGG/(*U(/AM&H &OZX!_U]_\ V- '
M9T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__
M  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8
M-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5Q
MW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_
M /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\
M"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"M
MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4
M?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\
MZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&
M#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W
M3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '
M8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__
M  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8
M-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5Q
MW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_
M /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\
M"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"M
MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4
M?\*W3_H8-;_\"_\ ZU '8T5QW_"MT_Z&#6__  +_ /K4?\*W3_H8-;_\"_\
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MJVV_Z#>L?^!(_P#B:.8.4MT54_X5;;?]!O6/_ D?_$T?\*MMO^@WK'_@2/\
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M;?\ 0;UC_P "1_\ $T?\*MMO^@WK'_@2/_B:.8.4MT54_P"%6VW_ $&]8_\
M D?_ !-'_"K;;_H-ZQ_X$C_XFCF#E+=%5/\ A5MM_P!!O6/_  )'_P 31_PJ
MVV_Z#>L?^!(_^)HY@Y2W153_ (5;;?\ 0;UC_P "1_\ $T?\*MMO^@WK'_@2
M/_B:.8.4MT54_P"%6VW_ $&]8_\  D?_ !-'_"K;;_H-ZQ_X$C_XFCF#E+=%
M5/\ A5MM_P!!O6/_  )'_P 31_PJVV_Z#>L?^!(_^)HY@Y2W153_ (5;;?\
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MT&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\
MQ-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#
M>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@
MY2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_
MT&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\
MQ-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#
M>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@
MY2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_
MT&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\
MQ-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#
M>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@
MY2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_
MT&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\
MQ-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#
M>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@
MY2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_
MT&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\
MQ-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#
M>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@
MY2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_
MT&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\
MQ-'_  JVV_Z#>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#
M>L?^!(_^)HY@Y2W153_A5MM_T&]8_P# D?\ Q-'_  JVV_Z#>L?^!(_^)HY@
MY2W6!X\_Y%._^B?^AK6I_P *MMO^@WK'_@2/_B:CF^%%G<1-'+K&K2(W59)U
M8'\-M','*6;/_CT@_P!Q?Y5-51?A;;* !K6L #_IX'_Q-'_"K;;_ *#>L?\
M@2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+
M=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;
MUC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"
MK;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\
M@2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+
M=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;
MUC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"
MK;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\
M@2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+
M=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;
MUC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"
MK;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\
M@2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+
M=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;
MUC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"
MK;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\
M@2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+
M=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;
MUC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"
MK;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\
M@2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+
M=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;
MUC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"
MK;;_ *#>L?\ @2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\
M@2/_ (FCF#E+=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E+
M=%5/^%6VW_0;UC_P)'_Q-'_"K;;_ *#>L?\ @2/_ (FCF#E,S7O^1@\,_P#7
M\O\ 2O2:X@?"VS^T0S-J^K.\+;T9K@94^H.WBM7_ (0P?]!O6O\ P-/^%2RD
M=%1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y
M^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y
M^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\
MA(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\
MA(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQO\*/^$BT_P#Y^/\ QQO\*XFB
M@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQO\*XFB@#MO\ A(M/_P"?C_QQ
MO\*/^$BT_P#Y^/\ QQO\*XFB@#MO^$BT_P#Y^/\ QQO\*/\ A(M/_P"?C_QQ
MO\*XFB@"M'_R&_$'_80?_P! 2K-5H_\ D-^(/^P@_P#Z E6: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3?\ KA/_ .BS7V;?7T.FV-Q=W#B."WC:61CV51DG\A7C<1*^+BO[J/H^#';
M3?\ >?Y(^8OVN?&7VK5M,\-0/E+5?M5P!_?880?@N3_P*E^!/PG3Q1\+/%-U
M<Q#S]60VMFS#[OE_,&'UDP/^ 5XCXR\23>+_ !3J>L3YWWD[2!3_  KG"K^
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M?</\S7A_[+?_ "5BV_Z])O\ T$5[A^U-_P DGN/^ON'^9KP_]EO_ )*Q;?\
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M4ER\KY]NI@:!\*?"/A>YBN=,\/V5O<Q',<Y3?(AQC(9LD'\:ZNL/P_XX\/\
MBI1_9&LV6H,1N\N&93(![IG</Q%6?$VO0>&/#^HZM<G$-G TS>^!P/Q.!^-;
M5%6J3Y:MW+SO?\3EH_5J=-SP_*H>5K?@?*O[57C+^W/&T&BP2;K;28\. >/.
M?!;\AM'YUN?#_P"$/]L?L]ZW<-#G4]2;[;;<<XAR$'_ OWGX.*\#U35)=<UF
MZU"]=FFNIVFE8<G+-DXS]:^H='_:H\#Z)I-GIUMI>N+;6L*01KY$/W54 ?\
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MG7PBT&PO)=^L:7>^5*6/,L?EL$D]S@8/N,]ZZYX:&)Q%''T=GO\ YG!1QE3
MX3$Y1BM'%/E_R7D]ST']C?[WBOZ6W_M6L/\ :\U1KCQMI-AD[+:R\S;VR[G)
M_)!6Y^QO][Q7]+;_ -JUSG[7%C)#\0M/NB/W<^GJJGW5WS_,?G7)&W]NROV_
M1'=>2X47+WU_\".Y_8_TB*+POKFJ;1Y\]XMN6]%1 P'YR'\A7T#7@?['^H1R
M^#=:L@1YL-\)67OM>-0#^:-7OE?,YSS?7JG-Y'V_#2BLKH\O9_\ !,/Q9X)T
M3QQ9PVNN6"W\$,GFQHSLNUL$9RI!Z$\=*9X<\!>'?",C2:-HUGI\S)Y;30Q
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M/E/4"O2Z^=SG'/%55247%0Z/>Y]APUE:P5&6(<U*4[.ZVL%%%%?-GVH4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG!'1G(/!/45WE%>3+&XF2:=1M/S?^9]!'+,#&2G&A%->2/C']J;_ )*Q<?\
M7I#_ "->X?LL_P#))X/^OR;^8KG/C1^S]XB^(WC>76=-O-,@M6@CB"74LBOE
M1SPL;#'XUZ-\%_ E_P##GP1'H^I36T]TL\DI>U9F3#$8Y95.?PKZ/%XNC/*X
M48S3DK:'QV!R_$T\^JXF<&H.]GTZ'S/^T_\ \E<U#_KW@_\ 0!7TE\ _^20^
M&O\ K@W_ *,>O//C)^SWXB^(7CJYUK3KW2X;66*- EU+(KY5<'(6,C]:]<^&
M7A>Z\%^!-(T6]DAENK.-DD>W8E"2['@D ]#Z5ECL51J9;1HPE>2M=?(VRO X
MBCG>(Q%2+4))V?1ZH\7_ &JOACYT*>,-/A^>,+%?J@ZKT63\/NG\/2OF2OTC
MU#3[?5;&XL[N)9[:XC:*2-APRD8(KY7U;]D/Q'_:=U_9NIZ2=/\ ,8P?:995
MDV9X# 1D9QZ&O1R7-J=.C['$2MR[-]NQX_$_#]6M76*P<+\WQ)=^Y[?\ _\
MDD/AK_K@W_HQZ]!KE_AEX7NO!?@32-%O9(9;JSC9)'MV)0DNQX) /0^E=17Q
MV+E&I7G.+NFW^9^BY;3E2P=&G-6:BD_5)'RW^V-_R'/#7_7O-_Z$M;7['/\
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M<?\ AI#X=?\ 0Q?^25S_ /&Z/^&D/AU_T,7_ ))7/_QNO#O^&1/&/_02T/\
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M3Z7_ ,F=I1117R9^A!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %:/_D-^(/\ L(/_ .@)5FJT?_(;\0?]A!__ $!*LT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:/_ )#?B#_L(/\
M^@)5FHK70-8U/6/$,MC<6,</]H.NVXC<MG8GH>E7?^$-\2?\_FE?]^I?_BJ
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M_P#BJ *]%6/^$-\2?\_FE?\ ?J7_ .*H_P"$-\2?\_FE?]^I?_BJ *]%6/\
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M_?J7_P"*H_X0WQ)_S^:5_P!^I?\ XJ@"O15C_A#?$G_/YI7_ 'ZE_P#BJ/\
MA#?$G_/YI7_?J7_XJ@"O15C_ (0WQ)_S^:5_WZE_^*H_X0WQ)_S^:5_WZE_^
M*H KT58_X0WQ)_S^:5_WZE_^*H_X0WQ)_P _FE?]^I?_ (J@"O15C_A#?$G_
M #^:5_WZE_\ BJ/^$-\2?\_FE?\ ?J7_ .*H KT58_X0WQ)_S^:5_P!^I?\
MXJC_ (0WQ)_S^:5_WZE_^*H KT58_P"$-\2?\_FE?]^I?_BJ/^$-\2?\_FE?
M]^I?_BJ *]%6/^$-\2?\_FE?]^I?_BJ/^$-\2?\ /YI7_?J7_P"*H KT58_X
M0WQ)_P _FE?]^I?_ (JC_A#?$G_/YI7_ 'ZE_P#BJ *]%6/^$-\2?\_FE?\
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M^-,_[]R?_%4>SEV#VL.Y9HJM_8OB+_GXTS_OW)_\51_8OB+_ )^-,_[]R?\
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MB_Y^-,_[]R?_ !5']B^(O^?C3/\ OW)_\51[.78/:P[EFBJW]B^(O^?C3/\
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MB_Y^-,_[]R?_ !5'LY=@]K#N6:*K?V+XB_Y^-,_[]R?_ !5']B^(O^?C3/\
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M3/\ OW)_\51_8OB+_GXTS_OW)_\ %4>SEV#VL.Y9HJM_8OB+_GXTS_OW)_\
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M (JC^Q?$7_/QIG_?N3_XJCV<NP>UAW+-%5O[%\1?\_&F?]^Y/_BJ/[%\1?\
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M?]^Y/_BJ/[%\1?\ /QIG_?N3_P"*H]G+L'M8=RS15;^Q?$7_ #\:9_W[D_\
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M\:9_W[D_^*H]G+L'M8=RS15;^Q?$7_/QIG_?N3_XJC^Q?$7_ #\:9_W[D_\
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M )$W4O\ <7_T-:Z.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#AX?^1P\2?]=+?_ -$K6E6;#_R.'B3_ *Z6_P#Z)6M*NV'P
MH\RK\;"BBBK,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH PO"?\ J-3_ .PC<_\ H9K=K"\)_P"HU/\
M["-S_P"AFMVA;%2W"BBB@D**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ K#U[_D/>&O^ON7_ -)I:W*P]>_Y#WAK_K[E
M_P#2:6DRH[FY1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L/
MQU_R*.J_]<3_ #%;E8?CK_D4=5_ZXG^8HZ%1W1N4444$A1110 4444 %%%%
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M?7?-&37R)_PWV_\ T(H_\&W_ -IH_P"&^G_Z$8?^#;_[36W]B8__ )]_BO\
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M^XO_ *&M='0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!P\/_ ".'B3_KI;_^B5K2K-A_Y'#Q)_UTM_\ T2M:5=L/A1YE7XV%
M%%%69!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!A>$_]1J?_ &$;G_T,UNUA>$_]1J?_ &$;G_T,UNT+
M8J6X4444$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %8>O?\A[PU_U]R_^DTM;E8>O?\A[PU_U]R_^DTM)E1W-RBBB
MF2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8?CK_ )%'5?\ KB?Y
MBMRL/QU_R*.J_P#7$_S%'0J.Z-RBBB@D**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#+U3_D.>&/^PD?_2:>NX;K7#ZI_P ASPQ_V$C_
M .DT]=PW6N2IN>A0^$Y_P?\ Z_Q#_P!A23_T7'715SO@_P#U_B'_ +"DG_HN
M.NBK(Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6LK
MQ1J#:3X9U>^3[]M:33+]50D?RIK5V$W97/@W]JCXN3_$'Q[<Z5:SM_8.CR-!
M#&K';+*.'D([G.0/8>YKK?@'^R;'XWT:W\1>+)[BVTZY DM+&W(1Y4[.[$'"
MGL!R1@Y'?YTTRV?6M<M+>1\R7=RD;.WJ[ $_K7ZLZ?9Q:?8V]K BQPPQK&B#
MH% P!^0K[[-*TLKPE+#X=V;Z^EK_ (L_(\EPT,_S"MC,6N:,;63VUO;Y)(\<
MU7]C_P"&=]8/;V^DW6G3,,"ZM[Z9G!]<2,R_I7QE\8/A;??"/QA-HUW)]I@9
M1-:707:)8B2 <=B"""/45^B^O>/_  SX7O%M-9\0Z7I5RR>8L-[>QPN5)(#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P\/\ R.'B3_KI;_\
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M^@ZDI:*^0/T4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M444 %%%% !1110 4444 -/2N)TCXBVS>,+_PUJ<D=KJL;-+;HQQYD)8A"/?
M_&NVYKQ[]H+P!=:_I-KKFD1A=5TMS*3"F)IH^FP,.<#.['M6D$I.S-Z,8SGR
M2=K]3TOQ/H-MXJT"^TJ[&8+N%HF8=1D$9'N*^&;#7/$OP7^)-QHMK-=+!IID
MGV3DE9(_FV\9 .0 :]M^#?[1EE';VNA^*M1CBO?N17$A"]_NMSDGWJ#]KCX3
M:SXT\-KKG@JU^UZ\4$96'DRQG !'T!-?291BEA9RPU>W)/OM?N?'\3935DHU
MZ2:G!Z-;M>1XU\/_ /@ILEU=7,?B'09IE0LJ"S"JW!ZG)KU[P3^W9X>\=:FF
MGZ?X9U8W<G^KA4QLSG&<  UY#\&_^":RV]Y_:7CG5%EAFB+?8]/9HY$<_P!X
MD8_*OL3P#\&_"?PVTVTM-%TBWC-L"([F6)6F_%\9K?'5,H@FJ4'*?D[(XL%3
MSFHUS3Y8>:39O>%=>F\2:/#>W&F76DR2#)M;Q0LB_45M"FX].!2BOD79MM*Q
M]G%.,4I.['4444BPHHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \JU#QYX:\/^./$=MJGB#2]-N!);YAO+R*)_\ 4*>C
M,#T(_.I?^%M>"?\ H<-!_P#!G!_\77QI^U=E?C]XJ'O;?^DL->2,QK[O"Y'"
MM0A4YVKI/[U<_(\?Q56P^*J453349-;]G8_2;_A;7@G_ *'#0?\ P9P?_%T?
M\+:\$_\ 0X:#_P"#.#_XNOS99CZTFX^M=?\ J_#_ )^'#_K?7_Y]K[S])_\
MA;7@G_H<-!_\&<'_ ,71_P +:\$_]#AH/_@S@_\ BZ_-;S&]:3S&[&C_ %?A
M_P _ _UOK_\ /M?>?I5_PMKP3_T.&@_^#.#_ .+H_P"%M>"?^APT'_P9P?\
MQ=?FKYC^M)YK>M+_ %?A_P _']P?ZW5_^?:^]GZ5_P#"VO!/_0X:#_X,X/\
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M]LN/[_\ XZ/\*/[!I_SO[@_UKQ'_ #[7WGZ<?\+:\$_]#AH/_@S@_P#BZ/\
MA;7@G_H<-!_\&<'_ ,77YC?;;C^__P".BC[;<?W_ /QT4?V%3_G?W#_UKQ'_
M #[7WL_3G_A;7@G_ *'#0?\ P9P?_%T?\+:\$_\ 0X:#_P"#.#_XNOS%^VW
M_P"6GZ#_  H^W7/]_P#\=%']A4_YW]P?ZUXC_GVOO9^G7_"VO!/_ $.&@_\
M@S@_^+H_X6UX)_Z'#0?_  9P?_%U^8GVZY_YZ?\ CHI/MUS_ ,]/_'1_A1_8
M=/\ G?W#_P!;,1_S[7WGZ>?\+:\$_P#0X:#_ .#.#_XNC_A;7@G_ *'#0?\
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MU][/U%_X6UX)_P"APT'_ ,&<'_Q='_"VO!/_ $.&@_\ @S@_^+K\NO[0O?\
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M_'5_PH_M"]_Y[?\ CJ_X4_[$I?SO[@_UJQ'_ #[7WL_47_A;7@G_ *'#0?\
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M?_!G!_\ %T?\+:\$_P#0X:#_ .#.#_XNOR[_ +1O?^>W_CJ_X4?VC>?\]O\
MQU?\*/[$I_SO[@_UIQ'_ #[7WL_43_A;7@G_ *'#0?\ P9P?_%T?\+:\$_\
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M2_\ "_?A[_T-6G_]]-_A7YX44?ZOT?YW^'^0?ZWXK^2/]?,_0_\ X7Y\/?\
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M?:_'_,_1FV^-'@:\N(X+?Q/IT\TC!4CCFW,Q/0 #J:V/^$VT7_G]_P#(3_\
MQ-?FC!/):S1S1.8Y8V#HZ\%2#D$5]@^#=?3Q/X8T[4E96>>)3*%Z+(!AQ^#
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M^>__ (XW^%']MV1_Y;?^.-_A7)TY*/91']8D=7_;5G_SV_\ '6_PI?[8L_\
MGM_XZW^%<M3EI>R17MI'3_VQ9_\ /;_QUO\ "C^U[3_GK_XZ?\*YFG4O9H?M
MI'2?VO:?\]?_ !T_X4O]K6G_ #U_\=/^%<U3Z/9H/;2.C_M2U/\ RU_\=/\
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M>A_X*?\ [=5BS_8+MHYHS>>,I)X@?F6'3A&Q^A,C8_(U]:8]Z/QKM>=X]_\
M+S\%_D><N&,I3O['\7_F<%\,?@[X;^$>FO;:':N9IL?:+VX8//-CIN;   ]
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M4]4_T%DF;_7H.C77+5AHU^IT5%)2U\\?4A1110 4444 %%%% !1110 4444
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M=\DTK8"CUKRIOVQ?@XK$'QS89'^Q)_\ $TU&4MD7"C4J:PBW\CV<T+6#X/\
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MISPZGMY9G]3$XIX/%4^2?0^C+JZALX3-<2)#$O+/(P %<O\ \+;\(?:A;_\
M"0Z?YF[;CSUZ_G7Q_P#MJ?';6)/%8\&Z'>26B0MY=R(S_K">F:\RG_8_\<V_
MA%O$S)\RQ?:2OF?-MQG/K6N$R*C*A"MBZO)S_"C+&<0UHXB='!4>?D^)GZ;6
MMU%>0K+!(LT3#*LAR#^-3;C7PI^QC^T#JL/B,^"O$5P\T3*QBEF/,9' 7%?=
M0YKP<QR^IEU=T9Z]4^Z/H\KS&GF=!5H:=&NS/'/VDO@39_&'PE*(HECUFV4R
M03 89B!PI/I7R#\ ?B]K/[/_ ([D\.>(_.CL#+Y4L+@X!Z!ESVK](N:^:/VM
MOV=%^(^BG7M$MU&NVBY*J,>8O4FO:RC,:<H/+\9K3EL^S/ SO+*BFLQP6E2.
MZ[H^BM*U2UUJPAO+*9+BVF4,LD;9!_&KE? W[)/[05YX+UH>#?$DTB6;/Y40
MFR/(;)SUK[VAGCN(4DB8/&PR&4Y!%>1F>75,NK.G+5/9]T>WE.9T\SH*I'22
MT:[,FHHHKR#VPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH YSXA_\B;J7^XO_ *&M='7.?$/_ )$W4O\ <7_T-:Z.@ HHHH ****
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MG&G-,\BA3=/"UX26JL>I?&;]@_Q!\8/B%J?B6]\=1*;LCRX)+1R(5"@!1AL
M<?SKXP_:*^"$WP!\>Q^&YM675V:TCNO/CC,8&\L-N"3_ '?UK]G<=Q7Y<_\
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MOZVW_I+#7DE>N_M7?\E^\5_[UM_Z2PUY+7[)EZ_V2E_A7Y(_FK-G_P *%?\
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M&P22,@])_P $H_%EW\3OV/Y]#U^1M2L](U*ZT-%N&+;K4Q1R"/.<[0)V4>@
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MHN<N>.J9GB<#+$5?;T?>C+S./^(W[<GBCQYX'\6^%-6TR-(]7G?RVW8:UA+
MB+&.<8ZGFNO_ .":OP[FU3QYJWC+SMMOI<#61CQ]YI5SG/MMKYYT'P#XW_:&
M\>7=SINF27NIZG*]P\S+Y<.3R?FQM%>@_!3Q]\2OV6OB!>Z-#HEU>133!;S2
M?+8QS.!A6#A3TSU!QUK>45R.$=&>E6HPCAYT:-E)]+GZSTM9/AC4Y]:\/Z;?
MW-N;.XNK>.:2W)SY;,H)7\*U37CGP[5G86BBB@04444 %%%% !1110 4444
M%%%% !1110 4444 ?G-^U=_R7[Q7];;_ -)8:\EKUK]J[_DOWBOZVW_I+#7D
MM?LV7_[I2_PK\D?S3FW_ ",:_P#BE^84445WGD!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*ILO5?FBX;G0_P#!-?\ Y,K^&O\ U[W7_I7/6Y^WQ_R9S\5/^P0W_H:5A_\
M!-;_ ),K^&O_ %[W7_I7/6Y^WQ_R9S\5/^P0W_H:5OC]ZGS(P?V/5?F>&_\
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M,0H&.[#,V!D?9G_!)W_DS#PSZ?;K_P#]*7J*<6G-O2Z7YBJR5H)=&_R/"_\
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M*^F?%*QU\V@\[2K>..*V,/G?Q1W$P8MYOMC9W[?.GQ[Y_P""PWP^ X_X\/\
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M7WC#6]:\,^,K70?B#"(_[5FT2XAOHRQ&$>ZM0X*L0A 8,F<$G=BOFJ\_8?\
MVNOV4;>;4_A7\0)-?T:R+2IINBZ@Z,R@9+-87 \ES_LJ9&/8$U)XH\"_%W_@
MFO\ M)>)?'/@CPA<>,OA7KA>26&UC=H5MRYD$,S1JQMY(F)"2,I4J>^64=IJ
M_P#P6#USQYI,FA_#3X-ZM>^,[N)HXEDN&O%MI2/O+#%%OFP<\$IT_"L8W4$Z
M>]MOT-Y?&U+5='Y'M_\ P3D_;6UK]J;P[KVB>,K:WA\8^'1"TUU:IY27T+EE
M$ACZ(ZLF& PIW @#H/GS]J7!_P""N'PIS_U"?_1DM>V_\$QOV2?$_P  _#/B
M3QCX_A^P^+?%318TYW#26MNA9OWN.!([.6*Y.T*N<'('A/\ P4FTGQ?\&/VP
M/ 7QSLO#<^N>&].@LY&F16\CSH)G+P2R*#Y1967:Q'.3@':16TI*-:FWIKK;
M;8P47.G5C'6Z=K]=C]&/CY\9M&_9_P#A'XA\=ZZCS66E0!EMHB ]Q,S!(HE/
M8L[*,]LD]J_/CX>_%S]M?]M2&Z\3_#_4]#^&G@AY7@MI)HHDAD*M@A9'AFGD
M8="ZA4)!  (('INK>/[G_@J-^Q;X]M?#6@?\(MXBT_4HX[33;B_%PMQ)"(IU
M!DV(%$@9T&1@$ DXZ?.W[-G_  4$\4_L3^"+;X3_ !*^%>JD:3+.;.1I&LKE
M$DD:0HT<B$2#>[D.K 8(X/6HC&TYJIOI9=+/KZFC^"+AKKKY'3_'7]@_XWQ?
M!3QGXO\ BS^T'?:]'HNG7&I'0+>>ZN[.X>-"RH#+)&J9('2(^PKV#_@BX?\
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MJ>@^"]'\,22/IMC':O)]XHH&:BEFD(9;+ N-VW>Y5;*9U,TCCU*R2M8_/?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@R\_]&VU=%7.WG_)0M(_[!EY_P"C;:@#HJ*** "BBB@ HHHH **** "BBB@
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MQ%6E.C-TZBLT??T:T,1356F[I[#J***R-PHHHH **** "BBB@ HHHH ****
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M;6_]G:Q"HC:<D,)B3\OTP*J>/OB5K'AVYT*/2=/AU%=0F,+LN3L*L QX["I
M]/HK@)/%VOVOA7Q-?SV-L;[3IF2VCC)*2J,8)_,UG77Q6N]-\2-87=BL=FML
MMQ]K .QOD#,H/KVH ]0HKE]+\7&\6&>6,"VNX!/:[.7<'^''KBN7A^/VB2:V
M-,;3=5AE^T):F22VPBNQPH)SQ0!ZA1110 4444 %%%% !1110 4444 %%%%
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M=/86JDX-6:'T4E+2*"BDHS0 M%)2T %%%% !1249H 6BDI: "BDHH 6BBB@
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MC_AB+XS_ /0Y:3_X,[K_ .,UP_V9EW_06ON/1_M;,O\ H#?WGW2?%&D_\_\
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M HHHH **** "BBB@#G/B'_R)NI?[B_\ H:UT=<Y\0_\ D3=2_P!Q?_0UKHZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS+4/@S'_;EUJ&DZWJ&D+=
MDF>WMI=D>3U8 #KFO3:* /,M(^!UGI/B2QUPZ]JUWJ%JGE^9<3!C(N<[6..E
M7=9^%4>I>-)?$-OK-_ITUP(UN([63:'$8&T=.GK7H%% 'GWBKX1VNO>*H_$=
MEJ-YH^JK#Y+M9N$69<DX?C)Z_H*L>%/AC!X=U8ZK>ZE>ZWJ"@B&2^DW_ &8'
M[PCXX![UW-% 'E-]\ [2X\27^MV_B36K"^O6;S&MIPORDYV9QTXK9\)?"]_"
MNM)J!\3ZUJ@5&3[-?7&^(Y[XQU%=[10!YE??!KR]8O=0TC7]2TS[;,TT]K%-
MMB+-U8 #K6WX'^&=AX)FO+I;FYU34;IMTE]?,'E/&,9]*[*B@#E-$^']GH&D
MZOI]I<W")J5W-=RR[OG5I""P4^E<WKWP'TC7?#.D:"VH7]OINFAO+AB<8<DD
M[F!')Y->GT4 >40_ <V\,<,7C7Q)'#$H1$6[ "J.@''2MWQ-\+8/$OA'3M&G
MU6^$^GR+/!J'F#S_ #%S@EL>]=U10!Y1J/P)3Q&L1UKQ'JMX$*$V_G;HB5.0
M<$=3WKL[[P19W_B/3]7EDE#V,?EPVZG]V,'(;'K7244 <[XR\&6OC?3X;*]F
MFCMXYDGVQ'&YD8,,_B*L^+?#=OXP\.7VC73/';WD?E.T>-P&0>,_2MFB@#@O
M%WPHM/% T62/4KW3+O28C%;7%I)M;:0 03[X%95Y\"[37+&ZM]:US4]46XB"
M!+B4.D#@YWH".#VKU*B@#S_7OA#8>)/#%AH6H:E?W%K:(5#/("SGLS''4=JR
M5^!KKIL&F#Q=KJ6$)!3;<X<C^X>/NXKU:B@"AH^DVF@Z;!8V4*6]K"NU(XQ@
M#N?UR?QJMXJ\-VWBW0+O2;MW2WN5"NT9PPP0>/RK8HH \[M?@GH5GH+Z7$]P
MJ-,LXF##S%<# (-7;_X4Z-?^&)]";S([.4 Y0@,KYRSC_:;O7;T4 <'IOP>T
M+2[6."-9'5=.;3&9L9DC9LDMZFG6/PBT.Q\!R>$<23:5)(TA$A!;);=_.NZH
MH XCP_\ "NP\/FQ1+V\N;>Q<26]O,^4C8="!6CI/@>RTFU6%9IIMKRR(\IR5
M,AR<5TU% %"/2(%T];-LO%C#;NK_ %]:Y37OA3IWB#1;73;B\NUBMRQ$B. S
M!CG!/I7=44 <3I_POM-/T_2K6/4;YAIMR;B&1I/FY7&P_P"S[5%XE^&L?B+7
M;6[,WV:VCGCN9$B8AI9$/RD\<UW=% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'DVH^ _#6O^./$EQJ?A[2]2N"]N#-=V<4K_P"H4=64
MGH!^5.;X3^"?^A.T'_P60?\ Q-;D/_(W^)/]^#_T2M:%>C3JS4$DW]YX=;#4
M95&W!7]$<A_PJCP5_P!"?H/_ (+8/_B:0_"CP5_T)^@_^"R#_P")KKMIINTU
MK[:I_,_O,?JM#_GVON1R!^%/@O\ Z$_0?_!9!_\ $TUOA/X+_P"A0T'_ ,%D
M'_Q-=@5IK+FCVU3^9_>'U2A_(ON1Q_\ PJ?P7_T*&@_^"R'_ .)IA^%/@O\
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M &H]M5_F?WA]6H?R+[D>9?\ "I?"?_0K:/\ ^"^'_P")H_X5+X3_ .A6T?\
M\%\/_P 37IG]G>U']G_[-'MJO\S^\/JM#^1?<CS'_A4OA/\ Z%;1_P#P7Q?_
M !-'_"I/"?\ T*VC_P#@OB_^)KTW^S?:C^SJ/;5?YG]X?5:'\B^Y'CGA_P"%
M?A>XAOC)X:TERM[,B[K"(X4.<#[O05J_\*C\*?\ 0KZ-_P""^+_XFNT\+Z=F
M'4?E_P"8A<?^AFMK^S?]FI5:I;XG]XWA:%_@7W(\Q_X5'X4_Z%?1O_!?#_\
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M'MJO\S^\/JM#^1?<CR__ (5)X4_Z%?1__!?%_P#$TG_"I/"G_0KZ/_X+X?\
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MFO3?[-']VC^S1_=I>VJ_S/[P^K4/Y%]R/,O^%2>$O^A6T?\ \%\/_P 32_\
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M7_"E_LBQ_P"?.W_[]+_A5JBCF?<.6/8J_P!DV7_/I;_]^E_PH_LJR_Y\[?\
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MP>A42$AB"!C.#BOV L? ?AK2_$5YK]GX>TFSUV\.ZYU2"QB2ZG.T+EY0NYN
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MW9T4P%F5'F"%6GEEVLPB+!%"]B"S?7&EWUQI?_!+F*ZM&9;J+X9DQLAPP/V
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M10 5A^.O^11U7_KB?YBMRL/QU_R*.J_]<3_,4/8J.Z-RBBB@D**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+U3_ )#GAC_L)'_TFGKN
M&ZUP^J?\ASPQ_P!A(_\ I-/7<-UKDJ;GH4?A.?\ !_\ K_$/_84D_P#1<==%
M7.^#_P#7^(?^PI)_Z+CKHJR.@**** "BBB@ HHHH **** &MS7YR_P#!;#CX
M*^ ?^P^W_I/)7Z,UYM\:_P!G?X?_ +1FBZ?I/Q#T#_A(-/T^<W5M#]MN+;9*
M5*ELPR(3P2,$D5$ES6]4RX2Y7=]F8O[''/[*?PD_[%G3_P#T0E>R5A^#/!^D
M_#_PKI'AK0;0V.BZ3:QV=E:^8\GE0HH5%W.2S8 '+$GWK;Z5O4DIS<EU=S&"
MY8I,4U^0_P#P5>T^\\(_M:?#7QMXDTB;6O :6MFIMV7=#/Y%T\ES;<_+N9&7
M@]0WL:_7BN<\<?#[PS\3O#]QH7BS0=/\1:/,P+V6I6ZS1EAT8!APP[,.1V-8
M:QE&<>C-4U9Q>S5CP'3?^"DG[-\GAB+4T^(UI9P+&H-E)872W$? ^3R5B+''
M3Y01QP<<U^8/_!0K]IRY_:N\4:)XCT+0-3L/AMH3S:9IFJ7T!07MTVUYVS]T
M':D>$R6"@%L%MH_4?2?^";O[-VAZQ'J=O\+K&2Y1MX2[O[RY@S[PRS-&1[%<
M5Z+\4/V9_AE\9?!.E>#_ !5X1M+WPSI,RSV&G6<DMC%:LJ,@V?9WC*J%9AM!
MQSTX%5]I3ZIZ"B^5-=&C)^.%U%?_ +'_ (\N83NAF\%7TB'KE38N1^AKY>_X
M(K_\F\^,\_\ 0SR8_P# 6WK[<3X8^&H_AF?A^+!V\)?V8=&-A)<S.QM#%Y1B
M\TN9/N';NW;O?-9'P6_9_P# 7[/'AV\T+X?:%_8&E7ET;V:W^V7%SOF**A;=
M-([#Y448!QQTK122G4E_,DE\G?4A7]E"#W3N_N*O[42_\8U_%3_L5M4_])):
M^0_^"+'S?L\^,A_U,\G_ *2V]?>GBKPSIWC+PWJV@:Q;?:])U2UELKRWWLGF
MPR(4==RD,,JQ&001G@UR'P5_9^\!_L[^'[S0_A]H7]@:5>71O9[?[9<7.^8H
MJ%MTTCL/E11@'''2II^ZYW^TDON=RYZQC%='<_-+XZVNO_\ !/G]O-_B_%H]
MSJGP\\67$TMP]N.&6X^:Z@W'@2K(/-120& 49^]C[*NO^"FW[.EOX1;75^("
M7!V$KIL>GW/VUGQGR_*,8P<\;B0G^UCFOI'Q1X3T;QMHEQHWB'2;'7-)NEVS
MV.H6Z3P2C.0&1P0>0#T[5\_Q?\$W?V;H=<&K+\+[(W0D\SRVO[QK?.>GD&;R
ML?[.W'M6<;J"@]EL_()6E+GZO?S/E']A.R\7_M2?MD>-/VA+V&_T;P5#+)':
M0&5DCN9?*$$$) .V3RX1N<\@/M]>,_Q)S_P6NT\=O,B_],@K]1-#T#3?"^CV
MFE:/I]KI6EV<8BMK*RA6&&%!T5$4 *!Z 5YS<_LM_#&[^-B?%R;PSO\ B'&5
M*ZQ_:%T,8@\@?N1+Y7^K^7[GOUYJXVC.#6T4UYBNY1J7WDODMCU?';VK\B?V
MDM'\3?L!_MT1_&G3=(FU'P'XENY)YS",1N9U_P!*M6;HLF[,J9P#@8SM;'Z[
M@UE>)/#.D>,=&NM(U[2[/6-*NDV3V6H6Z3P2KZ,C@@CZBHUC)3CNOR8U9Q<)
M;,^;-+_X*9_LZ:EX5_MI_'\=CM0-)I]U87(NT8@?)Y:QG<1G&4++[XYKY8^#
M_P"T!\6_VV_VVH]7\!ZYXA\*?"/0VA:]M5G9+=[2-BP6:,$QF>X;*X'S!.Y"
M9KZTO/\ @FM^S9>ZL^HR?"^T6X9MY2'4KV*'/M"LXC ]MN*]Y\%> _#?PYT&
M+0_"V@Z?X=TB'+)8Z;;)!$">K;5 !)[D\GO6L7&,N=[]NA#ORN"Z]3\WO^"V
M7ACQ!=:3\--?ABFG\,64MY;7+)DQPW$GE&,OZ;EC< _[)'>OH#X.?\%$_P!F
M]?A;HB1>+;/P='IUA%"^@W5E-')9[$ \I%2,K(!C@QEL\=^*^K_$'AW2O%FC
M7FD:YIMIK&E7D9BN;&^@6:&9#U5T8$,/J*^>9/\ @FS^S;+K']J'X7V8N?,\
MSRUU&]6#.<X\D3^7C_9VX]JSA>*<.E[ERM)J75*Q^?'_  4:_;(M?VJM!L](
M^'NCZG=_#KPQ>I=:CXDN+1XHIKN16CA4 CY%VM)@/AF)/R@)D_IO^Q?=Q7G[
M)OPGDB.5'ANSC_%8@I'Y@UO^)OV<_AKXM^%DOPVOO!VFQ>!I61VT73T:RA#(
MX=64P%&5MR@D@@GG.<FMSX7_  O\-?!GP78>$?"&GR:5X=L-YMK.2ZFN?*WN
M78!YG=\;F)QG SQ5Q]V$H=VG^ I7DXOMH?D[^R_\</!_[,W[?OQLO?B1J,GA
MS3[V[U6SCNI+6655E:_65 RQJS ,BD@XQT]:^@O^"M/B[2/'G[&O@WQ#H-VN
MH:/JGB"RN[.Z5602Q/:73*V& (R"." :^H/B]^Q=\%OCMKPUSQQX"L]7UC:%
M:_@N+BSFE & )'MY$,F  !NS@  5?\5?LG?"SQM\)]"^&>M>&&OO!.AR1RZ?
MI;:E=IY#(KJA\U91*V!(XPSD<^PQF_>I1@]XV]+)W9::C5E46SO]]K&)^S7X
M7L_&O[$_P^\/:BGF6&K>#+6RN%]8Y;4(P_)C7YY_LF_&ZZ_X)N_&[QG\*?BY
M:W=CX7U.=9X=8AMWD1"FY8[M$4%I(94P#LRRE ,9# ?K5X-\'Z3X!\+:3X;T
M&U^PZ)I5K'9V5KYCR>5"BA47<Y+-@ <L2?>L3XH?!7P+\:M%72O''A;3?$UF
MFXQ+?0!GA)&"8Y!AXR1W0@UK4D_;2JP^UNOG=&<4O9J$NFNG0^9/CM_P5$^#
M/@7X=ZC=>#?%,?B_Q3<6K?V;I]A;S;1*RD(\SNBJBJ<$J3NXP%KG?^"3'P5\
M6>!_A1K?C7Q=+J$4WBV>*;3]/O)'_=VR;B)]A/RF5I">G*HIZ-7MW@7_ ()_
M_L^_#?7(M9T3X9Z<-1A8/')J%Q<Z@L; Y#*EQ+(JL#R"!D=J^AA\O &!2C:%
MVMWIZ>@I7DE%[+7U'9KA/C9\)])^.7PK\2>!]:!%AK%JUN90H+0OPT<J@_Q(
MX5A[K7=^E&*B4>9-,M2<6FMT?C7^SS^T3XV_X)E_$;6_A9\5_#]]>^"[JY:Y
M@FLQN9&X7[5:%B%EBD 7<F001V8,K?<\/_!4#]FN331=GXB^4VW)MVT:_P#-
M!_N[1!U^AQ[U]#>.OAOX5^*&BG2?%WAS2_$NF%MXM=5M$N$5L8W*'!VM_M#!
M%>"3?\$S?V:;B\-VWPQA$N[=M35]02//^X+@+CVQBJO)KWM^XK13;CI?IT/@
M[]J;]JCQ3_P44\;:+\(O@[X=U)O#2W(N9I+E DEVZG:+B?;D0V\>XGYCR2"<
M-M4?H+8?L[W'PB_8IUKX6>"W,VMQ^&;VUAN8_D:YOI87+R ]B\CG'/ *CM7K
MWPZ^$O@OX1Z6^F>"_"^E>%[*0AI(]+M$A\U@,!I& R[8[L2:Z\4I17LW377?
MS&I/G4WTV1^.G_!+G]I[X6?LYQ^-/#GQ&E_X1+Q'?WL935KRSD8,B+L-M(RJ
M6B*/N;Y@%^8Y((KZO^/7_!4#X8Z#X9N]'^%U_/\ $;Q_J"_8]+L=)LYVA6>0
M81W<J-X!(^2/<S$!?ESN'MGQ5_8I^"7QLUJ36/&'P^TW4M6E;=-?6TDUE/,>
MF9'MWC:0X &6)Z5L?"']E?X3_ B47'@;P+I>AWFTH+\(UQ=[3U7[1*SR;3@<
M;L4Y?O%:>G302M"5XZZWU/SM_P"",7VC2?BQ\6='U*.2WU9+.V$L$PVNC1S2
M+(&'7(9P#6C_ ,%$/^4C/P%Q_=T?_P!.LM??W@7]E;X7_#7XH:U\1/#7AC^R
M_&&LF<W^H1ZA=,L_G2"27,+2F(9<!N$&".,4[XA_LL_##XK?$;0?'?BKPS_:
MGBO0O)_L[4/M]U#Y'E2F:/\ =QRJC8D8M\RG.<'(XJXRM.E-_9=W^.P?\_5>
M_-_P#UCL!7Y3_P#!1#_E(U\!O]W1_P#TZ2U^K->3?$3]EKX8_%CXC:#X[\5>
M&O[4\5Z%Y/\ 9VH?;[J'R/*E,T?[N.54;$C%OF4YS@Y'%1'W:L)]$[_@.]H3
MCW5CCOV\OV?[O]HW]G'7O#FD1+-XBLWCU32XG('F7$.?W8)X!=&D0$\989XK
MY1_8&_X*$^#?AO\ #6U^%/Q@OKCP;KWAF5["UO+^UE,<L8=L0R[5)ADB.4(<
M 85><Y%?IOUZ5X_\7?V1_A!\>+W[;XY\!Z7K.I<!M0026MTX P T\+)(P Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &7JG_(<\,?]A(_^DT]=PW6N'U3_D.>&/\ L)'_ -)IZ[ANM<E3
M<]"A\)S_ (/_ -?XA_["DG_HN.NBKG?!_P#K_$/_ &%)/_1<==%61T!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !24M% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[
M>?\ )0M(_P"P9>?^C;:NBKG;S_DH6D?]@R\_]&VU '14444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.?$/\ Y$W4
MO]Q?_0UKHZYSXA_\B;J7^XO_ *&M='0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!P\/_ ".'B3_KI;_^B5K2K-A_Y'#Q)_UT
MM_\ T2M:5=L/A1YE7XV%%%%69!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!A>$_]1J?_ &$;G_T,UNUA
M>$_]1J?_ &$;G_T,UNT+8J6X4444$A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %8>O?\A[PU_U]R_^DTM;E8>O?\A[
MPU_U]R_^DTM)E1W-RBBBF2%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %8?CK_ )%'5?\ KB?YBMRL/QU_R*.J_P#7$_S%'0J.Z-RBBB@D**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+U3_D.>&/^PD?_2:>
MNX;K7#ZI_P ASPQ_V$C_ .DT]=P>M<E3<]"A\)QGA_Q)I6EWVOQ7>H6]O(VI
M2,%DD .-B#/Y@C\*V?\ A-] _P"@O9_]_17.>#=%T_5-0\3R7EA;7;KJDRJT
MT*N0,]!D5U'_  B.A_\ 0&L/_ 9/\*R.@B_X3?0/^@O9_P#?T4?\)OH'_07L
M_P#OZ*E_X1'0_P#H#6'_ (#)_A1_PB.A_P#0&L/_  &3_"@"+_A-] _Z"]G_
M -_11_PF^@?]!>S_ ._HJ7_A$=#_ .@-8?\ @,G^%'_"(Z'_ - :P_\  9/\
M* (O^$WT#_H+V?\ W]%'_";Z!_T%[/\ [^BI?^$1T/\ Z UA_P" R?X4?\(C
MH?\ T!K#_P !D_PH B_X3?0/^@O9_P#?T4?\)OH'_07L_P#OZ*E_X1'0_P#H
M#6'_ (#)_A1_PB.A_P#0&L/_  &3_"@"+_A-] _Z"]G_ -_11_PF^@?]!>S_
M ._HJ7_A$=#_ .@-8?\ @,G^%'_"(Z'_ - :P_\  9/\* (O^$WT#_H+V?\
MW]%'_";Z!_T%[/\ [^BI?^$1T/\ Z UA_P" R?X4?\(CH?\ T!K#_P !D_PH
M B_X3?0/^@O9_P#?T4?\)OH'_07L_P#OZ*E_X1'0_P#H#6'_ (#)_A1_PB.A
M_P#0&L/_  &3_"@"+_A-] _Z"]G_ -_11_PF^@?]!>S_ ._HJ7_A$=#_ .@-
M8?\ @,G^%'_"(Z'_ - :P_\  9/\* (O^$WT#_H+V?\ W]%'_";Z!_T%[/\
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M^$WT#_H+V?\ W]%'_";Z!_T%[/\ [^BI?^$1T/\ Z UA_P" R?X4?\(CH?\
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M&L/_  &3_"@"+_A-] _Z"]G_ -_11_PF^@?]!>S_ ._HJ7_A$=#_ .@-8?\
M@,G^%'_"(Z'_ - :P_\  9/\* (O^$WT#_H+V?\ W]%'_";Z!_T%[/\ [^BI
M?^$1T/\ Z UA_P" R?X4?\(CH?\ T!K#_P !D_PH B_X3?0/^@O9_P#?T4?\
M)OH'_07L_P#OZ*E_X1'0_P#H#6'_ (#)_A1_PB.A_P#0&L/_  &3_"@"+_A-
M] _Z"]G_ -_11_PF^@?]!>S_ ._HJ7_A$=#_ .@-8?\ @,G^%'_"(Z'_ - :
MP_\  9/\* (O^$WT#_H+V?\ W]%'_";Z!_T%[/\ [^BI?^$1T/\ Z UA_P"
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M=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\
M07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W
M]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+
M_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P
M_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_
MA1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$
M=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\
M07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W
M]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+
M_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P
M_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_
MA1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$
M=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\
M07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W
M]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+
M_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P
M_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_
MA1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$
M=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\
M07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W
M]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+
M_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P
M_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_
MA1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$
M=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\
M07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W
M]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+
M_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P
M_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_
MA1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$
M=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\
M07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W
M]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+
M_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_A1_PB.A_] :P
M_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$=#_Z UA_X#)_
MA1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\ 07L_^_HJ7_A$
M=#_Z UA_X#)_A1_PB.A_] :P_P# 9/\ "@"+_A-] _Z"]G_W]%'_  F^@?\
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M?\)OH'_07L_^_HH_X3?0/^@O9_\ ?T5+_P (CH?_ $!K#_P&3_"C_A$=#_Z
MUA_X#)_A0!%_PF^@?]!>S_[^BC_A-] _Z"]G_P!_14O_  B.A_\ 0&L/_ 9/
M\*/^$1T/_H#6'_@,G^% $7_";Z!_T%[/_OZ*/^$WT#_H+V?_ ']%2_\ "(Z'
M_P! :P_\!D_PH_X1'0_^@-8?^ R?X4 1?\)OH'_07L_^_HH_X3?0/^@O9_\
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M_ 9/\*/^$1T/_H#6'_@,G^% $7_";Z!_T%[/_OZ*/^$WT#_H+V?_ ']%2_\
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M_A$=#_Z UA_X#)_A0!%_PF^@?]!>S_[^BC_A-] _Z"]G_P!_14O_  B.A_\
M0&L/_ 9/\*/^$1T/_H#6'_@,G^% $7_";Z!_T%[/_OZ*/^$WT#_H+V?_ ']%
M2_\ "(Z'_P! :P_\!D_PH_X1'0_^@-8?^ R?X4 1?\)OH'_07L_^_HH_X3?0
M/^@O9_\ ?T5+_P (CH?_ $!K#_P&3_"C_A$=#_Z UA_X#)_A0!%_PF^@?]!>
MS_[^BC_A-] _Z"]G_P!_14O_  B.A_\ 0&L/_ 9/\*/^$1T/_H#6'_@,G^%
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M - NS_\  =/\*/\ A&])_P"@79_^ Z?X4>\'N>9'_P )9H__ $$K;_OX*/\
MA+-'_P"@E;?]_!4G_"-Z3_T"[/\ \!T_PH_X1O2?^@79_P#@.G^%'O![GF1_
M\)9H_P#T$K;_ +^"C_A+-'_Z"5M_W\%2?\(WI/\ T"[/_P !T_PH_P"$;TG_
M *!=G_X#I_A1[P>YYD?_  EFC_\ 02MO^_@H_P"$LT?_ *"5M_W\%2?\(WI/
M_0+L_P#P'3_"C_A&])_Z!=G_ . Z?X4>\'N>9'_PEFC_ /02MO\ OX*/^$LT
M?_H)6W_?P5)_PC>D_P#0+L__  '3_"C_ (1O2?\ H%V?_@.G^%'O![GF1_\
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M_P!!*V_[^"C_ (2S1_\ H)6W_?P5)_PC>D_] NS_ / =/\*/^$;TG_H%V?\
MX#I_A1[P>YYD?_"6:/\ ]!*V_P"_@H_X2S1_^@E;?]_!4G_"-Z3_ - NS_\
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M - NS_\  =/\*/\ A&])_P"@79_^ Z?X4>\'N>9'_P )9H__ $$K;_OX*/\
MA+-'_P"@E;?]_!4G_"-Z3_T"[/\ \!T_PH_X1O2?^@79_P#@.G^%'O![GF1_
M\)9H_P#T$K;_ +^"C_A+-'_Z"5M_W\%2?\(WI/\ T"[/_P !T_PH_P"$;TG_
M *!=G_X#I_A1[P>YYD?_  EFC_\ 02MO^_@H_P"$LT?_ *"5M_W\%2?\(WI/
M_0+L_P#P'3_"C_A&])_Z!=G_ . Z?X4>\'N>9'_PEFC_ /02MO\ OX*/^$LT
M?_H)6W_?P5)_PC>D_P#0+L__  '3_"C_ (1O2?\ H%V?_@.G^%'O![GF1_\
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M_P!!*V_[^"C_ (2S1_\ H)6W_?P5)_PC>D_] NS_ / =/\*/^$;TG_H%V?\
MX#I_A1[P>YYD?_"6:/\ ]!*V_P"_@H_X2S1_^@E;?]_!4G_"-Z3_ - NS_\
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M#I_A1[P>YYD?_"6:/_T$K;_OX*/^$LT?_H)6W_?P5)_PC>D_] NS_P# =/\
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M/_T$K;_OX*/^$LT?_H)6W_?P5)_PC>D_] NS_P# =/\ "C_A&])_Z!=G_P"
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M (#I_A1[P>YYD?\ PEFC_P#02MO^_@H_X2S1_P#H)6W_ '\%2?\ "-Z3_P!
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M  '3_"C_ (1O2?\ H%V?_@.G^%'O![GF1_\ "6:/_P!!*V_[^"C_ (2S1_\
MH)6W_?P5)_PC>D_] NS_ / =/\*/^$;TG_H%V?\ X#I_A1[P>YYD?_"6:/\
M]!*V_P"_@H_X2S1_^@E;?]_!4G_"-Z3_ - NS_\  =/\*/\ A&])_P"@79_^
M Z?X4>\'N>9'_P )9H__ $$K;_OX*/\ A+-'_P"@E;?]_!4G_"-Z3_T"[/\
M\!T_PH_X1O2?^@79_P#@.G^%'O![GF1_\)9H_P#T$K;_ +^"C_A+-'_Z"5M_
MW\%2?\(WI/\ T"[/_P !T_PH_P"$;TG_ *!=G_X#I_A1[P>YYD?_  EFC_\
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M^@79_P#@.G^%'O![GF1_\)9H_P#T$K;_ +^"C_A+-'_Z"5M_W\%2?\(WI/\
MT"[/_P !T_PH_P"$;TG_ *!=G_X#I_A1[P>YYD?_  EFC_\ 02MO^_@H_P"$
MLT?_ *"5M_W\%2?\(WI/_0+L_P#P'3_"C_A&])_Z!=G_ . Z?X4>\'N>9'_P
MEFC_ /02MO\ OX*/^$LT?_H)6W_?P5)_PC>D_P#0+L__  '3_"C_ (1O2?\
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MXH_["LW\Z[*N-^'W_']XH_["LW\Z[*LS8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N-U+_ )*AI'_7E)_-J[*N-U+_
M )*AI'_7E)_-J .RHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .2^*G_ "(NH_6+_P!&+73VW_'K#_N#^5<Q\5/^
M1%U'ZQ?^C%KI[;_CUA_W!_*@":BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7,^*/^1@\-_\ 7=_Y"NFKF?%'_(P>&_\
MKN_\A4RV-*?Q'344451F%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<_X^_Y%"_\ HG_H:UT%<_X^_P"10O\ Z)_Z&M*6S+A\2-JS_P"/.#_KFO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XW4O^2H:1_UY
M2?S:NRKC=2_Y*AI'_7E)_-J .RHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .2^*G_(BZC]8O_1BUT]M_P >L/\
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M* "N-U+_ )*AI'_7E)_-J[*N-U+_ )*AI'_7E)_-J .RHHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S
MO2_^1V\5?]=(/_06K>K!TO\ Y';Q5_UT@_\ 06K>KLI[(\VM\3"BBBM#$***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .9\!_\>>J?]A"7^2UTU<SX#_X\]4_["$O\EKIJF.QI4W844451
MF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5S/BC_D8/#?_ %W?^0KIJYGQ1_R,'AO_ *[O_(5,MC2G\1TU%%%49A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRKC?A]_Q_>*/^PK-_.NRJ#<**** "BBB@ HHHH **** "BBB@ HHHH ****
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MA?<O\CP#_AY._P#T3O\ \K!_^1Z/^'D[_P#1._\ RL'_ .1Z]_\ ^&6_ /\
MT"Q^8_PH_P"&6_ /_0+'YC_"CZUD7_0._P#P)_YA]3XA_P"@A?<O\CP#_AY.
M_P#T3O\ \K!_^1Z/^'D[_P#1._\ RL'_ .1Z]_\ ^&7? /\ T"_U'^%._P"&
M8/ 7_0+'YC_"E]:R+_H'?_@3_P P^I\0_P#00ON7^1\_?\/)W_Z)W_Y6#_\
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MJNS)****\L]@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^&ZH_P#H3X__  ;C_P",T?V1C/Y/Q7^8?ZQ9;_S\_!_Y'U517RK_ ,-U1_\
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M -"E'_X.!_\ &:/[)QG\GXK_ ##_ %ARW_GY^#_R/JRBOE/_ (;N@_Z%&/\
M\&X_^,T?\-W0?]"C'_X.!_\ &:/[)QG\GXK_ ##_ %ARW_GY^#_R/JRBOE/_
M (;OM_\ H4H__!P/_C-'_#=]O_T*4?\ X.!_\9H_LG&?R?BO\P_UARW_ )^?
M@_\ (^K**^4O^&[H/^A2B_\ !N/_ (S1_P -W0?]"E%_X-Q_\9H_LG&_R?BO
M\P_UAR[_ )^?@_\ (^K:*^4O^&\(/^A2B_\ !P/_ (S1_P -X0?]"E'_ .#@
M?_&:/[)QO\GXK_,/]8<N_P"?GX/_ "/JVBOE+_AO"#_H4HO_  <#_P",T?\
M#>%O_P!"G%_X.!_\9H_LG&_R?BO\P_UAR[_GY^#_ ,CZ'\!_\>>J?]A"7^2U
MTU?'^@_MK6VB0W4?_",13>?<//G^U@N-V./]4<].M:?_  WA!_T*47_@X'_Q
MFICE&,2^#\5_F7/B++7*ZJ?@_P#(^K:*^4O^&\+?_H4XO_!P/_C-'_#>%O\
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M*_S#_6++?^?GX/\ R/JNBOE3_ANE/^A.7_P;#_XS2_\ #=,?_0G)_P"#8?\
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M))I'_03LO_ A/\:7_A)M)_Z"EE_X$)_C1ROL'M(=T:-%9W_"3:3_ -!2R_\
M A/\:7_A(])_Z"=G_P"!"?XT<LNP>UAW1H45G?\ "1:5_P!!.S_\"$_QH_X2
M+2O^@G9_^!"?XT<LNP>UAW1HT50_X2#2_P#H)6?_ '_3_&C_ (2#2_\ H)6?
M_?\ 3_&CEEV'[2'<OT50_P"$@TO_ *"5G_W_ $_QI?[>TS_H(6G_ '_7_&CE
MEV%[2'<O451_M[3/^@A:?]_U_P :/[=TW_H(VO\ W_7_ !HM+L'M(=R]15+^
MW=-_Z"%K_P!_E_QH_MS3?^@A:_\ ?Y?\:.678?/'N7:*I?VYI_\ T$+7_O\
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MS_B+_D8/#'_7\/Z5Z(W6O/O$$+MKWAHA&(6]!) Z=*]!/6N*K\1Z-'X$<?\
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M][Q4N:^]VM_3L?'/[+G_ "7?PM_OW'_I/+7Z.K_2OSB_9<_Y+OX6_P!^X_\
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MTQ:>M9ECUI:1:6@L?'2_Q4D=+_%4L:)%[51\0?\ ('N/^ _^A"KR]JH^(/\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %(>12T4 ?G'^TK\,9_AO\
M$J_,<!71]3D:[LI!]W#'+IGU5B1CT(]:]C_9T_:HTG3?#]GX9\87+64EF@AM
M-292R21CA4DP"5*C@-T(')!'/T?X^^'^B_$C09=(UZS%U:L=R.IVR1/V=&['
M_)R*^2O&W[$/B;2[B63PUJ-KK-GG*0W+>3<?0Y^0_7(^@K[3#X["8_"K#8U\
MLH[/_@_YGYEB\JQ^4XZ6/RQ<T97O'UU:MZ[6/I_4/CK\/-/M6N)?&&C.BC.(
M+M)G_P"^$);]*^0?VH/CEH_Q<O-*M-#MIQ9Z8TI^V3C9YQ?:/E3J -O4\G/0
M5CQ_LF_%)Y@A\-+&N<>8U_;X^O$F?TKTCP/^PSJ=S,DOBS6X;.VR";73,R2,
M.X+L JGZ!JVP]#+,NJ*NZW,UM9I_@CEQ>*SO-Z;PL<-R1ENVFOQ9;_8*S]L\
M9X_N6?\ [6J_^VY\,9[R'3O&EC"9%MT%I?[1RJYS&Y]LDJ?J*^B_ _P_T/X=
M:*FEZ!I\=C; Y?&2\C?WG8\L?K]!@5NWUC;ZC9S6MU"D]O,A22&10RNI&""#
MU%>'5S3_ (4/KE):::/JK6/J<-D?+E']G5Y7;OJNCO=?<?GU^SI\=C\']<G@
MU".2X\/Z@5,Z1<O"XX$JCOQP1W&/0 _9^G?'GX>ZCIZ7<7C'2$C<;MMQ=K%)
M_P!\.0P/MBO"/B;^Q&;J^FOO!&HQ6T4A+'3=0+!4]DD )QZ!A_P*O(YOV3?B
MC',47PVLR@X\Q+ZW"GWYD!_2O=Q$,LS22K>UY)/>]E^?Z'RN%J9WD,7AO8^T
M@GI9-_=;H>E?M+_M/:=XIT.?PIX2G:ZM;C O=2VE%90<^7&" 2"1RW3' SG-
M>>?LL?#6?QW\3+*_DB8Z3HLBW=Q+CY3(#F)/J6 ./1376^!_V)/$^J7<4GB:
M_MM%LLYDAMG\ZX^@Q\B_7<<>AKZZ\#>!='^'7A^WT;1+5;6RCY/=Y'/5W;NQ
MQU^@&  *RQ&.PF7X5X;!/FD]W^MS?"Y9F.<XV.-S*/)".T?36UNWJ<W^T5Q\
M$O%X_P"G(_\ H2U\$_!WQ%8>%/B=X>U;4Y_LVGV=UYDTVQGV+@\X4$G\!7Z(
M?%?PG=^./AYKN@V#PQ7=];F*-[EBL8;(/S$ G''8&OD/_AAWQ[G']I>'_P#P
M)G_^,UCDN*PU+#U*5>?+S?Y'3Q-@<;7Q5"OA*?-R?G>Y]%?\-:?"OC_BIF_\
M%]U_\;KB?BU^UQX-D\%ZIIWANYFUG4;ZW>V1OLTD446]2I=C(JDX!Z ')KRO
M_AAWQ]_T$O#_ /X$S_\ QFK5C^PSXQFF07>M:+;Q$_,T+RR,![ HN?S%7#"Y
M-3DINLW;I_PR,JF8<258.FL.DWU[?>SQSX3>';GQ5\2O#>G6J,SR7L4C[1]R
M-6#.WX*I/X5]W?M0<? 7Q0/2*'_T?'4?P5_9YT3X-PRW$,SZIK<Z[)=0E4+A
M<YV(N3L4X&>23CKT Z+XS>#;[XA?#76_#VFRP0WMZB+&]RS+&-LBL<E5)Z*>
M@-<F8YE3QF+I2A\$&M?FKL]')LFKY?E]:-7^)43T731V7XGP+\!_%6F>"OBQ
MH.M:Q<_8]-M6E,LVQY-NZ%U'RJ"3RP' [U]I#]K+X6=_%#?^"ZZ_^-5\Z?\
M##OC[_H)>'__  )G_P#C-'_##OC[_H)>'_\ P)G_ /C->SCGE>85%4J5K-*V
MG_#,^8RO^W<IIRI4<-=-WU_X#1]&?\-:?"O_ *&<_P#@ONO_ (U7;Z7XLTOQ
MSX)DUK1KDWFFW,$OE3>6T>[;N4_*X!'((Y':OCO_ (8=\??]!'P__P"!,_\
M\9KZF^$/P_U'P#\)[#POJ,MM+J$$<R,]L[-$2\CL,%E!Z,,\5\[CL-@*--2P
MM5RE?;R^Y'V>4XW-\17<,=148VW5]_O9^;-K(([J%V.%5U)/MFOT*C_:S^%@
M10?$S @8_P"0?=?_ !JOG;_AAWQ]_P!!+P__ .!,_P#\9H_X8=\??]!'P_\
M^!,__P 9KZ;'5<LS!0]K5MRWV\[=T^Q\/EE'.\HG5>'P]^?>_E?:S7<^B_\
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MUX45[V>XFCB:T949<R2/D>%<%7P.&J0Q$7%N5]?1#Z***^;/N HHHH ****
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M^'^J066OP*UJK 317$1\W'?K7WS\.?'VG?$KPG9:YIK'[/<+G:W53[U\B_\
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MM=CMDC(!K[XOO%UEJG@^+5=(NOMEKJ"K';75H0ZJ7X#Y'0 ]?3%?#G_!0/\
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M:^=O^"=W_(:US_?'\JK+,2\-EF(K4-+/0G-,(L5FF&H8C6ZU\SAOVDOV7?\
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M.ISP17QY^WQHOA2.WL;X,L?B-F.%A(W-QQN[UL?L(ZAXON-/N(M0#-X96!S
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ^)'E7,#M%(G]A:D=K*2",BVP>1VJ/\ X>B_LQ_]%,_\H&J?_(U?GQ_P3Q^
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MO4R&I7P]2DWS;-;,Q_@#HTWB'X]:0MKRJWSN3[9->T?\%"M)BAU;3+Y1^_\
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M>'Y1NKWV^9E7I3?$49V=K+7Y'S-\8--FT;X\ZK!>1@'[6N5/3!(K]%[3X?\
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M/;I7,_\ #M'3?^@\_P#WTW^%?<?XT?I6RKS2LF=<<PQ$4HJ6B/AS_AVCIO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M I*6B@#QW1?V5/AKI/QDUOXJ/X?BU/QUJLR3-J>HGS_LI6)(P+=#\L?RH/F
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M@ HHHH **** "BBB@ HHHH *XW4O^2H:1_UY2?S:NRKC=2_Y*AI'_7E)_-J
M.RHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]C\(/"$%JL2'4I5#7,N 2&QR ?2N5_9=_9]L_A;X=CU&]MD.NW29:0CE4(!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZT:J<9+HRHR2C*+ZJWXI_H?'?_#ZKX(?]"M\0/\ P76/_P F4?\ #ZKX(?\
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MU?FGK.F>*/V0OBA]JLF>72FDRH8_),GOCJ17VMX%_:-\(>,_#=MJ0U.&U=E
MDBF8*0V.>">F:Z\TRETY+$81<U.>JMT\CBRC.54B\-C'RU8:._7S/5\48KB/
M^%S^#_\ H-VO_?U?\:/^%S^#_P#H-VO_ ']7_&O"^J8C^1_<?2?7,/\ \_%]
MYV^VC;7#'XU>#Q_S&[7_ +^K_C2_\+J\'?\ 0;M?^_J_XTOJF(_D?W"^NX;_
M )^+[SN-M&VN'_X75X._Z#=K_P!_5_QH_P"%U>#O^@W:_P#?U?\ &CZIB/Y'
M]P?7<-_S\7WG<8HQ7#_\+J\'?]!NU_[^K_C1_P +J\'?]!NU_P"_J_XT?5,1
M_(_N#Z[AO^?B^\[C;1MKA_\ A=7@[_H-VO\ W]7_ !H_X75X._Z#=K_W]7_&
MCZIB/Y']P?7<-_S\7WG<8HQ7#K\:/![=-;M?^_J_XTO_  N?P?\ ]!NU_P"_
MJ_XT?5,1_(_N#ZYAO^?B^\[4_>HZ<UQ/_"Y/"'_0;M?^_J_XUX3^TY^U=8>'
MM"?1?"ETMUJET"CS1GB-2.H([UU8;+<3B:L:4(.[.3%9KA<+1E5E-:=GN<S^
MV!^TA.;@^"?"]QF60[+F>(Y(;.-O'UKHOV1?V;X_#>GQ>*_$%OYNJ3?/!',/
MFC]V!KBOV3/V<I/%-^?&WBQ7N-S[XX[@9\QCSN.:^XHHTAC6-%"(HP%'0"OH
M<RQE++Z']G8-_P")]WV/F<KP5;,L1_:>.7^&/9=R7IP*6BBOBC[X**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y+XJ
M?\B+J/UB_P#1BUT]M_QZP_[@_E7,?%3_ )$74?K%_P"C%KI[;_CUA_W!_*@"
M:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP[2;?Q-\/?&&MSGPV=<.H
M2%X=0\]58C)(CP>F,U[C10!XC#;^-/$/Q.T76=5\,&UTR&#RS URK"!]V?,]
MR/ZUHZA#XAT'XP:EJEOX>;5[.^AMXK>;SE3RMJXD(S]?TKUVB@#Q6\T3Q'\.
M?BEJFN:1I+:UHFL1^;<A9%C,$I;EN>O 'YUT&CW'BKQMKUM)J>FMX?T*SRSP
M&42->L?N$$<J%(_'->E44 >"^(X?'&H?$234;WP>VN:18.?[.MQ=)&JN.DI_
MO<$\$5WOA/Q9XLUK65L]9\&MHU@T;%KHW:R $#A=H]:[VB@#Q/P[+XF^%VH:
MY81>&6U#3;S49KR"\6X5?OXPA'X=:V/!_A[Q#XH\<?\ "5^*+(:4+.-H+#32
MRR;%8#<Q8=3D5ZI10!YKX!\.ZOX>T/Q5+>6/F:C=ZE=2V\>\9DA8_)SV[UQV
MH^'_ !WH/P=T;POH6G,U_)%(E[<)*@,2L['8,]R&'(KWNB@#PKP->>+? /A^
MWTS3?AHZA!F:;^T$+32?Q.2>>3VK?^)=OXBUSPKX9U>VT-GU/3]0BOI]+\Y<
MJ%W9&[IZ?G7JU% 'AOQ"U3QM\0] ;2=-\,26=I<-$9+S[2I(&X%EQQTKH]8\
M!WDNN>#M.MK;.B:*R77G[@,2J2,8^AKT^B@#@/C+X?U+Q3X5AT[3;7[1*U[;
MRNVX#:J2!B?R%:GQ0TR_UCX?ZY8Z4ADU">W*0JI );(KJZ* /&/&'AK7='U#
MP1J&FZ&-9M]*M9([NQ\U47>RK\W/!(()JOX^?QS\1O!^I:59>'CHT#PJX=ID
M<W0W#]T!QM]<U[?13N!XY\1M&\4^+/AWH=G8:+]EU.&2*Z>,RJ1#)"?E7WS5
MJ/Q]X]_L>"!O!#2:O@),!=H%48QYGY]J]9HI <C\.?!(\%Z.ZSS?:]4NV\Z]
MNB,&5^<<>P./PJ?XC6.I:EX+U.VTE=^HR(!$N<<[AW^E=/10!\]Z/\+_ !78
MV,>KS0^9KEO>1RI'O'S1@<KGZU:\6_!W5M>T+4=2DA\_Q//\[,K!%F0GY8B.
MGR>O>O>J*=P/G_P;\(?$>A:/<V_F-#]NT26&2,ON$-R6X _#TJY8_#'Q%<?!
MZ\L;J../Q;,VS[4X5W,:M\HS_NU[I11<#R'PCX9\0?8?"UAJ.E"V?2'42WKR
M*YFC&?EQ[DU<O/ -UXTCTFX\06.VXTRXGEC0./F^?,?3Z"O4J*+@<C+X/BO/
M#>J6+P+$^K,TMPHQA6.,_P A7 >+/ >N21P:UI>EDZ_-"UK<#S@ J ;%/I]V
MO;:*0'ENBV/B2'1_#XGTDI/&WV.^C$PRT 7B3/N:XSQ#\*3HWC>TDTE;JXGF
MOX;@$W+;88E/SC!/-?0M%.X!1112 **** "BBB@ HHHH **** "BBB@ HHHH
M **** "DI:* /A;X[?!GQCX\^-'BJ_T31_MUIYD'[S[5#'_RP1>CN#U5ORKA
M?^&8_B7_ -"U_P"3]K_\=K[<TW_D=O%7_72#_P! :MLBOK</G>)I4H4THV22
MV?33N?G>,X6P=?$3K2D[R;;U6[U['P/_ ,,R_$O_ *%K_P GK7_X[1_PS/\
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M_0MM_P"!MM_\=K[D,(II@]J/]8,3_*ON?^8?ZI8'^>7WK_(^'?\ AGOXA_\
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MVOL[^S1V%)_9H_R*/[>Q/:/W,/\ 5/ _S/[U_D?&/_"F?''_ $+DO_@7;?\
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M[>Q/:/W,/]4\#_,_O7^1\9?\*=\;?]"[-_X%VW_QVC_A3OC;_H79O_ NV_\
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MB#_T+;_^!MM_\=K[:%M[4[[-[4?V]B?Y5]S_ ,P_U2P/\TOO7^1\2?\ #/\
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MK_H6C_X'6O\ \=I?^&9_B7_T+1_\#[7_ ..U]XA:=M-'^L&*_EC]S_S#_5'
M_P \OO7^1\%_\,R_$O\ Z%K_ ,GK7_X[3O\ AF3XF?\ 0L_^3UK_ /':^] I
MIZBC_6#%?RQ^Y_YA_JC@?YY?>O\ (^"/^&8OB9_T+'_D]:__ !VE_P"&7_B;
M_P!"R?\ P.M?_CM??"]*>O2E_K!BNT?N?^8?ZHX'^>7WK_(^=/ ?[/>O:#X7
MLK>9K&VNG7SKB-IF9ED89()52"1PO!(XX)ZUT/\ PI;7/^?G3_\ OX__ ,17
MM5%>9+'UYR<F]SW*>3X:G!0BG9>9XLOP8UL'_CYT_P#[^/\ _$4__A36M_\
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MU_[[;_XFC_A7NHY_UUK_ -]M_P#$UZ%11]8J#^I4C@/^%?ZC_P ]K7_OIO\
MXFLKQ9X+OK/P_=S/+;E5VY"LV?O@?W:]4KG_ !]_R*%_]$_]#6IEB*EF7'!T
MG)'/VW@6_:WB(FML% ?O-Z?[M2CP'J'_ #VMO^^F_P#B:[6S_P"/.#_KFO\
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M/_R17VUS17K87-L;@J?LZ%2T>UD_S3/$Q>2X#'5/:UZ=Y=[M?DSXD_X=M/\
M]%&;_P $Y_\ DBC_ (=M/_T49O\ P3G_ .2*^W,>]&/>NS_6',_^?OX1_P C
MB_U9RO\ Y]?^32_S/B/_ (=M/_T49O\ P3G_ .2*/^';3_\ 11F_\$Y_^2*^
MW,>]&/>C_6',_P#G[^$?\@_U9RO_ )]?^32_S/B/_AVT_P#T49O_  3G_P"2
M*/\ AVT__11F_P#!.?\ Y(K[<Q[T8]Z/]8<S_P"?OX1_R#_5G*_^?7_DTO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#SC2_^1U\5?\ 72#_ -!:MTK6
M%I?_ ".OBK_KI!_Z"U;]=E/X4>;6^)D>VFE14NVDV>]:&)%MINT5-Y?O2&,"
M@"+:*0J*EV"C8* (-M-9!5GRQ2>6* *OEBD\H5;\H4GECTH I^2/2D\GVJ[Y
M?M^M'ECTH H^335C##*G(]0:OF('C'%-CMDA7:BA5] * *7V>D\DUH>31Y-
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MH 2G+TI-M+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7/^/O^10O_HG_ *&M=!7/^/O^10O_ *)_
MZ&M*6S+C\2-JS_X\X/\ KFO\JFJ&S_X\X/\ KFO\JFID!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 <_P"(O^1@\,?]?P_I7HC=:\[\
M1?\ (P>&/^OX?TKT1NM<57XCT:/P(X_X??\ ']XH_P"PK-_.NRKC?A]_Q_>*
M/^PK-_.NRJ#<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N-U+_DJ&D?]>4G\VKLJXW4O^2H:1_UY2?S:@#LJ*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D
MOBI_R(NH_6+_ -&+73VW_'K#_N#^5<Q\5/\ D1=1^L7_ *,6NGMO^/6'_<'\
MJ )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_X^_Y%"_\
MHG_H:UT%<_X^_P"10O\ Z)_Z&M*6S+C\2-JS_P"/.#_KFO\ *IJAL_\ CS@_
MZYK_ "J:F0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!S_B+_D8/#'_ %_#^E>B-UKSOQ%_R,'AC_K^']*]$;K7%5^(]&C\"./^'W_'
M]XH_["LW\Z[*N-^'W_']XH_["LW\Z[*H-PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *XW4O^2H:1_UY2?S:NRKC=2_Y
M*AI'_7E)_-J .RHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .2^*G_(BZC]8O_1BUT]M_P >L/\ N#^5<Q\5/^1%
MU'ZQ?^C%KI[;_CUA_P!P?RH FHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#SO2_P#D=O%7_72#_P!!:MZL'2_^1V\5?]=(/_06
MK>KLI[(\VM\3"BBBM#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .9\!_P#'GJG_ &$)?Y+735S/@/\
MX\]4_P"PA+_):Z:ICL:5-V%%%%49A1110 4444 %%%% !1110 4444 %%%%
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M'XL7PK>'4Y=+:RRGF"V#^9]]<8R,=<5MP0^.?)CVSZ+MVC&1)G&/I5GXJ?\
M(BZC]8O_ $8M=/;?\>L/^X/Y4 <IY/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T
M4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y
M[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOH
MGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T
M4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y
M[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOH
MGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T
M4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y
M[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOH
MGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T
M4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y
M[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOH
MGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T
M4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y
M[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOH
MGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T
M4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y
M[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOH
MGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T
M4 <=Y/CK_GOHGY2_X4>3XZ_Y[Z)^4O\ A78T4 <=Y/CK_GOHGY2_X4>3XZ_Y
M[Z)^4O\ A78T4 >.V,?B3_A)M>$4FGB\#Q?:2P?83M.W;QGIG.:UO+\7?\]M
M*_)_\*L:7_R.OBK_ *Z0?^@M6]75!>ZC@J2M-Z',^7XN_P">VE?D_P#A1Y?B
M[_GMI7Y/_A7345KR^9ES^1S/E^+O^>VE?D_^%'E^+O\ GMI7Y/\ X5TU%'+Y
MAS^1S/E^+O\ GMI7Y/\ X4>7XN_Y[:5^3_X5TU%'+YAS^1S/E^+O^>VE?D_^
M%'E^+O\ GMI7Y/\ X5TU%'+YAS^1S/E^+O\ GMI7Y/\ X4>7XN_Y[:5^3_X5
MTU%'+YAS^1S/E^+O^>VE?D_^%'E^+O\ GMI7Y/\ X5TU%'+YAS^1S/E^+O\
MGMI7Y/\ X4>7XN_Y[:5^3_X5TU%'+YAS^1S/E^+O^>VE?D_^%'E^+O\ GMI7
MY/\ X5TU%'+YAS^1S/E^+O\ GMI7Y/\ X4>7XN_Y[:5^3_X5TU%'+YAS^1S/
ME^+O^>VE?D_^%'E^+O\ GMI7Y/\ X5TU%'+YAS^1S/E^+O\ GMI7Y/\ X4>7
MXN_Y[:5^3_X5TU%'+YAS^1S/E^+O^>VE?D_^%'E^+O\ GMI7Y/\ X5TU%'+Y
MAS^1S/E^+O\ GMI7Y/\ X4>7XN_Y[:5^3_X5TU%'+YAS^1S/E^+O^>VE?D_^
M%'E^+O\ GMI7Y/\ X5TU%'+YAS^1S/E^+O\ GMI7Y/\ X4>7XN_Y[:5^3_X5
MTU%'+YAS^1S/E^+O^>VE?D_^%'E^+O\ GMI7Y/\ X5TU%'+YAS^1S/E^+O\
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MOR?_  H\OQ=_SVTK\G_PKIJ*.7S#G\CF?+\7?\]M*_)_\*/+\7?\]M*_)_\
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MY/\ X4>7XN_Y[:5^3_X5TU%'+YAS^1S/E^+O^>VE?D_^%'E^+O\ GMI7Y/\
MX5TU%'+YAS^1S/E^+O\ GMI7Y/\ X4>7XN_Y[:5^3_X5TU%'+YAS^1S/E^+O
M^>VE?D_^%'E^+O\ GMI7Y/\ X5TU%'+YAS^1S/E^+O\ GMI7Y/\ X4>7XN_Y
M[:5^3_X5TU%'+YAS^1S/E^+O^>VE?D_^%'E^+O\ GMI7Y/\ X5TU%'+YAS^1
MS/E^+O\ GMI7Y/\ X4>7XN_Y[:5^3_X5TU%'+YAS^1S/E^+O^>VE?D_^%'E^
M+O\ GMI7Y/\ X5TU%'+YAS^1S/E^+O\ GMI7Y/\ X4>7XN_Y[:5^3_X5TU%'
M+YAS^1S/E^+O^>VE?D_^%'E^+O\ GMI7Y/\ X5TU%'+YAS^1S/E^+O\ GMI7
MY/\ X4>7XN_Y[:5^3_X5TU%'+YAS^1S/E^+O^>VE?D_^%'E^+O\ GMI7Y/\
MX5TU%'+YAS^1S/E^+O\ GMI7Y/\ X4>7XN_Y[:5^3_X5TU%'+YAS^1S/E^+O
M^>VE?D_^%'E^+O\ GMI7Y/\ X5TU%'+YAS^1S/E^+O\ GMI7Y/\ X4>7XN_Y
M[:5^3_X5TU%'+YAS^1S/E^+O^>VE?D_^%'E^+O\ GMI7Y/\ X5TU%'+YAS^1
MS/E^+O\ GMI7Y/\ X4>7XN_Y[:5^3_X5TU%'+YAS^1S/E^+O^>VE?D_^%'E^
M+O\ GMI7Y/\ X5TU%'+YAS^1S/E^+O\ GMI7Y/\ X4>7XN_Y[:5^3_X5TU%'
M+YAS^1S/E^+O^>VE?D_^%'E^+O\ GMI7Y/\ X5TU%'+YAS^1S/E^+O\ GMI7
MY/\ X4>7XN_Y[:5^3_X5TU%'+YAS^1S/E^+O^>VE?D_^%'E^+O\ GMI7Y/\
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M_L*S?SKLJXWX??\ ']XH_P"PK-_.NRJ#8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N-U+_ )*AI'_7E)_-J[*N-U+_
M )*AI'_7E)_-J .RHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .2^*G_ "(NH_6+_P!&+73VW_'K#_N#^5<Q\5/^
M1%U'ZQ?^C%KI[;_CUA_W!_*@":BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7,^*/^1@\-_\ 7=_Y"NFKF?%'_(P>&_\
MKN_\A4RV-*?Q'344451F%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<_X^_Y%"_\ HG_H:UT%<_X^_P"10O\ Z)_Z&M*6S+C\2-JS_P"/.#_KFO\
M*IJAL_\ CS@_ZYK_ "J:F0%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!S_B+_D8/#'_ %_#^E>B-UKSOQ%_R,'AC_K^']*]$;K7%5^(
M]&C\"./^'W_']XH_["LW\Z[*N-^'W_']XH_["LW\Z[*H-PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XW4O^2H:1_UY
M2?S:NRKC=2_Y*AI'_7E)_-J .RHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDHH 6BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH Y+XJ?\ (BZC]8O_ $8M=/;?\>L/
M^X/Y5S'Q4_Y$74?K%_Z,6NGMO^/6'_<'\J )J*** "BBB@ HHHH **** "BB
MB@ HHHH **3-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'G>E_\ ([>*O^ND'_H+5O5@Z7_R
M.WBK_KI!_P"@M6]793V1YM;XF%%%%:&(4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <SX#_X\]4_["$O\
MEKIJYGP'_P >>J?]A"7^2UTU3'8TJ;L****HS"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YGQ1_R,'AO_ *[O_(5T
MU<SXH_Y&#PW_ -=W_D*F6QI3^(Z:BBBJ,PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KG_'W_ "*%_P#1/_0UKH*Y_P ??\BA?_1/_0UI2V9</B1M
M6?\ QYP?]<U_E4U0V?\ QYP?]<U_E4U,@**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#G_$7_(P>&/\ K^']*]$;K7G?B+_D8/#'_7\/
MZ5Z(W6N*K\1Z-'X$<?\ #[_C^\4?]A6;^==E7&_#[_C^\4?]A6;^==E4&X44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9VK:]I
MV@VYN-2U"UT^ =9+J98E_-B!32;=D3*2BKLO\T?A7'P?%WP-<3"*+Q?H,DI.
M BZE"2?PW5U<-Q%=1J\4BR(PR&0Y!'KFJE3E'XDT9TZU.II"2?HR>BBBH-A*
M3)J*XN([6-I)9%BC499G(  ]237*3?%SP/;S>5-XOT&.7."C:E"&SZ8W5<82
ME\*N8U*U.G\<DO5V.RHJAI>L6.M6J7-A>6]];M]V:WE61#]"I(J]4M-.S-(R
M4E="T4F:;YJ?WU_.D.Z6X^BF>8G]]?SI?,7^\OYTQ<R[CJ**3(')-(H6BFB1
M3P&!/UIU KI[!1110,**9YJ?WU_.CS$_OK^=.S)YEW'T4SS4_OK^=*)%;@,"
M?K0',NXZBFLZKU8#ZFD\U/[Z_G0/F7<?13/-3^^OYT>8G]]?SHLQ<R[CZ*0,
M&Y!R*6D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<;J
M7_)4-(_Z\I/YM795QNI?\E0TC_KRD_FU '94444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 444UF"J23@#DT (S!>O ]
M:3S%Q]X?G7QE^V/^T-&T,O@S09UFD<[+O;SDYX KPKP[^R3X^\4:7%J/V"2U
M28;E61.2#R#7UF&R%3H1KXJLJ2ELFKW_ !1\5BN(I4\3+#X2BZO+NT[6?;9G
MZ@^8G]Y?SH\Q/[R_G7YH_P##%/C[_GB?^_='_#%/C[_GC_Y#K;^P\%_T&+_P
M'_@F/^L&/_Z I??_ , _2_S$_O+^='F)_>7\Z_-#_ABGQ]_SQ_\ (=-/[%GC
M[_GW8_\ ;.C^P\%_T&K_ ,!_X(?ZP8[_ * I??\ \ _3'S8_[Z_G1YL?]]?S
MK\S?^&*_'W_/L?\ OW1_PQ7X^_Y]C_W[I_V%@O\ H,7W?\$7^L&/_P"@)_?_
M , _3+S8_P"^OYT>;'_?7\Z_,W_ABOQ]_P ^Q_[]T?\ #%?C[_GV/_?NC^PL
M%_T&+[O^"'^L&/\ ^@)_?_P#],O,3^\OYT>8G]Y?SK\SO^&*_'W_ #[M_P!^
MZ=_PQ3X^_P">/_D.E_8>"_Z#5_X#_P $?^L&._Z I??_ , _2_S$_O+^='F)
M_>7\Z_-#_ABGQ]_SQ_\ (='_  Q3X^_YX_\ D.C^P\%_T&K_ ,!_X(?ZP8[_
M * I??\ \ _2[S$_OK^=*)%;HRGZ&OS0_P"&*?'W_/'_ ,AUR^N?#[QG^SKX
MDTW6+RTD@$<JM%<LGR%ASBKAP_AZSY:.+4I=%;?\3.?$N*HKGK81QCU=]OP/
MU9HSQTKR[X#_ !DLOBYX1M[M)5_M")0MQ'GG=CD@5ZC_ "KY"O1J8>I*E45F
MC[;#XBGBJ4:U)W3'4445B=(4444 %%%% !1110 4444 %%%% !1110 4444
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M\;?]#;KW_@TG_P#BJ/[!J_SK\0_UMH_\^G]Z/TOHK\S_ /A<GC7_ *&O7O\
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MVG_^*H_L2I_.OQ#_ %KI_P#/I_>C].J*_,7_ (7CXU_Z&?7O_!M/_P#%4?\
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MT?V'/^=?B/\ UJI_\^G]Z/T]HK\P_P#A>GC?_H9]>_\ !O/_ (T?\+T\;_\
M0SZ]_P"#>?\ QH_L.?\ .OQ%_K33_P"?3^]'Z>45^87_  O;QM_T,^O?^#>?
M_&C_ (7IXW_Z&C7O_!M/_C1_8<_YU^(_]::?_/I_>C]/:*_,/_A>GC?_ *&?
M7O\ P;S_ .-'_"]/&_\ T,^O?^#>?_&C^PY_SK\0_P!:J?\ SZ?WH_3RBOS#
M_P"%Z>-_^AGU[_P;S_XT?\+T\;_]#/KW_@WG_P :/[#G_.OQ#_6JG_SZ?WH_
M3RBOS#_X7IXW_P"AGU[_ ,&\_P#C1_PO3QO_ -#/KW_@WG_QH_L.?\Z_$/\
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MN\;?]#/K_P#X-9__ (JC^PZG\Z_$/]:Z?_/I_>C].:*_,;_A=_C7_H:=>_\
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M:]>_\&T__P 51_8-3^=?B'^M=+_GT_P/TTS1FOS+_P"%T^-O^AJU[_P;3_\
MQ5'_  NGQM_T-6O?^#:?_P"*H_L&I_.OQ#_6RE_SZ?X'Z:9HK\S/^%T>-?\
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M !5'_"X_&W_0UZ]_X-9__BJ/[!J_SK\1?ZVT?^?3^]'Z7YHS7YH_\+B\;?\
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M_P"-:QX?J=:B^XA\84[Z4G]Y^G>:,U^8G_"5:U_T%[__ ,"7_P :</%6M?\
M07O_ /P)?_&G_J]+_GY^'_!)_P!<(?\ /E_?_P  _3FBOB[X=^('\0>&XI)F
M+7,#>1*S')8@##?B"/QS74UYL\K=.3BY[>7_  3W*>>*K!3C#1^?_ /JBBOE
ME?O5)6?]G_W_ ,/^";?VQ_<_'_@'U%17R_']ZGT?V?\ W_P_X(_[8_N?B?3M
M%?,:U(O2E_9_][\/^"7_ &O_ '/Q_P" ?3%%?-*T]:GZA_>_ /[6_N_C_P
M^DZ*^;Z*/J7][\/^"/\ M3^[^/\ P#Z0HKYUH7K1]2_O?A_P2O[4_N?C_P
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M;X@_\%4__P 17N_['?@?Q)X9^)E_=:MX?U32K=]-D19;VRDA0L98B%#,H&<
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M* "BBB@ KC=2_P"2H:1_UY2?S:NRKC=2_P"2H:1_UY2?S:@#LJ*** "BBB@
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M1%U'ZQ?^C%KI[;_CUA_W!_*N8^*G_(BZC]8O_1BUT]M_QZP_[@_E0!-1110
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M7R=X1_:ZUOQM:P7%NB0I,N656R4;/"].M>B>'/%7Q-\7/_H-O)';A@&GED5
M%/< KS7#6S>KCG><F_+I]QZ<>!:F4Q<JBC"W5O7[SZ*Y]<T<_6L?PWI5_I=J
MR7^I/J,K'.YT"[>.G%:_ZU*/GYQ49.,7==Q]%%%!(444E "T444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?G!^U-_R7SQ7_P!=
M(/\ TGBKR@BO5_VIO^2^>*_^ND'_ *3Q5Y17[)@/]UI>B_)'\U9M_P C"O\
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M7::=MVT$C:5:-M+0 F/FI:** "G+3:<M-"9V_P )]=;3?$8LV;%O>C8<G@.
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M_P#3*$_^1XZRS3"0P^84JD7\;5^NMT;Y#F%3%Y77HS2_=II65M+,^.?V7/\
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M.KX8_0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .2^*G_(BZC]8O\ T8M=/;?\>L/^X/Y5S'Q4_P"1%U'ZQ?\ HQ:Z>V_X
M]8?]P?RH FHHHH **** "BBB@ HHHH **** "DI:* /@KPO\)+#Q[_P4/\8Z
MS?:,FH:;HVVX>X?.(KKRHC">.XP37L/[>'C.W\/?!6?2)#B?6Y%@A^J,KG]!
M7KO@OX9V7@OQ?XRU^WN))KCQ-=Q7<\;* (VCC\L 'OQ7G'Q]^$L_QL\>>"M-
M>,KHNBW+WM_(3C<K+A57UY49%3BY.K!J/9(^JRW%4I9E1KUG:%-)_P#@*O\
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M#URS\2:1::II\RW%E=1B6*1>C*>AK\K_ /@H$<?M+:UW_P!%M?\ T4M>T?\
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MJTF M.6FTY:D!:?3*?04%.IM.I,!1WI*5>M)2*1F:K_R%M&_Z^178UQVJ_\
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MI>J7NBWT=[IUY/87D6=EQ;2M%(N00<,I!'!(X]:Z$?%CQR.GC+Q /^XI<?\
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M^>*O^ND'_I/%7E-?L^ _W2E_A7Y(_FC-?^1A7_Q2_,****[CR0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#VO
MX.:I)>^'9+5P<6DI5&]5;YL?@<_F*] KGO ^@KX=\.VMKMQ,P\V8^KMU_(8'
MX5T-?(UY*563CL?H6$C*G0A&>Z0Z/[U/ID?WJ?6!V(5:D7I4:U(O2H-!RT]:
M8M/6DRQ]%%%(:)J%ZT4+UJ66AZT]:8M/6H8QU.7I3:<O2D4A]/IE/H*05+45
M2TF4*M/6F+3UK,H>M+35IU!2'QTO\5)'2_Q4F6B2J/B#_D#W'_ ?_0A5ZJ/B
M#_D#W'_ ?_0A4/8UCNC1A_U,?^Z/Y4]:9#_J8_\ ='\J>M(D=2K24JT%(=4B
MU'4BTF6A:?3*?4C04ZFTZ@T0JU(M1K4BTF,<M+2+2U#*1(GW:=34^[3J0QU%
M%%!0^E6DI5J"N@ZG)3:<E T/IRTVG+298M.IM.J1H*?3*?04.2GTQ*?4LH5.
ME.IJ=*=0 O\ #24O\-)062T445!0^E6DI5H =2K24JT +3EIM.6H+%I],I])
M@%.IM.I%(5:=35IU!2%6G4U:=4#%6EI%I:"Q]%%% T%*M)2K04.I5I*5:3 6
MG+3:<M2 M/IE/H*"G4VG4F 4444BD9FJ_P#(6T;_ *^178UQVJ_\A;1O^OD5
MV-<\]SLI['&_#[_C^\4?]A6;^==E7&_#[_C^\4?]A6;^==E4&H4444 %%%%
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M/A:X_?L=EU/$>5;.-M>-E^!J9A75*G\WV1[69YC2RV@ZU3Y+NSC/VK/C?/\
M%CQ1'X.\.H;BP@DV%X@292>M?1G[+7P#A^$^@1ZI=H#K=Y"4=L<K&Q1MOYJ*
MXC]D7]FN#PW8Q>*]?M_-U.;Y[>.8?-%SU/UKZRZ<5[V;8ZE1I++<'\$?B?=G
MSN39=5KUGFF-^.7PKLAU%%%?'GW(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <E\5/\ D1=1^L7_ *,6NGMO^/6'_<'\JYCXJ?\
M(BZC]8O_ $8M=/;?\>L/^X/Y4 34444 %%%% !1110 4444 %%%% !1110 4
M444 -Q7@W[;UO+<?LU^*4AC:5R;?Y47)_P!<F>*]YJGJFEVFM6,EG>V\=S:R
M</%(,J>]5&7+)2[&U&I[*I&IV=S\ZO\ @FSI=[8_%+7&N;.>!#IK -)&5&=Z
M\<U^D)K'T?P?HWA^9IM-TVWLY6&UGB3!(]*V0:NI4]I+F-\7B/K-5U+6/QR_
M:FT+4KC]HCQ])%87,B-J<A5EA8@C Y!Q7H&G_MF?%G3=.M+.*QF$5M"D*?NI
M/NJH [>U?I7??#_PWJ5Y+=76C6D]S*VYY'CRS'U-0_\ "LO"G_0 L?\ OT*Z
M?K$6DI1O8]19E2E",*E.]C\X_P#AMGXN_P#/G-_WZD_PK[<_9AUCQEXN^'BZ
MYXV5HKK4#NBM9008T!(Y4],]:] _X5CX4_Z %C_WZ%=(L:QJ%  4# %8U*D9
M*T58XL3BJ56/+2@HGYI_MB_LBZ[X9\7ZAXO\+6DNJ:'J,AGEAMU+303,26 1
M1RGH:Y#X2_ML?$/X-6<VCWD"Z]!%A([?5F=3;@?PC'(K]72H88QD5YSK?[.O
MPT\1:E-J&I^"])O+R8[I)I8 68^]:QQ"<>6HKG32S*$J:IXF',D?F3\6/C[\
M1OVF-4^S"VNC8 *!H^F(\D2MG[Q&,\\=:^UOV,/V6)/@SI<VO^(8(F\37B;4
M*-N^SQ,!E,^^!FO=_!GPB\&_#R:67PWX<L-&DD&':UB"DBNP^E34K\T>2"LC
M+$Y@JE/V-&/+$_+[_@H%X9UC5OVA;F:STN\NHCIMJ!)#;NZG ;/(&*X_PG\=
M?C/X+\-Z?H6E+K%MI]C'Y4$:VTF%7.<?=K]9+K2+*]E$L]K%+)C&YU!.*C_X
M1W2_^?"#_O@54<0E%1<;V-:>91C2C2G33L?EM_PTY\=C_P MM:_\!Y/_ (FO
MM3]D+_A8FO\ A%_$WC[4[F1[[_CQL9#PL/'SL#R&SD8]*]U_X1W2_P#GP@_[
MX%7HH5@C6.-0B*,!5& *SJ5E)64;'-B,7"M#EA343\K/V]])OKO]I+6Y8;.X
MFC^RVIW1Q,P_U2]P*_0W]G!C)\"? [&-XB=+A^2088<="*ZO5O N@:Y>/=W^
ME6MU<NH5I9$RQ Z"M:SL8-.M8[6VB6"WA7:D:# 4>@I5*O/",+;$XC&*M0A1
MM;E/CK_@H#^SS#XL\.+X[T2P=]=LML5VEK%N>YC) #-C^X!^1KS+_@F=IMW9
M?$SQ4UQ:S0*=*4 R1E1_K5]17Z*RPI/"T<BAT<%64]"#P167HO@_1?#LTDVF
M:=;V4LB[6:%,$C.<4U6?LW!FD<?+ZM+#R5^S-FOS+_X*'>&]6UCX\P2V6F7E
MW%_9-N/,A@9UR&DR,@>X_.OTUJE=:/97TGF3VT4LF,;F7)Q6=*I[.7,<V#Q'
MU6K[2USRO]DFUN+']GGP9!=026TZ6K!HI5*LO[QNHK4_:3ADG^"/BM(D:21K
M7A5&2?F%>D0P1VL2QQ(L<:]%48 IEY9PZA;26]S$LT+C#1N,@U/-[W,9>UO6
M]K;K<_,W_@G7I=[9?'ZYDN+.>!/[)N 6DC*@?-'QS]#^5?H+\8OAS:?%CX<Z
MSX8O6:.*]B^5TZJZG<I_,"MG1_!>A:#=FZT[3+>SN"NPR1)@X/:MOO6E2KSS
MYT=&*Q;KUE6BK-6_ _'GX9WWBK]FCXXP3WEO?6PTN[%OJ:649<30;@74'&""
M #^%?J]K&JQ>(/AQ?ZA:AFAO-+DFC!7YL-"2 1Z\]*GU#P#X<U6\ENKO1[2X
MN)3EY)(\EC[UK6NF6MG8BSA@2.VVE?*4?+@]JJK551IVU-,7C(XEQGRVDM_,
M_(#]EG0]1M_VAO <LEA<I&NI1[F:%@!UZDBOUE^('@/2/B5X3U#P]K=JEW87
MD95E<9VMCY7'NIY'TI]C\/\ PYIMW%=6FC6EO<1-N21(\%3ZBNBI5:OM)*2T
M)QF,^LU(U(JUC\@_BQ\ _'7[-?Q%6[TM;UX;1S=:=K5BA8J@)"LQ5<(WJ*]&
MTK_@I!X\L/#*:;+HVGWMXL1C_M*9Y/-)(^_CIFOTKU32;36K&:SO;>.ZM9EV
MR12#*L/0UYL_[+7PFD9F;P%HQ+')/V?KG\:V6(C)?O(W.Y9E2JQ2Q-/F:ZGY
M;>$OA/X__:(\9W-W8Z?-<WFI2-<2W]TK1P%CR29,8KN_A+JOQ<_9A^)%SI.F
MZ)?79DE"7.FK%(UM<G& ^X+SCUK]3O#OAG2O".E0Z9HUC#IUA",);VZ[57Z"
MKC64$EREPT2F=%*K(1\P!ZC-#Q5[IQT">;<]X."<.Q2\+ZA=:MX=TZ]OK<6M
M[<6Z2S6XSB-RH)7GT-:]-6G5PG@,****!!1110 4444 %%%% !1110 4444
M%%%% !1110!^<7[4_P#R7SQ5_P!=(/\ TGBKRFO5OVI_^2^>*O\ KI!_Z3Q5
MY37[/@/]TI?X5^2/YHS7_D85_P#%+\PHHHKN/)"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,J\9&\<UYZWB3_@I/XBQK%GI7]F64P\U+$6^A1;%Z[?+G)F'T8YKVC_@E/\
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M444 %%%% !1110!R7Q4_Y$74?K%_Z,6NGMO^/6'_ '!_*N8^*G_(BZC]8O\
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M-_$WQQL[*5R(=!M5OXU'3=)E#6IX1\37WB3Q!XZT\R+LTV[2WM64]-T>3^M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH U/#&BOX@UVTLD7*R.#(>P0<L?RS7T@JK&JJJA548"@8
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M[!-U_P"EL-?KYWK\@_\ @DG_ ,G>?$W_ +!-U_Z6PU^OG>K_ .75/T_S"?\
M'J_XOT0ZBBBI 8?Z5^*OQD^%-A\;O^"M&I^#-5#-I6HZO:M>QH2#)!%I\4TB
M9'(W+&5R.F<U^U9Z&OR8T4?\;M+@_P#3U-_Z8FIT8\V(CY)O\A5+^QE8_4K3
M_!>@Z/X4C\-V.BZ?:>'X[?[,FE0VR+;"+&#'Y8&W;CMBOQ3_ &>_V<_#'CK_
M (*.>(?A]>VB2^"]$UW5)VTIL^7-#;22>3"P[J&* @]5!'>OW(/W3]*_)#]D
M'C_@K)\31_U$-?\ _1[4J?\ '7I)_=L5+2@_5'ZGZQX)T'7_  C<>%]0T:RN
M?#UQ;&SDTMX%^SM"1C9LQ@#'0#I7Y9?\$C6;PO\ M/?%KPK:22?V:EC)A6/4
MV]V(XR?4[9&_,U^MK?=K\D?^"6'_ ">M\7O^O&^_].$=%+^-ZQD35_@/R<?S
M,#_@JD(X_P!N3P')J()TUM)TW=DC!C%Y/OQ^M?L7&P:,$>E?FC_P6<^"=WK/
MA'PC\4--MVE&BN^F:HT:Y*02L&@D/HJR;E^LRU]:?L6_M'Z/^TE\#]!UJUO8
MI/$-E;QVFN6.\>;;W2KM9BO4))M+J>X..H(#I>]1<>J;O\]AUM*D9=&DON/?
M:3BBOSR_X*G?MCW_ ,)=/T#P%\/O$MQI7CB2[CU&_N--E(DM+90?+B<CC,K$
M'8<Y5.1AAG-NS26[=BE%RO;H?H8> WTK\&M)_P"%Q_\ #>WQ._X47_R/?]N:
MUY?_ !Y_ZC[2_F?\??[KICW]*_9']F2/QU_PHGPA/\2]2EU3QM=62W6H2S6\
M<#QM(2ZQ,D:JH9$94/&25.<U^;7[%O\ RE4^(_I_:'B#_P!*&J^2V(Y;[*0N
M9/#N276/ZFWK6L?\%+M TFYU"[2Z>WMT,CK9VGAZZF( _ABB5G<^RJ37B?@/
MQ]^T'^WQX@NOAIXC^->GZ$Y;9/HVL;=+:^ )\R-8;:W43LNTDQ.1TSC@D?N9
MBORY_P""J_[),VB7$'Q\\!1S:=J5G/$=>%@3&Z.& AOT*X*N&VJY'^PW&&)G
MF49+G5X_D4DY)J+L^A]C_LA_L?>%?V1_!%QI>D3OK.O:DRR:IKMQ$(Y+EESM
M14!/EQKEL+D\L22<U\@?\%NHKG_A'OA1(N[[(MSJ*N>V\K;;?QP'_6OIC_@G
MU^UBG[47P=B?5IXO^$WT'99:Q$I ,W'[JZ"CH) #GL'5P.,5B?\ !4?X)WGQ
M@_9?U"[TJ!KK5_"]RNM0Q1KEY(55DG4#OB-V?'?RQ2Q*<6I2Z-?<&%>NVZ:^
M;5CVG]E-K9OV9OA4;,;;;_A%]-V#CC_1H^N.^<YKUCK7PI_P2D_:3TGXD? R
MP^'E[?Q1>+O":-;BTD<"2YLMQ:*5!_$$#>6V.FU2?O"ONK=736_B-]&[HYJ6
MD%'JM )QWHS7R9_P4<_:@MOV>_@3J5CIFKM8^//$49L](2UE*7$"D@2W(*G*
M!%SAO[Y7'?$W_!-_Q)\4O'7[/%KXH^*.OW6MW.JW+/I/VRWBCECLD 169E16
M<NX=@SEB5VD'FL(7GS-;(VE[G+?J?6%%%%, HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KC=2_P"2H:1_UY2?S:NRKC=2_P"2H:1_UY2?
MS:@#LJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \6_:2^!-M\7?"\IMT5-7MU+1,HY<XX6OE7]G?XU:I\ /&4_A'Q0
MDD>ER3%&60X\M\X!R>U?HB?K7S-^UI^SK'\0M';7]&MU76K5<NJ#&]1R3QWK
MZW*<PIU*;R_&:TY;/LSXK.<MJ4ZBS+ Z5([KNCZ.TS4[76+&&[LYEN+:9=R2
M(<@BK?%?"W[(O[1$GA/4!X&\62R6XW>7;27!(\HCJ&)K[ECF6:-9(R&5@&##
MH0>]>-F.7U,OK.G+;H^Z/<RO,J>94%5CH^J[,FHHHKRSV0HI,T9H 6BDS1F@
M!:*3-&: %HI,T9H 6BBB@!M+S1_%7,^/O'FE_#KP[=:OJLZQ0PH6"E@"Y'\(
M]ZJ$)5)*$%=LSJ5(THN<W9(P/C1\8M(^#_A6?4;Z53<D8@M]V&9CT_6OAOX?
M^"?$O[5WQ-GUK5#(FFB0/+(P^6->PJMK%]XG_:Y^+"K:I(-,CD(BW A$BR#S
MVSBOT ^%WPWTWX8^%;71]/C4>6O[R7 W.?<]Z^[;AP]AK1UKS7_@*/SR*J<2
MXN\M,/!_^!,UO"GA>Q\':);:7IT*PP0J%PHZG')K;'6C%'&*^#E*4Y.4G=L_
M1(0C3BHQ5DAU%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^_L'_P 9KWW[+_LTGV7VH_M+&?SL/[%R_P#Y\H\"_P"&4?#/_05US_O[!_\
M&:8?V4_#7_05UO\ [^P?_&:]^^R4AM?44?VEC/YV']BY?_SZ7W'@/_#*OAK_
M *"NM_\ ?V#_ .,TG_#*OAO_ *"NM_\ ?V#_ .,U[[]E/I2?8_:C^TL7_.Q_
MV+E__/I?<> _\,J^&_\ H*ZW_P!_8/\ XS2']E?PY_T%=;_[^P?_ !FO?OL9
M]*3[&?2C^TL7_.P_L7+_ /GTON/ ?^&6/#G_ $%=;_[^P?\ QFD_X98\.?\
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M ?\ /I?<?/7_  S#HG_05UG_ +^0?_&J/^&8=$_Z"VL_]_(/_C-?0O\ 9O\
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MXP_L7 ?\^E]Q\]_\,OZ%_P!!?6?^_D'_ ,9I?^&8-"_Z"^L_]_(/_C-?0?\
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M] _V?_LTO]G4?VEB_P#GXP_L7 ?\^E]Q\_\ _#+^@_\ 06UK_OY!_P#&J/\
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M9K,U7]FW0;'4-,MTU36"EU(R.6DAR  .G[KWKZ0^P>U<]XDL\:YX?X_Y;O\
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M]A:<JT?VAB_YV3_8F7_\^4>!C]C/P7_T%=>_[_P?_&:</V,?!?\ T%=>_P#
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M_P#B:/\ A5FE?\_%Y_WVG_Q-=E12]M4_F%]4H_R(X[_A5NE?\_%Y_P!]I_\
M$TO_  J[2_\ GXO/^^T_^)KL**?MI_S#^J4/Y4<?_P *QTO_ )^+S_OM/_B:
M=_PK'2_^?B\_[[3_ .)KKJ*7MI_S#^JT?Y3D?^%8Z9_S\7G_ 'VG_P 33O\
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M_?2__$T[_A";'_GK<?\ ?2__ !-=!11[2?<?L*78Y_\ X0FQ_P">MQ_WTO\
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MN1))( <^0QC58;>+.,K#G=EN5)W5^E5I90Z?8Q6EK#';V\,8BBAC4*B*!A5
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MT_N+^0H_MC ?] 2_\"?^0?V+F/\ T&O_ ,!_X)^>'_#?OC#_ *!4'_?PT?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVH\OVH H?9Z/L]7_ "_:CRZ ,_[.?2C[.U:'ET>70!G?9CZ4?93Z5H^71Y=
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M35$&9]C]J/L?L*T_)H\F@#,^Q^PH^Q^PK3\FCR: ,S['["C['["M/R:/+]J
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M FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SO
M2_\ D=O%7_72#_T%JWJP=+_Y';Q5_P!=(/\ T%JWJ[*>R/-K?$PHHHK0Q"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTI_$=-1115&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S_C[_D4
M+_Z)_P"AK705S_C[_D4+_P"B?^AK2ELRX?$C:L_^/.#_ *YK_*IJAL_^/.#_
M *YK_*IJ9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^B@#<HK#_P"$WT#_ *"]G_W]%'_";Z!_T%[/_OZ* -RBL/\ X3?0/^@O9_\
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M^@?]!>S_ ._HH_X3?0/^@O9_]_10!N45A_\ ";Z!_P!!>S_[^BC_ (3?0/\
MH+V?_?T4 ;E%8?\ PF^@?]!>S_[^BC_A-] _Z"]G_P!_10!N45A_\)OH'_07
ML_\ OZ*/^$WT#_H+V?\ W]% &Y16'_PF^@?]!>S_ ._HH_X3?0/^@O9_]_10
M!N45A_\ ";Z!_P!!>S_[^BC_ (3?0/\ H+V?_?T4 ;E%8?\ PF^@?]!>S_[^
MBC_A-] _Z"]G_P!_10!N45A_\)OH'_07L_\ OZ*/^$WT#_H+V?\ W]% &Y16
M'_PF^@?]!>S_ ._HH_X3?0/^@O9_]_10!N45A_\ ";Z!_P!!>S_[^BC_ (3?
M0/\ H+V?_?T4 ;E%8?\ PF^@?]!>S_[^BC_A-] _Z"]G_P!_10!N45A_\)OH
M'_07L_\ OZ*/^$WT#_H+V?\ W]% &Y16'_PF^@?]!>S_ ._HH_X3?0/^@O9_
M]_10!N45A_\ ";Z!_P!!>S_[^BC_ (3?0/\ H+V?_?T4 ;E%8?\ PF^@?]!>
MS_[^BC_A-] _Z"]G_P!_10!N45A_\)OH'_07L_\ OZ*/^$WT#_H+V?\ W]%
M&Y16'_PF^@?]!>S_ ._HH_X3?0/^@O9_]_10!N45A_\ ";Z!_P!!>S_[^BC_
M (3?0/\ H+V?_?T4 ;E%8?\ PF^@?]!>S_[^BC_A-] _Z"]G_P!_10!N45A_
M\)OH'_07L_\ OZ*/^$WT#_H+V?\ W]% &Y16'_PF^@?]!>S_ ._HH_X3?0/^
M@O9_]_10!N45A_\ ";Z!_P!!>S_[^BC_ (3?0/\ H+V?_?T4 ;E%8?\ PF^@
M?]!>S_[^BC_A-] _Z"]G_P!_10!N45A_\)OH'_07L_\ OZ*/^$WT#_H+V?\
MW]% &Y16'_PF^@?]!>S_ ._HH_X3?0/^@O9_]_10!N45A_\ ";Z!_P!!>S_[
M^BC_ (3?0/\ H+V?_?T4 ;E%8?\ PF^@?]!>S_[^BC_A-] _Z"]G_P!_10!N
M45A_\)OH'_07L_\ OZ*/^$WT#_H+V?\ W]% &Y16'_PF^@?]!>S_ ._HH_X3
M?0/^@O9_]_10!N45A_\ ";Z!_P!!>S_[^BC_ (3?0/\ H+V?_?T4 ;E%8?\
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M]_11_P )OH'_ $%[/_OZ* -RBL/_ (3?0/\ H+V?_?T4?\)OH'_07L_^_HH
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M_HH W**P_P#A-] _Z"]G_P!_11_PF^@?]!>S_P"_HH W**P_^$WT#_H+V?\
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MV_[^"C_A+-'_ .@E;?\ ?P470<LNQJT5E?\ "6:/_P!!*V_[^"C_ (2S1_\
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M6>]AA+WTCJ'<#*D+@CVKH/\ A+-'_P"@E;?]_!4Q:L7*+YGH:M%97_"6:/\
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M +^"C_A+-'_Z"5M_W\%%T'++L:M%97_"6:/_ -!*V_[^"C_A+-'_ .@E;?\
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MLT?_ *"5M_W\%'_"6:/_ -!*V_[^"G=!RR[&K165_P )9H__ $$K;_OX*/\
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MNQJT5E?\)9H__02MO^_@H_X2S1_^@E;?]_!1=!RR[&K165_PEFC_ /02MO\
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MH_\ T$K;_OX*/^$LT?\ Z"5M_P!_!1=!RR[&K165_P )9H__ $$K;_OX*/\
MA+-'_P"@E;?]_!1=!RR[&K165_PEFC_]!*V_[^"C_A+-'_Z"5M_W\%%T'++L
M:M%97_"6:/\ ]!*V_P"_@H_X2S1_^@E;?]_!1=!RR[&K165_PEFC_P#02MO^
M_@H_X2S1_P#H)6W_ '\%%T'++L:M%97_  EFC_\ 02MO^_@H_P"$LT?_ *"5
MM_W\%%T'++L:M%97_"6:/_T$K;_OX*/^$LT?_H)6W_?P470<LNQJT5E?\)9H
M_P#T$K;_ +^"C_A+-'_Z"5M_W\%%T'++L:M%97_"6:/_ -!*V_[^"C_A+-'_
M .@E;?\ ?P470<LNQ4\1?\C!X8_Z_A_2O1<5Y5KGB#39]:\/2QWT#QPW@>1E
M<81>.37=?\)QH'_07L_^_HKBJ_$>A1T@CG/!NBZ?JFH>)Y+RPMKMUU295::%
M7(&>@R*ZC_A$=#_Z UA_X#)_A6)\/O\ C^\4?]A6;^==E4&QD?\ "(Z'_P!
M:P_\!D_PH_X1'0_^@-8?^ R?X5KT4 9'_"(Z'_T!K#_P&3_"C_A$=#_Z UA_
MX#)_A6O10!D?\(CH?_0&L/\ P&3_  H_X1'0_P#H#6'_ (#)_A6O10!D?\(C
MH?\ T!K#_P !D_PH_P"$1T/_ * UA_X#)_A6O10!D?\ "(Z'_P! :P_\!D_P
MH_X1'0_^@-8?^ R?X5KT4 9'_"(Z'_T!K#_P&3_"C_A$=#_Z UA_X#)_A6O1
M0!D?\(CH?_0&L/\ P&3_  H_X1'0_P#H#6'_ (#)_A6O10!D?\(CH?\ T!K#
M_P !D_PH_P"$1T/_ * UA_X#)_A6O10!D?\ "(Z'_P! :P_\!D_PH_X1'0_^
M@-8?^ R?X5KT4 9'_"(Z'_T!K#_P&3_"C_A$=#_Z UA_X#)_A6O10!D?\(CH
M?_0&L/\ P&3_  H_X1'0_P#H#6'_ (#)_A6O24 9/_"(Z'_T!K#_ ,!D_P *
M/^$1T/\ Z UA_P" R?X5KT4 9'_"(Z'_ - :P_\  9/\*/\ A$=#_P"@-8?^
M R?X5KT4 9'_  B.A_\ 0&L/_ 9/\*/^$1T/_H#6'_@,G^%:U+0!D?\ "(Z'
M_P! :P_\!D_PH_X1'0_^@-8?^ R?X5KT4 9'_"(Z'_T!K#_P&3_"C_A$=#_Z
M UA_X#)_A6M2T 9'_"(Z'_T!K#_P&3_"C_A$=#_Z UA_X#)_A6O10!D?\(CH
M?_0&L/\ P&3_  H_X1'0_P#H#6'_ (#)_A6O10!D?\(CH?\ T!K#_P !D_PH
M_P"$1T/_ * UA_X#)_A6O10!D?\ "(Z'_P! :P_\!D_PH_X1'0_^@-8?^ R?
MX5KT4 9'_"(Z'_T!K#_P&3_"C_A$=#_Z UA_X#)_A6O10!D?\(CH?_0&L/\
MP&3_  H_X1'0_P#H#6'_ (#)_A6M2T 9'_"(Z'_T!K#_ ,!D_P */^$1T/\
MZ UA_P" R?X5KT4 9'_"(Z'_ - :P_\  9/\*/\ A$=#_P"@-8?^ R?X5KT4
M 9'_  B.A_\ 0&L/_ 9/\*/^$1T/_H#6'_@,G^%:]% &1_PB.A_] :P_\!D_
MPH_X1'0_^@-8?^ R?X5KT4 9'_"(Z'_T!K#_ ,!D_P */^$1T/\ Z UA_P"
MR?X5KT4 9'_"(Z'_ - :P_\  9/\*/\ A$=#_P"@-8?^ R?X5KT4 9'_  B.
MA_\ 0&L/_ 9/\*/^$1T/_H#6'_@,G^%:]% &1_PB.A_] :P_\!D_PH_X1'0_
M^@-8?^ R?X5KT4 9'_"(Z'_T!K#_ ,!D_P */^$1T/\ Z UA_P" R?X5KT4
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M/\*/^$1T/_H#6'_@,G^%:]% &1_PB.A_] :P_P# 9/\ "C_A$=#_ .@-8?\
M@,G^%:]% &1_PB.A_P#0&L/_  &3_"C_ (1'0_\ H#6'_@,G^%:]% &1_P (
MCH?_ $!K#_P&3_"C_A$=#_Z UA_X#)_A6O10!D?\(CH?_0&L/_ 9/\*/^$1T
M/_H#6'_@,G^%:]% &1_PB.A_] :P_P# 9/\ "C_A$=#_ .@-8?\ @,G^%:]%
M &1_PB.A_P#0&L/_  &3_"C_ (1'0_\ H#6'_@,G^%:]% &1_P (CH?_ $!K
M#_P&3_"C_A$=#_Z UA_X#)_A6O10!D?\(CH?_0&L/_ 9/\*/^$1T/_H#6'_@
M,G^%:]% &1_PB.A_] :P_P# 9/\ "C_A$=#_ .@-8?\ @,G^%:]% &1_PB.A
M_P#0&L/_  &3_"C_ (1'0_\ H#6'_@,G^%:]% &1_P (CH?_ $!K#_P&3_"C
M_A$=#_Z UA_X#)_A6O10!D?\(CH?_0&L/_ 9/\*/^$1T/_H#6'_@,G^%:]%
M&1_PB.A_] :P_P# 9/\ "C_A$=#_ .@-8?\ @,G^%:]% &1_PB.A_P#0&L/_
M  &3_"C_ (1'0_\ H#6'_@,G^%:]% &1_P (CH?_ $!K#_P&3_"C_A$=#_Z
MUA_X#)_A6O10!D?\(CH?_0&L/_ 9/\*/^$1T/_H#6'_@,G^%:]% &1_PB.A_
M] :P_P# 9/\ "C_A$=#_ .@-8?\ @,G^%:]% &1_PB.A_P#0&L/_  &3_"C_
M (1'0_\ H#6'_@,G^%:]% &1_P (CH?_ $!K#_P&3_"C_A$=#_Z UA_X#)_A
M6O10!D?\(CH?_0&L/_ 9/\*/^$1T/_H#6'_@,G^%:]% &1_PB.A_] :P_P#
M9/\ "C_A$=#_ .@-8?\ @,G^%:]% &1_PB.A_P#0&L/_  &3_"C_ (1'0_\
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ME0!G?\(CH?\ T!K#_P !D_PH_P"$1T/_ * UA_X#)_A6O10!D?\ "(Z'_P!
M:P_\!D_PH_X1'0_^@-8?^ R?X5KT4 9'_"(Z'_T!K#_P&3_"C_A$=#_Z UA_
MX#)_A6O10!D?\(CH?_0&L/\ P&3_  H_X1'0_P#H#6'_ (#)_A6O10!D?\(C
MH?\ T!K#_P !D_PH_P"$1T/_ * UA_X#)_A6O10!D?\ "(Z'_P! :P_\!D_P
MH_X1'0_^@-8?^ R?X5KT4 9'_"(Z'_T!K#_P&3_"C_A$=#_Z UA_X#)_A6O1
M0!D?\(CH?_0&L/\ P&3_  H_X1'0_P#H#6'_ (#)_A6O10!D?\(CH?\ T!K#
M_P !D_PH_P"$1T/_ * UA_X#)_A6O10!D?\ "(Z'_P! :P_\!D_PH_X1'0_^
M@-8?^ R?X5KT4 9'_"(Z'_T!K#_P&3_"C_A$=#_Z UA_X#)_A6O10!D?\(CH
M?_0&L/\ P&3_  H_X1'0_P#H#6'_ (#)_A6O10!D?\(CH?\ T!K#_P !D_PH
M_P"$1T/_ * UA_X#)_A6O10!D?\ "(Z'_P! :P_\!D_PH_X1'0_^@-8?^ R?
MX5KT4 9'_"(Z'_T!K#_P&3_"C_A$=#_Z UA_X#)_A6O10!D?\(CH?_0&L/\
MP&3_  H_X1'0_P#H#6'_ (#)_A6O10!D?\(CH?\ T!K#_P !D_PH_P"$1T/_
M * UA_X#)_A6O10!D?\ "(Z'_P! :P_\!D_PH_X1'0_^@-8?^ R?X5KT4 9'
M_"(Z'_T!K#_P&3_"C_A$=#_Z UA_X#)_A6O10!D?\(CH?_0&L/\ P&3_  H_
MX1'0_P#H#6'_ (#)_A6O10!D?\(CH?\ T!K#_P !D_PH_P"$1T/_ * UA_X#
M)_A6O10!D?\ "(Z'_P! :P_\!D_PH_X1'0_^@-8?^ R?X5KT4 9'_"(Z'_T!
MK#_P&3_"C_A$=#_Z UA_X#)_A6O10!D?\(CH?_0&L/\ P&3_  H_X1'0_P#H
M#6'_ (#)_A6O10!D?\(CH?\ T!K#_P !D_PH_P"$1T/_ * UA_X#)_A6O10!
MD?\ "(Z'_P! :P_\!D_PH_X1'0_^@-8?^ R?X5KT4 9'_"(Z'_T!K#_P&3_"
MC_A$=#_Z UA_X#)_A6O10!D?\(CH?_0&L/\ P&3_  H_X1'0_P#H#6'_ (#)
M_A6O10!D?\(CH?\ T!K#_P !D_PH_P"$1T/_ * UA_X#)_A6O10!D?\ "(Z'
M_P! :P_\!D_PH_X1'0_^@-8?^ R?X5KT4 9'_"(Z'_T!K#_P&3_"C_A$=#_Z
M UA_X#)_A6O10!D?\(CH?_0&L/\ P&3_  H_X1'0_P#H#6'_ (#)_A6O10!D
M?\(CH?\ T!K#_P !D_PH_P"$1T/_ * UA_X#)_A6O10!Y=INAZ=)XO\ $L+6
M%JT,+PB.,PJ53*G.!CBMK_A&])_Z!=G_ . Z?X52TO\ Y';Q5_UT@_\ 06K>
MKKII<J/.K-\[,[_A&])_Z!=G_P" Z?X4?\(WI/\ T"[/_P !T_PK1HK30RYG
MW,[_ (1O2?\ H%V?_@.G^%'_  C>D_\ 0+L__ =/\*T:*- YGW,[_A&])_Z!
M=G_X#I_A1_PC>D_] NS_ / =/\*T:*- YGW,[_A&])_Z!=G_ . Z?X4?\(WI
M/_0+L_\ P'3_  K1HHT#F?<SO^$;TG_H%V?_ (#I_A1_PC>D_P#0+L__  '3
M_"M&BC0.9]S._P"$;TG_ *!=G_X#I_A1_P (WI/_ $"[/_P'3_"M&BC0.9]S
M._X1O2?^@79_^ Z?X4?\(WI/_0+L_P#P'3_"M&BC0.9]S._X1O2?^@79_P#@
M.G^%'_"-Z3_T"[/_ ,!T_P *T:*- YGW,[_A&])_Z!=G_P" Z?X4?\(WI/\
MT"[/_P !T_PK1HHT#F?<SO\ A&])_P"@79_^ Z?X4?\ "-Z3_P! NS_\!T_P
MK1HHT#F?<SO^$;TG_H%V?_@.G^%'_"-Z3_T"[/\ \!T_PK1HHT#F?<SO^$;T
MG_H%V?\ X#I_A1_PC>D_] NS_P# =/\ "M&BC0.9]S._X1O2?^@79_\ @.G^
M%'_"-Z3_ - NS_\  =/\*T:*- YGW,[_ (1O2?\ H%V?_@.G^%'_  C>D_\
M0+L__ =/\*T:*- YGW,[_A&])_Z!=G_X#I_A1_PC>D_] NS_ / =/\*T:*-
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M3_T"[/\ \!T_PK1HHT#F?<SO^$;TG_H%V?\ X#I_A1_PC>D_] NS_P# =/\
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M=_PC>D_] NS_ / =/\*/^$;TG_H%V?\ X#I_A6C11H',^YG?\(WI/_0+L_\
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MC>D_] NS_P# =/\ "M&BC0.9]S._X1O2?^@79_\ @.G^%'_"-Z3_ - NS_\
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M1O2?^@79_P#@.G^%'_"-Z3_T"[/_ ,!T_P *T:*- YGW,[_A&])_Z!=G_P"
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M_"K=G_QYP?\ 7-?Y5-5:$\S[F=_PC>D_] NS_P# =/\ "C_A&])_Z!=G_P"
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M?\(WI/\ T"[/_P !T_PH_P"$;TG_ *!=G_X#I_A6C11H',^YG?\ "-Z3_P!
MNS_\!T_PH_X1O2?^@79_^ Z?X5HT4:!S/N9W_"-Z3_T"[/\ \!T_PH_X1O2?
M^@79_P#@.G^%:-%&@<S[F=_PC>D_] NS_P# =/\ "C_A&])_Z!=G_P" Z?X5
MHT4:!S/N9W_"-Z3_ - NS_\  =/\*/\ A&])_P"@79_^ Z?X5HT4:!S/N9W_
M  C>D_\ 0+L__ =/\*/^$;TG_H%V?_@.G^%:-%&@<S[F=_PC>D_] NS_ / =
M/\*/^$;TG_H%V?\ X#I_A6C11H',^YG?\(WI/_0+L_\ P'3_  H_X1O2?^@7
M9_\ @.G^%:-%&@<S[F=_PC>D_P#0+L__  '3_"C_ (1O2?\ H%V?_@.G^%:-
M%&@<S[F=_P (WI/_ $"[/_P'3_"C_A&])_Z!=G_X#I_A6C11H',^YG?\(WI/
M_0+L_P#P'3_"C_A&])_Z!=G_ . Z?X5HT4:!S/N<EKVBZ=#KGAV..PMDCEO
MLBK"H#CC@C'(KO/^$1T/_H#6'_@,G^%<AXB_Y&#PQ_U_#^E>C5QU?B/0H_ C
MC?A]_P ?WBC_ +"LW\Z[*N-^'W_']XH_["LW\Z[*H-@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH 915:]O+?3K66YNIX[:VA4O)-
M,P554=22> *\ \9_MJ^$/#]U+:Z-9W?B*6,X,T>(;<GV=LL?KMQZ$UTX?"UL
M3+EHQ<C@Q6.PV"CSXB:BO/\ 1;GT/FG9-?)$/[>Z--B7P2R1YY9-4#'\O*'\
MZ];^&/[3'@[XG7BV%M/-IFJM]RSU!0C2>NQ@2K?3.?:NNME>,P\>>I3=OO\
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M_H#>(/\ OQ!_\>KTO[,QO_/IG@_V]EBT=:)]&>XI:^</^&Z/!/\ T!O$&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;_Z[O_(5,MC2G\1TU%%%49A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7/^/O^10O_HG_ *&M=!7/^/O^10O_ *)_Z&M*6S+C\2-JS_X\X/\ KFO\
MJFJ&S_X\X/\ KFO\JFID!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 <_P"(O^1@\,?]?P_I7HC=:\[\1?\ (P>&/^OX?TKT1NM<57XC
MT:/P(X_X??\ ']XH_P"PK-_.NRKC?A]_Q_>*/^PK-_.NRJ#<**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***SO$&I?V1H.I7W_/K;23_]
M\H6_I36KL)NRN?$W[7'QJN?%7BBX\):7=,FB::^RY\MN+FX'7..JJ> /4$^E
M8_P1_9=U7XJ6"ZUJ%V=%T-B1"_E[YKC!P2@) "]1N.>1P#7CL*S^(=<C5WWW
M5]<@,Y[N[<G\S7ZHZ%H]MH.C66FV:"*TM84@B0# 554 #\A7W^.K/)\)3H8?
M24NOI:[]7<_(<LP\>),QK8G%W<(VLO6]EZ*W0^=-2_84\,26$BZ?X@U>WO<?
M)+<^5+&#[HJ(2/\ @5?*7CWP-K/PJ\83Z1J7[F^M662*XA8A9%SE)$/7''U!
M'M7ZCE@O5@*XSQG\)O!_Q!U"TO\ Q#H\.I7-JACB>25U 4G."%8 \^H->/@<
M\KT9_P"T-SB_O^1])F?"^$Q%+_8TJ=1=>EO,YS]F_P")LWQ0^&MI>7K[]6LG
M-G>-TWNH!#_\"4J3[YKG/VL/C-<?#?PO#H^D3>3KFK*P$R_>MX!PSCT8DX'X
MGM7KWA?P?H/@VVDMM!TJSTN*0@NMG$L>\@8!; Y/UKX5_:]UI]5^-FI0EB8[
M&""V12>GR!S^KFL\OH4<=F.D;0U=OT^\VS;%8C*LF]Z=ZFD;KN^OW'$_"WX5
MZW\7O$ITS2@J!1YMU>S9\N%"?O-W))Z <D^P)'U'I_["OA9;%5O=?UB>[Q\T
MMN88XR?4*48C_OJMG]B_PS%I?PE_M,*OGZI=22N^.=J-Y87Z JQ_X$:^@*Z<
MTS;$1Q$J5&7+&.FG7N>?D/#^$J8..)Q4>><]=>W0_/+XX?LVZM\((EU."Y_M
M?0)'\O[4(]DD#'HLBY/7LPX/MQ7<_L=_&BZTO7HO ^J7#2:9>;CI[2-GR9@"
MQC!/16 /'][&/O&OK#XD>'X/%7@+7])N%5X[JRE09[-M)4_@P!_"OS$\-ZM+
MH/B'3-3@.)K.ZBG3G'*.&'\J]/ UI9SA*E"OK)=?R9X>;X:/#>84<7@_=A+=
M>EKKT:/T8_:,'_%D_%Q_Z<S_ .A+7Y\?#WPB?'GC32/#XNOL)OYA%]H\OS-F
M03G;D9Z>HK]!/VAFW_ OQ6?[UCG_ ,>6O@+X6^*K7P/\0-#UZ]CFFM+&X\V1
M(%#2$ $?*"0,\]R*C(.>.%K<F]]/6QT\6^SGC,+[3X7OZ75_P/HS_A@=L<^.
M1_X*?_M]><_&C]EO5?A'H*ZW'J\.MZ6LBQ3,(#!)$6.%)7<P()XSGJ1Q7N2_
MMS^".^C>(,_]<(/_ (]7E/Q\_:IM?BAX7;P[H6EW5E8SNKW%Q>E0[A3D*%4D
M 9 ).>V*G"5LXE7@JJ]V^MTEIUZ$X_#\-1PTW1:Y[.UFV[]-&^Y:_8C\;7UC
MXVOO##3,^FWMN]T(B<A)4V_,/3*Y!]<+Z5]#?M18_P"%$^*O^N4/_H^.O'?V
M,_A!J6EWUQXTU6W>SCD@-O813*0\BL06DP>0N  /7)/3&?8OVHO^2$>*<]?*
MA_\ 1\=>;F4Z4\U@Z/>-_6Y[>1PKPR.:KW5U)J_:Q\<?LN?\EV\+?[]Q_P"D
M\M?HZO\ 2OSB_9<_Y+OX6_WY_P#TGEK]'5_I6G$G^]1_P_JS'@G_ '.I_B_1
M!V-4=:_Y ][_ -<7_P#035[L:HZU_P @>]_ZXO\ ^@FODT?HA^3\$?G31QYQ
MO8+GTR:^LE_8'8J#_P )T!D?] C_ .W5\G6\@AN(I&R0KACCV-?;B?MS>"54
M Z/X@Z?\\(/_ (]7Z?FM3'05/ZE?K?1/M;]3\'R"CE52=?\ M*W3ENVN]]GZ
M'*_\,"O_ -#T/_!3_P#;J]"^"'[,;?!GQ;<:T?$@U<36C6OD_8?)VY=&W9\Q
MO[F,8[UE?\-U>">VC>(/^_$'_P >KTSX2_&;2/C)IM]>:/:7MI'9RK#(M\B(
MV2,C&UVXKY3%8C-71DL1?DZZ+_(_0,#@^'WB(_5+.HM59OI\S@OC5^RNWQ>\
M:'7QXG&E9MX[?[.;#SONYYW>:O7/3%>.?$K]CMOAYX'U;Q$?%HOQ81"0V_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAHSHHSM@NTF?_OE"6_2OD']J'XYZ/\7;S2K/0[:X%GIC2G[9<#9YQ?:/E3J
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MF^ WP3/P5TG5++^V1K/VZ=9O,^S>1LPN,8WMG]*J?\-:?"O_ *&=O_!?=?\
MQJM?PC^T)X"\<Z];Z-H>O&]U*X#&.$V<\>[:I8_,\8 P 3R:^1Q.(S2M2E"N
MI<O7W;;:]C]#P6%R'"UXU,+**GLO?OOI:UV>D_Q5YC^TM_R0_P 6_P#7LO\
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M;_CUA_W!_*N8^*G_ "(NH_6+_P!&+73VW_'K#_N#^5 $U%%% !1110 4444
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M ,-0?#+_ *&7_P D+K_XU1_PU!\,O^AE_P#)"Z_^-4?4\3_S[E]S_P @_M3
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MU_\ &J/^&H/AE_T,O_DA=?\ QJCZGB?^?<ON?^0?VI@?^?T?O7^9ZI17E?\
MPU!\,O\ H9?_ "0NO_C5'_#4'PR_Z&7_ ,D+K_XU1]3Q/_/N7W/_ "#^U,#_
M ,_H_>O\SU2BO*_^&H/AE_T,O_DA=?\ QJC_ (:@^&7_ $,O_DA=?_&J/J>)
M_P"?<ON?^0?VI@?^?T?O7^9ZI17E?_#4'PR_Z&7_ ,D+K_XU1_PU!\,O^AE_
M\D+K_P"-4?4\3_S[E]S_ ,@_M/!?\_H_>O\ ,]4HKRO_ (:@^&7_ $,O_DA=
M?_&J/^&H/AE_T,O_ )(77_QJCZGB?^?<ON?^0?VG@O\ G]'[U_F>J45Y7_PU
M!\,O^AE_\D+K_P"-4?\ #4'PR_Z&7_R0NO\ XU1]3Q/_ #[E]S_R#^T\%_S^
MC]Z_S/5**\K_ .&H/AE_T,O_ )(77_QJC_AJ#X9?]#+_ .2%U_\ &J/J>)_Y
M]R^Y_P"0?VG@O^?T?O7^9ZI17E?_  U!\,O^AE_\D+K_ .-4?\-0?#+_ *&7
M_P D+K_XU1]3Q/\ S[E]S_R#^T\%_P _H_>O\SU2BO*_^&H/AE_T,O\ Y(77
M_P :H_X:@^&7_0R_^2%U_P#&J/J>)_Y]R^Y_Y!_:>"_Y_1^]?YGJE%>5_P##
M4'PR_P"AE_\ )"Z_^-4?\-0?#+_H9?\ R0NO_C5'U/$_\^Y?<_\ (/[3P7_/
MZ/WK_,]4HKRO_AJ#X9?]#+_Y(77_ ,:H_P"&H/AE_P!#+_Y(77_QJCZGB?\
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MN?\ D']IX+_G]'[U_F>J45Y7_P -0?#+_H9?_)"Z_P#C5'_#4'PR_P"AE_\
M)"Z_^-4?4\3_ ,^Y?<_\@_M3 _\ /Z/WK_,]4HKRO_AJ#X9?]#+_ .2%U_\
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M_0R_^2%U_P#&J/J>)_Y]R^Y_Y!_:F!_Y_1^]?YGJE%>5_P##4'PR_P"AE_\
M)"Z_^-4?\-0?#+_H9?\ R0NO_C5'U/$_\^Y?<_\ (/[4P/\ S^C]Z_S/5**\
MK_X:@^&7_0R_^2%U_P#&J/\ AJ#X9?\ 0R_^2%U_\:H^IXG_ )]R^Y_Y!_:F
M!_Y_1^]?YGJE%>5_\-0?#+_H9?\ R0NO_C5'_#4'PR_Z&7_R0NO_ (U1]3Q/
M_/N7W/\ R#^U,#_S^C]Z_P SU2BO*_\ AJ#X9?\ 0R_^2%U_\:H_X:@^&7_0
MR_\ DA=?_&J/J>)_Y]R^Y_Y!_:F!_P"?T?O7^9ZI17E?_#4'PR_Z&7_R0NO_
M (U1_P -0?#+_H9?_)"Z_P#C5'U/$_\ /N7W/_(/[4P/_/Z/WK_,]4HKRO\
MX:@^&7_0R_\ DA=?_&J/^&H/AE_T,O\ Y(77_P :H^IXG_GW+[G_ )!_:F!_
MY_1^]?YGJE%>5_\ #4'PR_Z&7_R0NO\ XU1_PU!\,O\ H9?_ "0NO_C5'U/$
M_P#/N7W/_(/[4P/_ #^C]Z_S/5**\K_X:@^&7_0R_P#DA=?_ !JC_AJ#X9?]
M#+_Y(77_ ,:H^IXG_GW+[G_D']J8'_G]'[U_F>J45Y7_ ,-0?#+_ *&7_P D
M+K_XU1_PU!\,O^AE_P#)"Z_^-4?4\3_S[E]S_P @_M3 _P#/Z/WK_,]4HKRO
M_AJ#X9?]#+_Y(77_ ,:H_P"&H/AE_P!#+_Y(77_QJCZGB?\ GW+[G_D']IX+
M_G]'[U_F>J45Y7_PU!\,O^AE_P#)"Z_^-4?\-0?#+_H9?_)"Z_\ C5'U/$_\
M^Y?<_P#(/[4P/_/Z/WK_ #/5**\K_P"&H/AE_P!#+_Y(77_QJC_AJ#X9?]#+
M_P"2%U_\:H^IXG_GW+[G_D']IX+_ )_1^]?YGJE%>5_\-0?#+_H9?_)"Z_\
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MW/\ R#^T\%_S^C]Z_P SU2BO*_\ AJ#X9?\ 0R_^2%U_\:H_X:@^&7_0R_\
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ME?\ /U_Y#?\ PH]G/L+VM/\ F7WFO163_P )9I?_ #]?^0W_ ,*7_A*M+/\
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M0?W_ -#1]N@_O_H:+,.9=R>BH?ML/_/3]#1]LA_O_H:+,.9=R:BH?MD7]_\
M0TOVJ+^_^AHLQW1+147VJ+^]^AI?M"?WOT-(5T245']H3^]^AH^T1_WOT- 7
M1)14?VB/^]^AI?.3U_2@+CZ*9YR>OZ4OFKZT#'44WS%]:/,7UH =11N'K2;A
MZT +12;AZT;AZT +11D44 %%%+M- "44NTTNT^E [,;13MI]*-C>E 68VBG;
M&]*-C>E*X69SOB+_ )&#PQ_U_#^E>C5Y]KUK+)KWAME7*I>@MR.!Q7H-<=7X
MCT:/P(XWX??\?WBC_L*S?SKLJXWX??\ ']XH_P"PK-_.NRJ#8**** "BBB@
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M++3LMCU,NR3!Y7=T(^\^KU9R'Q7\)W?CGX>:[H-@\,5W?6YAB>X8K&&R#\Q
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M* "N-U+_ )*AI'_7E)_-J[*N-U+_ )*AI'_7E)_-J .RHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &_SI.,4N<UP/QB^*VG
M?"?PG/JEXRO-MQ%!NPSGV^E:TJ4ZTU3@KMF%:M3P].56J[11S7[1WQRM?A#X
M5E,4BMJUPK) H/*G'6OCOX#_  FUO]HGXA2>(==,DFDQS&2:>3H[ YVX]*RO
M#.C>*/VL/BN9[YI);+S09Y%!")%GI^5?HWX)\&Z;X#\.VFD:9"D$,$:H648+
M8'4U]S6J4^'\+["EK6FM7V1^>X>G4XDQ7UFK=4(/W5W9JZ3I%IH>GPV5C MO
M;0KM2-!P!5P5P?Q5^,&C_"33(KW5@QCDSM"D#I7DA_;N\$JP'V><@]]Z_P"%
M?)T<OQF*C[6G3<D^I]E6S+!8.7L:DU%KH?2_XTO6O)_!7[3'@7QM)%#!K-O;
M74G"V\T@W$^E>K*P900<@\BN2MAZN'ERU8N+\SMH8FCB8\U&:DO(?1116!U!
M1124 +1124 )BDZ]:P/'/C&T\"^'[C5[U6>"$9(4X/2N&^#?[16@?&>XNX=(
M@EA:W;:WF,#G\JZ886M.DZT8WBMV<<\70IU8T92M)[(];HHHKF.P**** /+?
MCQ\%]-^,/A&>TGA5=0B4M;W&/F!&3M_$U\/_  A^)_B+]FWXBS:'K/F1V(EV
M7-NQ.TCL17Z8#/%?/O[5'[/=K\4O#,FI:=;A-?LU+Q-&.9/KCK7U>3YC3@G@
ML7K3G^#[GQF=Y74G)8_!NU6'XKL>X>']>M/$FDVNH64JRP3H'!4YQD9Q6C7Y
MZ?LN_M!:G\+O$A\(>(R_]FM+Y063@Q.3C=D]J_06TNH;ZUCN()%EAD7<CJ<@
M@]Z\S,\NGE];E>L7L^Z/5RC-(9G1YEI):279EFBDI:\<]X**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#DOBI_R(NH_6+_T8
MM=/;?\>L/^X/Y5S'Q4_Y$74?K%_Z,6NGMO\ CUA_W!_*@":BBB@ HHHH ***
M* "BBB@ HHHH *9)&)%*L,JPP13Z2@#\6OVK(=4D_:VUGX=^$?\ B36TVI0V
M-O#&259IEC[GI\SFOU#OM2_X9U_9QMIYT\Z;0=,@BFVG=YDH"HQS[L:^;?"_
MPDL?'G_!0[QAK%_HT>H:=HNVX>X?.(KKRHC">.XP37L/[>'C*W\._!6?2)#B
MXUN06\/N497/Z"KQ<W"GOJD?6X>@L7CL+@WJI.-_GJ_P.#\(_M=:WXVM8+BW
M1(4F7+*K9*-GA>G6O0_#?BCXF>+6Q8VSQVX8!IY9%0!3W *\UYO^R-\%="^'
M/PCN?&GCF&(?:)!?P&Z)1K=$!& N1R2,X->Q1?M@_"I(U":WM3' $6/ZUYN&
MHUZL%*;?R/H<YQ>7X>O/#9;A5+E=G)JZNNUOU/6/#>FZAIEJR:AJ4FHRL<[G
M4+MXZ<5L_I7B7_#8GPN_Z#K?]^C_ (UV/PX^-7A/XK2WT7AS41>O9[3,I7:1
MNSC'KTKTO9RBMC\[JTZUW.<;?*R.]Q1^->1^)?VI/AWX3UZ^T;4M9\B_L9#%
M/'Y>=K#M6;_PV+\+O^@ZW_?L_P"-')+L2L/6DKJ#/;MU)^->)?\ #8_PNX_X
MGS=<?ZLU[%INI6VKV4-W9SQW-M,H>.6-@RL#Z$4G%QW1$Z4Z?QQ:+>:2JNI:
MM9Z/;&>]NH;2$=9)Y B_F:\&U[]NSX3>'M8NM-N-7NY+BW;8[6]FTB9]F'!I
MQA*6R'3HU*WP1;]#Z$-':O$_AW^U]\-/B9KATG2=9>*[V[A]N@,"'Z,W!->U
M1RK,@=&5T89#*<@TI1<=&B:E*=-VFK,=THKQCXI?M9?#WX0>+&\.^(KV\@U-
M(4G98;-Y$"M]WYAQGVKE/^'@GP?_ .@GJ/\ X /5JG-JZ1M'"UYI2C!M/R/I
M*CI7S;_P\&^$'_03U#_P72?X5[EX(\<:1\1/"^GZ_HEQ]JTZ^C$L3D8.#V8=
MC[&IE"4=6B*E"K25YQ:1T(XI#7EWCC]H[P+\._$DNA:WJWV34841WBV9P&&0
M<_2O0M!UNS\2:1::GI\RW%E=1B6*1>C*>AI.+2NT9RISBE)K1E^EJIJ6H0Z3
M87-[<MLM[>-I9&QT5023^0KA?AM\>/!_Q7U*[L/#>I?;;BVB$\B[-N%)QG\Z
M5FU<%"4DY):(]$ZT5Y1\6_VE_ GP3U"RL/$^HRQ7EVK2)%:PF9E48Y<+]W.>
M,]:X3_AX+\(/^@IJ/_@ ]6J<VKI&T,+6J14HP;7H?2?2D_"OFL_\%!O@^HS_
M &IJ)'MI\E>VQ?$70IO!,?BR.]5]#DMUNEG7GY& (R.QYZ4I4Y1W1,\/5IVY
MXM7.HY]:.?6O$?\ AL;X7<_\3T^G^J/^-2VO[7OPPO+A(8]= =S@;DP/SS3]
MG/L5]6K?R/[CVDXH^[61H/BK2/$UNDNF:C:WRLN[$,RNP'N >*OWEU'8VLUS
M,VR*%&D=O10,D_D*@Y^5IV9/DTM>1>%_VI/AYXPUZRT?3-9\^_O)?)ACV$;F
M]*]<'*TY1<=RI4YTW::L&:/QKF_&/Q T#P#I<]_KFI6]E#"GF%6D'F,OJJYR
M:\0;_@H)\'UW?\3346Q_=T^0Y^E.,)2V1K3P]6JKPBW\CZ3R:,]*XOX=_%WP
MM\4-'@U'0-5AN8IONQ.P27\4)S767EXFGV<]S*2(X4,CD#)P!DU+33LS&491
M?+)699_"C;7F/@_]H?P7XZ\2?V'I%]-<:CN*F/R2 I'7)[5Z;Q@4--;A*$H.
MTE8=1112)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X3_;0)_X3:T_Z
MZ3?^@PU\ZLQKZ)_;0_Y':U_ZZ3?^@PU\[MUK]6R3_<8?/\S^?^*/^1M5^7Y(
M-Q]:;N/K0U#>U>Z?*#=[>M'F-ZTM)M% ">8_K2><_K2[32;?:@>@;W_O?I3?
M-D]?TI=M)MJ=2M!/.D_O?H*3SI/[WZ"EV^U&T4M1Z#?M$O\ >_04GVB7^_\
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M^>G_ (Z/\*3[=<_\]/\ QT?X4_RJ/)%'O=RO=[#/MUS_ ,]?_'1_A1]NN?\
MGK_XZ/\ "G^32>32][N'N]AGVZ[_ .>O_CH_PH^W7?\ SU_\='^%.\GVH\FC
MWNX>[V&?;[O_ )Z_^.C_  H_M"\_YZ_^.C_"G^31Y-'O=P]WL1_VA=_\]?\
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M;_QU?\*/[0O?^>W_ (XO^%3_ &<T>0:+2[BO'LB#^TKW_GM_XZO^%']H7O\
MSV_\=7_"I_(-'D&BTNX[P[(@_M*]_P">W_CJ_P"%']I7O_/;_P <'^%3^0:/
M(-/WNXKP[(A_M*]_Y[?^.#_"D_M*]_Y[?^.K_A4_D&CR#1[W<5X=D0_VC>_\
M]O\ QU?\*/[1O?\ GM_XZO\ A4_V<^M'V<^M3[W<?N=D0?VC>_\ /;_QU?\
M"C^T;S_GM_XZO^%3_9SZT?9SZU7O=Q>YV(/[1O?^>W_CJ_X4?VC>_P#/;_QU
M?\*L?9Z3R*7O=Q^YV1!_:-[_ ,]O_'5_PH_M*[_Y[?\ CH_PJ?R*/)I^]W)]
MWL0?VC>_\]O_ !U?\*7^T+W_ )Z_^.C_  J;R?:CR*/>[A[O8B_M"\_Y[?\
MCH_PH_M"\_YZ_P#CH_PJ;[/2>11[W<?N]D1?VA>?\]?_ !T?X4OV^\_YZ_\
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M[75[>6^C>//F*T"N7!7!W CC!S1UL'2YVE%%% !1110 444E "T444 %%%%
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M.6]U^A^LE%%%2:A2-]TTM(WW32>P'X^:A_RFH'_88B_]-2U^P/;\*_'[4/\
ME-0/^PO%_P"FI:_8'M^%*G_N]/\ KL3+^/+Y?J*WW3]*_'_]E/\ Y2X^-_\
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M477P[729M8T<))8K&\:E0V2@SVZYK\__ (L6IO\ XS:W; [3+<A<_6O;[/\
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M[V\S\URGFCF]2&7ZT?M=K^1[]1117YZ?IH4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(I!3Z93Z!BK3J:M.J"A5I:1:6@I#EI:1:6@84444%(?2K24JTF,6G+3:<M2
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M.F144-*U1?W5^;'4UI1:[_Y'[&TM>0_\-?? S_HL7@7_ ,*&T_\ CE:WA/\
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M2Y/^P_>?^@Q5G3WJ+R7YE5O@I?XG^1\R:#IMMJO_  6DN(KF/S$CUBXG5?\
M;CTMG0_@R@_A7Z_?PGZ5^1?@_P#Y357G_82O/_3/)7ZZ=1CVJHZ8:C;^4)?Q
MYGX4WWQ1\:Z+_P %&?'?C;PQX'N?B3XFTC7=22VT:WMI[IA''OMDDVPJ6Q&F
MWG& <5]6?\/"/VJ?^C4]>'_<#U7_ .-5Y+^T*-8_8/\ ^"B,'Q5;3I[SP;XC
MNI;\M ,>='.FV\A!/'FH[&0+D9S'R,FOTL\'_M6?!_QQX67Q#I7Q*\,MIGE"
M61KG4X;>2W!&<31R,K1'V< U%/\ @0UV5O3N:5/XTG;?5>A^3/[7WB3]H/\
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M^U?K@N  ,5^6'_!5SX=Z]\-?C9\//C[H=HUU:6$EK#=L%)2&ZMI_-@,A'19
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M>>%/A+H^L?#7QWJD/ANRU*];5-(UC49/*M&D*+'+"\C85/\ 5JRL2%)W D'
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MH **** "BBB@ HHHH **** "BBB@ JEJFEV>M6,EG?6\=U:R??BD&5/>KM%
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MY':S_P"NDW_H,-?/%?K&1_[A#Y_F?S[Q3_R-JWR_)!1117NGR@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=E/8XWX??\?WBC_L*S?SKLJXWX??\?WBC_L*S?SKLJ@U"BBB@ HHHH ****
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M445XI[X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]>^#
M>A?9]/N=5D3Y[@^5$QZ[ ?FQ]6_]!KRG3[&74[ZWM(5W2S.(U'N3BOI32[&/
M2].MK2( 1PQK&,#'08S7F8^KRP4%U/=RFASU75>T?S+2U+42U+7SS/KD*OWA
M4E1K]X5)2*%6GK3%IZU!J/6G+35IRTF62+THH7I12&B5:6D7[HI:EE(=4BU'
M4BU+*'4JTE*M2-$E.6FTY:"T+4BU'4BTF4.6GK3%IZU#*'+3J:M.I%(<M.:F
MK3FI,M#UJCX@_P"0/<_1?_0A5Y:H^(/^0/<_1?\ T(5+V-8[HT;?_CWC_P!T
M?RI],M_^/>/_ '1_*GU(D/I5I*5:!H=3UIE/6I92'4Y:;3EI%"TZFTZ@T05(
MM1U(M)C'K2TBTM0QH?'WI],C[T^D4*M+2+2T%#Z***@I#Z5:2E6@9)2K24JT
MF6.IR]*;3EZ5(T%/IE/H&*M25&M25+*0+]ZGTQ?O4^@8JTE*M)062)]VEI$^
M[2U!0^BBB@!]"]:*%ZT .IRTVG+292%IRTVG+4,8M.IM.I%(*?3*?0,5:=35
MIU04*M+2+2T%(<M+2+2T#"BBB@I#Z5:2E6DQBTY:;3EJ0%IRTVG+06+3J;3J
M& 4445(T9>J?\A;1?^OD?TKLJXW5/^0MHO\ U\C^E=E7//<[*>QQOP^_X_O%
M'_85F_G795QOP^_X_O%'_85F_G795!J%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 44E!Z4 %'6OSQ^+'_!7O1/AC\;M;\#Q_#]]:T71]3&G7/B
M&/6O+/RL%G=8/L[9V-Y@ \SYMG49X_0/3=0M]5L;:]M)DN+6XC6:&:,Y5T8
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MHU"(BW> JCH!QTK=\3?"NW\3>$=/T6?5+X3:?(LT&H>8//\ ,7."6Q[UW=%
M'E&H? F+Q$(CK7B+5;L(4)@\_=$2IX.".I[UV=]X(L;_ ,2:?K$CRB2QC\N&
MW4_NQ@Y!QZUTE% '/>,O!MIXVT^&RO9IHX(YDGVQ-C<R,&&?Q%6/%GANW\8>
M';_1KMWCMKR/RW9,;@,@\?E6S10!P7B[X4V?BA=&DCU&]TR[TF(Q6UQ:2;&V
MX ()]#@5E7?P)LM:L;JWUG6M3U07$00)<3!TA8'.] 1P>U>I44 >?Z[\(=/\
M2>%[#0M0U&_N+6T0J&>3+.>S-[CM62OP,9=-ATT>+=<2PA(*;;G#G_8/'W?:
MO5J* *&D:3:Z'IT%C90I;VL*[4CC& .Y_7)_&JWBKPW;^+=!N])NV=+>Y4*[
M1G#<$'C\JV** /.[7X)Z#9Z"^EQ/<(C3+.)@P\Q7 P"#5_4/A5H^H>&9]";S
M([.4 Y0@,KYRSC_:;N:[6B@#@]-^#VA:7:Q01I(ZKIS:8Q;!,D;-DEO4T^Q^
M$6AV/@.3PEMDFTJ21I")""V2V[^==S10!Q'A_P"%EAX?^PK'>WEQ;V+B2WMY
MGRD9'0@=JTM)\#V6DVJPK---M>61'E;)4R')Q72T4 4(])@6P6T.7BQAMW5_
MKZURNO?"G3?$&BVNFW%Y=K%;EBLB. Q#'."?2NYHH XG3_A?9Z=I^E6L>HWS
M#3;DW$+M)\W(QL/^S[5%XE^&L?B+7;2[,WV:VBGCN9$C8AI)$/RD\<UW=% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PG^V=_R.UG_U
MTF_]!AKYXR*_1:Z\)Z)XH\:^(_[8T;3]5\B2+ROMUJDWE[E.[;N!QG SCK@5
M.WPG\$_]"=H/_@M@_P#B:^UR[.8X7#1I.#=K_F?EV<\-U,?CIXB,TE*VEGT2
M1^<.X>M&X>M?HW_PJCP5_P!"AH/_ (+8/_B:;_PJ?P5_T*&@_P#@M@_^)KTO
M]88?\^SQ/]3ZW_/U?<S\Y=P]11N'J*_1<_";P5_T)^@_^"V#_P")IK?"?P5_
MT)^@_P#@M@_^)I_ZPT_^?8_]3ZW_ #\7W,_.O>/[P_.C>/[P_.OT2/PG\%_]
M"AH/_@M@_P#B::?A1X+_ .A0T'_P60?_ !-+_6"'_/MA_J?6_P"?B^YGYW>8
MO]X?G1YB_P!X?G7Z'GX4^"_^A0T'_P %D'_Q-,_X51X,_P"A0T'_ ,%D'_Q-
M'^L$/^?;#_4^M_S\7W,_//S$_O+^='F)_?7\Z_0H_"GP9_T*&@_^"V#_ .)I
MA^%/@S_H4=!_\%L/_P 33_U@A_S[8?ZH5O\ GXON9^?'FI_?7\Z/-3^^OYU^
M@O\ PJGP;_T*.A?^"V'_ .)IA^%/@W_H4M"_\%L/_P 31_K!#^1A_JA6_P"?
MJ^YGY^><G]]?SH\Y/[Z_G7Z _P#"I_!O_0I:%_X+8?\ XFFGX4^#?^A2T+_P
M6P__ !-'^L$/Y&'^J%7_ )^+[F? 'G1_WU_,4>='_?7\Q7WZ?A3X._Z%+0__
M  6P_P#Q-,;X5>#O^A2T/_P6P_\ Q-'^L%/^1A_JA5_Y^+[F? OGQ_\ /1?^
M^A1]HB_YZ+_WT*^^?^%4^#_^A2T/_P %T/\ \33/^%4^#_\ H4]#_P#!=#_\
M31_K!3_D8?ZH5?\ GXON9\$_:(O^>B_]]"D^T1?\]$_[Z%?>Q^%/@_\ Z%/0
M_P#P6P__ !--_P"%4^#_ /H4]#_\%T/_ ,31_K!3_D8?ZH5?^?B^YGP7]HB_
MYZ)_WT*7[1%_SU3_ +Z%?>7_  J?P?\ ]"GH?_@NA_\ B:;_ ,*I\'_]"GH?
M_@NA_P#B:7^L-/\ D8_]4*O_ #]7W,^#_M$7_/5/^^A1]HB_YZI_WT*^[_\
MA5'@_P#Z%30__!=#_P#$TG_"J?!__0IZ'_X+H?\ XFC_ %AA_(Q?ZH5O^?B^
MYGPA]IB_YZI_WT*/M,7_ #U3_OH5]VM\*?"'_0IZ)_X+H?\ XFF_\*I\(?\
M0J:)_P""Z'_XFC_6"G_(Q_ZH5?\ GXON/A3[5#_SU3_OH4?:H?\ GJG_ 'T*
M^Z?^%4^$/^A4T3_P70__ !--_P"%4^$?^A5T3_P70_\ Q-'^L$/Y&'^J%;_G
MXON9\+_:H?\ GK'_ -]"C[5#_P ]H_\ OH5]S_\ "J?"/_0JZ)_X+H?_ (FF
MGX4^$?\ H5=$_P#!=#_\31_K!#^1B_U0K?\ /Q?<SX:^U0?\]H_^^A1]J@_Y
M[1_]]"ON3_A5'A'_ *%71/\ P7P__$TG_"J?"/\ T*NB?^"^'_XFC_6"'\C'
M_JA5_P"?B^YGPY]J@_Y[1_\ ?0H^U0?\]H_^^A7W#_PJGPC_ -"KHO\ X+X?
M_B:3_A5/A+_H5-%_\%T/_P 31_K!#^1A_JA4_P"?B^X^'_M4'_/:/_OH4?:H
M/^>T?_?0K[?_ .%4>$O^A4T7_P %T/\ \32_\*H\)?\ 0J:+_P""^'_XFC_6
M"'\C#_5"I_S\7W'P_P#:H/\ GM'_ -]"C[9!_P ]8_\ OL5]O?\ "I_"7_0J
MZ+_X+X?_ (FD_P"%3^$_^A5T7_P7P_\ Q-'^L$/Y&'^J%3_GXON/B'[9!_SW
MC_[[%'VR#_GO'_WV*^W?^%3^$_\ H5=%_P#!?#_\32?\*G\*?]"KHO\ X+X?
M_B:/]8(?R,/]4*G_ #\7W'Q']L@_Y[Q_]]BC[9;_ //>/_OL5]N?\*G\*?\
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M;1O_  7Q?_$T?\*D\)?]"MHW_@OB_P#B:/\ 6"'\C#_5"I_S\7W'Q1]NM_\
MGXB_[[%)]NMO^?B+_OL5]L?\*E\)?]"KHW_@OA_^)H_X5+X2_P"A5T;_ ,%\
M7_Q-'^L$/Y&'^J%3_GXON/BG[;;_ //>+_OL4?;;?_GO%_WV*^UO^%2^$_\
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M_P _%]Q\0?:H/^>T?_?0H^U0?\]H_P#OH5]P?\*I\)?]"IHO_@NA_P#B:/\
MA5/A+_H5=$_\%\/_ ,31_K!#^1A_JA4_Y^+[CX?^U0?\]H_^^A1]J@_Y[1_]
M]"ON'_A5'A$]/"NB_P#@NA_^)H_X5/X2_P"A5T7_ ,%T/_Q-'^L$/Y&/_5"K
M_P _%]S/A[[5!_SVC_[Z%'VJ#_GM'_WT*^X?^%3^$?\ H5-%_P#!?#_\36'K
MOPR\+PZQHD<?AG1T225@ZK81 ,,#@_+S2?$4%]A@N#ZK=O:+[F?'7VJ#_GM'
M_P!]"C[5#_SVC_[Z%?<G_"J?"/\ T*NB?^"Z'_XFG#X4^$?^A5T3_P %T/\
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MRKC?A]_Q_>*/^PK-_.NRJ#8**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!F*\J_:@^,4/P'^ OC+QM(RBYTZQ;[$KC(>Z<B.!<=P9'7/MFO5<YK\
MP?\ @L#\4+WQ1KGP]^!_A\-=:EJ5TFI75M$>9)'8P6D7XL93C_<-8U$Y6IQW
MD[?YFE.R;E+9:G@7P<_9/O/BA_P3_P#BQ\1KF"2Y\1S:I'K&FS399Y8;$2?:
M&!ZDN)[D>[1BOO/_ ()9_')?BW^S'IVBWEQYNN>#W_L>X5C\QMP-UL_T\O\
M=Y]8C7T5\'?A3IGPH^#GAGP#;11S6.E:9'8RY08G;;^]=A_ML78_[QK\N?V5
M-2?]BO\ X*,>)?AAJ$KVWAK7[EM*@\QL(5D(FT^0YZMAECSZRM77%KVTJ*V:
MT]8Z?B<[O*DJKW3N_1_Y'[">M>6:-^TY\-/$'Q@U+X6V'B3S_'>G*[W6DFQN
M4\M4178^<T8B.%93PYZUZEUZ=*_$'XS>#O$_Q,_X*9>-_ GA;6IM N/%.H?V
M5>7T'WDLFMHWN?<CRXVR 1NQM)P37/%N554UU3^]6-'90<F]C]-?&G_!0?\
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MHD6[)+K<^D? ?[??[/\ \2M7CTS0OB=I1OI6"11:E%/I_F,3@*IN8XPS$D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_9)?_L/WG_H,5> _M)>-_P!H?]NKX6Z_-IGPYN/AG\*-!LY=:N!K$DBW6L-
MAD14RBM(,#*JJ; PRTA(4#V?_@C3XFLM4_9KUW1HY8_M^EZ_,9H<_,$EBB9'
M(]"5<#_<-73O:HI:::+RN95=?9VUUU?R/!O!_P#RFJO/^PE>?^F>2OUS7[HK
M\C/!_P#RFJO!_P!1*\_],\E?KFO05HO]VH?X?U'+^/,7%?D#_P %3M"O_@W^
MU_\ #[XLVT#26EREI>(PXS=6,REDSVRGD_F?2OV )KQC]JO]FG0?VJ/A/?>#
M]9D-C=*XNM-U2.,.]E<J"%<#^)2"59<C*L>0<$<[;C.-2/V6:QLTXRV:L>E^
M#?%NE^//"ND^(=%N4O=)U.UCO+6X0Y#QNH93^1Z=JVN.M?CCX'\>?M4_\$W9
MKGPWJW@^;QA\.[>5I8_W,MUIZ*6)9[>ZC&;?=UV2#N3Y8))KMKS_ (+/>,/%
MD+:1X,^"L:^)IODM_-U6;41OZ?\ 'O%;QNWT#BM6T]:>J,HQE%6ETZGTW^WI
M^W-)^R$?!UKI&EV'B'6M7GDENM.O)70I9(,%PRGY&:1E"DJP(1^../98OCM!
MH/[.</Q9\::0_AF)=%76+S2EG\^6#<@98 Q5-SG<J@$#YFQ[U^>_[.?[#7Q3
M_:8^,\?QA_:,@NK33_-2Z71]4C$5U?%,>5";<8^SVZ]T8!B!C;\Q:OT&_:B^
M#L_QV_9]\9^ [&6.UO=3L@MG(YVQB>.198@Q X4O&H.!P":SFI4Z+ZR>OHBX
M.,ZJ7V5OYGY_>"?VF/VPOVW->U2]^$::7X!\&6<YMFN6C@,49(W*DD\T<DDD
M@4@GR4 &02HR,]E#_P $]/VC/B-#<CXL_M)WT6F2C]_I^C7EY=P2Q_Q*4<P1
MKD<?<8>QKQ;]F']KSQC_ ,$\=-U+X:_%;X8:PFE/J$EW;W" 03QR$*L@C+#R
M[B-M@(97&.>6!&/;O$W[9'QJ_;-T.Y\%_ KX5:MX:TG6(S;W7C;7I#'%;V[?
M+)L<+Y:-@]5>1\;MJ9 (NI%<O[K73?Y=0BWS/VFFOX'EW_!%B);;XL?$V)&W
MHNF6X#>H\YN:U?\ @MM_R-GP@_ZX:E_Z';5D_P#!)NU?X4_M6?$_X=ZY)'#K
M<5G-9XR0)9K6Y"R!,X)R"S#C.!FM;_@MO_R-OP@_Z]]2_P#0[:M8:U</U5_\
MR8_%6T_K0_5C35"V,"@8 0  =N!7YQ?\%M/^28_#?_L+W'_HD5^CVG_\></^
MZO\ *OSA_P""VG_),?AO_P!A>X_]$BN>OO\ -?F7A=EZ/\CW3XX6=Q??\$U-
M6CME+3+X$MI#CKM6WB9__'0U>:?\$9=0M;C]F7Q#:QE1=0>)9S,HQGYK>W*D
M_4 CG^Z:^L?A+H=GXE_9U\':1J5NEUI]_P"&;.VN;>0962)[5%=3[$$C\:_,
M^Q\&_&[_ ():_%S7]5\-^&;KXB?"353YDS6Z2-&T*$F,S.BL;:>,,5WLI1@3
MU_AV;4:U1/:77T9S4H\^'II;K7[U8_7K[O6O#[7]HCX>_'KP[X]\-> /%=MK
MGB+3].O(;BSACECDA<*T>[YT7*[R!N7(/8FOB3QG_P %7/&WQN\/W?A#X-_"
M?6(_%NHP& WRRF^DLBWRLT<4<7) )P[D!2,E3TKZ'_X)R?L;:A^R_P##W4M4
M\5K'_P )UXD,<E[#&XD%E"F3';[QD,V69G(XR0 3MR<94W4A-2T36GFS?F4>
M7EU=_P /,_-?]@K]E*__ &H-1\96.E_%"]^'.H:/%;2M#9V3SM>1NT@).VXB
MQL*@<Y_U@Z5]A_\ #H?QI_T<UKW_ ()Y_P#Y/KA_C=^S/\8?V*?VC+WXR_ [
M1I?$OA2_EEEN-)LK9[@VR2MNEM9X$.]H-WS*Z?<VC.TJ"W22?\%H;B[TW^S;
M#X,:@WC-SY2V#ZF7B63H#A8!(W./DV@]MW>KYU.*<59VV\P<7&3UTZ$7A7_@
MF;H?@WX\>%[_ %O]I;3]:\7:-J%EJ0T2_P!/1;^=(YE=$P]^TBAB, [3UX!K
MT+_@M$/^,;/"V/\ H:(?_26YK@?V*_V2_B9\6_V@YOVB/CC83Z3=?:3?:=I5
M["89Y[C;LB<PGYH88E V*V&)5#T&6[[_ (+1?\FU>%O^QHA_]);FIJ<RIQC+
MNM.UVC2BTZLFMK-7^3/I7]B7_DTGX3?]B]:_^@"O;EKQ']B7_DT?X3?]B]:_
M^@"O;EK>M_$EZLYZ?P(6BBBLC0**** "BBB@ HHHH **** "BBB@ HHHH **
M** "N-U+_DJ&D?\ 7E)_-J[*N-U+_DJ&D?\ 7E)_-J .RHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .2^*G_(BZ
MC]8O_1BUT]M_QZP_[@_E7,?%3_D1=1^L7_HQ:Z>V_P"/6'_<'\J )J*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \YTO_D=O%?_
M %T@_P#06K>K#TO_ )';Q5_UT@_]!:MZNRGLCS:WQ,;13J*T,1M(5)I]% #-
MM&VGT4 ,VT;:?10 S;2>74E% $?ET>74E% $?ET>74E% $?ET>74E% $?E^U
M'E^U244 1^7[4>7[5)10!%Y='EU+10!%Y='EU+10!%Y='EU+10!%Y='E5+10
M!%Y='EU+10!%Y='EU+10!%Y='E5+10!%Y5'E5+10!%Y5'E5+10!%Y5'E5+10
M!%Y='EU+10!%Y='EU+10!%Y='EU+10!%Y='EU+10!%Y='EU+10!%Y=+Y=244
M <KX#C_T/5/^PA+_ "6NF\OVKG? ?_'GJG_80E_DM=-4QV-*F[(_+]J/+]JD
MHJC,C\OVH\OVJ2B@"/R_:CR_:I** (_+]J/+]JDHH C\OVH\OVJ2B@"/R_:C
MR_:I** (_+]J/+J2B@"+RZ/+J6B@"+RZ/+J6B@"+RZ/+J6B@"+RZ/+J6B@"+
MRZ/+J6B@"+RZ/+J6B@"+RZ/+J6B@"+RZ/+J6B@"+RZ/+J6B@"+RZ/*J6B@"+
MRJ/*J6B@"+RJ/*J6B@"+RJ/+J6B@"+RZ/+J6B@"+RZ/+J6B@"+RZ/+J6B@"+
MRZ/+J6B@"+RZYGQ1'_Q4'AS_ *[O_(5U=<SXH_Y&#PW_ -=W_D*F6Q</B.A\
MNCRZEHJB"+RZ/+J6B@"/RZ/+J2B@"/RZ/+J2B@"/RZ/+J2B@"/RZ/+J2B@"/
MRZ/+J2B@"/RZ/+J2B@"/RZ7RZ?10 WRZ/+IU% #=E&RG44 )L%&T4M% ";:7
M:*** #:*-HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_ !]_R*%_]$_]
M#6N@KG_'W_(H7_T3_P!#6E+9EQ^)&U9_\><'_7-?Y5-4-G_QYP?]<U_E4U,@
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_$7_ ",'
MAC_K^']*]$;K7G?B+_D8/#'_ %_#^E>B-UKBJ_$>C1^!''_#[_C^\4?]A6;^
M==E7&_#[_C^\4?\ 85F_G795!N%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 E%+10 4E+10 E%+10 4F!Z4M% "44M% "44M% "4M%% !1110 4
ME+10 E+110 E%+10 F/:EHHH *2EHH 2BEHH **** "BBB@!**6B@!*6BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N-U+_ )*AI'_7E)_-
MJ[*N-U+_ )*AI'_7E)_-J .RHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .2^*G_ "(NH_6+_P!&+73VW_'K#_N#
M^5<Q\5/^1%U'ZQ?^C%KI[;_CUA_W!_*@":BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /.]+_Y';Q5_UT@_]!:MZL'2_P#D=O%7
M_72#_P!!:MZNRGLCS:WQ,****T,0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGP'_QYZI_V$)?Y+735
MS/@/_CSU3_L(2_R6NFJ8[&E3=A1115&84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7,^*/^1@\-_\ 7=_Y"NFKF?%'
M_(P>&_\ KN_\A4RV-*?Q'344451F%%%% !1110 4444 %%%% !1110 4444
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MPH D^*G_ "(NH_6+_P!&+73VW_'K#_N#^5<)KF@>,M?TN:PNKC1Q!+MW>69
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MQ?&G_/QH_P#Y$_\ B:/:1#V,S9HK&_L7QI_S\:/_ .1/_B:/[%\:?\_&C_\
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MS\:/_P"1/_B:/:1#V,S9HK&_L7QI_P _&C_^1/\ XFC^Q?&G_/QH_P#Y$_\
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M )^-'_\ (G_Q-']B^-/^?C1__(G_ ,31[2(>QF;-%8W]B^-/^?C1_P#R)_\
M$T?V+XT_Y^-'_P#(G_Q-'M(A[&9LT5C?V+XT_P"?C1__ ")_\31_8OC3_GXT
M?_R)_P#$T>TB'L9FS16-_8OC3_GXT?\ \B?_ !-']B^-/^?C1_\ R)_\31[2
M(>QF;-%8W]B^-/\ GXT?_P B?_$T?V+XT_Y^-'_\B?\ Q-'M(A[&9LT5C?V+
MXT_Y^-'_ /(G_P 31_8OC3_GXT?_ ,B?_$T>TB'L9FS16-_8OC3_ )^-'_\
M(G_Q-']B^-/^?C1__(G_ ,31[2(>QF;-%8W]B^-/^?C1_P#R)_\ $T?V+XT_
MY^-'_P#(G_Q-'M(A[&9LT5C?V+XT_P"?C1__ ")_\31_8OC3_GXT?_R)_P#$
MT>TB'L9FS16-_8OC3_GXT?\ \B?_ !-']B^-/^?C1_\ R)_\31[2(>QF;-%8
MW]B^-/\ GXT?_P B?_$T?V+XT_Y^-'_\B?\ Q-'M(A[&9LT5C?V+XT_Y^-'_
M /(G_P 31_8OC3_GXT?_ ,B?_$T>TB'L9FS16-_8OC3_ )^-'_\ (G_Q-']B
M^-/^?C1__(G_ ,31[2(>QF;-%8W]B^-/^?C1_P#R)_\ $T?V+XT_Y^-'_P#(
MG_Q-'M(A[&9LT5C?V+XT_P"?C1__ ")_\31_8OC3_GXT?_R)_P#$T>TB'L9F
MS16-_8OC3_GXT?\ \B?_ !-']B^-/^?C1_\ R)_\31[2(>QF;-%8W]B^-/\
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MV+XT_P"?C1__ ")_\31_8OC3_GXT?_R)_P#$T>TB'L9FS16-_8OC3_GXT?\
M\B?_ !-']B^-/^?C1_\ R)_\31[2(>QF;-%8W]B^-/\ GXT?_P B?_$T?V+X
MT_Y^-'_\B?\ Q-'M(A[&1LUS_C[_ )%"_P#HG_H:U/\ V)XT_P"?C1__ ")_
M\3535O"/B[6-/EL[BXTGRI,;MAD!X(/]WVH=2+14:,E),WK/_CS@_P"N:_RJ
M:L2/0/&<4:HMQH^%  _UG_Q-._L7QI_S\:/_ .1/_B:/:1%[&9LT5C?V+XT_
MY^-'_P#(G_Q-']B^-/\ GXT?_P B?_$T>TB+V,S9HK&_L7QI_P _&C_^1/\
MXFC^Q?&G_/QH_P#Y$_\ B:/:1#V,S9HK&_L7QI_S\:/_ .1/_B:/[%\:?\_&
MC_\ D3_XFCVD0]C,V:*QO[%\:?\ /QH__D3_ .)H_L7QI_S\:/\ ^1/_ (FC
MVD0]C,V:*QO[%\:?\_&C_P#D3_XFC^Q?&G_/QH__ )$_^)H]I$/8S-FBL;^Q
M?&G_ #\:/_Y$_P#B:/[%\:?\_&C_ /D3_P")H]I$/8S-FBL;^Q?&G_/QH_\
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M,[H[*<7&-F=E1114&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !124M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 444E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWA/6+;7-!OT\RWO;5LJPZ$$=58'(*L 0000"*Z>FTT]1)IZH**2EI#"BBB@
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M5AJ,Z7CH)9(II=[,'7S -K'( %>YYK62Y9<IG&7-%2%HHI*184<"OS-\9?\
M!9B?PKXW\0>'(?@P^IMI-_<61GC\2%3((I6CW[19G;G;G&3C/4UE?\/L=1_Z
M(+=?^%*W_P @TEJE+N-Q<6T]T?J,U''-?G?\%?\ @K1??&#XL>%?!<GP:GT-
M-=OXK(ZBVO-,(-YQOV?8UW8]-P^M>R_MF_MR']D?Q!X(TK_A"O\ A*_^$F\_
M]]_:OV+[-Y;1+T\F3?GS<]5QM]^*Y7>*[[$W6OEJ?5M(13(GWH#ZC-/Z]:0)
MW5T+1110,2BEKD_B1\4/"WPA\(WOB;QCK=KH&A68_>WETQ R>B*HRSN>RJ"Q
M[ TFTMQI7.LHKF/ASX^TKXH>!]%\6:$\TFC:Q;+>6<D\1C=HFY5BIY&1S@\\
MUT]/5.Q*=]1/>D':AFVYKY<_9?\ VVF_:1^+GQ"\#_\ "&CP[_PB,KQ?;O[4
M^U?:]L[Q9\OR4V?<W?>;KCWI+67*M]PE[JYGMHOO/J(TX>M?*'QZ_;H/P1_:
M>\!_"#_A"O[9_P"$I:P7^V?[5\C[+]INF@_U/D-OV[=WWUSG''6OJY6SBA:Q
M4NG^0Y>[+E>]D_O'4444P"BBB@ HHI* "CTH]:^=OVUOVMO^&0/A_HGB<>%?
M^$M_M+5!IOV7^T?L7EYBDDW[_*DS_J\8P.N<\5+:6HTG)V1]%45\N?L2?MPZ
M?^V1IOBAE\-?\(CJFA2PA[#^T?MOFPRAMLH?RH\?,CJ1@XP#GFOJ+/2K<6M&
M2FF)CYJ2O%OVMOVD[#]E3X/W7CB\TS^W+A;J&SL]*^U?9C=2R-RHDV/MVHKO
M]T_<QWKSW]A[]N8_MF-XQ'_"%?\ "'CP\+0_\A7[=]H\_P [_IA%MV^3[YW=
ML<J'[R_+TW'+W4F]F?5M+7 _&3XV^#?@'X*N/%/CC6H=%TB-A$C.I>6>4@E8
MXHU!9W."< < $G !(^"_$W_!;+04U1X?"/PEUCQ!9+SYVHZJEE+]?+CBG&/^
M!5-U>R'9VN?IC0:^"O@U_P %?OA7\0=8M-'\8:1J7P[OKF38+J[D2ZT]&)P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0^)'[.EEI/AO;,;J^MYKD6EE97",.0BY;RID9E:.-2!M;@!J^^_&7C*'X?\
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M2^!%GK$EE%IOC*_ME?8-0M],@$##^\ ]PLF/J@/M7T[\#/VDOAU^T=H<^J>
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M1<U\[?\ !+C]G#P_\:[?Q7\;/B380^,=>N]9D@M$UB)9X1* LLUR48%6<M(
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MV%?9GP;_ &5/AI\%? %KX6T;PGI4\7V98+Z]O+..:XU!L?.\[LI+[B2=I^4
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MBEN&VIN=]LDL8V+\H)SG+KQS7!_\$T_C/_PN']E+PT+B;S=6\-YT*\R<M^Y
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MPI\1-#T.ST3Q%)K(TZZN-.@6#[4CPR2!I H&YU:(88\X8C/3'T1\;/VA-7\
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M&W[.'["OAOPAJ'B'^T_&>L"'P]>:Y:;D:2%$9II 6^;<\:+&Q/)\QCQ6+^Q
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M':;\$]*^)_B#0K+7?&/B*6:YBO-2A6X:SA65HT6(,"%9MK,SCYCOQG Q3/\
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MP3M2A.V[_0^EO!W_  5[^ WBG7DTZ\'B?PM QVKJ6LZ9']FSG SY$LK@>Y4
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M"RUOQKXBM1J,^KZC L\T4;D^5%$7!\M1'MSMP6.<Y& /GW_@L!\$_"WP_M?
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MYL_\%;OV4_"/PVT[P]\3O!NCVGAY=1OSIFK6&GPB*WDE:-I(IE1<*C$1R!L
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M,BDLRA2W&-Q;&17H'IS2'O6*]V#CT>IJ_>DI/H?D_P#\$J?^3OOC5_U[W/\
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M+OA'X;\"WNHR>*H-$M5M([S485W21H3Y8*\CY5PH]E%?GA_P3)T:PU#]K/\
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MK&EQ:6+J$A2MX\WV6:5,=&&V5QZ$#TI2E^[=1+5-+YO82C[ZC?1_@>A_'/\
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M8STXI4K)U+N]OQ[>A51MTX>;?RT1[W\:_P!HCX>_L\Z#'JWCWQ+:Z%!.2MM
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MZ;#J.J:Y?0+/=2S3HLCH)'!*H-P4*, [<G)))^*_^"HGPU\.?L__ !W^%'Q
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** (9Q^Y<^QK\N_^"+'_(<^-?\
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M6Z E2!GVYKY!_P""='[&_C7]D73_ !Q;^,-3T'4GUR2T>W.AW$\H01"4-O\
M-ACQGS!C&>AZ4Z/NNI?JDE]X5/>C%+H[GAGCM4_9,_X*K:+X@W?8O"GQ(A6*
MY<_+&LEP1$^3TXN8XI23T$E=3^P3#)^T)^UI\:OC_=+YNEQW)T+0G8<>7\H!
M&>A$$4.?^NS5Z_\ \%"OV-=6_:Z\#>&K?PQ>:3IGBC1+YY([G6))8X6MY$Q+
M'NCC=L[DB(^7'RGI7H_[&_[/<G[,?P#T+P3=2VEUK432W6IW5B6,,US(Y)*E
ME5BH78@)4'"#BIH^[#WMXII>C?\ EH55U?N_:M?Y?YZ'PO\ MY?\I._@/_OZ
M%_Z=)*]$_P""TG@N]U?X)^#/$EO%)-;:/J[PW109$:SQX5V]!OC5<^K@=Z[O
M]IG]BKQQ\8_VQ/AI\5]%U30+;PYX9.FF\M;^XG2[D^SWCSR>6J0LARK #+KS
MUP.:^M?'O@/0OB=X/U7PKXETZ+5M"U2!K>[M)LX=3Z$<JP(!# @@@$$$5%OW
M$8]5)O\ %&SFO;<W2R7X69\7?LZ_L/?LJ?'7X,>%/&>G^ 8;Q]0L8C=^7K^I
M9AN@H$\3 7/#*^X8QZ$<$52_:._94_8R_9=\"Q^*/&/PWNWM9[I+.WL].UO4
M)+J>1LD[$>\0$*H+,<\ =R0#RY_X)I?&7X&>)+V\_9\^-?\ 8.E7DF]M-UR2
M6%5XP!)Y<<L<[ 9PQB4@<>]7?"__  2_\=_%3QU8^*?VC_BM)XX^QR971]+E
MF>*1<@^6)I!'Y,9(^98X@3V93S6DFJDKQT5]3GBO9JTM;;>9]/\ P7L? -E^
MR9"_PQT2]\/>![S2KR[TVQOVE:94D\QBY\V1WPS$L,L>&&.*^6?^")>/^%4_
M$7_L,V__ *)K]#X_#^GV^@)HD-I%;Z6EO]D2TB0+&D(7:$51P %X ]*_,K2_
M^"8OQY^"WCJ_NO@Y\7;'2?#%Q=).;>XU.]T^6>-&W)'/'!%(DA4$KN)YR>%R
M13BU[:=]I))/M9B:_=KNG>PO[=GQ2\>?'+]K[0?V;?#OBF?P7X9G-O;:A<0L
MR?;))HO.=I-I4R(L;!5BR%9\Y[%?7/!O_!'7X&^'VAFUB\\4>*G51YD-]J"0
M0,>Y @C1P/;>?K71?MI?\$];?]IKQ)IOCCPUXE/@SXA:?%'&+O8S07/EG=$6
M9"'CD0GB1<G  V\ CS'2OV,?VQ/$]E'X?\8_M)0:9X<5?+:XT2YN;B]=?1G,
M4#MD==TISWS65/W86^U^9K)\TDT]++3L^I\]^*_"OPV\ _\ !3WX:^%/A?I]
MKIN@Z'J&GV-S#;2R3+]K#L\NZ1V9G<;U4DDX*X[5^B/[37[3WPD^%>N:!\._
MBAI<VJP>+#'&L%SIT=QIXC:81[YVE8(%1L,W4J,''2OF;6_^"4]_\._BQ\+?
M%WP?U;36A\-W$%YK!\5WTZSW\\5R)=Z^5 ZC<F4P H&U3R26KZL_:V_9%\+?
MM<> X-%UN632-9L':;2];MXP\EI(P 8%21OC;"[DR,[0000#5-M4XIZV;N19
M>UE):722]5<\@^)G_!)+X$>/)'NM%MM8\$7+Y8?V+?>9 S'G)CG$F%_V4*"O
ME+X%Z/XV_87_ &^/#_P>TSQC-XH\*ZY+$EW91JT<3QSQL5D>#<PCFC*AMRG)
M4=<,0/6]&_8K_;-^'NFGPYX1_:"TG_A%XE$-N;Z\NA/'$!@*BM;2F( =%23
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M8K!)2,;MYV8&"<B..-CQ\V.#4[3A:&BM;S_JX)\L[RUU,;_@BC_R0_QV,_\
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M<$DX4#RS]KS_ ()PS_&KXE+\4?AMXO;P+\0!Y;RN_F)#/-&H6.99HCYD$@4
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M(MOK$FMZXTMW#'9WQ@2.UW;8?E .2P7?GT<>E>\?\.AOV>O^?'Q%_P"#=O\
MXFOK_P )^&;'P;X9TG0-+B$&G:9:Q6=M$HX2*- BC\@*UZZ9M.3Y=NAA'FLN
M;<_'KX,1K^P'_P %(;KP(9IHO!'B1DT^"2Y;<3;W.&M78X&2DV(RWIOKLO\
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M[B:2>,-<O*/-#PHH^5@/E9N<_6H4FZJ;[,)Q_=-+>Z?XZGSI^WI_RD[^ _\
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M?M:?#[PQH7A#4=%TZ\TS5&O9GUJ>:*-D,3)A3%%(2<L.H QWK?$6G4;CWO\
MB84?=23[?H>2_MX>!+WQC_P3;\'WEE').V@6>C:I-'&I)\L6XA9C[*)]Q] "
M:Q?V(/V/_P!F3]HW]GGPYXCO/!$>I^)K>/[%KA77-0C=;M"06:-+@*F]=K@
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M5_P2Z_:NL?%_@S[1/\-/$4A=;'>3%-;[@9K&0G^./=NC<\X*G)^<5^NGP_\
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M])<JU5OZ0^ORN_X+;<ZG\'_IJ?\ .UK]4:^*?^"B7[%OC?\ :VO/ <G@[5-
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M^!/^"1=CHFHQ/;ZA:Z+H_P!HAD&&CD>[MW9#[@MC\*]R_P"":_\ R93\-?\
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M&;P5J/A/Q=I<.L:#J";)K>7(((Y5T8<HZGD,"""*_/#7/^"3?Q&^&&O7FI_
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MW\6/A=XM^$&JZ:T/AJX@O-8/BN^F6>_GBN!+O7RH'4;DRF % VJ>22U>Y?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 E+110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% "4M%% !24M% !1110 4E+10 4444 %%%% "4M%% !1110 44
M44 )2T44 %%%% !1110 4444 %%%% #>N17C7P5_9KTKX/\ C3QUXREUG4O%
M/BWQ??&XO=6U1E,D5NK'R+6,#A4C4@>^T= %4>RM2>E);WZ@]K/8?1113 **
M** "BBB@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I:
M** $I:** "BBB@ HHHH **** $I:** "DI:* "BBB@ HHHH **** "BBB@ H
MHHH ;7'_ !8\#W?Q)^'.O^%['Q!?>%KG5+5K9-8TW'VBVW=63/J,C@@X)P0<
M&NQXHJ9)233&G9W.&^#7PC\/_ OX;:'X'\+PR0Z-I$/E1M,P:65B2SRR$ 9=
MV9F. !D\ # KN,TN.*.E4VY.[)24=A:2EHH&%%%% !1110 E+110 4444 %%
M%% !24M% !1110 4444 %%%% !1110 4E+10 4444 %%%% !1110 4444 %%
M%% !1110 444E #<5XWX!_9KTKP;\<?&?Q6OM;U+Q)XH\0*MI;-J+*8]*L1M
M;[+ H'"[QG/H!WW,WLF[BBDM'S+<-U9[#Z***8!1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4M%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>oncyf-20221231_g1.jpg
<TEXT>
begin 644 oncyf-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (; I\# 2(  A$! Q$!_\0
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M%ZS.0*N^<95(]:I2V+>9\O/-!!>TFY9E^:K5U<;!4>E6+ #=UJQJ%IN@/;%
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MI7_@CQ!Y/_!0OP![_P!H_P#IMNZ^:K>;SACK7T]_P2(BV?\ !0GX?'_L(_\
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M%^R1^V3\+=+N_%GB6]^*FJ>';C6I[06,9T<Q2V\J-$L@(D1UPY!.X,(SG:6
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MB7-U<16)9,>J.W^KQV\K9S[U\NZ-XSUZ[^)]D_B-;(6<*E8RKMY0)^Z_))8
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MVM:M::;>V.GMI5GYXDN]P2ZN';9;V:8'^NG?*IGCY23P*XS23OB&ZO8/A_\
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M3TMMIYH-K!;VBQ**^D_^"2+@?\%"_A\O_81_]-MW7S=)/Y5?1/\ P2*DW_\
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MM@L6%<3\.?V4?^%@^'O!<[>,=$TK6/B))<V^@:7<6MP[3S0S-"5FE12D",P
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M-TO28E2)HN6VJN /K[^I-?F7'/%=+&91'#X;2<VN:Z?NVZ;:MO:W1:V/;R_
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M7P/^V-=?#H:;'IG@_0%M=!U:?5M+MGOK_P FU:?;YBR(LP%P?EPCS!FCW''
M '<_#O3;7P%JOQ,\$Z#X-T/Q'K6A>![>SOXYK&6^N-4U..]M'O5"(X+(CR.F
MU!TM5;H#E/AK\']/U@^ ;"3X>V&I>&_%EE<W/BKQ&T$ZR:!.L]PLZ).'\NS%
MFD<;>6X)?/S;@PJ3.52FT^9?U:_^9Y#-\8-?^&^I_#/5UT&STZT\'M<:MX=B
ME\QHKN&6]DE.YBVYT617C!R"0ASD\U2\(?%WQ5^S]+X6M9M$@MVTW6(_&^G+
M?1NK7?G6PBC8X89A:-=P(P<]^U>O>(?AYH?BO]G7P=>0M:^)/'5I\/9YM'\/
M7$,BQM;1ZE>&YO01@33QQLSQV^>D<CG=L5#RUMX$\+^#=!UW6G\+Z3K4VD_"
M_P -:Y:07[S26XO[JXMXI;AU5U+Y$C$ID*>F,<4Q>T@[IKK;\?\ @_F>9:?\
M1;V'X=Z?X=6&U-GINNMX@CD(;S&G:**(H><;-L2G@9R3S7HFA?MMZ]X;UF74
M'\.Z#?72^*;GQ=;!Y[R&&&\N'1Y!)%%*JW"+L'EB8,8^<$YQ7>^"/A)X1UW6
M]0UQ?#UJE]<^ ](\26>@VNESZM:I<W$OEW<T5DLR22QQJH<1^80GFEB&5<!^
MF_##PFOQ+\6K:^ M862#3])DC34/"MWJ-GHUS,I:XWZ;#<&YCBFPIB8M(8LL
MI4$J0!*I2EI*/].W^9X'=?&WR? %_H(\-:2ML=9GUW1YQ<W(N/#]Q,(U?RF\
MS$HVPQX\X-@KGG-2^//VI+KQMI7B".W\,^'-!U+QG-%/XCU.P\_SM7*2B; 2
M21HX%>8"5UB4!F4= -M5/C]X(_X07XO^*-#^RZ?9_P!F:E+ +>PN7N;6  Y"
M1R2?.R@''S_,,8/(->?FP828]Z9T*G%VDO4]S^$WQ@LO$O[3MS\2_%6K:7H.
MW4'U:^T];.>X76(I RW%E$JAA^]C+1_O65<2$[N*\^\;^,[KXA^-]6U_4-OV
MS6KN2[E4?=C+L2$7_9484>@45AV5OLAQW]*DV,.*"X4U%\R[6^1+),H7:*SK
MN?#FKIBRO-9FJQL#\M!;+EC?!FQ3KZY*"L_3@1-6I-8F:.@.AB_;6,W)K8TM
MS(N:SQIC>=S6UIUOY4.*!(JZI/Y<=9D-]F3ZFM?5[/S86Q6+;V+"6@3-RV3S
M5IWV4+18?+%4SR;!040O"N/2F-&![_A2_:,M[4OFX% R*1=OX5&4XJ5I-QI@
M.:!,:C;#3I;K:OX5&PKKO@_\"]>^/.K7UAH(L5DT^V^TSR7EP((D7.U1NP>2
M>!QZDX%8XK%4</2=>O)1C'=MV2"$92?+%79P]Q<;Z(;<DU>\6>"]5\!>*;C1
M]:L9M/U*U.)(9!U'9E(X93V920?6IK&TS&M:0J1G%3@[IZIK9ARM.S*OEE8\
M5]'?!O6OV;?B'HUKH?BSPWXF\#ZS(HC&MQZL]Q9M)TW.V"8U)[M$RCN0.:^>
M;N+86J&Q:-+N+SUDDMPZF58VVNRYY )Z$C.#7/BL)'$1LY2C;9QDXO\ !I/T
M=T3*-]+GMW[67[$^N?LS:A%>0W,>N>&;V-9[:]@=9'CC?E#($X*D$8D7Y6]C
M@5X/K#F* [@5SZC%?7'P;_X*&>'_  #HFG^%+[P/>R>"[&%X+=O[6>XOK0,<
MG ^16CSDF/<.O!'2OI;X5?M ?"#]J47'A#0M/UB?6KZ#Y9+70[@QV?& \YF9
MXT0=R&R>V:^;_M3-,%1?UJDIJ-WS<RC[O]ZRE%/OJD;<M)64F_DKKUW3_ ^8
M_P!A?QWX@^+_ ,+;3P_>7SWEEX1OGB@:3YGB@949(]_)*JVX!2< $8'%?2/Q
M@^-][X?BTOPXD?D-JDP223' 4?3GW_*NYTC0_"O[/D=MIJ_99YTCWW$L$(BC
MDDZ$C;C//XFN1\0^!HOBWK,VH16UY')9.LL*R+LDD4$<X[ \>_ K\_IT:689
MB\97H^Y-IJ.]GHEVNWKTMJ>]3Q:C",(_#!.TFK7?DO(ZW21'X:T*.Z:6SEM8
MXA(5/"D]\*.OXU@>$M'\1?&?QBTEK;+::7,A6*21_+C1NF0HY=A^E7O%VD:A
M/X=T^TBN!%'YGDKQ^\R7YVCL!GJ?K7H'@F<>#='CMXXU1+=1'M Y7/\ M9Z^
MOO7[14R'#XC#JDGRI=%Z?D?'2S:I1;J4[.<KZOHO\SS/Q=\(-%T/S5OM4U*\
MGM<"7RX_*MT/ID]3[#)H\+^-/!GAB-O[%L9+&]+>3<3E?,9AW^8XPI]  #W!
MK;\;EO%.A72,TGEVL[S0D _.VT\'U')Y[5\Z-:"&:XFU76ETIKI\1G.UH6.
M>O4'(X-?#YCP70QM&5'#SY*RV:5K^3O??OOU5CV<OSBI)<]>\HK=?\!(]L\0
M?M&3:7XBM[73;KN?O)O4^Y]23^%3>.O$S:U/97D=JR17$"W!BQ]UFRK1CZL#
MC_ZU>$:7\*K[3(&NM0\6Z?=1PG<T41_UI_AY!W#/!Z5ZG\4?C9H_P4^".H>*
MKV.2^US3T2VT/2RC/]HNI$RCLH_Y9)@N['C V]6%?E5/AO$8>I'"TXWG-V5[
M:M;\W:W7R/<P>84859U6KQBNBWOM_72Y\H_MQ_':XU'QA=>#])F:WBLXTAUN
MXB;#W<V-QM@PZ11Y 91]Y\YR% KYP.G%5V[5V=,8XJ==4GUC5KBXNKAKB\NI
M7FG=S\\DCDLS'W+$FM(P*8\?K7]!95EM+ 86.&I=%J^[ZM^OX;;(^?Q%>5>H
MZD^OX>7R.H?]H/Q;JOP?M? EYJOVCPU9RI)!#);QM-&J$LD7G;?,\I68L(RV
MT'IT KL]$T"_^,7[+6F>&O"L<>I:OHOB2]U#6-'2YCBN+R*:"W2VN@DC*)4C
M\N:,D9,9?) #9KQV8>6<!:P-<7SV*R*&QTR,UW1IQC?E25W=^;[G-.-TK=#Z
MH^#^B1PR^/(;R\3QU\3]/O-,MUDTU]-UJXCT\6SB5(?[1S#+Y4@AAE:+<55
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MKN%^8G)SJ^)?VIM4U_Q%KE]J?A[PAJMKXJC@;6M-N+.4V>IW$))2\(64/'<
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M/6G@Y4DITW[OXO\ R\NI]R?"OPQ\._%-];S7G@'PO+JEQ)Y(E@.XN!@Y /
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M?LCW5C9W#:U,NB:I!;&^US49E#1^&[$9+1 GC[0R@[AV.%Z*^?F;XL^(]/\
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M[CPE+;Z=! VM7(L[9XWA=<>?(,,$))(.57GBOF,1M/(L:*TDDC!551EF)X
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M>I\X_"">\N_A_INE^'9O MI8ZA+=0^.'U@6YO6A,B&!0L[*K6;1@API)#*>
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M!LM/'9'V_*V/^>:80=RU9_B/X^R>/=$NM)\26[76CRNDD=K"Y@6 IG:$V\*
M"1@<8-?18''8'*J\73;J3NN:2^%+JHK3F?F].J1^=YQE.<\2X2;K15&G9N$'
M;GD^CF[/D7]V.O1LP?BA;_\ "/\ PQ\$V,[O)>-8?:Y#(<F-969T3Z!"O%>T
M?LS_ +/$GAGPVOB2^D\GQ!=0[K:(CG3H7'7'>9U)'/"*V/O$X\Q^';0_&WXV
MPZCJL?EZ'H,'VZYC5-RI#%M6./&>07,:X[C-?4NI_&/P;\./A+<>++W[5J&V
M[>VTRQ9A')K5RRB0EQC*PQA@S'D$L,@\*WY'QQF5?&UY8#".TZK<I);V;?N^
MCUOY>5S];X:R]9;E]*^OLE&*?FDE?\K#_!4NBZYX<\3:5):-);B+SX6'S- 4
M/[PD^G()SQUKSCQ%^S,UUHZW=OMMEMT^T%@-\,B9^Z._/3TK@(/^"@OCJUUF
M9KC^SIM#O&VW.D6T7V6%XB>8U9,$9''.0>XK[0\:_%/0=<^ /AGQAX358]%\
M36?EK;.N6MID?;+$P_O*V0?IGO7YUF&3YIDLHXFE*R=D];KTMW]?D?3X;'0K
MR]A:[EWZ:?\  _S/E?P=\#]4\5ZG/JT<>G6Z6X^15?&0.<]/PKT;X,?LP^)O
MB%K,FM220VFBV+E)[RX'DP1J<;@C'J<=6Z^E>\?"3X.6NKZUI>FR6J2ZE=*L
MDS0L L4(^9BX[#MGKD@5[5JNL>#[SQ3<:+?W^GRR>&XT/]D6TJ.--! *RSQ
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M0K<Z)/M$LMM-;D,L9)'W&^8 'HW/%>OZ#^UK)X3M9KR9K>Y5GPT:JWES*/\
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M[ U\=I936S-'*C1RH2KHPP4(Z@UUG@;]HF3X52M%?:6TUY<I:V%C>6]P85A
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MJ1_,*DNAF(LOI3KCPYJNF^'+/6)M-OHM'U">2VM;YX66WN98\&1$?&&9=RY
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MIF>2,.[/R>%$6 !C.:\M^)]Q#?Q^'+W3+A6OK56T\J[*[,5!SYB8P 5QM4C
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MTKFIU2*?Y8UX.1QTHW+J4.:5V_Z_R_4CTR&2:[FFD6-7N)&D8)&(T!)).%4
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MHW>24=4X^JL^UC<\1ZQ9ZYXFNKJQMUM;60KL01+%DA5#/L7Y4WL"^U>%W8'
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M<JG*HSE?FIV=WR:V7-LW:]O)N_#^/+3PWXIT^WLM4TS3_#]NO""&R2T:!B,
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MO$$D>1UW]Z]NNOVB;GQ1\&]4\;:'XCUKQ)8:WJD&GVVC7D'EQ^%!%ES%L P
M(Y(XU:/.]5W-R,#ZS.,QKX_A_#8JA=RHWI5)*S2BK.%^JW:3_NGY-P_PQ3R7
MC3'97.M#EKN%:C!I_O)MVJJ*2Y;*RE)-K25EOI5U[]G+6O$OB_1[*TTFQT_5
M)+!)-:-FFS3[68N_W/F8 ^7L+*K,-V<>@FU7X2>#_AI?-#JVI-J%XH)D(.R,
M'T"CD_G3[GXB>,)?"JSWFO:+X4LK+#RS3W(V1%P652[<;BH)P V "3@"OGKX
MS#Q!JWBW4+)8;N.YM9#%=.TH=Y2>0Y<<%6!!&WY2"#S7Y[6SZIRJA3J6459O
MJWYL_:<MX/E7KRK8I1@I-NRTBM;V2OLKJRZ)J^ZOZKX@O/!=S;R&'^TEQE4>
MVA=PON00<XK@9HK7[0LEO=QWT); 9 5<>Q4\BO.-+^&6O:*6OH&FBCC4RM.C
MG&T?>8>H7N1TJW=>9#=-)#K"27$BY9R^ Q_E^-=5+-<;A6G7=XRVNGJNZT_'
MJ:UN$\GQ=25/!8A-QWM9V?9V>C\MSZM^%G[./_":Z:)M2O%M8MH(AA(,G/\
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M59$FG6\JPJ?:M?Q=\1)-;\.^%=+G@CMT\*VLUK!+&QWS"6YDN"S>A#2$#'8
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MB_M=.B\CWLRR'+,(U"CC%.,X*<>6-WS-V]G47-[CNI-N\M$G;73P?]G>XNO
M_A?&GZAJUPUU(98XIU7Y3RO'/!XZGUKMM)N+NYN;6^6XNHX)[D_:K>5%/F]
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M5IQ_9]Q$A93;1*(D)49*DA-V" ><TGBK7]"?P;))</Y&L!&:21Y"TDDA*[5
MR<KC<<@#@>HYXGPQK+:VBVLEPODR/\JNP!&?3=W]J^<Q<<3@Z,5)QDIVE:-]
M-+?+^O1?6Y=3PV8U:F*IJ5.='FIWE%*ZNI-KHUHM;K[FFZ/P%\0O\1/&-KX?
MTG[5;7EYF&?RV,1=.K;SQP/?H*]6\4>*-/\ $FKN\WF?\*W^'@QR<)JUT?\
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MT5;[1-#T^5U $(!W*?<@\5Q_ZQ8>^D7^'^9U+)L1'W9V3_KL?"^K>']0U.W
ML;&[O)&X AA9\G\!6Y\-/V4_B)XP9;AM'?2[64_(]^WDEA[*?F_2OO6VN=+\
M/> [>STF&PL[5?E M@J>8?KW_$UP-K<:EXR\3M$LW]EPK*(A/.K*SMQ@(O\
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MFI[@;R\GD_?L2,8)Q@+C[J+P/U/'VWB#P;:?#SP_JFC^9HEK>VJ1P70^_$5
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M#[_PW\(-=\O1+6'2]-,C"6Z<AYF/7!D;D*., '%9?C;]HR_2_P#,BN)&M6)
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M+O?M^GZC;[5+RIG*G+@@JN,@D$ \'V3X2_%^+5]?ACDL+.X\/JF(?(TW;]F
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M$?M?_'WQ%\3I(]8^#$GA[QQI5[:M(IT9H]3U**=2"8Y[(LLD< 3HP4G=P=@
MS]+A,SAEV7JC@6_:3DY3=W%6M91=OB6[UZV/C:W#^(Q^?.OG$(RH4HQC24DI
M>]S<\IJ]^1WLFEO[U[W=_D;Q#YE_J*0WUG.MOYH^T><@/F+GYA@@]03SC-=!
M^T)G]HKP9#8^'[&XEU*\N8Q:VL%@8UM0$!:",!B2K28PN,*%..N*]T\+?!.&
MZ\0277C;5=-DU[4H8-/OO#UM*L4/A_4?+\UT(^9VD9?0X7."3\K5] ?"KX(-
M\$M*FU2U33=)D:']S<11"YDA&]/.4DR#:[)O3*L"A8'!Q@^9CLRS+!X:7MJ7
M+&NKIM/9?RW:^?JG>S1]5A9</9MF,*_UCGK81M<D)JRE))KG2BWIHU9/X6K-
MW1\;^'OV0_#O[//ANXT7Q+?&_P!?GBB-Z;>%9HH)  WD)NXPAX+ 99@>0H%>
M!_M'>#="\4Z@[?VAJT<TRE4NX<!#_OQ],CV(S7T9^T4MM>:].D-]>V<7FR/+
M("[,RDD*C.N&PN=Q(QG;W&0?GOXU:]HNC^.&L[74)-5L(T2&5!*DB+*!\VV4
M 9R?F''1L9)%?/O(<:L.LV56Z;LH+?UU5M+>9^IX'BK#5<Q?#M6E+E4%)R=E
M!Z*R7*W*[NVFVENKWW^9OC9H&N> _#JM9*FJ::R>4LMJLF^(L, /'DG))X*Y
M!)[&OVEN]:F\'?L-?#W0?$%I9Z7KG_"+:+;7.F6[;A97L%L$G3T&W"*P'20.
M,G%?GS\%+WP5'\=?A_J>J7LMCH^G>)-.N=16?#*($N8RYSC& !GD=!7Z(?'K
MX-7FO-;WBSM9PV1,*&[&(O*+EEE+[B!O!W#<PW9'<X'Z#P9BOK*E.HVG&RL_
MZ\NFA_+7TCL&L!5H4,(KPJ*4N]FK)I/KH[ZW>VIS'@CQKKM[IC+Y$$FD7=NL
M-TB0J&*(,%E;J&; # 8#"NYET&ZU+P9#+>:3<:OX;LH9'L;+[4(GLFS@E'*_
M=!8D*P[DC)%<O^S]IS?\)1>:#))%<?,SVUO.T+><S+@@>6[,IP"<9.?Q-=O;
MVFK?">35K-$T6\O;M4M&\R!I$CA8C"N!RNW.0QR0.0/3].C+G@W#=6T[^?D_
M,_ \#6J3POM+7M9?=J]/Q\SBO"-R/&T<5A/??V,]C$8;6$6TDTEVS#.PDKD<
M=> #GD]2#Q=\*O%5E<7'EP1WDFU6:,$*KCD_,4R >>0?Z5=^)'A^^BT66ZN+
M?32UTGVAI[:X9@&Y'F>8^&7D$%>2#[&O5_V;OB-X9U'P3;KJ?@]))%T]K;SE
MFF6UFF*%(5*[0B=?F<N%W.&SN/';BL56C!5Z-_-::/?3U/66(Q%5\\&Z;V=]
MN^BL]_ZW/E7Q%IE]9^'TAU33KR+4))G%K+';LL?7#8;H0&!7T[=:Z;PI\'=2
MU[3HY(K4+90RHDLA!S(Q!' _BY4G KV*[^$=QK]]"^M:7!X?N/"NZUNK2T :
M2X\L>;N,BDAT*^6">#USELD]C^S/^SS)JTT.MRR7UK:V]T42YNGV;'V%@$1M
MR[0>HP 1W)P:Y\5C^7#\TI?UY&\95_8VG)MR?S7RZ6ZGAUCX N/$^OS:#;PW
M-K\\=A-=B,LM@(I \F>P\R0*H!_A5^E?/?Q$\):UJG[1OBC3O#OAO7-4:XN3
MJ%O'!;LTBQ3?/'DI\JG\1T-?I!K/A_3?AG\4+A52\N+ V#37THF*0SW#R$J&
M&/F8X8J,Y SZUYK\0OVFI-);^S]&L;/3K, *PC 9VP, DCDG ZG-?E?%&<35
M:G"EJTF][:NUG?T6Q]SX;Y+.-/$8NH[.;4;^4;MV775I7VT:OI8^1F_9W^+5
MOX<+-X=UQ6DP[07MQ"^1Z88Y!X[\USE_\-/%VF7;+J7AS4-,CP&#R0G:I(Z
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MI.T5TZWLTON=V[>1X1+^S#\5--U;^T;&WT:YE"^7Y1U) SJ>#UP/UKH_@/\
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M%23YBOL.X]ZU/A39W&N:M&MHUPUQNQY.TACCGI7+?\,X>-O"PGELM8;6-/\
MNQ)!;_O I//!SU''?K7<^&-'U+X'^";B^U)?L>J:Y)LB5P-T,0 !('8GI]!3
MS*GE/U=5,#?GTNNEOGUO;;0]6-.7M$I)IOOL?0EYKVC6V@0V\VFV-Q?7$7E7
M%P /FX[GN![UY5K?Q'NO U])9VHLX1G:OV.-44CZC&?_ *U>7>(_CO'IR+;Q
M7"S*F=S9[^F>]8&G_%C1)[&-;BX:>\NL_<?YU)S]T9Z?KQ7)D^2SQ[GSS48Q
M2W\_TTU.F->$6XTU9[W/8;[XM:IKMM]GOHUFADY_>Q@CC\.:W?AO\#?#NHRM
MX@MK&2WOD42&VM,+'(V?O[/X3GKVKB?AOX9M_%5U##<3[A(N^1Y7)6!0,ECC
M[Q [#J<"O5?"WQ"TG1-&NK73HA:V%F"S-G]Y,1_$Q_O'VX':O'JN%)N%/76V
MFS\_0?M'5CRU=5_6QY]XY_93\0:EXUN=:'B"WT>RN"0(O):X;<><<$ ?G7EO
MCS]D/4[W7))M-\?27$C$/)'?6.T,XXXV-P *]W\6?M(MXI\R&QL5\E8]GEHZ
MMMQUSGJ>>F.*\MNO']U?ZONMO/\ W?S2*WR^4.F"3GK[&O3I4\UPEL<H^S3V
M=M'?U[]+_(YY2IU$O:+[V^FG3J<1X+_8,\=:IXN62>;3VL7 )O4;<N,]EZC_
M '<5UGQ<\<0_!WQ9;>%8([Z_AT&UCAC6VA:5YF(R2JH#DEB?QKWKPCXNM="\
M*0C4H)9KJ10?L0E*B->H,C+@\]=HY]?2M?Q5\1+;2_"OVBSFTJQN&3Y8K9%C
M95/OU/YY%<M?,95G^_O*5[M_Y[F,<)"G-^SE[LE;5:WT_KIN?%'B.;XD>,]1
M36K/PEXFA!0B*.33Y!\A]B.I'6F?#V\\7>*O$6EZ/K45S9M).!Y,]NT4@7/S
M$ X.  >G6OH"T^.DU[.WG*[,K$;TEW!_?GFN@^'OQ,_M/Q3ONHH;FU52&6:,
M,T8/&5/4$>U=\<\Q<,/]3;M3VMY/Y?\ #C^I-IJ,W?SM9_Y'EGB;XIFYU9EM
M62UM[<>3!"A^5(Q]U0/UK@/$7[4FFWOCK;J5Q/-:V[+&P7E3M '7H1D=.^*]
M"\2?L%>+-2\4:A?1:]::)I5],\D,LBF2X$3<C8G8G/4D5S%Q_P $]= L(F^U
M:_K]XP7!D1(XE1NYQSD5GE^,HX/$>UJ6DUT>OS[7['3*%>IK222\W;TT.Y\/
M^/= ^(UI"((YFW;56% 55C_,8([<<5ZOJ?C*S^%?A2WTRW58;[4D26Z.?F8'
M[D8_V0#T]2:Y+X.?LWZ3X*\+)=0W]SJ$EF JL%!!' &:X']O#QS-\*M6M[BX
M7;-J"(\1)_U; #@_Y[5MG&:5LUJJ=2R25DEVO]^O4T4>1/V[M:^GFK?IK\KG
M5ZG\9I/#EU>6MK<1KN8-.P.50'CG^58UYXOFOM5A$9A99FXV'G=P<''KFOE^
M#XDS>*)/-M9+N::8A6,4;.I/I_\ KXKTC]GJ]U75O$4?EZ==S26\FSRU@;$8
M_OGC]*ZHT<OHX#DY'*LUN]+/RUV\M;]?+S(XJ-:[BKL^XO@U<Q^'/"-SJVJ1
M11PJ!"$<?ZTL/ND=QZUF^,O'<GCJ>YA@NEMY+=-J$X6-<=!C^E<K\5/'4F@^
M$[*VD'DP6]NLC*1]YV]?TKQF[^+O[^T>51)8R,?,=DRJOVS_ +)]^XKP\OP/
MUW$QP\Y<JOUVO;\^BU/1]FJ*NG[S_!?UK_PQV6J>/KC0;MMTB2'E2R$#]:ZK
MX=>+C##)>+(UR[ D[APP[J?4'UKR'QI8PZE=6L]LL4=O<(0S0(1&Q!P&8].3
MFN\^&_AG6+70[E(H)KB/R]RN@^0 ]OK[5W9QEO\ 9V*=#F4K6=]MU?;6WWBY
M95:GLW_5SQ']IOP-:^+_ !?%KPL]L:S#[+#)GR9@2?W\P'\"E2 I^\1GH.>3
MTSXR/X5TN6VTV%9'<"(7C1*)'8GEE7 5%'09R2>_%8OQCT[XL>*O&.KVK6$N
MA>%=#>:14N'):\?!.]44$N2%55XP!C'>K7[$,EY\9/#\S?V9ITFI:6YNKFVO
MIDAF$<> S;7Y*H<9(!"DC(KP*WMJTU/$-<CDD[/2*;W=K^K/N<OS3#9/AG]6
MIN4XQ;U6LFNG,[7MHO\ -C=2\5:]J5A]LNGNO+DSM:0<O^@R*[K]EK]H2&_U
MRZ^'_C*^W>"?%3+;WL,P,D5C-TAO(QU22)R"2.J;E((-;'[48E\0^*+'1V:*
M/5[IGN+R[2)?)ACD">6J%&*R, I&>%YR #D5\W_$+X,:OX O6U"UU$74.[<&
M.<MWZ>M>[1X:J2JR>'J1G!+W6G\6FMOQ6^IW9+QO/-L!'$8ZA*E*3=XNS<;2
M:33Z-635TFGTT-GXN2ZI\//B3=Z4K))#I\_[E8S^[D3LRXZ@X(R/SJOJ'QW\
M0>.],;1[N^/V&-'\^0C++$-QVE^K<,0-Q/6O5_ -GHO[5?P@MY75K7Q[I9%F
MBC"I?1L<>6X/*EF */TW%E.!@TOP<_8@UWQM/J4'B3PJL-C:R&U"7&JM8FS9
M3\^^) 7=ATP<<UXT<54P].6'@W%/226EVGU7?0^@S+*\MQ&(CC:]*,G#6$FE
M=)[V;Z:[=_-'D7[._B#Q;?0W%CX7T>ZUQO.+'R^!!&.2S%L*../<\"OI'X5?
M#+XF:I933S:/I$4>XQ1-]HCO&D)&#L2/.,<YS@@UU/AO]C_X>_ ;PLVJW'C3
MQ5I,<A,7FPZI)90[B,[411\YZXZTNH?MD>"_AYI,.E^'?[>UMHP(Y[J2,0-.
MH[L[J"[D\EMJ].IZ5OB,\J3I>QT\W;7\S?#X*I77+E].4UL]'R^:N[+\3R3Q
M=^R%\4KOX@0^'KSP6\=OJ' OYHPL-NG(\TN#\JC_ "*[&/\ 9&U;P!X5?P1K
M.O:;K5OKELUM;M8L?+TN\W@0EY7PH+X=?</Z'->J>#?VM--\=V4EQHO@F:XU
M9HC"8[O5YV,PZ\*J#YO0YP.PKS3Q#\8_BEJD-UI<;3:?8^8=L"V<>^(#HOFA
M-W']XG/O7R+QV"B^2$US+?\ X-TM_(]W+89G"JZ<^2CRI)J4DKONN5S=EHUM
M?OT*_P"S=^RKX%\$>)9-!\>ZS=>&/$]K+BZLM9LS!&0,DE6;C=C:0IP>HP>#
M70?$7]DKX5?'/6FL_#OQ4T.WU99U5(YK,PQ%'_YY$L RY(&,<$'@&N'M?^"F
M<OPTUEX_BUX2C^)T=N1;P7%S<?9[ZVVC_GX"F1UP<!6R!Z5Z99_M/?L@_M!Z
M':?V7>:IX!\37!_TBSU!I'M=Q[>>JLG'8L$'KBNK^RX5I?6:<E][3_\ D?Q^
M1Y.:?6J6-Y\0ZJNEK2Y*D$^_*[5.7UCI_,]SRF^_X)_^/OA[J5U9VNDMXFDL
M[HI#<Z?.)E\L8ZH6#KD<@%?H37OO[+7P#G;5UF\5^&S'Y958;9RZR2D?WHUY
MQZER!7-#Q?-\$M8L->TO7-+\4:"X:#24BU)+Q7VMA]\L;,(U0]D(8DX&/F(]
M%^&O[8>L6<3QV+:3IL,^?,DM[1?.!)W$B1]S9SWSFNS \E-\V)W_ !.3,L/F
ME:@_8VG%K26L+]_YM5ULM[K='T-XH\+6'AGP]J.IZUHUQ?+'%!'::9HU@%NX
M<_NV9%#AI<EE<EL",*0,BO OVN[?X;?!+X)^+-:^+&BQ^*O"MB@_LM(P8Y%O
M=D<5O <L<-)(O+J=H0-G/2M32/CAIKW,FFV<4=O<+<R7BJUQM69YF>=L,[<F
M24N!S@$8X'%>?_&3QM\1/B'\>_"?AW3;7Q%??#_58;J76M0NX+6YTZT%W;N(
MFC4Q^6T=L\4<D4<FX[G8@D<C[CFQ."PT7IR55M>_1Z^>_IH?A/U+ YMF$X:^
MUP[MS?#HG&RTO9^[=ZW=VVWN_P JH?'-EXN\97FI:A:V-O!>N\I@TF)8+>!C
MT5$7@*.!CK@=Z[7P]?ZC+\/?[216>*PF 0CJI'.1Z8Z9]:^XOVTOV/?!_P 4
MOV,_$GB2U\&:Q9_$#X5Q+;67B#RX+&X\66EN8_M%W/# HBDB*-*Z':'Q$,'!
MP?@7X4>)_%T&G:HNB:3?:AIOA^U.J:HZV?F0V%J?^6LSG 1&Q@9(W'A<DXKQ
M:M!3A[NI^AX/.G3;5;W;::O1^:.^\2Z/#J26MWI$[6\D(586A CV)@$+M'5?
M:NKMOC!K>E:"T-];6,TBK@39V,WZ=_2N T[7-/\ &NA?VSX=F6&['_'YIRMN
MV>DD7JI].U=!8_"S5?'^G>?<7T=BH'RAQDG\/ZUPX3%8S"M4Z<O=\U<[,9&C
MC*BJ-+\CG]>^)M[XCL7L[V>&.U:0.T<><''09]!]*YF7QA=:/XLT^1;6!O#)
MGA36Y))E;99%U#N(^'5DW,P=,\'OT'JVM?!?PSJ%ZK/JBV\WD1>?#$-Q_P!4
M&RJ_>Y3#=#US7GWC+P]HL5W&=.NX;S2]AANA=IS<QX&5VXY5NG;'Y5V5*TJ]
M7GQ#N_/]#3$4DJ$J5!N+W36]_.Z>CZI:M:;'2^.O@9:_#^_N+.'5&O=TB>9:
MR*H>*.3[C<=2#W'45[I_P3=^"VGWW[7&C:C:Z%-KUKX%TF^\07(15+/+% R6
MZ?.0NYYI$55)&6'8 D>2>"=2U3XE^-M'\*:)X=6X\67EM!8V:@MO^S,HEB0L
MYX58\,9&P @). *_031_@%:_L[? BP^%RFQU.W\<VUQ<>,?$FGZA+I^I&] #
M6XLW5<M!&240;E8'+X.]A7/@\'-UO:*\DM?-M>7XOR/D<VQ33]C4:CS-)N^B
M3\_G:*O=NQT7@_Q%K_P7UZ[T/3]9^%O@WX?S6POM&@AAN5U*PN9FWRV]S"0\
M:E=SY*DC=P!Z96M:LWB#Q$7N/BAX=OV7+"?48V%C<9X*Q.JAE;G'S @5\E_M
M:-KZ7&C:?X;\0/:6&F(EK.FHH;R6[C3 #-*WSM(0#DG[Q.<BO&?$'B76M,=E
MAU*1X=VX1.Y"G]:X\8Y3ES12O\S[[(,AH5*3JMZM;I0;=^M[7_$^I/VH/^">
M.F_$33+CQ''X;;1[VZOUDN_$5I<R:QIFH1E"!@1DM$<XX*@< <9KPW]K+P1\
M._@#\'5\ ^$EU5O$VL7,%UJUYJ%L;>6S@1,K$!C!+D[M@8[>I/05R/A3XQ^-
M=*UA=0\+Z]K6BZO;C+?9;LE;L=U/9^/X7!%?2'A?]KGP+\8/#&CZ#\5])T_0
MYIE2"?5%T16M7N2QQ-,JD"/<I 8*A4X) !/'+3C&<K3F^9=+Z?H;5<GE&K=2
MYK:V5]5Z-R;^3N_Y4CX'A\9S:/(TD$RQ+"HAEBN&V[,\!L^HXYK2\ ^//%JW
M-QI^C23_ &&^#2S((-RQLF29%XRS8)48Z[@.<U]W7?\ P2N\.Z9?WWBEO"UG
MKGAO;YUMJFA7<MY9RX)^5HED8ID=#C&>,"O>/V0?V>?"W@#6]2^//Q,BFT7P
MM:B.'PCH=Y;*EQ<QP#_6O'_"ID4;%/+; QXP#[.!DZ=:^&?+)K5[6CL[^1S9
ME4RVKA_]LIJLHR7+&*YG*HG>,4M?>[I[)-NRN;G[%/[*N@_\$R/V-YO&WQ-F
ML[7QQXFMFE_L^Y82&S$J_P"HVD_/)L(#9R%Z<]3^?_QY_;L\6>#_ !JWB'P'
M<:5::9-*\4FG36L%]:E1P/\ 1Y4:,$8&&"@C  XJO_P5)_X**>+_ -I7XLW%
MC9S21:>SL(+:-1(R1$G;$.#@XY)'6OD+^T-22X5;RVD1%^8F9>,^_>MW'%2D
MJF$BU".S5[ONVUU?Y')]1HT8U:.<QA6Q->RFI).%-*W+3BFFFH]6]W?7=OZK
MB\5ZM^V-HPL?'FN76J6;@'S;D)YUG"6W-%;G;B%&Y!\M1@=,5N?L>>)M:_8O
MUS4O#MCKVB:EX5FG:\T?2]>LY;BQM+IN!*DJL'A!4!6 .Q^K+D9KY\^&WC^W
MT+6;>4(L+!<;1G;@]0/;ZU[+XRL[B/3;>^EC,=M,F'25<>6.0,8Z9P<!L'VK
MS:.-S##XEU(S?+UZVOW9ZV.X6X?S&C'"XNE!1:M&*2BKJVR5OPV.!_:F_:0\
M6:E^TE]JUKQ-HNO:E;VS0PBSTX#2]$9R7-O;HY8;L$%I#ER3R<CCB;'Q&VJ/
M(5D,DMP?,9MOS9]17=:_\"=/^*NF7=TZ+#-" PEB3]Y(!P#QP<<9SS7U[^PS
M_P $\_",>C+JVH1S:]=1H&$UU@;SW*)T49'N?>NRIF$*S<IW<EOUU/E<5E-/
M(TJ<N6-%?"EHE:VEN^I\\>!OA;JOA72(;Z'2=2U[4+JZ@M;:TBAWR6#$EIKA
ME'9%7:AX&]\_PU]1>%?VG]%\"V%OHFK^']2LKI5"[;I&A/ZCFO7O%?@C2_!\
M31Z:L=FJG<P=1DGZUY3XL\6Z/XL#:7K5I#<C<5&_# GU!['Z5G3K0G[W*?,Y
MYC?K=G3DU%+1?KTW.@TCXKZ??SK-9W$D<4GS%';<!6M'\3K8)*RR^9L()5!E
MA7B_C/X62_#_ $Y=6T>66YT<C]Y&6W/:^_NOOU%<98?%)?L-Y"QW,L@.]NG*
M_*/IPW4=S7O\/Y33QN*]G.3Y;-Z;NW3]?1'S4:TE+EDSZ9N/VQM2TY&ACU*\
MGC7Y1NNG&".,=?PKSKQ_\8M6UC0+C7-%UC7+74+<%I88]0FVR#OA=W![UX7X
M^\1W/A)H[P[1#< E8R>"<X_R>_!J[\./$=[<!FF#(+CD;?NT\RROZCBI4;WL
M_P '9K\&8QG'VCA8U+7]JGQ'/)'O\4:TOFG!?[;,=F>I'S=:UO%/QPOI-)Q9
M>+-4,DGS+_Q,)]RD<==W^!_.O&?C;X>OO"GQ1N]+M=-GP'5X5CB++('4,,8Z
M8SBNB\(?!+XA^,(HXH]#^PQR+D379* #\LDU[F5YJL#3E!04E/77TV]".>=Y
M*,+]+V-33_V@?$U]>-:2:UKF,?,1J$YW ]<_/7NGP'^(4?A+X2_$/7+ZTFNE
M7P9JVGQ^7C=!)<6_E*WTR1D#D\5Y/X?_ &/M2\+2K/J6L6*S.<LJAF-?2WPV
MT/3_ (,?"NWL-3,4=YXDN 75U#,L"G(&T^N"V#[5X=E[1-:6U^2_JQG&C/D<
M)Q^+1+NW_EO\C@_A[^WO\1/&/PG^$\EO\+/%&J>.O _B2TUK5]5>W9;3Q/;6
MMK):1[B066X,#QH7VD9B#9/07+#XH'X5WOAJP\(?#?XDVNA6OQ*MOB'K[^))
M+=;MGAR%L[41_)MPQS+(0S$#..:]VT;Q3_PD;+.S:H\+_<^;:JCM]*C\3>.M
M+\-1,K,;B3&7$LVX(*SEG-1NS6VP?V)A4^52;]#S7]DO6KJ\\3_&NPUC2+I5
M^*TDD\?G21R"TB-U+.PGY.[Y'"G&>1Z5WOQ+L/ 6@:_X@UJZT_6KBZU[X6I\
M.9O*NAM2(1(@(7H!\N<CGGI7#:M\9M-M)9IK.&.S:8&'SH,*[JW4<]17E/Q7
M^-.H> [VV;4##?:7J&?(N&'4]U8=F%13QTY:1T=_P[?BRYY;12<OB5NO?37[
MDE]Y[9IWQ6^"OA[X+>)O!N@^#=3T&S\4^'K?2;D):6;NLT!5D>2<@SW"LZC/
MF/A%X5!VY_XW>/\ X>?&OX^0^-;/3;BUU2XM[<7RW:1\2PPI$!&RGE-J#[W/
MTKY?UGXJ+-KXE@F6/<&D"\K$^3]T9Z\<X'0UBR>-+B_L9(YIU6=5,BRQ_P 7
M^>E?28S*,5'"K%*2<&D]&G;UT\[:&%'#T:$E4BM?7O;_ "/N+XU_MK^#/%&N
MMK6K:+XNL_%EU;VJ11+>1KHZ/ 4_>KM^>56VC]VXPISS5WXJ_P#!1_0_B+:7
MG]BZ;K5M=ZU?V=]J,$MO8PVJK!(LI3SHX_/F+,GRER-O?/0_$FF^*I/B+X1F
MT6ZE9V6%I+64C,D4B@E67W[$=P:^:]%_:3\1:'XADAMK>XFFG;R61E;YCG'X
M5P933HSQ%\5\%_>MUW[:Z]32I3HKD;3:V76UK:>FBL?J5\9/V]?!_B30_B9I
M\>F^++6+QI>V^KV;L;<?9+Q%??%(,X\D[E.Y27.#TXKY;\-?&?\ M;5)+"\Q
M?V-QF*>-^OU!['N".AKS%+/Q]XUT9;B'P?K6PDO&%MV(Z8)YY_SWK0^#GPN\
M3>*O%MI:/I-];Z@TH00RQ-&^<X[BGG<<!*N_JGPI6O?=[WUUZ_>$:=2C-0Y9
M)/:]^R77R2(?B%\2-;^"OBZ:UCOBT&W?:S.V/M$#=-ZY_ ^X-1V/[4=OXET\
MO<6S&:$Y!B&Y\C@'CWX]\FOH?XM?L*Z1^T+\84N/$$VI:+X4\ 6$.DO+:L$F
M\03\R2E3_"@=BN\C)"\=<CT/X9^&_!?@"-;'PUX<M8;2R7RHE6V#2G']Z1LL
MQ]R:4,^K8"FJ,5S76J>RO_F=U# NI&<E*T;V76_<^)= ^.UOJWBM53=;7&=H
MC<%>>_!KUWQS_P $\]>^._B+1O%SZY'X;T&^T\76JR/'N>4JVQ?*7O(P'4\<
M9KZJO?!OASQ_-&^H>%=%G\LAFDEM5693_LGK^)J?Q/XYM[?2&T>Y2'R_)BCB
M7[JPQIG:GMG/7UZUX<,=!2<HIIV]1QR])*$VI*Z;Z.R_5['AO@S]D+X9^!+&
M-O[-O-8FCY\^_N&;=[E5(%?2'_!.GX#^ =&_:T\)ZYHWAFSL]7T\WCQWD$LG
MR;[*XC88+8(*NPP1[]J\A\9_%;P[:67DZ?IGV>ZA0B02L68-].U=_P#\$S/&
MFH:G^UWX$CDD;['?)>.J'&5_T"X/..V0<&O0R?+<7BW*O!Z4[-W;VWT7R]",
M9.B\%548)>[+HNS+?P.\7ZA'KO\ 9\L,<L>W)SCD=2<]@/4U7^-WPDTGXF:O
M&UUK6H?8[.1LBRD7YPW;S&7@#IA0?K7.VOB*P\"I)9_;")MI:]FSEI&[1C_9
M7^>:A\,_'H'4GM;98IUO8R$7;\V!QU[9KP<)AJU6K['"Q<F]K=?T^9[DJD8Z
MSUDOEN8WB3X _#&VMQ:2:1J7S?*9#=S%R?7.<?I7.^'/V*?#Y\2-=>'[W4X=
MW)%W^^1!_LGAOSS7JC6_F&%7CDMUF4LI+9 ?&=A!'ISD<=*Z+X?>%KBYU JE
MS)!\IE9W&(T0=2?Z>M:XZAC,!5]ABDXRM>S:>CZZ:#]IAZC4912^5G^!QWQ2
MM[/X+^ FA6>-KMWCB>0#8$0Y.[GL2HYKY_U7QIXB\?W,L/A+3]:U&V^[*]I:
MR3+)CJ 0,<5]QZEHFE^,XH[-M'T_5E1"/.U!-Z-@YSL^[P>1G.*X3QUXKOO!
M5Z+5+B.SAARHA@C$<2X] N!^5<D:U/:,;O\  BM3C4E[)2LU][\_(^4_#E_X
M]\/F2Q;POJEC'AG>\N+1T*Y/)Y')Y_6O2O ^A2^&_#5QX@U:WQ#8@&%)!_K)
M6/!;L<<G'L!7I&G_ !*(NFFO'DDPN5=<*I]>IJC^T=XCU#XP?LZW%KX>M?M&
MK6,Z,(4 'FIDCCCDYKV*V<XO&1AAZS?*METV\NOJ8O"N$>:]TNCLOZ\SRKQ+
M\?X;+2I]L[M),",Y^:1SW'TZU6\%^/K'Q'#NN+II&5MB;FSN.,'CO_G%>6>#
M_P!D3XQ>,-6:XU/0Y-/L57:)[QA;Q1CKA0?F/X#\:U[3X$ZIH'Q&;P38^+O^
M*ZN([>5-/@LG-O\ Z1%+-%&9R<J[1Q,<A2 6 R.<>YPQA:*Q<KP<Y1BY6C9M
M6M=ZM;+YZGAXK.*>#IPQ&+]VG*2BF^LI;+Y]]NY[/H@B\5ZFMG:[/LL!^=XS
M]YC_  #_ #UKUSX/_#:'PUJ@UJ\CC>X5O*TVU8Y6,_Q3N/XL<A0>,Y/85!^R
M9^S#?:?H5K>^*+DV5TG(@6, @=<L3WS_ /KJCXJ^+!\,^.-2\P,;B&5H;:U5
M<[ #@' [8_.O SC%5L5BYUDK<UK);VV7X+?YGL0Q-*492J224=^R\K[>O_!/
M0/'WC/3;4WD6H74TEP4")F3&YSS@C^+Z5\_>*?'OV35]MBRQMR2FTCS%]1V/
MX4NLZ3XA\3^(8M16*90'9Y#-((@^Y2">>>,] /45M1_!YO&WB&P\Z^@M<,J$
MHA;&2!DL<# !]/UKWLOX3IULO=>HW&KK:+LE\TU=W[_Y'@XCB_+:4F_:W?1)
M-_BM/Q+?P8\7:AHOB:&YMVED6[;RWMT'RR;N,8]:[/XB?!+19]/U#4O%UN_B
MQ=.M[B_LM+3#7$PCB9S&">K$#: /_K55\#ZGX)\.Z+JVJW6HZQI,F@K(;BPU
M/R]/U#RD?R_,AB+#<CM\N_/R8.['&?)OCA^V!JU_\-6U#PG96^AZ3>7[:3.D
M0\S5KF!HGW21RB1BRLK $+R&P2R?=KW<H\/,SJ5>6<HPC=*5[M=[7LGMU73;
M4^(S[Q@RFAA[TH2G/E?+\*?9.SNK)]'OUTN>W^%]$T;1O"&@ZAI'AZUT&SU"
MQBO8]+>W19K99!N56VKR<8.1U!!J]H_B>WBU;;!ILEK%,<2&.'RR3]3@9]Z^
M6OV;_P!H'XD>"TCM+OQ%#KV@>3';P:?=2EF@@B3HJ2AB2L:[?DVG=&ZC[N3]
M*^&/%>A^+M*U34FN[?0?^$?G^SZU:W\OD+8/G;O7S,':6^79RP8A>20*K/O#
MFMEDYXM7G3;V@W>*;LDTTVTFTKW;?4YN&?&"&;4X8%VA52M>:5I-+5IIJ*;2
M<K6270POV@?AUJWB]E2WCCM[:'_5O/,N9TQU(7.&'/'3%<!9?L\0?V1</J?B
M+1M/CTZ%;J\)\PM! PR&"D#S,Y PF[!8!L9KW*RN[?XY?!C3M:T9=6T>.2^F
MMXFU>T-I<(L1VF3RFYVD]CS]X'!!KQ/]NJVM;?P-X+\.--:WVEZK?W4\QN9S
M:QO=1)&L*)* QC):4D8&"S+N! XZLDX=RS%8]8"K!QJ:W7,[KE5WM=/1/YV?
MD<'$G%F=83+'FM*KS4U:TE%6:D[+=)JS:^5UYKD-6^+/AWX3>(--\-Z%X=UK
MQ%IMS:O-=R76H"P:>.X*!9(HP"BF/RF.),L/,S@#)KZ'\-_$/0_^$/FU6SU@
M:;I>@Q(]_:ZA$!-IZL#L)5>9=^T@% 69AC&<9_/G3M"\<>,[G0=.U".XDO+&
M=X]M].LEPA&_R[;SF1(V(78I;;DKU. ,?4/[#_PB\8^&M;TO5/'%]-_;4T=Y
M:6D4[J]Q]E$9!D256VLL?F81HL84YXW&OO.(N!<HJ8-)4[3II\KYFVTO><7S
M72O=ZVT>O2Q^8\)^)F?QS)WK<T:TDI*R5F[14DX\K=DHZ7]Y*VC::^@]:\)P
M^+)%ANI[9I9L*(UA1&D)&4'S' W<<MC&>>E?)?QEUOX7>%_&,R:3H]KJK?;&
MT[6-0U"Y>TD\D@C=#''PJLX)67+[C .JFOHOP3<,UW8ZC-=S3-G>^PX!93GD
MD'&XC!)SC.>U>$:O^RS-IWQ5T;RM+TWQ9IMUKZV=Y<J8T:+36#L&E#,-LD<6
M]?F4;PF=WS<?.\)<)Y=2<ZF:4X;>ZKZ--/F3>B;2M;YOII^@^)6;\28&E1IY
M96J-2?O-7=FFG&RULF[]]DNNKI/V:=-UWPK9^/\ P7K]Y+I*3BV:.:&.4!NZ
M[D;<Z@%6$NU582 #Y@P&?\6_!ND>&K&72?%WBZTCU75DB>$6<&V+35=':*:X
M,A7*'"C";B V>N ?8O%5_8_#?0=+A\,7VFS?\(W<2M:0Z<-MI+ P"_965@5D
M14C7+$MO9CP"H8Z/@/X!Z3^U?X\TOQL+6UTZ59XQ>:5]G6]M[N%(7C,4;.!Y
M3Y\K*MG!0-SD@^#E,N'<)F=7#U6HX=7Y.5R;OH[77-IO9Z:V/IJF-X\ED='%
M96W*O[OM5*,$HJ]KVDEY7LW9-WMH?%7PH^%_B3X,_M4:+IMPUOK&H7S1PW=M
MIL@*7UI.N\;@X7"[=L@8@%2%-?:W[;OQ1\2?!3X->$=2F"WFN:DKVD%Q*H98
MX(N!)(PXG;HJ<XQRV2 *]2T+]F&\U/Q6^M>'/"=G'K3QR0W6LWTBM<>6J^6H
M88!8A54\* =N<9)KXY_;,^(^M:3\9+_PFRPZ@WA*T6TU&61R8);C=YLJC<,$
M$LHY Y';%?D6<2G]9J3I7<92=F]-+W3>FKMY:']8<(UXXV6%AB^5SI14JD$T
MW?ELTK-I1YK6N[R25]-3P/7M8\0>)8I-7UJ\D:ZU"4[6FD.YNYY/W0!_",#&
M,"KGA/1X[VRB^U6OVAG?"G!Z>O; ^O6O<OAU!X8^(GP_TV.\M="L+2U!_M>X
MF@:[NK;S'\Q&5<C:%\L()4Y7<P/OX+I7Q ;P+=W%XZ1ZA-= 26ENRL(;<,?1
MOF+#ZXSZU7%'"F+R_ 4,5&I&4JRYN5/572>_S]>]CU^"O%RGQ+C<QR[#X6I1
M^IS<.9JT9>]))1MMI&^NC^S<[+X@ZWK'PO\ L>G:3;K'-=1"5/*):6?CGGV]
M,U>^&_C/QQJ7B/1UUR/48]&-RIDC21&81\[PP^^!P/N D\XP<5'\1?$<?Q'N
MM!F.+?4'M [J"4BC/0J%'0XP<=^:[7P5IGA_,<UQ)<?:U^;YE;\!Z;N *\[A
M;*\OAAZ>,S"'-43O)/R>V]_ZV.;-\\G7PE?!U6J-1J45*R<DVFE)7^]?TSS[
M_@H?X3\/W&A:+JFB+IMLUPLLUW%8)Y\.&C@\MR['>I<A_O\ S@J<KR#7SI\$
MOA0WCO6[>UM_)T^U9BUUJ$R?\>D Y:1O7 X5?XF*CO7W7\1/!MAXH\"WD:V=
MG"UXJ.49&$D\B@\X'KD 9Y.*P? 7[)%[IFG:3#=0S0PWS+>WA88W$J"@Z#Y4
M0]^[,:VSCB3#5<16KX>DH1NE%+;2*7II9[6N</A[A(X'*Z6#QV)E4E!S]^?Q
M2O)ROK=]=FY6VNTC@Y]3C\1K#8Z-:SZ3HFF6HL]/A?F188\XDE/\4CMEF(P"
M7..,5T_A33[RP\/0C)W.23N;YB:Z']H_PI8^!=/6W\/LNTQ*LUR!_K,8.T>G
M\Z\4O_'OB+1((699H[7<?])Q^ZN-IP0C_=;'3"D]#Z5\K1EC,=#VF'3MN]]-
M]7V/TZKCZ->A3C2E&$7I%2=F]EUU;NUW>JOJSZ*^&EK=:UJ$<)G6:1<'R5X9
M!GC)/W1[UZ9JVJP66D:AI>JV.DW5KJULMIJ2K'AKZ)8VB6.5P06"H[*,8X)^
MM>"_LW_$?_A(=.UJ::7R9K=B>7VMLQR<_05KZ/\ $FUNOB+';V\C:XUNXF>T
M2-Y@Z(06W[?X3T)R.O7I7V6197B:THQE>>BT[-K9??;NV?G>8QITY5Z^*DJ<
M8WYMEMKJ_DGKHK7Z'TQJ"V7C_P#9RUSPWI-K_H>HZ%/I=M96[B-=IA:(0 C[
MJX^7(Z"O(?V+OA[X9\#_  _;P[JW@K3UD^(9<:AIVI6SQIJ2VK?N;6=)%)5
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MO+/'?A^+0EDN;F[?IMWMS@]B .^>,?SZUSUW^T>N@Z]Y<"-,PS%<1(<,!D9
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MI:='=G3=.O"+568.ZIYC(4B=/+9I2/NAV0#<<']OX7G0KY31JT=K:[_%K?\
M%WZG\W\<4Z^&SS$8?$+7FTV^%VY?P5NG6YYKX=^(6N^%/"$=]X?_ +*T?7-0
MU9DTFW6*&XDC:.>+<B-*A0$EGDX 7RUZC^+[*_8_\/ZU=^*/!'C_ %+0]35Q
M=--<C6%=5N%\MH[:97=B7F*+)M?!VDAR6W*YYO\ 8[^'&B_M ^&M2CFTSPOK
MFC1VN;G[7:1*UO Q>-(5\[*0LYE8 *XF.Q2R,&&?;O#?B_3;7XF>%O"^G::O
MA_0[>[NM'B35HVC^U&*Y=08I9)R4D=5<>5M\UPH8KAE4].,J1M.B[-<OO7M\
M/*[]5:Z_"QPY;&:J4ZRNI<R<;7OS<RY;:.^N]^MSV#XD7<<WB6[T^ZOI&DC+
M;YYI,L<$XY)_&O)?C/\ #/1?C+\.KSPOJ%TL"^8ESIUR(=TEE>(C 33%@VZ,
M[BNR,+\K$G<RK1XY^(=OJ'BK6M0OEGMUN+EIA$T9$JIGCY.N,8]!63XPUO4=
M?T_[5I/EV\<2[FP5>Y9!C(_NJ<9P.3Q7X5P?E-6$)8[#RM.+]VZ3?1WUZO:_
MKW/ZZXDPM3.*;P$(.:M[R3M':S3>B\TK[I-+0\=^('[,GQ&_X6YX)NO#NA3&
M[:?=>O%<"[TVX194>5$/ 57B+8 Y!C<@ * /HW]HW28OAWXEOM2M5O+/7M0@
M,;JD9N[/2(C L)$R+@.'VYVPE&0,2KCD-Y_X&N-\OVJT=;N^\U;F)KE?-DAE
M"LBNIS]\+(XYR &-?1GCBU\1:KX,\*W\4.GQ2?9Y;;41<1DM.JA?+^;[HQR#
MN!SD8Z5WYMXC8G&1C1P\53E9\S:W5U=6;:LUO?S5[,^1X=\'Z&7S>(Q$G4]Y
M<J3M9V=G=13NGM;K9VNCY&O/%UQXAU>Y@M=0FM])5@+=))A I';C/KD_,3CC
M)S5'P]IVKMK2V6GW#7<>I#R'6RD\QV]5('/M^->]7GP[\-K<K<S>%[2ZG;[[
MVMFK*&[C[P'7VJ]<_%*Q^'>A3-I>CR6MQ#&V%2SCCDB[9SSD?3/TKX/%XO$8
MMKVM?F\N;1>BV^X_4J>6^R7-&A)=VX_FWK]YX_XE^&-_\-7L;.\39>:E,JPV
M,<X:1!W=AR%P,DD]/2N/US]IZZ^']YJ=KX7O+CPYI.J2B2YCTJ589M195V!Y
MI,EY<@8R<+@_*H%<KK/Q9^V6/C#4KF6:3Q=X@M_*DF>Z,R:?8Y7]W$QQAI/F
MW$8X?'7IY#HFFW7CCQ6+&.Z5-R>8T@7AB1PB]L?X5\U0]IB,8Z<6]-$MO5M]
MC]NX<P^$P&$^L8B"G+I=7MYI.^O9]->Y[3X/_:(NK75X]6F^W7'V"0$$7K(Z
ML>F60#:/0]Z^J?"6I_"']J&PMY?B)\/=2\&ZCKP!CUM)99X]1==N'D+ .2P4
M'J<@]"#FOG7X:^)V^&/PE;0M6TEKZ!/M%T5T^PC,FHR21B-5F:3A555^90"&
M!!&&7G%C^(_BSXA#6AX,^'\=SXBU%[*]O[?=*O\ :;0QF)'224F&,1INRL>!
MGKV%>OF^4U,N5&O3J1J*HO>72-ME?O\ -->AYN6\63SW%8K#X[#U,-[!\M.H
MI6YTVKM*Z7+:[5XS3:4;)W<?MG7?^"0_A&;5+/Q5HBWPL%C$D45G<&>)XB>4
M"2*65<<X7H21@5Y-XZ_X)=Z$UVVH6MQXBTJ\27,%M=V.Z-!DX[\I_NG(]*WO
MAO\ \%%[W]A_P3I^G^)-(O-6U[4;;SF\-:=<@I9#)S*\KC"?/N POS8/&!FN
M5U;_ (.2=?@UJ80_"K1UT]6P%N=:=Y2/<K&%S]!7+]7I5FIRDX]U:_W.YX#S
M3B+ XF5*A:K!;2O&+:Z)IWNUUW\GN.\$_L!>*;CQ-<2-IMJRVFT"<RJL-P#T
MV9_B]<XQWKU#X>?L7MXCM5O?LJC['=SVY%MISQ2N\#F-XRTJH<%E(5U#*P^8
M$CFO/;W_ (.1TDT1O+^$=K%?R)P9-7+Q$_00@X_&OE/]I3_@L)\:/VB9YK4^
M*+KPIH,H*_V;H!-@C*>SRJ3,_'&"^/:N>IE&#4O:N7-Y6_X/^8EF>>XZI^^H
M1@_YFT].NB3NWTU27Y?IG:?#R'X3VS:AX@_X1KPG9HNY+<RQ),3T :64C+'C
MH,Y]J\Z^)6HP_%;Q%IMQ\/\ Q7X*\10^$TND\:0PWAN]2@B.U;0Q!<(R[VD5
MY!E5VJ.XK\?7\9W=]=M)/<SSO(?FDED+NWU8G->I?LS_ ![U3X"?$73_ !+H
M,P2ZLPT<UN^?)O;=AB6WD'>-UX/H<$8(!K:6#PM2'(HV7Y>=C:5#&X>:Q/,F
MXO9*R:ZIW;Z=>]F]K/ZZ\>_#^\UJWECDC29%8S;67.?8^U<'\1?$2GX>:U9Z
MC;:MJUY>65M86EB8HS;:<L$S2;C*%!"%6.U4PX)(+$5]L>#?"'AKXV_#[2_&
M'A.\BN=*\1?-;VSL/.@< F6V?_II&?E/KE2!AA7E?QT^"\BZ-=(MKMC\LS*K
MKM;CC_(J<%G>*R6E7PM"$>6LK.Z3[[-I[WV=U;IK<TS7+\FXFQ^!QV,<U+"3
MYX<LY07-=/WDFG=<N\;23^U9-/\ -WQ+X@NM,62Q5;FUC888!C'N'OCK^-=U
M^R_\;V^%7BBZL-/NKVZ76H/(N(DV(PC."P$AR5+;0IXQMR>#@C)^(7P'U#Q?
M\0K?2['S)+W4F,5LFY8P'_AWEB %]3UQT!/%4?#_ .RWXR\'>/O#]MINF_VY
M<>(&F^P7EI+NLKH18#[6(!!4YSN &,8KJR+Z]@J']J86_LX/5M7BF[*S3TUO
ML?8<98OA[.:CX7S-P=2O'FY.:TY15Y<R:M)6Y6[I]'TN?<'@#XSVD.KS2/<6
M<#7CF1HVE::6/T!DQEB.['D]ZY_3_&'A?X3:AJ"V,K7%AJ&JSZE/ EQ)(;V[
MF;?*%9S\B9QG' !X'-8O@K]B;XS3:>K)::7%]H7GS;I(TB_WQU./09KG/B+^
MSC?Z-/J"VNN:=K">'4$5U';. RG"L[\GYMS%AQDC"@XQ7S..SBKB,1.I?1MM
MO:[>NAU<+Y+E5.<</3J+EA%144[V2LE=ZVMHE=^AZ+IWQ:AU<><JVN@V6IWC
MR-'9VZQPAW.9)-@P"[8 ))R3C)-9&K_$^#P3\3;'3]0OI+BPN"DY4$^=Y9=@
M$(7^+Y>>G7CL3XI\=_'9T7PE:Z;8M-YEBF+@M$5".>J8/H#]:\KT/QCJ%A(]
MW?-)N\O]Q+(VY@W4$D\G'O75D&:48X;WZ/-44T[M_9T]VWGZGI9IP/CL16J8
MC#XKV6'=*4%325U-WM44G>UE:RM^6OZ'_#Q['P=^V)X<OK6WLY9-2M]4M8KM
M8RT\$:65Q+Y!D;YB -A. %.5/S;LUX!X%^+%]\3!;W*M-!8PC+3*X:25QQP.
M-H'J.3S7(_L1_$"Y\5?MB^!;:>]NIO)M-5@B!D)38=+NR?RP/R'I65H.OP_#
MCX8:?:6WF27ABWDJ<*@QW[]S[U]]4IX7,,5]=H4^2+?NQ\^6-WIIT/S7A?)<
M9D^&_LK,JZKU8PC>>NJYZK2UN]$UJVSZ/\.^/;6#PI<:;:1R6J^7.J)'/LAF
MWJJDR1C/F,FW*$D;23UK#\=?$:R;P*MCJFUKRU,YO;VXNTA%G;"-3$55G&]B
MP8@*#D @\X!\+\&_$F;4]3MYI)/)<R$+O8A .>I![\_I[UF^.?C'I.M_$^S.
MIWEI#I]G/$C2M&)+=D .XLQ#<CC VG)QTKU(4<-AL3RUX1DZCM[ST3>G,[]E
MTNK^IYG&668BM@.; 5)T_8>^E33YI*%Y<B2_F>SL[.VEKH\?U[QS_;'B#=<W
M VL^5>)MT<BY(R/;K7W1^P3>Z'82M#J94V5U;2)&OS.CDIR71?FV[<_=Y'6O
MC?X[0Z3JGAW1&M[C1]4UMIY#/-IR1I#!; $1AW3#-.#RP90"3G KT3]E^_\
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MNZT3Q,9!IZ(BM,DL(59]Q[ 2' '?K7*^'OV*O!-M-]ML--#3<95Y0R(?H?\
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MHN1MD"GJ" PP#V(_2+2/^+K^'K.ZMY%\5>'=:3SM-O+><&50>-B,V3D'AHI
M2".QK\J?VI])T7X;?$VS3P_9V^D:A?6<-U?:7:3&2#2WV[3$X.0LCXW[48JJ
MLHX)KZ _X)@?&K5KC6_%WA*&^N+*UU326U(1([82XA=!O3!RK-&[!L=0J^E>
M#G66*G.IA*S3E#2ZU3M_7R\SP<ES#Z_A:.98:#C"LD[35G&[M?1W6OWKU/:O
MBM_P3"U;7?%ZWFDVWB+R&GC-U:W.GP31R)NR595E&0!VX)/I7;_L]?L3^-O!
M<=O:Z=\-M%T>UT,LNEZEJM^([RX5Y'9_,2,2%57<0J[L[2 >E?-?[0WC[6_#
M]Q<36?B"\:=R=["Y=9,C^\3@G\:^??%?[67Q*CL)&;Q-X@\J+]VGD:C*I.>G
M1J\=YYC*& EE<*D_8R?PJ23UMUY6];;+1W=TV?7XGPSH8_'PS[$3I/$PBHJ<
MJ;T2OVFDWK\4DY)))-+0_6_XP? #6[;2##JVIV=]:W8'G6RZJFCZ7:QCKN/,
MTG<X .<<D'BOF#]HSQU\(O"VIVW@OP/KFEW6M75KY3Q01,MFTQS\Q<DNX()7
M+[@"%;@9K\EOB9^T!XH\::PUTVJZK-(2=\\]S)-(V/<DX ]*XW4O&6I74UO>
M#4+E=2M6\R&Y\QED#>H;KFO'IY;A^7DC22YNK;G+Y-VM^/D?7Y+D$<N<98G$
M2J<NMHQ5.+?>2;E>W2RC?K<_2?0Y_P#A*?"/B+2_%WA*U\1>+O EL;=8?M4E
MMJ5[:X8B7;C;(T8.!G). /3/S9\8/@E-%X&B\1:/JEGJW@^XG-NM];$I=6TW
M5(;B-N8G(]RIQP2,5A_L]_M]ZMXP\9:3IOC:Y9M4MS!:VVLO(8;RT"G:'23(
MXQ@%6R",<<9K[F_:/_9ID^&6A-\7O#USX;U+0-2TWR=:T9,O9Z^-RKY_&55V
MR&Y7AT]6(JG3C0K<K]W3?HSZ269X>#BJ<[1K.R6MN:RO&S^%N[:VZIW5FOD;
M_@G;J"V7[<W@6.%FG:.UU?S,#.S&DW9Z_45Y=J_[14>KZ?;P^7*LT%L $A3&
M<*./;W)K["_9A_9NCT3]N[P'>VSZQJ%QXATW4+VV:&WCDL;>*73+I%4SQX4J
MI8#( ZCOFO%YOV!M'\$32:3XE\<6=O>Z;M34(-(TR2YDEB."8Q([(C,.F0#@
M]<U])0XE6 IPYXIZM*_R?ZGS4\'#$YI446TW"GLF_M5%TOY'D'@R37?C+J&H
M6MI/_9VDZ39/J&IWI.Y8( ,[1SR['Y0H.23V KT/P%^SC\1OVCM(TN3P[X;F
M.EZ>Z6T<K1?9X(-W/G2/@%CW+<\  =J]K^"7B'3_  GIEYX;\'_#M6@AN,VJ
MW,OG&Y0  2W11#N8D$\L ,X!&*]KTS]ISQII7AV30[B;0;>\GC,,ILK!56T4
MC'!#O@@<< FO#SS/*N*K1JQU?2RT7Z?B>R\CQF'A[.A23EUYGT]%K;[CY&\
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M,U[BO\D>;3PJY^6K)KU;_P _R*O[.EC\.=0NM3UU_AC-HS>'D:57;Q7=S*7
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MA/9RM:W#8^Q/?2Q*;3R\Y\@."4X+BOC?PI^QQKEG$LWVRTE7@22$-N"_3O\
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M]$UI:U^BO\KZ9;0ZSX;\(MJUWIVM:MX\N?*U:););B2UBCN$*Q,1(H:0,%9
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MI6-Y*$@EB#*;*1%1'C)R&R=V3U5F[5T&K^#)/#NIW%O<Q/#.&)96'6M7X?\
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M57AECC2>#@2H1E&!X(^A&>/>LZD*N%G['$Q^_P#X!RU(4ZDO9MV?1GSK>_M
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MXLM[Y>HMY[00D>P;D'\<5Z%:FOBN_DO^">!!Q<O=:^;_ $2?XG7_  F_9_\
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M"M9N_$?DP6-Q-'(0,%2=O_ZA7U6*XPC+%U*\E4JQ:CRJ5E9I:[:*[VT;L<7
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MGAB;:N'$; @[AN!(Q]WK6'??"'PYX@\&R7FK:;-X3UBX+7=C>Z?92/I^HQA
MRI)M9E8EB?NX*XY%>'AZ=.FFMK'[!#-G[!*$D^S7;I\TM#YTLO$TT&E1?VM$
M\D9_<JNSF5,Y!]>.E4-1O8KV=X]-M[TQ2-AMTY,8_,'%;OQJM;S0K=;>XM[B
M.Z=LABA\N5?]A\88'C!4D&N__8 \*Z7JWCSS/&'A^;4M!NY!9PW%Q(T-G'<G
ME%9<CS>ASC(7J1CFM/8U*5ZU*\7V3:1Q.FJ]3FG[S-K]AW]G:ZUC4=8\47VC
MVNJZ/I,+PM]J7SU65T9?W<7!D<!NFX 94X) KTS4?^"=TVN^/I-:M[BU\'^'
M[N'[0HU!_P!XDAR=CH6PC-G)&X[>?85Z5X*^/7P>_9SM]0T?0?[8U*03//.U
MAFZA23NGF,P4' Q\N< <FN2\1_&?7/VA=8@_L_18S=-B+2;20[UA0GF0KSEC
M_>;'L*,9GF-JX-8&:NKW[-^K_K\!97D+H9S/-<+S*3BHV>L8VZI/1/S]>[OZ
M#\'OAS)X0_:>^'NFR0^:MKH4UG$T(\Q9Y)].O+ESD<9VRJ,=\5\Y66A2?!VS
M?5KG3Y%MM-M=EQ&V$>$Y&T@>QX(ZBOOGX3_">;2/%'PX\2>>+G4-*TJ^TSQ1
M&L:HRSQV<V&93D@E%7:3Z$@<L*^5?CIK>O>%KV/PWX:U)=>M;JP%S"$TN&^G
MP26WC<K@D;L;DP 0!U%3&,:>&C).U2,M%NFFE>_RMVU./-,ZQN(S>U-)TW"*
MF]FI1G4V7FVVNG+;RO\ />H_M$V5CXWMFO(9+ZSN)XY4,I"PX'(W=!PQR?YU
M[WX-U;PS\;/A[J]UXB2.UU&206L5Q<7GV>-(@#AH@Y7=NP0N\D ^H.:\R^$?
MP%N/ .CW_C+QQ8:+8QV[B2U'B!#.MN=Q+3R0IQN)(PK_ '>O6O9_V?M;TWXK
M^)]+UJZUCPQXXCT0S7,NJF#;/%*[8CCCCS\BJHQ\P(Z8YYKL4TL2L?6IQJ-1
M<4FKKUM_5SGSC(XYAAO94:\Z4[I\T79V6O*NU^_YGSSXT_9(^)&E3VD$MG#?
MW$]O]OACL)A<;H"W#;E^48_N@DX]17TK^SQ:37_PX\1:/JR;?#=\D%[/%*[(
MUM(G7# ':<$J3@XP..#6I\:?VN->T[6]8T/2?#NER2:;!$DEU+*ZBU>12?W:
M[0)"J@-V'7/ S7@7Q2_;TO/A%X,L+'PG9K<7]PCQ/<2[7C>63/FROD$29#N,
M$$?-7S]'"UG4C3IQUOKVU/LWFDL'E\I8I):)W[-/1Z;:V2\Q\?[*G@KQOXDN
MGN/$NH0RK\MKY<0CBM]QSM$C?+(V>K9 /Z5Z38_##Q'^R-X1U/4)+^^UK388
M1/;J\ 62'@\M@G*=,X/2OF;P]^V!<:D%M?$5H;.!LA#;H$@BSUVJH 7/T%>K
M?#;X\7'A_6+5O[6NM1\.L"CVD(\_)9<#:K' ).#P><=#G%?0TJV)HKV,G9?@
M?(4L1A,6W*E+F;_$]<_9UOM7_: OFU'5-0O+C7=1F6+3-)@4)-=D@;3\PQ'"
M!GGT5CT&:^E/VE_C=IO[%O[)MY:BZ_M;5[F%(WF4[/[0N921Y@[F-1E8Q_=R
MW5ACC_A[<>%_V.9]6\5>,I(F\=>*+2$0VMRFU]%LC&GE6>S.[S90-\V/NJ5C
M[L*^<_VA_P!M_1?'WQ(U*'Q%<6EU!(\+3^8GG,OS(0D:*=R2%0VW&!S@XKU,
MMRZ.(Q"P_.HN5[M]%U^?_#;Z/Q<ZJ8C"X*6:^PE4HT[.,8[U)W]VW>*>M]K+
MF=XV:\%^*'[;=O\ %7X:3Z;?+JTGC*/4/M=A>P7)A2 Y0)M8,#&43S0!L;+2
M(V5V8/KW[.7_  4+U[5+.QT7Q%<#5]6M[9+>Z>6/YIWVX:16Z@D=2N.3FOAG
M4M5TR3Q[J5]I<5U;VBWLCPQS/NF ,C, P/*\8 !)/J3UKVSPA=G0/A%XN^(%
MYI<:ZC#&FFV))*B2YG&U?E_V5RYQC.!ZUX6*C/#UG1@G=RMOUVZ]#TJ,EB*?
MML1"]/E;EM=+=ZKKY[[+9(_2KX%>./#^K> 9)K6:ZETB.$(5N,W3I&2S2B62
M4GS(QN^5&4!57'/&.D\,?%72/$,3372M(NGWZWL-Q-))&LT\9?RYHPI'F)M?
M)W94LV"N5./@'P7^TI_PA7P%T&STM;Y_%R+%]J#P.06#.9&9RQ1HV7RPB*H*
MD'/JTU[^U3XJL? EJ-6\&W4/AB:XEBAO88V@C\UF9W"...6W''3(..A ^@P]
M;"K#5*=6FU4;23OI97OI?6_3[^A^;8K!XC^TJ5?"8M*BHMRCKS<TDK>\EHUM
M+STU3N?<'Q?_ &D_['\'226L_P!EL9,1O(L@\ZX!?RAMA4^8RER$SC;N."17
M@7BS]JG2?A/8B:-?M&O/R!)MFGA]!QE(_HN2/[U>#Z;XRO/$_A35ET/Q)J:Q
M6=C+<V6DW2J[/)O#E%EQNVYW.$SC> <9YK7_ &?M/U"&XC\36-C'>7EM#)&Z
MS,T<D>\8+(Z_,DHYPPY'->?)\J<E:4NG3T6NS\]?(]/_ &>CR**M%Z-[KS=U
MJU9[)I]SI/ .F7'Q[\33>)_$,;WEPS?N(Y/F55]?QKTG6O =O'9;+BSMVC(Y
M0IQCZ5/\(KQ3%=WDEDL'G2/*T4";8T9B3@#LH)X'850^(/Q%M?#B7#3*[,QP
ML:G)8^@]_P#"N"7M*E3EC>[?JV:1J1Y;SW_K1')S_"S2+#4(M1T^UATV[C.<
MQKA6'HR]"#3]6\+1^(K9421M,O+1 MM=JNY8<G[DBC[\.>AZK7$ZW\695F5[
MB.>WAEY0%MWRYZD8XK3\,?%W^S[E&MYEDC7'S,NX5W5L-B<+-*O%J_?L<M2K
M3DG1J?"_P\S7U'XB75DD>A^(K:*QU6UVO&Y7?%/@$!T8<,I!^OXUP'Q&^+FH
MIJD9\S[5)$@0A<MO [G/3H!QV%>VW1\+_'3P-++) L-UIBM)-"IPR*.#+">H
M]TZ'M7&:1\+O#4$ZF'5H;QI> &(SCT/_ ->O5PN;5\-3]GAY6B_31_-:'E\V
M(HQY7>W?^OZ^=SRO1?AIXF^.DKSV6F3-:HV6F9L+TYP3CTZ"O6_A7\*KK3]"
M-IYBM<1NB%,?,N>*](T?Q!H_@?1\+=PPI'&4CMXF4GIZ#I6/;>,X/!NEZCK4
MV^W:Z0BT61=K2,>-Z@^G;U//05Y.)KNK)RJ.[?S9W9?0E.?._4\_T_3?'WCS
MXO:U'H5YIMC8Z1/Y*M&JKO4' !./F)VY.:Z#Q+<?%CPI9LSZPUU&HPT;QHZ,
M/0XK:^ ^D*MI?2;O(-R5E8CJ3SBM7XE^(Y--LS'NWY&/]HURU,;54U&+T.[$
M4E6O43/G3Q!:)\9[^YTOQ$;C2]4F!:"3):)I<84 '[N3CGI5S]FCQ)<>#(-2
M\,^(KE;'5+.5K?#_ "[UYPPSUZ5TOB&>#5RLD\$2W$1RK \_2L3]I/PS9^,[
M+0]3T^\ATWQ+;62.QF_U=V <88]588ZUW4:W/*TOZ9SSJ3G2O%7E#MV\_P"O
MU.R\7_M07G@S0UTNX'VJWA3RUEA("LA_A*]1CD_4UYKXO^+FF^(=,%QILV-0
MDD"E2A5BI]?IZ<X]:K_#CX.:U\5;/=J5YIJE#]V*Z$A->\? K]GS1?!,[F^M
M[6ZN-IW22(&6-/09X'N:^BKY]7GAI8>O%2NK>GGZ]CSYXZ=:'*>0^ K&XO-0
MMVN2\FX\MCN.E:?CF$Z_\0IM%USPC?:II=C<*]G<7%N6C0LHW%'X.TGMR*[?
MQ9>Z7X9URXU2U@AFTNS9ML8X\Z3^%4'<GC\,UO?L5^)[&?X\_P!H>*I8=2O=
M2M+AY([H^9':C 9413P".G%?,4ZRHMRM=]KV/4P^!OA7.K\/:U[OR-CP5\%/
M %WX?@6\LM)L_E#*HF"E3[C.:Z#Q?/H]CHB65F=+DC5=BJ]X@7 &  ,UN?$7
MP5H/B'Q9<7 L+-?-X39$H&W\*\1^.G[-7AO6=*FFCAN-/NQRLEM(57\5Z4YX
MR$K.UOF<-+"1ISYFK^6QS?C?XY:5^S+X>UC43<6\FM:I#MMXH&^2UC;J0?[S
M>W:O /A)XSB^)/C&\U)I3-/,WFMSU->E6GP<T;Q!IBZ=XJ1K[38U\F.Z1MLU
MKGH6'=0?P^E>.?$SX?3_ +*GQ"AFMK=7TBYY@N(V*I,O\@?:NRC&,XO74TQE
M:2A%P5HK==;_ .2OIZ^I[1=>*Y=.C8KI[RJ@^\N.?H*M^'OB?9WB-&T8CEC.
M"C_*PKS*Q^.MC>Q">!&>-A\T+M_JR1V[$'N#^=9>I?$"'Q#<6^V/[/+&>64=
M0.Q/>O8K8'+987GA-J=M4^_I;\=CG^M0:]T]]U2ZT?Q?I2M/%#=0L0D@/WAZ
M?CZ'U^M>'?%*74/@-XMMEMYO^)/=,7LY2<*0>2I]Q6YX(:Z@L+B8/N2=C\A;
MT[UW$NF0>(_!>GKK5BU]83W#6Y#P"X0$*&7Y>N[)P"OK7SM'W9N+>AV4Z,L7
M1=);K5;O7MIKJ>53?&_4/%7[^UO6MV4#<R'Y7QTXKZC_ .".'P]U+4OV[?A[
MXJNEFDC5M27S)%ZYTVZ7/T).*I?#+]GCPZMK#)_PKW4KCRQNS-;BUCSVX/)_
M*OIS]@?QM967[6W@_1/^$1U[1;BX%XL4SJC6J;;*=L%ATR%('3G%=E/'2G*%
M!3;46K)O1:K8X,=EE>.&G*H]D^J[>IYA\:?VHO&'QM\%Q_\ "I?&%CX7UR*,
M_:--NK6,7-W_ -<[AL[& [%1GU%?*=O9>,_'[PQZY%KFI>(K2X=-1>]+-<X)
MW MNY[D#VQCBOH0>"=/^(.IR7US8K:WD9XN(QMD)_P!H#[P^OYUV'C30+RR^
M!FI:@K0C4-',<<5^\/FR6P<[5R>K*&(.&XQFN6.,=1*C-:MK7S/3^H1I1<H:
M:6:O?[KZKT;?J>(^!_ ]YI^HKI]Y#<"&=ALYQ@^A%?5MO\0_"?[(/A3P?=>+
MK'4KJW\57+6D<MJJ$6H386DD!.64!L@*"3@XKR3]F'XP>+-;U^/3O''@"UFC
MLY?*.J/-]F1L?QJ7^^I'.5]:](_X*N2V3:#\#6T%;/[0-<D:%7;]R7_T?8&(
M_AW=3Z9K[G@O+U7S&&"KOW)\U[.VT9-:]-C\I\0L\QF59-6QF#=IQY;-JZUG
M%/3KHV>W?LY_MA>"/B5\?_\ A7NK>"_%?@KQ!<0&[TN+7[58?[2C"EP=N=R%
MD!8 Y!"L,Y&*Q_'G_!6#P?9:QK$VA^!_&_B'P;X9NA8ZEXET^S3^S[=]VW*Y
M/*YZ$E<\$#D9XFZ\'?%']H_]O?0_B3XD\ W'@'1? ^G/IY\V]CNS=2;9US$R
MXWJ6G8@@8"J,G)Q7@NC_ +(GCSX5:-KG@^Z^&OBCQHFH79?3=0TWQ3)8Z/<P
MM@?Z1"K $D*"2VU@>#D 5]GA>'>'W5O4Y5+D@W!5(M)MR4[3<DFU%1=N9VN]
M&M#\JQG%7%D*-Z*ER^TJI5'1FI-1C%T[TU"32E)RC?E5^5*\7J>[?M#?&-_%
M?_!0;]G'4/#^NWS^&_$%G#=HMO<R1V]Y&\TA4O&" 3C (89&,=J[KX^?M_>'
M_!?Q#\1>'[7P'XP\;'P?$)M?O=-M%^S:4I&26=NH'=N%R#@G!->._&W]GOQI
M\-OB1\"O$G@_P+=:Y9?#W3TMKK2;'4!.UK*)FE,?G2 ,R?O& D*X^7D#BI/C
M'X)^.?QC^+?CC1]7\/\ C6\\/ZM:&T\-1:/K<6F:+;;EP'OG'S3JH8[D/+-N
M&-I&-Z66Y1BH8?VTHNG"G):U(Q>E5[I/5\K3W2ZIM*SF>;9W@I8QT(3C6J58
M.\:4IQLZ$=FU91YXM?#*5]&HMW7K7CK]KWX8^"?@'X4^)']CZEJWASQ9?BPB
M6%$CFLY 'W^:K-@;#&P.TGID9!K1F_;=^']K\!_%'C'7/"?BKP]H.CWL%AHK
MW]CY5QXE>56>)[5&Q\I5"VYC@+R3VKYKUS]E#XL>+O\ @GMX9\!Q?#?7H]>\
M*^,)KF:)W@_TJWDCF8S)\X&Q6<)UY/(XKZG_ ."GO[,GB+]IK]G70['PM'%-
MKWA:^BU&'3GE$(NT$)B>-&) 5QD$9('!&02*\RIDV04*]+#U))J=6<7-33Y8
M1DN5NVGO)VN[):O=:>C1XDXKQ.&KXJC%ITZ-.2@Z;7-4E%\Z5[/W)*_*KMNR
MO9ZYGP0_:\\(_%OXGV?@7Q7X!\2^ O$NJ6GV[2X?$%J(QJ4(!;*-P0=JL1D8
M.TC.1BL+6O\ @J!\-?"NJZP?#_P]\9>(O"GANY%IJ?B33;2/[% Y;&1N(+*3
MT+%<\$<$9Y+]F;]GC5O%W[1&@^(/$'PA\8>%;/P[9R9U?Q)XVN-0N8;ED==M
MO$Q(DC)<_*0 ,EBV<*?.-%^ GQD^ ?P/^('P;L?AK<^)[?Q7>N;'Q):7T:VB
MPN$0LZL>#MC4C<5*DG.0!79')<A>)E!*-[4_==2*2O)J<E)3E?EBD^5ROJ]&
MK(X)<2<4QP<:C<K-U??C1G*3<81=.+@X1LI3<DY*-FDE=.[/J#XZ?\%&?!WP
M>L_ ]U;I<:EH/Q M)+RPU.SC\S[/$FT?/&Q#!R6"[5!.X$5R_BG]NGPSH'P@
MT?7_ !%X)\86.M>(M2FT_3/#US:_\3;470H#+L.-JDNH&<G) &:\G\7?L9>-
MO"E_^S;I-CH\VO0^ [GS==N[9D-O:%KR*=_O$%E7Y\$ Y"9KT[_@I9^RUXJ^
M,NM^!_&WA73;CQ#-X1N)$O\ 2;:_-E=W4#R(^Z"7(*N-A7*G<-P(!P17#2RK
MAYUL/0;34W4;GSI:1E-036BCSKENVUIM:]SU:F><6+#XS%PBU*FJ2C#V;>LX
MTW4:>KE[-N=DD];WYK)%[X2_M6^"_'C^,-/U+P;X@\*^*_!NFRZM?:'J\(CN
MI;>--[&,YP3C;PP'WP>1S7&ZC_P4J\ W7@.Q\26_P]\=7'A^XE%OJ&H16R&V
MTF4L0L3OG9)(5P^U2,!E&<G%8OP@_9_OTL_BEXXU+X;Z]X+AA\(:C9V%YK_B
MJ;5-2NMULP>-HVR"H"\,=NW  #<D>6_ S3/BI\4O^"<J_#GPC\-Y/$6E^+-9
MD:'7H+Z-4LO+G1Y(YHVP4;>@Q(3MV-W(Q7MX/(\IC*<Z:7*ITU*]2*45*+<[
M24I)\MKI<S>ZUZ^+B.->):4(4W-JI*G6E&U&4I3<)15.\7"+CS7Y7+E4;--6
M;37UM??!S3O%EOI^L:.%U#3-8@2]M+F*/Y9HI%#JP';(.<=JZ>U\5V?PE\/-
MH]G:127[1[KIU/$:N"%3C^(C)]ASW%;&C^)-%_9#_9O\-^%]2U.QN=6\,^'X
MK0QB4;KJ6*(;]B_>*[L]N@KYUTWQM>>)-#MKZ29EN-6=[V8L/FW.>./90 !V
M%?@&>1A2Q4W2?,N9V;ZJ_P 7K^I_4'#,ZV,PD)8V/+HG)7ZVU7HGN8GQ/^".
MEZIH<MUH[7GAV\4962RF*J#G/S+_ !#KGG/-> :-\2O%GPI\8-9ZEJNI=QLE
MG:2.X4\9P>H-?1_B+6I8=&\^%[B\ACRLA5=V"/O#KV_I7D-_;:;\7=6:WN&5
MMA_T>=#\T1/^>AKGC3Q=&"JUXR49:IM-7]'U/;QE/[4?NZ?=L=AX(L[B;39[
MNWC_ '5Q)YR\_+C:, =>G3'458?Q-:V\4UKJ1>/@KGH2:T/AQ8R?#337LWD6
M:+@LQY5P!Z?Y-7_B/X)TOX@>#I;C3]POMP/R'D$_YS[UQRBI2YC'$2K<JG;W
M7^'EY'%^&K^/5+!M.O'62Q+^6%D^Y,F<AE_PYYJQHGP=MWU2Z73U9;6-QLV9
M.. >O&><]!BJG@#X)W6KZU;^=J$S1VYV="&B)ZC_ !KZX^$GPNT[0+$BZDCO
MO,&[#IW/O7UF<\1SS' 0P:A^\33<NEDFO76_^6YS8C'*5-*70\B^%GP=BO\
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MG=7=O\V[]&K)>:;-[Q'+IOAO]G'7(M#N/#>DZI,/L^BW5[,BP+>W'EI',,Q
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MB\5CJLY5Y.\E:W1*][)=OZW/CW1? 7]I6ICDC#$]B.M>\_LX^#HOV,O#-O\
M%_4(4/B+4/,M_ FBR']W<RCY)=5N$[VT&2L:G_6S?[*$UU'[-_P"TJ\TR_\
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MN[--07[1:J/,GB896;:1@$<YQG=@\$@"O8_V(OB=:>/OVUO![*L?VD&]&YF
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MT_7(98V$N=J72!@3$Y_A##C=V[\4Z=.G=*LVH]U_P>A,7@Y*])-2[/\ *_\
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MJM(0P-=52:9/L</-<ZIM?._X:?F>M?$:^O-;\+7*7VFW:76/W<3H?]']2S=
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M0?&:PMO[8\/W&GWT2!M\J;89F]48\\]:^BM3\90:/8*6BMH_+^9U27S&(Z]
M*_.7X;>-=6LYO,COKA79L$AJ[K4O&NK7^F_O=0N6W'GYL9_*O1J5KR=H_C_P
M#GCE>'DTW)WZZ?\ VUOP/I7XG_MF:I>Z/?:/I_AE?[(FADMYM36?YXCL.,Q
M9 /3.<<UX3X1^+]Y=Z/9JLC-Y8^?'& ">GH.:[?X 6<=]I]Y',ID6XM)%D#,
M?G!0]:\Q^%6@VC1LQASYD3ELL<$@^F:YI152ZM:W]=3KQ6'C@Z<71;M+76WZ
M'J>K_%7[=H=I:RWTK6$J?Z2D9*/)S]TGTQ^=;'@+Q;H.F-/=-(K2*X\F)7)!
M'91SVXR>G%>%:E>RZ?=W4$+E(DD^5>N/SKVO]D_PMI_B7Q58QW]K'=)N&5<G
M!KZ+*>)7E6']G2I1;[[:]VNOWK0Y\+BY)V[]37FT"_\ '6J->3+NM\@1G:5"
MJ.@)'4^_?VKT[PB;/X7>'I]4U*-4TG25\Z[\X?)(,?= /!SG&*^G] T6SM=)
MMX8[2UCB& $6)0H'TQ7R[_P5LO9-.^%-K;6[>3!</F1$ 4/CIGZ9KQL92JXB
MH\5B)7<G=^KU+P^8*<^6*UUU/GKX;?MMW$'C.^2&V,F@M<O)%%(PW*I8D >@
M'3 Z"O4-1_;WL[1E:RT':C8##[05R??'./QKYE^(WA+3?"WPZ\-WFGVJ6MS>
M6BM,Z$_O"5!).3C/-<,-6N1]G3SFVL"3^5/#8>6(JJ%-V<N^WZG/4?+/6*OI
MW_'S\SZ.^*7[7LGC_4K5/+6UBW^68=V5P>"1[C-6] \':[I^@1PQQS+!;NWE
M/L+*1][GWP<\UXO\&--@UC6H'NHQ,V"WS'O7VQ\";^:>\LXGD+1S699U/\14
M@+^0)%<N(@^:TGL_^ =4<0_J\Y1BKQU_I]?F>+V^C#6+:*:2X/VJU!$A;[AY
MR,>AY/\ D54T+QFTWB62VF6&:XC)"R#=)@'H"./7ZUW_ .TQX8L=)NDFM;<6
MTEP7,IB9D#D=,@'%<[^RGX1T[5?&"_:+<3!ITR&=OF^O/->A@\ZQF$I>RHRM
M;;1?JCCI8B<]V3Z=\/YO$_B+>UGC[4^3Y<955)[ 5[?\-OV9I-#U&"XO(9((
MYL")#PS'U'< 5[MX:TNVM-0BABMX8XEX"J@  K2U=R/$MW_TQT^1TX^ZVSK7
MD7G6J7F_B>OJWJSGEC%&[BMDV?%?[1G[0)^&/CJ;28;2#5[)&!$3CF'CG!]2
M>?QKF-,_:\U"[>,VGAV.UVC[TDV0/H,5P_Q(F;5?B5JTMPWG2?:Y!EO8G%6=
M&@C_ +,F;8NX=#CD5U3DK:(TIXE1E[RO^KZL[S4_VL_$>N7$=KM@MX6=0VR-
MG8#(R 6)'XX[U;^)/A+7O&.J3:EJ$,C+?8>-VZ;<< ?05Q'A*VCN-5M=Z[OG
M!Y_"OM#P]80ZIX,6&XC2:);?>JL/NG'4>E*3Z(RK8E5(-Q5K-?B?-O@GX02)
M:I]D82+)'O92/F0]\U=7P+8W\#6NJ>3"+=BG.%9@3D'WY],UT^I2MHOBJ06K
M-"/1354 :GK2K< 2AP2P8=:ZLGS*6$K.;7,I+5;?B<T*CC(Y6Z^!>GV06&QF
MA=]V1L?.X'/'-/TW]G5KF5Y9H]RQQLY!7@X']*^K?AKX#T9/"%C/_9MKYSQA
MBY3+$FL;Q)8PVT&L+'&J+':/M [5MCL='$8E2IPY5I\_/H%2:E%VZ'SW^T;>
M_#OXU>*O@CX>\1>(M4TG0_"OAV:QURYLK)VFM9MD1C50R'(9D(+*&Q^.1\\>
M -!TOX=_M%^%=:>>X;P[X?\ $UM>?;)(")6M(;E6$IC7)W&-0Q49.>*]>^*.
MEV__  L"4^4ORI&![#:*PM>TRW8MF)>:*V+?M-NIY\<-&,>6[M;\]?U._P!;
M^-/P)^"/[:GC/]H_3?&/B+QIXKU*TFCTGPO;:!-9Q0SR6\<),EQ)@,NV/&<+
M@.3AB *\[^!G[2GA2W_9P_9[TG6=3GC\1>"?BK+XQ\0PQV$S):VTD][*SJP4
MA_\ 7I\JDMSTX-<+XCT.TD>XW0)\O3_Q[_"K'@3P_9&U;_1X^OI7I5JE2BHR
ME;WE?3S.=Y=%)7;_ *T_4]>^"'[5%CX6_P""I?C3X@7EQJFN>"?%\EU865RT
M<DCV4,BQ"-TB?!"CR@I4 ':>AQ@]%\0?VD-'^!/B7X9:;HFI:7XMT'PEXN;Q
M#J.G:'X'70+6U4QS1;XMTA+7&)V8@#:[#)*\ \;\+/#&G_VUI[?98\K,I'YU
MZ1\<O!NEV]_?.EE"K?(<@=R.:PCC).+:Z,TJ9;"T6WTM]UO\SR7]J?X6_#WQ
MMX5^(GB7PO\ %;XBZY>^/?$']N?V$EK-9:;;;F!9;P/_ *UD&0C+@C:@QW&S
M_P %']3\!_M.6F@^-?#_ (BU*XURUTBTTJ;P[+IDL?V<1&1GE,Y^0L"X7:,Y
MZ[JI6EC"- U2'RU\IEY7'6N1\'VZW>N0VT@WPR2*&4GKEL'W[5ZV6XZG*C5<
MXZQ3>G5-6MJ%'!J,M6]/3_(ZS]GO7_!_CW]B&^^#/C#Q'K7P^N;?Q,GB*VUB
MSTV2]CNE!5O*=8SN#@@X)XXC/."*[KX%?%WP3X&O_C%X-U#6_$VL>'?B#):3
M:9XH\;:.==:XDB7:T5W; JTD6?\ 5@XXSD*<"NZT#X?:)9V4BQZ9:(N#T2N9
MN_#UC_PG]M']EA\NWAD>-=O"LJD@_A7S]/'S<HQ2\@J8&#N[NV_Z]O(K_P##
M;O@7X9?MI6G_  E'B^:?PK#X!G\)VNHVOADV-O82/)$^!;QL\AAQ'A20-N=O
M(^<^*_$3X\_#W4_^"<^@_#OP[XONF\6_#?7KN33(9]!F1?$,#SS*DRDG;;JT
M4OF89BP*E2,D&O'?B!;QZS\3]5FNE6:7[0XW-V .!4>J:3;)"VV%%P.,#I77
M5QKZ(G^S8PDK/5?FOD>H?L6_'OPE8_LN_''X<_$SQ)>:'=>.EM9M.N_[+DOH
M7$0RT6R/HQ95'S$##9SQBOJ3X7?$#4/AM_P3TL_'7BK1]9T#QW\/=)O_  3X
M=;4K=X);M;SR/(E3> S>4BXR!C$3U^?6G:?"]M+F-?7/OFO5?"OQ6\4?&":W
MMO%7B+7/$5OI9V6D>HWTERMN.GRAB<''&>N*%C'"-[=#2&7JM/D;T;N_NMIZ
M^9[U^R5\9?A7<_L^^$/#GQ(\9:?XLTGPK!,(]$U3PG+)JFF3$ML_L_4('4H.
M5&YLOQ]Y> N/X=^(_@SPU\!/@GX9T'7O$/A>\^'WCR_U\M#9&\O-,L99;TQ9
M,@\N=C'.B,,L2&8X8CGY3^.L"^"/BI&VDC[#]KE)F$1PLAVKU'3O7J7PIN&U
M6VA-QMEW8SE153Q;@EH*63Q;E:6S/J#]HJ3X9?'#X;M#I-QINL^/K[4UOIM:
MTC0I]$@E49!>ZB=RLLI!(W<G)R-HSG ^"'@Z^\':3XAL=0C-O&VFNQ8CY7"X
MY!Z8J3X5Z3;RVL;M"I;.,U=^,/B&\M='U&&.X:.-;)D"J /E/45YN+Q#<E)'
MHY5A7&]*+TUW/ ;GPXK2R+$C-YF G!/?'Y50UKX+7]Q'-))N5%.UGVX4MZ#W
M_&O0/AG&M[>Z?YRK(&VA@PR&!Z@BKOC&YDM-<O+>-F$,,PC13\VT;3Z]^!SU
MKZ3A7"X7$3G3K0YI=WM;_,UI1BY<LD?-/B#X67'AS4TFNE/V=^CA3@$]CZ&K
MWA6Z_L"_CD@/?C^HKVK6XEU+2IEN$28-&2=R@\G%>)PPJMJL@'SEB":SXGRF
MG@Y1]CM.^G9JWX:D5**C421]&2W%K\5?A]%K$DODZKH\2V=U*1N,D)/R,?7'
M3\/>N#\3>#O$VGVHFL1:ZC82?=EA^8?0CJ/H:Z+]FT_:M%UF*3$D<T"1NC#*
MLI8 @C\:\W^$?BK4H8]7C6^N-EK/*D8+DX4.0 ?7CUS7S<8N4+_RG1+"ZJSU
M>IB^)-'\32S%6T-59N1*G'\ZXJ\^ _C3QCJ31K&;9)>KRR@1@>_7]!7U)X=N
M&U;2)&N,2LR8.0*WO ND6L=BD8A7:PY!YJO9I>\<,K\UF?.&B?LE2_"^WM+^
M2=;Z:;F2-(MFWWSGI^'->@:S\5['X,?#* 6_ES3ZQ>!&28J?)5%.YD'\0!(!
M]<UN?%[4[B"T:-)659)1$0/[O3%?&_Q.U2XUCQ5JS74TDWV.9[: ,?EAC4\*
MHZ ?SKGY6ZG-V/>R_#QE!SG\*Z+J?0-OX_T7X@1EK>PTZ.^SCY"(]Y]<-_C7
M3Z5XN7X;Z(US-83JRC(=Y$V#Z8)-?#_]L75M"/+GD3C^$XJ>W^*7B!-'N8_[
M6NFC53@,0V/S%:\L]DPIK+ZLW[LH^C3_ ,CZ'\9?&S4O%MQ,-+M&6,']Y=N=
M@C!/.PGHQYY//I7%WVA-?ZD+?3X_W=[,SLN.<D\D^XKSSX8ZS=>)?%&GVE],
M]S;27$;-&WW20PYQ7N<MO'HOQ1U5;55B6UNR\0Z["=IXS]3QTK>5-1@G'Y^8
M1I_N)R@].GIM_D9]MX;D\/V7V&^TV1(X0 DL<.]I<G.3CGDG-=)IW@71=#M_
M,989]453(&)^:'I\H![[3STZU-KNNWAN[2;SW,C!&9CR6).>?7GUKSSQUXQU
M*;7)&:Z8LI(!VKD?I7JT^)JCA["O34E:V]KKST?Z'EQQ3BM5<L>*/%&D>(]3
M6WCMXX=0M6V%QC)]C7LMMXIC\._LS>(++5+&35--MO*N-@^_!&YV.0.^"4..
M/6OEKP3_ ,3+X@B2?]Y(S\D]^:^Q-6TV&U_9/\67$<>V9]#D)?)SR!7@.3IS
MBU_5S3!Q]LW3E]K_ (<\:^$/CKP_IEPDUOI:!E&=_P!]@N>"%8@C\J]*N_VG
M-$T,*L=Q"MPX.U[B5(U7'7OG\*^(?".N7D>IS[;B3]W]WGI5RZNY+[S&E8.V
MX\E171.%V=_]EX-ZQ<KKTM_F?47C7QCK.KQK':K=#^U+=YOM4<38AC)*EHSC
MYF/(W'@ \5Y;'X*N+6ZM;:.QFM[6-AM4H1D9ZGUSZU[+^QWX@O+KX(WTDEP\
MDFAZA MBS8+6ZR<.H/=6_NG(]JZW]HWP_9^'_'-K]BMX[87<(DE"<*S>H'0?
MABN>M'D::ZG)BW:*C':_Z)_K]Y%X<MH?#WA2/[/'YTLB*-F,%FQP/P_QJEX@
M-XNESR0R222VZ[FV, I8#. /_P!=&F.9TM6?YC# \B<?=8'@_6H9)&D 5F;;
M<8\SG[V<@U]WPQE-"I0]M52DY-[I.R6EM?0]",DJ%T?.OQG^(%QX@A^RWC*U
MSG&_;@X[5Z-^QGXRA\/WRV.J%9-'U1/LER'&Y4#<9(] <'\_6O ?C3.R^-FV
MG:/-88 ]*]0^":[=*7ZYKY#,I1C4E[-62D[>2OH?/T*C]K>6JZ^AT_Q__9CU
MCX0>.+B'P[<,VCW,N];0R96#/89_AYR".U6?#?P4AOK=/[9F7<.3'&0-WU/^
M%>>_M?\ Q$URT^+<-JFJ7GV=M*M',9?<H.W&0#TX Z5VGPXTJWUK0(9[J/SI
MFFC0L6(.".>E;2PSJ0556UU+C@U[5T^9Z.VW_!.IUSPM8^&K""/2;>VC:$[F
M=.6/MFJ/Q8\>N?AG=6\WDKJ&J)L* <K%TW-]2,#Z&NAL] M=.UI[2&-UMV0L
M4,K-S^)KY_\ %NO7>KG49KB9I)3J#QYP%^5.%&!Q@ <"O-E3YI6/H\+A7A(R
MK-WLFUZ]"K\-/!&GZ+J"7]U:QWEG:',L4IPLF>Q_#GV.*^VO^"7=EX"E_;S^
M']YX7U34+6ZD6_+:<6=X9<Z==94Y^Z5Z]>U?)OA2QAU'PI'YT:R?>;##ODC^
ME>X?\$B;2.Q_X*2?#E8EV*SZF",_]0J[->CA,'5KR]LGI!J_GKZ'SN*O#"32
'[/\ %'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>oncyf-20221231_g2.jpg
<TEXT>
begin 644 oncyf-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" 00!@0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKXZ_P""R?[17C+]G;X,^ IO
M"=QJ&EP>(_&5II.JZE93+#):PM',ZIO;A1)(B*3D9&5S\U;O_!*_]HKQ/^TM
M\*?$.N:]J,VL6*ZJ\.G7DD:J2H+!XP5 !"E5^A)'6O8ADM666O,E)<JERM=>
MGEYGB3SRE',UE;B^9QYD]+=?GT['U11117CGMA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD;\>?A]X7^&_AOX;:WI_BS0)=5NY/$NGWMS-'*EPT0$9M[N !=H!P03GOVH
M_6VBOY^/VL/^#S?Q1X+^'_P]TWX6>!_ >N^-KKPSI6I^,=6U1;N31;;4[BSB
MFNK*SMHITEQ#*[(7DG8JRLF&*[S^A_[=?_!<GP[_ ,$Q_P!@WX7^.OBEI=OK
MWQ<^(GARSO;3PCH;M9PWE\;6&2[8/(96MK2.27;O?S7^90 YW$ 'WQ17\U5_
M_P 'H_[2%UXC?7;'X._"B+P%;ZA!;S12VFJ37*!E+FW-\MRL*S2+',4)@X"D
M['"'/Z\?\$7_ /@N#X"_X+#?#W6?[+TFZ\&_$+PBD+Z]X;NIQ<!8Y,A+JUF
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M'X>F[GM['4/&,%[=W>LI&4RZ_9YX(X6 ;+)F8KYB9/K^JG_!$_\ X++>&?\
M@L5\!];URRT&3P?XR\&745EXBT)[M;I(/.5F@N89 %+0R[)0-ZJRO#(N" '8
M ^TJ**^0_P#@L+_P6%\!_P#!('X$V'B3Q)I]QXF\5^)I9;;PUX:M;A;>75)(
ME4R222D-Y5O'OC#R!'(,B *2U 'UY17\T^I_\'H?[2ESK;Z]8?!_X2P>!8]0
MBMF2:RU2:=<C>;<WJW21><R+(5/D< 9V,%.?U@_X(C_\%Y/!O_!8?PYKNE_\
M(_+X$^)GA.!;O4] >\%Y!<VC/Y8N[6;:C.@<JKJR QM(@RX8,0#[XHK\0_\
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M/IOQ<M;S0_@CX%TOX=WB_:+2QUI[Z35]1MO,D02I=I)'"H8ICBWD561QN;L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7YT_\ !UE_RA!^*?\ U_Z'_P"G:TK]%J^#/^#E
MOX/^+OCQ_P $>/B1X9\#^%O$?C+Q)?7NC/;:3H6FS:C?7"IJEL[E(859V"HK
M,2 <!23P* /YT/\ @C!X1_;0\6>*O'R_L<3:I%JD-I9GQ/\ 8M2TFR)A+S?9
M]QU!T#?,)>(\D=^U?41_X-Q?^"AO_!0[XR0:E\?=:DTE8)@IUKQKXUAUTVEO
M+(SS+9P6<UQL"]1"/)C)9 "J[F3ZB_X,Y_V0OBS^S%\4?CM<?$KX7_$3X>V^
ML:5I$=A+XF\-WFDI>LDUV76(W$:!RH920N<;AGJ*_=Z@#^??_@Y;_8_T7_@F
MI_P16_9_^"'@6XU&?POIOC1YM2O9Y,2ZO??8[J1YY5!Q\\DLKA!E4"JH^Z#7
MR/\ \$8/^"AW[8G[$/[-^L:?^SG^R_:_$OPWK^M2W>H>*!\/=?UR>ZN5CC3[
M,UU97"1;(E"D1 ?*9&)Y<D_T/?\ !8'_ ()H:/\ \%6?V*M:^&-]?0Z+KD5Q
M'J_AS5I(O,73=1A#K&SC!/ENCR1OMYVR$CD"OY_O@;\%?^"H'_!#_6-=\(_#
M7P!\0IM UZ]N)IH?#OAB+QEH]_.L0A6]0PQ3M Q5HG7=Y3/Y2K(C"-XP >.W
MG[+'[77QC_X*,:3\:I_V4_BAX%UK4/&FG^))K70/AMK.FZ1I]S'<0R-+&)(Y
M#$&D0RNS.?F9VX' ^O?^#W/_ )/!^"__ &)US_Z6O7L/_!&W]D'_ (*1?'']
MMVU^,'QK^(WQ0^&?@6^N(-5U^RUJ]C@D\2JNQELHM&P8K4$(B.S00F.-G5/F
M+ =S_P ';W_!*7XO?MGW?PU^*'PG\*ZAXZ/@W3;W2=<TC3!YVI11%Q/#/! /
MFG&?.1DCW29,>U&!8J ?;O\ P0$L[;4?^")WP&M[R.&:SN/"SQSQS -&\9N)
MPP8'@J1D'/:OS+U'_@J+^QK^Q?\ MWZA>?L1_LJZQ\8?C-=VUQH2W7AF6ZAT
M>9 F)9-/M52Y:0K]G0%K:WA66.29O-8-N;OO^#='PW^VSXD^$_B#X'_%?PAX
MK^&_P-T'P1K>D:%>^)/#3:3J2:E=/ ((AYP2YDBC6XN9%94V_*R%SM55_-;X
M*?\ !/W]OW_@D?\ MK6NN?#OX._$23QCH[R64.K:'X7D\1:%JEK+(8W5ITBD
MA$,JID[S'*BE6/E-@@ YK_@X2^+/QH^.'[>EKXG^.GPCTGX+^+-2\+60L]#L
M[E+J6XL$FN8X[FXE61]\S2),F2(R(X8ALP [_MM\>F+?\&?ECDD_\65T(<_]
M<[.OS*_X* _\$.OV^_VI/@W9_M%_%ZWU+XD?$^]F;3[_ ,(V,5K-K6CZ3#&S
MP3+!:8A;=(9?]%MD:13*C$%GD6/Z]_93^'?[5OQ*_P"#:GX\?#SXJ> ?'R:Q
MHNC6WAGX>^%[CPI):ZW<:?;R1GBV6(7,K#/EKO3)2W4@'+.P!\F_\&<G[,WA
M/XW_ /!0[Q=XF\4:79:U-\._"K7VCV]W LT5O>3W,4(N0&XWI'YJKD'!EW#!
M4&OUE_X.M]7O/"__  1=^)#Z6K6[:UJNBV6HS0GRWDM_M\3;7(Y92RJN/1O3
M-?$G_!GU^QK\8/V9OVJ?BWJ/Q(^%/Q)^'VGZEX4@MK2Y\2^&;W28;J47B,8X
MWN(T#,%!.T$G'-?M+^W3^Q_X;_;X_9,\;_"/Q8TD.C^,M/-K]IB17EL)U99(
M+E PQOBF2-P#UVX[T ?RM?\ !$#]M#]IK]B:3Q]K7[-_[/-K\8+[6_LEGK&K
MMX)UGQ#-I")YK1VZ26,T:P+(69F5AES&ISA!BC_P4*^!G[9'_!2#]I2_^*GB
MS]D#XB^%?$FK6D-OJ$7A7X6Z[9VM_)$"!<2K,LSM.RE59]_(C3C@D^W>#?\
M@G[_ ,%&_P#@@O\ 'GQ!J'P=\*^*O$6DZM<P6<^H^$-%3Q1IGBBVC9Y(C-9J
MDL\( \U2SQQ/&9&"R 2*S^V_L1_LW?\ !5']O[]L;0?B)X\\=_%OX+Z'A;;5
M=9U4)X?BALHW=6@BT,(BRRL"Y0RVNS=MD9\[6(!SO_!W7XS\8:C\/?V/-+\4
M+J5E=-X&FU'4[.Y9E9=3>.Q6X$B, ?-0KM)8 C<PP.17ZD?\&O/PO\,>%?\
M@B5\*[C2;.QDE\6G5;_6YQ$NZ_N?[2NH&$O'S;(XDBP?X8P*TO\ @OQ_P1I/
M_!6[]E[1['P_J=EIGQ0^'\TMYX<OM0 6WOEE15N+2=T0E%E\N-@RC"O&O&TF
MOQ/^!4__  54_P""4OP]U7X0^!?AW\8=-\/W0DN(;?2O!$7BNUTR:293)-:W
M<$%S&CMY3J4$A7$S2! [)( #Y]T6QB_9Y_X.%!IO@&/^Q['PI^T ^F:);V!,
M20VL?B%H(X$"_P#+,Q 1E>A4E3D$BON3_@]S_P"3P?@O_P!B=<_^EKUW/_!
MG_@VW^+7A[]KK2OCY^TKI4OAR/P?J;:SHVA:C>0WVJ:YJ@;?'>W)5I!'''*3
M*-["5Y8U; 3#/H?\'@O[&OQ@_:9_:I^$FH_#?X4_$GX@Z?IOA2>VN[GPUX9O
M=6AM93>.PCD>WC<*Q4@[20<<T ?>?_!L9^S!X0^"7_!(#X9ZSI.D6 UWXAVM
MSK>OZB;91<:C))<RHB.W)*1PI'&JYQ\A. 6.?QK_ .#QC7;Z\_X*Q:9I<WF1
MZ9HO@/2X-.@#?NHXVFNG8HHX7+LP_P" CL!7[X?\$,?ASXA^$G_!)7X&^&_%
M>@ZSX8\1:3H!AOM+U:RDLKVR?[1,=DL,BJZ-@@X8 X(KY8_X.3_^"#FN_P#!
M4'P_H/Q*^%?]GGXM>"[!]-?2[N:.UC\36&]I4@69\+'/'(\A0R,L9$KAF7@@
M _/;X2_\%.OV^M$_8>T3X-Z#^PQI6M?":3PM%H=M$?A!XHNX-5L'@"^>[K<^
M7,\JGS#*!AV<OWJ'_@UK_8M_:$_9C_X*P:3K7C#X,_%KP/X5U+PUJNFZGJ>O
M>$]0TNR"-&DL<;2S0JF6FABPI()(XZ8KE_A?\</^"M_[*7PKM?@3X;\$_&RS
MT728;;1]+GA^'\>IC2+8H56"#5!;21K%ME0;S,Q@\E0KQ;&%?J-_P;D_L-_M
M>_LV>&-:\1?M+?$OQA+I.H6[6^A> M8UM=;EL69D9KN:9FE,/RQ@1P12X'F2
MEU5CB@#\%?\ @M)I6GZ]_P %P/C=8ZM>?V;I=Y\0)(+R[R/]%A:2-7DYX^52
M3SZ5_35_P67^ ?@4?\$4_C7X5?0]&L_#/A'P#>76AVBVR"#3I[*V,EF85QA&
M62.,*5P>?<U_,[_P6/\ ""?$'_@NG\9= DF:VCUSXBG3VF5=S1"66.,L!W(W
M9Q[5]>?\%'OAI_P5-T'X?R?LR^(K'XC?%3X7I+_9EEK?A3PNE['XEL(FA%M]
MKN[:)IHD 524N'1B3)YC2A0P ,/_ (,Q/$6HZ=_P51\4:?;37']GZE\/-0-Y
M"LA$;>7>V!C=EZ%E8E0>H\QL<$Y_J*K\F?\ @V _X(E>,/\ @FQX,\6?$KXL
M6EOI7Q&\?VD.G6NC1S1SR:'IRN)66:1,KYTL@C9D5B%$*9.XD+^LU 'X;_\
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MO^"9_A/X?_\ !*[4/V6?#-U-8^';GP1?>$8]2>)!,TUW!*LM\ZJ ID>>9YF
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M:UI/B">70]6NS\*T0W]NX6 V[7\=H+?[/N4O]I1@3O9C.R8P ?J9_P &Z?\
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MYR<'TH ^+O\ @K_X5M_'7_!>+XO:'>%Q::Q\2/L,Y0X8)+-$C8/KAC7[U?\
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M&;XE_#/X@_#M=:A\/#3CXF\.WFDB_,3:GYGE?:(T\S9YD>[;G;O7.,BOD?\
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M/#.I?#WPOHGB&'QQ>R:R(K75M?OUF^V)$EDGSP;I]C2>:D052RJ"P*K]3?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _E/\ ^";O_!._
M]H#P-_P71\ >+M;^!?QBT?PG9_$J:_N-:OO!FI6^GP6YN)2)GG>$1K&00=Y;
M&".:_JPHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORQ\'_\$2?B
M%H/[0/B:\GUS1G\/^)-5OKV:]:4W \FXN#("4D'F/.(V:,[CM.[EB*_4ZBO8
MR?/,3ELISPUKR5M5>WFO/UNNZ/%SG(<+FD80Q5[1=U9V^_\ X%GV9YM\3?V<
M])\?_L^3> +-H]'MX=-%CIEW%;1N^ENJ!8Y8T("[EP#@8SR.*_';]LS]@CXL
M>$O%-FNK:II&I16UY>SF'Q&]Q.UY%&5"S6]G;R&*\AV\K"J"= <,7(%?NE7,
M_$KX4^'_ (O:"NF^(M-MM2MH95N(/,4;[:9>5DC;JCKU!'-=^0\25<!-PJWE
M"3N^Z?5KUZ_FCS>(N%J.804Z=HU(JR[-=$_3IZZIK0_%'PAX]\'_ +/?P/UO
M5=%\?_"NR\5ND^I'P),D^FVEYJ#'RK2YLM(NRLL4PY$P! D"%B#TKY;TGX;W
M>H^&/M5GXH^*%YH_A>>.S?1H+./4M/2;_6/':W+,)(SYCD1(4WHK8 PQ%?MI
M\9_^"8&C>*/$&HZPOAWP1XREF976/7=)A>\N%VA6BDG*G?D [6RI ."" *_-
MO_@H#^QSXZ_8W_9EUKQ)JFC:Q8W,>H16=E=:%;P6NF:1]KNX[>U</%AP8T=0
MP?<"Q )(Q7Z7DN;Y;73E*JE9771[7Y=TWKY.^BUL?E&?9#FE"453HMW=GNUO
M92V:6GI;5JU['FE]\9M(B\4)JFU;2UT&Q@T5;3QK8D2.7F@,5\L1C#.48RQ[
MTC!!4/DG*GO/#7[0$^O_ !:N]>\,^&H]2;Q89+#1K_1+>""33MHCAO+U;ME\
MFV$I27AT8,5&T+R1D1_\$Z?% \=O?0_"SQ8=2U#7+^PTZ[N--O;N&,1.%BN7
M9@RQI,C;X]IP3DD@@ _:G[.O_!+KXF7WPXT.#Q))IVAW5KB(V<6G6JV/DJQ,
M1E#*TT@0GS/+)4EV8D@@9]O,,TP=*GSXBK#WM-&_+H_*VEFM+WOH_ RO)<;6
MK.%"C/W==;6U\T^_6Z?2UM3Q/3?A[/?V+6^FZ)]HU#3-2@FCL]9=[*P>)W,<
MZLXRL[(NZ15PR;PIW8QC[L_X)S?LGZ9\,[S6O$\.GW%K:W5T?[-6XW.[97#2
M!V^9EQ\H)R"2<< 9] ^$7[!7AOX?W5G>:S?7_B?4+6:6X NF_P!##R8W!826
MPNY=P0'8&)PHX ]X1%B0*H"JHP . !7YIQ+QBL53EAL*WRRW>R^2^6[[M'ZS
MPMP3]3J1Q.+2YH_"M&]NK^>ROLGH8_COP3I_Q'\%ZIH.K6\5UINL6KVMQ%)&
MLBNC@@_*P*DC.1D'D"OS9_9E_P""(GBO]G3]I.PA76;?4/AGI]S]IMY_M16[
ML%0(8TMU^\C,5(<L6^]P1@&OU HKY3*\\Q6 C.&':M-6=^FEKKS_  VNM$?7
MYKD&$S"5.>(3O!W5NNM[/R_'>SU84445Y![04444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8(K["H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6UA<:UXDNVTK1O$D.GKIMW!J0RJV=[;H%CS(ZE%9$0K(55E(;*>O_P#!H?\
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MQQ3P3QQJL9=3+&RNBKD;PP) )_8^348(6VO/"C=PS@$5_+-_P9O_ /*7*_\
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MJG_!8*X*J%+^#-)+$#[QS.,_D /PK]C_ /@H?_RJ]ZQ_V1W1/_2:RH _GO\
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M^#-/3;>U_P""4&N3QPQI-=?$+4FF=5PTA%I8J"3WP  /:OQ9_P""7MG#<_\
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MI2QYEGFMLK MPK[5$C!8,.-REL!OT#_;ITRWTS_@U9O+:WABAMX?@QH(2-%
M5<6UB> ..O/UYK\Z/^#(^TC;]L+XSS-&AFC\&VZ*Y'S*K7J%@#V!*J<=\#TH
M \U^"_\ P<C?MF?L"_MGR>&OVA=3OO$UCH^J1VGBSPMKFCVEK>6<3%2[VTMO
M&A601L'C.6B<%3@JP-?LO_P73_X+9Z9_P2>_9G\.ZQX>TVQ\4?$+XC&1/"UC
M=.RVD4*(C2WLX4AVC021 ("I=I%&0 Q'X-?\'6R*G_!;;XEE57YM,T0G ZG^
MS+8<_E7T%_P>">"]8M_$'[+OB"2.8^'[OX?G3K>3!\L743122C/0,4FA..I
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MC]S[.BB0?ZOYGRW3GFO[%*_G*_X/>U/_  TA\"6YP?#6H@''<74?^- '-_\
M!%OXP_\ !2'2],_9^T7P=IOBR3]F?^W-/@,T7AW2I+3^QFU$?;#]H>+S]H#3
MY;=N'.T\"M'_ (*7_P#!>W]J[]G_ /X+!^/?A;X1^*7]E>!]%\8VVE6>F_\
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M=_P5A^/WB32?V;=)OO#6DZ'FZ_L/P]I=E))IUL6*QF[O;Q3^]8@\!D#$-M3
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M#P7JNK7&J_8X(?,N86NQ$_E1HL0V^6G 0 XY!R<_EO\ \&[O_!<7]I_]N?\
MX*<>'/A[\4?B7_PDWA"_T?4[J>P_L'3;3S)(;9GC;S(+='&U@#@-@]P17UG_
M ,$R?VS_ (6_"O\ X-CM)U+6_''ANS7PYX(UO2KZV>_C%U'?-+>*EKY6[>9I
M#)'L3&6$B$<$&OR9_P"#23_E-%X0_P"Q>UG_ -)&H ^M/^"\'_!=G]I;]AC_
M (*V^)OA_P"!?B-)H?P[T./1KG^RDT'3;IMDMI!-.!+- TI+EW/+\9P, #'G
M?[?G_!:/_@HQK7@VU^/FA:'XB^"OP!UR\0>&7M]%LIHY()"?L\EU).DDS&50
M"'8)$Y(V#!&?GO\ X.N_^4V_Q*_[!FB?^FRVK]I_^#A?3[?3_P#@W'\46\,,
M<,%MH_A:.&-% 6-5O]/ "CT X&.U 'PA^SM_P<H?ME?MY_L\V7PJ^#/PSM_%
M'[05K)-<:MXKT_3X&M8M*4((Y_L\A%O#<&1RC-)^ZP$VH6DPGF/["O\ P<I?
MM6_LL?MT:?X"_:*U:\\5:"_B"/0/$^D:UI%M9ZGH+M*(9)87ACC8/$3N\M]R
M. 0,%@X]J_X,=+.%O$G[2%P8U,R6WAZ-9-HW!2VHD@'W*@D>P]*^ _\ @NLH
M3_@OM\6MH"C_ (3#3CQZFVM"?UH _H5_X+T?\%GK/_@D'^SYH]UI&DV?B3XE
M^.IIK7PYIUVY%I;K"%,UY<!2&:./?&H12"[2 9 #$?CAX(_X*3?\%7OVI?A)
MJGQR\$WWBZ[^'>F&>=KK1_#>DK8*EN29?)@DB,UPD>&#%1)RK DE2!Z=_P '
MNO@S6+?]HKX&^()(YF\/W?AN^TZWDP?+%U%<K)*,] Q2:$XZD#VK]&?^"$?[
M9WPA\+_\$-?AGJVH>,_"VCZ9\/\ P]<VOB6*ZOXHGTV:"69IA*C$,&<'S%&,
MN)5(SD4 >+?\&[?_  <::_\ \%&?B1/\&OC)9Z3;?$9;&6_T/6]-@^S0>((X
M1NFAEA!*QW")F0&/".BO\J%1O^3_ /@IC_P<(?M&?L:_\%I?&'@>W^(D]O\
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M_P &7'PS\:> _"%I\*?B1K/@K7=!L?L>L7FM6 U6/Q'(79S<LJ21>1(-Q4!
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MQ!^)7C>Z^+.N>&[A+[3-+&EKIVD6]RA#1RRH9)'N"C ,JED3(&Y6 Q7Z_44
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MPYTW_A8W_"O?^$!N;^X\S^PO[4^V_:5@7&//AV;?)SG)SNZ#'/WE10!\S_\
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M4-GI.O\ ]@A-/\,;;F&:26*T\_=-,Z1M%O:50JROA<G-?9W_  1"_P"",/\
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MCU_PO/\ MC^P?%<GB;^Q/^$1\CS]\DC^3Y_VQL8WXW>6<XZ#/'TI_P %P_\
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M_P OY_YGV@__  6X\9#IX#\-_P#@?/\ _$T1_P#!;GQDQY\!^&@/^O\ G_\
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M4N4/[/P_\OYGVF?^"VWBX?\ ,B^'/_ Z?_XFF_\ #[SQ9NQ_P@OAW_P.G_\
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M/&)/_(B>&_\ P.G_ /B:^+XTW4]XPE%D"R^@_L_G_F?:(_X+7^+O^A%\._\
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M%+,0: ^*?*@^HX?^7\S[7_X?8>+O^A%\._\ @=/_ /$TI_X+7^+O^A%\._\
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M[\*_AJ5Q_P#$U?@_X+[>,Y?^:>^%Q_W$;C_XFOS8TO4\@'=6[8:EC%'*=?\
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M(OAO_P #Y_\ XFD?_@MKXO7_ )D7PW_X'S__ !-?&14-]*0Q\9HY4']GX?\
ME_,^R#_P6^\8*?\ D0O#?_@?/_\ $TG_  ^_\8?]"'X;_P# ^?\ ^)KXSE@#
M=JB^RY[4<J#^S\/_ "_G_F?:/_#\#QA_T(?AO_P/G_\ B:>G_!;KQ>R_\B+X
M;_\  ^?_ .)KXGDAP>G%.@7;1RH/J&'_ )?S/MK_ (?;>+?^A%\._P#@=/\
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MI_\ XFFG_@MEXO"_\B+X=_\  Z;_ .)KXSV?+[U#(<*U&@?V?A_Y?S/M,?\
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M#O\ X'3_ /Q-*/\ @M=XN/\ S(OAW_P.G_\ B:^)U;FIHJ.5 LOP_P#+^?\
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M /B:^+P=RXQ2[03CY=U%D-9?A_Y?S/LF3_@MQXQ3_F0_#?\ X'S_ /Q--/\
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M13U.10-(S]0M]@!JHGWJU[E-T1K,:':YH"2Z%VP&8\>E1WL=2V)VQTMQ%YE
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M[,'Q*^&W[5OQ=L?AC=?"'PKX9T'Q$D]OI&JZ;),=9TV58GDBDEG9\3$A,,"
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MO;^MA_B3P7X;^.G[27@[PWX9\,ZI\.[SQ!);V6N:7=*PBT^Z9CYKVZO\XCV
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M<DDU]!_LLWTG@S]C#X\>)M-9X=;:/3-$6YC)62VM;B8B;!Z@.#@GV'I7AGQ
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M[MG(6:)QT*NA((/?!Z@&O-SK(*&,IR<5:??OY-=;]_\ AAT\3.GL]#U;XH?
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MB=FU7Q1)-'@LJ6ECL<@''5F(!^@-<9X_T#P_\,K0?8_#5UJ,JXW3:E=.1R<
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MMH-@JPHP*6)0BDU!)+M(]ZH)#IDW#'K55[5E]ZL*^ZI%7=B@-BHELS8[5.L
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M./+(];_:J_95D^!=U8^(O#MZOB3X;^),2Z/K,3>8$#9(@F(& X&0&(&[!X#
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M .?6E<R=2*;3Z*[_ !_R.4^S[A5.]@P#Q6[XNTQ?#'B[6-,C=IDTV^GM%=@
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M KA<-2JNX_PU6EO<$XZTZVN\_6B(7+D46YZOV'AB\U[*VL#.J\,[$+&GU8D
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MI2+J<_V+?/\ X!G^!OV<_$'C7XZ:%X"OK"^\/ZMK5U'"Z7]LT4MK$P+-*48
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MB.F06^UJD(P_I210YI@HH,F[%9NHWWES<&M+P7IEQXRUZUTRT7=<7;[5ST0
M$LQ]E )^@I.:BG*6R!:NR-;PIX"OO'=Y)#9JBPPKNN+F4[8;93QECZGL!DD\
M 5[-/#<_$/7=!CO&;[.EO%HT<DXVRSF,!%=AU&<=_7VK>\ ?#?4-&M8[+3;&
MX989 L5L @DG8K\T[DD!<8R6) 48 /3-'6]&T?0_B!%'J'C32[&\B<.8DBDF
M^SR \AF^7GVQ^-?CO$F88K-,1R4HVIPNUIJ^EY=E^"ZZ[?48&-/#1<5K-]=[
M>2_S/$?VI/ACJTWCF[AF7_4_*'7DHJ@ 9]CCKVK@9%NM0\)65I:PN(]$$C,0
M> [D$X/7HHX_&OM:_P#A5<^/-6U/5&2;[$9V33[Z:,QFXCWC&5.<9#9ZFO&_
MBG\ H]-\82V5LLVGV<A#SSP-E'/0LPY ]A@5IPSQE5P]18?%+WH]5JOG\MFC
M3'8>$Z"E3:OU78^>5\$ZAXTT:9HT9BXP^]MN>G.>_ K8^#WP#DUFYN8[B/R(
MK-RSHYQO(!YQDYZD@9]*]VNOV;;J%;>Q\.OJ&H2WJA1%:P#S",X +<@#U)KW
M#]G_ /8HTWP'KD</Q&N+>:SN4WII<4[_ &@R$C!(3YFZ8.[@@]!7ZYA..,MJ
M>_>7W6U\V[?D?)XJEB%"24UY);V/EWPI\ /LWAEM0BFAC>XE41.J$M;*00$4
M9.21R.Y) %5?B5?PZ%%#I=]I4B1_9R(YI8L+'@X(P>21C&>!G/:OU>TNV\%_
M#S3;:VT?1]+2UA=0(X[96F1QG!)8@Y&.#DD'I7#_ !/\!Z?\<O .N:/JGAS2
M6DNK=X]*U)[1$:.8@[4;C,9S@9!(YQGI7A\2<;U<5+ZK@IQC%;Z7DU;2SO;7
MYZ]F<.'KS@^:I![[O=?@?EM\%?ACI][XM'G,K6\DN5=B<ACT![@<]?RKZ!U3
MX+:%\"K9_%FN:K)H^GPNICECP;R_D*Y$4 ;&2<_>) 4<D] ?*]9^&OB'X=^,
M4@U+39K.[L9"ET.500KG)D..&3!P3U XR<5QO[0_Q1N_BC^T9_9_BC4)G\*P
MV^D_V='$F94A*!9$B7IEV=F8GDE0.P ^/R/(UF^9*C.HU!)R=MW:RM\[]?\
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MW(:I3V.Z7TP<UJ!&#<CBAK<$]*-B[%6PAV=JOKTJ!1L(JU"FZF,@E4AJB,@
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M_=*#'"C'3/..<=3VVD?'36H]5T^#2[S5+72K:'?$AD$4T[L5+.[1\;F/08(
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MS)N6)., @' "CJ?K4,^;S2NY5>1;(]A\9_&K6O[2FO6MKFZM0,&:(C,6<Y+
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MDKJCH@X"M'Y9 ' ' Z5U/Q@\4PV7BM=!O]1ALAI%XP6X#GRTCX#!MIR",+@
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M2"W?S4U.%W!C=" 0'C PP)! Y!.37,>&M+32ET;4-3V2V]Y@B$Y& I*D$<9
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M\?1D[\BZGD/BK2=<\!ZE-8VY1Y-*NS P+X\L/AE=1W#*,8QUQCO7*Z]K]_\
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MQ"V"'@%G0$DG/T(QGTKL/"7Q2\-W-_\ 9[J&V.GV<(BAEDMXWFGWJRJZ'Y2
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M,=J?I\JRS 'L:J0M"U8Z=MCZ5>M5:,[3TJY:K&(_E&:)$52#C%+F(DC6T1\
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MS_9IE9"RNC!E8'!4@\$'J"#7T[\*/VN])^(&L6^G^*F;0I)(]D=[&H-L\IP
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M+9P,<Y/ )XKP_P")'AEOBY\4-2\)Z'JWA[5(O#,1\_1H]0#ZA;C(#3318"#
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MU2SBN[4NHP'$<@(W ="!G%>S0?"S3=9D^V:BJ:A?2JH:>X48VJ!M"H,!5&
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M7W3:MJ<Y9^'=)L?!]UX@\1>(+;P[H5I=Q:?]IDMY+F26XE!*HL<8R1@$DG@
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M.^-\ICC49?! SR<9QUJJFEZ]H7B2)KC1;^,/;3O:-<6LL<5X[ (%5L '@D@
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M955:T')VC?1;:>FM[KS:6IW=YX8T_P )WR;=7U6&XN<QP*=5(DR 6(4E3D@
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MK,FX&53R&7N!G/;@UU1JTJT_91EK\]#:MEN)AA(XVK3]QR<5+HY*S:];._\
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M@SW,2X@LA!$H3  !=N69B.I/YUXO\3/$$U_IS7EK-=/J$TPW77EGRHMWMR,
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M-?:M<"8J/+7Y0D2] %7& !TKYW%X_$X=\E2SZIH^TP-3!XJG[6+:MHXO=/\
MKK^3,'PS\)?#.C6_F:Q,^K798XA1C' ,9P!C#,2""<X (XR*V[^33;5&2RTV
MPL;=B?N6J?)DY.>,\GT%97BS25NH/M&@ZM;7$J@%8KE=FXCL&7(!)SC('UKR
MOQ7\;->^'TA76M-FLT$FP3.NZWD[\2*2IZ\#.?:N*-'$8I\SE\F[?<O^ =\:
M]*GK!+U/6M>\+:;=:5+--;PHI&XS6R%3DXY[@].XKM?A?XUU30/!@BTYK>[L
M8W"HFH!FWJ."%9<$8'&2./PQ7D7[/_C1OB1!<ZE=,MOI,,A0L&P;EP 3&H]@
M02<8 (ZDBN^;Q-+>YMK*U:WM;5=B1HI50O.,=SGUHCC<3@ZCA"5WUOJO^',,
M9EN%S*GRU8W6Z:T=_5?J<?\ 'SPC??%35A<06]O:QP[I 'N58.WH#D$>V1^5
M>8Z)^SI>>,=1E@N?ME@JXVL555)'4!@2"/R_I7H'CGQ)+9RMY<-U"_()*D#)
M]>/QKA[GQBUM,YFE96!&1DCCZU]7@.(,;4@VJ5TENKZ>KU/SG%>&6!JSYXU9
MQ=];I._;;EMZ_@+JG[&$^A6T-U)J]Q9_9V+R21$,\BD_+P"6(]< ?6K/AS6O
M"O@WPSJVDZM%_P )99ZU:K:W]MJ:F>WN-KAEPF[=D$< '.?IQD:[\8[?0+,R
MVT\B3$'.#SP.Q[5S7PNN_P#A97B+7K[5DODL]-LI[V]^PJIO+A8@,V\ [,=^
M6;!(&3P.OA<0<45W0=*:]V2VWO\ ?^A]OP/X88##XJ&.HRE*I3DFG=QM+IRV
M:U\VSI/B3^VSJ>F8T_P[IECHEO%$D$:01K&L<:*%5 JDA0J@  DGUKR#4OVR
M/%6EW6]M;#2E^ R\#/KW%7_V@]!T_P )>$/#_B;0K?4-)L=9O+O3&T^^N4NR
M'@('FQR* &1@<$$9# C)'->5_P#"!IKOEG?']IG8>6CL$))[<D<YKXBGB)3<
M;7O)V22U;VM;\C]IQ%' 9?S1Q,$N6_,VTVFM[N[6FMVG;S/H#P/^VG>:W-H9
MU[P_HOB>]\,WAU+1Y[@'[3IURRA3)$-RAB>."3R < @5[+X!_:YLO$EZEO?0
MR6<TG5)E* GOC.,'Z&OFC5/V;-1^'/A.SU.XNK!Y+C34U,00N&D>(EE?:&()
MD3;EEQ@ @@FNS_8#L_"_QJ^,,7A'6+Z.&?7X)H[< C9)<"-BF3R5;(&".<]"
M,\^OC,OQN"KPI8J'*ZEFKZ7OI?RMLTUHU;H?/87/<BS;"U:N JN2HJ6BNTK7
MDU%:K767NZ/FYNI]:Z=^T#:V6GSZ3I.IPV>M:A:7,.F7,YS'9W;P.('<C.%$
MFWDC XS7D/@Z+XA_#S3OB%J'CWQ!K<VGWNF0:?I\.NX2*]NECCQ/#$LTC;HW
M$H+I@2 @DY(QZ-^TA^R':_L]_#OPOINCZDD.VS>76M3FPTUT^,R3,W4(!PBC
MMP 3DGX6U7X[VFIWR!?._LV-REN9929)%!^^W;)]!P.@KS,TAB5B'!*W);K^
MFW^?X'N<)QH3RNI.CRN%?>\4YI1E?W97O&]OE>_Q)-=/XK^(&HZI<,H3[3..
M2TJ Y [[<E5'MS[DTS1?'MVS1Q:AH^EWS2Y5%:U12_'." "2!WJSIWCK0I8D
MDMX+=KB1#MC9L[I,?+D=<9QG^5;'B#Q/%XF\2)I>E>%K[4(=8L!J[%9$6+2/
M*F((61VV&/&"J@ACLY&"!7T>0\%U<WP4L9-M-723>K>C5V_A5G\^Z/CN*_%+
M 9%C:>5QPZ?-9N5ME=IVLFV[JUUMVDSGGCFTBX:XM1J&ES#YA]EN& 3ZHP9<
M?@*]+^$OQ.\<:/IT=QIKKK23,?,4KY=VB]" ,E6'?C!/H:\-F^-F^X::.97W
M] _<>I^M=U\!_C5</XMMXUM[::WW$SA&V[ .0?05\HY5Z$I4W9VTNG=:=NZ\
MS]-C1PV-HQ=:C9R2:NK23:ND^J?1KHSZ(TSQWXD^+?B_3_"6FPR:?X@U4B)$
MNMR1KD9+L",_*.2,9_2OG?XUZCXF^'GQ;U7POJ5Y>1W6FS"-YI&,2E2,JRJ.
M@8'(&3]:_2C]G?X2+XP\1>"?'ED]NT.GQW2W!E.Z4J\6V-%_W69CR1C)P.>/
MR^_;J\;6VJ?ME_$2XM+AKJ/^VID61WW$[3M('H%(P .@ KV\10DL'3KW<7+I
M\OQL?"\,XFG6S.O@YQ35-;M7:ES-6UTV1JVDLD5J?+U)IG"[GD:=P4SZ?-Q6
M0_Q*\0: TD>G:Y<J8W^<0W!W D \JV03@@].AJA\)UOM1M-5U!5TNUM-'TZ6
MZNM5U*Y\FUT97(B61UP?,SO.U ,DA<$8-;WQ/\):?X)T7POK<9MK^R\3V O[
M35K2Y#VNJ@81W1,!XRC*0RN."0,D@FG+(JU+ _7%B8N;BI>SYE>W-;FOL^W(
MM;]6URODJ<45O[3>#C@92H*?L_:ND^1SY.?DT5T[:\STLMK/F4ND_M7^)M&U
M&-KK4VU"* @/'.A'7N2I)(^@%>[_  E_;*6>\TU=4TBW;2);F-+J[M'$I@CW
M ,S+@. !R>/6ODFSOM#U:ZF\Z*XEEDPH,>6;.>..O?%=9I?@77/AA-'YEK<6
M+3,7CCOE,9*'J&&20#V)QZUXU&MB*D)2A%M1M?317[M;;;[+J>WBJF5RFL/B
M_P!U*6UFE?;9/UZ:GUI::MX]^).M?$72OB@VBV7PEUK2+JQMDTFW\O,<DLBV
MYMKDX,DK1K&S*I9"&^;:P(K=_9B\-^"/V?O#.J:3X7B6:/6+S[?<2R6(M4B5
M2QCBC3>[':7?YF<GG P.*^,M5T.X?4O,LKB]T69,OY*SB>TW'G*KD 9/4KCZ
M5ZU\+_C!I_@_XD>"/AOK\GB*X\8^-[-=1M;FQLQ)IMI&Y<1!WX9MQ0[BOW.I
M& :UPM;#**J5)>]MK?KZ;_\ !-LPH9KB7/ X.$?8./-*%-)1?LUS.;6_-:*;
MUUY5\32/L"#XQ:?>E=C*.W& 3^/7\JFO/%%E?;59H8V?IND 8GT&>]>&^*/@
MYKG_  FK3_VA;Z7H\\*3F5FW-YAX957.>HSD\5N/X3TB 1S745]X@F7'[RYD
MZ8QC"+@8_,U[E'!X23_?R?RU?IJTD?"14E=J.G]?-FUX]LO+DD\F13P=RN>"
M#VK@;/X;Z&8;_P 3:S<)IN@:%&)KE20%GD.?+B!_VF'(&3@$#DBKVH>+DO+M
MX=BVZ0\!2O"+Z?2M/78;S6=.T;19/#7AFY^%=]ILMWKVOSWI%Y;7^)$\I(PP
M*.N(BG#!]Q7 Y([,#46%Q$5)-QNM$KO7TT//S:A5Q.$J0PE2$:BC)ISDHKW4
MV[-]6DU%+5NQ\-_%O5;'XG>(;G7K6S:U::>17;)Q<,"!O /('48Z>PK@HK9O
M[2&V%;A8<-MVY''0GC&#7LFK_#*.3P!<-.[:>+"=+1(V!S(S?,6)[%MQ(&3C
M!![&H_AU\'KC11->3.TT<8D0F1,118 8[LGJ!C ]J_;\#1B_?>RLC^5<OII-
MUZNVR]6<?X<,VF>$&N&TZ&Y$EP98)<LHC8@*V0,\$ 8)'&.^>,[Q5X:O_%U^
MRW,MO"-.4SQ1*P3:H&<@<''''<\5V6B637\EMI\C?:XI;AF,4+A)(E.3D#D8
M';)Y'05LZQX"A\,*FJ/:?:(HXQ)$,Y653\I7D$DXR0,''7&*]:NH1?LVM7_F
M>Y6M&?+RZOM;J_Z3L<UX4^+TP\-Z?IFGO<&ZN' A2.,.\C8P8U7!(R2>QSZU
MUUQ\;O$'@*:-)K":XMT*K<6R7R.T1! !=D)\M@>P'/.:\P\-W%Y;>/CJ-C;7
M(O$W20QG&^!<X9!\HX*MP?0G&"*^@_!5G9ZAX&%K;SKLN"'>-(T*2(% 8G=D
MX!R,]>#TZ57U.ER+G_KU.N6'H4J2YTWKTZ7]-7^ISMM)JWCO7-4NH]'U71EO
M;='64CS8O-&</N4<ACR<#MSS61X+^'>L&*7^T$5I(7VMF0 1JPR%(X)4\?7.
M> "*]L^ \FFRV\NFM?6<,MJSNL:2DOL4 @DXX4CD$<$U1^-LVB^"?,>Q*75V
M_EB&W$^6D89 E88)"Y( )/(P,'FO+J8APJO#PCV_K4Y:CE3<H4>NG]7]>IXY
MXF^)>O?#3Q5;Z>@AO;+Q)?170NIX=]]$(TV>0LN=P4#C:.,;>N!7N\G[/]O\
M8=!FOK!OL_B5D$L<;D[+U@ #&QR0'./E/&2<-GJ/+=2M8]7TR.\N$MY[G2KD
M'<P CMV8A&9AU&TG.0.@/<8KW;X#:];Z ]K8C5[/4;Z*X+*]L2T7E@]0Y )+
M$YZ9P!7AXZ@FG%HX\LQM? X[VE-V[KIOJK=5_P .?.\<303^6RLC1L596&""
M#@@CL1T-;%D-Z+7J/Q)_9.\37_C[7+^RDT?[%>W<UW;![K;(ZNY8*05 !Y]<
M5PFN?#CQ!X&CW:IITT$8;:)%(DC)QGAE)%?'QQ=&4N2,E?U/Z!C&4H*I;1J_
MWE6*18L5JZ9(C$>M<\7+-6QHGS-SQ6]]#)ZG16W*UJ:8^<K6;8Q$@$<UJZ>,
M-3.>42S=0LR<=Z\]_;U\+?\ "9_L!:A,J[IO"^KP78_V%+[&_#$M>F")9HN,
M[JK^+/"O_">?LW_$WPWMWO>:/-+$O^VJ%EQ[[D6@QGHU+LT?D_9MY6*Z#1[W
MRB#GI7-V%V)57<.2!6D)=A JM4>BST#0]6\]L9KL=%A,KK7FGA.9C.N.]>I>
M&X695['BI''4Z;2;;RPO\5;=E'SGUJCI-MA!ZUKZ;8S:A?0VMO$\UQ.XBCC4
M9:1B< 8]2:GF+L2>7GK4B6^.>]:7BOP1JW@.."34;>-8[AGC22&=)TWH<,A9
M"0&4GH<$5G6T_GJ>V*(RC*/-%W0ZD'&7+)69#(F)OK6YK?Q1\1>)-'_L^_U:
MYN;/"AD8*&E"_=#L &8+V#$XK(N8,@-TQ4^B^'[S6YMEK;7%P3P B%N?P%$N
M3XII:$QE):+J4;.4FX"]ST'KCK7HOP;^#.N_%[4WCTNV865JZB]O9"%@M%)Y
M))(RV,D*,D^G>K'P[_9>\2>,F,T-HMI&Q*>;=L(@,'! 7[QY]N:^C? FH6/[
M.7PXL/#-\]M=W2K+?73Q/B%Y&)((.,L4 48[XQV!K.G6IU).,'=K<X\?B)X:
MFI6U>U_S/GOXV:U>>"M9LO#>EV=_I]EL:.V=F)NKP*_#-QA5=F)V)R21G.!7
MTU^R9\%H?@5\+7UK5&=M?UB$M)&^&-I'DD(.3DL<%CGK@=CGRS]FSX$QZG)!
M\0/&&MW5[=-*USI\!?S/E+$!W9B<#IM QCC!KUZ]U";QKID>G:7.UHK':)&!
M81*O.<#)/ / ZGCK70M%S,^1]ZI+NV<O\3QJ5E ?$TTFV!')CM,99%SP2<C)
M)YQT[5@7/QUNM,T%;S4-7AO8(8S*Y@<J"HXVA1EMPR!@CKD5%X*_:*T'XT_!
MS^T-)-WJ^GO?RZ5&+JP-G<)/$@=F568ED*L#CDCG(!&*\[TWX?VM]J5Y+JTW
MV6T$C- D<6 Q&=N?<YST![&MLMQ%.K36*I/FB]GT/7QF68O*\7/#9C3<*E-V
ME&6C3[,MZM^T=8_$YO*L8+F?R9 9;,L5N(ESRY!&"!CN".>N:])^'NI7GBC2
M5C;2H=*EA7]Q-*F3<XYP"",DC'8<]<5X+XB^$T?A?Q!IVHR7DEI<W\^8?*<J
M\4;#D%E((!ZE>0.,BNL\.7]YHT1>QU6ZN&LAM_?[C)M(R-O'''0XY]Z]:%&6
M(I\ZZ=+:??T]#'V=3$P<Z?3OM]^Z\SV3Q)\6&^&MHEYJ#1WBPKLE$!S(BGH2
MIZ8((R.G?->7_'/XEV/QFMENEW!H(@L3E@SR0A>0>?O!N1CL2.E8'C?1KZ&Q
MM;Q;R19KB7;.67?A<9Z8/)^GY5Z?\ _#?AS6]"_LJ\L;;5'UA60R&("X1N>
MR@$>@(P0>]>;7@E[JU.*5K66K74\A^"FIW6EZ)YC2-)!O/\ HTBB2.1,<YXX
M)_GWKV+P?\*]'\>^)],AN;*ZM=/OIA++<B0A4C# ,".<$?W<@C.1Q7J%U^SK
MX8\/^!I+2U1M$DO8A!!NQ))DGDA<EB#R,GL<@UY?J-SJGPW\;S>&S);.M],\
M<<,4Q8(L:J4D!QU8%@0<$ ?0GQ<=AY3@ZE-VDEWW\F>KD^92H5%0EK"3^YO2
MZ_7HRQ\*=0\5:EXI\96/BKPAHO@[PWH]F?LCVNGR6\]M<"X98XQ<,BK<"2(
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M. Q<Z"E&7*WMJM]M.O<^MX;SQYME=+'6<542?+)./1.Z3;T?1]5]Q]U_L^_
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M:7*K6?5WM'Q._CN-%TXS6DTGS_,L>XDGG!&.E7/!_P 9]?\ A_JT:R-,UNS
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M_A%(]'7QC)9+_8DNNP'^STD\U#)N8@*&,>\(6(7=CD"NBI3C1ESX5.W1;O\
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MW81H2RE04/ 9>Y!((SGIFN\\2:I#!X&DAMFLX#?1 I/>LS7+J7.0J[F0$@'
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M8,"",]P02*ZOX0_LO:+<>.M+U+XJ>/-'FMKU)+F4WM^\\LL87$3.B[I KG!
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M\(R+/<+IOB:!"^FWD0"DD=(I1W1B,,#T'(YZ^$Q^)K6W>W^SB219?G$C2B/
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M ?,@SG(YX))'8YY%>8^)=)O;S3+NWGF2SF6[DN5O)&8B=F0!E<LQ5%&T;0
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M)=W%U*=B@@ X4\#)XXZD#O7S9X3\"?\ "J]3U5M0=1%'JLEO9JH)S#@.A(Z
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MPD0(C07!FCCSQD#)  ]/SJA,MS9W.A^'X;C^S;+5KN*.YN-O5F8*">0/ES@
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M2NT#!(SG SR.O%?/XRI&NG&?O7Z6T^1PQQ]:G65>C-QFG=-:6?=/OYG@>O\
MB?[ ^D6<-E;V.G:=810:;:6TK%;",#@98EF)YW%B23R3FHOVN?V._#W_  4]
M_8]TO2]6D.A^.O#.J&?0-42(&6W?!7:0<;H95 #+D<@$$$"M(_ S7?%FA2ZM
MH+^==K?B&."2-4)4 $NV3A5!P ,'(]*]2T7PCKFL_!G[;>21^&K_ $O4H;FY
M=)E9$AMR7E<L#@1E5/.>@/.*X72IN'L[:;6\CGACL0L3]:4G[2]^;=W[ZWO?
MSWZW/Q!\6>"O$OPR\/V4T]Z]Y:M.UJ),A)[>6/<K1O%DE<%&Y(YV]N^Y\&OB
M-=7E]?6^H0W.JR7%FUM:()!F.X<X27# @B,\D8.1DXXK<_:;^-VD^)-=O9-)
MT./2].EU2^O6OWPMYJ(N9Y)MC8)"HN\D  GIDXP!A_!&TL9K6?7+&[9UM9T:
M.$ *78 C!.,G;GH.,_2OC\[AEV4YM#$0P_-2337NKE;2323U>^MW9]-=3^K.
M'8YQQ'PE/)<?5]EBYIQYDVI)-N_,HI1^%VY5>-FGH['KVAZ=K@N?#OBB^TK^
MP4NYE:X6W"?9G@@7+3*%)*M(^$ <$Y)[ BEUC3+SQU=LTTOE^8[3JY.TN2=Q
M('89X [  <'-<%XX^*RZ)H]KH]G/(\=K%*+MF<9N[J9B7<  #9&O[M0>,[R.
M3FN:T?XX7NA7\<T(3*@(JL<C'4@CT/0]Z^3XHE]=S&6)P%)4XZ6TMLNWF[M]
M[WT/I.!>$L?E&3T\+F%=5*JOS2;NVVW:[N[V5DNR5M3V?PCXAE\+7,:3:@ZN
M&(5.%R3QSZCZUZFFNV_B;3[+1OL;PW"I.9+^:&61G((8-E R[6BR$! (=7#=
MA7QYIOQ5M]?\2H))V2]N'<QVR*\GEX(P"V,#=N&"3STSP:^U/V;/#@O+6.2X
M@=)!&N=AW\@<@GIQ^5?09'B)Y'"I+&X:-1U8-+GM;57NKW35GKH^VES\[\1L
MKPW$5*DLLQ\J<L/4YI^S>ONNW+*UI1=T[7:OK))I'AOQM\%6^B73?9+%1M!#
M.5"*!W(.>_\ ^NL/X3^ ]/UZ[BCUB6:TT^>]M[,3Q2AI@)0[%U!!!"A!D8)^
M;H "1[Y\:_A=)XU\:)IENBM ,27+LW.2<J@], 9.,=13[3X%P^%&L&T^!,VT
MZW,H=B5=E! 5EQCA6;)!# G@GDUZW!>0X55H5LT=XN^FCZ-:_/:UFM&M;%<6
M<2Y[/))X?(6HUUR6DVT[J<6[/6RLFGS)IJZDTKGSCKW@*V\.ZG:7,ET]S87I
M,EK(8'AE$>[ :56 (Z@ X )XZ"F6/PTDU74)),LKNQ9,]".N/6O4OB/X1USQ
M+XJT^ZUR\O-1738#:P,Z&9H+=7+%=O5BH8D9R3QTP*Z[2[K2]2\;_P#"$Z'H
MEKJ_B;3Y6O8;J$O%#_9LD2F)Y'88,SY)$8P3D\8!KZS'>'_UNO4Q.7:05[)N
MRMTLVMM-4]?,^*_XC16R'"X7+^(GS5Y)<SBDVG=<W,E):V=TUH]-.[O@1\+K
MS2OA+XFN5NIK?S(UM'B4D+*)#DY'0@!,X]<5SNK_  59K(-9P>1$N#*J?Q]@
MQ_/D?E7T]\+=$A7X8M'Y4,L=U>LT9BE259-@*$$J<#:^\$9)RN*C^*GP:U&X
M^'$S:-KFE^%;@W=L;C4=0C1H(K43(9Q^\PN73* D@ L.]?EWU'DK<M177EJC
M]9CQ=>G*3^T]+IK9):Z7W3U[;:6/F_3/A3!X9TRSNM6NX]/T^[O!8/=NZ;;>
M5D+1[PS X<[5& 2"P) &2*NA?#V'Q'X=_M*.9KR.5#Y%R8S$)""5/!P1M((]
M<@$<'->H?MA>'/#'P4BBU_Q'-X=32TGBN8+#4W-J+F91Y<0A?E68 L7#C:!M
MR5SDV_\ A"O$VH_":PO?$^B6>EZTRL-MNZ,?)R1$S% %#&/;D D 8Y)S7WV8
MX;(\/E%.K@_]X]UMVM9V?1[Z[M;JSL^GXQDN<<4X[B2M3S*RP,G-15]&KQVD
MM=NC6CNDXW:?R_\ &R'Q)+HTD$UY&]H\ZSS/!&!<7<BQF-6EDQN?"DC!.#U(
M)YKPB6.Z=6_L^&0R0_,'!VG(YX(Y!'8CH:^Q-;\*V.J^(QH^I7MS%=7%E/+:
M6MJT44M[*B$K"CRD(KN> 6.,\8KA?$7[+UUIFM7MOX?TK6-:T_[1Y-M<10>8
MTK&%7DBW1Y21XW;8?+R&*DKD#CY/+99GGN(G4Q4I5))75[NZ6F^W376[LV?L
MN"Q>1\,9>L-A(4\/"3>W+%7;_P Y))O36U^ASMI^V=XHU'P?=:3=:C'HFJ:O
M;16MSK8TV+[9<K&ZDB::-1(R[5.[)(. 37G'B_QE'X>\3:7J>BZW>-J=BUP'
MU1+@-YDFX8DC8'< 0Q&#P,XQUJS\5_A=JWP]U@Z;JMCJ&@WS1><D%W#)!*48
M=2& ."..GM7C_C2"72]21&D2Z$Q#.H4;]N1@^YQZU[^(I_5LMEE\:<8IN]TK
M75UZIO>_RUT//R_(:/\ ;,<\5:4U:W+=2C\+6FS2M:R3<='IJK>L6OQ]\1>+
MVN;OQ-JUSJ-O%";>&[N?F=\=$7C P3DXQZFL;X5^"H?B3\>)=.OKK6)].CTB
M75VMM/P;B[$,9)AC+#:"Y7J<D?E7H/P4TKPW>_"RVANH+:2XF FNY+J/]_9(
MT^%E56(CV!4()7D?,<\8KR[Q1+<^#]5AUSPQJ5S%,ETZ+<VLA2:W#,0H# #
M)Y.#@AOPKY?-,BGE]&$[I>UC>-NFB:?SOT/H>'^+L)G-?$X#"TY1^K2LVU9.
M5Y*VFVBW;3M9I=N]\9_"M9-1\(?\(]I/B>UD\4V%S=KI=SMN+NS,)(\S*JI:
M-@I8Y4' (&3@4_Q+\"/$'@'43#>?9K]T6)[B2UF9_L;2#<J2C PQ&,C/&1S6
M5\,OCK=P^(OM>K7VJ:YJ4R2/<77G W,"X!9EF8' &T$C[N!@"O9-,^(GADZ5
MK%\KWT@UB>*]MOLTGE>6 N7$Z[0&(/ .3G YQQ7N93E.#KY-.K5F_;14NEGH
MEM&_O):N^G1NQ\QQ9QEQ-E_$-+"8/#+ZM-QVDY)<TY63FU>#M:/O)\UG;F;5
MN%_8L_9"'[:O[1FJ:;K&HWFD>$O"%FNI:FEJP6[OPT@2*VB8\)O(8M)@E54X
M!)!'Z:']H_PI\"_#4'A'P]8V_A/3=)B80V$5L4MW48RD;H"2SX)+N-Q)RQ)Y
MKX]_88^/_A_P3\>-0TBW>.(>,8!Y ;:C2W,(++$#U)=6<+V#!>,$UZM\7K/^
MU--3Q$DSO92NT<8G0H^#@@A>X.1R"1U'4$5]!PGE])853G'WGOW_ .&_KR/Y
MS\:>(,U>;.C5O&"2E&-[JS6KTMK>Z\MMM_5?#?[0>H_$+QHATF\U#14N5^RP
M2NS1S22L5'[Q@-I4;L\#C'45Z9H'@S0_ %W-K6O:A_:^N1DF&]OR0ENQ&/W2
MY."3U<DL> #VKC_"?P7T#1/ >@3V6H+<7!@6[CNA()8M\B\@;>",D@#^M,\5
M1WES;VIU*:^GUEI!;V]LT3#S%1?D,0^[A5!! R01D]>/J.2G-I0T[]W\S\WP
M\IQIQ]OJ]UVO^5]=/P-+XK>)O'OB[X3ZQ8?"W4M*T;Q9)J-O*\DDB&4Z<=XG
M$)9HU$Q8QD NIP#SG@X?Q./C3P7\#?#TOBBVM];UJUL!'J^L7%U%!*UP9,1)
M+M!CF98R [1$'/.2>GFGB_Q7]J\0SV:E6M'&R::/,C1XR2Q&0HVD<XSSCGM7
M!R7MY\;?$T\7B"ZU+6UTI$M],CNKIUB15SN=QG)!)!QCH, 9K3#<-KZX\PE-
MV2UC?3IY_?V7W'UL^(JE7(/[(J48*$)^T]HHKVC;5N5R>O+Y?\ ?I_@0>(_%
M2W4MS_:FEP."51#&K#.6 .2&/89/(X/7C-^+UKIGAR8WMG:R0VPD6WV.-B[,
M$D-P2#C@ #KTXKVCX1>$XY;J&Q6Y662U2286P6*)0,941;F!? 4DC&1G&.]>
M3_M/AM9L+2X6PD@TC5E$"37$!.9"-P=6QMRQ&"0>F.A%>U&K*5>-/ILCX27-
M*M"5_=TM>^RMU[=/\C@=!?\ X2Z!8?+19%$A@:WD.(E'1BO0 C'!!SW%=5X;
M\%^"?#.C^'M4\::IKVGWWCZY;1=.TW2]+-YF:,QK//*"-JQ@R(1R"5/&3@5R
M'PJ@AT7Q%)9K'<3S7(VPS* ,'(&TDY 4#D]\9[UW'_"^]4\&_$V;2]#N[&/0
MK2VCDB-[I\=T@U%(SF>(2 M$XVA <@D!3@'%8\087%RI_P#"=)0D^KV\UU^1
M]%E=3+,+FU.OFE.57#2C*\8-)MM.VO9-:_\ #&[\#O#VK?"GXM3^#8;N'5)-
M+U"9-6-MO2#2HEG:&,RLV /,0*PP<#.#G!-:7P\_96\3W;0VNL^-;.S<S&*V
MALX#*(U9R!N=B 1MP> <=.:X'P)8:MK_ (_N-5N9;F.]\4:?(UT_F'_2'.Y6
M+'HWS=SGG.*]3T_Q0NBWEE=->-%>:>L3B)<LT<BJ/O+G(.>H/?-?)\08C&X6
M,)X:=I;/2]W;I?S78]'PWQ%*GB<3A^5VW6NBL[)/K?5=>C^7"_ K7_AI^TOI
M'C"X\$>)_&6H_P#"%7RV6IC5-.CM$N0S%!-"#G*,RM@$ CJ0*N^-_A+<>*FB
M&DZO;)-  L=O=(5)48 4.">?<BN@UKQC#IT-]%INAZ3H,.IW7VN]_LW3OLQO
M9\8$DI )8\G&3@$GO7-V?B%M;F+0R>;(AX=.@/3D]!7QN(QF;2A'^T&]&[75
MDK_)'[/CJN"G6<<%&4:;4?B:<KV7-M;3FNUY6N=78?L\7WQ/^!VK:-J6HVVE
MWT7EN+B9B4M)%<%7PO+8&0 ,9SC(&:=X;^$'@3X6Z2EH;6;Q/=;3YMWJ,C'>
MQP2RQJ0B9/8 G'4FLJ#XA>64TVZ<2&9,R,CG]YSP 1UQUSZU0UWQ=I?A=TAO
MIIHQ<(7BD&?N]P?<'\N#6='$8B,/9TYN*>KL[7^9C5E%/G5NWI_7<Z_5?B#8
MZ)N^SZ7I=FK  B*T1<@=,G';)Z^M0W?Q%TW6K-(;ZUTV_MAD^7<6J-LR,<'
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M,2"1>0#A6Z'KU[U\W_"'XR-/J4LECX6L]2;S8$9;F 3#R(E**)%)P=JC).<
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MQ8[,*6+K/$1BHWMHOZW)JTZW*KK\;G%_M&Z_')X=T+76G^S"9Y+)U7@R,H#
M@Y'0&LWX?>'?B%XLC#:'X;FNM/D4;Y]0 LT<C. &?!8$@C(YZ<CBOH34]#T?
MX>>$/#^FZAI=C?ZY#YE[%)-$)&L/, 7*YR Q5>N,C/!%0V?B6:ZDROF-$#W)
MXQVS_C583-*V#=\-I*W7L];?D'*IOFF[>GEIOZW.;\+?!;QII-I+<;?#\.I"
M$B*!;W=M8C)&[9R?X1S@#J><UGR?!CXD1K"U]I:W$* DO;3QSX!.>0ISG)/
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M)I?NT[ZI)-ZM[O7?J:NBZ;I?Q5NH/%*Z>NCZ=J5VTS*#O1"K!5!W''!R,@$
M,23WKZ"_8N\/1:T\&K6<%Y,-/O;NW:W8@I<^:Q82D\D@ #D<= .F#P7@[X'R
M:9X>BUCQM?75G"%:&UTNV !OVC#NX5>5.], J1SR0.,CU3X>>.-=\ :1''8Z
M1-X8T^[D_>/=.EQ,F 2HV* $4#H "1W//'H9ABYN+A'5=/ZZOT^1Y=2I)1Y8
M;6MV_I^2-C]K_P#:!\?? /X9Z;>>#_#]EK%U?7<\,L]S#)/;Z2J1[XD:./+L
M96RJC(Z8!!(KHM?\97VH^&M*O-7TI;:ZDL89-4L+=R?LEQ+'\\08@$;22%)
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ME0R#-PDH9$&>2>X&/6NN\5>*='A\5ZB=(TZUM2\@2:[BB"S7C(H169NI "#
MS@>E>?3K1@_:+^G_ , TI\UE"6G7:^B_S9X_X%^$_P 3M>2#[5H>EV%BK81K
MZZ2"6-,9SY:@D'/!!'X#K7H%U\%?'$&@06NE3Z).[R"2<K=>6=PY&-R@;1@
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M"9('!&"986.5R><CCGH*O_#TV_C#6]2US2]<TFU\,-(+5K,VKI<229&)1D<
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M-6G2551;AP1;Q>=^\V(!G)P,Y(')%>(_"SX,Z7XVM_$6OZUJL<6G6"QPBWC
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M;B*=K>X4E) CAL J0RMQP0<#]#E_$#XL:QK-Q!_I<D:/*\-C;RN76VA9BWE
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M%]>J]&S]+-%^)WPU\-_!AM<LU:S^'NA2O"L=I;,HO9%?84PV&8%V_P"!'/.
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MC. <#GVQ751RO,:,/KBIR4>_^:O>WJK'F8B4*T.2K35OR\UV.\M/#%SX8O\
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M#X3FT&37+BXM4O)9Y9GMX(YQ%(Q:.U5855?+A7*H6R2#DXR /A_5O#NDZO\
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MU;F18T^=O[V<_P"<U6-]A.TJ4>5]>QQ2Q5]$=]=3KXO\+2*H_P!,M%+PL.I
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MG QJ5YJ%2F[OFT=_+I)6T_%I,\V^ GPFL_BQX_T[1[K;I-O*QDDNKV%V@>
MEG4C;N*D<@< $<DD ^OP?LAZ6/#>IZYKGB*:#PQI)2VMI-*LA=W=Z7>0)(4W
M!8XV5"03@'A1SS7M7P0_X([Z;X)M#K_Q&^*-QJ/BN*^EOE3P] R6%O$^"UGF
MX)\R(CC.Q"5P,@5P_P"V%X1^('[.FB6-YX(\4VLWAS38?LOVRRL8;6[2%G)B
M@NTPRR*A+>6XX#,3A2<'ZF?#.4U<@E0IZ8MV:;YDNEU=76RMMH]M&V_@<#Q)
MFU?C:DHM/+]FE))OIHVKWN[II.\>ETDODG]J_P"!,>D:EXH\"IJ*1:GI5S#/
M%,5VK>QA-X!!!*G:X)!Z$8SWK@?AY^P7\6_^$8EU"ZT3[+:7ACCL+AM3@0VP
M8!VEFC#-((S&RL,@$J2P! -8WQ3\7>+M9U'4+Z:5+W5[Z5B][>.[\L"&D8*"
M7;T' ^N,5ZC\(_VS]4BOM!\'ZQ=1ZA;Z+I8OKO4(1#:WUXL, M?WQ509V\MM
MJ9RP5<8SDUY'#F1U</B(87,>51UU=]?=>S2:WZMJR/T;CS'3PV!]OE//*JN5
M-QM:[G!6:E)-IKFTC&3;LK6O;GOB[\"M6^ NAG[%J,/BGR)H2^K:8\D5ND[Y
MX5, N"0!DDX(Y/.!YOJ?Q6\4:Y/NFOG&JVTIRJPI'(X'0(<!E=2,@ @GMR*]
MR\7^.]!_X5_>:%96ZS:[')*)H[:Z=["*U=@REAM7,B< %6(!=CD\"O%'^'[!
MV:1GE=LG<QR=W7.>N2?6NCBRCA,'BE3P<M+=-M+IZ]7>]^SNM+)'+X>X['YA
MEOM\VIVDF[-JTK.S5XOX=+-;*2L[.[;^Q_V#O^"U&L>$DM_"GQGGN=;T,CRK
M;Q!Y9DO]/(_AN5^],G;=C>.^X=/3/VSO%7B3XS/9:M\'_$FE>-/!MY:.@TSP
MAJ2+KMO=_>%Q,FX2O" &'EQX(;!8$<C\\/ ?PGO/CUXK;1;6]TG1+G3XVN]0
MU?59_LMAI]FHPTUS+@D!6**H )8NJ@$D"ON[]E#_ ();^ ?V1?B#X=^)GC;Q
M9J7C2UTO2Y_$UKXBT153PKIC0Y"[Y@6FN),X"J-H+O&-K\@?.[J\SZ'%T:5"
MMSX7>S;CLFDKMK:SM?1.[Z)F=\ /V,O$WQH^&?A^\^,>J:@FNZ9=2:WIF@ZC
M<1PZI<6$3QIYUS%RY1;CA2"'VG#$AL#Z&TS]G2Y\2ZL;BQDL+$LX0S1P1089
MCA55FP2Q/ 4')/ KWFWU?1_&L>I?V5JVGZDNDW;:3J'D+F6RGVI,UL[,H8<,
MC%02,XSR*Y?QW?\ AO2M&F74-$;7[?0;JUU8!M-DNUM+J,N8)TVC&Y/F)P2%
M&2P K@J8>=56HKF?2R\_+S_R'_;[PVM7]WWNEHM]I<OV=5=^=['G_C_04\#^
M"DANKB_D:"VN[0VYO2+6],VT&2>':3++&$_=DD!2<XXKX=^.T%CJ.H1/);W[
MQZ4))H5ABC8F3;@-A_EX7?C(/'09Q7NWQ'^*=SXO\207$TZ?\3*#[7#'%+N4
M1L21(0,X4L#R<@D\$UYW\0O -GXIT:9FW397YVP0<D'D#K]!T]Z^GRG(L7D^
M.C5Q%-IK6S5O+^FCKIXC!\0Y!.G2Q$9QJK>#4TG?F:=G9[M-/OZ'SC\>;WPK
MHNGZ58Z4]A<7VGP,SSZ?OC\U7VL#+N4 NK!P0O9@<Y!%<=X9U^'QSJMII*Z9
M#=7%ZQCC,89I3@$DX7); !) &>*]$\?_ +/6H:3>6\<LUK/:ME(23\VT@D8/
M&,].3G-2_L^:1<>"-;U0^3I5FNHV3>'VNKR!6@CANGQ."^1ABH.TG)!'3&2/
MH*?#='/<V4Z\N1MIOI=*U_>OV5K^FBZ>5FO$F(X.X1J0R^#K>RC+E5VY*4F[
M6C9Z*33<5;2^KLK^H?\ !*K2K?X=?&KXH^%]6T/4+'Q'XG\/6D>CV=\B6EQ+
M<178F"1"<#)>,,0X!(57(Y(KZ0^+_P $XK^]_M*>=],>>3=//*0+<$@EE\PG
M /*@#&#@DD' /Q+^V5XML5\ ^ UO?&MMK/C-+F34#K%C;SB]TJWM$,5M \V<
M-(TF<.A  4'ITZSX._\ !8!M-\'G3/B9X0O-:CDB1/[5T.[6"ZD9/NO)!+F%
MF X)!7/8#)KW*E&AE%=Y?&IS*/VM-]&U9;6O:[WLWZ?S?G&69IQAAH<21H<L
MZJUIMM64;Q4E)I)\UFVM'%-)WW/>O!=A9^&/B-$L[6\-DX#&2/6$FN$52,'!
M 0 GGL0,X)KW+Q_\,KIOL>N7&JI#Y;*L*M&D,,JY)  C)4EA@KSC';DXY[X/
M>)O!?[87[,J>-OAK-_PDT6GW)MM;T/5=)B&LI* ,*OV<%E= 0P;)4APW('&%
M_P )MXJ^%7B&\\"WFE6NJZ+=W!^P:=J,Q+V48=SL1\ Y !"!NG S7M8'&IS4
MD]/T^9\#1IRRRK+#XN+5]/1OH[=/ZMU.HDU7Q%XA\1B/_A);K3[2W,2P17UM
M+/ =QP54*K!5#=00#DY/'-<E\4-'U+0].N([J:,I#D/))(B)!("3A5W%BI[$
M =0,5U>E?%/X;^-/!*_9;Y="OWW1;[MW::VD48)W\AD&<'('&1[U:MO@'>1Z
M0VH7=S;R+<']S+ H9GB9>6SD@%@<# &!WKV,/3ITY*6UWII^3/0P^"H2<*D=
M;O2SNOO^[_@G5? ?]JI?A1\$Y_&'BJQFU'1?!KV\9-CHOVC4KF:8E884<9'E
MH.1*V F[;@  UJ_%ZQ\3>*O'\.HR7%S:>#OBE:0WENZ.+>\M(P@E,5TBG<V!
ME23G)(PQ&169X$U76/A;X/UC2M%MH[!;P1PR/=2I)8P*&!:20-D,0.VP@D@8
M!Y.I)XV.I>+Y+B:UAU>^CC#W5V7+0W%LA.[RC&"<H20(\'  SS7A_5:\<PJ8
ME22I6LE;6][WN?5.M@)Y9"DJ4H5XS;<V]'"UE%0MOOK?K\C@_$OPQL-!TO3]
M/ATJYO7N&:^D,:?/+*<HKE>>,KP.@V XYKV:3X6M\%OA#KOBB?PC_P )AJUG
MID%W9:':3"*=]\RQ[S*"$"!"9' R BYR,UYS\4/VO]/NYXX;5AH4D)1/LLT!
M$T\3 @L'56:, $C@J2&/%>J>%_C9]J\%^%2K2:;IUA TVG233O\ :[B,,0I!
M8!@KDD+G&4V@C.#7-G%3$5J;IQ?*]5H[V_0\O#YE@H8^,Z\%4A3:;A=VDDU=
M2:VYEHVM?P9S>ARS>([_ .'GBZZ\&V/A>74=#DO=0T^1?/&E2&1MABD90Z^:
M.<'!(Z@@<\OXR'A/PI\8?$WQ T/PW8Z7X]\76XL]4UE;B0O<1@(I*QDE%9@B
M D#G'O7E?QB_;9;3/BMK>AS:NM]K$-ZSZKNE+I'-C"0*3@D11D \?>9L<=<K
M2OB_'X]UFQ@NKL 7EQ'"7&,1AG"DXZ9&>O6OS3.(U*LHTJKY_9V5[;OJ_P!/
MD?JW#V(CA%6QF#@Z"Q+;<%)V5.33C3W]Z-DG:5]=]CO;GX@7FHRDS2M,Y/63
M)_$<XK-U[Q],D:K--&F. H!.?T/85S*>+[SQ7<?$FSU#X<ZQX#M_ E_'::3J
MMW=,XU]3+L)(;Y26 \P&,G ZXXS%I=E:Z[H]_=_VOI>GV>EVOVR_OM0G%O!:
M)D#YVYP2QP.,GL.<5GDN#PV-C*M*?)".][7_ !Z=V?29GEN+PV,6$JQ3J-1:
M46I7YDG&W*W=M-:(>_Q9L]-OF92UQ,N0@;(4'UQU(]JUM+^+W_"06"6M^BW%
ML^[S8Y.022>1Z$#H1R*\V\=>"&\'7]O-)=6=XE[ +JWN;>43P7<+?<EC=>&4
M\\]>,8KG;3Q,T<Y4G!/&1ZBNK$8&-*?+&7,M&FNJ9X=3$585'3J:-:6VL^S7
M?H[GH?CNYD^'"K-$[RZ7<G$4H/*9Z(Q]>P/?ZUS.F>*]/U==[S2-=*,D,^<
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MW_71GU+S/ZS5EB'&*=EI!**TBDK)62O:_F[MN]S5N?&^K2:=%;QR_9X5)9Y
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M6/$7CV"\O+_4+1+BVB%I.D$8B,WF2-.AB3Y8Q*-KEP5)/!&:](_:5_X)X/\
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MQ)9FTCDC.PJ<Y5NX8,IR<Y!(&#QT7A+XSMX3^'5H+6WCNF2=7E+,2X0%64J
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M23(&YL'/%:WPR^&5EJ_AG6]:\5);Q>$M-MA/JLLF2MP.%6)!U,SL0%P1@G/
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MKK/BBPLI 64SKN&>P.<@^V*^2?VSO'<OB7]L7Q8H?SK;3Y8M.7'(Q%& 0/\
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M&K76E_&2;7TM6M$NI(TN?XHI;H1 NP'/$BD.![D=J^2J8-XCE=[2CI>U]/\
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MUY3A9"^ N"PR, $$9!\C\<?#;X?V5[YVG0MJ2Z;;0:?ID=XI^R1+&@1,Y"C
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M@#D#!/4 _'WP]_8"^*7CKPQ'K']E6UG;WJF>4W,QBD2$_<+A5+#(Q@$@XZ@
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M3[_6O=E3A&-FU?\ KL?*RITX1LWK_78@M/VE8==O(H;VPMA82Y^X"< <$$$
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MVR,'$L(C=0VW!P0ZY!< XX/@G[3,%_9?%"]O=?D;4-2U>7[3,ZVS6N<\ A6
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MU4$R*6?YMI&-I(SSGZV_9G^"EOX<@6]CO6UBXA9HVO5^2%&4D.$!^9B#D$G
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MP)2($J22KR%!QDG.!SQ7BP4^3VC6G?IW_(^C]FI5O8P?O/TOV_,^)?\ @O\
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M3WL[O5K3?6I6PTL<\,W&$M9:_9BE>4VNLFEU^%67Q;<O^U?^T]X6_9S\'?\
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M \$@>^>?I^/2O+5UY8KL*S(I<Y;)_+COQ70^$_$46KWLD4D4<LB$($+''?D
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MI)&X)Y+;"R[B1G)P>V,5K>%OVS;?X??$9=4T^+4+J.YD6YN$D=(8)I@"IDV
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M"BG['5A^P5^U+J7@C2?$5]XDT-K&WU6PN+RW$5S'#,6 BD( 5W0HP+* "-O
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MI5_J"A+NYU)A CP)<AC*ETH#;UC4@QC'W2#U)#O!/QSTJZ\1EKJ^U;3+*>W
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M^Z_AO^SY\-/V>K"QUZX$>D-:JSA+VZDGN+"<K@J48 LQP "JC)  '0U]0_\
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M[*UJ1;BT>-DD(W3+MGB(^Z3M. P&,X/TKTCX7>([;2KME01^5-\K X)4YSD
M],GKTSWJLMXLGEM&M3J4%.4DTF]&G\K-I]5=6:4EJM>KB#PREQ)4PN)HXN5&
M-.2DXQU4D]>MXJ26SY7S)N,KIW3O"?P_A^"?Q0MO$6E3:U:W5E(TEG>Z;=O;
M2Q,2075P0V<$\9 (/-=-\9?COJW@LP^)H_''BKQKXHO%:UL8-<O'NX+:W8 2
MAHI,@+M)7J"2Q()QFMSQ#I+2V4-Y;(DB/A1$0(R/4@]QZ8ZUSM_X1L_$JII\
M\%O-#.X.V096-^F0>Q[5\[@>(\507M;M2COT?;0^[S+P\RS,<+RJ,9-JSNDU
MWU]?+3Y'E7BCXX:A\:M:MM5U>[NKR[BM8]//FS%\)&3Y8V\   XP!U&3R36G
MX1TN3Q+J%O:PQKF298P)#A4)( )/0 =2?2MB7]DNXB\>PVNGW'ES7SE98 I8
M 'T)Y!!Y'6ONS]F7_@EEI-IX?MM3\2F2Z,@#A&SM)]QW_&EBLR6)F\3-\SEJ
M?,T<'0R*$<-5BHJ%DDNUE:WR/GWP;\++RY\':HW@FVANO$6KK'IG[IR4LK<D
MBYG67 0,ZC8H!)"LQZ]/I?P/J_B[]GWP?;6I\./%;0Q!-\6V5$P  3M/ ^HZ
M5[^WP,\+_">;2_#UMKWAK1=9UEUAL--NI?+GN9&4,D>[!578$%58@G(QU%<I
MKGB3_A']2GL-0BDAFB8QLK#[C#@@CZUST<1&3?*D^K[GC\08BIB^2I)2C%Q]
MVZ:35WJKK76Z;6FENA0TW]HFX\0?$O4O$-Q\0DOO!M]H*:?:>"!IAC-G>",*
M\K.5V_ZP%]P)."!BG7OC'7K7X7WFK>!_!MOX]\4)J5M:_P!DS7GD)!:R E[D
M!2&<@@# /&<X.#7.:Q\+M'\:3/<6.VSO3R)(P ';T8="/UKE-*US4OA'XPMI
MIHD6]TJ=;B,/G9,%.00>I!Z>WUJ?JJE3DJ,FF]?->GD>1_;$HXFC7Q%*$XTE
M&/+R\L9*/2?+RMM]97YGW/;/$^N:;/'J6H:#?:+J5GIUS':7T%GJ*73:7=,N
M7@<]<A@P!Q@@=<Y%<?%\1V?4;:2075OIPN(TN;A$)C12P#$-C;D#/?\ "O.]
M)\5^$O#OA;6M-\'>%[/PRGB#4#J.ILEP\\EQ."Q7:SX"J-[G&,98GVKH-=\>
MO'J]YXFM?&VH)X3F\,C1K?P,E@4CMKIH]IG9_N$,V90Y._MC%?3RR?$4LLIU
M)4G*HWJXNZ4>[OIMVZG37PN5U\16>$KN%*,.:+J)WE)13<$H\UFY746W:R3;
M6IUW_">^,M1\1>-8?%GA+P_I?A>P#WGAGQ%HUV'M;R$RA(K9R23+,Z[F;@%#
MD8(YKQGXQ,=-N8M0MABVF.)=O2-CT/T-<A_PG=QJ(CM59S# <XW'8A[D#. 2
M.IQ7=:%;_P#"76GV)PT@FC,95N><9!'XUY.#PSPZY92<M;Z]/(\W,,TI8ZM&
MI2HQI+EBFH7LW%6<K-NSEN[65^AP7_"8<>OU-%<;JVM>7?R(K+ 8V*,D@Y#
MD'MTHKV?JYX#Q6I^D.D>#],\,V ;3[.."V,;*9E^Z,C'7L:\(^+%Z]QK$EM\
MT<</&/4^M?0'P^UB/6-.N-)U2)'@NEV-@?*3V..W->/_ !RT".T\0S:>HV7D
M2%H2W_+PHZX/<KW'I@UY-.E[:/M.J>Q[];$<D_9OX6E9^?F>>W>D27FF1_NU
M= 00W.X'U![4[3-5U![673YI%E21AABN)$4<8ST(_"H9/$&H^'+9+>XLVA@<
M;E=T)!!]#@C-;?PZ\%77CK5HI+/SE6-\R7!0B)%'7J!FNNCBL31@Z=.32?\
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M?4=LCD>XKTWQ)XBD\8>(+O7KTPK>7D@18D4(MLL>4$*@YQ@!>"1D<$=:\_\
M'=Z+.WQ8M;M*N,*.?+.<<'@#!.0.QK]&R_A.']GK$8B7O./-96LM+Z[_ #V_
M4\&K4CR\W3^OQ-[X??%O[25LYU4^8"/;'^>U4?'&AIX0T'7M2\-WWA'2_$=Z
M]NNE/XD3-E I<FXV*05,FW&W(XR<5ROAO0[G2;X7<@R[\L!Z]\=N?2ND^-GP
M_G^)WPKT>WM;N&!Q>R3,L@^=\( .^< DU\G]751.C%N-^JW^1&!Q$L/5CBH0
MC4Y&FE)<T79[275/JCC_ !AX_P!$O_BM>OIHL[BW9(59K$&&SGE$2+,45N0C
M.&(QVQVK/\66K>([U&PZMQA1Z 8&?7BLK0_V9/$&DZAN4)+@X7:_!KZ)^'OP
M$MM#\/6]SJQFN]1D4?N4&$C]BW4D#KBOH<1F6(>&CAYNZ5M>KMW9X]1UZU1N
M4;7=[+;Y'#_#CP=<SPQ*8&8C&2!T'UKV3Q-\(KQO .E6:VT<RW5QYLN]L>6,
M8'\ZW/"?A>U\+P'4+A8Q& /)MT/#GL2>_-.\4?%'RM>TNQDE66XF??(!@!%
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M%SI?PT7Q/K*QFTM9YWE.CW#LI+&56()>/Y0$8A3P02>3]AD,O90=)='IZ/\
MR9^-^(&%]I6CC%IS))[Z./R>ZV]&>(? OP;%XW6]T^X:VVV]N9)>2T\>X8&!
MT*XYR 2._'7T[P3J%UIGPZTQ8SJJ16JO;QNTQ5, G:<8QLSG&2>O  XKS/\
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M\PWL2!P!@\_J?[*7AOXE?&#4]#\,65]_9=I>%+AIOGMX%Y#[FR05C((WDY.
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MP1@$XR"#DUL_M%_!C0?VD["W\(F/5;>72+E;.TG60R&PO!"98I-V/F4 E6!
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MQAR078# !)XQ7*^+O'4WC_0(-WG+&$&0\A<Q\DDJS9(//(Z9Y&*V7TWPW8^
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MMW0G#  @$[F!(X' Q]>:L>!?A-=ZEK6I:]XHO?#-A\2M<\0QZGI5_!91:F-
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M_B;:=LWP7T*\LLB>N,X/4=0:Z#P9\,=0\:7,2Z=:75U*2"6C0_NQ[GH!]:]
ML?#T^E^('\*Z/;)J?B?4K>2-D>0".T4C:997.555SU.23@ $D _$UHTW"\]N
MO8ZL'>'O?@>O?LA_%GX,_M):8WB+09=%T7Q.]LHG6Z"F9$7_ )YNV-R*3C'!
M4X! X%>N:KIGA&WL5O+[4GUN&S)5':0RQ*W?_9SGCU[5\:_!'_@F7\,_@"\T
MFL:]X@\2ZO?$R7D<=X+'3O,).[8,&0CD@G*Y'4#I7T%\-['1=!C72=%L_!]G
MIJC;LNKO[=+(/?S)#^@!KYW%5\'']U2M)+K:3_"ZB_R.F.!K2O7YIQCOJTOD
MGK+\!_BOQ+'XBU;3YO"MUI>F:;:WB2ZI&;8^=<1(P9XW+#A2H/ '/K7Q]\6-
M?\0:_P",=3OKRUNM*CU&>6Y@@N('\UHF<L&;@8R#D^G>OT2^'O@$6VMV<UC8
M>&9+)'#2K;VT<;KCH003^5>F>)/"UOJL?F-;V<K*I ,D"N0#Z&NK*<CJUZ,J
MO1/1.-ONL[?U8X,5Q!0PU14E&]UOS7:];J_](_$_7]-O=?NUM_D8J<KGD'\,
MYK0M_B-JG@'2+NQT73+/5=0>1+"&[6V=[W2+R4D>A4J4VE<Y&.200:_3+QU^
MQ'X-\<WDET=#MH+L982V'[AL]\JORG/T%>(>._\ @GDME!?3:/=:I9W<FUXD
MO( 5=E8;<L"5('. 2""?<U]=PIFF$RO$N684N9-65XIV=U=W?339>?FG\OQE
MA<3G>$C0RZO[-IWE[S5TD]$E=7;=[O:R\FOE+XF6MYI/AC4K2*\U*\U:&53,
M;HMYCNHV2J 68!>XVG!/?)IW[.&E23Q?VC>2V^GZ3;2$W]U=RA7M8TB+F14^
M\X!VK\H^\Z@X&<>]7W[%7C+5K^,0PM>P2R$L975'#$Y+-R<\\DU8US]@3Q(F
ML0Z:D%B/M5C*9[YO-$5K%)B-@CJ"/.S@A"#P"< \U[7#N;9?7S2I+'WA2J<T
MNDDKIZ/9I+2UKV:2VVX>(L)F66Y)"EE$XSKPY5ORMV:U2=U*3U;4K)W;W/)=
M1^*%TUC#=6ME-<0>([>.ZTN.-$'E0 #YB%R=S[@Q#'Y00!R":<GAC6/$PGFC
ML+J2ZO<?N8266/ P![D#J?7I7T%\ ?V+K'PMHUFOB#1H4\5Z###:3WMQ:^3!
MJ'!=)E96)?&\[N!A]P(. :]HTKX<Z-X?9I;J:6^DC3>(H(MD>?08YY__ %UY
M?%TL)+&3H8!_NDU;ST5K.[O&VS>KW=VSU.$:^.JY92J9HOWKU:5WK=WOHK/R
M6BV5DCY6_9V_9#UI]<7Q)KU@$LM%D$PCF4!IY,C;D=2JDAB3UP!TS7L?CW5T
MM;)(?LTUPZ$L^TY=LG)('<]]O4GBNZ^.WQ)UWX+?"#4=2\(>%8?&7BJ> -IG
MA>.X$*7@=E1@6Y8D!B2< 84@8ZUQ?C;P%KOA/3+1?$%G;V&KW5G%-<0VLIF@
MMI64%T1R 6".2 2.<9[U\/BL Y-5'JEI;_ANY]?1Q4YIP3Y;WM9J^F^GE?>U
MM>MCXMN?B+>?$#XFZSHECX4\1#29K6'4;B6V@,CVC.2)%4JW*L/G8C!3DXYK
M8U'Q;YFEQ+'-(RAL$@$9P<$8^M>E>,?AS-!''<:?)-93V\QN)I8AM^V%E*R!
ME! &\$YQ@ \X->6^*;!M-N@2'.2<KM/;G@>U?0\1XW+L6J2P-)P<59_\'371
M+WFTVMT>/P?E>:8%5O[3K*IS-<OEZ?RZM^ZE9?99-\-O%T-A\5IUO;A8;>[B
M5XM[  G !..O!]/SKN/&OQGT+PZDD8O(99$<IB$[BX!!SC .1DCWKQ7Q5<6L
MUG^_56';(P03Z'J,^U<#_8=HFI&:)I;=XG5AOF9L$'@@=3C\:C+<=1BHQQ$7
M[METM;YV_P F?1RG.-YTK=;7OO\ *Y]-6GQ)U3Q%H<"C1KJVM[R+[5#=R8!D
MM2_EF54^\REL*"."W%;G[0M\]O\ !Z[O8+C7)M0F%O!#8V-UME=5< RPQ$%3
M,F\,< D@ 8)P#QWPCO=3\6S:>E_JFJ/;V=L;;3&L9/(MK9@QE+R1;"&\P\.&
M?!P-N"37T3X:UZ/2M/BA?R6GMT4;P H=@!DX[9(SC-?>9AB\ORW&X;&8&?M%
M&TG%-J^JMK9I7:U6K35ET9^74:V:Y[@,9@LTI>Q<FXQ;L[)JSTNFVD_=>BDK
M-]4?._[+FA>,;_XVW?BWQ,L/B>;P_):Z+9YE)/V<I(6F/RB,$9 ^?+ G)*'-
M?1W[17B74OBY\++KP+X3F\*V7Q3\3:0VI^'[#Q-!'<Q6Z1RQQSS%<.IDC60[
M2 0&Y.0#7E7P/^&N@_!OQ5XJ7P_>:K.GBK6)-8OHKN^-PGVF0DL8@0-H.<$9
M/ '/%?0;ZSX<^'$^G>+M0TO2[OQ9:6<EIH]S+$K3V4+D&0ANH0D#C.#C)XZ_
M/\9<9QS;%0J*"A9)*UW9;M=%NW;1=-3T^!^"5P]@Y4H595>:3E[R23>B3:NW
MJDN;WGI?J9?[8UA\2OAUX(^$^@_#^:.::/Q%H<7B9+:**"#3].AWO>RM]TLD
MS",, "0%7 Y->5_\%3/"VL?'C]E35;7PEI5SK?B;2+V*]TR&UDVW !W0S;!D
M;\PR.#'G##L2!5GQK\:]4\3:E?#^U4N[VXNHD18CNDC5PQ=G&,878<8R3GH
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MQ['#G"A0<DCVS@"JOPRGC,37$ENCQE@(PV2,=SCTKG?&'Q G^)^JP1L/*M
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M:YDDF.Q"-C1H1&> "%3DG-9WC_X\^'_A?'J6@^ UTNSGU*8W6K:K#&J&[NF
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M-K))!"5,C2R@D \#L" >W6OLG]E#]I#PYI,3>']2^&MKXBL2IGFE@GE>:V4
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MG:>AS7E_BKQIKGB.U;4M>6.*\OG)2$$DQA1R"['D#@#@9)QUXK*_:'\9ZOX
M_8M:358KA);KQ%;I:W#2'8(2)&,0[-@JN>>.!V%>%BYRE3E*_1D90E6S&C":
MO><5][7X=_(]-L?CHL4>XS<'OGK]:J^+_B+%XDM;=H]0M["]MI!+;W#D'81R
M1CJ0?4=" ><8/R/\,O'VM?$F[ETW1+1M3U".(3-ND\N&TBR%::5N J*6 R2.
M2 ,U[#X8L6^'2W$.MQ7)U;F*X\^,%HVS@;>2 ,9QV[UXF3X?&QDL;"\8IV4K
M7N]=%^M].Z:9^X9E@\KQ;GDU>495)1O*%[/ETUMNO)JVNS35TO[0MC_8/@5M
M9\7:;XH\?>#=1M8M'N_#N^YN)M6F>X21+Y)2PP(P,_NU!+$8(%>I?$74M#\$
M>%(_[-GU&SB@\/QZ)8Z*MQMTVSAC,9618<\2 (!R#@LQ).<5R/B_6[/Q+I6K
M7-G!-97^MW-O<WDC7+R_/$LBH(DP/+7YW)&2>@& ,5QNN^/W_P"$3TK1X]$N
MO$7B%M4FAO&6+)BM/*"JCLS@!V8ADVY+$ '&"1Z3X=QV>5I2J-*>KMV2V>BM
M;;?9/R/FLVSG+^"<#24(R]ES*.B6KE9R33D[/1V:^)J[2O8\%^*NOM?7,DCW
M<:?,04==F#GG#9.<>E-_9S^*O_"N_C)I>I32IJ5HZRV]RL4I69(9HFB<HW0.
M%<D'L0,XKROXW^)_LWC2_LUN'NK&.8K%." 0HR!N"D@$$$$$]1QD5H? 5[6Z
MU!MCI/*'4A&ZYSU_.OR[-L+/"PG"HMKK_@G[I@<XAB<&I_9E';JKK9]4]=>S
M/K+]HRTO/@K^S_=:C\+]4NKFXUSQ#:7.K7US;FV_L^TCB"QQK&'D,B@9W'.2
M"P P0!Y1^T1\-+7XA_#^ZE@EO$U31K-IKC4&L_+LM4ER)E$/EIF$")9#F0DD
MHP!R<5]7_#G2?"OC/]G#6/#^M6>EZD]]#(MQ8:C>FU2["H2@CF4%HV#<YX'&
M"><5\]^,OV6_%<7P*U.?7O$__",>&[P16XT^)_MD6JK$"MJ\]Q&Q,@3/ )P"
M,D8KZCP_XDRZAE-;#9E1<ZE1/D:[RYD[V3MTVN[[(_%O$+ \39AFV$QV!QGL
MH4YIU>9*]11Y'&UK*6BM:T8I*[E>Y\S?!./1[R]OK76YM>ET]K<QG^S(06O<
M9 9C( RH0>@ )!P178:SX.TWP[HLD/A6:[G_ +1C%K/=7-D;>Z$0(  96P<@
M8)P"0,D$DFN;^$=M)XE\46FEV&FZQ-]G$J1:A;*DXG:)R'98U)<1$<JSJ 1T
MR.3]-_#CX12ZBL?VZ)(6D8>8LF0YSR"1V!'4#H:Z\33SO*::IXCFIPJ?"KO9
M.[:B]5OK=)ZGM8'&<+<45I8C"N%:K1TFTDW=JR4I)6E\-U9M:*VQY[\'O@[<
M3R*55X8)-N5&>>, D=,@U]??LOZ!K7AE[G3;'>S7$+'RR@<94$%@",$[2W;M
MGM57P)\+8=-EC^SIC;@#CKCM7NGPE\%R/XIM;B.%HI$)&4&WD@@ ?7.,5Y="
M///G>[[:?D>QC,9'#T7".R777;O?5^KU9\R?&+]G^^U/688;6PC-E<7 DU+S
M(T)$8(=)(F)&)D9 02,$,RY&<BI\)?!NJ?!/X5PG3[BXU9FO;LZZQB2X(.]0
MA5%PR[ I!P2<8)S7V%X[\'QW3,P"_P"AMY,N2,_@/0=,^N:\WU[P]IGPG\):
MGKUS;WEIH\U]#;F6QTU[R6:XN) BD(@!.6.68]/K7U%7C3'X3*7E5-1]FNZ;
MNKMR3N[==--.A^1XSPYR[->(8Y_%S>(FTDHNRYK*,>51CS7_ .WKNY\P?M%_
M$'PWK.FM>6+HQC("!$QD8 .3@'(/(X'./<5\[#Q'.[->2W+!=I"^8OF?+SPP
M[A@3P.<#J.M?87QS_93LO&&L:C<_:-+O+:QO9;&XNM*G!'VF-MLD+A3@2H3\
MRD9'<UY$/@JOP6BO=<ET)-6L[<AH'U:,W&F1N#M8,@&&DV.Q3!R"O3&36W!T
MXX[%T\'A_<J/5-O2Z3>]TVW;IJ?2<79M0R/(:V.QE-U*<4E**5W:32V::5KW
MUT[GSAXR\>76N:-+)%IEM92WEPEQ,A4N<B/850MG*'&[# \X /&:Z/\ 9;^%
MK3_$/3-0:V_T99!YBN/N* ,@CT(->]?$C]BS5-'T2/6)]%^RIA;=Y/MT5RLD
MBDJ77:20KXW!2 5!P>:]O_9!_9"A&O\ AM;T,$U6Y6-TVC[O))_('\J^2XTJ
MXJEF4L/5FIRYN5-;-7MTT3>[MUT>MS[_ ,/<VRC"<.4LTP=-THU(J3C+XD^6
M[3;]Y\NJBWTV]VQ\;?'W]L'7?AS^T=;:#;:C=>&='LM-22XALV\MY9[H^>9V
MSU(B:%1CD 9!R37HOPB^)-BNAZM:ZYJM_/H7B;2+K2O[:T^8F^T];A"AE4]2
MZY/.03D\YKOOVW1J/Q8^,.OZ/:6&CW&CZ5*NGH-053:1VZ *J L"6;"CIDCM
MCBOFRY^$W@7PAJ+V>EZ[X@T2[R3,NFS--8;LX(59@V /4$#TK>GB<+3H_5ZB
MMI:ZM=VTOW.+.. <UQM6.:X:K%RG:?*V_=YO>23?NNVBU:^X[S0;C0O@U\&]
M#^'W@C4M;US3=&O[C4&U*_A,0+RA0(HT)8A0%R23R22!7L9^(/Q"^'_[-VE:
M]X'L=%CU#66U$ZYKMR"DME+"81;6T1V/\[QM(RJ0 Y!!/ !^=]7\":YX7T2&
M_P!(\527T;@;?.BAVY ]5.,'_)JK\/?VV?B-\%];DCM_%[Z,T@"2K# ZB3'0
MG!8<=CCCUK.&94G@7E^"K.,;WZ[_ )ZG/1RO.\)G/]LYM1IUVVW*+E!1DVK*
MR7NJVZ7*U=+1GVM\0_A+JD_ASPKK&K1Z78Z_JVEI-K"VT7V9)Y@S!9Q"0#&T
MD85F7 P3T&<5GS>'8/!?AE[Y0IFD5H@[G"D'J<>@''XUY7\-?VH])\8:C-?>
M)-8U+5=6C(:2.>7)E<\C)R<@^HXQ770^(]2_:&\7Z9HMJT=M%=R%5#';%;QJ
M"S.W^RJJ2?I713IJG33YMEO^K/B<='V6,G6J047*3?*M$KOX4NRV71+[B;X<
M7'GW$MWY49ASB/*]3GJ!7I$'CB:-%CQ'$",= ./H*YWX1^(_A;\1?$%_X<\&
M>+[C7M6TBP;42/LR+:ZA&BAI!"ZL2)$7YC'( 2.1T.+>M7"VVDI?1VL,B2%E
M,:N3( #QQZD>N/RK3!TJF/4I87WE'?6WZF^*R_&X&M[',*4J<VDTI*SL]GK\
MUZIK=,LZG="^BD3'F"489D;#8'?\*\$_:A\&:]!X(W:+OU2R1F>Y2/\ UT2G
MH=O5@.^,D=<8KT\?$"!!AA);LPR%88/(S]/RK%_X3:*YU3Y77/< _J/<4<V(
MH3Y*B:[IGFUJT;[6??U/G_PKXWNK7PS81+)(HC@5,#VXHKVK4OAAX9U.\>X:
M*2U>8EG6W<(CL3DMCU/?%%;?6(/4P]FOYOS/H[QIXU6PL)523_29<L<=4!S^
M1KC%UFXGN;:-)6,;L&9<X!(((!&0.3W/ZG@\)XK\;,;XY=MSY!;U/6I1JZ)8
M6UW#=-'-#DLBDY=2,$ =R.H_'OBM,EC3AC*4Z[]V^M_S^^QTU,5%22Z(O^/'
MN--OUDA#B.1B'A"_ZGOD#J #P1CGJ!5>WL[RYA*%,_*"6!XP?YUN^'/$MCXX
MM7CNC'S\K*Y*9'4EN3M(P!U[9'2L#2[F32-9-FKM-$)"$DR2'YX.<#(].*^D
MXKRJA2Y<73M>3LUWTO?_ #]4*I!2DI1/;/V:+VVUW2+KPSJ"_NYOFB+'[C8P
M"/8]#[5R_B'PWX3\<?:K%8IK>ZTVXDM3-%'L8.K$'AL C(XQG->G? GX;?V=
M(FK72^4 /,+-P-N,U3\7W5CJNLW(M%CG9IC(KR(,YSP0,< =CU/4U\G3K4U3
M_>K3IW\R:F!G5K_NG9V3?9/I?Y'C]O\ LZ*EP#'KNI&/JJJ@0@@]<@$ ^]=5
MX<^ ^@V))OI-5O"Y!;=,=KG/<<"N@U;PMI]KHU_K&N:TN@Z5IJ*]W?7%W)%
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MLK,&*/6-0MC))<+D$F* D*B\<%\D]2!TKB_A/_P6Q^)'@6Y6/Q%H/A'Q59G
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M9!(R",$')W]5^ GAWXNZ#;GPYJEKK=YYKW-O9ZE"6M(V,3IEP&5@"'. #@G
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M^BMHD[:I:I^3_%:GAZP7W[0/QNT/PIYKZ?=:K?+:_:@04B4Y+E1P"0H) [G
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M8*&$6) >A)*'! ST_P"S;\</#?A#X=Z+#_PE,?AJYLM7EO/$%L^E&[?Q#:G
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MC!JFJ:[XS.K7L]Y<F9%C"RRM*+= #M1,\JBYX'0<]\U<\$:LUQ"_*@0J&.6
M)!. 0.IY]/?TKM-:BA\6^+M/L]/U"UTZ1 ;B_>:Z-NC6P(5D+;2 7#E2"" ,
MG!'7ZW^)W@CP;XS\%7FCZ%X<T32?#+^';?4H;R[5(K7PXT Q,D=P@#&1U).&
M#?.1W8@S_JO5SBO6Q\)*#2;=[).6KWZ=6W;I9:[>+Q)QUE_##PV30I.46XQB
MHMMQBK*R3W=K**YNMWMKP'_!/?\ X*$:Q^Q+\1%%P;C4_ FM2!=8TL$MY?\
MT\PC.!(HZC@..#S@C]AO#?BCPK\7O =CXJ\)W%KK6@ZM$)K>XMOFC<=P1U#
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M 2H',@(&TD$<X R":POBE\,19Z4FH_V7)HTFI*MQ)!)$QCGD()!A<LQV\,&
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M@# Y.!DU[0^H"QTJUN$5A:RA$CF?&!D<@OT!R.<D?3O7#^,=4TOQAKMAIO\
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M<9.,U][_ +&%]HVI?!_0-)\$PZ'!HBZW;7'B3[>PCU*./>48WLRA5DMP69B
M<@%0!P"/TKAG!_VQ6E1YXPLK[:[J]D]]^ZZ,_'^/HX/@["T\:\-/$<TN75VC
M=IVNTM+M=8N^JT;3/9OA%_P6#\3?#KP/%J6G^"I+B\M%"7UII/B -8^<V276
MVDC<*N, !'.#P23UQ/C!_P %%?B!^T/JW_"8?8UOO!%A;"&_\.V<SK?6K9(,
MK2(%)P'<M&P$?R@X)YKX _:$\;^'_A!^T/XI_P"$ O6N="N-4N-WV%3_ &4@
M#C:;1F(=XR0Q#,%R" O Y^S?^";'BNP_:"\?-?37&D0>(;6 "&241J+\D8"L
MGR LPS@E@201D'@_,YAGM;*<5[7#-/E>C337D^S_ %?W'W67\!Y-G&3RJ8BE
M*/-&\X24HRMHVK-MKKJG>*[ZL\X^/=BWQ?\  6@:UX;MX]2T;3+"+2[U;> O
M/:3*2WFM$6=H2X(#!2%(0')R*\FT'PS%?_$#3_#/B".VT.QOIHUGNKU3$]HH
MRP(90QC+$8)((P>0.M?='[2/[*.I?L+^)-4\9>']2L[G3M?N8X+K2I[<I;@3
M$LR"56*@QL> <,%)(R :\+_:.^ ^A_"F6R3[/XFN;GQ9']K%O978N[=V/!19
M-N9!A\@XY!Z5Y-3B:>)S'^T<6W)W3DEKIU23=DK:>738^YROA?!8/AM95PZT
MH2@U3DVTU+>\FE=RB[-M+WFM7JV6O&%GX#^+OPZG;X?>%M2T;5]$T^:ZUF:S
MU R0Z0D"$[G$QS(9549PP*DMSR ?E/Q-XIO+W6EC9;BWBFA'E6H(DD3(&,M@
M DDGH.<^M?9>G_LGWGA?X4V=QXHUNP\*:3XLP988]":\U6Y1.$\Y@RK&&!&0
M2.0,C.:R+7X6^"/V=;6^OO#=AK7C#Q:[!K&]U6WBM;72U(/S1JLDA=@#P2>#
MCIBO8XCX]P%2M&CE;<%;WKJS;\G=JR6G1OS6I\]X4<'Y[2P]2GGU1UI2DW"S
ME**5_>NY*+YF[NUVEKHFVCD_V=/V/;BV\"'5O$EK<0Z]KL@CMUEM&N#IEL1D
MRF)3N,C@8'=0<@9%?37[/7[&,5QJ?B&S@?Q!I_AG6()-/FLIYW??)E!)*DBG
M"'=@*""0"02<$US/ASXU^-?B'I"6WAW1[6TO'@"7-TL$MY(AQ\Q4E5C4YY^8
MG%>@>"OBUX@\">$=?NM9\;:M:Z?H%H;[6)K(6L\CAF"8 C4G<2<?>X )-?%8
M[/,%++ZF'G1<ZDG?G[;=7MMKO<^PS;@_B1YQ0Q. Q*ITX<J]FM6Y7?*[*]W=
MKEV:>VIYA^VO\(?ACJ/B'1-%LSK4>J^']/\ [%TRUM%>XDN60D(9I7 4@,6)
M(QP>!@"O7O@[X!M?V=/A_-:ZK>1KHMO%;RFWB?+:C<^2I:,$DA8RX+L0,D$#
M@'GSGQ;\.XYM=L-8L[BZUOP]>P0:M'<E!;7%Y#,F[$BDF3:J]<D XPH&:^C?
MV8M,^'^K:/K?C+Q7:WEWH&@R6XB@>,YN;B7F*(+VRJ D<84<X&!7RGU.KC^3
M#MJ,5OVMOOVL?4YQ&IA\!S593J:KF25YRDY))*]FI-NVNJ;Z,P;KQH?@]\"=
M<^)GC@QRZYXU4Q^%])N5*-Y0P#<%#\WECHH.,GG &,^$_ [P#X9\?>#=1\0:
MQ]OU+7=6O[>V@M8KU(4D+.3*&BQN.,!E .2%R!U%;G_!5+X[>%_C%\6[5I;N
MZN]9T:U6QBM;1@EG9KDL4(Y'R[L9')([#%>7_"7Q#<6\EC-;S^7/9/'-;2A0
M6MF0$*R'&58!F&1@\G.<FOT[A'$Y9@<8GBZ7/2BG%:7UZNU[6>S5G[KTVU_(
M?$3*,\S/(EA<JK>PKR<9M*3227PP5E=.*7,G=7G=NU_=]LT7P-;^&]9DM;&Y
MMKV", K-:R%XW4\\-@9QT/'4<5Z[\./$EY9^(]*T&TTC4)_[1@EDN-4&%M+!
M  H5F)R9&+?*@!X!)( KSWX:13>(8;VX59KN>,&>5@"6=B1DENYR1D]LC.!7
M>ZGK&N^!?!5W?>']&_X2#684W6>GO<K;+<2$@8:1LA0 22<$X&!S7'F5I8EU
MZ=-TX2=XI]%IHK)72Z.VO5MW.C(N>G@HX&O656K324I)[O75W;LW9W5]-DDK
M'YB>,O!UY:ZCJ-C*S_;=.O)K>;=U+HY5L_B":X37I9O#]O)*R;I(B"JD9!8D
M 9]1GK7VQ^VA^SCJ'PS\?V/CEK2/^R?&!634EMR7AT_4F4&6,-C[CMED)QD[
MAZ5\X_%?PM'%?KY4:E+@9VD<'OP?45BXIR4F=E*;47&/H3_ #PGXC\<>$-2_
MM;7+RUT?4P1-;1RB..=%82",1  ,-P# $$<8&,FJ7C/X9:#H=O/<6\BVVU7D
MANBNQ;AE +*!D="0,>OXXE^#D$R:];17#7 M+2X6:0M<-#'+&" 8@5Z'G.00
M>W&<UZ#?^&8_BK<:Y+IOAR./3M'D#VMS9H-^G-@!G(^5C&K'YA@@MDXSR?U3
M X"IF.7O$\UTE:*?2UNLM]+VU2O97[?D^:\89=D&9++H44I3?-)Q2WES*_NW
MW:BV[-J/->%SYQUK0-/\9QQPZC:)="-B8QDAD)'."I!P>XZ&M[X0QR?"?5)+
M73HEFTR]F24VD\N&M' (9XF;KN& 4/4@$'(P8/%[K\.II=2?=);VK"=W9=@9
M"1NP.W!. *Z[X[>$;.[^&DVJ642W=O(IC? ($BYX?L1D8(^M?D\)5(+E;TO;
MNO\ +[OO/U:IAZ%:K[2$?WB2=[6=MM;J_JFOD9_Q"GLO#WB.R\9:7J5MI6N:
M?<)<PPB?R[D2*00RC !.>F">:_4G]FK]KO0OVW_V>#XFU+0]/N/%.ADZ;K=D
MDP1BZJ"MP(NJJX)/(X8. < 5YE_P0@^"_P .?$G[)NMZ#=GP]XHU+6M4FNM6
MTZ\CCGF@ADCCBCC96&0I"'D<9)Y!K;\;_LE>#_V-/"_Q ^+OPNDU+Q])Y[^'
MKO3;Z9K>WT.&";_2BT@02W#1.B1JY!P&R68!FKJC34=FFO/R/)Q6,6)E[.K3
M<:D6E=7<;R>B<M$KVTOO9VV,/QUXD^'?P[U=IK&W\67^LZU"+:[CCG%O)) 2
M%:V>=096C8# 0$\;>>*G\"?M^P_#CPG<6NG^%K7P7X?TG4'%PMW++=19)R+:
M"' 9IB -PSV).,Y$7@;0/^%X?"_1O%GAE;.Q7Q>DB1:;K$<37<<L>1(L8;#,
M4.3E.W)Z5SWP?^&OAKX\:.^O65U)J.F^$I?[*2UD@DB-A(/F)97 RTH_>;NX
M(Z8P.?,:>(S&K&6+J.32LFW=I=E<PR^CE&58:LJ&&BE>[2T3D]+R2LM-O.UD
M<MHGPI\1?MY_%"XU34+'^P?"VH737<&G3L(Q<%06:ZNV'RD@*2%Y2,# !.2?
M6/"7P'\&@ZI;^#_%>A^(K[PY:)=WME;0O"Z0M@":,L,2QC<N2IR-PR!D5W7@
MG7['PILMI;/[1I<]K-I]W;1GRVE@FC:*0*W\)*L<'L:YWX8_![P!^REX2U[_
M (09;J:XU>R^PP+<:<EN+&,HJRO(X=FFDD5%W$;5S\VW.,4J<\/5ITZ,5[/K
M_7_#LY\-C<NQN%Q%?,ZLU7BE[**^%ZZIZ/1+I>/=-O1\G\5/#=MX[^#'B3P)
M)XGU;P/+KAMY?[:L$,ORQ%F:"55.\)(&Y*]P,\5E^,+_ $G6+3P]9V.H7&I/
MX:TFWTQ-4N%,5U?M$"/.)R6'/ !)( &:AU;6/[?D\N5TCF4Y5"V,8/8YP.,G
MO[UJ7/\ PGT-_P##A_AW<>#(/"MO(S^-FU!;<SN_G$,',N&$?E8(V').<#->
MYGF6X;!TO[4HQ;;LK)W6IOE-3$9E2ADWMZ=.DG*HG4M%*7+_ #V;U2LEM>WD
M<#XR^"\?QHMY+J!DM/%-HI=9D4)]M &2''3?[CKUZUQ_C'1_ /Q?T/P;:_$$
M^+-/UKX?PM8KIUDB/;ZHOG&4,"Q'EN2<$D,,=!FO6'\26^F?%&\N-/"K81W\
MC6FS('E>8=N!Z$8X]*[+QOH6FW'C"1I]/MI))E61)1$/,VL 0"._I7GUL/1Q
ME-4L0KK<\7*\ZQ^4XN.995/V=5)JZMU5GO=;;=ONMY'<+J'QM\?7.H1Z;Y37
M6Q8[=&+);Q(@1 7;DX11DGJ<G%=Q>_L_2:'X>:::=7<8 5>F[T![U[!X=T+2
M]%TM'AA2'<H)W@1C/TZFL/Q;\0K'PW;K=26TUZ^X^6CQE8@ >3COTXKL5&2B
MHP6B/%I6G)U*DM6[^;?]=[$7PJ^!GVSP;;S75C&TDA+!I.&8<8HKQCXB?MVZ
MH/$TB64<D%M$H1$52%&,].**Q>'BW=W_  /0>(<7:\5Y6;_$_0W28=(\ >'G
MT^UMX[B67*-(X^0@=<^O-<_JMIILMO)-(ML)'Z?NPQ)['&"<#I69XH\3EK69
MHW578''^P.PQ]*X,^-;NUM6MXSYL]QE@QZ)CU/![< 'UKQ</"KBJBHT4[=%W
MZW9W1PRHPO'6;W?^1C>+/AKI.J7LD\UK]G=SGS;=C"X/L%('Y@U!\/?!4VF^
M-(/L^J75]:@[O)N3O. <XS5?7O&]Q:7,EK=HN[G:\62K]\$]B!53PCXQFTG6
MH[A8G"@@@G..#R*[*U#$X:?LZJ:DB'+FJ6FC=^,&G+;Z_A4VJS%L]SSG\,5S
M\6N+:7<>Y?D QCU]>.]>H>-K:W^(&CI>VB_Z2L8D/?..O'K7FWQ&\.'2HK6[
M\I8Q*H=0.GO@]P>U9QBE9]&+&2GRI3^):?\ !^9K>#O$TGAT,S"8Z;/(%0LA
M?RC@_*.H&#R#69XFU"RUKQ8LVF[(Y(=H9U "E@<@@^@].@.<51N/'RCPU]E6
M5"K*<C@8/'0=C[]ZYWPGI-QK'B-8[/S)-Y&Q8\MU[=,U])B,^KUL!]2J)/;W
MGNTG=?CUN<<*DYQ]FSU+PII:ZWKE_:Z=HNB:-/X@NEO=4FTZT$,NKW/($LN.
MIR2>P)))R237K_B+PA'_ ,(BWAQHTN($:-]0=AE<KRL:\YSD9)I/AE\-8?AO
MH$?B'5I&^V6D1;R0!A'(PHSU)_K6WI#KJ7AKSI)-IF=KB7W8GH?H*^7E+ZM'
MF6G;YG1[:>(J+VK<EI=MWTBK)7?1)))=M-D?$OQV_8+NM7UF2ZTA=+N48GRH
M7'E"W3)XZ8&.V!S7FFO?L5>,M%T!ETW0[.'4V=!#)<QM<6N-PW9$9)SLR1TY
MQFOMSXB>-M0\.^%?$>J:!X7U#QKJNCI%):Z)8R^3-J&^4(Q#8)"QC+$ 9(K6
M1+ZUU*U-O"]B\MK%<365Q*+B2T9T#/"S*2"48E20><<5Z6!PM7%+EC\5KZWM
M:]M]K^1U5Z&(A%8N-N3F<4N97NDF_=OS)6:UMRO9.Z=O$?@A^S3JNBV%FMQI
M;&557S)1$(D)QR0N20/8FI_V6OA?;_M:1:Y\4-/T72]$\6Z1>2>&]#GUI#J=
MA;Q0.K?:5@X F9)&4D'@\=02?=/BYJ'CB3X672_#?_A%[?QI'-$L"Z\)6L0N
M\>;N\OYLE,[3TSUKTKP;';Z5I4-O';V-B%4R2QVL0B@#M\TC@#  +%B2>3G)
M.<FLUAY0DXU%9K<\V>85(4VUNWWVMO==G^C/D#_@I#\"]%F\+ZI%J5W#<RW5
MGFXGEC"B,L"K$9)"C!) YQQ]:_.?]D']FB'PAX9UJ[CWO/=LR7%U(FU1;+(3
M$%'4!E57(/.6 /2OJ3_@J)_P45\&_%ZX_P"$5\):;X@?5;>[*WMQ- $2[B0X
M5$3)8J_4%@."#C)X^?\ X:_&_5/&'AV_T=])^PQHI^6-@'! Y5AU!'H17/4K
M-7A%Z,^KR3*6J<<3B5[ZV6ETFM_\CQ?X]VC6'B>4+*LDEW(0&4$A%)P./:O:
M/@P=+\)P:=:_VG"VORW$]M>::L9CALQ&AP2[DD@G)R0 .3T'/C/Q+MI9)96:
M62,G(!&02,YP?7D=/:M#1OCK:_#GQEH]Q8Z5;:GXD\07BI9W.H*)((U,6Q@Z
M9!)4+P<$<@9( -?7<*U,#34UC?*R[[_/UTMW/CN.JN;MP>5;/F4M=E[N]]KN
MZ6M^UKLM:G\7U^(][?/J2W%MHL<I6% VQI(@2I"$@C=D<MR ?P ^G8/'W@7Q
M%\ K:W@D\/+X<M-/N+S4!<-*]TUU#;J(?-;:7MWE)8*(_P!V[C(SC ^6/&?P
M;@\,^#I)FA9?-A>1!O9NK%B>O<M7G-E]MGNOM!N;GSO+6(2>8=VU5"JN<] H
M  Z <5ZN6\9T,&I*C04DU97MIY^>MG9[]TS@XDX#Q.:0HQJ8F5*<)*;<6_>:
MZ>3LVE)/2^SZ:5OJ\>O^/]8TVU-S=I8:5%J4L\J!7B9V4",KD@@!AR#U&>^!
MZ7HGBK7/&GAN\T71KV\M=(9XKFXTQKDR+<M&@7>QXW E2Q!XSC@D UXR^C7E
MAXOL]>TEFAU6V1;:6,-^ZU"$<&)QTR5X!]0,UV5AXL7X?>)_,D?[/8O<^4TY
MS_HS9)0L0"-A/RL3P 0<\5\%/&5XRDZ$W'G^*S:O:[MO>VNU^U]4K?HE'"T*
MBOF$%/V=W%R2=D[*^UE)):NUUK;1L[_PUH<CF1IHECDW$E0NT GG&.P]!7WU
M_P $*/!EYI_QA^(_BZVTVXU1O#OAU+6"TA9$>ZFFF#K&K.0H8B C)( SG.*^
M:]6\&QW?@NRUA;5;:292MQ&.L;@9S]".:_3G_@DKX"M/@I^PXGB22#_3O%]W
M-JDS#AI$#F"$9QP J$@?[1/>KP]E^\?3<\CB:M*G0=**OSV27J_RLK'G?Q6M
MM:^,<EUK^O>&9O!^I7KMYVCW%W'=R694E0#+'\C$@;N.!G&3C->"Z[\!5U'5
M<R,!'NYPN<5]7_%/5HI+RXC69)"S,=P(R<G/X'!KR589I]=\N.->>06.!^=?
M)XBK.[:W.NFU[%1[+;_A]3RRY^ 7A*UL7TVZT]-1UJ^F@CMV_>N8%=B"QB4J
M,!0Q60G ;AN.#XW\1OA#H?AMIMMN@BC<K&TJ>6[J#@9'9L#G!/U-?8/B+1;&
MYT]!<0O;S)("TB8VCD$D-@G)(P?4<5Y-8_#M?$LL^O>?#<6LLQ5 P#>4F2%
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MBP#*.Q&!DYKT+2OAM!\2/A?\%KS7+RZ2\LO%]KH9NTF=)[FSF;)MVD4ABK$
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M  !_9CT'X77/A?2-/UGP_P"#[OQQI\^NZMHE\HN/$&L&5%D)CED82+#!EQ@
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M R\Y^AKN_A3%9?"[2_)+Y3.21DLY]AS6]<SO\4-1A$VS3-)A):2:4@2.HY(
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M.=LJQN5=5/7!/5\ X.1DXQEV7Q[F^%.JZ!-I-C;_ /"1:Q=VL%C>W:B5[(J
MA.QE(8  ,"",'ICG/1^,O@]#IOA6XU6:"%IM166X=TCP&=R79CUY+$FOT7,,
M\RZC&$L-'FEKK]V]T[_YWW/RKAO*LZQ&*JK,Y>Y%1T_\"LE9JW?57M;OI]4_
ML_\ BW3/BK\%++2?#NF2?V/I\&_7-.M]'>YGN%6"1K5YUW9N TV\*8B"05R#
MC(^)_ '@/5/C=\<[[PYX?L6B>UT&;6]0_M*X2W33-KA0ID<@*JDXPQ).<'D$
MU]$?L,:/9+\"='A\1:C?:6VI^+C+X>^RW#I)J=Q%%&OE2%5;RXE8  GIEL
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MYYM]SJN]?,8(1C>6!(()4C@5E:=8?V5XBDEF^SQF%LA9&VYY['&*]K\'>--
MU_0@9;=8'E'D7>7RDBDX!4@ @CU!KX["\4?V%F<,;6P_M::W3MUZZI[=M+[.
MVYZGB5D5;,,L^KX"M.E)V]]2DWHM%\2=M%9_9W2[_!_[0?[/.G^%/&6I)IL&
M=+69HK.,X=T120%)488 Y(89R,$FO.],^%.N?$K4X-#L],U"2\6".VMK=4\B
M*5-^%#ME54 N27D./4Y(K[TUCX7:?XNU'4_$FEW2R0QW+((FR61%8+@<?C@#
MZ\4V?X>VHT\7$$TDLEW&]N5BROVB-D*LK!>=H!R?3 ((XK])X5IT,PQ$*N83
M=.-5WDHMJ,+ZI:WT5]V[*W7KX>?<08K!\/\ /@*2Q%>C#W%)+FDXKKIO)+51
M2<F[)J]U^?\ \2OV9M8TG6Y-/OM/:VO)'D$ODPK]GWJ2K*A7*L 1C*\9]:D^
M$OP?UKX6ZQ%JMC)<6TUL?,Q&[1R #DD'CCZ5^@LG@O18O#NEV+1S;K>RC:8M
M<E[=W*_O6@1OFBC9TWX).2Q).>!YW\;O"*:OH=S!I5HR_P !=< AL' )[#H?
M:NCBC+*,L;/#Y=4<H/[3U];]7]YAP?FV98O*Z%?,L/&CB$K.*T4;/2R226EK
M+73JR[X"_P""IEK\1?#">#_BAX3MO&FEIA7N6C,>I1*!@,DR $L!TW CL0:]
M(\.?"+_A/M$BN/@5XUUCQ/INCQ^8?#\TB1:QH:DY($,BGS4&>3&<@?P@5\1_
M#[3TTC79M.NMLM\\I65]O&P]"/7TKZ^_X)]^)=&^!?Q<U'Q-J=S<)IV@:+J%
M[/*B[I"HMF41@9 .XLJJ"<9*@5\70INEC/J=96>U_P#@]?G?3:Q^BX/"U(X*
MMC,/!)PBY*/+>$WV<-DV]+PY7??FV<>M?L_Z/XZ\4QS>.OC=X1TW5X4\L65Y
MJ+3-;$=(SY"&&,YZY)(/6NH\/?!CP+^SYJ:2>,O&7PZM+9XS(LBWB:\]VIY4
MQPP@LIQSEV7)]@*_..;QO>:EKUW=2!9%N9WE*2C+(&8D#((S@''X5V7ACQ8=
M:N+>S@L+>6>0DCJ6<@$X&2.<=!G)Z#FNJI%4YKDI\TO*^OE;=_*QZT\;)4I1
M==PIV=[1@K)=8NUDNKYN?U6Y]O)_P4*^%/PAE_L_0_A[>>.F25W6XU&_73K(
M \Y6W16X] S'\*S]0_X+!WVBB9O#_P (?AKI9NH3!))-8M*\X]&&0I4>X(KR
M/Q-^RAKG@'P[9:UJ46EPM=61O&@M)?M4UM$&V-+(%4JH$GR$;B000<CFOGWQ
M_P"*]8T2X?9<MM7(#&)&Z<X!*G\JUQ_U_!UHT,33=)M72:2;7?:]KW5WU36Z
M9\QD^:\*9TYU,')U^5VD^=RC?M;GY+];);-.UFK_ %@O_!6;XK>)[F[6ZT/X
M>PZ5?)]FN8T\.PH#$!@ /]X8'3DCVKT7Q/XV\8?&O]D#2M)\ VJ6;Z7<7%YJ
M,2H8S>S,0RSN6.6)7Y.#@!.!7Y_?#76+CQ'KHAU+4)F2;);<053@D''0<X'%
M??7_  3,^+-IINKW&DZLRBT>S>%=\7F1[@0RDC!((.2#C@9[5HJDN:*E+26C
M^?\ P3WZV%PV%PD\1@\.E*F^=))*[2<=H]5&3MU3L[Z'R+?>!=>\327NJ:I9
MW$ TE!]NEMU7R(&))^=B1EFP<=>01Q7=^#(H_#D3?:+K)@)B*JA5T<'HRD @
M_6O9/VDOAKH&H_%75)+6[2TT*YNHKG4KG3,N)"""A"J"H*GAL#&22.I%>0?$
M/4[7XG_'6XM;.>WO+2>0 WMC#]GBOQ'DGY5R0X!568  D$@<@G[V>0X:>"C5
MPL_?3U3VMNW?^[>STUTT3>OX?A^)\UGGDL/CZ-H3CS)[-/HFGNYI<Z2;LN;=
M*Z]B\&_$K5+KPO9:3ILEO:J+B2<W0C1YXXWC"S0C=@A90J@L"2I&0*^A/@M'
M:W.BJWV%;21HV9;:>[DD@BD"$H"V2PC+XRPYP2>M?,K?"W3-*,$EB%MY'RR?
MO"9  0#SDYP>,GFOH'X:ZWI_AZ^T;18;G5-5N-0(1G>':\9V@CGJ03E5..N
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M!]C73P_6IX3&PJU/AU3^:W.NIB)0K:G9>(O#']HZ4[2?NY3.%0%B3Q@Y'3C
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MI)IL @LN % &/4GDG-=5\??VB;K0=372M.O([^.ZM8KFVN;7_CWE@E4-&Z#
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M& "2,8_/->::7XIU#P>PTG6TV/L*K*#NBN%/0@X_2KNHZX\%H_EW6^.50N6
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M-<0ZG,K#S':7@0LZ/$R0G!() R017TGXJ\,Z1XA^"5CXLT^_VRZM%C:D?W'
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MO$.LB>1?5(U9OKC<Z?C7Q)X6TV2Z*LQPV/Y>W6OI[_@K#\08?^$Q\$>&K/;
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M5K$4&0CL&P>QV@XS]37ROXU^+/@.?Q]?ZZL=[J>N7Y/F7-S,7!!&-H' "@=
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M>H_%2X36O$^DW'B+1;=I;?4B+.*]O8RJ';N.!,JDD8DR>._!%>=>,OA1X/\
M"/BB/5H+2ZUS08+=W-K,9(Y[978;!(>,E"&^900"R[B<C-G2/BA>?"+XEW&D
M^+(=4\)ZOI,C6]PUDVV:.0'(.[.UE[C!&00<BK$/Q>L[[5Y7AU5+BS1S)',8
MBL^[DDD*202>,@X.>>,U>49QC<LKK$8=6>SZZ.VU[K6W^0\\P. XBPOU+&7<
M;WM=JS2T>EGI?:YY)^T7\:(_B'XDL+6U6_ETGPYIL>DZ1]LO1-+;*C%V,K8
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MN)%BW$;B2Q ! ]>>E?*,'QST&^U.*3[))IZ ;8KB(%_+ & '7J1[CGV->M>
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M+2:VE6.4&*0LLT3*[OYA(8L&# './,]&_:\G\0^$Y/%?AO45MKRVM+4W,"Q
MKJ$3&12=C @A2%.#@C>PR,5[/XK_ ."@.K?'']I+X:_#.Q\(Z?J+ZKHMOJWC
M6^U&%S;V<,ML)I!:.NU0$R2SD#+$#'6O!-?_ &?=2^(7Q7N)/!\VGZ;:V"R2
MW4]\XM[*"R5\9E*@X'*@  G)  Y-<?MH5Z<N65^3K:R?7\CZ:I]8RJ=*.(I6
MCB4Y0CSJ<E%R<5S62][F3ULKK=7O;EO$_P 1=#^/?B:TD\2^&M#NYYIX[:2X
MMY9-/= Q RQRR9 .<G''4XK$^-?[--G\/=.N-5TO5+?Q'X8U M;0,+@2RZ>
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M!1[Y)["OCO6-&\5?%F"WCOK^YN/#VBA+6!O,"V VX BC7),S@<$G'O@5[G\
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M[J?<?K5[0OA5;V%Y"LZQRK&0W(!Y'2L>?XA+XA\;:A>:AJ#6\$LA$;VK[&8
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M;CPW=()PN^2U#9$RGH\9[@^W2O-=<O?$&GHUO);S(R'T.,CV]:;X,^,FB>
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MPCI;L9#&K'!);IGM@9ZUC4BYR<GL>]2E*$(Q6^AZ/8>)%U)VCM9%%AI[>3&
M>)9NK/\ 11@#\372^'I8P[;I=P/WN>HZX]J\K\ ;O^$6TY9"R.Z!W [,W)&?
M7FO0_#GD,SV\:YN"GFX+!?E&!G/N3BN/V-7$U/9TE=O9(]114(<BZ[]V.\>>
M!K3QE:E)#M,>6BD'WD]L]P>XKS;0H+[PAXB%K,-JH^5?G$BCNI[_ ,Q7?>)M
M<ET1?)NE^S^9DQL3D''&"1T)ZC...:V/!FD6/C*S2&]5&P-R/D9!Z@@]O\BM
M:V'KX9\E:+7K^AYN(IVES+<[KX:Z%;^)-(:2$\D@^4_# D9RIZ$$YXZU)X@T
M2\T.XWPAFVKNV =_ZU-X:LAX7B\F-T\E#QSV_F,]?8UV?AOQ59ZW ;>9%D=P
M0-X'SXZ\]B/U'([UPRBI/4,12J.'M(ZI_AZGCFH^,O\ A)KI(+J98?)8/O)&
M8V&<9'7GH1Z&NB\"^,;>_O#$J1[UVKB0X#A03P%SD' YZYXXXIGB7X7VHUF6
MXDB81W#_ ".IZ>@)]:[KX4_"'3[)U\Y'*GHW3&>Q->]E.?U\!%PIQYD^C[]_
M\T<\,3*&B+/@KX9W&I6)F$6YI"6/EIZDD\=JZ+0_!D-E?_,GD)'RY?(.1VQ7
MJ?@K2]/\-VY6U#+D <G-+J]EI_BGQ1:6K2(?(8R7!XQ@<@$_XUX%2C4<W6K;
MR?XM[DX6LI3>]K7N>4_M;>)+'PW\%[>SN$\R?5&4K;#K*H.$0CN"><=Z^=KW
M]G/Q=>VD5W'KD<<LJ*?LJH42#(R5&.!CITKT7XO>+K7XO_M-+9;LZ;X?#, O
MW-ZX"Y]NGXUT$6O_ &2X\M6SY3<G/4=JWQ%:5/\ =4GHM_/S-L+237M'HW]Z
M73\/Q/F77_V>/&4=Z?.M)+R1OXEG5A^.2,&L*\_9^U[89+C1KX.I^]Y?\CWK
MZAU+X@3W6K&'3;=&E0X9I.F<XX'?G@GM^M-OI]4NK0,LMM,VWE9,)EL<J.01
M[<&N["Y7F6(I^UA%6[-V;_KS*>'DW='QGXD\,:AH4OE7-M<1D= ZE?P.>/Q!
MKT[]G[XTZKI%S;:7<W'V^S9MAAG(,D8/H6!! ]#GZBO1=7TW^VK[R;A-F!E@
MPRK\9^4]#^'6N??X5Z3%J_VF&':[$%@O'S#N!VS7/6]K2E[*O'EDBHXAP?+4
M]Y=F?6WP:\:?9;1/*L[-HB!G9&(V ]U''Y<5V/Q+\.I\9M$T6SB\2^)/#46G
M:O;:I,^C7OV.6_6%BPMI)!EA"[;2X4@L% )P2#XW\!M09UCTVX'F12+L!/WL
M8(P3]#7GO@7Q#/X8^)WBF%KVYN;30W9(H7D)7<6PI(]JTPG)4NY.UMSEQ%&+
MFJM)>G];'U7K.J>'_ ]_>Z9X=T_2=-O?$%TU[JL]E:QPO=S,/GEE*@;G(&-Q
MR3W-,U35[73=*+-,BHBY)9@  !U)KP/P1XSNIO$LUU.))))8R58Y.22"?TKJ
M+GQ1;>(-.FCN;NWC$1#LLK;1)M.=G0\GMGC.,T2E[:K&FWRQNM>R[G)3BH[O
MU?\ 7X'/_$?XD6>O7%VEC.BQ644EQ<7,C"*"TBC4L\KRMA550"2<\5XU\1_$
M-_?ZE$+BUMS:W&-2CFL(8?L]Z;E%<W(>( 2-*H0F0Y)P,GBNYUCXIVLVIW#6
MT<=J1N@=+A0T9#@@Q[>5D4@L#D$$$YJQX=\*ZO\ %K5"\,*7,<(2)611'$FT
M87 4!5 4 !1C    KZA<-X*E)5IU$X6WNKW[WVM;UU/:C*DJ#BI--O77W;=-
M.]^M_D'PGTMM/GL]9N=$6WNKC3ET:/5F28--:+.9Q",MY9Q(2<A0Q P3@5YS
M\$?V;?A[\:/B'J/Q=\5>$+SPG\1[+5[^6Q\-WVHEH+@1O&@UI;9U#F1OE4NN
M8MZY ) :OIJS_9SOHKO4=45'&I:U!907W^G32V^VU0I$8H6.R(D,2Y4?,>>.
M<U/&/@?3_#FGPZI/I]A)KJ12V$=\;=?M45N2&:(28W"-F 8J#@D XS7R$.6+
ME9*UW\_/IJ]SI6,YI*-*K*?NQC=NS22U@ES/W4[Q6UTKI1;L>>MX!L?%3W-U
M=1)<&-MJ*XR,D9)(Z$_6N2^-O[//@+XI?\(CJ7C!M2L;KP*LMM9BU@6XM[NW
MDE$S1F%F51(2& <AAM8@@D CM/!FM/! 0V[RWG8$'Z  U7\4O'_PEP:^$BVT
M"H5902 IR"Q' ()ZC.>!SCBM<+E/]HXE8>3]W?[B<HS+%9=B8XK!SY)J]FK=
M59[W6Q\>_M66#?%;XIZW?3:.\=O>.HLPPSLA1%1%)ZE@JC)]>>E?..J?"K4=
M(U1QIM]=6;+R(RY*\_CTK]!OC%H]CJ5BD=N\(NHOWB!?N."#G+'&2 .0  #7
MS;KWP^O-;OWO%3;@D!6.#MSQV[U]-F>5X?!TE%/79+R/+Q4G3GSQD[O4\O\
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MU3"3ISC"I'5]#Y#GJTYJ%_Q/ECPE'H?@GP^NE:"8[3RYFBM[2*W3,"@#)"J
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M>/)X[?6FN;/S'@Y1(W;< N<[2,>O.?6O>Y?BA%XDTYH]4TRWN(V_B@;:2/4
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M";X.MH]K,;>Z^T8?S8P5P0>X!SR#7*^.O%]G<: ]C?63QSP9V2<A@XR 0<8
M /3D5#X._:*DGA\FSN[:5<_+#<K^\0>F,C(^AK<UWQAI?BBW7^UM*RV/]9;O
MR/P;!Q[9-.G)TY*<&XR1R5J-=/WM5W1\[W=[+I-[+&D;7"2$M\Y+$D]2#ZGO
M6EH7PCU+QYF2QTN9\'+;%R >N2>E>P:=X>\*B96M6C=F;[EPA7'XX(_6O8O
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M"2<D\]ZJZOX7QX@>V:-E123NQQ@>]<.48)8&DZ47=MMM^9YF:M5;58*R>O\
M6^VQS/\ :LWA[P]/+'$OF74@ACY ( &3QC!'Z_6M+P)X+UKQ?,+B-+B2&%PY
M=,CRF!R,'L1[>E06]HWB3Q@MJJXBA^ZO;/3.*^H_AIX5M=!T6"&-5$4:#< .
M78\DGWS7O5LVQ4H<CE9>6AX\JC6AYXNI:U?0-:ZG=1R),ZO*?*2-KAE&%,K*
M SD= 6)(KD/VI_%4/@?X2&TMRHN=>G6 <\^4F"Q^A.!7MGQ0\-6Z-'>1IL3<
M,X!QD'N*^5?VK3?>-OBC9:?;1,;72H%0<?*68EFXZ#)(KRZ-.*>AW82KK[67
M]=ON.+T>V0V*R,N>/3UI)H(TRT8WL<\!<X[5TNA>";VZ>.QP@9@!N8X'IQDC
M/-;%WX0MK6:2U80Q21 >8,_ZLXQ@GDDG!Z=#7T&5X&&);4WMT74QJQ56=V>7
MRZ>MQ<%67YF.#FM[1]+CD15SE@ &^O?%=2_A:SO;4Y*E]N001GT'/;&!UZ_6
MN8MUFM;YEV-N0X88_7\:699>\-\+O%_F<KHN,CG_ !9^SYK6LZZ^I^$YEBU"
M6$I+"^-ESM!*C&""P/3((Y(]QY?\5OV??$TGC6WN?&&H7&J:A>0QS3*X"*&P
M.,=RO3G.>IKZX^&>LBSUFRDSRLRDCOU%/_;+\.*WB^&Z6/+.N\#ZC(S7E8>,
M=9-:JW^1[<L?7EAE0D]+/\+.WIN?*'A;3Y/ 6IQR0JD"1XP.G'I7TM\)/CM#
M=1*WFI;7901RAN4G X 8>PX##FN#^+WQDU3X%^-)/!?A/P+X=N#9Z%IVIWOB
M?71 T=RUUL+&-9^)(U#[/+BP_#,2 *K_ +0/@P>"/&=A/8V<.BW&J:3:ZA>Z
M=;.6@L+F129$C)Y"$C<H/(# 5QT<RIXBLZ44TUUZ.SL>[C^'\=E65T,;CN65
M*OK%*2<E>*DG;9736E[K:23M?Z4TWQ)HMS_I+63PS@??@^=,^HQR/KC-7!\8
MKKQ#;M9ZAKMQ+9AAB.9F XZ9XR2!TSFOC72_C)K'A;#1S.VWU)KNO '[6*ZK
M?QVM^K1NWRAP P/X$9KLY;:O_,^9CA\'5]ZG.WD]/\SZ$\2?$NQT^P\FQF\X
MJ,DAL+GW/0 5Y3XP^,4>E63R6MUBX *S76!@ \;(AV)[L>?2LGQ9XCOK_P 5
MZ;I4<'GQ:P':.Y48BRJ$A/\ >.!QQ^->8VVA7WB"\%O<%]Z.5V'  ;/Y9K7$
MX6-.W+-23UNEIZ:]3HPM6AAU*=2/,UM_P?(KZ]!?_$R0QQKY-D">_P SD]<G
MN:J6GP&T?2H]UY<*K$YQNKN='\(7WA_3FDDB<0@%L@8R!UY]JH>(K>WM DD<
MTQ>0A?FXR2#@@D'!(YR >#CWKT<GRF>,4G%VBM^YQUL1/%S<YGG7C3P)I-C$
M%L[N02=L,1BN9^P^*=*&;&\N6B7D;22..]>C#1K6=6:-TG=R4C&3NR!GD=R.
M@QZ<\<5N>%-&;3[AA<)^Y90%R!@<=_>NK,LKA@X)N5V^CW,OWD%[DVO1LXCP
M%\4O$5C=)#J!:ZA) 8,,XS7LWQ3\,6GBGX=Z1XBM84BGLY5CG1   IX! _G7
MF.MV,-GX@=4P5<Y '?GM7L/PX;^V/!AL&1GM;J+RW!YPP/!QZ@X->+-J-G$U
MH5JM:]*K)O32XGA_0+[5--CFMT>6! I.%Z9X%>L^ ]8\NWACD7!1><^U<[\+
MM5C\,^$9[>XB5IX9&B<'.3DX![9X_'TK2/B1;F\$T:)&",$<>F/Y5*@SR;M2
MLSH-9\1R>)+N2!)_)MK=PFQ6(#MGDD]<^WH<C/2J_A.ZN(/&.G6\G[V"2X P
M3N*!?F)SU[=ZY?2_$DT>KW:R%EC)+(5 !)V@8/J..O;-=?\ !99O$/C26Z9,
MP65N\S&,?(#C&<^P)K[:CA\.\"KI6M^-M_O,ZSO3T/@;_@H]X9NOC'^UMXLF
M8O\ 9M/F@BMI81YCQ>7$JLH';)W9]ZY7X8>)=/\ AD1#&VJ2S*</]IN7./\
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M2B\7-25&FJ4=$K15VEHE?5O5W=NIY;\??&6I1:?_ &4MLEW=BWD@\Z3 D.<
MDGH"""#[\9JQ\+;;7/!'PO\  ]C9^(?"N@:<-9GN_&%IJFGF[NM<LVC0QI <
M'@#<#@@Y(YP,'<G\,)X^^*]Q'Y#"QTORQ()$$SQQJ26^4Y!/)/.<D9.353]H
MR[CU+QK!)8V?V6RAMUMHDV[6&UB<D=L@\#TKY_-*+JX>4=5ML['G\/XN6&QJ
MKQC&32:M**DM5:]GI=;KL]>AXI\0/ ^H^'?&9\0^%T&^*Y\Y;=A\DBJ6V@CK
MPK$<<C/'-<EJ^I>*]#\(72Z;X$:R>VMWAL]8GN0][&)9"[E954$ $G !!&23
MUQ7O7AF8JZK<)MYXR*]?O-!M=?\ V>;G%O&&MI&&['/(SQ7@0I\TN5^9^B9?
MGE:C05*2NDTEY)M+]3\W-)^ E_KA&I:U--<3-SAY68*/3))))ZDGDGDU[_\
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MJJ=WLU:UO4XZ$:%*K>I[R2OH]]B;X@_$J_\ %NJ/!#,MS<L/*\T\+$H_A4=
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M*O?8_P"R?B;8ZS-$%CO@4GR./, X./<>G/7%:GBSXBQ7\TT*Q0ID@;QP#M
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MCQK7@^T#+=[GXP6&['M7"XRY5S:L]_%4Z<I2M*W;S7Z'WYIWQ#^P'$ENT(3
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M2KRJ8:'+%]//KZ>AG[-1]]:(YWX1-<V;*GS%<C+<_J*ZSQSX*.ML)[&94NE
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ME;L<7XUTK_A((MT;K'*X.[:WRGWQD$'L3W&0<YKSW4O!$D-WYDK/@-G!/R<
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MS_+%=<*BO?J<M;+:\7IJNZU.HT'PQ9>']/>Y\L23MC;N Y;USUP/3IQ7BO\
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M!,06 #8/" 9!W9YY%</JGPZN/'FMS76G1.T:$-)YXV_OBHWJO^RI! / .,@
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M4X\"^*HGSDYMXV'ORKFG:]\*/'TL6VQ^'WBAGQSFW1 3]=_%?H)11_9\>[_
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M5"'_ )-_F?G?-^SO\1VMEAO_  #JUT@_BMGC/Z,PY_&M33_@]XRTV$*OP_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MABI5@H4DDLYR .!DBA1?E_7X@ETT-2STGQ=>:<UQ;WVDPQ:@#-<;XR\AR/\
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M;*X162>VTU9'W'G!0E#@^QS_ +..:JS_  \"Z,NH3:E?Z9MROV5[MXK>X Y
M$>=I)QZ9..N*;<:E=>((5@U!M*M++3X&,+66K!KBX8* !NPHC8]@<D'G/'+U
MZ/\ ,YY83#3WA%_)'3:-^TS\4[;Y=0T7PHLWEF86\D[K<&,=3M4D ^PS]36I
MI7[8GBN_L1=6_@S3]>M]_EM)I6K(WEGN&#8(([@X(]*\]\'>&M0N5A>SFO\
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M@YJ2J,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_B7_ (.8_A%8JW]D^!_B-JV.[VD%J#^+2&N6IG&"A\56/WGN8;P[XFK_ ,/
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M/#>O:?J/V.*#P>]XL>TK;PO;Q6L9))*Q[F D);.20".>:D3Q+XTL$DMX]/\
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M./%LC?VQXZ\<ZFK\N+C7KEE/U&\#]*Y'6;*+4YMUP]S=D]3<7$DN?KN8UO7
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MK7':W_P7S^#MLQ72]!^(^M<<&'0C$I_&1U_E7)4S?!0^*K'[T>[A^!.(Z_\
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M;&%FEB8]%157YE[8 !'4Y'-,U6]U#65N[F+28;>WDV"4:CM$L '1@@# N<Y
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MA8[AMZF<GC,Q4$@YX&,CZ5M?\(U)JVI0V]WJEQ>+YS&0+;HL<DB@8<X)QC(
M XSSUQ5C4_ $EA874TFM:Q=P[#FUE=#"0>VT*, >Q%&@W5C>W?U,DZSJ/VMK
MJ\72H]3M$EC6..9O(+ 97)X8Y!X&#TXHN?"OB#Q39_:+JW\.^?. 'BN[5KF#
M:!QM4L&!]R?PIT5O'J-RZR>(M'O#"@Q(UE$HB(X$9?<06]\Y'7'-:>G^/KRV
MB:.^T2_=H?E^T:>HN83Z'&0PSZ8(]Z&NR$YM+W3E-2\"M/H]S>2+X?-JBA&D
MA@G7#+P22K@E%[ $$#C)'%7K+P;=:5:6:VJZ:(9MIMW@5O++$9!(+'*GKSR>
M>36D-9U*TTC[+'I>R*0DS75U*(HWW\XB0$LQ/O@#WJO'>312I##XET/4FLW'
ME6C@?Z,PXS(ZL6('0D@8./I5>\5[66P'2-?>>:*>/09)(X]LA@C:*/RR3\ZJ
M=V)!C !)&.?:LO3M/FT>PDOH]&\/M%YI5TM7, E..6E&TA6 YX!!]LUT6F>$
M[C7X9II/$VH1W*R$S-8S(J#N!ROW0/N\=.<FJ]EI/G-+=6OB)[*WE?9NN!#)
M!?@<$X/?W4CMD5*["52RM_F9<VHZMJ<T=LP\+W%G-@6T<.^1MIS@J^XAN.H*
M@ >O%6HD\0:!'/'"WAC2S%&)I08I&A@C (&Q5*Y]R3D<<$8J;3- M?,CABU=
M+7[8[",Z?%%#+;R$<AFR22P!Y('IC)JUK7AV3PFL,KZQ<WS2;XV.I7"KB-AA
M@'P !G!&003CI1IL#J*_*9.EZIKUEID]S8G1[V(D/<3WCS*[$]-JJ#A>< '!
M X/2I((-9NM,FN/LFB1VTV7N&4N)(V&.$XY4XYR0>3BM9_%=\FG"SL])N(KH
M8C>[E53: #C>&4_.3V'&#U('6&\\.00([-XHNB8Q\UC'<Q>42.JE!R3GKSG-
M'R#VAF:];ZQ>R6W]I:?X3GEN#Y=O%<EY+=P<8)W*3O[=,8[U/#?ZU:./*T33
M[&\LXF656E\NS*D\R*0"Q4 =" <\9Q6AI?@8:S+=*=9O[J"-@L<C3J[Q\ @H
M5 "@'IUZ>QIUYX)U#3IHXX==U*4R(Q=[LI(95'5"=O YSD8(/>C38GVD=O\
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MN);HQ"WVSPF)3(#]YN!P!TQ@'IG-"01E\S,,/AJ73/*#Z:-65?+V,$6XXX*
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MV$L.E0LL<$*-C *H!C]*XY<=5;VC32]6W_D>M1\%<#%?O<1.7I9?HSZ:OO\
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MTQX)DN%L[4< B=G+L3U&!T7T)ZD5)%<R)<"XN9MI#;G9<A5'< <G&*M>7<+
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MC5 =AA2+:<#WR3CWJ6;2'CMPZW5TS-C8&8?NR?3CBD+KJ0RPZA<3_O+?3&F
MW*I)*=>I.,DCM2"*^ D;R[/'(E&XG:<<[>,\CUJ::2[D.YE6S90$:1F#$#U
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M?_$4_P"SL5_(_N#_ %TR/_H*A_X$C!HK=_X9,_:&_P"B>^%?_"H3_P"(I/\
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M5D^8.DJ5"E)+Y?YG'A^..'E4<ZV+IM^IYVQW'ZU);V<EP_R(S9]*[^+]@_\
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M4B?_ !-7+/\ 8%_:"@_UO@3PK)Z >)4 _P#0*I<-YDW_  G^ ?\ $1>&TO\
M?(?>>8:19M+,JMW//TKM;:^MK2%8]Z]*WKO]A#]H:1<0^!?"<([_ /%2IG_T
M"J3?\$_OVC&/_(E^$O\ PI%_^)KLP^2YGAV^2BVWU.>MQYPW6MS8V"^9QOB>
MQ6\F\R.16SP1FN=FTI8/F ;(KU4?\$_OVBQ_S)GA/_PI$_\ B:=_PP#^T0WW
M_!/A-A_V,B?_ !-<U7A_,YS<E1:N=%/Q"X;A%1>-@_F>0+>SK)MV\9J2\LFO
M$!)QZUZW_P .^OV@MV?^$'\+_P#A2Q__ !%7;7]@[X^VJX_X5_X5;W/B6/\
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M[-^5?O5SC>-V,F/.7->N:Q_P3D_:*U:1V_X0_P )KNX_Y&)/_B:P_P#AU?\
MM%?:-_\ PBOA+KG_ )&!/_B:FMDF:U)M^SDET_JY='Q$X5C%7QE._77_ (!Y
MSJ=_->QE]VYL<5RVH6%UJ+G<OXU]!P?\$U?VB(HPI\(^$3C_ *F%/_B:D/\
MP37_ &@MO'@WPON]?^$B3_XFN6/#N:IW]B[_ ".M^)G"MK?78?>_\CYOM=%N
M+6<-C:/6KVL79GM5C63YN_->\7__  3*_:*NHBJ^$_"2?]S A_\ 9:R8O^"4
M?[1*3[W\,^$V[X_X2!/_ (FJ_P!7<SEK*D_P#_B)G"R5EC8?>_\ (\1TK09O
M,#L[ ?6MJ9&$!53\V*]J3_@F1^T1%"%7PCX3X_ZF%/\ XFJ[?\$P/VD"^?\
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M_'_(^<O$.KR6(_=C-<O?7UQJ<BJV[FOIR_\ ^"17[1U[(6_X1_PF!Z?VZO\
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MCH/YO_(^>GTV&5MVU2:N6*Q6RGG# <5[Y!_P1C_:3@7 TCPB?^XVO^%3V_\
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M*'##=UCH?>_\CX3V[C392!VK[M7_ (-V?VBB?^/?PC_X-5I6_P"#=;]HD_\
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MY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?'.C*P1[S0]4AOXHG(SL<QLVUL?PM@^U5[C]J?X9VGQBG^'<OQ"\$Q>/K:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !17Y:_\'2O_!13XQ?\$YOV=/AAKWP=\7?\(CJGB+Q'
M<6&H3?V;:7WVB%;8NJ;;B*15PPSE0#[XK[>^#_[4.B>$?V'/AK\2?BMXR\.^
M&H=:\+:->ZKK>MWMOIEF]W=6D+L2[%(D+R.<*,#)P!T% 'ME%>*_$[_@HS\
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M4@XP:\X^&W_!3_\ 9S^,?Q!3PIX5^.7PKU[Q'+)Y,.GV7B:TEGN7SC9$H?\
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M^"3GBCX"^/OV?],U'X>ZIJ5U>I*MMJ=S<>7<V/V26WNXWF=W24&1MQ#8)"G
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M^-7Q>^*7BC4;F:;4M/G_ -#LX&V[71Q?P227#OO=Y) >2 .A+?L5_P $$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<6^N>(M0N=5U9_#6F64EU<.9)94MO$4%M$68\L1'"@R22<9Y-?3G_!J(,?\
M!$KX:_\ 83UO_P!.=S5#X+?\$IO'GQ)_X-NK']EWQE!;>"_B)<>'KBV:*XN8
M[J"RO4U62^MA)) SJ8V*Q!BA8@,>"1BOC3_@G'\"_P#@J5^Q5\$+K]FOPG\,
M_ ?AWPO)?W/V/QQK5];7 \-QW+EIIX&ANCYH#,TB*8'<,QRI'"@&/_P9Z_\
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M(EBD=,JH*L22!S?@_6O^"L7[:WQL\&V^I^'? O[+_A+0KM9=9U2T@L[M=07
M$F^VEGNGN/EW%(P$0,06<$!@ >4_\'3G@;XU_M6_L]?LV_$S1_"_B;Q)\(QH
M46N>*='T196&GWUS';S"2X1 S*IA9XTF*,(CO!(+@-\X^#K_ /X)8_MKV?@_
MP_I%K\3/V1_'EC?VO_$]N;J>^M92DBEXWN6GF2-FY"W#I#Y;[6;*KL/[%?\
M!7[X9_MM2>)?ASXT_91\6>';NU\%B5M:\&Z@L5LWB.9U*"2221EAFB"$CR2\
M11\.K,VW9^8_[8?_  3I_;Q_X+9^/O".F_$;]G'X._ ^WT2Y\R_\6VJ6UM<S
M"0!9#*ZW,]Q.@ ++$BD;L989! !VG_!Z3;_\(?\ "S]E6.PU*\U'^RI-82VU
M&ZN/M-S=>7#IH6:24_ZQVVABW\1)/>O9/VG?^#:OX$:C_P $KO%GBZZBUS4?
MCE:^$+CQI?>/;W6KF>ZU;5EM#=S&:-G,)@ED5EP$RJMG<6!8^ _\'C/PQ@^"
M?[,_[(/@N&\N=0MO"-EJ>BQW4W^MN4MK73(1(W)&Y@F3SU-=Q^T=X$_X*D:E
M^R7#^S1X?\(^#/'W@+7=$AT.W^(^FW$%GJ.H:,\*H(+GS[I!#(83Y<C&'<1N
MPS$ER 8__!$S_@I+X^^%W_!MM^T)KD>H3WFN? U[S3O"=W.3,VGQ7-O ;=<-
MG*P3SR.H/ 7:N J@5F_\&Y'_  1&^"/_  4+_8P\2?&CX\:1JGQ*\6>,O$5_
M91R7FM7<)LHX]F^8M%(CR7$DKR,TCEN-F "6)^_/^"8O_!#G1_V4/^"2?BC]
MGOX@7EOJVK?%:WO9O&5YIK$QPW%U L*I;,P!(MXXXMK$ %U9L -@?"?[*'[+
M?_!2O_@AQ9>+OAC\(?AUX(^-OPXUK49=0TG4)KF(QVD[HJ>>L;7<$T)94C+Q
M.'3<ORL<EF ,7_@A3=ZQ_P $WO\ @X9^,'[*OAW7-3U3X7ZI)J2065W-Y@@D
MMH5N[6X(X7SE@+0NP WY!(^50/%?V8?V)/#_ /P4'_X.8OVBOAKXSOM:B\!S
M^)/$NK^(=-TZ]>S_ +>AMM15HK25T(;R_M#PR, 0?W7!!PP_1#_@A-_P1:^+
M7P _:N\>?M1_M,:AIUQ\8/'0NEM=)L[B.X_LUKJ027-Q,\1,0D(41I'$61$+
M#)) 7G?^":7_  2T^.OP _X.&?CI\<?%W@G^ROA?XQE\1MI&L_VM93?:Q=W\
M,T'[F.9IEWQJQ^9!C&#@X% 'Q#_P6-_8J\#_ /!(?_@M-^S?JGP"M;[P/:Z]
M/IFK&PBOIKB*UN%U(V\HC:5F?RYHL*\98@@N/NM@>[?\'>?P-^*GB7]I;X.^
M.M0\)^+/'7[.OAFPB&L:=HLDJI;78NY'O/.:-7^SM-:^3&EPRD JP'((/M'_
M  <'?\$M/CM^V]_P46_9[\=?#'P1_P )+X5\#P6J:U>_VM96GV,IJ?GM\D\R
M.^(^?D4YZ=>*]]_X*Z>"/V\-!^/O@GXC?LLZWX7\2>$_#FGS6VI^ -0$=M_:
M,\A^>:8RR(ERI4($ DB>(JVT-YC&@#\L/@]8_P#!+W]N'XK?#2U\"ZA\4/V1
M_'VE:U9R+/+=SF+4RC "!;UIYTMIF;:4N6,9!!RK$@#T[_@\*MOLG[:O[*<6
M^23R[2=-\C;G;%_:C+'N3U)]:YW]I'_@E'^VO_P6V_:"\&W'Q4^ OPE_9XT7
M0W:/5/$6EPVT%U>1RF,RO*([B:>Z<;"8D(5%+L"PR6KZ<_X.+?\ @DU\</VU
M/VAOV<]2^$/@R;Q?H/PYL&L]6NY=8LK62WQ<V[*6^T31M(2D;$E >1ZD"@#S
MO_@[Q_9RU3X(?%CX%_M<>#83!K7A'5[;1M4GC7&V:WF-[ITK$<_>2X0D]O+&
M>@J3_@Z4_;,;]KC]E_\ 9>^$?PUD;4+[]HB]L?%=O:1,&>>WDCCCL8FQVDGN
MR>GWK;VK]5/^"HW[&EO^W]^P1\3/A3)' VH>)-'D.CR2X"V^I0D36;Y/W0)X
MXPQR/E+#H37Y(_\ !%;_ ((H?M.:-_P4$^%OC[]ISPFFB^$?@%X2?2_"*R:Q
M8WQDF268VL 2WGD($37EQ,'( !BC')H \U_X.==1E_8B^ 7[*_[(^AZIJFE_
M#'0_#Z7WB(Z:O[W6WBE2'S&0LJR,'%S,$8A3),I."JD?*7[;OQA_X)X^./V3
MSHOP)^$GQX\#_%G1! ^D>(=4:.6+4G61?-%Z/MTB_,F\AH8E*N$P N5/[C?\
M'#'_  1D\0?\%1/AOX,\6?#/5;+1OB]\+IY9M(^US&"#5+>1HW: RX/ERI)$
MCQN1M!WJV VY?E[7?B=_P6$^.G@K3_AK#\+/ OPWU:.2*.^^(5O<V$%PZQLI
M\PM]JFC ?;\_DVY+ L%51D4 ?>G_  ;^_M,^)OVL_P#@DG\(_%OC*YO+[Q-'
M97.CWM[=9,U\;*[FM8YG8\L[1Q1EF.2S;B2237V97#_LY>#_ !AX"^!GA;1_
MB#XHM?&GC:QT^./6];MM/CL(=1NL9D=((P%1,G   R "0"2*[B@ HHHH ***
M* "BBB@ HHHH XOXG?M$> ?@KXE\,Z/XN\9>&?#.K>,[W^SM"L]3U**UGU>X
MQGRH$=@9&Z#"@\LHZL 6M^T9X!C^.2?#-O&7AD?$.33SJJ^&_P"T8O[3-J"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU\&Z3:>*[/1%MR#"EG'J]LL*H>Z! H4CJ #7T[\.?^#3OQK\ ?B!KVF_#/\
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M,;LY.,$ _'7X*>*O$>C_ /!E%XPDT.6X\X7EW8SM&3NCL9?$,:W(_P!UHY)
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M!_P7?_:(U3QEX?TWQ(W@:;7-4TBWU"W2XM[>[?6%A$Y1@5+I&\@4D'!;<,$
MC]@O^"17_!&'X;_\$AOAMJ^G^%;S4/%/B[Q2T;:]XFU*-8[B]$>2D,4:Y$,*
MEF8)EB2Q+,V%"^>_\$M_^"%G_#MG]MSXN?&+_A9O_"8_\+2CO(_[)_L#[!_9
MOGWXO/\ 7?:)/,V[=GW%SUXZ4 ?=^D^!=#T+3C9V.CZ79V9N?MA@@M(XXC/N
M#^;M  W[@#NQG(!SD5>FTRWN;V&XDMX9+BU#"&5D!>(-C=M;J,X ..N*LT4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 QXUDQN56VG(R,X/K08E9U;:NY<X..
M1FGT4 ?SM_\ !TQX'TWXG?\ !<S]F/PWK$*W6D>(=*T/3+Z$])8)M>N8Y%]>
M58BOK3_@[T^$_A?1_P#@D%HK6?A_1['_ (13Q?IEOHWV:SCA&F1-%<1M%"%
M"1LH *+@':O&0,>T?\%+/^"%/_#PW_@H-\(_CK_PL[_A$_\ A5J::G]B_P!@
M?;?[1^R:C)>Y\_[1'Y>[?L^XV,9YSBO8/^"P?_!-3_AZY^Q\_P *?^$Q_P"$
M&W:U::Q_:?\ 9?\ :/\ J!(/+\KS8OO;_O;N,=#F@#\O_P!N'Q1X@TO_ (,U
M_A2-+N+I;>_L="LM5=&.?L0O'(5C_<\Q(%QT(P.AQ7W)_P &ZWP9^'$O_!$3
MX6V>GZ)X?U#2_%VE7<WB=9;:.9-4NWN9H[E;H,,2;=OEX?.$15Z 5[=\#/\
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M_9O_  C$&G0_\)1_87F_:?LD_FY^R^>NW?TQYIQUYZ4 ><?\$+?V;O ^F_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928702304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ONCOLYTICS BIOTECH INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">804, 322 11th Avenue SW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Calgary<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">T2R 0C5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">no<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ONCY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">61,327,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001129928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">804, 322 11th Avenue SW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Calgary<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">T2R 0C5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Kirk Look<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">670-7377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">info@oncolytics.ca<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928490800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Calgary, Canada<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630953787936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,666<span></span>
</td>
<td class="nump">$ 41,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAvailableforsale', window );">Marketable securities</a></td>
<td class="nump">20,472<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables (note 5)</a></td>
<td class="nump">521<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepaid expenses (note 5)</a></td>
<td class="nump">3,025<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">35,684<span></span>
</td>
<td class="nump">44,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (note 6)</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets (note 8)</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPrepayments', window );">Prepaid expenses (note 5)</a></td>
<td class="nump">998<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">37,334<span></span>
</td>
<td class="nump">45,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities (note 7)</a></td>
<td class="nump">3,650<span></span>
</td>
<td class="nump">1,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities (note 5)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities (note 8)</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative (notes 9(b), 16)</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">3,945<span></span>
</td>
<td class="nump">2,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liability (note 12)</a></td>
<td class="nump">6,730<span></span>
</td>
<td class="nump">6,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities (note 8)</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,832<span></span>
</td>
<td class="nump">9,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CommitmentsAndContingencies1', window );">Commitments and contingencies (notes 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital (note 9) &#160;&#160;Authorized: unlimited &#160;&#160;Issued: December 31, 2022 &#8211; 61,327,914 December 31, 2021 &#8211; 55,043,789</a></td>
<td class="nump">404,040<span></span>
</td>
<td class="nump">391,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantsandRightsOutstanding', window );">Warrants (note 9)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalPaidinCapital', window );">Contributed surplus (note 10)</a></td>
<td class="nump">40,051<span></span>
</td>
<td class="nump">34,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">662<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(418,251)<span></span>
</td>
<td class="num">(393,416)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">26,502<span></span>
</td>
<td class="nump">36,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 37,334<span></span>
</td>
<td class="nump">$ 45,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssetsAvailableforsale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets available-for-sale. [Refer: Financial assets available-for-sale; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 8<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_d&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssetsAvailableforsale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAndContingencies1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAndContingencies1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsandRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsandRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630929781024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development (note 19)</a></td>
<td class="nump">$ 15,432<span></span>
</td>
<td class="nump">$ 12,920<span></span>
</td>
<td class="nump">$ 12,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">General and administrative (note 19)</a></td>
<td class="nump">11,492<span></span>
</td>
<td class="nump">13,315<span></span>
</td>
<td class="nump">12,514<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss before the following</a></td>
<td class="num">(26,924)<span></span>
</td>
<td class="num">(26,235)<span></span>
</td>
<td class="num">(25,459)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative (notes 9(b), 16)</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange gain (loss)</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(659)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents', window );">Interest income, net</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="num">(24,751)<span></span>
</td>
<td class="num">(26,255)<span></span>
</td>
<td class="num">(22,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense (note 14)</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">(24,835)<span></span>
</td>
<td class="num">(26,304)<span></span>
</td>
<td class="num">(22,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income (loss) items that may be reclassified to net loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Translation adjustment</a></td>
<td class="nump">274<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net comprehensive loss</a></td>
<td class="num">$ (24,561)<span></span>
</td>
<td class="num">$ (26,316)<span></span>
</td>
<td class="num">$ (22,569)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per common share (cad per share)</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per common share (cad per share)</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares (basic) (shares)</a></td>
<td class="nump">58,029,745<span></span>
</td>
<td class="nump">53,513,225<span></span>
</td>
<td class="nump">40,338,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares (diluted) (shares)</a></td>
<td class="nump">58,029,745<span></span>
</td>
<td class="nump">53,513,225<span></span>
</td>
<td class="nump">40,338,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928164704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-the-market agreement</div></th>
<th class="th"><div>Share Capital</div></th>
<th class="th">
<div>Share Capital </div>
<div>At-the-market agreement</div>
</th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Contributed Surplus</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at beginning of period at Dec. 31, 2019</a></td>
<td class="num">$ (108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,618<span></span>
</td>
<td class="nump">$ 29,339<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
<td class="num">$ (344,607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income (loss)</a></td>
<td class="num">(22,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(22,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan (note 10)</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan (note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to "At the Market" Agreement (note 9)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant derivative exercised (note 9)</a></td>
<td class="nump">6,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense (note 10)</a></td>
<td class="nump">2,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs (note 9)</a></td>
<td class="num">(1,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">24,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
<td class="nump">31,022<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="num">(367,112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income (loss)</a></td>
<td class="num">(26,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(26,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan (note 10)</a></td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan (note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to "At the Market" Agreement (note 9)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant derivative exercised (note 9)</a></td>
<td class="nump">687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense (note 10)</a></td>
<td class="nump">3,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs (note 9)</a></td>
<td class="num">(1,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">36,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
<td class="nump">34,161<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="num">(393,416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income (loss)</a></td>
<td class="num">(24,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="num">(24,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan (note 10)</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan (note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity', window );">Expiry of equity warrant agreement (note 9)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,618)<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to "At the Market" Agreement (note 9)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense (note 10)</a></td>
<td class="nump">2,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs (note 9)</a></td>
<td class="num">(764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 26,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 404,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 40,051<span></span>
</td>
<td class="nump">$ 662<span></span>
</td>
<td class="num">$ (418,251)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Expiration Of Warrant, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Incentive Share Awards, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630929816416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (24,835)<span></span>
</td>
<td class="num">$ (26,304)<span></span>
</td>
<td class="num">$ (22,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation - property and equipment (notes 6, 19)</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdjustmentsForDepreciationRightOfUseAssets', window );">Depreciation - right-of-use assets (notes 8, 19)</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation expense (notes 10, 19, 20)</a></td>
<td class="nump">2,378<span></span>
</td>
<td class="nump">3,826<span></span>
</td>
<td class="nump">2,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Interest (income) expense, net</a></td>
<td class="num">(76)<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized foreign exchange (gain) loss</a></td>
<td class="num">(1,625)<span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative (note 16)</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(3,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Net change in non-cash working capital (note 17)</a></td>
<td class="nump">391<span></span>
</td>
<td class="num">(908)<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operating activities</a></td>
<td class="num">(23,355)<span></span>
</td>
<td class="num">(22,433)<span></span>
</td>
<td class="num">(22,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Acquisition of marketable securities</a></td>
<td class="num">(20,348)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property and equipment (note 6)</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(20,403)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of stock options (note 10)</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payment of lease liabilities (note 8)</a></td>
<td class="num">(381)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
<td class="num">(461)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">12,205<span></span>
</td>
<td class="nump">33,015<span></span>
</td>
<td class="nump">39,773<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">(Decrease) increase in cash and cash equivalents</a></td>
<td class="num">(31,553)<span></span>
</td>
<td class="nump">10,296<span></span>
</td>
<td class="nump">17,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">41,262<span></span>
</td>
<td class="nump">31,220<span></span>
</td>
<td class="nump">14,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Impact of foreign exchange on cash and cash equivalents</a></td>
<td class="nump">1,957<span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="num">(604)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">11,666<span></span>
</td>
<td class="nump">41,262<span></span>
</td>
<td class="nump">31,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember', window );">Warrant Derivative and Shares Under Warrant Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">$ 12,574<span></span>
</td>
<td class="nump">$ 32,912<span></span>
</td>
<td class="nump">$ 38,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdjustmentsForDepreciationRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Depreciation, Right-of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdjustmentsForDepreciationRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951768384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract', window );"><strong>Disclosure Of Notes And Other Explanatory Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Nature of Operations</a></td>
<td class="text">Nature of Operations<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998, under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue S.W., Calgary, Alberta, Canada.   </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, we are exploring opportunities for registrational programs in gastrointestinal cancers through our GOBLET platform study.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue our research and development efforts. As at December&#160;31, 2022, we had an accumulated deficit of $418,251. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through the issuance of additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. There can be no assurance that we will be able to raise additional funds through the sale of our common shares. Failure to raise additional capital would have a material adverse impact on our business, results of operations, and financial condition. As at December&#160;31, 2022, we had cash and cash equivalents and marketable securities of $32,138. We believe we have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Notes And Other Explanatory Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951767520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate Information And Statement Of IFRS Compliance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statement of compliance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements for the year ended December&#160;31, 2022, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;2, 2023. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries, Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc., and are presented in Canadian dollars, our functional currency. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and have the ability to affect those returns through our power to govern. The accounting policies of our subsidiaries are consistent with our accounting policies and all intercompany transactions, balances, income, and expenses are eliminated on consolidation. </span></div>Our accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Information And Statement Of IFRS Compliance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951564784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents and marketable securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include interest-bearing deposits with our bank totaling $9,501 as at December&#160;31, 2022 (December&#160;31, 2021 - $39,902). Marketable securities include foreign currency term deposits with a maturity of greater than 90 days and less than one year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred income taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial instruments </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification and measurement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets include cash and cash equivalents, marketable securities, and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of the warrant derivative is at FVPL.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derecognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency translation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per common share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is determined using the weighted average number of common shares outstanding during the year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants if dilutive. The number of additional common shares is calculated by assuming that any outstanding "in the money" options, restricted share units, performance share units, and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion </span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based compensation </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan (the "Option Plan") available to officers, directors, employees, and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than ten years from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value-based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive share award plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incentive share award plan (the "Share Plan") is available to directors, officers, and employees. Under our Share Plan, performance and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are awarded to certain officers and employees and non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSUs/RSUs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduced a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies, and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div>In May 2021, the IASB issued amendments to IAS 12, which narrowed the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928668640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Judgments, Estimates and Assumptions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract', window );"><strong>Significant Judgments, Estimates And Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant Judgments, Estimates and Assumptions</a></td>
<td class="text">Significant Judgments, Estimates, and Assumptions<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which external factors outside of our control, including those related to the coronavirus infectious disease 2019 ("COVID-19") pandemic and the global political conflict in Ukraine, may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain. We considered the potential impact of these events, including global supply chain disruptions, inflation, and rising interest rates, when making certain estimates and judgments relating to the preparation of these audited consolidated financial statements. While there was no material impact to our consolidated financial statements as of and for the year ended December&#160;31, 2022, our future assessment of the magnitude and duration of COVID-19 and conflict in Ukraine, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Judgments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make judgments, estimates, and assumptions that affect the reported amount of revenue, expenses, assets, liabilities, and the disclosure of contingent liabilities at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and assumptions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates, and such differences could be material. Significant estimates made by management affecting our consolidated financial statements include:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement which provides, among other payments, upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress toward completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses represent significant components of our research and development expenses, and we outsource a significant portion of these activities to third-party contract research/manufacturing organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as achieving certain milestones. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that the contract research/manufacturing organizations have performed. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based compensation </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value for stock options granted requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options granted are disclosed in Note 10. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, share price volatility, and dividend yield, and making assumptions about them. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry-forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgment is required to determine the amount of deferred tax assets that can be recognized based on the likely timing and the level of future taxable profits together with future tax planning strategies.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. There are also no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Judgments, Estimates And Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630983003312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">Other Assets and Liabilities</a></td>
<td class="text">Other Assets and Liabilities <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1. This phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2022, we recorded US$360 ($488) (December&#160;31, 2021 - US$617 ($782)) in other receivables related to unbilled BRACELET-1 cost from Pfizer and nil (December&#160;31, 2021 - US$278 ($352)) in other liabilities representing unused payments received from Pfizer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">In 2022, we paid deposits to our manufacturer related to the production of pelareorep required for our clinical trial program. We classify the related prepaid expenses as current or non-current based on the timing of when we expect to receive services. As at December&#160;31, 2022, we recorded $1,327 in current prepaid expenses and $998 in non-current prepaid expenses.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory', window );">Other Assets and Liabilities</a></td>
<td class="text">Other Assets and Liabilities <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1. This phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2022, we recorded US$360 ($488) (December&#160;31, 2021 - US$617 ($782)) in other receivables related to unbilled BRACELET-1 cost from Pfizer and nil (December&#160;31, 2021 - US$278 ($352)) in other liabilities representing unused payments received from Pfizer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">In 2022, we paid deposits to our manufacturer related to the production of pelareorep required for our clinical trial program. We classify the related prepaid expenses as current or non-current based on the timing of when we expect to receive services. As at December&#160;31, 2022, we recorded $1,327 in current prepaid expenses and $998 in non-current prepaid expenses.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other liabilities. [Refer: Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630929880784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79__IAS16_g73-79_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928658144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">Accounts payable and accrued liabilities<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,398</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951599344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees or leases not yet commenced to which we are committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was 15%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recorded an addition for a new office space lease for our Canadian head office and a lease modification related to the office lease extension for one of our subsidiaries. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease modification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease liabilities activity for the years ended December&#160;31:    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">655</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease modification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(381)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at December&#160;31, 2022 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951759728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share Capital</a></td>
<td class="text">Share Capital<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,198,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,182,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,166,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,401,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,043,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)(e)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,235,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,327,914</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">404,040</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$30,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement expired on June 4, 2020. In 2020, we sold 6,741,518 common shares for gross proceeds of US$17,538 at an average price of US$2.42. We received, net of commissions of US$526, proceeds of US$17,012. In total, we incurred share issue costs (including commissions) of $857. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 16). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. In 2022, no warrants were exercised. In 2021, 201,722 (2020 - 1,418,369) warrants with a fair value of $456 (2020 - $4,636) were exercised for gross proceeds of US$182 (2020 - US$1,277). As at December&#160;31, 2022, there were 64,035 warrants outstanding (December&#160;31, 2021 - 64,035). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up US$40,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on March 4, 2021. In 2021, we sold 5,685,097 (2020 - 5,441,014) common shares for gross proceeds of US$18,503 (2020 - US$12,629) at an average price of US$3.25 (2020 - US$2.11). We received, net of commissions of US$555 (2020 - US$379), proceeds of US$17,948 (2020 - US$12,250). In total, we incurred share issue costs (including commissions) of $707 (2020 - $885).</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000 over a 16-</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">month period through the facilities of the Nasdaq Capital Market in the United States. In 2022, we sold 2,719,770 (2021 - 2,715,932) common shares for gross proceeds of US$4,560 (2021 - US$8,655) at an average price of US$1.68 (2021 - US$3.19). We received, net of commissions of US$137 (2021 - US$260), proceeds of US$4,423 (2021 - US$8,395). In total, we incurred share issue costs (including commissions) of $209 (2021 - $549). This sales agreement was terminated on June 16, 2022.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2022, we sold 3,515,462 common shares for gross proceeds of US$5,632 at an average price of US$1.60. We received, net of commissions of US$169, proceeds of US$5,463. In total, we incurred share issue costs (including commissions) of $555.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrants</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold for gross proceeds of $11,512. Each unit included one common share and one common share purchase warrant. Following the 2018 share consolidation, 9.5 common share purchase warrants entitled the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. These warrants were classified as equity. These warrants expired on June 1, 2022, and were transferred to contributed surplus on the consolidated statement of financial position upon expiry. There was no cash flow impact as a result of the warrant expiry. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,445,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,443,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,618)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951735888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract', window );"><strong>Disclosure of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted stock options to acquire common stock through our stock option plan. Our stock option activity for the years ended December&#160;31 was as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,334,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(62,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(304,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.49</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,963,185</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,420,482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,165,679&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164,551&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.84</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.54 - $1.89</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.90 - $3.05</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.37</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.06 - $3.29</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.30 - $3.75</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.43</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.76 - $27.46</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,963,185&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.01</span></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants vest either immediately or annually over periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzM4Mg_95eb31db-de86-4acf-a885-2ec978a753c1">one</span> to three years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.02%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.82%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.12</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Incentive Share Award Plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Share Units</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted RSUs to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date, or when the director ceases to be a member of the board. We have also granted RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a three-year period. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RSU activity for the years ended December&#160;31 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,560</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (1) The weighted average fair value of the RSUs granted was nil in 2022 (2021 - nil; 2020 - $2.41).</span></div>We have reserved 6,132,791 common shares for issuance relating to our outstanding equity compensation plans. Our share-based compensation expense for the year ended December&#160;31, 2022, was $2,378 (2021 - $3,826; 2020 - $2,559).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951743360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss Per Common Share</a></td>
<td class="text">Loss Per Common Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding for the year ended December&#160;31, 2022, of 58,029,745 (2021 - 53,513,225; 2020 - 40,338,789). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951838080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Contract Liability</a></td>
<td class="text">Contract Liability<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regional licensing agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract liability</span></div><div style="text-align:justify"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next five years, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109__IFRS15_g105-109_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFR15_g110-129_IFRS15_g110-129_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951717600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ContingenciesAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments totaling approximately $16,775 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next three years. We are able to cancel most of these agreements with notice.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification of Officers and Directors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges, and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingencies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630953857024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(24,751)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,255)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,505)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,693)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,039)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,401)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference in tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,552</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,334</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">547</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of tax pools</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(338)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(368)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,614</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(838)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to offset deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">765</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,162</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we have non-capital losses of $98,475 and $145,405 in Canada and Barbados, respectively (December&#160;31, 2021 - $89,537 and $162,986, respectively). These losses are expected to expire between 2023 and 2042, if not utilized. At December&#160;31, 2022, we have Canadian investment tax credits of $4,368 (December&#160;31, 2021 - $4,834) that are expected to expire between 2023 and 2040, if not utilized. As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of $27,663 (December&#160;31, 2021 - $27,663).&#160;We also have unclaimed U.S. credits for increasing research activities available to reduce future years' taxable income of $1,285 (December&#160;31, 2021 - $1,343) expiring between 2031 and 2041. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital losses carried forward</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,726</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,648</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,363</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,627</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,541&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any material income tax examinations currently in progress by any taxing jurisdiction.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88__IAS12_g79-88_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630953856992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory', window );">Capital Disclosures</a></td>
<td class="text">Capital Disclosures<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;We include shareholders' equity, cash and cash equivalents, and marketable securities in the definition of capital.  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,666</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 12, 2022, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 16, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreements (see Note 9). We use these equity arrangements to assist us in achieving our capital objective. These arrangements provide us with the opportunity to raise capital and better manage our cash resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928699616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents, marketable securities,&#160;other receivables, accounts payable and accrued liabilities, and warrant derivative.&#160;As at December&#160;31, 2022, the carrying amount of our cash and cash equivalents, marketable securities,&#160;other receivables, and accounts payable and accrued liabilities approximated their fair value due to their short-term maturity. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative, initially measured at fair value, with subsequent changes in fair value at each reporting period end recognized through profit and loss. Our warrants with an exercise price of US$0.90 (see Note 9(b)) meet this requirement, and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December&#160;31, 2022, the fair value of our warrant derivative was $79 (December&#160;31, 2021 - $56). We use the Black-Scholes valuation model to estimate fair value.   </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents, marketable securities, and other receivable from Pfizer in connection with the BRACELET-1 study (see Note 5) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents, marketable securities, and other receivable from Pfizer. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also mitigate our exposure to credit risk by restricting our portfolio to investment-grade securities with short-term maturities and monitoring counterparties' credit risk and credit standing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest savings accounts that have variable interest rates. Our marketable securities have fixed interest rates.&#160;We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market interest rates do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and the Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2022 by approximately $170. The impact of a $0.01 increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in 2022 by approximately $22.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies through the purchase of foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable and accrued liabilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies at December&#160;31, 2022, are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 15. Accounts payable and accrued liabilities are all due within the current operating period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928699616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Additional Cash Flow Disclosures</a></td>
<td class="text">Additional Cash Flow Disclosures<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,247)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,368)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(723)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(908)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">452</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section Presentation of a statement of cash flows<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17__IAS07_g10-17_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928398448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceAbstract', window );"><strong>Disclosure Of Economic Dependence [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceTextBlock', window );">Economic Dependence</a></td>
<td class="text">Economic Dependence<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical-grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical-grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by identifying an alternative toll manufacturer, establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951606544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory', window );">Components of Expenses</a></td>
<td class="text">Components of Expenses<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing &amp; related process development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">544</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,432</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,514&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, our research and development personnel-related expenses included employee compensation and benefits of $5,983 (2021 - $4,645; 2020 - $3,775).</span></div>In 2022, our general and administrative office expenses included employee compensation and benefits of $2,870 (2021 - $2,542; 2020 - $2,635).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630929835072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation of Key Management Personnel</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel consists of the Board of Directors, the President and Chief Executive Officer, and the executives who report directly to the President and Chief Executive Officer.   </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,615</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,923</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24__IAS24_g13-24_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951692768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofeventsafterreportingperiodAbstract', window );"><strong>Disclosure of events after reporting period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsBetween January 1, 2023 and March 2, 2023, we issued 1,499,044 shares for gross proceeds of US$2,570 through our June 2022 ATM equity distribution agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_IAS10_g17-22_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofeventsafterreportingperiodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of events after reporting period [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofeventsafterreportingperiodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928550416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents and marketable securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include interest-bearing deposits with our bank totaling $9,501 as at December&#160;31, 2022 (December&#160;31, 2021 - $39,902). Marketable securities include foreign currency term deposits with a maturity of greater than 90 days and less than one year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory', window );">Deferred income taxes</a></td>
<td class="text">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Financial assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). </span></div>Our financial assets include cash and cash equivalents, marketable securities, and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Financial liabilities</a></td>
<td class="text">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of the warrant derivative is at FVPL.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory', window );">Impairment</a></td>
<td class="text">Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory', window );">Derecognition</a></td>
<td class="text">A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div>We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per common share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is determined using the weighted average number of common shares outstanding during the year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants if dilutive. The number of additional common shares is calculated by assuming that any outstanding "in the money" options, restricted share units, performance share units, and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development costs</a></td>
<td class="text">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion </span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based compensation</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan (the "Option Plan") available to officers, directors, employees, and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than ten years from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value-based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive share award plan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incentive share award plan (the "Share Plan") is available to directors, officers, and employees. Under our Share Plan, performance and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are awarded to certain officers and employees and non-employee directors to which common shares shall be issued in accordance with the Share Plan.  </span></div>We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSUs/RSUs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">Accounting Standards and Interpretations Issued but Not Yet Effective</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduced a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies, and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div>In May 2021, the IASB issued amendments to IAS 12, which narrowed the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]
Effective 2023-01-01: The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for the derecognition of financial instruments. [Refer: Financial instruments, class [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for the derecognition of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for earnings per share.
Effective 2023-01-01: The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]
Effective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]
Effective 2023-01-01: The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.
Effective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for the impairment of financial assets. [Refer: Financial assets]
Effective 2023-01-01: The description of the entity's material accounting policy information for the impairment of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.
Effective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]
Effective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]
Effective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]
Effective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents And Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630953843056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of depreciation rates</a></td>
<td class="text">Depreciation is recorded using the declining balance method at the following annual rates:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630929887008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of property and equipment</a></td>
<td class="text">Depreciation is recorded using the declining balance method at the following annual rates:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">356</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630929887168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock', window );">Disclosure of accounts payables and accrued liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,252</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,398</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed Disclosure Of Trade And Other Payables Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951752832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Right-of-use assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease modification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock', window );">Lease liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease liabilities activity for the years ended December&#160;31:    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">655</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease modification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(381)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory', window );">Total undiscounted lease liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at December&#160;31, 2022 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 97<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Quantitative Information About Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630953856992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of share capital</a></td>
<td class="text"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,198,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(c)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,182,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,166,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,401,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,043,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)(e)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,235,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,327,914</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">404,040</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$30,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement expired on June 4, 2020. In 2020, we sold 6,741,518 common shares for gross proceeds of US$17,538 at an average price of US$2.42. We received, net of commissions of US$526, proceeds of US$17,012. In total, we incurred share issue costs (including commissions) of $857. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 16). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. In 2022, no warrants were exercised. In 2021, 201,722 (2020 - 1,418,369) warrants with a fair value of $456 (2020 - $4,636) were exercised for gross proceeds of US$182 (2020 - US$1,277). As at December&#160;31, 2022, there were 64,035 warrants outstanding (December&#160;31, 2021 - 64,035). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up US$40,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on March 4, 2021. In 2021, we sold 5,685,097 (2020 - 5,441,014) common shares for gross proceeds of US$18,503 (2020 - US$12,629) at an average price of US$3.25 (2020 - US$2.11). We received, net of commissions of US$555 (2020 - US$379), proceeds of US$17,948 (2020 - US$12,250). In total, we incurred share issue costs (including commissions) of $707 (2020 - $885).</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000 over a 16-</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">month period through the facilities of the Nasdaq Capital Market in the United States. In 2022, we sold 2,719,770 (2021 - 2,715,932) common shares for gross proceeds of US$4,560 (2021 - US$8,655) at an average price of US$1.68 (2021 - US$3.19). We received, net of commissions of US$137 (2021 - US$260), proceeds of US$4,423 (2021 - US$8,395). In total, we incurred share issue costs (including commissions) of $209 (2021 - $549). This sales agreement was terminated on June 16, 2022.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2022, we sold 3,515,462 common shares for gross proceeds of US$5,632 at an average price of US$1.60. We received, net of commissions of US$169, proceeds of US$5,463. In total, we incurred share issue costs (including commissions) of $555.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Summary of outstanding warrants</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,445,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,443,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,618)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.54 - $1.89</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.90 - $3.05</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.37</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.06 - $3.29</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.30 - $3.75</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.43</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.76 - $27.46</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,963,185&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.01</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928447088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract', window );"><strong>Disclosure of share-based payment arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of stock options and weighted average exercise prices of share options</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted stock options to acquire common stock through our stock option plan. Our stock option activity for the years ended December&#160;31 was as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,334,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,005,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.19</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(62,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(304,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.49</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,963,185</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,420,482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,165,679&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164,551&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.84</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Schedule of stock options outstanding and exercisable by range of exercise price</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.54 - $1.89</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.90 - $3.05</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.37</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.06 - $3.29</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.30 - $3.75</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.43</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.76 - $27.46</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,963,185&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.01</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,445,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,443,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,618)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.54 - $1.89</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,998&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.90 - $3.05</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.37</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.06 - $3.29</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.30 - $3.75</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.43</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.76 - $27.46</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,963,185&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.01</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Disclosure weighted average assumptions and fair value of options</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.02%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.82%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.12</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of number of other equity instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RSU activity for the years ended December&#160;31 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,560</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (1) The weighted average fair value of the RSUs granted was nil in 2022 (2021 - nil; 2020 - $2.41).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the range of exercise prices for outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share-based payment arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofsharebasedpaymentarrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630954035024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Contract liability balances</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next five years, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928481696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock', window );">Provision for income taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(24,751)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,255)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,505)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,693)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,039)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,401)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference in tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,552</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,334</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">547</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of tax pools</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(338)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(368)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,614</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(838)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to offset deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">765</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,162</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</a></td>
<td class="text">t December&#160;31, 2022, we have non-capital losses of $98,475 and $145,405 in Canada and Barbados, respectively (December&#160;31, 2021 - $89,537 and $162,986, respectively). These losses are expected to expire between 2023 and 2042, if not utilized. At December&#160;31, 2022, we have Canadian investment tax credits of $4,368 (December&#160;31, 2021 - $4,834) that are expected to expire between 2023 and 2040, if not utilized. As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of $27,663 (December&#160;31, 2021 - $27,663).&#160;We also have unclaimed U.S. credits for increasing research activities available to reduce future years' taxable income of $1,285 (December&#160;31, 2021 - $1,343) expiring between 2031 and 2041. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital losses carried forward</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,726</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,648</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,363</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">366</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,627</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,541&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951380368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock', window );">Schedule of capital components</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,666</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Capital Components [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfCapitalComponentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951576416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock', window );">Schedule of balances in foreign currencies</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies at December&#160;31, 2022, are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Foreign Currency Held [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928647280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CashFlowOperatingCapital1TableTextBlock', window );">Net change in non-cash working capital</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,247)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,662</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,368)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(723)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(908)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock', window );">Other cash flow disclosures</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">452</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashFlowOperatingCapital1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Operating Capital1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashFlowOperatingCapital1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928510592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock', window );">Other expenses and adjustments</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing &amp; related process development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,148</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">544</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">264</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,432</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,007</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,514&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Expenses And Adjustments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherExpensesAndAdjustmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928510752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of related party transactions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,615</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,923</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951817536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Operations (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract', window );"><strong>Disclosure Of Notes And Other Explanatory Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">$ (418,251)<span></span>
</td>
<td class="num">$ (393,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CashAndCashEquivalentsAndCurrentInvestments', window );">Cash and cash equivalents and current investments</a></td>
<td class="nump">$ 32,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashAndCashEquivalentsAndCurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Current Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashAndCashEquivalentsAndCurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Notes And Other Explanatory Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928702368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($) </div>
<div>plan</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents | $</a></td>
<td class="nump">$ 9,501<span></span>
</td>
<td class="nump">$ 39,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfStockOptionPlans', window );">Number of plans | plan</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement', window );">Maximum option expiration term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Term Of Options Granted For Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Stock Option Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928715792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Annual Depreciation Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PropertyPlantandEquipmentAnnualDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630954059280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets and Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Current prepaid expenses</a></td>
<td class="nump">1,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPrepayments', window );">Non-current prepaid expenses</a></td>
<td class="nump">998,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember', window );">BRACELET-1 collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">488,000<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">782,000<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,000<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Currency1 [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630926892384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">$ 392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">913<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(521)<span></span>
</td>
<td class="num">(1,042)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">(614)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical Equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical Equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer Equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer Equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(285)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">(321)<span></span>
</td>
<td class="num">(285)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember', window );">Office Equipment and Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember', window );">Office Equipment and Furniture | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember', window );">Office Equipment and Furniture | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">$ (148)<span></span>
</td>
<td class="num">$ (127)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928457728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 2,252<span></span>
</td>
<td class="nump">$ 594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued liabilities</a></td>
<td class="nump">1,398<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 3,650<span></span>
</td>
<td class="nump">$ 1,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630953538880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16', window );">Weighted average rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph C12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_C12_a&amp;doctype=Appendix&amp;subtype=C<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928013376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Right-of-use Assets and Lease Liabilities (Details)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_RightOfUseAssetsAbstract', window );"><strong>Right-Of-Use Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, beginning balance</a></td>
<td class="nump">$ 584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_LeaseModificationRightOfUseAssets', window );">Lease modification</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation expense</a></td>
<td class="num">(299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ForeignExchangeImpactRightofUseAssets', window );">Foreign exchange impact</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, ending balance</a></td>
<td class="nump">296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities, beginning balance</a></td>
<td class="nump">655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_EffectOfLeaseModificationOnLeaseLiabilities', window );">Lease modification</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payment of lease liabilities</a></td>
<td class="num">(381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(366)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GainsLossesFromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities, ending balance</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 44B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_EffectOfLeaseModificationOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of Lease Modification on Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_EffectOfLeaseModificationOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ForeignExchangeImpactRightofUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Exchange Impact, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ForeignExchangeImpactRightofUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GainsLossesFromForeignExchangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) From Foreign Exchange Impact</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GainsLossesFromForeignExchangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_LeaseModificationRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Modification, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_LeaseModificationRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_RightOfUseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_RightOfUseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630927998544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Total Undiscounted Lease Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">$ 447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than one year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">One to five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 58<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph B11D<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630927662752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 16, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,099<span></span>
</td>
<td class="nump">$ 24,752<span></span>
</td>
<td class="num">$ (108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(764)<span></span>
</td>
<td class="num">(1,256)<span></span>
</td>
<td class="num">(1,742)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,502<span></span>
</td>
<td class="nump">36,099<span></span>
</td>
<td class="nump">24,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
<td class="nump">$ 34,168<span></span>
</td>
<td class="nump">$ 40,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Warrant Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,043,789<span></span>
</td>
<td class="nump">46,166,980<span></span>
</td>
<td class="nump">32,198,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,327,914<span></span>
</td>
<td class="nump">55,043,789<span></span>
</td>
<td class="nump">46,166,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391,348<span></span>
</td>
<td class="nump">$ 356,824<span></span>
</td>
<td class="nump">$ 311,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(764)<span></span>
</td>
<td class="num">(1,256)<span></span>
</td>
<td class="num">(1,742)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 404,040<span></span>
</td>
<td class="nump">$ 391,348<span></span>
</td>
<td class="nump">$ 356,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Stock option plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="nump">123,159<span></span>
</td>
<td class="nump">133,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 381<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Incentive award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,560<span></span>
</td>
<td class="nump">150,899<span></span>
</td>
<td class="nump">234,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">$ 732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | At-the-market agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,235,232<span></span>
</td>
<td class="nump">8,401,029<span></span>
</td>
<td class="nump">12,182,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
<td class="nump">$ 34,168<span></span>
</td>
<td class="nump">$ 40,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Shares | Warrant Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 687<span></span>
</td>
<td class="nump">$ 6,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareCapitalAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareCapitalAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareCapitalNumberSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Number, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareCapitalNumberSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630924616528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital Footnotes (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 17, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 24, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsfromWarrantExercises1', window );">Gross proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,277,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember', window );">United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">19 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,741,518<span></span>
</td>
<td class="nump">6,741,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,538,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 526,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,012,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Warrant Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,619,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,742,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Warrant Derivatives | Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedFairValueOfCommonShare', window );">Shares issued, fair value of common share (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2020 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,685,097<span></span>
</td>
<td class="nump">5,685,097<span></span>
</td>
<td class="nump">5,441,014<span></span>
</td>
<td class="nump">5,441,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,629,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 379,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2021 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,719,770<span></span>
</td>
<td class="nump">2,719,770<span></span>
</td>
<td class="nump">2,715,932<span></span>
</td>
<td class="nump">2,715,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2022 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,515,462<span></span>
</td>
<td class="nump">3,515,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised', window );">Warrants exercised (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
<td class="nump">1,418,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClassOfWarrantOrRightOutstanding1', window );">Class of warrant or right, outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember', window );">Warrants | Warrant Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedFairValueOfCommonShare', window );">Shares issued, fair value of common share (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassOfWarrantOrRightOutstanding1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Outstanding1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassOfWarrantOrRightOutstanding1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights2</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromWarrantExercises1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Warrant Exercises1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromWarrantExercises1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareIssueRelatedCostCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Issue Related Cost, Commissions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareIssueRelatedCostCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedFairValueOfCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Fair Value Of Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedFairValueOfCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630953812176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Equity Warrants Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>May 22, 2018</div></th>
<th class="th">
<div>Jun. 01, 2017 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_StockholdersEquityNoteStockSplitConversionRatio', window );">Stock conversion ratio</a></td>
<td class="nump">0.105263157894737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingEquityWarrantsMember', window );">Shares Public Offering, Equity Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CommonSharePurchaseWarrantPerUnit', window );">Common share purchase warrant per unit (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1', window );">Warrants exercisable into common shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1', window );">Number of common shares issuable per warrant (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedWarrantPricePerShare', window );">Purchase price (cad per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Securities Called by Warrants or Rights1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharePurchaseWarrantPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Share Purchase Warrant Per Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharePurchaseWarrantPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedWarrantPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Warrant Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedWarrantPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_StockholdersEquityNoteStockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity Note, Stock Split, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_StockholdersEquityNoteStockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928085680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Summary of Outstanding Warrants (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantsAndRightsOutstanding1', window );">Warrants issued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,618<span></span>
</td>
<td class="nump">$ 3,618<span></span>
</td>
<td class="nump">$ 3,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantsAndRightsExpired', window );">Expired</a></td>
<td class="num">$ (3,618)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,443,500<span></span>
</td>
<td class="nump">16,445,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfSharesExpired', window );">Expired (shares)</a></td>
<td class="num">(16,443,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfSharesExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfSharesExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsAndRightsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsAndRightsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsAndRightsOutstanding1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Outstanding1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsAndRightsOutstanding1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928043632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_StockOptionsOutstandingAbstract', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, beginning of the year (shares) | shares</a></td>
<td class="nump">5,334,420<span></span>
</td>
<td class="nump">3,764,055<span></span>
</td>
<td class="nump">2,246,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted during the year (shares) | shares</a></td>
<td class="nump">1,005,000<span></span>
</td>
<td class="nump">1,832,500<span></span>
</td>
<td class="nump">1,817,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares) | shares</a></td>
<td class="num">(62,962)<span></span>
</td>
<td class="num">(110,612)<span></span>
</td>
<td class="num">(141,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired during the year (shares) | shares</a></td>
<td class="num">(304,940)<span></span>
</td>
<td class="num">(28,364)<span></span>
</td>
<td class="num">(25,520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year (shares) | shares</a></td>
<td class="num">(8,333)<span></span>
</td>
<td class="num">(123,159)<span></span>
</td>
<td class="num">(133,454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, end of the year (shares) | shares</a></td>
<td class="nump">5,963,185<span></span>
</td>
<td class="nump">5,334,420<span></span>
</td>
<td class="nump">3,764,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options exercisable, end of the year (shares) | shares</a></td>
<td class="nump">4,420,482<span></span>
</td>
<td class="nump">3,165,679<span></span>
</td>
<td class="nump">2,164,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WeightedAverageExercisePriceOutstandingAbstract', window );"><strong>Weighted Average Exercise Price $</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding, beginning of the year (cad per share) | $ / shares</a></td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="nump">$ 5.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Granted during the year (cad per share) | $ / shares</a></td>
<td class="nump">2.04<span></span>
</td>
<td class="nump">2.99<span></span>
</td>
<td class="nump">3.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited during the year (cad per share) | $ / shares</a></td>
<td class="nump">3.83<span></span>
</td>
<td class="nump">6.21<span></span>
</td>
<td class="nump">3.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Expired during the year (cad per share) | $ / shares</a></td>
<td class="nump">10.80<span></span>
</td>
<td class="nump">37.63<span></span>
</td>
<td class="nump">62.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Exercised during the year (cad per share) | $ / shares</a></td>
<td class="nump">1.45<span></span>
</td>
<td class="nump">1.94<span></span>
</td>
<td class="nump">1.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding, beginning of the year (cad per share) | $ / shares</a></td>
<td class="nump">2.91<span></span>
</td>
<td class="nump">3.53<span></span>
</td>
<td class="nump">4.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Options exercisable, end of the year (cad per share) | $ / shares</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 3.82<span></span>
</td>
<td class="nump">$ 4.84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_StockOptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_StockOptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WeightedAverageExercisePriceOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WeightedAverageExercisePriceOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630924371664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">5,963,185<span></span>
</td>
<td class="nump">5,334,420<span></span>
</td>
<td class="nump">3,764,055<span></span>
</td>
<td class="nump">2,246,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="nump">$ 5.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">4,420,482<span></span>
</td>
<td class="nump">3,165,679<span></span>
</td>
<td class="nump">2,164,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 3.82<span></span>
</td>
<td class="nump">$ 4.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">1,002,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">799,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">1,724,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">1,001,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">1.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">1,532,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">1 year 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">1,532,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">3.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">1,393,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">775,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">310,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 7.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">310,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 7.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">3.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 27.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630926785664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Narrative (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,378<span></span>
</td>
<td class="nump">$ 3,826<span></span>
</td>
<td class="nump">$ 2,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember', window );">Restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember', window );">Reserve of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Common shares reserved for issuance (shares)</a></td>
<td class="nump">6,132,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issue under options and contracts for the sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928964688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract', window );"><strong>Disclosure of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="nump">0.66%<span></span>
</td>
<td class="nump">0.34%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life | year</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected share price volatility</a></td>
<td class="nump">96.02%<span></span>
</td>
<td class="nump">110.45%<span></span>
</td>
<td class="nump">110.82%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value of options (cad per share) | $</a></td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630924564672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details) - Restricted share units<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of the year (shares)</a></td>
<td class="nump">40,560<span></span>
</td>
<td class="nump">134,618<span></span>
</td>
<td class="nump">209,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the year (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">154,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the year (shares)</a></td>
<td class="num">(40,560)<span></span>
</td>
<td class="num">(94,058)<span></span>
</td>
<td class="num">(229,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of the year (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,560<span></span>
</td>
<td class="nump">134,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Weighted average fair value at measurement date, other equity instruments granted | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928534240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of common shares outstanding (shares)</a></td>
<td class="nump">58,029,745<span></span>
</td>
<td class="nump">53,513,225<span></span>
</td>
<td class="nump">40,338,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928331872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ContractLiabilityRecognitionPeriod', window );">Expected recognition period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContractLiabilityRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Liability, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContractLiabilityRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928915120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability - Schedule of Contract Revenues and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, beginning of year</a></td>
<td class="nump">$ 6,730<span></span>
</td>
<td class="nump">$ 6,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Revenue recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, end of year</a></td>
<td class="nump">$ 6,730<span></span>
</td>
<td class="nump">$ 6,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951712592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ContingenciesAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PurchaseObligation1', window );">Commitment for payment</a></td>
<td class="nump">$ 16,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PurchaseObligationCommitmentTerm', window );">Commitment term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingencies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligationCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Commitment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligationCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630926771552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Loss before income taxes</a></td>
<td class="num">$ (24,751)<span></span>
</td>
<td class="num">$ (26,255)<span></span>
</td>
<td class="num">$ (22,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory Canadian corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Anticipated tax recovery</a></td>
<td class="num">$ (5,693)<span></span>
</td>
<td class="num">$ (6,039)<span></span>
</td>
<td class="num">$ (5,401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Difference in tax rates</a></td>
<td class="nump">3,552<span></span>
</td>
<td class="nump">2,716<span></span>
</td>
<td class="nump">3,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TaxEffectOfStockBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">880<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TaxEffectOfTaxPools', window );">Revaluation of tax pools</a></td>
<td class="num">(338)<span></span>
</td>
<td class="num">(552)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other permanent differences</a></td>
<td class="num">(368)<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TaxEffectOfExpirationOfTaxBenefits', window );">Expiry of tax benefits</a></td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative', window );">Change in fair value of warrant derivative</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(838)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1', window );">Provision to offset deferred tax asset</a></td>
<td class="nump">765<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">2,162<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current income taxes</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Change in Fair Value Of Warrant Derivative</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfExpirationOfTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Expiration Of Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfExpirationOfTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Stock Based Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfTaxPools">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Tax Pools</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfTaxPools</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630926702800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">CANADA | Non-capital losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">$ 98,475<span></span>
</td>
<td class="nump">$ 89,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">CANADA | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">4,368<span></span>
</td>
<td class="nump">4,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">CANADA | Unclaimed scientific research and experimental development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">27,663<span></span>
</td>
<td class="nump">27,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BB', window );">BARBADOS | Non-capital losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">145,405<span></span>
</td>
<td class="nump">162,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Unclaimed scientific research and experimental development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">$ 1,285<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630926844144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 38,627<span></span>
</td>
<td class="nump">$ 37,584<span></span>
</td>
<td class="nump">$ 34,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember', window );">Non-capital losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">26,726<span></span>
</td>
<td class="nump">25,158<span></span>
</td>
<td class="nump">21,488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember', window );">Scientific research and experimental development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">7,648<span></span>
</td>
<td class="nump">7,705<span></span>
</td>
<td class="nump">6,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember', window );">Investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">3,363<span></span>
</td>
<td class="nump">3,716<span></span>
</td>
<td class="nump">4,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember', window );">Net capital losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630951308912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Disclosures (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 12, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,666,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,262,000<span></span>
</td>
<td class="nump">$ 31,220,000<span></span>
</td>
<td class="nump">$ 14,148,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders' equity</a></td>
<td class="nump">$ 26,502,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,099,000<span></span>
</td>
<td class="nump">$ 24,752,000<span></span>
</td>
<td class="num">$ (108,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_EquityAuthorized', window );">Base Shelf securities authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_EquityAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_EquityAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630924486320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Shares Under Warrant Derivative Agreement | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">Increase (decrease) in net loss due to change in currency value</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency, amount</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">Increase (decrease) in net loss due to change in currency value</a></td>
<td class="num">(22,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights2</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=oncyf_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630926811280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,262<span></span>
</td>
<td class="nump">$ 31,220<span></span>
</td>
<td class="nump">$ 14,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(3,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAvailableforsale', window );">Marketable securities</a></td>
<td class="nump">15,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAvailableforsale', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAvailableforsale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-derivative financial assets that are designated as available for sale or are not classified as (a) loans and receivables; (b) held-to-maturity investments; or (c) financial assets at fair value through profit or loss. [Refer: Derivative financial assets; Financial assets at fair value through profit or loss; Held-to-maturity investments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 8<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_d&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAvailableforsale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_BalanceHeldInForeignCurrencyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance Held In Foreign Currency, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_BalanceHeldInForeignCurrencyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Currency1 [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630926741744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Other receivables</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="num">$ (776)<span></span>
</td>
<td class="nump">$ 1,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaid expenses and deposits</a></td>
<td class="num">(1,247)<span></span>
</td>
<td class="num">(349)<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,662<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables', window );">Other liabilities</a></td>
<td class="num">(352)<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="num">(723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet', window );">Non-cash impact of foreign exchange</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Change in non-cash working capital related to operating activities</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="num">$ (908)<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928478784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsfromInterestReceived', window );">Cash interest received</a></td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Cash taxes paid</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Interest Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630926871776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>manufacturer</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member', window );">Toll manufacturer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1LineItems', window );"><strong>Concentration Risk Type1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ConcentrationRiskNumber', window );">Concentration, number</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Concentration Risk Type1 [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928282960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Expenses (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,378<span></span>
</td>
<td class="nump">$ 3,826<span></span>
</td>
<td class="nump">$ 2,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">15,432<span></span>
</td>
<td class="nump">12,920<span></span>
</td>
<td class="nump">12,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">11,492<span></span>
</td>
<td class="nump">13,315<span></span>
</td>
<td class="nump">12,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClinicalTrailExpense', window );">Clinical trial expenses</a></td>
<td class="nump">4,970<span></span>
</td>
<td class="nump">3,205<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ManufacturingExpense', window );">Manufacturing &amp; related process development expenses</a></td>
<td class="nump">2,148<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">3,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IntellectualPropertyExpense', window );">Intellectual property expenses</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TranslationalScienceExpense', window );">Translational science expenses</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">Personnel-related expenses</a></td>
<td class="nump">6,023<span></span>
</td>
<td class="nump">4,754<span></span>
</td>
<td class="nump">4,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">2,087<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other expenses</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee compensation and benefits expense</a></td>
<td class="nump">5,983<span></span>
</td>
<td class="nump">4,645<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PublicCompanyExpense', window );">Public company-related expenses</a></td>
<td class="nump">6,790<span></span>
</td>
<td class="nump">8,161<span></span>
</td>
<td class="nump">7,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OfficeExpenses', window );">Office expenses</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="nump">2,963<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Depreciation - property and equipment</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee compensation and benefits expense</a></td>
<td class="nump">$ 2,870<span></span>
</td>
<td class="nump">$ 2,542<span></span>
</td>
<td class="nump">$ 2,635<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEmployeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of employee expenses that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEmployeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClinicalTrailExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trail Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClinicalTrailExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IntellectualPropertyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intellectual Property Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IntellectualPropertyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ManufacturingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ManufacturingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OfficeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Office Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OfficeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PublicCompanyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Company Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PublicCompanyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TranslationalScienceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Translational Science Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TranslationalScienceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630931005312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee compensation and benefits</a></td>
<td class="nump">$ 4,308<span></span>
</td>
<td class="nump">$ 3,919<span></span>
</td>
<td class="nump">$ 3,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation expense</a></td>
<td class="nump">1,615<span></span>
</td>
<td class="nump">2,703<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Compensation of key management personnel</a></td>
<td class="nump">$ 5,923<span></span>
</td>
<td class="nump">$ 6,622<span></span>
</td>
<td class="nump">$ 5,768<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140630928252928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - 2022 United States ATM<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 02, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,515,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (shares) | shares</a></td>
<td class="nump">1,499,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares', window );">Gross proceeds from common shares | $</a></td>
<td class="nump">$ 2,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GrossProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Issue Of Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GrossProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>oncyf-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:oncyf="http://www.oncolyticsbiotech.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="oncyf-20221231.xsd" xlink:type="simple"/>
    <context id="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3483d81850d4bb2b4f6474d2ebd0395_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied69a4c1e8dc444497553637c429c995_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieee4c1d19b10441a9fb87c20bf21e3fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib221189a8a8e442da5b933592a172090_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i34072d06dbc74709a44772e87c0d0628_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd91d05642e7401b8c8faeeb5459ba72_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b5762368dba4c919ee8061f3f934cd2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9d7d4f10038048718f7928d1bab94c89_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idadaa0cf361244f49594f3ef42b55e1c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie5e2093c82014efc936a23f9e66baceb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3fe43ded55bb48a19706afc4c1823657_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i57e65be9e20f459dbe2844e5091b0eb8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29cfb81f0a3a44299e19e6f5f7d4b3fe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic888e62d483b498baa6a74041afebae7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i11b5e4d511d249e2a405c432386bbc33_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6510299e4eb4121b35ad3c184f04164_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i290facf32bd147b3884843f453ff6807_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8306ac01dd1463bbd49d0c295bf272f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22e1e0507b4d45e393729762660f43a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i368b44deb2be4ae8a6ca25d3395395fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i948a576781cb440eb04b08b93b5d97f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55f95b5256b04475bef34fd27060d50e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e5170208d2a4bd9b4a4c6146ff70357_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c339f58b6a2498ea561adefe93e835c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3961fe68fe52450d88368027d3561fcf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a8cd87a2d5a464ba33b505012eb6589_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b43b9c4bfe449b6b1add7f653d88bf2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4041f6f067cb40d396837f84680e473b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbaf1681ace746c7a5991056ee03b717_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97c499ae0f4f4465949c6fe6c3000ab0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5cdf4a3d792142928c2a62b0fe7cbb14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01f7eba52a7942aeba915d83f45b1a80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i576c2a286bbc4d11b0b6d563390fe4b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1ca5b15a1b7044289a0c16a41d080756_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i74a140a0b6704c889a525c2e794ec55c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie50cc2fed39041bc905a4bcda62dfc62_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5bdab815bf824c749bcbfc48a0d04970_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i21011e791fea44a5a06778532673f5a7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8ed6a69506e34074a8db38ee94834bd6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i675ad40abe414c01b53d0b9d4f0b4bac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i926bb81a27e0480ca8b1aa8523ae7dbf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i77a1e98211ca443f9dfaca9d7e15ffb4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i92a4f596a4a24a67b57f8f348cf65e66_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee80e6ef283a466d847af7f4c18b0932_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8f2d18eb4014706985a616274ce8cf0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i15555db508714ca18e982d65eea9cb39_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5db0e2b8debf4e1987ee224438086d51_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:WarrantDerivativeAndSharesUnderWarrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f01ea7a336d44d2ab368965b5d555a1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1a49b5a6078743c4a0f6d1dc090f31ae_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc90711aec744857b2329d7bd8e24e98_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9166d82a922341729a9cfba07b6c19fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f8114e0983f40c18d9bd8848358071f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4783f947d474ec7a4043f3bd7016af3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3911bf2c955b405bac30a9b918de2d56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e33daaee7a04931a84b95d558b6feab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81ef8717fa2344528d67d8af749583ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i204d523ce7ab4b52896ed6d2295ef847_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie5f0b13be4b5469faca7dfca28e6f4c8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee36a908faae4b93971ba0cc2c7ca539_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia39c558d66984975b5b558b476007a29_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8ff1d10a78054a38a5d7f49b53d4d3b0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68bda01afab14d5cb26920e605f0ab42_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i286fea00b77e413c9c5eeffe49ab79c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefe509d23f474055870d8386107bed16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2dee205e673484b94ca9942a6585f62_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a0d89d731934218a9200c653646ae2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41042a36299746dfa6245b8f04eeb2fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4096288385ea4783bb39b83a9221722a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2dbc93ed0aff46e895933aedb6179359_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i22a8e62bdf6047f6b2871d5eb585c601_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iedb5bad8c9c64aeb82bab9cdcaaab035_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icff71c66ed2f49d7a3a5436aa04a7517_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icb257f4f952a40c895f4c48bb418df40_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i79304496df494f95b80359489d58d588_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2af36eb48c0d4fe2b8f76f15361a0a7e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb1ab3d5241c42b4bc1827326301115d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a666b3f60054f4cbf818f5e3df21b12_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1f67c6da798f44b594280ae812c6baaf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76d7a88ee04145c194ae4be4171aa00c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73b71a1c9b2748b48f0eef3f1e218dbc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0dcb43e627a74a66b65eccdde1930703_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f29e88f1e0a4dada070a283833ffdb9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic14ac3299f434c03908133a0c4a9205e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c6845c74acd4eb6bdee2a26eb7d8b31_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff53065b38874233bcc1a933461017ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0daba0652a364b148a3ad3df35cb62f9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8addce8064f24c3cb69be9a37be7346b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3c2b76821444aed993c937b01f9ce03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e99b1b5e9384ed6b69134ad46524aed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b3d9e57cf1f4065853436dbd64f88f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00001682505c41e0a1f6a5200e7369cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3050942226a5438fa9c685a3428ff7a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25cea6a2272341c1929aaaa1d18e0f5b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0f607fc35a524cb8b063cbac9f2c139c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1784fbe9117b4ee1a7b43ddcc71a0db3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie5d7a02883ec445c9158c8db51d57df8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f605b055eea4373ba168badd86607c3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iee540100ac1e473dbf3745fc5ffcc5be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf594b04da5249a0841abdc72a9802ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if236c6ed5fc6436b9c2654b18b4a3ada_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id315aa54ed3e46e19f179179a56a77ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if30f9fd81d8e488390af3fade7de9e46_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i513dceb1a6f14df9a09714d11d8a7b2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1feff0178e14474aaa4fc6a186497ad0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id202f8bc51ef4633b66140d696b4d861_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54cddc074de54f28b6e68ca6b670e5f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i777d047d5ec446409e8a5c8324aa324d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0a8c607d0de64f79bdc2e8ce8034a59c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie70c35bbd59a4905b781c7668e5cc70f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i963844cd43c644c7932afd7741a944d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0702f9b593a943e0aa89f870ac3bbdc4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0b95cc388ab54e769e83447ea9abf950_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia32318f895f946ecbe86b9b07e60fd1c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea62ebc777ac430eb1852b3dd64bf5a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i365cb71f7fa842589bd1fc05d704aec7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if692efdc55844ddd94d16e3f6ae99d73_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6541e8507efb4de5a913ca4fac61cf17_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8972058a330f4d2e80365843e754c2d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b1d0fbc8f1b4d968750fdb49b146c64_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b8eb310435f4b7089eb7c5f3035b88d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6cec7f0886424478a8adab4adfe59a0b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe25ae3bb8014f7cb475d95097c9166e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b552f25ccd04fdb86d1346a3975fa1b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic6493a759f124792b1e8928326aac134_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f593ff807bd4b97a79dd779ca1363b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2fe0be7fe344da59d4ec9cf38ef8816_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11172d73364741cc830ad4c4925edd65_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i10f8803a04704f94b4c3b16076075a61_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6efced05728f430dbc45b4b00278027e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e9e1c91dbd64b66a3ef5f637728d726_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie67556b574354bfbbbe629f9c4f83910_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if333223790564dcb96ea8ce18000124c_I20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-24</instant>
        </period>
    </context>
    <context id="i9c01aa3f72784c8eb36e0bca515d9aff_D20181024-20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-24</startDate>
            <endDate>2018-10-24</endDate>
        </period>
    </context>
    <context id="i809782423e5a496c9bb7e6d59de0f3a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i783080355c484f52b0c3ed3b1f30118c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i339d817f02da483dacfdea11d754715d_D20190816-20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-16</startDate>
            <endDate>2019-08-16</endDate>
        </period>
    </context>
    <context id="i0d502b20f5504524b12de442d39c71e8_I20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-16</instant>
        </period>
    </context>
    <context id="i95f4ddbdd41f46c28a3fa7900b833ed6_I20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-16</instant>
        </period>
    </context>
    <context id="i36f0549e16fb493899d3ce11e6663ed3_I20190816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-16</instant>
        </period>
    </context>
    <context id="ibb8660fe469e4e3bb809b223adeb1928_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f4f12b4c9ac415291240c8cd9609fe0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i711e0a27b9344e398357548811fe1ed6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c37cce29b8346b0ba836e6e496264d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if27e5cf46efd4450807817226f0625d7_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="ida0bae79a8bc43eb8fd183431b5b3f2d_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="i23e1543579db44e78472abe042745f89_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id7dd014e773644638183d9dbc0c3ba03_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i63384d0a252342c890796e05d336932d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90e7609d87f34c56bb2a2970072a4155_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia82e40c581724751808cdca1dd238e9b_I20210305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-05</instant>
        </period>
    </context>
    <context id="i998f1448e0f242f0a37474a940e5bb85_D20210305-20210305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-05</startDate>
            <endDate>2021-03-05</endDate>
        </period>
    </context>
    <context id="i98e916be7d9749dd9fdd5af0f4f92104_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i209bf45ef70c45e7b6c75d2906c6f1ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35bc0c0fb23d4de58f297cc59b64b8da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ab78014954745ca943db137b2067123_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cb45010a1f04a19bb8bb7c198eafcb7_I20220617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-17</instant>
        </period>
    </context>
    <context id="ibf3514ed6ca044d7810415c09e4274c5_D20220617-20220617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-17</startDate>
            <endDate>2022-06-17</endDate>
        </period>
    </context>
    <context id="ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b0440d3e41e4deaa503df6fed6a1cf7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c38fae9a1ca4c469aff3c034e794b8d_D20170601-20170601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-01</endDate>
        </period>
    </context>
    <context id="i15ebd1009ac5441788d5ea09d2d20d34_I20170601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-01</instant>
        </period>
    </context>
    <context id="iadb9b5984e0d4be9a1b244e2d939dde2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6f62a8b7a8c2458692b02a5416ac2ac4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49324b0a98f247d28e8710f0a21c58d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7cac766cbaa43fb9c4ad8b89138fec9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i451a07d69b99427c8835f34d48f9f9fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">oncyf:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i02abfa4251e340c3988374be2db0e2d2_D20180522-20180522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2018-05-22</startDate>
            <endDate>2018-05-22</endDate>
        </period>
    </context>
    <context id="i5d60827e07f44c119014f8e722b58bf9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9aadf4823bed41b0a081530e5fc4658c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic6368f5d59534a0d96175310350885fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i52f9ee94ed334d309ddc1b2501e78dc1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i669145b9554d41f3b9c524309e023747_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e8be41597da42568d4f86e247044361_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie679757fac604f0cb2a738bb1dd0ac7e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd74fcb0f8c9429fadb463a6eb81e2f0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if0265f11a01344f595e7fe503b2a3472_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idd36a13c83d745178281e200444da7ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3e89eeef735b47ceb3acd3ad40771e04_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib60b968ef3b34ea79492f56d45e6f2f1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0741691230d4e28b2d1df61be980984_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1818274641ed42299558348b53c621fd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f8f1d616d0e479fafc3b8c388acf7c8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i016d2b845c3c472d9148a20b8286ae27_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ff3b4848a624feab2a3c7841b598986_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5017488ebe3844d0ad6adf806e07f9b9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d0648f490594bd7ab0068f3dec9d739_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i48e149fb587f4b6b81178a578d0bd1fa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if8c782e17d83404aa29f79eba0b9cef7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac8d3f09febd4cb19e47cf23fefaaf0a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i771812f5ba4a4f9ba29a5246edf0bf00_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2320674fb5744c63bbf6953873d4a940_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0929be370c884a7cb1a0e5b4d741a8b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03a33fe7f4e34bb28f5d1cbf45984686_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9255ba83d384e38a8c5e9053e964622_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2dec10529d90451ba902ebe59a161f0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5de5eb425bc430e9593f5e707cf066a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0daf1c1f7fbd41b2933e6fc95c01304a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia520d0c500544f84866a7d2a4c1dacd9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i103420c5cde840e79af37985d2d0bc9d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i28afd4f827e34f3eae4c33b42849dabf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ab96394ca8b4ae0a266d0b54caf3191_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbbd14a8d6a34c3db1a86531714b2505_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e50e8d056f742639310ba89a351e073_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i948c9f76e8c14e789a92b32d5e0cd60d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2592d82deade43a389c57acec6861c6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa08ffbbd906412591e8727e7b92333e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie72bcfe2289d460cb870ee2ab6965abf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9934fdaa7cb54bed9e71b4949c27a412_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb1478bee3ac4873a8fa8d09e2c3af34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66c467d253d145219d761e8b50d9872e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1dd5a5d56ed3410cb4e81d1da02608b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b3ad9043f0443508a6e58ffe371b9e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97e1578bad4a4fd8b9eeb3cc0142c022_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf87bcb9d5a348e7987675a510c51f91_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e00e20520b0484b8e24ff13c4d70e87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i192f8af4da504af0a223d7c5399c0b89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d0f7801e4734c00bb6d8dd7c4f5b818_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i085395ab16f842a1a1512a6390a303e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82ebeaf310b04401931722c6c4601410_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92fb0107f20d4b31a60191a22ac916c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9d4db2a6855b40bc9001da783c6c23a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1bce01bfb3c140e19bceefb885e36144_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i661bfced363d425b983b07748d5e34d9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib701cd64a09142eaa49f3229d198e9f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6dc03510bb2241279358235d4f80a08e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i878d9a8a28ac42caa7c1e38319e6da4c_I20220612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2022-06-12</instant>
        </period>
    </context>
    <context id="i78092e29c72947a18acdd0770f54643c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7fd69d94537a4d46b4b4f06ee6771977_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c8fd43724f84c33ae13eca3658b27f6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8c04db7260c44d0a84dcee681e6b31a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id4078a67cca34e859712c16c4fb4b8ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3968ebc093542fb94bd695c6069eeb0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic4d7eaaabecc41fcad176194a92590f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:ConcentrationRiskType1Axis">oncyf:SupplierConcentrationRisk1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i66e81fab17754d28b557975b9a91350b_D20230101-20230302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="cadPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>oncyf:plan</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="year">
        <measure>oncyf:year</measure>
    </unit>
    <unit id="manufacturer">
        <measure>oncyf:manufacturer</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180L2ZyYWc6NjJlMGNkNWJjYTIwNDY0ODkzYWQwMzJjMGMzMDkzMmIvdGFibGU6MzE3ODAxOWRkMWNmNDMyOGFjZGI3ZjA3Y2I2N2YxNWQvdGFibGVyYW5nZTozMTc4MDE5ZGQxY2Y0MzI4YWNkYjdmMDdjYjY3ZjE1ZF8xLTEtMS0xLTM1Mzgz_a89fd1e9-b75e-4cc4-8d29-65c71fa83a5d">0001129928</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180L2ZyYWc6NjJlMGNkNWJjYTIwNDY0ODkzYWQwMzJjMGMzMDkzMmIvdGFibGU6MzE3ODAxOWRkMWNmNDMyOGFjZGI3ZjA3Y2I2N2YxNWQvdGFibGVyYW5nZTozMTc4MDE5ZGQxY2Y0MzI4YWNkYjdmMDdjYjY3ZjE1ZF8yLTEtMS0xLTM1Mzgz_0391f04e-bd55-4921-927e-d021e587cd46">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180L2ZyYWc6NjJlMGNkNWJjYTIwNDY0ODkzYWQwMzJjMGMzMDkzMmIvdGFibGU6MzE3ODAxOWRkMWNmNDMyOGFjZGI3ZjA3Y2I2N2YxNWQvdGFibGVyYW5nZTozMTc4MDE5ZGQxY2Y0MzI4YWNkYjdmMDdjYjY3ZjE1ZF8zLTEtMS0xLTM1Mzgz_a4f3af4d-704a-40a0-8b8f-39db71cf80fb">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180L2ZyYWc6NjJlMGNkNWJjYTIwNDY0ODkzYWQwMzJjMGMzMDkzMmIvdGFibGU6MzE3ODAxOWRkMWNmNDMyOGFjZGI3ZjA3Y2I2N2YxNWQvdGFibGVyYW5nZTozMTc4MDE5ZGQxY2Y0MzI4YWNkYjdmMDdjYjY3ZjE1ZF80LTEtMS0xLTM1Mzgz_0e109876-192e-4417-a5f7-a56a86582d4d">false</dei:AmendmentFlag>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180L2ZyYWc6NjJlMGNkNWJjYTIwNDY0ODkzYWQwMzJjMGMzMDkzMmIvdGFibGU6MzE3ODAxOWRkMWNmNDMyOGFjZGI3ZjA3Y2I2N2YxNWQvdGFibGVyYW5nZTozMTc4MDE5ZGQxY2Y0MzI4YWNkYjdmMDdjYjY3ZjE1ZF81LTEtMS0xLTM1Mzgz_aace8447-9e47-4318-a341-e39bbfedd10b">A0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180L2ZyYWc6NjJlMGNkNWJjYTIwNDY0ODkzYWQwMzJjMGMzMDkzMmIvdGFibGU6MzE3ODAxOWRkMWNmNDMyOGFjZGI3ZjA3Y2I2N2YxNWQvdGFibGVyYW5nZTozMTc4MDE5ZGQxY2Y0MzI4YWNkYjdmMDdjYjY3ZjE1ZF82LTEtMS0xLTM1Mzgz_c84b77c2-e150-440c-b786-bcecbe50cb69">false</dei:EntityEmergingGrowthCompany>
    <oncyf:StockholdersEquityNoteStockSplitConversionRatio
      contextRef="i02abfa4251e340c3988374be2db0e2d2_D20180522-20180522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjMvZnJhZzpjNTQzNDZjMDRiZmE0MGVlOWRiZDA1MTBhZTU2YmQ2YS90YWJsZTpmMWY1Yzg2Y2FkODQ0MmU5ODg0MGZhODMyZTY4MjQxNi90YWJsZXJhbmdlOmYxZjVjODZjYWQ4NDQyZTk4ODQwZmE4MzJlNjgyNDE2XzEtMS0xLTEtMzUzODM_87f353ae-039e-40d7-bb46-7339632761c3"
      unitRef="number">0.105263157894737</oncyf:StockholdersEquityNoteStockSplitConversionRatio>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1
      contextRef="if8c782e17d83404aa29f79eba0b9cef7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzM4Mg_95eb31db-de86-4acf-a885-2ec978a753c1">P1Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTk0_b7c1dfb1-f3f4-43b6-a176-0ae716d1cb33">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6ZjEzMDBkZGE4OGZjNDA5Y2E1YTY1OTg3MzE1MjkwZGEvdGFibGVyYW5nZTpmMTMwMGRkYTg4ZmM0MDljYTVhNjU5ODczMTUyOTBkYV8wLTAtMS0xLTM1Mzgz_1aaa5e06-d196-4ce4-b8f6-db071bd31e19">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6ZjEzMDBkZGE4OGZjNDA5Y2E1YTY1OTg3MzE1MjkwZGEvdGFibGVyYW5nZTpmMTMwMGRkYTg4ZmM0MDljYTVhNjU5ODczMTUyOTBkYV8yLTAtMS0xLTM1Mzgz_0cd1b8fb-3123-4b34-8f94-59ec984a4f22">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6ZjEzMDBkZGE4OGZjNDA5Y2E1YTY1OTg3MzE1MjkwZGEvdGFibGVyYW5nZTpmMTMwMGRkYTg4ZmM0MDljYTVhNjU5ODczMTUyOTBkYV81LTAtMS0xLTM1MzgzL3RleHRyZWdpb246Y2NlNjlmMzE5YzBiNDk2ZDk3Y2Y5YjM3OWRmZTg2NDVfNA_4b67ebcc-09b8-493b-81bc-2cbde23b5e2d">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6ZjEzMDBkZGE4OGZjNDA5Y2E1YTY1OTg3MzE1MjkwZGEvdGFibGVyYW5nZTpmMTMwMGRkYTg4ZmM0MDljYTVhNjU5ODczMTUyOTBkYV81LTAtMS0xLTM1MzgzL3RleHRyZWdpb246Y2NlNjlmMzE5YzBiNDk2ZDk3Y2Y5YjM3OWRmZTg2NDVfNA_5ed46be8-3327-4e07-ad62-8dbccd3881b0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6ZjEzMDBkZGE4OGZjNDA5Y2E1YTY1OTg3MzE1MjkwZGEvdGFibGVyYW5nZTpmMTMwMGRkYTg4ZmM0MDljYTVhNjU5ODczMTUyOTBkYV84LTAtMS0xLTM1Mzgz_4a5ca454-40a1-4fbf-81e2-59fd6a993cfc">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6ZjEzMDBkZGE4OGZjNDA5Y2E1YTY1OTg3MzE1MjkwZGEvdGFibGVyYW5nZTpmMTMwMGRkYTg4ZmM0MDljYTVhNjU5ODczMTUyOTBkYV8xMS0wLTEtMS0zNTM4Mw_39a62b85-10b1-4c9c-966f-6a3b89d18a36">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTg2_13f3f754-36d8-4b98-a78e-ba189af63b03">001-38512</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTk1_7ad9d4f7-02f1-4e07-933e-457f956a7361">ONCOLYTICS BIOTECH INC.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTkw_abdf19a8-de63-415e-aab1-57587283e550">804, 322 11th Avenue SW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTc5_f1553c63-6f85-49e7-a874-8076bdafb5c4">Calgary</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTkx_1520a183-6363-438f-94ca-1ecb6a0789f3">AB</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTcz_c27732ca-a783-4d35-a466-029dc1f5bab6">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTgy_d67545db-363a-463c-be27-99fe177932ef">T2R 0C5</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName
      contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTc2_33196c37-8c18-4dca-829f-dbb9b548e89e">Kirk Look</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTg3_d21dca40-eb91-436c-9633-c405186c5cf5">804, 322 11th Avenue SW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTgz_c8a941b6-97ee-4fd1-a89b-9ef23f1a597f">Calgary</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTg4_2088cef0-1a94-4456-a576-cb9c87ba9a11">AB</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTkz_06f0ad7d-15a3-47ce-8936-15e1c3a7996f">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTg5_2e1e1baa-c7ff-4f5b-b248-c85a6f5aeff7">T2R 0C5</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV80Nzg_47a295ae-d573-4638-847d-5d1fe5ba242c">403</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTg0_23671e57-848f-4c43-b5b0-3b7516df1b34">670-7377</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress
      contextRef="i1081933872524fd0b8bcd230b2c503e8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTg1_7d058528-8f24-43dd-833f-fa8317f93d75">info@oncolytics.ca</dei:ContactPersonnelEmailAddress>
    <dei:Security12bTitle
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6MjE4MWE3ODExNDFkNDJmNzk0OThkZmY3NTk0YmQ1MzEvdGFibGVyYW5nZToyMTgxYTc4MTE0MWQ0MmY3OTQ5OGRmZjc1OTRiZDUzMV8xLTAtMS0xLTM1MzgzL3RleHRyZWdpb246Nzg0MGNmY2JhNjQ5NDIwMWExMjYwMGVjZmJhOWI2YzVfMTk_e067f248-3e87-4f8c-b2f7-e7bf96d092a2">no</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6MjE4MWE3ODExNDFkNDJmNzk0OThkZmY3NTk0YmQ1MzEvdGFibGVyYW5nZToyMTgxYTc4MTE0MWQ0MmY3OTQ5OGRmZjc1OTRiZDUzMV8xLTEtMS0xLTM1Mzgz_4e7fcab2-6e9c-4fac-91f5-76dd24b49702">ONCY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6MjE4MWE3ODExNDFkNDJmNzk0OThkZmY3NTk0YmQ1MzEvdGFibGVyYW5nZToyMTgxYTc4MTE0MWQ0MmY3OTQ5OGRmZjc1OTRiZDUzMV8xLTItMS0xLTM1MzgzL3RleHRyZWdpb246YjBhOWFkNTA2ZDFiNDdhN2IxNTMyNzI1OTFlZTQxODhfOA_6a623d14-b889-4039-99f8-7b6d8d427deb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8xMDA0_84e0793f-c1c0-4328-aa01-ca6e242709eb"
      unitRef="shares">61327914</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTc1_6fa60c81-c219-4eeb-af8b-f0bbb74e9bfa">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTcx_07935899-9bdf-4bdc-aecf-8f17ed93d59d">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTky_5e1bf0d9-708e-4a2f-9484-440c17e4c552">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTk2_1c043148-4c7f-42ed-9544-6fad391e4e5d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6NTAzMmQzMzRhNjRlNGY4OTkxODc3YjNiMDJmYjA4Y2MvdGFibGVyYW5nZTo1MDMyZDMzNGE2NGU0Zjg5OTE4NzdiM2IwMmZiMDhjY18wLTItMS0xLTM5NDM1L3RleHRyZWdpb246MDE1ZjQ0MWM4YmU1NGNiZjkzMmQ0OWU5MzUyYmVlYmZfMjc0ODc3OTA2OTQ5Mg_dd591fbc-5b52-4033-a5fd-567cf2431a17">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTgx_13e2e678-3752-456b-841f-ce2fa9cebca6">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGFibGU6MzI0YTc0YzUyMWZjNDM0ZWI3MTFhMjYzNDNmN2QyOTUvdGFibGVyYW5nZTozMjRhNzRjNTIxZmM0MzRlYjcxMWEyNjM0M2Y3ZDI5NV8wLTEtMS0xLTM1MzgzL3RleHRyZWdpb246OGUwMmVhNTUxYzRhNDNlMmEyN2ZhNzgxZWY1MjU3YjFfNA_9857c344-f96c-4844-b248-225ab06085fa">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xL2ZyYWc6ZTk1YjJhYzA0N2E4NDM4YjhiMWU2NmJiOWRiZDc1MzkvdGV4dHJlZ2lvbjplOTViMmFjMDQ3YTg0MzhiOGIxZTY2YmI5ZGJkNzUzOV8zNTcy_9cefedee-04ec-4bdc-9fb5-0dda68456d5d">false</dei:EntityShellCompany>
    <dei:DocumentPeriodEndDate
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180Ni9mcmFnOjdlMTJlYzU5NzFmYzQwY2Q4YTQ4MTZiMzk1ZmJjY2ZiL3RleHRyZWdpb246N2UxMmVjNTk3MWZjNDBjZDhhNDgxNmIzOTVmYmNjZmJfMTA5OTUxMTY4MjA1NQ_4b67ebcc-09b8-493b-81bc-2cbde23b5e2d">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN180Ni9mcmFnOjdlMTJlYzU5NzFmYzQwY2Q4YTQ4MTZiMzk1ZmJjY2ZiL3RleHRyZWdpb246N2UxMmVjNTk3MWZjNDBjZDhhNDgxNmIzOTVmYmNjZmJfMTA5OTUxMTY4MjA1NQ_5ed46be8-3327-4e07-ad62-8dbccd3881b0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AuditorFirmId
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN183Ni9mcmFnOmVkYjVkNmQ2NTUzOTRkMjU5ZjkxMDIzMGYwODNhMTlkL3RleHRyZWdpb246ZWRiNWQ2ZDY1NTM5NGQyNTlmOTEwMjMwZjA4M2ExOWRfMTA5OTUxMTYyOTcyMg_cfb304af-8150-4e14-8a58-71788f76ebbb">1263</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMTUvZnJhZzpjZWMzYzA0MjE3MDQ0M2I4OTZjOTg4NDExMjI4ZmRkZS90ZXh0cmVnaW9uOmNlYzNjMDQyMTcwNDQzYjg5NmM5ODg0MTEyMjhmZGRlXzQ2MDE_2b016e78-338c-42ac-ab79-c6b169a1e20d">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMTgvZnJhZzoyNzNjMTUyYjhjZjU0Y2M5YmQ2YzBhNzkwNWI0ZjMxYi90YWJsZTpkMDJjMzllY2Q5M2M0ZGRiODdjYzI0N2EzODMyODBjMS90YWJsZXJhbmdlOmQwMmMzOWVjZDkzYzRkZGI4N2NjMjQ3YTM4MzI4MGMxXzMtMC0xLTEtMzUzODM_72faa160-3800-4e8d-b006-d4e8bcb09fa1">Calgary, Canada</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzMtMS0xLTEtMzUzODM_24885483-90b2-4164-a37c-c467ee314055"
      unitRef="cad">11666000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzMtMy0xLTEtMzUzODM_9f5e037e-442e-46be-ba7f-4872942e9a4d"
      unitRef="cad">41262000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentFinancialAssetsAvailableforsale
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzQtMS0xLTEtMzc0MDc_c04797eb-05d0-4732-b160-aba2a2dee5fa"
      unitRef="cad">20472000</ifrs-full:CurrentFinancialAssetsAvailableforsale>
    <ifrs-full:CurrentFinancialAssetsAvailableforsale
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzQtMy0xLTEtMzczOTk_5642a183-27ef-4421-8aa4-728e3e6237d3"
      unitRef="cad">0</ifrs-full:CurrentFinancialAssetsAvailableforsale>
    <ifrs-full:OtherCurrentReceivables
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzQtMS0xLTEtMzUzODM_5c4cca4a-e409-4cc7-b7c7-663f905e7dc3"
      unitRef="cad">521000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzQtMy0xLTEtMzUzODM_43a78718-b117-46ff-9669-b23df6c9735d"
      unitRef="cad">866000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepayments
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzUtMS0xLTEtMzUzODM_1aa3447a-4283-433c-8d75-5cae83b03c74"
      unitRef="cad">3025000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzUtMy0xLTEtMzUzODM_acfb028b-2f83-40a5-8c78-b6b0bb824ef5"
      unitRef="cad">2776000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentAssets
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzYtMS0xLTEtMzUzODM_6521a759-c9f4-4b54-b2a1-c721f3ea2373"
      unitRef="cad">35684000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzYtMy0xLTEtMzUzODM_9ae517a6-adee-4018-9ecb-2c8fb9821180"
      unitRef="cad">44904000</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzctMS0xLTEtMzUzODM_92c16ea8-01bc-463f-9439-00b34ec650c8"
      unitRef="cad">356000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzctMy0xLTEtMzUzODM_aa4e1ff2-55b1-4b75-bbf0-195683c87cd1"
      unitRef="cad">392000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzgtMS0xLTEtMzUzODM_03adbcaf-5666-422b-bafc-2c7e17b5dc93"
      unitRef="cad">296000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzgtMy0xLTEtMzUzODM_76f6b90a-b491-4c7e-ac2e-d63d4dc06dcb"
      unitRef="cad">584000</ifrs-full:RightofuseAssets>
    <ifrs-full:NoncurrentPrepayments
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzEwLTEtMS0xLTQ2MDEz_f63100f1-c93a-481e-8a9a-b634841f5469"
      unitRef="cad">998000</ifrs-full:NoncurrentPrepayments>
    <ifrs-full:NoncurrentPrepayments
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzEwLTMtMS0xLTQ2MDIy_5cf5ed06-2ea8-4b2a-af97-8ceb2a714ca4"
      unitRef="cad">0</ifrs-full:NoncurrentPrepayments>
    <ifrs-full:Assets
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzktMS0xLTEtMzUzODM_23688763-26d9-4a15-96fa-ca1e7bda49ba"
      unitRef="cad">37334000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzktMy0xLTEtMzUzODM_af2a7ecb-c40b-4f18-9a6e-f14ad91f5755"
      unitRef="cad">45880000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzEyLTEtMS0xLTM1Mzgz_9eff9e6a-b91f-4bd9-a4ff-03a91743e111"
      unitRef="cad">3650000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzEyLTMtMS0xLTM1Mzgz_49ee55c9-3f5e-4bf8-84bd-9d1b869e3797"
      unitRef="cad">1988000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzEzLTEtMS0xLTM1Mzgz_9e343fac-7d8e-48b4-a2e8-d520b94f71a3"
      unitRef="cad">0</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzEzLTMtMS0xLTM1Mzgz_6b629c9d-3427-40cd-918b-abf2452dbbc3"
      unitRef="cad">352000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE0LTEtMS0xLTM1Mzgz_ee1dbf8c-65f4-4356-8790-bfadf1c66ae2"
      unitRef="cad">216000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE0LTMtMS0xLTM1Mzgz_7e70d0a4-213c-4686-8115-5a8b0c8e6996"
      unitRef="cad">294000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE1LTEtMS0xLTM1Mzgz_fddbbb79-40cb-4506-ba5c-a3e3c6e49b01"
      unitRef="cad">79000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE1LTMtMS0xLTM1Mzgz_e564b154-ab98-4fcb-89de-347cb6d4ad4e"
      unitRef="cad">56000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE2LTEtMS0xLTM1Mzgz_5eaa39ce-117a-4ef0-824d-40837ea2ef6b"
      unitRef="cad">3945000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE2LTMtMS0xLTM1Mzgz_3a483890-201a-4ff3-82bd-b2a64dc858e0"
      unitRef="cad">2690000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE3LTEtMS0xLTM1Mzgz_910c6111-5bba-4031-b487-97fc0ebafa25"
      unitRef="cad">6730000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE3LTMtMS0xLTM1Mzgz_5be23796-4751-49ff-9c59-3a7f642885f1"
      unitRef="cad">6730000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE4LTEtMS0xLTM1Mzgz_1f4efc1c-4ed3-43f4-b931-0770dd942351"
      unitRef="cad">157000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE4LTMtMS0xLTM1Mzgz_da4719c2-48d1-4f73-b57a-e653db1e0ee3"
      unitRef="cad">361000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:Liabilities
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE5LTEtMS0xLTM1Mzgz_9f588a0e-8c56-4688-9371-111e4a0eb38b"
      unitRef="cad">10832000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzE5LTMtMS0xLTM1Mzgz_8d5e8490-1e11-4612-b1d5-74ee4deee880"
      unitRef="cad">9781000</ifrs-full:Liabilities>
    <oncyf:CommitmentsAndContingencies1
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIwLTEtMS0xLTM1Mzgz_af243222-6d95-496a-bc8b-f908a29ad344"
      unitRef="cad"
      xsi:nil="true"/>
    <oncyf:CommitmentsAndContingencies1
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIwLTMtMS0xLTM1Mzgz_a60da0b6-4d69-4124-a81d-57d75eb2d683"
      unitRef="cad"
      xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued
      contextRef="ied69a4c1e8dc444497553637c429c995_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIyLTAtMS0xLTM1MzgzL3RleHRyZWdpb246MWM3MWMzOGM4YmZiNGVjMzg5YjE0NDE5OTMzY2Y2N2ZfMTA5OTUxMTYyNzkxMA_c7640ad5-435c-494d-8c5b-129845408eb6"
      unitRef="shares">61327914</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="ieee4c1d19b10441a9fb87c20bf21e3fa_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIyLTAtMS0xLTM1MzgzL3RleHRyZWdpb246MWM3MWMzOGM4YmZiNGVjMzg5YjE0NDE5OTMzY2Y2N2ZfMTA5OTUxMTYyNzkyMw_7dcc1e13-351c-438a-bd4c-eb1b5316673e"
      unitRef="shares">55043789</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapital
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIyLTEtMS0xLTM1Mzgz_830880b7-21af-4567-a0eb-49a7421b7ddc"
      unitRef="cad">404040000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIyLTMtMS0xLTM1Mzgz_7a054ba7-eb8f-4535-9263-f1a2bd0abf91"
      unitRef="cad">391348000</ifrs-full:IssuedCapital>
    <oncyf:WarrantsandRightsOutstanding
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIzLTEtMS0xLTM1Mzgz_bce8a5fc-5c08-48ee-bf8d-f0b275378390"
      unitRef="cad">0</oncyf:WarrantsandRightsOutstanding>
    <oncyf:WarrantsandRightsOutstanding
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzIzLTMtMS0xLTM1Mzgz_b52dede6-6af3-4c5a-b442-158709e5eb90"
      unitRef="cad">3618000</oncyf:WarrantsandRightsOutstanding>
    <ifrs-full:AdditionalPaidinCapital
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI0LTEtMS0xLTM1Mzgz_7baa9be0-bb71-41b5-9a07-567acac1c947"
      unitRef="cad">40051000</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AdditionalPaidinCapital
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI0LTMtMS0xLTM1Mzgz_7a233600-fb03-4f8f-ba9a-944b994ce3f8"
      unitRef="cad">34161000</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI1LTEtMS0xLTM1Mzgz_e99d32db-4c7f-4f93-880b-53435def52d1"
      unitRef="cad">662000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI1LTMtMS0xLTM1Mzgz_993e3576-c403-4eee-a90f-1f73f7fdf336"
      unitRef="cad">388000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:RetainedEarnings
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI2LTEtMS0xLTM1Mzgz_1fc38420-d3ff-4663-850e-0f69a45bb844"
      unitRef="cad">-418251000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI2LTMtMS0xLTM1Mzgz_d69a3896-3e0b-4ba7-a3af-659372e700aa"
      unitRef="cad">-393416000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI3LTEtMS0xLTM1Mzgz_1c8eafd2-989f-44e7-8700-9b18308c20a9"
      unitRef="cad">26502000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI3LTMtMS0xLTM1Mzgz_16d029e1-c716-4612-9c87-8481899eb49f"
      unitRef="cad">36099000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI4LTEtMS0xLTM1Mzgz_a6f1071f-9037-453f-aa4e-341216f40dea"
      unitRef="cad">37334000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjEvZnJhZzphNzk0ZmY2YTlhZTU0MmI3ODhlM2QxZjVlYWRhOTU5MC90YWJsZTo2MzhiNjlhOWEyYjA0YWEzOTYxZDZiZjc1ODJmNDkwZC90YWJsZXJhbmdlOjYzOGI2OWE5YTJiMDRhYTM5NjFkNmJmNzU4MmY0OTBkXzI4LTMtMS0xLTM1Mzgz_0589c07b-a92b-4471-9a70-bd883ae20890"
      unitRef="cad">45880000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzItMS0xLTEtMzUzODM_adc16455-d36d-458f-93bd-6537389276cd"
      unitRef="cad">15432000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzItMy0xLTEtMzUzODM_8fbec08f-f42c-4ea3-b090-113116dd6b15"
      unitRef="cad">12920000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzItNS0xLTEtMzUzODM_48a98b30-cd3e-489b-b790-056b3000f82a"
      unitRef="cad">12945000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:OperatingExpense
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzMtMS0xLTEtMzUzODM_bd94e035-1e09-4a13-8050-fe920494abec"
      unitRef="cad">11492000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzMtMy0xLTEtMzUzODM_3f85011b-4017-48ba-9924-d552ca2b8f77"
      unitRef="cad">13315000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzMtNS0xLTEtMzUzODM_da2db7c7-4135-4b7b-94cf-4b463e60242b"
      unitRef="cad">12514000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzQtMS0xLTEtMzUzODM_46db4bac-4fb5-45de-a9b2-9ab3fe9440e0"
      unitRef="cad">-26924000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzQtMy0xLTEtMzUzODM_a5d5a010-62dc-4992-aa5b-e1affb4d7465"
      unitRef="cad">-26235000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzQtNS0xLTEtMzUzODM_af47bd97-6009-4ca6-8c2e-f8622c2fb0fb"
      unitRef="cad">-25459000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzUtMS0xLTEtMzUzODM_b2fb888f-755c-40b9-9bc2-ec86c067dc93"
      unitRef="cad">-20000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzUtMy0xLTEtMzUzODM_1ab593af-eece-41f4-a41c-953e9466a56c"
      unitRef="cad">17000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzUtNS0xLTEtMzUzODM_126f8f4d-8ea0-4e5b-ba99-dffbe404625f"
      unitRef="cad">3492000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzYtMS0xLTEtMzUzODM_658233ac-0291-40bd-8351-44b439d323f3"
      unitRef="cad">1665000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzYtMy0xLTEtMzUzODM_30681a4b-6949-46e5-bea8-0cd1609182e6"
      unitRef="cad">-136000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzYtNS0xLTEtMzUzODM_46d9ba3c-e640-4279-8a28-f086515788eb"
      unitRef="cad">-659000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzctMS0xLTEtMzUzODM_6a06203d-2839-45bd-a8e3-049bdf3e30bc"
      unitRef="cad">528000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzctMy0xLTEtMzUzODM_553f3020-4c6c-4988-a9e7-ae9e12a3fec2"
      unitRef="cad">99000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzctNS0xLTEtMzUzODM_6e0cc011-c134-4965-b7ac-8dd73b38c78a"
      unitRef="cad">121000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzgtMS0xLTEtMzUzODM_d3fe07c8-758a-42d0-baeb-a5febff9491b"
      unitRef="cad">-24751000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzgtMy0xLTEtMzUzODM_7b0c6a71-0ca6-4cab-93e9-844d68a0e4b4"
      unitRef="cad">-26255000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzgtNS0xLTEtMzUzODM_98110736-ed67-4df7-b624-303ce032bea6"
      unitRef="cad">-22505000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzktMS0xLTEtMzUzODM_26d39ef3-01ea-4ab9-84da-b57cfaa9fbcc"
      unitRef="cad">84000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzktMy0xLTEtMzUzODM_40859681-09f9-4f80-9c78-156ef981801a"
      unitRef="cad">49000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzktNS0xLTEtMzUzODM_4137b0c3-b4a6-47df-aed0-e23b3d0423e2"
      unitRef="cad">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEwLTEtMS0xLTM1Mzgz_1fc14330-df34-4d11-bb33-c02ed54779cb"
      unitRef="cad">-24835000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEwLTMtMS0xLTM1Mzgz_8cec9357-c29f-4097-a48f-357dcbd55ddd"
      unitRef="cad">-26304000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEwLTUtMS0xLTM1Mzgz_2e044fc2-857e-46d4-82fd-8599a468e8e9"
      unitRef="cad">-22505000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEyLTEtMS0xLTM1Mzgz_1043b641-2656-4ecc-93ee-9f2b69066d33"
      unitRef="cad">274000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEyLTMtMS0xLTM1Mzgz_fde1b278-a744-467c-a4ed-2f79a3d7408f"
      unitRef="cad">-12000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEyLTUtMS0xLTM1Mzgz_12f25d4d-3e4c-4f42-b87b-f2401a3e6179"
      unitRef="cad">-64000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEzLTEtMS0xLTM1Mzgz_5291b83a-695b-4f96-bd91-e25d14679ce0"
      unitRef="cad">-24561000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEzLTMtMS0xLTM1Mzgz_926b2d8d-fbae-41e1-8358-7b9ba243a588"
      unitRef="cad">-26316000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzEzLTUtMS0xLTM1Mzgz_fb8e4a73-8790-4d7e-966a-7af2258c2465"
      unitRef="cad">-22569000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE1LTEtMS0xLTM1Mzgz_35fa8cbb-85b7-437f-9a77-1b5fbea47724"
      unitRef="cadPerShare">-0.43</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE1LTEtMS0xLTM1Mzgz_d12df9c3-7b42-4da5-b382-df49eec0058a"
      unitRef="cadPerShare">-0.43</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE1LTMtMS0xLTM1Mzgz_7f25ba13-4693-4cd5-8025-4be66095fe14"
      unitRef="cadPerShare">-0.49</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE1LTMtMS0xLTM1Mzgz_eab74f69-785c-4288-b4b8-7e83a48c040a"
      unitRef="cadPerShare">-0.49</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE1LTUtMS0xLTM1Mzgz_1499e731-493b-4979-92cd-8f6ccd4ef476"
      unitRef="cadPerShare">-0.56</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE1LTUtMS0xLTM1Mzgz_c28840be-6f90-49a8-8792-ac17f79fda82"
      unitRef="cadPerShare">-0.56</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE2LTEtMS0xLTM1Mzgz_7c2a5fec-8b12-4cb7-93bc-eb9d39c8cfc6"
      unitRef="shares">58029745</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE2LTEtMS0xLTM1Mzgz_aa847d69-2a67-4fe1-ba4c-0da07f68006a"
      unitRef="shares">58029745</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE2LTMtMS0xLTM1Mzgz_50d877c4-f94f-4413-aea7-048943c0ce53"
      unitRef="shares">53513225</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE2LTMtMS0xLTM1Mzgz_62892829-bde9-4d3e-bdcb-222261987844"
      unitRef="shares">53513225</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE2LTUtMS0xLTM1Mzgz_608ec0f0-a6d4-49be-837e-e4517c46b4e3"
      unitRef="shares">40338789</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjQvZnJhZzoxZmVjZWM0Y2VmNDI0YWFlODcwYTk1OGIxMTAwMTJkYS90YWJsZTo2NzUyNDE5MjQ0MDQ0Y2ZmYTVjMzE0ZmJlNmZiMDM5OS90YWJsZXJhbmdlOjY3NTI0MTkyNDQwNDRjZmZhNWMzMTRmYmU2ZmIwMzk5XzE2LTUtMS0xLTM1Mzgz_e5fd7995-c12c-4604-9fa5-7fd48ebc3a7d"
      unitRef="shares">40338789</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:Equity
      contextRef="i34072d06dbc74709a44772e87c0d0628_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEtMS0xLTEtMzUzODM_83dbb6f7-00d5-4f9d-90e1-bd5e71fb1653"
      unitRef="cad">311078000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ifd91d05642e7401b8c8faeeb5459ba72_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEtMy0xLTEtMzUzODM_6f798099-2489-420a-985c-9330b12a22bc"
      unitRef="cad">3618000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i5b5762368dba4c919ee8061f3f934cd2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEtNS0xLTEtMzUzODM_040c90c1-407e-4588-81a0-6eaf28b3f655"
      unitRef="cad">29339000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i9d7d4f10038048718f7928d1bab94c89_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEtNy0xLTEtMzUzODM_3815b28b-12c8-4d9d-84e9-2bd079d564ee"
      unitRef="cad">464000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="idadaa0cf361244f49594f3ef42b55e1c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEtOS0xLTEtMzUzODM_7ede28ac-697b-4ab8-a13b-8c91de34836f"
      unitRef="cad">-344607000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ie5e2093c82014efc936a23f9e66baceb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEtMTEtMS0xLTM1Mzgz_6cf194b0-a793-4723-a46b-51f9986eedf6"
      unitRef="cad">-108000</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome
      contextRef="i3fe43ded55bb48a19706afc4c1823657_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzItNy0xLTEtMzUzODM_70859dbb-a6da-45d3-b679-59d56a629e1c"
      unitRef="cad">-64000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i57e65be9e20f459dbe2844e5091b0eb8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzItOS0xLTEtMzUzODM_ebb37e59-9f0d-4b93-8d1c-3f46294df259"
      unitRef="cad">-22505000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzItMTEtMS0xLTM1Mzgz_622965ae-f942-4a68-b634-97b3e3671fa5"
      unitRef="cad">-22569000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i29cfb81f0a3a44299e19e6f5f7d4b3fe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzMtMS0xLTEtMzUzODM_392d8c2b-bd0f-4b6d-ab2a-80c4a0ca0bd1"
      unitRef="cad">385000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="ic888e62d483b498baa6a74041afebae7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzMtNS0xLTEtMzUzODM_0721db19-9797-457c-a328-1e83ea9942e2"
      unitRef="cad">-144000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzMtMTEtMS0xLTM1Mzgz_cfbf5ae1-fe0e-4d27-b5b9-0f004cdfe22d"
      unitRef="cad">241000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i29cfb81f0a3a44299e19e6f5f7d4b3fe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzUtMS0xLTEtMzUzODM_d0367f14-d810-4d85-88c8-674c69049600"
      unitRef="cad">732000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="ic888e62d483b498baa6a74041afebae7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzUtNS0xLTEtMzUzODM_627f7f47-e10b-4db2-9a5e-d1d4e2c3c855"
      unitRef="cad">-732000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzUtMTEtMS0xLTM1Mzgz_e9844b9e-62c0-4650-b9e8-45a37e304d2f"
      unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i11b5e4d511d249e2a405c432386bbc33_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzYtMS0xLTEtMzUzODM_d625096f-f583-4c7d-989c-1855a85a05ed"
      unitRef="cad">40038000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="ie6510299e4eb4121b35ad3c184f04164_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzYtMTEtMS0xLTM1Mzgz_9f9deb94-7ae7-43a1-a76f-b27083b3a90f"
      unitRef="cad">40038000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i29cfb81f0a3a44299e19e6f5f7d4b3fe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzctMS0xLTEtMzUzODM_c4f2c850-f615-4808-ac7b-c9533ba7dd6e"
      unitRef="cad">6333000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzctMTEtMS0xLTM1Mzgz_bb4ad3ab-65a5-49d0-9358-7f9bdd101db0"
      unitRef="cad">6333000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="ic888e62d483b498baa6a74041afebae7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzgtNS0xLTEtMzUzODM_b14e76bf-77d1-4ee6-9c22-ea676afd05a3"
      unitRef="cad">2559000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzgtMTEtMS0xLTM1Mzgz_84f64af9-cb21-44f1-8d70-db7f9091ca05"
      unitRef="cad">2559000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i29cfb81f0a3a44299e19e6f5f7d4b3fe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzktMS0xLTEtMzUzODM_38796f0f-57a5-4626-bf08-5e0e86e0fb57"
      unitRef="cad">1742000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzktMTEtMS0xLTM1Mzgz_87dbdd5d-510c-48dc-b4f8-71d438d763b0"
      unitRef="cad">1742000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:Equity
      contextRef="i290facf32bd147b3884843f453ff6807_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEwLTEtMS0xLTM1Mzgz_3687b16a-356f-4c1a-9174-835d5f5b3bdb"
      unitRef="cad">356824000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ia8306ac01dd1463bbd49d0c295bf272f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEwLTMtMS0xLTM1Mzgz_9f541448-e635-496e-be28-5f1e5636c6e7"
      unitRef="cad">3618000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i22e1e0507b4d45e393729762660f43a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEwLTUtMS0xLTM1Mzgz_6b4f97d1-00c1-499d-82e2-70470b780725"
      unitRef="cad">31022000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i368b44deb2be4ae8a6ca25d3395395fd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEwLTctMS0xLTM1Mzgz_e82ce132-f408-4fc0-a0c0-2c995b59eb28"
      unitRef="cad">400000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i948a576781cb440eb04b08b93b5d97f4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEwLTktMS0xLTM1Mzgz_85616805-46ee-4ccb-9d74-245a9691f155"
      unitRef="cad">-367112000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEwLTExLTEtMS0zNTM4Mw_3ac85dcb-d320-4c7f-a518-c1651b08409b"
      unitRef="cad">24752000</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome
      contextRef="i55f95b5256b04475bef34fd27060d50e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzExLTctMS0xLTM1Mzgz_991e2918-f72b-484b-90dc-c48f4e7e50b7"
      unitRef="cad">-12000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i3e5170208d2a4bd9b4a4c6146ff70357_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzExLTktMS0xLTM1Mzgz_f51dc2e7-eb60-40bb-8b61-c289b9da0f35"
      unitRef="cad">-26304000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzExLTExLTEtMS0zNTM4Mw_6c211d6a-b853-4a7c-92e9-5184a9b69b02"
      unitRef="cad">-26316000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i1c339f58b6a2498ea561adefe93e835c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEyLTEtMS0xLTM1Mzgz_fc0d61a6-5c19-44b5-9e7f-4a3329a98c35"
      unitRef="cad">381000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i3961fe68fe52450d88368027d3561fcf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEyLTUtMS0xLTM1Mzgz_d0d4a202-dd46-4f29-8698-b2f9ea265f2a"
      unitRef="cad">-143000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEyLTExLTEtMS0zNTM4Mw_3600a658-0142-4469-a2df-877baf7839f2"
      unitRef="cad">238000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i1c339f58b6a2498ea561adefe93e835c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEzLTEtMS0xLTM1Mzgz_365cda18-6d88-44d6-aeed-08992e1ab50f"
      unitRef="cad">544000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i3961fe68fe52450d88368027d3561fcf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEzLTUtMS0xLTM1Mzgz_a68b3c1d-b47b-4b9b-bb29-9bab401ba565"
      unitRef="cad">-544000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzEzLTExLTEtMS0zNTM4Mw_3be0bde4-ae87-4267-ac98-75020c90bd2a"
      unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i7a8cd87a2d5a464ba33b505012eb6589_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE0LTEtMS0xLTM1Mzgz_92ef31f7-3955-439d-aaca-6bc9b2fd4174"
      unitRef="cad">34168000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i5b43b9c4bfe449b6b1add7f653d88bf2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE0LTExLTEtMS0zNTM4Mw_c29f4686-37c9-429d-baf8-a3cfbcad0cbb"
      unitRef="cad">34168000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i1c339f58b6a2498ea561adefe93e835c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE1LTEtMS0xLTM1Mzgz_c6998d52-6694-48ce-a80c-89238a75affc"
      unitRef="cad">687000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE1LTExLTEtMS0zNTM4Mw_85824ab1-5260-4746-a070-a19bde163b20"
      unitRef="cad">687000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i3961fe68fe52450d88368027d3561fcf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE2LTUtMS0xLTM1Mzgz_71d541da-e775-4c56-b3be-5b9e9c694133"
      unitRef="cad">3826000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE2LTExLTEtMS0zNTM4Mw_0ce2a1cb-71f3-40f9-afe5-5715c18426f9"
      unitRef="cad">3826000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i1c339f58b6a2498ea561adefe93e835c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE3LTEtMS0xLTM1Mzgz_d1eeaf5c-f959-43f8-83d4-7150c7f0da67"
      unitRef="cad">1256000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE3LTExLTEtMS0zNTM4Mw_adc1aaaf-d6f2-4973-a466-9d58bd5bd6a9"
      unitRef="cad">1256000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:Equity
      contextRef="i4041f6f067cb40d396837f84680e473b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE4LTEtMS0xLTM1Mzgz_613b1a36-ee16-4d90-b498-71b327c237c4"
      unitRef="cad">391348000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ifbaf1681ace746c7a5991056ee03b717_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE4LTMtMS0xLTM1Mzgz_94b00978-2ac2-4fa5-bf3b-3e40106bc08a"
      unitRef="cad">3618000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i97c499ae0f4f4465949c6fe6c3000ab0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE4LTUtMS0xLTM1Mzgz_8d5aad5c-2e4b-459b-9b78-e3b6344aab51"
      unitRef="cad">34161000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i5cdf4a3d792142928c2a62b0fe7cbb14_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE4LTctMS0xLTM1Mzgz_d17b490b-a027-4c02-911b-8297b60a3790"
      unitRef="cad">388000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i01f7eba52a7942aeba915d83f45b1a80_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE4LTktMS0xLTM1Mzgz_4aa0cf3f-f0ab-4bda-82d1-9fbefe357343"
      unitRef="cad">-393416000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE4LTExLTEtMS0zNTM4Mw_21c3f69a-5e29-423e-9b64-8a2ebb039288"
      unitRef="cad">36099000</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome
      contextRef="i576c2a286bbc4d11b0b6d563390fe4b3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE5LTctMS0xLTM1Mzgz_c803e678-f44c-4e8a-9ec7-125ea360b40e"
      unitRef="cad">274000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i1ca5b15a1b7044289a0c16a41d080756_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE5LTktMS0xLTM1Mzgz_50ba96c2-9978-4573-ac4b-d4e58ef60a1d"
      unitRef="cad">-24835000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzE5LTExLTEtMS0zNTM4Mw_aa461135-c6ca-41f1-a89c-b762d97f621f"
      unitRef="cad">-24561000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i74a140a0b6704c889a525c2e794ec55c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIwLTEtMS0xLTM1Mzgz_a78b2654-263c-49b0-9cb6-2e550be65904"
      unitRef="cad">20000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="ie50cc2fed39041bc905a4bcda62dfc62_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIwLTUtMS0xLTM1Mzgz_c8f776e2-68fc-4c69-9554-2c7df4c23459"
      unitRef="cad">-8000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIwLTExLTEtMS0zNTM4Mw_844b58c4-3219-4945-877f-f8f2e3411180"
      unitRef="cad">12000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="i74a140a0b6704c889a525c2e794ec55c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIxLTEtMS0xLTM1Mzgz_60de8914-25c1-4cbb-bf22-9a0bac25afe1"
      unitRef="cad">98000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="ie50cc2fed39041bc905a4bcda62dfc62_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIxLTUtMS0xLTM1Mzgz_4b71f5f8-2668-4be6-8250-aed136b5369d"
      unitRef="cad">-98000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIxLTExLTEtMS0zNTM4Mw_53d3e74b-2b4a-4cbe-8d35-a5763728e1bf"
      unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity
      contextRef="i5bdab815bf824c749bcbfc48a0d04970_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIxLTMtMS0xLTQ0MDEx_f8feec20-fda0-4b1c-8d22-52d8e357ba77"
      unitRef="cad">-3618000</oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity>
    <oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity
      contextRef="ie50cc2fed39041bc905a4bcda62dfc62_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIxLTUtMS0xLTQ0MDE5_7e2c71eb-02b3-4cd8-9840-4d533301ad77"
      unitRef="cad">3618000</oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity>
    <oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIxLTExLTEtMS00NDA0Mw_3b3a61bd-9250-432b-9deb-b4e7bf3f87e8"
      unitRef="cad">0</oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i21011e791fea44a5a06778532673f5a7_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIyLTEtMS0xLTM1Mzgz_c6c4e3df-0d2d-4981-b21a-24603727fb46"
      unitRef="cad">13338000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i8ed6a69506e34074a8db38ee94834bd6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzIyLTExLTEtMS0zNTM4Mw_faf0dd7d-b395-4fc7-b4cf-dc4adbb95373"
      unitRef="cad">13338000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="ie50cc2fed39041bc905a4bcda62dfc62_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI0LTUtMS0xLTM1Mzgz_e06a7260-fe07-4445-8852-d1852f52da28"
      unitRef="cad">2378000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI0LTExLTEtMS0zNTM4Mw_a1b805da-f25f-492b-bbc3-2c9cca4d9ba4"
      unitRef="cad">2378000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i74a140a0b6704c889a525c2e794ec55c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI1LTEtMS0xLTM1Mzgz_14e2674f-f36b-4125-b2ab-1e77e95e95fa"
      unitRef="cad">764000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI1LTExLTEtMS0zNTM4Mw_e3b9addf-8d56-4105-b0d3-8a41d92e617a"
      unitRef="cad">764000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:Equity
      contextRef="i675ad40abe414c01b53d0b9d4f0b4bac_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI2LTEtMS0xLTM1Mzgz_2878762d-6347-48e3-90a7-ffa4547cb2bb"
      unitRef="cad">404040000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i926bb81a27e0480ca8b1aa8523ae7dbf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI2LTMtMS0xLTM1Mzgz_15d3613b-48b9-4dea-bd1d-9bc989974960"
      unitRef="cad">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i77a1e98211ca443f9dfaca9d7e15ffb4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI2LTUtMS0xLTM1Mzgz_44263089-c3e8-4c7f-b8eb-36dbec6deaf1"
      unitRef="cad">40051000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i92a4f596a4a24a67b57f8f348cf65e66_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI2LTctMS0xLTM1Mzgz_cbd96f54-522f-421b-80e5-040918d04596"
      unitRef="cad">662000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="iee80e6ef283a466d847af7f4c18b0932_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI2LTktMS0xLTM1Mzgz_39e9a010-a88d-435c-9569-fa073baa4350"
      unitRef="cad">-418251000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMjcvZnJhZzpjZDJmMjYyMjAyMDc0YTZlOGNjN2ExNTUyZTA4ZWYyNy90YWJsZTpiZDIzNjdhOWI5MmM0ZGJmOGZlODJiMjdkZjk4OTI4NS90YWJsZXJhbmdlOmJkMjM2N2E5YjkyYzRkYmY4ZmU4MmIyN2RmOTg5Mjg1XzI2LTExLTEtMS0zNTM4Mw_1e13610f-206a-41ec-9e55-6b45bf53e0dc"
      unitRef="cad">26502000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzItMS0xLTEtMzUzODM_31058465-6f1f-4405-9859-9e4699cb99ae"
      unitRef="cad">-24835000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzItMy0xLTEtMzUzODM_87c5465e-f65d-40a5-8947-6b09d0a256f7"
      unitRef="cad">-26304000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzItNS0xLTEtMzUzODM_590eec4f-5554-4dc7-bc93-c58acc7e3769"
      unitRef="cad">-22505000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzMtMS0xLTEtMzUzODM_55a3231b-c0fc-4aee-95da-ff2831049fee"
      unitRef="cad">93000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzMtMy0xLTEtMzUzODM_93d49763-a9ad-4605-8a8f-207e8946b7d2"
      unitRef="cad">130000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzMtNS0xLTEtMzUzODM_01f9745e-7bc8-4bf6-a59e-42c3c39d9efb"
      unitRef="cad">89000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <oncyf:AdjustmentsForDepreciationRightOfUseAssets
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzQtMS0xLTEtMzUzODM_62dd1ae7-02a3-45a4-8b2d-13ea87ae7014"
      unitRef="cad">299000</oncyf:AdjustmentsForDepreciationRightOfUseAssets>
    <oncyf:AdjustmentsForDepreciationRightOfUseAssets
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzQtMy0xLTEtMzUzODM_f3dbdf69-0b9a-4496-8d0d-f6237922bf44"
      unitRef="cad">322000</oncyf:AdjustmentsForDepreciationRightOfUseAssets>
    <oncyf:AdjustmentsForDepreciationRightOfUseAssets
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzQtNS0xLTEtMzUzODM_874c3301-0659-42ad-bc34-b2997bc6327d"
      unitRef="cad">357000</oncyf:AdjustmentsForDepreciationRightOfUseAssets>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzUtMS0xLTEtMzUzODM_3206c960-c230-4198-84ab-65fdb8550c37"
      unitRef="cad">2378000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzUtMy0xLTEtMzUzODM_28cf69ff-d7a5-4377-86c6-88cfd1da195d"
      unitRef="cad">3826000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzUtNS0xLTEtMzUzODM_136a9029-546a-4b7d-9088-a7cd1e55eeac"
      unitRef="cad">2559000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:InterestRevenueExpense
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzYtMS0xLTEtMzUzODM_0f0bf05d-646e-4b82-87cb-8eb756382a08"
      unitRef="cad">76000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestRevenueExpense
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzYtMy0xLTEtMzUzODM_b2d802a0-9df8-4a5c-9ffd-f3c74970c1c6"
      unitRef="cad">-92000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestRevenueExpense
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzYtNS0xLTEtMzUzODM_23b7cee2-5e70-4a90-89ef-6d87d0877fef"
      unitRef="cad">-69000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzctMS0xLTEtMzUzODM_49f82822-f879-4578-a427-2adb1820ea3b"
      unitRef="cad">-1625000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzctMy0xLTEtMzUzODM_bfd6c951-3e4a-4c7b-b43f-2ced0668be95"
      unitRef="cad">426000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzctNS0xLTEtMzUzODM_de7c2f2d-0165-440f-9333-077872fa6a64"
      unitRef="cad">645000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzgtMS0xLTEtMzUzODM_42254430-5643-4304-9e79-6002932ad311"
      unitRef="cad">-20000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzgtMy0xLTEtMzUzODM_331aa4fb-769f-45ad-9dca-cb10e0cfd208"
      unitRef="cad">17000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzgtNS0xLTEtMzUzODM_9e07496e-4018-4f41-a3ec-d9a08b25ca2b"
      unitRef="cad">3492000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzktMS0xLTEtMzUzODM_f7f2ee95-f207-4926-a98e-c7001a63ff8e"
      unitRef="cad">-391000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzktMy0xLTEtMzUzODM_18be0f30-bb7a-4b2b-b921-b242a8043634"
      unitRef="cad">908000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzktNS0xLTEtMzUzODM_4c00b6d6-7cb5-41da-8ebf-776e20af5693"
      unitRef="cad">-210000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEwLTEtMS0xLTM1Mzgz_aac9cb2f-b9f1-44ff-a131-615c1e7ba6b6"
      unitRef="cad">-23355000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEwLTMtMS0xLTM1Mzgz_bf292f22-697d-4a4d-a848-a86ba421b48f"
      unitRef="cad">-22433000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEwLTUtMS0xLTM1Mzgz_209e56ce-d949-4675-8efd-783ccf4f8fb0"
      unitRef="cad">-22068000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEyLTEtMS0xLTQ0MDU1_36f4c626-54e0-4d2d-b0a7-412e282b9f81"
      unitRef="cad">20348000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEyLTMtMS0xLTQ0MDYz_1e44bc8b-9b38-410f-b367-b30c25776342"
      unitRef="cad">0</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEyLTUtMS0xLTQ0MDcx_8aa188e3-478b-4b85-943d-41eb597b151a"
      unitRef="cad">0</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEyLTEtMS0xLTM1Mzgz_303c618e-7213-4381-9b90-aa093e268197"
      unitRef="cad">55000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEyLTMtMS0xLTM1Mzgz_234bc89f-ccfe-41d6-abb4-b0bfe7b145f4"
      unitRef="cad">286000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEyLTUtMS0xLTM1Mzgz_773c8b88-eb0e-4e7d-9ef8-a4476eceda2c"
      unitRef="cad">29000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEzLTEtMS0xLTM1Mzgz_698b1235-6fe0-4a7e-87a3-81b5bcd242be"
      unitRef="cad">-20403000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEzLTMtMS0xLTM1Mzgz_b5e78f8d-88a7-453e-80ae-422bb46a04a1"
      unitRef="cad">-286000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzEzLTUtMS0xLTM1Mzgz_f91f46a4-b3f7-496d-b682-ba88509059d0"
      unitRef="cad">-29000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE1LTEtMS0xLTM1Mzgz_8d9ddc50-4982-41ed-84ba-421fc442a952"
      unitRef="cad">12000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE1LTMtMS0xLTM1Mzgz_ff6e88cf-99a8-4359-bf41-d167579b28a8"
      unitRef="cad">238000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE1LTUtMS0xLTM1Mzgz_e0b8d5b8-db75-43e1-b9a2-4e341d30464a"
      unitRef="cad">241000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="ic8f2d18eb4014706985a616274ce8cf0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE2LTEtMS0xLTM1Mzgz_0f882653-b346-4d66-b4ad-c19368a927db"
      unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i15555db508714ca18e982d65eea9cb39_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE2LTMtMS0xLTM1Mzgz_975afb9b-92a6-4b19-8ef2-6982306192e4"
      unitRef="cad">231000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i5db0e2b8debf4e1987ee224438086d51_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE2LTUtMS0xLTM1Mzgz_1e33574f-541c-4331-98d2-43472f21210a"
      unitRef="cad">1697000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i8ed6a69506e34074a8db38ee94834bd6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE4LTEtMS0xLTM1Mzgz_36ee32ce-ed47-4aa2-aedb-d2c2775ac4a5"
      unitRef="cad">12574000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i5b43b9c4bfe449b6b1add7f653d88bf2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE4LTMtMS0xLTM1Mzgz_eb32bc47-9b38-46fa-84a1-c7006d8deeef"
      unitRef="cad">32912000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="ie6510299e4eb4121b35ad3c184f04164_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzE4LTUtMS0xLTM1Mzgz_79332a0f-ee51-432a-8b82-29cecbc537e5"
      unitRef="cad">38296000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:CashOutflowForLeases
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIwLTEtMS0xLTM1Mzgz_90998dc7-47b5-4995-9b7c-410af9a99dce"
      unitRef="cad">381000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIwLTMtMS0xLTM1Mzgz_b701c200-db3a-493d-b7d6-ae4a14020418"
      unitRef="cad">366000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIwLTUtMS0xLTM1Mzgz_c1f37c9f-c6b9-44d4-b418-db09f1ec1bbb"
      unitRef="cad">461000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIxLTEtMS0xLTM1Mzgz_bfe52465-39e4-446d-a6ed-4ce74e215dc7"
      unitRef="cad">12205000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIxLTMtMS0xLTM1Mzgz_5c405128-285a-404b-a049-9b7742548cd0"
      unitRef="cad">33015000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIxLTUtMS0xLTM1Mzgz_b280cc5c-44d5-4c43-948b-bbf35bea2690"
      unitRef="cad">39773000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIyLTEtMS0xLTM1Mzgz_e345d845-250a-40b1-8a4d-827cf4e62827"
      unitRef="cad">-31553000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIyLTMtMS0xLTM1Mzgz_e79e05f2-500e-46a5-ac07-264bdb89abbe"
      unitRef="cad">10296000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIyLTUtMS0xLTM1Mzgz_d8aab862-d729-437b-ab00-83ac9dc37608"
      unitRef="cad">17676000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIzLTEtMS0xLTM1Mzgz_a9ffeb01-a7c8-434b-ac7c-a1d2149c3f51"
      unitRef="cad">41262000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIzLTMtMS0xLTM1Mzgz_1fd72f49-4fab-41e6-9516-ca79ee672c6d"
      unitRef="cad">31220000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ie5e2093c82014efc936a23f9e66baceb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzIzLTUtMS0xLTM1Mzgz_1f217491-0495-4d29-b58d-e1e2b3e93ce6"
      unitRef="cad">14148000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzI0LTEtMS0xLTM1Mzgz_da2c177c-70a4-4173-a48b-a273c5f94e60"
      unitRef="cad">1957000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzI0LTMtMS0xLTM1Mzgz_f4bb3bd5-c819-45b9-9dab-0dee97158a11"
      unitRef="cad">-254000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzI0LTUtMS0xLTM1Mzgz_de8571a8-3e4c-4603-8e31-a32315df57eb"
      unitRef="cad">-604000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzI1LTEtMS0xLTM1Mzgz_00e92efd-83aa-4b21-a29d-3dc289c5709b"
      unitRef="cad">11666000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzI1LTMtMS0xLTM1Mzgz_e727cfa1-2599-4e87-a4ed-7652dcdc1be1"
      unitRef="cad">41262000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzAvZnJhZzpkNzI3MTI1MjA2ZmI0YjEzYTMyMGJlMGE3ZjJlNjVhZC90YWJsZTo3M2FjMDUyMjkzODI0MDc3ODU3NjU2OGEwZDkzMGU3MS90YWJsZXJhbmdlOjczYWMwNTIyOTM4MjQwNzc4NTc2NTY4YTBkOTMwZTcxXzI1LTUtMS0xLTM1Mzgz_d0efcc28-ad08-499b-b045-e532a27722dd"
      unitRef="cad">31220000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzYvZnJhZzozMTAyZTAzNTk4YzU0ZjE4OTYwMTI3ZGYwNGQ5NzlmNC90ZXh0cmVnaW9uOjMxMDJlMDM1OThjNTRmMTg5NjAxMjdkZjA0ZDk3OWY0XzE0NjM_92d54099-ef82-4788-9bb8-3b498b185612">Nature of Operations&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Oncolytics Biotech Inc. was incorporated on April 2, 1998, under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Avenue S.W., Calgary, Alberta, Canada.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, we are exploring opportunities for registrational programs in gastrointestinal cancers through our GOBLET platform study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not been profitable since our inception and expect to continue to incur substantial losses as we continue our research and development efforts. As at December&#160;31, 2022, we had an accumulated deficit of $418,251. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through the issuance of additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. There can be no assurance that we will be able to raise additional funds through the sale of our common shares. Failure to raise additional capital would have a material adverse impact on our business, results of operations, and financial condition. As at December&#160;31, 2022, we had cash and cash equivalents and marketable securities of $32,138. We believe we have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:RetainedEarnings
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzYvZnJhZzozMTAyZTAzNTk4YzU0ZjE4OTYwMTI3ZGYwNGQ5NzlmNC90ZXh0cmVnaW9uOjMxMDJlMDM1OThjNTRmMTg5NjAxMjdkZjA0ZDk3OWY0XzEwOTk1MTE2MzIzOTQ_1fc38420-d3ff-4663-850e-0f69a45bb844"
      unitRef="cad">-418251000</ifrs-full:RetainedEarnings>
    <oncyf:CashAndCashEquivalentsAndCurrentInvestments
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzYvZnJhZzozMTAyZTAzNTk4YzU0ZjE4OTYwMTI3ZGYwNGQ5NzlmNC90ZXh0cmVnaW9uOjMxMDJlMDM1OThjNTRmMTg5NjAxMjdkZjA0ZDk3OWY0XzEwOTk1MTE2MzI2NDM_0a2f219d-c90f-46a3-9b3e-4d721e178d39"
      unitRef="cad">32138000</oncyf:CashAndCashEquivalentsAndCurrentInvestments>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMzkvZnJhZzpmM2JmZDU3MzJiZDI0YjhmODM4Y2I0NWI2MTNmZTk3NC90ZXh0cmVnaW9uOmYzYmZkNTczMmJkMjRiOGY4MzhjYjQ1YjYxM2ZlOTc0XzEyMjk_931989b6-8bec-4a04-a75e-b47139cd2e5a">Basis of Presentation&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Statement of compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements for the year ended December&#160;31, 2022, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;2, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries, Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc., and are presented in Canadian dollars, our functional currency. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and have the ability to affect those returns through our power to govern. The accounting policies of our subsidiaries are consistent with our accounting policies and all intercompany transactions, balances, income, and expenses are eliminated on consolidation. &lt;/span&gt;&lt;/div&gt;Our accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODQw_1244a4b9-3111-45a8-899b-fbb02fa8c361">Summary of Significant Accounting Policies&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and cash equivalents and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents include interest-bearing deposits with our bank totaling $9,501 as at December&#160;31, 2022 (December&#160;31, 2021 - $39,902). Marketable securities include foreign currency term deposits with a maturity of greater than 90 days and less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Classification and measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#x2019;s business model for managing the assets; and whether the financial asset&#x2019;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets include cash and cash equivalents, marketable securities, and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of the warrant derivative is at FVPL.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#x2019;s original effective interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derecognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contract involves the use of an identified asset;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to direct the use of the identified asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss per common share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per common share is determined using the weighted average number of common shares outstanding during the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants if dilutive. The number of additional common shares is calculated by assuming that any outstanding "in the money" options, restricted share units, performance share units, and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-based compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one stock option plan (the "Option Plan") available to officers, directors, employees, and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than ten years from the date of grant. Exercised stock options are settled with common shares issued from treasury. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the fair value-based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of options that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incentive share award plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our incentive share award plan (the "Share Plan") is available to directors, officers, and employees. Under our Share Plan, performance and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are awarded to certain officers and employees and non-employee directors to which common shares shall be issued in accordance with the Share Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSUs/RSUs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Standards and Interpretations Issued but Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Presentation of Financial Statements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the IASB issued amendments to IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and IFRS Practice Statement 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Making Materiality Judgements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 8 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies, Changes in Accounting Estimates and Errors&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the IASB issued amendments to IAS 8, in which it introduced a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies, and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 12 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;In May 2021, the IASB issued amendments to IAS 12, which narrowed the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzU0OTc1NTg1MjMxNQ_5a6e170b-48cf-46a4-8031-9b87ba2c9702">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and cash equivalents and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents include interest-bearing deposits with our bank totaling $9,501 as at December&#160;31, 2022 (December&#160;31, 2021 - $39,902). Marketable securities include foreign currency term deposits with a maturity of greater than 90 days and less than one year.&lt;/span&gt;&lt;/div&gt;</oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock>
    <ifrs-full:CashEquivalents
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE2NDkyNjc0ODAxMDk_579d0c67-1123-4428-806a-18f09489f10f"
      unitRef="cad">9501000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE2NDkyNjc0ODAxMzc_e238d4c1-0d3f-4032-9dd5-eb6cc574b044"
      unitRef="cad">39902000</ifrs-full:CashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODE4_4272b77f-37ef-45a5-838b-95adba679806">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.</ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODA2_1d9b272c-ef10-47fb-8583-d63ba5c60310">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#x2019;s business model for managing the assets; and whether the financial asset&#x2019;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). &lt;/span&gt;&lt;/div&gt;Our financial assets include cash and cash equivalents, marketable securities, and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODQ3_fdeef2e3-0f6f-4418-9c8c-1684759eb450">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of the warrant derivative is at FVPL.</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODEy_5f2f8dd9-9fab-41a9-9f25-cc7861bd902e">Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#x2019;s original effective interest rate.</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODEz_18f548f2-d6cb-4b26-8f5d-3730e40f5107">A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired.</ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODQy_03419fae-4a2e-43de-83f9-85d15824c93b">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODI4_42f7a0af-f71c-4132-94f8-2265d1d5e92f">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzU0OTc1NTg1MjMxNw_3bba5c03-d12e-4c65-ac78-05276f47de4e">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contract involves the use of an identified asset;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to direct the use of the identified asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/span&gt;&lt;/div&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODI5_fc37763c-f960-469e-9862-0be908de5866">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per common share is determined using the weighted average number of common shares outstanding during the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the treasury stock method to calculate diluted loss per common share. Under this method, diluted loss per common share is computed in a manner consistent with basic loss per common share except that the weighted average common shares outstanding are increased to include additional common shares from the assumed exercise of options and warrants if dilutive. The number of additional common shares is calculated by assuming that any outstanding "in the money" options, restricted share units, performance share units, and warrants were exercised at the later of the beginning of the period or the date of issue and that the proceeds from such exercises were used to acquire shares of common stock at the average market price during the reporting period.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODM4_3178e8f5-40f3-44bd-9fa5-19b8601b5586">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODM5_c5653fe9-c1fb-42f1-a066-d5e7ac08e31b">Depreciation is recorded using the declining balance method at the following annual rates:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Computer Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Equipment and Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="i9f01ea7a336d44d2ab368965b5d555a1_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90YWJsZToyMjVjNGFjMzhjNWM0Nzc2YTY0NTVkYWEwMzNmMjY3OS90YWJsZXJhbmdlOjIyNWM0YWMzOGM1YzQ3NzZhNjQ1NWRhYTAzM2YyNjc5XzAtMS0xLTEtMzUzODM_f0c75a85-f5f7-4cb4-bace-d6e85e4ae563"
      unitRef="number">0.20</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="i1a49b5a6078743c4a0f6d1dc090f31ae_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90YWJsZToyMjVjNGFjMzhjNWM0Nzc2YTY0NTVkYWEwMzNmMjY3OS90YWJsZXJhbmdlOjIyNWM0YWMzOGM1YzQ3NzZhNjQ1NWRhYTAzM2YyNjc5XzEtMS0xLTEtMzUzODM_04e9fd9b-756d-4508-8880-d6b222e326f3"
      unitRef="number">0.20</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="idc90711aec744857b2329d7bd8e24e98_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90YWJsZToyMjVjNGFjMzhjNWM0Nzc2YTY0NTVkYWEwMzNmMjY3OS90YWJsZXJhbmdlOjIyNWM0YWMzOGM1YzQ3NzZhNjQ1NWRhYTAzM2YyNjc5XzItMS0xLTEtMzUzODM_abf102c4-7c36-4ffc-ba85-a7b68fa4f884"
      unitRef="number">0.30</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODE1_236a3c46-d4d0-47d3-9b9c-622962b4a0b4">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed.</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODA4_c09a586c-316d-40eb-a06d-e85f2228fcba">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property, and therefore recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and therefore give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODUw_7e37da91-301a-4041-8216-5ea1696bd6ff">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one stock option plan (the "Option Plan") available to officers, directors, employees, and consultants with grants under the Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Option Plan, the exercise price of each option is set at equal to or higher than the trading price of our stock on the date of grant in accordance with Toronto Stock Exchange guidelines. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than ten years from the date of grant. Exercised stock options are settled with common shares issued from treasury. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the fair value-based method of accounting for stock option awards granted under the Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model and is recognized over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of options that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incentive share award plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our incentive share award plan (the "Share Plan") is available to directors, officers, and employees. Under our Share Plan, performance and restricted share units may be approved from time to time by the Board. Performance share units  ("PSUs") are awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share units ("RSUs") are awarded to certain officers and employees and non-employee directors to which common shares shall be issued in accordance with the Share Plan.  &lt;/span&gt;&lt;/div&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSUs/RSUs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of PSUs/RSUs that are expected to vest. The effect of these changes is recognized in the period of the change.</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <oncyf:NumberOfStockOptionPlans
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE0Njkz_561f61c4-5095-4afc-aea3-f30fe1568806"
      unitRef="plan">1</oncyf:NumberOfStockOptionPlans>
    <oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE1MjA0_fe088af5-7509-42d7-abed-90819f05c995">P10Y</oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDIvZnJhZzo4ZjQ4MDVkZTdmYmY0Mjc3ODQ2ZTM5YzIzYWMyZTViNC90ZXh0cmVnaW9uOjhmNDgwNWRlN2ZiZjQyNzc4NDZlMzljMjNhYzJlNWI0XzE4ODI3_8f422752-971e-4fce-87f4-adc02d750ab3">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Presentation of Financial Statements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the IASB issued amendments to IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and IFRS Practice Statement 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Making Materiality Judgements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 8 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies, Changes in Accounting Estimates and Errors&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the IASB issued amendments to IAS 8, in which it introduced a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies, and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 12 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;In May 2021, the IASB issued amendments to IAS 12, which narrowed the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNDUvZnJhZzowMjA5MTAwZTJiMDU0OTQwOGRjN2MwYzNmZDA2N2YyOC90ZXh0cmVnaW9uOjAyMDkxMDBlMmIwNTQ5NDA4ZGM3YzBjM2ZkMDY3ZjI4Xzc3NDE_59778405-5a53-45ec-ba1f-ecd63ca6e9ad">Significant Judgments, Estimates, and Assumptions&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The full extent to which external factors outside of our control, including those related to the coronavirus infectious disease 2019 ("COVID-19") pandemic and the global political conflict in Ukraine, may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain. We considered the potential impact of these events, including global supply chain disruptions, inflation, and rising interest rates, when making certain estimates and judgments relating to the preparation of these audited consolidated financial statements. While there was no material impact to our consolidated financial statements as of and for the year ended December&#160;31, 2022, our future assessment of the magnitude and duration of COVID-19 and conflict in Ukraine, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Judgments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our consolidated financial statements requires us to make judgments, estimates, and assumptions that affect the reported amount of revenue, expenses, assets, liabilities, and the disclosure of contingent liabilities at the end of the reporting period.  However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Estimates and assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates, and such differences could be material. Significant estimates made by management affecting our consolidated financial statements include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a Licensing Agreement which provides, among other payments, upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress toward completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical trial and manufacturing expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial and manufacturing expenses represent significant components of our research and development expenses, and we outsource a significant portion of these activities to third-party contract research/manufacturing organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as achieving certain milestones. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that the contract research/manufacturing organizations have performed. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of share-based compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value for stock options granted requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options granted are disclosed in Note 10. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of warrant derivative &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, share price volatility, and dividend yield, and making assumptions about them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry-forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgment is required to determine the amount of deferred tax assets that can be recognized based on the likely timing and the level of future taxable profits together with future tax planning strategies.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. There are also no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DisclosureOfOtherLiabilitiesExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF81NDk3NTU4MTU3NzY_08d8a78a-cd7f-4f6e-b9d0-d6df31e5f06e">Other Assets and Liabilities &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1. This phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2022, we recorded US$360 ($488) (December&#160;31, 2021 - US$617 ($782)) in other receivables related to unbilled BRACELET-1 cost from Pfizer and nil (December&#160;31, 2021 - US$278 ($352)) in other liabilities representing unused payments received from Pfizer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;In 2022, we paid deposits to our manufacturer related to the production of pelareorep required for our clinical trial program. We classify the related prepaid expenses as current or non-current based on the timing of when we expect to receive services. As at December&#160;31, 2022, we recorded $1,327 in current prepaid expenses and $998 in non-current prepaid expenses.&lt;/span&gt;</ifrs-full:DisclosureOfOtherLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF81NDk3NTU4MTU3NzY_e318e447-e4e9-49d8-8666-142586b0de78">Other Assets and Liabilities &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1. This phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2022, we recorded US$360 ($488) (December&#160;31, 2021 - US$617 ($782)) in other receivables related to unbilled BRACELET-1 cost from Pfizer and nil (December&#160;31, 2021 - US$278 ($352)) in other liabilities representing unused payments received from Pfizer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;In 2022, we paid deposits to our manufacturer related to the production of pelareorep required for our clinical trial program. We classify the related prepaid expenses as current or non-current based on the timing of when we expect to receive services. As at December&#160;31, 2022, we recorded $1,327 in current prepaid expenses and $998 in non-current prepaid expenses.&lt;/span&gt;</ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <ifrs-full:OtherReceivables
      contextRef="i9166d82a922341729a9cfba07b6c19fc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4MTU5_292e4eef-8211-4a2e-b97a-60fbf9da1e91"
      unitRef="usd">360000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="i9166d82a922341729a9cfba07b6c19fc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4MTY0_6cdfbbaf-8099-43a4-80c4-74f535a0d0c3"
      unitRef="cad">488000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="i8f8114e0983f40c18d9bd8848358071f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4MTc2_a4704a7e-7567-4973-b587-439bb98bcc2a"
      unitRef="usd">617000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="i8f8114e0983f40c18d9bd8848358071f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4MTgx_b9ceba8f-ca98-49cb-8361-1107ea4338a3"
      unitRef="cad">782000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i9166d82a922341729a9cfba07b6c19fc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4Mjk2_492f512f-9da4-440c-81b8-b043f25da7e3"
      unitRef="cad">0</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i8f8114e0983f40c18d9bd8848358071f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4MzA3_1e224f8e-6be4-4e0d-b1af-b472a6963141"
      unitRef="usd">278000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i8f8114e0983f40c18d9bd8848358071f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4MzEy_3151b0c6-3a67-427c-8390-28a600a61103"
      unitRef="cad">352000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4NzE1_84438060-973e-444e-b8e3-9065837fa032"
      unitRef="cad">1327000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:NoncurrentPrepayments
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTE3L2ZyYWc6YWE2OWMxYTIxNjQ0NDY5ZGE4YjFhYmFiNDRiMmM1MWQvdGV4dHJlZ2lvbjphYTY5YzFhMjE2NDQ0NjlkYThiMWFiYWI0NGIyYzUxZF8xMDk5NTExNjI4NzUx_bf3f28ee-f11e-4b30-b3bb-9b2d4785e435"
      unitRef="cad">998000</ifrs-full:NoncurrentPrepayments>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90ZXh0cmVnaW9uOmEzODVkYmIwMGI0NjRmZjBiNDk2OWJmZDRiZDIzNTE3XzM5_f66d3351-879b-44cf-b643-b3012dfb4de3">Property and Equipment&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Computer Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Equipment and Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;108&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;356&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ie4783f947d474ec7a4043f3bd7016af3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzItMS0xLTEtMzUzODM_a039cb85-8709-4c29-a53f-ad3599d2087f"
      unitRef="cad">62000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i3911bf2c955b405bac30a9b918de2d56_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzItMy0xLTEtMzUzODM_902f9dc2-7c49-4ab0-ac96-7156387a27a4"
      unitRef="cad">366000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i6e33daaee7a04931a84b95d558b6feab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzItNS0xLTEtMzUzODM_f46c35ab-0852-47db-9470-455fa8df919e"
      unitRef="cad">353000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i81ef8717fa2344528d67d8af749583ee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzItNy0xLTEtMzUzODM_669afd6c-1c74-41e1-ad32-36052891151b"
      unitRef="cad">497000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i204d523ce7ab4b52896ed6d2295ef847_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzItOS0xLTEtMzUzODM_7fe3091b-3d5b-4126-b8b7-2253e488806c"
      unitRef="cad">1278000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ie5f0b13be4b5469faca7dfca28e6f4c8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzMtMS0xLTEtMzUzODM_c3d0ba32-a56a-410a-9fc4-cdea27743be7"
      unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="iee36a908faae4b93971ba0cc2c7ca539_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzMtMy0xLTEtMzUzODM_2fd2123a-c189-42ba-8899-1fdfd5e5ef42"
      unitRef="cad">40000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ia39c558d66984975b5b558b476007a29_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzMtNS0xLTEtMzUzODM_3a1fb845-2396-4b45-a962-b8a25366a8a9"
      unitRef="cad">141000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i8ff1d10a78054a38a5d7f49b53d4d3b0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzMtNy0xLTEtMzUzODM_e7561551-40f6-4ff9-918d-6c119dd7522b"
      unitRef="cad">105000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i68bda01afab14d5cb26920e605f0ab42_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzMtOS0xLTEtMzUzODM_5ba9b9bc-24b3-4e9b-98df-8f9e602ae3fc"
      unitRef="cad">286000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ie5f0b13be4b5469faca7dfca28e6f4c8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzQtMS0xLTEtMzUzODM_7b97503d-3c34-41f7-9488-82aa05566a3d"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="iee36a908faae4b93971ba0cc2c7ca539_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzQtMy0xLTEtMzUzODM_c26e0aec-16d5-4cae-b94b-634685f6616b"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ia39c558d66984975b5b558b476007a29_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzQtNS0xLTEtMzUzODM_75ced53b-4fdf-447e-951f-100586faeac0"
      unitRef="cad">277000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i8ff1d10a78054a38a5d7f49b53d4d3b0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzQtNy0xLTEtMzUzODM_ab65be88-ceb9-4a77-8f50-2ecf93d23cef"
      unitRef="cad">374000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i68bda01afab14d5cb26920e605f0ab42_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzQtOS0xLTEtMzUzODM_c3884802-52e4-4106-8a1d-45279b7e4af7"
      unitRef="cad">651000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i286fea00b77e413c9c5eeffe49ab79c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzUtMS0xLTEtMzUzODM_5e666289-2d16-4fea-a03c-eeea40d2cefb"
      unitRef="cad">62000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iefe509d23f474055870d8386107bed16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzUtMy0xLTEtMzUzODM_5450a442-b2af-468f-8a8e-4204f13e8c38"
      unitRef="cad">406000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ia2dee205e673484b94ca9942a6585f62_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzUtNS0xLTEtMzUzODM_08c66b4b-b24a-46cd-bf4b-98ad1f209c9e"
      unitRef="cad">217000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i6a0d89d731934218a9200c653646ae2d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzUtNy0xLTEtMzUzODM_aeb22eef-b01a-4e65-9330-5cd2447cce9a"
      unitRef="cad">228000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i41042a36299746dfa6245b8f04eeb2fa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzUtOS0xLTEtMzUzODM_17d56b75-9a65-4b02-acf9-c2164450141d"
      unitRef="cad">913000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i4096288385ea4783bb39b83a9221722a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzYtMS0xLTEtMzUzODM_a4e9eb1a-ec82-41a4-8db9-74fdd3c50beb"
      unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i2dbc93ed0aff46e895933aedb6179359_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzYtMy0xLTEtMzUzODM_c83531da-4647-442e-80b4-3596fdbc7768"
      unitRef="cad">23000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i22a8e62bdf6047f6b2871d5eb585c601_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzYtNS0xLTEtMzUzODM_7bbcb187-73d7-49c7-aea1-b3b3d68bb6ed"
      unitRef="cad">31000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="iedb5bad8c9c64aeb82bab9cdcaaab035_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzYtNy0xLTEtMzUzODM_004d720d-6aba-4da0-8cf2-2bab6d3ab7b0"
      unitRef="cad">3000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="icff71c66ed2f49d7a3a5436aa04a7517_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzYtOS0xLTEtMzUzODM_dcf02bc2-c122-47d3-8b60-4f55be452427"
      unitRef="cad">57000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="icb257f4f952a40c895f4c48bb418df40_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzgtMS0xLTEtMzUzODM_af6633b3-c383-43d1-ae51-73859f2283aa"
      unitRef="cad">62000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i79304496df494f95b80359489d58d588_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzgtMy0xLTEtMzUzODM_394602a8-1cde-45f7-bb60-d21a78a0e9b3"
      unitRef="cad">429000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i2af36eb48c0d4fe2b8f76f15361a0a7e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzgtNS0xLTEtMzUzODM_eca9cdd2-ad27-42fd-a9af-510b49878d3e"
      unitRef="cad">248000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="icb1ab3d5241c42b4bc1827326301115d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzgtNy0xLTEtMzUzODM_f85379aa-084d-4619-8be5-719e4ea2858b"
      unitRef="cad">231000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i8a666b3f60054f4cbf818f5e3df21b12_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzgtOS0xLTEtMzUzODM_e10ed8cf-18fe-45b0-bd00-6920f65c3296"
      unitRef="cad">970000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i1f67c6da798f44b594280ae812c6baaf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzExLTEtMS0xLTM1Mzgz_23dd7765-85d9-417f-b367-d7b2e25bcad0"
      unitRef="cad">-48000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i76d7a88ee04145c194ae4be4171aa00c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzExLTMtMS0xLTM1Mzgz_7c5b5de2-98bc-4cab-b3e6-2464afe146ef"
      unitRef="cad">-249000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i73b71a1c9b2748b48f0eef3f1e218dbc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzExLTUtMS0xLTM1Mzgz_c4789f93-30bd-4265-8e17-0f285c307c22"
      unitRef="cad">-263000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i0dcb43e627a74a66b65eccdde1930703_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzExLTctMS0xLTM1Mzgz_fb1ddf5b-ce8d-4019-8c80-7004573dcad8"
      unitRef="cad">-482000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i9f29e88f1e0a4dada070a283833ffdb9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzExLTktMS0xLTM1Mzgz_3f6db12a-e42c-401c-89cd-61a41680b0d6"
      unitRef="cad">-1042000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="ic14ac3299f434c03908133a0c4a9205e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEyLTEtMS0xLTM1Mzgz_3f5ae8db-5fa5-4c8c-84a9-2996b732ab9a"
      unitRef="cad">3000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i0c6845c74acd4eb6bdee2a26eb7d8b31_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEyLTMtMS0xLTM1Mzgz_823e33bf-ebbb-4e50-94c1-64105144b6ee"
      unitRef="cad">36000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="iff53065b38874233bcc1a933461017ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEyLTUtMS0xLTM1Mzgz_06cda8c0-e2f7-4eb3-86ee-2eab5bd22673"
      unitRef="cad">72000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i0daba0652a364b148a3ad3df35cb62f9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEyLTctMS0xLTM1Mzgz_b661bab6-2e75-4a1c-be42-cba8501d5340"
      unitRef="cad">19000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i8addce8064f24c3cb69be9a37be7346b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEyLTktMS0xLTM1Mzgz_f748c1e2-9dfd-4bcb-be1a-794e0447161a"
      unitRef="cad">130000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ic14ac3299f434c03908133a0c4a9205e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEzLTEtMS0xLTM1Mzgz_48c2910f-f8d9-45ae-b914-9ff90f57ce90"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i0c6845c74acd4eb6bdee2a26eb7d8b31_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEzLTMtMS0xLTM1Mzgz_8e0fab97-294d-41bc-a0da-c4274cf4889f"
      unitRef="cad">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="iff53065b38874233bcc1a933461017ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEzLTUtMS0xLTM1Mzgz_ba526a89-88c4-4760-ba20-d9cdc7412c83"
      unitRef="cad">-277000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i0daba0652a364b148a3ad3df35cb62f9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEzLTctMS0xLTM1Mzgz_29b9347e-e045-4740-9381-20aff6a9d6c0"
      unitRef="cad">-374000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i8addce8064f24c3cb69be9a37be7346b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzEzLTktMS0xLTM1Mzgz_c45b3092-b02e-4fce-8f7f-a47b3c449f9a"
      unitRef="cad">-651000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ic3c2b76821444aed993c937b01f9ce03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE0LTEtMS0xLTM1Mzgz_2691ff6e-a842-4e3b-b04b-4e93c5551860"
      unitRef="cad">-51000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i2e99b1b5e9384ed6b69134ad46524aed_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE0LTMtMS0xLTM1Mzgz_7f0106f0-9c88-4849-9e89-4d04d4b75034"
      unitRef="cad">-285000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i0b3d9e57cf1f4065853436dbd64f88f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE0LTUtMS0xLTM1Mzgz_915f224c-2ebc-4db7-a503-da36de3794eb"
      unitRef="cad">-58000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i00001682505c41e0a1f6a5200e7369cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE0LTctMS0xLTM1Mzgz_5ffae66f-83e4-4b38-8955-7dd9db7f8adb"
      unitRef="cad">-127000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i3050942226a5438fa9c685a3428ff7a1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE0LTktMS0xLTM1Mzgz_e48cbe3f-59f6-48c8-ad47-7a9d9be310bb"
      unitRef="cad">-521000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i25cea6a2272341c1929aaaa1d18e0f5b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE1LTEtMS0xLTM1Mzgz_83ffcd68-fd27-4b1a-a92b-37fc5d1bd19c"
      unitRef="cad">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i0f607fc35a524cb8b063cbac9f2c139c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE1LTMtMS0xLTM1Mzgz_6c30531b-180d-4853-8c0c-2b41504b1093"
      unitRef="cad">36000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i1784fbe9117b4ee1a7b43ddcc71a0db3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE1LTUtMS0xLTM1Mzgz_e964a25d-63ee-4899-875c-bb9666b5d9ea"
      unitRef="cad">34000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="ie5d7a02883ec445c9158c8db51d57df8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE1LTctMS0xLTM1Mzgz_416d2905-69a0-4fb1-9572-f962002bb22d"
      unitRef="cad">21000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="i4f605b055eea4373ba168badd86607c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE1LTktMS0xLTM1Mzgz_5782b229-eb2e-4a53-876f-3e0ac19af879"
      unitRef="cad">93000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iee540100ac1e473dbf3745fc5ffcc5be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE3LTEtMS0xLTM1Mzgz_910be633-62d6-4b4b-9c69-fb6eaffa31ff"
      unitRef="cad">-53000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iaf594b04da5249a0841abdc72a9802ec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE3LTMtMS0xLTM1Mzgz_94d27e6c-5cd9-4cec-8831-ecf8c1ec752d"
      unitRef="cad">-321000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="if236c6ed5fc6436b9c2654b18b4a3ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE3LTUtMS0xLTM1Mzgz_18b9366b-cbe9-485a-9b29-e4110776258c"
      unitRef="cad">-92000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="id315aa54ed3e46e19f179179a56a77ee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE3LTctMS0xLTM1Mzgz_a0a563da-39c8-4c4a-9511-7848b256dc2d"
      unitRef="cad">-148000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="if30f9fd81d8e488390af3fade7de9e46_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzE3LTktMS0xLTM1Mzgz_a3aca7be-cadc-415a-aefd-541b086fd85a"
      unitRef="cad">-614000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i513dceb1a6f14df9a09714d11d8a7b2d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIwLTEtMS0xLTM1Mzgz_7f18d94c-3c7c-4da7-a6af-6ae1e5ced3f8"
      unitRef="cad">11000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i1feff0178e14474aaa4fc6a186497ad0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIwLTMtMS0xLTM1Mzgz_9c3f60f7-2253-4e1e-9cac-696c06437870"
      unitRef="cad">121000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="id202f8bc51ef4633b66140d696b4d861_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIwLTUtMS0xLTM1Mzgz_9b59b4fa-e16e-4cb5-929c-0bb3437065a3"
      unitRef="cad">159000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i54cddc074de54f28b6e68ca6b670e5f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIwLTctMS0xLTM1Mzgz_6070f269-945c-483b-9f68-82f68531823e"
      unitRef="cad">101000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIwLTktMS0xLTM1Mzgz_2775bfd3-5a03-4c91-a0e9-4d79abf4a38d"
      unitRef="cad">392000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i777d047d5ec446409e8a5c8324aa324d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIxLTEtMS0xLTM1Mzgz_7ef910a3-0c4a-4f52-8c1f-b16ae5afdc03"
      unitRef="cad">9000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i0a8c607d0de64f79bdc2e8ce8034a59c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIxLTMtMS0xLTM1Mzgz_7f34cad2-23c3-4a7f-a3cd-52201688addf"
      unitRef="cad">108000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ie70c35bbd59a4905b781c7668e5cc70f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIxLTUtMS0xLTM1Mzgz_c344e870-bf8e-4c60-875b-7b5fc6f941d5"
      unitRef="cad">156000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i963844cd43c644c7932afd7741a944d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIxLTctMS0xLTM1Mzgz_4ad5bdac-a3a7-49c9-8c63-74d94a7eadd5"
      unitRef="cad">83000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTEvZnJhZzphMzg1ZGJiMDBiNDY0ZmYwYjQ5NjliZmQ0YmQyMzUxNy90YWJsZTo4Nzk1ZjlmY2Q3ZTA0MjM3YjMxNDFkNzI2ZmU5MTAyNy90YWJsZXJhbmdlOjg3OTVmOWZjZDdlMDQyMzdiMzE0MWQ3MjZmZTkxMDI3XzIxLTktMS0xLTM1Mzgz_1ea8dcca-9672-4c54-b3a5-16cc48311633"
      unitRef="cad">356000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGV4dHJlZ2lvbjoxZDhlNGE0MDE4MTQ0YjM5OGM3YTM4OTExMTYxZWIxM181NDk3NTU4MTU5OTQ_589990a5-1845-4f0a-8bca-e0103c748e08">Accounts payable and accrued liabilities&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,398&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGV4dHJlZ2lvbjoxZDhlNGE0MDE4MTQ0YjM5OGM3YTM4OTExMTYxZWIxM181NDk3NTU4MTU5OTU_acc084c3-5ac2-4201-87c6-20e796f8fe46">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,398&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGFibGU6ODJhMDI1YjJiNTQwNDQxMjk1M2YzM2ZhOTRhNGI1ZGQvdGFibGVyYW5nZTo4MmEwMjViMmI1NDA0NDEyOTUzZjMzZmE5NGE0YjVkZF8xLTEtMS0xLTQ0NjY5_8292ee41-5b4a-4e8f-8bb9-122c006e9300"
      unitRef="cad">2252000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGFibGU6ODJhMDI1YjJiNTQwNDQxMjk1M2YzM2ZhOTRhNGI1ZGQvdGFibGVyYW5nZTo4MmEwMjViMmI1NDA0NDEyOTUzZjMzZmE5NGE0YjVkZF8xLTMtMS0xLTQ0NjY5_fcfc4486-dca8-493b-8bcc-078ad4275492"
      unitRef="cad">594000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGFibGU6ODJhMDI1YjJiNTQwNDQxMjk1M2YzM2ZhOTRhNGI1ZGQvdGFibGVyYW5nZTo4MmEwMjViMmI1NDA0NDEyOTUzZjMzZmE5NGE0YjVkZF8yLTEtMS0xLTQ0NjY5_89697c82-ca8e-4f50-bb89-8f940155b9f8"
      unitRef="cad">1398000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGFibGU6ODJhMDI1YjJiNTQwNDQxMjk1M2YzM2ZhOTRhNGI1ZGQvdGFibGVyYW5nZTo4MmEwMjViMmI1NDA0NDEyOTUzZjMzZmE5NGE0YjVkZF8yLTMtMS0xLTQ0NjY5_d4c9ccb0-9e3b-45cb-a422-abd261975a27"
      unitRef="cad">1394000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGFibGU6ODJhMDI1YjJiNTQwNDQxMjk1M2YzM2ZhOTRhNGI1ZGQvdGFibGVyYW5nZTo4MmEwMjViMmI1NDA0NDEyOTUzZjMzZmE5NGE0YjVkZF82LTEtMS0xLTQ0NjY5_6d8aefb1-37b1-483e-8323-10c46f88f31c"
      unitRef="cad">3650000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xMDk5NTExNjI5NTk3L2ZyYWc6MWQ4ZTRhNDAxODE0NGIzOThjN2EzODkxMTE2MWViMTMvdGFibGU6ODJhMDI1YjJiNTQwNDQxMjk1M2YzM2ZhOTRhNGI1ZGQvdGFibGVyYW5nZTo4MmEwMjViMmI1NDA0NDEyOTUzZjMzZmE5NGE0YjVkZF82LTMtMS0xLTQ0NjY5_aee920f2-38ac-4d36-a058-46276907b3e8"
      unitRef="cad">1988000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzEwMjA_15aacf43-66de-4dd5-94f9-11abeb38bc8e">Leases&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of leases consists of office spaces with lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees or leases not yet commenced to which we are committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was 15%. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we recorded an addition for a new office space lease for our Canadian head office and a lease modification related to the office lease extension for one of our subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;         &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease modification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;296&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our lease liabilities activity for the years ended December&#160;31:    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;              &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;655&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease modification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(366)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our total undiscounted lease liability as at December&#160;31, 2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More than five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease liability &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <oncyf:OperatingLeaseRemainingLeaseTerm
      contextRef="i0702f9b593a943e0aa89f870ac3bbdc4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzEwNg_bfd19354-b968-410c-8bf4-acf5539394a3">P3Y</oncyf:OperatingLeaseRemainingLeaseTerm>
    <oncyf:OperatingLeaseRemainingLeaseTerm
      contextRef="i0b95cc388ab54e769e83447ea9abf950_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzExMg_e2eb5a18-c00c-4fb0-81dd-3977b1a0abaf">P6Y</oncyf:OperatingLeaseRemainingLeaseTerm>
    <ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzEwOTk1MTE2MjkyNDE_1f6d9b4d-7178-4fe9-b08d-2bf3d3831dfd"
      unitRef="number">0.15</ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzEwMTc_06d9ac29-6062-4929-8b63-f5300374d858">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;         &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease modification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;296&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzEtMS0xLTEtMzUzODM_8666f3d6-d0c1-4d69-a5ea-768fe788903e"
      unitRef="cad">584000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzEtMy0xLTEtMzUzODM_b9987946-9b00-4e2d-83dc-dd77a6c0b621"
      unitRef="cad">372000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzItMS0xLTEtMzUzODM_16728520-8e54-41fe-aab0-f5bd324b4635"
      unitRef="usd">0</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzItMy0xLTEtMzUzODM_ac9a49c1-2bdc-41a5-8938-a7a476931c71"
      unitRef="usd">210000</ifrs-full:AdditionsToRightofuseAssets>
    <oncyf:LeaseModificationRightOfUseAssets
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzMtMS0xLTEtMzUzODM_864d2da2-8221-4a1e-a973-bb1ef8cbfad0"
      unitRef="cad">0</oncyf:LeaseModificationRightOfUseAssets>
    <oncyf:LeaseModificationRightOfUseAssets
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzMtMy0xLTEtMzUzODM_251b2eee-be7b-4ec1-b194-fc7b2c506150"
      unitRef="cad">324000</oncyf:LeaseModificationRightOfUseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzQtMS0xLTEtMzUzODM_c1269302-0e5e-4514-9c56-2876414c098e"
      unitRef="cad">299000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzQtMy0xLTEtMzUzODM_6cf6329e-1b9d-4223-89e5-a2d447baaa4e"
      unitRef="cad">322000</ifrs-full:DepreciationRightofuseAssets>
    <oncyf:ForeignExchangeImpactRightofUseAssets
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzUtMS0xLTEtMzUzODM_3a233808-b5e5-47b8-9c0f-4925c6cac112"
      unitRef="cad">11000</oncyf:ForeignExchangeImpactRightofUseAssets>
    <oncyf:ForeignExchangeImpactRightofUseAssets
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzUtMy0xLTEtMzUzODM_e8c48ca9-82bc-47a7-8415-000c23827d9a"
      unitRef="cad">0</oncyf:ForeignExchangeImpactRightofUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzYtMS0xLTEtMzUzODM_60412f4c-23fb-4143-bd6f-3cd656d551f7"
      unitRef="cad">296000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTpjZGVkMWRiZjY1MTg0MTFiYTUyODE4ZjMxY2M3MDQ1Yi90YWJsZXJhbmdlOmNkZWQxZGJmNjUxODQxMWJhNTI4MThmMzFjYzcwNDViXzYtMy0xLTEtMzUzODM_8ca06ffe-f9c2-46ff-a9de-32f65d25df10"
      unitRef="cad">584000</ifrs-full:RightofuseAssets>
    <oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzEwMTg_3bf2ec7a-c50d-4e54-a2b3-7f39c9cf1e9e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our lease liabilities activity for the years ended December&#160;31:    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;              &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;655&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease modification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(366)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock>
    <ifrs-full:LeaseLiabilities
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzEtMS0xLTEtMzUzODM_b6c6e0bd-ed85-41e9-ada6-c981b3df61ce"
      unitRef="cad">655000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzEtMy0xLTEtMzUzODM_abf638ad-9d1e-465f-8e09-9aaaf461d368"
      unitRef="cad">402000</ifrs-full:LeaseLiabilities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzItMS0xLTEtMzUzODM_72442b9c-3916-40db-9eb4-810f33c88f5c"
      unitRef="usd">0</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzItMy0xLTEtMzUzODM_b384126e-33b0-4acf-bdb5-7de2796a8e59"
      unitRef="usd">203000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <oncyf:EffectOfLeaseModificationOnLeaseLiabilities
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzMtMS0xLTEtMzUzODM_dddf44c5-819f-44ca-b780-fe213777767d"
      unitRef="cad">0</oncyf:EffectOfLeaseModificationOnLeaseLiabilities>
    <oncyf:EffectOfLeaseModificationOnLeaseLiabilities
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzMtMy0xLTEtMzUzODM_77506c62-61c2-4593-9257-1cc84e5aa378"
      unitRef="cad">324000</oncyf:EffectOfLeaseModificationOnLeaseLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzQtMS0xLTEtMzUzODM_8ea1d9a1-6003-46e7-9f19-c7d6eade2f21"
      unitRef="cad">381000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzQtMy0xLTEtMzUzODM_b74db20a-9758-43cc-a6cc-fe4c3dcc63ba"
      unitRef="cad">366000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzUtMS0xLTEtMzUzODM_23071cb6-bbff-458d-91a6-15da71f50f9f"
      unitRef="cad">80000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzUtMy0xLTEtMzUzODM_ba72cbee-821c-4b81-b548-bd372b464607"
      unitRef="cad">92000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <oncyf:GainsLossesFromForeignExchangeImpact
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzYtMS0xLTEtMzUzODM_11215f40-3d6b-4841-9f8a-fbdb76cf83fb"
      unitRef="cad">19000</oncyf:GainsLossesFromForeignExchangeImpact>
    <oncyf:GainsLossesFromForeignExchangeImpact
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzYtMy0xLTEtMzUzODM_e60b3fe4-3823-4c6e-bb9b-c6e0e2ac1b57"
      unitRef="cad">0</oncyf:GainsLossesFromForeignExchangeImpact>
    <ifrs-full:LeaseLiabilities
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzctMS0xLTEtMzUzODM_4aff6427-13ab-4f41-ad7b-fcb673002366"
      unitRef="cad">373000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTplMjRjMjgzOGVmODE0YTIxOGZhYWUxNWNiNTY5OGZhYi90YWJsZXJhbmdlOmUyNGMyODM4ZWY4MTRhMjE4ZmFhZTE1Y2I1Njk4ZmFiXzctMy0xLTEtMzUzODM_3b1335be-fa6f-443e-8681-e43045d822eb"
      unitRef="cad">655000</ifrs-full:LeaseLiabilities>
    <ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90ZXh0cmVnaW9uOmU4NGM5ZDdjMGM2NjRhNTM4ZGJlYTI5MTg2ZDRmMDIyXzEwMjI_f05d1afe-c63b-4d5e-a3b1-1e3eeb272de6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our total undiscounted lease liability as at December&#160;31, 2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More than five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease liability &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="ia32318f895f946ecbe86b9b07e60fd1c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTo2ZDUzZDg5OThmZjU0YjliYThlOWQzNjNjOGE2YTMxNC90YWJsZXJhbmdlOjZkNTNkODk5OGZmNTRiOWJhOGU5ZDM2M2M4YTZhMzE0XzEtMS0xLTEtMzUzODM_b4ab8461-0787-405b-9916-fef547e3836f"
      unitRef="cad">251000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="iea62ebc777ac430eb1852b3dd64bf5a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTo2ZDUzZDg5OThmZjU0YjliYThlOWQzNjNjOGE2YTMxNC90YWJsZXJhbmdlOjZkNTNkODk5OGZmNTRiOWJhOGU5ZDM2M2M4YTZhMzE0XzItMS0xLTEtMzUzODM_7d073e1d-707b-41ef-bb27-4eae43b5734b"
      unitRef="cad">196000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i365cb71f7fa842589bd1fc05d704aec7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTo2ZDUzZDg5OThmZjU0YjliYThlOWQzNjNjOGE2YTMxNC90YWJsZXJhbmdlOjZkNTNkODk5OGZmNTRiOWJhOGU5ZDM2M2M4YTZhMzE0XzMtMS0xLTEtMzUzODM_b026283d-dfa9-4f94-9e8f-4d254d31786d"
      unitRef="cad">0</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNTQvZnJhZzplODRjOWQ3YzBjNjY0YTUzOGRiZWEyOTE4NmQ0ZjAyMi90YWJsZTo2ZDUzZDg5OThmZjU0YjliYThlOWQzNjNjOGE2YTMxNC90YWJsZXJhbmdlOjZkNTNkODk5OGZmNTRiOWJhOGU5ZDM2M2M4YTZhMzE0XzQtMS0xLTEtMzUzODM_19b416c4-5493-4b43-9baa-c198bc79519e"
      unitRef="cad">447000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM5MjM_ca9250dd-c3fc-442b-a6dc-79af8d30d58c">Share Capital&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Authorized:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unlimited number of no par value common shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,198,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,182,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,166,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,401,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,043,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,235,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61,327,914&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;404,040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$30,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement expired on June 4, 2020. In 2020, we sold 6,741,518 common shares for gross proceeds of US$17,538 at an average price of US$2.42. We received, net of commissions of US$526, proceeds of US$17,012. In total, we incurred share issue costs (including commissions) of $857. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 16). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. In 2022, no warrants were exercised. In 2021, 201,722 (2020 - 1,418,369) warrants with a fair value of $456 (2020 - $4,636) were exercised for gross proceeds of US$182 (2020 - US$1,277). As at December&#160;31, 2022, there were 64,035 warrants outstanding (December&#160;31, 2021 - 64,035). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up US$40,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on March 4, 2021. In 2021, we sold 5,685,097 (2020 - 5,441,014) common shares for gross proceeds of US$18,503 (2020 - US$12,629) at an average price of US$3.25 (2020 - US$2.11). We received, net of commissions of US$555 (2020 - US$379), proceeds of US$17,948 (2020 - US$12,250). In total, we incurred share issue costs (including commissions) of $707 (2020 - $885).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000 over a 16-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;month period through the facilities of the Nasdaq Capital Market in the United States. In 2022, we sold 2,719,770 (2021 - 2,715,932) common shares for gross proceeds of US$4,560 (2021 - US$8,655) at an average price of US$1.68 (2021 - US$3.19). We received, net of commissions of US$137 (2021 - US$260), proceeds of US$4,423 (2021 - US$8,395). In total, we incurred share issue costs (including commissions) of $209 (2021 - $549). This sales agreement was terminated on June 16, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2022, we sold 3,515,462 common shares for gross proceeds of US$5,632 at an average price of US$1.60. We received, net of commissions of US$169, proceeds of US$5,463. In total, we incurred share issue costs (including commissions) of $555.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold for gross proceeds of $11,512. Each unit included one common share and one common share purchase warrant. Following the 2018 share consolidation, 9.5 common share purchase warrants entitled the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. These warrants were classified as equity. These warrants expired on June 1, 2022, and were transferred to contributed surplus on the consolidated statement of financial position upon expiry. There was no cash flow impact as a result of the warrant expiry. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our outstanding equity warrants: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,445,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,443,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,443,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,443,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM5MjU_6684721f-bb37-4ab6-bfba-54c928896ca1">&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,198,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,182,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,166,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,401,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,043,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,235,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61,327,914&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;404,040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$30,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement expired on June 4, 2020. In 2020, we sold 6,741,518 common shares for gross proceeds of US$17,538 at an average price of US$2.42. We received, net of commissions of US$526, proceeds of US$17,012. In total, we incurred share issue costs (including commissions) of $857. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit for gross proceeds of US$3,742. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability (see Note 16). Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. In 2022, no warrants were exercised. In 2021, 201,722 (2020 - 1,418,369) warrants with a fair value of $456 (2020 - $4,636) were exercised for gross proceeds of US$182 (2020 - US$1,277). As at December&#160;31, 2022, there were 64,035 warrants outstanding (December&#160;31, 2021 - 64,035). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up US$40,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on March 4, 2021. In 2021, we sold 5,685,097 (2020 - 5,441,014) common shares for gross proceeds of US$18,503 (2020 - US$12,629) at an average price of US$3.25 (2020 - US$2.11). We received, net of commissions of US$555 (2020 - US$379), proceeds of US$17,948 (2020 - US$12,250). In total, we incurred share issue costs (including commissions) of $707 (2020 - $885).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000 over a 16-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;month period through the facilities of the Nasdaq Capital Market in the United States. In 2022, we sold 2,719,770 (2021 - 2,715,932) common shares for gross proceeds of US$4,560 (2021 - US$8,655) at an average price of US$1.68 (2021 - US$3.19). We received, net of commissions of US$137 (2021 - US$260), proceeds of US$4,423 (2021 - US$8,395). In total, we incurred share issue costs (including commissions) of $209 (2021 - $549). This sales agreement was terminated on June 16, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. In 2022, we sold 3,515,462 common shares for gross proceeds of US$5,632 at an average price of US$1.60. We received, net of commissions of US$169, proceeds of US$5,463. In total, we incurred share issue costs (including commissions) of $555.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="if692efdc55844ddd94d16e3f6ae99d73_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzItMS0xLTEtMzUzODM_09a78326-48d8-4b29-9c21-a292d63fa49b"
      unitRef="shares">32198453</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="if692efdc55844ddd94d16e3f6ae99d73_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzItMy0xLTEtMzUzODM_4e0c9d9c-ab2f-4b92-aa1f-91baf75010f7"
      unitRef="cad">311078000</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="i6541e8507efb4de5a913ca4fac61cf17_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzMtMS0xLTEtMzUzODM_8011d346-4d34-4e90-8d67-1cb1802e91b1"
      unitRef="shares">133454</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i6541e8507efb4de5a913ca4fac61cf17_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzMtMy0xLTEtMzUzODM_2c1b4b40-a218-4562-b44e-384abb8e5019"
      unitRef="cad">385000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i8972058a330f4d2e80365843e754c2d1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzQtMS0xLTEtMzUzODM_76164e53-3a15-4b5c-89ca-306de7595b96"
      unitRef="shares">234172</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i8972058a330f4d2e80365843e754c2d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzQtMy0xLTEtMzUzODM_f71b1f91-de70-4baf-9ea3-d515763db73c"
      unitRef="cad">732000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i6b1d0fbc8f1b4d968750fdb49b146c64_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzUtMS0xLTEtMzUzODM_28f7e432-686b-4d35-9d58-516de0fc334b"
      unitRef="shares">12182532</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i6b1d0fbc8f1b4d968750fdb49b146c64_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzUtMy0xLTEtMzUzODM_32ac45c4-3b77-4423-927e-a4a0fd2380f7"
      unitRef="cad">40038000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i6b8eb310435f4b7089eb7c5f3035b88d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzctMS0xLTEtMzUzODM_8f9e3041-85a5-41ca-a082-37e5d15b85d7"
      unitRef="shares">1418369</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i6b8eb310435f4b7089eb7c5f3035b88d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzctMy0xLTEtMzUzODM_455b3db5-7c02-4b6c-b94b-ac4b1bc87b8a"
      unitRef="cad">6333000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i6cec7f0886424478a8adab4adfe59a0b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzgtMy0xLTEtMzUzODM_15c7ebd4-75c5-4d58-85bc-77586077956d"
      unitRef="cad">1742000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued
      contextRef="ibe25ae3bb8014f7cb475d95097c9166e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzktMS0xLTEtMzUzODM_06908972-c0c2-4ecd-8920-86d697eb0809"
      unitRef="shares">46166980</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="ibe25ae3bb8014f7cb475d95097c9166e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzktMy0xLTEtMzUzODM_b7ff970c-f305-4dc9-a99b-5f0208cf807c"
      unitRef="cad">356824000</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="i8b552f25ccd04fdb86d1346a3975fa1b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzEwLTEtMS0xLTM1Mzgz_d32f1f84-0ae4-466b-b552-d114204a2dc5"
      unitRef="shares">123159</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i8b552f25ccd04fdb86d1346a3975fa1b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzEwLTMtMS0xLTM1Mzgz_8d751118-6e2c-4d25-80ea-aa18c8dddce2"
      unitRef="cad">381000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="ic6493a759f124792b1e8928326aac134_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzExLTEtMS0xLTM1Mzgz_067d6cd5-fd67-4ce6-85f7-b4e1c2655781"
      unitRef="shares">150899</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="ic6493a759f124792b1e8928326aac134_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzExLTMtMS0xLTM1Mzgz_f4991dbd-117e-4bc8-9c67-a0ef4ec80ddc"
      unitRef="cad">544000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i7f593ff807bd4b97a79dd779ca1363b4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzEyLTEtMS0xLTM1Mzgz_b002db3b-3660-4d79-b7f6-a7ee63cb1844"
      unitRef="shares">8401029</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i7f593ff807bd4b97a79dd779ca1363b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzEyLTMtMS0xLTM1Mzgz_e4e071ea-2f7d-423c-9004-3acf6340322e"
      unitRef="cad">34168000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="ic2fe0be7fe344da59d4ec9cf38ef8816_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzEzLTEtMS0xLTM1Mzgz_5674b61d-5b7d-449f-844a-5bde8f7cca76"
      unitRef="shares">201722</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="ic2fe0be7fe344da59d4ec9cf38ef8816_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzEzLTMtMS0xLTM1Mzgz_92558305-a175-44e6-83bd-d50cd72cc4d2"
      unitRef="cad">687000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i11172d73364741cc830ad4c4925edd65_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE0LTMtMS0xLTM1Mzgz_ec92d503-1338-4af8-a7a1-a35bf0efefaf"
      unitRef="cad">1256000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued
      contextRef="ieee4c1d19b10441a9fb87c20bf21e3fa_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE1LTEtMS0xLTM1Mzgz_7dcc1e13-351c-438a-bd4c-eb1b5316673e"
      unitRef="shares">55043789</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="ieee4c1d19b10441a9fb87c20bf21e3fa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE1LTMtMS0xLTM1Mzgz_e7aeac44-e294-4130-a183-56f7eed771e4"
      unitRef="cad">391348000</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="i10f8803a04704f94b4c3b16076075a61_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE2LTEtMS0xLTM1Mzgz_0cfb61b9-cfb7-4c8a-b9c8-1020190969dd"
      unitRef="shares">8333</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i10f8803a04704f94b4c3b16076075a61_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE2LTMtMS0xLTM1Mzgz_d242abf3-6710-4f8b-91a7-3952a57ccf4b"
      unitRef="cad">20000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i6efced05728f430dbc45b4b00278027e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE3LTEtMS0xLTM1Mzgz_06a6ff74-b59d-4b04-a783-ede0b3da6191"
      unitRef="shares">40560</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i6efced05728f430dbc45b4b00278027e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE3LTMtMS0xLTM1Mzgz_33901540-2d8d-4939-bb96-6054934b6073"
      unitRef="cad">98000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="i0e9e1c91dbd64b66a3ef5f637728d726_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE4LTEtMS0xLTM1Mzgz_e264fa33-917a-4171-96d4-b05056b04882"
      unitRef="shares">6235232</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity
      contextRef="i0e9e1c91dbd64b66a3ef5f637728d726_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzE4LTMtMS0xLTM1Mzgz_9c6c639c-d8c0-4dea-bc3a-57b6af20f964"
      unitRef="cad">13338000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ie67556b574354bfbbbe629f9c4f83910_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzIwLTMtMS0xLTM1Mzgz_674be6ae-0db1-45b0-8712-6b22e8cd1782"
      unitRef="cad">764000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued
      contextRef="ied69a4c1e8dc444497553637c429c995_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzIxLTEtMS0xLTM1Mzgz_c7640ad5-435c-494d-8c5b-129845408eb6"
      unitRef="shares">61327914</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity
      contextRef="ied69a4c1e8dc444497553637c429c995_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo1N2Q2YjYzYjY0OTU0YzUzOTAzMzcyNjJjZDg4OTIwZC90YWJsZXJhbmdlOjU3ZDZiNjNiNjQ5NTRjNTM5MDMzNzI2MmNkODg5MjBkXzIxLTMtMS0xLTM1Mzgz_c7075f23-371f-48f7-8c3b-c47544666e23"
      unitRef="cad">404040000</ifrs-full:Equity>
    <oncyf:SharePurchaseAgreementAmount
      contextRef="if333223790564dcb96ea8ce18000124c_I20181024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzg3NQ_52b04d8a-3cbd-43c0-bbc2-f374d4505102"
      unitRef="usd">30000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm
      contextRef="i9c01aa3f72784c8eb36e0bca515d9aff_D20181024-20181024"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM5Mjk_0c5b20ee-f235-4c06-87e9-ec0057ef5a61">P19M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="i809782423e5a496c9bb7e6d59de0f3a5_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwODg_a36333b0-12c0-4131-a2e6-e9c62665b9b4"
      unitRef="shares">6741518</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i809782423e5a496c9bb7e6d59de0f3a5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzExMzg_55a93b9a-dbb5-4961-9e56-f6d997af2baa"
      unitRef="usd">17538000</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i783080355c484f52b0c3ed3b1f30118c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzExNzQ_f0312a12-a6cb-4453-a8fe-8e95964b289f"
      unitRef="usdPerShare">2.42</oncyf:SharesIssuedPricePerShare1>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="i809782423e5a496c9bb7e6d59de0f3a5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEyMjM_36b30698-4731-435d-9f6f-1ea9047b3903"
      unitRef="usd">526000</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="i809782423e5a496c9bb7e6d59de0f3a5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEyNDk_19f7802a-6d26-411d-84ca-0ebf7bda25fd"
      unitRef="usd">17012000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i809782423e5a496c9bb7e6d59de0f3a5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEzMzA_d9c79b5a-2d02-412e-940c-e86f288b6222"
      unitRef="cad">857000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:IssueOfEquityShares
      contextRef="i339d817f02da483dacfdea11d754715d_D20190816-20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE0MDI_3391e198-acf8-4391-9666-6429d09f389c"
      unitRef="shares">4619773</oncyf:IssueOfEquityShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i0d502b20f5504524b12de442d39c71e8_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE0NDQ_8d9b49d0-10e1-4e3a-a594-33d813d577b6"
      unitRef="usdPerShare">0.81</oncyf:SharesIssuedPricePerShare1>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i339d817f02da483dacfdea11d754715d_D20190816-20190816"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE0Nzg_2b6dc86f-b39c-4faf-b0f3-9e4cb58ed5ce"
      unitRef="usd">3742000</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:CommonSharesPerUnit
      contextRef="i95f4ddbdd41f46c28a3fa7900b833ed6_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE1MDE_e6e6df0a-b2b2-461d-ace8-1b6b442d4f12"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:SharesIssuedFairValueOfCommonShare
      contextRef="i95f4ddbdd41f46c28a3fa7900b833ed6_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE1Mzg_b4a8f6ab-a455-477e-9a3b-f1ecbd648992"
      unitRef="usdPerShare">0.54</oncyf:SharesIssuedFairValueOfCommonShare>
    <oncyf:CommonSharesPerUnit
      contextRef="i36f0549e16fb493899d3ce11e6663ed3_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE1NDU_be456a62-9a6f-4cff-99cc-c9883c1c04e6"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:SharesIssuedFairValueOfCommonShare
      contextRef="i36f0549e16fb493899d3ce11e6663ed3_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE1OTk_98fab594-875b-4360-bb67-d19efc6cda1e"
      unitRef="usdPerShare">0.27</oncyf:SharesIssuedFairValueOfCommonShare>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1
      contextRef="i0d502b20f5504524b12de442d39c71e8_I20190816"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE3NDA_dd6507fb-fa9e-47ed-a46b-cb21f111bb1e"
      unitRef="shares">1</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1>
    <oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2
      contextRef="i36f0549e16fb493899d3ce11e6663ed3_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE3ODA_c4d1b9a6-2f51-4446-b5e2-ea890bdd885a"
      unitRef="usdPerShare">0.90</oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2>
    <oncyf:ClassofWarrantorRightNumberofWarrantsExercised
      contextRef="ibb8660fe469e4e3bb809b223adeb1928_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzYzNjE_6eff737b-1907-45ba-aa67-834a3f42530d"
      unitRef="shares">0</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
    <oncyf:ClassofWarrantorRightNumberofWarrantsExercised
      contextRef="i6f4f12b4c9ac415291240c8cd9609fe0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE2NDkyNjc0NTA1ODI_bcd0efbe-fe3f-4b27-9c3f-ee1fcc30ee26"
      unitRef="shares">201722</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
    <oncyf:ClassofWarrantorRightNumberofWarrantsExercised
      contextRef="i711e0a27b9344e398357548811fe1ed6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzE2NDkyNjc0NTA1OTM_af0512d3-ca36-4bb0-958d-fb2a03f54989"
      unitRef="shares">1418369</oncyf:ClassofWarrantorRightNumberofWarrantsExercised>
    <oncyf:ClassofWarrantorRightWarrantsExercised
      contextRef="i6f4f12b4c9ac415291240c8cd9609fe0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzIwMjk_99d0b608-7087-4dd2-9e1b-028b0c5d922b"
      unitRef="cad">456000</oncyf:ClassofWarrantorRightWarrantsExercised>
    <oncyf:ClassofWarrantorRightWarrantsExercised
      contextRef="i711e0a27b9344e398357548811fe1ed6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzIwMzg_27d8d09f-27f1-421a-bf25-041269d4ad8d"
      unitRef="cad">4636000</oncyf:ClassofWarrantorRightWarrantsExercised>
    <oncyf:ProceedsfromWarrantExercises1
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzIwODQ_48a2b865-c8fb-4bf5-9043-4b7c12f141fd"
      unitRef="usd">182000</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:ProceedsfromWarrantExercises1
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzIwOTM_8d37c23f-b147-4ce5-8e96-c13a9c770c8a"
      unitRef="usd">1277000</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:ClassOfWarrantOrRightOutstanding1
      contextRef="i9c37cce29b8346b0ba836e6e496264d0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzY0NjY_be4b9d0d-7821-4a53-9bd4-9fc40115b3ed"
      unitRef="shares">64035</oncyf:ClassOfWarrantOrRightOutstanding1>
    <oncyf:ClassOfWarrantOrRightOutstanding1
      contextRef="i9c37cce29b8346b0ba836e6e496264d0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzY1MDA_be4b9d0d-7821-4a53-9bd4-9fc40115b3ed"
      unitRef="shares">64035</oncyf:ClassOfWarrantOrRightOutstanding1>
    <oncyf:SharePurchaseAgreementAmount
      contextRef="if27e5cf46efd4450807817226f0625d7_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzIzODA_155a9add-9eb1-4a4b-8d94-1c2898126adc"
      unitRef="usd">40000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm
      contextRef="ida0bae79a8bc43eb8fd183431b5b3f2d_D20200615-20200615"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM5MzA_5cdfda69-4438-46cd-903b-e1c0db95a277">P25M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="i23e1543579db44e78472abe042745f89_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzI1MDQ_7d9621af-bfa5-4894-9850-494e80a6794a"
      unitRef="shares">5685097</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="id7dd014e773644638183d9dbc0c3ba03_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzM4NDE_03530b9a-d87d-4c47-8b26-9ba915f99aee"
      unitRef="shares">5441014</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i23e1543579db44e78472abe042745f89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzI1NTM_6cd7bb5a-7bae-4888-a164-d723cc0fd639"
      unitRef="usd">18503000</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="id7dd014e773644638183d9dbc0c3ba03_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzM5NTg_4f2dce15-a25e-425b-9ced-734deab594e3"
      unitRef="usd">12629000</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i63384d0a252342c890796e05d336932d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzM5ODI_08b15831-759e-4921-9596-9aea8e86232a"
      unitRef="usdPerShare">3.25</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i90e7609d87f34c56bb2a2970072a4155_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzI1ODk_0d6b9981-6c09-4754-9634-250817be6438"
      unitRef="usdPerShare">2.11</oncyf:SharesIssuedPricePerShare1>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="i23e1543579db44e78472abe042745f89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzM5OTM_7c298a88-b66f-4256-87de-6d15251655eb"
      unitRef="usd">555000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="id7dd014e773644638183d9dbc0c3ba03_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzI2Mzg_68ebd544-5eb9-4f13-aa9a-b4520204914d"
      unitRef="usd">379000</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="i23e1543579db44e78472abe042745f89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQwMDU_f5430843-e40e-47a3-ad90-7844ba16ab0f"
      unitRef="usd">17948000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="id7dd014e773644638183d9dbc0c3ba03_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzI2NjQ_5d75bfbe-7eee-4e10-bb7b-36f65fef7650"
      unitRef="usd">12250000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i23e1543579db44e78472abe042745f89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzI3NDU_3aa3abdd-d293-4648-8ea1-a6bea4d59ef4"
      unitRef="cad">707000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="id7dd014e773644638183d9dbc0c3ba03_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxMTU_9cb5caca-35c8-4987-bd3e-48f349fa739c"
      unitRef="cad">885000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:SharePurchaseAgreementAmount
      contextRef="ia82e40c581724751808cdca1dd238e9b_I20210305"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMwNDg_519482ec-2578-4f57-a994-198151e18324"
      unitRef="usd">80000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm
      contextRef="i998f1448e0f242f0a37474a940e5bb85_D20210305-20210305"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM5Mjc_a9fcb434-8263-4ee8-a518-f242c84d403c">P16M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="i98e916be7d9749dd9fdd5af0f4f92104_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxMjQ_00f66ef1-4c06-4050-81bd-abf4e6b6ea2a"
      unitRef="shares">2719770</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="i209bf45ef70c45e7b6c75d2906c6f1ad_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMxNjM_b6089d1a-2842-4282-9520-4fe6e27b90ee"
      unitRef="shares">2715932</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i98e916be7d9749dd9fdd5af0f4f92104_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxNDM_d23ee2a2-2177-4146-bf5c-8c64f2418290"
      unitRef="usd">4560000</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i209bf45ef70c45e7b6c75d2906c6f1ad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMyMDI_80aecb0a-7792-415d-9b15-941fbbf79acb"
      unitRef="usd">8655000</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i35bc0c0fb23d4de58f297cc59b64b8da_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxNTc_c9a6c91c-9648-4a2f-b42b-9505423b089d"
      unitRef="usdPerShare">1.68</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i5ab78014954745ca943db137b2067123_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMyMjg_119058b1-12ef-47eb-b493-e982817f4659"
      unitRef="usdPerShare">3.19</oncyf:SharesIssuedPricePerShare1>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="i98e916be7d9749dd9fdd5af0f4f92104_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxNjk_8a3c3538-7a34-4898-9812-50dd64f8fef6"
      unitRef="usd">137000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="i209bf45ef70c45e7b6c75d2906c6f1ad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMyNjc_2ebac8d3-9fb7-49e4-8f15-b6761739ccbe"
      unitRef="usd">260000</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="i98e916be7d9749dd9fdd5af0f4f92104_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxNzQ_949af166-f2b9-42f8-9f0b-8b7f159b844c"
      unitRef="usd">4423000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="i209bf45ef70c45e7b6c75d2906c6f1ad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMyODM_c1de8248-5490-4876-87e2-a86df7682cb4"
      unitRef="usd">8395000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i98e916be7d9749dd9fdd5af0f4f92104_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQxOTY_c1e4cfcb-12ec-4d41-b5bc-882ad271f37a"
      unitRef="cad">209000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i209bf45ef70c45e7b6c75d2906c6f1ad_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzMzNTQ_6ecaa692-95e8-4f21-88e9-f64824879ce9"
      unitRef="cad">549000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:SharePurchaseAgreementAmount
      contextRef="i6cb45010a1f04a19bb8bb7c198eafcb7_I20220617"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ1MjY_be02c942-e1de-4242-ba91-b58c1f3510b6"
      unitRef="usd">65000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm
      contextRef="ibf3514ed6ca044d7810415c09e4274c5_D20220617-20220617"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzU0OTc1NTgyMTEzMA_b9cd41d9-0a7a-48cf-abde-388c69b33a80">P25M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ1NjI_12b54cff-47cc-4f9a-901d-37693e3a4203"
      unitRef="shares">3515462</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ2MjY_3592095b-02b9-469a-ae8e-91833bf8a623"
      unitRef="usd">5632000</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="i7b0440d3e41e4deaa503df6fed6a1cf7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ2NTQ_2de9d73c-597f-4c0a-a202-a16ffa3cf1e7"
      unitRef="usdPerShare">1.60</oncyf:SharesIssuedPricePerShare1>
    <oncyf:ShareIssueRelatedCostCommissions
      contextRef="ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ2OTc_3baad7f0-0f41-4fe7-bda1-2d67aead4e18"
      unitRef="usd">169000</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ3MTU_744c6d00-f3df-4289-8b12-8f394a1b1996"
      unitRef="usd">5463000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzEwOTk1MTE2MzQ3OTA_4a3b0709-5b41-47dc-abfa-02cd7a518446"
      unitRef="cad">555000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:IssueOfEquityShares
      contextRef="i8c38fae9a1ca4c469aff3c034e794b8d_D20170601-20170601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM0Mzk_c27f7fce-b171-4b35-a6c5-9b67f8565761"
      unitRef="shares">16445000</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i8c38fae9a1ca4c469aff3c034e794b8d_D20170601-20170601"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM0ODA_9c0c64bb-cd42-4be2-8f5d-864253a8484b"
      unitRef="cad">11512000</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
    <oncyf:CommonSharesPerUnit
      contextRef="i15ebd1009ac5441788d5ea09d2d20d34_I20170601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM1MDM_d6752cbf-af25-481b-94a0-c7ff9f521b6b"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:CommonSharePurchaseWarrantPerUnit
      contextRef="i15ebd1009ac5441788d5ea09d2d20d34_I20170601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM1MjM_c2a5788d-d497-41b8-ba09-eef61ea6d9ad"
      unitRef="shares">1</oncyf:CommonSharePurchaseWarrantPerUnit>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1
      contextRef="i15ebd1009ac5441788d5ea09d2d20d34_I20170601"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM1OTc_cf4b42f7-312e-40a4-b7cb-820f416073c0"
      unitRef="shares">9.5</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1>
    <oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1
      contextRef="i15ebd1009ac5441788d5ea09d2d20d34_I20170601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM2NjM_c8fb9612-caa8-421e-9d64-dc73417b4cba"
      unitRef="shares">1</oncyf:ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1>
    <oncyf:SharesIssuedWarrantPricePerShare
      contextRef="i15ebd1009ac5441788d5ea09d2d20d34_I20170601"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM3Njc_e9416b98-ece4-4457-878f-f0cf445087fa"
      unitRef="cadPerShare">9.025</oncyf:SharesIssuedWarrantPricePerShare>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90ZXh0cmVnaW9uOmI0NTdkYmUxMDM5MDRhZTFhNTg3OWFhYWRmMTYxNWZiXzM5MzY_895cf3bf-cbbe-474c-8087-5b6673d0192e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our outstanding equity warrants: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,445,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,443,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,443,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,443,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.54 - $1.89&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.90 - $3.05&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.06 - $3.29&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.30 - $3.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.43&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.76 - $27.46&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,963,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="iadb9b5984e0d4be9a1b244e2d939dde2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzEtMS0xLTEtNDExOTk_4404899a-9ec7-467d-801d-c60499c6eff8"
      unitRef="shares">16445000</ifrs-full:NumberOfSharesOutstanding>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="ie5e2093c82014efc936a23f9e66baceb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzEtMy0xLTEtNDEyMDk_df35f0e7-6f3d-40a8-a967-f100cee346b0"
      unitRef="cad">3618000</oncyf:WarrantsAndRightsOutstanding1>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i6f62a8b7a8c2458692b02a5416ac2ac4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzEtMS0xLTEtMzUzODM_4ce1eab2-45ae-417f-ac80-221c7ccf8c16"
      unitRef="shares">16443500</ifrs-full:NumberOfSharesOutstanding>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzEtMy0xLTEtMzUzODM_41c58865-f34e-47cf-874a-159bb2da1749"
      unitRef="cad">3618000</oncyf:WarrantsAndRightsOutstanding1>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i49324b0a98f247d28e8710f0a21c58d2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzItMS0xLTEtMzUzODM_1f5a4962-d6a7-455d-90bb-7eed35512f1e"
      unitRef="shares">16443500</ifrs-full:NumberOfSharesOutstanding>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzItMy0xLTEtMzUzODM_1a143a95-1af5-4109-abed-8875f87b53ed"
      unitRef="cad">3618000</oncyf:WarrantsAndRightsOutstanding1>
    <oncyf:NumberOfSharesExpired
      contextRef="ic7cac766cbaa43fb9c4ad8b89138fec9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzMtMS0xLTEtMzcxNzI_b24892b0-58cb-4951-ad47-58afae05c46a"
      unitRef="shares">16443500</oncyf:NumberOfSharesExpired>
    <oncyf:WarrantsAndRightsExpired
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzMtMy0xLTEtMzcxODA_dcc5d613-d6f5-47a5-8ccd-0111e09ebbf2"
      unitRef="cad">3618000</oncyf:WarrantsAndRightsExpired>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i451a07d69b99427c8835f34d48f9f9fa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzMtMS0xLTEtMzUzODM_89806d01-df94-46be-ae57-bde3ea0125e5"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <oncyf:WarrantsAndRightsOutstanding1
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjAvZnJhZzpiNDU3ZGJlMTAzOTA0YWUxYTU4NzlhYWFkZjE2MTVmYi90YWJsZTo0NjdkOTQ5MTYwZjQ0ZDM1YmNkNTc0Y2UzODMxYTA5Yi90YWJsZXJhbmdlOjQ2N2Q5NDkxNjBmNDRkMzViY2Q1NzRjZTM4MzFhMDliXzMtMy0xLTEtMzUzODM_37b79888-ddff-4d8e-ab63-5a4705c5454e"
      unitRef="cad">0</oncyf:WarrantsAndRightsOutstanding1>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMzc_00c0693e-a71f-4ad4-8eff-9278a789b1a4">Share-Based Compensation&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Option Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted stock options to acquire common stock through our stock option plan. Our stock option activity for the years ended December&#160;31 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,334,420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,764,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,005,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,817,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(62,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(304,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,963,185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,334,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,764,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,420,482&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,165,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,164,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.54 - $1.89&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.90 - $3.05&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.06 - $3.29&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.30 - $3.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.43&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.76 - $27.46&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,963,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option grants vest either immediately or annually over periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzM4Mg_95eb31db-de86-4acf-a885-2ec978a753c1"&gt;one&lt;/span&gt; to three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.66%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.34%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected share price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96.02%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.82%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$1.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Incentive Share Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted RSUs to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date, or when the director ceases to be a member of the board. We have also granted RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a three-year period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our RSU activity for the years ended December&#160;31 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,560&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(40,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; (1) The weighted average fair value of the RSUs granted was nil in 2022 (2021 - nil; 2020 - $2.41).&lt;/span&gt;&lt;/div&gt;We have reserved 6,132,791 common shares for issuance relating to our outstanding equity compensation plans. Our share-based compensation expense for the year ended December&#160;31, 2022, was $2,378 (2021 - $3,826; 2020 - $2,559).</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMzg_f2a5552d-14f8-4875-84e8-08d284ebb1e1">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted stock options to acquire common stock through our stock option plan. Our stock option activity for the years ended December&#160;31 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,334,420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,764,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,005,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,817,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(62,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(304,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(8,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,963,185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,334,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,764,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,420,482&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,165,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,164,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzItMS0xLTEtMzUzODM_315d2d2b-b525-4de3-b1ba-ded6d53ac69d"
      unitRef="shares">5334420</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzItMi0xLTEtMzUzODM_70d2db3c-9d3a-4385-bf48-ffacc9b1ff44"
      unitRef="cadPerShare">3.53</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzItNC0xLTEtMzUzODM_7ac725d5-d022-4a30-970b-2e9f523d0962"
      unitRef="shares">3764055</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzItNS0xLTEtMzUzODM_eff78988-627c-4ad2-aa58-de4ebc8236b8"
      unitRef="cadPerShare">4.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ie5e2093c82014efc936a23f9e66baceb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzItNy0xLTEtMzUzODM_08cd9e6d-bb65-4240-955e-4ec2d0d3648c"
      unitRef="shares">2246947</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="ie5e2093c82014efc936a23f9e66baceb_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzItOC0xLTEtMzUzODM_dc9a22b1-ce8a-4930-9ebe-1b3251b563a5"
      unitRef="cadPerShare">5.31</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzMtMS0xLTEtMzUzODM_c94a07ac-47a5-4783-a931-6303deec3f8d"
      unitRef="shares">1005000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzMtMi0xLTEtMzUzODM_90639db4-d453-4547-ade2-fa3b6a15a2e2"
      unitRef="cadPerShare">2.04</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzMtNC0xLTEtMzUzODM_0afe0f0e-fbdc-42c2-be68-b45f90afe82e"
      unitRef="shares">1832500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzMtNS0xLTEtMzUzODM_9a6b1432-db2e-4b87-9a49-c30c66a600cf"
      unitRef="cadPerShare">2.99</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzMtNy0xLTEtMzUzODM_8ac60755-1ff2-4bdd-aa3d-e27b3083e3e5"
      unitRef="shares">1817500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzMtOC0xLTEtMzUzODM_9066c33a-355d-4d82-953b-016a87910b44"
      unitRef="cadPerShare">3.19</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzQtMS0xLTEtMzUzODM_285e346e-a4e9-438e-a6af-97b21120ef11"
      unitRef="shares">62962</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzQtMi0xLTEtMzUzODM_85dbae98-e3a7-4709-a354-386989e11405"
      unitRef="cadPerShare">3.83</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzQtNC0xLTEtMzUzODM_1ddbeb71-4284-4d96-b74d-ce3dbbc0a749"
      unitRef="shares">110612</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzQtNS0xLTEtMzUzODM_f3c4db5d-387a-4109-b19f-5a21807ff3d3"
      unitRef="cadPerShare">6.21</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzQtNy0xLTEtMzUzODM_f4bdbe78-4c74-42fe-b51d-007a6e8832e3"
      unitRef="shares">141418</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzQtOC0xLTEtMzUzODM_3609b04a-e1f2-4146-99e2-8ac9f478859a"
      unitRef="cadPerShare">3.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzUtMS0xLTEtMzUzODM_333518c8-0799-4dfb-80dc-416c0a3b5950"
      unitRef="shares">304940</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzUtMi0xLTEtMzUzODM_877a4f76-2238-402c-9853-08099b924364"
      unitRef="cadPerShare">10.80</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzUtNC0xLTEtMzUzODM_3817cb2a-1e1e-486b-932d-00f0ead3e2e5"
      unitRef="shares">28364</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzUtNS0xLTEtMzUzODM_570f79a6-50bb-414f-8c47-73b312a78d39"
      unitRef="cadPerShare">37.63</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzUtNy0xLTEtMzUzODM_ea0bf491-5d93-4b2c-8557-189ae56753e3"
      unitRef="shares">25520</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzUtOC0xLTEtMzUzODM_0edb2057-8f15-45c9-9a48-7bf91a60bfba"
      unitRef="cadPerShare">62.49</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzYtMS0xLTEtMzUzODM_c3f30ebf-a0fb-48e8-a426-572029448105"
      unitRef="shares">8333</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzYtMi0xLTEtMzUzODM_588ba3d5-ad72-40fe-883a-2775f6a7f0bc"
      unitRef="cadPerShare">1.45</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzYtNC0xLTEtMzUzODM_e8471f0c-ecb6-4739-9f66-845616c87a37"
      unitRef="shares">123159</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzYtNS0xLTEtMzUzODM_77e2ab83-aa6e-4c11-a8ab-322720c83b00"
      unitRef="cadPerShare">1.94</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzYtNy0xLTEtMzUzODM_3e609f3e-3fcd-4ad3-a292-9b88cfe81814"
      unitRef="shares">133454</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzYtOC0xLTEtMzUzODM_ad4b0764-c57d-4a05-adfc-6da9a8a46e4a"
      unitRef="cadPerShare">1.81</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzctMS0xLTEtMzUzODM_c111ffc9-6469-4e25-99db-1eff42d53a8d"
      unitRef="shares">5963185</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzctMi0xLTEtMzUzODM_73f0e3fa-5856-4071-870e-9556fe76ea0c"
      unitRef="cadPerShare">2.91</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzctNC0xLTEtMzUzODM_e9320b8d-c942-4756-b187-9a5382fa6627"
      unitRef="shares">5334420</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzctNS0xLTEtMzUzODM_da101e60-a57f-46bd-9d7f-bac0cc53ce98"
      unitRef="cadPerShare">3.53</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzctNy0xLTEtMzUzODM_2aadf2c9-9dca-4304-bc88-38745d4eb72a"
      unitRef="shares">3764055</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzctOC0xLTEtMzUzODM_cd5a6d20-4138-4947-865e-f35cbc647695"
      unitRef="cadPerShare">4.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzgtMS0xLTEtMzUzODM_1db31b13-448c-410d-89d2-3bded39f0d5b"
      unitRef="shares">4420482</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzgtMi0xLTEtMzUzODM_b160bbf9-e0b8-42d2-bdd9-83fd6c1b1d4c"
      unitRef="cadPerShare">3.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzgtNC0xLTEtMzUzODM_ae96e4ee-9573-48fa-bb10-c39ef5a67c28"
      unitRef="shares">3165679</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzgtNS0xLTEtMzUzODM_aeb69241-7111-42ab-b537-7de0d214046c"
      unitRef="cadPerShare">3.82</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzgtNy0xLTEtMzUzODM_a08af516-1d7c-41d3-87bf-e6d03909bb6d"
      unitRef="shares">2164551</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZToxMTk3MzhhNTQ1ZDU0ZmFmYTA5Y2M3ZDQ2OTQxM2U1ZC90YWJsZXJhbmdlOjExOTczOGE1NDVkNTRmYWZhMDljYzdkNDY5NDEzZTVkXzgtOC0xLTEtMzUzODM_8e5ec239-7dec-4976-a037-702bf0fbb93f"
      unitRef="cadPerShare">4.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMTc_8d3e58dd-5b9e-4b72-a280-c05ab9f0c695">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.54 - $1.89&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.90 - $3.05&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.06 - $3.29&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.30 - $3.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.43&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.76 - $27.46&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,963,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i5d60827e07f44c119014f8e722b58bf9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjozMGIzNmU2ZmVkOGM0OTJhYTgxN2Y3NzlhNDRmMzAyNV80_35313e50-3213-4d09-8e14-be3b9d36bd0b"
      unitRef="cadPerShare">0.54</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i9aadf4823bed41b0a081530e5fc4658c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjozMGIzNmU2ZmVkOGM0OTJhYTgxN2Y3NzlhNDRmMzAyNV85_4e7ac235-92b8-48ef-9588-b1094e74374d"
      unitRef="cadPerShare">1.89</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ic6368f5d59534a0d96175310350885fc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtMi0xLTEtMzUzODM_0ca6bd58-93ad-44e9-82fa-67a0c0b2f0f5"
      unitRef="shares">1002498</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i52f9ee94ed334d309ddc1b2501e78dc1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtNC0xLTEtMzUzODM_17e5a84a-e6df-4f7b-8e08-5fc976dd90f1">P1Y9M3D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="ic6368f5d59534a0d96175310350885fc_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtNi0xLTEtMzUzODM_b8d9e3d4-b67b-403a-ae77-8f48b1bfd395"
      unitRef="cadPerShare">1.39</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ic6368f5d59534a0d96175310350885fc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtOC0xLTEtMzUzODM_62759f93-bf07-4238-8313-733f7c24efe7"
      unitRef="shares">799998</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="ic6368f5d59534a0d96175310350885fc_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzEtMTAtMS0xLTM1Mzgz_5233bd4b-3149-4072-aea3-e2e60315026c"
      unitRef="cadPerShare">1.40</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i669145b9554d41f3b9c524309e023747_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjpiM2QxODI4YjFjY2E0YTYyYTAwODQ5ZTU3N2U3OTg1ZV80_7e8a2f5d-e1ff-424e-bdd3-4ceaed9d70a4"
      unitRef="cadPerShare">1.90</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i9e8be41597da42568d4f86e247044361_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjpiM2QxODI4YjFjY2E0YTYyYTAwODQ5ZTU3N2U3OTg1ZV85_e34b430e-dddc-4993-a6b0-127260545c5a"
      unitRef="cadPerShare">3.05</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ie679757fac604f0cb2a738bb1dd0ac7e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItMi0xLTEtMzUzODM_e9ab9a06-d474-4daa-a11a-bcad5c631ad6"
      unitRef="shares">1724442</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="ifd74fcb0f8c9429fadb463a6eb81e2f0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItNC0xLTEtMzUzODM_8d81d02c-391c-416b-a27d-186e138daaee">P3Y3M21D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="ie679757fac604f0cb2a738bb1dd0ac7e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItNi0xLTEtMzUzODM_5a9aca0d-8809-4bff-a962-39764c7b9b32"
      unitRef="cadPerShare">2.34</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ie679757fac604f0cb2a738bb1dd0ac7e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItOC0xLTEtMzUzODM_8936d444-a3f4-4b71-9362-53a31e39290c"
      unitRef="shares">1001738</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="ie679757fac604f0cb2a738bb1dd0ac7e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzItMTAtMS0xLTM1Mzgz_58ed95c5-70f8-4cf5-8031-de998ae861fd"
      unitRef="cadPerShare">2.37</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="if0265f11a01344f595e7fe503b2a3472_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjozMWYzZWIwNDY1M2M0ZjJlYWJjNjA2Y2Y1YWY0MWQzOF80_27199d5f-07ba-4500-a393-2a6c259de60c"
      unitRef="cadPerShare">3.06</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="idd36a13c83d745178281e200444da7ee_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjozMWYzZWIwNDY1M2M0ZjJlYWJjNjA2Y2Y1YWY0MWQzOF85_726cd574-e1f1-40f0-8070-b2e2b5131dc2"
      unitRef="cadPerShare">3.29</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i3e89eeef735b47ceb3acd3ad40771e04_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtMi0xLTEtMzUzODM_74906f0a-ece9-4a39-9e73-3792cbb91f53"
      unitRef="shares">1532500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="ib60b968ef3b34ea79492f56d45e6f2f1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtNC0xLTEtMzUzODM_368e133f-7662-43e0-9e1d-37023ae56ff5">P1Y11M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i3e89eeef735b47ceb3acd3ad40771e04_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtNi0xLTEtMzUzODM_f9508348-04f8-40e0-95d0-59a8c6fa4c34"
      unitRef="cadPerShare">3.17</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i3e89eeef735b47ceb3acd3ad40771e04_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtOC0xLTEtMzUzODM_de68095b-1726-41fa-a141-42b9b310b664"
      unitRef="shares">1532500</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i3e89eeef735b47ceb3acd3ad40771e04_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzMtMTAtMS0xLTM1Mzgz_e6b479c1-44f0-465a-b615-dca8471ce018"
      unitRef="cadPerShare">3.17</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="id0741691230d4e28b2d1df61be980984_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjpiMDM4YWExNjA0MmY0OTcwYWI3MGE1YzY4Y2Q1YWM4Ml80_576fadea-1ae1-4ae0-a297-fb5c6d85274c"
      unitRef="cadPerShare">3.30</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i1818274641ed42299558348b53c621fd_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjpiMDM4YWExNjA0MmY0OTcwYWI3MGE1YzY4Y2Q1YWM4Ml85_49a6ed47-5039-42c0-b63b-51cfd63c6d0e"
      unitRef="cadPerShare">3.75</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i8f8f1d616d0e479fafc3b8c388acf7c8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtMi0xLTEtMzUzODM_69592c84-7293-4f02-a23b-9d06d6202c72"
      unitRef="shares">1393131</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i016d2b845c3c472d9148a20b8286ae27_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtNC0xLTEtMzUzODM_e6c9ddbb-a138-4988-8a19-66d6bc92d1c8">P2Y10M13D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i8f8f1d616d0e479fafc3b8c388acf7c8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtNi0xLTEtMzUzODM_5754d3d8-01de-4982-8d35-32b6f782ad6b"
      unitRef="cadPerShare">3.42</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i8f8f1d616d0e479fafc3b8c388acf7c8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtOC0xLTEtMzUzODM_0afd9ae0-6749-40b6-bd84-24e65463fb17"
      unitRef="shares">775632</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i8f8f1d616d0e479fafc3b8c388acf7c8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzQtMTAtMS0xLTM1Mzgz_77b855bf-c7eb-4658-89be-8fbde142bba6"
      unitRef="cadPerShare">3.43</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i6ff3b4848a624feab2a3c7841b598986_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjo4ZWY5NDhiNDdkYjM0ZDU4YjA1NWRhYTU1ODNhOGZiZV80_1e2b4ce3-421c-455e-9212-4f9d2812ca44"
      unitRef="cadPerShare">3.76</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="i5017488ebe3844d0ad6adf806e07f9b9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtMC0xLTEtMzUzODMvdGV4dHJlZ2lvbjo4ZWY5NDhiNDdkYjM0ZDU4YjA1NWRhYTU1ODNhOGZiZV85_d229d30f-7d79-4e3a-8a3e-72030cae5e02"
      unitRef="cadPerShare">27.46</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i0d0648f490594bd7ab0068f3dec9d739_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtMi0xLTEtMzUzODM_1887d196-8bdc-4657-897d-669a6574a3f1"
      unitRef="shares">310614</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i48e149fb587f4b6b81178a578d0bd1fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtNC0xLTEtMzUzODM_87b58632-f217-48e6-8da3-e7a8f4141039">P2Y2M8D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i0d0648f490594bd7ab0068f3dec9d739_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtNi0xLTEtMzUzODM_468fc655-60fb-4f4b-ba97-d449aad2f50f"
      unitRef="cadPerShare">7.39</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i0d0648f490594bd7ab0068f3dec9d739_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtOC0xLTEtMzUzODM_a9a5c5e0-5912-46cc-a074-de1e13ae8514"
      unitRef="shares">310614</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i0d0648f490594bd7ab0068f3dec9d739_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzUtMTAtMS0xLTM1Mzgz_23005542-1bae-4955-abbf-0a2a573e1684"
      unitRef="cadPerShare">7.39</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzYtMi0xLTEtMzUzODM_9a8a3595-9989-40a6-8094-02bd88cb580c"
      unitRef="shares">5963185</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzYtNC0xLTEtMzUzODM_03b11e84-c96a-4494-9664-eb178630e6fb">P2Y6M14D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzYtNi0xLTEtMzUzODM_ccc3a79b-f2d7-46cf-ac39-8a01266c0ae4"
      unitRef="cadPerShare">2.91</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzYtOC0xLTEtMzUzODM_b19edfa2-7eab-4ca3-95c2-c0d6fa929efd"
      unitRef="shares">4420482</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo5ZWRjNjc0Y2E4OTY0NjJmYWRiMjNmZjJiODM2ODRiOS90YWJsZXJhbmdlOjllZGM2NzRjYTg5NjQ2MmZhZGIyM2ZmMmI4MzY4NGI5XzYtMTAtMS0xLTM1Mzgz_ffa18d99-3be0-4016-b026-0651750bb696"
      unitRef="cadPerShare">3.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1
      contextRef="iac8d3f09febd4cb19e47cf23fefaaf0a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzM4OA_018919db-8220-419c-9452-e1c192c6fb66">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMzM_eb5072a4-26e2-4a47-9db9-f8651fcc2d21">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.66%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.34%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected share price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96.02%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.82%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$1.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzEtMS0xLTEtMzUzODM_9757b9cc-a287-418a-b953-8cd93e7871c5"
      unitRef="number">0.0335</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzEtMy0xLTEtMzUzODM_143e9fc3-949f-4c6b-96b3-e5d010c222d4"
      unitRef="number">0.0066</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzEtNS0xLTEtMzUzODM_183fbb83-3802-45e7-8e52-5f96044d172a"
      unitRef="number">0.0034</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzItMS0xLTEtMzUzODM_b0a92d3c-02c5-4501-87b9-2ff6a146a573"
      unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzItMy0xLTEtMzUzODM_80fbb3fb-9180-4e18-8cd1-6c1ccf35c07c"
      unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzItNS0xLTEtMzUzODM_3979b5ad-4f26-4e63-b9c5-8fabe92c6470"
      unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzMtMS0xLTEtMzUzODM_9403e806-77a0-4714-983a-e872625ab135"
      unitRef="number">0.9602</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzMtMy0xLTEtMzUzODM_954ced68-e2fb-4dc4-a788-461bcc82d1dc"
      unitRef="number">1.1045</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzMtNS0xLTEtMzUzODM_b62dd4b9-ffeb-4cb3-9ce6-9325fcb42175"
      unitRef="number">1.1082</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzQtMS0xLTEtMzUzODM_ea1b6a80-de2a-4415-b8bf-e7019653b31a"
      unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzQtMy0xLTEtMzUzODM_09301c9a-dfdd-494f-9455-5bf706cbe13f"
      unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzQtNS0xLTEtMzUzODM_8c5f2ec9-66fc-4ac0-8769-1e36381f865a"
      unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzUtMS0xLTEtMzUzODM_ace4c685-2b64-4bf4-9556-b1e355428ea9"
      unitRef="cad">1.24</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzUtMy0xLTEtMzUzODM_a2577c6c-cdee-42d9-86c4-5411e801f221"
      unitRef="cad">1.99</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTplMmIzZmVkNTljYzU0ODBiYWZiOThhZTkzOTZhMDdlZS90YWJsZXJhbmdlOmUyYjNmZWQ1OWNjNTQ4MGJhZmI5OGFlOTM5NmEwN2VlXzUtNS0xLTEtMzUzODM_b356b7fa-a0d2-4305-a6ca-8ffa5a67342c"
      unitRef="cad">2.12</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1
      contextRef="i771812f5ba4a4f9ba29a5246edf0bf00_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMjM_0fa62ac7-91f4-4d0c-bbb7-ac85966b81c9">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMzQ_66933618-a8ec-47a9-bbe1-845a93267189">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our RSU activity for the years ended December&#160;31 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,560&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(40,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; (1) The weighted average fair value of the RSUs granted was nil in 2022 (2021 - nil; 2020 - $2.41).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i2320674fb5744c63bbf6953873d4a940_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzEtMS0xLTEtMzUzODM_d7afefcf-adf7-4e0c-b144-9ff031d28ba4"
      unitRef="shares">40560</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i0929be370c884a7cb1a0e5b4d741a8b2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzEtMy0xLTEtMzUzODM_81748905-0245-4990-8c41-b0e1d5bdbfc3"
      unitRef="shares">134618</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i03a33fe7f4e34bb28f5d1cbf45984686_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzEtNS0xLTEtMzUzODM_b88871d1-0f4e-4c6b-a089-44ed8574665b"
      unitRef="shares">209657</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i771812f5ba4a4f9ba29a5246edf0bf00_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzItMS0xLTEtMzUzODM_348704d4-18ac-4654-a79b-2cca2a268d3b"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ie9255ba83d384e38a8c5e9053e964622_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzItMy0xLTEtMzUzODM_d7601cf4-df27-4c74-a66e-48386c1e0f9d"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i2dec10529d90451ba902ebe59a161f0a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzItNS0xLTEtMzUzODM_260509cf-42b5-420b-9b49-a53bc661de57"
      unitRef="shares">154923</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i771812f5ba4a4f9ba29a5246edf0bf00_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzMtMS0xLTEtMzUzODM_67ef235b-9056-4058-a584-967fe4998fd0"
      unitRef="shares">40560</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ie9255ba83d384e38a8c5e9053e964622_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzMtMy0xLTEtMzUzODM_d668d04f-b52a-4d48-b5a9-79ece9890113"
      unitRef="shares">94058</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i2dec10529d90451ba902ebe59a161f0a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzMtNS0xLTEtMzUzODM_1df72c1f-8bac-441a-9ba5-72a0d5dc6143"
      unitRef="shares">229962</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="if5de5eb425bc430e9593f5e707cf066a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzQtMS0xLTEtMzUzODM_2c87cd0a-3f15-4011-8b2f-f79bed16861a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i2320674fb5744c63bbf6953873d4a940_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzQtMy0xLTEtMzUzODM_8175e4e5-3041-4480-b5bb-d41a49733547"
      unitRef="shares">40560</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i0929be370c884a7cb1a0e5b4d741a8b2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90YWJsZTo2ZTYwMzVlYzIwZjE0M2U3OWYwZjA5N2M1ZGVkYjAxZC90YWJsZXJhbmdlOjZlNjAzNWVjMjBmMTQzZTc5ZjBmMDk3YzVkZWRiMDFkXzQtNS0xLTEtMzUzODM_b4717941-37f2-4105-84d0-48090464f5f5"
      unitRef="shares">134618</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="if5de5eb425bc430e9593f5e707cf066a_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzE1Nzc_91a38a87-925c-492e-91ac-e388d532779c"
      unitRef="cad">0</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="i2320674fb5744c63bbf6953873d4a940_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzE1OTE_68875ccc-a791-4e38-890c-4d8bf41b9201"
      unitRef="cad">0</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="i0929be370c884a7cb1a0e5b4d741a8b2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzE2MDE_9bf41e55-27c2-4935-92bd-3599eaae3624"
      unitRef="cad">2.41</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="i0daf1c1f7fbd41b2933e6fc95c01304a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzE5MTM_30096b6c-5bab-45fc-81ef-82e89712745d"
      unitRef="shares">6132791</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIwODU_14a7cf8c-bcf2-4338-8d55-3c30e8cf928a"
      unitRef="cad">2378000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIwOTQ_c3dc72bf-5f2e-45d8-b3f6-bcb0530be893"
      unitRef="cad">3826000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjYvZnJhZzo1MDk2NzA1YjQ1NDA0MGI0YWE0MWUyODc4ODExOWRmZC90ZXh0cmVnaW9uOjUwOTY3MDViNDU0MDQwYjRhYTQxZTI4Nzg4MTE5ZGZkXzIxMDM_db721b1e-7a57-4e2e-8fc3-f2f0c1b52edf"
      unitRef="cad">2559000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzQxMQ_4b2bf72e-265a-4acc-b94d-e76233d690e6">Loss Per Common Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding for the year ended December&#160;31, 2022, of 58,029,745 (2021 - 53,513,225; 2020 - 40,338,789). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzE4OA_7c2a5fec-8b12-4cb7-93bc-eb9d39c8cfc6"
      unitRef="shares">58029745</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzE4OA_aa847d69-2a67-4fe1-ba4c-0da07f68006a"
      unitRef="shares">58029745</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzE5Nw_50d877c4-f94f-4413-aea7-048943c0ce53"
      unitRef="shares">53513225</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzE5Nw_62892829-bde9-4d3e-bdcb-222261987844"
      unitRef="shares">53513225</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzIwNg_608ec0f0-a6d4-49be-837e-e4517c46b4e3"
      unitRef="shares">40338789</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNjkvZnJhZzphNzIxNmNlYjM2OTk0MDA3ODNjNTU3MTg3MzZhZTM3Ni90ZXh0cmVnaW9uOmE3MjE2Y2ViMzY5OTQwMDc4M2M1NTcxODczNmFlMzc2XzIwNg_e5fd7995-c12c-4604-9fa5-7fd48ebc3a7d"
      unitRef="shares">40338789</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90ZXh0cmVnaW9uOjA1NmFhNzIyM2U4ZjQ0NzZhOTAyZjFmYzk0N2JjODAzXzY2OQ_502e06c6-fa9f-4e4f-9be7-d476f6f3cd64">Contract Liability&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regional licensing agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liability balance at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31&lt;/span&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e expect to record in revenue over the next five years, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90ZXh0cmVnaW9uOjA1NmFhNzIyM2U4ZjQ0NzZhOTAyZjFmYzk0N2JjODAzXzY2OA_9ce014fb-acaf-4fa7-b487-7bef13785222">&lt;div style="text-align:justify"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liability balance at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31&lt;/span&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e expect to record in revenue over the next five years, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
    <oncyf:ContractLiabilityRecognitionPeriod
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90ZXh0cmVnaW9uOjA1NmFhNzIyM2U4ZjQ0NzZhOTAyZjFmYzk0N2JjODAzXzY0Ng_ede879f6-e388-4ac8-bc5f-601c49ebc646">P5Y</oncyf:ContractLiabilityRecognitionPeriod>
    <ifrs-full:ContractLiabilities
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90YWJsZTowOGRkOTdjMjU3ZTM0MmU2YTI4MDAzZTkyNDQwOGFhZi90YWJsZXJhbmdlOjA4ZGQ5N2MyNTdlMzQyZTZhMjgwMDNlOTI0NDA4YWFmXzEtMS0xLTEtMzUzODM_cfc29551-9102-45af-8948-fe03b4b6b52d"
      unitRef="usd">6730000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90YWJsZTowOGRkOTdjMjU3ZTM0MmU2YTI4MDAzZTkyNDQwOGFhZi90YWJsZXJhbmdlOjA4ZGQ5N2MyNTdlMzQyZTZhMjgwMDNlOTI0NDA4YWFmXzEtMy0xLTEtMzUzODM_dcae6ed9-7409-4eaa-a827-f8dee162b2d3"
      unitRef="usd">6730000</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90YWJsZTowOGRkOTdjMjU3ZTM0MmU2YTI4MDAzZTkyNDQwOGFhZi90YWJsZXJhbmdlOjA4ZGQ5N2MyNTdlMzQyZTZhMjgwMDNlOTI0NDA4YWFmXzMtMS0xLTEtMzUzODM_5ee995b1-f697-40f4-ac9a-213e2c6f65c5"
      unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90YWJsZTowOGRkOTdjMjU3ZTM0MmU2YTI4MDAzZTkyNDQwOGFhZi90YWJsZXJhbmdlOjA4ZGQ5N2MyNTdlMzQyZTZhMjgwMDNlOTI0NDA4YWFmXzMtMy0xLTEtMzUzODM_e9686eba-2c3c-41ee-876b-2c8783b55614"
      unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90YWJsZTowOGRkOTdjMjU3ZTM0MmU2YTI4MDAzZTkyNDQwOGFhZi90YWJsZXJhbmdlOjA4ZGQ5N2MyNTdlMzQyZTZhMjgwMDNlOTI0NDA4YWFmXzQtMS0xLTEtMzUzODM_7437afa8-32d7-4523-94e0-232a64eb763f"
      unitRef="usd">6730000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzIvZnJhZzowNTZhYTcyMjNlOGY0NDc2YTkwMmYxZmM5NDdiYzgwMy90YWJsZTowOGRkOTdjMjU3ZTM0MmU2YTI4MDAzZTkyNDQwOGFhZi90YWJsZXJhbmdlOjA4ZGQ5N2MyNTdlMzQyZTZhMjgwMDNlOTI0NDA4YWFmXzQtMy0xLTEtMzUzODM_e581bd29-596d-4b8c-a48d-e37b35ab3913"
      unitRef="usd">6730000</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzUvZnJhZzozNjJiZmUxNjhlZDA0MjYxOTAxYTVhYjUwNzE1ZDNhYy90ZXh0cmVnaW9uOjM2MmJmZTE2OGVkMDQyNjE5MDFhNWFiNTA3MTVkM2FjXzExNzk_c8a61482-8ee7-43c7-b7c0-32ec2b90eb30">Commitments and Contingencies &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are committed to payments totaling approximately $16,775 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next three years. We are able to cancel most of these agreements with notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnification of Officers and Directors&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges, and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#x2019; and officers&#x2019; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <oncyf:PurchaseObligation1
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzUvZnJhZzozNjJiZmUxNjhlZDA0MjYxOTAxYTVhYjUwNzE1ZDNhYy90ZXh0cmVnaW9uOjM2MmJmZTE2OGVkMDQyNjE5MDFhNWFiNTA3MTVkM2FjXzY2_80e67f4c-f189-4606-becd-e5a3ec19cefe"
      unitRef="cad">16775000</oncyf:PurchaseObligation1>
    <oncyf:PurchaseObligationCommitmentTerm
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xNzUvZnJhZzozNjJiZmUxNjhlZDA0MjYxOTAxYTVhYjUwNzE1ZDNhYy90ZXh0cmVnaW9uOjM2MmJmZTE2OGVkMDQyNjE5MDFhNWFiNTA3MTVkM2FjXzIwNw_560863af-3b6a-400e-822f-b72d68d1cbb6">P3Y</oncyf:PurchaseObligationCommitmentTerm>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzE2MzU_5a18df19-2e80-40c4-b352-5079aaf19bc7">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(24,751)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,255)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,505)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory Canadian corporate tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anticipated tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,693)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,039)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,401)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Difference in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,552&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,716&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,334&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;547&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation of tax pools&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(552)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiry of tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,614&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(838)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision to offset deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,162&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, we have non-capital losses of $98,475 and $145,405 in Canada and Barbados, respectively (December&#160;31, 2021 - $89,537 and $162,986, respectively). These losses are expected to expire between 2023 and 2042, if not utilized. At December&#160;31, 2022, we have Canadian investment tax credits of $4,368 (December&#160;31, 2021 - $4,834) that are expected to expire between 2023 and 2040, if not utilized. As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years&#x2019; taxable income of $27,663 (December&#160;31, 2021 - $27,663).&#160;We also have unclaimed U.S. credits for increasing research activities available to reduce future years' taxable income of $1,285 (December&#160;31, 2021 - $1,343) expiring between 2031 and 2041. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,726&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific research and experimental development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,648&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,363&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;366&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;518&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38,627&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any material income tax examinations currently in progress by any taxing jurisdiction.</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzE2Mjc_3fa70936-8e38-4e26-b2f4-4a3f9b5f1a24">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(24,751)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,255)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,505)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory Canadian corporate tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anticipated tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,693)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,039)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,401)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Difference in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,552&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,716&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,334&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;547&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation of tax pools&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(552)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiry of tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,614&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(838)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision to offset deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,162&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock>
    <ifrs-full:AccountingProfit
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEtMS0xLTEtMzUzODM_c22a7823-94b1-4ce6-8e21-5e6d9458924f"
      unitRef="cad">-24751000</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEtMy0xLTEtMzUzODM_83ddc947-c9a2-4187-833e-2ea2cea1df7b"
      unitRef="cad">-26255000</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEtNS0xLTEtMzUzODM_09a73375-e524-4298-aca2-8d0cf65a1c3e"
      unitRef="cad">-22505000</ifrs-full:AccountingProfit>
    <ifrs-full:ApplicableTaxRate
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzItMS0xLTEtMzUzODM_2b3bf521-14b1-476f-aeed-53edd202b762"
      unitRef="number">0.2300</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzItMy0xLTEtMzUzODM_41ee8d40-96fe-4999-bebc-15c00d10d691"
      unitRef="number">0.2300</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzItNS0xLTEtMzUzODM_e1a2cfcc-94bc-43e2-85b1-7278c8b2c4e0"
      unitRef="number">0.2400</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzMtMS0xLTEtMzUzODM_f2c05afc-548a-4230-ad62-ab61d6eddf7b"
      unitRef="cad">-5693000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzMtMy0xLTEtMzUzODM_1c20b0b4-79e3-481a-807f-c9f1fafffa49"
      unitRef="cad">-6039000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzMtNS0xLTEtMzUzODM_07a9f71c-0b4b-4493-b591-32fb361a124d"
      unitRef="cad">-5401000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzQtMS0xLTEtMzUzODM_300936ee-d396-464e-980f-6fc94dabcd6a"
      unitRef="cad">3552000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzQtMy0xLTEtMzUzODM_d13fdb49-873c-4214-ad73-5a2873160c07"
      unitRef="cad">2716000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzQtNS0xLTEtMzUzODM_591a96b2-87c0-4856-b61a-f9d6c56a8cae"
      unitRef="cad">3334000</ifrs-full:TaxEffectOfForeignTaxRates>
    <oncyf:TaxEffectOfStockBasedCompensation
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzUtMS0xLTEtMzUzODM_752bdf72-849e-4fe3-9f30-fe713c244955"
      unitRef="cad">-547000</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfStockBasedCompensation
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzUtMy0xLTEtMzUzODM_2e900fd3-c3e5-4871-a057-7d16b989f142"
      unitRef="cad">-880000</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfStockBasedCompensation
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzUtNS0xLTEtMzUzODM_18e4ce54-4b60-4e07-805d-6d9033d33ab2"
      unitRef="cad">-614000</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfTaxPools
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzgtMS0xLTEtMzUzODM_598aeb45-b241-4bf8-9312-88c423f2955d"
      unitRef="cad">-338000</oncyf:TaxEffectOfTaxPools>
    <oncyf:TaxEffectOfTaxPools
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzgtMy0xLTEtMzUzODM_11958a72-9a28-4847-b13d-ce613c485af7"
      unitRef="cad">-552000</oncyf:TaxEffectOfTaxPools>
    <oncyf:TaxEffectOfTaxPools
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzgtNS0xLTEtMzUzODM_4d944ca7-0e29-43b8-8b7b-a659f976c578"
      unitRef="cad">21000</oncyf:TaxEffectOfTaxPools>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzktMS0xLTEtMzUzODM_90b05941-8724-4a34-a024-7202302244ee"
      unitRef="cad">-368000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzktMy0xLTEtMzUzODM_a4835a93-37e5-4dfe-9154-e6ccf5eee6ab"
      unitRef="cad">45000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzktNS0xLTEtMzUzODM_63e05ed7-37e6-4295-bd2d-3618a0a4db8f"
      unitRef="cad">108000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <oncyf:TaxEffectOfExpirationOfTaxBenefits
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEwLTEtMS0xLTM1Mzgz_8a688a8f-1a96-47e1-ab85-34c2ddb41f13"
      unitRef="cad">1614000</oncyf:TaxEffectOfExpirationOfTaxBenefits>
    <oncyf:TaxEffectOfExpirationOfTaxBenefits
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEwLTMtMS0xLTM1Mzgz_5d78c594-fab3-485c-a786-bb36e74ec49d"
      unitRef="cad">1661000</oncyf:TaxEffectOfExpirationOfTaxBenefits>
    <oncyf:TaxEffectOfExpirationOfTaxBenefits
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEwLTUtMS0xLTM1Mzgz_311f4f7a-5bfe-4531-be91-924251393303"
      unitRef="cad">0</oncyf:TaxEffectOfExpirationOfTaxBenefits>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEwLTEtMS0xLTQ2NTE2_8da565f9-a243-4c78-ae71-ffdb98e9b2f5"
      unitRef="cad">5000</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEwLTMtMS0xLTQ2NTE2_86d63b3f-a589-49df-aa6e-605f81ee4f74"
      unitRef="cad">-4000</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEwLTUtMS0xLTQ2NTE2_de2d727c-258e-4e40-aef4-01365c4c6040"
      unitRef="cad">-838000</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzExLTEtMS0xLTM1Mzgz_2a36de01-dc85-4881-8425-56a7ecdbb5a3"
      unitRef="cad">-765000</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzExLTMtMS0xLTM1Mzgz_152d0d3c-14fb-4de1-9036-21f93c14a010"
      unitRef="cad">-1342000</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzExLTUtMS0xLTM1Mzgz_05990097-750f-4f8c-ae6f-077e3a914798"
      unitRef="cad">-2162000</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEyLTEtMS0xLTM1Mzgz_180a1674-0aa7-48f4-924a-9bb46a9d3eac"
      unitRef="cad">84000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEyLTMtMS0xLTM1Mzgz_e6cd0291-ac04-4935-abae-63b0b6e59416"
      unitRef="cad">49000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1NTJkYTEzOWJhZmY0MDkxOTZiZjUyNDk4NzRjODJlZC90YWJsZXJhbmdlOjU1MmRhMTM5YmFmZjQwOTE5NmJmNTI0OTg3NGM4MmVkXzEyLTUtMS0xLTM1Mzgz_7684a0be-a512-4edb-bf6c-6ed3084b7c1f"
      unitRef="cad">0</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzE2MzY_526c6418-de6e-4b57-9018-5e7a95d68e64">t December&#160;31, 2022, we have non-capital losses of $98,475 and $145,405 in Canada and Barbados, respectively (December&#160;31, 2021 - $89,537 and $162,986, respectively). These losses are expected to expire between 2023 and 2042, if not utilized. At December&#160;31, 2022, we have Canadian investment tax credits of $4,368 (December&#160;31, 2021 - $4,834) that are expected to expire between 2023 and 2040, if not utilized. As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years&#x2019; taxable income of $27,663 (December&#160;31, 2021 - $27,663).&#160;We also have unclaimed U.S. credits for increasing research activities available to reduce future years' taxable income of $1,285 (December&#160;31, 2021 - $1,343) expiring between 2031 and 2041. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,726&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific research and experimental development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,648&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,363&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;366&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;518&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;38,627&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="ia520d0c500544f84866a7d2a4c1dacd9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2Mjk2NzQ_24b4a3e4-3bf7-4ad3-8f2a-65bab0ae75b6"
      unitRef="cad">98475000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i103420c5cde840e79af37985d2d0bc9d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2Mjk2ODI_3678fb69-179e-48aa-bfc6-eed9e3755869"
      unitRef="cad">145405000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i28afd4f827e34f3eae4c33b42849dabf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2Mjk3NjE_4f3d9da2-8229-4e07-ad4d-97471540a97f"
      unitRef="cad">89537000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i4ab96394ca8b4ae0a266d0b54caf3191_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2Mjk3Njk_fe30e426-4cfa-4a82-8826-a1066e2bfc6a"
      unitRef="cad">162986000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="ibbbd14a8d6a34c3db1a86531714b2505_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2Mjk5NDU_d51b274a-8a51-42b6-b61b-fa4660b38b5d"
      unitRef="cad">4368000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i9e50e8d056f742639310ba89a351e073_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2Mjk5NTY_affb94a7-b335-4c38-8602-06d05dfdf6a4"
      unitRef="cad">4834000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i948c9f76e8c14e789a92b32d5e0cd60d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2MzA5NDQ_1fd932ee-d608-48f6-9efc-915351c74103"
      unitRef="cad">27663000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="i2592d82deade43a389c57acec6861c6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2MzA5Mzg_99397de0-eef6-4a0a-8c2f-d08e49ccd0ac"
      unitRef="cad">27663000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="iaa08ffbbd906412591e8727e7b92333e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2MzA5ODU_5b6a1d3c-33e0-48a7-8b24-81c02c358243"
      unitRef="cad">1285000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised
      contextRef="ie72bcfe2289d460cb870ee2ab6965abf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90ZXh0cmVnaW9uOjBmZDU4YjVmM2VkODQ0NDE5NTc3YTY0ZGNmOGEyMDA0XzEwOTk1MTE2MzA3ODI_dd8412fb-ddf0-4150-8a06-d58a977f1211"
      unitRef="cad">1343000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i9934fdaa7cb54bed9e71b4949c27a412_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzEtMS0xLTEtMzUzODM_9a2c0306-f1f9-4e41-ac81-b82c984849d1"
      unitRef="cad">26726000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ifb1478bee3ac4873a8fa8d09e2c3af34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzEtMy0xLTEtMzUzODM_4a9fc99e-28fe-4906-be3f-90f16264c618"
      unitRef="cad">25158000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i66c467d253d145219d761e8b50d9872e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzEtNS0xLTEtMzUzODM_b6b18a9a-6cfa-4ad2-9e64-3a0d1ab4661c"
      unitRef="cad">21488000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i1dd5a5d56ed3410cb4e81d1da02608b8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzItMS0xLTEtMzUzODM_2d06600b-dec8-4b9b-87f5-0abad118f490"
      unitRef="cad">7648000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i0b3ad9043f0443508a6e58ffe371b9e3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzItMy0xLTEtMzUzODM_60f8f550-468d-466f-931f-50b3d9bb9bab"
      unitRef="cad">7705000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i97e1578bad4a4fd8b9eeb3cc0142c022_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzItNS0xLTEtMzUzODM_00c4f411-a339-4661-b578-621669732a5c"
      unitRef="cad">6362000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ibf87bcb9d5a348e7987675a510c51f91_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzMtMS0xLTEtMzUzODM_fd256cac-f9de-4ac8-80a5-20350d7038ce"
      unitRef="cad">3363000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i6e00e20520b0484b8e24ff13c4d70e87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzMtMy0xLTEtMzUzODM_a071fbb7-125f-4fca-b7ea-f45ff5d17aec"
      unitRef="cad">3716000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i192f8af4da504af0a223d7c5399c0b89_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzMtNS0xLTEtMzUzODM_11db9901-e92e-4b3f-b6c5-e01128c7639a"
      unitRef="cad">4068000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i9d0f7801e4734c00bb6d8dd7c4f5b818_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzQtMS0xLTEtMzUzODM_9d055a87-d79e-4147-a008-601ebc5a4da9"
      unitRef="cad">366000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i085395ab16f842a1a1512a6390a303e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzQtMy0xLTEtMzUzODM_28b31cd2-9240-445f-8503-a75a7437d355"
      unitRef="cad">351000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i82ebeaf310b04401931722c6c4601410_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzQtNS0xLTEtMzUzODM_cb4547f0-6823-4746-a93d-c287ffb0968e"
      unitRef="cad">1928000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i92fb0107f20d4b31a60191a22ac916c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzUtMS0xLTEtMzUzODM_9774bbe8-716d-4e31-bedf-c75ca5a3f150"
      unitRef="cad">518000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i9d4db2a6855b40bc9001da783c6c23a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzUtMy0xLTEtMzUzODM_defe0420-2546-4a25-b362-aba10073da10"
      unitRef="cad">648000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i1bce01bfb3c140e19bceefb885e36144_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzUtNS0xLTEtMzUzODM_b24cf817-3b59-4428-bae8-395800a74b78"
      unitRef="cad">689000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i661bfced363d425b983b07748d5e34d9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzYtMS0xLTEtMzUzODM_39a20e94-6918-4404-8ea9-61dd1beab5d1"
      unitRef="cad">6000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="ib701cd64a09142eaa49f3229d198e9f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzYtMy0xLTEtMzUzODM_baa26899-e8af-4536-9c6d-070026d61c70"
      unitRef="cad">6000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i6dc03510bb2241279358235d4f80a08e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzYtNS0xLTEtMzUzODM_78534b8f-b8f7-46a6-adff-c13875bc9e6d"
      unitRef="cad">6000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzctMS0xLTEtMzUzODM_eab9c9e2-63d6-44cb-bf36-5ce9e0073e64"
      unitRef="cad">38627000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzctMy0xLTEtMzUzODM_40fb0044-a9be-4734-b5c5-f7e5ff5eebc2"
      unitRef="cad">37584000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="i96a23ba3cfe248f9a219b793f13a9c4e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODEvZnJhZzowZmQ1OGI1ZjNlZDg0NDQxOTU3N2E2NGRjZjhhMjAwNC90YWJsZTo1ZTg2OTYxNTAwNjY0NGI1YWY0MjZlNDZiZTJmZTBiZC90YWJsZXJhbmdlOjVlODY5NjE1MDA2NjQ0YjVhZjQyNmU0NmJlMmZlMGJkXzctNS0xLTEtMzUzODM_7c5a9db3-3f33-4431-9d83-c17bc9638b6c"
      unitRef="cad">34541000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90ZXh0cmVnaW9uOjhhYjRiNmY3N2E1YzQ1NjNhYTc0MTIxNmFmYmE1YzBmXzM2MTI_1edc376e-2096-495f-835b-8f16c3df38a7">Capital Disclosures&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;We include shareholders' equity, cash and cash equivalents, and marketable securities in the definition of capital.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,666&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders' equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have no debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#x2019;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 12, 2022, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 16, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Base Shelf allowed us to enter into our ATM equity distribution agreements (see Note 9). We use these equity arrangements to assist us in achieving our capital objective. These arrangements provide us with the opportunity to raise capital and better manage our cash resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2022.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory>
    <oncyf:DisclosureOfCapitalComponentsTableTextBlock
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90ZXh0cmVnaW9uOjhhYjRiNmY3N2E1YzQ1NjNhYTc0MTIxNmFmYmE1YzBmXzM2MTE_9fc5c0b0-2ced-44b1-9ae6-ebe8b2e7f8ae">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,666&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;20,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders' equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</oncyf:DisclosureOfCapitalComponentsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90YWJsZTpkY2E3YmU4NmI3NWU0ODQ0YTIxODZiNDhkM2QxZDczNC90YWJsZXJhbmdlOmRjYTdiZTg2Yjc1ZTQ4NDRhMjE4NmI0OGQzZDFkNzM0XzEtMS0xLTEtMzUzODM_24885483-90b2-4164-a37c-c467ee314055"
      unitRef="cad">11666000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90YWJsZTpkY2E3YmU4NmI3NWU0ODQ0YTIxODZiNDhkM2QxZDczNC90YWJsZXJhbmdlOmRjYTdiZTg2Yjc1ZTQ4NDRhMjE4NmI0OGQzZDFkNzM0XzEtMy0xLTEtMzUzODM_9f5e037e-442e-46be-ba7f-4872942e9a4d"
      unitRef="cad">41262000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentFinancialAssetsAvailableforsale
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90YWJsZTpkY2E3YmU4NmI3NWU0ODQ0YTIxODZiNDhkM2QxZDczNC90YWJsZXJhbmdlOmRjYTdiZTg2Yjc1ZTQ4NDRhMjE4NmI0OGQzZDFkNzM0XzItMS0xLTEtMzc0MTU_c04797eb-05d0-4732-b160-aba2a2dee5fa"
      unitRef="cad">20472000</ifrs-full:CurrentFinancialAssetsAvailableforsale>
    <ifrs-full:CurrentFinancialAssetsAvailableforsale
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90YWJsZTpkY2E3YmU4NmI3NWU0ODQ0YTIxODZiNDhkM2QxZDczNC90YWJsZXJhbmdlOmRjYTdiZTg2Yjc1ZTQ4NDRhMjE4NmI0OGQzZDFkNzM0XzItMy0xLTEtMzc0MTk_5642a183-27ef-4421-8aa4-728e3e6237d3"
      unitRef="cad">0</ifrs-full:CurrentFinancialAssetsAvailableforsale>
    <ifrs-full:Equity
      contextRef="i87a99f2dd79f447287ac4cc2bdc8c046_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90YWJsZTpkY2E3YmU4NmI3NWU0ODQ0YTIxODZiNDhkM2QxZDczNC90YWJsZXJhbmdlOmRjYTdiZTg2Yjc1ZTQ4NDRhMjE4NmI0OGQzZDFkNzM0XzItMS0xLTEtMzUzODM_1c8eafd2-989f-44e7-8700-9b18308c20a9"
      unitRef="cad">26502000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="if3483d81850d4bb2b4f6474d2ebd0395_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90YWJsZTpkY2E3YmU4NmI3NWU0ODQ0YTIxODZiNDhkM2QxZDczNC90YWJsZXJhbmdlOmRjYTdiZTg2Yjc1ZTQ4NDRhMjE4NmI0OGQzZDFkNzM0XzItMy0xLTEtMzUzODM_16d029e1-c716-4612-9c87-8481899eb49f"
      unitRef="cad">36099000</ifrs-full:Equity>
    <oncyf:EquityAuthorized
      contextRef="i878d9a8a28ac42caa7c1e38319e6da4c_I20220612"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODQvZnJhZzo4YWI0YjZmNzdhNWM0NTYzYWE3NDEyMTZhZmJhNWMwZi90ZXh0cmVnaW9uOjhhYjRiNmY3N2E1YzQ1NjNhYTc0MTIxNmFmYmE1YzBmXzE5MzU_a1355ee8-8e93-4cda-9103-7806f3c40230"
      unitRef="cad">150000000</oncyf:EquityAuthorized>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzM1NDA_5026a7a4-311b-4142-876b-3cfef4bbc24c">Financial Instruments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist of cash and cash equivalents, marketable securities,&#160;other receivables, accounts payable and accrued liabilities, and warrant derivative.&#160;As at December&#160;31, 2022, the carrying amount of our cash and cash equivalents, marketable securities,&#160;other receivables, and accounts payable and accrued liabilities approximated their fair value due to their short-term maturity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants with an exercise price denominated in a currency that differs from an entity's functional currency are treated as a derivative, initially measured at fair value, with subsequent changes in fair value at each reporting period end recognized through profit and loss. Our warrants with an exercise price of US$0.90 (see Note 9(b)) meet this requirement, and we have presented the fair value of these warrants as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at December&#160;31, 2022, the fair value of our warrant derivative was $79 (December&#160;31, 2021 - $56). We use the Black-Scholes valuation model to estimate fair value.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial risk management&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents, marketable securities, and other receivable from Pfizer in connection with the BRACELET-1 study (see Note 5) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents, marketable securities, and other receivable from Pfizer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also mitigate our exposure to credit risk by restricting our portfolio to investment-grade securities with short-term maturities and monitoring counterparties' credit risk and credit standing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest rate risk &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest savings accounts that have variable interest rates. Our marketable securities have fixed interest rates.&#160;We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in market interest rates do not have a significant impact on our results of operations due to the short term to maturity of the investments held.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign exchange risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and the Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2022 by approximately $170. The impact of a $0.01 increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss in 2022 by approximately $22.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate our foreign exchange risk by maintaining sufficient foreign currencies through the purchase of foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable and accrued liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant balances in foreign currencies at December&#160;31, 2022, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 15. Accounts payable and accrued liabilities are all due within the current operating period.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2
      contextRef="i36f0549e16fb493899d3ce11e6663ed3_I20190816"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzEwOTk1MTE2MzM2NTk_61375e40-749c-4f0c-be62-6b2f5de12afd"
      unitRef="usdPerShare">0.90</oncyf:ClassofWarrantorRightExercisePriceofWarrantsorRights2>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="i78092e29c72947a18acdd0770f54643c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzYwNA_8a42b91c-6675-4afd-822b-53515f1078bf"
      unitRef="cad">79000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="i7fd69d94537a4d46b4b4f06ee6771977_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzYxMw_fbdbeb39-b6b9-48f3-a079-407e9ab23a94"
      unitRef="cad">56000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount
      contextRef="i9c8fd43724f84c33ae13eca3658b27f6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzI3NDU_634dbc6c-f343-4e48-9ca2-368406a89fd4"
      unitRef="cad">0.01</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings
      contextRef="i9c8fd43724f84c33ae13eca3658b27f6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzI4ODg_eedd2d4e-1386-4cb5-9a93-527070ed6436"
      unitRef="cad">-170000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount
      contextRef="i8c04db7260c44d0a84dcee681e6b31a3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzEwOTk1MTE2MzI0NjQ_94b974fe-5458-4900-a035-4e6c66691c49"
      unitRef="cad">0.01</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings
      contextRef="i8c04db7260c44d0a84dcee681e6b31a3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzEwOTk1MTE2MzIzMDI_deaff2f9-e2ef-404b-b335-de94cd134f5a"
      unitRef="cad">22000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90ZXh0cmVnaW9uOjBlZmUyNTRjMTJhNzQ0OWFiMzRhYTliY2M0MTE2ZDM3XzM1Mzg_d94a72f8-37a8-4cf8-9a94-fed93a86e6af">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant balances in foreign currencies at December&#160;31, 2022, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="id4078a67cca34e859712c16c4fb4b8ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzEtMS0xLTEtMzUzODM_7bd8cb02-2eac-4393-8bb2-3f849ced1dbb"
      unitRef="usd">6635000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="if3968ebc093542fb94bd695c6069eeb0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzEtMy0xLTEtNDQyODk_f97ae185-a8d7-47af-b856-850d4cc2e186"
      unitRef="usd">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:FinancialAssetsAvailableforsale
      contextRef="id4078a67cca34e859712c16c4fb4b8ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzItMS0xLTEtNDQyNjc_5cd89210-0040-4649-99fc-5891101f7689"
      unitRef="cad">15115000</ifrs-full:FinancialAssetsAvailableforsale>
    <ifrs-full:FinancialAssetsAvailableforsale
      contextRef="if3968ebc093542fb94bd695c6069eeb0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzItMy0xLTEtNDQyODk_4a6b574c-cf9b-40f8-bdd2-6d1a3620ab79"
      unitRef="cad">0</ifrs-full:FinancialAssetsAvailableforsale>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="id4078a67cca34e859712c16c4fb4b8ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzMtMS0xLTEtMzUzODM_b534b818-aac2-4e0e-88f9-d0c3e1b660b5"
      unitRef="usd">1093000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="if3968ebc093542fb94bd695c6069eeb0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzQtMy0xLTEtNDQyNzU_d7a74626-1d9e-4286-8697-fba271781975"
      unitRef="usd">1035000</ifrs-full:TradeAndOtherCurrentPayables>
    <oncyf:BalanceHeldInForeignCurrencyNet
      contextRef="id4078a67cca34e859712c16c4fb4b8ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzQtMS0xLTEtMzUzODM_8954bf41-1856-499d-9cdd-75d0a2dc236b"
      unitRef="usd">20657000</oncyf:BalanceHeldInForeignCurrencyNet>
    <oncyf:BalanceHeldInForeignCurrencyNet
      contextRef="if3968ebc093542fb94bd695c6069eeb0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xODcvZnJhZzowZWZlMjU0YzEyYTc0NDlhYjM0YWE5YmNjNDExNmQzNy90YWJsZToyYTU5YjE1ODI3Y2I0ZGUyYTEyNGUzODRhN2VkNmJiNi90YWJsZXJhbmdlOjJhNTliMTU4MjdjYjRkZTJhMTI0ZTM4NGE3ZWQ2YmI2XzUtMy0xLTEtNDQzNDM_7049e8c7-e37d-434c-83ee-24ff0dbe0d06"
      unitRef="usd">-1035000</oncyf:BalanceHeldInForeignCurrencyNet>
    <ifrs-full:DisclosureOfCashFlowStatementExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90ZXh0cmVnaW9uOjMzMjA4YWRiYmM0NzQzN2NhMDJlMzUzZGJmYjg1ZGIwXzEyNQ_e280f70b-c199-4bad-8156-76aaaaf3ed4c">Additional Cash Flow Disclosures&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Change In Non-Cash Working Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Change in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;345&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,662&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash impact of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in non-cash working capital related to operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;391&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Cash Flow Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash interest received&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;452&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
    <oncyf:CashFlowOperatingCapital1TableTextBlock
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90ZXh0cmVnaW9uOjMzMjA4YWRiYmM0NzQzN2NhMDJlMzUzZGJmYjg1ZGIwXzEyNg_495cc6e8-e779-4d7e-bb9b-3f9bb6334aec">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Change In Non-Cash Working Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Change in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;345&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,662&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash impact of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in non-cash working capital related to operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;391&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:CashFlowOperatingCapital1TableTextBlock>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzItMS0xLTEtMzUzODM_6ce66037-ace9-4f44-992c-26f457306bba"
      unitRef="cad">345000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzItMy0xLTEtMzUzODM_7b6eb412-fc5b-47a4-89f8-f51063259101"
      unitRef="cad">-776000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzItNS0xLTEtMzUzODM_714a9922-eaa1-4264-b45a-9f4849e6459f"
      unitRef="cad">1979000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzMtMS0xLTEtMzUzODM_b047ee59-afc7-4620-a2e8-ca9a00c9ce2c"
      unitRef="cad">-1247000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzMtMy0xLTEtMzUzODM_81597387-fdbb-4edd-9ba2-71e760c96f3e"
      unitRef="cad">-349000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzMtNS0xLTEtMzUzODM_871b2e91-15a7-43c9-b725-faf0677d27ab"
      unitRef="cad">286000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzQtMS0xLTEtMzUzODM_1db09ab2-a5da-404a-8d6e-595ea4bf3ed5"
      unitRef="cad">1662000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzQtMy0xLTEtMzUzODM_bbe337b3-0082-4434-8f9d-d2c08a57932c"
      unitRef="cad">183000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzQtNS0xLTEtMzUzODM_2a275a61-e20a-4974-a5e4-29b7bd95ab44"
      unitRef="cad">-1368000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzUtMS0xLTEtMzUzODM_1b56ebd3-3822-4a22-ac16-9ebead01faae"
      unitRef="cad">-352000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzUtMy0xLTEtMzUzODM_ad99e36f-974d-474d-8e11-ac8cabf4066f"
      unitRef="cad">228000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzUtNS0xLTEtMzUzODM_fb0964df-bfc9-4d2f-a4fc-615d938165fb"
      unitRef="cad">-723000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzYtMS0xLTEtMzUzODM_d263dc05-c274-4bc0-a8c6-d4aae6e8ed06"
      unitRef="cad">-17000</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzYtMy0xLTEtMzUzODM_cb6aeb40-ed9a-405a-831a-c014d20001aa"
      unitRef="cad">-194000</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzYtNS0xLTEtMzUzODM_9098f892-5879-4c0e-87d4-eac5d7059379"
      unitRef="cad">36000</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzctMS0xLTEtMzUzODM_545e0401-e17b-417d-bfa3-a2d419c05609"
      unitRef="cad">-391000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzctMy0xLTEtMzUzODM_5c60a739-a442-4730-8526-a714e1ce5b9e"
      unitRef="cad">908000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTphYTA2NmZjOTFkMDk0YzY1OTFkNjRjMTdlOTllNzhmYy90YWJsZXJhbmdlOmFhMDY2ZmM5MWQwOTRjNjU5MWQ2NGMxN2U5OWU3OGZjXzctNS0xLTEtMzUzODM_4e30d3c0-9e5e-46f5-a315-78585a074230"
      unitRef="cad">-210000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90ZXh0cmVnaW9uOjMzMjA4YWRiYmM0NzQzN2NhMDJlMzUzZGJmYjg1ZGIwXzEyMg_2239b96d-e3b6-4684-b960-6bf976c584b9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Cash Flow Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash interest received&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;452&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock>
    <oncyf:ProceedsfromInterestReceived
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTpmNDhkYTMyODM3ODM0NjAwYTFhNzI3MTlmNDBkNmNkYS90YWJsZXJhbmdlOmY0OGRhMzI4Mzc4MzQ2MDBhMWE3MjcxOWY0MGQ2Y2RhXzEtMS0xLTEtMzUzODM_4fee8e8f-3df1-4fcd-8f83-223b594b7336"
      unitRef="cad">452000</oncyf:ProceedsfromInterestReceived>
    <oncyf:ProceedsfromInterestReceived
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTpmNDhkYTMyODM3ODM0NjAwYTFhNzI3MTlmNDBkNmNkYS90YWJsZXJhbmdlOmY0OGRhMzI4Mzc4MzQ2MDBhMWE3MjcxOWY0MGQ2Y2RhXzEtMy0xLTEtMzUzODM_83c72ba2-ac08-4f23-8334-f4db3f868cc3"
      unitRef="cad">190000</oncyf:ProceedsfromInterestReceived>
    <oncyf:ProceedsfromInterestReceived
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTpmNDhkYTMyODM3ODM0NjAwYTFhNzI3MTlmNDBkNmNkYS90YWJsZXJhbmdlOmY0OGRhMzI4Mzc4MzQ2MDBhMWE3MjcxOWY0MGQ2Y2RhXzEtNS0xLTEtMzUzODM_21b7cf92-da98-439a-a8c5-645f403f81f0"
      unitRef="cad">190000</oncyf:ProceedsfromInterestReceived>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTpmNDhkYTMyODM3ODM0NjAwYTFhNzI3MTlmNDBkNmNkYS90YWJsZXJhbmdlOmY0OGRhMzI4Mzc4MzQ2MDBhMWE3MjcxOWY0MGQ2Y2RhXzItMS0xLTEtMzUzODM_a255c668-5a3d-4e50-854a-b441107cf6dd"
      unitRef="cad">46000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTpmNDhkYTMyODM3ODM0NjAwYTFhNzI3MTlmNDBkNmNkYS90YWJsZXJhbmdlOmY0OGRhMzI4Mzc4MzQ2MDBhMWE3MjcxOWY0MGQ2Y2RhXzItMy0xLTEtMzUzODM_e88ca83d-471e-4503-8c7a-9410302530cc"
      unitRef="cad">35000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTAvZnJhZzozMzIwOGFkYmJjNDc0MzdjYTAyZTM1M2RiZmI4NWRiMC90YWJsZTpmNDhkYTMyODM3ODM0NjAwYTFhNzI3MTlmNDBkNmNkYS90YWJsZXJhbmdlOmY0OGRhMzI4Mzc4MzQ2MDBhMWE3MjcxOWY0MGQ2Y2RhXzItNS0xLTEtMzUzODM_a5dab940-bc26-4bd2-95f3-d41d848016f8"
      unitRef="cad">12000</ifrs-full:IncomeTaxesPaidRefund>
    <oncyf:DisclosureOfEconomicDependenceTextBlock
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTYvZnJhZzo3ZjU1M2Y0OTliMzA0OWFlYjQ0MDQ5OTFlMzM3OTJkZi90ZXh0cmVnaW9uOjdmNTUzZjQ5OWIzMDQ5YWViNDQwNDk5MWUzMzc5MmRmXzc5Ng_2dc51586-90d2-49df-898a-14b822216a71">Economic Dependence&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical-grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical-grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by identifying an alternative toll manufacturer, establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.&lt;/span&gt;&lt;/div&gt;</oncyf:DisclosureOfEconomicDependenceTextBlock>
    <oncyf:ConcentrationRiskNumber
      contextRef="ic4d7eaaabecc41fcad176194a92590f5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTYvZnJhZzo3ZjU1M2Y0OTliMzA0OWFlYjQ0MDQ5OTFlMzM3OTJkZi90ZXh0cmVnaW9uOjdmNTUzZjQ5OWIzMDQ5YWViNDQwNDk5MWUzMzc5MmRmXzExMA_cfbfc848-b33a-4bea-b369-a7f11a4fc53a"
      unitRef="manufacturer">1</oncyf:ConcentrationRiskNumber>
    <ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzQ0NA_645fbf9e-3112-46e9-be8f-2751ed2737e2">Components of Expenses&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,970&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing &amp;amp; related process development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,148&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;544&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translational science expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;264&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public company-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,007&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, our research and development personnel-related expenses included employee compensation and benefits of $5,983 (2021 - $4,645; 2020 - $3,775).&lt;/span&gt;&lt;/div&gt;In 2022, our general and administrative office expenses included employee compensation and benefits of $2,870 (2021 - $2,542; 2020 - $2,635).</ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory>
    <oncyf:OtherExpensesAndAdjustmentsTableTextBlock
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzQ0OA_c0c31ec0-6f07-4a8a-8ee8-44bca876a24c">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,970&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing &amp;amp; related process development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,148&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;544&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translational science expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;264&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public company-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,007&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;299&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</oncyf:OtherExpensesAndAdjustmentsTableTextBlock>
    <oncyf:ClinicalTrailExpense
      contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzEtMS0xLTEtMzUzODM_aa9c93eb-f6f5-4d0d-a367-0357bce5917d"
      unitRef="cad">4970000</oncyf:ClinicalTrailExpense>
    <oncyf:ClinicalTrailExpense
      contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzEtMy0xLTEtMzUzODM_af1680e0-ffde-41e6-a6a2-c48d80bd4b82"
      unitRef="cad">3205000</oncyf:ClinicalTrailExpense>
    <oncyf:ClinicalTrailExpense
      contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzEtNS0xLTEtMzUzODM_ae4cea9a-21b3-4977-803a-ed19a6a7ee38"
      unitRef="cad">3055000</oncyf:ClinicalTrailExpense>
    <oncyf:ManufacturingExpense
      contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzItMS0xLTEtMzUzODM_956797c8-2386-49ff-b0b1-a28e3e63f236"
      unitRef="cad">2148000</oncyf:ManufacturingExpense>
    <oncyf:ManufacturingExpense
      contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzItMy0xLTEtMzUzODM_c65ac3b3-846c-4bd2-b7c9-3a5458fe210e"
      unitRef="cad">1547000</oncyf:ManufacturingExpense>
    <oncyf:ManufacturingExpense
      contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzItNS0xLTEtMzUzODM_287bdcf8-90e7-48b5-a14d-480517a89b73"
      unitRef="cad">3384000</oncyf:ManufacturingExpense>
    <oncyf:IntellectualPropertyExpense
      contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzMtMS0xLTEtMzUzODM_cd9982c7-5528-4646-81c3-45be1f8d71b7"
      unitRef="cad">544000</oncyf:IntellectualPropertyExpense>
    <oncyf:IntellectualPropertyExpense
      contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzMtMy0xLTEtMzUzODM_29c43de1-8bb6-4e61-8027-b3c96439f662"
      unitRef="cad">618000</oncyf:IntellectualPropertyExpense>
    <oncyf:IntellectualPropertyExpense
      contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzMtNS0xLTEtMzUzODM_a866f30c-53ff-4b16-aebf-faef087f24ce"
      unitRef="cad">907000</oncyf:IntellectualPropertyExpense>
    <oncyf:TranslationalScienceExpense
      contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzQtMS0xLTEtMzk3MDY_51343bde-e16a-4e8e-bc5f-88471df48376"
      unitRef="cad">264000</oncyf:TranslationalScienceExpense>
    <oncyf:TranslationalScienceExpense
      contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzQtMy0xLTEtMzk3MDY_c69275a1-50d3-424b-86a3-ccca64009fbc"
      unitRef="cad">673000</oncyf:TranslationalScienceExpense>
    <oncyf:TranslationalScienceExpense
      contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzQtNS0xLTEtMzk3MDY_66baa284-b3c5-403d-9e31-3970fbf14741"
      unitRef="cad">318000</oncyf:TranslationalScienceExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzUtMS0xLTEtMzk3MDY_7f1087d2-fb0e-48b5-b14a-bcb781a15def"
      unitRef="cad">6023000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzUtMy0xLTEtMzk3MDY_3ffd3004-e813-425e-a8e2-fce415592712"
      unitRef="cad">4754000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense
      contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzUtNS0xLTEtMzk3MDY_c100b4e2-9e81-4b33-8788-293474376c30"
      unitRef="cad">4135000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzYtMS0xLTEtMzk3MDY_e03c1d9d-757c-4b6a-a1e6-2dcb879c76df"
      unitRef="cad">1371000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzYtMy0xLTEtMzk3MDY_b98be474-61c3-4820-8782-dbc93dc87240"
      unitRef="cad">2087000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzYtNS0xLTEtMzk3MDY_0735dfc6-01ac-4e63-8c4c-06eed2080a9c"
      unitRef="cad">1043000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzctMS0xLTEtMzk3MDY_69f10c65-4857-46be-9d7a-45914d9d005d"
      unitRef="cad">112000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzctMy0xLTEtMzk3MDY_8e6a576b-74f0-4c74-96b5-74a50ba273dd"
      unitRef="cad">36000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzctNS0xLTEtMzk3MDY_8f1db406-9ee8-472e-bb95-e1f39df2fbb1"
      unitRef="cad">103000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzgtMS0xLTEtMzk3MTE_ab4a0006-195a-4bc2-8dfb-41cbebcc84d5"
      unitRef="cad">15432000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzgtMy0xLTEtMzk3MTE_db8cf775-0bee-46c4-a572-c8a7244b857a"
      unitRef="cad">12920000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzgtNS0xLTEtMzk3MTE_143dcb23-e283-4948-99e0-2744bf5a8a7c"
      unitRef="cad">12945000</ifrs-full:ResearchAndDevelopmentExpense>
    <oncyf:PublicCompanyExpense
      contextRef="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzEyLTEtMS0xLTM5NzMz_94477279-9d87-4d91-9463-c8aca4303df0"
      unitRef="cad">6790000</oncyf:PublicCompanyExpense>
    <oncyf:PublicCompanyExpense
      contextRef="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzEyLTMtMS0xLTM5NzMz_97151d19-d551-4247-8d1e-a75ee8dbf9dd"
      unitRef="cad">8161000</oncyf:PublicCompanyExpense>
    <oncyf:PublicCompanyExpense
      contextRef="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzEyLTUtMS0xLTM5NzMz_e25f941a-bb6f-4829-8474-5c74b087e574"
      unitRef="cad">7432000</oncyf:PublicCompanyExpense>
    <oncyf:OfficeExpenses
      contextRef="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzQtMS0xLTEtMzUzODM_0d0ece23-0bff-4501-9700-7dc4f32f170d"
      unitRef="cad">3303000</oncyf:OfficeExpenses>
    <oncyf:OfficeExpenses
      contextRef="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzQtMy0xLTEtMzUzODM_0dad6110-f557-4e51-a79e-2f9946df3165"
      unitRef="cad">2963000</oncyf:OfficeExpenses>
    <oncyf:OfficeExpenses
      contextRef="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzQtNS0xLTEtMzUzODM_2560aef9-95bc-4f6e-a9c6-3cd3c745ca33"
      unitRef="cad">3120000</oncyf:OfficeExpenses>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzUtMS0xLTEtMzUzODM_9542cabb-0feb-490f-92f0-53ae14e93171"
      unitRef="cad">1007000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzUtMy0xLTEtMzUzODM_311b7af5-bab7-4c86-a328-10d6b57d1169"
      unitRef="cad">1739000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzUtNS0xLTEtMzUzODM_cafcc352-42c5-4074-8324-d2e2c48cff18"
      unitRef="cad">1516000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:AmortisationExpense
      contextRef="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzYtMS0xLTEtMzUzODM_53e08834-aa57-4963-bf39-104668db8dd4"
      unitRef="cad">93000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzYtMy0xLTEtMzUzODM_09788c68-353d-4ee0-b71e-3c70cd2d21f5"
      unitRef="cad">130000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzYtNS0xLTEtMzUzODM_a8fe0d5d-9211-427a-894b-d80d6151b08b"
      unitRef="cad">89000</ifrs-full:AmortisationExpense>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzctMS0xLTEtMzUzODM_d64270f1-d46e-431c-8fdc-4907d7362c8a"
      unitRef="cad">299000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzctMy0xLTEtMzUzODM_eea7b43b-9016-4f68-befd-cee998d2a856"
      unitRef="cad">322000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzctNS0xLTEtMzUzODM_d30bab00-91ee-47c5-b88b-83bb60e8a306"
      unitRef="cad">357000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzgtMS0xLTEtMzUzODM_a5c13b2b-c657-4df3-aaa8-226dcbed6bf7"
      unitRef="cad">11492000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzgtMy0xLTEtMzUzODM_5c6e0b22-8f6f-4d46-ac7d-137429d99b57"
      unitRef="cad">13315000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90YWJsZTphOGFhYjYyZThhMmE0Y2E2YmZhODA5NzljOGEyNzJkNC90YWJsZXJhbmdlOmE4YWFiNjJlOGEyYTRjYTZiZmE4MDk3OWM4YTI3MmQ0XzgtNS0xLTEtMzUzODM_13df979b-d049-4690-90b5-2bb0fd077d03"
      unitRef="cad">12514000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i0f8c023761ad45a88529fbbf86f5c15b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzEwOTk1MTE2Mjg4OTU_404b0131-446b-4e53-8944-4d4ac6e5b163"
      unitRef="cad">5983000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i404e979d0ec544eb843282cbfb702af8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzEwOTk1MTE2Mjg5MjQ_af7889db-43af-4d31-b0b0-be8abad011b1"
      unitRef="cad">4645000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="iaeffa43cac82471ea0a6f38ab1110f07_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzEwOTk1MTE2Mjg5MzY_aca3cb22-73ac-47a6-8a91-69cd582f7fa4"
      unitRef="cad">3775000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="ie4e8f7c71e02455d94d05c56fca9514c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzEwOTk1MTE2Mjg5MDA_14b5b0b3-aef1-49ac-bf50-940ff2d0a9b4"
      unitRef="cad">2870000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="ifb0d8a5c0f634cd291f3e060519720f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzEwOTk1MTE2Mjg5NTA_b6a4768c-0935-4544-9a25-62750cf08ea0"
      unitRef="cad">2542000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="ic182829d92bc496cbeb9f1b6826e37bd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18xOTkvZnJhZzpjNWRkZWY2YzM0NjQ0YWJkODFmMjExNTg1Y2U1ZWRjYS90ZXh0cmVnaW9uOmM1ZGRlZjZjMzQ2NDRhYmQ4MWYyMTE1ODVjZTVlZGNhXzEwOTk1MTE2Mjg5NjE_e476e9ca-fa0c-4c3c-8774-3b6d5ea628c7"
      unitRef="cad">2635000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90ZXh0cmVnaW9uOmNhYmRjNmE3MTBlMzQ1ODliM2ZiNTdlY2M0YzE0M2FiXzM4MA_f063d5bf-336b-4d55-bbe1-a64d6ab192c0">Related Party Transactions&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation of Key Management Personnel&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel consists of the Board of Directors, the President and Chief Executive Officer, and the executives who report directly to the President and Chief Executive Officer.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,308&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,615&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,923&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90ZXh0cmVnaW9uOmNhYmRjNmE3MTBlMzQ1ODliM2ZiNTdlY2M0YzE0M2FiXzM4MQ_dede2c7e-5680-430e-8144-e2563c710e16">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,308&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,615&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,923&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzEtMS0xLTEtMzUzODM_654dfe71-18df-450f-9d98-1e5e6eceb47c"
      unitRef="cad">4308000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzEtMy0xLTEtMzUzODM_39e44e0c-5b03-480e-b710-670da40981c2"
      unitRef="cad">3919000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzEtNS0xLTEtMzUzODM_b2eccc70-e416-491f-94b5-88d5eea9f703"
      unitRef="cad">3515000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzItMS0xLTEtMzUzODM_cde8762f-a0c4-4f8a-bdfb-de4ac87398ad"
      unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzItMy0xLTEtMzUzODM_0ddd62d8-0732-4870-8f60-4f47ebf146cd"
      unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzItNS0xLTEtMzUzODM_c4f43749-7670-4a50-8e75-0de92dee2c83"
      unitRef="cad">495000</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzMtMS0xLTEtMzUzODM_1426309c-0e5e-4717-9255-8b7480824315"
      unitRef="cad">1615000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzMtMy0xLTEtMzUzODM_e4080561-b55c-400e-aa27-59da2c0bee68"
      unitRef="cad">2703000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzMtNS0xLTEtMzUzODM_d011b5a3-5a93-479c-ae49-1b1539966957"
      unitRef="cad">1758000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzQtMS0xLTEtMzUzODM_d23d7884-caec-42ca-932e-ab2c66026744"
      unitRef="cad">5923000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzQtMy0xLTEtMzUzODM_1e50328f-dd80-42d3-9b1d-18541d108556"
      unitRef="cad">6622000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="ib221189a8a8e442da5b933592a172090_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDIvZnJhZzpjYWJkYzZhNzEwZTM0NTg5YjNmYjU3ZWNjNGMxNDNhYi90YWJsZTozZTVmOGU0ZGQzZTA0ZjNkOGIzNjA1ZjZhZjU0MWY0MC90YWJsZXJhbmdlOjNlNWY4ZTRkZDNlMDRmM2Q4YjM2MDVmNmFmNTQxZjQwXzQtNS0xLTEtMzUzODM_1027b0d6-d15e-48cb-8a90-f7a1e583cd38"
      unitRef="cad">5768000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDUvZnJhZzozMWVjZGY5OWY2NTI0NWI3OWZiZjgxMTA0ODAzZTE0YS90ZXh0cmVnaW9uOjMxZWNkZjk5ZjY1MjQ1Yjc5ZmJmODExMDQ4MDNlMTRhXzU4Nw_1e58c703-629a-4da1-b899-9cfd9e895f68">Subsequent EventsBetween January 1, 2023 and March 2, 2023, we issued 1,499,044 shares for gross proceeds of US$2,570 through our June 2022 ATM equity distribution agreement.</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <oncyf:IssueOfEquityShares
      contextRef="i66e81fab17754d28b557975b9a91350b_D20230101-20230302"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDUvZnJhZzozMWVjZGY5OWY2NTI0NWI3OWZiZjgxMTA0ODAzZTE0YS90ZXh0cmVnaW9uOjMxZWNkZjk5ZjY1MjQ1Yjc5ZmJmODExMDQ4MDNlMTRhXzE2NDkyNjc0NDMzNjU_1eebbe03-a632-499f-a4af-3084cafe7d02"
      unitRef="shares">1499044</oncyf:IssueOfEquityShares>
    <oncyf:GrossProceedsFromIssueOfOrdinaryShares
      contextRef="i66e81fab17754d28b557975b9a91350b_D20230101-20230302"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYyYzY2Njg3Y2Y4NTQ2YzRiNzY1NWY0NWQ5ZWFjZGY3L3NlYzpmMmM2NjY4N2NmODU0NmM0Yjc2NTVmNDVkOWVhY2RmN18yMDUvZnJhZzozMWVjZGY5OWY2NTI0NWI3OWZiZjgxMTA0ODAzZTE0YS90ZXh0cmVnaW9uOjMxZWNkZjk5ZjY1MjQ1Yjc5ZmJmODExMDQ4MDNlMTRhXzE2NDkyNjc0NDMzNzg_195e534f-e238-46bd-8ea6-ffaf49de5198"
      unitRef="cad">2570000</oncyf:GrossProceedsFromIssueOfOrdinaryShares>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MRX&08U">!O'^?3?E^U#+^R "W_),K#CXG,WIO.E@( =?,4 '!C?(Z3&B\2>
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M*LA32@&G\9:UA]2WY-3#OK[86'"Z6'!"FK1J-03=<DBCY9)#H*5_F1JF;U:
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MOB>'R:VTN,",1;)A/8D;R!BFGX4M*LIBS(L1#4UKCIOVOJRD+E1;,AE8GS1
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MHU\^)GWK#A-OFOA:YL;C[8W#"A\[;(,!]M<&(MU/0H#A\VG^'U!+ P04
M" #:6F-6RPQGK4P8  # 2P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;.5<6W/;1K+^*RCMQ785+=ERDDU\JY*=N-9;]EHG<N(Z=>H\@,"0G!C$,!A
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M<GF!*+'>T>/0% /*+NWA9[HHS18 W%&T(#-0R'86,2D-SB@5\+'J8^_-=&&
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MIP3L8_8D93,B$G&<G@6O:-G$3)YNX6EP;6OJ>9;$,P65W8!F/&V00[@<1MR
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M7)=Y!&9L2./&Z3XT@95VU%+"LJ$>CL8+T/>UUFZ_\08._PH6/P!02P,$%
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M(4K5-X7]_\9H.IG@.1X>C-%P]+T8W;=MLYM73YB^&LT2B=5T>H(Z1@.P#[M
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M$>J3^E^(KA]Y-,TR$H5'I_HJ=//II)@2T,0#01BB0@'CKP,7K*,)8R1.D_/
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MCE5D!^#^0N$QL#^Q$PR?DF[^ E!+ P04    " #:6F-6J&.*/PH'  #_$
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6R]6&UOXS82_BN$NULX@"+K
MW58V"9"D[5Z!;C=(NK<?#O>!EFA+B"2Z)!UO[M?W&5)2[+SLMH>B0&*+U,S#
M>9^A3W=2W>E*",.^M$VGSR:5,9N3V4P7E6BY]N5&='BSDJKE!DNUGNF-$KRT
M3&TSBX(@F[6\[B;GIW;O6IV?RJUIZDY<*Z:W;<O5PZ5HY.YL$DZ&C9MZ71G:
MF)V?;OA:W KS:7.ML)J-*&7=BD[7LF-*K,XF%^')94+TEN#?M=CIO6=&FBRE
MO*/%S^79)""!1",*0P@<7_?B2C0- 4&,WWO,R7@D,>X_#^@_6=VARY)K<26;
MSW5IJK/)8L)*L>+;QMS(W;]$KT]*>(5LM/UD.T>;@KC8:B/;GAD2M'7GOOF7
MW@Y[#(O@%8:H9XBLW.X@*^4/W/#S4R5W3!$UT.C!JFJY(5S=D5-NC<+;&GSF
M_+;B2AQ?0J^27<D6OM:<S'4Z,T GFEG1(UTZI.@5I#!B'V1G*LU^[$I1'@+,
M(-8H6S3(=AE]%?$'4?@L#CT6!5'T%;QXU#6V>/%K>+4N&JFW2C"Y8D[SI=7\
MFC\@T R[4(IW:T'/FOWG8JF-0MC\]R5CN*.2EX^B5#K1&UZ(LPER10MU+R;G
MWW\79L&[KRB2C(HD7T/_2T[[_Y#8K9'%'?NXL8OKAG?LLV 5OQ=L#1,9D&M+
M(2V%9D8BP7[?UK!M(=L63.Z]J93<KBLFM^J @VV Z;./3[=MEM;F@:'>@%FP
M!\&59H)"BB$@1+L4"D'!=EPS_*UD@[JB3VR,T$=('P'[=6L)X>=!PL\V08%R
M<2\4Z@W[\8M01:T%NU9U(?X1CH];HPWORKI;>VPIUG77X9$02$V6>G&<> G$
MC_TT9K$WSQ(O2%.6^,&"15Z49%Z>S%GJPP#O>S^$7A"D^ ]8Y <)EHLX\E*[
MS'-:AG.[C/TP9ZAD*U$3VS2+O#R+CK"_B-DT# ,O"[',?)AP&B:AEX0+^S:!
M%ALX%CQQD$" X(B%@;\(V#1:>'&6@&KN9P")4B^-\#:+_"0?=0<?R.(87'Z2
M CN*O3#-:9DG6,:QEZ0)+1?AH87@]3W;Y!GX%BGI%7[#5/W1?-F(0Q3+XB6+
M"&Q!"+8P2[ULGI.>"!\L$R]-0Z! [=\0?BZ^R$F&T/KF5?]/:%9WKB?:L%VB
MX=EX/4P+^:@.PQ<3CX(Q;O8#VE6Y$W9#!8CD/0P=/43;GH&>A]N-H#Y,KZY0
MBJEV;7G#?JE7@DUM(AW]V:#>L^ W6=X$?IJP8_8&'LQM/$9>DB_@T'F&CSAG
M\SSW<KN3!$26!T0.%Z0@GT?P2D(>051'?IQ8".S'"UK.+6'F&"+"3_L !TY*
M83W?V[-+$,;]"7,Z(<[A: N^F(,"9\WG<'M,9R:Q);/XT=Q/,OB"4B$!-1)F
M3N(/.W:Q'XAIXJ+Q25CU9=-62LWNA38,25?!K'7;BK+F1C0/# 6.=QT<1,^P
M+-L(5<M2,^I!Y,.5DBV3'3F ;6%M"J_+AA=WQ[=%)1O$Q#UOMBX 6UF*AJHP
M#JL1E(A<7BM+(/P!H*H1G7 98J+$L'! 3N#BRP;#$AQ=H@:7E#</M6C*/G+[
M=_>RP9$-U6BJ?&,!KSM,0T:HU@4@X3V*0*3/LL.W&:9J?7>\4D(  >QD+$4"
MU9JYY@SMB/4]V:BS;1I@5[SC)4<-[8H*"7G'EG(4E]@I/9E8K2 S)1H!0%$K
MAW6+U>E YX:RI!=S2%\E;/<F+UK:WE@@%MW:5):<4/=YT% ?06%A97-ROQ(X
MO1_!#LUT6$"&;EMNU6#55SLBC#>Z .^V>O3#6,1V0RKS/I6Y1D5S9SWKH3>O
M> ;9E;YE@9]E]!DG;ZE![!D1.= +^=+32*MI]F ;6T+V@BK/_"!ZR]"0T"W<
M]R+:.^));/Y:-^/_YZ?:'5IVL"D*4)38,I0CYWT,KC]W!9R,ZX&;"MG%CJO2
MC3TW4!LB$JI[]ZFKC7XV#=W<?K)#4">[8]%N&OD LY7HF@4R3A^,0?5XF+,
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MI:7MQIE-KOT]^_;=B<+:P>ZD0LMMYT?.R+8D1@FNQ>=]A-P^]1DX);<\Z(X
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M<VAE970R,BYX;6RM6=MN&SD2_15"8\S$@*R;;TG&-F![$FR S&X03W8>%OM
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M/;@DD.I"/2N7::_$PND,$I2QX!(6KX%[$(USRF0K"(5[<CV;*>?%S-F*=YL
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M-.[]MBD:,:A#S<6]J8I^F_L25N/^8%;6Q&(X8JHR6<> )'4QYA*>$FTBS8'
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MVI$FAF5-/R$TWH#NUUJ[_<8_</BM+7X"4$L#!!0    ( -I:8U8)/B?6: ,
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M+M:V[8RC+Q@^^S+EZN$//U]]>#3#]Y&')V2$!GYZ]_Z1"']9$W7LT9EVVCF
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MA_CR.[$B;7;]*:YS +ZR2!.LP2</]JX',#7L6OKR<IPV)26IN>Y\NBWN,Z%
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MZ4BM1QVA<V.0!E0RG4)*U9GFA0L,"[.I#Q7Q97D?JIQE<*[3HI,)V:#>^'?
MD"^=M/VP'&Z'I^:FG[!'\?Z=>N!Z(Z2!&M>D&E\5>="S/1RL:OV\72E+T]MO
MM_1<HG8"]'^ME#T<G('A 5[\ U!+ P04    " #:6F-63]BXDHT"  "<!0
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M.&B6A1W8J)V#/<^5?;Z=X69"_Q>0_ 902P,$%     @ VEIC5N?S&I^Z @
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MBLV1\/TF?+\U_ VD>%3X/EG'XK9"/#,_@X;@X"V4P. 5) X;B<,7*X'A_Y?
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MNIA6.U968L^B: +HDIR!+GC;P7EEHPM+N,<!()=D+'));"BAUJ39)40]Y)(
MN22O(9<3IFVXWL%W9)2CN[VSNY<ZO!OV].X8(), R"0C@DQB@\P5H>:"EDN*
MSSS3H@0()<$)Y=1Y6^):(C%-=/"(9UEY!C@R.^/$+MYV:!+-'/M1O=5O!D@Q
M&^MPS$&QU#+#6KUR2E%SK)SVWDZR4>53]]*6*EH4N[S>O^OC^.OQQ3#ON]>A
M&+]_(._N]J]W 37[M\U\3,LFW:MHK1X;E?';MBZ7^Q>X[+_4Q;9[!\I#4=?%
MIONX4NE2E:U \_?'HJB_?FDO<'R-SNT?4$L#!!0    ( -I:8U8@%EQ!@ (
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M@28?<KER:Q%@DLJ9]<PS\94(.S[_BH4L# Q /J<&=#,X, P6C&'. $HCD'<
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M*!V.2<LQL7)\X$P(*#F+"(D%))SE:@?GN=J]S7'Y-USTT5EE3Z6KQ<:'="A
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M)K((1$P!Y/R*4K'KJ 7JLM+_ U!+ P04    " #:6F-6A0V,I)P$  !I%
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M[8G<>ZRYUVH>!-W6-SU+*@0MZ^:&)!EA2B"_KR@5SP^J@^YV<?XO4$L#!!0
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MS256?2 - .<S(?2N8Q9HZLCH+U!+ P04    " #:6F-6O\T>K( #  "W"@
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M:&5E=',O<VAE970V,2YX;6Q]5-N.TS 0_17+2 @D:"Z]@$H3J9=%K,2B:E?
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M:W2ILO&ZJJH[DA55%;!D4M4453-5A2AP':#F5XS)UXXN+-K2-OP'4$L#!!0
M   ( -I:8U;C#\!*700  "T9   9    >&PO=V]R:W-H965T<R]S:&5E=#8X
M+GAM;,V9;6_;-A#'O\I!*X8$:"U1?HHSVT 2I5B M0@:I'TQ[ 4CT381B?1(
MRDZ!??B1E"Q;C<+% PODC:T'WD]W_R//.GJZY>)1K@A1\%3D3,Z"E5+K\S"4
MZ8H46/;XFC!]9\%%@94^%<M0K@7!F34J\C".HE%88,J"^=1>NQ7S*2]53AFY
M%2#+HL#B^R7)^786H&!WX0M=KI2Y$,ZG:[PD=T3=KV^%/@L;2D8+PB3E# 19
MS((+=)Z@,V-@1WRE9"L/CL&$\L#YHSFYR69!9#PB.4F506#]M2%7),\-2?OQ
M=PT-FF<:P\/C'?VC#5X'\X EN>+Y-YJIU2PX"R C"USFZ@O?_D[J@(:&E_)<
MVD_8UF.C -)2*E[4QMJ#@K+J&S_50AP8Q/$+!G%M$+_6H%\;]'\T&+Y@,*@-
M!E:9*A2K0X(5GD\%WX(PHS7-'%@QK;4.GS*3]SLE]%VJ[=3\(V68I13G<,.D
M$J5.J9+P 3YC(;!)"9PD1&&:R]-IJ/0#C5F8UO#+"AZ_ $<Q?.),K21<LXQD
M;4"H/6W<C7?N7L9.8D+2'O31>XBC.(:KBP1.WG4Y=O5Z#')@$C?FHESV (T,
M!DW@'80@5U@0Z0BTW^2E;]']ESRD,LVY+ 4!O@"&E3G"+ /RI'2*S$5!Y:,$
MK+\H6\)"\ (633;I03;_-'"@BA3RKZXD5IX,NCTQA>=<KG%*9H&N+)*(#0GF
MO_Z"1M%O7<+[A"6>8*T,#)H,#%ST^3>S K32&1%T8Y="EW858V09IL9NYN-)
M%$73<',HRO-1P]&S48G3G_\9[;")=NB,]LY.7+C7ZU3 +O2D"1TNEH(0,YW@
MG]UMV:6'\RG'SB6?L,03K*7NJ%%W]&96\\AG!GS"$D^P5@;&30;&SOE]_41$
M2B6!M:"I_E$K909K/=5MP3[5D_JEZEV)ZH0?*ZI/6%+!Q@>E)>I-FL+2TNJL
MT>K,J=55*01AZ7<[)[4T][V['F0\S['H%,=).U8<G[#$$ZREXJ11<?)FUOS$
M9P9\PA)/L%8&4+1_N8V<,_FFT' K-66I;HOT^J<,-C@O;5+2>J*_!USPDJG.
M-]SJ"2ANK; (_? +[W;D6-5\T=JR'?0$R"W;3JR3C%1'IT8WIMM0/:,E9%H^
MQ2%=8;:TBNZ$K*3ME+%ZXO! 132.GK\IN3T[6D=/M+:.\5['^*A">ET*WBF.
M$W/L^O5*2WS1VA+NVR#T=OH@Y+41\DI+?-'::=CW0LC=#/DHI(/7%5)/75 M
MV\_HJ="^J4+NKNIG%-+ALT+Z(8X["JG7YLD7K:WCOGU"SMY@_@?9D!SB3CV\
M]CM>:8DO6ENU?<N#QF^G=GKMD+S2$E^T=AKVW11RMU.OVTBJ(?^UD]0QK&LK
MR>W2L2&'!_O+!1%+NT\O(36EOMIJ;JXV_P5<V!WP<#^\^B/A$Q9+/:\@)PMM
M&O7&NK"(:F^^.E%\;7>K'[A2O+"'*X*U=F: OK_@7.U.S .:?TCF_P)02P,$
M%     @ VEIC5@OURL-?!   #A\  !D   !X;"]W;W)K<VAE971S+W-H965T
M-CDN>&ULM9GO;Z,V&,?_%8N=ICOI&C $FG1)I#: 5FF3JNOU]F+:"Y<X#2K@
MG&V2ZW\_FU 2$N*%[=F;!(.?SV.>KW\^3+:,OXH5I1+]R+-"3*V5E.L;VQ;)
MBN9$#-B:%NK)DO&<2%7D+[98<TH6E5&>V:[C!'9.TL*:3:I[#WPV8:7,TH(^
M<"3*/"?\[8YF;#NUL/5^XTOZLI+ZACV;K,D+?:3R:?W 5<EN*(LTIX5(68$X
M74ZM6WP3XT ;5#6^I70K#JZ1?I5GQEYUX7XQM1S=(IK11&H$47\;.J=9IDFJ
M'=]KJ-7XU(:'U^_TN'IY]3+/1- YR_Y(%W(UM4866M E*3/YA6U_I?4+^9J7
ML$Q4OVA;UW4LE)1"LKPV5BW(TV+W3W[4@3@P<-TS!FYMX%YJX-4&WJ4&P]I@
M>*F!7QOXEQH$M4$EIKT+5A7ID$@RFW"V15S75C1]4<E56:L IX7N68^2JZ>I
MLI.S."U(D:0D0_>%D+Q4G48*=(4>51=>E!E%;(GN2*;J4('2 BDYE5@%FI><
M4V6H[GX,J21I)CZA#[K&UQ4K!2D6XO-1>6)+U6#MUD[JQMWM&N>>:5Q(DP'R
M\&?D.JZ+YK<A^OCA4P=FW@?S]'@.$UZ.P8;61)=C' ,FOAB#Q]T86_6%ID.X
M38=P*ZYWAEL+^X;1G[^I1^A>TES\U:7=CC/LYN@9\4:L24*GEIKR!.4;:LU^
M_@D'SB]="D+"0DA8! F+@6 M9;U&6<]$G\V)6"$U$%&B+^CW,MV03 _W+G%W
MJ*!"Z=5I,\,X"(*)O3E4S>BPKVJG+H?8#=RVR^BTEH==UVG7BCN:/\3#45.K
M%<!A$\"A,8"W2<)*/3VNR1MY5G.C#B9)$E[2!<I2\IQFJ50S8E<\=V3_H$%7
M7N ?-7MN]-\WGL.3&%SA\6AT%$](ES$0K*6.WZCC&]5Y&CP.T()E&>&="ABM
M^TY7D+ 0$A9!PF(@6$O/H-$S %J( DAE(6$A)"R"A,5 L):RUXVRUW +D1'5
M5]SKDRDQ"#R_/2.&D!XC2%@,!&N)-FI$&QE%^YWP5[7/U\N>H$G)SZYTHY.5
M#OL8'P5Y;G36=YA!PB)(6 P$:RDV;A0;_V_;%2.Y[Z@;G^Y]L#/VCH8=I,L(
M$A8#P5HB8F=_0'>,,AZ>OI?UZ3MI3M^=AVHCL*]Z->U0/M<)_.LC^4"=1J"T
M&(K65O @Q8*-"D8E9YTZ&<UZZP1)"T%I$2@MAJ*UY=PG2#!4A@2#IDA :2$H
M+0*EQ5"TML#[/ D&3)286;TU]DXF6^=XHH5T&('28BA:6[A]?@:;$S07[U'Q
M:6[D.!5C=M5[M$'2(E!:#$5KB[9/VV!SWN:_;%/-Z-Z#S^_:J)Z<#T&=1J"T
M&(K6UG*?LL'&O,&_V:N")F]J6O!/"H+F94!I,11MIZ!]\&50?RE6,^1+6@B4
MT:7".X-KU5_X[N/KKB#9NOI8^,RD9'EUN:)D0;FNH)XO&9/O!?W]L?D$/OL;
M4$L#!!0    ( -I:8U;%^124@P,  /0*   9    >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;*U6VX[;-A#]%4(-B@2H5U=+UM8VX+4;) ])%TG;/!1]H*6Q
M140B59*V-W_?(26K7DEV%T5>;)$ZYVC.#"\S/PGY514 FCQ5)5<+I]"ZOG==
ME150474G:N#X9B=D134.Y=Y5M02:6U)5NH'GQ6Y%&7>6<SOW*)=S<= EX_ H
MB3I4%97?'J 4IX7C.^>)3VQ?:#/A+N<UW<-GT+_7CQ)';J>2LPJX8H(3";N%
ML_+O-ZG!6\ ?#$[JXID8)ULAOIK!^WSA>"8@*"'31H'BWQ'64)9&",/XN]5T
MND\:XN7S6?VM]8Y>ME3!6I1?6*Z+A3-S2 X[>BCU)W%Z!ZV?J='+1*GL+SFU
M6,\AV4%I4;5DC*!BO/FG3VT>+@A^?(40M(2@3XBN$,*6$+Z4$+6$R&:FL6+S
ML*&:+N=2G(@T:%0S#S:9EHWV&3=E_ZPEOF7(T\M5GC-3 %J2-54%>8OK@&R8
MRDJA#A(4F9"/N/C6!>5[(.\Y^2CXQ"*_8#T9WR.M9AKIKS>@*2O5&Z2L5QOR
M^M4;\HHP3GXKQ$%1GJNYJS%B\UTW:Z-[:*(+KD3G!^2#X+I0Y!>>0_Y<P$6K
MG=_@[/<AN*FX@>R.A/Y/)/""8"2@]<OI_@A]\W*Z=\--V%4OM'KA_ZW>GZNM
MTA(WUU]CR6_$HW%Q<^#<JYIFL'#P1%$@C^ L?_S!C[V?QQ+W/<4VWTGL65*C
M+JG1+?7EK[H B4=:!NQ(MR6,KMM&(K82YF@]+L-H.G>/EQD98B9)$C\';88@
M/TW2#O3,P;1S,+WIX%%"35E.X EO!X7+ '<?'H:U4$R/NFGDII>1^D&4]/R,
MH,(H[?D9@H)9/&XG[NS$-^VLLDP<N%:DIM],0:P=FF7R #DI&=VR$G?!>)WB
M03A^' <]8R.@6=CS-<1,_#">C3M+.F?)"Y;:?UA(1M(^[5L8@H)@UK,P(I0$
MX;B#6>=@=M.!N0XR<_2P"C>D)F)'L!?!VY;CZLOLK3'F:3:2S?YR&\.D4<_3
M$!1>66UIYRB]Z:B]ZO#BXF=OI_:JR]JK3D))-:X]+0CV7Y)J\])V,%>+F [/
MB]3O&1YB)JG7+^(0%/A>S[%[T0]4(/>VKU+$[J+FJNQFN]9M93N6WOP#MG1-
M!_:O3-,/?J!RS[@B)>Q0TKM+L 2RZ;&:@1:U[3JV0F,/8Q\+;$M!&@"^WPFA
MSP/S@:[17?X#4$L#!!0    ( -I:8U;SA,?OE0(  '@'   9    >&PO=V]R
M:W-H965T<R]S:&5E=#<Q+GAM;*U56V_3,!3^*U:8T";!<FV!T49J&R9XF)@V
M+@^(!S<Y;:PE=K"==OQ[CITT])*6">TE\>5\G[_O.#EGM!;R0>4 FCR6!5=C
M)]>ZNG)=E>904G4I*N"XLQ"RI!JG<NFJ2@+-+*@LW,#SAFY)&7?BD5V[E?%(
MU+I@'&XE47594OE["H58CQW?V2S<L66NS8(;CRJZA'O07ZM;B3.W8\E8"5PQ
MP8F$Q=B9^%?)P,3;@&\,UFIK3(R3N1 /9O(I&SN>$00%I-HP4'RM8 9%88A0
MQJ^6T^F.-,#M\8;]VGI'+W.J8":*[RS3^=AYZY ,%K0N])U8?X36CQ68BD+9
M)UFWL9Y#TEII4;9@5% RWKSI8YN'+8 _/ ((6D"P#XB. ,(6$#X5$+6 R&:F
ML6+SD%!-XY$4:R)--+*9@4VF1:-]QLVUWVN)NPQQ.IYD&3,70 LRHRHGU_@=
MD(2IM!"JEJ#(:_)9YR"/[)XGH"DKU 7&S28).3^[(&>$<?(E%[6B/%,C5Z-,
M<YB;MI*FC:3@B"0_(#>"ZUR1#SR#;)? 17^=R6!C<AJ<9$P@O22A_XH$7A#T
M")H]'>[WP).GP[T3;L+NRD++%_[OE?V8S)66^$?][$M^0Q[UDYLJ<Z4JFL+8
MP3*B0*[ B5^^\(?>^[[$/2=9\DQD.TF-NJ1&I]ACFTG&-2"UQGJ6 I:CK"]_
M#<_0\IBBNHJC 7Y4J^VT',;X[[S=F.1TS(Z)06=B\&\3FC[B-U!1UJM^<*A^
MN"?^,"0<[&D_#/&#/>GN5DTJ02YM;5<D%377S9_;K7;M8V*KYM[Z%-M*TP7^
MTC0]Z8;*)>.*%+! 2N_R#<J239UO)EI4MO+-A<8Z:H<YMD:0)@#W%T+HS<0<
MT#7;^ ]02P,$%     @ VEIC5KS@_%8X @  1 4  !D   !X;"]W;W)K<VAE
M971S+W-H965T-S(N>&ULM91M;]HP$,>_BI5)TR95F 1H)Q8B%>BT2JN$:+>]
MF/;") >Q\$-F.]!^^YV=D%&IY-W>)'ZX^]W_;-^E1VWVM@1PY%D*96=1Z5PU
MI=3F)4AF![H"A3M;;21S.#4[:BL#K A.4M!D.+RFDG$596E86YDLU;437,'*
M$%M+R<S+'(0^SJ(X.BVL^:YT?H%F:<5V\ CN>[4R.*,=I> 2E.5:$0/;670;
M3^<3;Q\,?G XVK,Q\9ELM-[[R7TQBX9>$ C(G2<P_!U@ 4)X$,KXTS*C+J1W
M/!^?Z%]"[IC+AEE8:/&3%ZZ<19\B4L"6U<*M]?$KM/D$@;D6-GS)L;$=H7%>
M6Z=EZXP*)%?-GSVWYW#FD-Q<<$A:AR3H;@(%E4OF6)8:?23&6R/-#T*JP1O%
M<>4OY=$9W.7HY[*[7"LM>4Z6@/=<@,J!?%B"8US8CREU&,(;TKS%S1M<<@$7
M)^1!*U=:<H>PXC6 HK9.8'(2.$]ZB4O(!V047Y%DF"28N:JW>).U =,#'W79
MCP)\? '^I(7H83;Z>A&^:*:V8CG,(JP*"^8 4?;^77P]_-PC<-P)' ?ZZ(+
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M(+_F2VG.FT_PT&)]"4X/7-"B"Y8M*+*R_<8_NT0<!<!@(@!U 4@-\"8"W"[
M?6Z UP5X369:*4T>$BSP>L7H V U6K+5/YID-M%2?E;6[_U&,/EO)N/$>D.+
MBI:D%!S0'?CX4]83)QR\28C 6<[?@C.P^9" -Z_>@E<@*\&W/3UP7&[Y:BGD
MXVN29=H]ZK)]%)IX%$3@"RW%GH./Y99LQP1+V>Z^\>BI\9?(RIB0]!UPX>\
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M?0_NO8_"S7LJW/[G<OP;4$L#!!0    ( -I:8U:7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ VEIC5BRN, ?#!0
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MS_'3L^QM.[SDL^F?M>L_4$L! A0#%     @ VEIC5@=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #:
M6F-6D#Y+E^X    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #:6F-6F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -I:8U8G+ /N
M2 8  .L=   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #:6F-6I1KQN3H"  "[!0  &
M@(&+#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ VEIC
M5DQ."7BS!0  QQ<  !@              ("!^Q   'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( -I:8U:7Z+JS.@4  !,4   8
M      " @>06  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" #:6F-6N2/)8?L'  !:0@  &               @(%4'   >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ VEIC5MS>!D/2!@  JQ\  !@
M             ("!A20  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( -I:8U9!B"]6=08  &D-   8              " @8TK  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #:6F-6-<_$*@@$  !*
M"0  &               @($X,@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ VEIC5LL,9ZU,&   P$L  !@              ("!=C8
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( -I:8U;/B@]!
MU@H  "D>   9              " @?A.  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ VEIC5ME?7N;< P  00P  !D
M ("!!5H  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #:
M6F-6AZTCNV8#   A"   &0              @($87@  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -I:8U;_'&7Y7P(  (\%   9
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M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ VEIC5KC
MLHWB @  4P8  !D              ("!M7@  'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6Q02P$"% ,4    " #:6F-6_F48TY0#  #>!P  &0
M    @('.>P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M -I:8U;BPIHJFP0  $0*   9              " @9E_  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ VEIC5@T+2X+/!0  ;PT  !D
M             ("!:X0  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " #:6F-6S*6<0DT(   T$P  &0              @(%QB@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -I:8U;.^N 3& D
M &D9   9              " @?62  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ VEIC5M+K;U$, P  X@8  !D              ("!
M1)P  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #:6F-6
M"3XGUF@#  #9!P  &0              @(&'GP  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( -I:8U;2ZW(OK0,  !,(   9
M      " @2:C  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ VEIC5@;='ZPV P  ,P<  !D              ("!"J<  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #:6F-6T?:LNW4"  !5!0
M&0              @(%WJ@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( -I:8U8OB:!S%!@  !9-   9              " @2.M  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ VEIC5JO1^F'2
M P   0D  !D              ("!;L4  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " #:6F-6FK\0!MP#   -"0  &0
M@(%WR0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( -I:
M8U:Y>GWW<0(  'X%   9              " @8K-  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ VEIC5LPX2@!O P  30D  !D
M         ("!,M   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " #:6F-6=J\3UET(   I&@  &0              @('8TP  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( -I:8U;"O\M\5@8  &X3
M   9              " @6S<  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ VEIC5DLH4+N: @  U 4  !D              ("!^>(
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #:6F-6Y-@,
M-OX%  !'#@  &0              @('*Y0  >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( -I:8U;]=BTX?P(  &<%   9
M  " @?_K  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
MVEIC5NP^MB6Z @  W@4  !D              ("!M>X  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " #:6F-6+N[I_S@#  !U!P  &0
M            @(&F\0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( -I:8U;#6'IX@@,  (P'   9              " @17U  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ VEIC5D_8N)*- @
MG 4  !D              ("!SO@  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " #:6F-6GN"V"WP"   .!@  &0              @(&2
M^P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( -I:8U;G
M\QJ?N@(  (('   9              " @47^  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ VEIC5IIKAL_9 @  O0D  !D
M     ("!-@$! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -I:8U;ZR6Y[O00  "L=   9              "
M@206 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ VEIC
M5IDV?"S. @  ? H  !D              ("!&!L! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " #:6F-6S9=@:?(&  !+.   &0
M        @($='@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( -I:8U:](5.4%Q   %SX   9              " @48E 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ VEIC5J#!K\F? P  J0T
M !D              ("!E#4! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " #:6F-6U.Q"5S0#  !B#@  &0              @(%J.0$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( -I:8U:%#8RD
MG 0  &D4   9              " @=4\ 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ VEIC5EM&ZK)B"@  8W8  !D
M ("!J$$! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #:
M6F-6/S(LO?X#  ##%@  &0              @(%!3 $ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( -I:8U;TW@@57 ,  %,*   9
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M970V,BYX;6Q02P$"% ,4    " #:6F-6^,- =$$"   Z!0  &0
M    @('77P$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M -I:8U:RS)Z--@0  ,4.   9              " @4]B 0!X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ VEIC5E=89G&Y P  &A(  !D
M             ("!O&8! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    " #:6F-6J,RZK7T$   I'   &0              @(&L:@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( -I:8U9(?Q,^[P(
M .8*   9              " @6!O 0!X;"]W;W)K<VAE971S+W-H965T-C<N
M>&UL4$L! A0#%     @ VEIC5N,/P$I=!   +1D  !D              ("!
MAG(! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " #:6F-6
M"_7*PU\$   .'P  &0              @($:=P$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Y+GAM;%!+ 0(4 Q0    ( -I:8U;%^124@P,  /0*   9
M      " @;![ 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%
M  @ VEIC5O.$Q^^5 @  > <  !D              ("!:G\! 'AL+W=O<FMS
M:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " #:6F-6O.#\5C@"  !$!0
M&0              @($V@@$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+
M 0(4 Q0    ( -I:8U:]K9=AH 4  !L>   9              " @:6$ 0!X
M;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ VEIC5F?Q)*4/
M P  &0D  !D              ("!?(H! 'AL+W=O<FMS:&5E=',O<VAE970W
M-"YX;6Q02P$"% ,4    " #:6F-6,Z*#3AP#  #T"@  &0
M@('"C0$ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( -I:
M8U;!^"P[2 ,  ,84   -              "  161 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ VEIC5I>*NQS     $P(   L              ( !B)0!
M %]R96QS+RYR96QS4$L! A0#%     @ VEIC5BRN, ?#!0  5C$   \
M         ( !<94! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( -I:8U9G
M_%)"3 (  &@L   :              "  6&; 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( -I:8U:&IF-(# (  &$K   3
M      "  >6= 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !3 %, O!8
' "*@ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>245</ContextCount>
  <ElementCount>280</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/NatureofOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Significant Judgments, Estimates and Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions</Role>
      <ShortName>Significant Judgments, Estimates and Assumptions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Other Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities</Role>
      <ShortName>Other Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Contract Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiability</Role>
      <ShortName>Contract Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Capital Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</Role>
      <ShortName>Capital Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Additional Cash Flow Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</Role>
      <ShortName>Additional Cash Flow Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Economic Dependence</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependence</Role>
      <ShortName>Economic Dependence</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Components of Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ComponentsofExpenses</Role>
      <ShortName>Components of Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyandEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareCapital</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Contract Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityTables</Role>
      <ShortName>Contract Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ContractLiability</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Capital Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</Role>
      <ShortName>Capital Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/FinancialInstruments</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Additional Cash Flow Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables</Role>
      <ShortName>Additional Cash Flow Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Components of Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables</Role>
      <ShortName>Components of Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ComponentsofExpenses</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails</Role>
      <ShortName>Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/NatureofOperations</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Other Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails</Role>
      <ShortName>Other Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Right-of-use Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails</Role>
      <ShortName>Leases - Total Undiscounted Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Share Capital - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Share Capital - Equity Warrants Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails</Role>
      <ShortName>Share Capital - Equity Warrants Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails</Role>
      <ShortName>Share Capital - Summary of Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Share-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails</Role>
      <ShortName>Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/LossPerCommonShare</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Contract Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails</Role>
      <ShortName>Contract Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Contract Liability - Schedule of Contract Revenues and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails</Role>
      <ShortName>Contract Liability - Schedule of Contract Revenues and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Capital Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails</Role>
      <ShortName>Capital Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails</Role>
      <ShortName>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Economic Dependence (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails</Role>
      <ShortName>Economic Dependence (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/EconomicDependence</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Components of Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails</Role>
      <ShortName>Components of Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="oncyf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SubsequentEvents</ParentRole>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityEmergingGrowthCompany, dei:EntityIncorporationStateCountryCode, oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1, oncyf:StockholdersEquityNoteStockSplitConversionRatio -  oncyf-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" original="oncyf-20221231.htm">oncyf-20221231.htm</File>
    <File>ex121ceocertification2022.htm</File>
    <File>ex122cfocertification2022.htm</File>
    <File>ex131ceocertification2022.htm</File>
    <File>ex132cfocertification2022.htm</File>
    <File>ex151-2022mda.htm</File>
    <File>ex152ey2022consent.htm</File>
    <File>ex21exdescriptionofsecurit.htm</File>
    <File>ex419mattcoffeyamendment4-.htm</File>
    <File>ex420kirklookamendment4-em.htm</File>
    <File>ex421allisonhagermanamendm.htm</File>
    <File>ex422andrewdeguttadauroame.htm</File>
    <File>ex423thomasheinemanamendme.htm</File>
    <File>ex80subsidiaries2022.htm</File>
    <File>oncyf-20221231.xsd</File>
    <File>oncyf-20221231_cal.xml</File>
    <File>oncyf-20221231_def.xml</File>
    <File>oncyf-20221231_lab.xml</File>
    <File>oncyf-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>oncyf-20221231_g1.jpg</File>
    <File>oncyf-20221231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
    <BaseTaxonomy items="664">https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "oncyf-20221231.htm": {
   "axisCustom": 3,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 46,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 664
   },
   "contextCount": 245,
   "dts": {
    "calculationLink": {
     "local": [
      "oncyf-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "oncyf-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "oncyf-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "oncyf-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "oncyf-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "oncyf-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 458,
   "entityCount": 1,
   "hidden": {
    "http://www.oncolyticsbiotech.com/20221231": 2,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 8
   },
   "keyCustom": 67,
   "keyStandard": 213,
   "memberCustom": 29,
   "memberStandard": 28,
   "nsprefix": "oncyf",
   "nsuri": "http://www.oncolyticsbiotech.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.oncolyticsbiotech.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Significant Judgments, Estimates and Assumptions",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions",
     "shortName": "Significant Judgments, Estimates and Assumptions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Other Assets and Liabilities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities",
     "shortName": "Other Assets and Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Accounts Payable and Accrued Liabilities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.oncolyticsbiotech.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Share Capital",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapital",
     "shortName": "Share Capital",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Loss Per Common Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.oncolyticsbiotech.com/role/LossPerCommonShare",
     "shortName": "Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Contract Liability",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiability",
     "shortName": "Contract Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.oncolyticsbiotech.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Capital Disclosures",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosures",
     "shortName": "Capital Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Financial Instruments",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Additional Cash Flow Disclosures",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures",
     "shortName": "Additional Cash Flow Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfEconomicDependenceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Economic Dependence",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.oncolyticsbiotech.com/role/EconomicDependence",
     "shortName": "Economic Dependence",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfEconomicDependenceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Components of Expenses",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.oncolyticsbiotech.com/role/ComponentsofExpenses",
     "shortName": "Components of Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.oncolyticsbiotech.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "28",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
     "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:CurrentFinancialAssetsAvailableforsale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.oncolyticsbiotech.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Share Capital (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalTables",
     "shortName": "Share Capital (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Contract Liability (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityTables",
     "shortName": "Contract Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Capital Disclosures (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables",
     "shortName": "Capital Disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:CashFlowOperatingCapital1TableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Additional Cash Flow Disclosures (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables",
     "shortName": "Additional Cash Flow Disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:CashFlowOperatingCapital1TableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:OperatingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Components of Expenses (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables",
     "shortName": "Components of Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Related Party Transactions (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:RetainedEarnings",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Nature of Operations (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails",
     "shortName": "Nature of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "oncyf:CashAndCashEquivalentsAndCurrentInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i9f01ea7a336d44d2ab368965b5d555a1_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:PropertyPlantandEquipmentAnnualDepreciationRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Depreciation Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i9f01ea7a336d44d2ab368965b5d555a1_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:PropertyPlantandEquipmentAnnualDepreciationRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:OtherCurrentLiabilities",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Other Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails",
     "shortName": "Other Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:CurrentPrepaidExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "if3483d81850d4bb2b4f6474d2ebd0395_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i204d523ce7ab4b52896ed6d2295ef847_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Accounts Payable and Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails",
     "shortName": "Accounts Payable and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "if3483d81850d4bb2b4f6474d2ebd0395_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "if3483d81850d4bb2b4f6474d2ebd0395_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "if3483d81850d4bb2b4f6474d2ebd0395_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails",
     "shortName": "Leases - Right-of-use Assets and Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:AdditionsToRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie5e2093c82014efc936a23f9e66baceb_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i34072d06dbc74709a44772e87c0d0628_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails",
     "shortName": "Leases - Total Undiscounted Lease Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "if3483d81850d4bb2b4f6474d2ebd0395_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Share Capital - Schedule of Share Capital (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
     "shortName": "Share Capital - Schedule of Share Capital (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "if692efdc55844ddd94d16e3f6ae99d73_I20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ShareIssueRelatedCost",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
     "shortName": "Share Capital - Schedule of Share Capital Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "icfbfdffadff046e9a764a7fad96e4145_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "oncyf:ProceedsfromWarrantExercises1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i8c38fae9a1ca4c469aff3c034e794b8d_D20170601-20170601",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:IssueOfEquityShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Share Capital - Equity Warrants Narrative (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
     "shortName": "Share Capital - Equity Warrants Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i8c38fae9a1ca4c469aff3c034e794b8d_D20170601-20170601",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:IssueOfEquityShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:WarrantsAndRightsOutstanding1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Share Capital - Summary of Outstanding Warrants (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails",
     "shortName": "Share Capital - Summary of Outstanding Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:WarrantsAndRightsOutstanding1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "if3483d81850d4bb2b4f6474d2ebd0395_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails",
     "shortName": "Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
     "shortName": "Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Share-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i771812f5ba4a4f9ba29a5246edf0bf00_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails",
     "shortName": "Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i2320674fb5744c63bbf6953873d4a940_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails",
     "shortName": "Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i03a33fe7f4e34bb28f5d1cbf45984686_I20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:AdjustedWeightedAverageShares",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Loss Per Common Share (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails",
     "shortName": "Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ContractLiabilityRecognitionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Contract Liability - Narrative (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails",
     "shortName": "Contract Liability - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ContractLiabilityRecognitionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "if3483d81850d4bb2b4f6474d2ebd0395_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ContractLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Contract Liability - Schedule of Contract Revenues and Liabilities (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails",
     "shortName": "Contract Liability - Schedule of Contract Revenues and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i96a23ba3cfe248f9a219b793f13a9c4e_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:ContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:PurchaseObligation1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:PurchaseObligation1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AccountingProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AccountingProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ia520d0c500544f84866a7d2a4c1dacd9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ia520d0c500544f84866a7d2a4c1dacd9_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Capital Disclosures (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
     "shortName": "Capital Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i878d9a8a28ac42caa7c1e38319e6da4c_I20220612",
      "decimals": "INF",
      "lang": "en-US",
      "name": "oncyf:EquityAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentDerivativeFinancialLiabilities",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Financial Instruments - Narrative (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i9c8fd43724f84c33ae13eca3658b27f6_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i87a99f2dd79f447287ac4cc2bdc8c046_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails",
     "shortName": "Financial Instruments - Schedule of Balances in Foreign Currencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "id4078a67cca34e859712c16c4fb4b8ef_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Nature of Operations",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.oncolyticsbiotech.com/role/NatureofOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:CashFlowOperatingCapital1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails",
     "shortName": "Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:CashFlowOperatingCapital1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ProceedsfromInterestReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails",
     "shortName": "Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ProceedsfromInterestReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ic4d7eaaabecc41fcad176194a92590f5_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ConcentrationRiskNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "manufacturer",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Economic Dependence (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails",
     "shortName": "Economic Dependence (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ic4d7eaaabecc41fcad176194a92590f5_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:ConcentrationRiskNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "manufacturer",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Components of Expenses (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails",
     "shortName": "Components of Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie547a88df85d45db8ff101f4bb78ba98_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "oncyf:IssueOfEquityShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "i66e81fab17754d28b557975b9a91350b_D20230101-20230302",
      "decimals": "INF",
      "lang": "en-US",
      "name": "oncyf:IssueOfEquityShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.oncolyticsbiotech.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "oncyf-20221231.htm",
      "contextRef": "ie4f1f2e398c94f8689fba7203bad81c3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 60,
   "tag": {
    "country_BB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BARBADOS",
        "terseLabel": "BARBADOS"
       }
      }
     },
     "localname": "BB",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "CANADA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "U.S. dollars"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r191",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r191",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r191",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address",
        "terseLabel": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r191",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]",
        "terseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r191",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_AccountingProfit": {
     "auth_ref": [
      "r30",
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accounting profit",
        "terseLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "AccountingProfit",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accruals classified as current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccrualsClassifiedAsCurrent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "auth_ref": [
      "r42",
      "r205",
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated depreciation and amortisation [member]",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income [member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AdditionalPaidinCapital": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      },
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "terseLabel": "Contributed surplus (note 10)"
       }
      }
     },
     "localname": "AdditionalPaidinCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions, net of foreign exchange impact"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share",
        "terseLabel": "Weighted average number of shares (diluted) (shares)"
       }
      }
     },
     "localname": "AdjustedWeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other operating receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in prepaid expenses",
        "terseLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense",
        "terseLabel": "Depreciation - property and equipment (notes 6, 19)"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in other operating payables",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share-based compensation expense (notes 10, 19, 20)"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "auth_ref": [
      "r168",
      "r213"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for unrealised foreign exchange losses (gains)",
        "terseLabel": "Unrealized foreign exchange (gain) loss"
       }
      }
     },
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r13",
      "r92",
      "r103",
      "r104",
      "r125",
      "r140",
      "r141",
      "r142",
      "r148",
      "r161",
      "r176",
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]",
        "terseLabel": "Aggregated time bands"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "auth_ref": [
      "r44",
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]",
        "terseLabel": "All levels of fair value hierarchy"
       }
      }
     },
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmortisationExpense": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation expense",
        "terseLabel": "Depreciation - property and equipment"
       }
      }
     },
     "localname": "AmortisationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of income and expense [abstract]",
        "terseLabel": "Analysis of income and expense [abstract]"
       }
      }
     },
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Statutory Canadian corporate tax rate"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r11",
      "r84",
      "r85",
      "r86",
      "r135",
      "r137"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r53",
      "r54"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic loss per common share (cad per share)"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r88",
      "r117",
      "r142",
      "r170",
      "r171",
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "auth_ref": [
      "r35",
      "r39",
      "r58",
      "r59",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r122",
      "r128",
      "r129",
      "r220",
      "r221"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountMember": {
     "auth_ref": [
      "r39",
      "r59",
      "r61",
      "r63",
      "r64",
      "r122",
      "r128",
      "r129",
      "r185",
      "r186"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount [member]",
        "terseLabel": "Carrying amount"
       }
      }
     },
     "localname": "CarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r9",
      "r71",
      "r82"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashEquivalents": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r66",
      "r72"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r66",
      "r72"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "auth_ref": [
      "r166",
      "r168"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operations",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashOutflowForLeases": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash outflow for leases",
        "negatedLabel": "Payment of lease liabilities (note 8)",
        "negatedTerseLabel": "Payment of lease liabilities"
       }
      }
     },
     "localname": "CashOutflowForLeases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]",
        "terseLabel": "Classes of liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]",
        "terseLabel": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]",
        "terseLabel": "Classes of other provisions [axis]"
       }
      }
     },
     "localname": "ClassesOfProvisionsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]",
        "terseLabel": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]",
        "terseLabel": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r1",
      "r23",
      "r76",
      "r78",
      "r81",
      "r169"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Net loss and other comprehensive income (loss)",
        "totalLabel": "Net comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComputerEquipmentMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer equipment [member]",
        "terseLabel": "Computer equipment",
        "verboseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContractLiabilities": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      },
      "en-us": {
       "role": {
        "label": "Contract liabilities",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year"
       }
      }
     },
     "localname": "ContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r132",
      "r143",
      "r144",
      "r145",
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency risk [member]",
        "terseLabel": "Currency risk"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r14",
      "r79",
      "r169"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current derivative financial liabilities",
        "terseLabel": "Warrant derivative (notes 9(b), 16)",
        "verboseLabel": "Warrant derivative"
       }
      }
     },
     "localname": "CurrentDerivativeFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentFinancialAssetsAvailableforsale": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets available-for-sale. [Refer: Financial assets available-for-sale; Current financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current financial assets available-for-sale",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "CurrentFinancialAssetsAvailableforsale",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentInvestments": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current investments."
       }
      },
      "en-us": {
       "role": {
        "label": "Current investments",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "CurrentInvestments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities (note 8)"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r15",
      "r80",
      "r169"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepaid expenses",
        "verboseLabel": "Current prepaid expenses"
       }
      }
     },
     "localname": "CurrentPrepaidExpenses",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentPrepayments": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepayments",
        "terseLabel": "Prepaid expenses (note 5)"
       }
      }
     },
     "localname": "CurrentPrepayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "totalLabel": "Current income taxes"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease through performance obligation being satisfied, contract liabilities",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deductible temporary differences for which no deferred tax asset is recognised",
        "terseLabel": "Unrecognized deferred tax asset"
       }
      }
     },
     "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r41"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "negatedLabel": "Depreciation expense",
        "verboseLabel": "Depreciation - right-of-use assets"
       }
      }
     },
     "localname": "DepreciationRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]\nEffective 2023-01-01: The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for deferred income tax [text block]",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for the derecognition of financial instruments. [Refer: Financial instruments, class [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for the derecognition of financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for derecognition of financial instruments [text block]",
        "terseLabel": "Derecognition"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for earnings per share.\nEffective 2023-01-01: The description of the entity's material accounting policy information for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for earnings per share [text block]",
        "terseLabel": "Loss per common share"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for fair value measurement [text block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets [text block]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial liabilities [text block]",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for the impairment of financial assets. [Refer: Financial assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for the impairment of financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for impairment of financial assets [text block]",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.\nEffective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]\nEffective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]\nEffective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]\nEffective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]",
        "terseLabel": "Accounting Standards and Interpretations Issued but Not Yet Effective"
       }
      }
     },
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Expected share price volatility"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Option life, share options granted",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r53",
      "r54"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted loss per common share (cad per share)"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "terseLabel": "Significant Judgments, Estimates and Assumptions"
       }
      }
     },
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCashFlowStatementExplanatory": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for a statement of cash flows."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of cash flow statement [text block]",
        "terseLabel": "Additional Cash Flow Disclosures"
       }
      }
     },
     "localname": "DisclosureOfCashFlowStatementExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "terseLabel": "Schedule of share capital"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]",
        "terseLabel": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of commitments and contingent liabilities [text block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [text block]",
        "terseLabel": "Schedule of depreciation rates",
        "verboseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]",
        "terseLabel": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of general information about financial statements [text block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/NatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
        "terseLabel": "Disclosure weighted average assumptions and fair value of options"
       }
      }
     },
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [text block]",
        "terseLabel": "Total undiscounted lease liability"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [line items]",
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [line items]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of operating lease payments [table]",
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [table]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]",
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "auth_ref": [
      "r126",
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]",
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]",
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]",
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "terseLabel": "Schedule of number of other equity instruments"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "terseLabel": "Schedule of stock options and weighted average exercise prices of share options"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]",
        "terseLabel": "Schedule of weighted average remaining contractual life and outstanding stock options by exercise price",
        "verboseLabel": "Summary of outstanding warrants"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of objectives, policies and processes for managing capital [text block]",
        "terseLabel": "Capital Disclosures"
       }
      }
     },
     "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherAssetsExplanatory": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other assets. [Refer: Other assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other assets [text block]",
        "terseLabel": "Other Assets and Liabilities"
       }
      }
     },
     "localname": "DisclosureOfOtherAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherLiabilitiesExplanatory": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other liabilities. [Refer: Other liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other liabilities [text block]",
        "terseLabel": "Other Assets and Liabilities"
       }
      }
     },
     "localname": "DisclosureOfOtherLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating expense [text block]",
        "terseLabel": "Components of Expenses"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [text block]",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]",
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]",
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the range of exercise prices for outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of range of exercise prices of outstanding share options [text block]",
        "terseLabel": "Schedule of stock options outstanding and exercisable by range of exercise price"
       }
      }
     },
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of revenue from contracts with customers [text block]",
        "terseLabel": "Contract Liability"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "terseLabel": "Share Capital"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapital"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]",
        "terseLabel": "Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [text block]",
        "terseLabel": "Schedule of related party transactions"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, property, plant and equipment",
        "terseLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]",
        "terseLabel": "Earnings per share [abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r68",
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Impact of foreign exchange on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "auth_ref": [
      "r0",
      "r26",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Employee benefits expense",
        "terseLabel": "Employee compensation and benefits expense"
       }
      }
     },
     "localname": "EmployeeBenefitsExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r11",
      "r17",
      "r75",
      "r77",
      "r84",
      "r85",
      "r86"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Equity balance at end of period",
        "periodStartLabel": "Equity balance at beginning of period",
        "terseLabel": "Shareholders' equity",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "terseLabel": "Liabilities And Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options",
        "terseLabel": "Exercise price (cad per share)"
       }
      }
     },
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected dividend as percentage, share options granted",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ExpenseByNatureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses by nature [abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "ExpenseByNatureAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Explanation of significant changes in contract assets and contract liabilities [text block]",
        "terseLabel": "Contract liability balances"
       }
      }
     },
     "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_FinancialAssetsAvailableforsale": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-derivative financial assets that are designated as available for sale or are not classified as (a) loans and receivables; (b) held-to-maturity investments; or (c) financial assets at fair value through profit or loss. [Refer: Derivative financial assets; Financial assets at fair value through profit or loss; Held-to-maturity investments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets available-for-sale",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "FinancialAssetsAvailableforsale",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0
      },
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on change in fair value of derivatives",
        "negatedTerseLabel": "Change in fair value of warrant derivative (note 16)",
        "terseLabel": "Change in fair value of warrant derivative (notes 9(b), 16)"
       }
      }
     },
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r6",
      "r45"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "verboseLabel": "Foreign exchange gain (loss)"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r35",
      "r58",
      "r62",
      "r65",
      "r122",
      "r129",
      "r130",
      "r174",
      "r220",
      "r221"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "auth_ref": [
      "r102",
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross lease liabilities",
        "verboseLabel": "Total undiscounted lease liability"
       }
      }
     },
     "localname": "GrossLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]",
        "terseLabel": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r24",
      "r29",
      "r30",
      "r31",
      "r52",
      "r83",
      "r134"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedTerseLabel": "Income tax expense (note 14)"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefund": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded."
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund)",
        "terseLabel": "Cash taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefund",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes",
        "totalLabel": "(Decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in working capital",
        "negatedTerseLabel": "Net change in non-cash working capital (note 17)",
        "negatedTotalLabel": "Change in non-cash working capital related to operating activities"
       }
      }
     },
     "localname": "IncreaseDecreaseInWorkingCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of options, equity",
        "terseLabel": "Issued pursuant to stock option plan (note 10)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of warrants, equity",
        "terseLabel": "Issued pursuant to warrant derivative exercised (note 9)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based compensation expense (note 10)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r167",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase through new leases, liabilities arising from financing activities",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "verboseLabel": "Interest expense on lease liabilities"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestIncomeOnCashAndCashEquivalents": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income on cash and cash equivalents",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeOnCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestRevenueExpense": {
     "auth_ref": [
      "r135",
      "r139",
      "r203"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income (expense)",
        "negatedTerseLabel": "Interest (income) expense, net"
       }
      }
     },
     "localname": "InterestRevenueExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Issued pursuant to \"At the Market\" Agreement (note 9)",
        "verboseLabel": "Issued shares"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share capital (note 9) \u00a0\u00a0Authorized: unlimited \u00a0\u00a0Issued: December 31, 2022 \u2013 61,327,914 December 31, 2021 \u2013 55,043,789"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share Capital",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Compensation of key management personnel"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Short-term employee compensation and benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, termination benefits",
        "terseLabel": "Termination benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationTerminationBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "auth_ref": [
      "r103",
      "r104",
      "r148",
      "r176",
      "r178",
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years [member]",
        "terseLabel": "More than five years"
       }
      }
     },
     "localname": "LaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r175",
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than five years [member]",
        "terseLabel": "One to five years"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "periodEndLabel": "Lease liabilities, ending balance",
        "periodStartLabel": "Lease liabilities, beginning balance"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities [abstract]",
        "terseLabel": "Lease Liabilities [Abstract]"
       }
      }
     },
     "localname": "LeaseLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      },
      "en-us": {
       "role": {
        "label": "Leasehold improvements [member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 2 of fair value hierarchy [member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "Level2OfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "auth_ref": [
      "r44",
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]",
        "terseLabel": "Levels of fair value hierarchy [axis]"
       }
      }
     },
     "localname": "LevelsOfFairValueHierarchyAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r11",
      "r84",
      "r85",
      "r86",
      "r135",
      "r138"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesMember": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities [member]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Major ordinary share transactions [member]",
        "terseLabel": "Share transactions"
       }
      }
     },
     "localname": "MajorOrdinaryShareTransactionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r13",
      "r92",
      "r103",
      "r104",
      "r125",
      "r131",
      "r140",
      "r141",
      "r142",
      "r148",
      "r161",
      "r176"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]",
        "terseLabel": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating expense",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "MiscellaneousOtherOperatingExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]",
        "terseLabel": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]",
        "terseLabel": "Non-adjusting events after reporting period"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current contract liabilities",
        "terseLabel": "Contract liability (note 12)"
       }
      }
     },
     "localname": "NoncurrentContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities (note 8)"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentPrepayments": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 4.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current prepayments. [Refer: Prepayments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current prepayments",
        "terseLabel": "Prepaid expenses (note 5)",
        "verboseLabel": "Non-current prepaid expenses"
       }
      }
     },
     "localname": "NoncurrentPrepayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r12",
      "r103",
      "r104",
      "r148",
      "r176",
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r121",
      "r216"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Granted during the year (shares)"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "negatedTerseLabel": "Vested during the year (shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding, end of the year (shares)",
        "periodStartLabel": "Outstanding, beginning of the year (shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r109",
      "r114",
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding, end of the year (shares)",
        "periodStartLabel": "Outstanding, beginning of the year (shares)",
        "terseLabel": "Number Outstanding (shares)"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercisable in share-based payment arrangement",
        "terseLabel": "Options exercisable, end of the year (shares)",
        "verboseLabel": "Number Exercisable (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "negatedTerseLabel": "Exercised during the year (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options expired in share-based payment arrangement",
        "negatedTerseLabel": "Expired during the year (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "negatedTerseLabel": "Forfeited during the year (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Granted during the year (shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "periodEndLabel": "Share capital issued ending (shares)",
        "periodStartLabel": "Share capital issued, beginning (shares)",
        "terseLabel": "Share capital issued (shares)"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "terseLabel": "Number of shares outstanding (shares)"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OfficeEquipmentMember": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Office equipment [member]",
        "terseLabel": "Office equipment and furniture"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OperatingExpense": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Operating expense",
        "terseLabel": "General and administrative (note 19)"
       }
      }
     },
     "localname": "OperatingExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income (loss) items that may be reclassified to net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r16",
      "r25"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations",
        "terseLabel": "Translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other liabilities (note 5)",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentReceivables": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "terseLabel": "Other receivables (note 5)"
       }
      }
     },
     "localname": "OtherCurrentReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherEmployeeExpense": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of employee expenses that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other employee expense",
        "terseLabel": "Personnel-related expenses"
       }
      }
     },
     "localname": "OtherEmployeeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherProvisionsMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other provisions [member]",
        "terseLabel": "Other provisions"
       }
      }
     },
     "localname": "OtherProvisionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherReceivables": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Presentation of leases for lessee [abstract]",
        "terseLabel": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "terseLabel": "Proceeds from exercise of stock options (note 10)"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issue of ordinary shares",
        "terseLabel": "Net proceeds from issue of ordinary shares"
       }
      }
     },
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Proceeds from share issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r22",
      "r67",
      "r76",
      "r78",
      "r135",
      "r136",
      "r169",
      "r183",
      "r184"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      },
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net loss for the year",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r123",
      "r151",
      "r152",
      "r181",
      "r182"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r162",
      "r203"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Loss before the following"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r8",
      "r39"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "periodEndLabel": "Property and equipment, ending balance",
        "periodStartLabel": "Property and equipment, beginning balance",
        "terseLabel": "Property and equipment (note 6)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r40",
      "r163",
      "r173"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of financial instruments, classified as investing activities",
        "negatedTerseLabel": "Acquisition of marketable securities"
       }
      }
     },
     "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedTerseLabel": "Acquisition of property and equipment (note 6)"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r88",
      "r117",
      "r142",
      "r170",
      "r171",
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]",
        "terseLabel": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r88",
      "r117",
      "r142",
      "r170",
      "r171",
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]",
        "terseLabel": "Ranges"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [axis]",
        "terseLabel": "Ranges of exercise prices for outstanding share options [axis]"
       }
      }
     },
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [member]",
        "terseLabel": "Ranges of exercise prices for outstanding share options"
       }
      }
     },
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in property, plant and equipment [abstract]",
        "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]"
       }
      }
     },
     "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "terseLabel": "Research and development (note 19)",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      },
      "en-us": {
       "role": {
        "label": "Reserve of share-based payments [member]",
        "terseLabel": "Reserve of share-based payments"
       }
      }
     },
     "localname": "ReserveOfSharebasedPaymentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r156",
      "r157"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 5.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r4",
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "periodEndLabel": "Right-of-use assets, ending balance",
        "periodStartLabel": "Right-of-use assets, beginning balance",
        "terseLabel": "Right-of-use assets (note 8)"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Share issue related cost",
        "negatedLabel": "Share issue costs",
        "negatedTerseLabel": "Share issue costs (note 9)",
        "terseLabel": "Share issue related cost"
       }
      }
     },
     "localname": "ShareIssueRelatedCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremiumMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium [member]",
        "terseLabel": "Contributed Surplus"
       }
      }
     },
     "localname": "SharePremiumMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]",
        "terseLabel": "Share-based payment arrangements"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares reserved for issue under options and contracts for sale of shares",
        "terseLabel": "Common shares reserved for issuance (shares)"
       }
      }
     },
     "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]",
        "terseLabel": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]",
        "terseLabel": "Statement of changes in equity [abstract]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]",
        "terseLabel": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]",
        "terseLabel": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect of foreign tax rates",
        "terseLabel": "Difference in tax rates"
       }
      }
     },
     "localname": "TaxEffectOfForeignTaxRates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income) at applicable tax rate",
        "terseLabel": "Anticipated tax recovery"
       }
      }
     },
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [member]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r88",
      "r117",
      "r142",
      "r170",
      "r171",
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "negatedTerseLabel": "Accounts payable and accrued liabilities",
        "terseLabel": "Accounts payable and accrued liabilities (note 7)",
        "totalLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "auth_ref": [
      "r154",
      "r202"
     ],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r124",
      "r126",
      "r127",
      "r143",
      "r144",
      "r145",
      "r147"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]",
        "terseLabel": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r124",
      "r126",
      "r127",
      "r143",
      "r144",
      "r145",
      "r147"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]",
        "terseLabel": "Risks"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]",
        "terseLabel": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax credits for which no deferred tax asset recognised",
        "terseLabel": "Unused tax credits"
       }
      }
     },
     "localname": "UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UnusedTaxCreditsMember": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for tax credits that have been received and are carried forward for use against future taxable profit."
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax credits [member]",
        "terseLabel": "Non-refundable federal investment tax credits"
       }
      }
     },
     "localname": "UnusedTaxCreditsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses for which no deferred tax asset recognised",
        "terseLabel": "Unused tax losses"
       }
      }
     },
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses [member]",
        "terseLabel": "Non-capital losses"
       }
      }
     },
     "localname": "UnusedTaxLossesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement",
        "terseLabel": "Options exercisable, end of the year (cad per share)",
        "verboseLabel": "Weighted Average Exercise Price (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement",
        "terseLabel": "Exercised during the year (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement",
        "terseLabel": "Expired during the year (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement",
        "terseLabel": "Forfeited during the year (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement",
        "terseLabel": "Granted during the year (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r109",
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding, beginning of the year (cad per share)",
        "periodStartLabel": "Outstanding, beginning of the year (cad per share)",
        "terseLabel": "Weighted Average Exercise Price (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average fair value at measurement date, other equity instruments granted",
        "terseLabel": "Weighted average fair value at measurement date, other equity instruments granted"
       }
      }
     },
     "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average fair value at measurement date, share options granted",
        "terseLabel": "Weighted average fair value of options (cad per share)"
       }
      }
     },
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16",
        "terseLabel": "Weighted average rate"
       }
      }
     },
     "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options",
        "verboseLabel": "Weighted Average Remaining Contractual Life (years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share",
        "terseLabel": "Weighted average number of shares (basic) (shares)",
        "verboseLabel": "Weighted average number of common shares outstanding (shares)"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Shares Under At-the-market Agreement, United States",
        "label": "2020 Shares Under At-the-market Agreement, United States [Member]",
        "terseLabel": "2020 United States ATM"
       }
      }
     },
     "localname": "A2020SharesUnderAtTheMarketAgreementUnitedStatesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Shares Under At-the-market Agreement, United States",
        "label": "2021 Shares Under At-the-market Agreement, United States [Member]",
        "terseLabel": "2021 United States ATM"
       }
      }
     },
     "localname": "A2021SharesUnderAtTheMarketAgreementUnitedStatesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Shares Under At-the-market Agreement, United States",
        "label": "2022 Shares Under At-the-market Agreement, United States [Member]",
        "terseLabel": "2022 United States ATM"
       }
      }
     },
     "localname": "A2022SharesUnderAtTheMarketAgreementUnitedStatesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_AdditionalCashFlowDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Cash Flow Disclosures",
        "label": "Additional Cash Flow Disclosures [Abstract]"
       }
      }
     },
     "localname": "AdditionalCashFlowDisclosuresAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_AdjustmentsForDepreciationRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments For Depreciation, Right-of Use Assets",
        "label": "Adjustments For Depreciation, Right-of Use Assets",
        "terseLabel": "Depreciation - right-of-use assets (notes 8, 19)"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationRightOfUseAssets",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_BalanceHeldInForeignCurrencyNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance Held In Foreign Currency, Net",
        "label": "Balance Held In Foreign Currency, Net",
        "terseLabel": "Balances in foreign currencies"
       }
      }
     },
     "localname": "BalanceHeldInForeignCurrencyNet",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_CashAndCashEquivalentsAndCurrentInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents And Current Investments",
        "label": "Cash And Cash Equivalents And Current Investments",
        "terseLabel": "Cash and cash equivalents and current investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndCurrentInvestments",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_CashFlowOperatingCapital1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Operating Capital1 [Table Text Block]",
        "label": "Cash Flow, Operating Capital1 [Table Text Block]",
        "terseLabel": "Net change in non-cash working capital"
       }
      }
     },
     "localname": "CashFlowOperatingCapital1TableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_ClassOfWarrantOrRightOutstanding1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Outstanding1",
        "label": "Class Of Warrant Or Right, Outstanding1",
        "terseLabel": "Class of warrant or right, outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding1",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassofWarrantorRightExercisePriceofWarrantsorRights2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price of Warrants or Rights2",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights2",
        "terseLabel": "Exercise price (usd per share)"
       }
      }
     },
     "localname": "ClassofWarrantorRightExercisePriceofWarrantsorRights2",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right1",
        "terseLabel": "Number of common shares issuable per warrant (shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightNumberofSecuritiesCalledbyEachWarrantorRight1",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights1",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights1",
        "terseLabel": "Warrants exercisable into common shares (shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightNumberofSecuritiesCalledbyWarrantsorRights1",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassofWarrantorRightNumberofWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Warrants Exercised",
        "label": "Class of Warrant or Right, Number of Warrants Exercised",
        "terseLabel": "Warrants exercised (shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightNumberofWarrantsExercised",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ClassofWarrantorRightWarrantsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Warrants Exercised",
        "label": "Class of Warrant or Right, Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassofWarrantorRightWarrantsExercised",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ClinicalTrailExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Trail Expense",
        "label": "Clinical Trail Expense",
        "terseLabel": "Clinical trial expenses"
       }
      }
     },
     "localname": "ClinicalTrailExpense",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "BRACELET-1 collaboration agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_CommitmentsAndContingencies1": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies1",
        "label": "Commitments And Contingencies1",
        "terseLabel": "Commitments and contingencies (notes 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies1",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_CommonSharePurchaseWarrantPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Share Purchase Warrant Per Unit",
        "label": "Common Share Purchase Warrant Per Unit",
        "terseLabel": "Common share purchase warrant per unit (shares)"
       }
      }
     },
     "localname": "CommonSharePurchaseWarrantPerUnit",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_CommonSharesPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Shares Per Unit",
        "label": "Common Shares Per Unit",
        "terseLabel": "Common shares per unit (shares)"
       }
      }
     },
     "localname": "CommonSharesPerUnit",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_ConcentrationRisk1Table": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk1 [Table]",
        "label": "Concentration Risk1 [Table]",
        "terseLabel": "Concentration Risk1 [Table]"
       }
      }
     },
     "localname": "ConcentrationRisk1Table",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ConcentrationRiskNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Number",
        "label": "Concentration Risk, Number",
        "terseLabel": "Concentration, number"
       }
      }
     },
     "localname": "ConcentrationRiskNumber",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oncyf_ConcentrationRiskType1Axis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk Type1 [Axis]",
        "label": "Concentration Risk Type1 [Axis]",
        "terseLabel": "Concentration Risk Type1 [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskType1Axis",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ConcentrationRiskType1Domain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Concentration Risk Type1 [Axis]",
        "label": "Concentration Risk Type1 [Domain]",
        "terseLabel": "Concentration Risk Type1 [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskType1Domain",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ConcentrationRiskType1LineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Concentration Risk Type1 [Table]",
        "label": "Concentration Risk Type1 [Line Items]",
        "terseLabel": "Concentration Risk Type1 [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskType1LineItems",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ContingenciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingencies [Abstract]",
        "label": "Contingencies [Abstract]",
        "terseLabel": "Contingencies [Abstract]"
       }
      }
     },
     "localname": "ContingenciesAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_ContractLiabilityRecognitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Liability, Recognition Period",
        "label": "Contract Liability, Recognition Period",
        "terseLabel": "Expected recognition period"
       }
      }
     },
     "localname": "ContractLiabilityRecognitionPeriod",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "label": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "terseLabel": "Corporate Information And Statement Of IFRS Compliance [Abstract]"
       }
      }
     },
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_Currency1LineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Currency1 [Table]",
        "label": "Currency1 [Line Items]",
        "terseLabel": "Currency1 [Line Items]"
       }
      }
     },
     "localname": "Currency1LineItems",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails",
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_Currency1Table": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency1 [Table]",
        "label": "Currency1 [Table]",
        "terseLabel": "Currency1 [Table]"
       }
      }
     },
     "localname": "Currency1Table",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails",
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents And Marketable Securities",
        "label": "Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents And Marketable Securities [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detailed Disclosure Of Trade And Other Payables Explanatory",
        "label": "Detailed Disclosure Of Trade And Other Payables Explanatory [Table Text Block]",
        "terseLabel": "Disclosure of accounts payables and accrued liabilities"
       }
      }
     },
     "localname": "DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfCapitalComponentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Capital Components [Table Text Block]",
        "label": "Disclosure Of Capital Components [Table Text Block]",
        "verboseLabel": "Schedule of capital components"
       }
      }
     },
     "localname": "DisclosureOfCapitalComponentsTableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfEconomicDependenceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Economic Dependence [Abstract]",
        "label": "Disclosure Of Economic Dependence [Abstract]",
        "terseLabel": "Disclosure Of Economic Dependence [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfEconomicDependenceAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureOfEconomicDependenceTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Economic Dependence [Text Block]",
        "label": "Disclosure Of Economic Dependence [Text Block]",
        "terseLabel": "Economic Dependence"
       }
      }
     },
     "localname": "DisclosureOfEconomicDependenceTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependence"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Indemnification Of Officers and Directors [Abstract]",
        "label": "Disclosure Of Indemnification Of Officers and Directors [Abstract]",
        "terseLabel": "Disclosure Of Indemnification Of Officers and Directors [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfIndemnificationOfOfficersandDirectorsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Indemnification Of Officers and Directors [Text Block]",
        "label": "Disclosure Of Indemnification Of Officers and Directors [Text Block]",
        "terseLabel": "Indemnification of Officers and Directors"
       }
      }
     },
     "localname": "DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Notes And Other Explanatory Information [Abstract]",
        "label": "Disclosure Of Notes And Other Explanatory Information [Abstract]",
        "terseLabel": "Disclosure Of Notes And Other Explanatory Information [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Quantitative Information About Lease Liabilities",
        "label": "Disclosure Of Quantitative Information About Lease Liabilities [Text Block]",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Share-based Payment Arrangements [Abstract]",
        "label": "Disclosure of Share-based Payment Arrangements [Abstract]",
        "terseLabel": "Disclosure Of Share-based Payment Arrangements [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfShareBasedPaymentArrangementsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "label": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "terseLabel": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]"
       }
      }
     },
     "localname": "DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofeventsafterreportingperiodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of events after reporting period [Abstract]",
        "label": "Disclosure of events after reporting period [Abstract]",
        "terseLabel": "Disclosure of events after reporting period [Abstract]"
       }
      }
     },
     "localname": "DisclosureofeventsafterreportingperiodAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofincometaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of income tax [Abstract]",
        "label": "Disclosure of income tax [Abstract]",
        "terseLabel": "Disclosure of income tax [Abstract]"
       }
      }
     },
     "localname": "DisclosureofincometaxAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofrelatedpartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of related party [Abstract]",
        "label": "Disclosure of related party [Abstract]",
        "terseLabel": "Disclosure of related party [Abstract]"
       }
      }
     },
     "localname": "DisclosureofrelatedpartyAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of revenue from contracts with customers [Abstract]",
        "label": "Disclosure of revenue from contracts with customers [Abstract]",
        "terseLabel": "Disclosure of revenue from contracts with customers [Abstract]"
       }
      }
     },
     "localname": "DisclosureofrevenuefromcontractswithcustomersAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_DisclosureofsharebasedpaymentarrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of share-based payment arrangement [Abstract]",
        "label": "Disclosure of share-based payment arrangement [Abstract]",
        "terseLabel": "Disclosure of share-based payment arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureofsharebasedpaymentarrangementAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_EffectOfLeaseModificationOnLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of Lease Modification on Lease Liabilities",
        "label": "Effect of Lease Modification on Lease Liabilities",
        "terseLabel": "Lease modification"
       }
      }
     },
     "localname": "EffectOfLeaseModificationOnLeaseLiabilities",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_EquityAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Authorized",
        "label": "Equity Authorized",
        "terseLabel": "Base Shelf securities authorized"
       }
      }
     },
     "localname": "EquityAuthorized",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Five [Member]",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "$7.42 - $52.63"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Four [Member]",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$3.91 - $7.41"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range One [Member]",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "$0.54 - $1.79"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Three [Member]",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$3.02 - $3.90"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range Two [Member]",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$1.80 - $3.01"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ForeignExchangeImpactRightofUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Exchange Impact, Right-of-Use Assets",
        "label": "Foreign Exchange Impact, Right-of-Use Assets",
        "terseLabel": "Foreign exchange impact"
       }
      }
     },
     "localname": "ForeignExchangeImpactRightofUseAssets",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_GainsLossesFromForeignExchangeImpact": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains (Losses) From Foreign Exchange Impact",
        "label": "Gains (Losses) From Foreign Exchange Impact",
        "terseLabel": "Foreign exchange impact"
       }
      }
     },
     "localname": "GainsLossesFromForeignExchangeImpact",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General And Administrative Expense",
        "label": "General And Administrative Expense [Abstract]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General And Administrative Expense",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_GrossProceedsFromIssueOfOrdinaryShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Proceeds From Issue Of Ordinary Shares",
        "label": "Gross Proceeds From Issue Of Ordinary Shares",
        "terseLabel": "Gross proceeds from common shares"
       }
      }
     },
     "localname": "GrossProceedsFromIssueOfOrdinaryShares",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_IncomeStatementLocation1Axis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Statement Location1 [Axis]",
        "label": "Income Statement Location1 [Axis]",
        "terseLabel": "Income Statement Location1 [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocation1Axis",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_IncomeStatementLocation1Domain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Income Statement Location1 [Axis]",
        "label": "Income Statement Location1 [Domain]",
        "terseLabel": "Income Statement Location1 [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocation1Domain",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Expiration Of Warrant, Equity",
        "label": "Increase (Decrease) Through Expiration Of Warrant, Equity",
        "terseLabel": "Expiry of equity warrant agreement (note 9)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExpirationOfWarrantEquity",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net",
        "label": "Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net",
        "terseLabel": "Non-cash impact of foreign exchange"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Incentive Share Awards, Equity",
        "label": "Increase (Decrease) Through Incentive Share Awards, Equity",
        "terseLabel": "Issued pursuant to incentive share award plan (note 10)"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughIncentiveShareAwardsEquity",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_IntellectualPropertyExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intellectual Property Expense",
        "label": "Intellectual Property Expense",
        "terseLabel": "Intellectual property expenses"
       }
      }
     },
     "localname": "IntellectualPropertyExpense",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_InvestmentTaxCreditsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Tax Credits [Member]",
        "label": "Investment Tax Credits [Member]",
        "terseLabel": "Investment tax credits"
       }
      }
     },
     "localname": "InvestmentTaxCreditsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_IssueOfEquityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue Of Equity, Shares",
        "label": "Issue Of Equity, Shares",
        "terseLabel": "Issued (shares)"
       }
      }
     },
     "localname": "IssueOfEquityShares",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_LeaseModificationRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Modification, Right-Of-Use Assets",
        "label": "Lease Modification, Right-Of-Use Assets",
        "terseLabel": "Lease modification"
       }
      }
     },
     "localname": "LeaseModificationRightOfUseAssets",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ManufacturingExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Expense",
        "label": "Manufacturing Expense",
        "terseLabel": "Manufacturing &amp; related process development expenses"
       }
      }
     },
     "localname": "ManufacturingExpense",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Term Of Options Granted For Share-based Payment Arrangement",
        "label": "Maximum Term Of Options Granted For Share-based Payment Arrangement",
        "terseLabel": "Maximum option expiration term"
       }
      }
     },
     "localname": "MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_MedicalEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Equipment [Member]",
        "label": "Medical Equipment [Member]",
        "terseLabel": "Medical equipment",
        "verboseLabel": "Medical Equipment"
       }
      }
     },
     "localname": "MedicalEquipmentMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_NumberOfSharesExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Shares Expired",
        "label": "Number Of Shares Expired",
        "negatedTerseLabel": "Expired (shares)"
       }
      }
     },
     "localname": "NumberOfSharesExpired",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "oncyf_NumberOfStockOptionPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Stock Option Plans",
        "label": "Number Of Stock Option Plans",
        "terseLabel": "Number of plans"
       }
      }
     },
     "localname": "NumberOfStockOptionPlans",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "oncyf_OfficeEquipmentAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office equipment and furniture",
        "label": "Office equipment and furniture [Member]",
        "terseLabel": "Office Equipment and Furniture"
       }
      }
     },
     "localname": "OfficeEquipmentAndFurnitureMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_OfficeExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Expenses",
        "label": "Office Expenses",
        "terseLabel": "Office expenses"
       }
      }
     },
     "localname": "OfficeExpenses",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_OperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Remaining Lease Term",
        "label": "Operating Lease, Remaining Lease Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "OperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_OtherExpensesAndAdjustmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Other Expenses And Adjustments [Table]",
        "label": "Other Expenses And Adjustments [Line Items]",
        "terseLabel": "Other Expenses And Adjustments [Line Items]"
       }
      }
     },
     "localname": "OtherExpensesAndAdjustmentsLineItems",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_OtherExpensesAndAdjustmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Expenses And Adjustments [Table]",
        "label": "Other Expenses And Adjustments [Table]",
        "terseLabel": "Other Expenses And Adjustments [Table]"
       }
      }
     },
     "localname": "OtherExpensesAndAdjustmentsTable",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_OtherExpensesAndAdjustmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Expenses And Adjustments [Table Text Block]",
        "label": "Other Expenses And Adjustments [Table Text Block]",
        "terseLabel": "Other expenses and adjustments"
       }
      }
     },
     "localname": "OtherExpensesAndAdjustmentsTableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_ProceedsfromInterestReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Interest Received",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Cash interest received"
       }
      }
     },
     "localname": "ProceedsfromInterestReceived",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ProceedsfromWarrantExercises1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Warrant Exercises1",
        "label": "Proceeds from Warrant Exercises1",
        "terseLabel": "Gross proceeds from warrant exercises"
       }
      }
     },
     "localname": "ProceedsfromWarrantExercises1",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]",
        "label": "Property, Plant, Equipment Related Temporary Differences [Member]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantEquipmentRelatedTemporaryDifferencesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_PropertyPlantandEquipmentAnnualDepreciationRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant and Equipment, Annual Depreciation Rate",
        "label": "Property, Plant and Equipment, Annual Depreciation Rate",
        "terseLabel": "Annual depreciation rate"
       }
      }
     },
     "localname": "PropertyPlantandEquipmentAnnualDepreciationRate",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofSignificantAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "oncyf_PublicCompanyExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Company Expense",
        "label": "Public Company Expense",
        "terseLabel": "Public company-related expenses"
       }
      }
     },
     "localname": "PublicCompanyExpense",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_PurchaseObligation1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation1",
        "label": "Purchase Obligation1",
        "terseLabel": "Commitment for payment"
       }
      }
     },
     "localname": "PurchaseObligation1",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_PurchaseObligationCommitmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, Commitment Term",
        "label": "Purchase Obligation, Commitment Term",
        "terseLabel": "Commitment term"
       }
      }
     },
     "localname": "PurchaseObligationCommitmentTerm",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_ResearchAndDevelopmentExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense",
        "label": "Research And Development Expense [Abstract]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development [Member]",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_RestrictedShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Share Units [Member]",
        "label": "Restricted Share Units [Member]",
        "terseLabel": "Restricted share units"
       }
      }
     },
     "localname": "RestrictedShareUnitsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_RightOfUseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Assets",
        "label": "Right-Of-Use Assets [Abstract]",
        "terseLabel": "Right-Of-Use Assets [Abstract]"
       }
      }
     },
     "localname": "RightOfUseAssetsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_SaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock [Axis]",
        "label": "Sale Of Stock [Axis]",
        "terseLabel": "Sale Of Stock [Axis]"
       }
      }
     },
     "localname": "SaleOfStockAxis",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_SaleOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Sale Of Stock [Axis]",
        "label": "Sale Of Stock [Domain]",
        "terseLabel": "Sale Of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockDomain",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Foreign Currency Held [Table Text Block]",
        "label": "Schedule Of Foreign Currency Held [Table Text Block]",
        "terseLabel": "Schedule of balances in foreign currencies"
       }
      }
     },
     "localname": "ScheduleOfForeignCurrencyHeldTableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]",
        "label": "Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]",
        "terseLabel": "Other cash flow disclosures"
       }
      }
     },
     "localname": "ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]",
        "label": "Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Amount",
        "terseLabel": "Impact of increase in value of currency, amount"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings",
        "negatedTerseLabel": "Increase (decrease) in net loss due to change in currency value"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_ShareCapitalAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Capital, Amount",
        "label": "Share Capital, Amount [Abstract]",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "ShareCapitalAmountAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ShareCapitalNumberSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Capital, Number, Shares",
        "label": "Share Capital, Number, Shares [Abstract]",
        "terseLabel": "Number"
       }
      }
     },
     "localname": "ShareCapitalNumberSharesAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_ShareIssueCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Issue Costs [Member]",
        "label": "Share Issue Costs [Member]",
        "terseLabel": "Share issue costs"
       }
      }
     },
     "localname": "ShareIssueCostsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ShareIssueRelatedCostCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Issue Related Cost, Commissions",
        "label": "Share Issue Related Cost, Commissions",
        "terseLabel": "Share issue related cost, commissions"
       }
      }
     },
     "localname": "ShareIssueRelatedCostCommissions",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_SharePurchaseAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Amount",
        "label": "Share Purchase Agreement, Amount",
        "terseLabel": "Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementAmount",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_SharePurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Term",
        "label": "Share Purchase Agreement, Term",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "SharePurchaseAgreementTerm",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1",
        "verboseLabel": "Vesting period, if not immediately vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "oncyf_SharesIssuedFairValueOfCommonShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Fair Value Of Common Share",
        "label": "Shares Issued, Fair Value Of Common Share",
        "terseLabel": "Shares issued, fair value of common share (usd per share)"
       }
      }
     },
     "localname": "SharesIssuedFairValueOfCommonShare",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_SharesIssuedPricePerShare1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Price Per Share1",
        "label": "Shares Issued, Price Per Share1",
        "terseLabel": "Purchase price (cad and usd per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare1",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_SharesIssuedWarrantPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Warrant Price Per Share",
        "label": "Shares Issued, Warrant Price Per Share",
        "terseLabel": "Purchase price (cad per share)"
       }
      }
     },
     "localname": "SharesIssuedWarrantPricePerShare",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "oncyf_SharesPublicOfferingEquityWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Public Offering, Equity Warrants",
        "label": "Shares Public Offering, Equity Warrants [Member]",
        "terseLabel": "Shares Public Offering, Equity Warrants"
       }
      }
     },
     "localname": "SharesPublicOfferingEquityWarrantsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesPublicOfferingWarrantDerivativesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Public Offering, Warrant Derivatives",
        "label": "Shares Public Offering, Warrant Derivatives [Member]",
        "terseLabel": "Shares Under Warrant Derivative Agreement",
        "verboseLabel": "Warrant Derivatives"
       }
      }
     },
     "localname": "SharesPublicOfferingWarrantDerivativesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderAtthemarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under At-the-market Agreement [Member]",
        "label": "Shares Under At-the-market Agreement [Member]",
        "terseLabel": "At-the-market agreement"
       }
      }
     },
     "localname": "SharesUnderAtthemarketAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderAtthemarketAgreementUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under At-the-market Agreement, United States [Member]",
        "label": "Shares Under At-the-market Agreement, United States [Member]",
        "terseLabel": "United States ATM"
       }
      }
     },
     "localname": "SharesUnderAtthemarketAgreementUnitedStatesMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under Incentive Award Plan [Member]",
        "label": "Shares Under Incentive Award Plan [Member]",
        "terseLabel": "Incentive award plan"
       }
      }
     },
     "localname": "SharesUnderIncentiveAwardPlanMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SharesUnderStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Under Stock Option Plan [Member]",
        "label": "Shares Under Stock Option Plan [Member]",
        "terseLabel": "Stock option plan"
       }
      }
     },
     "localname": "SharesUnderStockOptionPlanMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Judgments, Estimates And Assumptions [Abstract]",
        "label": "Significant Judgments, Estimates And Assumptions [Abstract]",
        "terseLabel": "Significant Judgments, Estimates And Assumptions [Abstract]"
       }
      }
     },
     "localname": "SignificantJudgmentsEstimatesAndAssumptionsAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_Statement1LineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Statement1 [Table]",
        "label": "Statement1 [Line Items]",
        "terseLabel": "Statement1 [Line Items]"
       }
      }
     },
     "localname": "Statement1LineItems",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_Statement1Table": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement1 [Table]",
        "label": "Statement1 [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "Statement1Table",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_StockOptionsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options, Outstanding",
        "label": "Stock Options, Outstanding [Abstract]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "StockOptionsOutstandingAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "oncyf_StockholdersEquityNoteStockSplitConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "oncyf_SummaryOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Abstract]",
        "label": "Summary Of Significant Accounting Policies [Abstract]",
        "terseLabel": "Summary Of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "xbrltype": "stringItemType"
    },
    "oncyf_SupplierConcentrationRisk1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier Concentration Risk1 [Member]",
        "label": "Supplier Concentration Risk1 [Member]",
        "terseLabel": "Toll manufacturer"
       }
      }
     },
     "localname": "SupplierConcentrationRisk1Member",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Change in Fair Value Of Warrant Derivative",
        "label": "Tax Effect Of Change in Fair Value Of Warrant Derivative",
        "terseLabel": "Change in fair value of warrant derivative"
       }
      }
     },
     "localname": "TaxEffectOfChangeinFairValueOfWarrantDerivative",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_TaxEffectOfExpirationOfTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Expiration Of Tax Benefits",
        "label": "Tax Effect Of Expiration Of Tax Benefits",
        "terseLabel": "Expiry of tax benefits"
       }
      }
     },
     "localname": "TaxEffectOfExpirationOfTaxBenefits",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_TaxEffectOfStockBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Stock Based Compensation",
        "label": "Tax Effect Of Stock Based Compensation",
        "negatedTerseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "TaxEffectOfStockBasedCompensation",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_TaxEffectOfTaxPools": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Tax Pools",
        "label": "Tax Effect Of Tax Pools",
        "terseLabel": "Revaluation of tax pools"
       }
      }
     },
     "localname": "TaxEffectOfTaxPools",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_TranslationalScienceExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Translational Science Expense",
        "label": "Translational Science Expense",
        "terseLabel": "Translational science expenses"
       }
      }
     },
     "localname": "TranslationalScienceExpense",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unclaimed Scientific Research And Experimental Development Expenditures [Member]",
        "label": "Unclaimed Scientific Research And Experimental Development Expenditures [Member]",
        "terseLabel": "Unclaimed scientific research and experimental development expenditures",
        "verboseLabel": "Scientific research and experimental development"
       }
      }
     },
     "localname": "UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_UnusedCapitalLossCarryForwardNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unused Capital Loss Carry Forward, Net [Member]",
        "label": "Unused Capital Loss Carry Forward, Net [Member]",
        "terseLabel": "Net capital losses carried forward"
       }
      }
     },
     "localname": "UnusedCapitalLossCarryForwardNetMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_UnusedNetOperatingLossCarryForwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unused Net Operating Loss Carry Forwards [Member]",
        "label": "Unused Net Operating Loss Carry Forwards [Member]",
        "terseLabel": "Non-capital losses carried forward"
       }
      }
     },
     "localname": "UnusedNetOperatingLossCarryForwardsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1",
        "negatedTerseLabel": "Provision to offset deferred tax asset"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_WarrantDerivativeAndSharesUnderWarrantAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Derivative And Shares Under Warrant Agreement",
        "label": "Warrant Derivative And Shares Under Warrant Agreement [Member]",
        "terseLabel": "Warrant Derivative and Shares Under Warrant Agreement"
       }
      }
     },
     "localname": "WarrantDerivativeAndSharesUnderWarrantAgreementMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_WarrantsAndRightsExpired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants And Rights Expired",
        "label": "Warrants And Rights Expired",
        "negatedTerseLabel": "Expired"
       }
      }
     },
     "localname": "WarrantsAndRightsExpired",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_WarrantsAndRightsOutstanding1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants And Rights Outstanding1",
        "label": "Warrants And Rights Outstanding1",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding1",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants [Member]",
        "label": "Warrants [Member]",
        "terseLabel": "Warrants",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalSummaryofOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "oncyf_WarrantsandRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and Rights Outstanding",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants (note 9)"
       }
      }
     },
     "localname": "WarrantsandRightsOutstanding",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "oncyf_WeightedAverageExercisePriceOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Outstanding",
        "label": "Weighted Average Exercise Price, Outstanding [Abstract]",
        "terseLabel": "Weighted Average Exercise Price $"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOutstandingAbstract",
     "nsuri": "http://www.oncolyticsbiotech.com/20221231",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r10": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r100": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "58",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "C12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r110": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r130": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA__IFRS07_APPA_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r140": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r150": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_d&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r152": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r153": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r154": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r155": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r156": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r157": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r158": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r159": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r16": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r160": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r161": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r162": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r163": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r164": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r165": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r166": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r167": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r168": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r169": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r17": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r170": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r171": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r172": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r173": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r174": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r175": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r176": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r177": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r178": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r179": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r18": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r180": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r181": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r182": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r183": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r184": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r185": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r186": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r187": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r188": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r189": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r190": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r191": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r192": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r193": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r194": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r195": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r196": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r197": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r198": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r199": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r2": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r20": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r200": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r201": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r202": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r203": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r204": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r205": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r206": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r207": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r208": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r209": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r21": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r210": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r211": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r212": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r213": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r214": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r215": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r216": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r217": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r218": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Effective 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r219": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r22": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r220": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r221": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r23": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS10_g17-22_IAS10_g17-22_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r30": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r40": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS16_g73-79__IAS16_g73-79_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "134",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_134&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r50": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r60": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r70": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "Presentation of a statement of cash flows",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS07_g10-17__IAS07_g10-17_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r80": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Clause": "ix",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r90": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFR15_g110-129_IFRS15_g110-129_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS15_g105-109__IFRS15_g105-109_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0001129928-23-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001129928-23-000008-xbrl.zip
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MQ\!NT(U^S!5*-%J\TNB<0="BT1'A*3Q*2F33@#WUS\C7KNV& "CI<O! \<9
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M'OHK5YI%BU=W4>-1%XTX!()S&IA* 7.F8] Q!<)Y3A*0-!-2@XA@S!'10K-
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M/RXA<R720C]>\I6#B=6U.B8I#VR._P)02P,$%     @ VEIC5A93%2<,A
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M+B@F2O8.27/NS\$%6-&_=?[U16*'9W^[%-E_Q>HS8!'Z"9@QI43HP*J0W7Z
MM-.^ASPA?'4ZO/;6 ?FQ4.ZM)GT19Q3&X] !&@0.*9S CZ<SJ46<"!G>CBW@
M:P?^&Z,?"R_0M;B4<VZBX*Z'RW:&VV#3M]CW(?OAXO*/L\MWC4\7%__^^.4W
M[0J.63)#KHZ0G;\!4TQ '/TEJN&,+ ,O1*;CD8Y;@G)IN+[_'9])U9].RHHD
M0)"XX\<@YU>"3\.V\5XIK]\]4MY7^-TPV:9'6C"-^-J)8'^M+;8 IAL'8!#
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MBAOZ\HY=8/4%58FR,_9MEJ3<\I>=4%( T_UDQ!*#:JF+OY*Q*_PMJ';*9N"
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M0T>MLQV98MD=P!2<F5!3W[2CDGGP4/W6SPGA$Y-QQKUBLKR,";6X*S K3^O
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MS:"BR?HW4O #7BUAFZ9L=SY<,J&-?L R'=RE=T$\U<YD8J2\DSCY\.[L5/N
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M'(QC([LR.%ZB@.E +=9L8+* _@-Q$(3^G5G =GC7G6V,HWW:0.;8OTZ7CC1
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M($*GN32#0G3@HZ1=MVJT^T-H3AC&0*R^WAYV0:GV<@0*"?D:"4EYL(O !_/
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M!TC6PHYA$?R"OGQ*ZCMFEH(_Y:NR!RY."FP$>#G.$/6$-7/$=2H);,7YI.J
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MEVM%J@A#U.H.A.N[-5B%8S-V@_K$=4RZS.1X-UT[AX(2:'VO_,HHN2C*Y&/
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MY_8YS;4TF_0;NH:0.ZDQ=\2;LV(RC,IQ%*<U0O':SWW>8[<DP+;%B*4;T9:
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M\7',C1_?_O9P"RG'-OT*AC,N%G!MM"'GT@3/\PRGY1RY/I \UEO7]EMV^\>
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MY+G@L$J)I*H%84HA$5DF=J;5F0("JLR1^=X8:UPMI-@RA?,%U[0F48IP6H#
M"$ZPSL]Z@_'_44LC02JRF$JKVS-B@#^ X\S,LHHZI[ 5&J5!296Q064@IU2C
MAA;#?JPQ'>,B:439EJ*V40HH"XLICQ%904RC#(UC6.^MW%>"R!B3%Q^[F9@D
MS0GC)DN8$=Q9[ZT548IBPLL"XXV94B(KS6$ 0@*F%&=XT8*[KU+B J4NUQ]H
MI,U>A.\A*76)*Q'),@-@L)6R1X(-**6&JG7%(&B3YH7&\!Q3=UND6N^+;.P*
MOMDQ>EHX5@)5E]^E68-W1$;I^9G7;X]]QQXK#NPP*02I]WUGX/>=86_P#PK(
MM:254J+42N,#BH.0B<:T;%!CE(HF24W/:$L_4QDQ14V0J)66;%V+A>UB*#_A
M@+ $E%4F^E0R9'VRO_/,HZZ$'>9/P0:/97N$<JP!N_E,R$)(8E#/SP:^=S%6
ML."1*2RD:4'ATCC#?8:]:W@=;PA%B2(1#!YM#+BR&NU$F<6U4@-GT.LZWL5W
M*_6R^%VGW>F]$,<!GW'T]H;PJV%K*/J(:#X\UH;VFS?^[32* "L#CNT.O::L
M;%47F31\V=CTWTE()3ID<%EN<(Z U[<LNHXAAT)^27HA641-JA]6/[=;PW;K
MVY/_AYA-%_5L.BH<S(H"3IGIQ*?)P;&<"\+BH\&"IE7-G30]CRL V[W*M#7#
M(N6'%BC(WM3Q"RB)J.H9_R,&)>N,UG.C]4T]CR]LA:BNJR-),V)J_]D5[N!5
M'Q;M)Q>RMO/MN<L+M[[ZM[J VJOP]&]02P,$%     @ VEIC5I;#C#T?"@
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M/&29=%:C 2+9OUT-+@<3V"OK[+R"_7-T6I/U4ZPT]Y:IM& S>;$Y;-L@5,[
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M^^.#7.S\?][.5I)_AC/_EG?Q/U!+ P04    " #:6F-6B3RS+1X*   <.
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M<)FF;M+ 0)+2$AII:3*5J6NKAJK;TV2PDU@E&-E.:/;K9PRL'TF;]&73UO*
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M_<>1;?L6O-?%P?&GXQUX'E B:VS\"=>>,&CC')[-@#);\,Z7C8U-\N^K,97
MWZN/5]#N%R4CY=0$<!8U* 3D968M$YFD5 M*I ">!BM^%0-R@F(NE6:2RC'1
MC*GDJS(C*B<5"5AZ!33"C"$Z2AVL05:[$.579,:(*(Y,$9++[Y.L")U>J2+6
M"G"J#T.R$^SES24?S&4ZM'9N"E_^^A1Z?1 V0S,1SYQ.]D=TTL4@+4CC:@WO
M'_^)&QMK@/4V8 OT\OGCY<Z& PPWD^1H'ZQK=/#O(^3:GSKFLQ[L''\\WVE"
MKS<^Y0UX7AVPWC_>/=IO_GEQT-QFC:M#5F\FR7%P\N^K.JL??M$\6(J]S7P
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MYAD/5%-)M!1$"/!EP/:M,B#/'XF<(C!4*,N8#Y;8P$Q01CA#N*=4<_B)?C&
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MQU6S7TJ,G0%>XP9;B1@C2AODL# ,>Z20Y&+!4'[F.-Q,()7,X%3JRPJ U"F
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MZTC39B76(;#O&8DV59P5FCN!1,J^0)4<^"FSQ]/L[\N\! _9V. <P]$9CZ7
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M\NS(17UC#7U1:=FOIC%SV*$L;;F<&0,*WAD1"&@$I)-*$/@5)?*5QFRL%L8
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M+2$U]O>2M$JG4[VKI=1Z,JGUJ=L:=/JF*&LF%2\OI<-=?$D6"U<:O%?K8\;
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M=[6O6M[$^X>9]OD%.)IE>.M6M?=O53:?WF8 \TP6:_-&$"]I\)_)R"]CK.L
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M"KGKY,\R];.7#HTE0H@QE#'LSF@I>EZ*1%"/'=,J#>JBVZJEE,];4N@F!W@
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M4E'0-=L=],=[FN_FO9,E@R\*D0BV9/ J8L<G,[XP>8C!-T+/%?GIN C:K5T
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M)?>=T0%^XY,R&1AA:T-B*\Q[J,>=IO&#3>-+->P='PG^<.Z'@$.[+ E_T(
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M9?VPI<JZJRH!;=(GVK7C-@WENS-=U(RE@0T4-[_3IV&A%QQ!?4\-M.R8X1:
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M7M]]X;_6K#1QA<S$&V?612PX],>6(\W&X=6X#K5)T/BNO#?J)]=,L?;?S*Q
M(7.$,TE3H"7 E?]#4>V[4H0M.L>!;GQT2L 4;Y@8>5EV>)+X.H<JEDIAFVA/
M.VX:X[I3+/B3*P2\+J5PFN7 -)Q$'R7>2#/Q3 Z?SJ(AWS<[GKM;LT1>([:-
MXQI V@6%N[*?PU02$QH-MT--_(Q$7WS47U!ZG[W-ONF!XT"[#)S[B6T1IG%.
MRV2T7^<JG/"0N/U2EB!G.JC3:[$WV!!.2_"%L6YEB1;"?:W+@*(#K>*TKMPN
MB :%8=EDJU!)B3-O%SBOT;@PF'X^\=TR[]PYYC8RSJDEMU>RFH2I#&] EHRI
M:6(_="@J*D7^9$!YIGSD6 ,"P)4H Q]0'LL\7LOR9H6XL?!#H(%:6I$=<9]0
MB<D_?W(UH8"2A RT'U*VC!!1^V]?@/9"ZYE$JXY!L<P11XSQ>]O]U.S_[HJ;
M<<BBQ>/BWP'277MB;HJ.<_7,8[\?5SZG)^:D+8%X7,BX!^HPOUJI:?,0=2ZM
M]B<___/YTX>/_IRA"+XME\* 4Z_]>Z.J_<N;EGC?[J"]?<I8H<=?/7Z<'Q^I
M\:AHK6;9M$U=7)8M3B205-+I*N>NO[(?N <ZA%^F8TC7N:B:!87*326L:3,#
MFVM;O;>Y?E)=I4VPZQ0X$!?+69@U^]RE_PZ]8H'^2UI.2_1XK6P^@=>.+LP1
MYLS"ONR9S<5E-?8&\V 2"W0YK;,]U,J-+"5N=XH)"#]\E& S]$LI]Y>DO_QC
MEW4N^#5F;YH,'MY3D]1!_^&RH?.DTF,J:G7MS[)79$7-B$@"8G4 _!.@-)NF
MZ40K@;/FL?$T'_4\:)>\8BCW.K+^2V[KSV8_2^0D7OK/-*V,DLE(=KV?)LJJ
MM,!GLC?=%E=10XV_XB]5,Y$08'8&;=,EK\CP!?(J W+%K<;]3\J5E$+_Z*0E
MI8M^PN;6H.!>Q?5) T,^#,T('WW>F)G6J[/LG(_KY,)TJ=D#IBK_/93^!^DA
MKOS<N/8AN8_J6?I]9HUIZ[:HJOA3O"V6;\ZRORF"@P=$2)<8:U6@(CIG:IE=
M+&D9JP:"-P:'A#.@XAKDNL?]\5PWV/LRU\G>] LWRN6V(+AA7YP$D%JF6J(_
M,?7%$D$?*OKBKH!9D,^/H2U,W-:Y-*<FHV#(KP*AF3G<3;V&!U]4C-ZZY2!4
M'L;<W#W+/ZXG34[&*___7"UDMCSY4GT@_P6+;45P5A_2X2K^X7(3>;$VEH^!
M&*X,>-N5"[P%"8Z'P=D*Y%DUQDV N!%-C>$+B\91LK_"1A<79)4F;&>@+A,<
ML VE(DUH9/4,FWCV"#@1ZM_&-@!SBE)]O5XI1<,H= [>9V.3_@D9=QNHU^/\
M>T/#%" U\P.NL*Z:3I@<6T<D8R2&ZE>B9-K]HJ<-1J;%7^"[P_74T_3_]NF/
M^D*8=&*\U&A0:OT1XFM#7 M%.F(S3K/W<8G6=48BZW)LQ(BY 2I9HZG\X;#+
M+HG3^S0QGWM;);Y^ABRZI,M-S#3ZCC?'[5"F_8WR]8BX$W*=Y.\(!4Y3_HD.
M4G;OA;"#^)X[@JE&](<]'D=%=6K)&9BJB(["0-F1TK6*Y':@YDQ#JJ1UIY9,
MZISC=MTQKJ*66)I.\Z#47#)7XS\MKX^\O"AQ)Q&;B>_\=&IAYLK'H$%1U/3T
M34E)DBQ5>N6FVU&VDJ1V6A#_*F1CKK$0L:9\0_,- \H&>O'#CW%:+Q]WO00O
M/G(X&_$.)G>>I>@%'[KN>2HHG%R[SS!_4W8\[<&F_ % ?6B4:&KF6)S/PEN5
M#B5=QL& J^-+5[),^*.SX*TV[&/)=C%?OI%>$TPO(CI[G^B73EGAO0EK+B".
M?5I*G\@41.(O9 V+I33*)RR:7?8@/2"^?WK^99[YF?)>3&COUE0C>S0EY:-)
M80U@PJ6J;2!K+[DR2038JBU%E]ZA:/;.GF, V+95,UQL:)E',DE-L_$5*:_6
M4<]%=9(2^I2^K=@:R5?'I+L6N<4^'"REC#/EIAUV/K7<N25K.%,;;='U0O 9
M>@IZH2KL$MRVR9=JZ0.YI@,=)<L"3DSJ9R=-M@<>-!080K7.'[ #X ^T5;Q7
MU6V\ >V.] 7<VOPWJ*(H:P=D@$!K;!6$*3PEU:UJC-/2QVCY)/5(+IX$$(%)
M21_ A*5%\:,Y*.TXXWO8(">I3R78%IUM6PY!\:1S<W_"X2B2MZ%:DIN^(A]Z
MK4J&=<0:RK0%_+@PS.\9X?KG>X9P_9R[_3W0*!,LJ15/JHG7K 48"0@15N#L
M0M=HP-]#=,LEI:@Y9:4RU0V1<"5GIV&L-BC(?>UO47P7<%WBBJHPG35&(6M"
M7.3>6:5R61=)-UEC.C3]S;0@W&D\TG%[S[7W<6\[0SS).E/=W:_<*B ^5ZC3
M%V1=_0X<+X0P16M((G4!C=JE9?5CXFI&%>;8<J,W)DR-X)OT@()MUPY/KM8O
M]JR4U#5+E@.>$#AXQ[0W]=Q^T\(7)61,)!B*9X ]DJXVCEIS'B;=_]P(.L(?
M=@QDH#]!@6JD%D]#NRB#6EP$]1U&_(VVJ KX'!LU'2U_30D%"!UZR6@4(YUF
MZ;[PA>1")H>YW/?-&P+4^-^1<Y8'<(1[ZU^N7=#3O:F)HF@T4^,)&0_BS/@]
M/PBJ1V^3WR!%RH,\':BI4B.0JE:HUBJ7)?HBZ0LHVY3^/7GCW_JNEJ7#:A9N
MBJJ/*G5:=)A;I <[$!@8XD,\!O ^^_'<)*I):HQX*P]DBMB0-RV-H>05X)''
MZD=Z?_J-;3(X]$P,H:AYH_H-S%!VEV!Z[[,9W@1>FX>ZMY(-EP!Q%% GQ2$-
ME$><'US%C?B[1.PNTKZFQV;<]P$T7>HUEU51$JQH3(LU-@X&PFS:3BO,K=#/
M^2=O_/G\'Z:;X*-DI9!QV+N O-8T\PA%$Q"J:VF+"*(TP>50+(UHAE"K+?@,
MWY9+K<30:].=D!REA5G[35A-!:GE=6KBJ*-3T7L0S1 H43@ZYB-SION"+?L^
MO$[(8H"/((J8J4A23P#%Z:>SH1MW3<3M ^XIORG1BHAS:^90]@/@HX)-;!J:
M3_,R]'&'!]]/E2]I 2@9/#^KD('II$I)";.J":6XKM(#Z9 YX/4>UV4PI_)%
M_[ZZK%/(:=%O[K&=2-O8RT.C)]VTW8PO&\3[H@1M!3V'T 5PT'L0;XJ[2>2<
MP\*V8L+);$CD39T;/FIG#&:$)30+*CCQ%A'$'"TAHAY<\7T2H;E@QJXV3>@7
MCK[19'<0<MLT:^@"]+OW^MC +K\3GNV6IRJ/Z$Z2X5\1 #K6P;1)25;).U-Q
MGZ;FPTR-5HU,M'=5@%46O5UT:""N/TW0QYR@^2"#^S^HW%AV;S)J,1VB)[,M
ME9<T=&K"DQ@GTIF>H;#LT%#N(M>M*I4^F,4:PZY,#IPU0%11]"8]]0OM*92+
M@Q>9OF*@$L+-U'(]X \AR@F],KUD'UB>FGI83^OM(Z\W7A^0C].$DO._J)C9
M"1-(NNGB;9@I/Q7]/O;L< UF-VBUEDP#Z4"Y]C[[U*'? \D/[=^C13K61B^6
MF])=AOB&Z=C*()4^ZH6. K:#24M%-QT.O"9^SK*$YWU*:M:R9TI3@OUQ@U;;
ME$LA:02YV_/YCD4-4:P$\]U*2KA,R1LA"&1GAM:;)&KDB9,6TT\836+CXUXO
MU([!8E<G?>=6JH"FDF-O3A\"E-W&JBI36Q=!4J\JW[BJW#3<.B2<?I^17>ZC
M;[V_.JXJC9F2XVJ6.FYQP>V+8;Z0'F7"!W!R2Z>*T(<KF0J1!"*]3LY!3PH#
M43P^Q+N@Q1+RV"3=2-GZ(@2!XBFQB8@96"R:DI.="3,+Y^JE)W3N060U")IF
MO(0X*(=M"+DA72>V(J9A[5GV,Q?0A0K.!]FR;B/UABGC8<'/KV:A6$S+;C:A
MKLMYCI"&'R,TL1*?G&DSDVKZP;;V&TS?H=D*:;I]2=Y$FKF*Q)&AE' ?-M6\
MM?L^;)XG>A1D+\G)OM.O_.XF'UN&= ,820)58):L8!KG;%-VB$RI :WI.M=%
MNFO_M0@KLH(S9E>0)D;(IF'U4753? 3'[) =.FEUSR"-?B]6WKPY_Y5Y*8N0
M4/:SYBTW535'M4XJ0_@M&@<<\%)01IO<',\*<18*B(O^L>,<="A<7X4IZPTS
MD5$O#;-..*3UNG,!:S1OA!A8AB6R7#:@*@(AY>0>#*Q!4WBWR=:DQ *WD*+>
MVBP[GGX<)WZI/75+1TG)__?_>?3M5]]]_2@7F@F\QPJX!N_N;0<N A'=UI*/
ME__VS:,_G7WMP^^J4G?DR@Q<[<* T8<??W/V)_UL[G_\-GZ5%^U_>_SX[+_"
MU93L>N_'A*1P* %[Z$G]_W_$U_#_^BHE;\>,&DD</6TGD@R,)YZ9[57@WOA:
M@(7!->\<XPU$ @-ES&)+A1AHJRIF+US*P+QR%+>\7Y=K<HEID\+7+MKFJM]H
M04)(DJ,*AX$/CA5PCCAHOT?PUJ.O[AEZZ]:85_66);2L!W\2$0"&,V@I7PDP
MD&/ 2VJ#9ZC7\BFUL#*,57O%-2;\'ZW9@!$"'+8/HAW':M7E.@^6@$K#X09\
M7J:'))F150.#&PNDA%G9I!\DKO0*0@'^(;PWB\4DQ,Z!$EWB8/5;)Q5-[/H:
M1S9"MI&>]EGVS&]T5-L.?R@K;*R7EDT)"<I%ZA(E4#%/P70O]N201Q<"V=@E
M@>"/DHO?(5CAK^HA4<8O)OPESN/RL<%=0X]!L-6'.;#&$U C6[AU<L '*B:.
M;C3!S?#>.\X9>2-7@MR2G)T3>G4012H-/\=N7.,EL#W'K.0X?/WX[)&Z!4=/
M\W>=S(,3^4X3Q^\Z>_+/?7X,]0;P;H:[2UT3[SG":T1XB7!4I+<@=4 ";.AO
M\EMS?S!ZS2=?M,VX2:NV*:V(VH_!M.5 RPB_#HLVC$WZNF0^0\KR$0-/:.%U
MM7>8EJ$B7@#1SP >1:5W,["TJ-DV \K5P7]>"P!,)PV5F[G1SZWK1Z6=V,V3
MK=%/%%$ZY$@?7B)M2]UKV[B S<+;#0MOA3@YX5<Y@<ET*4X:F\3F2H9VY19]
M:.(HNV[0U*VY.KT.<:&&7?)E6-$@1VPE8<B,D#;;*ZF,2#5IP%6L)29'J']Z
M/[OX(<FEW'$C%?6:<FE2IN5, ">0(A7H(&&D+ TD \=3'^7@@J!QY%X.3HCS
MXNG;DAL6@R!?:/)9%/4;S+?L#\PJ_CW[<$CU^><P3HU?I2WCQ;%W?#Q7D=#A
MQ6;:W>*WE=\61,@:XT;NOQ1/H)+\F"7!H4&(B<\$T*9$8HY!. #5$,4@=X/R
ME;B]DV!85+/U%F=;#EM.8HI]-'2;ZH0)A]=*%4II67<FQ,7(1,-N>VC&ZBW0
MCRA5R0<'](@U-IA=$"4*"US72QRF]B-M*B.2"]IB.R)C%9@H_W9KJ5='RZ:L
M5W[EBXFF!S5GG,2!O$WO<3+F5=!6<)7XSYV?_6[-LCUP"[BS4RKA@GD?F\(X
M=#DYJL0X0.#24OH\V.#N*C_XBD-5>[Q>!PL7J&RO!?\C^E[[:>;B?%N42BM-
M:Q. >UF[5M&P"7DWG/*LI+0N+ILV"JTHR9I[6S)E%;KT-DU%^  ]VLCT"[21
M]X)*:$35ED/7#R4"Q7%*]V$W+ B5*=@S0L]1F:.F6W!%JJ3=R9GM0_8NCP0=
MXN^&/$Z$^$6'>-=T5K*"7IQ)W?F==*KMJ:JP]';'D%DYH:0:D;9XM\2B['_A
M5U!+*TYPX$P;*$^10&@C$!])FV/S/Q,A\AHP1[*:BC+5;(P>2.#':&F,-]YD
MSO+$WZ6]_NX!EV38B+5TG-4JZX#S%W=(>R:Q.]<J-<[CQZL)!.O)=ZBB*L<.
MEHREN[SKOLOL^!V-8!3_S<XIMW:(6WM\W&E+EULPN\+X_G+VZLP?IQ4=3VR5
M)*\>YN;HG$RG@B]R7G6-$)^+<C$2XDG3Q[^\I>\HQ\-]MVRJI9A=U+'_6L(:
M_5I8!GBNWYLZ\6NCF+"D%%D/%^R.;P 1'...!X+#M%W8!PD/Z50>5D.\@7;#
MY(A)6ZT8"^&/R'^1CS($K@$XL3@0&*PK'V?IP74!^>Y:^D>C,#B5GT/0H0O7
M;)9^?JK"@1CHS@\^?7+>:"@;&\U5SROQWH5F9<=5@QFZE3SRO\H5#?7F15%+
MFK(S[!LR(#$BC^IPK,$A\5&H\2-0Y_&R;VC&CCYE0S9VNEA^4A'Q0D,6Z:23
MM@R:$C/^ZGS?A!#X'MH%S7E*)Y0X,^*(V968"%V$2AP%F:,<YTPN^-8-TE&C
M\D,D=K%P\+'RT:[8(T[$"J2\B409#.RES44[K3.\UPS&<TQ(G>R9'/B7E5->
M)&=Q-DYD3G8,[.',0$=I4?BVR;Q4=-Y3/"W'-7C<8WT2I[9!'B<AJ/^BNU*\
M%R:6]J!_9+KR679T6!SX3L:#(SNQ)UIX;<1M6%B>,WL+44OA? 4%VQ<NI+IB
MZG2Z]DP.RPS66?9+Y,+G$&JL3)1>BN+ZH1-!E6K_,#:XSE:ANJGD2[)[0O2%
M1XRBRFS_Q,.I1WNIRRZ\_>[=REY*89O<880Q$@Q9\DUS1^;7F\P -S$@Q&,)
MQRT@3DTK,BQCZA@F>RP156O?9-+9;!K25XUC+GP?BE8*4AL)XI3CV>,5FJU*
M.)\;*;J-/H0,35U"FI3<VZ)R07W%E-6N%*3]F_6V3CI^APKEC^Y9H7Q4C_Q,
M\+>7L7 QCWJ[=4?F._H5+PX9T-8%1QH FQXEHYE"#CAG'1!OMW]TKNV;-R\H
M[\6'1#),@4Y7^I*ZI":7L$912_BN0DY9P%03G?EU!B0"A%0&#J2CVX#F:U:=
MQ=DOLK/>Y!=O$,+X8XIA5GSD(;/&.F0F'\@(\) YC$FMLRQ*!\.Z3Z<73)$H
M)I;A"%1O2C\#0#P=A-5858WC%YS\#JI^G4&MEQ'<CKPC&A>B1#WH!?:!_L0O
M:!RAYB&3XNRR." L9WA\H(BC7+5S5<G(:NQGM*CH%YTK_R-C:+31# Z4*T51
M<7+9(B5;Q4(J%;^E(R.WA(2DR+042CLD/2;E2/-A2^.IT:BN$PCI!&HD[30)
MN/*Y-QVK?8ZY&(HP*3S[2@5@X].QF9#"-U;89>FNSK)_ &,>R]P81/^W9NC
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MEP5[?S8FL(YG-*SI9N -H$N$;L4+7_Q\ 0L(4D7<2GX' 1XLB9:5Y4L4)Z/
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MU\<W:8Q-8?S,1'%9)/I(0;ATGL$_4"RC;2<%7/K!R"V]H1+Z@*'Z&K'M7&O
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MV-@YEJYTPD&+=3'\N61.!HV:S:[IQ^]GEC>'8S@!5X?]')LQ1'J0F(.*@SX
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MI\O?H[79?Y*8S4?:;IR#5%"8X<\+GB#/\OG*VY_L)Q_V[EWV5T4$9D^:,UI
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ME5CE?^Z6Q8XIS\?K53-$L&;H^Q3\) (;<C2SO=_JG=A SF)15JTV:2Q_Y>4
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M&+,Y9)/7T&R?FX%(19;@L4#:L'X)<0[B-%J09?N!_/#ZW+(U!QO.[4=EX2'
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M9U)*6H:E\/0:R>0D=N'9)@1"9MO$H85P4K.!7>49>1%8N7N%5]I,XG>:1 $
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M:=][\RQ&HV 54 2;_/Y..AB>JZY6ALX)-OEC(\C=4=EFLKY^LLY,.<XB1AG
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M):;I0P)Q0H0P"(L8K!>FY0D+ T,\JA^L]BGT2M1N(GZ%<0O'X[3S-*?\\[I
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M)17Y/)9>(>O(<,]YQ%?#*(:0&=PZ,A2J^5 _KN9/-0 M0L0K'=N\F(#1?&E
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M@ \K""3126XN7J1-I-_0LBEY*8Y,1 ?N$*9&"F<Y::AR$['%1L-34VAJI[7
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MD@W"&EE8@?7)H;&X;U1R904 [IEB];Y.< E_HS".@)6F*)A66,+%/"->*7B
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MZOD!ENY,."!BM%+ XF7AK"3/>%XP=F3E?]($!/X8"2FZ=!W"7#*#&TH6 KD
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M6=$F]<;$+"7U3[99PF]38Z+@2-=OYH!-6-"4'BREX<+)^N),8+P)WF;6&<+
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MI.1I00O:2,DS@!8T0#SM@FG=5E'NCOK8?.NKW[6'QQ7QEC23PO< +6C-VV<
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MR1&M"EF]%*Q6A7SZ1*PVAZ%QBL-.Y)*VW:P:JYJUW:Q:U>R!&5FM9M8VLZH
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M ,_K["@*FLO[()4J15@ Z'X@D$3T\1@SBZR]"K#_YZNSRL A">6PT>!4MI6
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MN!SN_@7[L7[K7'4T5B*FD:BA,NU53/]$>AB%:IF,E'NW$5]-)31M/1!F;6-
M,@U]J3;(.--XHN&7,W>1O(?'C#9KP8FL.:2CQB_3 ;\09G0 [.@YBTB\4?]X
M.W$CT/]7;UR?F(I^]#:MSA?D$Q+?\]<R8G9ZVCD9]C%H%H?P_Q/U8AE/ZU \
M[74\R7\WZ'<&AZ>E7Q]VNJ7?K1NVV^N</,6PW<[QR: VL^UWCDXV&_8U[1OO
M'7 '<ME_O^J_RN@W;WJ+'U8W+?DX'II+.27N>'Z=YY!OYSODD#Y&DBR-6_$F
M\KMQ1+C4RU\CBQN\ZJWOI<;1XO/#[NF,D;>!7!PYX^_78;#T)P=RC>.Q$-/I
M6WGCDJJXB"T"0[,4 ;8F*@SS_)HE4;1[.MR 2QI/AJ.>?=([LD^')RTU7OUM
M>%I*A=XC4N'0*J %V9T5(L7 'IP.[:/#;H'P2!2N1V$)(L?AAL38^9TY.>H<
M#RJV*2]!A[_D[[/79.=ME*^HOWQYMTVN\.;E'4]KG3)G$BXL[^RC$ DG&F/<
MQ:R61H^B[KIZCJ@'6,VB,!,(,PN!X$:<_A-3UK1M5"BM[1M'HVWD0ZB4OT[5
M68'R]@E)5T<''6_HB-!C4MNABXVT+]E.[;ULPE+LY"5_T41B]1KA8<=7[6MU
MT?T>%:CX*TJ9 H+(XB<N= [,\FA*1&1 #4]<PS\8U=VV(FQ8RH[GT/H6N#[,
M(,]-&V& 5C=>\E.%XB4G R3#%XG \MD)XY7U-2E2K.$Y^%UP=C IM%2KBK!/
M25D0L3&L3KIY"9A(AE9D, 6FX+"PE)D-D;47"6%]B,7<.MKOF+'[MG+"K)SH
M-JQRHK),?N7Z$M-[)&"&G%S#0G_J1J 3,FX,9Y]>B#&QL=7ODGK0LY8+O/]+
M@H03T$0)3P))R<<GD=P*JVE!DL(H9^9P)/X\X)9>CFQ[[@6.GX;OX-QG')*C
MEG8"94&G[QOU>=9!R1KDN=0V=']>H:N(0_<?2&Q'G&WS[@?69#-KG8,5%8ER
MC;PNS%"9>5["*3W3%0C/GF@T.*Q^HM%)QWK_X?+L\OS#V:_6A\OWG[Y\/,-L
MHNIO;FTE4O62B<YUHQ&5OL%V- HE,A:M]QH4,/FZ2BQ23.D*R:DMK?6JT[O>
M]\)7F4&K>3[!O(P2[I^Z'E>4HR:H"[TD@%DH,$F&TLWX.4YP)0.J>_*(5TWU
M>?57\F]\#@,$9P/9<@]&K=#B[V2<='9B3-B"VII.NZ64I8!>*96+J+JZVY;#
M<!\!@E_*7#!V%>&X(\?_'BX7\1@!ES1E+>?:<?V(<L#G;['AG<)HT)XN:OS$
M?.M@68*+,*]3\FH:;S<&-29@>6".7Y.GZYXNJ=KNE-HB="5G]Z5P!^!'B%?(
MN)'X8DU;S+%/LNT)UH7;/K/:O[$GN0ZG94M1<:'PJC^#Z!VO:KWT#=J#,&MA
MRP]J'^VXC ,QD52(L) 9\>I2.1;2^6:.@%4@"^>N'ZHTW.D2:^!EW<>U\+&^
MFQ&-IO ;.?P9SD.,N945U?UEAE\WM.K)1F4ILI!JQ!AE4^/421PI BA57"\<
MP@J+;./.3=5]4WZ5]+OK CGQPV5$&+/;2:6\)O=20*MKHU3/@7\%NTD-&$%V
M<Q"S58@?T5%B109]%0 ,>3@)RA7##)'VR"J4*8PH2'VX4(.6X#&R0""G/(-\
M>!^$<ZMW>/"^4H=YN\W<T!G4K[XSZ+1C??WEG?7I_?MW7ZC8[-</5U\_7/[<
MW'L:/80&1HG11)8LN=/.66= 5Y+\\[S>ZMI:6GR"TYQ"JZ""5C!^&6C;9FR5
M$.[\R>M_+P,)$X_RX-*))LZ_M9;]]>I_C'K/:#4?!5ZDX @^79[_\8H>33Z0
M@ 2VJC,%]?O>0?&=C$KVRJ.26TBH(RVA:AG*K)8L[1Y*3=LZN[CX@"[UUL&^
MLPYVKGD_=Q9H*==^YRLSSR>+[U6>Q:MGGWT4\R"$:WTYI\O]#!-W)<[;610%
M8!K@G5I]GJH0[Y<ZUTI290V28[:GZU-?EYH[<G_GFGY.M.3$3#([58]F8]&(
MU&=TED3E\Y4BRJM]0R7]2370,/HI1=89 YR<>2-$R4^!:\-7NDL<>>=Y$J/5
M@>?<1O0H\\VKG_BC5_L="_5I-9B:&':*0ZA$564(-G'O\/CX]+A_TI._4 N2
M %*Z"U6HP U02Z:&L0R=(YUL:DFW@MR%A#Z 7U);05G5?8N)?O(!A6K0D5Y&
ME[Q\>IYF_T8DC,)5T/"QU):!>\^ASHZN RL@I%G"EE&01])SZ(;&3FG";9Q%
M_:QI:5L>NPOE[ZST6>KVTEU"Q]P)0EJ\R$EF@^(TY(\$JPA\"2!,5I'T&S/&
MH\"4^8"S3IEA.8L.N=B=<WL%F8ZOW,-_Q394\Z4O5#NSQ&^LX"7AO83UF;PQ
M2K]21[/TNRF[3GYH=B*1C9!T%AZU@I<9?A*MR!S#^"DWBS-"26$6%#Y9! ;=
M)+!_MJUL!J<\W=AC:FDFXM1!.N3:*<Z=)RRPN</E7*+]"8Q-<5,&^<OL1,EY
M1^ 2LF=#^D!CRK 4 2S+@C!DY N2$PG@L[.$_PW=/U,@L4;RHGPQCLEP;*FF
MD!'3B 66= +R@$CZ61@LKV?$/!3I^&M4)":L/0*(5<\BBJL[#Y;IYI.Z(<F^
M#<(P1A+2MJ:$)6X>\/;"<\;<PFH99:0N2G<IPU7T5NZ$05I8$KY5!4=P((3]
M)_<I\\RE<&6#"6&H0O+VD<,CPSD4E[6PUI;A+;/;SKBX9M^,S(:;;2,=Z3H!
M!AW#GCK7)'\37N$8#6=\PZB^N,5C(@F+&T>M0CW&,^3Y+"A09UO.)%A(C\_?
M@=^M_B'FTW:'V(L4KB;)ST6,:8X&NX]]:D ^='N4OQN9O>[5NTI.QAQCV1A\
ME4=9M7=B5B:\1B>ACBP)H;?;>/X3]L]T'.!YR0@7%9?D0[4&C>$U61Z7T"3(
M6=3"88PB@AN]DC $0A>?66)(D&=8!B*P1](U]N)!W"$-MQY$"J978*JHBW#%
MU',/)^<%\!WV\L-G$L:HM8]RR^OW"_X;=O%S**:P:;REN$D7.IIY%L?8GY>;
M'K%KL^9*\5>-7!D5U.@KP4\UE&;CDB3 BXV0,)D=D;(G8NQA6^".]0XK11)$
MS S(4-);0Z(*41A(MP.#ZU@(;LP-9\&\(IV8#R=#<8\=:OXM^'HG#$V'KM_D
M90PSX"1PA.8+50A8QI)@U->838\Z*/R9S$$K,UDP?CI+GD+O0D%XD/R9DJ^&
MOI1'1L=+4XIR;@^44F!(Y "+P.?R:I# B-AXDUH^JZ=MB\H&B!+&5%BZLYF0
MO"\O%1/%G&ZU"=$G=JZO56D0O!!1@?%.9+!?^"'AF"#Y[NUFK\Q1^.23U,=+
M?K14>^A$$3:NIJ9_MRXE\1PL%ZAC1DJ5M)->9MRWFCB>/72IENMY37G?0(XM
M.'^L 7)U2/X,LC'TQ-Z;+64H,#:;KW#'.2_9ODD>?W7LS6VE\Y#8P' K4H>#
MZ=*?\"&>B#EMCWE,TW8, Z>:J3:D^Z6T5=EV _05I3;#WJG.T(H]L*=C1!EV
MV,-Y'3P0)XA2ER^9_C.A'K3(H%%4[+6LU_F[#%2ZCD>+HLU+>C%0[@#6N$KC
M(!:ZKP(1K ;+W]8-QS?)I=D2XSS!/V9])=NFI_I4N%,?D0C"CJELL:(^)<4L
M+N 0"6]\XX2R"9JZQ@TGPP)_-.&:?7F[\V%VY(A_S2CCU:?EMARE-1WK2M+G
M(Q.B:7ST6]KG2++4T+(DOJOI@P2C$"AC709D=2%4A&01_/'')-WW@T^V+7'4
M.=I_V/.4KN5K;.U"^4WF/8 JE6PF#F3H26 :ZGS',CPV<5T/N2=>JC6N2I*B
MO&.>E.ROI3Q4P/] ;3P 7$(P#OQ$7.I.,T9ZBNRYCJY:-A5! UQI?PI[<*US
M6/3$T<D8B-0E(]$%[K\\!GNBTAH.I_@V(-<:KCA%)AQ"-M3$.QB;T0I?-BE#
M2-,5J4DRRUQ_CW_K!]*4GJ*.M#?\R[Z""]5]7C/@?"7WK10LPO\6$/AN"FA7
MVPY*CKA1BIE@0O!6C_H$P#&(E[%("YV4G)%$-<DAB0X*WF2)R=_:LB=X5Z$:
M/ZA8@"8(9:;D?8O87V>27)I&NEVQU?/HLJ_-M<GGVO0;A@!0X8OO5]UK4,>Y
MI/H$I^'3K=\<9X[V$4N?<^(;7AD=%S450DT%!#I2QLP[SEY$YX*(QF XH1P6
M7G"KP)+2"CE9.<G0[AP#=B2YZ0IQ41J#5251;.BFX Q?\EZG9T*5,_X!3,.=
MR#[A"B*'T9@I**V&->XQY4J''Y _B((+R=?H"#(M/[@T ^W:+YE]RN=N^O.S
MCJ $LWT]/'3EV&GK"&4T]@+T1R>]=#XIC.SJK_:N_BM<XN+9JNWV.GV)8H%*
M1T(=)]%>QAHG;*L& 5+!,%[%/5E(/R&X#QQP@QX"&XQ$<;*1T>T>[M&97=1I
MH'M8W&I FF?2+^MY'+6A%_PU#6&2GPWE[^O>;'BP4'WE4(6+KS1T9)R;&&-'
MZ6OC1S8INA)R7E4!R,"+UL-03S>ZH2>JM-GT46X;O,.9"^,-[#65(Y-V/6'F
M%[+R*A0<X55;6(8;;QMX8$7]'M*[%.N7LE:)].Q89[(Q$'*1?1<SJGR/2(?]
M@%92[=2T(E0RO07&-\EKD=TBH=3N2-9RV))V)F6TW2$W<&CLG]%0?)6FO&KE
MY'S'Z#ZZG&L@,.]V7E!/4M7' DPFF7"D8F\):\0SN"/HRG)&F(4@&Z ;D>CD
M645FQ8,3NL/8BHJQ?3KUB<+S&M.FX7-+]G;@V& N2I[K]A67O5,]4-% YDLO
M,G@@W4)5&6>R)^"8X]B%'+^'J0M468?16A=5B"EE*@!-O@!Q8 J3@[X11#4G
MLH^SR[8Y<=@[(X48SBM>J4.P,NUN'E,OM5>T5&ELF=*>6TS)]1&ED9N+Q1'I
MX#)LA%2(9,,N?;!(7A6015OA5^_.E5*F>,(U7 IHQRF-:R7%@3KC47J%/*WB
M'=6!Y&1DE+JH])AVZ@BOMJ3%F+H@IEGM24;<*+ZFF^=2O#[W9"C%,M=WU.!(
M;ZD#,8S)YY2[HTA)K/["[Y)E28PD'0C)IJ+(!><[\]8F-;HL@?>DUSMZ^W)A
MK'1^='?0H5XR$^$YJG\\;,S,';GLIU0WJNN;6+/2-B&-E%S=Z)EB-4@Y!\W^
M\M9<A-?4H#(1;ZS!)+XFN'*6XWB)]TZUJSKJM:^8AP2&*"KEN)T)/$12M<Y;
MKDK;C P+%2B+Z"8B^&$5^\QH%,PJB%D<8P]STQ5J&J_MQC[:QO*%RXE5IOTL
M0]1*15C;T[4E^I9$3[1N58..8I'#[C+54"I^R=VV7J?6>M-(]FR#2Z]Q>,O5
M [G\J+*PSV5:=;73XZM6^K,9_O-&D,^J<28EIR_GF(W_)]MUC/;\4T=B_,E#
M(Z+BD2G\*M-CXC3V= *>FR31)T-*W3,(@4LP'P)3DSE]51>MD/\+'_(P.1"C
MC3(YN+PO9F6J?6M;)GM1.:&A36'9K""JU/;76VAH+R,%G#T%2V5%JPC% )Q&
M[2&09DB42;G3X9NB^K-0+!SX4'NF5:H<I?<RY!,[A?0HB^4(3/?$R G2$237
MOX'7J#*'9!84R4F\IM2?5\X[7>K!'F3IJPD%AM$QX9]3?&4>M*U0L6R=\V];
M8;!R//2*V 88U<)9L5,M.T\C#90!]I5/Q59H(I3LJQQ[%(_#^2M_USN[8LF@
M7YT?J5+=EV#6YOF?OF3.3"8*AU[#2V K=3H:Y8<RX[2) YFCR%/C(,.I((4E
MO'9\]T^RO(+Q4ONRDY(&^)6,+HLP'T).AV8,1XH^D:JDMF(G[P.)/-*Z)%'.
MQO&+IF-C?J8J?PO%C0O#HDCD"DS'4[[NCZY/SGRD]P=_ IP':MX>KX%B RK=
MS/!.T>;(\FIYX<@2ZZS["X->ZDG?."/R<0[Y)6$9*I;,O$<YUMQ(Q0^\E8YP
M@'P>"2YP%0?QS TG.M<M'4*5WIHDDQRGUU%3N\Q/S7C97#B^C)_2[8-)7!B4
MD9V)C'MQ#-/^4W!]0E(X3N$*+%B5 L.VXI"BKZJ+D'4#?+,,9;TX#+N$.PPS
M#3F=S>AK9-+P.6O%VF2R?#+9H&')9-FZ_1+K)\4>E3&(WE7((&)0%:6+;68'
M;[*7+W<"BFG^\>SKNR_8>^+\[/+LXL/9I?7^W<6[+X25=?[IXSOKZ]G_6.>?
M+J\^X*<(G'55?]4([BC/XV)[-U58F>2,9\$R;?+^H_=FI1Y>A)B/MT ?6S9?
M#X$\$'O ^4&IS)@MDM._JJ;[T(R!X5]<Z=&*BTJA-T/YE$C)1$PAQ+R<Y" I
M\=)$T^@XB<9CY.&1BU!;]&8R2L3:5SKS(HU"*0N5 ULG1FEL&7D0Y/KU?GTQ
M]HO4U9A2W4"1$#<(;QO3RB<"*S#PNW"N^T=ZPK^.9TG:1[;RGX+HU]3N46EN
M4\S3(L2<PE_).:=_)'Y@L:+,LH+9,T-A;T+K0V95MEJ_03+X %5=C?QO0G8"
M/97OA<L98E#%G2JPZ2_D*:D"EW:LGQ6;VGD::GAS)3IUTDV.L!1ZYW6I_+U)
M8EW*+R:!X%TG\R3_.ND?3]SB.I^3ZI>UD]SH1(*0(1.E\'.B(IA8VM5.S4?Y
M(L%TGAIX4^ZX,=U(7WXI$RXC8Q3%25H4GGH6(B4"Y(VUY^[+(\K'3O6-1609
MR00$4JM<E,I.OTLRR=:PQG2-&SH&S3Y>R6W$306Q\99>O^?"?#3[D!Q UL0_
MEA%M/+)4:JJIAPAS2$V='RUD/WBO+]V1),-*&#!9;S4$"EK<7]1F5$FZU/R\
MJ2)32HI5F<,*9R)Q92M0=WDR;?(6(8NOS I##0,U<V*)OX29%&&4YC*?/R</
M?0'#(5L++Q*< 4#'27&@PJ?BU'$J.<'F.<H%L^>D<EF-4[DORS%_D3.,9L'2
MHRI,2L3A.CYJ) [/@[AU(XW/9:9>*<5FKD2">;J:)GH1>&AB+1?2'2N+B0K*
M2)7D X+ KHS%1D:.+(^D+IA:)2/=2)<E*.>;?#&61Z+O,207$2-(J<Q7QEC@
M_CV,RJ2G(+GJBP!QNV3E;+RJC#Y__N6L"G*,(W31C _.;>BJNEVBX)>SLG+G
M[*[*I&;%15PYP'D#8]QLOJ<UB"0J5T&$NCD^@3"?*8;BL"'>_;X//QY+2%!"
MN1R)F>--U2:;7FGNIR<2VV[#N5>&)W#YGQ5E*L$=\H@MYPKE3.V2GJ96I(7O
M$.:0ZB*$%3Z\S0*U%P^ASJX)]1 'Y$M@[.!^6M=PK/WMQ@>IK<0#O0EO"^*Q
MVE_,Z3R=-#'LU&6<:(T4OKY%E$<\>.ES1_<H"$9W0<!:H*$:67>><TL9=_1.
M.&(>5FRP*]Z6U3%XY5$GNY04YIC$<L(6O6XR16$9CF-@WSJ:H!L7STI97C2G
MI/+4QNH4D$,!9989-:;E_JZ]P*09%=FD:V.E[5V!(ZY=H;]=?OCZ[L*Z^@H?
M7&WN#WU)::"TQ SUY]15#/%?S/Y"(+QU?=D6KLM2S3-SP5"YC.;_/'\E?*X$
M4ID6@2R[1HGX<M:Q+@V9%94(+<S:%O]>"J.S$I\O>D'!NU>)"2?[!U) $BBY
MDJX"/^:H^#1#B-H(N));+J-N4L:0-/>U5\-'KXUVI,T<G/$-W=^H1X TC%RT
ML+?@+,-^QC0@ A:7QCZ**FD8N+%R"L7A,GF">W:B,B'-A+%T>*[(7>,RU P;
M&9T'&AL$A"+G3QPUYA)Z^'R>W'[&:[-0IQH4T4"6T<Y-(7EM*LO;B%Q)"A2^
M6"5MT!G"TX1VGQ30@I ,8S+/O&",.+*X%H7V6Q]3J$0K)YVBH&EE59=1++'?
ME_N_&,;2F>.^1HS@;>!XI0HG97FQS:71D8J\&[U-#0_37L)V1N:=,T%"$.P1
M5LDZ$?.:[+4:<9Z>'GE?%ILK_$[$^U5 H'+"RD.AO 9X]B>!!\< WL8G%Y26
M6"4M9Y^1MBT[(Y*<0F1H [B;DE@0C)245.WQEQ2L.X]?J.VIS3K*$"\4T"VA
M+J)&&8J)2P#68<J=6_" 7\#"Y%TN\#=J<]B,$U&-BH;:TGR&S*+0L$@RLG80
M2N.SAV73_.[K,$!__YS5805=STM"F N"RV)@7/PQH5A-EN.D^!C9555>FSYR
M[6WN8.=%X')GOL":Z:I&A=E:/_C-IYVYBJFE )ZU<^TIM_:ZIR>'^R^I!%/0
M334DJ8S#@/:Y&K:!R>;94P [."D_K:7G3N;..?G@L9G?K6.GKJRPE.A$?*32
M;%48&.+0C#$*8[F:(&WQ3$$JQ-G?I6)5E 7+/^D.-3K+NJ-.?0_@414@E*#O
MQ011:7^.E2H;SB'9H-CQ!);9&!@Q*6%G!# J$M7ANWT97C/Y[E":X0E]8<MG
MY'[-)6@"J#:N4!T!TB(R%Y=[_ 3)G4QT'#8\T;%"*IS6F64G,.-HUURM^VT1
M2+1W;7#L49:TU.A2]@)7&QFK3_L"@YS>)O4JN - ]S>PY,QG5"WC0O@6L,!W
MH?&K8'%X^[B^B0BDC!+LJH(0V.;0**)E*Q:5T,<54?EW[-LE0C^Y7<AA!"?'
M W+B'2 S51"-0-)(?>3!A;./>#QHH$O3CJ^?T<I$V"JVPS0^0;93L(B57P!F
M$04^25,T[;(C<!_A:Q2NL *:&_R-I-]/7-L%QF'1B]4""FA3'U.L!/1YDPV7
M21Z&M9%DDV6BL 8.?H8])-=HRR>UVV'!V2HX6A0,2K$8[*H;R>@^F^D;#&PN
M"GM^7/LTL?R"Y%G-ZBX&<*]N. T4<5+^0)6]I3($#.^?^@G=_ ?P8,S-,K(_
MV:,":R.S(#?#?76HBW916G[4%RQ[O(KH4G=>_IRDQF4-:SK[;B0-;YU6-!$8
M+Z"LRB@.QM^U0T:W"B]-Z[#V9"A" YW*/H7,+I=G5Q=G_Z!-_WKU/_OVFLTH
MRI8J.( &6'0IKY7K[8XJ1X/W:]O>X2@%S6E"B#TTE:-#"Z82$^R9&\#"Y\ H
M+M?X++#!B';MFBP5IQ+.L;@>9CQQDXYH<Q&GL,<Y#PY;],B\M0SJY)ZS7\;:
MMK4WVD]0Y] ]!H;3O/0D3-R)S+!#4.NB7%S.;ML;[YO53U%RSY:-3'>>A(E\
MC'G(GD3RRJ::3=TFK!@;U%*=U20EJ:+,7(1-%NN$/3_IBC.);IY4G-$V,)X>
M%AF'LKHQ79)F:"I& J&)4Z\MOJGCADJ#N7&\97*_RB%OZ8"%8(],RM9'0;SU
M;()W"_T*SM -'0U](H [EXZ,VBL\5F0>*0',:O-@B1E$\I>P\@URNVQB&27/
M7=GQ[CXCX?3W)ICO "J94@*3V]3F###)"2[7[:$O80Q6/&$EZRY $L]9[0!L
MRW7 D44F21)NAY\C-RJD&R88P4E%&'*,D:%U2E1J,#M[,V,(-LD!2&6$CM8)
MK%+/RYH$6LHEE7E_J<A3?2ZP+7P2#+2:OAYD0Y-RLFX4]]O(Y_ 8U5YU*Q+;
M,C/BT:OFI-4O'3'=WLL8_IO5E1F1<Z-P3!U/W267P&XW")%G,NWI9U(BF,*3
M<FKVM?)/5P3>1&NCB0G>*CZ:L33NR*>MQ]:DTQI0A*J]2:'(:K'J>^QUUFDL
M]%48JZX@Y.3U!&5M.=XJ<DDO\!3>H$J%P"#I%IM,BF@JBSN]T??<5?ON;;4^
M8$7+1*O=19EL^4P>3E/0]?13 L"B'&+S\E'JDY$682XJ632G/U!D8 V]S+P+
MNJ"-P>RG<9SW-BM<?,E@CP[Q&ZUK->R'G63W%E$QS62;>>5!W1@3HM@UUW"E
M#UA1)@_RA;Q]I8<A2>5Q(B./IVSS96Y/O@!@9<X_DXR65.],)J%R6:3>X'@@
MB7W._L)4L/ER;J>?\(6"0Y(U!CBES#."4V]PD=?N-);?)A]20HZM^P_2MT5[
M8:Q$:W>/=*H3."3%#61'8T-H$(% 5-VKI(A^,OLO&\XNACZ7K6Q-T%63Q3)*
M& 7NLE$DT*>=4.O7)JWMRN[?3E^REX$ZP@O8!5@,W5)$*/Y<%I90)[*EI^\Q
M)-0'G_;0TQ4A5]A3&^L%C&C^AR]7.OE]1F7+PB>N$^B^(KM/):0'(U2R\,-R
M-BJ]5QY\ZJRLOD'RSI4%-&S=PF)L7=$,?ZC'T(V$SK*)*D[^SLC#AC>)X\Q)
M6T=\T):E.XC^2"TOV7>61*+P\O;SB;LI 8'=/+"ND59O-+4S^D\452-E\FVP
MF62PC-@FA^5(Y"E;K]3LC$=5MS%V94&! &1UKD,A9;SIMM&8/WC-<:%3DD>>
M7=5=Q^?NH.%F9LB#Q]G)2/11&XE^'JO]:APLDK*J*SX<SP<W]<QPUC2/"?:I
M)WGSAM18?.K5W\X26=;4Y9=5BJK;)GN_G@<38HWNZ<E1:?H</I0DD6%.5;2$
MP4UXCSWE,9VZ/M<'S=$#CEGI#+I/-6;PZZ26D>]^?<W219A\FRO',%(I]./L
M:]<9B#^)^!9U@6SGU51Z&?8;F0-IQP[?+E\2"^*K\X-ON0]&RCT.)V'/,12&
M X'VS/D"/: 99CV64T[F3>(-ETZ73.B);TFN0%VG951J)ZHV/8WE XPLC9EH
M]&[\@*UF"@#?.*XG'R^N]E5XCF"^)8[P+:YZOJ9'J@L5IV,GOBR:Q.1&((Z&
MS,<P(FF\9/R+S'8-=BN'I-4B?X@X#!PR&KQL:5'.&F$E1[E9F!91XL=7DP%>
M3!+Q;.V0D.R9E-9)_0HH/55%C79^AA0H-::9[2\!M'+O5N)?\L+85H*:5FES
M16B^-,-$5U!YW>J,&S1142P),EF8$YO)9Y=:_'2-OT--)=\AZ YL\Y=&]ZM5
MQXM"2%!'H8!RV^PU:<M; \^WF[/-YICXJY2KQBF$E$^\8E\D(\BFG]SD6.TK
MH.-4^I JL,MMM,TW%SF$< Y"]JC$!R]<!I?F<^XMYR/7:1GCB4^M]-AQ%%CN
M+\EK[8DHX0!F$78,4;8/[!JZ(#DYX3[]A-JMV^I,$W(R7X%[W?W,IG'NJTOJ
M7K1<H!\PTCF/K"K+#I/:AZ04?K-]F^$[HF=42A2A4R/<B=')*U&],=6DQ]Y%
M!]-R7$0]DLA<B:Z=ZW-<:!K)! ]31!DS>4;<YVJJD=95LN<*\(J^?R\/K(%(
M^H6ZPUZ"WG_&41PQ:2KY,H;\W>&K35,&4K37)J9Q\"*Y"0:65'(MHBO *%^W
MK=$RIGDE555V_A5O* >-\L2='P<2=%/>NLHKC'GP[E0:?C)^A'V-?2J7UXJ9
M\:6,/D=T_>K2>&"YJ0@1*U)]_Y;2V?#M4T(?<HE:G"K*[Z;U(;"2".EM&ON&
M*KBHAP@ET,FKQH@AD0CC&4AT6C*&]?=ZA+>4!X>3&(7!=Q$>8(8CO4[_ Y4(
MA(D,R9XWNR<H(!T"PZ ](VE$44_*$' HA1!,R0.92BC73LW(P00.)F\I=X[:
M1NGDWNG2'W-?;#6^3JQ.H;5(3N/Z;$RZWJ<P72:!V$#%M-!O,YF@ V(F)M<4
M=0&*1@IWABO 29QG/^?FF&@]1XXGC*W%,,)U2/0U?@.SF>[KCLIW BIRR3JW
M@*=6.]1?2PB9W,QYA9%^*:7J(9 K[** 5VJ=,N*P%.[J]3[CB:;?;="/E5*9
MD8\P)JF+"TU%F2J2=%[N=9-,THF =R0HJ3J!C=)@IY0(JKE-J[0PKQES6RI9
M5Q-SZ@6W!RHMEI1HY*P]JON7/T@>YIB74G9Q;)?'OC)U;?ESHUUFT4\*Y Q%
M>Q-VY0[@.YN_D<UJ2+'56U),OM'QL_DP<^:R"GGBL=Q3><&VD2-,!PF+G6(P
M4$9+KLRBPM-T8"T.8HK08@(QC"L;;BR"6TZ&U1G*5!BUC'7NZYK\Y[WON:V'
M+<<??0,!%TUT,QY]9&S9A$9%)'48,^/)-4]IP1DL./\.2U@BA@2WM%$1@VW#
M\X/RG1S0<P*)Q@1B]P<FTU'=$RP7;M4"T]_:\WB))";%#]F!BZ>(664"@5A
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M?,<J:PX%E O0HD(1TN'6<"\$[YPURE&MF9S'!2^@R,P9!LOO!X,!+U>1WA6
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M#-7<,+ULZE\DW7]D"\15A0[PTM+W V9YIW?(,TBH:UQPJ?$]=RQ.$L.#S,I
M-JH* +HX1B)<<QD@$T;$/);A7$I(P\QB<2%AO SM=6Y8]9#^)#YNWYV-&)2S
M8PFH^-VWHUKG\WL>=Q"F)4P8_#ATP7'!WA9C0&+(3]ZX)OP-V]4+/O68:S,"
M%33DGH<!N9W+ 2PRS>6Q ],!C6(OV&5<FSA*.T#-[\=O-.XX9',3_CQHDJT'
M3NK!?%8<NOW)8-J;LEBL.5&L6]XH!99XB?B\A5Y_'&6OQIO*/4.W@) #$D>N
MTA!QD&\#\X>@5]-A-05SPT6(,YY., *.A9LN'@-+3,9\I9E(20$W*?E*)7V&
M-Z6,D\(0  ==>2$,A#N 4N+B->VSI(EB204^#6$Z\"Z84^R89R$I?%;,X1_[
MQ_G1LNP.7!N>4Q5J<!P2+J)G]N&6KC!)O%KP*EZI!Q>=A0VMAA6M?9W@P*+B
M%-,(XVEXC5L(#XDAAGLTEU&&\L##&SI"%%K!L$WFR\@+?L6#'Y<S1K;1F,</
MQB_>09[J9-DH+H4:4P@+S8QCN;B3GD=E\0."Q>>M(^!DL?-#N^\E[DJ6]9:'
M@!S*CYK868IDP(92%;JX$9DOI].A=[!P(Q9!@" H3+!TIX/'>$6@&#@R8@%:
MV<!&,L03@B,INGY!"(Z?N79:_!R,ES(;0(DQD&0P)6D$;#;R-80O!=<(ZVF%
M*XQ;8TT!81GG<:E#XM'ET%6"+(>Q%]'R*Y"243C-B[W/'_Q/=!4/ GH3XV"&
MK9/P&I(%/2<5@S*B=-%EMR,\(%T4/QGNM7@,R>XQ;3H/CM]Q+ P#W_GO 4-%
M%J68C;N.Y?\4^=>>4O%QR&*+A\/IB+6I])!/EZ2@A<NQY,,?[Z9Q&TE9MT/A
MG?P^UO 8HG!>8#&4649+ \M3>(D?O#:\XIWR'CCN9CRXB84#)HKQZ%\0A4"'
M'%TR#(BFSA4_%BKX5M1V!_1N'B#.>,&C\-HABQAE0YFPJ&P6Z3X6W-SE+P[Q
MYQ/-A^C#FDC 7 OBB]/T'^,,_VCDBNW1VCI6??$^6):N/BJXQ*C:BKKUX!)=
MJEJFN4EPR9*'0-9XQ;%[?6 2>L R[\A^-1S?\M_U^V];\WK] :_?!1=<8CB$
MVV]XB/NB8!I'KX$D@)*); ,EY7EC'[,\;VF9GS_T_&3,.SJ_>OCY91Q^/IZU
M,82\=S8[O^I?75R=2>=*2S\?XOL^]]N_?]VV?S:EBZO6W7E@2^<__XHN>M>_
M6O6_KEJ_!X-SY;O>4EK2Q9?3H%/WKLY_-Z6VTOC=J;=FG?KGJU8WON???_6=
MH3?H#+_?PCA_PUBN+NJ_?L.<?EU\:>*8KUI7W]7S7DMK_6YJK2^MNW__;DU:
M1]+=2:\Q:?T^PV?^;2H^(;(AB:HE2:)&+4]T),D0/?C5<1W)]HD,!P,9@&@.
M>M<1B+X>60Y<WQ9G[ )%\VKA"J^Q^E2/??[A:=TGY^[@DS;TGBY1#I99?BL.
M<64K#G%%+HL*W+\?\E8KYA9MW$>==K=STJS7>HVZD%9&Z&)IA.-FN]8^:M9.
MA&^=;K/7[+0+-)LU/1V8P6<\A6=P,S([@P(8B(?J0H@6I#N77D]X3E-B-WK_
MH/K7Z<Q>6"\!'<&2'Z.7&&954[??GU?6JNHCV_[>?TW3E&<9K+S'$?HK7,VP
MMQ:MN*N?%A;YJOW1\N>X4.#GSY.Z3\_=U?G+><+TNMDYQ/UU&0+>>6(\1->E
MU/<_[A9A8V[W [9][6QCO&;&/3P',(A$2 9^SU*$.(I":1</#G?^X\X_@#?>
MYGINS%(^^V^G6.HH*?#R>-;Z\ZQ?<[?SI_T$[EF:[J.XI]A+]GP,4N@S9TT&
M!L;KI>&3Z$N[(8.%$-A%R?)!DY:$8DT]GTG^^TE3+ HUY\\M-C<?A[S\D3 =
M!=S8[!+O8-'Z;)G$MGW%\TS;US13@;]=S745QW,M5]*,OYMSH[-'W6!(!M&_
M#D0U,4$'?AB)6';A$&FI-O+PG\:<D X$7LD(OGDW.1Q-AZ(W9IT4\$G 3+!B
ME+'5ZYJM\3V\:@J:IJ6+(;RE-^A?],ZDUK"I=NK]04OY?G=Q]6-P_O.TW^F=
MZ:VCQ&P]5EJ_^T'[:M#O_&S,SJ]J\'GC=Z=W?G=1OP@NKERY4_\+WOGK]N)H
MR6Q]=?Z[\Z6IP'WZ>>^OH%4_[9_W6GK[ZOA7>PCW_#[36L-SJ=/[_(N9K;N+
M9FM%LRQ=LU31EAQ%U&1#$XEJNJ*K&2:EJJQ)NG[P298KAF$DUNJ$*E+S4T'P
M=D,61(EL0U;<IARYRX"8OR7[ 8CW^M\> HB^"OSD6;*E2Y[F.(JC^89F:IY"
M'4]2;9T!HEP"8D$ <;8(B+:O4TDUJ:AI"OPP'"HZQ/1%S3(5&SZRB>8=?-+D
MBF(H*X#X>J"T7\K86H_A+QK;E], \;5*BK+9Y',AMA3,. YQ+3A-EN&&IMH-
M"0:X&P!'$6!.B4O;PZ7O&4'-E5IU]V_8,=,VJ2-*NB>)FJDJHH/A!L0A"E$\
M2G6?H-VS CN]RX):/BX]JZ#V4)/%KB-*D22;1R"*']Q13_Q-PW$))IN"22KD
MN/#\7W_KAJ80&;0^Q:0^2CJR:!&BB7!(4)4:BFIZ*G*N!<?#QZ=*.5ODZ+=@
M4>NP=!(L&0H"OX/9%.\P>5C0WS]*U'FH-EF*.@R8V.K'Z'0ZWX,2<1XMOG"U
M2L?](!H1J2;9(OQNBHX)/PQ#]6U)IZ;G N+HZ+7=7=FE>$:FO8&( LDN)41L
M6RCA$*&IQ+1,V0*]1C9%S?!]T38,6W04U?,-US95W3OX9.78H4NSRS,7F;LF
M@<>Z08RBI\HCNZ H%4@>B7&&[<%L6)I_MPM"9RMRBDR("CM&1$T!]4A355>T
M/%,7=9=02W4DU36U@T]J15+T79942BO+6Y!42O!X9O!8DF"(ZSN28CFBXB-X
M2$07+=<$@<9P),>Q%(WZ^L$GI6*:3Y9A2J/*1F=W;XQMN=R'1?,]0%=:&]A9
M;&PJGF###;\E+&T/ELY79!I#5V1BZK;HPJ:)FJ-KH%,1671-1?952A355$&F
MT2N&I>VR4+,1;^Z0869'P:9X@E )-L\ -LOQ,X3JLDD,D7B4@@PD6Z)-71")
M7,MW; OVRY(./FE:Q996P::(#/\V3#Q8BC4NA(M!W->L\!DW]!BEH><%Y*%D
M"[X-" #5R&LDNU BTD:(Y*Z(/[;BR@8EEBC)CBMJANJ+MJ;:HB0YJD9=0Y=<
M"\6?G8YO+@TZ;T&.*4%B:R"Q;+HA&I5]7Q%UW9%!1S)UT7%\291MW;!4US)=
M3P:0L)\<\UL:;C9BLU/\71S[(NM#S9M7<['$*N-A7D L8>L_]F'U$^6I!)H-
M@.9R11J15.(Y+O%%W3 ,45,41W2([X)^9%+9='3/M=6#3XJ]T])(&0CS%J21
M$AN>B@U+0HAI^(9C2T1T-!N$$$ $D;@*%3U#]33/E0S/=0X^Z3E6VC("IHR
MV5,)I#T>N3E^[!)J-H":QBV#&2:*?%=:]<;OOWU#A4WU91'D#2)JEDQ%B]@
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M)5,U1.H9IJAYOBDZAJ*)JJ2Z5%(5AQ(#H$"IZ-(N0,';=+LT4UU'H+Q61E+
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MC(1)GTR$(9D)#A5"Z@Y(% 5^0#UA,L:<D_LUH!=JP+OWS]@O=?K/+K=,LI]
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M'2RV<;"W$3&9:YL-[;:$ZTBY.\R0N#,,^:\7<]I5"+Q#"%SM@QX9%T%S@:C
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M?[:W)5M_+HFOV\>E.HR9L)W;I_-Z]2L+;B)SP["4&YA__:3W"8_N0T'45>_
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MFAO?SYL;?QPW3[9^PAC%]L8ZW__09'N7?QPUZ?[WYL8>VS_:XO^Y]&Q[8_-
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M;HVYJIR8CH>FP%L]W$AJYE6OE#>-R;SBYWD _C.LX9#K(=ZNTMHRGGZ5!72
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M.(DD:U@4,8EAP8"PBEQ.G9OI"*D:=VK<64[<H9@'09D'ON.XR]M8QB #I48
M('&U$-QY#E&8SP64=B;(D$J184,<8D$X "4JD=-.(4H%BUQKC:7/@9NS<L6>
M#I9>EH_L&LMY5;ZZMUK64DM9#N -(TT;RE:'USK2Z-TF9";P/FMTRD6?'&$N
M C1Q:9+U5H7D+=51)NYU$0=)!G&0M\I3'*Y*D;"X"^NP>P@3^^WPCZKUZKO.
MB:NZI_5NB6DS\I9K.+L-G#6G3-F>!>PLD"HKI 4XPQ:9Y#GR(5JJ%(>]H%8
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MW"(RR^\D"L_(#_A:93NF*+ !8IFXXA@4>X6#9EH2K%R$K53+]A/(]H12(+C
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M)+=4!"19C""]QB"MA$?.F=Q/1P03<WV+Z="?6GI?C/1&$93%5&L6/>?"&R)
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M+@;;Q)(-485H .%J/'M2/)MP6P!C]E:YB& A/>)P%"$;4T""$X>UA'44N=H
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MXS#7'FAC=MK^(KW=B'W;.H[A+IMS-_]B%\;PQW''?Z^WZLA6_7( .P9K[G/
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M/)9(JVA0]!@+%5,.KEU9(P:!X/</!PM:+=Q:XQ3^Z81&_Q!.PF^'11! LAX
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MPUY1<BV-_K!>4<HB$9P)98+C/"K-%;4N8DX5%TF;6=/I5;GP]$8%@,O6K@J
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MUQ\4@Z[:XC\@LL7B=0=O#)OXRP;Y_E#Q%K 1^"7T[-MNHE8(00,BL EYSHU
MFD>-L X4?G".9%;=\<;>!1+-R3W 7V.Q9[_'XEO&>F4'?1;5[F#?2QX[_W^G
M[=[/J0SEZY>,Z[E%^/HGBBPGJT5S],\9GGS/S<.9\RRWTI]'V\M4)9G@ZC*S
M,P 0C)0M^;8_;$WNOWD<,>#2="13OFHHFW^3+[S(GJ!W^.&7?8%&Y^H9/.DS
M,,_20RZ7M%/ZSF3UZ[C_VVLV7\?]X[FVR4_!)3"7VI8%?ZX_N1F&<&4*(7L-
MS^42V!=#9%]<0ONBQ/9ESF(LR5K)826'E1PN]?.NY'!><CBG^LPR(RU6Q80#
MMQO#)_GJA-CR10N?KAWUU H7(0K.O'%9M'+@_CJ[I^=16_&P8O0[:RMNX>Y;
MEJ+/AZ7SAJ=T/^JM U:_V-N#=9$=^*Z=P_>'Y:D<K;.=]3S59^M'G7XF5Y^Y
M.J7+Y#7^HOEA@^0U-5H?#[>_[N13N?WMBW#06-\6C?6-BYW6EX-);3B,B$Q$
MZI 3F? [1(8<<1:>;Y!!,.NE"7DJ#&-Y_OEXS><2G=,M:/OV+^2?'L".^S [
M0L>MR%V' #?/ *[9F<VCNT[E,HM-96!F-3#MFP9&8; OCGED K.(,RV02URC
ME*SWQI&4.%]YRU;%^-2I!Z&^.=9Y+Z^'GT>+[<.X BH/_](*V'@WHH#6*RJ"
M0 %3BKAE&!F%':(Q#_1@ 1M95H(KR6MXPFRORLN^F)>=O67T%B_[,%VNO.SB
M*OD(C(\I*6VT1I(JGZMG*+)6:#"B/#JO*9-.K[SEJWB\VZ/RLB_I91_&I5AY
MV1=7P)%J5ZQ]@$T+R#D)<33EX&6%B(A'3P,.3'+M5][2&N6R9KBJO.POZ&4?
MILN5EUU8)6^.0.G@ 3E11Y"/&F)9DZ%T=!$1QZ@@3DAFQ<I;L<K(W5[VU^IU
MG*P_'X9E>(]I;EQH[S^/+/HC6ZWO;U4<FHGA9MQM(BJ ,#_;,=[/Z/,<38C%
M![W87&F&K&$$2899B-&SI,/*6U+#>#*Y_!(EVB=;J^=L2UPTB#&W=/DC#<:C
ML,941J3"&0^Q%2,Y<X,E,\%Q%+A@B NND V1@A0R)RT1ED8*P<0JYO.)YJ>M
M0EEVESV/@-TGET)*%O[#7$9CE>16P>]&1DZX*#607&K@ R@H*Y?]4FHXFCG'
M-D6<<$3)!?#;U%/DHM3(<9%,?E'33%%9TXS.D:&R<IOSC\P?J;25VUQ,?1V!
MV,9*1SBC*+@\B=IIA8SE!GF&O9168NQ3=IO&5&[SN=VF S!*M+':ZL@Y#58X
MPY@PU!* KP:7&H@O-? !8S<JM_EB:CB2"M?62ZR$0"0E"FH8 K*6!12I<@QK
M%EEF[@&W253E-A= 7V]WFX]4VLIM+J2^CF:U(=J4GC&+6"9AYT%39 1S"!-I
MM3($NT&%%KG';;X&+N#WW5Z*[0?GM9>!0'1RKFI&.N#G2FQ?[4?E\)_+@&R-
MI;:I%GEF8$261Y-+/.$G:1,RRN58"L=$R,I;26M&TL4@&YV?A:K2RH]U]%.J
M<.7J'Z*I(XEE+8*ST6@461ZZHO($ B8X8EH:;2(A'(OLZO7B%6,OM,^<#X7^
M,V66*Y_Y IHXFELF(;CH%$&<:@Z@VTCD% >ACRPXY[$M![D1@FN25$YS(:/C
METPJ5T[S"55U!-XFYGEP$!HSK>Q@;(\C)B%A*=%8I<0" WB[2N^I^JJ<YA,X
MS>?**U=.\R4T<22SG+@#KZDTXEZ!TZ0I(B=(0!@K*Z/6#$(8<)J<U/BBC+6H
MG.;BI)0KI_ETJCJ:5&82&X>Y19'D0R#")3(F4J2M-XDKK86Q9:1Y3PG3:RB5
M?LR N64X/UZJC/)P,RHW_URVX_,X)PDX!**]1E@9 [%Q<DCC7(%%) 3&S DC
M,-@.S&N&/V8*775R_$LFE*?2X,K)/T111]/)2EF>E$24,@#EF'IDM& (:VR,
M,Y0SR0&/XU5]>S]#57&U[/GDRF,^NR*.9I.9)LH[:A&))"*NI4.&T1P8)QQM
M8)'FDBNJ:Z"0E<-<Q+CX)9/)E<-\,CT=0;9"X:2,E4A@YW)4G)#V7"'%'"/4
M*AV8 62K5N6<#F KA[F N>3*83Z_(HYDDJ/%+G%#D B&(>X N6HA%,K;'X54
M@N5,,A4U,8'SLG*8"^ P7S*17#G,I]+3T30RCL%1#(JI$Q&("V]R2X]&RB5#
MK 0E=C:7%J[RJCCY[:7$/BR3O Q'QDN621YN1^7HG\N ;(_3;K#$<'0)69P
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ML.KU+^T&?%]]?>ML>__CWC;@A9W6)F]<?./UUH;8^; #_G\3<(;?U8%%H4-
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MC>Y)+ AY<R=S\-QY8C=L+W.AY=E*)9)8).;7@R$0.-YK@)-N',(U]NNTV3H
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M\_F=1<8Y+JT)+%J_MJ&7E)2RG!9ISPJ5'JY[VO-"I2KX;S4J/10JS?E>4?J
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MJ2MH\QTX;%Q*[)AVF5^0KU]'R;*D/<]$@:,.6,BD0'V8800[JXUE@@"RLI^
MMUI4EBTJ>_N'-B5GN%7(,28 Y)A&6F**,&Q&(J20I,VIX>OZF@X+OS1&QW9T
M%QC#U\'8$."JT[D$K7'/=VR["Q>[@*^A;P-TM5/;9T"-=N"/BTOFVP[:&=;
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M@C=B+_?DO;;G,[WQ2:[V2IWG+7G2A_M'@4S@+@!V%?UF7\.N$=HPD)#;OPX
MU>(W'[-76)3XV2YXE[EC+D =[#*YZ*\'QG;N-/S+,I[_]B[=#[_V'>/E;L;(
M0MO<A[&A^SU_EJ[8SQ-+[?5%0^ ]6X1UOHU^[_3]YQ=I(V\?FN2%QPXCZF-
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M2><<KZ--F39>FXRA42$-(H", V#%VE.<VU!0N2[P2MN7U2-X7&4 7%(@M)(
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M>>)<CC46DB GA$<@,A%92Q42)ECJL8M1ZESQHW#=$?T9J_H3G0;5JOZ JKY
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MGACUWQL/EZ-Q'!S1MFR0)L=(,,$1"A:"T<Y3WU_523VY7EFI\AV1\<U94-]
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MK['9SUW \W=N-NG"'W6C*!.F(AB*@DJ22'0)Q#(,-@1CW&D5I*$];O"]#OS
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M48X2INE3V:V_I-(]XBH-@B':*T&!DW(<G(@#]'HM+J^*BH"0(]]77E17";8
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M]A8M'"+$'C+=F\ YAZ*%@\3^0,K[,3+K@TJ9M9&>@R2&@HB:@N%,@DM.98N
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M0 :#;!,71!O(5I5<@'+R@K! EI8? BUB:?OK8?, V//4GYH,=1-/NXFK_(A
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MTMK6US\P.#0\,CHV/3.+F)M?^+VXL;FUO;.[]V?_X.SO^<7EU37JYM]_N-
M&&C_V_X?<9$^X4)_6@-,G/]PH:'[_?< *2;6*P%L,GD='"N/YTR"GW#)WZ04
MU/7B,0OI(BFL/7_A4[((;[">_0?M?Y#]OP,6_O\+V?\%[/_&M0@@Q$![6CP,
M4H LX)Q%LMS6VB!"*M8[L;/2YH(O0JER&:8-<5ZZ^9&U@.\L,U2^GF,K-4M%
M":4-TL'/GB4S29$G_]/MBR7/G*9K(G/Z=6:9@%=$6<VGHW*Z "*(0T'H,LKZ
M*M-^J:E"J'H+POZU'O'>TY%AIV5("^P_1%9IVF7(D&YGR:G!W&IQ@6,1Y 4Z
M9L(:U P8U__PX:9(M91!!-]U0!R(KIHV5[-4^JWQBM^+X<9$&!C'$S%J+@)U
MO2VI=NDQT%-)2"#B%1T\]SG6"V#V47;I G4JS6=9BN<3.?LW\T]_][N-5><>
M](;39 4DG\F;XY>'JNN4:79RQ1;RY"4X*;KO]G >J"8;G5*$+D$"9I0>%+4R
M-F6^1GUAIO/261[=@8IG.5N7'_ 9.RW;I.[QSE^6K PXB%<(J+P-;^)-EF*>
M2W;3:VQ:XK7T'O >8C#5KVO:D)L8M1Y'9+'VI6AG/+.<+HJB;\1+))A42_8N
M^=I3D,=6^=64=*SCWJG\KUYNY<@C0+18Y9K-J]/C':T7)!?13 ^S<AWBX-:5
MM%O\.@X[IZ(0JL9Z7:(HZ,/!VS2T;VBEP35-/J@6#0&0X.G@A8(S+-OU%W(N
MHF<[NCL2RU;*5PQ=ETAG#9^=YMN'XKGHIR@M5?29/ *R]<.?Q<E+O.KZ\.7-
MK%">\ R?[>)NZIS<-#X^[94>.SBA*E96RN"'ZZ"RL!4<\X^.!XP(1.KN,0<+
MG6#L%.2V(WO'IFF#:X1#P5)!KI]2_9Q"6S=[@*OI612K_3KB&_9@E?>L #O,
M43D@O1S=N=XV9L[I2WJETJI/9FRJNB(G!.";ZIL/-V]3_%O)8AZ@?5%9MQ9P
M=IE?-&8HTOMM1O';VTK=^P.7PD0)ZXJ1%)?:CD"#B$+OL$A[>;:YW<:XTXA[
M+K4ODP?76.R#@D/K#=8)3KBM1=.\CX"@-'G6+T<0^4&9<<7><1#BT. 'UW,H
MEE'D2Z/,6.=<+LFLG82F:5/X+@U.Z.<%?<]X_%HELDHSU>98S!&$##A(+#J6
M.:0OOS58&G3!TL!XBJ7H@:%W,3^.IF?Y,SG6L.5()R+T;U?!(R#\35?8>H$L
MR?!]1-C%DI\EWZ"8DW]-6=AZ\N<'D>?(1\##INP_U_8BJ[@'S$= WR. >=<O
MN:SB^(,ZHMQZ&8:^N-$ ^N,F\?OO6H)Y) 8O*%&69_;@3C_!3=FSE;IDJ8]\
MMK[$47XG?HI>A>^XB1#!VD8J;=[=.>!Z8RCM\6%<]%:8[$)"73V]-;'(463.
M(E+T&Z+QKAB+5RT)UT9Y0<EIZXLL37VQ)52/@+PC)SJ1L\MW;M BZ'U?Q8KI
M9NF'.@O59J $E:[ *H1WLA.=30&.5B 2&MAI)X--9*\,:: ]$KXF^FZC*[G!
M5L= -&U0E1I-8=:;4428^'8)C&7_#0]8\&%)B[/IK+);F$QD]EM*$*CG;3EH
M%S\Z%H)HJ8@AA95./HV"15WTW?<5,-VO+,!U$&,!T9)C0Y?R;MBG8XY[K?%X
M#KJ@,M&79MT)9]^>U3,-*/,PD, ';4_I0#*"&&IZ;V$_;'728JOFC< *=2R_
M>0=E>")_+'\Q!'+SCVOU,=O#I1D)Y@J9L5.R'$NG%+;3'$NXW8HL5V._,Y43
M&^#GL8(Z-*3->9OR6Y,FR.^&8EQ9%BZ+H"G&5E)-E:^7/51^C#-PMI9(GI3Q
ML7%]Q=\>DC/)C<MU!O*]1A2ZBOPYEPM7B*SX^:8+/)&0#C2PNVG0D$A3YE-4
M\408L"]Z&!@H$FB^;HGWG=&(BG+=32Y19/A4R+G"_^WFGO.E9H(!9!G?Z3/!
MJ:XT'_JA4S$5_J4%J(3E6[ZY>FK72$M%B=XN*,;V7,]]1T/$M2M<7:3^).D&
M8>[XG,(X2I;30Z,S;B*Q,I]:@)NGX]_<C[>]7-TIMXN=F$LVB\KH1>B_< .G
M ]#[)XOU/TW=+YI^%U4"5QD*I)69'[>*[1L(5^8<-P/5WT5\KW#E8DLT.]=5
MK3>$*(D#N8A&-5)4*%03!WTV#KR\=MXZ_3+EIN&#AOE,%_%,Q)43GKL!W;7C
M&($*5[Z"H/PN_: P"4P)595DO47=5T +H=NQC/VK11B&D/W7QC4]$Y/ Y_3V
M/P(:0H&=]KEF&/MRF\I"]# E QY$H,KU[@^1]@0T[A33:BSE0)CC<"TH*'T%
M-&6N<O0E,:M<DM2 Y_TRPFU+P[CPCDO9;0BK>HLWQ/(1@!DA_I18G^]D'@$M
M20]9;I6[\J55KI::8;VOAM90'.[]:[=?PO;K3SYG4=SA/0(B'Y3AE;<#%<VN
M]5DE*W7F)26=G^%:'!+!8[4K H%3G].K4*Y+?M.-^;2Z$'(_O% =D!N[U:!Q
M\K9UI2;Q58FX&R@[(,YX9J$N-+V9J(M+J<F0+C9%6N.>:7FI!=JSUE8Q9>("
M9!D&3PF_W=LK-FZ*K;IF 8J-?]O_]\F3.]>Q)1A2B6V$R#1[6<10R&Q'_KLI
M-]U@<\^V7;[(&**\&<$TP85;KF')*D^>:[P'-8K=\-"> J^H3/AO36?-%=LO
M@_E*("Q0+X:](I78I&)-3M NI-[-+'#ZT.JK&XN]C:%WLCE71\;2:O7"\ [O
M2].D3A=YL^H2^"Z=H:%W^]8=-_Z>U@H0/<50H]G)V6UL<N0%T&*,OX%PJ]A$
M?;E9FD-.8[<HYDPG4Q?&8DOS(WGI*RM-@ZT9$"P^-DL$^.ED1!_#:SEN >YI
M)0+MF9?&@FUI%.I\3(%$/:.EKVZ<)D1C@^*LFL9AW32-X[# 61TNJ(J2(NYS
MIF5U_5C!]!?F)>FV/24JHQM]"!\QH,_/[0HH)4-ZK*YBS+RGOM_K$X5#O:6D
MU P=B"]%8VOJRYN#G7;RQ)QM]-V\:^7I..S/4[8Z/+*<Q3'KNA,H-1YI'IT4
MWT[@+E/VFN2,^ZO[A7)J4_,'I)>AWXXSVV_?3L<2M5BL*8)S+2U-8866/0JF
MDL7W0_??;0]!_/E&ECO[AK^07!EU7!67VU.J%$6_DT.<5?68:J%K9!BGIB)_
M,^6U7HH_Z.A(H23!QM$4)D9UY^].I+&E@K**E9FH%XM5K\ZTK1M8502I7WS=
MA9*FZ/03$VGN[$)(Z3*<N2YV4VG-H09J[_7MU0+17DOZETA]<W/*M5<4\6%U
M7,"#GB!H84:I6W#MIYE,_^PS:%3?ZH:AG[CS5V3&7&I,](2")TP0@5O%]*JL
M-:9M$ZK:AW!H?[?BA(8I<FL+90TI@ZF)]P;6Q[4ZD4>_0"L7W=:7]+6/8/O8
MLJ^T6"[UN32P3N3-;GUIZ_W&93[#;O%GM'B#3^^9JQ*X7 \A[5(#4$ 34TOK
M39VERE..,/K=D4MNG-X/=%_\]K,4;M3D@5W,WY'1+(T]955$L+3L%>DC8,9U
M!4=&"/4\5/NOC#6LR1;<N+]3:N+2S,2\F)]Q:1ZX^SD_++LB[!_B]5>).9MN
MN('K0HKVAX5OV1#]V]GH%+4O@R)?6(?&G,0HV,1*MG8'5?/=3M\M3\;"Z(*^
M(@@68JP=B3.8+%<A7J] #_J'1N73:BWY<75-V:J&MB[*H.,IAG2I:#RY">=)
MB)Z!]ZI>7J<69,;KI/1M%)K20*HVY1K4\!P?4INT"U-Q^60VI4.H%T7A1.4Y
MYSUYI:?5A(CZ,/2)*6BD[@;D/W5"(35?M@E)Y="<Q<D?_OH6K.(N-0D>[>ZT
M JH63>Z.RR58>VGX*T!R;/KV%@N3CX&&4Q(4#O$<FY4%XI6)HO@J&SJZF+0'
M*@XO?TEY*[@/'>"W"L)S+TJL(%4'BDP.Y.0FKV_B-"D/LB&0A1VPY-YO(AUI
MW(Y+'(K7'_J!*5=Y>6=0R5>[RA#F5I:1CME?Y8/ YQ2O7']$;^M.)<RS%3@L
MZ8ZR:>JV9SI/75'ICG4=O,N"RUO?HJ!H#)(Z$\)13$<FL0H&]!^X<#0;WS+T
M T;AS#ZE&)^U%M1VRU+(-[\=F.0TN_(XMTS/?'A!)U9B:66X6AT0I%NVQLFO
MFNXLV,B= <42H]!:95P%?;$GA:BW4.*H*<OR"KZ(",^0\WJ#+?!MSB)_R! *
MVN$J'LS=^S<3,LJQL-0X/3?QSL52S2Z]-JHDX]".EHATE*U?TW>%%A3@1E@#
M@3#F.+D-Z+([TS2[,J#VH>YM:NV8;\3VT<B4WLWT#/)$0QQ==Z& WT4+,C +
M<85NN/;LNR$AX[,5T6P8[Z<&<D9>\1]CLQGL/^4OBMIEU*:Y%E_,B[!.DB]
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MD9_ ?-F?VP3)'RME7(!J4#]C_Z29$>?Z?-\D]+./)]-[LC&$T;+[.P7AZEX
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MP:IZ+X 5GZ@:0*P,R";,)DQ5/0#1^%=['TCSUJP\.&0Q;83"=-=#KQ=K1CI
MQLS+EQHGC!B,_!1Y@=2C(]!*6I<:N.)/"/1<ESY^A?4%+>1?Z0/><_8[%]H-
MU.7#K_^VK!'!P_2U\?/3:TB5M$< +0GJ29-[_+?_-?73Q1#)_C];UF)\#^!&
MI3^'A W8=\ZZ?;Z.R%EZ3-$DV)^&G+CUV>:,58<)SJ:Y05-A-)_G'R;!+GFL
M8B*4A6F[^=61QKML%2LF(?725071!2\JA]8\RIGCWJ^_4YTLB:3S? 24QSM\
MCCPVA0C+.LA5B-04:TQQ0]90EB7R97>JR!78@,>DNT?E[WYA+<%Z9JW8,>4/
M\B_O'8E@ GPV,24K*5O5 JN5-^ ).$Q=%',+&IH0;(HR1V8-R")U>:G6-<*(
MI?@W)DE&RY8.YA>+VX4-(5_#AU0-!@4^D1,'U^K@\NCG0D'=SB3A:P2V*,\9
M3>3!EB;BPI+F]S[EY[XNDMG&I&-:I=9$<1<+U>%,X=/GXJKZ'R>>.[T0-Q0+
M:V1:-N1&L%\?A?JCY]>,=;.O;)W,_@JP"]T,!?U[=>OX,)E+,1OFX$[IG(N#
M<E\WYU= Y@QF:UQ+L!44^,<I3ORJ:I]8:^_XJ89\L]&0*399X=Q=[_[1+<SY
MV'1C)IA@RJ4# XK2.&AFX(Z=,UH<V@F5JU5_J*:S834D-LI@2>1HE5W4@1W]
MN]IW/Y=EM4T4":[G"R+CG*AC4.,[:1T.,[DG0Y$B<?HLB%% )(5W340;_Z!*
M*/>!X"*JTK*S,?7XHJP#WIJ0N=.\($J73;(B>D87[_[LC@%E=0M\^+G&T*'J
MOFY)A/KK'AU&2J7U*PPV/E(W,.XH,\D2H]#A(3Q-%+'Q7>GH7.LI_1V5L]+9
M.]O\FL<M]GKTN-1[T3*[E!15R7'AK2"O> >ZK>ENU0[+6XF[5TCMX\UIBV!@
M2]N4#PG %/6)1_B8*41=[==IKE_\LK8SSD]K+G+7=TH*](62F>I/!:6.*N(.
M=&N*<K.D\!?=N"Q)#UH_7/'3;$!>B/HVY3*WQAJ]^5[%.I 2X#%1.FX^."K.
M[C;5&O,P'8XHA4U.V#<DN4DU+A++#:.GK%M^.[+,._68ZWJBA.%Q_L][?!FQ
M@Y]O:E+U'6XD48*ISA=7FG(V3.]QU&:AL[*<%%/4J2+Z.-DY$P'4P\/PD9+O
MOY7JRQE\"C S_N@'5Z9O^.]?5!1J)7RY7Z1[!#08?GNO3R0R7P+'Y3N>$W9/
M#[4Z]YBK7)(K =$:@O.^VGRZJ)RIR>;DA;Y^!*C)F4=2<B K*$( 52'!VP9]
MV7Q<4:7.>]6.M.+CCM_WH,>RVC=^-#5821EKOM4$43'OWZFZ$%4.LCCLEFVT
MKLJX<:GL&( +TDA3C*\]-@[ELO4%E5B K(+Q:J!S X-#\M3AR'502$M^ZL%H
MRQZ,9<MSUO>F7(Z'\Q,A!K^A_GM]CG9MM6]TTYQN;_=XM1.SF,XA&-9E*;9Q
M'RHT^T$[H5QX/Y:="$/*EK_N,X_]<FLW*/*0>^&YM/$(H*D#B_"J_2H/GNE9
MY*B-3$K3%K!S2J&;6=5@9<H8Y)QWGG79<?H;^E?A+?)A:_4C4^PAB>% >T:]
MM6:-B0"G0"P>Z0YMQ=M#N6@_L5+<JQDT3*ZABK4!)C<<"@^:<O!YI&6@G(*S
MB"U%666*D<'Q[=I0$V_1A/=+AD< [YN9C;J;V<ES_!IA(]HZ?9S"T+&P^H>Z
M6XM@BZ3>-OJ'O)(#LH7)X#0+' '29V8U8WBCRP*+G<_EGM;:T;F+_:P)6F*,
MNNT1E;",;$R?O=.N-EWI^!<6O>V0(C-T]/$[.S:[F$Z\W[9#YOVG1P#85?9*
MYK[@^,ZIPDGT'Z)(P@?^I:DAA?EK8\'KWY[8V#,W\YJWI \KE;=<%OZ;3VU3
M:Z[Z3G)K%GU7DP9E#(:XE$U3[X8K#*W7OWZ9,J*7FS\Z;+JT:C%9W[Q6LQQW
ME8=4LXPQB1XZ)NDS<8-NA*AKGA''/KRJ/Z/34Q&^X7GWH_V8>]>=B,?FO=YU
M[T^AV$7EN^=MYX-K='?<ZV'$=RJHL$W.#E.*[60+8VWND(C%@@#*3?0NEZ"Z
M2!:KQ!#NHOGN]?Q5VC.<8Z)\_U17V<W!X>@[R<+)4I-QT026A\7$3=?V4XKA
MD]GT=X3&"P/H@5@U?O>Y8:[W.%<5]UTR)/*E?_S^!8<^KT789)G/ES:'&(+6
M[-=Y)LDJ7,U;Z3VUY7\:E$H=;!8RV+>)S@3)HG#&P\@> >O9%FQ(A][;;BJG
M4!9D4GRF$F)KZA(J^Z;-.2Z!Z6S;*(.=!<O^G)[\6(KR!(TY:+ ;J29+Y:^@
M<(;YP;^]Y]]D_!U[,5\#U%]MZ'A)M[Z)N]U7+=*>X"<VVA;FCM>O.Z/[MF!N
MY/C&6D+P<^1D[Y-Z@M4\\Q\X-%DM""OGW6G.<?9GT7$!$.TT]!5A#R'L7]B$
M"W<8/A&<MT@SR'Q"A]_&6G3@:M:9S29VN##]FY-#D*IW%G"AS#[VM6B#U;/U
M3ZEQ:?/\.A7?2AHM,S/^'7<-"ZV'H5AE8^Z<'-:=:#=Q/@J7=S$['E;\$<E,
M&VLVK+(F:^2F-DN-D7>@(XRW;UV+6D-JR3[W;^AIN_[2H;I9@X<B4)CR&>V0
M9)VK9*FO:DYN351DT,VIB\)TMQ:*WZ*;URQ](M!O+VAE8_(:?L(> ;@_&Z?N
M*'_EJ7?&34:'%L%=DJ-C]O#1S.X6Q(#E2)('?-D-Q@@9P3.#9I\?=QI-+?/!
M>@&;KQB2:@9X3G] -$>=?9PY!((+P\_NX&DCZ[JSGAE\:\B5M7VW/0SD\ />
M=;7_W-K@8O%U@A11@;]VGT3S%4L74^KQ2>.]TM'Q#6^\FGK9:JO-1[QA%KJ
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MT=W<K!E)9!93QMKM R=/1L- (Y5:__U[ /MTR>(6][>:!ZY!QJQ#M 5+;O\
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M^S9L]PV/?0X=NL)MS[ U%J6R+*<_/K$E5LGW*I/0L[;Q*>N;5-:3K;BD%-J
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M#PR+SL4[\J3EB(:6S B]25/A^I-US)T$:EW1%B-P^2GQD/\]M,J8[UN79O(
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M!U-*E*<3&(J,3,3?[U]K<>L[:@C%-1R>2F#:OY!NFZD'39@]#@"B+Y6PZ6[
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MPKD8QNKP^?\ 9P\46OQ#/AJ:R2QOE$DDLM[(+>WMHHU+22R2-PJ*H))-</\
M96)RR,H8YRN_>O+2R:Z/MYK2_8]O#\39?GW+4RM0]U*#4'>\EHVUOS-_IZOU
M7Q[KNKWW@[Q_/XS\1^$=0\'30/%X)T[1UM_+7]\3:/$JN9HY4CVB4E$&W<K9
M(!/SE&Y?:M;WCCX5ZAX&UFPM6:QU1=8A6XTZ[TR7[3;ZE&S% 8F !8[U*E2
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M=+BADD*7-Q;Q/#M(6S95B1\PA-S\MD<5XU\0/V??%WPSL(;K7M!N["*YNC9
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M.>WR,T>HRW;W)[=#2,GF/5>!65>:FCX>D!.++*;CTKZ'_P""2J!?^"@_P_\
M^XC_ .FVZKY^5LVWTKW_ /X)+DG_ (*%?#_Y3C_B8\^G_$MNJ#GQG\"?H_R/
MF.^<@UGG4&205:DN/,4AJI&,L_%,U+HN#<BI;:UW/2:?9L8^E:$4*Q)0-=R&
M2WVCVJE,P67VK1FG#H16=-"78X[_ *4 RWI\H8[:T$M5D[UFV<31+4\5YL?_
M #S1<HL7NGY2NU^"'Q<M_"TZ^'_$4C?V'</_ */=$9;3)#W_ .N1/4=NH[UR
M4-TDT>UNM5-4LUD:I(G34E9GU5<>!)+"X\MU5E8!T=#N253R&4]P>N:O67A
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M#^02LH?Y6;!7H29M ^$4FC_'SQ-X]F\7>)=2B\0:7#IEOX=N&QIVD*BQ@^4
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MUS*Y\[G]I'Q)=:E87$=UHME'I+SRQ6=EI-I;V1DG01SO) L8CD:1 %8NIRH
MX%:5S\6/'%AXLU>XN+S0]#O/"&F2:=/HMS:VMI:BV>4>;8I8E?+E+2/YC1[2
MQ(+]5R-KQM\;9O$W@7Q7J$][HJ:KX9\;6S^&OLMI;0R6-FWVP2) J*-T \N
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MTTV#S4VF9Y(P[L_)X418 &,YKRWXGW$-_'X<O=,N%:^M5;3RKLKLQ4'/F)C
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M*5)W7>]_Q.'$4\9@,7*GB(.G43]Z+7*U?6SC96T=UIML?CGXTT_P]IFGVO\
M9%U;W$ID5?,CNGE>XC\I2SRQLBB!Q*74(">!STR<'5-9O-0L;>SFO+N:UM ?
M(@DF9HX,]=JDX7\!7Z0_MA?\$ZM%_:0FNO$W@U+'P[X^?,MS:'$.GZ^WJ>T,
MY_O#Y6/WN?F'YT>,?!&K_#KQ7J&C^(-.O-'U;3G,=S:7<9CDA/N#U!Z@C((Y
M!(HH4N2/+*3EOJ[7U?RVV7D?0+,:>,ESPBH:).*O9625]6WK:[=[7;LDM%G^
M#? NK?$;QGI^@:#87&IZSJTZVUG:PCYYW;H!G@ <DDD  $D@#-9_C;PGJ7@S
MQ'J>AZQ;2V.J:3<R6=W;2$;H)8V*LIQQP1U'![5^EW_!-K]D0_L]^ 5\>^(+
M7R_''BJVQIT,J_/HM@_.X@_=FF')[JF!W85\Q_\ !7GX9?\ "%_M<3ZW;Q^7
M8^.M,M]80@<>>!Y,X^N^,,?]^MD<-/'*I7=&.UM_,^5K;0+P6*WOV6Z^Q>9Y
M8N/);R=_]W?C;N]LYKI=&#>2*]LA^/WAVY^%4EJ=2UV5G\.?V'%X6-OMTZVG
M\I(S<;A\C#S%:?<<R;VP ,$GR&PL6$6T#M7'@\15JJ3JP<+.ROU7<^@QF$H4
M?9^PJJIS13=DURR>\==VNK6G8FM%7?\ -WJY<,OD[0/QHT;PCJ7B"VO);.*-
MX[%=TI>14R=KL$7/WF*QR,%'.$;TJGIRM?CU&.*Z.:,FTGJM_(YN2<4I23L]
MGWZ:=R%8@)^O>MS3%1$&:RKZS:T&:33KM_,56)JFKHC8Z"=U49 J![2ZEM9;
MA;>X:UB8(\RQL8T8] 6Q@$^AJ2.%C%DUOZ7XA2+3;>+R[X7%M8W6G($OW6SD
MCN) [O);@;7F&-JN3P O!V@USUI5(I>SCS:J^MK+J_EVZG5A:=*;:K2Y59M:
M7NTM%NK7>E^E[V8GACXWZMX)\/QZ=;0Z5));I<1V-[<6BR7NFI.,3+!)U4/U
M((."21@UE>"-9N/#.LVU]:R&&6U<,I!QC%;$3I9S:/,FN65EH=I:7<>MZ(^D
MB>YUJX??Y$B7!!VJH,8QN0H4+#<6Q6/\.?"\WC+5;BW^W:?I=GI]JU[?:A?R
M^5:V4*%07=L$_>95  R2P%<M&M33JRE3Y$GJW9<VFYV8K"RE"A"%557..D5S
M-P;DUR--;MZVC=>]YGTWK'B'1]!\-ZK\6M%\0P^"-:\6+::7K6KG2O[1CMG0
ML95\O8^PW2B/+E""\!'!D!KQS]L;X:Z?X;^*5WJVA>3_ ,(SXD5=1TN6%0L,
ML,JA@R#HH.2=O\.<=J[;X*6-IHMW<^"O$5Y9ZKX-^(&F#RKVT9FAFBD)$=Q'
MN 9621<X8 ADQ6A\#;3Q5!X7;X1_\)'X>T?Q!\-];N9]5BU33DNI-2T0M"Z_
M9F=6!A&9F:, LPG3' ROT%51Q.73S2BY5:M-13BG=.GM&45TY=%+RL]S\^P=
M2KE?$-#AS$*EA\+6=5J<H\CC6;YI0J22;ES6?(FKJ7,MMO+KGXQ^$[3Q!)XR
M70]6D\=2:>]D4D??8I*UM';><C&3Y(PB9$2Q@DNP+E< >6>!=)ADUBQM;BX6
MU@GGCBEG;I"A8 N?H,G\*]#'A+3?'WQ-UZ&QF@\/^'K62\OWN;M69-.L8BSE
MF498D)@!1R20/>L[Q=\-K'1-&TO6M#U236M!UEYXK:YDLGLY1)"P$BM&Q/\
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M^7IX;$0O&-]'V_NO\OP//]5\'6-P(UO-<BTG6/,\F&Q2%?-MTW8VKR#O (Y
MP 21[=1%X1B\'_#J^TVZ\)36KI*ME8G17 GN]_+RAY!\OS?[Q(;OSC'^*F@>
M(_"ECX=M_P"T9[>ZN9RES:W?E3R6;\8DC&"?49!X. ,<UTR^ /&'A+3[K3=?
MUS3[IC,8[>&\N)9)]BK\K@0,PY;'#@,#ST%=6/S%5W&:;]/3T.?%8]8BIS)2
M36FRLKKU>OW?@=-\/?V6K/QEX5N[&\L;71;29(5.J7DVZ2[3.5"8VAFR3D#
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M1=-KON[L_:+]EW]HCX8?M&>'F3X<3Z?H]]-(;R[\-S6\=C?I*0 SA1\LP
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MKOGUW^QM+O+B:ZDM+&UMY;NZ=<G9%'&SNV!R2$5N!R>E5B.;D]R7+YVOIU_
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MZ)IG[,'C"7;&VFK#YBY"M("R^Q S@UZ7\ /CWH=CX9N-0L[>TF9CYC.BJ9&
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MR;>XDBT_1U;Y--L@4@'^^>LA]V_(5RUI;R&9<#C//M6W'I2%254<=,"KFDZ
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M]FALTC1Z<UL)96A9_-,9<["^,;MO3=@D9ZXKV?\ X)@!HOV[/ JXPK?;\_\
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M07**R)/<22QJ5!XX8'MBNC^*?CW4/#\,.F-"\"Y>5I ,K=.^%9L]"%"JBX/
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MW Y4$_>&173E_$$*<HT:SUV36WS?Z[=SS\W\+<TK49YC@H7^UR?::M=N*_\
M;79OHGHG]>>/O@1;^$?&VM>*-#M?[/UC6%5-3U)[E)&MT4HTK1+M ^?RDSER
MH .%%7;/Q!I^AV=MJ$>J7VN2:C:G[##:$S_:TR-PBQ\H4=SGL1STKB+SPIXD
ML_#,VJ>'];AO[*XE1VL]+O?M^GZC;[5+RIG*G+@@JN,@D$ \'V3X2_%^+5]?
MACDL+.X\/JF(?(TW;]F "EPBC&T \X'3\*^KP<Z>'@XTHV3;;MU;W/S/'9MC
M<744L;4E.44HJ[U48JRCZ(\K\>-\9?AC\-6UKP1>1W?BK6;J)6AO;47LMMIZ
MQ2NZVEL 5=GG6%,JK!$))VY++[!!\;;Q]%L=/U318H_%G]G0/JLUI:G[+#=F
M/$BKR=O/123@Y&3UKG?CUX7T75/%=OKFFZS]JUY;66V@:WW;1;G)+OUVLH8C
MY>23@9S@<+=?MG^ _@;>ZMH?B&SOK:30 JS:K;V$EU&]QL5RA"ODE20"2IP1
M[5YF,QE+"UOK.*K<L9VBDVDK^7GH>GA?K&9X*.6X'"*52#<W.*;J23LE%[Z)
M[)+Y7NWA_P#!1?\ :DM?V$?V<[+Q\? &E>,O$E]J$>B:7%?XCMUN9UE<23X&
MYHHQ&QVC#,2!E02:^*[_ /X*9_$_X[_#R32/&&O6MGI6H%7N;#3;"*Q2Z'40
MLR_,T0_NEB#QG-8O_!4S]NC2_P!NC5/"7A_POI.J6_A/P;>3ZA'<:B +K5;N
M5!&9/+4D1QH@PH)+'<Q..!67\"OV7O\ A-O#ENVI7U[)=:HJ_8+"PA\QR?-5
M3YAQNC7[^3M(.W@\BO&Q'US-,0\-E_O1MKK:ZZ_+H?LV09'E7!N3QS;BN"A4
MG)<O-'GE%]$K7Y96]YVLUUU6F>/$NBZXR^3;S7%T7'RKRJ#/7/8=ZZJQ\9Z=
MI:>7J.E_;-,N\"[MI(SY9DSRP'&#[@@\5R-U8#PSJ%Y86\,=K;6Y(DE1P3,1
ME0H[D'T[9.>E7;/Q1-/I4MIJ$,-U!,HRF?G0*, @^O _*OSS%<TJ_(H.+CHU
M=W\]_P C]\R^7M:"JTZCG"233OI9JZL>F:O\,=-^'OA+2M?AM)O%G@W5)Q=6
MC!V$L%VB-&BW" C<B;B-O&"%/H*7X5^*]=/BY[[0[;R+?5-1C>[MTNBL5C"
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MC$8;6$6TDTEVS#.PDKD<=> #GD]2#Q=\*O%5E<7'EP1WDFU6:,$*KCD_,4R
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MZI%K@.C;P7#<*#N;:C*TMO!?H51[*MP,DF"-E^FSY^N(0;TP#IZ9D9&XM)N
M)W57,V^S72!\!U#/MX=^6(64[GLSNI>BA9N23F9&+@\1E3U?'0NFW5&K/A\*
MBD"'<Y<_D#2S;\V73&::4 +=F<D#L:+Y-1JM82IH, Q*,%"G:*N#@\.DWB3:
MSG51PCJ:S10=QJASUVF)Z"S>F,7[\%;PL.FK"<>O.6(<;0-PG6;F'J+V6.<C
MN6O 7*.E;)CUL#0+AJIT<6C,V>96/M%BQ.'O.,Q:JMHTDV:'$-J6G]681^D^
M@-P%/JV?"I>=WW;^W$8^<C-:^,XEV@![:'4-^'#V6& FM*7Q97/ZJ-W<,?%Q
MOH^:SO.CI0^IX$4U=%E*;P#OF_>]06CCM2_OJ?<O8G1* ZP+>IO]P0M-N /+
M*7ZO;B2_KB+@]IY(@W3W"A8^,;2CY-\!<[WRKU=RFPF>]IE$1)C.J$HM1]"%
M:DS(40WSC+!W3KW[ZKEY[.S6\B",R<F1]P6Z %J]VI$QGZ95X=:J>G;,W68]
M_S#UU-;B"W3MK"1=!YG=O<IM,L'IW; 163RX)221^/J2UMV.M1>CT;OKY.99
M_OC^W"WOF[YCQ]NC//#=R95Y+6L)R5YT?$#'?$[8N5UHQNRTJK^&ZQ 5<.-R
M)T YL =YFVC3'#,Q?B@K\BG@B<<6B(GWG%<M+"D@G_TJSY\NMH!.CJ!W2J,\
M$]"J][ ED>6XB.K=\V0=4Q3,83M@!DGEM]$X2<S$W5K"'2M>=/Y&'@_++!&&
MT8FTRNOXK+61CI4!AF&(X[&](,.Z:S!C7OED.7JBO6+3*OEQF+:<@(E$,1H7
MO+U5Q''F!=<CU%O_-<.Y=OTY32(' _$&5NPY/NE.VI-S^#8><$HG7@*GHOM
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MV*$;*_>/IZI]@?$NS+@+F*)93EO90<V<^>SA- A? (SZ]=@4]J33++;<*-]
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MQ?C0WV4E):YJN;:)T2&[=C@2*"&M6#'3%M^FOHJ7\^6-5>7SK79/U>(2OO6
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MJ/\#RQ)9BX^R;IT\K4Z A:RXARKE#+9RFCQ@N/\@^,;1%E]^L 5-=:C+I(=
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M,07",N]I%>095=JCN*_'U_&=W?7;23W,\[R'YI)9"[M]6)S7J7[,_P >]4^
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MI6J9O9^;1AVBT,B?)\ "$[@;6YV&E_@$=O6T66X@9:DL)YCX;'-^XK5U].<
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MVPIWN^9B6/97=M6CK0QD5P[#IEEEEV_13">;F06GF% 7@">BQJ03KI;HYM,
MYE(/_3$GFF308HN11&<7YT (LHK9>D:CV0]LO;91-0MG =EE-*:2II]%&]=0
M*6#4WJ\+@-\Z)9=$"[Y.=2%'>N)R&*Q<<QB6">Z90<&_UXUL=;P+;)]-C.0E
M.G6&1:<NT_9^8II]W(G86F2(7JB<._J>C-4GIT(+[Q^,!"Q5C9D;.E"5U3$.
M#M]V1:E'_8%=VZ:X>+VEW088=X,6BQI3R9$RFR'-!:!BQ@(L^H$[0F]%2(74
MG(]@I4C%.YPSQRH<-D0XO_UT]O/A\$G,ZQLH Z77M.Y!E\%\-TL*:&^]%C(L
M'%/,&X79:L'\K?C+XMERG"S0R=7*=]['%2OY%/4RQN7(9)"BVS:EO-P1/=Z/
MU&22:Z;L'I\U2:"O!$"!$>=<,Y,VUYEE&X@V0(^OGQC5/WIRJ>>8NH=^Q#["
M \G"'IB&][ZQG?,\PU[YX$F?/DZOK--M0<( H&0A6DK+/Q\.U:BJ;R0*%-88
MGV0L$Y4JGO\N[WQ-^?;]4L<'+V+\=^K4X.>084AE8U<46L_#"?M)[H>/:08?
M^W2)='9CPQF41VBE3]KY7:YUQMWZY&'54X%#:]M&*[>3\VNXF ",M1;KMQ5B
MKIW>4E% C[5>C<*ONB81_M<9MN)!:BT2,WTXK8_G F1W,"-\>JMS@B3_<W-.
M0DY&+OG6KI#?V\D-S*56KC#C\\F<"F \50(G@,VK&T>;+"TP2I#>U3[:MRX_
M^3.8'/)RUIE#]6C1[OJP!()F>&H.IFDY83%[ZV6"9'9N!,2?C,=A4+CF*7]U
MEVFZTIOSDO3+'VN_@2PF$P(=V'EY^8YE!_68.'2V@L4;S2X D4WX0^%)4UG=
M;(YGCU-6LJI&S4K=:U:'UV?VH(A@PD&'63U_7!!L-\WO ;.<<IU@W*6!8(U@
M;D(-#M'$.R;38+WUP6*'U_J-F/OWA\R97P@,UUK=1'P-M;GN0,2I(")]_ =,
M-%]#VO.( <_KO->^+(?3OJ(/?DJ F(]1C? 7 &F]4;/Y_0FI6R5W^HQ[M407
MQ,$*I]BIE?)2/7KAS\[."EO5@^,>J]5U)VI,CG!1'_RM%RR-<4ANJZKT(!4T
MRDIDP6%SC\ZU^)>=>@"IR!X5U9.Z/3*O)EK[]A^K+"1*>V'R+U^IBLA&G4P1
MMW 9Y$W2*(XF=:FOGT&='(&37B+"^-PG<#L9 FG:RZ^?&.&\!:_0/=3]GO4=
M.UO/D+"'YH?29Z-+6?% $&:2*Z6='OV2XFFN*G+>7Y^^D\E5[P#_X3-X:W(F
M%'H68RWM,\'6ML$G[R)=;60,E!,JQ;K2?":!X.Q*"7=>3#<5Y'S1RXA(;W<D
M^D'$%F!S@_W-L9"K(/TE!IKU<]&F(0F9"\!U<LQ*2=6.DP5I>NZ__###J0N
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MD^7W/RN5NH#STR7@WL=*V(:0[M#*.60[Y,,T*9]PT)GA\0$M@BL54&Y(C,Y
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M3M5:;G7PE/%B?/PBJ_G\!\0T!G^]C\T8G:I;[@KZ;6;F JV.V8-QEG>V3/$
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M-J^+Y WXO'T^5/<Y:?7VJBR'1=>QUYR%0R(YR',I='(UV+K33BI9@(B-$7O
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M0,L^^B5 1S7O".E&B)P:4F6"-^"NK:;?VWR,R8!%\Q4FKWJB0B D<W'/N,5
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M41< YQTUPRB<VAV+R:Z  -BMI/J__5Q)>^RB"<U2NHKMM[5DUWKV"_A=] K
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MMV*GGTF7KE?D-;DQJPH/C=^3BUV.J?BH;[]54C8; K/MB06DG\0/F(5K71>
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MX/OC8[C,1"G1R//34&Q4-T="7L1:!ZZT7EMSV[>6,J'@0^A745J_W4Z #%^
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MVSSR+L_QQH(TT?O;/%DIA'[+0*/AX/T!&^HM(-[[8DG]W#BUNM909"%/)S;
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MLZY1ZW.?F=6(LB!$1=F/'PTZLFS+6W;YI S =KP"=&;93NAB3Y+"##IB+V]
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M.?!JJQD+R]NO4-G>'M4%'Y_S[NU9Z<@G'OVC(/L G"Y#@O[HY)S [RO XRN
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M/SQX3U]LKLPDF?(KMY@\]3&=VLEI;9T]6)C219J"H8YY\!0E2P:O64<O,$Y
MA?';/?[9P65F<PMF0J\W=/=OO]&0DQV3ZJ$S6PG.4US#=*:=&?38K$:7?=.>
M&6Y?+!W3.Q@S*=]<)!P>*B<2BTA6@\L7FE.*]?5Q(1DV\^E=2RE[SXR.&"C!
MS;!/7.(HB2ZWW57E[B&UA?5%2D5T')EMXMVTU ^>+?%G[Y"_@M"SP.ON:_D'
MHX+)==ZF&;Z@WK<?.Y+YC$4>,F2/!X&(E&\]&;8./[]'<(>4H-<@;>WQ4G%.
MQ:E+%V63=Q^X-P8,H+ZM7 %2#"5%V>L6^%,Q]I'@Z$&:^_,"US:HEM';EE>
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M=XWHEPA."!)&QMKB]W=&<#3"^OW:!MH-!U72#!TWW/SD*-IOJR0J@5<1-ZX
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M'RA6OU?4^'!E4-KA7[-1LX*Q02UD5?/@VZ$(4C@=7]Z)IG>!(PPMIW[5?IG
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MP/XW]MX[J*DX^A<,TGOO)511JDI30&*EB(B5*D1%I E! 8D2B-([(@(*2FR
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M+[FS!Y=RN*.-!,]\L;(-5.08Z/CL;,_!_OC!^&KAZD%@O./!%DOD;5>>: 4
MU831>HF1TJ9GY72D#O6\[\,&&\>[ZM9_2"\XA(L\T%!W)YE^#!F% F[]+B$
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MLD@2D]6O)DOB0HSK9TP?.<]]2OE3F>*_EU5LV2YZ+=G_<)<V<Q]Q@0#QM\(
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MA+O9S#,'-,,.OLR0819#@O=A 1?#G=U^:!Y&PZ0@94M> _V)1GVRC:@WH'_
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MB;':"L\\=20R]1NX95"<$;UTB(P$ @H[]&6N>I,XUO.'6#8<W([UC4!CGO(
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M$<0^$KA/>"5HCCA!9GB.-=H4>4]UIGQ]$.UPS]%%LE&J_E8ZH^'CZNI5<Z=
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M,BSL+'E<_?KY3 *_L4FRJO"MN3N(C6QM>"XB(?;;^RJ)Y2A*.0JX';K*R8S
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M\?)YP4.E)I:\&\#]L?%C4PD6WZESA&*##72YBH+TBRN&.;(@3@TQ81"A_-;
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MQNS\Q@QAZ105&"^*V>8C*I9(OAC*ST>A@F0,9BRD,]\80T3?,B-,*:!=-KF
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MP* \F@=P!_6*OQY"T:S1MS]C=6/\>1]2VI22936=&IK66@YS+W8B"AHP.^&
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ME3E"(%U0=&ET_R 1$J3,G-A, UE;A*0'S\Z@XN:@J^#9U^FC%([?K V\-S5
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MEY?CD?P&H+N#*,X3YU*_F*@MQW'V>$7>VF-YAJPR9Z=*N]YZVIZBZ,Q"*ZP
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MTXF%X]>5%W5'"30- $,A,[MRHYG9UIM:'0X7Q+<U+%P6,@+=/@DNA7@_AVC
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M[!&T>IKU4)W<^P"['!V'M%^YTF_X+GXL=UF7@P\4PRR)AX$M7W"A%66KY]&
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M4?G2>ZV'R@[&>X+3UWV>,!IV/[83W)6AG]/\'K413F(DAJ;!,UL>OO 3 ,)
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M1E6YV4>\%QF"L\+EYG1"NR1%796\Z]J9YQ@T0Q9?5?>30(GF/H((\9/\L@J
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MTX>*&AA*+9B3F')__J@B/TS7S,3^4B3.8B>!Y^ME4P'2:=U)269*^VV@A#]
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M)(B:)$3C.G)=PR+$]CEU5J_&XW'FK"@F5$]8=?/(O[.DWI?_I8!O$@<<[49
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M+.]>CL]8:NM5#^.\S?J*_VF^*Z"'GP/"2PU//M%-YY]SRL,!.3\DC]86 S\
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MT)^$1J2%%3JQOZ<+&E;&J6TL[6?Q1VVE.;;OBD=0,TJ@)13'=9\E0HV:_)9
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M)"5AHFY\=+ZE-=V@K,Y)!VN$705:\(WQ8*OH9B<H''++^%@*P\+[*:DVU[3
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M50O*Y<X7MF"/C52]<ZEU;\M+P7@"7Y<+CVB'4_'94F7"YH013$1QY69ZO%(
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M9!Z^2-(% RI9:=]5X!IX%?"9+B+%%^']/EDH%O_"/*H=*N>$'@!*F\-:*,A
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M /F)YQV!QBO,S;"Q6$Y8+6._]>K-J/-+"+F^);GT!XWU[P7>Z>UHL4-QHNN
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M&&0K=0;OH5&?I3O'.I_8/@=X3T^W3RK2_N)]2D /^L<*J@GUQO<C_>K\ZSC
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M9*/*U=>[=[I\J9[;^SQ\.-9UZXU>[MY+/[+ D6G2S&(J% 0,[(F1DLSYR<\
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M">@P?3)/-?.WQ#^ G@WP5\5U\26=C8+X^TO23X?LM6NYY>+$AP@95!5V59'
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M1L5NQ.<<5/,=B#)KMOAWX!A\2:?:R-I>O:J+S5$TR233?*$>D(T9<W=P7/\
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M=UI7B>";29IA?VER&M)K8'S"ZM\K*!SDXSC\*^K?#GQ[\/\ Q!L+&+7-4O\
MP?XDT]_W]E/(UO;.XQ\Q9QAE(!(0@%#T)'->EB/:8BE'#JIRJZ;TOS1ZQL^Y
M\;3PN&RK'5,VCA?;2<&H6E*#I5?LU8N.K<=TMKKLS%L[[3XO VC>$]#\%-:0
MZ5$MII \/L)XDM2Y+%DD+;P3DL^=V3DXP:P?$^B&#6+[P_KSV.@:HID2#365
M2"ZKN7)=E#JP8G(R#T'.*]'\4VFB:]%;_P#".ZQ;7>OVT2J(X)HXY(\$$B/R
MVW,Y#  =#N))&!7)?&-O$OA_PGH5I>;M:@OIB)[#6+=)EM)D *D%L2+SDC!
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M]EG5OBQX3U/QEK7QX\4.;>;3I(1&6$>G7EUM_P!'>U;>VZ82 -YD:@%&;.,
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MSSUJS\4_C'%^SUXKTOPOX;^&MSXS\4306$MWJM\%CTVW>\@DFBB220B"-@$
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MB:5?F4OLZZ$<00P>.RBCEM7!PC*FVW57QSNW:[L[6O:U[:*R3O?Z+\<?ML>
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M9IY%P&9F"(A/ !;IDGH!DGTK)O1#HVBW.J7DRQ6=H1N&[#..2<<'@#J<'J
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MLZ=XZT*6))+>"W:XD0[8V;.Z3'RY'7&<9_E6QX@\3Q>)O$B:7I7A:^U"'6+
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M:=U=/VG]ISQ=-\9OC-X@UC35N)=,U&Z:2 LA177 !?;P 7(+'ZUPL?@'5FE
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M4GWP0,BL:V Q*C[24&EW<7;[[%>V5U9'K#?$S7%MH=UO?3O,WEJD:ELL/?H
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M;<0.H%?D%\)-(;QU\4+6PU*9[&QN&:W 1$EDD8H2$5<[E)QPX!QU'-?:>O\
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MQJ.1NP0"20<Y/UK<^/O@R[\&7=K.]QI]]87;;Q):D2P2G )&<?> *D@@$9Y
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M&P+G+]YHCQ?7_P!E>;2/"EOI6CZ=I7AO33?3ZE+:"]DNI)+F;&]R[=L  *.
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MM*ISM)/ R 0JY (KO/ _[)6K^-F@N-)\1:L_@30(9;V]LAC&F0Q1F4><,!9
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MO,QW"0D  9)(QG&\<>$/@?HOC*;^Q=3MM0TZ*17B*6-U-#P1D$2*&P<=L]<
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MRMXALU_>>=!<&2=.C%F3:K'!SR"2.>@)KW<'6R=UI3FW*#2M&UFGU?-=7O\
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M?DV>J1VSF:6^(CP%E"RMY;# *KY17!PX<M@ 8JC\1-5UJ]G9KZ\S&,XC0%0
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M"5:F&;:AT:=]5HWTO>_7IJ>+^/?#[W/B?5)%LV:[NKR5@K*/E!8L">W0_C7
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M,JE2FZLITX)I[)O9=F_(\,\"7,SZ?&L<4>H+#<CRBTP1KQ>,@'&552.IQDY
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MCI@Z7\+9=.1K?3;99=H^>0J,GOP>PK[XT?PC8Z5\!]-A7$4EU<+*^U1N*HI
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M6FZ'I.@PZG=?:[W^S=.^S&]GQ@22D ECR<9. 2>]<W9^(6UN8M#)YLB'ATZ
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M_56?W/5/3O?T/MR/5M LM.TAM>2XN;R[TTW,PCF6);.9G(0OR,*1M(<DCDC
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M/3F_V7]6TSXJ?&76OAMXFUB_M?B)I>C6]YJNDZ8\8L]*,9"O;;E!5CF:.0@
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M?&7P?_P45^&VI>,/A7#I^E>-M'O;>WU0>)+8W$VG1/O<HI4E67&XQL <!9
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MI/FBK.3][16;CRI6TDT[V/1?@-=2>*]=6UELTBL8,DRL/]6">A.<X)->E/\
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M.Q< # R 5X'W0#X[/\?I/@WH'A/PKX=T;Q1X,TWP6DCZ?/?2[KPRR2;VD+J
M  <  9'!/<U]QE^,Q.#QBH5-8M6=]+[:6[VM]_F?GG%'#. S;)Y9A1O& #M
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M4@(A]\+G\>:[C3_%\&CZ6UQ-<9N6&$A+9 SW/:JOAGQ#9VFLOJTEO;2:E,#
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M%I_B+Q'=W-FT;%TG@60Q12HQ^\'6,,".,D@8  KI/ +/HGEM$[/M .QCM)]
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M:<9-W3337A?PJ\/>+OCQ?ZXNL^&T\.^&[34FBT^8K^_U.U !5^IP&.?FP.^
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M#M6TMI7AC<Y&<Y&2!P.!@DD5T4&NS:A(6C#;.K\Y'K^9JU<_$%;.%4*2*YR
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M=:.(A>C+FC_=:>ROYGTIJGB;P3^SWKGA'3_$'B32=$U'QS?'3-%M+EG'VVY
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M/BS\-=0?4O"^G/'X O+(RZ+K?AJW36FO)U(,GVPJD@MUVG]V N'Y._((%?\
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M9^(&)8F\YEQ@]>?SKZZ.)PCBE*DEZ)?GN<=3'-^ZSUS0T:T=UDD?S&!4KM(
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M<5\BK_P4OOO"OQ)*Z;HNDWNAI(H>W3S8PZJ-@$>]F.T+_>'S$ D8XKU;2/\
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MN:VNMOD];=-SZ'^!6L>$]'^+MQ\/M'CTV[\26UM!JEQ8W3>=-;V\F K*<
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M;;1@GY5+@ G!'S-_PWO\<M0T9=*D^)/C2'03&8I+=-0,DKHR!'#3E?-8-@D
ML<9XP>:][/:-')W"A5K*I.VJ71[/RZ=;/R/R_@WA_'\5.MB</AWAZ2FU'VE]
M8O56NKO1^:T^+H>Z_M?_ /!0GX@?"G]IF&S^%FLZ(_@WPQ:C3;J*;3XK^VU3
M4D8FX(9OF*(66-2K $JQYSFO7_AS^W[\2/BUX"M_MUCH]EJ&HWH@O=+TBV5[
M._A,!(\[[SQQR$;"HP <;L@G/SM^SY\&['X@?#A9H;>%_P"S]4#B55Y$,L04
M ^@WQ_@2?45:^+GA/Q)X*\86UQHMW-H\FD-');7L3F.:W9<DX (!!!(YXQT%
M?(Y+XA8' 9S;,(.5/E;5K.SZ:/K?16V?WK[/BSPHQN8X-91E,XTJ\9*\Y75X
MW5]5Y/F::>UEV?D7[>7@_0]'\4^'QH^H:7<:K-I\;ZI%IF98#<D[C'G ,1B5
MRH3G(P< FJ'[/'P2M?$T,NJ:U<O#;V#Q$VJLT,LC-*%38_())R".Q(Y&<C#\
M8ZM'I7B"221H]1N6D<N^W" LY8@-R3RQ)))Y/?FMCP9\5Y_#EK--)?1VD:\B
M'R3<1SD$$1^42!MR#DXSR?;&U3BC+<PS_P"NXJG:C)^;]&U?ONEIV5S]8AP/
MG^0\ PR?*ZSEBXQ2YDUWNXQ?+?1:1;U6B<N5'KWQ5^&ECX%T.+5M'T6XT?3]
M3O+C['!>J1//$AQO9V)W-N4\'D@Y"BO-W:X:R$EP8WO[CA=IR @SEF]"20 .
MP'O4?Q8^/A^(3Q7S!Y?[1N&:TM(WD6+3V(^8!&)"J"21ZYZ]AZ!X<^$<<?A"
M)I-M[>7"K(78;MX/)[<<\8S^/2O'XBP&$S''RKX!<E+17MO;JDDM.]^NVAZO
MAW4S7+<II87/9N=?5N[;:N[V<FY7MY6TM?6YR^C>(;[1T,:W/G^8-\D94'>>
MX]\CFO0/V=OB/=>$O$;7VBR_V?>PAN442)(K @AE8$$'H0<C!]JX'6/AM>:!
M<+<JDD:%@9%YZ9P2!V(X-=A8^ =:\$:*=<L["2[FE>2"!44D7$B@,Z%<ALJ"
M">!GH#DUYLLAK0FU23;BD[KHN[[)=6]%U9]AFO$V H15/$RC'VEX\KM[S[)?
M:;Z1M=]$>RZ_\9_!O@73K'Q9XKM]ME--%;SPV]LY@,LI*JS*F2BJ<DD$ #KZ
M5[;XC^,?A;]G/1='US5K;4+71-?OHM)MS86+ZA!;-,I.Z8J"%@(ZLP(P<<UY
M3^R#ITWQ,^+'@+P_KD*:+?W&F7.O:]H_V,W4,MG"@1HC-TC/G/$!R2<L#T!K
M[.\8?%S3/AXB6.FQ-INFR*%C^R@1QH!QC'0@8P:]S*\KJ5H<\I:??_7WGX7Q
MYQ9A\)BE04'*5DWK9)?CKIVV/RY_X+T^(8?$'Q@\%Z$LT=Q<Z)I;RR,K94?:
M'#!0.@PL:=.Q ' K)\4?MP:Y^TY^Q3I/@7QC+,VO^$]8LYK.\107UBT$$R'S
MAP%>(;?G'W]PR,@D_7G[8'[$?@#]L?51KUUJ+>'_ !T( L.LP1![+45481+N
M'/.,8\R/# 8R&&!7SG\,?^"1GQ8O]0EDNKSX?Q0VLK 02Z\!_:##&TADC8K&
M<Y)(#8! 7.*,=EV)C+DIQYD]--K>9RY1GV1XG QJ5YJ%2F[OFT=_+I)6T_%I
M,\V^ GPFL_BQX_T[1[K;I-O*QDDNKV%V@>  EG4C;N*D<@< $<DD ^OP?LAZ
M6/#>IZYKGB*:#PQI)2VMI-*LA=W=Z7>0)(4W!8XV5"03@'A1SS7M7P0_X([Z
M;X)M#K_Q&^*-QJ/BN*^EOE3P] R6%O$^"UGFX)\R(CC.Q"5P,@5P_P"V%X1^
M('[.FB6-YX(\4VLWAS38?LOVRRL8;6[2%G)B@NTPRR*A+>6XX#,3A2<'ZF?#
M.4U<@E0IZ8MV:;YDNEU=76RMMH]M&V_@<#Q)FU?C:DHM/+]FE))OIHVKWN[I
MI.\>ETDODG]J_P"!,>D:EXH\"IJ*1:GI5S#/%,5VK>QA-X!!!*G:X)!Z$8SW
MK@?AY^P7\6_^$8EU"ZT3[+:7ACCL+AM3@0VP8!VEFC#-((S&RL,@$J2P! -8
MWQ3\7>+M9U'4+Z:5+W5[Z5B][>.[\L"&D8*"7;T' ^N,5ZC\(_VS]4BOM!\'
MZQ=1ZA;Z+I8OKO4(1#:WUXL, M?WQ509V\MMJ9RP5<8SDUY'#F1U</B(87,>
M51UU=]?=>S2:WZMJR/T;CS'3PV!]OE//*JN5-QM:[G!6:E)-IKFTC&3;LK6O
M;GOB[\"M6^ NAG[%J,/BGR)H2^K:8\D5ND[YX5, N"0!DDX(Y/.!YOJ?Q6\4
M:Y/NFOG&JVTIRJPI'(X'0(<!E=2,@ @GMR*]R\7^.]!_X5_>:%96ZS:[')*)
MH[:Z=["*U=@REAM7,B< %6(!=CD\"O%'^'[!V:1GE=LG<QR=W7.>N2?6NCBR
MCA,'BE3P<M+=-M+IZ]7>]^SNM+)'+X>X['YAEOM\VIVDF[-JTK.S5XOX=+-;
M*2L[.[;^Q_V#O^"U&L>$DM_"GQGGN=;T,CRK;Q!Y9DO]/(_AN5^],G;=C>.^
MX=/3/VSO%7B3XS/9:M\'_$FE>-/!MY:.@TSPAJ2+KMO=_>%Q,FX2O" &'EQX
M(;!8$<C\\/ ?PGO/CUXK;1;6]TG1+G3XVN]0U?59_LMAI]FHPTUS+@D!6**H
M )8NJ@$D"ON[]E#_ ();^ ?V1?B#X=^)GC;Q9J7C2UTO2Y_$UKXBT153PKIC
M0Y"[Y@6FN),X"J-H+O&-K\@?.[J\SZ'%T:5"MSX7>S;CLFDKMK:SM?1.[Z)F
M=\ /V,O$WQH^&?A^\^,>J:@FNZ9=2:WIF@ZC<1PZI<6$3QIYUS%RY1;CA2"'
MVG#$AL#Z&TS]G2Y\2ZL;BQDL+$LX0S1P1089CA55FP2Q/ 4')/ KWFWU?1_&
ML>I?V5JVGZDNDW;:3J'D+F6RGVI,UL[,H8<,C%02,XSR*Y?QW?\ AO2M&F74
M-$;7[?0;JUU8!M-DNUM+J,N8)TVC&Y/F)P2%&2P K@J8>=56HKF?2R\_+S_R
M'_;[PVM7]WWNEHM]I<OV=5=^=['G_C_04\#^"DANKB_D:"VN[0VYO2+6],VT
M&2>':3++&$_=DD!2<XXKX=^.T%CJ.H1/);W[QZ4))H5ABC8F3;@-A_EX7?C(
M/'09Q7NWQ'^*=SXO\207$TZ?\3*#[7#'%+N41L21(0,X4L#R<@D\$UYW\0O
M-GXIT:9FW397YVP0<D'D#K]!T]Z^GRG(L7D^.C5Q%-IK6S5O+^FCKIXC!\0Y
M!.G2Q$9QJK>#4TG?F:=G9[M-/OZ'SC\>;WPKHNGZ58Z4]A<7VGP,SSZ?OC\U
M7VL#+N4 NK!P0O9@<Y!%<=X9U^'QSJMII*Z9#=7%ZQCC,89I3@$DX7); !)
M&>*]$\?_ +/6H:3>6\<LUK/:ME(23\VT@D8/&,].3G-2_L^:1<>"-;U0^3I5
MFNHV3>'VNKR!6@CANGQ."^1ABH.TG)!'3&2/H*?#='/<V4Z\N1MIOI=*U_>O
MV5K^FBZ>5FO$F(X.X1J0R^#K>RC+E5VY*4F[6C9Z*33<5;2^KLK^H?\ !*K2
MK?X=?&KXH^%]6T/4+'Q'XG\/6D>CV=\B6EQ+<178F"1"<#)>,,0X!(57(Y(K
MZ0^+_P $XK^]_M*>=],>>3=//*0+<$@EE\PG /*@#&#@DD' /Q+^V5XML5\
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M:C44VKJ44]4TVG>VUVFE??=;,](_:;\,1^#?']UIL=O8PVL\"W5HUQR'C?)
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M?"3"&:99GC5\%MKD;SU&><'!Z9KU_P 7>&+?4_!&K-(J27A3RH(0-SRR$@*
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MC8I&/+9LH"6)(QQ[^E2ISEK=EU/9KX2U;_"GP=I<>V/2;=&.#F-R#^')KH_
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MOX:O?%@\ Z>WC9?$S6ADEUD(!HT%U]FBG$2KMRT9$J LC$@D$C!K $5 NK_
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MEN?-\2<21RK#VY>:3^'IM:^NNFJL8NEZ^/A1\.XK675H;K4-2?SI+2V3(3H
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M!E"%VP5*G+)D*P(7 .=P&<' YA^._P ,-<O+V]U:>TCT]9V-S!:J6FE$+8P
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MU[+ \W^C0E@SR2D!G Y.T8!/Y8]ZX?2?'%CI:G[/%&CHRJ[-)YLB;N0S$X
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M 4@$GKU!SFKG@R_\+Z/\-4\)7-O?PZ/93BYM%>[,AMY\C>D1;#",DL>3CDX
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M3;F+4+88MICB7;TC8]#]#7(?\)W<:B([56<PP'.-QV(>Y S@$CJ<5W6A6_\
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M F/VD?@MW PIY)%?$XK%*E3Y%MVZ?=L?>8;#\U3VKWZ/]>_]6W9C_'#]H/\
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M.ZO;?96-%\"6+?V+X)\*:3\.;+X4WJ70\5Z*^G[I=1#!=BQ(I"?,P_>/("V
MN,GI%_P5NFTT_P#!++XFV*V%N]GI&F6DEA;B,;+)XKF!8GC'12@X!'0<5SVI
M:K)X6U""^MT5?L[ALH0.??N<BO4OB/X"TW]HWX(^)_ NMR2)I7B_2Y=/EECP
M7@$B_+(HZ$HVU@#P2M<&(PLL/)6=TSZ&LG*I&4]XM/\ &]_4_,'_ ((*_P#!
M/K3?VSOC!XF\7>-M%L-4\">%;62SLUO)-T,FLL8GA#Q*P9ECC+.0WR-D YY
MXO\ X*&_\$N_'W_!+S3/#'B_7/&NF>)H_%.KW%L]QIMJ]JEC/@RI]XX(<;\
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MM[>>&Y4AD:,,O3'(QC':O#?BC^Q-;ZKX6N]-TVXN(+*< M;I*?+?&,97/;
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M#U[7;70FE+S:>[ML0^XZ%>W(_*O%? 6E+JGCBWL[RXL+6&^E6/S[V4QQP!W
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M'>'O?@>O?LA_%GX,_M):8WB+09=%T7Q.]LHG6Z"F9$7_ )YNV-R*3C'!4X!
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M"D22SO?6PECDLKD*2C*5(#JY?# 9*G# <$CZQN_ 7V"YT^1D8-+; $,/X0S
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MP='==MT?$/B[]G'Q!XI\3M]H2YT72[K5K:WF:)6QJ-B)"PWHSA5D4OY9R-I
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M"#R3].E>S?'SX'?#/0?AYK-Q\0O#/]LVBVABLUEE,:V:*@+2PX(Q*TCDAB,
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MK7SC\/+IKK38]SK.$78%+@=>F!W.*^DR^M2<YUDE?OV5DSV,KFG2YN]V>L>
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M@<8)YQ7SWXR_9;\5Q? K4Y]>\3_\(QX;O!%;C3XG^V1:JL0*VKSW$;$R!,\
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M:LK)>ZK;I<K5TM&?:WQ#^$NJ3^'/"NL:M'I=CK^K:6DVL+;1?9DGF#,%G$)
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M<<U\K7'CR^\8XN9=/N3IHE/,*!5P.I"]\>I)YZFM7XI76J>*?"Z133PR7\<
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MD;L D#FL/PK^QUXLT?Q1I-WK&GW.F2+"9-RWICN=.@VL0#!&2Y+.(MQ(PJ9
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M*ZKJBLEPJN0)(P#@'N,$Y!'((!!KB?B=\2-6\2^-Q<S31RS:D1%$[$NR*J!
M,DDG"J,9/7)ZDUQNO^.I+/7OL-LCB!055ARHSV)]?:JGABY&J?$2W\QE!MV
M0%@,D@$X)X!)Z'&..:^NRJMBL32IY?7J-T8-RY>FGZ7_ #;/G<5DN78?,*N:
MX>DE7J+E<[--K\[_ .270^K_  3XUN-%^$^C6NJ[#I>C+.;6QCNGMUN?-(8Q
M.RDN8PRB0*KC#G)R.*Q8OC +UMMO(R, '8)E=BJ3G;SUSC'K722^.?#?AWP5
MI*7>I^%8M$@TZ[A\0Z;=V9FU>]O61A ;=U!(4?( 5( (;.217S?H_B>'2[@S
M2.S32H&8C/R =1GDG'4_GC%?<8?.<3F,'#$1<8TG975D_-):?,\3)^$\KR>=
M3&X*SGB??DTW)K65DW)77>R;BTT_3Z@G^(5I<>"KL:DLC 6[&10I7)Q@-UP1
MCOW[<U\[^)-0&L0ZNNIOJ%U9Z?:B[BMFOS:0.BX4RDE6W;%)(P#GID9&>B^&
M7B*3]H+6K'PE#J5MI.ERW*V\EY(I<2LQ^6- OWGXQ@<'N1BJ/Q"^&NI>#/"=
MUXD\%W7B>_TE[ZYT?4H]1\/GS8/)0L' &[]PQR,D  X)Z<>'3XBP%+-*>$QD
MG[-W4E]EWVO?31I-[>NECSN).'\QQV65\9E44JM/E<9VUBVWLTKWDN9+=-_>
M<MJ>C6NFZ?X?\065GJT&B:S(T=BVHC<[JB@@D  J2<\'&!@X (KTO4M+G\?_
M  JU"TT>S:+5);7S;<%A$'=7#':>@)QQG'7L*YWX"^!-7_;#^(5OIANK"PNC
M;B5I8MXMH50!20F2=Q&!@$#Z#-?6OPY_9IC^'F@727%]#+#:SM81R#EKQ@"'
M8+S@#./^ GFOSOC3&82IF7MLO5HW36ZUTO=/SOHN_P E]#PEE>-P^ HTLYG>
MLKIZIZ7=FFM_=MOKI\WXII?[2,^L^&-)L_'6GW6EW.FLL%S<M%F>3:I0';@%
M1P1D$C((P0<G?U7X">'?B[H-N?#FJ6NMWGFO<V]GJ4):TC8Q.F7 96 (<X .
M"< X'-=9X7^#>J?#WX3OI$EQ)>7FL:G>ZFK3 LFQY,E6#9RN"1CIQG%0?!O3
M?!&MZZ\9OM5\&ZY:RM%NM@DNG3E3C*H>5!/) 8#G@5U9/F=7 8^&*PWNSAKK
ML^MFM';R/H^*N'(YIE,L#F%JE.HFG9+GCTO%NZNMKI7WL=G\!OV8VT7PQ'X?
MOI+C3+JRB@>^L;5R^F^:58F2!@BD!CD$$OM"(#@$$^QZ!\%5\+W-M%:SQW*R
MJ2V7!*8ZD#L!QR:S_#>N>)O#@19&AO[6+!6[@3?$Z]BR]4/UQ[$U'^T_^TI_
MPHG]GC5_&44<+:JLB66GQ2+\MQ=OG8&Z$HH!<C/(4^U>QG6<8G-L1]8Q6LFE
MMHEM>UOUN^EW8^%X?X<PW#^$67Y<K03>][N[=KW[7Z65[M)7-SXS?M!>#_V6
M?!XOM<OU2ZF1OLUC;D-J&H,.,1IT1,]7;  ZG.!7P;\5_P#@JY\4O$'B4W6B
MIHOAO3U<LEHEHMVSY/\ RTDDY)/?:%'M7SOXL^*>K?$/Q3?:_K^I7&JZIJ$I
MDGNIVRTK>PZ*HZ*H  ' %'@3P])\7_'-CH5O?V.F/=N=UU>$K#;QJI9Y6/95
M523W/;)KGHTG4:I4U>3T2[L]J4(8:,L3B7[L5=M[)+=_Y]CZ^\.?\%LM7U>*
MYL?%G@72[K3KJ%8M^D7K6=U"0N"ZEE92<\@8 ''7&:]:_8<^/'PN^('@R\\,
MZG\2M6U.\O[M+S[!X]CMYGBV/OABBF8%)%B8!E)8L" 0!T'YR^-? MC\,OB+
M80ZE>K>Z-)?(EP;8;FCC20">(G)RZJ01C(8,#D=*]2^/?C[P_K7@O4+.'6/!
MNL>;K$3^'(-'L1"^EZ>$8,D[;%.3F,88DDJ3Q7+F,9X7%+!8FFV]GUMIU?G^
M1U970PV/R^689?648VC*.Z<GS)>XK-7B]7JK6=G=6/TZ\27'B8ZIH]G\/=1\
M%R+=ZG-#XFU&ZO(FU&TLWC(2>UY(,H9BX&#DJHX!)K2\*?"ZSTVSM]-U>YN/
M$.H2VGV'4-:O3B\U%0[LK%U8LNP, N') 5<G(&/Q9.C[9DVLUG<$?(,X9R/[
MI!Y_"NJ\(?M:_%#]G#2%N-!\5ZQ%IL$@;[)/)]JM"<\@HX( /<+C\Z=%U:$W
M4HS:OIN[6NG;3S2?J8XG+_K6&CA9Q@U%WOR+F;]Y7E+5Z*3BDK+ELK-I,_93
MP)X1L+?Q7JMK>6EKI43ZE+!IZP:BMRM[:K@QSL=J^6[DMF+DJ%SDDUX/^UC\
M0](\5WOC#1M2NKR.;16BB^SK:.EH(Y$P@2=AMD< #=L)VD@'DX'@^G?$OPK^
MW]\*= ^+WBR]D\(2_"V^"-#_ &J(-'-Z5#+=G< YD/3!8[<8&03FYJ'A5/BE
M/J5K?ZK-+:6VFR:C:P0ON?570*ZQ+*3MC)W(=QZ@\9YQ. R>MCL1]2PD&Y3U
M;2V2ZO9)+:[T5^YY.99]1X>IRS:O-1<;*SOO=:1NY.4FM;+5]TKEQ?@EX@\$
M_!%9]&M[:*TNHF=1#(%D 8Y)9E(.3^?H*XGX-OKB:-JEQI_VR>'183+?P/+'
M-Y2DE2X#$L0#@D#. <XQS7:?#_XN7%W?'P;X3MV\7WVMF&WL+*2Y\N6PC92Z
M"42;8PQ(E!<$@B( DC%9?Q<^!7CCX0_&N+2]+M;:WUOQ%;A)%M6\ZWB1QF96
ME90"J<EB, #H>17)Q)P[++)RPF-NJMU;?WD_5M->:[6WT/6X5X_J\0QA6P==
M.$KZ*VB3MJEJGY/\5J>'K!??M _&[0_"GFOI]UJM\MK]J!!2)3DN5' )"@D#
MN<"NPUWX6>"OC-\.]>A\+Z3XTT"?PKI3:W8>(=65]NJ11!FEB<,J_*RJQ1D)
M3*$#!SGNOB5K_P -?V0(K"2&VNO$7C(&.:!;>3;<W+JP8L7 /EQ@C@ 8/ .[
M!KC-?^/WQ$_:(MM;CA\'>#O!6G>)$$-[#IMH5N+R -N$4DS$Y4GE@H0,23@9
MQ7#@\MKN4*E-\L8VZ_?Z^A]1FV<8'"4ZU#%*52I4C[NK]UW^TKZW5K7[;:IK
MB/A'?3-X?MI)F9IG4-\QZ]\<^U>Z?#;6HYMJGY7)!Q7 >'/#UWINA+:^*O#6
MH6^D0J(X]7M+=L6A!P"S@%2 >Q.:I>+M>U;X275K-*4O]-G(:UU"')BN%SD9
MQ]U@."#7VDJ2J+W&?B\XRI^]NNY[_J?B&\CGBFM6W-;KS$0"),'(QVR#Z\'-
M:UOXPL?$MJS*Z1S@@2!@0R'(!&WGDGVZ=.M>/^&?C1;:Q91O]V0KG@_Y[U;N
MO&:7DJS1QJ+A",.IP?H?4>QKULJS26%7L:JO'\5_P#:.-26FQVVK0?V7=[I.
M(W8[@,@<=3SSSGC]>:TO#>L_OPD,BM&>W<5P<NO76O0JDA8EVR>_/<D]<UTW
MA73_ .SMC;OF[@=:Y\RJ4ZU9U*6SM^1Y\JCJ3O'8[?Q="MUX3MY)(V>.28Q'
M:N2"5R#^E<;X6^#U]KGB*WCLKF%[:XG5663.Y,D X'<XKUWPVVB6WP]-UKVG
MR7JQ39LXU8H0^T@G.1QCCO79?!WX9:7K6OV%YY#)(S>>(_,.V(8R!ZG&1R:Y
MZ=:,5RLVQ&'C.#G+2W7Y=MS\[?\ @JEJ27/[6$FD>>LH\/Z7:VFW'1F!E88^
MCBO-?A%\.+K5KE)(4\F$$9+?*![^OY5V7[35W;^-_P!JSQWK4;6[)<:S/'&>
M6^2-O*4?D@I?"_B-M)"KN^7_ &".GL*U<8.]Y+7H;T7*G2C&,'L>\_#CPMIO
MA#P^\S.LUT( /T# OS.&/;CL*IWGBI;6T>-'_P!(ER3@] >WUK@;7Q[_ *$Z
M0%S+("K%R<@>HS65>>)R+A?F;DX)[UYV(I>\DE9';A:G+%S;U_(]5T:[>]FM
M525L,P+#\1C\,^Q_J+/C"SNK>=;B)75BQ\Y!PN" 21U (/3USDUQNCZI;S:9
M;S+*RW,)W #^+C! Y&,BN_\  GC*S\0H;>\V*RX39*@^[CG<,@'(X&!R./0U
M]EP]0PV)P3PM3>[NOR?_  >ECHIUH5$X,;I.EW5W#MW(ZE0=P/;^M>Y_LI>(
MHK"[O?#^I6MO=:=JD+6UQ;W""2&XC=2K*ZD8*L"00>H)%>%Z>&TG6_)M2TMH
MTI,;X.""<@CDG'IFOI_X&?#9=,ACU>]58\ 2[F] .:^(Q%)4JTJ5-W2;2?>S
MM<(TH^SDYZ*WX]+?/4X5=-\*^#=*O?"/A3P[?>"]/TO5U=_(N)2+QHCB- TQ
M<&WZ$1C R 3R,U5\)?"2SMM4\2W.J3ZE>)X@LI(-EI_HY\UW&YGD8N2555V[
M% !+<=,=_P"+=;M]>UN[6Q5G,TFX-(-Y/H0,< =A6%XGT7PSX9\)ZGXD\8ZG
M8Z)H.AQ(][J5R3A-[B-$ R!N9V  ..3R<5UX?/(8*#I4(VBO2W^9Y.;\&O.L
M5'%XZI*=:=EKS3G)O1+?5ZV2LWT.A\$>&?#-OJL;:DMUJ-BUH=+6WNG6WDMX
M=BKO>YW?O68( Q8#++&0 1R_X_6?PR^*UEJ7@?Q-X)OY-#\664$-]<:?,9)[
M@02":*5GB+(9$D12000<G=D$BO*X=0\.^+/ ^D>*/"EW=7OAW7U<0M-;26TL
M;QD!XI8)"2K#(/4@@@@D'-?./[4F@:IX<U :UH-]<Z<?)>(303/%+;LQ!!5E
MPP#8P1GH:WEQ%1Q%)JI#F36U]'^:.'!^'^(P..B\)B'1JTY73</>C*+ZIM23
M3\].Q]:6OPA\*_LB? [4(];U1[KPM'>1ZS?WNKV_]DOYR6QCM88[53NFGPP!
M" !]J@D $U^7'QY^)VN?M4?'G5_%%[;>9<2A8;>W4;(=+LHAL@@49( 5<9P>
M7+'DDUK^.M=UKQA/:C4]2FO+_3(E,[:A=/-,'<%R%W$GA2 ??K53X8ZG9>!?
M$UPUU*XCF8R;Y3\LBG/S9QQC<<@=#[UYN7XI5G'!TX\E.-]+W;?JS]>P^1UZ
M&+K9SF-;VV+K64I\JBDDM$HK3HON5DCU/]D[P[X;M/!VMK>>'9K_ ,7W4EO;
MVGVEXA#8*KAY9]TN$,)4 2+@N ?E'.:]BL_$_A3X;^'M0\*Z'\0]0^%>L:;X
MFBU>_N=#4:H-3@5!_H,;QGA5.64-\F7(;."*X#P]<^%_&F@6S17JO$N5C:"4
M$Q9'S#.0W(SSCIQ60O[/&CZUXE:VMM1N=+L94$XNK.80S1,A# $L""IY!!'(
MSFO?XC^HXK)5A:5)0G!W;ZO;MWZI[NS5G9+YO(\ES/!<35,\K8QSIRTC3:C)
M1:ONIJ4965VGR^ZFUK;F?HFD?MF>'[;]HS5FT35;OPQ<ZGJ)GMK*.\@CFB+'
M<H\L;1E@0< C&X@<5^BOP]_;C\.Z;\.EO/B)KF@^'EDYMKG4KI+>.\7T(R3N
M!ZXS^=?''P?_ &4O"MWXPLM:C\+:/=WRZ4)/^$G^T(UY/=!U7[,(L8 *EOF'
M.%!S@@5\,?$NXU/XW^)?%_B;Q,KW-]I-U+:1V9.(M.BC<JL*KV"@ '')))))
M-?#X"4J:;A=+9I[?<?8<38'!YI2IT*J7-%*TDTY)=-5=ZI:IZ^29^O'BO_@K
MW^RRFKO8ZAXTT74S"=F^WTJXN(E/M)Y>T@'N./>M?PW_ ,%&_P!E/4XO/M?'
MWA&R:/G]YYENW/;&T?E7X(_#OX=7WQ=^)FG>&])%G!?ZM*R1M*2D4:JK.S':
M"2%5&. "3C !) JQ\9?A->_!K7;.SEOK758-3TZ+5+2[M$E2.6"0L%)215=2
M"A!# =B."*[%F5.,_9<L;O6UCY9<#TE1YH5*BC=*ZEI=WLMK7=F[>3/VJ^/'
M_!8_]FOX7:8S:;>2>/+S<LB6.E66Z,NAW*[23!44@\AAD@\CFOAG]HC_ (.!
MOBA\2+FXM? ND^'OAYI;$B.6.$:AJ6TG.3-(-BD]]J<>IKX':WN;D;O+D()V
MY;@9Z]3CFJ+E]KLH;"$!C@X!/0'T)HJ8M_82CZ*QWX#A3!T6N>]1K^9WM\MO
MP/9O'?[;_P 6/B\DL/B3XC>,M8AE^9X)=3E$.!QRBX7 )Z8Q7+:=?WMSJ=OJ
MAO+QKZW=6@NS*QEB9"&4JY)(*G!&#QQ71?!OX'6/Q0^'?C"XT1_$6I:YMM=-
MTO3[2[BMII3.X28S+AR85SG(P0!G(()&S^T;\!X_V<F\,V6V2WO-5MI[MXFU
M!+R.6%'V+.'P"I8JR^6=QRO#'D#ZVMPGB890LWE--/I?7XFDUT>BU2U7GK;X
MO"^(67U.)9\,TJ,HRC]KELM(*336\7=I)O1[;VO^B7[*OQ^_X;M^&4EY?B,?
M$#PQ'%#KD,28.HQ$;$OU'^T0!( .'.>C#'5:]\%V:%K:XA51M$@W X;(X_,5
M^:?[*/[06N_LW_%_2?&7AZ13=6#%+BV<GR;^W;B2"3U5UX]C@CD"OU]\ _&?
MP[^T?X2?Q%HC+J>AWMNLCQK(JW^D,HRT+Y(RR$D$'[PPP)!KX3&8/VL?:0W_
M *U/OZ>98G!R^K1^!;=&MM.VG3RTZ:_'GQ'^'$7AK5(Y([*US#+S)(I*HQSM
M<#!!*MM.#D$;ABM#X;>++[Q!X2EM=;U5M6$*#7OLMCF*YL[R=PN;F)DV1@%!
M\JDC Y )!/T5\4OAEI_C+0KF^T8?;+0ILGB:+]]:,.C.G)P2,AAD?0U\G_"'
M3]$^%O[4MG;^(KBWL=%UN.;3)+F<DVL4LF/*,P4@B,L-C$8*AR<C&:^CX?XJ
M5' O)JE*-Y2OS]>GWZK>^VA\-Q/P34SC,)Y_"O/GI4[>R>JNFV]-UH](V=WK
MUU^XOAKI^I?&#3_"NMZ#-)97%CI<=A.(<-)(TDGES(?[HB:,.3U&1C'6L+X[
M_LK)XC\1MIMQ)?V36\MPUK/E1+J"JJAKEQU!W9 /<9&,8SP'A'2/B!\$OB-?
MV.I6^HZ5;WES_:$<.F M87"JZLQBE ;9&RD X(XSDGBO0OBWXV&K>#Y]8U"7
M;=6^H^3/9M)/#]LA )BB60LK,5+;G*@J!T )!KZ>CB9TG>#/S.,FMB7X+#2?
M!7B>V\+^8MU#=W4=D8I&4"R9T#B8,P (*X!&0#E1D'&/I?PC\#+'1X#>M;R7
M-](QE*WX1\8!VJ ,@ G;W) &,YYKX"\'^(=:MM<M8;>.XNSJ$8D@8PRNELJD
MC*R;2L97NY!!SR237U/\*?VT[/PY?V7AWQ1%<6MY#(JW.H&0&W<LH(.5R !D
M#G QCG-36K.I/G:M<*C<G<](^%/P6>PU^ZU+6+&SA*CRX+>)<1#L6P<DD]<G
MJ:F^/'@/PWI_@'6=0OM&COH8(//DM^B2;"'4$>A* $=\XKT#3O$MCJMFEQ#<
MQM%(N]23MR#WYQQ[UXY^VY\0;KPC\$=4_L^WANM7U1#;V-I-(4CE;(V&0@95
M/,V[FZ ')( -3",IR4(ZMZ(QE*,4Y2=DM6^R[GRG?_$?PK\(-=D\1?%#Q=X9
M\,P>)AY#Q7\:):Y1=R11H(W+&/@D*.I!(R01\*_\%&_V\W_:3\:1:9X3U)KC
MP!X5W+9-)9"V_M"3#(UP(VR54JV$! ('. 2,?-W[97Q%^*OC+XEV$WQ6OKB_
MUJSB>WM88(XQIEM"LA'^B&+Y'1BN3(,DD?,21FN5BN2]I K\"9@K<]L9P17+
MCHUJ=;ZJ_=DVD^ZV^[S^X_9N">%\$Z<,S<E5T;5K.'5)K37R>SW71GU-^QGX
MCU?0+F_OK::VM5U.REMIY"@#O"XVL@8$$C'(!R P!QD"NT\6_&2QMM1^SV\%
MM:6]LJJK1;I)+@@@F261B"\C'J3C)&<"L?\ 9<\8:9X2\$:@)M:L]!U&[L#:
MZ1J]Q +J+3KG()=H\$@E<J#@X+9'MQO[0WQ)T7QM\15O-/N%O5@L[:&[OEM!
M:KJ-S&@66=8\Y4,<=LG&2*]C"YGBG-Y2HM48I-.RMY:[O2[[:M^9]1A^%\H_
MM)\1QC'ZR[P;NV[+=VLX*[]VZ?/>-G:-[^P> _B/,+]EFD<I+RP1=^PY)7'(
M(XZX]QT.:X/X]^+;?7?$M]]ACF2!/*2\:)V7 .5))4$@\\<''3!Z5Y>?V@U\
M$W/EV(\V]N (D0YX!Y##N ,YXZYQZUZYI'[+\/C/0O#=]-?^(IO%7BBRN-4B
MOM,AB?2M&EB+&**<L,F0E1D \;@.M?.YYGV&P%>$:C=N9-V>NGWK[UM?:YZN
M(R6IF-.I&BH\W)*SDM%I=]4]$KZ.]TK)NR/.=6^$&C^+]3\3:+IOAZ:UNM#C
M>]DO(;^7[-Y2Q%HD/F !I3G+J  !G&,8KR[X1:Y=:-JD=QIYN+R-MI;;'M?D
M D8YR >X/\ZW_B'\0O'6A7MQX1\5"YC$D45Q/'JEJ(K@N4P"KJ23'U (/('4
M9(KV+]EC]BO4OB?\.'\=)J%M9Z5IKLAM<'S;@H07"GH!@X!.23VKRO$'-LKQ
M"@\O@DK.^EO/HVFM=UU]=?.\+>%\ZR_+ZU3B?$.7-)<CYN;I;6\5)/163LDN
M]M.R^"OQT6U^&OC*WU:\:S%Q:V[V\^"9+29)<[MI!)RI8<8)Z9&:ZKX ^"?&
MGQBC_M#P3XN\+^($M9A+)HAOGBED<$G:;60 ,&Y.!DG)^M:&O?LD7D.BZNET
MJV\VK6L5R\)(+VZ*@;<Q[G)4 >IKYO\ #VH7WP&^-/VK0KJ_A-N C/$%V.P/
M&Y2"" >_!ST(KX#(Y*=*$XKTZ=;[[]3](S"GA:N6.47%Q;2=US+563MI=:6M
M?SUV?U5\+?V8=6^&_BN5]8T9;")$MK:R%C9O87&GNKG)E=-QDA(VAC)P%W#@
M$FO9O O[,]];WH,TKI #EB1O9P?[HS@\=.U/_9Z_X* ZQKNAV=OX@CM;Y$ W
MI.F]6'0X;)9"?KCMS7O\GB/PKXZT*.X\/Q3Z9=286>&*X\I8B3][&"" .<@
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M 96'1@01P0037)Z]K^GZ=X=TK1-'M6L-%T2%H;6.9Q+-(S'+R2, H+,0.@
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ML<6%0*,<]SCVIGB+6+31$:WE210@PV>5/N#VKL/$ETVE:4)85Q@'<I)&\9/
M/8_6O-]9OF\2-O4J)!U0D @$'((Z<<9[U]5EN P^+@X_:7WA2DDK(JI:PVEZ
M;_3)%@N /O)C+@CD,O1@1P0>HKE/&_P*_MZVF\2>&HDM;VW'F7UA$?W<@[N@
MZ@'N.U;]IJUO!)) B;9$QT&." 173_"?Q&NG^,+?S!MCE?RW7J"IX((_&O-J
M*6'K2I2UY78QE*-9.G(\>T#5UE$&[<)22K1GJA'M7J'PZ\'77B6Y2&&"263C
M.!P@/<GH!7>S_#GP^OC"X,NEVT=P)2&E6/(//7'7FO7_  OX5TWPYIP-K$D<
M9&2=H1>G?N:T23^$\GV,D[2/.YOA#<Z)I:22,K-G@+SS_6O5/#^DVG@GX4W$
MUU&L4]XFW+?>.>N/8UGZGXVTO0C#-=?Z9CY@F"$C7UKS'XA_'UO'FMF!6V6T
M/RQH.!@>U'LW]K[CH<E3AI]_Z+]3W#X.6UK#X'BN&9&FN)I), = 20!^E>5_
M\%8O'7_"#_L/VM@LFV3Q1KL$ &<%T3=*V/4?(N1[UT'PP\7QP>$[95=CY>X$
M>^2?ZUX7_P %G=?DUZ'X8^%UDPEK;7&IS)G^)MD2G'X/6%-7J-]C*'-*I%WU
M;N?&OAC;K]F\.5$N"5/J?2J)L;G2[]O,#J0PK8\+^')-+FA96R01P/>O3;SP
M<);:QEN+)YDO"4.Q"3P,Y]L5O&:F^7J>PZ;4>?\ JYE> %^VPJ6V@E>IP?S[
M5W?@CPW?7'BQ;*VB>;>%\M4  .>!C'&?6KO@;X5>&V2(S7LT*/SM9PGZFO?/
M@7X5\-_#_6UO+<-<R[3L9Y@^S/!P,UG*A5U2.6->G!\V_P F==\%/@L? CPW
ME\-^H2)NV\$1CJ<GUJ_XS\:MK^M)"TC101G8@_OGH2*/$7QQMY;^ZL;=&ENY
M;6202(I,4:J0"I.,9)(KSJ+6S=WL<KR;'C&,9SC/>O)Q7-!*'?<^AP=3F@Z[
M^SHO5ZM_I]Y[%X1O+>TL9HY)%AMT!^=L9./\:XGQMX>\"^-O$_A_7O$GA_\
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M+:*BU=)I6C%=EW?Y>9Y1X8_9Z729)-8UN5]5\0ZD?-N[R<!I)&/8#HJCH%&
M!Q7:VO@3^P;!':/(*&1L'&.N!^%=E=7$=_<*3'N.<' Z<URWCS7I-$FPJJ8G
M/?\ Y9^I(S@BO<P-.C*JJ=79[=CYN-=SFZE5W;W;*EY?2-^T-;^.9_B/,?!,
M/AUM(3P')"Z?OC (W!508V1G D\PG(Y &:XV+3K>TL'LS##=Z3>\7%H^3$_^
MTO=6'8CZ$4NJ(LJM<;DDA;GAMWS8/0=0>.U0V^N1W5HK0IQCI5XS)89;+GHM
MVFV[-[6M^&IZ>9YU6Q3I1K6_=P4%9)>ZMKVW>N[UV[(X[Q?\'+KX3W4.I:?)
M)>>';\DH3R]L2>5/TK2\,W OKDQQ'?@CY@<\>]>T?">ZA\0>%=4TVXA2X01^
M>(Y!N4XX('ID&N@^&OP_\/R7ZK'I\-N,9VK%GGU![_C41DI*_4^:Q.'<9\T%
MHSG?AG\++SQ+&LT<31PK_P M7X!]AZUW6G_#&6S\2VUKAIC(0' ';^E>@B*U
MT.VCC0K",A5R,D?11TK"USXTZ=X#BN9(8&DN0"%G<?,6[X':M.23\A48Q6N[
M[?Y]E^)J?&&2SL;#2M&A,<<JE4(7G86P"3]!7I>G:Q9>!_"NOZPKKY.BZ5-=
M,W0?)&6Z_P# :^28_B8WBW7EO+B1F8RAF/I@YKTG]IOXC_\ "*?L,_$:_CD9
M)-1M!IL+9YS*RQD#WP[5BU[R5C*I)U/=O_3?]6/S%/B.:]DDO)2S37LC3/\
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M=B1DENYR1D]LC.!7>ZGK&N^!?!5W?>']&_X2#684W6>GO<K;+<2$@8:1LA0
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MEW(0&4$A%)P./:O:/@P=+\)P:=:_VG"VORW$]M>::L9CALQ&AP2[DD@G)R0
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M77534X/++':1%,K!21@YXQZ9K4T3QW\7/VMM9308_$WB#4[.Z!1=,M9TL-.
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M.Q_<Y)13P6?>>5&>?_;A^+GCKQ?XJNM0C\.:C%LG\R%[R9401 $@J=Q!(QG
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M+&""HV@G.TD\GCQ+X@>/[S6;]XO-D7!X'^!KWCQEH-CXMUVZA4S:7J5NQCG
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MMMKFE)6A:,G+P/\ 93_9DL/"J>(KVSCD6.YEEQ>384_8]P,2!>Q(4DC/)89
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MXPRG!!R"*P_V9OAKXJ^(7PGN--'A?Q/<:2H:ULKJ+2KF^BN\*2D2M&K$,,;
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M=9(;#.=S+@E<\ =LG\A7J9?FE;"^Y#6+Z?UL>?6Q=EJ=/HUHNNZBOV)/-?:
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ML?IU-?FEX]\7^(_VN-)NO"NF6=YJ-U%+%=QM#(%-@Z./)N"[$(H5RH^8@$L
M!S7Y[A/;8C$.E17-9V22NWZ=_D?JF#S!X/"1KUZO)&6LF[:*]KW>B5DC1\>?
M\$U/$GPBTG1?&7PI\2/XOU&Z*W-AXK\.ZB\5P&&"4EM6=Q)&>#OBD+#H4(K[
M$_9__:4^)%W^SA?6_P 1K'0?#WQ6"36OAP7VV(ZW*(00ZQ,58D,0I VAB,9'
M)KXY_8KU[Q!^S;K_ (L\&^*OMEI;:G>I<Q:2[LAM)MG[V6,MG8S.V0!D$#)&
M#BOHGP!\<M(^(6KP:3XTTZQU#5?#EZ'M)+I=[6\\3Y21&[[6 8 \9 .*]2$&
MJLJ,E:2Z?F;8W&1Q5&,XM58JSYDM6FKKRL]FOU/6_ D5U\4/@# OCG0[.P\2
M>,]$%MXGAMX/LKW#/&T;!]OS [6. 22A) /%:OB/P1XWT/\ 9J3PU\'==TOP
M[XFTX6-G:W>K.'=].BC*21)+(<+<8$9WL<':<YZ5J^#9[>+P;81ZA>WFK:A#
M JSWTL"Q->-U+E4^5<^@XJ];>*+.V5LF- /[_7CH?PKT*-H4YTI7]Y6NG9KT
M9X.'QU:ABE7A!2Y9<W+)7@[/1.+W72VFA-XB^%DGBJPTS^V=36\U2UT^"/4;
MFUC15OKH*!)+P H!/<  G)  Q7EOCCP/I>@WK+;R.Y3.XRD=NN>,5UGC+X]6
MOA_3Y%BG4;0<R2$*B=NIQ7CM_P#%KP[=:1JGBC7M;T_3_"WA]U%]J]^[)I\,
MCG"1J%!>>5CP  !W)K'%2E-<TG9)6N]DEW84,)7Q&(^'WIO2,5JVWM&*5_1)
M'9?#"VN(?$Z7L5GNLXU>.>Z,AAC$;(48*>I8!CM(YSBOG7X@:1X*^ 7AC3OA
M[X'7Q!J^GZ7J-QJ?GZE>&>ZDFFP""RX 4 8]2>2<UU7Q]_:)NM!U-=*TZ\CO
MX[JUBN;:YM?^/>6"50T;H,  $'IC/K6/\(/"7V^!M1NX_.O;@[RQ&<>@%<JI
MT8N-:.LEM+U[?YGI0Q&(P]&I@>9J,VN:'G&]G/S5W:/2^NJ1=\*_%3Q1IVC)
M'+H]G+#C*K.Q=P.W)YJAJO[3U]9226USX76)&!4RPIRGN/>O1Y="E2WW.<;A
MD9%95U:1S2>3)&CJPYRN1]#Q5QQLF]3C=-15DE]W^5CS_2=;U2]@GU'3YYK]
MKK$< 8E/(D8X"N.@]CT/;FLNT\-:Q?:G+_:4D;ZBCGS8"YWCW'&"/0BO0+;P
MY#I%Q));(HCG&)802%D7(.,_7D>AQ5R\\.P>+;15NGDMKB-BMKJ"_P"L@/9)
M1U(]^_6MXU?:/WCGQG-4HKV73==_\SOM&UIM&T-)&A81PPJ64>P  ],9K4T"
M]AUG3Y+[5KIV <JD*OL6/@D8 )(QC\\UYII?BG4/![#2=;38^PJLH.Z*X4]"
M#C]*NZCKCP6C^7=;XY5"Y8!BB]@I]??\Z]K)Y8>@VZZUZ.USSJ>-4E[QU6KR
M6,C'[.LBQ $@,<<#N#UYZ_UKF]0\7+IUTT:C?&<?,3DX_E6%!XDN61HPK/&W
M #'@]N!6_HOPSU;Q' +MK5UA4;MS<<>PZFMLQQ=&JK0C\_\ +^OD<M;$*6B/
M1/A5XA_LOP]XC\0,C,FBZ5+<*.Y(0L #ZG9C\:_.N#XY^+!))-#X?:W>X)D9
MY6WX9B2<XX/)K[J^.,3?#?\ 82^(EPMP]M<ZI"NG1.I^8-*RQ_*3U(#-Q7YH
MZ0OB;1-0B":BUS;;AG&0P7/.1SV]#7FPJJFN6QUX"C*2E/SM^'_!/9M*\3WC
MZ:EQ>'-U*-\A P"Q/IVKH-%U-M13 .6ZY]*YW4+477AJWN$;=(5P2/XS@?XT
MZRG;2;>/EMKJ-PSR#WKRZT>:;E\SWJTG3IQ2Z?H>H_#VQFBTRX4EI)#(RA3G
MG').<<G],?C73R^#A+J4!CVEQ$ XSZD$ GU &?Q'X\)X-\4BQN$:W59#,07\
MP_=.,9 ]>G^37M/PGT<^(K^**,O)<7#C 0#YF;J2.F3W-?39IG5&66JC3UFT
MDUVM:_S;7W&<JW/3L4M!\+WE[=?9TM?-;@+M!SG/\Z]T\3^ M2\(?LZZYJ%Q
M+]FO[.U$MOM <O(H!5<=R3@<<\\5Z5\./@]8>#--B:;9-?SX!?&%C'?']35K
MQ-XCM[LE+;8;2SRL.X B1QUDQ[=!^=?'T:L8OVM9:1_%]$9QQDJB6&HZN6_H
MNO\ 7R/FCX;ZL?C1X8CN/%F@)I&IJ K+)*JN^1U R<>X(!!KK-)_9R\*.%D^
M61P<@-,/RZU:^(WPHT7XBQLS&2SOL,\ES:/Y;@]BQX!_$'WKY@^)OPG\8^!;
MJ5]+U>\U&WA)_C*S  ^G1OP_*MX5Z55<W+RW\_\ @!+"^S;BI[?W?_ME^!]9
M^.OC#H_[-/@V.X:RNC:C*YTVT,Y&,<LW"K[$UP]Y\6)/B?\ $#0]0A$D.G21
M),$E?+XP2 QZ$YY.*^9? '[2/B+PKJ36>J7%Q>V,QV7%O<$LK@\$$$?I7O5G
M;V^LS:-J^CA%L&V@+$.(L#!'MBKQ%.FZ7+%:^;OH;8>]W/F4EV2L[^>_GUL>
M@>,O%TU\2JR,XY 4G'-<W'JC:5'?Z]<W4VGV.@VAO;UXK>6Y<Q*RJ=L48+NV
M67&!D=20 :LZY:,\ZR=X\%A_4>M;.DWBVMC%)8WLBZDQV1);DK*,XR21T';@
MUQ8.I5PZYZ+Y9+9_\#KZ$+%1A44JR<HW5TG9M7U2=G9M=;.W9['H=CXIF74Y
M+?5+AIIHE4*SN_W2 PQN&1G=R" 0>",UT>A:'9[M8U('1+,6D2C5[Y1#]ICA
MAC+HERRYD^2,DJLAR <@#-8-H-*^!OPCU7QYXRM]4O;/2(OM#6ME:/=W=PQ8
M*H6)069F9@ .G.20,UJ>+?AOX3^)_P /O$>@W7AJVT6^^+=DMSXILK60V]_<
M"6(1@SNAW"14."1@ ANO.?9QF95,33C"<5H[W\[6T[7.2C4C44HOF5]+JUG9
MQ;4M5HEKHFN;E3MNOA?]I>?X+_M4_M3Z=H>M:G\74US4-.LS?P:5=![/1K"Y
MB5HY8HRA1@Z,&D .\%G(#;37W'X-^'?@OX1_#"Q\%>!=#TW2?"MK&(BL40_T
MU0.6E;&Z4L>6+DDGKZ5^=/C?]JRZ^)?QVT#X9? [P;9K9^";N'PA!J]YHYN-
M>MH(G,=W?M<MGR8XU++&9B23N? )"C]#]0U"ST_2K.RLRT,-C$MO"'8LQ1 %
M4LW4D@9)/4\UX&#EB*52?M6G>VOY^A]?Q%1PLL-A*>&A*#C%\R<KIN^DK=-.
MG3;HV_D']NK_ ()]:3\./#^L_$;P+YMMI4A$_B308(0ULD1^]=P*#E"I(+H,
MC;N8 8(/Y[>(OA!XN\;^,[VQ\'65O>I!B-[N52MM;9_CDD4$@8Z <L>!W(_;
M7Q+J">+OAEXFT':L\FK:3=V C)QO:2!T /U+"O!/^"2OP8TO0_V1/$*>,/LN
MF3:]XMFACDNY1;KO"Q0PQ(TA4LS.'55(R6#  XS7;*SDI+1'%A<SJ0P<Z<[R
MDFE'J]>WIT/R\_9$^">K?![XE^)=.\2(J:Y;7<4\[I)OCO(G5C'+'P"5RL@/
M&0>"!TKV#]H3X,?\)S,-1TV7R[ZW"S1JIQEA@AE/J"*^F/\ @H?X.^&/[/'Q
M;\"Z7J*>)M5\2>+9+BUMDT:WB*:>A>)0TK,"=Q).(P02#G'(KSOQ5\,?'7P\
MU:^75/ ?BZ;2-!E:W;6%TF>.T=%X$F[:0%.1UX!SS7'+%*IB)0C\2M<^FRW
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M5FD]UY23_%._8]@U/[-\7/!\LU];WDUQH%L;2WCGN//,\@=B\H;Y5)8D$JH
MR!P.2?$['X3:9%KK7%^K6(:<3I&0LKI&#@@+G:Q!S\I/M7:?!7QIXD\?^$(Q
M:Z?J%U:V-T(M1\NV:2TLE8@L7;!(8<D;<D=QBO;-;\$:)^T[;Q:/X?>S@%C"
MD<=S:6B0^7=,Y+2,H!8L(U$;!I%4]1DDD\^#P=3-,=BLYQM9>[+FLWR\RW2O
M9):)).]UHM-&OAJTI\-T,/DN!HR2JIQ3BN90T2<FFVV]7)JS3U>MFGY=-X1T
MSP7 ^NZ7I&J:1;^'GCLY;I@UQ#J<RL/,=I>!"SH\3)"<$@D#)!%?2?BKPSI'
MB'X)6/BS3[_;+JT6-J1_<<#!)QP!DG.>F1ZU\^^-_P!D+XAW6G7S1SR7FGZ=
M</)+93(+3S)515$Z1 _O&** &))P,=,5]%_\$Y1#XB^$&N>"_&%Y]CT;B_TR
MYF09@)(9XE+8R'&X@ ]0.F1E<59MEF8X]5,NH^RCR\J3TU3NG:]EIV[W9]GX
M>X#.^'\J;SO%/$3Y^>5M7RRM=)M<TFGKKT5HGR)^V1X$_P"$5\0V<NF%A#KF
MEI?GDA$P2&'IP0Q/YFN8^#7QT_L/0&TN]CD-C,^8L$@YQ@2#L<CTY-?9/[1M
MO8G6=.TFQL["^TVV@6VM9]1@0V[A&9E+' ,;9;+ N 3Q@]:X$:;X1M+V2QUW
M1=*2=U2-I[-1+;)D@L8Q'DJQ&,8W #=WI<,XR#J^QK2W:U]#V.*L4Z2>,I4K
MI+X5H]>MNGGL;'[/T>EGPVUY%=6UP][R)IRS1QKN^8*JLIR5XY/7DG&0?)=5
MT_Q3XS^,.K:=%K4.F_#S3]1T_4+T$//;3E9'C$D*J"V-H 9<@H[$DX(8=CX[
M^ 5OX<^$-S-X(O8]=A$AF-M:R,_EL#R(QP25/8C..QZUM_LV:)H=UX%UK2=4
MTEM1\772M:26-TF\1"4!54*O.XJV2>".@YXK[G*^.EE->K*,.>]E?;9[WM=J
MUVO.W>Y^5<<>';XKH47[1T^5MV:OHULU>R=[)VZ7U=DCZ2^"/@^;XO"ZT77K
MBU\4>&KR/[)<VUYIJ117"G*L'3<P.]=N5)P,9SD\>?\ [;/_  3NT#X]^*]
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M%*:C'&UO=.2DN  ,D] ,#@'/3I7N_C.VM]"_9ZTRUA29=7\6W<DT\V,*+*V
M54'KOG=B?^N"UVWA[_@G?X?\)2ZG?>)O$D.GEBSZ<J21VZ=R-RL22,\8';GK
M2_M3> Y/!FG:=!Y?VFST+PS:P0M;X=1+=;KDY(]/.QGVQG/3X'$R]OBY5HKT
M_!?E<_:LOS;#1PL:"EK'WGT5DF_PDXZ?>?#%C\+M4UD3WL,:"%G9E9WV[P20
M,#J17O7@#]FC2+'PI;S7\,<E\"'EE:8@QD8/R<8!.<@CIBNBTWX2:A9^&;6.
M\TR;3Y+RV B60IYH!  <("2%]R!SP<&L'XC_ !0N?#MXWAK4HH3/9VPVR(P(
M<C'.1@DGCCKQWKT\')4J[IXM<LM&KK=>5_/?[CX:>>4,1>.%ES1U3Y7?7SMU
M\CUKP]\7+KQ=?QZ/JKOJB:Q"MO+=1RO\D44A8N8EVIF3D.Q7YNN.2:\__:@^
M&L-]XA>QTVRMO[-^5UF$R* !R0J]2Q[X&!Q7EWPZ_:3O-#\4M9L?[.)A,'VC
M=ED)Y)4="6., Y/8^E?4?P=^*^GMX,UZ&\NK&P-U.J-JE]!%97$L)*@2A&+/
M"VT2*RD$,&)!STZ<QPV)XFSY2QF*Y84X63:LODE97O:^U[/6]C\JJX'#\%X&
M6+R?!.TYWY(MWU:O=N[M:Z6]K[<M[><?"3X7>'=:TFRM;'P\VO:SJ4S645S%
M*BW-@(<SNMH@8+,[Q^8 'R08^" 13/@EXVT_X7?%Z\:WN6O8=+U QSEL G#G
M RI(+ ##>X8<CDT?BE\'M9\/>&M:\4:!XITVS\-:C?N(+729GN+A%8%0 ZC(
M7;D8)& <$5X3:ZSJOP[UO4+6\MXX(]0 ='BQMW*< KMZ9#$X_&O4X@S# 8S
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MQOO"=P9;GQ+J&II#=7PNFNF?RI@Y4"U$+* 5&0 0/F SC.J_8>TBF^FFKO\
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MC[:*O%[7?_#'I7P1_98U#^T()-2NO+C3&(E'^L'7DU[U\2_&L?@_0@OG+M@
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MI*\7=,\Q_9W_ &K[5/ ]U\+M=UB:;31'_:?@S5GF+&)0 PM0_!PI.^,YR 6
MZ 54^(?QPUOQK;Q:?XH2QUV&V("QZE;*T@ /(6=-K@GIDD_C7AGQL\#0:G:Q
MQV2QV'V *+80#RQ;[>%V@=,8 &.E<WHG[1FM>#K9;/Q);M=PH-JWRINR!TW
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M]QFNRT?P[)KZ")@G'J@+#Z_6OFJE3V4W3GNG;T:/+NN>\?\ @/U/4;C0=/\
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MK5M-T:&YM_M,6J6Z9Y3R!,=@9.@*Y.<C/?)S7JX[+X3@U-:?E;JC\\P6-Q6
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M_(^!\KK8N&;3@G7A'D<^MEHW965]KNU[)*]D?2[^ M$^'MQK=KK7P\\9>"M
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M;:Z@E&'7-<7I&L^'_"G@?0/"/A6PFT;P[X;A>.SM[B<S7!:1]SO(Y !9CR
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MQLPZR9 ' . S=<C'3'/X5Z#X?\)R>*]7\Y8H]J1*@*#<3@$Y)QSDG\.GUP/
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M!@>HKX$^.O\ P5VOOVC+:\\/_#>^M]1OUGMX[:2'S=/A56DQ-*^YBTBHG)Y
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M&]FP29ESQ$3R2.X'?T&?4YU?%7P0M+Z]N+B-FELXK07T2)@L\1(R%/\ %M#
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M=T_2=-O?$%TU[JL]E:QPO=S,/GEE*@;G(&-QR3W-,U35[73=*+-,BHBY)9@
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MV.5]#MVDC\:]4UK]KJ\\(_"F&'P?X8N!?6(D8O+(XD+.26(8DL!DDD@Y/ X
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M4\"W=O9S:QIYO+A@D<,+>?*['@#"Y"Y/<G@5Y5:-2M*^K_KN=TJDH1LM/4]
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M2:)HU])?SW$\,4$L\A0HA58PJJD:D@$9)&,G@"OD7QA\-/$W@NX::&22XA?
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MZ2[CK)*8SYERW;)(  ..237P[^USXY\3^-_C;KVJZQK5]J=WJ;>9-,\I.?,
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MOB._N=#>[UJ9;)88X8P6FE; 2)1U)/88_$US_P 5O$5OIVDMI]I<;K>7!FF
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M1XG\>_AC\4O&'AQ6\4:@MKI>EW)CM+>T0*KAU!>4O@%MV<$GG[V<Y-<3X?\
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M?QI9EE[PWPN\7^9RNBXR.?\ %G[/FM:SKKZGX3F6+4)82DL+XV7.T$J,8(+
M],@CDCW'E_Q6_9]\32>-;>Y\8:A<:IJ%Y#'-,K@(H; XQW*].<YZFOKCX9ZR
M+/6;*3/*S*2._44_]LOPXK>+X;I8\LZ[P/J,C->5AXQUDUJK?Y'MRQ]>6&5"
M3TL_PL[>FY\H>%M/D\!:G')"J0)'C Z<>E?2WPD^.T-U$K>:EM=E!'*&Y2<#
M@!A[#@,.:X/XO?&35/@7XTD\%^$_ OAVX-GH6G:G>^)]=$#1W+76PL8UGXDC
M4/L\N+#\,Q( JO\ M ^#!X(\9V$]C9PZ+<:II-KJ%[IULY:"PN9%)D2,GD(2
M-R@\@,!7'1S*GB*SI13377H[.Q[N/X?QV5970QN.Y94J^L4I)R5XJ2=ME=-:
M7NMI).U_I33?$FBW/^DM9/#.!]^#YTSZC'(^N,U<'QBNO$-NUGJ&NW$MF&&(
MYF8#CIGC)('3.:^-=+^,FL>%L-',[;?4FNZ\ ?M8KJM_':WZM&[?*' # _@1
MFNSEMJ_\SYF.'P=7WJ<[>3T_S/H3Q)\2['3[#R;&;SBHR2&PN?<] !7E/C#X
MQ1Z59/):W6+@ K-=8& #QLB'8GNQY]*R?%GB.^O_ !7INE1P>?%K =H[E1B+
M*H2$_P!XX'''XUYC;:%?>(+P6]P7WHY78< !L_EFM<3A8T[<LU)/6Z6GIKU.
MC"U:&'4IU(\S6W_!\BOKT%_\3)#'&ODV0)[_ #.3UR>YJI:? ;1]*CW7EPJL
M3G&ZNYT?PA?>'].:22)Q" 6R!C('7GVJAXBM[>T"21S3%Y"%^;C)(.""0<$C
MG(!X./>O1R?*9XQ2<7:*W[G'6Q$\7-SF>=>-/ FDV,06SNY!)VPQ&*YG[#XI
MTH9L;RY:)>1M)(X[UZ,-&M9U9HW2=W)2,9.[(&>1W(Z#'ISQQ6YX4T9M/N&%
MPG[EE 7(&!QW]ZZLRRN&#@FY7;Z/<R_>07N3:]&SB/ 7Q2\16-TD.H%KJ$D!
M@PSC->S?%/PQ:>*?AWI'B*UA2*>SE6.=$  "G@$#^=>8ZW8PV?B!U3!5SD =
M^>U>P_#AO[8\&&P9&>UNHO+<'G# \''J#@UXLVHV<36A6JUKTJLF]-+B>']
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M>"2*^KOV6_A#I?Q>_8MT^3Q%;7UMXA34IXG?3 BK$%F+^:T2;5)V,HY )"@
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M/7')P:6!QS4N1)7>M_\ -];#CCJ[7LZ>_=_UL=7\-OAEI?BC]KO3/BE;>/\
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M)/5K9V\_<YOC#X'\+Z+H3>//%>DZ9/XD"MID$\;274D3.4663;RL996&_!
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MF>"M/UOP;H>N:3;)';66+2YMURWV< =!WP,Y'MQVJEH_B=-#TTV+1(%5< J
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MA79Z]IX\Z)(I0 BROD%#CGGICCGDU9\+^&+71[@*L/F9[CI[<=LUM:=?2>+
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MR7;K3&1S@1R7Z(Y!J& FD&9HPP,*G$=;VUJCZC+NU5B*9^;08_'R#NRWU]<
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M[)NMN':5NV>Z2LWGY1S9G5^\M9)]IU>YRG?W3.(:4/Y29:^8\>1(4O7SOM2
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M"%YPQ=PZ;'C?!^".3%0^!HU?*I])K+7CGMLS-#L2[AV_A50'?=,6,[%EG'$
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M4.LWP$#OXN-0[?3($1'1HR 4!/N$L\K6SMF7K?L&:%UYVN6&_\#K^6+H!76
M"5="DZ]I3D%AU.@+[=LUS111(6=Q^3(G^HE0Q6Z)ZVOX[S= _,6/%PHHI.<&
M<^)$B/.U];6TH >Y4^X-@$;H/_]I+9JM9]OHL.)O;[BLU[@?5JRW3^3-!6%
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MNBGR<[PI15_-'LL%F475T]NFI+=UEDJ<E6G/B?,ML?Z.E:>C+4?.R>Z4$_!
M_R8H<IQJ=LCZMJ[09<1G*]R6"K+J?<MR^R"]P)D.KA:*M99H]']PMY9O3"F2
M?]".(C M+Q#6^[) F,H1#Y[\^-NWID]#*YRM0(%/?B>CT#&!X+F;5::L;-RV
M)#O6Z^M,;+\5)6^SDF,#/?:TO_I+Q4++T-07MGX=&H<'E>M*WKU%>&[/5E3/
M=8Q#F,0]KL03A:K,"YX/7+7V<@3>=_ &^&+->HM%<_G?80_=HTI$P*Y5Q!N
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M&OL,I(P\I.NX(HD^:&UO;EDXK2[^0C#DTK7LXY*%KSQ;&YV%%93UWCL<\PV
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M415I&"-%D'Y'J(_L:,K&P-*C$LJ\DRLS=U;JBNF O-(P.1^]PQ.J2EY)W9N
MJ\RK9@-![2II&8(OVX2I-KL.MF3(0F>8L88TF)D T8(JU:R<1U'9'B^*:9RB
M'^U<B(;N8VJ-UO*GLD!V_%.#LM(8[C]IN<[EUD/6-+S]DRT<1-WOM;KY>(AY
M2(FM2)3H$SQ1ZN0H[2B1QI#(:H*J[]@Y%8%+L_GM01')Y/<GMO/XZ.A]FDDX
M>V'2GGV42R57Z_<]I9#5@>TNDV4;"QF/F,)G/MO27S*V&$@X:.. BQ"9TGWJ
MN=N7:>D#I?HE3M.;%Z9*ZWM/8SOS;O?%#_;/X>D-DBK?C8(6Z(+*2PPLN\G
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MY5NE&GYH5?"Y(!APPAFR9$]8)J7'#I;<2AB2'"$=*9;R*O[[U]IDO=/.CW]
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M<@8"D]"0<#& !CBO&;G_ (*:?!'P+KJ-;>/+SQ%&L96X^QV,]T\YYP?E0*S
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M(OR-9_ZP9Q5A[2,]/)+_ "/2I>'?#%&?*Z%WYRF__;C-N_VV_C=J48MH]4\
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M98;7#(H=NRE<8([8Q^-,NXK7[7Y*K:H^&3RTMF,H&>,,,A5QT''UIXO;B?\
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M/_RZ6-'CU3>A/X=E]GN0VA(9):]C6Q^+]?]:?OKPF3-VF[P(E)4QW04,;U=
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MXU!!,-#%D0\H3)*U7:5<?<BG A\BVNHMQ#<<])! JDK<XZS7$Y!.*&50Y,Q
ME?PS,J4C[F(Z#D,1SI^-3>GV%$TS[G3*;\FXZ4O-7W;\+$1%_9!K'!..3XPY
MWCBBK<E?2Z<><N:[U]\[^I=>WOV"-$0MUS=*\JZZ-^^0F,SK@G?%T"^\62',
M[C,8\%2%0JWU^!3]+W?-Q9;X2Z@'PK$_+3?J9?U'67X,CXV9GXI(/OOS%8QQ
M&P?K9OLY=HRB$F3?6UOW6>OU@X-$A_UH8/GR77E,WN*H-"$$I&;T[JKB 57\
MS]65"S^$%Y+[?<JX5/-;_GRE7E>58HT><7U\JE=MIO&NI$;@ _NG9:N8%;D*
MD0M[?453HU\V IN_7QF9^:S@]B=QV&T.I"2D+5!W[=B"5SIY\DW\KH5PU>4'
M9,7#UU:^;_LL1X=,W)GH84-$>W9/J3(-7O;DL&+QUTO&N"W(E6):PA]!)A4D
MJ.+FW.6WI:P=_1\[,K];OO\QIIKW+\,P.0FD_<B+>D/7%,ZK<C_._C,5F^R5
MC0*FCX]WI;;T!6LE&C/VQL5.+%L.;(1%A-ZJ!3=2=L9-^GLF: Y.FP08DL6'
MS.4K%P^KGES->-78JLJP*P!C8DDB+S9O)'/#'V*UW0J=HW8P _Y2"'I40.AI
MWH7TR[@83Q:829IJG6RV@(WIY9M/[JDR"2JS-UR:2AN;5V6=:HY]P1)&&VW_
M\Z1/ZJ389HQ5]NV.E^?@GS\,X;M]1RM1BCO%-[]OWZ4A'BP^MW\_5Z+*,UTL
MU<=>=R\*>YUIH*:'3;LQLY 9M2(''&(ON"J;:C#T^;(]0_!M^4=;(W"U>[6?
M?PYA9NA\YRY^I<[P&A8=J><)[1X^^US_38,U2Z!WM;3*Z=U/]G)=XG#WMP^U
MI0S?5A)YR(-GWL7_W&L')K660(F++N+IVK0^5BR_XGF>^Z]2P0*F19<MXH)N
MC"V[HK3HL7<H@B]KE':7QL$7AAU\/WO;?-X:]GLLN9DZ+9%'2(+R9$F^Z'1R
M^QDZ<.L'[5LM<ZA,1;F;E/Z=6 6C[PG*5 E:LBKM[(MCK3!C0JL"A8^&.4\;
M-U9M_K?UU/#2/+4\W7NK[.&F3%LB>2C:H(,&0TGG$ZP?%)7,J#38>-S^X*K6
M5%6R2(AW&FYT2[O7@Q?>T3ET_JIU$HA]LW!R%2HT_+TU2L74@[< /4<5:NE+
MD-KF+1])*E)E3K3O_51S*3J2EH<!-_>&,F?'0F2>!&K7P;/VN*0BH=&, U2?
MH-67U:3^OF'?2I QD,@'KO!2TY4YUF/$V]C<%:S>MG?]IP<6BGG<X-#7A_S\
M00B\\9;V4NLN]!:C^M3 H=W9P8A!N.9'E5V.6#UPTN?@==LXVDOO9=RZ'M]+
M6$>(2Y"/=MR:C32[*$H8[<.@+!C-H>V/B (.U+Q;BQ1XX7Q%LAM>%<G,9Q'C
M4IAA/L83S _"5Z_864$BZ^9F3XBI[^Y;61#]!Z,!Z8[R=%PV_M)8/G+8F]O[
M6L^4&X%)8:%AU#KLF?:5:CFH--6<FL])7]](H1H\?Z>/WL@EYG;OZK5?CZ,>
MRKUUFYX6/R5X[%>NK'_?G@;3H6KQ!&3AYL-B_%Q69F-9RX\GR^]J*\0I8Q84
MXM](6]<F,"EQP\F;P!_*.+-?;*;C4K;]]/""@QMXD^\6TA!"+8%:8D@^YN/%
MEKPO_;K>E]^-2/>,E6P3I;XWJ"!,!\1O?^!H:HY5_$YDK@'=\MOX6CE4KKRT
MA^>@X4^#1[<&EJG\V/7::B*!VE1ZD/HI&">THZC8F=ETV5RBE[_<+X*W]- K
M?B+$!ARY.88N<,4V)AU$0S/BSR@J@\:(E.BAGRDZ^[;!3M;Z[/TI%B$7V[YM
M%!WUK)AI5@&Y8\0^0;[<X?XE=&VX-'. 8G:(A[M"@OT2S*5N'P7_"2>S=R.!
M\K 6BL]8Z!'LX*$/7#5K:$\9Z]G 1(V:][8PKGG=TPOF+I)1#J.&L7SX&=12
M*_O/B7>E$2E]G*=S9]6N6#[*#ED&=E/3Q=N./+<4,V65FY*RY3S?:/=4B:<L
M"V'Y&H)1%7DRKA\4N+:#S)<ARSH"DP</I=_UXDL[4,?/?A]U'09AI"Y%]4W(
MJ1.^07WIV7?,Z"L$RNEQK24ORQ:W_?Y87*\.YQO)4L>K!FDKUVH!/ME/><DK
MI2MA)9?OV-]]G?G$H*'!XI>@EDDA%/CR.K:K],G:;( T6B&=L7)WM74J/_4W
M[M3APIEA.M9\8>K-(;O%@O>0R;[X ,)^</2XFT=WI*HBN-S <37EE&5QG]+]
MFK[>UF\2Z&<^-PG4P)@E0&@A@>QN],1)5;0Q;7&:NAWP<S>QCW/^N71F* 3%
MZ>&#IABU9)>3RC_VJ[XJQ 9=[E9^_2L^:F,U*3-:8EGCVF/(W^G!J67^CF\5
M);4M[-O?YRCCM:/4;US%+V=ON#7#8HD/=H ;8*V",/[1Y[Z!:,<O*#TBP+5,
M2W,LVZ%IRKOB91(([%#(I(4(>/SV,6L('V5_<WJB*^/[])H=S7'.>FI4JLQ)
MA;15E3[G@,S(GFVY,L_ 9O?1]WW8-S8XQUN/@.OHLAB-[A3.K6'UER\UI"$O
M!QW6T]'9'6>.P63AGG:8(\@;1:@(A9=, K^ASA6PH$]).Z;.;=C#9<PY*U^J
M2WG>0*)V7G!JMM/V;[W$VVK8J?7%RH.+U>H/7=6:"AQAEOF&-\/K3,)U:K("
MQSH;T!4E":'63/U#? X>BH*)*2V>Q[]?LNTN4XC8G$;%I99%5ABO\OMR-=O+
M*5G1LIH4Z,6]U[_&S^\E332<R9K,=^!5$T.*L_'HK;EGY(YR!U>N23Z36Q/.
MSG?<7N",?NY<N.[Z6,?>C]G$"=JR[3\ML.PO;06/_R+!E%.IJ%,9TI$_?2#]
MBA&8[H_P R?F@F'[Y+5RC!N[-B\V8B[ZT-%'CM:DQ=D'LR8M3_W2K&F=V=;)
M(_=[%"^HGU;OJ7%!/$+=Y?Z',D<??9AF8\7XDSH-)HV;?W^(:+BF(%<,*MM^
M3#8EB]2$R,\O=/DZW4</%2<R?4.9M966$.K?V3,EGI'/[0O^N)5/F9RQ=(PR
M6\6H"^]HL1@P+PPGGAA:MH^G",EK151\*AOJ-'R"I!!>V!DDTN.FK,,B.1(H
M(N9.Y/GJ?M>20']QG!;#E8(=S4EZ6;W"?T*ON9?/>,8\J(!TO]-LL":!0L-$
M7P:Z*PA-&LU] 3[Y39>FN^-8O-O"KYKDHSRE:ZRX2* ?.JIN&"/T7-I=G3EL
ME[H(?Y4M0V7*L<+':9&*/_.J!U$-A7]"F>H/M?-$U&,S]!J\19[FV94$?GHZ
M5S/NS%$':65U8Q$U2LL,"<7L6K/EUC0GK:Y:+;3(DP_+*VL:I%Y8*7^GG7<<
MWD>;:!$YHI.7V[2ZF]H!?=,+C:IKE<]7.=%&S1]D))IDW<]:U$@<B!,?T0GD
MXUKLHK@4&P=/LMGJSM0T;IFMROU<>*/=A##<:9A:+C;%-R'@.]P0R 89:.%.
M</S>L/_4&QC!T2KXG?0V(^-96;_]M*U!OHYO>0]:*KI]&$4^NB5,=-5.6!_^
MY/_%^-+ZFPW]?-1H')^74P4B7(]"#-*RL67N+;(^RAI:*R*PGG9U3E+_BQ=?
M),<EQ]?IKJ^DH2U1">NGJ%N_,^*.W2?NA#_.:6?YB^1:>5M>U H&(68@F6XF
M+J4<8W$,;@O-\Y)=T:YV=RQGP.5>2_F/_9/&CJ7WM<L(VUJK&I7&)B;&SI:E
M<5EU?4/.M#%!^ESU<LHE%24#:QF&<O4T@7FRLPQ;1BN\BE[R0]02';J?[7&X
MI$K/XBP=;71=/I(@:.NEE=K$<&:P$)G??5_$++;M_>1^L='6*/X;9;Z]\HW!
MSR5]'+Q?HB7IN6:4==$^&2X:/Z0ONYD1CM.V!-N3G@CENUA@9^UE+Q8=<U6Y
M5J3HO^/O5_?3LU*H)($$7<\87^F[GOIXI 1Q?7JN&$<[4;_PX$WWTL^SR79D
MXY/=+AE3/B.W3U^CUM<+1UG>V61%5ZK+67L+W[HE.O4=_RCE<K;0.W</4W.6
M9'K7N[M+:+Z@D\[?%IE_VN6[O+0[)\IO="W,,X2J_<Z7%7<\EFM;Z-_V[?DB
MTG8\;I?%@#.ZHJ]WJY#N=P^27KN!57FJUK(^;NIA">V%EV+5I_V&I;E_([)D
M>(+V/**GC\*K^^,>,S.NWTKUQ<!^=#N.!2B)"2,:OMSE_EH!UIM:&8]C*G=_
MS<.K+_VJG 2Z5$JI/1$N%IGS+ [$E-QEN6.0XIU(=VFU_ 8E54^@X$)8I0;O
MLY9TF-]J2_#$WS&5U75TV>\.YD"D8:WJ+JVONR!HSV31-<RJ5B3QN'B,"5J3
M;-/IIW_85/IP37N2WJ2@@3.CQ4""+8)\YVT01DX_\]GNPJ2W:NVD+)1JMC6J
MM$O-?*\Y:J>4*[B#_-9:9,1QE[)OH6DNG9=V'(53982)K#Q<4'BJ"7S'X7U!
MES3W6&UUHII B$OBNDHJOU/NI^JDWC(-O^.TI1(95('=5(*Y&3+ZO0.F&"EW
MWYJS5(.=3_5C:UZNL/78FX>GZ8WBD/"RNZA'M9FRND'MGBO]]S^NUP(Z<>,+
MAX'@S%%)L:Z&D:*D'[NR=DO<U.*&%'V%MT2-F3!EF,)Q5:7=4)$BG::P$;4/
M%"<>/,!]L3I_P/E8(G.O*K6T5&#FM%I6OUP(91#O$FL4K&T^Q'S"/L!0D?V4
MZ>^$B%74PK=3JRJQ%5\ZL7'.[>Q:Y?&IW);)<:WLUUVGY!/-K6$#LE'EAA=O
M_%8+M3++F/9V?)*7DFO%].+0Z7FZ1X_:JKA_<K+[@H'T4;F J5YC=2-OZ8&?
MMK,7H?3Z$U;FDRY/71AWJRV/!ZY :F)*Y9>[$)V8.;/CY"&;U-6\"3$&I\AW
MFSP">%7QW"N:5USYZOQLW*K?I;H2J7C2L8C/6/'AN1:#M@_^XD>/>F6F'Q>;
M=KI:*NA3&/'HV;?\]70?-SB48E%^%#9)ELHMAF+A+X_S%MQN6C8U<KU 6&?V
MGU+(1/9Q-0Y[<^I9#U'Z)CZH@WBQ@#$Q-\-O-5;HOJS%O40^&.@K/Y63R*4)
MLYP<V4:8VJ.2$CET<OJS8DKFIDX^$2 =Y2+)B?D&+:FU0_M?7^G\V3'45BD-
M8VN^,OYJ@LV8XW%C5+&>6Q#Q5P>Y^MS<>FTLJ\:+Y+F.\I<^_"&<IES--TR-
MG,+NVAV72M9T6UVY2\\\Y4K%M1M+=RW?GIEI=L$^[MWNSU(#R7$'ZH@UV-OR
M&XNW>4>^=_54\*FK?93]'JIMZ%UGSQM;;O"M(ZTM!AC>C[ROBFGO18VE*%(]
MTG3O*,C"R L*1$YXE<W(Z4@N-6L[N!EDSN*C6F=;/9^!(W(S4Z@JIX"9LTK,
M4+;B[HV7OVIZ/"5?N0?R<1OA^#O?A#XN*C19V.;-Y\,-=C1-)XROA1K2QF/#
M-%K2^(ET>> P@=U;:T[EYC#5,'H,ZC)YDUY!,Q6C/M/<NN"Q:?2' SY>F$,N
MHFPT><[CI<'7J>^* TT7*JS_YJ5MD!,TG-6T'?6L=2CD!])85A.&%91ZRIT<
MFC^-ES<$-)6UO+RZO'A58FG2V6]X26B/Z9Z!3@RW>$58?$8.1810P-/I%7NS
M]9Q L0$["WJVU,+92U*">A>T)@3I>_7!:Q59>MG\M_SKFPIL/NIH[Z3-!O*J
MSRI9NTQ^^B[Z7+;.^;E+^5]:MK&R^<D&WB@#;^'=(^G<1/IY$X-1P72KIG&.
M27_'V8*F"TD1>VD+#VI,\>U:+'R\XP[]SVHMTUVXQ-N*67ZUR+7:(@HUR"72
MO8>RU4K]BY5>>83"XG6-?1*DC2X=U#W/$U@VXV3Y-B1192?00 5SZ)STDG::
MPS>9;-[5.12(^C[L/Z7Y%7/(8\B7EC00*"Z6(AJ'D6XA/$&%^C/6Y",&KSDO
M"G#EY+-1C&9.LM0V/)"H^&NH7A.;Z]:];1@O3ZS_W39?I^F(W7C9)=*=Z64K
MW[- =_.=2#OW?#Y]^_U^79?Y:\ T24<;VRA6[Y<HU^+6J=?@]NO+W$.'1"JF
M=6'#_C3.)J7DO3T&)I?!J#!VYBCCE*L?BG<5Z3WT3)ZE]I*5/[=O,6K2F]K1
M;J@)2UP#/RC(;Q[.?&O/^>'SQ&LNBSV#>H-JZ;V*_ BQ==WIJ,JB]M7LSP:A
MB>M"Z>7\Z-);AN+ALCH3VWKC<6&L&P7/C7N&3!H>ACRI%7146)?H8:N+2;25
MVVK,9?*1U'7)>Q'(4_(WK  AJ"SOD.^Y2U5C5I0[)\X1,UCG59XDJMT<4)OY
M].QB;K\XBU&&QXO&]3J=IIC<<3:;H?M;FD&U/;A:]ZU7'L9S5C>C7)GL?UF.
MOREF:OEC14!$SJ:EY7F5;&J.:+>*BW^YI&G=,<&!<O$M=/=UD<[O$LM68[@<
M''7;J8#Q@AFY'9.&//'XZ;:ZU]>+I?."R)]#1FX?7LC%,FRE77R@8OC:X\6<
MF1.]>9VUZ:!)E*F7O!UW19YS)]UIRT1Z4]&"9?0'_=$WOAZ(C\9R@S]C<S^S
M2G]M&]6W;K(-+'TL]RV%>F--=TB"UAK7G<G2MOCEP)XK>P!E0LV?4'(I46\]
M]1OTD^YCTR9**3J'!W+?OD8^=;HU#']8?!WQH*1A696LW^TQ=:3H7-%R_!N*
M&,8<UDSV>N.T<B7[M1B;HI$D&M;/W4P:]Q/[Z5WL:"X^6!?U[*[K*$7M:31%
MVD162Y%#DPR;;XY_S"V3''"9V0%:!F^N-.76!O':K_,_O\[\_W]^I26!L&PD
M$#[/"@DC!(\0PR8,=WP@)SY^0KTD$*0QD?CL3_;9*83 DQGV<3"[UAL6D6:G
MUV-'F9P##VZ\1WS=$G&$74L3J.KDX'WX^-$OR8"L'D2K[8IY]/[X3Q*(Y7C(
M% G_& !>=F8W^7C5,5/76**2IF2I,*7GN:WTO6!$8Z#C"T+-WK=W-6CNCDRI
M!J])%N#<WF!(1%FFBVF%X<%SS(.E%9/;">6:?,D0VN6L2 ']W<"GGK->=8>M
MGZDE%RP?NF6 QW)4G ^>OYU3V(U;JN+PE);[$'>\7]& %)J%&VE4-;P_.NZ[
MA^ASH@^\<8>H/^P K1E!=56.M.&ZJ 4?7W'RFI5]'/S'.6*Y*EE$W4$7RDFT
MS5>^WSF _;)-!=P#9_&Y@0@QG#1DHHM\4$707.XS:^//87G[Z?$_FU7?DQV-
MU@(R6BZO3!Q(L1; 98\I_[!C<J97^$HU*AVB?B54!SQY4"COHW>Q>I%XW77?
M;ZW!/$!F7)QKUU7.FW_F;'5:KNI/W&<./\]&VP?0KB&>RJ>+ZZ,GZPW[-3]9
MF1ML?NPKAZ(DLA=275\__S#!')^V(KXXV[GD&F[3-?)+B+RCM,_(1:Z;;)KJ
MH^/J#0B6BZSKQJ4OQ)MXB,UQXB^J7JB$KFDR^#ND^P>WZTP;#?;JHJN6D.D'
M%?Q3KYBJ/XLUR@ 'WOOI^;B&3N][B!&D#==G=A&5>+I+2V943>%=C&'Y_&]"
M35E$MMV5<=R6(/\WY'W-)-#'L@!9FN "K/(R5UT2#KUY56!CA_UFC.&7+AQK
MT.\7-[D[%Z]_)8%L?U7!" G?P-5@%"4)I$@92@*A"[6(;%7)0J+^N@U]YW\=
M&.W%\D)8A0>FW"P^:P[H K;S5'U:Q+(_M@EFTF8$UN\B)BESNE7!H1YG*7C:
M)\L&13N$;'1BI\0#N#?NB?DA>1!5(5T:](T6@HD8"5R)H/].@&&!A;O_9Z$J
MR6GR".I. K&/Y@4OF4 /#BBGOL&?A<T'(199O>Y^FIT)>#CJ39$3(BFI&?R;
M^A% OUAE3#"6!%I^,.D2Q&F'<+>Z(D8"43Z5.FOB%J^&O+% T%.><A/I2*".
M3 @VRALO(GGNY5/@,QRK6T@"41FI2:<O?CDJ6I;BRN[8Q/\E@60SE!9*]V6-
MYS%[,>8B#T[[9WJN%&U4SNOXED4#4%/23@TF6]WV:0R JU[6V='7H MNL(X?
MLD0&,":,C*BZ]]\  NZY(L#_U[WDNRQ"D:J$C7SU""F3%'2)-BPW"A^_"D4/
M95&F67%.97L5J?C5K>?(=<&*YX[]M;#7ES)%6;5":Q\IOZLWA*2_F2Z$=K('
M_5X\TL+S 69EH/NT<#10B;42D-5L'T,2B-P3B 6?T-^_N@N4N[)6W;ZTGG&\
M8"Q5CY'/$^6Q7IQ@4OXLU<^#<FW()[H\1GZ^.GT]OP<_*\*)#-R8,!(H-Q!I
M@><9)X$B\H@,?/]6_/]W!2=+@X^!3#^'$3_FD$ ?V"^YY;@M-)! R 2XG>L9
M=]M_@PSY?Q9J]B&]7<3F-] C.DK\=7I/@SV\B"WJIDR /+J22+M% OW2(8$Z
MN8B_2: CK=;_>D8"U519]!*72*"7(I S\G#BY1A&/F\B@^C_XN*E 7!](X'"
M- @ HLTL['D$0L[90!SN@K+C@@F>0' V@0!0/]PLW\.^63SGW][_I"/Q_S$%
MN$B'A^U2'H^SDT!?BZ!+*ATETPT/$8K&]=//H6]&$/2P4\ M\(GH/^8@&OYJ
MX92VW7=)H!!P1PE\'GBF OZN_[)TJX+M;DD,V>W'/>;QQS9R;K^56?B.R"#&
M5S[61Z'2=JUCKQJ7M@+(*0FYUTF@>*:.;*S.N5$#H G\@6'"QF<]@RZB"U.W
M YYGXY4"]LY:4B>*APS2#^4KCTF@\/LW=+LZ]X0]!;AQC).I<:;%9?+^OT3,
M!_=OL5^..KJ$8R6.468N7$%'LF:C$\[M&C> OV>C*.1:PC\$\#:MPK"J0!5'
M5/PUT/HBHY9$KJ.^1K1E!<=)^>IYE$<7+!9O.'F#RU5=;3D[\1' %+6W3 @F
M@>ST X>6+,CC-^74 %#.,\2>[%JZSX]UD8NA/B10<1:$R-;X'2\$2R3\9=:>
M-OVE"8XZ$7X!%>W?]72,:#MRQ6I;Y6EY2?R.N>K+85@.^1N/4Y2T" ^B@?PG
MH(K$<RHS4J8 ]H 4P<X!+AYKPL7_HC8]H+]4^IR)^S> 1:2K'%N#1"GBD<P4
MYV*8H//(V8^?WG3;/9CGA!SX_V$!;WTA[E[0J'>\,^RG.2UL#IM*2>PS76YT
M^)8WQ.@.CX^EO.WNTR)G)K#!WFM=;S?+<BWG1;>O^"8,1QXTJB.QCH:$_,D"
MBOE? #6@?R"8"#<2B$TR%(+.!_C3JG7L*$H"90NAS]_#9G[_[8;9&X7#8<XO
MN\5_8\+>S+:\>\;7"ODNA+JMA8\@4@/%D 20HZJ0V+%8*Y_4+^MSM\/I;@.>
MHQC@O[YR6 U?Y3SDI\[^C7"! D&P+T7R7C77;F.AEBU+[^FT^)C0WT3<DPLD
M$,?)?Y5+&2]BB*( Q.Q_5RR,F2MI!OJ7B"L;\&FSA!.C<PHO'8_<Z!1H$;,:
ML&98;KJ1\52+A<+_>7:U)(J"#:C0T/\M^3*6)YC;A*^[:[9:%[ &\O./]WG!
MA(36YSWAPNX.GCP0A?#2#_N7V*+62J/#%WP#O-.UGNMO3*XU-1P@%*U82NM=
ML=PD$.IF#_$IE)P2EPKP*[*P"W>!.$IU2XX2J87G.5^IE"6\'*(>2R2VV7KL
M7PK+PO8& A&FE,SD$&I?SKPAIGIH^"W[#Q\F G+(CM4"$JEWGDAI8 X20G"]
MZ<'?5Z#!!ZADXS6TSAI2?VS"?^8OWP5B\!N(?+ 6E2HY\DVW?,ENRO)I@G93
M0['<V;1.-EK+%7$O<.\R5H4$FNL%MFJXXD!!OT>!J8$6$K*_R,JA1>2JCU-.
M;U\06[45E$/Z\LF]A,")H%G[MG'R[YM*5MCP3D5LZMVP'O$%$V*/1:UXV0UZ
M+!1I)D1X?BY>NJY0*SB";7<F/N 2TJAOCP2Z+@)$[L?9C )7N:#)YUEH\<K8
M2ED<3:O;6]P(4UJ7Y9=BA,I1R<F8G..!X;<1 ,VH>YS<7:1<]EDJH$.1!<K
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M7D''FD[QHJZ6LZLN5P*UBZ#MG("]V:&N %DDA\VNURIDK&H/NA0'K@T]^(0
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MSVD <?:5U93G<^>XE2?K6UE6 5T*AM3JC;G --$)0H68CHED.%I1""$Q%X"
MALP25VYH%E*N4]?H?=$%:&F5]Z\_!P0'YN?5&_&4^3>M5'\J4L/Y0-O)H78?
M%9Q%.[+#OB=E%T/;+T'L',>;//>N5TX;JO&L,L02MC47[Q4OIUQ'[/<HDD"0
M P5P"Q\?=:N^>Q=CVQR ,0AN5WEZ@(81*:8*HHE +R+DT"2/!W!I$4+'FB%5
MPEO0ZQF+^S0^QBT$O^Q_ 8'V)FBWK(N+=*-G,P?&V@ BW/-&7:?_.1YP7O2>
M!4 _OGR3D&.M ZG!\T)V!;-7C.42A?V ^P9C)4VCJN/QOXBP30M63E\L9 S;
MW,?K8P"I0+NFH*CX NJ#J"\M&J@I :8"H';6N*D@&HB&,>_:IQ4+?/.;GJY;
M=RT.6?[E=__2=5-LH]CF"O_#'O&3RXMHUQ$4%8>_P4!','&Y[P70 *^>$$<=
M3ATMKA,9JX&^9[E. ;U^/IT\"04&HZ!_(@G.HHTXX&'G#4(%#@GAF59P3]0@
M*R/ #59"+0;:_L.B]B%X?POYF 1RTR.!&+/_,G<L=D _6 !DU987_D\OI6GY
M7+Q<FOKGEN-N,71I 8S@G.5S18)[]-5@Q/MSA%P8ON6\&U\M-56^WSUK\KS;
M_,';3F^CS?/Q* 2S*S:CPE*Z"PP$P>^@=KG0E<4."%;<!!BU@KW@=HDDD" 1
M& 3;2\:)G3T66*=L;&2KD.O)-O1\!%P:$^')=^?; V/#=3$1)%#6OYZ:2P+%
M/@2>S1:UAOC]\\S>R:A^[H%(IPUXCK1ND_A/%L7/)ESX]IX N#:(H\I$H_]
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MWJ$":V+GL>:TWW9XX<#PE4]<35>//'JQ]V!,Y*SBW^"W%Z\(Q:DRVA&$PID
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M?KXP>E>[#\_O,7%C8K=Q]+:/'.[BD.1#^475EMB#=])H0/WD!&HS>51HG-:
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M&# \X-HXT*<FC.)1/'0PX_^; %!+ P04    " #:6F-6O79$#EW9  #?00D
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M+'K$\)QK80;*:<Z%X7.N!/3[DSXS:Q/#CD.5'U:=\?L0$\IBBD"*N#+S4DH
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M!2R]!4<$>QP(VU$]^A2."A^[&:Z#.*>LZZ:&^I[44;U9G4G,PS3AE& @LX@
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M\<PZYN"<\H_%LU/E=9PTO;TMR:I2'*BOG1SF'&"HG,HP28# NBI8HJL;$TY
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M!E\WW3OX9"OL<M([^;IY/>R=:LD&=]8; ++GAGHNDKYJ'[T!T/:USQLRM$L
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MXV,YM8=WE%8H6IGW[8R\W.LW@,IK<F"7/*^8 F@ 4W>BG\D HQR G#&++Q[
M'+YGF%*8Q@D'+,Y# '-(  H)!#2A.4.0H83G XY$',6:&_5M91YVBCO*@CF=
MEGA8!H]Q,46;9!^_>&SB%_J6:4^#ZJEX=42D_1Z[N K[F@<Q P'N.9H9.KIS
M/9:ZY.F-/*AC>KZZZ?;0-(RB.(5)#-*4*]X6 @&"& -Q#BE/$Y*J_UF6:K$4
M86X<W8IUVBRRMJHJ^V(NMDMBRLQ3 CTQ"__>6_5[>XKMN9>C*Z;3ESVQ%<QW
M111'X,X42W$=R94SKU=D^5P5E9ZRKIZJN+FI+;2K_TLDH3)%.4CB1'=/),IW
MSXAB2193+C )\]RHWJG-I'/CQ:W$^JUM"P77=M&VBEQ_T6!W_$TI<5Q4)R;!
MX8 Z$)PY0I-3FH$HGDG,')Q3VK)X=D"N-!."5SJ2N4W*OI%MNL\"8HQ9+'*0
M)1@K#SS) (IXHMB*H2S&<<J(9=&]SOGF1D];89O#@EWM(-TE>J,\M5UV7%.3
M+PJM[;AN]$T9:C1,)R:GRW#VU;UR2YGN!\5'PG2'%/[3I?LA.9LL;?#8&$<=
M%]W9NGG>0H9Q$@NI_$I>%U%!""A_D@.2Q%%*8I:&DKF?=G1//C=J.H[4<[$A
MQ;+V;%Y>_N^+.VGE!A5MZ%DTE\.2\9;"ZWG)9*LP\$#%#$ZO9RH](KWBL8H9
M6-TG*X9CN%+F-D?[;?&MX&+%K_41#M-Y>G?B[-42+!D1D@&:\5A7E4L X2D$
M&%&9T!SG,K<\1[&48&[DN;OPP%OY@^="+"_?;AAI'4RI<$)T)^;#4V!)?7K<
M"N_A5HDC=I.3GZU<GAG0$;93&G0=R(X+N2@6[W25FN</:I2R3MX2;\F&-!V7
M-XM<1!&6$=5G#KDR%74;Y"R1@* 8AH2S-(JH">7U330[9JME#0Z$#;2T;;-P
MPU/A7G2[B6Q,S*;F*T>XC(G)%(N.JG]JB*;BG_IA7^VO=V O!&*JWI8GC#\_
MAC=YJRBFTE,HNOE5;+X+L?HLED2QSB=2ZC2]P]2%.,,HY9P"EE"INX\A@%E"
M0,82*07F-$T'E FT$65NE'+86;=LA X>B4XXV1QH-<2#M%HH%W]R*OB]>I>'
M: >TT>)H0>K[4A[R\US0].I<6@GXBJZF"Y#=CJ?3B,YGG/P_GJI-?6Q:7W1Y
M+ 4KFEJ!RNY[6*L)J_K7]LQB02 5*&$()(QS78H5 \00!EG.<YE"D6/;AK2V
M(LR-6P\E#L N2O0B/%0?+U1!=A5$V/J(P7J5C,]%)\1^ZE/2O>AU;AX_7 :-
M/3D0?WMX.NJ)J2-VTY^?V@KF^S35$;@S9ZNN(SE'[1X>E^MG(7X5*R&+NA=X
M_;YAF%">(V5J9C %,"<,($D@0#25G"IS-,PL[W!<F&ENY+<5LVX8K03<OWZT
M%;SWU;.$VC@ -QS J1W7+7;&4+G$TKIAF#YF=F%^W[&Q;AC.Q,!Z'G"IFK+-
M8/NB$P^:&)H^7:@6BBI(E&02Y(E( (Q("DBN_Y-1%">2TE"FYJ5-+DTS-^[8
M)WMJ>]:JMLA%)+O983Q\)J:&%IH;&=1"!HV4P:?1<+(I<#$&7IZJ4#CA9EDO
MH@^.GJ(.%Q_W6'FA3X7C\@B]GW:K(-6<L[_P?+G.CZO3>C^1Y[IOSX&W6Y^\
M[HNT4(%#BA '(A*ZD'*8 LI1#N($YG$6PRS$1D;76 +-C5^/0T_MC:9*9\K7
M>C1.$F/ED^"'M^OM:O,,7D43QO:[-E-'!+<9)@?KHPBKUJ>N=M-T#MNJ%!SH
M%'RMM7*OI#1XM>P*(_E<-6]UCIQ7;[R"16/AVEM_:/!$7LL)C07+R^I HXWK
M&G;X=_'\FQJYN=;T26T=Z]5*+-\<N-SUL7Q]$^I3<Q%J040,8R@QR%@L <PQ
M!AA%$<@9E3&,))6AY=44!RGFMB5^.;@Q=A2Q< Q2N"R,:0!C8K@GWN64],'#
M3GR=/]3(?P3[U;DK?&-&/P9@.'EDQ$4VSU&3 ?"=1E2&##;TVG,]<O6AJI2M
MN\A" 1E+(" TX0#&:GUPR@G@,H<D"B7/0NAVM?EPFEE27\#(8[$A"JI:QL%W
MEX]PA8CC"#,!"(0$0))E"E>U[<10[3B1<M1DB!:*"(HU_[(AY<87NB^G](OQ
M54#%7;&J:UZ."C=B4'U98P02%%( 80@!$C 'C'(6XICGG(L6[G<K[A?L[82>
MO\ZB:0 _*LRFV_50X/Q$%/6UMUK %K(I[LB?0\#;/?BCR5_IKOLY "[?9S_[
M:=<-K\G!8\^?B^K/MG=+2K,L3*D +.4,P#!- $KR&* HC:),_14FEF>3IY/,
M;;/;2AB42D1;&CB#H2D)#$-F8@HX F62%C>7U9_\_3\SM>>W_[+RI^]^QV?M
MD^A_?:J*E:BJ-^O5AK!=@RS(A7JS8R!"'1W/L00T"AG@E$8BQAFGTJA=PL49
MYO;.;X4,6BG-\^3/ ]C]SH\"R\0O_$M$1FQ_UZN^4S+\^1&]9<%W*G28_M[]
M09?CL&N-0V,)_+%2#UUO;N]%4T?\^JX4M<_\QZK8".W';$35?D<AHS16;A5(
M<90!F"8"T)@(D"KW%HD8)0(;!?F&"#$W'M!*!(V802-G<'W[F\TYB>-BF)QD
M30_QQ)Q2H]LH$-0:!-<;L+D7H.D7$^RTN'JQ!BX-3!T7PN:0:OH%\70PY;HP
M8YU*#0.RYR3*<7"/IT_#U#\^<1HXUE3U?KO*:4>04)E!"216AB8,&0,T5%L2
MQCG%%*:0<\N8Z@!IYK8CU87-=?UMUA0VKYP*FP]8'5/WU1/F$V]11J5\?=9%
M'X[JJY?MG5/]].%PVA?IG;+.>IM:K$LSG9R '5X&^T>QN=^F)5<+(:(L3U,*
MPC0+]677") \%<J_1TG.0Z[OR]L7!+&68VY<._8)O]OBF!+NY)!/3+6M_$TQ
MN'/E>(\NO'Y76@1BJ\;8%4.<<?12-\1>NE>H'N(,X?D:(N[#C5$ZX,V25)6H
MV@.6-\U)85//#$$.4Q0Q$*,D OI'0&B> *:[= O,LIP8W;>PG7AN9'F<(<P:
MN7=GA+O3U1$*S'4LAK%Q.CK$4]NAXZ [\*9_/U1>[_5WB/.*M_C[0>J^LV_P
MO$M4^*@&W:X 75L-X%;MI.N2E,]O"RF%/D[:!<#2B,@P0C$01*"FR":&:G&8
MR'*<(,P0,RH6-TB*N9'=D!X[PY;#)##L >2)Z>[3KCQFK<-5L-,B:-4(=GH$
M!XHX189=E\(F-.QA23S%ACN61E]9T'6<EDO!-D]J.]J])@,7S3)\/!#LGOBQ
MZ^@> \@# 3B.( \=S&6SVI:5_E063'S635ANOZ_;UPZ+3(9<Q"!*H-Z0& ,D
MU,&*B$5Q3K.8VUQP[IAI;IO./T4_HS  P3\E/X>1#<%UH6FRGXR$T>3Q@[9^
M?"UF4,L9*$&=]H0NR&QX?R3H/'&[.X26#&T 2P\+=XW@D6D-%#EF4Y,'7",6
MM^1'&RIIVX-LKA\?EP6K+Y"1'Y\582\@PACF' $6H13 !$N 0Y@!"4F,< 1Y
MGEO6S#>8=6Y,>KW:%*QXK$T2Y94&I6#K;Z+C5N4 P$U#$B/#.#'9*HEV381^
M:AH+_34@FX#L9&Z 55*/&8RP &GR2(2)+)[#$!;PG,8@;!ZV3RQ]V^Y@7^Z5
M>Z O:I'5\V>A;,?-0G*"XIBF@,81!9"+""">,670)2CE.8^1,**D[FGFQD%;
M28-:U/^?O7==<AM7UD1?A3$S,>..*$P0! @"LW]5^[*/YW1W^;C=JV-'_U#@
M:FLOE51;4KE=^^D/0%(JJ70A !(LGLN*%6V[2@0R/XB)1"+SRZR5-6N$]<\W
MO8+K=<LS'%JI0Y]10 5EGW;C$)6">F78T?)0NU4[3$;U^'0T.^@9:DE:0J-+
MA0'!F %,5 EH@07@*'>4*\90'9CI\_\6CL]@5L\^Q)W3YN9,3;WYFNR:$R#0
M#.+('(P&LZ7#V%][K,QF?[/;WO<?=-_=]^@T7"E1,G=<J0S VIH.3CFUIH,Q
MQGFI2^B5J!(W_>0LR=&E8$<'X^ROV[#FJ9%+Y!-02@G\J!>Q$\$\B$DI(?9C
M\28-O0:AI$F1$'91)(4..R8A4J3*+^B/8D?IM[G<F=\<8?J.8^D@W_+C<V.^
M_<LDN6:42D>]C'. "^2HE^U&8QU3AHTJ\TH'7'A'2C'AK>;.9+4B!PQEA[1R
M!\KT-G]A"Q>V\R1;CO$VH,FN1-Q^E&Q%QM^6AEV9Z.TI"E'O72IL]%?9K*(
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MU099&Z4)8)A"H)FF.;(N%?*OF+@TR=1,TIX6[%G0Z ;:)X!V1\.&@"FQ?8E
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M??^P6O/UT[NY,7JMK69_+%THZPO_\<MJTQ!>[W_R=JW5?+LY+"WGUJAK+3B
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M^ Y;>^ )51=E<<<H8[(7^RGT@LC8\Z'8D+HS_&O]S=KY^7?=6/Z9HDBP2E<
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M.#^[L\WOW_3"9!LM']?SK2ORY7MY0TSF"90^NU8?@!)O/XUHV>TP8(1L!'U
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MI0FF9JWV$F9_.1FS6L@P?J=3$*^;H"&@21WT38%*4+5G+W1&2K,YQ*:N;3J
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MH _27@'6@?%+'5YUXF9O&H%_:D)_.SAW0F<?T\ 9%%L=&-:Q(JL#P!L:6 U
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MQ! 6=*R"[REI2&P36X$#46L"Z\T!S ^MN,.2&?A!,P*K08<@H],;^ %SCN?
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MF.L3IMYQYD_@L]'1:=?R["U?KY\<S<N]N[)JW1?-.=95KH"NB+7E4BA =<$
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M!ADV)@A3<Q#L>K;>+M4!=\$79SUF$)<5Y)@#41048"$<=R6% "(NJDHR58J
M5/NNZ:;F_-;R9ON>MHYQ\)#ZXZ]:Z*#S<R?@/K&&(6%,;!5? <&06,202(X4
ME>B):&"$PA>@CEA%YS C1BU\53J.7W@_%>LL-ZU\MHV%;PCB*IUK66AB=TW7
M:8,A!CA6!E10(V*,Y#GA?C'<:]-,,(8[A/=Z!D]?E[0?1HDM:BM<ZSX.SJAW
M6??DKN"9J4?V[RXK?^JT7?EL=.UT?7%^9^X>MYLM7RI7J^W2D>[J(_QFQJ 1
MNBPEX 8J@(VKH);2 *Y13C3%!15L]J#7\Y7Z?<O76U^;T#%OR)?_Y>P)]\%G
M86\RH;_.ERX;SYV^7&?UNFPX+)G+?QU4R4IK?@5 PEBG&',**!7051!(KH6D
M,,?M.KQ?JE=;A=W<(ZV!=CQW(Z /I:P(HR50!<< *[LULIP:('*-=($TQ,2K
M'5T2Y$=,:#R0-AG6OCOF@ @FWCZ?L]-JR+)5(V&V.D!SOCQ'7)O5B4M?!^ID
M%XQ=>CJ"#CG&)B7P@^4,-8'G@]%7C@<ELV>Y' \OKJ0U5)@[LEJB(<"TU( I
MEH."*L*ID26F7L3W<=-/S7+MV6H_';#5WK9LM;_$L]4&+8GW76(BH%-?'#X7
MV+O=^ (%;;H[P@C4TE\(A@@U]NU?!&!GKOIB1@EO%-RF]#[!0GR9;UU\F,A<
M\Y( JH4!6!,)6,FMI4,E,B8OL)!>\>%S@T_->M5"N9<*%F_$3[OL=L_\V[/H
M73=%?3%);&A"X0AJ\GM)[ZB^OB>#C=;*]Y(:A]U[+WXFUD'9$S-]F'^OF9DV
MNRR]"BEHN+)')65/3J(@0)0E \KD%=3&E$0%,K!=FFIJK^ZOJ[5N.,6,HP5V
MY]-@)^,BK+X.Q1!@)7ZG?WDF7WL&*DEZ?1<8R7V"BP*,O/]W 7&ZUW<^,<3)
MIKYU=D6R]=FI[8]XZ$8S.TC!C0$%@03@"I: PP(!US^H@(4]V'"O1/VXZ:=F
M8'Z7W[1Z;/;#)K#0U1%TB#6(.<H,B>RH1QG9"'Z"\"A'&5_41CW*= KUBD<9
M7\"N'V6\1XGB&=I:0^JB>;!)'"B-8<8@!!BVQ@PC4KM'): LMWA8FT:+@-*C
M%Z-/SF#MQ(O)P7B)W'4[U!N/Q&;F6;(AL CBB(G'9"P^%W]L0KE6SNO>Q8OR
MXJDQ.4S."_R";^3"AZ*X05[0<S]];DC[W8I_JF_X9IP**141U@D3&F#)#* $
M24 1$Z7&6"G- [@_.B><FA5S"3G2=;9?/TN:-;>?08P0W4C[F+AA\4ML]7;"
M[N/N3XZ.Z1G%3RE0#.+-&!3-L7@Q^J$:RG;A#5$7FT7W0&.R57BK]8*-PO^Y
MV"/R9[W1Z^^Z=4B/&F/N*"B8K$I4:NL[%A)@#1F@6' @\I(I>RC6E)=AY^+.
M.:=FE5N!]R<UWP:PT9C[GH,'13*Q?>X ,4E0SAN?Y,?<;DE&/MMZ0W-ZH/5_
MM%_/A)59:]<]0SWP]?9I3RN?PPH7I"R @@BZSE@0,$(5@% 9G&O)-(WJEG!^
MNJG9HN,84BMQ5HO<F\W_ N ^KN*0,(X:A1L%P;A."/V1'+\'0@RBT=T/K@/D
MW??@PC"OTO'@NDJ7>AUT/!7K'+:THHXR=.>98 @+;2 $/"<5L'88 :[L ;VJ
M#.>0<.L:!GJ#IY-,S>36HH4Z>6>P\_7J^B&2VHUS4B5QUBZKG=P[.S/UR.[8
M9>5/_:\KGXUQN)P[9Q_Y=KM4[_1WO5@]M+P)KC1LU^NNA"6AF@ N2N%8S 1@
M>>4B=*@0 FNE2J_7WGO&R=F 5N0Z]5 ]"YWIMH0NQ%_P0=S'Z1H8QQ$.@#6$
MKL3S0-Y=[6<4?Y</E"'>U\"0CN2 781V:(*O '@ZW"^?D4;TP (4.W;"0AZ,
M]<-N%XM?W-C6Z.\I;OZ/N5Z[>7?$IWE%&#0E!3"7UD)SDP-FS\9 5E@S4M%"
MY#C,,?.8=6I6VHJ<+6J9:]:29S:I;SNY0]TX'^A]_;J! 4ULKKNQ3.(%!H"4
MW"WTD65D/S$ GE/',>3A(7+NFLHE:QG_U(X;6ZO;[W:RK_JSON=S5]VZN^!X
MY(M?YD9?K'%J,A%866&$*P*J@BF &5$N-Q^!LC3"5+@R517*;9A,V*E9QN,0
MS;(I&G2^[-^MMAEOU,W6.WWW+=JMPMG":NR>/"PK/"XX_&L;D&HRRO?%URY/
MXULP:M3S-;X /3,6TZS,J/F- ZOPBMF0:1;C>NYDHCG#B\;>+[>N_9)2]OW<
MO'4%H.NG646M YX3!A E%-C-B $N%0-E418,&UT9Z96Y=&F"J6THC8Q9*^1-
MUHKI7SQV%L7K)GL(;!*;V5!8@HK(KND>54AV=L#1BLFNJ7-84';U<]%GZF>^
MJP^K];NVR^>N[^='UQ/M@<_5CB%K5N52(R@A$'F> XP$!)1:@P\5H9PR11 .
MK#4+E&!J!J 5;Q\ ;2.C#ZO-/#PE)G0UO(_<Z3!.??P^X,!SU-B[/K39F_GR
MH"/MPXM5&/0H'@=>^F-YH%QC']'C8#MS7(\<:)"C.]_:/ZVS]?['U@K0WC;=
MKN<;ZTQ]L%J?8W9MCEV"\**$N@!5C@7 1:X U10!(9F0PF!=JJ+',3U:L*D9
MT!<GLEJOVHCJ6K,ZE:*^;.6-<IG[LIVG8A[D\!V_XE$'[5'6<=Q#==(E['M\
M[HWWN$?E>'%?\UC<&^2.(W#_\6,WAYI\I>6(/& VFADA"XI, ;B6"F!(#."J
M*H#$M'0=#PI,5)BUOS#3U,QWPUN\>!8P>[-<;756!I/678(6661E2>P9PVZ9
M /," <8MTA92(B G&D,12I<[ +CC<.:>P#L4JKZ;U0!()=Y]&HADRY_K U7$
M'M(!0_)-X=+\(UOY#AA.S7;7 U$%WOM\^[>K>^?TUVDEM\\TCN+I)"7_]F^^
M5O5__M%T6F@*A^"L1%A4&I4 &4FMF\X(H%1IH$I<$:H9+G,4TE!Q2.&F9XY:
M^=I:S)ML;MV]U3:;W]]K->=;O7C*'&^R#BHP''0]K]NUUUVCQ(;P]X-ZHD/%
ML@/-7*ONP\^UVF6U9C?-']ENE5L57VTM@VKN7VE-QRK8'WMM0\O^$\#?Q1DP
MY)1C$@XD@.H%6T&*&6)/3'VO*8L<LEE>F8H;6@"L9>D:P&- $:H *R7-L2"(
MB"KT##"$8-/;H7=:9:U:V5ZO[$"QS&F6O:EYX((/:H.LJ._Y8^Q52KQ'_SE0
MFLF09YLA(4Y^$!I$V)%/34,"?'K$&G3T9 V;=Q&Y@T/@(>4=@7F%(.2 5]I:
M>8ASP'@N +,'L"+7A!,U=,/FZQ)-+<ZV%[=/,*CO*GG?<(R'?>JK#:]^S>?6
MYO7:-?N!^_KMFCODG%J[9C]8(]HU>PX\Q'WVN8N1?7D^*;6 594#414"8$DP
M$-C5.!="<)(KJ+ 7HT3XU%,SML<7FDIO^7QA?;;YTK[M]\VYFPOKFUVZP^1A
M] D1:Q5SUSS4"HQZFYP"_)YWR#XXCGI+?%6@5[P']@'J^DVOUPA1=PCSK\NY
MF4N^W/[O1_6U'OC]9CNW7["F#^AF\WC?^,?[=ZXPW/"B*D$A['^P,=0U3<9
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MYYX<,67SBN#'N9K7/IB*4.:SEJNO+@O<_?ZS_JZ7CWJ6FP)2@QA V"" &2>
MYPP!B5")2EH492&&)9(Y)\;43&,K5K9^EG5H^IBSJ^'KS*;&.+&%]:*+.<#>
M?6C=+LEK,<9<@_35F6+."C<QAIAK (8SPUP=+<8E?"[E6ADWW';#S=:1SSRL
MUFYF>^Z=K]3^FK.JK+T410X(*PC REI0#@T%'+.<B%P72@4T;0F;?&K6\D45
M7"U_5BN0[37(&A4B"V0"%\?'!TT'>6KC.36T0WS;=*B/Y/8.C'Z@8QP'7X?/
M'#CHB.YTG+K'GG;D&#%;R&>]T:Z;ZNU2O7.=5E<U/]#[AF/]>><@1:XP+@"K
M4 YPR2&@W.2@*BN.-"J(8,9_Y_":<VH;QD[H.E56/8N]XZ/WO+\*0=UG2Q@<
MR\0[P1Y&*W!V(''6BAQI_OT #;'Z@P,[DK'O G@HLQZ$3X<U]QMK1",>I-RQ
M[0Y[-,9D.TK)FDSCSOR^M4?*GUW ^>U!BXQ9SEP8A!M05;D$6&(&6"$$(*1@
MBD)<%C"?+?57OM7JBZ_5[IS6ZV5@S<MP,GFZ%Z*KD4B(F>F&WL=F#X/D2 4D
M_$=+W9+=F:P6-ZOES0X%'A;#$#,]*)8CF>B>F 8::F^$.HQT]S@C&FAOI8Z-
ML_]CL0'MWQY=$<SQ#>'N\K#CAG"&95%!B B@E38 YZ2R9CL7 **2<2@40:0(
M,-N#"#51H[Z7_C3AHTX+V 1G>O19.-\0>.IU&&=+:+0X3<[0^S49-SEC %23
M!\/[R#AR3'P .$]#XT,,&FN2#Q/2[9<[-XA(H 4J $:5 *QT-1C6/2;VGS+/
M^6R[VO*%KVV-K;38SY'0SW!S>*6C>R#G:^.FF;#_2YJ<_-?(O'_%_'JO+/K^
MN?('&?D+1P.[N3,'@][^F&]F)6%&<7ND%:5[CRFE@!$D 36&H)S1PE"OQ*?N
MJ:86AVSE=-OOP9N=_<6MK,'EOQ?Q]7W;AT M\:L?!UA,@4X'%NEK<BX),'89
M3@<09RIONIZ([AVI5'W?OOFR^NP2.E?F<:,;<N)9+BEANA! ,YX##$L"F-W^
M@<!0$%X4G"H8V$CR\FQ3,R-[48,;2UY!U-=J#(138L.QES+;KK*UDQ.L#+"2
MMMSD@W:@[$8D?3O**S*,W9NR&XXSC2H]'NKMB'Q:K[[/-VZ6>I]$2N#"^2$E
MRBG  B/ 5)X#CG-42%YJ4WE=C';.-#7[<;"KKK;?]-JU#6K%[>N+O( XV!6)
M!VX\3R04LS[NR'D\QO-&7LS_6L[(>1BN^"(7'H@V(3OZD@]6RC_JL,?'Y7>]
M<0D=MXX9OSEGYY1P5A$#*DBQM2B.9LY@Y6AJA<:*4DVKL B%W\13"UXXJ;/'
M-IHXW\F;\;W P?;%#W]O<S,XJJFMSS/CD7M/LC<MN#^%H1MCB8*@2F^8_,09
MVTX%@73&;(4]'VO%FLX>;_G#W)J 684E89!A0+AU>C!QY#:\RBWLA: Y-LAP
M'N;^'(T_-:>GZ6DF&^$:UIJ,_93]]_\*2?XOS7]O'[??5NOY?VKUO[+'Y6)^
M7U>K'GZBT?!_9>^TK GS,@1O,O=EM9^B!83_DA%X@XKJAD%\\B&X_U!9WN08
MW524A1K"XR7TM7?1"Y/8K+6M9MI%&=)LG=4XN74ZGG5D(W16Y5-;<_YC,;E,
MS_6<CE'2M5.TYDHOI355<(8JEDO%!= 5%JZ)G'6%$(1 ESQGN3U>$;\@;_=4
M4S,T![+6^:;R4-H=719$GI?<'E!?MP+# IC:SSG SN5 '@LZ&&(A24I#(3=2
M?E(D@H%Y23Z@=*0D71UBQ&PD'U6.$Y&\GHC.0;)S-%16=7]:Z]0?T> )J K.
M'<$40P KXR+>I@(E(EHS0DIDO%J@>,XW/=/:B+B_#'IJ'3E8A.<,707:U[,:
M#+[$AM7*"5I!ZPWI",6!CXQ>F*3/VKDJQ=AY.3Z0G,F\\7JL7_7IG7DO'=IS
M^4X_Z*5R?.%?](_MSZ[B>:9)3J76'!2(N9P;*@&3) ?N_IZ3JG2=@F/*3J_.
M.C6SLQ,U>Y8UKKSQ.M8^?EP"!!-;GH,"QCN3G8$R^\N)G?U\O<*^!ZYQ]:*#
MX3M^H6@?G*,+1+WP\JX,O3[:JY2$>BEXJ1;4[^$(+O1F>_A@)^*+?]-\_7ZI
MWO&MGFDM2JD=L11#[C^" DZ, $KFFE18Y;#R;IAU:9*IV>D=LV\C:.8DS=Z[
M2CHKJS]#Z45(K]OGH8!*?<*.P2B,@+X#A#@N^DN#CD=+WZ'6$4-]UV>C*9<.
M#,JG]>I!K[=/G^SZ;NU!]/U_/,YW]8KV1VZ%GF82\U+@ROIOVBA[8&0EX!R6
MH(!$8VJ*2@L<2+<4*,+4C,1.YCHVMQ<XF&TI="%\#Y0IX1W/TUL9EQ]1"W^3
M.5FW-=QZIT Z5J5(^-(S*H4*-C:;4B1P9YB48D>*3LY8W3^LEBX<9[TL.\'V
MJ<X]$@CGN900%-)P@ M= 5&A"DBHJ[R$4)2(!J9WG9UH:@;N6<J:,::6,S:M
MZSRROK:L/U[IKQN"H8K)H;B*0_J<B?/3CYTC<16$,SD1US\?$_0Z(@+^[&K4
M/MBO4MM;TNA<%<I5I0C7G<YP^S=620"KBC I5)57S#_2=6VJJ1F,_X;^)X,9
MR/Y;]3]QT!W;53Q]HEE#H9383.S$S&HYLUK0S$F:_?5K1X_-4-1"8E5#H3=2
M@*H'BH%!*1]@.B)15X<8,?SDH\IQS,GKB1CK^?OCP\-BKM=OG=SN-L)]73[/
M-_^$.PL*M2HK)D!![3:$2XD P_:L:8VJX9AQKLK<WX)V33<U*_IEM5AD]WSY
M:+C<6N?7LS&[)[8^UG1(Q!);U)VHV9&L62ULE%'M!##$L X)Y$C&M1^@@?;5
M%Y\.&]LYS(AVUE>E8UOK_53/YI2'E94[/CRABQ)7I 1$4 FPNYX5+LI?(*VP
M-+(H65Q'RC.33<W6[H+8/>@1KB#K?;P=!*^1XOW'Y=,IFB9WPS%68\-S(KQ.
M-\,K8%QL87CMF?0-S_[5]1;U:H2%2E0516X-$)(EP%4. >>< <8+(V3!!$*!
M- X)I)R:Y6H%?[U69_[KZVL&7WG5$MO/X#9G7]L5GFJ3L^!%F%"+,W_9)]O@
M+!C^/NW-PB>+W6 ^ZRV?+[5ZS]=+:]@V[:F+E@HQ*!BHH*0 8\( EXH *B5E
M=H\P7 7F*Y^?:&IF_E;:4]_CPC$J9N^TF<MY\ WS!41]K7)_G!(;UIV F6XE
MS/ZZ'^J8Z@M#<M-V8?J1K=-U$$X-3,?G([+45LNM=6,_V3=OM5SJQ6_V>S'3
M5"-!-0>:%@)@:ESKPYR!DN>0*,94Z=?1YM($4[,)K8S97LC,21F0EW8.Q.OF
M8 AHDE_!!J$2EHEV1?6X++1S XZ7@79%G:/LLVN?B]W@]PT$+^=TU.0;<S.W
MGLGF'#M#A7.,I,2@0E4%<%$JP"K[-U*Z7J?:.@H<1E$D]Y?-ZX48GRGY5EKY
M-_N6= ^'J6O/N51-"10)/C0.L*2^WLA(*S1RO]:N++>;3.Z5RO@F.5?'<"@G
M=XP&$'5D)VHX<$\=K@''CK7O;8K-4IV+B&OKC'&N(4!::X"-@D (5@+!$<."
MTZ*2@6R+UZ:;FN-V(&)=4ET?IK^M%A;>3<WH4?U+UN@3:H&O@NYK6X>",K'5
M;,2L#63ZNP@?3)+;N*M"C&R]?  YM4M>3\5:G"^KASM3)ZCLKN@1-)0+#I2B
MULJ45  A%08EPE6N$1*E#JQ5>#G%U"S+K_S'_/[Q/M1LG"#G:RKZX)'8/%C1
MZJ[+=598BDC0)=V3FX&3B4=^]2\I?OJZ7_QDW_[&\Z5<W6N+YGYS,XAQPQ0%
MT&![%LPE Y1!^]8+5 EL1*%8%=?.^&2NJ;WTQV4RC;B9E7> YKFG.%^W# .C
ME]A$C I<;)/A7@"^2D_A,"![-!"^"$U O^#3,5ZI/?!%92YW [[\2+0+M>9*
M6_?LSC$2M^DCG_@3%PN]F5&H<VM=&4 0,H"Y:Y?#(02E,JR@6)::EX'NU)7I
MIF9E;Z5</;K"GH=&P/K@P:5<.\+!PP-($SVK@J-G5[$790YS)CDH3,$!KA@!
M/$<80*J%U*:2%2S"B( 'PWX$^E]?[(>%W%0*4HMQ::3K*D,@X P*8-^"W!"N
M5%'&19=[(_\:<>-76 #O0\A W^34!Q(G9@U<P_>^8\]J(1TT<.L#2?ISRC4A
MQCZS> !RYOSB\U0/8CZN_OVQCKN^_UZ3_QF[D7W6_W=UU];C-HZEW_=7$-C%
M; 8(![I0$H4!!JC.I;<PZ4Z0RS06_6#P6M&.2ZZU[*0SOWY)27;995LB:9&E
M?<FERB;/^2A]/#P\EX?56O_L@UA7*][FQ\J<QI$N R^(5%3$RD1'1F;ZRHMF
MLD@C%ME7Z3.<?&[[L"X\MQ<=B&]=650M/%COI->!CTI\QR1EBX4QI2@_<'LF
MK F1=BOZ9PE9B J IB*%+P=H"=;9VH"V8[A2W\^B%FNR5,QZP^^KNFK:3)=O
MXDW7A'T1YSA2%JV )244HEB4D":(0"E8&F/.\LRL2*#QC',CN5[<SLPZ$GC7
MJ-[:U!K#W)3*)D32,W^-@S@E7QGBXIVDQN0(S$R&L)S2D>D7IZA\=5OS:BW8
MYA=!] ^TQ^R]?$NJ]3_(<JM^__-JQ9OWZT]B_:UBHODHF%"2\#.1T:_;-(R.
M*@^K-44120E11_<BQ>K\GK;=W!F'"4])FDLF.38J!O%,\L^-'P\<CM^?YE.0
MIMG>][D3^M67"@?P30/1]MIZ<&IT&/9I,>7BV3X#@1WWG>;@_E%U_?/CA;_3
M^BN. $V/@#)B.PA>7DBXZ5.J=A9N@ )CP=8P:'4R_UH]8VFS8$LV7!<MG!@N
M5[?[<#2ZK.[:NZC'E@>?Q?I^D68$I]J]S1C'.O<\AB7&&20XC]*,E;G(C(K+
MFDTWM]WL43J@IC.,WC!$UN2^=DJ\/#/_/E3V4=:7X "_SU/C9W-M.R6.@6YN
MK\+3\NK6%)Z1V]O180)>X)JJ='R':_PMIZI*FM*;+[7Z_&U;1$3Q_,UWLN8Z
M K@/[\JCA$6HS*!(2DVWF3J-H)2I_Q881S+*#4\CQC/.C7'W<@*B!6UC[:VJ
M QF ;,*\$T/GF7P[:4$K+GB$L!48:(G=*BT98&E5;&E:3$/56[H>6]NB2^8X
MC=5=,A@I9.DE<\6>5%^R^*)S6D1O4JN'Z;W\5-W5E:R8,KQ??=5ADLUMO6O,
MT_6J[_N!/>G4<^@KD!+IC(D"8A)'.I5"6<U)G$(>%[F,6<IH:MEU=6H1YT;^
M9YI^4:(^P>R=ZI.OIJGGYSG7R/,N<Z!:6PSE43G .NUT*91]SS'2*KAOC/FT
M#YDWOXVO%?"?13*UX*$S3SP!?R9;Q==,KIO'3ZO-9G5_G*I1)BAA0D<&E@Q!
M1$4&L9 )C),$I82CK"PLDUS.S#(W"O^EJEWR7,[A9\JX5Z+BF30[Z?PFO P@
MX)VTSLT=F'<&U#^ECJ$/N[[];13:A_7J6]5H?VW__*),ENJ%EQ#GA:Z:EZGW
M/XI*6(B48QP728R,7*<C\\R- 5HA=;9\+Z4M%9P'TY0,KH;(,QT\1<<+'PR"
MX)T1SL\>F!,&(3AEA>&/VY=!>J..J)L?-YRK9Z?I_WI7U2)>Y*BD!56L$"=$
MG0HCW=<Y%0S&6"(L,AR5L7$MI(NSS(T3.D%!+^++W3^ %A:\KRU*(UT&=I@A
M)H/+]QG+%2FK<DFC2#C53+H\:K#"2:.*'59/&O_P%"%,G[;W]V3]X^B<TF=M
MZ.O<U;)B3UP-<4)I6N8<YB72Z5QI DE<Z#QYEJ,XD8@71MT5)I)G;F32*Z!-
MZ@,5P*,.8*?$-;%$]LMF:J($6PS/5'4<ZW/H#2*/2_'0JQ D2L<9S:!1-_92
M/F,4C3.DPU$Q[L.ZW+R.1*SV1PP619G,&(62EXIV4T0@SA(,HR)-"TE243 C
M?XW%G'.CULFBVVUP-[F.G1Q-S]RX U(7D3J6&/0B.]W(F@%J<R<[.;"!;F7'
M 9[J-M8*H9'[6+.Q M[(6BEW?"=K]U47VOYUJX?HZYSKS:!:"[Z0"2^RDC*(
M8ZX.T(Q3G7*90X%1BG.,(X*P1?;WP%1&CWWXE.]>.O"B#8YN#,L9#$%JPL#N
M" 7*B6SE ^\EZ ,V>A&O1\>&3J]&*1!]6J-E29J#.(R0Y/GO!B3%0>&/27#X
MHRZD]XHT7]\N5]_?/PC-I_7=*_)0;<@R_JR3VS^K0]1/^@RUH FG2<0BR/."
M*VM59) H2Q4F95%@0@0GA5'/:ZM9YV:O_BIVH0<Z\J!>U9 I1<#WU?J?^O#)
M.B5L*, 4?A/*] "J9Q+5$@,M\DNP%QKLI :_MW(#+3CX:?@@?P6R-G3K >%
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M7/P7AMDU#RZDP R3]9RD__C"P:$TQ)(4.J-FWAUG.+:MW @A^MD@I!4!#\2
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M+:1KL9CH,$1-!'M&!C+5W!Y,&3A+7C%6D@[=.4MW:6L$I]9;1G1B9HY0PB!
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MNPYP^64Y0^"1,2XW3CG6'H_&.D"=J[26Q2_> Y=&&Q9"8++#%H5[T3X,=_=
MJ#S,A3J=W@:!RXV&R<)S1?^G:B_14,MM! 0?+%B;9*ACXT,>;*/J4];WGQ !
MN_I7[Z..04!IU5NJ[K[YZ^GL)1(E:;Q2U"2?74YGB_%\^=OK86DD#*F\DJ!]
M7E;X%1(5_:I.54Y6<9,[[,.Z+_5]IX%V"LN3JK9WQVP[=Q]JE[3S0N(]F\]Q
M,1^AU0QMY%!DJ&T4*$P)D25BSG"?BRV,-[TV:+YJW\F>'4#MI(H8H'5\\)(\
M'Z50.]+&!*48#DH["=XR#F3F,[=$4\+N4EF>HK;OS- >K=^1JAL$&*_'27W
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MBYN@F.2-)FAO7G_X6(><7(P))'B#2E6"C=+4]UE7)T]:!=%'#R0CEK07_L$
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M$$D_^3G,?L-%;:OU$=/5;)E.OOK8[4V.C9J)>OU,\51MYZ441.MK1E.)+E"
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M6D36FPGA%.>+]03.1S:+4LR*.NZD>!_K9K'@/3HPW(I0LBG&==>.Y$ER^VX
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M]G9Y_2YW5&R),,J7G /D0@AX<%@N?3$808E&9FP6,<?I7K2?V6 3R#E)XD_
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MP5T$-"((2*:,4@K-$3_=J^"KVZU]OXZ%O+$DU@0(SS%*OK_E1!45RX%"RMR
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M$S>EZ;(%)YP&152PW@KB2>\XWS/?KXF0$42X')2?U1'QFUO<963"79EKM:-
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M,C R,BYH=&U02P$"% ,4    " #:6F-6TK7A\@ (   N)P  '0
M    @ $T"   97@Q,C)C9F]C97)T:69I8V%T:6]N,C R,BYH=&U02P$"% ,4
M    " #:6F-6)!I!T(\$  "!$P  '0              @ %O$   97@Q,S%C
M96]C97)T:69I8V%T:6]N,C R,BYH=&U02P$"% ,4    " #:6F-68'LSZ'H$
M   +$@  '0              @ $Y%0  97@Q,S)C9F]C97)T:69I8V%T:6]N
M,C R,BYH=&U02P$"% ,4    " #:6F-6%E,5)PR$   F P4 $0
M    @ 'N&0  97@Q-3$M,C R,FUD82YH=&U02P$"% ,4    " #:6F-6;V)1
M;FD$  #G$0  %@              @ $IG@  97@Q-3)E>3(P,C)C;VYS96YT
M+FAT;5!+ 0(4 Q0    ( -I:8U9.-<Z/;00  &4+   >              "
M <:B  !E>#(Q97AD97-C<FEP=&EO;F]F<V5C=7)I="YH=&U02P$"% ,4
M" #:6F-6EL.,/1\*  #Q-P  '@              @ %OIP  97@T,3EM871T
M8V]F9F5Y86UE;F1M96YT-"TN:'1M4$L! A0#%     @ VEIC5HD\LRT>"@
M'#@  !X              ( !RK$  &5X-#(P:VER:VQO;VMA;65N9&UE;G0T
M+65M+FAT;5!+ 0(4 Q0    ( -I:8U;_:WSD<PP  $!&   >
M  "  22\  !E>#0R,6%L;&ES;VYH86=E<FUA;F%M96YD;2YH=&U02P$"% ,4
M    " #:6F-6R9R$Q(H*  #X.   '@              @ '3R   97@T,C)A
M;F1R97=D96=U='1A9&%U<F]A;64N:'1M4$L! A0#%     @ VEIC5O9O6--%
M#0  44@  !X              ( !F=,  &5X-#(S=&AO;6%S:&5I;F5M86YA
M;65N9&UE+FAT;5!+ 0(4 Q0    ( -I:8U:2[#\/\ (  + -   8
M      "  1KA  !E>#@P<W5B<VED:6%R:65S,C R,BYH=&U02P$"% ,4
M" #:6F-6H'_<R05. P#\UQ\ $@              @ % Y   ;VYC>68M,C R
M,C$R,S$N:'1M4$L! A0#%     @ VEIC5CCN&UL^%P  :0\! !(
M     ( !=3($ &]N8WEF+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( -I:8U8S
M_ZT?P!,  *&V   6              "  >-)! !O;F-Y9BTR,#(R,3(S,5]C
M86PN>&UL4$L! A0#%     @ VEIC5B)1SCP#4   1%D# !8
M ( !UUT$ &]N8WEF+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #:6F-6
MLK1M=J=! @"&0@( %0              @ $.K@0 ;VYC>68M,C R,C$R,S%?
M9S$N:G!G4$L! A0#%     @ VEIC5DGF102\U 8 .P<' !4
M ( !Z.\& &]N8WEF+3(P,C(Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( -I:8U:]
M=D0.7=D  -]!"0 6              "  =?$#0!O;F-Y9BTR,#(R,3(S,5]L
M86(N>&UL4$L! A0#%     @ VUIC5I;_8D[/A0  7>\% !8
M ( !:)X. &]N8WEF+3(P,C(Q,C,Q7W!R92YX;6Q02P4&     !4 %0#3!0
&:R0/

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
